Textbook of Cosmetic Dermatology

Series in Cosmetic and Laser Therapy

Series Editors
Nicholas J. Gary P. Lask, and David J. Goldberg 

Robert Baran and Howard Maibach, Textbook of Cosmetic Dermatology, 
Fifth Edition, ISBN 9781482223934

Philippe Deprez, Textbook of Chemical Peels, Second Edition: Superficial, 
Medium, and Deep Peels in Cosmetic Practice, ISBN 9781482223934

Jenny Kim, Gary Lask, and Andrew Nelson, Comprehensive Aesthetic 
Rejuvenation: A Regional Approach, ISBN 9780415458948

David J. Goldberg and Alexander L. Berlin, Disorders of Fat and Cellulite: 
Advances in Diagnosis and Treatment, ISBN 9780415477000

Neil S. Sadick, Paul J. Carniol, Deborshi Roy, and Luitgard Wiest, Illustrated 
Manual of Injectable Fillers: A Technical Guide to the Volumetric Approach to 
Whole Body Rejuvenation, ISBN 9780415476447

Kenneth Beer, Mary P. Lupo, and Vic A. Narurkar, Cosmetic Bootcamp 
Primer: Comprehensive Aesthetic Management, ISBN 9781841846989

Anthony Benedetto, Botulinum Toxins in Clinical Aesthetic Practice, Second 
Edition, ISBN 9780415476362

Robert Baran and Howard I. Maibach, Textbook of Cosmetic Dermatology, 
Fourth Edition, ISBN 9781841847009

Neil Sadick, Diane Berson, Mary P. Lupo, and Zoe Diana Draelos, 
Cosmeceutical Science in Clinical Practice, ISBN 9780415471145

Paul Carniol and Gary Monheit, Aesthetic Rejuvenation Challenges and 
Solutions: A Global Perspective, ISBN 9780415475600

Avi Shai, Robert Baran, Howard I. Maibach, Handbook of Cosmetic Skin 
Care, Second Edition, ISBN 9780415467186

Benjamin Ascher, Marina Landau, and Bernard Rossi, Injection Treatments in 
Cosmetic Surgery, ISBN 9780415386517

David J. Goldberg, Laser Hair Removal, Second Edition, ISBN 
9780415414128

Paul J. Carniol and Neil S. Sadick, Clinical Procedures in Laser Skin 
Rejuvenation, ISBN 9780415414135

C. William Hanke, Gerhard Sattler, and Boris Sommer, Textbook of 
Liposuction, ISBN 9781841845326

David J. Goldberg, Fillers in Cosmetic Dermatology, ISBN 9781841845098

Textbook of Cosmetic Dermatology
Fifth Edition

Edited by
Robert Baran, MD
Nail Disease Center
Cannes, France

Howard I. Maibach, MD
Department of Dermatology
University of California San Francisco, School of Medicine
San Francisco, California, U.S.A.

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2017 by Taylor & Francis Group, LLC 
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper

International Standard Book Number-13: 978-1-4822-5734-2 (Pack - Book and Ebook)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data 
and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The 
publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do 
not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific 
or health-care professionals and is provided strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s 
medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any 
information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national 
drug formulary and the drug companies’ and device or material manufacturers’ printed instructions, and their websites, before administering or utilizing 
any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a 
particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and 
treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and 
apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write 
and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, 
mechanical,  or  other  means,  now  known  or  hereafter  invented,  including  photocopying,  microfilming,  and  recording,  or  in  any  information  storage  or 
retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the 
Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses 
and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been 
arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without 
intent to infringe.

Visit the Taylor & Francis Web site at
http://www.taylorandfrancis.com

and the CRC Press Web site at
http://www.crcpress.com

Contents

Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .ix

Section I: Skin Science and Parameters

1. Skin Physiology and Gender  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Ethel Tur

2. Climatic Influence on Cosmetic Skin Parameters  . . . . . . . . . . . . . . . . . . . . . . . 16

Mathias Rohr and Andreas Schrader

3. Transepidermal Water Loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Jan Kottner and Annika Vogt

4. Nail Penetration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

Rania Elkeeb, Xiaoying Hui, and Howard I. Maibach

Section II: Pharmacology of Cosmetic Products and Ingredients

5. Sensitive Skin: New Findings Yield New Insights  . . . . . . . . . . . . . . . . . . . . . . 45

Miranda A. Farage and Howard I. Maibach

6. Organic Acids with Novel Functions: Hydroxy, Bionic, N-acetylamino 

Acids and N-acylpeptide Derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Ruey J. Yu and Eugene J. Van Scott

7. Retinyl Propionate and Related Retinoids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

John E. Oblong

8. Idebenone (Hydroxydecyl Ubiquinone) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76

Birgit A. Neudecker, Falko Diedrich, and Howard I. Maibach

9. Antioxidants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80

Frank Dreher

10. Topical Retinol: An Efficacious Solution for Improvement of 

Main Photodamage Signs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Christiane Bertin and Thierry Oddos

11. Applications of Non-Denatured Soy in Skin Care . . . . . . . . . . . . . . . . . . . . . . . 93

Jue-Chen Liu, Jeff Wu, and Miri Seiberg

12. Kinetin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113

Stanley B. Levy

13. Urokinase and Plasmin in Dry Skin and Skin Aging . . . . . . . . . . . . . . . . . . . 117

Yuji Katsuta

14. Ceramides and the Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123

David J. Moore, Clive R. Harding, and Anthony V. Rawlings

vi 

 CONTENTS

15.  4-Hexyl-1,3-Phenylenediol, an NF-kB Inhibitor, Improving 

Clinical Signs of Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
Cécilia Brun, Simarna Kaur, Michael D Southall, Christiane Bertin,   
and Thierry Oddos

16.  Perfumes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148

Jeanne Duus Johansen

17.  Alternative and Natural Treatments in Dermatology . . . . . . . . . . . . . . . . . . . 153

Daniel Oxman and Cheryl Levin

Section III: Non-Pathological Skin Treatments

18.  Skin Care Products for Normal, Dry, and Greasy Skin  . . . . . . . . . . . . . . . . . 167

Christine Lafforgue, Céline Try, Laurence Nicod, and Philippe Humbert

19.  Self-Tanning Products  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174

Stanley B. Levy

20.  Astringents, Masks, and Ancillary Skin Care Products . . . . . . . . . . . . . . . . . 178

Zoe Diana Draelos

21.  Regulatory Overview of Cosmeceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182

Lauren A. Hassoun, Howard I. Maibach, and Raja K. Sivamani

22.  Photodamage: Protection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185

Laurent Meunier

23.  Photodamage and Skin Cancer: How Successful Are Sunscreens as a 

Means of Prevention? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Xinyi Du and Douglas Maslin

24.  Photodamage: Protection and Reversal with Topical Antioxidants . . . . . . . 199

Karen E. Burke

25.  Actinic Keratosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214

Brigitte Dréno

26.  Safety of UV Nail Lamps as Used in Professional Nail Salons . . . . . . . . . . . 220

Douglas Schoon

Section IV: Specific Locations and Conditions

27.  Hair Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

John Gray

28.  Dandruff and Seborrheic Dermatitis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248

James R. Schwartz and Thomas L. Dawson, Jr.

29.  The Periorbital Wrinkle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259

Martin R. Green

30.  Cosmetology for Normal Nails . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264

Robert Baran and Douglas Schoon

31.  Cosmetics for Abnormal and Pathological Nails . . . . . . . . . . . . . . . . . . . . . . . 276

Douglas Schoon and Robert Baran

32.  Evaluating Hand and Body Lotions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287

F. Anthony Simion

33.  Anticellulite Products and Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308

Enzo Berardesca

 
CONTENTS 

 vii

34.  Therapy of Telangiectasia and Varicose Veins and Their Complications . . 312

Christian R. Halvorson, Robert A. Weiss, and Margaret A. Weiss

35.  Management of Hirsutism and Hypertrichosis  . . . . . . . . . . . . . . . . . . . . . . . . 321

Ralph M. Trüeb and Daisy Kopera

36.  Pigmentation: Dyschromia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330

Thierry Passeron and Jean-Paul Ortonne

37.  Treatment of Keloids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 349

Joshua E. Lane

38.  Keratolytic Treatment of Acne  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 360

Brigitte Dréno

39.  Hidradenitis Suppurativa  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369

Emil Knudsen List and Gregor B.E. Jemec

Section V: Specific Groups

40.  Age-Related Changes in Male Skin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 377

Stefanie Lübberding and Nils Krüger

41.  Ethnic Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384

Enzo Berardesca

42.  Ethnic Variation in Hair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390

Nina Otberg

43.  Ethnic Differences in Skin Properties  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 398

Rishu Gupta and Howard I.Maibach

44.  Changes in Female Hair with Aging: New Understanding and Measures . . 413

Paradi Mirmirani, R. Scott Youngquist, and Thomas L. Dawson, Jr.

45.  Menopause, Skin, and Cosmetology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424

Michel Faure and Evelyne Drapier-Faure

Section VI: Cosmetological Treatments

46.  Mesotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431

Maria Pia De Padova, Gabriella Fabbrocini, Sara Cacciapuoti,          
and Antonella Tosti

47.  Microneedles and Cosmetics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436

Raja K. Sivamani and Howard I. Maibach

48.  Photodynamic Therapy in Dermatology  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .442

Jacques Savary

49.  Cosmetic Cryotherapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450

Eshini Perera, Poorna Weerasinghe, and Rodney Sinclair

50.  Botulinum Toxins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459

Doris Hexsel

51.  Soft Tissue Augmentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473

Kathleen Sikora Viscusi and C. William Hanke

52.  Bioelectricity and Its Application in Cosmetic Dermatology  . . . . . . . . . . . . 481

Ying Sun and Jue-Chen Liu

53.  Chemical Peels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498

Philippe Deprez

 
viii 

 CONTENTS

54.  Lasers and Light Sources for Vascular and Pigmented Components 

of Photoaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510
Anne Marie Mahoney and Robert A. Weiss

55.  Nonablative Laser Rejuvenation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519

Christian R. Halvorson, Karen L. Beasley, and Robert A. Weiss

56.  Cryolipolysis for Non-Surgical Fat Reduction  . . . . . . . . . . . . . . . . . . . . . . . . . 535

Christine C. Dierickx

Section VII: Assessment Techniques

57.  Using the Behind-the-Knee Test to Evaluate Lotion Transfer 

from Products to Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 551
Miranda A. Farage

58.  Assessing the Efficacy of Moisturizers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561

Whitney Hannon

Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585

 
Contributors

Robert Baran  Nail Disease Center, Cannes, France

Karen L. Beasley  Department of Dermatology, University of Maryland School of 
Medicine, Baltimore, Maryland; and Maryland Laser, Skin & Vein Institute, Hunt 
Valley, Maryland 

Enzo Berardesca  San Gallicano Dermatological Institute, Rome, Italy

Christiane Bertin 
Research Institute, Issy les Moulineaux, France

Johnson & Johnson Group of Consumer Companies, Skin Care 

Cécilia Brun 
Beauté France, Val de Reuil, France

Johnson & Johnson Skin Research Center, Johnson & Johnson Santé 

Karen E. Burke  Department of Dermatology, The Mount Sinai Medical Center, 
New York, New York

Sara Cacciapuoti  Department of Dermatology, University of Naples, Napoli, Italy

Thomas L. Dawson, Jr.  Agency for Science, Technology, and Research (A*STAR), 
Institute of Medical Biology, Singapore 

Philippe Deprez  Clinica HERA, Empuriabrava, Spain

Falko Diedrich  Private practice, München, Germany

Christine C. Dierickx  Skinperium Clinic, Boom, Belgium

Zoe Diana Draelos  Department of Dermatology, Duke University School of 
Medicine, Durham, North Carolina

Frank Dreher  NEOCUTIS, a Division of MERZ North America, Inc., San Mateo, 
California

Brigitte Dréno  Department of Dermatology, University Hospital Hotel Dieu, 
Nantes, France

Xinyi Du  University of Cambridge, Cambridge, United Kingdom

Rania Elkeeb  Department of Dermatology, University of California, 
San Francisco, San Francisco, California

Gabriella Fabbrocini  Department of Dermatology, University of Naples, Napoli, 
Italy

Miranda A. Farage  The Procter and Gamble Company, Cincinnati, Ohio

Evelyne Drapier-Faure   Edouard Herriot Hospital, Lyon, France

Michel Faure  Department of Dermatology, University of Orléans, Orléans, France 

John Gray  Procter & Gamble Technical Centres Limited, Egham, United Kingdom

x

CONTRIBUTORS

Martin R. Green  Unilever Research, Colworth Science Park, Sharnbrook, 
United  Kingdom

Rishu Gupta  Keck School of Medicine, University of Southern California, Los 
Angeles, California; and Department of Dermatology University of California, San 
Francisco, San Francisco, California

Christian R. Halvorson  MD Laser, Skin & Vein Institute, Hunt Valley, Maryland

C. William Hanke  Laser and Skin Surgery Center of Indiana, St. Vincent’s 
Hospital, Carmel, Indiana

Whitney Hannon  Private practice, Seattle, Washington

Clive R. Harding  Unilever Research Port Sunlight Laboratory, Wirral, United 
Kingdom

Lauren A. Hassoun  School of Medicine, University of California—Davis, 
Sacramento, California

Doris Hexsel  Department of Dermatology, Pontificia Universidade Catolica do 
Rio Grande do Sul, Porto Alegre, Brazil

Xiaoying Hui  Department of Dermatology, University of California San 
Francisco, San Francisco, California

Philippe Humbert  Department of Dermatology, University Hospital Saint-
Jacques, Besançon, France

Gregor B.E. Jemec  Department of Dermatology, Roskilde Hospital, Health 
Sciences Faculty, University of Copenhagen, Copenhagen, Denmark

Jeanne Duus Johansen  National Allergy Research Centre, Department of 
Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, 
Denmark

Yuji Katsuta  Shiseido Global Innovation Center, Yokohama, Japan

Simarna Kaur 
Johnson & Johnson Consumer Companies, Inc., Skillman, New Jersey

Johnson & Johnson Skin Research Center, CPPW, A Division of 

Daisy Kopera 
Medical University Graz, Graz, Austria

 Center of Aesthetic Medicine, Department of Dermatology, 

Jan Kottner  Clinical Research Center for Hair and Skin Science, Department of 
Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany

Nils Krüger  Rosenpark Research, Darmstadt, Germany

Christine Lafforgue  Dermo–Pharmaco & Cosmeto, Châtenay-Malabry, France

Joshua E. Lane  Department of Surgery, Division of Dermatology, Department of 
Internal Medicine, Mercer University School of Medicine, Macon, Georgia; and 
Division of Dermatology Department of Medicine, The Medical College of Georgia, 
Augusta, Georgia; and Department of Dermatology, Emory University School of 
Medicine, Atlanta, Georgia

Cheryl Levin  Harvard Vanguard Medical Associates, Department of 
Dermatology, Boston, Massachusetts

Stanley B. Levy  Duke University School of Medicine, Durham, North Carolina

CONTRIBUTORS 

 xi

Jue-Chen Liu  Liu Consulting LLC, New York, New York 

Emil Knudsen List  Department of Dermatology, Roskilde Hospital, Health 
Sciences Faculty, University of Copenhagen, Copenhagen, Denmark

Stefanie Lübberding  Rosenpark Research, Darmstadt, Germany

Anne Marie Mahoney  Maryland Laser, Skin and Vein Institute, Hunt Valley, 
Maryland

Howard I. Maibach  Department of Dermatology, University of California San 
Francisco, San Francisco, California

Douglas Maslin  Addenbrooke’s Hospital, Cambridge, United Kingdom

Laurent Meunier  Department of Dermatology, University of Montpellier, Nimes, 
France

Paradi Mirmirani  Department of Dermatology, The Permanente Medical Group, 
Vallejo, California

David J. Moore  GSK, Research Triangle Park, North Carolina

Birgit A. Neudecker  Department of Dermatology, University of California 
San Francisco, School of Medicine, San Francisco, California

Laurence Nicod  Cellular Biology and Genetic Laboratory, University Hospital 
Saint-Jacques, Besançon, France

John E. Oblong  The Procter & Gamble Company, Miami Valley Laboratories, 
Cincinnati, Ohio

Thierry Oddos 
Santé Beauté France, Val de Reuil, France

Johnson & Johnson Skin Research Center, Johnson & Johnson 

Jean-Paul Ortonne  Department of Dermatology, University Hospital of Nice, 
France

Nina Otberg  Skin and Laser Center Potsdam, Hair Clinic, Potsdam and Hair 
Transplant Center Berlin–Potsdam, Berlin, Germany

Daniel Oxman  University of Minnesota, School of Medicine, Duluth, Minnesota

Maria Pia De Padova  Department of Dermatology, Nigrisoli Hospital, Bologna, 
Italy

Thierry Passeron  Department of Dermatology, University Hospital of Nice, Nice, 
France

Eshini Perera  The University of Melbourne, Melbourne, Australia

Anthony V. Rawlings  AVR Consulting Ltd, Northwich, United Kingdom

Mathias Rohr 

Institut Dr. Schrader Hautphysiologie, Holzminden, Germany

Jacques Savary  Private practice, Paris, France

Douglas Schoon  Science & Technology, Creative Nail Design, Inc., Vista, 
California

Andreas Schrader 

Institut Dr. Schrader Hautphysiologie, Holzminden, Germany

 
xii 

 CONTRIBUTORS

James R. Schwartz  The Procter & Gamble Company, Beauty Care Product 
Development, Cincinnati, Ohio

Miri Seiberg  Seiberg Consulting, LLC, Princeton, New Jersey

F. Anthony Simion  Kao USA, Cincinnati, Ohio

Rodney Sinclair  Department of Dermatology, University of Melbourne and 
St. Vincent’s Hospital, Melbourne, Australia

Raja K. Sivamani  Department of Dermatology, University of California—Davis, 
Sacramento, California

Michael D. Southall 
of Johnson & Johnson Consumer Companies, Inc., Skillman, New Jersey

Johnson & Johnson Skin Research Center, CPPW, A Division 

Ying Sun 

Johnson & Johnson Consumer Personal Group, Skillman, New Jersey

Antonella Tosti  Department of Dermatology and Cutaneous Surgery, University 
of Miami, Miami, Florida

Ralph M. Trüeb  Center for Dermatology and Hair Diseases, Zurich, Switzerland

Céline Try  Department of Dermatology, University Hospital Saint-Jacques, 
Besançon, France

Ethel Tur  Department of Dermatology, Sackler School of Medicine, Tel Aviv 
University, Tel Aviv, Israel

Eugene J. Van Scott  Private practice, Abington, Pennsylvania

Kathleen Sikora Viscusi  Dermatology Consultants, Marietta, Georgia

Annika Vogt  Clinical Research Center for Hair and Skin Science, Department of 
Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany

Margaret A. Weiss  Department of Dermatology, University of Maryland School 
of Medicine, Baltimore, Maryland; and Laser Skin & Vein Institute Hunt Valley, 
Maryland

Poorna Weerasinghe  Department of Dermatology, University of Melbourne, 
Melbourne, Australia

Robert A. Weiss  Department of Dermatology, University of Maryland School of 
Medicine, Baltimore, Marylandand; and Laser Skin & Vein Institute Hunt Valley, 
Maryland

Jeff Wu 

Johnson & Johnson Consumer Personal Group, Skillman, New Jersey

R. Scott Youngquist  The Procter & Gamble Company, Mason Business Center, 
Mason, Ohio

Ruey J. Yu  Private practice, Chalfont, Pennsylvania 

 
Section I 

Skin Science and Parameters

1

Skin Physiology and Gender

Ethel Tur

INTRODUCTION
Many  characteristics  of  the  body  are  reflected  in  the  skin, 
gender being a prominent one. Genetic and hormonal differ-
ences affect skin structure and function, resulting in variations 
between  women  and  men  and  causing  these  gender  varia-
tions to change with age. In addition, exogenous factors differ 
according to differences in lifestyle between the sexes.

During the last few decades, methodologies used in der-
matological  research  have  improved  substantially,  providing 
means of objective evaluation of skin function and characteris-
tics.  The  number  of  studies  addressing  various  aspects  of  dif-
ferences between women and men has increased in the last few 
years along with the growing interest in studying gender-related 
differences of physiological and disease processes (1,2). However, 
the subject has not yet been systematically studied, so much of 
the data are by-products of studies with a different focus. This 
chapter outlines the various aspects of physiological differences 
between the skin of women and men, based on the available data.

STRUCTURAL AND ANATOMICAL 
CHARACTERISTICS (TABLE 1.1)
The skin of female frogs is thicker than that of males in all body 
regions (3) (the opposite is true for rat skin[4]). In humans, skin 
thickness  (epidermis  and  dermis)  is  greater  in  men  than  in 
women (5), up to 1.428 times (6), whereas the subcutaneous fat 
thickness  is  greater  in  women  (7).  The  skin  of  men  is  thicker 
across the entire age range of 5–90 years (8). Hormonal influence 
on skin thickness was demonstrated when conjugated estrogens 
were given to postmenopausal women (9). Following 12 months’ 
therapy,  the  dermis  was  significantly  thicker,  and  histologic 
improvement in the previously atrophic epidermis was noted. 
Epidermal  thickness  alone,  as  measured  by  optical  coherence 
tomography, does not differ between men and women, except 
for the forehead epidermis which is thinner in women (10).

Skin  collagen  and  collagen  density  were  measured  in 
addition  to  dermal  thickness  (11).  The  skin  of  men  demon-
strated  a  gradual  thinning  with  advancing  age  (12–93  years), 
whereas the thickness of women’s skin remained constant up 
until the fifth decade, after which it decreased with age. The 
male forearm skin contained more collagen at all ages in the 
range 15–93 years. In both sexes there was a linear decrease in 
skin collagen with age. Collagen density calculated as the ratio 
of skin collagen to thickness was lower in women at all ages. 
The  rate  of  collagen  loss  was  similar  in  both  sexes.  Women 
start  with  lower  collagen  content;  therefore  they  seem  to  age 
earlier than men. Collagen density, representing the packing of 
fibrils in the dermis, is lower in women than in men. This may 
be due to androgen, since skin collagen density is increased in 
patients with virilism.

Forearm  skinfold  thickness,  as  measured  by  a  caliper, 
decreases starting at age 35 for women and 45 for men. Starting 
at age 35, it is thinner in women than in men (12). In younger 
subjects  17–24  years,  forearm,  thigh,  and  calf  skinfold  thick-
ness in women is lower than in men (13).

Heel pad thickness, an indicator of soft tissue thickness 
in the body, was thicker in Ethiopian men than in women (14). 
Skinfold  compressibility  in  Japanese  students  was  greater  in 
women than in men at the pectoral site, and smaller at nuchal, 
submental,  biceps,  thigh,  suprapatellar,  and  medial  calf  sites 
(7). The changes in the distribution of fat between the ages of 6 
to 18 years were studied in 2300 subjects (15). Up to 12 years of 
age, there was no difference between the two sexes: the mass 
of the subcutaneous fat increased more than threefold, while 
that of the internal mass increased less than twice. After the 
age of 12, the relative mass of the subcutaneous fat continued 
to increase in girls but not in boys.

The distribution of fat over the body is different in men 
and women (16). In men, an increase in fat tends to accumu-
late  in  the  abdominal  region  and  upper  parts  of  the  body, 
whereas in women it is located in the lower body, particularly 
in the gluteal and femoral regions. In addition, the proportion 
of body fat is higher in non-obese women than in non-obese 
men.  The  characteristic  difference  in  body  fat  distribution 
between the sexes exists both in non-obese and obese subjects. 
Lipoprotein  lipase activity and mRNA levels were higher in 
women in both the gluteal and abdominal regions. In women, 
higher enzyme activity was found in the gluteus than in the 
abdomen,  whereas  in  men  it  was  higher  in  the  abdomen. 
These regional and sex differences in lipoprotein lipase activ-
ity might underlie the difference in fat distribution and total 
fat  content.  Variation  is  at  both  the  mRNA  level  and  post-
translational level.

BIOCHEMICAL COMPOSITION (TABLE 1.2)
Significant  age-related  differences  in  the  stratum  corneum 
sphingolipid  composition  were  found  in  women,  but  not 
in  men  (17).  From  prepubertal  age  to  adulthood  there  was 
a  significant  increase  in  ceramide  1  and  2  accompanied  by 
a  decrease  in  ceramide  3  and  6.  After  maturity  there  was  a 
decrease in ceramide 2 and an increase in ceramide 3. These 
findings indicate an influence of female hormones on the com-
position of stratum corneum sphingolipids. These lipids play 
an important role in the water permeability barrier function of 
the human epidermis, and thus endocrinological factors may 
influence this barrier.

Human  tissue  kallikreins  are  a  family  of  15  trypsin  or 
chymotrypsin-like secreted serine proteases (hK1-hK15). hK5, 
hK6, hK7, hK8, and hK13 have been identified in the stratum 

5

8

6

9

13

7

14

7

15

16

4 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 1.1  Structural and anatomical characteristics

Ref.

Finding

Obtained by

Subjects

Conclusions

Optical coherence 

83 Caucasians; 

(a) Significant differences
10

Forehead epidermis thinner in women
Other sites: Epidermal thickness does not differ 

between men and women

Skin thickness in humans greater in men than in 

women, except for lower back in young 
subjects

Men’s skin thicker than women’s across the 

entire age range of 5–90 y

Men’s skin thicker than women’s, up to 1.438 

times

tomography

Echographic 
evaluation

Ultrasonic 

echography; 
forearm
12.0-MHz- in 
B-mode

Thickening of dermis following 12 months 

Conjugated 

estrogen therapy

11

Men: Gradual thinning of skin with advancing 

age

Women: Thickness constant up to 5th decade, 

then decreasing with age

estrogen therapy; 
ultrasound 
measurement
Skin collagen, skin 
thickness and 
collagen density, 
measured 
chemically and 
histologically

Young: 20–40 y 
Old: 60–80 y

24 women; 24 men; 

half 27–31 y 
half 60–90 y

69 women; 54 men; 

5–90 y

112 healthy; 

43 women; 69 men; 
19–28 years; 
24 sites
28 estrogen; 

26 placebo; 
women: 51–71 y

Collagen: 

80 women; 79 men; 
15–93 y
Thickness: 

107 women; 90 men; 
12–93 y 

Density: 

26 women; 27 men; 
15–93 y

Estrogens affect skin 

thickness

Rate of collagen loss 
same in men and 
women, although total 
skin collagen content is 
less in women than 
men at all ages

12

Forearm skinfold thickness decreases starting at 

Caliper; forearm

145 women and men; 

8–89 y

Caliper; forearm, 
thigh, and calf

42 women; 37 men; 

17–24 y

Caliper and 
ultrasound

Ankle x-ray

Caliper and 
ultrasound

45 women; 41 men; 
Japanese; 18–22 y
113 women; 125 men; 
Ethiopian; 10–70 y
45 women; 41 men; 
Japanese; 18–22 y
1292 women; 1008 men; 

ages 6, 8, 10, 18

age 35 for women and 45 for men

Starting at age 35 it is thinner in women than in 

men

Skinfold thickness lower in women

Subcutaneous fat thickness greater in women

Heel pad thickness thicker in men than in 
women; correlation with body weight

Skinfold compression in women is greater in the 

trunk and lower in the limbs

sexes

Subcutaneous fat increases more than threefold, 
while internal fat mass increases less than 
twice

After 12 y, the relative mass of the subcutaneous 

fat increased in girls but not in boys

Lipoprotein lipase activity higher in women
Women: Higher values in gluteus than abdomen
Men: Higher in abdomen

Up to 12 years of age no difference between the 

Caliper

Lipoprotein lipase 
activity and 
mRNA levels 
measured; 
hybridization, 
Northern blot

8 women; 11 men; 

Regional and sex 

37 ± 4 y

differences in lipoprotein 
lipase activity might 
underlie the difference 
in fat distribution and 
total fat content

Variation is both at mRNA 
and post-translational 
levels

(b) No significant differences
15

Up to 12 y: The mass of the subcutaneous fat 
increases more than threefold, while that of 
the internal mass increases less than twice in 
both sexes

Caliper

1292 women; 1008 men; 

ages 6, 8, 10, 18

 
SKIN PHYSIOLOGY AND GENDER 

  5

Table 1.2  Biochemical composition

Ref.

Finding

Obtained by

Subjects

Conclusions

Significant differences
17

Stratum corneum sphingolipid composition 
differs with age in women but not in men

Ethanolic extracts; 

27 women; 26 men; 

biochemical methods 
of lipid identification

10–79 y

Female hormones 
influence the 
composition of stratum 
corneum sphingolipids

19

Women: Higher concentrations of metals in 

Liquid chromatography; 

60 women; 72 men; 

hair

Concentrations of copper did not differ with 

age in men, whereas in women they 
increased with age

trace metal 
determination

6–40 y

corneum  (SC),  stratum  granulosum,  and  skin  appendages. 
HK6 and hK14 were significantly lower in women between 20 
and 59 y (18).

Differences  in  the  metal  content  of  human  hair  were 
found  between  men  and  women:  higher  concentrations  of 
metals were noted in women. Concentrations of copper did not 
differ with age in men, whereas an increase with increased age 
was noted in women (19).

MECHANICAL PROPERTIES (TABLE 1.3)
Clinical assessment, as well as objective measurements of stra-
tum corneum hydration, and grading of scaling (by adhesive 
tape strippings followed by densitometry readings) showed no 
differences between men and women (20). A positive effect of 
estrogens  on  stratum  corneum  hydration  and  wrinkles  was 
demonstrated when estriol or estradiol cream was applied on 
the face of perimenopausal women (21).

The degree of facial wrinkling is affected by gender. In 
men,  forehead  wrinkles  were  increased  in  all  age  groups  as 
compared  with  women.  However,  no  gender-dependent  dif-
ferences  were  found  in  upper  eyelid  wrinkles.  Other  facial 
wrinkles were greater in men than in women in all except the 
oldest group (65–75 years), in which wrinkles in women were 
greater than or equal to those in men (22).

Photographs  and  dermal  elasticity  measurement  by 
cutometer showed that the morphology, areas of sagging, and 
elasticity  in  male  faces  are  similar  to  those  in  females  in  the 
cheek, but sagging at the lower eyelid is more severe in males 
after middle age (23).

Epidermal hydration affects the friction between the skin 
and textiles. Friction of women showed higher moisture sensi-
tivity than men, when measured at different hydration states, 
when  forearm  skin  was  rubbed  with  dry  to  completely  wet 
textile. Higher skin hydration caused gender-specific changes 
in its mechanical properties and surface properties, leading to 
softening and increased contact area (24).

Other studies showed no difference of frictional proper-
ties of the skin, as well as stratum corneum hydration, between 
men  and  women,  in  both  young  and  old  subjects  (25,26,27). 
In  addition,  transepidermal  water  loss  showed  no  difference 
between  the  two  sexes.  In  contrast,  another  study  (28)  found 
lower basal transepidermal water loss values in women com-
pared with men aged 18–39 years.

The  adhesion  of  the  stratum  corneum,  measured  in 
vitro in skin biopsy samples, did not differ between men and 
women  in  several  body  regions  (29).  But  age  (and  probably 
hormonal) related differences were demonstrated in vivo by 

measuring the speed of dermal–epidermal separation utiliz-
ing the time required for blisters to form by controlled suc-
tion  (30).  From  15  up  to  69  years  of  age,  women  exhibited 
longer  blistering  times  than  men  in  both  antecubital  and 
abdominal sites. The difference was more pronounced in the 
age range 15–39 years than 40–69 years, and disappeared in 
older ages.

Skin elasticity did not differ between the sexes, as mea-
sured utilizing two suction cup methods (24,31). Similarly, tor-
sional extensibility of the skin, as measured by a twistomenter, 
did not differ between the sexes (8).

Cutaneous  extensibility  was  identical  in  men  and 
women, but after hydration it increased only in women (32). 
Hydration  changes  the  properties  of  the  stratum  corneum, 
softening  it,  thus  allowing  the  difference  in  dermal  thick-
ness  to  express  itself  as  a  difference  in  extensibility.  Since 
the dermis is thinner in women, elimination of the stratum 
corneum  factor  allows  a  rapid  extensibility  of  the  skin  in 
women.

Plasticity was found to be greater in women than in men 

in three sites of the foot in one study (33).

FUNCTIONAL DIFFERENCES (TABLE 1.4)
Following  pilocarpine  iontophoresis,  sweat  secretion  rates 
were higher in men than in women in both healthy and chronic 
renal failure subjects (26).

Body  sweat  distribution  over  the  upper  body  in  nine 
clothed male and female runners of equal fitness while run-
ning at 65% and subsequent 15-min rest in a moderate climate 
(25°  C,  53%  rh)  was  investigated  using  technical  absorbent 
materials  to  collect  the  sweat  produced.  Local  sweat  rates 
were higher in men for the mid-front, sides, and mid lateral 
back  as  compared  to  women.  Both  sexes  showed  similar 
sweat  distribution  patterns  over  the  upper  body  with  some 
exceptions.  Men  showed  higher  relative  (local  to  overall) 
sweat rates than women for the mid lateral back, while it was 
lower for the upper arm, lateral lower back, and upper cen-
tral back. Sweating in both sexes was highest along the spine, 
and higher on the back as a whole than the chest as a whole. 
Upper arm sweat rate was lowest. Men showed a higher ratio 
of highest to lowest local sweat rates (34).

Increases  in  sweating  as  a  function  of  increasing  con-
centration  of  acetylcholine  significantly  differed  between 
males and females. Maximum values were lower in females in 
response to acetylcholine (35).

The  fatty  acid  composition  of  sebum  is  affected  by 

androgens in both sexes (36).

 
6 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 1.3  Mechanical properties

Ref.

Finding

Obtained by

Subjects

Conclusions

(a) Significant differences
30

From 15 y to 69 y women exhibited 
longer blistering times than men

The difference was more 

pronounced in the age range 
15–39 y than 40–69 y, and 
disappeared in older ages

24

Friction of women showed higher 
moisture sensitivity than men

Measuring the speed of 
dermal–epidermal 
separation utilizing the time 
required for blisters to form 
by controlled suction; 
antecubital and abdominal 
sites

Corneometry
Forearm skin
Rubbing with various hydration 

states, dry to wet textile

178 women, 15–101 y
209 men, 16–96 y

11 women
11 men

Photographs: Replicas from 
five facial sites used to 
measure surface roughness

173 Japanese men and 

women

22

Men: Increased forehead wrinkles 

compared with women; no 
differences in upper eyelid 
wrinkles

Other facial wrinkles were greater in 
men than in women in all except 
the oldest group (age, 65–75 y), in 
which wrinkles in women were 
greater than or equal to those in 
men

23

Sagging in male faces: Similar to 

Photograph-based grading, 

98 Japanese men, 108 

females in the cheek, but sagging 
at the lower eyelid is more severe 
in males after middle age

cutometer

women

20–60 y

(b) No significant differences
20

Stratum corneum hydration, and 
grading of scaling showed no 
differences between men and 
women

A positive effect of estrogens on 
facial skin: Moisture increased, 
wrinkles decreased

No difference between men and 
women in friction, moisture, 
transepidermal water loss

No difference in moisture

Clinical assessment and 

50 women; 22 men; 

bioengineering 
measurement

21–61 y

Stratum corneum hydration 

and wrinkles– profilometry 
of skin replicas

Bioengineering measurement

Bioengineering; healthy and 

18 women (8 applied 
estriol, 10 estradiol) 
46–66 y

7 women, 25 y (mean)
7 men, 29 y; 7 women, 
75 y; 8 men, 74 y

Healthy: 24 women, 21 

chronic renal failure subjects

men

Skin elasticity did not differ between 
the sexes, as measured by suction 
devices

In vivo suction device 
(bioengineering)

Skin viscoelasticity comparable for 

Suction chamber; forearm 

women and men

Torsional extensibility did not differ 

between men and women

skin; rubbing with various 
hydration states, dry to wet 
textile
Twistometer

The adhesion of the stratum 

Biopsy; in vitro measurement 

corneum did not differ between 
men and women

of the force needed to 
separate cells

Patients: 30 women, 50 

men

Young: 8 women (26 y); 

8 men (28 y)

Old: 9 women (75 y); 

8 men (75 y)
11 women, 11 men

69 women; 54 

men 
5–90 y
9–34 women and men 
(number varied with 
site studied)

20–40 y

21

25

26

31

24

8

29

Higher skin hydration 
causes gender 
specific changes in 
its mechanical 
properties, leading to 
softening and 
increased contact 
area

Men tend to have more 
severe wrinkles than 
women

This tendency 

disappeared or was 
reversed in some 
regions of the face 
and in individuals 
more than 60 y old.

Dermal elasticity of 
male facial skin 
decreased with age 
similar to that of 
females, except for 
the lower eyelids

Topical treatment with 
estrogen seems 
promising

 
SKIN PHYSIOLOGY AND GENDER 

  7

Table 1.4  Functional differences

Ref.

Finding

Obtained by

Subjects

Conclusions

Significant differences
26

Men sweat more than women

34

Local sweat rates higher in men for the 
mid-front, sides, and mid lateral back

Men showed higher relative (local to overall) 

sweat rates than women for the mid 
lateral back, while it was lower for the 
upper arm, lateral lower back, and upper 
central back

Pilocarpine 

iontophoresis – 
healthy and chronic 
renal failure subjects

Healthy: 24 women; 

21 men

CRF patients: 30 

women; 50 men; 
18–75 y

Technical absorbent 

9 clothed male and 

materials to collect the 
sweat produced in a 
moderate climate (25 
degrees C, 53% rh)

female runners while 
running at 65% and 
subsequent 15-min 
rest

32

Cutaneous extensibility increased only in 

Bioengineering 

15 women; 14 men 

Hydration allows the effect 

women after hydration

methods

23–49 y and 60–93 y

35

Increases in sweating with increasing 

concentration of acetylcholine significantly 
differed between men and women

Maximum values were lower in women in 

response to acetylcholine

Intradermal 

microdialysis

12 women, 12 men

of thinner dermis in 
women to be reflected 
in extensibility

Peripheral modulation of 
sudomotor activity in 
females

Sex-related  differences  in  the  metabolism  in  the  skin 
of  topically  applied  compounds  were  found  in  guinea  pig 
skin (37).

DIFFERENCES IN RESPONSE 
TO IRRITANTS (TABLE 1.5)
The incidence of irritant dermatitis is higher in women than 
in men, but experimental irritant dermatitis does not differ 
between men and women (38,39). Occupational factors lead-
ing  to  a  greater  exposure  to  irritants  by  women  may  pro-
vide  an  explanation  of  this  discrepancy.  In  a  study  of  skin 
irritability  by  sodium  lauryl  sulfate,  women  showed  lower 
baseline  transepidermal  water  loss  compared  with  men, 
but  after  irritation  both  sexes  gave  similar  transepidermal 
water  loss  values  (28).  The  importance  of  interpretation  of 
the results, and the lack of a standardized way of analyzing 
them, is illustrated in the latter study. The authors define an 
irritation index as the ratio of the difference between the val-
ues  for  irritated  and  non  irritated  skin  to  the  value  for  non 
irritated  skin.  Although  the  value  for  irritated  skin  did  not 
differ  between  men  and  women,  this  index  was  higher  in 
women,  since  the  value  for  non  irritated  skin  was  lower  in 
men, and so the authors conclude that women’s skin is more 
irritable.  A  review  article  considering  the  absolute  values 
following  irritation  interpreted  the  same  results  as  indicat-
ing  no  sex-related  differences  in  sodium  lauryl  sulfate  irri-
tation.38  Until  a  universal  way  of  interpreting  the  results  is 
established,  contradictory  conclusions  may  be  reached  by 
different analyses of the same set of data. In another study, 
baseline  transepidermal  water  loss  did  not  differ  between 
men  and  women  (40).  This  study  found  no  significant  dif-
ferences  between  men  and  women  in  developing  cumula-
tive irritant dermatitis when visual scoring, transepidermal 
water loss, skin blood flow, and dielectric water content were 
assessed.  Changes  during  the  menstrual  cycle,  however, 
were  demonstrated  by  measuring  baseline  transepidermal 
water loss (41).

CUTANEOUS MICROVASCULATURE 
(TABLE 1.6)
Hormonal  factors  affect  the  skin  blood  flow:  differences 
between  men  and  women  were  found  during  the  reproduc-
tive years, and differences were found within different phases 
of  the  menstrual  cycle  (42).  Moreover,  vasospastic  diseases, 
such as Raynaud’s phenomenon, are more common in women, 
more prevalent in the reproductive years, and improve during 
pregnancy,  suggesting  an  influence  of  female  sex  hormones 
(43). Skin circulation varied during the menstrual cycle. There 
might be a direct influence of sex hormones on the blood vessel 
wall or an indirect systemic hormonal action causing a cyclic 
pattern  in  women.  Estrogens  influence  the  sympathetic  ner-
vous  system,  inducing  an  upregulation  of  (vasoconstrictive) 
α2-adrenoceptors.  Thus  blood  flow  measurements  utilizing 
laser Doppler flowmetry revealed a reduction of basal cutane-
ous  blood  flow  in  women  compared  with  men  (43,44,45),  but 
these  differences  existed  only  in  young  women  and  not  in 
women  over  50  years  (46).  This  reduction  was  due  to  a  basal 
increase in sympathetic tone rather than to a local structural or 
functional difference in the cutaneous circulation.

The vasodilatation induced by local heating occurred at 
a lower skin temperature in women (47). However, the maxi-
mum  skin  blood  flow  following  heating  of  the  skin  was  not 
different between men and women, and neither was the post-
occlusive reactive hyperemia response in a study including a 
group of women aged 20–59 years (43). In contrast, in a study 
that divided women according to age, the reactive hyperemia 
response  was  lower  in  young  women  compared  both  with 
women  over  50  years  and  with  young  men  (46).  The  latter 
study also measured the response to cooling, which was pro-
longed in young women compared with the other two groups.
Skin microvascular response to vasodilators was evalu-
ated  by  laser  Doppler  perfusion  imager,  an  instrument  that 
maps the skin blood perfusion. The substances used were ace-
tylcholine, an endothelium-dependent vasodilator, and nitro-
prusside  and 
isoprenaline–two  endothelium-independent 
vasodilators  with  different  modes  of  action.  The  substances 

 
Occupational factors

Comparing the irritation 
index (the difference 
between irritated and 
unirritated values over 
unirritated): female skin 
more irritable

Barrier function is less 
complete just prior to 
the onset of menses 
compared with the days 
just prior to ovulation

8 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 1.5 

Irritants

Ref.

Finding

(a) Significant differences
38

Incidence of irritant dermatitis higher in 

28

women than in men

Lower baseline transepidermal water loss 
in women compared with men, but after 
irritation similar values in both sexes

Obtained by

Subjects

Conclusions

Sodium lauryl sulfate 

15 women; 23 men; 

irritation; evaporimeter

18–39 y

41

Higher on the day of minimal estrogen/

Back and forearm sites; 

9 women; 

progesterone secretion compared with 
the day of maximal secretion
Also higher on the day of maximal 

progesterone secretion compared with 
the day of maximal estrogen secretion

baseline 
transepidermal water 
loss; evaporimeter

19–46 y (mean 32)

(b) No significant differences
39

No significant differences between men 

and women with or without hand 
eczema

Irritation tested for 11 
irritants at several 
concentrations

40

No significant differences between men 
and women in developing cumulative 
irritant dermatitis

Repeated once-daily 
application of 3 
concentrations of 
irritant (SLS), 5 days, 
followed by a patch 
test; upper back; 
bioengineering 
measurements

21 women; 21 men with 

hand eczema; 
21 women; 21 
men without hand 
eczema; 
20–60 y

No tendency to stronger 
reactions in either sex 
Speculation:

Women’s occupations 
lead to a greater 
exposure to irritants

7 women; 7 men; 

No sex-related 

16–65 y

susceptibility to 
develop cumulative 
irritant dermatitis. 
Speculation:

Women’s occupational 
and domestic duties 
lead to a greater 
exposure to irritants

were iontophorized into the skin. The response to nitroprus-
side,  and  to  a  lesser  extent  to  acetylcholine,  was  higher  in 
women before menopause than after (48), reflecting functional 
and structural changes in skin vasculature with aging.

The cutaneous blood flow response to topical and intra-
dermal  administration  of  histamine  was  comparable  in  men 
and women at three anatomical sites: the back, the volar side of 
the forearm, and the ankle (49). These observations indicate that 
there are no functional differences between men and women in 
the skin microvascular response to histamine. However, hista-
mine  administered  by  iontophoresis  produced  bigger  wheals 
in women, as measured by laser Doppler flowmetry (44). The 
bigger wheals were attributed to differences in the stratum cor-
neum layer, which is the main obstacle to penetration.

Transcutaneous oxygen pressure is a method that measures 
changes in oxygen pressure at the skin surface that are mainly 
determined by changes in skin blood flow. During skin surface 
measurement,  significantly  higher  values  of  transcutaneous 
oxygen pressure were noted in women (50,51). The difference 
might be explained by the thinner epidermis of women. Age-
related sex differences were noted in measuring transcutane-
ous oxygen pressure during postocclusive reactive hyperemia. 
Greater values were found in adult women than in men, but no 
differences were found between boys and girls (52).

The  contribution  of  endothelin-B  receptors  to  resting 
cutaneous  vascular  tone  differs  between  men  and  women. 
In  men,  endothelin-B  receptors  mediate  vasoconstriction, 
whereas  in  women,  endothelin-B  receptors  mediate  vasodi-
lation.  Blockade  of  endothelin-B  receptors  by  a  competitive 
antagonist (BQ-788) in men caused skin vasodilation consistent 

with removal of a tonic vasoconstrictor effect of endothelin-B. 
In women, it caused a vasoconstriction, demonstrating release 
of tonic vasodilator activity (53).

SENSORY FUNCTIONS (TABLE 1.7)
Thermoregulatory Response
Studies of human thermoregulation were conducted by expos-
ing subjects to various thermal environments. The importance 
of  taking  into  account  all  the  possible  variables  is  demon-
strated in studies of the physiological responses to heat stress 
(54):  data  showed  differences  between  women  and  men.  But 
when taking into consideration the differences in the percent-
age of fat in the body and the ratio between the body surface 
and mass, the effect of gender disappeared.

In contrast to these results of heat stress, the response of 
Japanese  young  subjects  to  cold  stress  differed  with  gender, 
although  body  surface  area-to-mass  ratios  were  similar  (55). 
Subjects were exposed to cold (12°C) for 1 hour at rest in sum-
mer  and  in  winter.  In  winter,  women’s  tolerance  to  cold  was 
superior to men’s, whereas no significant differences between 
the sexes were found in the summer. The differences in cold 
tolerance may be caused by differences in the distribution of 
fat over the body, even though body surface area-to-mass ratios 
were similar in the two sexes.

The  thermal  sensitivity  distribution  (topographical 
mapping)  over  the  glabrous  skin  of  the  hand  in  men  and  in 
women was assessed by measuring warm and cold thresholds 
in 25 healthy volunteers (12 women, 13 men), applying a multi-
site test of 23 locations on the volar part of the hand. The palm 

 
45

44

42

46

47

48

4

53

Table 1.6  Cutaneous microcirculation

Ref.

Finding

Obtained by

Subjects

Conclusions

SKIN PHYSIOLOGY AND GENDER 

  9

(a1) Significant differences
43

Reduction in basal skin blood flow in 

Reduction in basal skin blood flow in 

Bioengineering 

26 women; 23 men; 

women

Reduction in facial basal skin blood flow 

in women

women

Skin circulation varied during menstrual 
cycle: Basal flow lowest in the luteal 
phase, highest in the pre-ovulatory 
phase

Greatest cold-induced constriction and 
lowest recovery in the luteal phase
Reactive hyperemia response lower in 
young women as compared to both 
women over 50 y or young men

Response to cooling prolonged in young 
women compared with the other two 
groups

Vasodilatation induced by local heating 
occurs at a lower skin temperature in 
women

Response to nitroprusside higher in 

women before menopause than after

Bioengineering 
measurement

Laser Doppler

56 women; 44 men; 

20–59 y

5 women; 5 men; 

25–52 y

measurement; cooling 
and warming to 
change sympathetic 
tone

23–38 y

Bioengineering 

31 women; 15–45 y

measurements at 4 
times during the 
menstrual cycle

Sympathetic tone is 
Increased, not a 
structural or functional 
difference in the 
cutaneous circulation
Skin blood flow and its 

response to cold varies 
during the menstrual 
cycle

Bioengineering 

measurement; 
postocclusive reactive 
hyperemia and direct 
and indirect cooling

12 women, 19–39 y
13 women, 51–67 y
13 men, 22–47 y

Hormonal factors might 

explain the differences 
Different dressing habits 
may also contribute

Bioengineering 
measurement

9 women; 6 men; 

age not specified

Laser Doppler perfusion 
imager; iontophoresis

21 women; 13 men; 

18–80 y

Indicating functional and 
structural changes in 
skin vasculature of 
women with aging

Histamine produced bigger wheals in 

Histamine administered 

33 women; 38 men; 

Differences in the stratum 

by iontophoresis

15–52 y

corneum layer

women

Endothelin-B receptors mediate 
vasoconstriction in men and 
vasodilatation in women

Laser Doppler, 
microdialysis

(a2) Significant differences: Transcutaneous oxygen pressure
50

Significantly higher values of 

Bioengineering; anterior 

Resting tone is different in 

women and men

11 women; 11 men; 
33± 3 women; 
30± 3 men

18 women; 42 men; 

transcutaneous oxygen pressure in 
women

Significantly higher values of 

transcutaneous oxygen pressure in 
women

chest, forearm

22–88 y

Bioengineering; 23 sites 
on face, extremities, 
and trunk

7 women; 12 men; 

21–63 y

Transcutaneous oxygen pressure during 

Bioengineering 

Adults: 

51

52

postocclusive reactive hyperemia 
greater in adult women than in men, but 
did not differ between boys and girls

(b) No significant differences
49

No difference in cutaneous blood flow 

response to histamine

43

No difference in postocclusive reactive 
hyperemia and maximum skin blood 
flow following heating

measurement; 
forearm; 
postocclusive reactive 
hyperemia, 35–37°C

30 women; 37 
men;
22–60 y

Children before 
puberty: 34

Topical and intradermal 

10 women; 10 men; 

administration; 
bioengineering 
methods

Bioengineering 

methods

24–34 y

56 women; 44 men; 

20–59 y

Might be explained by 
women’s thinner 
epidermis

Hormonal influence is 

indicated

area was more sensitive than the fingers to both warm and cold 
stimuli. On the palm itself, the proximal part was the most sen-
sitive. Women were more sensitive than men to both warm and 
cold sensations (56).

Cold-induced vasomotor response was measured by laser 
Doppler flowmetry in 12 healthy men and 12 healthy women. 
Both direct response (at the site of cooling) and indirect response 
(at a site remote from the cooling site) were measured (57). The 

women were tested twice, once in the follicular and once in the 
luteal phase of the menstrual cycle. Blood flow was measured 
before and during local cooling of one hand at 15° C. Local cool-
ing evoked a significantly greater decrease in cutaneous blood 
flow  in  women  than  in  men  in  direct  as  well  as  in  indirect 
response conditions. Direct response to local cooling was signif-
icantly greater in the luteal phase than in the follicular phase. In 
contrast, there was no menstrual-cycle–dependent difference in 

 
10 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 1.7  Sensory function

Ref.

Finding

Obtained by

Subjects

Conclusions

(a) Significant differences
61

Women more sensitive to small 
temperature changes and to 
pain caused by either heat or 
cold

Marstock 

67 women; 83 men; 

method–quantitative

10–73 y

Lower threshold values in 
women than in men

Pricking pain sensation 
to heat; threshold 
determination, volar 
forearm

93 women; 165 men; 

18–28 y

132 women; 135 men; 

50–90 y

Women more sensitive than 

Pressure threshold 

68 women; 68 men; 

62

63

64

men: Palm and sole, but not 
on the forearm

Neonate girls: Significantly 
higher conductance than 
boys

measurement; palm, 
sole, forearm
Skin conductance 

17–30 y

20 women; 20 men; 

These differences may represent 

(autonomic function)

neonates: 60–110 h

differences in maturation

55

Women’s tolerance to cold 

Exposed to cold (12°C) 

7 women; 8 men; 

superior to men’s in winter

for 1 h at rest in 
summer and in 
winter; skin and 
body temperature

Japanese; 18–26 y

Very young: No effect yet of training 
and different behavior accorded 
the sexes

Differences in fat distribution over 
the body, even though body 
surface area-to-mass ratios were 
similar in the two sexes, might 
have contributed to the 
differences in cold tolerance

Possible explanation: Difference in 
vascular autonomic sensitivity to 
music

60 women; 60 men; 
young students

15 women; 15 men; 

Possible hemispheric differences in 

19–27 y; right-handed

response to auditory stimuli

Awake human subjects

59

Greater decrease in women in 

Auditory stimulation, 

finger temperature as a 
response to musical stimulus

60

Men: More asymmetry between 

hands, larger skin 
conductance responses on 
the left hand

Women: Less asymmetry, 
larger skin conductance 
responses on right hand

65

Acute muscle or skin pain: Skin 

blood flow increased in 
women, whereas in men it 
decreased

music; skin 
temperature, index 
finger

Auditory stimulus 
Magnitude and 
frequency of skin 
conductance 
responses

Skin sympathetic 
nerve activity 
Hypertonic saline 
injected into tibialis 
anterior muscle or 
into skin

Skin blood flow 

measurements

(b) No significant differences
54

Physiological responses to 

Heat stress; 

12 women; 12 men; 

Differences between women and 

heat stress differ with gender, 
but depend on fat content 
and body surface area

ergometer; oxygen 
uptake; body and 
skin temperature; 
sweat rate

20–28 y

men disappeared when 
differences in the percentage of 
fat in the body and the ratio 
between body surface and mass 
were taken into account

the indirect response to cold. Thus, sympathetic neural reactiv-
ity, as assessed by way of an indirect response to a cold stimulus, 
significantly contributes to gender differences in the response to 
local cooling. In contrast, the variation in microvascular respon-
siveness  to  cold  exposure  due  to  the  menstrual  cycle  is  most 
probably caused by local vascular mechanisms rather than by 
variation in sympathetic neural reactivity to local cooling.

Sex-related  differences  in  thermoregulatory  responses 
while  wearing  protective  clothing  were  found  (58).  Women 
were at a thermoregulatory disadvantage compared with men 
when wearing protective clothing and exercising in a hot envi-
ronment.  This  disadvantage  can  be  attributed  to  the  lower 
specific heat of adipose versus non-adipose tissue and higher 
percentage body fatness.

Thermal Response to Stimulation
The  decrease  in  finger  temperature  as  a  response  to  musical 
stimulus was greater in women (59). This may be due to dif-
ferences between men and women in vascular autonomic sen-
sitivity to music, or to differences in sensitivity or density of 
peripheral vascular adrenergic receptors.

Electrodermal  responses:  electrodermal  asymmetry  has 
been  considered  as  an  index  of  hemispheric  specialization. 
A  study  recorded  the  magnitude  and  frequency  of  the  skin 
conductance  responses  when  subjects  listened  to  tones  (60). 
Subjects  were  right-handed  in  order  to  control  the  effects 
of  handedness.  Men  displayed  more  asymmetry  between 
hands,  with  larger  skin  conductance  responses  on  the  left 
hand. In women, asymmetry was less marked, and larger skin 

 
conductance  responses  were  found  on  the  right  hand.  These 
results indicate a possible hemispheric difference in response 
to auditory stimuli.

Thermal and Pain Sensation, 
Pressure Sensitivity
Sensation in the skin can be studied in relation to pain. Pain 
can be induced mechanically, electrically, by chemical stimulus 
or by thermal stimulus. Pain sensation is best determined by 
the threshold at which pain begins, and the stimulus required 
to produce it can be quantified. Thermal and pain sensations 
are  mediated  by  cutaneous  receptors  and  travel  through 
myelinated  (Aδ)  and  unmyelinated  (C)  nerve  fibers.  Women 
were more sensitive to small temperature changes and to pain 
caused  by  either  heat  or  cold  (61).  Another  study  measured 
the threshold of the pricking sensation provoked by heat pro-
jected to the skin from a lamp (62). The pricking pain threshold 
increased with age in both sexes. In addition, the threshold of 
women was lower at all ages in the range 18–90 years. Possible 
explanations to the difference between the sexes are:

•  Anatomical differences in skin thickness
•  Differences  in  blood  flow  and  blood  vessels  that  absorb 

part of the heat transmitted to the skin
•  Differences in nervous structure or function

Unlike the forearm lower pricking pain sensation threshold in 
women, pressure threshold was lower in wteomen than men 
on the palm and on the sole, but not on the forearm (63).

Autonomic Function
Skin  conductance  measures  one  aspect  of  the  autonomic 
function.  Neonate  girls  manifested  a  significantly  higher 
conductance  than  boys  (64).  These  differences  may  represent 
differences in maturation.

Both acute muscle and skin pain evoked a measurable 
sympathetic  activity  in  human  subjects  who  were  awake. 
Sweat  release  was  increased  to  the  same  level  in  men  and 
in  women,  but  dissimilar  changes  in  skin  blood  flow  were 
recorded:  skin  blood  flow  increased  in  women,  whereas  in 
men it decreased (65).

SKIN COLOR (TABLE 1.8)
An  article  by  Tegner  (66)  gives  several  examples  of  artists 
depicting their female models as lighter skinned than males. 
Such  differences  were  indeed  found  utilizing  spectrophoto-
metric measurements, in various ethnic populations. A lighter 
skin  in  women  was  demonstrated  in  studies  from  Iran  (67), 
India  (68),  and  Australia  (69).  In  addition  to  hormonal  influ-
ences, differences in melanin, hemoglobin, and carotene might 
be involved, as well as differences in sun exposure. Skin reflec-
tance spectroscopy was measured in 10 anatomical sites in 20 
healthy  Caucasian  babies  (mean  age  5  months,  range  1  to  10 
months).  The  level  of  skin  pigmentation  was  the  same  in  all 
the 10 measured sites and there were no gender differences in 
pigmentation  for  any  site  (70).  In  general,  both  sexes  darken 
as  age  increases  (69).  But  the  changes  are  more  intricate  (68): 
from the end of infancy to the onset of puberty there is a pro-
gressive  skin  darkening  in  both  sexes.  During  adolescence 
they both lighten, but women lighten more. Simple hormonal 
effects cannot explain this difference, since both testosterone 
and  estrogen  provoke  darkening  rather  than  lightening  of 
the  skin.  These  changes  might  be  partly  attributed  to  differ-
ences in exposure to sunlight, since UV irradiation increases 

SKIN PHYSIOLOGY AND GENDER 

  11

the  number  of  melanocytes  in  both  exposed  and  unexposed 
skin. Another study assessed skin color in adolescents (71). The 
forehead (sun-exposed) pigmentation of boys was darker than 
that of girls. But the medial upper arm (less sun exposure) pig-
mentation  varied  among  the  different  phases  of  adolescence: 
girls were darker than boys during early adolescence, during 
middle  adolescence  the  pigmentation  was  similar  in  the  two 
sexes,  and  during  late  adolescence  girls  were  significantly 
lighter than boys.

The lighter skin color of women was attributed to differ-
ences in melanin, hemoglobin (variations in vascularity) and 
carotene  (72).  Natural  selection  might  give  an  explanation  of 
the overall visual effect of lighter skin. In addition, women are 
more homogenous in color than men, since regional variations 
in reflectance spectrophotomery were smaller in women than 
in men (72). Colorimetric measurements revealed a darker and 
redder skin in elderly men (65–88 years) compared with elderly 
women, but such differences were not found in young subjects 
(18–26 years) (73). Another study of 461 women and 346 men 
aged 20–69 years found that both sexes darken with age (69). 
Yet  another  study  did  not  find  differences  between  men  and 
women in epidermal melanocyte counts (74).

HORMONAL INFLUENCE (TABLE 1.9)
Any of the above differences between women and men might 
be  related  to  hormonal  effects.  Some  evidence  for  hormonal 
influence on the skin has already been mentioned above, like 
the increase of skin thickness following conjugated estrogens 
treatment of postmenopausal women (9), or the positive effect 
of  estrogens  on  stratum  corneum  hydration  and  wrinkles  of 
the face of perimenopausal women (21), or the changes during 
the menstrual cycle demonstrated by measuring baseline tran-
sepidermal water loss (41) and skin blood flow (42). Hormone 
replacement  therapy  for  menopause  had  an  effect  on  skin 
extensibility (75): in untreated women a steep increase in skin 
extensibility was evidenced during the menopause. Hormone 
replacement treatment limited this age-related increase in skin 
extensibility, thus having a preventive effect on skin slackness. 
Other  parameters  of  skin  viscoelasticity  were  not  affected. 
After  menopause  the  skin  becomes  thinner,  associated  with 
loss in skin collagen content. Collagen content increased with 
hormone  replacement  therapy  by  48%  compared  with  non-
treated subjects (76). Moreover, the ratio of type III to type I col-
lagen in the skin is reduced with age. Postmenopausal women 
receiving hormone replacement therapy showed an increased 
proportion of type III collagen in the skin (77). In the future, 
further hormonal manipulation might change the skin of both 
men and women in ways we cannot yet predict.

PILOSEBACEOUS UNIT (TABLE 1.10)
The sebaceous glands are hormone-dependent. The increase in 
their activity during puberty can be stimulated by the admin-
istration  of  the  appropriate  hormone.  Androgenic  steroids, 
of either gonadal or adrenal origin, have a direct stimulatory 
effect on sebaceous gland activity. Most of the hormones (TSH, 
ACTH, FSH, LH) act indirectly by stimulating their respective 
endocrine  tissues.  In  other  cases  the  hormones  (for  instance 
GH)  act  synergistically  with  another  hormone  to  which  the 
sebaceous gland is sensitive. Average values for sebum secre-
tion were significantly higher in men than in women for age 
ranges 20 to over 69, but not for 15–19 years (78). This differ-
ence in sebaceous gland activity becomes more apparent in the 

 
12 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 1.8  Skin color

Ref.

Finding

(a) Significant differences
19

Women’s skin lighter

Obtained by

Subjects

Conclusions

Spectrophotometry

Review article

Not a simple hormonal effect
Differences in melanin, 

hemoglobin and carotene

67

68

71

69

73

Women’s skin lighter

Spectrophotometry

33 women; 68 men; 

Differential tanning; 

Women’s skin lighter

Spectrophotometry; 
upper inner arm

Forehead: Boys darker than girls.
Medial upper arm: Girls darker than 

boys during early adolescence, not 
different from boys during middle 
adolescence, and during late 
adolescence girls lighter than boys

Women’s skin lighter
Both sexes darken with age

In the elderly: Skin of men darker and 
redder compared with women, but 
not in the young

Skin color, measured by 

reflectance of 
forehead and medial 
upper arm, in 
adolescents

Spectrophotometry; 
inner upper arms, 
lateral forearms, back 
of hands

Colorimetric 

measurements of 
forehead (sun-
exposed) and forearm 
(protected)

8–24 y

vascularity variations

566 women; 578 men; 

During puberty, males darken, 

1–50 y

105 women, 10–16 y; 
105 men, 12–18 y

females lighten

Different levels of MSH 

Hereditary and 
environmental factors

Physiologic changes during 
adolescence may cause 
these sex differences

461 women; 346 men; 

Different levels of MSH 

Difference in sun exposure 
(tanning and thickening of 
skin)

20–69 y

8 women, 5 men; 

65–88 y

9 women, 4 men; 

18–26 y

(b) No significant differences
74

No difference between men and 

5 mm paraffin 

38 skin samples of men 

women in epidermal melanocytes 
counts

embedded sections

73

In Caucasian babies: Pigmentation 

Colorimetric 

same for men and women

measurements of 10 
sites

and women of 
different ages
DOPA reagent.
10 women, 10 men; 

1–10 mo

Table 1.9  Hormonal influence

Ref.

Finding

Obtained by

Subjects

Conclusions

Significant differences
75

Hormone replacement treatment 

limited the age-related increase in 
skin extensibility

Other parameters of skin 

viscoelasticity were not affected

Computerized suction 
device measuring 
skin deformability and 
viscoelasticity; inner 
forearm

76

Collagen content increased by 48% 

with hormone replacement 
therapy compared with nontreated 
subjects

77

Increased proportion of type III 

collagen in the skin of 
postmenopausal women receiving 
hormone replacement therapy

Hydroxyproline and 
collagen content; 
biopsies of right thigh 
below the greater 
trochanter

Analysis of collagen 
types; biopsies of 
lateral thigh

Women: 43 nonmenopausal 

Hormone replacement 

(19–50 y)

25 menopausal not treated 

(46–76 y)

46 on hormone replacement 
therapy since onset of 
menopause (38–73 y)
Postmenopausal women 

(35–62 y)

29 untreated; 26 estradiol+ 

testosterone

Postmenopausal women 

(41–66 y)

14 untreated; 11 estradiol + 

testosterone

therapy has a 
preventive effect on 
skin slackness

Estrogen or testosterone, 
or both, prevent the 
decrease in skin 
collagen content that 
occurs with aging

The clinical improvement 
in the skin following 
hormone replacement 
therapy is due not only 
to increase in total 
collagen but also to 
changes in the ratio of 
type III to type I

 
Table 1.10  Pilosebaceous unit

Ref.

Finding

Obtained by

Subjects

Conclusions

SKIN PHYSIOLOGY AND GENDER 

  13

Significant differences
79

During January women’s hair was 
denser and the percentage of 
telogen hair lower compared with 
men

78

78

Higher sebum secretion in men than 
in women for age ranges 20 to 
over 69, but not for the 15–19 age 
range

In the 50–70 age range the 
secretion in men remains 
unaltered, whereas in women 
there is a significant decrease in 
sebum output, probably as a result 
of decreased ovarian activity
No correlation between sebum 

production and plasma 
testosterone

Phototrichogram; hair 
count after washing

7 women, 29–49 y; 
7 men, 25–47 y

Sebum production

330 women; 458 men; 
15 y to over 69 y

Sebum production and 
plasma androgen 
levels

8 women; 28 men

50–70 age range, when the secretion in men remains unaltered 
whereas in women there is a significant decrease in sebum out-
put, probably a result of decreased ovarian activity.

Beginning  in  young  adulthood  there  is  an  age-related 
decline in wax ester secretion—thus hormones also affect the 
composition of sebum.

The distribution of hair over the body differs between 
men and women. The hair follicles possess individual mech-
anisms controlling the evolution and triggering of successive 
phases, but systemic factors like hormones and external fac-
tors  also  play  a  significant  part.  The  season  of  the  year  has 
an effect on hair growth and hair shedding. From data given 
in a study concerning this seasonal effect (79), we calculated 
sex differences, which were not discussed in the study. The 
data  referred  to  the  month  of  January.  Women’s  hair  was 
denser  and  the  percentage  of  telogen  hair  lower  compared 
with men.

The diversity of male and female hair patterns is deter-
mined  by  a  difference  in  the  transformation  of  vellus  to  ter-
minal  hair,  stimulated  by  androgens,  but  also  by  racial  and 
genetic factors. In Koreans, women had a significantly higher 
number of terminal hairs than men (80).

The effect of androgens on hair growth varies according 
to body site, and may be opposite, like transforming vellus hair 
on the face to terminal beard hair at puberty and the reverse on 
the scalp. The face, scalp, beard, axilla, and pubic hair follicles 
are targets for androgens. Androgen affects different cells in 
the dermal papilla, which is also affected by melanocyte-stim-
ulating  hormone  (MSH),  prolactin,  thyroid  hormones,  preg-
nancy,  and  nutritional  state  (81).  In  addition  to  higher  serum 
levels  of  testosterone,  female  facial  hirsutism  correlated  with 
obesity and age (82).

Despite  exposure  to  the  same  circulatory  hormones, 
the activity of hair follicles depends on the body site, varying 
from no effect on the eyelashes to stimulation in many other 
areas. High levels of testosterone inhibit the hair papilla cells 
and outer root sheath keratinocytes and have a lesser effect on 
fibroblasts  and  interfollicular  keratinocytes,  while  low  levels 
of  testosterone  have  no  effect.  The  opposite  was  found  with 
estrogen and cyproterone (83).

The effect of estrogens (17-beta-estradiol, E2) on estrogen 
receptor (ER) expression and gene regulation of human scalp 

hair follicles was studied in vitro. The distribution pattern of 
ERbeta  and  TGF-beta2-immunoreactivity  differed  between 
male and female hair follicles after 48 h culture. Of 1300 genes 
tested,  several  genes  were  regulated  differently  as  relates  to 
gender.  Thus,  substantial  sex-dependent  differences  were 
found in the response of frontotemporal human scalp hair fol-
licles to E2 (84).

CONCLUSIONS
Maintaining skin health is an intricate orchestration of many 
variables.  The  need  for  hard  data  is  paramount,  not  only  for 
gaining knowledge about the anatomy and biology of human 
skin,  but  also  for  the  assessment  of  pathophysiological  pro-
cesses and for clinical management of skin diseases. New and 
improved instrumentation will allow for more studies, leading 
to a detailed description of physiological differences between 
men and women.

We hope that this chapter will trigger further investiga-

tions of the subject.

REFERENCES

1. Dao H Jr, Kazin RA. Gender differences in skin: A review of the 

literature. Gender Medicine 2007; 308–28

2. Giacomoni PU, Mammone T, Teri M, Gender-linked differences 

in human skin. J Dermatol Sci 2009; 55(3):144–9.

3. Greven  H,  Zanger  K,  Schwinger  G,  Mechanical  properties  of 
the  skin  of  Xenopus  laevis  (Anura,  Amphibia).  J  Morphol  1995; 
224: 15–22.

4. Magerl  W,  Westerman  RA,  Mohner  B,  Handwerker  HO. 
Properties of transdermal histamine iontophoresis: Differential 
effects  of  season,  gender,  and  body  region.  J  Invest  Dermatol 
1990; 94:347–52.

5.  Seidenari S, Pagnoni A, Di Nardo A, Giannetti A. Echographic 
evaluation  with  image  analysis  of  normal  skin:  Variations 
according to age and sex. Skin Pharmacol 1994; 7:201–9.

6.  Krackowizer  P,  Brenner  E.  Thickness  of  the  human  skin:  24 

points of measurement. Phleb 2008; 37:83–92

7.  Hattori  K,  Okamoto  W.  Skinfold  compressibility  in  Japanese 
university students. Okajimas Folia Anat Jpn 1993; 70:69–78.
8.  Escoffier C, de Rigal J, Rochefort A, et al. Age-related mechani-
cal properties of human skin: An in vivo study. J Invest Dermatol 
1989; 93:353–7.

 
 
 
 
 
14 

 TEXTBOOK OF COSMETIC DERMATOLOGY

9.  Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, 
placebo-controlled study on the effect of conjugated estrogens 
on skin thickness. Am J Obstet Gynecol 1994; 170:642–9.

  32.  Auriol F, Vaillant L, Machet L, et al. Effects of short time hydra-
tion  on  skin  extensibility.  Acta  Derm  Venereol  (Stockh)  1993; 
73:344–7.

  10.  Gambichler  T,  Matip  R,  Moussa  G,  et  al.  In  vivo  data  of  epi-
dermal thickness evaluated by optical coherence tomography: 
Effects of age, gender, skin type, and anatomic site. J Dermatol 
Sci 2006; 44:145–52.

  11.  Shuster S, Black MM, McVitie E. The influence of age and sex 
on skin thickness, skin collagen and density. Br J Dermatol 1975; 
93:639–43.

  12.  Leveque JL, Corcuff P, de Rigal J, Agache P. In vivo studies of 
the evolution of physical properties of the human skin with age. 
Int J Dermatol 1984; 18:322–9.

  13.  Davies  BN,  Greenwood  EJ,  Jones  SR.  Gender  differences  in 
the relationship of performance in the handgrip and standing 
long jump tests to lean limb volume in young adults. Eur J Appl 
Physiol 1988; 58:315–20.

  14.  Tilahun  M,  Atnafu  A.  Heel  pad  thickness  of  adult  Ethiopian 
patients in Tikur Anbessa hospital, Addis Abeba. Ethiop Med J 
1994; 32:181–7.

  15.  Malyarenko TN, Antonyuk SD, Malyarenko Yu E. Changes in 
the  human  fat  mass  at  the  age  of  6–18  years.  Arkh  Anat  Gistol 
Embriol 1988; 94:43–7.

  16.  Arner P, Lithell H, Wahrenberg H, Bronnegard M. Expression 
of lipoprotein lipase in different human subcutaneous adipose 
tissue regions. J Lipid Res 1991; 32:423–9.

  17.  Denda  M,  Koyama  J,  Hori  J,  et  al.  Age  and  sex-dependent 
change  in  stratum  corneum  sphingolipids.  Arch  Dermatol  Res 
1993; 285:415–17.

  18.  Komatsu  N,  Saijoh  K,  Sidiropoulos  M,  et  al.  Quantification  of 
human tissue kallikreins in the stratum corneum: Dependence 
on age and gender. J Invest Dermatol 2005; 125:1182–89.

  19.  Sturado A, Parvoli G, Doretti L, et al. The influence of color, age 
and sex on the content of zinc, copper, nickel, manganese, and 
lead in human hair. Biol Trace Elem Res 1994; 40:1–8.

  20.  Jemec  GBE,  Serup  J.  Scaling,  dry  skin  and  gender.  Acta  Derm 

Venereol (Stockh) 1992; 177(Suppl):26–8.

  21.  Schmidt  JB,  Binder  M,  Macheiner  W,  et  al.  Treatment  of  skin 
ageing  symptoms  in  perimenopausal  females  with  estrogen 
compounds. A pilot study. Maturitas 1994; 20:25–30.

  22.  Tsukahara K, Hotta M, Osanai O, et al. Gender-dependent dif-
ferences in degree of facial wrinkles. Skin Res and Technol 2013, 
19(1):e65–71

  33.  Hashmi F, Malone-Lee J. Measurement of skin elasticity on the 

foot. Skin Res and Technol 2007; 13:252–8.

  34.  Havenith G, Fogarty A, Bartlett R, et al. Male and female upper 
body sweat distribution during running measured with techni-
cal absorbents. Eur Journal Appl Physiol 2008; 104:245–55
  35.  Gagnon D, Crandall CG, Kenny GP. Sex differences in postsyn-
aptic sweating and cutaneous vasodilation. J App Physiol 2013; 
114(3):394–401.

  36.  Yamamoto A, Serizawa S, Ito M, Sato Y. Fatty acid composition 
of  sebum  wax  esters  and  urinary  androgen  level  in  normal 
human individuals. J Dermatol Sci 1990; 1:269–76.

  37.  Boehnlein J, Sakr A, Lichtin JL, Bronaugh RL. Characterization 
of  esterase  and  alcohol  dehydrogenase  activity  in  skin. 
Metabolism  of  retinyl  palmitate  to  retinol  (vitamin  A)  during 
percutaneous absorption. Pharm Res 1994; 11:1155–9.

  38.  Wilhelm  KP,  Maibach  HI.  Factors  predisposing  to  cutaneous 

irritation. Dermatol Clin 1990; 8:17–22.

  39.  Bjornberg  A.  Skin  reactions  to  primary  irritants.  Acta  Derm 

Venereol (Stockh) 1975; 55:191–4.

  40.  Lammintausta K, Maibach HI, Wilson D. Irritant reactivity in 

males and females. Contact Dermatitis 1987; 17:276–80.

  41.  Harvell J, Hussona-Safed I, Maibach HI. Changes in transepi-
dermal water loss and cutaneous blood flow during the men-
strual cycle. Contact Dermatitis 1992; 27:294–301.

  42.  Bartelink  ML,  Wollersheim  A,  Theeuwes  A,  et  al.  Changes  in 
skin  blood  flow  during  the  menstrual  cycle:  The  influence  of 
the  menstrual  cycle  on  the  peripheral  circulation  in  healthy 
female volunteers. Clin Sci 1990; 78:527–32.

  43.  Maurel A, Hamon P, Macquin-Mavier I, Lagrue G. Flux micro-
circulatoire  cutané  étude  par  laser–doppler.  Presse  Med  1991; 
20:1205–9.

  44.  Cooke  JP,  Creager  MA,  Osmundson  PJ,  Shepherd  JT,  Sex  dif-
ferences  in  control  of  cutaneous  blood  flow.  Circulation  1990; 
82:1607–15.

  45.  Mayrovitz  HN,  Regan  MB.  Gender  differences  in  facial  skin 
blood perfusion during basal and heated conditions determined 
by laser Doppler flowmetry. Microvasc Res 1993; 45:211–18.
  46.  Bollinger A, Schlumpf M. Finger blood flow in healthy subjects 
of different age and sex and in patients with primary Raynaud’s 
disease. Acta Chir Scand 1975; 465(Suppl):42–7.

  23.  Ezure T, Yagi E, Kunizawa N, et al. Comparison of sagging at 
the cheek and lower eyelid between male and female faces. Skin 
Res and Technol 2011; 17(4):510–5.

  47.  Walmsley D, Goodfield MJD. Evidence for an abnormal periph-
erally mediated vascular response to temperature in Raynaud’s 
phenomenon. Br J Rheumatol 1990; 29:181–4.

  24.  Gerhardt LC, Strassle V, Lenz A, et al. Influence of epidermal 
hydration on the friction of human skin against textiles. J Royal 
Soc Interface 2008; 5:1317–28.

  25.  Cua  AB,  Wilhelm  KP,  Maibach  HI.  Frictional  properties  of 
human  skin:  Relation  to  age,  sex  and  anatomical  region, 
stratum  corneum  hydration  and  transepidermal  water  loss. 
Br J Dermatol 1990; 123:473–9.

  26.  Yosipovitch G, Reis J, Tur E, et al. Sweat secretion, stratum cor-
neum hydration, small nerve function and pruritus in patients 
with advanced chronic renal failure. Br J Dermatol 1995; 133:561–4.
  27.  Li W, Qu S, Zhou Z. Frictional properties of human skin at dif-
ferent ages, gender and anatomical regions. J Biomel Eng 2007; 
24:824–8.

  28.  Goh CL, Chia SE. Skin irritability to sodium lauryl sulphate – as 
measured by skin water vapor loss – by sex and race. Clin Exp 
Dermatol 1988; 13:16–19.

  29.  Chernova TA, Melikyants IG, Mordovtsev VN, et al. Mechanical 
properties  of  the  skin  in  normal  subjects.  Vestn  Dermatol 
Venereol 1984; 2:12–15.

  30.  Kiistala  U.  Dermal–epidermal  separation.  Ann  Clin  Res  1972; 

4:10–22.

  31.  Pedersen L, Hansen B, Jemec GB. Mechanical properties of the 
skin: A comparison between two suction cup methods. Skin Res 
Technol 2003; 2:111–5.

  48.  Algotsson A, Nordberg A, Winblad B. Influence of age and gen-
der  on  skin  vessel  reactivity  to  endothelium-dependent  and 
endothelium-independent  vasodilators  tested  with  iontopho-
resis and a laser Doppler perfusion imager. J Gerontol Med Sci 
1995; 50:121–7.

  49.  Tur E, Aviram G, Zeltser D, et al. Histamine effect on human 
cutaneous blood flow: Regional variations. Acta Derm Venereol 
(Stockh) 1994; 74:113–16.

  50.  Glenski  JA,  Cucchiara  RF.  Transcutaneous  O2  and  CO2  moni-
toring  of  neurosurgical  patients:  Detection  of  air  embolism. 
Anesthesiology 1986; 64:546–50.

  51.  Orenstein  A,  Mazkereth  R,  Tsur  H.  Mapping  of  the  human 
body skin with transcutaneous oxygen pressure method. Ann 
Plast Surg 1988; 20:419–25.

  52.  Ewald  U.  Evaluation  of  the  transcutaneous  oxygen  method 
used  at  37°C  for  measurement  of  reactive  hyperaemia  in  the 
skin. Clin Physiol 1984; 4:413–23.

  53.  Kellogg  DL  Jr,  Liu  Y,  Pergola  PE.  Gender  differences  in  the 
endothelin-B receptor contribution to basal cutaneous vascular 
tone in humans. J Appl Physiol 2001; 91:2407–11.

  54.  Havenith G, van Middendorp H. The relative influence of phys-
ical fitness, acclimatization state, anthropometric measures and 
gender on individual reactions to heat stress. Eur J Appl Physiol 
1990; 61:419–27.

 
 
SKIN PHYSIOLOGY AND GENDER 

  15

  55.  Sato  H,  Yamasaki  K,  Yasukouchi  A,  et  al.  Sex  differences  in 
human thermoregulatory response to cold. J Human Ergol 1988; 
17:57–65.

  72.  Frost P. Human skin color: A possible relationship between its 
sexual dimorphism and its social perception. Perspect Biol Med 
1988; 32:38–58.

  56.  Li  X,  Petrini  L,  Defrin  R,  et  al.  High  resolution  topographical 
mapping of warm and cold sensitivities. Clin Neurophysiol 2008; 
119:2641–6.

  57.  Cankar K, Finderle Z, Strucl M. Gender differences in cutane-
ous laser Doppler flow response to local direct and contralat-
eral cooling. Vasc Res 2000; 37:183–8.

  58.  McLellan  TM.  Sex-related  differences  in  thermoregulatory 
responses while wearing protective clothing. Eur J Appl Physiol 
Occup Physiol 1998; 78:28–37.

  59.  McFarland RA, Kadish R. Sex differences in finger temperature 

response to music. Int J Psychophysiol 1991; 11:295–8.

  60.  Martinez-Selva JM, Roman F, Garcia-Sanchez FA, Gomez-Amor 
J. Sex differences and the asymmetry of specific and non-spe-
cific electrodermal responses. Int J Psychophysiol 1987; 5:155–60.
  61.  Meh  D,  Denislic  M.  Quantitative  assessment  of  thermal  and 

pain sensitivity. J Neurol Sci 1994; 127:164–9.

  62.  Procacci P, Bozza G, Buzzelli G, Della Corte M. The cutaneous 

pricking pain threshold in old age. Geront Clin 1970; 12:213–8.

  63.  Weinstein S, Sersen E. Tactual sensitivity as a function of hand-
edness and laterality. J Comp Physiol Psychol 1961; 54:665–9.
  64.  Weller G, Bell RQ. Basal skin conductance and neonatal state. 

Child Dev 1965; 36:647–57.

  65.  Burton  AR,  Birznieks  I,  Spaak  J,  et  al.  In  vivo  data  of  epider-
mal  thickness  induced  acute  pain  on  skin  sympathetic  nerve 
activity  in  human  subjects.  Experimental  Brain  Research  2009; 
195:317–24

  66.  Tegner  E.  Sex  differences  in  skin  pigmentation  illustrated  in 

art. Am J Dermatopathol 1992; 14:283–7.

  67.  Mehrai H, Sunderland E. Skin colour data from Nowshahr City, 

Northern Iran. Ann Hum Biol 1990; 17:115–20.

  68.  Banerjee  S.  Pigmentary  fluctuation  and  hormonal  changes. 

J Genet Hum 1984; 32:345–9.

  69.  Green  A,  Martin  NG.  Measurement  and  perception  of  skin 

colour in a skin cancer survey. Br J Dermatol 1990; 123:77–84.

  70.  Lock-Andersen  J,  Wulf  HC,  Knudstorp  ND.  Skin  pigmen-
tation  in  caucasian  babies  is  high  and  evenly  distributed 
throughout  the  body.  Photodermatol  Photoimmunol  Photomed. 
1998; 14:74–6.

  71.  Kalla AK, Tiwari SC. Sex differences in skin color in man. Acta 

Genet Med Gemellol 1970; 19:472–6.

  73.  Kelly RI, Pearse R, Bull RH, et al. The effects of aging on the cuta-

neous microvasculature. J Am Acad Dermatol 1995; 33:749–56.

  74.  Muhammad  MI,  Janjua  MZ.  Microscopic  analysis  of  epider-
mal melanocytes in human abdominal skin. J College Physicians 
Surgeons Pakistan 2003; 13:79–81.

  75.  Pierard  GE,  Letawe  C,  Dowlati  A,  Pierard-Franchimont  C. 
Effect  of  hormone  replacement  therapy  for  menopase  on  the 
mechanical properties of skin. J Am Geriatr Soc 1995; 43:662–5.

  76.  Brincat M, Moniz CF, Studd JWW, et al. Sex hormones and skin 
collagen  content  in  postmenopausal  women.  Br  Med  J  1983; 
287:1337–8.

  77.  Savvas M, Bishop J, Laurent G, et al. Type III collagen content 
in the skin of postmenopausal women receiving oestradiol and 
testosterone implants. Br J Obstet Gynaecol 1993; 100:154–6.
  78.  Pochi PE, Strauss JS. Endocrinologic control of the development 
and  activity  of  the  human  sebaceous  gland.  J  Invest  Dermatol 
1974; 62:191–201.

  79.  Courtois M, Loussouarn G, Hourseau S, Grollier JF. Periodicity 
in  the  growth  and  shedding  of  hair.  Br  J  Dermatol  1996; 
134:47–54.

  80.  Lee HJ, Ha SJ, Lee JH, et al. Hair counts from scalp biopsy speci-

mens in Asians. JAAD 2002; 46:218–21.

  81.  Randall VA, Thornton MJ, Messenger AG, et al. Hormones and 
hair  growth:  Variations  in  adrogen  receptor  content  of  der-
mal  papilla  cells  cultured  from  human  and  red  deer  (Cervus 
Elaphus) hair follicles. J Invest Dermatol 1993; 101:114S–20S.
  82.  Ruutiainen  K,  Erkkola  R,  Gronroos  MA,  Irjala  K.  Influence  of 
body mass index and age on the grade of hair growth in hirsute 
women of reproductive ages. Fertl Steril 1988; 50:260–5.
  83.  Kiesewetter  F,  Arai  A,  Schell  H.  Sex  hormones  and  antian-
drogens influence in vitro growth of dermal papilla cells and 
outer root sheath keratinocytes of human hair follicles. J Invest 
Dermatol 1993; 101:98S–105S.

  84.  Conrad F, Ohnemus U, Bodo E, et al. Substantial sex-dependent 
differences  in  the  response  of  human  scalp  hair  follicles  to 
estrogen stimulation in vitro advocate gender-tailored manage-
ment of female versus male pattern balding. J Invest Dermatol. 
Symposium Proceedings. 2005; 10:243–6.

 
2

Climatic Influence on Cosmetic Skin Parameters

Mathias Rohr and Andreas Schrader

INTRODUCTION
In addition to good compatibility, which should be a matter 
of  course  for  cosmetic  products,  the  physiologic  effective-
ness,  in  particular  moisture  and  smoothing  effects  on  the 
skin, is the main interest for cosmetic products. Techniques 
such as fast optical in vivo topometry of human skin (FOITS) 
(1,2)  and  corneometry  are  used  to  investigate  their  effec-
tiveness.  A  high  degree  of  standardization  is  required  to 
quantify  the  effects  of  cosmetics  (3,4).  To  obtain  reproduc-
ible and statistically significant results, experimental condi-
tions, such as test panel–controlled climatic conditions and 
a  test  design  including  a  positive  and  a  negative  standard, 
are  the  basic  starting  tools.  Nevertheless,  as  the  following 
discussion will show, it is not only the normal standardiza-
tion procedures, such as acclimatization of volunteers in spe-
cial air-conditioned laboratories, which have to be taken into 
consideration  when  interpreting  objective  and  subjective 
cosmetic parameters, but also the effect of the actual climate 
during the application phase and especially during the days 
of  measurement.  The  influence  of  the  indoor  climate  in  the 
laboratory  as  well  as  the  outdoor  climate  will  be  analyzed. 
What  will  happen  to  the  level  of  skin  moisture  during  the 
preconditioning phase or what will happen at different sea-
sons of the year? Will it be influenced by the level of relative 
room  humidity  and/or  the  actual  climate  conditions?  Will 
the  influence  vary  for  different  kinds  of  products?  Will  the 
influence  on  skin  moisture  and  skin  structure  be  compara-
ble?  Will  the  influence  change  for  different  types  of  volun-
teers? What is the best time for preconditioning? Could the 
regeneration  of  the  stratum  corneum  be  influenced  by  the 
climate?  Will  effects  felt  subjectively  (washing  the  bend  of 
the  elbow)  be  equally  dependent  on  climatic  conditions  as 
objectively rated parameters?

A summary of individual results and averages of thou-
sands of volunteers will be given. Both a positive standard (in 
the sense of increasing moisture and smoothness) and a nega-
tive standard (in the sense of increasing dehydration, rough-
ness  or  side  effects)  are  used  to  present  the  effect  of  climatic 
conditions on skin physiology tests.

MATERIALS AND METHODS
Climatic Data
To  be  able  to  correlate  climate  data  with  skin  physiology 
parameters,  the  relative  humidity  and  outside  temperature 
are  measured  continuously  at  a  station  by  a  computer  (CAN 
system,  Lufft  Company,  Fellbach,  Germany).  Capturing  the 
data by computer ensures that the climate is recorded day and 
night. Let us take climatic changes in Holzminden (longitude 
9.27 east and latitude 51.49 north; Middle Germany) over a year 
as  an  example.  As  Figure  2.1  shows,  temperature  fluctuates 

between  values  of  about  −10  and  25 °C  in  a  year.  Relative 
humidity is about 50% in summer and 90% in winter.

Positive and Negative Standards
Tests have been carried out with the same products repeatedly 
over a period of several years, and these will serve to demon-
strate the effect of climatic conditions on skin physiology. The 
positive standard is a well-accepted former brand product that 
is currently unavailable on the European market. However, we 
have been making it at a constant quality level for years using 
the known formulation. This product, referred to hereafter as 
“standard L” (Table 2.1), is tolerated very well by the skin and 
demonstrates a moisture-retaining and skin-smoothing effect 
that can be easily classified in terms of physiologic effective-
ness. This makes it an ideal standard, because other products 
can be classified as better or worse with respect to their effec-
tiveness. Another aspect of demonstrating the effectiveness of 
products  on  skin  physiology  relates  to  negative  effects  that, 
for  instance,  can  be  induced  by  aggressive  surfactants.  Here, 
too, we have been using the same standard product for years. 
This is sodium dodecyl sulfate (SDS), which is referred to as the 
“negative standard” from now on.

Laser Profilometry
The laser profilometry technique is used to investigate the anti-
wrinkle effect. Skin replicas are taken from the test areas on 
the volar forearms by means of a white pigmented silicone sub-
stance (two components, Optosil, Bayer, Inc., Germany), before 
the first application and 12 hours after the last application. A 
round impression having a diameter of 18 mm is made using 
a label especially designed for this purpose. While the impres-
sions are being made the volunteers are seated on chairs with 
adjustable armrests so that the angle between the upper arm 
and  the  forearm  can  be  adjusted  to  90°.  Fixing  the  forearms 
in this way ensures that no factitious smoothing or roughen-
ing effects, due to stretching of the arms when the impressions 
are taken after application, are evaluated and included in the 
documentation.

An  automated  laser  scanner  with  an  optical  autofo-
cus  sensor  is  used  for  contactless  scanning  of  the  skin  repli-
cas (UBM, optical measuring system Microfocus, UBM RC14, 
Karlsruhe,  Germany)  (5).  The  measuring  range  of  the  laser 
scanner is ±500 mm at a resolution less than 0.01% of the mea-
suring  range.  The  measuring  spot  (focus  of  the  laser  diode) 
has a diameter of about 1 mm. The z resolution is increased to 
±25 mm by an additional shift of the z-axis if necessary. The 
resolution  in  the  x-  and  y-directions  is  identical  to  be  inde-
pendent  of  any  predominant  direction  of  wrinkles.  The  skin 
replica taken from the volar forearm of a volunteer is scanned 
over an area of 8 mm × 8 mm in the x- and y-directions at a 

CLIMATIC INFLUENCE ON COSMETIC SKIN PARAMETERS 

  17

100

)

%

i

(
y
t
i
d
m
u
h
e
v
i
t
a
e
r

l

)

C
º
(
e
r
u
t
a
r
e
p
m
e
T

80

60

40

25

15

5

–5

Aug

Nov

Feb

May

Aug

Figure 2.1  Climatic outdoor conditions at Holzminden, Germany, 
from August 2001 to 2002.

Table 2.1  Declaration of Positive “Standard L” According to the 
International Nomenclature of Cosmetic Ingredients

Ingredients

Water
Liquid paraffin
Caprylic/capric triglyceride
Hydrogenated coco-glycerides
Glycerine
Myristyl alcohol
Isohexadecane
Glyceryl stearate
Cetyl alcohol
Proprietary composition
4-Methylbenzylidene camphor
Tocopheryl acetate
Butyl methoxydibenzoylmethane
Aloe barbadensis
Isopropyl myristate
Methylparaben
Polyaminopropyl biguanide
Bisabolol
Soluble collagen
Simethicone
Sodium hydroxide
Ethylenediaminetetraacetic acid

resolution of 25 points/mm. Thus 40,000 individual measure-
ments  are  available,  permitting  an  exact  three-dimensional 
reconstruction of the skin surface (5,6).

Ra Parameter
The Deutsche Industrie Norm (DIN) parameter Ra represents 
the mean roughness index according to DIN 4768. Ra indicates 
the arithmetic mean of the absolute values of the skin profile’s 
deviations from the center line over the total distance.

If the overall structure of the profile remains unchanged 
(Rz constant) but the fine structure of the profile changes, then 
the Ra parameter will indicate smoothing or roughening by a 
reduced or increased value, respectively (7,8).

Rz Parameter
The  Rz  parameter  represents  a  mean  peak-to-valley  height 
according to DIN 4768/1. If, in the two-dimensional case, a pro-
file line is divided into five equal parts and the Rmax param-
eter is calculated for each part, Rz will be the arithmetic mean 

Ra/DIN 4768/1

Ra

Yi: Absolute value of the profile

Ra = 1/n

n
Σ
i=1

|Yi|

(a)

Rz/DIN 4768/1

Y1

Y2

Y3

Y4

Y5

e

l
i
f
o
r
P

e

l
i
f
o
r
P

Yi: Maximum profile difference (Rmax)

Rz = 1/5

5
Σ
i=1

|Yi|

(b)

Figure  2.2  Definition  of  DIN  parameters  Ra  (a)  and  Rz 
(b) according to DIN 4768/1.

of these five individual values. The Rz parameter will indicate 
roughening  of  the  skin  profile  by  a  significantly  increased 
value  if  the  profile  is  changed  by  the  influence  of  a  product 
(Figure 2.2).

FAST OPTICAL IN VIVO TOPOMETRY 
OF HUMAN SKIN
After a successful validation phase, the new FOITS technology 
was introduced in 1997 (1). In comparison to the replica-driven 
technique  during  the  previous  decade,  the  touch-free  tech-
nique of fringe projection became state-of-the-art to investigate 
skin surface (2,9–11). Because of many technical advancements 
(for example, improved camera resolution, the use of blue LED 
lighting systems, or laser-supported and computer-optimized 
overlaying  procedures),  an  easy-to-operate  system  has  been 
realized recently. As there has always been a great deal of sci-
entific interest on the mechanisms of wrinkle evaluation, the 
technical developments led to a tool of high scientific standard 
(12–15).

FOITS is a touch-free optical technique with a history 
of  more  than  a  decade  of  investigating  skin  surface  struc-
tures  in  a  direct  three-dimensional  measurement  by  fringe 
projection  (16).  The  fringe-projection  technique  used  is  a 
combination  of  gray-code  and  phase-shift  technique  (7).  In 
less  than  a  few  hundred  milliseconds,  the  absolute  space 
coordinates  of  all  object  points  in  the  selected  image  area 
are measured with great precision. The FOITS measurement 
system consists of a projection unit and a CCD camera. Both 
are  fixed  under  the  triangulation  angle.  In  the  gray-code 
method,  grids  with  a  rectangular  brightness  distribution 
by  different  numbers  of  lines  are  projected.  The  number  of 

 
 
 
 
 
18 

 TEXTBOOK OF COSMETIC DERMATOLOGY

lines is doubled at each new projection. This gives a clearly 
defined hierarchy of lines for each image point. In the phase-
shift  technique,  only  one  grid  with  a  sinus-like  intensity 
distribution  is  projected  several  times  with  different  phase 
positions.  The  FOITS  technique  is  able  to  realize  a  depth 
sharpness area of ±10 mm on an inspection area of 30 mm × 
40 mm. The resolution in the vertical z-direction with 0.2% of 
the measured area leads to an effective resolution of 4 mm in 
the z-direction. A CCD camera with horizontal and vertical 
resolution in x- and y-directions of about 30 mm is used. The 
resolution in the z-direction is not limited by 256 gray steps 

of the CCD camera. The high resolution in the vertical direc-
tion  is  achieved  by  analysis  of  the  intensity  and  phase  dis-
placement of the projected grids. The surface structure of the 
analyzed area causes a deviation of the intensity and phase 
information  of  the  projected  grid  structures  from  the  theo-
retical model structure of a plane surface. With correspond-
ing mathematical algorithms, the absolute three-dimensional 
coordinates of the inspected area can be calculated of these 
deviations.  A  synopsis  of  the  most  important  experimental 
side parameters is shown in Figure 2.3, from the first experi-
ments up to the current time (Figure 2.4).

FOITS

Technique

1995

1998

2003

2006

Gray-code and phase-shift technique

Contact free direct skin measurement in vivo

Halogen light

Blue LED technique

Superimposition

Mechanically aided by online overlay procedure

LASER aided 
mechanically

Software aided on top 
of all

Measurement area

Inner side of the forearm

Crow’s-feet, under the eye, cheek, glabella, lips, nasolabial, dé colleté, 
forearm, leg

875 mm2 (25 mm × 35 mm)

20 mm × 20 mm

1200 mm2 (30 mm × 40 mm)

20 mm × 20 mm (or as needed)

Area of inspection

Area of analysis

Resolution x-direction 
y-direction
z-direction

~40 mm 
~40 mm 
4 mm

Time to digitize the fine 

~320 msec

structure

Figure 2.3  Synopsis of the Technical Side Parameters of FOITS.

~30 mm 
~30 mm 
4 mm

~260 msec

1995

1998

2003

2006

Optical

Touch Free

Real Time

3D-Analysis Of Skin Surface

Fringe Projection

Figure 2.4  Presentation of various FOITS system from 1995 to today; example of FOITS data presentation on an individual subject. 
3-DIM data presentation of the crow’s-feet area before and after 4 weeks of product application.

End value

 
CLIMATIC INFLUENCE ON COSMETIC SKIN PARAMETERS 

  19

Starting  with  analysis  of  the  inner  side  of  the  forearm, 
the crow’s-feet area eventually became the area of most interest. 
Increasing the power of FOITS technique as described in Figure 
2.3, more areas could be investigated such as the cheek, glabella 
area, under the eye, nasolabial area, lips, or all body areas such 
as the décolleté and legs. The latest technique combines the fast-
est data measurement with the best superimposition technique 
to  guarantee  a  perfect  comparison  of  baseline  and  end-value 
data.  Superimposition  is  realized  in  a  combination  of  laser-
aided  mechanical  alignment  of  the  subject  in  a  first  step  fol-
lowed by a software-driven rotation and shifting procedure of 
measured data/pictures to find the optimum superimposition.

Parameter of Analysis
Bringing into focus the periorbital wrinkle  area (crow’s-feet), 
the  morphological  structure  of  this  test  area  has  to  be  taken 
into account if wrinkles are investigated. Having this in mind, 
analysis  is  carried  out  perpendicular  to  the  main  wrinkle 
direction  based  on  the  Rz  parameter  (according  to  DIN  4668 
[12])  or  the  frequency  distribution  of  depth  (FDD)  analysis. 
Starting  close  to  the  eye,  50  separate  lines  with  a  distance  of 
400  mm  are  analyzed.  The  resulting  roughness  is  shown  as 
a  function  of  line  number  (Figure  2.5).  Ten  successive  lines 
are averaged, resulting in five areas of evaluation. Separating 

the area of analysis into these five subareas (areas 1 to 5, see 
Figure 2.5), the area close to the eye, called area 1, represents 
the deepest structures, while with area 5 smaller structures are 
quantified. An example of this analysis is given in Figure 2.4. 
In comparison, analysis of the lip area is shown. Because of the 
smaller test area, only four areas are defined with 40 separate 
lines with a distance of 250 mm. As shown by Figure 2.1, cor-
relation of line number and Rz results in a more flat link for the 
lip area in comparison to the crow’s-feet area.

To document the surface structure by a global parameter, 
the frequency distribution of all depths is used. The FDD is cal-
culated in the range from −600 mm to 600 mm (after polynomial 
correction) by using interval steps of 5 mm. The defined evalu-
ation area is equivalent to a surface of 2 cm × 2 cm and accord-
ing to the technical resolution of the camera represents 640,000 
single points. Therefore, a calculated FDD parameter is based on 
a rearrangement within these 640,000 values of depth.

Working with a distribution function, the zero level has to 
be kept in mind. Thus, the zero level of each volunteer is defined 
as the first plane representing a level of about 0.1% of all single 
values (about 600 counts). This plane is set as zero and all further 
calculations are done with these resulting standardized values. 
From the surface structure, a frequency distribution of all depths 
is obtained, as shown exemplarily in Figure 2.6 (left curve).

Area

1

2

3

4

5

Area

4
3
2
1

0.20

0.15

0.10

]

m
m

[

z
R

0.05

0.00

0

Crow’s feet
Lips

Area 1

Area 2

Area 3

Area 4

Area 5

10

20

30

40

50

Line number

Figure 2.5  Definition of subarea of analysis. Rz as a function of subarea lines of an individual example in the crow’s-feet area and 
lip area.

 
 
20 

 TEXTBOOK OF COSMETIC DERMATOLOGY

30000

25000

20000

15000

10000

5000

y
c
n
e
u
q
e
r
F

Improvement

Baseline
End value

Rough structure >–170 µm
Fine structure –55 to –170 µm
Microstructure 0 to –50 µm

0
0.0

0.1

0.2

0.3
Depth [mm]

0.4

0.5

0.6

Figure  2.6  Histogram  of  depth  of  a  surface  profile  (crow’s-feet 
area),  classification  of  structural  regions  as  well  as  visualization 
of smoothing effect/age effect–baseline: 65-year-old subject, end 
value: 15-year-old subject.

According  to  the  selected  zero  level,  a  classification  of 

depth is made as follows:

•  0 to 50 mm → Microstructure (about 5%)
•  55 to 170 mm → Fine structure (about 65%)
•  <170 mm → Rough structure (about 30%)

The  given  proportion  will  give  a  rough  estimation  of 
structure ranges found in the crow’s-feet area of women with 
distinct wrinkles and Caucasian skin. Taking into account a 
product’s  smoothing  effect,  the  green  FDD  curve  as  shown 
in  Figure  2.4  can  be  expected.  Consequently,  an  improve-
ment of skin structure is defined by a shift of maximum and 
a change of width of the distribution function. A reduction of 
rough structures can be expected, while for fine- and micro- 
structures  an  increase  is  obtained  in  the  case  of  structural 
improvements.

Corneometer
Water differs markedly from most substances as far as its dielec-
tric  constant  is  concerned.  A  quantitative  proof  of  changes  to 
the water content of the skin can thus be achieved in a noninva-
sive manner by means of capacity measurements (17,18).

A corneometer (Courage + Khazaka Co., Köln, Germany) 
is used to measure the water content (Table 2.2). A measuring 
capacitor reacts to the samples in the volume to be measured 
by way of capacitance changes (depending on water content). 
Those capacitance changes registered by the measuring head 
capacitor  are  processed  fully  automatically  by  the  equip-
ment  to  form  a  digital  measured  value.  There  is  no  conduc-
tive  (galvanic)  connection  between  the  object  measured  and 
the measuring equipment. Consequently, almost no electricity 
flows  through  the  object  measured.  Properties  such  as  ionic 
conductivity  and  polarization  effects  have  no  influence  on 
the  measurement  result.  The  fact  that  the  electronics  adapt 
to  the  moisture  circumstances  almost  without  inertia  means 
that the measuring process is very fast and that it is possible, to 
a considerable extent, to eliminate effects on the results caused 
by  involuntary  movements  or  moisture  accumulation  during 
the measuring process.

Table 2.2  Summary of Experimental Conditions for the Various 
Skin Physiology Tests

Investigation brief description corneometer 20–30 volunteers 

2–3 wk of application; twice a day
Baseline measurement on the forearm
Final value 12 h after the last application
Statistical analysis of data
Corneometer kinetic frequent measurements up to 5 h
Laser profilometry 30 volunteers
3 wk of application; twice a day
Silicone replica of the forearm (baseline)
Silicone replica 12 h after the last application (final value)
Robot-controlled laser profilometry
Analysis of Ra and Rz
FOITS frequent measurements up to 4 h
No replica
Analysis of Ra and Rz
Washing test on the bend of the elbow 20 volunteers 5 days of 

application

Twice a day, 2 × 1 min of washing
Subjective rating of side effects in a direct comparison
Reddening/stinging/skin tautness/itchiness
Skin roughness/dull feeling/bad skin feeling
Statistical analysis of reaction points
DHA decoloring 20 volunteers, aged >50 years
Measurement of skin color by chromameter (baseline)
Application of DHA to inner side of forearm
Application of test product twice a day for 18 days
Measurement of skin color every day
Analysis of decay curves

Abbreviation:  DHA, dihydroxyacetone.

All tests mentioned in this discussion were carried out 
in an electronically controlled air-conditioned laboratory that 
ensures  that  room  temperature  and  air  humidity  are  kept 
constant.  The  volunteers  were  kept  seated  in  this  laboratory 
at  22°C  (±1)  and  60%  or  50%  (±5%)  relative  humidity  for  45 
minutes before the test and during the complete standard test 
procedure.

To quantify the influence of this procedure of standard-
ization, frequent measurements were carried out immediately 
after the volunteers arrived at the institute and for up to 5 hours. 
To show the basic influence of the indoor climate, no product 
application  was  performed  during  the  time  of  the  investiga-
tion. In a second series of measurements, five different brands 
and five different formulations with an increasing amount of 
glycerine  (3%–25%)  as  an  active  ingredient  were  investigated 
in a short time test design up to 4 hours after product appli-
cation. To quantify the influence of the indoor climate on the 
product rating, the second test series was carried out twice. In 
a first run, the relative humidity was set at 60%; in a second 
run the relative humidity was reduced to 50%.

Transient individual side effects that may have an influ-
ence on the skin are standardized in this way. However, this 
procedure does not compensate for climatic conditions such as 
winter or summer.

Regeneration
Dihydroxyacetone (DHA) is a substance that is tolerated very 
well and is approved in the cosmetics industry as a suntan sub-
stance. It tans by means of the Maillard reaction, forming com-
binations  with  amino  acids  in  the  skin  that  do  not  wash  off. 
The color disappears within approximately 3 weeks as a result 
of desquamation of the colored horny cells. The tan of the skin 
decreases accordingly.

 
CLIMATIC INFLUENCE ON COSMETIC SKIN PARAMETERS 

  21

For this investigation the desquamation effect, and con-
sequently the rate of regeneration, is measured in the labora-
tory color room by measuring the decoloring  with a  Minolta 
Chromameter CR 300 (L-a-b color room). The yellow value b 
differentiates best, and this is used to establish the color decay 
curves (19,20).

The region that is tested is again the volar forearm. Areas 
of 4 cm × 4 cm in the middle of the region of application are 
colored with DHA after a defined washing procedure to stan-
dardize the baseline conditions. In the coloring process, a spe-
cial emulsion with 10% DHA is applied to the area to be tested. 
The  amount  applied  is  6  mg/cm2.  In  addition,  an  adhesive 
bandage saturated with DHA emulsion is applied for 24 hours. 
Over the next 18 days, the volunteers continue to use the prod-
ucts  twice  a  day.  The  forearms  are  permitted  to  be  washed 
only  twice  a  day  with  warm  water.  Surfactants  and  abrasive 
cleansing  agents  are  not  allowed  to  be  used.  Measurements 
are  taken  directly  before  DHA  coloring,  and  then  every  day 
over the next 18 days with the exception of weekends. For each 
time  and  area  of  measurement,  three  values  are  recorded  at 
different  places  in  the  measurement  area  and  averaged.  The 
b-values of all 30 volunteers per product are averaged, and the 
standard deviations, percentage changes, and percentage dif-
ferences standardized to the coloring are calculated. The color 
decay curves can be described under normal conditions with 
the following exponential function:

b = a1e − a2t + a3

Further statistical treatment is described in detail in Refs. 3 and 9.

Washing Test on the Bend of the Elbow
To  assess  the  skin  tolerance,  the  cleansing  effect,  and  the 
acceptance of surfactant products, we carry out the washing 
test on the bend of the elbow. In a practical test, the bend of 
the elbow is washed under intensive conditions. Twenty vol-
unteers take part in this test. In each application, the bend of 
one  elbow  is  lathered  vigorously  with  the  first  sample  and 
washed for 2 minutes by hand. After being rinsed with luke-
warm  water,  this  bend  of  the  elbow  is  again  lathered  and 
washed for 2  minutes. This is followed by a period of drying 
also  lasting  2  minutes.  After  the  second  rinsing  with  luke-
warm  water,  the  area  is  carefully  dabbed  dry  with  a  towel, 
ensuring  that  there  is  no  rubbing.  The  bend  of  the  other 
elbow  is  treated  in  exactly  the  same  way  with  the  negative 
standard SDS (21,22).

To determine any side effects induced by the test prod-
ucts, the volunteers are asked at the end of the test about any 
reactions  they  noticed  directly  after  washing.  The  following 
parameters  are  ascertained:  reddening,  stinging,  skin  taut-
ness,  itchiness,  skin  roughness,  dull  feeling,  and  dehydrated 
skin feeling. The ratings are given on the basis of a coded vol-
unteer questionnaire.

RESULTS AND DISCUSSION
Outdoor Climate
One  of  the  major  factors  in  cosmetic  skin  physiology  is  the 
moisture-retaining  effect  of  a  product.  Figure  2.7  shows 
a  summary  of  this  for  1992–1995.  The  data  have  been  sum-
marized  on  a  monthly  basis  in  each  case.  The  percentage 
increase in moisture induced by the positive standard L after 
correction for changes in the corresponding untreated area is 
shown. The recorded averages are based on at least 100 volun-
teers a month.

Standard L

)

%

(

r
e
t
e
m
o
e
n
r
o
C
Δ

14

12

10

8

6

4

2

0

1

2

3

4

5

7
6
Month

89

1

0 11 12

Figure  2.7  Percentage  increase  in  moisture,  after  correction 
for  the  untreated  area,  of  positive  standard  L  monthly  summary 
(12 hours after last application, 4460 volunteers, 1992–1999).

Standard L

)

%

(

r
e
t
e
m
o
e
n
r
o
C
Δ

40

20

0

–20

–40

–60

0

1

2

3

4

5

7
6
Month

8

9

10 11 12

Figure 2.8  Standardized differences of moisture for the positive 
standard L after correction for the untreated area (12 hours after 
the last application, 3100 volunteers, 1992–1995).

Calculations  led  to  an  average  moisture  increase  of 
approximately  12.7%  for  all  data  recorded.  To  make  it  easier 
to  compare  seasonal  dependency  of  the  achievable  moisture 
increase, Figure 2.8 shows the difference from the overall aver-
age after the data have been standardized on the basis of the 
overall  average.  A  change  of  0%  corresponds  to  the  above-
mentioned  overall  average  of  approximately  12.7%  moisture 
increase. A bar in the positive direction thus shows an increase 
in moisture that is higher than the average, whereas a bar in the 
negative  direction  indicates  a  reduced  level  of  effectiveness. 
Figure 2.8 shows that from November to February, there was 
about 15% above the average moisture increase, whereas in the 
summer  months  of  June,  July,  and  August,  the  level  of  effec-
tiveness was approximately 50% below the average achievable 
moisture increase.

Figure 2.9 shows the relative change of the laser profilom-
etry parameters Ra and Rz both for the positive standard L and 
for  the  untreated  area  in  a  way  that  is  comparable  to  Figure 
2.7.  The  area  referred  to  as  “untreated”  has  not  been  treated 
with  a  cosmetic  but  has  been  subjected  to  a  washing  proce-
dure to obtain better results, as described in the “Materials and 

 
 
 
 
 
22 

 TEXTBOOK OF COSMETIC DERMATOLOGY

8

4

0

–4

–8

)

%

(

I

N
D
z
R
/
a
R
Δ

–12

Ra standard L
RzDIN standard L

0

1

2

3

4

5

6

Month

Ra untreated
RzDIN untreated

7

8

9

10

Figure 2.9  Percentage of differences for the DIN parameters Ra and Rz for the positive standard L and the untreated area in a summary 
of laser profilometry data (1000 volunteers in general, 12 hours after the last application, 1994–1996).

0

–4

–8

)

%

(

I

N
D
z
R
/
a
R
Δ

–12

–16

Ra
RzDIN

0

1

2

3

4

5

6

7

8

9

10

Month

Figure 2.10  Differences of the DIN parameters Ra and RzDIN after correction for the untreated area in laser profilometry (12 hours after 
last application, 1994–1996).

Methods” section below. Figure 2.9 shows clearly how impor-
tant this prior treatment is. Whereas the Ra and Rz parameters 
for the positive standard fluctuate between −6% and −8% from 
January  to  October  1994  to  1996  without  showing  a  definite 
trend, these parameters fall noticeably for the untreated area 
from January to August, followed by a rise in September and 
October.  After  allowing  for  the  untreated  area,  the  profilom-
etry tests result in the dependency that is shown in Figure 2.10. 
Again, the positive standard L was found to be less effective on 
average in the summer months of June, July, and August than 
in the other months.

The data clearly show that the seasonal dependency was 
based  on  both  the  reduced  positive  effectiveness  of  standard 
L  in  the  summer  and  the  reduced  negative  sensitivity  of  the 
untreated  area  (prior  treatment  with  a  surfactant  of  all  areas 
tested). External climatic conditions thus have a distinct influ-
ence  on  the  cosmetic  effects  that  can  be  achieved.  The  basic 

level of the skin is increased in the summer months to such an 
extent that, first, skin moisture and smoothing can be increased 
further by cosmetics to only a limited degree and, second, that 
the deliberate use of substances that are detrimental to the skin 
also  has  a  limited  negative  effect.  This  leads  to  an  apparent 
reduction of cosmetic effectiveness.

In  addition  to  these  objective  skin  physiology  param-
eters, subjective information gained from volunteers’ answers 
to  questions  indicates  a  comparable  dependency  on  external 
climatic conditions. Figure 2.11 shows the total negative reac-
tion points that volunteers gave for reddening, stinging, skin 
tension,  itchiness,  skin  roughness,  dull  feeling,  and  bad  skin 
feeling in the elbow washing test. The negative reaction points 
for the negative standard fluctuated between 11 and 18 in May, 
depending on the comparative product. Since the comparative 
product is of crucial importance in rating effects subjectively, 
the same test setup was repeated in November with the same 

 
 
 
 
 
CLIMATIC INFLUENCE ON COSMETIC SKIN PARAMETERS 

  23

comparative products. Here, the average total negative reaction 
points for the comparative product SDS were distinctly higher 
in all four groups taking part in the test. Whereas the average 
for  May  was  approximately  15  negative  reaction  points,  this 
rose to approximately 23 reaction points in  November under 
otherwise identical conditions as far as the volunteers’ subjec-
tive feelings were concerned. These data, based on 80 volun-
teers, clearly show that it is possible and necessary to correlate 
information  derived  from  volunteers’  subjective  ratings  with 
climatic conditions and to consider this along with the objec-
tively demonstrable parameters for skin physiology.

Another  example  of  how  external  climatic  conditions 
make it almost impossible to evaluate the results of skin physi-
ology investigations is the turnover of the stratum corneum on 
the basis of DHA decoloring tests. When the stratum corneum 
has been colored with DHA, it can generally be expected that 

i

s
t
n
o
p
n
o
i
t
c
a
e
r
e
v
i
t
a
g
e
N

25

20

15

10

5

0

SDS, May
SDS, November

1

2

3
Comparison groups

4

Figure  2.11  Negative  reaction  points  in  a  subjective  rating 
system  for  four  individual  comparisons  of  the  negative  stan-
dard sodium dodecyl sulfate (SDS) to four different products in 
a washing test on the bend of the elbow (20 volunteers in each 
comparison).

100

there will be a constant exponential reduction of skin color-
ing  of  both  the  untreated  area  and  the  areas  that  have  been 
treated with the test products (19). Figure 2.12 shows average 
curves that have been standardized to the maximum coloring, 
on  the  basis  of  20  volunteers  for  two  test  products  (A  and  B) 
containing α-hydroxy acids and one untreated area. The obser-
vation period was 18 days. In contrast to theoretical expecta-
tions and preliminary experiments, this investigation revealed 
a reduction in skin coloring from about 70% to about 30% on 
day 8. Both before and after this sudden change, the curve is in 
keeping with theoretical expectations. When all potential tech-
nical sources of error had been eliminated, the solution to this 
problem was found in the temperature and relative humidity 
data  for  the  days  of  measurement,  as  shown  in  Figure  2.13. 
As the curves show, relative humidity fell from about 90% to 
about 60%, whereas the temperature rose from about 0 to 68C 
over the same period of just a few hours, and then fell to 18C 
after  a  short  time.  Since  temperature/humidity  fluctuations 
were  far  less  extreme  in  the  rest  of  the  test  period,  it  seems 
reasonable to suppose that the strong fluctuations of tempera-
ture  and  humidity  correlate  with  the  recorded  inconsistency 
in the DHA color decay curves. This inconsistency induced by 
extreme climatic fluctuations made it necessary to repeat the 
test, because it was no longer possible to carry out an exponen-
tial analysis of the decay curves.

As  the  measured  curve  was  constant  before  and  after 
day 8 but higher humidity fluctuations accompanied by lower 
temperature  fluctuations  were  recorded  on  day  7,  it  can  be 
assumed that humidity is of greater importance in examining 
the regeneration of the stratum corneum and that the outside 
temperature plays only a subordinate part in the quality of this 
skin physiology investigation.

Indoor Climate
Figure  2.14a  presents  the  results  of  the  “no-product  corne-
ometer  kinetic”  (i.e.,  without  application  of  a  product).  The 
kinetic  measurements  were  carried  out  on  four  different  test 
areas  (forearm—lower,  middle,  and  upper—and  upper  arm). 
In Figure 2.14b, the forearm data are summarized on the basis 

Product B
Product A
Untreated

)

%

l

(
e
u
a
v
r
o
o
C
-
b
-
Δ

l

80

60

40

20

0

0

2

4

68

1

0

12

14

16

18

Days

Figure 2.12  Exponential decay curves of the dihydroxyacetone (DHA) decoloring test standardized to the maximum coloring character-
ized by changing of the b-value of the L-a-b color room.

 
 
 
 
 
24 

 TEXTBOOK OF COSMETIC DERMATOLOGY

7

6

5

4

3

2

1

0

)

C
º
(
e
r
u
t
a
r
e
p
m
e
T

100

90

80

70

60

)

%

i

(
y
t
i
d
m
u
h
e
v
i
t
a
e
R

l

–1

6.0

6.5

7.0

8.0

8.5

50

9.0

7.5
Days

Figure 2.13  Climatic data of temperature (grey) and relative humidity (black) from day 6 to day 8 during the dihydroxyacetone (DHA) 
investigation.

Upper arm

Forearm upper

Forearm middle

Forearm lower

0

60

120

180

240

300

Time (min)
(a)

< 40 CU
40–55 CU
>55 CU

54

52

50

48

46

44

6

4

2

0

–2

–4

–6

–8

)

U
C

(

s
t
i
n
u
r
e
t
e
m
o
e
n
r
o
C

)

%

(
e
n

i
l

e
s
a
b
m
o
r
f
e
c
n
e
r
e
f
f
i

D

–10

–12

0

60

120

180

240

300

Time (min)
(b)

Figure  2.14 
corneometer—difference from baseline; data summarized for different volunteers, without any product application (n = 120).

(a)  Kinetic  corneometer—data  summarized  for  different  test  areas,  without  any  product  application  (n  =  120).  (b)  Kinetic 

 
 
 
 
 
 
 
 
 
CLIMATIC INFLUENCE ON COSMETIC SKIN PARAMETERS 

  25

of the first measured value. The first group  had  starting  val-
ues below 40 corneometer units (CU), the second group sum-
marized the volunteers between 40 and 55 CU, and the third 
group was based on starting values above 55 CU.

Analyzing  the  data  of  different  test  areas  resulted  in  a 
decrease of about 2 CU for the upper forearm and a little less 
for the other test areas independent of the absolute level, which 
was different for each test site (lower forearm < middle fore-
arm < upper forearm = upper arm). These data were calculated 
without  taking  into  account  the  individual  skin  type  of  the 
volunteers.  Figure  2.14b  reflects  this,  showing  the  individual 
starting conditions. As can be seen from the differences from 
baseline, the group with 40 to 55 CU did not show any changes 
above  about  1%  during  5  hours  of  investigation.  The  group 

below 40 CU showed a constant increase of approximately 2%, 
whereas for the group with high starting values above 55 CU, 
a decrease of up to 10% was obtained. Independent of the test 
site, the preconditioning phase seems to be most effective for 
a high skin moisture level at the beginning of the study. A dry 
skin might be less influenced by the indoor climate. The data 
to determine the optimal time of preconditioning to generate 
stable skin conditions are represented in Figure 2.15.

As  shown  in  Figure  2.15a,  the  difference  from  baseline 
(–D– curve: mean overall) became stabilized at 30 minutes and 
remained  constant  from  60  minutes  on.  Thus,  45  minutes  of 
acclimatization  seems  to  be  the  best  choice—a  time  not  too 
short for “moist” skin and not too long to reflect a reliable test 
design.

6

4

2

0

–2

–4

–6

–8

–10

–12

4

2

0

–2

–4

)

%

(
e
n

i
l

e
s
a
b
m
o
r
f
e
c
n
e
r
e
f
f
i

D

)

%

(
e
n

i
l

e
s
a
b
m
o
r
f
e
c
n
e
r
e
f
f
i

D

< 40 CU
40–55 CU
>55 CU
Mean

0

10

20

30

40

50

60

70

80

90

Time (min)
(a)

Corneo
FOITS Rz
FOITS Ra

0

60

120

Time (min)
(b)

180

240

(a) Kinetic corneometer—difference from baseline; data summarized for different volunteers up to 90 minutes, without any 
Figure 2.15 
product application (n = 120). (b) Kinetic FOITS and corneometer—difference from baseline mean overall up to 240 minutes, without any 
product application (n = 120/40).

 
 
 
 
 
 
 
26 

 TEXTBOOK OF COSMETIC DERMATOLOGY

The data describing the skin surface are given in Figure 
2.15b.  No  significant  changes  occurred  during  the  4-hour 
kinetic  investigation.  Differences  between  lower  and  upper 
forearm  were  comparable  to  the  corneometer  measurements. 
Summing up the Rz and Ra values for up to 4 hours, no trend 
in  the  changes  was  observed.  Consequently,  the  influence  of 
the  indoor  climate  seems  to  be  of  minor  impact  if  compared 
to skin moisture. In any case, changes of the skin structure are 
obviously on a much slower time scale if the producing event 
is as indirect as the indoor climate.

Changing  the  kinetic  view  to  more  static  analysis,  the 
data  of  five  different  brands  are  summarized  in  Figure  2.16. 
Figure  2.16a  shows  the  difference  between  baseline  and  end 
value 4 hours after unique product application in absolute CU. 
The dark gray bars represent the data at an indoor climate of 
60% relative humidity, whereas the light gray bars are obtained 
at 50% relative humidity.

With  the  exception  of  product  no.  1,  no  difference 
occurred from changing the indoor humidity. For product no. 1, 
a tendency was calculated for the comparison of both measure-
ments. Taking product no. 1 as a hint that an influence might 

)

U
C

(
e
c
n
e
r
e
f
f
i

D

d
e
t
a
e
r
t
n
u
y
b
n
o
i
t
c
e
r
r
o
c
r
e
t
f
a

)

U
C

(
–
e
c
n
e
r
e
f
f
i

D

d
e
t
a
e
r
t
n
u
y
b
n
o
i
t
c
e
r
r
o
c
r
e
t
f
a

20

15

10

5

0

25

20

15

10

60% relative humidity
50% relative humidity

–

4

–

–

5

–

–

td

–

1

2

3
Brands
(a)

60% relative humidity
50% relative humidity

–

**

**

1

23

4

5

Increasing glycerine concentration (3%–25%)
(b)

(a)  Corneometer  for  brands  1–5.  Difference  from 
Figure  2.16 
baseline  after  correction  by  untreated.  (b)  Corneometer  for 
increasing concentration of glycerine (bar 1, 3% increasing to bar 
5, 25%). Difference from baseline after correction by the untreated 
test area. **, significant difference; –, no significant difference.

be possible, a second run of five formulations with an increas-
ing amount of glycerine was carried out under the same condi-
tions. In this case, significant changes occurred for the first two 
low-glycerine concentrations (concentration below saturation). 
At 50% relative humidity, the level of measured absolute units 
decreased significantly. Thus, the selectivity became better if 
the relative humidity was reduced and the product contained 
hygroscopic  active  ingredients.  The  hygroscopic  ingredient 
seems to pick up the air humidity like a sponge as long as it 
is  in  the  upper  stratum  corneum.  Nevertheless,  the  origin  of 
moisture  should  be  irrelevant  for  the  skin,  but  in  the  case  of 
ranking  and  differentiating  products  as  quickly  as  possible 
after the product application, it might be helpful to measure at 
50% relative humidity.

CONCLUSION
The data recorded, from both objective skin physiology param-
eters such as moisture and smoothness and subjective factors in 
the  elbow-washing  test,  clearly  show  that  such  tests  are  influ-
enced considerably by climatic conditions. Differences, such as 
between summer and winter, cannot be compensated for by accli-
matization in air-conditioned laboratories. Alongside standard-
ized measurement conditions, it is therefore essential to record 
the quality of the test panel not only by including an untreated 
area but also by means of a positive or negative control. Only in 
this way is it possible to establish a classification system for test 
products that is not dependent on a particular season and allows 
the quality of cosmetic products to be rated objectively.

As demonstrated by the obtained results, the indoor cli-
mate also plays an important part in cosmetic efficacy testing. 
In addition to the outdoor climate, which might have an effect 
on a long-term basis, the indoor climate (especially the time of 
preconditioning)  is  decisive  for  short-term  and  kinetic  inves-
tigations. While the influence of the moisture level is strongly 
dependent  on  the  starting  value,  the  changes  of  the  skin 
topometry seem to be not so marked. On the basis of the cor-
neometer kinetic data, 45 minutes of preconditioning appears 
to be an optimal compromise between effect, standardization, 
and  costs.  The  laboratory  conditions  (relative  humidity)  may 
also be of great influence. Depending on the active ingredients 
(hygroscopic or not), a ranking of products might be of greater 
selectivity if a lower level of relative humidity is used.

The data presented underline the importance of a stan-
dardized procedure to investigate cosmetic effects on a statisti-
cal and reproducible level.

REFERENCES

1. Rohr M, Schrader K. Fast optical in vivo topometry of human 
skin  (FOITS)—A  comparison  to  LASER-profilometry.  5th 
Congress of the International Society for Skin Imaging, Vienna, 
1997.

2. Rohr M, Schrader K. Fast optical in vivo topometry of human 

skin (FOITS). SÖFW-J 1998; 124(2):52–59.

3. Rohr  M,  Schrader  A.  FOITS  (fast  optical  in  vivo  topometry 
of  human  skin)—A  classical  method  in  modern  efficacy  test-
ing. A history of fringe projection in cosmetics. SÖFW-J 2009; 
Jahrgang; 135(8):2–10.

4.  Jaspers S, Hoperman H, Sauermann G, et al., Rapid in vivo mea-
surement of the topography of human skin by active image tri-
angulation using a digital micro-mirror device. Skin Res Technol 
1999; 5:196–207.

5.  Rohr  M,  Schrader  K.  Surfactant-induced  skin  roughness: 
Quantitative  analysis  of  the  surface  structure  of  the  skin  via 
laser  scanning.  Eurocosmetics  1994; 
automated  non-touch 
8:24–28.

 
 
 
 
 
 
 
 
 
 
 
 
CLIMATIC INFLUENCE ON COSMETIC SKIN PARAMETERS 

  27

6.  Hartung  J.  Statistik,  Lehr  -  und  Handbuch  Der  Angewandten 
Statistik. 9th ed. Munich, Oldenburg: Oldenbourg-Verlag, 1993.

7.  DIN 

4768:  Ermittlung  der  Rauheitskenngrössen  Ra, 
RzDIN,  Rmax  mit  elektrischen  Tastschnittgeräten:  Begri ffe,  
Mess bed ingungen. Berlin: Beuth Verl, 1990.

8.  Stout J, Sullivan PJ, Dong WP, et al. The development of meth-
ods  for  characterization  of  roughness  in  three  dimensions. 
Report EUR 15178 EN. Eur Community, 1993.

9.  Lagarde JM, Rouvrais C, Black D, et al. Skin topography mea-
surement by interference fringe projection: A technical valida-
tion. Skin Res Technol 2001; 7:112–121.

  10.  Jaspers S, Hoperman H, Sauermann G, et al. Rapid in vivo mea-
surement of the topography of human skin by active image tri-
angulation using a digital micro-mirror device. Skin Res Technol 
1999; 5:196–207.

  11.  Ferraq Y, Black D, Lagarde JM, et al. Use of 3-D imaging tech-
nique for non-invasive monitoring of the depth of experimen-
tally induced wounds. Skin Res Technol 2007; 13:399–405.
  12.  Rohr M, Schrader A. FOITS (Fast Optical in vivo Topometry of 
Human Skin)—A classical method in modern efficacy testing—a 
history of fringe-projection in cosmetic, SÖFW-J, 2009; 135(8):2–10.
  13.  Nouveau-Richard S, Yang Z, Mac-Mary S, et al. Skin ageing: A 
comparison  between  Chinese  and  European  populations—a 
pilot study. J Dermatol Sci 2005; 40(3):187–193.

  14.  Rohr M, Yan Qi, Schrader A. Anti-wrinkle performance of cos-
metic  products  differentiated  by  FOITS,  a  statement  of  effec-
tiveness,  age  and  ethnic  background,  IFSCC  Congress  2006; 
Japan.

  15.  Rohr M, Brandt M, Schrader A. Skin surface—Claim support by 

FOITS. SÖFW-J 2000; 126(8):2–11.

  16.  Breuckmann  B.  Bildverarbeitung  und  optische  Messtechnik  in  der 
industriellen Praxis. München: Franzis-Verlag GmbH, 1993.
  17.  Schrader  K.  Untersuchungen  wasser-retinierender  Kosmetika 

auf der Haut. Parfümerie Kosmet 1981; 62:265–272.

  18.  Piérard  GE,  Piérard-Franchimont  C.  Dihydroxyacetone  test 
as  a  substitute  for  the  dansyl  chloride  test.  Dermatology  1993; 
186:133–137.

  19.  Rohr M, Schrader A, Schrader K. The multifunctional effects of 

AHA. Parfümerie Kosmet 1996; 77:762–767.

  20.  Neter  J,  Wassermann  W,  Kutner  MH.  Applied  Linear  Statistical 
Models, Regression, Analysis of Variance and Experimental Design. 
2nd ed. Homewood: Irwin, 1984.

  21.  Schrader  A,  Eckey  H,  Rohr  M.  Die  Prüfung  der  Wirksamkeit 
reizlindernder  Stoffe  an  der  menschlichen  Haut  am  Beispiel 
verschiedener Kamillenextrakte. SÖFW-J 1997; 123:3–11.
  22.  Schrader K. Praxisbezogene hautphysiologische Untersuchun-
gskriterien  mit  Seifen  und  Syndets.  Parfümerie  Kosmet  1990; 
71:686–695.

 
 
 
 
 
3

Transepidermal Water Loss

Jan Kottner and Annika Vogt

INTRODUCTION
The physician Santorio Sanctorius (1561–1636) who lived more 
than 500 years ago in Italy is considered to be the first person 
to  work  systematically  on  the  phenomenon  called  perspiratio 
insensibilis,  the  invisible  loss  of  water  from  the  human  body. 
Since  then,  it  was  widely  agreed  that  water  gets  lost  via  the 
respiratory system and via sweating, but alternative passages 
of water through the skin were less clear (1). In 1911 Loewy and 
Wechselmann proposed for the first time that besides sweat-
ing there is the possibility of passive water diffusion through 
the skin (2). Why and how this water penetrates and leaves the 
skin was another issue of debate for the following 40 years (3,4). 
Irrespective of these discussions, the American dermatologist 
Stephen Rothman introduced the term transepidermal water loss 
(TEWL) in 1955, characterizing continuous water loss through 
the  epidermis  excluding  sweat  secretion  (5).  Today  TEWL 
plays an important role in characterizing the skin barrier func-
tion  in  physiological  and  pathological  conditions.  This  chap-
ter gives a brief overview about the structural and functional 
determinants of TEWL, how it can be measured, and what this 
parameter means.

BIOLOGICAL BACKGROUND
Without effective protection of the “moist inside” of the human 
body, life in the dry environment on land would be impossi-
ble. The main anatomical barrier limiting the amount of water 
loss is in the stratum corneum (SC). At most skin areas the SC 
consists of 15 to 20 stacked layers of flat, terminally differenti-
ated keratinocytes connected by desmosomes embedded in a 
matrix of lipid bilayers. Depending on the hydration state the 
diameter of the corneocytes is approximately 20 to 50 μm and 
the thickness is approximately 1 to a maximum of 3 μm if fully 
hydrated  (6,7).  The  thickness  of  the  intercellular  lipid  bilayer 
is  up  to  0.1  μm  (Figure  3.1)  (8–10).  This  paper-thin  but  dense 
and compact structure separates the outermost boundary, the 
skin surface, from the living epidermal cells underneath. From 
the  deeper  highly  hydrated  tissue  there  is  a  constant  flux  of 
water molecules to the skin surface where it evaporates, result-
ing in equilibrium between the ongoing process of water loss 
at the surface and replenishment from beneath. Under physi-
ological  conditions  the  water  concentration  underneath  and 
in the innermost layer of the SC is approximately 70%, and it 
is approximately 10% to 30% in the outermost layer of the SC 
depending on environmental conditions (7,11,12).

In theory, water molecules may take two routes through 
the  SC:  diffusion  via  the  transcellular  route  through  the  cor-
neocytes or intercellular penetration (Figure 3.1). Because the 
water diffusion coefficient of the intercellular lipids is consid-
ered to be ten times higher compared to the corneocytes, the 
intercellular water flux might also be higher (13). The structure 

and  order  of  these  lipids  is  considered  most  important  for 
water barrier function (8,14) and they are widely considered to 
be the major barriers for perpendicular water transport (6,9,15). 
The composition of the intercellular matrix, however, is com-
plex and includes lipophilic, but also hydrophilic subcompart-
ments. Although hardly detectable under normal conditions or 
on tissue sections, studies suggest that such aqueous regions 
can  be  expanded  to  tube-like  structures,  e.g.,  by  means  of 
sonophoresis, which enable entry of large molecules (16). Such 
phenomena  are  further  supported  by  work  that  focuses  on 
pathways of deformable carrier systems across intact skin (17).
Finite element and microscopic transport models increas-
ingly support the importance of the transcellular permeation 
pathway  for  hydrophilic  chemicals,  including  water  (6,13,15). 
The surface area of the corneocytes is also much larger com-
pared to the intercellular lipids and therefore the total amount 
of transcellular water transport and the subsequent evapora-
tion  are  major  determinants  of  TEWL  in  healthy  skin  under 
physiological conditions (13).

MEASUREMENT OF TRANSEPIDERMAL 
WATER LOSS
The flux of water through the SC cannot be observed directly. 
Today  the  established  method  of  measuring  TEWL  is  by 
placing  a  measurement  probe  on  the  skin  and  recording  the 
amount  of  water  that  evaporates  from  the  skin  surface.  The 
measured water flux density is expressed in g/m2/h. In order 
to  infer  that  this  amount  of  evaporated  water  per  area  and 
time equals the water flux within the SC several assumptions 
need to be met: two of the most important are that sweat gland 
activity is reduced as much as possible, and that the water flux 
within the SC is in a steady state. In clinical and research prac-
tice  this  is  accomplished  by  standardizing  the  measurement 
conditions and procedures, but total control of these variables 
is impossible (18).

Several  TEWL  measurement  devices  are  commercially 
available. They can be classified as open-chamber and closed-
chamber instruments (12,19). Open-chamber instruments con-
sist of a small hollow cylinder which is placed onto the skin. 
In  still  environmental  conditions  the  water  vapor  from  the 
skin surface diffuses through the lower end of the chamber to 
the upper end into the ambient atmosphere. The steady-state 
humidity gradient between the skin surface and the ambient 
air is the physical basis for the water flux measurement. Using 
these types of devices continuous measurements are possible, 
but their accuracy depends on the ambient conditions.

Closed-chamber instruments have only one orifice. The 
open end is placed onto the skin surface and the water vapor 
diffuses into the closed chamber. The change of the constantly 
increasing  water  concentration  inside  the  closed-chamber  is 

Transcellular transport

Intercellular transport

Corneocytes

TRANSEPIDERMAL WATER LOSS 

 29

Skin surface

Lipid
bilayers

Stratum granulosum

Corneodesmosome

Figure 3.1  Two-dimensional model of the human stratum corneum and possible inside-out diffusion pathways of water.

used  for  TEWL  estimation.  The  accuracy  of  the  TEWL  esti-
mates is much more independent from ambient conditions, but 
continuous  measurements  are  not  possible.  The  probe  needs 
to  be  dried  between  measurements.  The  condenser-chamber 
method also uses a closed-chamber but the water vapor inside 
the chamber is controlled. Water vapor diffuses from the skin 
surface  toward  a  condenser,  creating  a  humidity  gradient 
which,  comparable  to  the  open-chamber  method,  is  used  to 
TEWL estimation. Continuous measurements are possible.

Based on the different measurement principles, techni-
cal  specifications,  measurement  ranges,  and  degree  of  preci-
sion,  different  instruments  produce  slightly  different  results 
(20). Even placing a probe onto the skin surface will influence 
the TEWL, because the water flux density on uncovered skin 
is  different  from  the  flux  density  within  small  measurement 
chambers  (12,21).  However,  available  method  comparison 
studies indicate that TEWL estimates seem to be comparable 
and are highly correlated (22).

In  order  to  achieve  valid  and  reliable  TEWL  estimates, 
measurement  guidelines  have  been  proposed  (18,23–25). 
Selected key recommendations are:

•  An  acclimatization  period  prior  to  TEWL  measurement 
is  required.  During  this  time  the  skin  areas  that  will  be 
measured must be uncovered by any material (e.g., cloth-
ing). Recommended durations vary but they should not be 
shorter than 15 minutes.

•  Acclimatization  and  measurements  should  be  conducted 
under  standardized  ambient  conditions.  Room  tempera-
tures should be lower than 22°C and the relative humidity 
should be around 50% or lower.

• 

•  A calibration according to the manufacturer's instructions 
must be conducted regularly and/or before a larger set of 
measurements.
If  the  “baseline”  or  “normal”  TEWL  is  the  parameter  of 
interest,  no  cleansing  procedures,  leave-on  products,  or 
similar applications must be used before measurement.
•  Neither too much nor too little pressure must be applied 
when placing the probe head onto the skin surface. It must 
be  ensured  that  no  gaps  arise  between  the  lower  orifice 
and the skin.

•  The probe head should be placed vertically onto the hori-

zontal skin surface.

In research or clinical settings these and other details are usu-
ally  specified  in  the  standard  operating  procedures.  These 
protocols  are  especially  important  when  measurements  are 
conducted by many different persons, at multiple centers, and 
over long durations.

WHAT DO TRANSEPIDERMAL WATER LOSS 
VALUES REALLY TELL US ABOUT THE SKIN?
TEWL  is  considered  one  of  the  most  important  parameters 
indicating  the  state  and  integrity  of  the  epidermal  (water) 
barrier.  It  is  elevated  in  a  large  range  of  dermatological 
conditions  (e.g.,  atopic  dermatitis),  and  TEWL  decreases 
indicate  barrier  restoration  and  skin  health  (18,23).  This 
parameter is also very sensitive and can indicate functional 
changes  before  clinical  signs  become  obvious  (26,27).  On 
the  other  hand,  there  are  numerous  non-pathologic  factors 
influencing  the  TEWL.  Despite  the  measurement  instru-
ments  and   measurement  conditions,  TEWL  is  dependent 
on  many   factors,  including  age,  skin  area,  skin  tempera-
ture,  circadian rhythm, season, or cigarette smoking (23,25). 
Because of this complexity and interdependence of the vari-
ous factors it is strongly recommended that TEWL values be 
interpreted  very  cautiously,  and  not  necessarily  in  absolute 
terms (14,28).

Hundreds of descriptive and experimental studies mea-
suring  TEWL  have  been  conducted,  and  larger  scale  studies 
reporting  skin  barrier  characteristics  of  hundreds  of  persons 
are  now  available  (29,30).  Two  systematic  reviews  and  meta-
analyses have been conducted to summarize the available evi-
dence about TEWL in adults of 18+ years (22) and infants from 
0  to  24  months  (31).  Despite  large  variations,  these  reviews 
provide  reference  TEWL  values  for  more  than  50  skin  areas 
in  healthy  individuals.  These  reference  values  are  useful  for 
study  planning  and  for  comparison  with  existing  data,  but 
nevertheless  it  must  be  emphasized  that  a  “normal”  TEWL 
seems to be unknown so far (22,23). Consequently, cutoff val-
ues or possible TEWL thresholds are also arbitrary. According 
to  Menon  and  Kligman  “…  there  is  no  single  optimal  TEWL 
value for the entire skin and that what is important is not how 
‘tight’ a barrier is but rather when the barrier is good enough to 
allow for survival and subserve other biological functions…” 
(p. 180) (32).

 
30 

 TEXTBOOK OF COSMETIC DERMATOLOGY

TRANSEPIDERMAL WATER LOSS AS 
A PARAMETER IN SKIN RESEARCH
In  clinical  research  changes  (delta)  of  TEWL  over  time,  e.g., 
during the course of disease, during artificial irritation tests, 
or  during  cosmetic  treatments,  are  much  better  parameters 
for  measuring  skin  barrier  changes  or  effects  of  treatments 
compared  to  single  measurements  (33,34).  Whether  these 
changes are large enough to be considered clinically relevant 
is a  matter of debate, but they should be larger than random 
variation  (e.g.,  two  standard  deviations)  in  the  data.  While 
there is a clear relationship between substantially increased 
or  decreased  TEWL  with  skin  barrier  function  and  SC 
 integrity,  smaller  TEWL  changes  might  rather  indicate  bio-
logical variability only. For instance, a mean TEWL decrease 
of 1 g/m2/h is unlikely to indicate “… an improvement of the 
skin  barrier…” (p. e368) (35). Similarly, lower TEWL in aged 
skin or senile xerosis should not be interpreted as a “better” 
skin  barrier  function  (p.  93)  (36,37).  It  must  be  emphasized 
that  the  applied  TEWL  measurements  on  the  skin  surface 
are  indirect  (12).  Besides  random  variation  or  bias,  the  exact 
biological  or  functional  reason  for  value  changes  must  not 
be  obvious.  Water  diffusion  through  the  SC  is  for  instance 
determined  by  the  horizontal  corneocyte  overlap,  the  cor-
neocyte  volume  and  composition,  or  the  number  of  layers 
(10). All these parameters might not necessarily have clinical 
relevance.

In  the  course  of  cosmetic  or  dermatological  studies, 
comprehensive  and  transparent  reporting  of  results  is  of 
utmost  importance  to  ensure  reproducibility,  meaningful 
communication, and comparisons within and between stud-
ies. Details must be reported about demographic and health 
characteristics of the sample including dermatological condi-
tions, season, geographical area, procedures, prior measure-
ments  (e.g.,  use  of  products,  acclimatization),  measurement 
device, the exact anatomical location, the method and num-
ber of measurements, and ambient measurement conditions 
(23). Irrespective of the subsequent statistical analysis, TEWL 
values must be reported at least using arithmetic means and 
standard deviations (22).

In  clinical  controlled  intervention  studies,  randomiza-
tion is a key design element to reduce bias. Because the TEWL 
is  strongly  dependent  on  the  anatomical  location,  baseline 
comparability even between adjacent skin areas is limited. For 
instance,  available  empirical  data  indicate  increasing  TEWL 
from  proximal  to  distal  on  the  volar  forearm  skin  (22,38) 
which  was  supported  recently  by  new  empirical  data  (39). 
Consequently, randomization even within small skin areas is 
complicated.  Contralateral  skin  areas  are  very  well  compara-
ble, and randomization should be preferred in such so-called 
“split body designs.”

CONCLUSIONS
TEWL  is  a  valuable,  straightforward  parameter  to  measure 
the SC integrity and the inside-out water barrier. Highly stan-
dardized  settings  are  required  to  yield  accurate  and  reliable 
data.  This  parameter  is  extremely  sensitive  to  environmen-
tal  factors  as  well  as  intra-individual  variations  among  body 
regions. TEWL is only one parameter to characterize the skin 
barrier function. Other techniques might be used in addition 
to obtain a comprehensive picture of the skin barrier structure 
and function.

REFERENCES

1. Renbourn  ET.  The  natural  history  of  insensible  perspiration: 
A  forgotten  doctrine  of  health  and  disease.  Med  Hist  1960; 
4:135–52. Epub 1960/04/01.

2. Loewy  A,  Wechselmaa  W.  Zur  Physiologie  und  Pathologie 
des  Wasserwechesels  und  der  Wärmeregulation  seitens  des 
Hautorgans. Virchows Archiv F 1911; 206(1):79–121.

3. Newburgh  LH,  Woodwell  Johnson  M.  The  insensible  loss  of 

water. Physiol Rev 1942; 22(1):1–18.

4. Pinson  EA.  Evaporation  from  human  skin  with  sweat  glands 

inactivated. Am J Physiol 1942; 137:492–503.

5. Rothman  S.  Physiology  and  Biochemistry  of  the  Skin.  2nd  ed. 

Chigago: The University of Chicago Press; 1955.

6. Wang  TF,  Kasting  GB,  Nitsche  JM.  A  multiphase  micro-
scopic  diffusion  model  for  stratum  corneum  permeability.  II. 
Estimation of physicochemical parameters, and application to 
a large permeability database. J Pharm Sci 2007; 96(11):3024–51. 
Epub 2007/09/197.

7.  Igaki M, Higashi T, Hamamoto S, Kodama S, Naito S, Tokuhara 
S. A study of the behavior and mechanism of thermal conduc-
tion in the skin under moist and dry heat conditions. Skin Res 
Technol 2014; 20(1):43–9. Epub 2013/06/21.

8.  Lane  ME.  Emollient  therapy  and  skin  barrier  function.  In: 
Lodén  M,  Maibach  H,  eds.  Treatment  of  Dry  Skin  Syndrome. 
Berlin, Heidelberg: Springer 2012; pp. 513–23.

9.  Barbero  AM,  Frasch  HF.  Transcellular  route  of  diffusion 
through stratum corneum: Results from finite element models. 
J Pharm Sci 2006;95(10):2186–94. Epub 2006/08/03.

  10.  Naegel A, Heisig M, Wittum G. Computational modeling of the 

skin barrier. Method Mol Biol 2011; 763:1–32. Epub 2011/08/30.

  11.  Crowther  JM,  Matts  PJ,  Kaczvinsky  JR.  Changes  in  stratum 
corneum  thickness,  water  gradients  and  hydration  by  mois-
turizers.  In:  Lodén  M,  Maibach  HI,  ed.  Treatment  of  Dry  Skin 
Syndrome. Berlin, Heidelberg: Springer 2012; pp. 545–60.
  12.  Imhof  RE,  De  Jesus  ME,  Xiao  P,  Ciortea  LI,  Berg  EP. 
Closed-chamber  transepidermal  water  loss  measurement: 
Microclimate,  calibration  and  performance.  Int  J  Cosmetic  Sci 
2009; 31(2):97–118. Epub 2009/01/30.

  13.  Xiao P, Imhof RE. Two dimensional finite element modelling for 
dynamic water diffusion through stratum corneum. Int J Pharm 
2012; 435(1):88–92. Epub 2012/02/09.

  14.  van der Valk PGM, Kucharekova M, Tupker RA. Transepidermal 
water  loss  and  its  relation  to  barrier  function  and  skin  irri-
tation.  In:  Fluhr  J,  Elsner  P,  Berardesca  E,  Maibach  HI,  eds. 
Bioengineering of the Skin: Water and the Stratum Corneum. New 
York: Informa Healthcare 2005: pp. 97–104.

  15.  Wang  TF,  Kasting  GB,  Nitsche  JM.  A  multiphase  micro-
scopic  diffusion  model  for  stratum  corneum  permeability.  I. 
Formulation, solution, and illustrative results for representative 
compounds. J Pharm Sci 2006;95(3):620–48. Epub 2006/02/01.

  16.  Menon  GK,  Bommannan  DB,  Elias  PM.  High-frequency  sono-
phoresis: Permeation pathways and structural basis for enhanced 
permeability. Skin Pharmacol 1994; 7(3):130–9. Epub 1994/01/01.

  17.  Cevc  G,  Vierl  U.  Nanotechnology  and  the  transdermal  route: 
A state of the art review and critical appraisal. J Control Release 
2010;141(3):277–99. Epub 2009/10/24.

  18.  Rogiers V. EEMCO guidance for the assessment of transepider-
mal water loss in cosmetic sciences. Skin Pharmacol Appl 2001; 
14(2):117–28. Epub 2001/04/24.

  19.  Sotoodian  B,  Maibach  HI.  Noninvasive  test  methods  for  epi-
dermal barrier function. Clin Dermatol 2012; 30(3):301–10. Epub 
2012/04/18.

  20.  Miteva  M,  Richter  S,  Elsner  P,  Fluhr  JW.  Approaches  for  opti-
mizing  the  calibration  standard  of  Tewameter  TM  300.  Exp 
Dermatol 2006; 15(11):904–12. Epub 2006/09/28.

  21.  Grove GL, Grove MJ, Zerweck C, Pierce E. Computerized evap-
orimetry  using  the  DermaLab  TEWL  probe.  Skin  Res  Technol 
1999; 5:9–13.

 
 
 
 
  22.  Kottner  J,  Lichterfeld  A,  Blume-Peytavi  U.  Transepidermal 
water  loss  in  young  and  aged  healthy  humans:  A  systematic 
review  and  meta-analysis.  Arch  Dermatol  Res  2013;  305(4):315–
23. Epub 2013/01/24.

  23.  du Plessis J, Stefaniak A, Eloff F, et al. International guidelines 
for the in vivo assessment of skin properties in non-clinical set-
tings:  Part  2.  Transepidermal  water  loss  and  skin  hydration. 
Skin Res Technol 2013; 19(3):265–78. Epub 2013/01/22.

  24.  Pinnagoda  J,  Tupker  RA,  Agner  T,  Serup  J.  Guidelines  for 
transepidermal  water  loss  (TEWL)  measurement.  A  report 
from  the  Standardization  Group  of  the  European  Society  of 
Contact Dermatitis. Contact Dermatitis 1990; 22(3):164–78. Epub 
1990/03/01.

  25.  Primavera G, Fluhr JW, Berardesca E. Standardization of mea-
surements  and  guidelines.  In:  Fluhr  J,  Elsner  P,  Berardesca  E, 
Maibach HI, eds. Bioengineering of the Skin: Water and the Stratum 
Corneum. New York: Informa Healthcare 2005; pp. 83–95.
  26.  Marks R, Black D. Methodologies to produce and assess stan-
dardized trauma to the skin.  Am J Ind Med 1985; 8(4–5):491–8. 
Epub 1985/01/01.

  27.  Del  Rosso  JQ,  Levin  J.  Clinical  relevance  of  maintaining  the 
structural  and  functional  integrity  of  the  stratum  corneum: 
Why  is  it  important  to  you?  J  Drugs  Dermatol  2011;  10(10 
Suppl):s5–12. Epub 2011/11/09.

  28.  Rogiers  V,  Houben  E,  De  Paepe  K.  Transepidermal  water  loss 
measurements in dermato-cosmetic sciences. In: Fluhr J, Elsner 
P,  Berardesca  E,  Maibach  HI,  eds.  Bioengineering  of  the  Skin: 
Water and the Stratum Corneum. New York: Informa Healthcare 
2005; pp. 63–76.

  29.  Kleesz P, Darlenski R, Fluhr JW. Full-body skin mapping for six 
biophysical parameters: Baseline values at 16 anatomical sites 
in  125  human  subjects.  Skin  Pharmacol  Appl  2012;  25(1):25–33. 
Epub 2011/09/14.

  30.  Luebberding S, Krueger N, Kerscher M. Skin physiology in men 
and women: In vivo evaluation of 300 people including TEWL, 

TRANSEPIDERMAL WATER LOSS 

 31

SC hydration, sebum content and skin surface pH. Int J Cosmetic 
Sci 2013; 35(5):477–83. Epub 2013/05/30.

  31.  Ludriksone  L,  Garcia  Bartels  N,  Kanti  V,  et  al.  Skin  barrier 
function  in  infancy:  A  systematic  review.  Arch  Dermatol  Res 
2014; 27(2):90–6.

  32.  Menon  GK,  Kligman  AM.  Barrier  functions  of  human  skin: 
A  holistic  view.  Skin  Pharmacol  Appl  2009;  22(4):178–89.  Epub 
2009/08/04.

  33.  Lu  N,  Chandar  P,  Tempesta  D,  et  al.  Characteristic  differences 
in barrier and hygroscopic properties between normal and cos-
metic dry skin. I. Enhanced barrier analysis with sequential tape-
stripping. Int J Cosmetic Sci 2014; 36(2):167–74. Epub 2014/01/09.

  34.  Elsner P, Seyfarth F, Antonov D, et al. Development of a stan-
dardized  testing  procedure  for  assessing  the  irritation  poten-
tial  of  occupational  skin  cleansers.  Contact  Dermatitis  2014; 
70(3):151–7. Epub 2014/03/05.

  35.  Waring M, Bielfeldt S, Matzold K, Wilhelm KP. A new method-
ology for evaluating the damage to the skin barrier caused by 
repeated  application  and  removal  of  adhesive  dressings.  Skin 
Res Technol 2013; 19(1):e366–74. Epub 2012/06/15.

  36.  Tagami  H,  Kobayashi  H,  Zhen  XS,  Kikuchi  K.  Environmental 
effects  on  the  functions  of  the  stratum  corneum.  The  Journal 
of Investigative Dermatology Symposium Proceedings. Society 
for Investigative Dermatology, Inc [and] European Society for 
Dermatological Research. 2001; 6(1):87–94. Epub 2002/01/05.

  37.  Boireau-Adamezyk  E,  Baillet-Guffroy  A,  Stamatas  GN.  Age-
dependent changes in stratum corneum barrier function. Skin 
Res Technol 2014; 20(4):409–15. Epub 2014/02/13.

  38.  Hofmann  H,  Maibach  H.  Transepidermal  water  loss  in  adhe-
sive tape induced dermatitis. Contact Dermatitis 1976; 2(3):171–7. 
Epub 1976/06/01.

  39.  Kottner  J,  Ludriksone  L,  Garcia  Bartels  N,  Blume-Peytavi  U. 
Do repeated skin barrier measurements influence each other's 
results? An explorative study. Skin Pharmacol Appl 2014;27(2):90–
6. Epub 2013/10/26.

 
4

Nail Penetration

Rania Elkeeb, Xiaoying Hui, and Howard I. Maibach

INTRODUCTION
Human nail, equivalent to claws and hooves in other mammals, 
acts as a protective covering for the delicate tips of the fingers 
and toes against trauma, enhances the sensation of fine touch, 
and enables one to retrieve and manipulate objects. The nail is 
also used for scratching and grooming, as a cosmetic organ, and, 
by some, to communicate social status. The nail plate appears as 
a thin, hard, yet slightly elastic, translucent, convex structure (1).
Disorders of the nail resulting from conditions such as 
infections  or  physical-chemical  damage  can  result  in  painful 
and debilitating states, and often change the nail plate's appear-
ance. Onychomycosis, the most common nail plate disorder (2) 
thick ens the nail, makes it white and opaque, and in the toe-
nails it may cause pain while wearing shoes. Onychomycosis 
is a fungal infection of the nail plate—usually caused by the 
species  Epidermophyton,  Microsporum  and  Trichophyton  –  and 
affects 14% of the human population. Aging increases the inci-
dence significantly, with the rate estimated at 48% in persons 
70 years of age (3).

To cure the infection, the patient is obliged to take oral 
systemic medication for an extended period, generally months, 
or  undergo  surgical  nail  removal  (4).  These  treatments  have 
adverse effects such as pain (surgery) and systemic side effects 
(oral treatment). Thus, topical therapy is a desirable approach, 
but has met with limited success. Topical therapy is limited by 
the infection's deep-seated nature and by the ineffective pen-
etration of the deep nail plate by topically applied drugs (5,6).

How  can  topical  drugs  be  delivered  effectively  into  the 
nail? And, perhaps as importantly, how can the drug content in 
the human nail be assessed in order to validate nail drug delivery? 
Our challenge was to develop a system to assay drug content in 
the inner nail bed in which infection often resides. We developed 
a  micrometer-controlled  drilling  instrument  that  removes  and 
collects from the inner nail bed a powder sample from which—
by mass balance recovery—we assay the amount of penetrated 
radio-labeled drug. With this procedure, the effectiveness of topi-
cal nail drug delivery can be assessed (7,8). This paper reviews 
the results of studies undertaken with drilling system.

REVIEW OF NAIL PHYSICAL AND 
CHEMICAL PROPERTIES THAT 
AFFECT TOPICAL PENETRATION
The  human  nail  anatomy  consists  of  nail  plate,  nail  bed,  and 
nail matrix. The nail plate consists of three layers: the dorsal and 
intermediate layers derived from the matrix, and the ventral layer 
from the nail bed (9,10). The upper (dorsal) layer, is only a few cell 
layers  thick  and  consists  of  hard  keratin.  It  constitutes  a  main 
barrier  to  drug  diffusion  into  and  through  the  nail  plate.  The 
intermediate  layer  constitutes  three-quarters  of  the  whole  nail 
thickness,  and  consists  of  soft  keratin.  Below  the  intermediate 
layer is the ventral layer of soft keratin—a few cells thick—that 

connects to the underlying nail bed, in which many pathological 
changes occur. Thus, in the treatment of nail diseases, achieving 
an effective drug concentration in the ventral nail plate is of great 
importance.  The  nail  bed  consists  of  non-cornified  soft  tissue 
under the nail plate. It is highly vascularized. Beneath the nail 
bed is the nail matrix, which is a heavily vascularized thick layer 
of highly proliferative epithelial tissue that forms the nail plate.

The human nail is approximately 100 times thicker than 
the stratum corneum, and both are rich in keratin. However, 
they exhibit some physical and chemical differences (11,12). The 
nail possesses high sulphur content (cystine) in its hard kera-
tin domain, whereas the stratum corneum does not. The total 
lipid  content  of  the  nail  ranges  from  0.1%  to  1%,  as  opposed 
to approximately 10% for the stratum corneum. This suggests 
that the role of the lipid pathway in the nail plate is probably of 
much less importance than that in the stratum corneum. The 
human  nail  acts  like  a  hydrophilic  gel  membrane,  while  the 
stratum corneum acts like a lipophilic partition membrane.

Under  average  conditions,  the  nail  contains  7%–12% 
water, in comparison to 25% in the stratum corneum. At 100% 
relative  humidity,  the  maximal  water  content  in  the  nail  is 
approximately 25%, in sharp contrast to the stratum corneum 
that can increase its water content to 200%–300%. The rate of 
chemical  penetration  into/through  the  human  nail  depends 
upon its water solubility (11) and its molecular size (12).

Topical  therapy  for  onychomycosis  has  been  largely 
ineffective, and this failure may be due to minimal drug pen-
etration  into  the  nail  plate  (5).  The  nail's  unique  properties, 
particularly its thickness and relatively compact construction, 
make it a formidable barrier to the entry of topically applied 
agents  (6).  The  concentration  of  an  applied  drug  across  the 
nail drops about 1000-fold from the outer to the inner surface 
(13). As a result, the drug concentration presumably does not 
reach a therapeutically effective level in the inner ventral layer. 
The existing clinical evidence suggests that a key to success-
ful treatment of onychomycosis by a topical antifungal prod-
uct  lies  in  effectively  overcoming  the  nail  barrier.  Currently 
available  topical  treatments  have  limited  effectiveness,  pos-
sibly because they cannot sufficiently penetrate the nail plate 
to transport a therapeutically sufficient quantity of antifungal 
drug to the target sites (14) and eradicate the infection.

To  achieve  an  effective  chemical  concentration  into/
through the human nail plate, penetration enhancers that tend 
to promote diffusion through the skin's horny layer have been 
studied. However, these studies were conducted on a few lim-
ited nail penetration models that may not provide an intimate 
contact  between  the  receptor  compartment  and  the  nail  sur-
face, and the nail plate can be easily hydrated beyond normal 
levels  (6,11,12,14,15).  Moreover,  nail  samples  prepared  with 
scalpel or sandpaper are time consuming, and may not accu-
rately represent the three nail compartment structures (10,16).

Challenges in Overcoming the 
Nail Permeation Barrier
Overcoming  low  ungual  permeability  to  xenobiotics  can 
be  achieved  by  several  approaches,  and  is  an  active  field  of 
research. Their effectiveness and applicability will vary from 
drug  to  drug  depending  on  the  physicochemical  nature  of 
the compound. A drug absorbed topically must partition into 
the nail bed and maintain concentration higher than the cor-
responding  minimum  inhibitory  concentration  (MIC)  to  be 
effective.

A hypothesized quantitative structure–activity relation-
ship  (QSPR)  model  was  developed  based  on  the  available  in 
vitro data set for eight drugs studied in the laboratory, listed 
in  Table  4.2,  later  in  the  chapter.  (17)  This  small  sample  size 
weakens the predictive power of the model, and a larger sam-
ple is needed to improve predictability. As this model has been 
derived  from  data  in  one  laboratory  where  the  study  design 
and  methodology  of  the  nail  study  and  nail  sampling  have 
been the same with similar sensitivity, precision, and robust-
ness  of  the  analytical  method  using  radioactivity;  thus  one 
main factor contributing to a variation in ungual drug delivery 
in vitro has been eliminated.

Limitations of Current Ungual Drug 
Permeability Studies (18) 
1.  Animal  hooves:  May  not  provide  a  representative  model 
for nail penetration in which diffusion through the human 
nail can be evaluated.

2.  Nail  clippings:  May  not  provide  a  complete  representa-
tive  model  for  nail  permeation  studies  as  they  are  not 
 connected to the nail bed.

3.  Hydration-controlled  method:  Modified  diffusion  cells 
are  a  commonly  used  in  vitro  method  in  ungual  drug 
permeation. These assays super hydrate the nail and pos-
sibly alter the physical property and nail permeability. Hui 
et  al.  modified  the  conventional  modified  diffusion  cells 
commonly used for in vitro studies by using a cotton ball 
soaked in saline to provide moisture (but not saturation), 
and hydrating the nail throughout the experiment.

4.  Correlation  of  in  vitro  onychopharmacokinetics  assays 
and  the  in  vivo  onychopharmacokietics  studies:  The  in 
vitro  data  obtained  with  the  use  of  modified  diffusion 
requires comparison to human in vivo data with the use of 
radioisotopes and possibly attenuated mass spectroscopy. 
Until these correlations are defined and until we enhance 
our understanding of the pathophysiology of the disease, 
biological interpretation remains tenuous (19). Additional 
references are found in Murdan 2002 and 2008 (1,20).

NAIL PENETRATION 

 33

technique developed by Hui et al. enables the determination of 
drug concentration within the plate, where fungi reside. This 
method relies on a drilling system which samples the nail core 
without disturbing its surface. This is achieved by the use of 
a micrometer-precision nail sampling instrument that enables 
finely controlled drilling into the nail as well as the collection 
of the powder created by the drilling process. Drilling of the 
nail occurs through the ventral surface. The dorsal surface and 
ventrally-accessed nail core can be assayed separately. The core 
from  the  ventral  side  provides  drug  measurement  at  the  site 
of  disease  while  the  dorsal  surface  sample  contains  residual 
drug. This method allows for drug measurement in the inter-
mediate nail plate, which was previously impossible (21,22).

Murthy  et  al.  developed  the  TranScreen-NTM  method, 
based on a simple and rapid technique for screening that uses 
a simple microwell plate based high throughput (23).

A novel model of infected nail plate made of human hair 
keratin for testing the efficacy of topical antimicrobial formula-
tion was recently developed by Luisiana and Muller-Goymann 
(24). This was subsequently infected by Trichophton rubrum, 
the  common  causative  agent  of  onychomycosis.  The  infected 
keratin films were treated with selected topical formulations—
cream,  gel,  and  nail  laquer—and  compared  to  bovine  hoof. 
They  demonstrated  that  the  keratin  film  model  was  compa-
rable to the bovine hoof, as both gave an equivalent response 
to  the  tested  antifungal.  The  gel  formulations  were  superior 
to  the  cream.  Thus  this  model  may  be  able  to  differentiate 
between efficacies of different topical antifungal formulations 
based on their activities against T. rubrum.

Infrared (IR) and impedence microscopy (IS) tools have 
been studied to show their usefulness in the development and 
optimization of topical drug delivery systems in treating nail 
diseases. The authors used IR and IS to characterize the effects 
of drug transport enhancement techniques such as hydration, 
iontophoresis,  and  N-acetyl–L-cysteine  on  human  nail  plate. 
The findings utilized nail clippings of healthy human volun-
teers; further testing will be needed to characterize the spec-
troscopic properties of diseased nail and the extent to which 
they  are  modified  by  the  drug  transport  enhancement  tech-
nique used in the study (25).

ADVANCES IN METHODS OF IDENTIFICATION 
OF THE FUNGAL ELEMENTS IN THE NAIL
The conventional method for the identification of a fungus is 
the use of KOH preparation of nail samples with consecutive 
culture of the nail samples on agarose plates as well as histo-
logical  examination  of  the  nail  plate  (26).  These  methods  are 
known to produce false negative results ranging from 20% to 
40%.  If  false  negative  results  are  obtained  in  a  clinically  evi-
dent onychomycosis case, an invasive nail plate punch biopsy 
for giemsa staining may be performed.

ADVANCES IN NAIL PERMEATION 
TESTING AND SAMPLING
Nail topical therapy has been a challenge for scientists due to 
the minimally permeable nature of the nail plate; thus much 
interest has been directed toward finding a more efficient and 
robust screening method.

As mentioned earlier, Hui et al. modified the conventional 
Franz diffusion cell by using a Teflon one-chamber diffusion 
cell (Permegear, Inc., Hellertown, PA) along with a cotton ball 
soaked in normal saline in order to maintain the nail at a physi-
ological levels of temperature and humidity. A novel sampling 

EMERGING NONINVASIVE DIAGNOSTIC 
TOOLS FOR ONYCHOMYCOSIS
Optical Coherence Tomography
This method allows for noninvasive cross-sectional imaging of 
the nail plate. Abuzahra et al. conducted a pilot study to com-
pare  optical  coherence  tomography  (OCT)  with  conventional 
methods. They examined the potential of OCT as a noninva-
sive tool for the diagnosis of onychomycosis. The authors were 
able to demonstrate a reliable pattern for identifying onycho-
mycosis  using  OCT  where  it  detected  fungal  elements  in  all 
histologically positive specimens, and no false positive results 

 
34 

 TEXTBOOK OF COSMETIC DERMATOLOGY

were seen in their controls (27). In contrast to Abuzahra's find-
ings,  Rothmund  et  al.  conducted  a  study  to  evaluate  the  use 
of confocal laser scanning microscopy (CLSM) and OCT as a 
noninvasive diagnostic tool and compare them to established 
techniques.  Rothmund  et  al.  had  a  very  low  specificity  and 
a  high  number  of  false  positive  results  with  the  use  of  OCT, 
possibly  due  to  the  lower  resolution,  which  may  not  allow  a 
clear-cut  differentiation  between  hyphae/spores  and  other 
nail  creases/artifacts,  like  trapped  air,  that  may  appear  simi-
larly (28). Contradictions are an indication for further, larger, 
and more detailed investigations.

Confocal Laser Scanning Microscopy
CLSM is regarded as a helpful noninvasive tool in the diagno-
sis of skin lesions of the human skin, primarily for pigmented 
lesions, as well as other skin tumors and diseases. It has been 
investigated as a noninvasive tool in diagnosis of onychomy-
cosis possibly offering higher precision and faster results com-
pared with KOH preparations. The study by Rothmund et al. 
showed  that  CLSM  had  the  best  specificity  superior  to  KOH 
preparations,  culture,  and  OCT  (28).  One  major  drawback  to 
this technique is the cost.

Methodology
Chemicals/Formulations
[14C]-Urea  (specific  activity  55  mCi/mmol,  99%  purity), 
[7-14C]-salicylic  acid  (specific  activity  55  mCi/mmol,  99% 
purity),  and  [3H(G)]-ketoconazole  (specific  activity  5  Ci/mmol, 
99%  purity)  were  purchased  from  American  Radiolabeled 
Chemicals, Inc. (ARC, St. Louis, MO). [14C]-AN2690 was synthe-
sized by Amersham Biosciences UK Limited (Buckinghamshire, 
UK).  [14C]-Econazole  [chlorophenyl  benzyl-14C]-(D,L)-econazole 
(chemical  name:  1-[2-[(4-chlorophenyl)-methoxy]-2-(2,4-dichlo-
rophenyl)ethyl]-1H-imidazole), 
(pyridinone-
6-(14C)-ciclopirox)  was  obtained 
from  Perkin-Elmer  Life 
Sciences,  Inc.  (Boston,  MA).  [14C]-Terbinafine  freebase  and 
[14C]-terbinafine hydrogen malate were obtained from Novartis 
Pharma AG (Basel, Switzerland). The radiochemical purities and 
specific activities of all chemicals were >98% and >98%, respec-
tively. Penlac1 nail lacquer (ciclopirox 8% topical solution) was 
manufactured by Dermik (Berwyn,PA). 2-n-nonyl-1,3-Dioxolane 
(SEPA), a penetraton enhancer, and all necessary lacquer com-
ponents were provided by MacroChem Corp. (Lexington, MA).

[14C]-ciclopirox 

Formulations
Nails  have  a  high  content  of  disulfide  bonds  (10.6%  versus 
1.2% for human skin), which make the nails both strong and 
impenetrable.  To  deliver  a  therapeutically  sufficient  quantity 
of  an  antifungal  drug  to  fungally-infected  sites,  such  as  nail 
plate, bed, and matrix, a suitable carrier is needed to enhance 
drug penetration through the nail barrier. In the case of urea, 
ketoconazole,  and  salicylic  acid,  a  lotion  (Pennsaid  lotion, 
Dimethaid  Research  Inc.,  Markham,  Ontario,  Canada.)  con-
taining  the  penetration  enhancer  dimethylsulfoxide  (DMSO) 
had  previously  been  shown  to  enhance  skin  penetration 
(7,8,29). To test these three drugs, we prepared three formula-
tions with [14C]-urea, [3H]-ketoconazole and [14C]-salicylic acid 
at  0.002%,  0.1%,  and  0.07%,  respectively,  and  corresponding 
saline controls with each drug at the same concentrations (7).

For the antifungal drugs econazole, terbinafine free base, 
and terbinafine salt, we used a nail lacquer formulation, which 
is a popular choice for topical antifungal treatment. Nail lac-
quer contains a film-forming agent and a solvent, in addition 

to  the  antifungal  drug,  and  possibly  a  penetration  enhancer. 
Once  the  lacquer  is  applied,  it  forms  a  thin,  water-insoluble 
film  containing  the  supersaturated  antifungal  drug.  This 
provides  a  chemical  gradient  to  drive  drug  flux  as  the  drug 
is released. Thus, a lacquer formulation is suitable for topical 
treatment  of  nail  diseases.  We  selected  a  commercial  lacquer 
formulation,  EcoNail™  (MacroChem  Corp).  The  components 
of this lacquer formulation include econazole with penetration 
enhancer,  2-n-1,3-nonyl-dioxolane  (18%)  and  were  assembled 
into a test formulation in the lab prior to use (8). The control is 
the same formulation minus 2-n-1,3-nonyl-dioxolane.

[14C]-Ketoconazole  was  mixed  with  a  filming  solution, 
Time Off Nail (Neutrogena Corporation, Los Angeles, CA) to 
be a final 2% nail lacquer formulation. 2% [14C]-Ketoconazole 
commercial cream was purchased from TEVA Pharmaceuticals 
USA (Sellersville, PA) and used for control.

AN2690 

(5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxa-
borole) was obtained from Anacor Pharmaceuticals, Inc. (Palo 
Alto, CA). Trace amount of [14C]-AN2690 was mixed with pro-
pylene glycol/ethanol (1:4, v/v) to a final 10% (w/v) test formu-
lation (30). Penlac® nail lacquer (ciclopirox 8% topical solution) 
was manufactured by Dermik (Berwyn, PA) (31). Trace amount 
of [14C]-ciclopirox was mixed with the lacquer to be a control.

Human Fingernail Plates
Nail  plates  were  collected  from  adult  human  cadavers  and 
stored in a closed container at 0°C. Before each experiment, nail 
samples were gently washed with normal saline to remove any 
contamination,  then  rehydrated  by  placing  them  for  3  hours 
on  a  cloth  wetted  with  normal  saline.  Nail  samples  were  ran-
domly selected and allocated to test groups. Nail thickness was 
measured by a Sony microdigital meter (Sony Magnescale Inc., 
Japan) before testing in order to determine the drilling depth for 
each nail. Five nails were used for each formulation tested.

Dosing and Surface Washing Procedures
A  10-µl  dosing  aliquot  of  each  of  the  test  formulations  was 
applied  to  the  surface  of  a  nail  plate  with  a  microsyringe. 
Topical application was usually conducted in the morning. For 
twice  daily  dosing,  a  second  one  was  done  in  the  evening,  8 
hours  after  morning  application.  Surface  washing  to  remove 
the residue dose was done in the morning, 24 hours after the 
previous morning application, and 10 minutes prior to the next 
one if necessary. The nail was washed with cotton tip swabs in 
a cycle as follows to simulate daily bathing: a dry swab, then 
a swab wetted with 50% Ivory liquid soap (Procter & Gamble, 
Cincinnati,  Ohio),  then  a  swab  wetted  with  distilled  water, 
then another swab wetted with distilled water, then a final dry 
swab. The nails treated with lacquer also received an alcohol 
wash to remove residual lacquer that was insoluble in soap and 
water. The samples from each cycle from each nail were pooled 
and  collected  by  breaking  off  the  cotton  swab  into  scintilla-
tion  glass  vials.  An  aliquot  of  5.0  ml  methanol  was  added  to 
each vial to extract the test material. The radioactivity of each 
sample was measured in a liquid scintillation counter.

Nail Incubation
To  keep  the  nail  at  physiological  levels  of  temperature  and 
humidity,  we  incubated  it  in  a  Teflon  one-chamber  diffusion 
cell  (PermeGear,  Inc.,  Hellertown,  PA).  The  nail  surface  (top 
center) was open to air and the inner surface made contact with 
a small cotton ball acting as a nail supporting bed (Figure 4.1). 
The cotton ball was wetted with normal saline. The incubation 
period  started  24  hours  prior  to  the  first  dose,  and  ended  24 

 
NAIL PENETRATION 

 35

After  completion  of  the  dosing  and  incubation  phase, 
the nail plate was transferred from the diffusion cell to a clean 
cutting  holder  for  sampling.  The  nail  plate  was  secured  in 
position  so  that  the  ventral  surface  faced  the  cutter  and  the 
dorsal-dosed surface faced the holder. The cutting holder was 
moved to bring the plate surface just barely in contact with the 
cutter tip. The drill was then turned on and a fine adjustment 
moved  the  stage  toward  the  cutter  tip,  removing  a  powder 
sample from the nail. In this way, a hole approximately 0.3–0.4 
mm in depth and 7.9 mm in diameter was drilled in each nail, 
enabling the harvest of powder sample from the center of each 
nail's ventral surface. We refer to these samples as having been 
taken from the “ventral/intermediate nail plate.”

After  the  nail  had  delivered  its  ventral/intermediate 
nail plate powder samples, it was removed from the sampling 
instrument.  The  nail  outside  the  dosing  area  was  cut  away 
and  discarded.  The  nail  within  the  dosing  area  but  outside 
the  sampling  area  was  trimmed  away  and  saved;  we  refer 
to  this  as  the  “remainder  nail  plate.”  It  surrounds  the  dorsal 
layer above the sampling area where the powder samples were 
taken; we refer to this as the “sampling area dorsal nail plate.” 

Dorsal layer

Topical dose

Dorsal/intermediate center

Intermediate layer

Remainder nail

Ventral layer

Ventral/intermediate center

Cutting tip
for nail sampling

Figure 4.2  Nail and nail drilling tip.

hours after the final dose. A small cotton ball wetted with 0.1 
mL normal saline was placed in the chamber beneath the nail 
plate to serve as a “nail bed” and provide moisture for the nail 
plate, and hydration was monitored and controlled during the 
experiment  (7,8).  This  cotton  ball  method  prevented  overhy-
dration of a liquid interface. Cotton is a hydrophilic fiber which 
can  contain  a  high  degree  of  moisture  content  and  absorbs 
water-soluble substances. It also absorbs lipophilic substances, 
which can fill the lumen and lie between the numerous inter-
nal  layers  of  the  cotton  (32).  Thus  the  cotton  ball  is  an  ideal 
receiving medium for in vitro transungual delivery.

Nail Sampling
The  objective  was  to  determine  drug  concentration  within 
the nail where the disease resides. Treatment is applied to the 
nail surface. The drilling system samples the inner core of the 
nail without disturbing the nail surface. The two parts (sur-
face  and  inner  core)  can  be  assayed  separately.  The  surface 
contains  only  residual  drug  after  washing.  The  drilled-out 
core (from the ventral side) is thus a true drug measurement 
at the target site where the disease resides (Figure 4.2). Drug 
penetration into the nail was sampled by a unique microm-
eter-controlled nail sampling instrument that enabled finely 
controlled drilling into the nail and collection of the powder 
created by the drilling process (7,8). The nail sampling instru-
ment (Figure 4.3) has two parts, a nail sample stage and a drill. 
The nail sampling stage consists of a copper nail holder, three 
adjustments,  and  a  nail  powder  capture.  The  three  adjust-
ments control vertical movement. The first coarse adjustment 
(on the top) is for changing the copper cell and taking powder 
samples from the capture. The other two adjustments (lower) 
are  used  in  sampling.  The  second  coarse  adjustment  allows 
movement  of  25  mm  while  the  fine  adjustment  provides 
movement  of  0.20  mm.  The  nail  powder  capture  is  located 
between the copper cell and the cutter. The inner shape of the 
capture is an inverted funnel with the end connected to a vac-
uum  pump.  By  placing  a  filter  paper  inside  the  funnel,  nail 
powder  samples  can  be  captured  on  the  filter  paper  during 
sampling. The nail is fastened in a cutting holder below the 
cutter and surrounded by a funnel containing a filter paper. 
The  funnel  is  attached  to  a  vacuum  pump.  During  drilling, 
the vacuum draws the powder debris onto the filter paper so 
it can be collected and measured and increase total collection 
for mass balance determination.

Cotton ball

Top cover & metal holder

Nail chamber

Figure 4.1  Nail support and incubation system in a Teflon one-
chamber diffusion cell. The cotton ball prevented the over hydra-
tion  of  a  liquid  interface.  Cotton  is  a  hydrophilic  fiber  which  can 
contain  a  high  degree  of  moisture  content  and  absorbs  water-
soluble substances. It also absorbs lipophilic substances, which 
can fill the lumen and lie between the numerous internal layers of 
the cotton (32). Thus the cotton ball is an ideal receiving medium 
for in vitro transungual delivery.

Figure  4.3  The  nail  sampling  system.  The  instrument  has  two 
parts,  a  stage  and  a  drill.  The  stage  consists  of  a  copper  nail 
holder,  three  adjustments,  and  a  nail  powder  capture.  During 
drilling, the vacuum draws the powder debris onto the filter paper 
so it can be collected and measured and increase total collection 
for mass balance determination.

 
36 

 TEXTBOOK OF COSMETIC DERMATOLOGY

The  ventral/intermediate  nail  plate  powdered  samples,  the 
sampling area dorsal nail plate, and the remainder nail plate 
were  individually  collected  into  a  glass  scintillation  vial  and 
weighed. The nail samples were then dissolved by adding 5.0 
mL of Packard's Soluene®-350 (Packard Instrument Company, 
Meriden, CT). The total mass of nail collected was measured 
by the difference in weight of the plate before and after drill-
ing (7,8).

Results
Nail Incubation Conditions
Table 4.1 shows that the average hydration of the wetted cot-
ton balls 109 ± 6.2 AU (arbitrary units [a digital expression of 
capacitance]) that resembles the average hydration of human 
nail  bed,  99.9  ±  8.9  AU  measured  from  fresh  human  cadav-
ers.  During  the  experiment,  the  holding  tank  temperature 
was 25 ± 2ºC and relative humidity was 44 ± 8%. Thus, there 
was  no  statistical  difference  between  hydration  conditions 
for nails treated with either the test formulation or the saline 
control.  This  incubation  device  is  nonocclusive  and  hydra-
tion  controlled,  and  approximate  normal  physical  condition 
is reached.

Accuracy of Nail Sampling Process
The  advantage  of  the  micrometer-controlled  drilling  and 
nail  powder  removal  system  is  the  accuracy  of  the  sampling 
process.  The  sampling  instrument  allowed  well-controlled, 
accurate, and reproducible sampling of the inside of the nail. 
Table 4.2 shows that the average depth of nail sampling from 
the inner center surface was well controlled at 0.26 ± 0.05 mm, 
which was close to the expected depth of 0.24 mm. The weight 
of the nail samples collected was consistent for all experiments.

Mass Balance of Radioactivity Recovery
Table 4.3 summarizes the econazole mass balance recovery fol-
lowing the 14-day nail treatment. Overall recovery of applied 
dose was 90.8 ± 16.4% for the test formulation and 96.4 ± 7.3% 
for the saline control, indicating that essentially the entire dose 
was accounted for. 

Table  4.3  also  indicates  what  happens  to  chemicals 
applied to the nail. Approximately 72% was washed from the 
surface. The dose absorbed from the surface of the nail pene-
trated to the sampling area dorsal nail plate (11.4%), the ventral/
intermediate  nail  plate  (1.4%),  and  the  supporting  bed  (0.7%), 
which is the cotton ball upon which the nail rested. Note that 
econazole recovery in the test formulation is greater for both 
the  ventral/intermediate  nail  plate  and  the  supporting  bed, 

which is an effect of the drug delivery enhancer. At the sam-
pling area dorsal nail plate, there is more econazole from the 
saline control because the dose remained on the nail surface.

Effects of Dosing and Washing Frequency
Figures  4.4  and  4.5  show  the  weight  normalized  of  14C  econ-
azole equivalent in different layers of the nail plate and cumu-
lative  14C  econazole  equivalent  collected  in  the  cotton  ball 
supporting bed following different frequency of topical dosing 
or surface washing treatments. As expected, after twice daily 
application  (and  surface  washing  once  daily)  for  14  days,  the 
14C econazole content in all nail and cotton ball samples was 
significantly higher than that in the dosing and washing once-
daily  group  (p  <  0.05).  Comparison  of  the  once-daily  dosing 
and washing treatment group and the once-daily dosing and 
once-weekly  washing  group  did  not  show  significant  differ-
ence for all collected samples (p > 0.05).

Enhancer Effects
Table  4.4  summarizes  the  penetration  of  ketoconazole,  urea, 
and  salicylic  acid  into  the  human  inner  nail  plate.  Each  test 
formulation contained a drug delivery enhancer (7,8) and was 
compared  to  a  control  formulation  without  any  penetration 
enhancer.  In  each  case  the  test  formulation  enhanced  drug 
delivery  (p  <  0.05).  Table  4.5  compares  antifungal  efficacy  of 
econazole,  terbinafine  base,  and  terbinafine  salt  following 
topical  applications.  Each  test  antifungal  agent  contains  18% 
2-n-nonyl-1,3-dioxolane  (SEPA),  a  skin  penetration  enhancer, 
and the control (no 18% 2-n-nonyl-1,3-dioxolane). All test for-
mulations show the antifungal efficacy coefficient (E) was sig-
nificantly higher than that of corresponding control (p < 0.05).

Topical Formulation Comparison
Table  4.6  compares  [14C]-ciclopirox  penetration  into/through 
nail plate in vitro from three topical formulations: market gel, 
experimental  gel,  and  lacquer.  The  order  of  deeper  penetra-
tion, amount detected in the ventral/intermediate nail center, 
and cotton ball supporting bed samples was from the highest 
to the lowestmarket gel, lacquer, and experimental gel, respec-
tively. Figure 4.6, however, shows that the deeper penetration 
of a lacquer formulation of ketoconazole was greater than that 
of cream when comparing their antifungal efficacy coefficient 
(p < 0.05).

DISCUSSION
Topical therapy for onychomycosis is not yet maximally effective, 
and this failure may be due to inadequate penetration of drugs 

Table 4.1  Hydration of Nail Plate and Nail Bed

Source

Human cadavers

Diffusion cells

N

6
8

Measurement*

Time

24-hr post mortem
Twice/day for 7 days

Hydration (AU)**

Nail plate

7.6 ± 0.9
8.5 ± 2.4

Nail bed

99.9 ± 8.9
109.9 ± 6.2

Note:  During the experiment, the holding tank temperature was 25 ± 2°C and relative humidity was 44 ± 8%. The importance of this controlled tem-
perature and humidity is to mimic normal physiological condition of the human nail to prevent over hydration which was easily occurred in nail in vitro 
studies.
*Hydration of the nail plate and the supporting cotton bed was measured with a Corneometer CM 820 (Courage & Khazaka, Cologne, Germany).
**AU, arbitrary units—a digital expression of capacitance. Thus the Corneometer CM 820 gives only an estimate of the nail (or other membrane such 
as stratum corneum) hydration. Agache et al. (33) used a sorption–desorption test to assess the water content of the stratum corneum. They corre-
lated the results measured with the Corneometer CM 820 (as AU unit) and TEWL (g.m–2.h–1) measured with an evaporimeter and found that water 
retained in the SC(µg.cm–2) = In(AC/3.8)/0.0436.

 
NAIL PENETRATION 

 37

Table 4.2  Nail Core Sampled from the Ventral (Inner) Surface Center of the Human Nail Plate

Test

Urea (control) 

Urea (test)

Ketoconazole (control)

Ketoconazole (test)

Salicylic acid (control)

Salicylic acid (test)

Average

Nail core sampled from the ventral (inner) surface center of the nail plate*

Whole nail 
thickness (mm)

Depth of core 
(mm)

% Whole nail 
thickness

Total core sample 
removed (mg)

Powder sample 
collected (mg)

0.65
(0.09)

0.71
(0.07)

0.68
(0.05)

0.73
(0.03)

0.77
(0.07)

0.60
(0.12)

0.69
(0.09)

0.25
(0.03)

0.27
(0.03)

0.28
(0.03)

0.28
(0.02)

0.25
(0.08)

0.21
(0.06)

0.26
(0.05)

39.52
(8.05)

37.97
(2.69)

41.88
(1.16)

38.62
(2.69)

32.62
(9.38)

35.03
(6.45)

37.61
(6.20)

16.4
(4.3)

17.6
(4.3)

14.3
(6.7)

14.1
(5.1)

12.1
(2.4)

23.4
(8.3)

16.3
(6.2)

5.2
(0.8)

6.4
(1.3)

6.7
(2.6)

4.3
(1.6)

6.0
(0.5)

4.7
(0.8)

5.5
(1.6)

Source: Hui X et al., J Pharm Sci; 91:189–95, 2002.
*Nail sample, approximately 0.24 mm in depth and 7.9 mm in diameter, was drilled from the center of the ventral surface of the nail. The amount of 
nail sample removed was measured by difference in weight and depth of the drilled area before and after sampling. Each number represents mean 
(± S.D.) of 5 samples. The data demonstrated the repeatability and accuracy of the nail sampling system.

Table 4.3  Mass Balance Recovery of Econazole following 14-Day Human Nail Treatment with a Test Formulation Containing a 
Penetration Enhancer and a Control without a Penetration Enhancer

Sampling Area

Dorsal//intermediate nail plate

Ventral/intermediate nail plate (powdered 

samples)

Remainder nail plate

Supporting bed (cotton ball)

Surface washes

Total

Carbon-14 recoveryas percent of dose

Test Formulation

Control Formulation

11.4 (3.6)

1.3 (1.1)

5.6 (3.9)

0.7 (0.3)

71.7 (12.5)
90.8 (16.4)

20.1 (2.9)

0.22 (2.9)

3.2 (2.3)

0.0 (0.0)

72.8 (5.1)
96.4 (7.3)

Source: Hui X et al., J Pharm Sci; 92:142–8, 2003.
Note: The data represent the mean (SD) of each group (n = 5). The test formulation group contains 18% 2-n-nonyl-1,3-dioxolane and the control 
formulation contains no 2-n-nonyl-1,3-dioxolane. The data demonstrated not only the importance of the penetration enhancer but the high recovery 
rate of two groups when using the nail sampling system.

into  the  nail  plate.  The  nail's  unique  properties,  particularly  its 
thickness and relatively compact construction, make it a formi-
dable barrier to the entry of topically applied agents. The concen-
tration of an applied drug across the nail drops about 1000-fold 
from the outer surface to the inner surface. As a result, the drug 
concentration presumably does not reach a therapeutically effec-
tive level in the ventral/intermediate layers. To optimize the nail 
penetration of topical treatments, it is important to consider the 
nail's unique barrier properties and develop an antifungal drug 
formulation that has matching physicochemical properties.

Nail  lacquer  formulations,  a  popular  choice  for  topical 
antifungal  treatment,  typically  contain  a  film-forming  agent, 
solvent, antifungal drug, and possibly a penetration enhancer. 
Once the lacquer is applied, it forms a thin film containing a 
supersaturated  antifungal  drug.  This  film  provides  a  chemi-
cal  gradient  to  drive  drug  flux  as  the  drug  is  released.  For 

example, 14C-ketoconazole lacquer yields a significantly higher 
antifungal  efficacy  coefficient  than  that  in  cream  (p  <  0.05; 
Figure 4.6). However, the deeper penetration of [14C]-ciclopirox 
from the commercially available formulation, Penlac nail lac-
quer  (ciclopirox  8%  topical  solution),  was  statistically  lower 
than that of market gel formulation (ciclopirox 0.77 % topical 
solution) (Table 4.6) (31). When compared with other antifun-
gal  topical  formulations,  such  as  [14C]-AN2690,  10%  (w/v)  in 
propylene  glycol/ethanol  solution,  it  decreased  (p  <  0.05)  the 
deeper nail layer penetration rate (Figure 4.7) (30).

Transungual  enhancement  has  been  examined:  DMSO 
and  2-n-nonyl-1,3-dioxolane  used  as  transdermal  deliv-
ery  enhancers  were  tested  for  enhancement  of  antifungal 
agents  penetrating  into  and  through  the  nail  plate  in  vitro. 
The  two  enhancers  increased  the  deeper  nail  penetration  of 
[14C]-ketoconazole (Table 4.3), [14C]-econazole, [14C]-terbinafine 

 
 
38 

 TEXTBOOK OF COSMETIC DERMATOLOGY

e
l
o
z
a
n
o
c
e
-
C
4
1
d
e
z
i
l
a
m
r
o
n
t
h
g
i
e
W

)
l
i
a
n
g
/
g
µ
(

t
n
e
l
a
v
i
u
q
e

80000

60000

40000

20000

0

*

Dorsal/intermediate nail center 
Ventral/intermediate nail center
Cotton ball supporting bed

*

*

Twice daily

Once daily

Dose frequency

Figure 4.4  Nail penetration profile of  14C-econzaole following a 14-day treatment/incubation period in vitro. Each bar represents the 
mean (SD) of 6 samples. The frequency of topical dosing was different but the surface wash was the same, once daily. *The group that 
received twice-daily topical doses was statistically significantly higher than the one treated with a once-daily dose (p < 0.05).

Dorsal/intermediate nail center
Ventral/inermediate nail center
Cotton ball supporting ball

t
n
e
l
a
v
i
u
q
e
e
l
o
z
a
n
o
c
e
-
C
4
1
d
e
z
i
l
a
m
r
o
n
t
h
g
i
e
W

70000

60000

50000

40000

30000

)
l
i
a
n
g
/
g
µ

(

20000

10000

0

Once daily

Once weekly

Surface washing frequency

Figure 4.5  Nail penetration profile of  14C-econzaole following a 
14-day treatment/incubation period in vitro. Each bar represents 
the  mean  (SD)  of  6  samples/group.  Each  group  received  once-
daily  topical  application  for  14  days.  The  frequency  of  surface 
washing  for  each  group  was  different.  The  group  that  received 
daily washing was not statistically significant from the correspond-
ing bar from the once-weekly washing group (p > 0.05).

salt, [14C]-terbinafine base (Table 4.5) significantly compared to 
the controls (p < 0.05). DMSO has been previously reported to 
facilitate the penetration of some topical antimycotics  (15,35). 
The enhancement function of 2-n-nonyl-1,3-dioxolane has not 
previously  been  determined.  The  mechanism  of  2-n-nonyl-
1,3-dioxolane in skin penetration was suggested to reversibly 
fluidize the stratum corneum lipids and alter barrier function 

(36).  However,  [14C]-dioxolane,  the  radiolabeled  2-n-nonyl-
1,3-dioxolane,  had  minimal  penetration  to  and  through  the 
human nail plate in vitro (8). 2-n-nonyl-1,3-dioxolane can func-
tion  as  an  adhesion  promoter  and  a  plasticizer  for  the  film-
forming polymer of the nail lacquer (37,38). The enhancement 
function  of  2-n-nonyl-1,3-dioxolane  for  the  tested  antifungal 
agents was possibly to soften the lacquer film to increase releas-
ing  per-unit  time  (8).  As  shown  in  Table  4.5,  the  amounts  of 
[14C]-econazole, [14C]-terbinafine free base, and [14C]-terbinafine 
salt detected from the deeper layer, ventral/intermediate nail 
layer  in  the  test  groups,  which  the  lacquer  formulation  con-
tains  18%  2-n-nonyl-1,3-dioxolane  were  significantly  greater 
than that in the controls (p < 0.05). The results suggest that the 
enhanced level of these antifungal agents in the ventral/inter-
mediate  layers  and  supporting  bed  dramatically  increased, 
which  exceeds  the  minimum  inhibitory  concentration  (MIC) 
of  econazole  for  most  common  onychomycosis  organisms 
(Table 4.5).

MIC is a laboratory index in the determination of anti-
fungal  potency.  Mertin  and  Lippold  (11)  introduced  an  effi-
cacy coefficient E to better estimate and compare the relative 
efficacy of antifungal agents. The efficacy coefficient E is the 
ratio of the flux of an antimycotic drug through the nail plate 
to the MIC. For econazole, the range of MIC for the dermato-
phyte species is 0.1 to 1.0 µg/mL and for yeast species it is 1.0 
to  100  µg/mL  (39).  After  14  days  of  exposure,  the  econazole 
content  measured  in  the  test  group  was  11.15  ±  2.56  µg/mg 
for  the  ventral/intermediate  layers.  This  content,  multiplied 
by  the  density  of  the  nail  sample  (1.332  mg/cm3,  measured 
under  current  experimental  conditions),  yields  14,830  ±  340 
µg/cm3  of  econazole,  almost  15,000  times  the  MIC  for  most 
dermatophyte species and 150 times that for most yeast spe-
cies (Table 4.5).

This study demonstrated that with our in vitro nail study 
methodology, the nail plate can be scientifically studied, and 
with proper formulation one can deliver a variety of chemicals, 

 
 
 
 
 
 
 
 
 
 
NAIL PENETRATION 

 39

Table 4.4  Radiolabeled Drug Penetration into Human Nail from a Test Formulation Containing DMSO, a Penetration Enhancer, versus 
a Control without a Penetration Enhancer

Radioactivity content in ventral/intermediate center layer of the nail plate

Test chemicals

Ketoconazole

Penetration 
Enhancer*

Dimethylsulfoxide

Urea

Dimethylsulfoxide

Salicylic acid

Dimethylsulfoxide

Unit** 

µg
Eq/g

µg
Eq/g
µg Eq/g

Test formulaton

Control 
formulation

Significant
(p < 0.05) 

53.9
(10.6)

0.3
(0.1)

10.2
(0.6)

34.0
(15.9)

0.2
(0.1)
7.0
(1.1)

Yes

Yes

Yes

Source: Hui X et al., J Pharm Sci 91:189–95, 2002.
Note: The data represent the mean (SD) of 5 samples per formulation group. The nail sample drilled as powder from ventral/intermediate layer of 
human nail plate.
*Dimethylsulfoxide (DMSO) is a transdermal delivery enhancer. The enhancement mechanism of transungual delivery is not clear. However, it did 
enhance the nail penetration of the test chemicals.
**µg Eq/g = microgram equivalents drug per gram of nail sample. Because radioactivity is used, the drug mass is referred to as “equivalents” because 
radioactivity was measured, not the drug itself.

Table 4.5  Comparison of Econazole Concentration and Relative Antifungal Efficacy with a Test Formulation Containing 2-N-Nonyl-
1,3-Dioxolane, a Penetration Enhancer, and a Control

Parameter*

Econazole in the deeper layer 

(µg/cm3)
ED (MICD = 1 µg/mL)
EY (MICY = 100 µg/mL)

Terbinafine salt in the deeper 

layer (µg/cm3)
ED (MICD = 0.04 µg/mL) **
EY (MICY = 1.77 µg/mL) **
Terbinafine base in the deeper 

layer (µg/cm3)
ED (MICD = 0.04 µg/mL) c
EY (MICY = 1.77 µg/mL) c

Test formulation

14,830 (341)

14,830

148

5946 (1029)

5946

134

727 (372)

1527
34

Control formulation

Significant(p < 0.05)

2,371 (426)

2,371

23.7

463 (271)

463

10

407 (106)

156
3

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes
Yes

Note: The data represent the mean (SD) of each group (n = 5). The test formulation group contains 18% 2-n-nonyl-1,3-dioxolane and the control 
formulation contains no 2-n-nonyl-1,3-dioxolane.
Abbreviations: E, antifungal efficacy coefficient; MIC, minimum inhibitory concentration (of the tested antifungal agent); D, dermatophytes; Y, yeast. 
(Reference 8)
*The deeper layer is the center of the ventral/intermediate layer of the nail plate. The data represent the amount of drug in the sample after a 14-day 
dosing period. The amount of antifungal agents in the tested nail layer (µg/cm3) was computed from the average of the cumulative amount of the test 
agent permeated into the area (area × thickness) of the deeper layer of the nail (dorsal/intermediate layer).
**See Reference 34.

Table 4.6  Summary of Weight Normalized 14C-Ciclopirox Equivalent in the Nail and Supporting Bed Samples after 14-Day Treatment

Items (Unit)

Marketed Gel

Experimental Gel

Lacquer

Significant (if P value < 0.05)

Normalized 14C-Ciclopirox Equivalent

Dorsal/intermediate center within 

surface of nail

(μg eq/mg)

Ventral/intermediate center within 

infection-prone area

(μg eq/mg)

Penetration through the nail into the 

supporting bed cotton ball

(μg eq/sample)

71.7
(16.8)

0.6
(0.3)

46.3
(4.1)

Source: Hui X et al., J Pharmaceut. Sci; 93:2545–8, 2004.
Note: The data represents the mean (SD) of each group (n = 5).

103.4
(38.1)

0.2
(0.1)

6.0
(1.3)

2162.1
(526.4)

Lacquer vs experimental gel
Lacquer vs marketed gel

0.3
(0.1)

15.5
(3.1)

Marketed gel vs lacquer

Marketed gel vs experimental gel
Experimental gel vs lacquer

Marketed gel vs lacquer
Marketed gel vs Eexperimental 

gel

Experimental gel vs lacquer

 
40 

 TEXTBOOK OF COSMETIC DERMATOLOGY

*

ED (MIC = 0.125 µg/mL)
EV (MIC = 0.190 µg/mL)

*

e
l
o
z
a
n
o
c
o
t
e
k
f
o
)
E
(

t
n
e
i
c
i
f
f
e
o
c
y
c
a
c
i
f
f
E

500

400

300

200

100

0

Lacquer

Cream

Figure 4.6  Comparison of antifungal efficacy coefficient of two 
ketoconazole formulations, lacquer and cream. Each bar repre-
sents the mean (SD) of 5 samples/group. Each group received 
a  once-daily  topical  dose  and  washing  for  a  7-day  treatment. 
The lacquer group shows that the antifungal efficacy coefficient 
was statistically significantly higher than that of the cream group 
(p < 0.05).

14C-AN2690
14C-Ciclo pirox

t
n
e
l
a
v
i
u
q
e
g
m
s
a
y
t
i
v
i
t
c
a
o
d
a
r
e
v
i
t
a
l
u
m
u
C

i

l
l
l
a
b
n
o
t
t
o
c
n

i

5

4

3

2

1

0

0

3

6

9

12

15

Time (days)

Figure 4.7  Cumulative amounts of AN 2690 and ciclopirox (mg 
equivalent)  in  cotton  ball  supporting  bed  samples  following  a 
14-day treatment. The test   were dosed daily and the dose resi-
due was washed 24 hours later and 10 minutes prior to the next 
application.  Each  bar  represents  the  mean  (SD)  of  6  samples/
group. Each bar of the AN2690 group was statistically higher than 
the corresponding one from the ciclopirox group (p < 0.05). (From 
Hui X et al., J Pharmaceut Sci; 96:2622–31, 2007.)

including drugs or nail modifiers (cosmetics). The nail is now 
ready for serious attention and treatment just as hair and skin 
have been in the past. The nail barrier can be breached.

These findings presumably relate to delivery of cosmetic 
agents for the management of nail abnormalities, such as nails 
that  are peeling or fragile. R&D on these agents will be  sim-
plified when the rules describing the relationship of physical 
chemistry to flux are developed for the nail, as they have been 
in part for the skin.

Taken  together,  the  methodology  appears  robust;  as 
with other models, inclusion of other chemicals with varying 
physicochemical  properties,  and  in  vivo  replication  will  add 
strength to the results.

REFERENCES

1. Murdan S. Drug delivery to the nail following topical applica-

tion. Int J Pharm 2002; 236: 1–26.

2.  Tayloor EJ, ed. Dorland's Illustrated Medical Dictionary, 27th edi-

tion. Philadelphia: Saunders, 1988.

3.  Elewski B, Charif MA. Prevalence of onychomycosis in patients 
attending a dermatology clinic in northeastern Ohio for other 
conditions. Arch Dermatol 1997; 133:1172–3.

4.  Nolting S and Korting HC, eds. Onychmycoses - local antimycotic 

treatment. New York: Springer-Verlag, 1990.

5.  Meisel CW. The treatment of onychomycosis. In: Nolting S and 
Korting  HC,  eds.  Onychmycoses  -  Local  Antimycotic  Treatment. 
New York: Springer-Verlag, 1990; pp. 12–28.

6.  Walters  KA,  Flynn  GL.  Permeability  characteristics  of  the 

human nail plate. Int J Cosmetic Sci 1983; 5:231–46.

7.  Hui  X,  Shainhouse  JZ,  Tanojo  H,  et  al.  Enhanced  human  nail 
drug delivery: Nail inner drug content assayed by new unique 
method, J Pharm Sci 2002; 91:189–95.

8.  Hui X, Barbadillo S, Lee C, et al. Enhanced econazole penetra-
tion into human nail by 2-N-nonyl-1,3-dioxane, J Pharm Sci 2003; 
92:142–8.

9.  Runne U, Orfanos CE. The human nail - structure, growth and 

pathological changes. Curr Probl Dermatol 1981; 9:102–49.
  10.  Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y. Drug 
permeation through the three layers of the human nail plate. J 
Pharm Pharmacol 1999; 51:271–8.

  11.  Martin D, Lippold BC. In vitro permeability of the human nail 
and  a  keratin  membrane  from  bovine  hooves:  Influence  of 
the  partition  coefficient  octanol/water  and  the  water  solubil-
ity of drugs on their permeability and maximum flux. J Pharm 
Pharmacol 1997; 49:30–4.

  12.  Martin D, Lippold BC. In vitro permeability of the human nail 
and a keratin membrane from bovine hooves: Prediction of the 
penetration rate of antimycotics through the nail plate and their 
efficacy. J Pharm Pharmacol 1997; 49:866–72.

  13.  Stüttgen G, Bauer E. Bioavailability, skin- and nail penetration 
of topically applied antimycotics. Mykosen 1982; 25:74–80.
  14.  Walters KA, Flynn GL, Marvel JR. Physicochemical character-
ization of the human nail: Solvent effects on the permeation of 
homologous alcohols. J Pharm Pharmacol 1985; 37:771–5.
  15.  Walters KA, Flynn GL, Marvel JR. Physiocochemical character-
ization of the human nail: I. Pressure sealed apparatus for mea-
suring nail plate permeabilities. J Invest Dermatol 1981; 76:76–9.

  16.  Polak  A.  Kinetic  of  amorolfine  in  human  nails.  Mycoses  1993; 

36:101–3.

  17.  Elkeeb  R,  Hui  X,  Elkeeb  L,  et  al.  Onychopharmacokinetics: 
Proposed  model  insight.  In:  Murthy  SN,  Maibach  HI,  eds. 
Topical Nail Products and Ungual Drug Delivery. Boca Raton, FL: 
Taylor and Francis; 2013; p. 215–22.
 Elkeeb R, AliKhan A, Elkeeb L, et al. Transungual drug deliv-
ery: Current status. Int J Pharm 2010; 384:1–8.

  18. 

  19.  Elkeeb  R,  Hui  X,  Murthy  N,  Maibach  HI.  Emerging  topical 
onychomycosis therapies—Quo vadis? Expert Opin Emerg Drug 
2014; 19:489–495.

  20.  Murdan S. Enhancing the nail permeability of topically applied 

drugs. Expert Opin Drug Deliv 2008; 5:1267–1282.

  21.  Hui X, Wester RC, Barbadillo S, Maibach HI. Nail penetration: 
Enhancment of topical delivery of antifungal drugs by chemi-
cal  modification  of  the  human  nail.  In:  Baran  R,  Maibach  HI, 
eds.  Textbook  of  Cosmetic  Dermatology.  New  York:  Taylor  and 
Francis 2005; pp. 57–63.

  22.  Elkeeb  R,  Hui  X,  Maibach  HI.  Hydration-controlled  nail  sys-
tem for the evaluation of topical formulations and a novel nail 
sampling device. In: Murthy SN, Maibach HI, eds. Topical Nail 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAIL PENETRATION 

 41

Products and Ungual Drug Delivery. 1st ed. Boca Raton, FL: Taylor 
and Francis; 2013.

  23.  Murthy  SN,  Vaka  SR,  Sammeta  SM,  Nair  AB.  TranScreen-N: 
Method  for  rapid  screening  of  trans-ungual  drug  delivery 
enhancers. J Pharm Sci 2009; 98:4264–71.

  24.  Lusiana,  Reichl  S,  Muller-Goymann  CC.  Infected  nail  plate 
model made of human hair keratin for evaluating the efficacy of 
different topical antifungal formulations against Trichophyton 
rubrum in vitro. Eur J Pharm Biopharm 2013; 84:599–605.
  25.  Benzeval I, Bowen CR, Guy RH, Delgado-Charro MB. Effects of 
iontophoresis, hydration, and permeation enhancers on human 
nail  plate:  Infrared  and  impedance  spectroscopy  assessment. 
Pharm Res 2013; 30:1652–62.

  26.  Tchernev G, Penev PK, Nenoff P, et al. Onychomycosis: Modern 
diagnostic  and  treatment  approaches.  Wien  Med  Wochenschr 
2012; 163:1–12.

  27.  Abuzahra F, Spoler F, Forst M, et al. Pilot study: Optical coher-
ence  tomography  as  a  non-invasive  diagnostic  perspective  for 
real time visualisation of onychomycosis. Mycoses 2009; 53:334–9.
  28.  Rothmund G, Sattler EC, Kaestle R, et al. Confocal laser scan-
ning microscopy as a new valuable tool in the diagnosis of ony-
chomycosis  -  comparison  of  six  diagnostic  methods.  Mycoses 
2012; 56:47–55.

  31.  Hui X, Wester RC, Barbadillo S, et al. Ciclopirox delivery into 

the human nail plate. J Pharmaceut. Sci 2004; 93:2545–8.

  32.  Hatch  KL,  ed.  Textile  Science.  St.  Paul  Minneapolis:  West 

Publishing, 2006.

  33.  Agache P, Mary S, Muret P, et al. Assessment of the water con-
tent of the stratum corneum using a sorption-desorption test. 
Dermatology 2001; 202:308–13.

  34.  Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, 
terbinafine,  ketoconazole  and  itraconazole  against  der-
matophytes  and  nondermatophytes,  and  in  vitro  evalua-
tion  of  combination  antifungal  activity.  Br  J  Dermatol  2003; 
149:296–305.

  35.  Franz  TJ.  Absorption  of  amorolfine  through  human  nail. 

Dermatology 1992; 184(Suppl 1):18–20.

  36.  Morganti  F,  Bramanti  E,  Solaro  R,  et  al.  Thermal  and  spec-
troscopic  characterization  of  interactions  between  2-n-nonyl-
1,3-diozolane  and  stratum  corneum  components.  J  Bioactive 
Compatible Polym 2000; 14:162.

  37.  Samour CM, Krauser SF. Antifungal nail lacquer and method 

using same. U.S. Patent, May 1 2001; 6,224,887.

  38.  Samour CM, Donaruma LG, Daskalakis S, et al. SEPAs, a new 
class  of  percutaneous  absorption  enhancers.  Proc  Int  Symp 
Controlled Release Bioact Mat 1989; 16:183.

  29.  Hui  X,  Hewitt  HG,  Poblete  N,  et  al.  In  vivo  bioactivity  and 
metabolism  of  topical  diclofenac  lotion  in  human  volunteers. 
Pharm Res 1998; 15:1589–95.

  39.  Thienpont,  D,  Cutsem,  JV,  Nueten,  JMV,  et  al.  Biological  and 
toxicological  properties  of  econazole,  a  broad-spectrum  anti-
mycotic. Arzneim-forsch 1975; 25:224–31.

  30.  Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel 
oxaborole  antifungal  (AN  2690)  into  the  human  nail  plate. 
J Pharmaceut Sci 2007; 96:2622–31.

 
Section II 

Pharmacology of Cosmetic Products and Ingredients

5

Sensitive Skin: New Findings Yield New Insights

Miranda A. Farage and Howard I. Maibach

INTRODUCTION
The goal of product testing is to ensure that consumer products 
are  free  of  irritant  potential  and  to  prevent  unexpected 
consumer reactions to the product once it reaches the market-
place. It is not uncommon, nonetheless, for postmarketing sur-
veillance efforts to receive reports of sensory perceptions not 
predicted by even the most robust methodology (1). These sen-
sory perceptions, though often transient and not accompanied 
by a visual dermatological response in rigorous experimental 
testing, strongly influence consumer product preference (1). In 
fact, 78% of consumers who profess sensitive skin report avoid-
ing some products because of unpleasant sensory effects asso-
ciated with their use (2).

Unpleasant  and  subjective  sensory  effects,  often  unac-
companied by objective physical signs, define a controversial 
and  still  evolving  dermatological  condition  known  as  sensi-
tive skin. Consumer reports of sensitive skin are typically self-
diagnosed and may be increasing (3). The concept of sensitive 
skin  arose  in  the  1970s  with  the  observation  that  despite  the 
fact  that  previous  safety  evaluations  had  found  no  evidence 
of  toxicity,  some  patients  reported  stinging  sensations  upon 
using  a  particular  sunscreen  that  contained  a  derivative  of 
P-aminobenzoic acid (4). Growing consumer awareness of the 
potential  for  irritation  from  common  products  fueled  a  huge 
increase  in  products  marketed  for  the  supposedly  rare  indi-
vidual  with  susceptibility  to  components  of  everyday  prod-
ucts, particularly since no requirement for proof of safety and 
efficacy for such products has existed (5). The initial conceptu-
alization of sensitive skin as a minority complaint has not been 
borne out by epidemiological surveys, which consistently find 
a high prevalence of sensitive skin across the world (Table 5.1).
Sensitive skin is a term whose definition continues to be 
refined. It is now generally agreed to describe unpleasant sub-
jective sensory reactions (such as, prickling, burning, tingling, 
or pain) in response to common external factors (such as ultra-
violet light, heat, cold, wind, cosmetics, cleaning products, etc.) 
and intrinsic stressors (such as stress or hormones) (6). Sensory 
effects  are  only  occasionally  accompanied  by  erythema  or 
other demonstrable irritation or immunological responses (6).

Although  sensitive  skin  is  now  generally  accepted  as  a 
real physiological disorder, there is still no consensus regard-
ing its etiology, classification, or criteria for diagnosis. Several 
issues have hindered a better understanding of this condition. 
It  is  typically  self-diagnosed  (7).  Patients  may  interpret  an 
underlying  dermatological  condition  as  well  as  any  reaction 
to product use as sensitive skin (8). There are also some psy-
chological disorders characterized by similar symptoms (e.g., 
cosmetic  intolerance  syndrome,  dermatological  non-disease) 
(9). Many people who profess sensitive skin do not predictably 
experience  visible  signs  of  the  sensations  reported,  whereas 
some who describe themselves as non-sensitive react strongly 

to tests of objective irritation (10). The diversity of methodology 
approaches  employed  in  sensitive-skin  research  has  also 
contributed  to  interpretive  difficulties.  Further,  much  of  the 
research to date has been published in cosmetic journals that 
are inaccessible through major databases and may be ignored 
by leading dermatological publications (5).

Irritant  testing  reveals  profound  interpersonal  vari-
ability in individual response to specific irritants (11,12), even 
among chemicals with similar modes of action (13). Some have 
reported sizeable variation within the same individual at dif-
ferent anatomic sites (12), and even at the same anatomical site 
on symmetric limbs (14).

The etiology of sensitive skin is unknown, but the dis-
order is believed to be the product of multiple etiologies with 
multiple  components,  including  deficiencies  in  barrier  func-
tion,  neurosensory  dysfunction,  compound-specific  irritancy, 
and cultural influences (15).

Deficiencies  in  barrier  function  have  been  shown  to  be 
a critical component of skin discomfort (16). Increased perme-
ability is believed to be the result of a functional compromise 
of  barrier  function  in  the  sensitive-skin  patient  (17).  Lipid 
content of the stratum corneum has been shown to be a more 
accurate predictor of skin permeability than stratum corneum 
thickness or cell number (12). The permeability barrier in the 
stratum  corneum  requires  the  presence  of  well-organized 
intracellular lipids (7,16) and depends highly on lipid composi-
tion (12). Increased neutral lipids and decreased sphingolipids 
are  associated  with  superior  barrier  properties  (12).  A  weak 
barrier  inadequately  protects  nerve  endings  and  facilitates 
access to antigen presenting cells, a mechanism which would 
support  an  association  with  atopic  conditions  (16).  Irritation 
results  from  the  abnormal  penetration  in  skin  of  potentially 
irritating substances and a resulting decrease in the skin toler-
ance threshold (7). Alterations in barrier function in sensitive-
skin patients have been observed (18,19). Alterations of baseline 
capacitance values imply barrier impairment and support the 
view  that  hyperreactivity  to  water-soluble  irritants  results 
from increased absorption (20). A derangement of intercellular 
lipids, specifically, was also associated with a decline in bar-
rier function in sensitive skin (21). The pain sensations, which 
are the hallmark of the disorder, also imply possible integra-
tion dysfunctions in the central nervous system. Cho et al. (22) 
found that individuals were classified into sensitive skin and 
non-sensitive skin based on a lactic acid sting test performed 
on the face. There were no differences in transepidermal water 
loss  (TEWL)  and  erythema  index  values  between  the  two 
groups.  However,  the  mean  value  of  the  quantity  of  stratum 
corneum ceramides on the face was significantly lower in the 
sensitive skin group compared to the non-sensitive group.

The  pain  and  other  unpleasant  sensations  that  are 
the  hallmark  of  sensitive  skin  imply  a  likely  relationship  to 

46 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 5.1  Prevalence of Sensitive-Skin Perception in Various Geographies

Population(s) studied

Population characteristics

Definition of sensitive skin

France (2000)

319 women, conducted by 

interviews

Cutaneous discomfort in 
the absence of clinical 
and histological evidence 
of skin lesions

Percentage of people who 
claimed sensitive skin

Reference(s)

90% (23% very sensitive skin)

4

France (2005)

1006 men and women, 

Sensitive skin

59% women, 44% men

identified by questionnaire

France (2006)

8522 men and women, 

Sensitive skin

61% women, 32% men

France (2008)

identified by questionnaire

1004 men and women, 
opinion poll survey

Sensitive scalp

44.2% (47.4% women, 40.8% 

men)

France (2008)

18 women, identified by 

Sensitive skin

50% (facial skin, specifically)

France (2008)

Germany (2001)

England (2001)

questionnaire

400 identified by 
questionnaire

Sensitive skin

85% (facial skin, specifically)

420 men and women

Sensitive skin

75% (48% severe)

3300 men and women, 
conducted by mailed 
questionnaire

Intolerance to cosmetics 
and toiletries, including 
both sensory and visible 
signs

51.4% men (5.8% very 

sensitive skin)

38.2% women (10% very 

sensitive skin)

Italy (2005)

Greece (2008)

1870 women

Sensitive skin

25 women, identified by 

Sensitive skin

questionnaire

Greece (2008)

25 women with atopic 

Sensitive skin

dermatitis

USA (San Francisco) 

800 women, conducted by 

Sensitive facial skin

(2002)

telephone interview

USA (Cincinnati) 

1039 men and women 

Sensitive skin

(2009)

surveyed by 
questionnaire

USA (Cincinnati) 

29 women with light 

Sensitive skin

(2006)

USA (2011)

incontinence

994 subjects by phone 

survey (495 men and 499 
women)

Rate their skin as: “very 
sensitive,” “sensitive,” 
“slightly sensitive,” or “not 
sensitive at all”

USA (2013) primarily 

rural southern states

89 women by questionnaire

Sensitive skin

Japan, USA, Europe 

15 000 men and women, 

(1992)

conducted by 
questionnaire

People whose skin reacts to 
particular insults more 
than the majority of 
people

56.50%

64%

100%

52%

68.4% reported some degree 

of sensitivity (“slight”–“very”) 
(69.0% women, 64.4% men)

83% reported some degree of 
sensitivity (“slight”–“very”)

44.6% reported “very 

sensitive” or “sensitive” 
(38.2% men, 50.9% women)

77.5% reported some degree 
of sensitivity (“slight”–“very”)

50% women (25% very 

sensitive skin) 30% men

China (2012)

408 women surveyed by 

Sensitive skin

23%

questionnaire

China (urban dwellers) 

9154 surveyed by 

Sensitive skin

13% (8.62% men, 15.93% 

(2012)*

questionnaire (3931 men 
and 5223 women)

women)

Mexico (2013)

246 subjects (78 man and 

Sensitive skin

36%

Dermatologist opinion 

survey
USA (2013)

168 women)

300 dermatologists 
surveyed by email 
questionnaire

Europe (2013)

1531 dermatologists 

Sensitive facial skin

surveyed by 
questionnaire

*Year of publication, not year of study.

Sensitive facial skin

58.3% have noticed an 

increase in male patients 
reporting sensitive facial 
skin over the past 5 years

82% have noticed an increase 
in male patients reporting 
sensitive facial skin over the 
past 5 years

36

67

70

65

6

60

32

31

61

61

2

3

71

70

72

73

74

75

76

77

77

 
SENSITIVE SKIN: NEW FINDINGS YIELD NEW INSIGHTS 

 47

dysfunctions in the central nervous system, possibly involving 
several neuromediators and sensory receptors (23). Of the two 
studies  reviewed  that  did  evaluate  the  relationship  between 
neurosensory  responses  and  objective  clinical  irritation  and 
included only subjects with demonstrated sensory sensitivity, 
both showed a correlation between sensory and objective signs 
(18,19).  In  a  study  regarding  sensitivity  to  facial  tissue  which 
did not exclude non-sensitive individuals, sensory effects were 
demonstrated be the most reliable measure of product differ-
ences (18,19).

Although  no  predictive  value  was  demonstrated  for 
any individual sensitivity when subjects were tested with a 
seven-irritant  panel,  a  weak  association  between  tests  was 
demonstrated by statistical analysis of binomial probability 
(13).  However,  studies  which  evaluated  the  association  of 
barrier  function  and  sensitivity  have  yielded  arguably  the 
most conclusive results. A high baseline  TEWL was associ-
ated  with  increased  susceptibility  to  numerous  cutaneous 
irritants  by  numerous  studies  and  a  variety  of  assessment 
methods (14).

Most methods focused on objective assessment of physi-
cal  effects  to  skin  rather  than  the  sensory  effects  reported 
(24),  and  few  reports  have  quantified  sensory  effects  or  cor-
relate sensory effects to degree of irritation. Most testing has 
included  few  subjects,  and  few  have  restricted  subjects  to 
those with demonstrated sensitivity (25). Few have attempted 
to evaluate the influence of endogenous hormones or lifestyle 
factors.

Ultimately,  traditional  irritant-testing  methodologies 
have not proven to be good predictors of consumer response 
(1).  Response  to  one  irritant  does  not  predict  sensitivity  to 
another, and has not correlated well with evaluation of objec-
tive signs (26).

FACTORS IN SKIN SENSITIVITY
Numerous potential host factors (Table 5.2) undoubtedly play 
a role in experimental variability observed in sensitive skin. To 
date, no constitutional factors have been identified (23).

Gender
Sensitive skin is self-reported far more often in women than 
in men (Table 5.1). There is biological plausibility for greater 

Table 5.2  Possible Contributors to Sensitive Skin

Factor

Female sex
Hormonal status
Cultural expectations in technologically 

advanced countries

Fair skin which is susceptible to sunburn
Susceptibility to blushing and/or flushing
Skin pigmentation
Thin stratum corneum
Decreased hydration of stratum corneum
Disruption of stratum corneum
Increased epidermal innervations
Increased sweat glands
Increase neutral lipids and decreased 

sphingolipids
Decreased lipids
High-baseline TEWL
Atopy

Reference(s)

32
44
60

34
32
34
25, 33, 78, 79
7, 80, 81
34
7, 63
33
82

20, 83–86
14
59, 61

Abbreviation: TEWL, transepidermal water loss

sensitivity, as thickness of the epidermis was observed to be 
greater  in  males  than  in  females  (p  <  0.0001)  (27),  and  hor-
monal  differences,  which  may  produce  increased  inflam-
matory  sensitivity  in  females,  have  also  been  demonstrated 
(14,28).  Irritant  testing,  however,  generally  finds  no  differ-
ences  (12).  One  study,  though,  found  among  1039  subjects 
a  68.4%  prevalence  of  self-reported  sensitive  skin,  with  no 
difference between men and women (3). It may be that with 
increased  marketing  of  products  for  sensitive  skin  in  men 
it  has  become  more  cultural  acceptable  for  males  to  define 
themselves as having sensitive skin.

Age
The  physiological  changes  that  occur  as  skin  ages  would 
predict  an  increased  susceptibility  to  irritants  (29).  Existing 
studies,  however,  are  ambiguous  with  regard  to  the  influ-
ence  of  age  on  skin  sensitivity.  Clinical  assessment  of  the 
erythematous  response  to  irritants  in  older  people  suggest 
that susceptibility generally decreases with age (29). However, 
objective signs of irritation often show little correlation with 
the intensity of subjective complaints (29). A study of sensory 
perceptions  of  sensitive  skin  conducted  on  1029  individu-
als in Ohio stratified subjects into four age groups (subjects 
under 30, in their 30s, in their 40s, and over 50), and evaluated 
subjective data according to age (29). Those over 50 were more 
likely to claim sensitive skin than younger adults and more 
likely to perceive genital skin (to the exclusion of other body 
sites)  to  be  more  sensitive  (29).  Older  adults  also  stated  that 
their skin had become more sensitive over time (46%) (29). The 
turnover  rate  of  the  stratum  corneum  has  been  reported  as 
longer  in  aged  skin  (30),  which  may  contribute  to  increased 
sensitivity. However, in a large Italian study that performed 
lactic  acid  sting  tests  on  more  than  100  elderly  subjects,  the 
intensity of the stinging response was inversely proportional 
to age (31).

Ethnicity
There  are  pronounced  differences  in  skin  structure  depend-
ing on skin type (Table 5.3), and racial differences, with regard 
to skin susceptibility to irritants, are among the fundamental 
questions in dermatotoxicology (25). Two large epidemiologi-
cal studies reported no observed racial differences in reporting 
product sensitivity (2,32). Most testing, however, has focused 
on Caucasian females (25).

Differences  have  been  observed  in  sensory  percep-
tions,  although  substantive  conclusions  are  hard  to  provide. 
Asians have been reported to complain of unpleasant sensory 
responses more often than Caucasians, supported by the obser-
vation that a higher incidence of dropouts in a Japanese clinical 
study withdrew because of adverse skin effects as compared 
with  those  in  Caucasian  studies  (33).  There  have  also  been 
reports of an increased sensory response, as well as speed of 
response  in  Asian  subjects  versus  Caucasian  in  sensory  test-
ing (33). Another study, however, found fair-skinned subjects 
prone  to  sunburn  had  higher  sensory  responses  to  chemical 
probes than those with darker skin tones (34). No racial differ-
ences in innervation on  an architectural  or  biochemical level 
have been observed (13).

Studies  of  racial  differences  with  regard  to  irritants 
have  yielded  conflicting  evidence.  Although  black  skin  was 
demonstrated to have greater potential for irritant susceptibil-
ity than white skin (12), another study found blacks to be less 

 
48 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 5.3  Comparison of Racial Differences in Functional Skin Properties

Skin property

Permeability

Types

Racial differences

In vitro penetration of fluocinolone 

Lower in blacks than in Caucasians

acetonide

In vitro penetration of water

No differences

Topical application of anesthetic mixture

Less efficacy in blacks than in Caucasians

In vivo penetration of C-labeled 

Lower in blacks (34%) than in Caucasians

dipyrithione

Methyl nicotinate-induced vasodilation

Time-to-peak response equal

TEWL

Baseline TEWL (in vitro)

Slower in blacks

Higher in blacks

Higher in blacks (in vitro)

TEWL in response to SLS irritation 

Higher in blacks and Hispanics

(in vivo)

Baseline TEWL (in vivo)

Blacks > Caucasians > Asians

Return to baseline TEWL after tape 

Blacks faster than whites

stripping

Reactivity to SLS (measured by TEWL)

Higher in blacks than Caucasians

Skin irritant reactivity Reactivity to dichlorethylsulfide (1%)

Lower in blacks (measured by erythema, 15% vs. 

58%) than Caucasians

Reactivity to o-chlorobenzylidene 

Lower, longer time to response in blacks than 

malonitrile

Caucasians

Reactivity to dinitrochlorobenzene

Lower in blacks, but trend towards equalization 

Reactivity to octanoic acid, 20% SLS, 
100% decanol, and 10% acetic acid

Stinging response

Stinging response

after removal of stratum corneum than 
Caucasians

Asians more reactive than Caucasians (react 

more quickly)

Lower in blacks than whites

Equal in blacks and whites

Higher in Asians than whites

Skin transparency

UV protection factor of stratum corneum

Higher in blacks (about 50% higher) than in 

Caucasians

UVB transmission in stratum corneum

Lower in blacks (about 50% lower)

Spectral emittance

Lower in blacks (above 300 nm: 2–3-fold)

UV protection factor of epidermis

Higher in blacks (4-fold)

UVA transmission through epidermis

Lower in blacks (almost 4-fold)

UVB transmission through epidermis

Lower in blacks (4-fold)

Contribution of malpighian layer

Black skin: twice as effective in absorbing UVB 

Photoprotection of 

Skin extensibility on dorsal (sun exposed) 

epidermis

and volar (sun protected) forearms

Consequence of 
photoaging

Elastic recovery

Drying

Hypertrophic scarring

Response to insult

Pigmented dermatoses

Wrinkling

Wrinkling

as white skin

Black skin maintains extensibility on sun-exposed 
sites, but Hispanic skin extensibility is reduced 
on sun-exposed sites

Black skin maintains recovery on sun-exposed 

sites, white and Hispanic skins reduced

Higher in Caucasian and Asians than in 

Hispanics and blacks

Higher in Asians than Caucasians

Higher in Asians than Caucasians

Average onset is 10 years later in Asians than 

Caucasians

Average onset 20 years later in blacks than 

Caucasians

Thermal tolerance

Blacks have a lower threshold than whites

Reference(s)

87

87, 88

89

90

91

35

35

92

81

93

94

92

95

96

97

98

99

100

33, 101

102

102

103

102

102

102

102

104

104

105

106

106, 107

107

108

109

Somatosensory 

Elastic recovery (tested on the cheek)

1.5 times greater in black as compared with white 

110, 111

function

subjects

Abbreviations: SLS, sodium lauryl sulfate; TEWL, transepidermal water loss; UV, ultraviolet; UVA, ultraviolet band A; UVB, ultraviolet band B.

 
SENSITIVE SKIN: NEW FINDINGS YIELD NEW INSIGHTS 

 49

reactive than Caucasians (11). Asians seemed to be more reac-
tive than Caucasians in some studies and less in others, even 
within studies done under the same investigator and protocol 
(25).  Tristimulus  colorimeter  assessment  of  skin  reflectance 
observed  that  skin  pigmentation  was  inversely  associated 
with  susceptibility  to  irritation  (14),  supported  by  the  find-
ing  that  irritant  susceptibility  to  sodium  lauryl  sulfate  (SLS) 
is decreased after ultraviolet B (UVB) exposure (tanning) (14).

Methyl  nicotinate  assessment  of  vasoactive  response 
suggests  that  there  may  be  genuine  racial  differences  in  per-
meability  (35).  Increased  percutaneous  absorption  of  benzoic 
acid,  caffeine,  and  acetylsalicylic  acid  was  demonstrated  in 
Asians when compared with Caucasians, and decreased per-
cutaneous absorption was observed in blacks (33).

More  studies  have  observed  that,  while  overall  preva-
lence of skin sensitivity is similar across skin types and ethnic 
groups, there are some observable differences with regard to 
what triggers discomfort and how discomfort is experienced. 
Caucasians report visual effects more than African-Americans, 
while  African-Americans  are  more  likely  to  report  sensory 
effects  (26).  In  addition,  African-Americans  of  both  genders 
were more likely to report sensitivity in the genital area than 
other groups (p = 0.0008) (3).

A  study  of  800  women  in  San  Francisco  enrolled  200 
subjects in each of four ethnic groups to interview by phone 
and  found  no  significant  difference  in  overall  prevalence 
between  ethnic  groups  studied.  Euro-Americans,  however, 
were found to have a relatively higher susceptibility to wind 
than  other  ethnic  groups,  Asians  had  significantly  higher 
sensitivity  to  spicy  food,  and  Hispanics  had  relatively  less 
reactivity to alcohol (2).

Cultural Factors
Cultural factors may play a role. Fastidious cleansing routines 
(with  douches,  perfumes,  medication,  antifungal  medica-
tions, and contraceptives), which often precede irritation (28), 
undoubtedly  have  some  cultural  component.  Hygiene  prac-
tices are the most common cause of vulvar irritation (28).

Confounding lifestyle factors should be considered with 
regard to some observed differences, as cultural practices may 
produce widely different exposures to potential irritants (23). 
For  example,  older  women  were  found  to  be  more  likely  to 
report  irritation  due  to  incontinence  products  than  younger 
women, who were more likely to report irritation due to tam-
pons (29). Air conditioning is more likely to be reported as a 
trigger for sensitive skin in July than in March (36,37). These 
findings  are  quite  likely  to  be  based  on  increased  levels  of 
exposure than on actual physiological differences.

Environmental Factors
A  majority  of  sensitive-skin  sufferers  report  unpleasant  sen-
sory responses to cold temperatures, wind, sun, pollution, and 
heat (2,7). An increased susceptibility to SLS was observed in 
the winter compared with the summer (14). Low temperatures 
and humidity characteristic of winter cause lower water con-
tent in the stratum corneum (14). Large-scale epidemiological 
testing  in  France  conducted  phone  interviews  of  over  1000 
people each in March and then in July, and observed the fre-
quency of sensitive skin in women to be significantly higher in 
summer than in winter (71.2% in July vs. 59.39% in March) (36).
Numerous  other  host  factors  that  could  influence  skin 
sensitivity include unusual occupational or leisure exposures 
to  chemicals  and  home  climate-control  measures  (26).  Long-
term or excessive use of personal-care products can also create 

sensitivities  (7).  Daily  topical  use  of  corticosteroids  has  been 
demonstrated to produce fragile skin (7), and excessive use of 
topical medications has been demonstrated to be the source of 
up to 29% of vulvar dermatitis (38). Drug-induced sensitivity 
is also possible, although no reports on that issue were uncov-
ered. Interestingly, the thickness of the epidermis in one study 
was demonstrated to be inversely proportional to the number 
of years that the subject had smoked, with a p = 0.0001 (27).

The  specific  methodologies  and  conditions  involved  in 
the  testing  of  skin  sensitivity  introduce  a  significant  amount 
of  variability  into  the  published  results;  however,  one  study 
reveals  that  parameters  of  the  testing  can  themselves  induce 
sensitivity  apart  from  that  of  the  specific  irritant  employed. 
Sahlin et al. (39) evaluated the sting potential of the vehicle used 
in  testing  the  adverse  stinging  reaction  related  to  lactic  acid 
application. The results showed that the ordinary oil-in-water 
emulsion induced stinging in and of itself; use of a water-in-
oil emulsion created less discomfort. It was also observed that 
decreasing the mineral oil content in the oil-in-water emulsion 
resulted in decrease in the degree of sting experienced (39).

Anatomic Site
Differences  in  skin  sensitivity  between  anatomical  regions 
have  been  observed.  Analysis  of  structural  differences  found 
that  stratum  corneum  density  varies  tremendously  by  ana-
tomical site: palms and soles are the thickest, whereas the geni-
tal area is the thinnest (30). The face is the most common site 
of skin  sensitivity.  In a study  of 1039  men  and women, 77.3% 
reported facial sensitivity, compared with 60.7% for the body, 
and  56.2%  specifically  with  regard  to  genital  skin  (3).  Saint-
Martory also found the face to be the most commonly reported 
site of sensitivity, with hands, scalp, feet, neck, torso, and back 
also  reported,  in  order  of  frequency  (6).  The  nasolabial  fold 
has  been  reported  to  be  the  most  sensitive  region  (13)  of  the 
facial area, followed by the malar eminence (13), chin, forehead, 
and upper lip (6). Misery et al. (40) found 44.22% of sensitive-
skin  subjects  questioned  experienced  sensitivity  of  the  scalp. 
Factors contributing to facial sensitivity are likely the number 
of  products  used  on  the  face  (particularly  in  women),  a  thin-
ner barrier in facial skin, and a plentitude of nerve endings as 
well (9). Individual susceptibility appears to be dependent on 
anatomical site (41). Most studies have been conducted in facial 
skin because of its sensitivity. Stinging sensations, particularly, 
are readily elicited on facial skin (42). Further, the face is readily 
accessible for both visual (43) and biophysical assessments (20).
The  vulva  is  an  area  of  particular  interest,  since  it  is 
formed  partially  from  embryonic  endoderm;  it  differs  from 
skin at exposed body sites (10). Differences in irritation seem to 
be dependent on relative permeability of the irritant in vulvar 
skin;  vulvar  skin  is  significantly  more  reactive  than  forearm 
skin  to  benzalkonium  chloride  and  maleic  acid  (44),  but  less 
reactive than the forearm to SLS (10). When both venous blood 
and  menses  were  evaluated  for  irritant  potential,  the  vulva 
was less responsive to both than was the upper arm (45).

Nonkeratinized  vulvar  skin  exhibits  clearly  increased 
permeability  related  to  the  absence  of  keratin  and  loosely 
packed,  less  structured  lipid  barrier  (10).  In  addition,  the 
inner epithelia are thinner, representing a shorter distance to 
penetrate  (10).  Buccal  tissue  is  often  employed  in  a  surrogate 
model for vulvar testing, as it has very similar structure and 
biochemistry (10). Buccal skin has been demonstrated to be 10 
times more permeable than keratinized skin (46).

Although  the  vulvar  area  may  be  particularly  suscep-
tible to cutaneous irritation (47), little objective published data 

 
50 

 TEXTBOOK OF COSMETIC DERMATOLOGY

exists  with  regard  to  sensitive  skin  (42).  Irritant  reactions  to 
feminine-care  products  have  been  reported  (38)  with  a  few 
feminine products that contain chemicals known to be irritants 
in  certain  doses  (48).  However,  the  potential  for  heightened 
vulvar susceptibility to topical agents is not widely reported in 
literature (10). The contribution to irritation by topical agents, 
though,  is  substantial  (11)  and  often  underestimated  (28).  In 
fact, 29% of patients with chronic vulvar irritation were dem-
onstrated  to  have  contact  hypersensitivity,  and  94%  of  those 
were  determined  to  have  developed  secondary  sensitization 
to  topical  medications  (38).  Thus,  reported  sensitivity  in  the 
vulvar area may often be related to underlying contact hyper-
sensitivity  because  of  excessive  use  of  topical  hygienic  and 
medicinal preparations.

Some  studies  have  evaluated  skin  sensitivity  in  the 
vulvar  area  with  regard  to  sensory  responses  to  consumer 
products meant for the vulvar area. It was hypothesized that 
patients with erythema related to a previous genital infection 
may represent a population of sensitive subjects; however, no 
increase  in  sensory  effects  to  exposure  to  feminine  hygiene 
pads was observed (42).

In  a  similar  population,  however,  in  which  observed 
erythema  was  evaluated  against  perceived  sensory  effects, 
women who perceived themselves as particularly susceptible 
to facial erythema were significantly more likely to have medi-
cally  diagnosed  vulvar  erythema,  a  potential  indicator  of  a 
underlying biological origin (42).

Interestingly,  a  separate  study  evaluated  percep-
tions  of  sensitive  skin  in  women  with  urinary  incontinence, 
expecting  to  observe  an  increased  sensitivity  of  genital  skin 
(49).  Increased  sensitivity  specific  to  the  genital  area  was  not 
observed,  but  incontinent  women  were  significantly  more 
likely  to  assess  themselves  as  having  overall  skin  sensitivity 
than continent subjects (p = 0.014: 86.2% in incontinent subjects 
vs. 68.3% in controls) (49).

SENSORY EFFECTS AND OBJECTIVE SIGNS
It was observed early on that some subjects report a greater 
incidence of adverse reactions to certain products because of 
higher  sensitivity  (2,32).  Some  individuals  possess  exagger-
ated  sensitivity  to  specific  individual  irritants  (34).  Despite 
the  fact,  however,  that  studies  have  demonstrated  that  sen-
sitive-skin  patients  are  capable  of  distinguishing  products 
on the basis of blinded sensory endpoints (13,24), a clinically 
satisfactory description of observed sensitivities remains out 
of reach.

Tantalizing  clues  to  the  underlying  mechanisms  of 
sensitive  skin,  however,  continue  to  be  reported.  If  deficits 
in  barrier  function  do  play  a  role  in  skin  sensitivity,  regular 
use  of  moisturizer  should  improve  sensitivity;  patients  who 
completed  four  daily  treatments  with  moisturizer  improved 
(8).  Evaluation  of  the  potential  role  of  the  stratum  corneum 
in  sensitive  skin  using  corneosurfametry  demonstrated  that 
subjects  with  demonstrated  sensitivity  to  detergents  had  an 
increased reactivity to tested products as compared with the 
control group. It may be a specific subgroup of sensitive skin 
with some sort of defect in the stratum corneum that caused 
weakened resistance to surfactants (18).

Local anesthetics block response in lactic acid sting tests; 
stingers respond more vigorously to vasodilators (9). An Italian 
study compared self-reports of sensitivity with response in the 
lactic  acid  test  as  follows:  stingers  were  found  at  very  simi-
lar  prevalences  to  self-reported  sensitivity  (56.9%  of  women 
perceived  skin  as  sensitive,  54.3%  revealed  to  be  stingers).  In 

addition, those who believe skin to be sensitive were revealed 
to be more likely to be stingers (59%) than among nonstingers 
(48.9%) (31).

Simion et al., by exaggerated arm-washing with synthetic 
detergent bars, observed signs that correlated statistically with 
sensory perceptions (dryness, tightness, and itching). In addi-
tion, consumers were able to reproducibly distinguish between 
test products purely on the basis of sensory effects (50).

Another  study  evaluated  specific  biophysical  param-
eters in 32 subjects medically diagnosed with sensitive skin in 
parallel with a non-sensitive skin control group. Patch testing, 
skin hydration, sebum production, alkali resistance test, lactic 
acid sting test, methyl nicotinate 0.5%, methacholine chloride 
1:1000, pH, dermographism, and measurement of total and spe-
cific Ig were performed (19). Patch testing found that patients 
with  sensitive  skin  were  ten  times  more  likely  to  respond  to 
allergens in the European standard series (p < 0.01) and three 
times  more  likely  to  respond  to  cosmetic  allergens  (p  <  0.01) 
than those without sensitive skin. Sensitive subjects also had 
significantly less sebum production (p < 0.01) and dryer skin (p 
< 0.05). Sensitive patients had a four-fold risk of a decrease of 
alkali resistance (p < 0.05).

Vascular  reactions  to  methyl  nicotinate  and  methacho-
line  chloride  in  sensitive-skin  patients  were  observed  to  be 
characterized  by  a  significant  hyperreaction  of  skin  blood 
vessels,  with  a  more  intense  erythema  after  methyl  nicotin-
ate application (19). The risk of and intense vascular reaction 
to methyl nicotinate was 75 times higher in sensitive patients 
than  in  non-sensitive  subjects,  and  nearly  one-third  of  sensi-
tive-skin subjects experienced an abnormal vascular reaction 
(skin  blanching)  after  application  of  methacholine  chloride. 
A  strong  association  of  sensitivity  with  fair  skin  was  also 
observed.  This  may  relate  to  well-established  differences  in 
skin structure and permeability across different skin types.

SENSITIVE SKIN: ZEROING IN 
ON BIOLOGICAL ORIGIN
Part of the reason for the observed breakdown between sensory 
effects and objective signs is the fact that an objective sign like 
erythema is the end result of a complex, multistep physiologi-
cal process. Numerous underlying processes (e.g., changes in 
blood flow, moisture content, pH) would be expected to occur 
before  the  appearance  of  visible  external  changes  (1).  A  goal 
of our research has been to increase the ability to predict and 
quantify these subjective consumer responses. Our approach 
has  been  three-fold:  to  exaggerate  testing  conditions  to  elicit 
corroborating  physical  findings,  to  increase  the  sensitivity  of 
assessment of physical findings, and to find a way to quantify 
sensory endpoints (1).

Exaggeration of Test Conditions
One study evaluated four versions of facial tissues, with and 
without  coating,  with  repeated  wiping  to  accentuate  irrita-
tion (48). Affected skin had been compromised by tape strip-
ping  prior  to  wiping  protocol  initiation.  Erythema  as  well  as 
dryness were evaluated daily by trained graders. In addition, 
panelists  were  interviewed  about  specific  aspects  of  product 
preferences.  Statistical  analysis  revealed  that  the  panelists’ 
subjective product preferences were more consistent in distin-
guishing between the test products than were either erythema 
or dryness.

A second method of accentuating test conditions, devel-
oped in our laboratories specifically for testing paper such as 

 
SENSITIVE SKIN: NEW FINDINGS YIELD NEW INSIGHTS 

 51

catamenial products, has proven very effective at accentuating 
irritant response to inherently mild products. The behind-the-
knee (BTK) protocol uses the popliteal fossa as a test site and 
adds a relevant mechanical friction component to old testing 
(51). BTK testing consists of a test product placed  behind the 
knee and held securely by an elastic knee band. Levels of irri-
tation  produced  in  BTK  testing  are  consistently  higher  than 
those achieved with standard patch testing, and have proven 
to be consistently reproducible (51). BTK testing, in conjunction 
with the other two approaches below, has proven useful in the 
development  of  potentially  valuable  protocols  for  sensitive-
skin testing.

Quantifying Sensory Responses
A  study  similar  to  the  facial  tissue  study  above  tested  femi-
nine  hygiene  products  according  to  four  combinations  of 
test  conditions  (wet/dry,  intact/compromised  skin).  Products 
tested were inherently nonirritating and were tested in paral-
lel in arm patches and BTK. In addition, the study evaluated 
observed  erythema  grading  against  a  patient  log  of  sensory 
effects.  Although  no  differences  were  observed  between  any 
combinations tested, a significant correlation of reported sen-
sory discomfort with mean irritant scores was observed. Skin 
sites where patients experienced burning, itching, or sticking 
had  consistently  higher  mean  irritant  scores  (52).  Ultimately, 
eight  separate  comparison  studies  were  able  to  statistically 
associate perceived sensory effects with an increase in irritant 
scores (51).

Companion papers that utilized only BTK methodology 
(53) but also evaluated patient diaries in conjunction with the 
irritant  testing  observed  correlation  between  sensory  effects 
and mean irritant scores as well (52).

Increasing Sensitivity of Assessment 
of Physical Response
Our laboratories evaluated several new methodologies in the 
pursuit  of  an  increased  sensitivity  of  the  evaluation  of  the 
physical response. Visual grading of erythema has been relied 
on for a number of years; trained graders achieve a high degree 
of reproducibility with no specialized equipment (54). A new 
approach  in  our  laboratories,  however,  utilized  cross-polar-
ized  light,  which  allows  visualization  of  the  skin  at  a  depth 
of  1  mm  below  the  surface  (55).  Testing  was  performed  with 
SLS in a standard, 24-h patch test on the upper arm, and with 
two different feminine hygiene products (identified as A and 
B)  in  the  BTK.  It  had  been  established  previously  that  these 
two products differed in consumer preference, but no discern-
able difference had been found in objective measures of skin 
effects (24). With the minor irritation produced the SLS patch 
on  the  upper  arm,  both  unaided  visual  scoring  and  subsur-
face visualization detected eythema associated with irritation. 
With multiple, shorter exposures (2-h and 6-h) to lower concen-
trations of SLS, the subsurface visualization detected eythema 
earlier than unaided visual scoring. Using the mild feminine 
hygiene  products  in  BTK-enhanced  visual  scoring  through 
subsurface  visualization  allowed  the  observation  of  signifi-
cant differences in the irritation produced by the two different 
products,  thus  establishing  a  potential  link  between  sensory 
effects and subclinical irritation.

A second approach evaluated the potential for changes in 
skin temperature related to inflammation to act as a subclinical 
measure of skin irritation. Previous research has demonstrated 
a correlation between surface temperature measurements and 

inflammatory response (56). A high precision, handheld infra-
red  thermographic  scanner  makes  it  feasible  to  conveniently 
measure  local  changes  in  skin  temperature  in  situ  (57).  Two 
catamenial  products  were  compared  in  a  BTK  protocol.  Skin 
surface temperature was measured using an infrared thermo-
graphic  scanner.  Subjects  were  also  asked  to  keep  a  diary  of 
skin discomfort experienced at test sites, specifically including 
sticking, chafing, burning, itching, pain, edema, or any other 
issue.  Skin  temperature  changes  observed  were  closely  asso-
ciated with visual scores. In addition, the study incorporated 
diary-derived  data  on  sensory  effects  experienced  by  panel-
ists  as  an  additional  endpoint.  The  diaries  of  subjective  sen-
sory experiences over the course of the exposure made a clear 
distinction between the two test products that was consistent 
with both visual scoring and skin temperatures. A significant 
t-difference  was  also  observed  between  mean  visual  scores 
of  those  who  reported  specific  adverse  sensations  as  com-
pared with those who did not report negative sensations. Skin 
temperature  means  were  significantly  higher  for  those  who 
reported the adverse sensations rubbing and chafing (interest-
ingly,  burning  sensations  were  not  associated  with  increase 
in skin surface temperature). Conditions in this protocol were 
optimized for using erythema as the primary endpoint; refin-
ing  the  protocol  to  optimize  detection  of  differences  in  skin 
surface temperature would be a logical next step. Skin surface 
temperatures  correlated  well  with  visual  signs  of  irritation; 
six of eight sensory effects were associated with higher visual 
scores.

An  additional  new  technique  in  development  uses 
a  commercially  available  product,  Sebutape®  (CuDerm 
Corporation,  Dallas,  Texas),  an  absorbent  tape,  which  is 
applied to skin for 60 seconds and then removed. Application 
of the tape to both healthy skin and compromised skin was fol-
lowed by extraction of different cytokines from the Sebutape, 
which were then quantified. Levels of IL-1a, IL-1RA, and IL-8 
were  evaluated.  Compromised  skin  was  associated  signifi-
cantly with increased IL-1a levels, increased IL-8 levels, and 
increased  IL-1RA:IL-1a  ratio.  This  technique  has  not  been 
substantially applied to the problem of sensitive skin yet, but 
shows potential (58).

Links between Sensitive Skin and Immunology
Evidence for a link between atopy and sensitive skin has accu-
mulated.  An  assessment  of  1039  individuals  (83.6%  female) 
found that individuals who claimed overall to have sensitive 
skin were 5 times likely to have skin allergies confirmed by a 
doctor (p < 0.0001), and more than 3.5 times more likely to have 
relatives  with  sensitive  skin  (59).  In  a  study  in  older  adults, 
those  who  claimed  sensitive  skin  had  a  higher  frequency  of 
medically diagnosed skin allergies than younger people who 
claimed  sensitive  skin  (29).  Loffler  et  al.  (60)  observed  a  link 
between sensitive skin and nickel allergy.

A  study  compared  25  Greek  women  with  medically 
diagnosed  atopic  dermatitis  with  25  healthy  women  (61).  A 
significant association was found between the clinical diagno-
sis of atopic dermatitis and the self-diagnosis of sensitive skin 
(p < 0.001). All patients in the atopic dermatitis group described 
themselves  as  having  sensitive  skin  to  at  least  some  degree, 
with  80%  claiming  either  moderately  or  very  sensitive.  By 
contrast,  64%  of  individuals  in  the  control  group  described 
their skin as sensitive to some degree, with only 16% claiming 
either  very  or  moderately  sensitive.  Patients  with  atopic  der-
matitis were also significantly more likely to indicate a family 
history  of  sensitive  skin  than  were  non-sensitive  individuals 

 
52 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(68%–24%, p = 0.004) 76% of atopic patients who claimed a fam-
ily history identified a parent as having sensitive skin.

Atopic  individuals  were  significantly  more  likely  to 
report  genital  sensitivity  after  contact  with  hygiene  pads, 
although  not  more  likely  to  experience  sensitivity  to  genital 
cleansing products, fragrances, or antiperspirants (61). In addi-
tion,  the  study  demonstrated  a  link  between  clinically  diag-
nosed atopic dermatitis and sensitive skin, with the frequency, 
severity, and history of skin sensitivity in patients with atopic 
dermatitis far more pronounced than in controls. This link has 
substantial biological plausibility, as contact allergy and skin 
sensitivity are phenomena that share similar cytokine induc-
tions (59).

Of potential utility for large-scale screening in industry, 
postmarket surveillance, and epidemiological testing, a rapid 
algorithm containing only three questions has been developed 
to quickly identify atopic individuals (62). Testing indicated the 
algorithm was capable of successfully categorizing individuals 
as “atopic” and “non-atopic” with a 90% success rate (45 out of 
50 individuals in the test).

Insight into Neurogenic Causality
Sensitive  skin  is  predominantly  sensory  in  nature  and  thus 
ultimately  a  neurological  disorder.  Sensory  differences  may 
be  related  to  innervation  (63).  Dermal  nerve  fibers  extend 
throughout  viable  epidermis  as  free  nerve  endings,  but  the 
epidermal  component  of  this  network  is  still  poorly  charac-
terized (63). Epidermal nerve density variation could explain 
the  different  sensitivity  thresholds  in  various  anatomical 
sites (64). Hyperreactivity of the neural response of the skin 
is  postulated  to  play  a  role.  Possible  mechanisms  for  neu-
ral  system  hyperreactivity  include  nerve  fibers;  endothelin 
receptors; burn, itch, and heat receptors; cold receptors; and 
neutrophins (23).

Neurogenic inflammation probably results from release 
of  neurotransmitters  such  as  substance  P,  calcitonin  gene-
related  peptide,  and  vasoactive  intestinal  peptide,  which 
induce vasodilation and mast cell degranulation. Nonspecific 
inflammation may also be associated with the release of inter-
leukins  (IL-1,  IL-8,  prostaglandin  E2,  prostaglandin  F2,  and 
tumor  necrosis  factor-a)  (40).  Other  studies  have  evaluated 
what  contribution  neural  dysfunction  may  play  in  the  devel-
opment of sensitive skin.

Functional  magnetic  resonance  imaging,  which  mea-
sured  cerebral  activation  associated  with  skin  discomfort, 
was  used  to  evaluate  neural  reaction  to  application  of  lac-
tic acid to the face in 18 women, with and without sensitive 
skin  (65).  Lactic  acid–induced  skin  discomfort  resulted  in 
increased activity in the primary sensorimotor cortex contra-
lateral to the application site as well as in a bilateral fronto-
parietal network that included the parietal cortex, prefrontal 
areas around the superior frontal sulcus, and the supplemen-
tary  motor  activity.  In  addition,  in  sensitive  skin  patients 
only,  group  activity  spread  into  the  ipsilateral  primary  sen-
sorimotor  cortex  and  the  bilateral  periinsular  secondary 
somatosensory  area,  a  phenomenon  which  did  not  occur  in 
the  control  group.  Subjects  with  self-assessed  sensitive  skin 
were also observed to have significantly greater increases in 
neural activity than those without sensitive skin, demonstrat-
ing an increase in neural activity specifically associated with 
sensitive skin.

Another  study  measured  calibrated  electrical  stimula-
tion of the skin, which stimulates sensory nerve fibers such as 

the myelinated A fiber, A delta fiber, and unmyelinated c-fiber 
independently (66). In subjects with clinically documented sen-
sitive  skin  (lactic  acid  sting  test,  cosmetic  compatibility  tests) 
versus  non-sensitive  controls  (all  subjects  male),  nerve  fibers 
were stimulated by three different current strengths, and cap-
saicin (0.075%) was applied to the zygomatic arch. Sensory per-
ception was verbalized by the subject and recorded. Baseline 
perception  of  current  revealed  no  significant  differences 
between sensitive and non-sensitive subjects at either 2 kHz or 
250 Hz, but at 5 Hz—a current known to selectively stimulate 
the c-fibers of sensory nerves. Sensitive skin subjects displayed 
a significantly lower perception threshold. In addition, stimu-
lation  of  the  skin  by  capsaicin,  in  non-sensitive  subjects,  had 
no effect on perception of the 5-Hz current, whereas sensitive 
subjects displayed a long-lived increase in the sensory percep-
tion threshold (still in place at last time point of 60 minutes). 
These findings imply that sensory perception in sensitive sub-
jects is easily disturbed by weak stimulation, inducing a wide 
variability of response compared with non-sensitive subjects, 
an effect that appears to be c-fiber modulated. The study was 
conducted in only eight subjects (four with sensitive skin) and 
should be followed up in a larger population.

CONCLUSION: A VALID SYNDROME 
WITH MULTIPLE ORIGINS?
Sensitive  skin,  though  now  largely  recognized  as  genuine 
syndrome  of  physiological  origin,  is  still  a  subjective  com-
plaint  with  no  consistent  associations  (60),  no  predictable  or 
classical visible signs of irritation, no immunologically verifi-
able  response,  and  no  accepted  and  reproducible  diagnostic 
test  (23).  Although  it  is  clear  that  specific  individuals  clearly 
have heightened sensitivity to different kinds of sensory and 
physical irritants, observed reactions are not predictive of gen-
eralized  sensitivity,  and  the  relationship  between  observed 
sensitivities is unclear (24,67). Evidence suggests that sensitive 
skin may not be a single condition, but the product of multiple 
etiologies with multiple components. Therefore, the condition 
may encompass different categories of subjects and sensitivi-
ties  based  on  different  mechanisms  (20).  Multiple  etiologies 
would not be farfetched, as the nervous system does not act in 
isolation but is interdependent with both the immune system 
and the skin, sharing numerous cellular contact as well as the 
same language of cytokines and neurotransmitters. All three 
interact to affect cutaneous responses (19).

There is an urgent necessity to establish methodologies 
with the capacity to accurately identify sensitive skin (5), inde-
pendent of self-assessed reports (23). Methods are needed that 
are capable of detecting very subtle skin benefits or potential 
for adverse effects. Testing has been done primarily on normal 
subjects, bringing into question the need to focus on examining 
populations that may be inherently more sensitive to irritant 
effects (10). Some studies did compare the irritation potential 
of products between self-declared sensitive skin to non-sensi-
tive–skin  subjects  (68,69).  A  summary  of  current  methodolo-
gies used to identify sensitive skin is shown in Table 5.4.

Subclinical  irritation  may  be  the  key  to  understanding 
sensitive skin, as sensations elicited by product exposure are 
generally  discerned  long  before  observable  differences  (50). 
One significant advance in the understanding of sensitive skin 
is the development of new, noninvasive techniques; for exam-
ple,  cross-polarized  light-enhanced  visualization,  which  has 
demonstrated good correlation with sensory perceptions and 
the ability to measure subclinical damage (55).

 
SENSITIVE SKIN: NEW FINDINGS YIELD NEW INSIGHTS 

 53

Table 5.4  Some Methodologies Used for Sensitive Skin

Methodology

Sensory affect 
evaluated

Physical effect 
evaluated

Relevant irritants

Advantages

Disadvantages

Lactic acid (8)

Stinging

None

Cosmetics, other 

Highly sensitive and 

Does not predict 

Capsaicin (23)

Stinging

None

Sodium lauryl 
sulfate (14)

Burning

Erythema

Cross-polarized 

None

light (55)

Subclinical 
erythema

Thermoscan (57) None

Temperature 
increases 
resulting from 
inflammatory 
processes related 
to skin injury

personal 
preparations 
meant to be left on

Cosmetics, other 

personal 
preparations 
meant to be left on

Industrial exposures, 
cleaning products

specific*

Sensitive, detection 
threshold well 
correlated (inversely) 
to perception of 
sensitive skin

sensitivity to other 
irritants

Does not predict 

sensitivity to other 
irritants

Cheap, quick, reliable 

Sensitivity to one irritant 

assessment of 
individual 
susceptibility to 
specific irritant

not predictive of 
general sensitivity, 
relationship to sensitive 
skin in question

Any potential irritant

Permits detection of 

Requires specialized 

physical changes not 
apparent by standard 
visual scoring, 
noninvasive

equipment

Any potential irritant

Noninvasive, objective, 

Requires specialized 

quantitative

equipment

Sebutape¹ (58)

None

Measurement of 

Any potential irritant

Noninvasive, objective, 

Requires training, 

cytokines 
produced by 
injured skin

quantitative, 
potentially very 
sensitive

specialized equipment; 
utility for sensitive skin 
still unassessed

*Lactic acid test positive in 90% of women who claim sensitive skin.

An immediate need is to build on what is known with 
improved techniques, carefully crafted protocols that evaluate 
appropriate  exposures  and  study  populations,  and  rigorous 
methodological and statistical procedures, bringing the study 
of  sensitive  skin  out  of  the  realm  of  fairy  tales  and  into  the 
realm  of  a  genuine  physiological  disorder  worthy  of  focused 
research. The challenge of the future is to unravel the biologi-
cal  link  between  subjective  clinical  signs  and  their  physical 
sequelae as a means to develop appropriate diagnostic criteria 
as well as to understand the etiology of this still largely mys-
terious disorder.

REFERENCES

1.  Farage  MA.  Are  we  reaching  the  limits  or  our  ability  to 
detect  skin  effects  with  our  current  testing  and  measuring 
methods  for  consumer  products?  Contact  Dermatitis  2005; 
52:2005–52.

2.  Jourdain  R,  de  Lacharriere  O,  Bastien  P,  Maibach  HI.  Ethnic 
variations in self-perceived sensitive skin: Epidemiological sur-
vey. Contact Dermatitis 2002; 46:2002–46.

3.  Farage MA. How do perceptions of sensitive skin differ at dif-
ferent  anatomical  sites?  An  epidemiological  study.  Clin  Exp 
Dermatol 2009; 34:e521–30.

4.  Morizot F, Guinot C, Lopez S, et al. Sensitive skin: Analysis of 
symptoms, perceived causes and possible mechanisms. Cosmet 
Toiletries 2000; 115:2000–115.

5.  Kligman  AM,  Sadiq  I,  Zhen  Y,  Crosby  M.  Experimental 
studies on the nature of sensitive skin. Skin Res Technol 2006; 
12:2006–12.

6.  Saint-Martory  C,  Roguedas-Contios  AM,  Sibaud  V,  et  al. 
Sensitive  skin  is  not  limited  to  the  face.  Br  J  Dermatol  2008; 
158:2008–158.

7.  Pons-Guiraud A. Sensitive skin: A complex and multifactorial 

syndrome. J Cosmet Dermatol 2004; 3:2004–3.

8.  Kligman A. Human models for characterizing “sensitive skin.” 

Cosmet Dermatol 2001; 14:2001–14.

9.  Chew A, Maibach H. Sensitive skin. In: Loden M, Miabach H 
(eds.).  Dry  Skin  and  Moisturizers:  Chemistry  and  Function.  Boca 
Raton, CRC Press 2000; pp. 429–40.

  10.  Farage  MA,  Maibach  HI.  The  vulvar  epithelium  differs  from 
the skin: Implications for cutaneous testing to address topical 
vulvar exposures. Contact Dermatitis 2004; 51:2004–51.

  11.  Basketter  DA,  Wilhelm  KP.  Studies  on  non-immune  imme-
diate  contact  reactions  in  an  unselected  population.  Contact 
Dermatitis 1996; 35:1996–35.

  12.  Cua  AB,  Wilhelm  KP,  Maibach  HI.  Cutaneous  sodium  lauryl 
sulphate irritation potential: Age and regional variability. Br J 
Dermatol 1990; 123:1990–123.

  13.  Marriott M, Holmes J, Peters L, et al. The complex problem of 

sensitive skin. Contact Dermatitis 2005; 53:2005–53.

  14.  Lee  CH,  Maibach  HI.  The  sodium  lauryl  sulfate  model:  An 

overview. Contact Dermatitis 1995; 33:1995–33.

  15.  Farage MA, Berardesca E, Maibach HI. Sensitive skin: A valid 
syndrome of multiple origins. In: Wilhelm K-P, Zhai H, Maibach 
HI (eds.). Marzulli and Maibach's Dermatotoxicology, 8th edition. 
London: Informa Healthcare 2012; pp. 238–47.

  16.  Muizzuddin N, Marenus KD, Maes DH. Factors defining sensi-
tive skin and its treatment. Am J Contact Dermat 1998; 9:1998–9.

  17.  Primavera  G,  Berardesca  E.  Sensitive  skin:  Mechanisms  and 

diagnosis. Int J Cosmet Sci 2005; 27:2005–27.

 
 
 
 
 
 
 
 
 
 
54 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  18.  Goffin  V,  Pierard-Franchimont  C,  Pierard  GE.  Sensitive  skin 
and  stratum  corneum  reactivity  to  household  cleaning  prod-
ucts. Contact Dermatitis 1996; 34:1996–34.

  19.  Roussaki-Schulze  AV,  Zafiriou  E,  Nikoulis  D,  et  al.  Objective 
biophysical findings in patients with sensitive skin. Drugs Exp 
Clin Res 2005, 31 Suppl:17–24.

  20.  Seidenari S, Francomano M, Mantovani L. Baseline biophysical 
parameters  in  subjects  with  sensitive  skin.  Contact  Dermatitis 
1998; 38:1998–38.

  21.  Ota M, Hikima R, Ogawa T. Physiological characteristics of sen-
sitive skin classified by stinging test. J Jpn Cosmet Sci Soc 2000, 
24:163–7.

  22.  Cho HJ, Chung BY, Lee HB, et al. Quantitative study of stratum 
corneum  ceramides  contents  in  patients  with  sensitive  skin. 
J Dermatol 2012; 39:2012–39.

  23.  Stander S, Schneider SW, Weishaupt C, et al. Putative neuronal 

mechanisms of sensitive skin. Exp Dermatol 2009; 18:2009–18.

  43.  Vie  K,  Pons-Guiraud  A,  Dupuy  P,  Maibach  H.  Tolerance 
profile  of  a  sterile  moisturizer  and  moisturizing  cleanser 
in  irritated  and  sensitive  skin.  Am  J  Contact  Dermat  2000; 
11:2000–11.

  44.  Britz  MB,  Maibach  HI,  Anjo  DM.  Human  percutaneous  pen-
etration of hydrocortisone: The vulva. Arch Dermatol Res 1980; 
267:1980–267.

  45.  Farage MA, Warren R, Wang-Weigand S. The vulva is relatively 
insensitive  to  menses-induced  irritation.  Cutan  Ocul  Toxicol 
2005; 24:2005–24.

  46.  Squier  CA,  Hall  BK.  The  permeability  of  skin  and  oral 
mucosa to water and horseradish peroxidase as related to the 
thickness  of  the  permeability  barrier.  J  Invest  Dermatol  1985; 
84:1985–84.

  47.  Farage MA, Stadler A, Elsner P, Maibach HI. Safety evaluation 
of  modern  hygiene  pads:  Two  decades  of  use.  Female  Patient 
2004; 29:2004–29.

  24.  Farage MA, Santana MV, Henley E. Correlating sensory effects 

  48.  Farage MA. Assessing the skin irritation potential of facial tis-

with irritation. Cutan Ocul Toxicol 2005; 24:2005–24.

sues. Cutan Ocul Toxicol 2005; 24:2005–24.

  25.  Robinson MK. Racial differences in acute and cumulative skin 
irritation responses between Caucasian and Asian populations. 
Contact Dermatitis 2000; 42:2000–42.

  26.  Farage MA. Perceptions of sensitive skin: Changes in perceived 
severity  and  associations  with  environmental  causes.  Contact 
Dermatitis 59:226–32, 2008.

  27.  Sandby-Moller  J,  Poulsen  T,  Wulf  HC.  Epidermal  thickness  at 
different  body  sites:  Relationship  to  age,  gender,  pigmenta-
tion,  blood  content,  skin  type  and  smoking  habits.  Acta  Derm 
Venereol 2003; 83:2003–83.

  28.  Farage MA. Vulvar susceptibility to contact irritants and aller-
gens: A review. Arch Gynecol Obstet 2005; 272:2005–272.
  29.  Farage  MA.  Perceptions  of  sensitive  skin  with  age.  In:  Farage 
MA, Miller KW, Maibach HI (eds.). Textbook of Aging Skin. Berlin 
Heidelberg: Springer-Verlag 2010; pp. 1027–46.

  30.  Tagami  H.  Racial  differences  on  skin  barrier  function.  Cutis 

2002; 70:6–7; discussion 21–3.

  31.  Sparavigna  A,  Di  Pietro  A,  Setaro  M.  “Healthy  skin”: 
Significance and results of an Italian study on healthy popula-
tion with particular regard to “sensitive” skin. Int J Cosmet Sci 
2005; 27:2005–27.

  32.  Willis CM, Shaw S, De Lacharriere O, B et al. Sensitive skin: An 
epidemiological study. Br J Dermatol 2001; 145:2001–145.
  33.  Aramaki J, Kawana S, Effendy I, et al. Differences of skin irri-
tation  between  Japanese  and  European  women.  Br  J  Dermatol 
2002; 146:2002–146.

  34.  Farage MA, Stadler A. Risk factors for recurrent vulvovaginal can-

didiasis. Am J Obstet Gynecol 2005; 192:981–2; author reply 982–3.

  35.  Kompaore F, Marty JP, Dupont C. In vivo evaluation of the stra-
tum corneum barrier function in blacks, Caucasians and Asians 
with two noninvasive methods. Skin Pharmacol 1993; 6:1993–6.

  36.  Misery L, Myon E, Martin N, et al. [Sensitive skin in France: An 
epidemiological approach]. Ann Dermatol Venereol 2005;132:425–9.
  37.  Misery L, Myon E, Martin N, Cet al. Sensitive skin: Psychological 
effects and seasonal changes. J Eur Acad Dermatol Venereol 2007; 
21:2007–21.

  38.  Marren P, Wojnarowska F, Powell S. Allergic contact dermatitis 
and vulvar dermatoses. Br J Dermatol 1992; 126:1992–126.
  39.  Sahlin  A,  Edlund  F,  Loden  M.  A  double-blind  and  controlled 
study on the influence of the vehicle on the skin susceptibility 
to stinging from lactic acid. Int J Cosmet Sci 2007; 29:2007–29.

  40.  Misery  L,  Sibaud  V,  Ambronati  M,  et  al.  Sensitive  scalp: 
Does  this  condition  exist?  An  epidemiological  study.  Contact 
Dermatitis 2008; 58:2008–58.

  41.  Green BG. Measurement of sensory irritation of the skin. Am J 

Contact Dermat 2000; 11:2000–11.

  42.  Farage  MA,  Bowtell  P,  Katsarou  Z.  The  relationship  among 
objectively assessed vulvar erythema, skin sensitivity, genital 
sensitivity,  and  self-reported  facial  skin  redness.  J  Appl  Res 
2006; 6:2006–6.

  49.  Farage MA. Perceptions of sensitive skin: Women with urinary 

incontinence. Arch Gynecol Obstet 2009; 280:2009–280.

  50.  Simion  FA,  Rhein  LD,  Morrison  BMJ,  Set  al.  Self-perceived 
sensory responses to soap and synthetic detergent bars corre-
late  with  clinical  signs  of  irritation.  J  Am  Acad  Dermatol  1995; 
32:1995–32.

  51.  Farage  MA.  The  Behind-the-Knee  test:  An  efficient  model  for 
evaluating mechanical and chemical irritation. Skin Res Technol 
2006; 12:2006–12.

  52.  Farage MA, Meyer S, Walter D. Evaluation of modifications of 
the  traditional  patch  test  in  assessing  the  chemical  irritation 
potential of feminine hygiene products. Skin Res Technol 2004; 
10:2004–10.

  53.  Farage MA, Meyer S, Walter D. Development of a sensitive test 
method to evaluate mechanical irritation potential on mucosal 
skin. Skin Res Technol 2004; 10:2004–10.

  54.  Farage MA, Maibach HI, Andersen KE, et al. The use of visual 
grading scales in evaluating skin irritation and sensitization: A 
historical perpective. In: Berardesca E, Maibach H, Wilhelm K 
(eds.). Non Invasive Diagnostic Techniques in Clinical Dermatology. 
Berlin Heidelberg: Springer-Verlag 2013; pp. 369–81.

  55.  Farage MA. Enhancement of visual scoring of skin irritant reac-
tions  using  cross-polarized  light  and  parallel-polarized  light. 
Contact Dermatitis 2008; 58:2008–58.

  56.  Camel E, O’Connell M, Sage B, et al. The effect of saline ionto-
phoresis on skin integrity in human volunteers. I. Methodology 
and reproducibility. Fund Appl Toxicol 1996; 32:1996–32.

  57.  Farage  MA,  Wang  B,  Miller  KW.  Surface  skin  temperature 
in  tests  for  irritant  dermatitis.  In:  Berardesca  E,  Maibach 
H,  Wilhelm  K  (eds.).  Non  Invasive  Diagnostic  Techniques  in 
Clinical  Dermatology.  Berlin  Heidelberg:  Springer-Verlag  2013; 
pp. 383–94.

  58.  Perkins MA, Osterhues MA, Farage MA, Robinson MK. A non-
invasive method to assess skin irritation and compromised skin 
conditions using simple tape adsorption of molecular markers 
of inflammation. Skin Res Technol 2001; 7:2001–7.

  59.  Farage MA. Self-reported immunological and familial links in 
individuals who perceive they have sensitive skin. Br J Dermatol 
2008; 159(1):237–8.

  60.  Loffler  H,  Dickel  H,  Kuss  O,  et  al.  Characteristics  of  self-esti-
mated  enhanced  skin  susceptibility.  Acta  Derm  Venereol  2001; 
81:2001–81.

  61.  Farage  MA,  Bowtell  P,  Katsarou  A.  Self-diagnosed  sensitive 
skin  in  women  with  clinically  diagnosed  atopic  dermatitis. 
Clinical Medicine: Dermatology 2008; 2:2008–2.

  62.  Farage MA, Bowtell P, Katsarou A. Identifying patients likely to 
have atopic dermatitis: Development of a pilot algorithm. Am J 
Clin Dermatol 2010; 11:2010–11.

  63.  Marriott M, Whittle E, Basketter DA. Facial variations in sen-

sory responses. Contact Dermatitis 2003; 49:2003–49.

 
SENSITIVE SKIN: NEW FINDINGS YIELD NEW INSIGHTS 

 55

  64.  Besne I, Descombes C, Breton L. Effect of age and anatomical 
site  on  density  of  sensory  innervation  in  human  epidermis. 
Arch Dermatol 2002; 138:2002–138.

  88.  Bronaugh  RL,  Stewart  RF,  Simon  M.  Methods  for  in  vitro 
percutaneous  absorption  studies.  VII:  Use  of  excised  human 
skin. J Pharm Sci 1986; 75:1986–75.

  65.  Querleux B, Dauchot K, Jourdain R, et al. Neural basis of sensi-
tive skin: An fMRI study. Skin Res Technol 2008; 14:2008–14.
  66.  Kim SJ, Lim SU, Won YH, et al. The perception threshold mea-
surement can be a useful tool for evaluation of sensitive skin. 
Int J Cosmet Sci 2008; 30:2008–30.

  67.  Guinot C, Malvy D, Mauger E, et al. Self-reported skin sensitiv-
ity in a general adult population in France: Data of the SU.VI.
MAX cohort. J Eur Acad Dermatol Venereol 2006; 20:2006–20.

  68.  Farage MA, Stadler A. Cumulative irritation patch test of sani-

tary pads on sensitive skin. J Cosmet Dermatol 2005; 4:2005–4.

  69.  Farage MA, Maibach H. Cumulative skin irritation test of sani-
tary pads in sensitive skin and normal skin population. Cutan 
Ocul Toxicol 2007; 26:2007–26.

  70.  Misery L, Sibaud V, Merial-Kieny C, Taieb C. Sensitive skin in 
the American population: Prevalence, clinical data, and role of 
the dermatologist. Int J Dermatol 2011; 50:2011–50.

  71.  Farage  MA,  Katsarou  A,  Maibach  HI.  Sensory,  clinical  and 
physiological  factors  in  sensitive  skin:  A  review.  Contact 
Dermatitis 2006; 55:2006–55.

  72.  Farage  MA,  Miller  KW,  Wippel  AM,  et  al.  Sensitive  skin  in 
the  United  States:  Survey  of  regional  differences.  Family  Med 
Medical Sci Res 2013; 2:2013–2.

  73.  Johnson  A,  Page  D.  Making  sense  of  sensitive  skin  (poster). 
Yokohama,  Japan:  Congress  of  the  International  Federation  of 
Society of Cosmetic Chemists 1992; 700.

  89.  Hymes J, Spraker M. Racial differences in the effectiveness of a 
topically applied mixutre of local anesthetics. Reg Anesth 1986; 
11:1986–11.

  90.  Wedig JH, Maibach HI. Percutaneous penetration of dipyrithi-
one in man: Effect of skin color (race). J Am Acad Dermatol 1981; 
5:1981–5.

  91.  Guy RH, Tur E, Bjerke S, Maibach HI. Are there age and racial 
differences  to  methyl  nicotinate-induced  vasodilatation  in 
human skin? J Am Acad Dermatol 1985; 12:1985–12.

  92.  Wilson  D,  Berardesca  E,  Maibach  HI.  In  vitro  transepidermal 
water loss: Differences between black and white human skin. 
Br J Dermatol 1988; 119:1988–119.

  93.  Sugino K, Imokawa G, Maibach H. Ethnic difference of stratum 
corneum lipid in prelation to stratum corneum function (abstr 
594). J Invest Dermatol 1993; 100:587.

  94.  Reed JT, Ghadially R, Elias PM. Skin type, but neither race nor 
gender,  influence  epidermal  permeability  barrier  function. 
Arch Dermatol 1995; 131:1995–131.

  95.  Marshall  E,  Lynch  V,  Smith  H.  Variation  in  susceptibility  of 
the  skin  to  dichlorethylsulfide.  J  Pharmacol  Exp  Ther  1919; 
12:1919–12.

  96.  Weigand  D,  Mershon  M.  The  cutaneous  irritant  reaction  to 
agent  o-chlorobenzylidene  malonitrile  (CS);  quantitation  and 
racial  influence  in  human  subjects.  Edgewood  Arsenal  1970; 
Number 4332.

  74.  Farage  MA,  Mandl  CP,  Berardesca  E,  Maibach  HI.  Sensitive 

  97.  Weigand  DA,  Gaylor  JR.  Irritant  reaction  in  Negro  and 

skin in China. J Cosmet, Dermatol Sci Application 2012; 2:2012–2.

Caucasian skin. South Med J 1974; 67:1974–67.

  75.  Xu F, Yan S, Wu M, et al. Self-declared sensitive skin in China: 
A community-based study in three top metropolises. J Eur Acad 
Dermatol Venereol [Epub ahead of print] 2012.

  98.  Robinson  MK.  Population  differences  in  acute  skin  irritation 
responses. Race, sex, age, sensitive skin and repeat subject com-
parisons. Contact Dermatitis 2002; 46:2002–46.

  76.  Hernández-Blanco  D,  Castanedo-Cázares  JP,  Ehnis-Pérez  A, 
et al. Prevalence of sensitive skin and its biophysical response 
in a Mexican population. World J Dermatol 2013; 2:2013–2.
  77.  Vanoosthuyze K, Zupkosky PJ, Buckley K. Survey of practicing 
dermatologists on the prevalence of sensitive skin in men. Int J 
Cosmet Sci 2013; 35:2013–35.

  78.  Freeman RG, Cockerell EG, Armstrong J, Knox JM. Sunlight as 
a factor influencing the thickness of epidermis. J Invest Dermatol 
1962; 39:1962–39.

  79.  Thomson  ML.  Relative  efficiency  of  pigment  and  horny  layer 
thickness  in  protecting  the  skin  of  Europeans  and  Africans 
against solar ultraviolet radiation. J Physiol 1955; 127:1955–127.

  80.  Corcuff P, Lotte C, Rougier A, Maibach HI. Racial differences in 
corneocytes. A comparison between black, white and oriental 
skin. Acta Derm Venereol 1991; 71:1991–71.

  81.  Berardesca E, Maibach HI. Racial differences in sodium lauryl 
sulphate induced cutaneous irritation: Black and white. Contact 
Dermatitis 1988; 18:1988–18.

  82.  Lampe MA, Burlingame AL, Whitney J, et al. Human stratum 
corneum  lipids:  Characterization  and  regional  variations. 
J Lipid Res 1983; 24:1983–24.

  83.  Reinertson  RP,  Wheatley  VR.  Studies  on  the  chemical  com-
position  of  human  epidermal  lipids.  J  Invest  Dermatol  1959; 
32:1959–32.

  84.  Brod  J.  Characterization  and  physiological  role  of  epidermal 

lipids. Int J Dermatol 1991; 30:1991–30.

  85.  Elias  PM,  Menon  GK.  Structural  and  lipid  biochemical  corre-
lates of the epidermal permeability barrier. Adv Lipid Res 1991; 
24:1991–24.

  86.  Swartzendruber DC, Wertz PW, Kitko DJ, et al. Molecular mod-
els  of  the  intercellular  lipid  lamellae  in  mammalian  stratum 
corneum. J Invest Dermatol 1989; 92:1989–92.

  87.  Berardesca E, Maibach H. Racial differences in skin pathophys-

iology. J Am Acad Dermatol 1996; 34:1996–34.

  99.  Frosch  P,  Kligman  A.  A  method  for  appraising  the  stinging 
capacity of topically applied substances. J Soc Cosmet Chem 1981; 
28:1981–28.

  100.  Grove GL. Physiologic changes in older skin. Clin Geriatr Med 

1989; 5:1989–5.

  101.  Foy V, Weinkauf R, Whittle E, Basketter DA. Ethnic variation 
in  the  skin  irritation  response.  Contact  Dermatitis  2001; 
45:2001–45.

  102.  Kaidbey KH, Agin PP, Sayre RM, Kligman AM. Photoprotection 
by melanin-–A comparison of black and Caucasian skin. J Am 
Acad Dermatol 1979; 1:1979–1.

  103.  Anderson  RR,  Parrish  JA.  The  optics  of  human  skin.  J  Invest 

Dermatol 1981; 77:1981–77.

  104.  Berardesca E, de Rigal J, Leveque JL, Maibach HI. In vivo bio-
physical  characterization  of  skin  physiological  differences  in 
races. Dermatologica 1991; 182:1991–182.

  105.  Diridollou S, de Rigal J, Querleux B, et al. Comparative study 
of the hydration of the stratum corneum between four ethnic 
groups: Influence of age. Int J Dermatol 2007; 46 (Suppl 1):11–14.

  106.  McCurdy J. Cosmetic surgery of the asian face. In: Paper I (ed.). 
Facial Plastic and Reconstructive Surgery. New York: Thieme 2002; 
pp. 322–43.

  107.  Nouveau-Richard  S,  Yang  Z,  Mac-Mary  S,  et  al.  Skin  ageing: 
A  comparison  between  Chinese  and  European  populations. 
A pilot study. J Dermatol Sci 2005; 40:2005–40.

  108.  Kelly AP. Aesthetic considerations in patients of color. Dermatol 

Clin 1997; 15:1997–15.

  109.  Edwards RR, Fillingim RB. Ethnic differences in thermal pain 

responses. Psychosom Med 1999; 61:1999–61.

  110.  Rawlings AV. Ethnic skin types: Are there differences in skin 
structure and function? Int J Cosmet Sci 2006; 28:2006–28.
  111.  Warrier  A,  Kligman  AM,  Harpert  R,  et  al.  A  comparison  of 
black and white skin using noninvasive methods. J Soc Cosmet 
Chem 1996; 47:1996–47.

 
6

Organic Acids with Novel Functions: Hydroxy, Bionic, 
N-acetylamino Acids and N-acylpeptide Derivatives

Ruey J. Yu and Eugene J. Van Scott

INTRODUCTION
Organic  acids  cover  a  wide  range  of  organic  compounds 
having an acidic group such as carboxyl, sulfonyl, or phos-
phoryl,  which  include  retinoic  acid,  salicylic  acid,  benzoic 
acid,  and  its  peroxide  form,  benzoyl  peroxide.  The  present 
discussion  will  focus  on  certain  organic  carboxylic  acids 
and related derivatives with unique cosmetic and dermato-
logical  effects  on  the  skin.  These  acids  are  α-hydroxyacids 
(AHAs), β-hydroxyacids (BHAs), polyhydroxy acids (PHAs), 
aldobionic  acids  (ABAs),  N-acetylamino  acids  (NAAs),  and 
N-acylpeptides (NAPs).

Abnormal keratinization is a principal event associated 
with  a  majority  of  dermatologic  conditions  including  ich-
thyosis,  xerosis,  eczema,  psoriasis,  and  acne.  As  a  result,  we 
estimate that over 50% of all skin problems are due to or are 
associated with disturbed formation and shedding of the stra-
tum corneum, and in part attribute the cosmetic and therapeu-
tic uses of AHAs on skin to their unique ability to modulate 
the process of keratinization and normalize stratum corneum 
exfoliation.

Hydroxyacids  and  related  acids  of  nonphenolic  origin 
are  a  group  of  natural  and  physiological  substances  which 
have  profound  effects  on  keratinization  and  the  synthesis  of 
dermal  components.  Many  hydroxyacids  and  related  acids 
occur  in  food,  fruits  such  as  sugar  cane,  tomato,  oranges, 
lemons,  grapes,  apples,  mangos,  and  body  tissues.  For  many 
years, cosmetic chemists have used lactic acid along with other 
organic acids to adjust pH, and citric acid as a chelating and 
antioxidant stabilizer in topical formulations. In addition, lac-
tic acid has been used as a stabilizer in urea formulations for 
topical treatment of dry skin.

In 1974 the term AHA was first introduced to dermatol-
ogy when it was discovered that AHAs substantially improved 
the  severe  hyperkeratotic  conditions  of  ichthyosis  (1).  AHAs 
are also beneficial for topical treatment of dry skin, dandruff, 
calluses, acne, keratoses, warts, wrinkles, photoaging skin, and 
for  other  cosmetic  conditions  and  dermatological  purposes 
(2–5). AHAs such as glycolic acid and lactic acid are routinely 
used  in  peel  solutions  by  estheticians  and  dermatologists.  In 
dermatological  office  procedures  they  are  used  for  topical 
management and treatment of various skin conditions includ-
ing  skin  smoothing,  acne,  and  skin  changes  associated  with 
intrinsic  and  extrinsic  aging  (6–9).  AHAs,  on  topical  applica-
tion,  have  been  shown  to  markedly  increase  biosynthesis  of 
hyaluronic acid and collagen in the papillary dermis, although 
the mechanism of action is unknown (5,10).

Polyhydroxy  AHAs  constitute  one  of  the  two  major 
components of hyaluronic acid, chondroitin sulfate, dermatan 

sulfate,  heparin,  and  heparan  sulfate.  In  combination  with 
numerous cosmetic or pharmaceutical agents, hydroxyacids 
have been found to enhance desirable  topical effects, and also 
to  reduce  or  prevent  side  effects  caused  by  topical  agents. 
Because most hydroxyacids are nontoxic, natural, and physi-
ological they are used as primary or secondary ingredients 
in many cosmetic and pharmaceutical products.

NAAs  and  NAPs  are  derived  from  amino  acids  or 
peptides  by  substitution  at  the  amino  group.  N-acetyl-
L-cysteine  (NAC)  has  been  shown  to  be  a  potent  anti-
oxidant.  We  have  found,  for  example,  N-acetyl-L-proline, 
N-acetyl-L-glutamine,  N-acetyl-L-valyl-L-alaninamide, 
N-acetyl-L-tyrosyl-L-tyrosinamide,  and  N-acetyl-L-tyrosyl-
L-tyrosyl-L-tyrosinamide  to  be  topically  effective  for  reliev-
ing  itch  and  improving  lesions  associated  with  eczema  and 
xerosis. We have also found that NAAs and NAPs are effec-
tive for topical treatments of aging-related skin changes.

In this chapter we discuss the scientific basis for topical 
effects of certain organic acids in dermatological therapy and 
in various cosmetic applications.

HYDROXYACIDS: NOMENCLATURE 
AND OCCURRENCE
Organic  hydroxyacids  of  non-phenolic  origin  may  be  clas-
sified  into  the  following  four  groups:  AHAs,  BHAs,  PHAs, 
and  ABAs.  For  group  names,  the  spellings  α-hydroxyacid 
and β-hydroxyacid are preferred instead of α-hydroxy acid and 
β-hydroxy acid because α and β indicate the position of hydroxyl 
group  in  the  hydroxyacid  molecule.  In  contrast,  the  spelling 
polyhydroxy  acid  is  preferred  instead  of  poly-hydroxyacid  or 
poly-hydroxy  acid  because  in  the  word,  poly  indicates  many 
or multiple hydroxyl groups, not the position of hydroxyl group 
in the acid (11).

α-HYDROXYACIDS 
AHAs  are  organic  carboxylic  acids  having  one  hydroxyl 
group  attached  directly  to  the  α  position  of  an  aliphatic  or 
alicyclic carbon atom, but not to a benzene or other aromatic 
ring. On a broader scope, AHAs may include those molecules 
having additional carboxyl groups (11). Glycolic acid, present 
in sugar cane juice, is the smallest molecule of all the hydroxy-
acids,  and  is  a  major  ingredient  in  most  AHA  products  on 
the  market.  All  other  AHAs  may  be  considered  derivatives 
or substituted glycolic acid. The AHAs may be divided into 
three  subgroups:  alkyl  AHAs,  aralkyl  AHAs,  and  polycar-
boxyl AHAs.

Table 6.1  Nomenclature and Occurrence of Glycolic Acid and 
Alkyl α-Hydroxyacids

Table 6.2  Nomenclature and Occurrence of Polycarboxy 
α-Hydroxyacids

ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 57

Systematic name 
Chemical structure

2-Hydroxyethanoic acid

CH2OHCOOH

2-Hydroxypropanoic acid

CH3CHOHCOOH

2-Methyl 

2-hydroxypropanoic 
acid
(CH3)2COHCOOH
2-Hydroxybutanoic acid
CH3CH2CHOHCOOH
2-Hydroxyoctanoic acid

CH3(CH2)5CHOHCOOH
2-Hydroxyeicosanoic acid

CH3(CH2)17CHOHCOOH
2-Hydroxytetraeicosanoic 

acid
CH3(CH2)21CHOHCOOH

Common name

Glycolic acid
Hydroxyacetic acid
Lactic acid

Occurrence

Sugar cane

Tomato

Methyllactic acid

Mango

Systematic name 
Chemical structure

Common 
name

Occurrence

2-Hydroxypropane-1,3-dioic acid

Tartronic acid

HOOC CHOH COOH

2-Hydroxybutane-1,4-dioic acid
HOOC CH2 CHOH COOH
2-Methyl-2-hydroxybutane-1,4-

dioic acid
HOOC CH2 C(CH3)OH COOH

Malic acid

Apple

Citramalic 
acid

2,3-Dihydroxybutane-1,4-dioic 

Tartaric acid

Grape

α-Hydroxybutyric acid

α-Hydroxycaprylic acid

α-Hydroxyarachidonic 

acid

Cerebronic acid

Skin as 

ceramide

acid
HOOC CHOH CHOH COOH
3-Carboxy-3-hydroxypentane-1,5-

dioic acid
C(OH)(COOH) (CH2COOH)2
3-Carboxy-2-hydroxypentane-1,5-

dioic acid
HOOCCHOH CH(COOH) 
CH2COOH

Citric acid

Orange

Isocitric acid

Lemon

Alkyl AHAs
A  radical  attached  to  the  α  carbon  of  glycolic  acid  can  be  a 
simple  hydrocarbon  called  alkyl  group.  The  smallest  alkyl 
group is a methyl group and in this case, the AHA is lactic 
acid  (present  in  tomatoes).  Representative  alkyl  AHAs  are 
listed in Table 6.1.

Aralkyl AHAs
Aralkyl is an abbreviation of aryl plus alkyl. Aralkyl AHA is 
formed when a phenyl group is attached to an alkyl AHA, and 
is  represented  by  mandelic  acid,  benzilic  acid,  3-phenyllactic 
acid, and atrolactic acid. Mandelic acid has been used in com-
bination as methenamine mandelate for oral administration to 
treat urinary tract infections.

Polycarboxy AHAs
AHA  may  consist  of  more  than  one  carboxyl  group,  as 
shown  in  Table  6.2.  Malic  acid,  occurring  in  apples,  is  also 
called  apple  acid,  and  tartaric  acid,  present  in  grapes,  has 
been  called  fruit  acid  in  the  past.  Citric  acid,  occurring  in 
oranges and lemons, has one hydroxyl group and three car-
boxyl groups. The α- or β-hydroxyacid refers to the position 
of  a  hydroxyl  group  as  related  to  a  carboxyl  group  in  the 
hydroxyacid.  When  a  hydroxyacid  has  more  than  one  car-
boxyl group it can be an AHA and BHA at the same time. For 
example, malic acid, tartaric acid, and citric acid can be both 
AHA and BHA.

β-HYDROXYACIDS
BHAs are organic carboxylic acids having one hydroxyl group 
attached to a carbon atom at the β position, and are represented 
by β-hydroxybutanoic acid and tropic acid. β-Hydroxybutanoic 
acid,  also  known  as  β-hydroxybutyric  acid,  is  excreted  in 
amounts  as  much  as  30  grams  per  day  in  the  urine  of  dia-
betic subjects. Salicylic acid, 2-hydroxybenzoic acid, has both 
hydroxyl and carboxyl groups directly attached to a benzene 
ring.  It  is  not  chemically  a  true  BHA,  but  it  is  erroneously 
referred to as a BHA (12) in casual jargon.

3-Carboxy-3-hydroxyhexane-1,6-

Homocitric 

dioic acid
HOOCCH2 C(OH)(COOH) 
CH2CH2COOH

acid

3-Carboxy-2-hydroxyhexane-1,6-

Homoisocitric 

dioic acid
HOOCCHOH CH(COOH) 
CH2CH2COOH

acid

3-Carboxy-2-n-hexadecyl-3-

Agaricic acid

hydroxypentane

1,5-dioic acid

HOOCCH2 C(OH)(COOH) 
CH(C16H33)COOH

n-Hexadecyl 
citric acid

POLYHYDROXY ACIDS 
PHAs  are  organic  carboxylic  acids  having  multiple  hydroxyl 
groups (13). Many PHAs are also AHAs; they are derived from 
carbohydrates,  and  are  important  intermediates  in  carbohy-
drate  metabolism.  PHAs  may  be  divided  into  three  groups: 
aldonic acid, aldaric acid, and alduronic acid.

Aldonic Acid
An  aldonic  acid  is  a  carbohydrate,  called  aldose,  having  the 
carbon  atom  at  position  1  changed  to  a  carboxyl  group,  and 
is represented by ribonic acid and gluconic acid, as shown in 
Table  6.3.  Vitamin  C,  L-ascorbic  acid,  is  a  1,4-lactone  form  of 
the AHA 2,4,5,6-tetrahydroxy-3-ketohexanoic acid, a keto PHA 
with  chemical  structure:  HOCH2  CHOH  CHOH  CO  CHOH 
COOH. The lactone form of vitamin C has two acidic hydroxyl 
groups at carbon positions 2 and 3, and does not have an effect 
on keratinization comparable to that of α-hydroxy PHAs.

Aldaric Acid
An  aldaric  acid  is  a  carbohydrate  having  two  carbon  atoms 
at  the  end  positions  changed  to  carboxyl  groups,  and  is  rep-
resented  by  glucaric  acid  (saccharic  acid)  and  galactaric  acid 
(mucic acid).

Alduronic Acid
An alduronic acid is a carbohydrate having the terminal carbon 
changed to a carboxyl group, and is represented by glucuronic 

 
58 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 6.3  Nomenclature and Occurrence of Aldonic Acids

Systematic name and chemical structure

Common name stereoisomer name

Occurrence

2,3-Dihydroxypropanoic acid
HOCH2 CHOH COOH

Glyceric acid

3,3-Dimethyl-2,4-dihydroxybutanoic acid

Pantoic acid

In vitamin B5

HOCH2 C(CH3)2 CHOH COOH

2,3,4-Trihydroxybutanoic acid
HOCH2 (CHOH )2 COOH

2,3,4,5-Tetrahydroxypentanoic acid

HOCH2 (CHOH )3 COOH

2,3,4,5,6-Pentahydroxyhexanoic acid

HOCH2 (CHOH)4 COOH

Erythronic acid
Threonic acid
Ribonic acid, arabinoic acid, xylonic acid, lyxonic acid

Allonic acid, altronic acid, gluconic acid, mannoic acid, gulonic 

In skin

acid, idonic acid, galactonic acid, talonic acid

2,3,4,5,6,7-Hexahydroxyheptanoic acid

Alloheptonic acid, altroheptonic acid, glucoheptonic acid, 

mannoheptonic acid, guloheptonic acid, idoheptonic acid, 
galactoheptonic acid, taloheptonic acid

HOCH2 (CHOH)5 COOH

acid which is produced in the body as a detoxifying agent, and 
forms hyaluronic acid with N-acetyl glucosamine.

ALDOBIONIC ACIDS 
ABA, also known as bionic acid, consists of one monosaccha-
ride  chemically  linked  through  an  ether  bond  to  an  aldonic 
acid, as shown in Table 6.4. An ABA may also be described as 
an  oxidized  form  of  a  disaccharide  or  dimeric  carbohydrate, 
such as lactobionic acid derived from lactose and maltobionic 
acid from maltose. Lactobionic acid solution is currently used 
in preservative media for organ transplants.

AHA-RELATED COMPOUNDS
An  α-ketoacid  has  a  keto  instead  of  hydroxyl  group  at  the 
alpha carbon of an organic carboxylic acid, and is related to its 
counterpart alpha-hydroxyacid. Pyruvic acid (2-ketopropanoic 
acid, CH3 CO COOH) and lactic acid have such a biochemical 
relationship  in  that  the  latter  can  be  converted  to  the  former 
when the hydroxyl group is oxidized to keto group by lactate 
dehydrogenase.

HYDROXYACIDS: PHYSICOCHEMICAL 
PROPERTIES 
Stereoisomers
Stereoisomers are formed when a carbon in a hydroxyacid has 
a  stereocenter  in  the  molecule,  i.e.  the  carbon  has  four  non-
identical  radicals.  Whereas  glycolic  acid,  methyllactic  acid, 
and  benzilic  acid  do  not  have  stereoisomers,  lactic  acid  and 
mandelic  acid  have  stereoisomers,  D  and  L  forms.  Tartronic 
acid and citric acid do not have stereoisomers, but malic acid 
has D and L, and tartaric acid has D, L, and meso forms. For 
PHAs  and  ABAs,  stereoisomers  usually  result  in  different 
chemical names, such as ribonic acid and arabinoic acid, glu-
conic acid and galatonic acid, lactobionic acid and maltobionic 
acid, and often retain similar though not identical functions.

Lactone Form
In contrast to AHAs and BHAs, many PHAs can form spon-
taneous intramolecular lactones by elimination of water mol-
ecules between the carboxyl and hydroxyl groups, especially 
when  these  two  functional  groups  are  separated  by  two  or 
three  carbons.  D-Gluconolactone,  known  as  D-gluconic  acid 

Table 6.4  Nomenclature and Source of Aldobionic Acids

Common name

Chemical structure

Lactobionic acid

HOH2 C CHOH 

Source

Lactose

Isolactobionic acid

Maltobionic acid

Isomaltobionic acid

Cellobionic acid

Gentiobionic acid

Kojibionic acid

Laminarabionic 

acid

Melibionic acid

Nigerobionic acid

CHOR(CHOH)2 COOH

R=galactose;4-O-β-D-
Gal-D-gluconic acid
6-O-β-D-Gal-D-gluconic 

acid

HOH2 C CHOH 

CHOR(CHOH)2 COOH
R=glucose;4-O-α-D-Glc-

D-gluconic acid

6-O-α-D-Glc-D-gluconic 

acid

HOH2 C CHOH 

CHOR(CHOH)2 COOH
R=glucose;4-O-β-D-Glc-

D-gluconic acid

Isolactose

Maltose

Isomaltose

Cellobiose

ROH2 C (CHOH)4 COOH Gentiobiose
R=glucose;6-O-β-D-Glc-

D-gluconic acid
HOH2 C (CHOH)3 
CHORCOOH

R=glucose;2-O-α-D-Glc-

D-gluconic acid
HOH2 C (CHOH)2 

CHORCHOHCOOH
R=glucose;3-O-β-D-Glc-

D-gluconic acid

Kojibiose

Laminarabiose

ROH2 C (CHOH)4COOH Melibiose
R=galactose;6-O-α-D-
Gal-D-gluconic acid
3-O-α-D-Glc-D-gluconic 

Nigerose

acid

Sophorobionic acid

2-O-β-D-Glc-D-gluconic 

acid

Sophorose

δ-lactone, is formed by eliminating one mole of water between 
the carboxyl group and the hydroxyl group at carbon 5 posi-
tion of D-gluconic acid, forming a six-member ring lactone.

 
Solubility and Gel Matrix
AHAs and BHAs with small molecular weight, and most PHAs 
and ABAs, are soluble in water. Certain AHAs and BHAs such 
as  methyllactic  acid,  mandelic  acid,  malic  acid,  phenyllactic 
acid,  atrolactic  acid,  and  tropic  acid  are  also  soluble  in  alco-
hol. Some aralkyl AHAs are lipophilic, and are more soluble in 
alcohol than water, such as benzilic acid.

One unique property of ABAs is their potential to form 
a gel matrix with water. Maltobionic acid can form a clear gel 
matrix containing 29% water molecules complexed with mal-
tobionic  molecules.  Under  the  same  conditions,  lactobionic 
acid  and  cellobionic  acid  can  form  clear  gels  containing  14% 
and 7% water respectively. The gel matrix may add protective, 
soothing,  and  healing  effects  for  inflamed  skin  or  in  wound 
healing.

Acid Strength and pKa
The  acid  strength  of  an  organic  hydroxyacid  is  determined 
by  its  proton  dissociation  from  the  carboxyl  group  in  aque-
ous  solution.  After  equilibrium  is  reached,  the  dissociation 
constant  Ka  is  defined  as  hydroxyacid  anion  multiplied  by 
proton ion, and divided by undissociated hydroxyacid based 
on  molar  concentration.  The  acid  strength  is  expressed  as 
pKa, and the latter is a negative logarithm of the dissociation 
constant. The hydroxyacid is a stronger acid if its pKa number 
is  lower  (14).  The  acid  strength  of  a  hydroxyacid  may  not  be 
related to its topical action on keratinization, although its pKa 
is crucial to the determination of bioavailability and bioavail-
able concentration.

Antioxidant Property
Oxidation is defined as removal of electrons or reaction with 
oxygen.  An  antioxidant  is  defined  as  any  substance  capable 
of  preventing  or  inhibiting  oxidation.  In  biological  systems, 
an  antioxidant  may  be  described  as  a  substance  capable  of 
disposing, scavenging, or suppressing formation or actions of 
peroxide, superoxide, or free radicals. There are three simple 
screen  methods  which  are  useful  to  determine  antioxidant 
properties:  prevention  or  retardation  of  air  oxidation  of  (1) 
anthralin,  (2)  hydroquinone,  or  (3)  banana  peel.  Based  on 
these three tests, all the PHAs and ABAs we have tested are 
antioxidants  which  include  ribonolactone,  gluconolactone, 
galactonolactone, gulonolactone, glucoheptonolactone, lacto-
bionic acid, and maltobionic acid (11,15,16). Among AHAs and 
BHAs, citric acid, isocitric acid, tartaric acid, and malic acid 
are antioxidants.

HYDROXYACIDS: BIOCHEMISTRY
Relationship to Amino Acids
Many hydroxyacids are related to or derived from amino acids. 
Based on chemical structures, the only difference between an 
AHA and an amino acid is the hydroxyl group instead of the 
amino group, as shown in Table 6.5.

Carbohydrate Metabolism and Citrate Cycle 
Many hydroxyacids are intermediate products or end metab-
olites  in  carbohydrate  metabolism;  these  include  glyceric 
acid  in  glycolysis.  In  anaerobic  glycolysis,  D-glucose  is  con-
verted to L-lactic acid as the end product. Gluconic acid and 
gluconolactone  are  important  intermediates  in  the  pentose 
phosphate pathway for the synthesis of nucleotides in DNA 
and RNA. Gulonic acid and gulonolactone are carbohydrate 

ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 59

Table 6.5  Biochemical Relationship between Hydroxyacids and 
Amino Acids

Hydroxyacid and amino acid

Chemical structure

Glycolic acid

Glycine

Lactic acid

Alanine

Isopropylglycolic acid

Valine

3-Isopropyllactic acid

Leucine

3-Methyl-3-ethyl-lactic acid

Isoleucine

Glyceric acid

Serine

3-Methylglyceric acid

Threonine

Malic acid

Aspartic acid

3-Phenyllactic acid

Phenylalanine

CH2OHCOOH
CH2NH2COOH
CH3CHOHCOOH
CH3CHNH2COOH
C3H7 CHOHCOOH
C3H7 CHNH2COOH
C3H7 CH2CHOHCOOH
C3H7 CH2CHNH2COOH
(C2H5)CH(CH3)CHOHCOOH
(C2H5)CH(CH3)CHNH2COOH
CH2OHCHOHCOOH
CH2OHCHNH2COOH
CH3CHOHCHOHCOOH
CH3CHOHCHNH2COOH
HOOCCH2CHOHCOOH
HOOCCH2CHNH2COOH
C6H5 CH2CHOHCOOH
C6H5 CH2CHNH2COOH

intermediates  for  the  synthesis  of  vitamin  C  in  plants  and 
some  animals.  Citric  acid,  isocitric  acid,  and  malic  acid 
are  important  intermediates  in  the  citrate  cycle  for  energy 
production.

Glycosaminoglycans
Glycosaminoglycans  (GAGs)  are  large  carbohydrates  widely 
distributed in the body, for example in skin, fibroblasts, mast 
cells,  cartilage,  bones,  synovial  fluid,  cornea,  and  loose  con-
nective tissues. Their physiological roles include formation of 
extracellular  matrix,  specific  interactions  with  collagen  and 
elastin, binding of water and ions, facilitating cell migration, 
formation of anticoagulants, and facilitating cell adhesion, cell 
interaction, and cell receptors. There are six different types of 
GAGs,  namely  hyaluronic  acid,  chondroitin  sulfate,  keratan 
sulfate I and II, dermatan sulfate, heparin, and heparan sulfate. 
Each GAG is formed from two major carbohydrate components 
which include PHAs. For example, glucuronic acid is one of the 
two major components of hyaluronic acid, chondroitin sulfate, 
and heparan sulfate. Iduronic acid is an important component 
of dermatan sulfate and heparin.

HYDROXYACIDS: BIOAVAILABILITY AND 
BIOAVAILABLE CONCENTRATION
Stratum Corneum Barrier
In normal human skin, the stratum corneum consists of 14 to 
30 layers of corneocytes, including the inner level stratum com-
pactum and the outer level stratum dysjunctum. The keratin-
enriched  corneocytes  in  the  stratum  corneum  are  embedded 
in a lipid matrix and are very resistant to penetration by ionic 
compounds or large molecules with molecular weight greater 
than  800  to  1000.  While  undissociated  glycolic  acid  or  lactic 
acid molecules can readily penetrate into the stratum corneum, 
the  ionized  glycolate  or  lactate  anions  from  the  metallic  salt 
cannot. Although the active form of a hydroxyacid may be the 
anions once inside the skin, a topical formulation must contain 

 
60 

 TEXTBOOK OF COSMETIC DERMATOLOGY

a bioavailable form which can penetrate into and through the 
stratum corneum.

therapeutically  effective  with  minimal  or  no  irritation  to  the 
skin.

Partial Neutralization and Buffered Formulation
A topical formulation containing a hydroxyacid without neu-
tralization  has  a  pH  below  2.  Since  the  pH  of  skin  surface  is 
approximately 4.2 to 5.6, many commercial products contain-
ing  glycolic  acid  or  lactic  acid  are  partially  neutralized  with 
sodium  hydroxide  or  ammonium  hydroxide  to  pH  3.5  to  4.5, 
and  claim  to  be  buffered  formulations.  A  buffered  system  is 
designed to control pH changes of a formulation and does not 
effectively reduce or eliminate skin irritation without compro-
mising topical efficacy. Therefore, lessened irritation is mainly 
due to decreased penetration of glycolic acid or lactic acid.

Efficacy Potential
Cosmetic or therapeutic efficacy of a topical formulation con-
taining a hydroxyacid is proportional to bioavailable concen-
tration  of  the  hydroxyacid  in  an  optimal  vehicle  (13,14).  The 
bioavailable concentration is obtained by bioavailability mul-
tiplied  by  initial  total  concentration  of  the  hydroxyacid.  The 
bioavailability is defined as a ratio or fraction of the undissoci-
ated hydroxyacid, because only the free acid, not the anion, can 
substantially  penetrate  the  stratum  corneum.  Bioavailability 
decreases sharply when the pH is raised.

HYDROXYACIDS: OPTIMAL 
RELEASE FORMULATION
Skin Stinging and Irritation
A topical formulation containing a hydroxyacid without par-
tial neutralization usually has pH of below 2. Such formulation, 
especially with a small molecular AHA, may provoke sensa-
tions of tingling, itching, stinging, or irritation when applied 
to sensitive, atopic, diseased, or inflamed skin. The undesired 
skin reactions may be due to the lower pH of the formulation, 
or  uncontrolled  release  and  fast  penetration  of  hydroxyacid 
into the skin. We have found that faster penetration of an AHA 
is the major factor in causing skin stinging (17).

Molecular Complex
In  an  amphoteric  system,  the  control-release  mechanism  is 
based on intermolecular attracting forces between a hydroxy-
acid  and  an  amphoteric  substance  to  form  a  molecular  com-
plex.  Amino  acids  are  the  best  amphoteric  substances,  and 
the  preferred  ones  are  arginine,  lysine,  histidine,  trypto-
phan,  and  ornithine.  There  are  three  major  attracting  forces 
between  a  hydroxyacid  and  an  amphoteric  substance:  ionic/
ionic, dipolar/ionic, and dipolar/dipolar (17). The amphoteric 
formulations are therapeutically effective with minimal or no 
irritations to the skin.

In a non-amphoteric system, the control-release mecha-
nism is also based on intermolecular attracting forces between 
a  hydroxyacid  and  a  non-amphoteric  substance  to  form  a 
molecular complex. The non-amphoteric substances are multi-
functional organic bases such as amino acid esters, amino acid 
amides, aminocarbohydrates, aminoalditols, or aminocyclitols. 
Examples  include  glycine  ethyl  ester,  glycinamide,  arginin-
amide,  lysinamide,  ornithinamide,  glucosamine,  glucamine, 
meglumine, and streptamine. In contrast to that of an ampho-
teric system, the main attracting force of a non-amphoteric sys-
tem is from ionic/ionic force between a hydroxyacid anion and 
a  cation  of  a  non-amphoteric  substance  such  as  glycine  ethyl 
ester ammonium ion. The non-amphoteric formulation is also 

HYDROXYACIDS: TOPICAL ACTIONS
Effects on Keratinization
On topical application, hydroxyacids exert a profound effect 
on  desquamation.  At  low  to  moderate  concentrations,  the 
hydroxyacid,  such  as  glycolic  acid  10%  cream,  on  topical 
application to ichthyotic skin (Figure 6.1) causes initial sepa-
ration of stratum corneum at lower levels near stratum com-
pactum (3,11). The separation of stratum corneum as a sheet 
indicates that topical action of the hydroxyacid is not a dis-
persive keratolysis, such as by salicylic acid. A similar event 
can also happen to normal skin. For example, DL-mandelic 
acid 10% cream on topical administration twice daily to nor-
mal skin causes sudden separation of stratum corneum as a 
thin sheet after a few days of application. The skin exposed 
after  the  separation  of  stratum  corneum  shows  light  pink-
ish coloration with a shiny smooth surface. With continued 
applications such desquamation returns to normal, i.e. can-
not be perceived. Because of their marked effects on desqua-
mation,  hydroxyacids  can  be  topically  effective  for  various 
cosmetic objectives.

Effects on Dermal Components 
and Skin Thickness
Hydroxyacids at concentrations of 10% to 25% on topical appli-
cation have been shown to increase biosynthesis of glycosami-
noglycans and collagen fibers, and also to improve the quality 
of  photoaged  elastic  fibers  (5,10,18,19).  Hydroxyacid  10%  to 
35% creams topically applied twice daily to one forearm and 
control cream to the opposite forearm for 1 to 9 months have 
been found to increase skin thickness very substantially (4,8). 
The increased skin thickness is mainly due to increased bio-
synthesis of glycosaminoglycans and collagen fibers as shown 
by  histological  analysis  (5,19).  The  degree  of  increase  in  skin 
thickness  is  quite  variable,  as  shown  in  Table  6.6,  and  seems 
to depend on individual subject and the type of hydroxyacid 
used. In some cases hydroxyacids have been found to increase 
skin thickness more than 40%. Although epidermal thickness 
is also increased, the major part of the increase in thickness is 
the dermis. The increased skin thickness is not due to edema 
formation, because it persists for many weeks to months after 
discontinuation  of  topical  application.  Because  of  these  der-
mal  effects  and  increased  skin  thickness,  hydroxyacids  are 
found  to  be  therapeutically  effective  for  topical  treatment  of 
skin  changes  associated  with  aging,  including  wrinkles  and 
photoaging.

In contrast, under the same test conditions salicylic acid 
at 5% concentration has been found to cause a reduction in skin 
thickness, as shown in Table 6.7. Forearm skin treated with sal-
icylic acid clinically appeared thinner.

Peel Solutions and Skin Peeling
Certain AHAs can be used in office procedures as peel solu-
tions  for  topical  treatment  of  various  cosmetic  and  dermato-
logical indications, including acne, keratoses, warts, wrinkles, 
and photoaging (20,21). The AHAs adaptable for such include 
glycolic acid, lactic acid, citric acid, and mandelic acid. In wide 
use  is  glycolic  acid  in  20,  35,  50,  and  70%  aqueous  solutions 
containing small amount of ethanol and propylene glycol for 
uniform penetration with pH 1.6, 1.3, 1.2, and 0.6 respectively 
(7,8). DL-Lactic acid can be used in the same manner, and 90% 

 
ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 61

(a)

(b)

(c)

(d)

Figure 6.1  Thirteen-year-old girl with lamellar ichthyosis before (a,b) and after (c,d) topical application of 10% glycolic acid in hydrophilic 
ointment twice daily for 3 weeks.

Table 6.6 

Increased Skin Thickness by Topical Application of Hydroxyacids and Related Compounds*

Substance

Benzilic acid

Citric acid

Glycolic acid

Gluconolactone

Lactic acid

Lactobionic acid

Mandelic acid

Methyllactic acid

Pyruvic acid

Subject number

Age range (Years)

Duration (Months)

Percentage increase 
over control

2

13

4

6

4

7

2

3
4

68–72

50–83

58–77

62–81

59–70

49–76

55–62

65–76
62–82

2

5–9

4–8

2–7

5–7

1–3

1

1–3
2

22–45

7–55

11–43

7–19

17–42

5–58

22–27

14–20
14–27

*10%–35% Concentration twice daily on forearm skin.

 
 
       
 
 
 
 
   
 
 
 
 
62 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 6.7  Decreased Skin Thickness by Topical Application Of 
5% Salicylic Acid Solution Twice Daily on Forearm Skin

Subject (Age and 
gender)

Duration (Weeks)

Percentage decrease 
over control

57F

60F

59F

63F

61F

60F

67F

49F

73F

8

3

6

10

2

5

6

3
7

–6

–7

–8

–11

–12

–14

–21

–23
–32

syrupy liquid having pH 0.5 is commercially available. Citric 
acid peel can be used as 20, 30, 40, and 50% aqueous solution 
with pH 1.5, 1.4, 1.3, and 1.2 respectively. DL-mandelic acid 50% 
in ethanol solution can be used for light desquamatory peeling.
Pyruvic acid, an α-ketoacid, is the most powerful peeling 
agent  but  is  unsuitable  for  clinical  use  because  of  its  chemi-
cal instability. Glycolic acid 70% solution or DL-lactic acid 90% 
liquid can provoke epidermolysis on the facial skin, generally 
requiring several minutes of exposure depending on skin type. 
The  clinical  sign  of  epidermolysis  is  blanching  of  the  skin, 
which indicates the threshold between superficial peeling and 
deeper peeling. For new patients it is best to begin with 20% or 
35%  glycolic  acid  solution  and  establish  a  reaction  profile  for 
each subject. In most cases the appearance of erythema is good 
indication that the skin will be peeled superficially. The peeling 
process should be terminated by neutralization with sodium 
bicarbonate  solution.  The  patient  may  feel  mild  stinging  but 
degrees of discomfort are mild to moderate and acceptable for 
the intended end result. Superficial peeling may be repeated at 
intervals of 2 to 3 weeks or longer to provide beneficial effects 
in  acne,  acne-prone  skin  of  younger  age,  older  skin  prone  to 
milia and comedones, post-acne scaring, wrinkle-prone skin, 
keratosis-prone skin, and photoaging skin.

For  superficial  peeling  with  milder  reactions,  glycolic 
acid 50% in ethanol may be used. Application of this solution 
to facial skin is associated with rapid onset of a burning sen-
sation  and  erythema.  After  1  minute,  the  skin  is  rinsed  with 
sodium bicarbonate solution to relieve the burning sensation. 
In  most  cases,  the  erythema  fades  within  1  to  several  hours. 
Epidermolysis can occur if glycolic acid 50% in ethanol is left 
on facial skin for several minutes. The erythema may persist 
into  the  next  day,  with  denudation  of  skin  and  degrees  of 
serous oozing. In some cases, sheet-like separation of stratum 
corneum  occurs  1  day  after  the  procedure,  leaving  the  skin 
light pink in color and smooth without other overt signs of an 
unwanted reaction. For most cosmetic procedures, superficial 
peeling with 50% or 70% glycolic acid is adequate and can be 
repeated every 2 to 3 weeks. For deeper peeling, glycolic acid 
70% in water or 50% in ethanol can be left on the skin for lon-
ger periods, and can be so used in the treatment of seborrheic 
keratoses and actinic keratoses.

Synergistic Compositions
Associated with the ability of hydroxyacids modulating kera-
tinization  and  inducing  biosynthesis  of  glycosaminoglycans 

and collagen fibers is the capability of these natural and physi-
ological  substances  to  enhance  or  amplify  pharmacologic 
actions of many topical agents. Such topical agents include cor-
ticosteroids,  retinoic  acid,  hydroquinone,  diphenhydramine, 
5-fluorouracil,  and  antifungal  agents  (11,22).  The  mechanism 
of  this  synergistic  action  is  not  known.  It  may  be  because 
hydroxyacids  disrupt  skin  barriers  and  promote  better  bind-
ing between a topical agent and its receptor molecule, resulting 
in  enhanced  topical  effect.  The  enhanced  therapeutic  effects 
appear not due to an increased penetration of the topical agent 
into the skin. Hydroxyacids can also reduce or eliminate tachy-
phylaxis, as well as rebound worsening associated with topi-
cal  corticosteroids.  It  has  been  found  that  certain  side  effects 
associated with topical corticosteroids, such as atrophy, can be 
reduced or avoided with concomitant use of an AHA (23).

HYDROXYACIDS: MECHANISMS OF ACTION
Specificity of Chemical Structure
Unique  biological  and  biochemical  actions  of  a  hydroxyacid 
depend on specific chemical structure of the molecule, although 
its  receptor  molecule(s)  in  the  skin  has  not  been  identified. 
Regarding the three attachment or binding sites, the hydroxyl 
group must be neutral and not acidic in chemical property, like 
that in alcohol but not like aromatic phenol, which is slightly 
acidic. The carboxyl group must be attached to a non-aromatic 
carbon,  preferably  an  alkyl  chain  carbon.  The  amide  or  ester 
form  is  substantially  less  active  than  the  free  acid  form.  The 
side chain can be H, alkyl, or aryl, but the one preferred is a 
short chain. In the case of glycolic acid, the three attachment 
points  or  binding  sites  to  a  receptor  molecule(s)  in  the  skin 
are  hydroxyl,  carboxyl,  and  one  of  the  two  hydrogen  atoms 
attached  to  the  alpha  carbon.  Among  related  compounds, 
pyruvic acid is the most active and effective α-ketoacid. In con-
trast with the hydroxyacid, the ester form of pyruvic acid, such 
as methyl pyruvate or ethyl pyruvate, can be topically active. 
It has been speculated that the ester form is hydrolyzed to free 
pyruvic acid by an esterase enzyme in the skin.

Biological Action
The precise mechanisms of actions induced by the hydroxyacid 
are not known. Based on the available laboratory and clinical 
data, hydroxyacids at different concentrations provide the fol-
lowing actions: diminished corneocyte cohesion at lower level 
of  stratum  corneum,  near  the  stratum  compactum;  a  dimin-
ished number of desmosomes; reduced epidermal thickness in 
lamellar ichthyosis (Figure 6.2); increased epidermal and der-
mal skin thickness in aging skin; increased synthesis of glycos-
aminoglycans  and  collagen  fibers;  and  increased  activities  of 
dermal dendrocytes (3,5,24).

Biochemical Action
Biological  actions  are  usually  due  to  or  caused  by  biochemi-
cal  reactions.  In  normal  stratum  corneum,  extractable  lipids 
contain by weight approximately 45% to 50% ceramides, 25% 
cholesterol, 10% to 15% free fatty acids, and less than 5% each 
of  other  lipids  including  cholesterol-3-sulfate,  which  appears 
to  be  involved  with  cell  cohesion  in  the  lower  layers  of  stra-
tum  corneum  (25–27).  The  conversion  of  cholesterol-3-sulfate 
to cholesterol is required for normal desquamation of stratum 
corneum in the upper layers (28). It has been shown in X-linked 
ichthyosis that the skin is deficient in steroid sulfatase enzyme 
(29). While cholesterol is non-ionic, cholesterol-3-sulfate is an 
ionic  compound  which  may  cause  stronger  intercorneocyte 

 
ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 63

(a)

(b)

Figure 6.2  Two-year-old girl with lamellar ichthyosis, including scaly skin and erythema, before (a) and after (b) twice daily topical appli-
cation of 8% gluconolactone in control-release combination formulation for 4 weeks.

binding and cohesion, resulting in retarded desquamation. We 
might speculate that the hydroxyacid activates steroid sulfatase 
to  enhance  hydrolysis  of  cholesterol-3-sulfate  to  free  choles-
terol in the stratum compactum of ichthyotic skin. AHAs such 
as glycolic acid, lactic acid, and citric acid have been shown to 
activate factor XIIIa transglutaminase enzyme, tumor necrosis 
factor-α, and to stimulate mast cells, fibroblast cells, and der-
mal dendrocytes.

HYDROXYACIDS: COSMETIC AND 
DERMATOLOGICAL INDICATIONS
Dry Skin and Skin Smoothing
Hydroxyacids  can  modulate  keratinization  at  the  levels  of  the 
stratum  compactum,  and  such  action  is  desirable  for  topical 
treatment of dry skin conditions. Most cosmetic products for dry 
skin contain humectants or moisturizers which tend to improve 
water content or prevent water loss from the stratum corneum. 
Although lactic acid has been claimed to be a moisturizer, most 
AHAs are not primary humectants or moisturizers. Rather, they 
modulate keratinization to normalize or improve the quality of 
stratum corneum so that water loss is minimized. Most AHAs 
and BHAs, 4% to 10% cream or lotion, are therapeutically effec-
tive for topical treatment or prevention of common dry skin or 
xerosis (30,31). PHAs and ABAs 5% to 10% concentration have 
extra benefits for dry skin because of multiple hydroxyl groups 
in the molecule, which seem to bind water molecules through 
hydrogen bonding. In addition, these hydroxyacids are gentle to 
sensitive or inflamed skin without causing skin stinging.

Hydroxyacids such as glycolic acid, lactic acid, and man-
delic acid at 10% concentration are therapeutically effective for 
topical treatment of ichthyosis and other severe dry skin con-
ditions.  PHAs  and  ABAs  such  as  gluconolactone,  lactobionic 
acid,  and  maltobionic  acid  10%  to  15%,  alone  or  in  combina-
tion with other topical agents, are beneficial and soothing for 
topical treatment of eczema and psoriasis (58). Combination of 
several hydroxyacids seems to be the best for topical treatment 
of severe dry skin.

cohesion and dislodge early comedones from follicular orifices 
(6). A gel or solution formulation in water, ethanol, propylene 
glycol  40:40:20  ratio  containing  5%  to  10%  hydroxyacid  and 
applied twice daily is usually quite beneficial for topical treat-
ment  or  prevention  of  early  acne.  The  hydroxyacids  include 
glycolic acid, lactic acid, methyllactic acid, mandelic acid, and 
benzilic  acid.  In  general,  improvement  of  acne  lesions  is  dis-
cernible within a few weeks of starting topical treatment.

For moderate to severe acne, hydroxyacids at higher skin 
peeling concentrations can be used to cause epidermolysis to 
unroof  pustules  and  beneficially  modulate  follicular  epithe-
lium to the level of sebaceous glands (7,33). Glycolic acid 50% or 
70% aqueous solution containing small amounts of alcohol and 
propylene  glycol  can  be  effectively  used  as  peeling  solution. 
The  solution  is  applied  to  acne-involved  areas  with  a  cotton 
ball  or  suitable  brush.  The  patient  will  feel  a  mild  to  moder-
ate sense of burning as erythema develops over a period of a 
few minutes. When skin blanching or perifollicular edema is 
detected, the skin is neutralized with 5% sodium bicarbonate 
solution  to  stop  further  epidermolysis.  With  this  procedure, 
most  pustules  will  become  unroofed.  The  procedure  may  be 
repeated every 2 to 3 weeks. During intervening periods, a low 
concentration such as 5% to 8% hydroxyacid in gel or solution 
may be used by the patient once or twice daily to keep follicles 
opened.

Rosacea  is  characterized  by  vascular  dilatation  with 
erythema  near  the  center  of  the  face.  The  cause  is  unknown, 
although sunlight may play an important role in the develop-
ment of rosacea lesions. Rosacea lesions can evolve into telan-
giectasia with acneiform papules and pustules, and the skin is 
quite sensitive to many topical agents. Metronidazole 0.75% gel 
is beneficial for topical treatment of rosacea but has no effect 
on telangiectasias. Because PHAs and ABAs are antioxidants 
and gentle to sensitive skin, substances such as gluconolactone, 
lactobionic acid, and maltobionic acid at 5% to 10% concentra-
tions are beneficial for prophylactic as well as topical treatment 
of rosacea (34).

Acne and Rosacea
All  acne  lesions  involve  retention  of  follicular  stratum  cor-
neum.  Hydroxyacids  are  therefore  therapeutically  effec-
tive  for  topical  management  of  acne  (32).  Topical  action  of  a 
hydroxyacid at lower concentrations can diminish corneocyte 

Warts (Verrucae Vulgares) 
Hydroxyacids  are  therapeutically  effective  for  topical  treat-
ment of warts caused by human papillomavirus, which induces 
extreme  degrees  of  hyperkeratosis  (6).  A  rational  approach 
to  topical  treatment  includes  removing  the  hyperkeratotic 

 
 
64 

 TEXTBOOK OF COSMETIC DERMATOLOGY

“armor,” destroying the tissue harboring the virus, and intro-
ducing antiviral agent(s).

Much of the hyperkeratotic plate can be removed by scal-
pel paring. Thereupon an AHA in 70% solution or gel can be 
applied under occlusion twice daily by patients for a week or 
more to cause epidermolysis. In most cases, destruction of wart 
tissue occurs by epidermolysis and is sufficient to eradicate the 
virus as well as the lesion. However, combined use of an anti-
metabolite such as 5-fluorouracil (5-FU) is more curative, and 
it can be applied concomitantly (7). For home use by patients, 
0.5% 5-FU solution is prepared by dissolving the drug in 70% 
glycolic acid. The solution is applied twice daily with a cotton 
applicator to the center of the wart, which is then covered with 
tape.  Applications  are  discontinued  if  discomfort occurs  and 
resumed if the wart lesion is not yet resolved. We have found 
that  this  treatment  usually  results  in  complete  resolution  of 
lesions within 3 to 4 weeks.

Eczema and Pruritus
Eczema  may  be  defined  as  persistent  inflammatory  skin 
lesions  with  constant  or  repeated  itch.  Eczematous  disorders 
can occur at any age and in various forms, such as nummular 
eczema and lichen simplex chronicus, and is a common skin 
disease  in  Asian  countries.  Eczema  may  be  caused  by  endo-
geneous and exogeneous factors. Pruritus is the main distur-
bance. Corticosteroids have been used for topical treatment of 
eczema, and the pruritus diminishes secondarily as the inflam-
matory process is subdued. In cases of eczema wherein inflam-
mation is  not a  primary event, topical corticosteroids are  not 
very effective in eradicating the pruritus. Hydroxyacids such 
PHAs and ABAs incorporated into topical antipruritic formu-
lations  can  greatly  enhance  efficacy.  For  example,  addition 
of  gluconolactone,  lactobionic  acid,  and/or  maltobionic  acid 
to  diphenhydramine  topical  formulations  greatly  enhances 
antipruritic efficacy. The best results are obtained when gluco-
nolactone,  lactobionic  acid,  and/or  maltobionic  acid  are  com-
bined  with  hydrocortisone-17-valerate  and  diphenhydramine 
in cream or lotion vehicles.

Onychomycosis
Onychomycosis  is  a  paramount  cosmetic  affliction,  heretofore 
difficult to treat. When an AHA is incorporated into a compo-
sition containing an antifungal drug, the formulation becomes 
topically  very  effective  for  nail  infections.  Improvement  of 
fingernail  and  toenail  infections  progresses  at  the  rate  of  nail 
growth; approximately 1 mm per week for a fingernail and 0.5 
mm  per  week  for  a  great  toenail.  The  improvement  rates  also 
suggest  that  fungal  infection  of  the  nail  is  arrested  by  topical 
treatment with synergistic compositions containing both AHA 
and antifungal drug. Fungal infections of fingernails have been 
regularly  eradicated  with  up  to  6  months  of  topical  treatment 
with solutions containing 2% clotrimazole and 20% glycolic acid.

HYDROXYACIDS: INTRINSIC AND 
EXTRINSIC SKIN AGING
Cutaneous  aging  is  caused  by  internal  and  external  factors 
(35–38). Intrinsic aging is a physiological degeneration caused 
by  declining  ability  and  functions  inherent  with  increasing 
age. Upper arms and buttocks are typical skin areas showing 
intrinsic aging, where the skin thins and develops fine wrin-
kles. Daily topical application of glycolic acid, gluconolactone, 
or lactobionic acid 5% to 10% cream or lotion has been found 
to be beneficial for prophylactic as well as topical treatment of 
sun-protected areas of aging skin.

Extrinsic  aging  is  a  combination  of  intrinsic  aging  and 
accelerated degeneration caused by ultraviolet (UV) radiation, 
ionizing  radiation,  air  pollution,  wind,  cold,  heat,  dampness, 
chemicals, smoke, and cigarette smoking. Face and hands are 
typical  skin  areas  showing  extrinsic  skin  aging.  Photoaged 
skin is rough, dry, mottled, yellowish, leathery, and thickened. 
It lacks elasticity, has keratoses and pigmented age spots and 
coarse and deep wrinkles. Aging of the face and the hands in 
elderly people is due to a combination of intrinsic aging and 
photoaging. Physiological aging cannot be stopped, but signs 
of extrinsic cutaneous aging can be modified by topical appli-
cation  of  AHAs,  PHAs,  ABAs  or  combinations  to  improve 
appearance and slow the process (39–42) (Figure 6.3).

Sunburn Cells
Sunburn cells are dead or dying keratinocytes caused by UV 
radiation, and are physiologically programmed for cell death 
(apoptosis). The cells are eosinophilic and appear in the epider-
mis within 30 minutes, and are maximal at 24 hours after UVB 
radiation (290–320 nm) (43). The action spectrum appears to be 
just below 300 nm, and UVA (320–400 nm) radiation does not 
seem to produce any detectable or significant numbers of sun-
burn cells in epidermis. The mechanism of action is unknown. 
It appears that DNA damages have occurred in certain kera-
tinocytes at the lower epidermis after the UVB radiation, and 
these sunburn cells move rapidly upward through the epider-
mis into the stratum corneum.

Preliminary study showed that glycolic acid 10%, pH 3.5, 
on  topical  application  for  12  weeks  decreased  minimal  ery-
thema dose by 18% and increased the number of sunburn cells 
by twofold, as compared to control group (44). Under the same 
test  conditions,  a  cosmetic  surfactant,  sodium  lauryl  sulfate 
at 0.5% concentration, increased the number of sunburn cells 
sixfold.  Topical  formulations  containing  an  AHA  and  a  sun-
screen agent with a sun protection factor (SPF) approximately 
3–4  appeared  to  prevent  any  increase  of  sunburn  cells  (45). 
Topical formulations containing a PHA, 5% to 10% gluconolac-
tone, without any sunscreen agent have been shown to provide 

(a)

(b)

Figure  6.3  Fifty-five-year-old  woman  with  photoaged  skin, 
including  coarse  wrinkles  and  textural  signs  of  elastosis  on  her 
face, before (left) and after (right) 70% glycolic acid peels monthly 
and home use of twice daily 10% glycolic acid cream for 9 months.

 
 
therapeutic  effects  and  protect  the  skin  from  any  increase  in 
sunburn cells (46).

Nevertheless, regular use of a sunscreen is advisable.

Actinic Keratoses
Actinic keratosis is a precancerous lesion of keratinocytes, also 
called  solar  keratosis,  which  is  caused  by  photodamage.  The 
lesions are on the sun-exposed areas of skin. Actinic keratosis 
may progress to squamous cell carcinoma. One conventional 
treatment is continued topical application of 5-FU for several 
weeks. A combination of a hydroxyacid and 5-FU can shorten 
the treatment time and the period of discomfort from several 
weeks to just 1 week. First, the lesions or sites of actinic kera-
toses  are  identified  by  topical  application  of  5%  5-FU  cream 
twice  daily  to  affected  areas  for  5  to  7  days  before  the  office 
procedure. Once the lesions are identified, 70% glycolic acid in 
ethanol:propylene glycol 80:20 is applied to the lesions. After 2 
to 5 minutes when the lesions begin to blanch, 5% 5-FU solu-
tion is applied.

Alternatively,  the  lesions  may  be  treated  with  0.5%  to 
1%  5-FU  dissolved  in  30%  glycolic  acid  aqueous  solution  (7). 
In  most  cases,  this  procedure  results  in  complete  eradication 
of the lesions.

Age Spot Keratoses
Aging-related macules and papules on the face and the back of 
the  hands  are  pigmented  lentigines,  non-pigmented  keratosis, 
and/or  seborrheic  keratoses.  For  rapid  removal  of  keratoses, 
100% pyruvic acid, 90% lactic acid, or 70% glycolic acid peel solu-
tions may be used as an office procedure (Figure 6.4). After the 
area is degreased with 70% ethanol, the peel solution is applied 
with a fine camel-hair brush, and the skin is neutralized with 
5%  sodium  bicarbonate  solution  when  epidermolysis  occurs. 
Among the above peel solutions, 70% glycolic acid is preferred. 
The skin peel may be repeated after an interval of several weeks 
to eradicate remaining lesions. Home treatment with a cream or 
gel containing 10% hydroxyacid with or without 2% hydroqui-
none may be continued to subdue re-emergence or new lesions. 
Age spots on the dorsa of the hands and forearms, more resis-
tant to simple topical treatment, may need sustained treatment 
with 20% or higher concentration of hydroxyacid (7). The addi-
tion  of  hydroquinone  seems  more  effective  in  the  eradication 
of pigmented skin spots such as lentigines and freckles (Figure 
6.5).  The  time  required  for  their  clinical  resolution  is  variable, 
from a few months to a year or more.

Wrinkles and Aging Skin 
AHAs  are  therapeutically  effective  for  topical  treatment  of 
skin  changes  associated  with  aging,  because  they  increase 
skin  thickness  by  stimulating  biosynthesis  of  GAGs  and  col-
lagen fibers. An AHA such as glycolic acid at concentration of 
10%  can  be  used  by  a  patient  at  home  to  treat  fine  wrinkles 
on  the  face  (6,7).  Substantial  improvement  may  be  perceived 
after several months of treatment. However, the time required 
for  clinical  improvement  of  coarse  wrinkles  may  take  years, 
depending on the degree of severity. Office procedures using 
90% lactic acid or 70% glycolic acid peels seem to provide faster 
resolution of coarse wrinkles, combined with sustained home 
use of an AHA at or near 10% concentration (8,40,47,57,59).

Five parameters may be used to monitor the progress of 
therapeutic effects: improvement in dyspigmentation, skin tex-
ture, overt fine lines, overt wrinkles, and increased skin thick-
ness. It is essential that “before” and “after” photos be taken for 
each patient to assess progress.

ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 65

(a)

(b)

Figure  6.4  Eighty-year-old  woman  with  photodamaged  skin, 
including coarse wrinkles and multiple lesions of actinic keratoses 
on her face, before (left) and after (right) 70% glycolic acid peels 
and home use of 10% glycolic acid cream for 4 years.

(a)

(b)

Figure  6.5  Sixty-three-year-old  man  with  age  spots,  including 
multiple lesions of seborrheic keratoses and lentigines on his left 
face,  before  (left)  and  after  (right)  twice  daily  topical  application 
of 10% glycolic acid and 2% hydroquinone cream for 21 months.

Antioxidants and Photoaging
The  human  body  needs  oxygen  for  energy  and  life  itself. 
Therefore,  oxidation  is  inherent  to  living.  Reactive  oxygen 
species (ROS) are produced by oxidation or peroxidation, and 
include  superoxide,  hydrogen  peroxide,  hydroxyl  radicals, 
and  peroxyl  radicals  (48,49).  Among  these  ROS,  the  hydroxyl 
radicals are most reactive and cause cellular and tissue stress 
by reacting with proteins, nucleic acids, lipids, and other bio-
chemical  entities.  Under  quiescent  conditions,  endogenous 
or available antioxidants and reductive enzymes in the body 
are  capable  of  neutralizing  these  harmful  ROS.  Known  anti-
oxidants and enzymes include vitamin C, vitamin E, reduced 
α-lipoic  acid,  reduced  ubiquinones  (coenzyme  Q),  reduced 

 
 
 
66 

 TEXTBOOK OF COSMETIC DERMATOLOGY

glutathione (GSH), reduced nicotinamide adenine dinucleotide 
phosphate  (NADPH),  and  superoxide  dismutase,  which  con-
verts  superoxide  to  hydrogen  peroxide  and  oxygen.  Catalase 
and glutathione peroxidase in turn convert hydrogen peroxide 
to water and oxygen. Many other antioxidants probably have 
ancillary or primary roles.

Sunlight is essential for life on earth, but UV radiation is 
harmful to human skin. Human skin is equipped with antioxi-
dant systems that counteract or dispose of some ROS induced 
by  UVB  (50).  However,  the  amount  of  these  endogenous  or 
available  antioxidants  may  not  be  sufficient  to  overcome  the 
increased ROS produced by continued exposure to UVB. The 
skin reactions or damages caused by UVB include erythema, 
edema,  exfoliation,  tanning,  abnormal  thickening  (elastosis) 
or thinning of the epidermis and dermis, and numerous other 
changes known as photoaging, including carcinogenesis.

Hydroxyacids have been shown to improve the appear-
ance  of  photoaged  skin  by  improving  epidermal  renewal 
and desquamation and by increasing dermal biosynthesis of 
GAGs and collagen fibers (5,10). Because PHAs and ABAs are 
antioxidants, they can be used to prevent or counteract ROS 
induced in the skin by UVB, in conjunction with sunscreens 
and  sunblocks  in  cream,  lotion,  or  gel  form  to  prevent  sun 
damage (34).

SIMILARITIES AND DIFFERENCES 
OF HYDROXYACIDS 
The chemical structure of a hydroxyacid determines whether 
the substance belongs to AHA, BHA, PHA, or ABA, and such 
classification  is  also  based  on  its  characteristics  and  usage. 
Different  members  of  the  same  group  may  possess  different 
physicochemical  properties,  e.g.,  hydrophilic  or  lipophilic, 
but they have similarities in their topical actions with differ-
ent degrees of potency; these include glycolic acid, lactic acid, 
and mandelic acid. We have found that BHAs as a group are 
similar to AHAs in many ways, and the same is true between 
ABAs and PHAs. However, PHAs and ABAs are functionally 
different from AHAs and BHAs in certain aspects, as shown 
in Table 6.8. Because of multiple hydroxyl groups in the mol-
ecule, PHAs and ABAs are antioxidants, are gentle to the skin, 
and they do not increase sunburn cells following UV radiation. 
Certain  members  of  PHAs,  such  as  glucuronic  acid  and  idu-
ronic acid, are known constituents of GAGs. In the past, AHAs, 
especially  glycolic  acid,  have  been  used  quite  extensively  for 
cosmetic  and  dermatologic  indications.  More  recently,  PHAs 

and  ABAs,  such  as  gluconolactone  and  lactobionic  acid,  are 
used as unique ingredients in cosmetic products.

Antagonistic Acetoxyacids
Like  some  substances  with  antagonists  in  nature,  hydroxy-
acids  appear  to  have  their  own  antagonistic  counterparts. 
When  the  hydroxyl  group  at  the  α  position  of  an  AHA  is 
acetylated to an acetoxyl compound, the modulation on kera-
tinization  changes  to  reverse  direction,  causing  hyperkera-
tinization. The antagonistic action is noticeably pronounced 
when  an  aralkyl  AHA  such  as  mandelic  acid,  benzilic  acid, 
or  phenyllactic  acid  is  acetylated  to  O-acetyl-mandelic  acid, 
O-acetyl-benzilic  acid,  or  0-acetyl-phenyllactic  acid,  respec-
tively.  Aralkyl  O-acetyl-AHA  5  to  10%  creams  have  been 
shown to increase thickness and compactness of stratum cor-
neum in hairless mouse and human forearms (3). The hyper-
keratotic action of aralkyl O-acetyl-AHAs has been found to 
be  useful  and  effective  for  topical  treatment  of  brittle  nails, 
psoriatic nails, and cheilitis caused by oral administration of 
13-cis-retinoic acid.

N-Acetylamino Acids and N-Acetyl Compounds
An amino acid is an organic acid having one or more than one 
alkaline radical such as amino, guanidino, imino, or hydrazine 
radical attached at any carbon atom other than carbon one, and 
NAA is obtained by N-acetylation of the amino group. In fact, 
the NAA can be considered as the organic acid in which one 
H  is  replaced  by  an  acetamino  group.  There  are  20  common 
amino acids present as L form in natural proteins, and there are 
also a number of related amino acids with different chemical 
structures and configurations. These common amino acids and 
related amino acids can form NAAs and are related N-acetyl 
compounds.  N-Acetylglucosamine,  N-acetylgalactosamine, 
and  N-acetylmannosamine  are  N-acetylated  derivatives 
of  aminocarbohydrates  glucosamine,  galactosamine,  and 
mannosamine,  which  are  organic  aldehydes  instead  of 
organic  acids.  Topical  actions  of  N-acetylglucosamine  and 
N-acetylgalactosamine have some similarities to that of NAA, 
as shown in Table 6.9. We have found that N-acetyl-L-proline 
and  N-acetyl-D-glucosamine  at  5%  to  10%  concentration  are 
topically effective for ichthyosis and also for eradication of itch 
associated with eczema and xerosis.

Some  NAAs  and  N-acetylaminocarbohydrates  occur 
in  nature  as  metabolites,  biopeptides,  glycoproteins,  or  gly-
cosaminoglycans,  e.g.  N-acetyl-L-glutamic  acid  in  liver  (51), 

Table 6.8  Similarities And Differences In Characteristics And Use Of Hydroxyacids

Characteristics/Use

AHAs

Physiological nutrients or natural substances

Antioxidants against superoxides, free radicals

Gentle to sensitive skin

Gel matrix formation/wound-healing

Constituents of GAGs

Modulate keratinization, dry skin, acne, keratosis

Increase dermal components GAGs, collagen, elastin

Reduce wrinkles, photoaging

Synergistic effects of corticosteroids, antifungal agents

+

*

+

+

+
+

BHAs

+

+

+

+
+

PHAs

ABAs

+

+

+

+

+

+

+
+

+

+

+

+

+

+

+
+

Abreviations: AHAs, α-hydroxyacids; BHAs, β-hydroxyacids; PHAs, polyhydroxy acids; ABAs, aldobionic acids; GAGs, glycosaminoglycans
*Polycarboxy AHAs; malic acid, citric acid, tartaric acid are antioxidants

 
Table 6.9  N-Acetylamino Acids and N-Acetyl Compounds

ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 67

Chemical name

N-Acetyl-L-alanine
Nα-Acetyl-L-arginine
N-Acetyl-L-aspartic acid

N-Acetyl-DL-asparagine

N-Acetyl-L-cysteine

N-Acetyl-glycine

N-Acetyl-L-glutamic acid

N-Acetyl-L-glutamine

N-Acetyl-L-histidine

N-Acetyl-L-isoleucine

N-Acetyl-L-leucine
Nα-Acetyl-L-lysine
N-Acetyl-L-methionine

N-Acetyl-L-phenylalanine

N-Acetyl-L-proline

N-Acetyl-L-serine

N-Acetyl-L-threonine

N-Acetyl-L-tryptophan

N-Acetyl-L-tyrosine

N-Acetyl-L-tyrosinamide

N-Acetyl-L-valine
N-Acetyl-β-alanine
N-Acetyl-γ-aminobutanoic acid
Nα-Acetyl-L-ornithine
N-Acetyl-L-citrulline

N-Acetyl-creatine

N-Acetyl-creatinine

N-Acetyl-phenylglycine

N-Acetyl-4-hydroxyphenylglycine

N-Acetyl-D-glucosamine

N-Acetyl-D-galactosamine

Ichthyosis: 3+, 75%; 4+, 100% improvement
Itch: 4+, eradicate itch completely for 8 hours

Chemical structure

CH3 CH(NHCOCH3) COOH
H2NC(=NH)NH(CH2)3 CH(NHCOCH3) COOH
HOOC CH2 CH(NHCOCH3) COOH
H2NOC CH2 CH(NHCOCH3) COOH
HSCH2 CH(NHCOCH3) COOH
CH2(NHCOCH3) COOH
HOOC CH2 CH2 CH(NHCOCH3) COOH
H2NOC CH2 CH2 CH(NHCOCH3) COOH
C3H3N2 CH2 CH(NHCOCH3) COOH
CH3 CH2 CH(CH3) CH(NHCOCH3) COOH
(H3C)2CH CH2 CH(NHCOCH3) COOH
H2NCH2 (CH2)3 CH(NHCOCH3) COOH
(H3C)SCH2 CH2 CH(NHCOCH3) COOH
C6H5 CH2 CH(NHCOCH3) COOH
N(COCH3)C4H7 COOH
HOCH2 CH2(NHCOCH3) COOH
H3C CHOH CH(NHCOCH3) COOH
C8H6N CH2 CH(NHCOCH3) COOH
HOC6H4 CH2 CH(NHCOCH3) COOH
HOC6H4 CH2 CH(NHCOCH3) CONH2
(H3C)2CH CH(NHCOCH3) COOH
CH2(NHCOCH3) CH2 COOH
CH2(NHCOCH3) CH2 CH2 COOH
H2NCH2 (CH2)2 CH(NHCOCH3) COOH
H2NCONH(CH2)3 CH(NHCOCH3) COOH
H2NC(=NCOCH3)N(CH3) CH2 COOH
-HNC(=NCOCH3)N(CH3) CH2 CO-
C6H5 CH(NHCOCH3) COOH
HOC6H4 CH(NHCOCH3) COOH
HOH2C (CHOH)3 CH(NHCOCH3) CHO
HOH2C (CHOH)3 CH(NHCOCH3) CHO

Topical effects 

Ichthyosis

Itch

4+

3+

3+

4+

4+

4+

4+ 4+

4+

4+

4+

3+

3+

4+ 4+
4+

N-acetyl-L-aspartic  acid  in  brain  (52),  N-acetyl-L-serine  in 
melanocyte-stimulating  hormone  (α-MSH)  (53),  N-acetyl-
(53),  N-acetyl-D-
L-tyrosine 
glucosamine in hyaluronic acid and keratan sulfate (54), and 
N-acetyl-D-galactosamine in chondroitin sulfate and derma-
tan sulfate (54).

in  N-acetyl-β-endorphin 

NAC is a potent antioxidant against free radicals such 
as hydroxyl radical (55) and is a good precursor for glutathi-
one synthesis in the body. NAC is used as a mucolytic, detoxi-
fying,  and  antiviral  agent.  We  have  found  that  NAC  8  %  in 
hydrophilic  ointment  is  topically  effective  for  ichthyosis 
(Figure 6.6).

An amino acid can be in amide or hydrazide form, e.g. 
N-acetylaminoamide  and  N,N'-diacetylaminohydrazide.  We 
have  found  that  N-acetyl-L-tyrosinamide  and  N,N'-diacetyl-
L-tyrosinhydrazide in oil-in-water emulsion on topical appli-
cation  to  normal  human  skin  can  stimulate  biosynthesis  of 
hyaluronic acid, and increase skin thickness.

N-Acylpeptides
NAP  is  an  acylated  peptide  derivative.  A  peptide  is  formed 
from  two  or  more  amino  acids  by  a  covalent  amide  bond, 
C(=O)NH, when the carboxyl group on one amino acid reacts 
with the amino group of the other amino acid in a dehydration 
reaction.  A  dipeptide  is  formed  from  two  amino  acids,  a  tri-
peptide is formed from three amino acids, and a polypeptide 
is formed from multiple amino acids. The 20 common amino 
acids are represented by chemical names, such as “glycine,” or 
abbreviated symbols such as three letters, “Gly,” or one letter, 
“G.”  Except  for  glycine,  all  other  common  amino  acids  have 
stereoisomers, i.e., enantiomer, D, or L form. The amino acids 
in most natural peptides and proteins are all in L-form.

The three-letter symbols used for the 20 common amino 
acids are as follows: alanine (Ala), arginine (Arg), aspartic acid 
(Asp), asparagine (Asn), cysteine (Cys), glycine (Gly), glutamic 
acid (Glu), glutamine (Gln), histidine (His), isoleucine (Ile), leu-
cine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), 

 
68 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 6.6  Six-year-old boy with lamellar ichthyosis before (a) and after (b) topical application of 8% N-acetyl-L-cysteine in hydrophilic 
ointment twice daily for 4 weeks.

proline  (Pro),  serine  (Ser),  threonine  (Thr),  tryptophan  (Trp), 
tyrosine (Tyr), and valine (Val).

Common acyl groups are acetyl (Ac) and propanoyl (Pa) 
radicals, such as N-acetyldipeptide and N-propanoyldipeptide. 
The  NAP  derivatives  can  have  different  forms  at  carboxyl 
terminal  group  such  as  free  acid  (OH),  amide  (NH2),  ethyl 
ester  (OEt),  hydrazide  (NHNH2),  and  N-acetyl  hydrazide 
(NHNHAc).

NAP  derivatives  at  concentrations  of  0.5%  to  10%  on 
topical  application  have  been  found  to  increase  skin  thick-
ness.  For  example,  N-acetyldipeptide  amide,  N-Ac-L-Tyr-L-
Tyr-NH2,  at  3%  increased  skin  thickness  15%  to  20%  after 
4  weeks;  N-acetyltripeptide  amide,  N-Ac-L-Tyr-L-Tyr-L-
Tyr-NH2,  at  0.5%  increased  skin  thickness  5%  to  10%  after 
7  days;  N-acetyltripeptide  ethyl  ester,  N-Ac-L-Tyr-L-Tyr-L-
Tyr-OEt,  at  0.5%  increased  skin  thickness  20%  to  30%  after 
10 days. The increased skin thickness or plump was not due 
to  increased  water  retention  or  edema  of  the  skin,  because 
the  thickness  was  maintained  for  many  months  after  dis-
continuation of the treatment. As shown earlier (5) increased 
skin  thickness  was  due  to  increased  biosynthesis  of  GAGs 
and  collagen  fibers,  improved  quality  of  elastic  fibers,  less 
clumping  of  melanin,  and  lighter  appearance  of  age  spots. 
Therefore,  increased  skin  thickness  is  expected  to  improve 
aging-related  skin  changes,  including  fine  lines,  wrinkles, 
photoaging, age spots, blotches, hyperpigmented skin, mot-
tled skin, and can be used for younger-looking skin and skin 
lightening (Table 6.10).

NAP derivatives at concentrations of 0.5% to 5% on topi-
cal application have been found to eradicate itch within a few 
minutes and improve eczema lesions within a few weeks with 
continuing topical application (Figure 6.7).

CONCLUSION, DISCUSSION, 
AND PERSPECTIVES
Organic acids cover various organic compounds which include 
retinoic  acid,  salicylic  acid,  α-hydroxyacids  (AHAs),  polyhy-
droxy  acids  (PHAs),  aldobionic  acids  (ABAs),  N-acetylamino 
acids  (NAAs),  and  N-Acylpeptides  (NAPs).  On  topical  admin-
istration, these organic acids exert distinctive pharmacological 
actions  on  keratinization  and/or  biosynthesis  of  dermal  com-
ponents;  i.e.  glycosaminoglycans,  collagen,  and  elastic  fibers. 
However, these organic acids also have certain similarities and 

differences  in  topical  actions.  Both  salicylic  acid  and  glycolic 
acid  have  similar  beneficial  effects  on  disturbed  keratiniza-
tion,  e.g.  acne,  ichthyosis,  calluses,  etc.  Glycolic  acid  increases 

Table 6.10  N-Acylpeptide Derivatives

N-acylpeptide derivatives

Aging related 
skin changes

Itch, 
eczema

N-Ac-L-Ile-L-Ala-NH2
N-Ac-L-Ieu-L-Ala-NH2
N-Ac-L-Ieu-L-Ala-OH
N-Ac-L-Val-L-Ala-NH2
N-Ac-L-Val-L-Ala-OH

N-Pa-L-Val-L-Ala-OH
N-Ac-L-Cys-L-Cys-NH2
N-Ac-L-Cys-L-Cys-OH
N-Ac-L-Ile-Gly-NH2
N-Ac-L-Ile-Gly-OH
N-Ac-L-Ieu-Gly-NH2
N-Ac-L-Ieu-Gly-OH

N-Pa-L-Ieu-Gly-OH
N-Ac-L-Pro-Gly-NH2
N-Ac-L-Val-Gly-NH2
N-Ac-L-Val-Gly-OH
N-Ac-L-Ala-L-Ile-NH2
N-Ac-L-Ile-L-Ile-NH2
N-Ac-L-Cys-L-Tyr-NH2
N-Ac-L-Tyr-L-Tyr-NH2
N-Ac-L-Tyr-L-Tyr-OH
N-Ac-L-Tyr-L-Tyr-NHNH2
N-Ac-L-Tyr-L-Tyr-NHNHAc

N-Ac-L-Tyr-L-Tyr-L-Tyr-OH

N-Ac-L-Tyr-L-Tyr-L-Tyr-OEt
N-Ac-L-Tyr-L-Tyr-L-Tyr-NH2
N-Ac-L-Val-L-Val-L-Ala-NH2
N-Ac-L-Tyr-L-Val-L-Tyr-NH2

2+
3+

2+

4+

2+

2+

3+

3+

3+

2+

3+

2+

2+

2+

2+

2+

2+

3+

2+

4+

4+

4+

4+

2+

3+

4+

2+

3+

4+
4+

3+

4+

4+

4+

2+

2+

4+

4+

4+

3+

3+

4+

4+

4+

3+

4+

3+

4+

4+

2+

4+

3+

4+

4+

3+

4+

Note:  Aging  skin  including  age  spots;  itch  and  eczema:  2+:  50%  effi-
cacy; 3+: 75% efficacy; 4+: 95%–100% efficacy

 
 
ORGANIC ACIDS WITH NOVEL FUNCTIONS 

 69

(a)

(b)

Figure 6.7  Forty-three-year-old woman with chronic eczema on both arms, before (a) and after (b) N-Ac-L-Val-L-Ala-NH2 0.5% in oil-in-
water emulsion applied twice daily for 4 weeks.

while salicylic acid diminishes the biosynthesis of dermal com-
ponents, i.e. glycolic acid but not salicylic acid is beneficial for 
wrinkles  and  aging  skin.  NAAs  and  NAPs  have  similar  ben-
eficial  effects  on  disturbed  keratinization,  e.g.  ichthyosis,  and 
hyperkeratoses.

N-Acetyl-L-tyrosinamide is more effective than N-acetyl-
L-tyrosine for increasing the skin thickness by stimulation of 
hyaluronic acid biosynthesis. N-Acetyl-L-glutamic acid diethyl 
ester is more effective than N-acetyl-L-glutamic acid for topical 
treatment of ichthyosis. Based on these observations, the active 
form of the NAA or NAP may not be in free acid or anion form.
Since  1974,  many  studies  have  shown  that  physiologic 
and  nontoxic  hydroxyacids  can  promote  normal  keratiniza-
tion and increase synthesis of dermal components, including 
hyaluronic acid and collagen fibers. AHAs, specifically glycolic 
acid, have been widely used in cosmetic products and derma-
tologic practice for topical treatment of dry skin, acne, kerato-
ses,  wrinkles,  photoaging,  and  photodamaged  skin.  Because 
of multiple hydroxyl groups in the molecules, gluconolactone 
(a PHA lactone) and lactobionic acid (an ABA) are gentle to the 
skin and are antioxidants.

Topical effects of most organic acids appear to be from 
the free acid form, and the amide or ester form seems ineffec-
tive or much less effective, e.g. retinoic acid, glycolic acid, sali-
cylic acid. On the contrary, for NAAs and NAPs, the amide or 
ester form appears more effective for topical treatment of itch, 
eczema,  and  aging-related  skin  changes.  N-Acetyl-L-proline 
ethyl ester appears more effective than N-acetyl-L-proline for 
topical treatment of itch associated with eczema.

The mechanisms for itch eradication by NAAs or NAPs 
are unknown. Acetylcholine, by injection into lesions, has been 
reported as a pruritogen to induce itch in eczema patients (60). 
Based on chemical structures, acetylcholine has O-acetyl radi-
cal,  whereas  NAAs  and  NAPs  have  N-acetyl  or  N-propanoyl 
radicals.  Therefore,  we  can  speculate  that  the  anti-itch  effect 
is due to the interference of acetylcholine action on free nerve 
endings  in  the  epidermis  by  NAAs  and  NAPs.  The  relative 
potency of anti-itch, and the associated improvement of eczema 
lesions by NAAs and NAPs, may be due to relative affinity of 
the binding to receptor molecules. For example, N-Ac-L-Tyr-L-
Tyr-NH2 is more potent than N-Ac-L-Tyr-L-Tyr-OH in eradicat-
ing itch and improving eczema lesions.

We are fortunate at this time of general awareness and 
concern  over  aging,  photoaging,  photodamage,  and  environ-
mental and disease impingements disfiguring the integument 

that an entire category of physiologic and nontoxic substances 
can be drawn upon to repair or prevent such disfigurements. 
The  hydroxyacids  and  other  organic  acids  can  be  utilized  to 
nudge skin  form  and function toward a  more youthful state. 
They can be topically applied to decelerate the otherwise inex-
orable progression toward old-looking integument.

The  antioxidant  PHAs  and ABAs are  especially  benefi-
cial and can be utilized to repair and prevent damage caused 
by UV radiation. However, these latter substances are still new 
on the scene, and expanding use is projected. Dermatologists, 
cosmetologists,  pharmacologists,  pharmacists,  and  formula-
tors need to be closely familiar with chemical attributes of the 
various hydroxyacids and other organic acids including PHAs 
and ABAs, their clinical performance, and how best to design 
and compound formulations to provide maximal achievement 
of intended objectives.

REFERENCES

1. Van  Scott  EJ,  Yu  RJ.  Control  of  keratinization  with  the  alpha 
hydroxy  acids  and  related  compounds,  Arch  Dermatol  1974; 
110:586–90.

2.  Van  Scott  EJ,  Yu  RJ.  Substances  that  modify  the  stratum  cor-
neum by modulating its formation. In Frost P, Horwitz SN, eds. 
Principles  of  Cosmetics  for  the  Dermatologist.  St.  Louis:  Mosby 
1982; pp. 70–4. 

3.  Van Scott EJ, Yu RJ. Hyperkeratinization, corneocyte cohesion, 

and hydroxy acids. J Am Acad Dermatol 1984; 111:867–79.

4.  Van Scott EJ, Yu RJ. Actions of alpha hydroxy acids on skin com-

partments, J Geriatr Dermatol 1995; 3:19A–25A.

5.  Ditre  CM  et  al.  Effects  of  alpha-hydroxy  acids  on  photoaged 
skin. A pilot clinical, histologic, and ultrastructural study. J Am 
Acad Dermatol 1996; 34:187–95.

6.  Van Scott EJ, Yu RJ. Alpha hydroxy acids. Procedures for use in 

clinical practice, Cutis 1989; 43:222–8.

7.  Van  Scott  EJ,  Yu  RJ.  Alpha  hydroxy  acids.  Therapeutic  poten-

tials, Can J Dermatol 1989; 1:108–12.

8.  Van Scott EJ, Ditre CM, Yu RJ. Alpha-hydroxyacids in the treat-
ment of signs of photoaging. Clin Dermatol 1996; 14:217–26.

9.  Newman N, Newman A, Moy LS et al. Clinical improvement 
of photodamaged skin with 50% glycolic acid. A double blind 
vehicle-controlled study. Dermatol Surg 1996; 22:455–60.
  10.  Bernstein  EF,  Underhill  CB,  Lakkaakorpi  J,  et  al.  Citric  acid 
increases  viable  epidermal  thickness  and  glycosaminoglycan 
content of sun-damaged skin. Dermatol Surg 1997; 23:689–94.

  11.  Yu  RJ,  Van  Scott  EJ.  Hydroxycarboxylic  acids,  N-acetylamino 
sugars, and N-acetylamino acids. SKINMed Dermatol Clinician 
2002; 1:117–22.

 
 
 
 
 
 
 
 
 
 
70 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  12.  Yu  RJ,  Van  Scott  EJ.  Salicylic  acid.  Not  a  beta-hydroxy  acid. 

Cosmet Dermatol 1997; 10:27.

  13.  Yu  RJ,  Van  Scott  EJ.  Bioavailability  of  alpha-hydroxy  acids  in 

topical formulations. Cosmet Dermatol 1996; 9:954–62.

  14.  Yu RJ, Van Scott EJ. Bioavailable alpha hydroxy acid in topical 
formulations. In Moy R, Luftman D, Kakita L, eds. Glycolic Acid 
Peels. New York<Marcel Dekker 2002; pp. 15–28. 

  15.  Green BA, Briden ME. PHAs and bionic acids: Next generation 
hydroxy acids. In Draelos Z, Dover J, Alam M, eds. Procedures In 
Cosmetic Dermatology: Cosmeceuticals, 2nd edition. Philadelphia: 
Elsevier Saunders 2009; pp. 209–15.

  16.  Yu RJ, Van Scott EJ. Alpha-hydroxy acids. Science and therapeu-

tic use. Cosmet Dermatol 1994; 10(suppl):12–20.

  17.  Yu  RJ,  Van  Scott  EJ.  A  discussion  of  control-release  formula-

tions of AHAs. Cosmet Dermatol 2001; 10:15–18.

  18.  Bernstein EF. Dermal effects of alpha hydroxy acids. In Moy R, 
Luftman D, Kakita L, eds. Glycolic Acid Peels. New York: Marcel 
Dekker 2002; pp. 71–113.

  19.  Bernstein EF, Lee J, Brown DB. Glycolic acid treatment increases 
type I collagen mRNA and hyaluronic acid content of human 
skin. Dermatol Surg 2001; 27:429–33.

  20.  Rubin  MG.  Glycolic  acid  peels.  In  Rubin  MG,  ed.  Manual  of 
Chemical Peels. Philadelphia: Lippincott 1992; pp. 89–102.
  21.  Drake LA, Dinehart SM, Goltz RW, et al. Guidelines of care for 

chemical peeling. J Am Acad Dermatol 1995; 33:497–503.

  22.  Kligman  AM.  The  compatibility  of  combinations  of  glycolic 
acid  and  tretinoin  in  acne  and  in  photoaged  skin.  J  Geriatr 
Dermatol 1995; 3(Suppl A):25A–28A.

  23.  Lavker RM, Kaidby K, Leyden J. Effects of topical ammonium 
lactate on cutaneous atrophy from a potent topical corticoste-
roid. J Am Acad Dermatol 1992; 26:535–44.

  24.  Griffin  TD,  Murphy  GF,  Sueki  H  et  al.  Increased  factor  XIIIa 
transglutaminase expression in dermal dendrocytes after treat-
ment with α-hydroxy acids. Potential physiologic significance. 
J Am Acad Dermatol 1996; 34:196–203.

  25.  Yardley HJ, Summerly R. Lipid composition and metabolism in 
normal and diseased epidermis. Pharmacol Ther 1981; 13:357–83.
  26.  Madison KC. Barrier function of the skin: “La raison d’etre” of 

  39.  Green  BA,  Edison  BL,  Wildnauer  RH,  et  al.  Lactobionic  acid 
and gluconolactone. PHAs for photoaged skin. Cosmet Dermatol 
2001; 9:24–8.

  40.  Bergfeld W, Tung R, Vidimos A, et al. Improving the cosmetic 
appearance  of  photoaged  skin  with  glycolic  acid.  J  Am  Acad 
Dermatol 1997; 36:1011–13.

  41.  Bernstein  EF,  Uitto  J.  Connective  tissue  alterations  in  photo-
damaged skin and the effects of alpha hydroxy acids. J Geriatr 
Dermatol 1995; 3(Suppl A):7A–18A.

  42.  Rendon MI, Okan G. The use of alpha hydroxy acids in xerosis 
and photoaging. In Moy R, Luftman D, Kakita L, eds. Glycolic 
Acid Peels. New York: Marcel Dekker 2002; pp. 115–39.

  43.  McGregor  JM,  Hawk  JL.  Acute  effects  of  ultraviolet  radia-
tion  on  the  skin.  In  Freedberg  IM,  Eisen  AZ,  Wolff  K  et  al., 
eds.  Dermatology  in  General  Medicine,  5th  edition.  New  York: 
McGraw-Hill 1999; pp. 1555–61.

  44.  KGL Protocol Final Reports #3929, #3813, #3800: An investiga-
tion of the short-term effects of topical treatments on the sensi-
tivity of human skin to UVR. Pennsylvania: KGL 1996.

  45.  Johnson AW, Kligman AM. Application of 4% and 8% glycolic 
acid to human skin in commercial skin creams formulated to 
CIR guidelines does not thin the stratum corneum or increase 
sensitivity to UVR. J Cosmet Sci 2000; 51:343–9.

  46.  Green  BA,  Wildnauer  RH,  Edison  BL.  Polyhydroxy  acids 
(PHAs) provide conditioning effects to skin without increasing 
sensitivity to UV light. Am Acad Dermatol Poster Exhibit No. 74, 
New Orleans, LA, February 22–7, 2002.

  47.  Moy LS, Murad H, Moy RL. Glycolic acid peels for the treatment 
of wrinkles and photoaging. J Dermatol Surg Oncol 1993; 19:243–6.
  48.  Pinnell SR. Cutaneous photodamage, oxidative stress, and topi-

cal antioxidant protection. J Am Acad Dermatol 2003; 48:1–19.

  49.  Thiele JJ, Schroeter C, Hsieh SN, et al. The antioxidant network 
of the stratum corneum. In Thiele J, Elsner P, eds. Oxidants and 
Antioxidants in Cutaneous Biology. Basel: Karger 2001; pp. 26–42.
  50.  Dreher F, Maibach H. Protective effects of topical antioxidants 
in humans. In Thiele J, Elsner P, eds. Oxidants and Antioxidants 
in Cutaneous Biology. Basel: Karger 2001; pp. 157–64. 

  51.  Meister  A.  Biochemistry  of  the  Amino  Acids,  2nd  edition.  New 

the epidermis. Prog Dermatol 2000; 34:1–12.

York: Academic Press 1965; p. 690.

  27.  Rawlings AV, Scott IR, Harding CR et al. Stratum corneum mois-

  52.  Meister  A.  Biochemistry  of  the  Amino  Acids,  2nd  edition.  New 

turization at the molecular level. Prog Dermatol 1994; 28:1–12.

York: Academic Press 1965; pp. 444–5.

  28.  Williams  ML.  Lipids  in  normal  and  pathological  desquama-
tion.  In  Elias  PM,  ed.  Advances  in  Lipid  Research.  New  York: 
Academic Press 1991; pp. 211–62.

  29.  Shapiro LJ, Weiss R, Webster D et al. X-Linked ichthyosis due to 

steroid sulphatase deficiency. Lancet 1978; 1:70–2.

  30.  Dahl MV, Dahl AC. 12% Lactate lotion for the treatment of xero-

sis. Arch Dermatol 1983; 119:27–30.

  31.  Berardesca E, Distane F, Vignoli GP et al. Alpha hydroxyacids 
modulate stratum corneum barrier function. Br J Dermatol 1997; 
137:934–8.

  32.  Briden  ME,  Cacatua  LS,  Patriots  MA  et  al.  Treatment  of  acne 

  53.  Granner DK. Pituitary and hypothalamic hormones. In Murray 
RK,  Granner  DK,  Mayes  PA  et  al.,  eds.  Harper's  Biochemistry, 
25th edition. Stamford, CT: Appleton & Lange, 2000; pp. 550–60.
  54.  Murray  RK,  Keeley  FW.  The  extracellular  matrix.  In  Murray 
RK,  Granner  DK,  Mayes  PA  et  al.,  eds.  Harper's  Illustrated 
Biochemistry,  26th  edition.  New  York:  McGraw-Hill  2003;  pp. 
535–55. 

  55.  Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action 
of  N-acetylcysteine:  Its  reaction  with  hydrogen  peroxide, 
hydroxyl radical, superoxide, and hypochlorous acid. Free Radic 
Bio Med 1989; 6:593–7. 

with glycolic acid. J Geriatr Dermatol 1996; 4:22B–27B.

  56.  The  Merck  Index  13th  edition.  Whitehouse  Station,  NJ:  Merck 

  33.  Atzori L, Brundu MA, Biggio AOP. Glycolic acid peeling in the 

2001; pp. 803–4.

treatment of acne. J Eur Acad Dermatol Venereol 1999; 12:119–22.

  34.  Bernstein  EF,  Green  BA,  Edison  B,  et  al.  Polyhydroxy  acids 
(PHAs). Clinical uses for the next generation of hydroxy acids. 
Skin Aging 2001; Sept Suppl: 4–11.

  35.  Kligman  AM,  Kligman  LH.  Photoaging.  In  Fitzpatrick  TB, 
Eisen AZ, Wolff K et al., eds. Dermatology in General Medicine, 
Vol II. New York: McGraw-Hill 1993; pp. 2972–9.

  36.  Gilchrest  BA.  Overview  of  skin  aging.  J  Cutan  Aging  Cosmet 

Dermatol 1988; 1:1–3.

  37.  Uitto J, Fazio MJ, Olsen DR. Cutaneous aging. Molecular altera-
tions  in  elastic  fibers.  J  Cutan  Aging  Cosmet  Dermatol  1988; 
1:13–26.

  38.  Yaar  M,  Gilchrest  BA.  Aging  of  skin.  In  Freedberg  IM,  Eisen 
AZ, Wolff K et al., eds. Dermatology in General Medicine, 5th edi-
tion. New York: McGraw-Hill 1999; pp. 1697–706.

  57.  Green  BA.  Cosmeceutical  uses  and  benefits  of  alpha,  poly 
and bionic hydroxy acids. In: Farris PK. ed. Cosmeceuticals and 
Cosmetic  Practice.  West  Sussex,  UK:  Wiley-Blackwell  2014;  pp. 
69–80.

  58.  Akamine KL, Gustafson CJ, Yentzer BA, , et al. A double-blind, 
randomized  clinical  trial  of  20%  alpha/poly  hydroxy  acid 
cream  to  reduce  scaling  of  lesions  associated  with  moderate, 
chronic plaque psoriasis. J Drugs Dermatol 2013; 12(8):855–9
  59.  Farris  PK,  Edison  BL,  Brouda  I,  Weinkauf  RL,  Green  BA. 
A  high-potency,  multimechanism  skin  care  regimen  provides 
significant antiaging effects: Results from a double-blind, vehi-
cle-controlled clinical trial. J Drugs Dermatol 2012; 11(12)1447–54.
  60.  Stander  S,  Steinoff  M,  Schelz  M,  et  al.  Neurophysiology  of 
pruritus:  Cutaneous  elicitation  of  itch.  Arch  Dermatol  2003; 
139:1463–70.

 
7

Retinyl Propionate and Related Retinoids

John E. Oblong

INTRODUCTION
Retinoids  represent  a  class  of  lipophilic  compounds  that 
are  comprised  of  natural  derivatives  of  vitamin  A  (retinol) 
as  well  as  synthetic  analogues.  Naturally-occurring  reti-
noids are sourced via dietary intake of beta-carotene as well 
as  retinyl  esters,  both  of  which  are  found  in  a  broad  range 
of  foodstuffs  and  animal  by-products.  Structurally,  beta- 
carotene  exists  essentially  as  a  dimer  form  of  retinol  and 
the  enzymatic  conversion  in  the  intestinal  tract  via  retinal 
production  is  the  initial  sourcing  of  retinoids  for  usage  by 
the human body. Most eukaryotic cells have the capability of 
enzymatically converting retinol and retinyl esters to various 
metabolites that are critical in maintaining cellular homeo-
stasis,  regulating  proliferation  and  differentiation  patterns, 
as well as embryonic development. Of the metabolites gen-
erated, the true “business end” of retinoids is retinoic acid, 
which is present in cells as various cis conformations as well 
as  trans-retinoic  acid  (tRA).  Retinoids  play  such  a  critical 
role  in  developmental  biology  and  the  metabolic  pathways 
are tightly regulated. This includes not only enzymatic pro-
cesses but transport via cellular retinoid binding proteins as 
well.

Topical  usage  of  potent  forms  of  natural  and  syn-
thetic  retinoids  such  as  tRA  has  shown  a  high  degree  of 
efficacy  against  acne,  psoriasis,  icthyosis,  and  actinic  kera-
tosis.  Relative  to  photodamaged  skin,  tRA  has  clearly  been 
established  as  having  a  robust  effect  (1,2)  and  is  currently 
marketed  as  a  prescription  drug.  These  retinoid  effects  in 
diseased skin can be ascribed on some level as being a nor-
malization  of  altered  skin  conditions.  However,  two  of  the 
key negatives associated with highly potent topical retinoids 
are irritation that, in some instances, does not mitigate itself 
completely even after long term chronic exposure and tera-
togenic side effects.

Less potent topical retinoids such as retinol and vari-
ous retinyl esters (Figure 7.1) have been building a rich his-
tory  of  usage  in  the  cosmetic  marketplace.  More  important 
for  the  cosmetic  marketplace  is  the  ability  of  retinoids  to 
positively  impact  changes  in  the  appearance  of  photodam-
aged  facial  skin,  particularly  for  fine  lines,  wrinkles,  and 
pigmentation-related  changes.  Additionally,  understand-
ing  the  basic  biochemical  metabolic  processes  that  control 
endogenous  retinoid  levels  and  synthesis  has  shown  that 
cosmetic-type  retinoids  present  an  attractive  compromise 
for less serious conditions such as photodamaged skin. This 
chapter focuses on cutaneously delivered retinyl esters. The 
topics covered include an overview of the metabolism, bio-
chemistry,  and  molecular  biology  as  well  as  human  study 
findings.  The  principle  focus  in  terms  of  treatment  effects 
will be upon photodamaged skin.

Biochemistry and Molecular Biology of 
Topical Retinol and Retinyl Esters
Of  most  relevance  to  the  cosmetic  industry  was  the  confir-
mation that cosmetic forms of retinoids have the potential to 
be  enzymatically  converted  to  various  retinoid  metabolites 
including  tRA  when  topically  administered  (3–8).  The  bio-
chemical conversions are shown schematically in Figure 7.2a, 
where retinol is oxidized via small chain alcohol dehydroge-
nases to retinal and in turn to form tRA (5,9). This process is 
begun when free retinol associates with a specific cytoplasmic 
retinol-binding  protein  (CRBP).  This  family  of  proteins  with 
high retinoid specificity includes CRBP as well as retinoic acid 
binding  protein  (CRABP),  of  which  there  are  two  isoforms, 
I and II (7). These binding proteins play a direct role in regu-
lation  of  retinoid  responses  in  cells  by  acting  as  chaperones 
in  enzymatic  conversions,  sequestration,  and  stabilization. 
The retinol-CRBP complex is a substrate for retinol dehydro-
genase, a microsomal enzyme uniquely capable of catalyzing 
the  conversion  of  retinol  to  retinaldehyde.  Retinaldehyde  is 
then  rapidly  and  quantitatively  oxidized  to  retinoic  acid  by 
retinaldehyde  oxidase  (5,10).  However,  the  primary  reaction 
that occurs with CRBP-bound retinol is esterification of retinol 
via lecithin:retinol acyltransferase (LRAT) or acyl CoA:retinol 
acyltransferase  (ARAT)  to  retinyl  esters,  the  primary  storage 
form  in  lipid  bilayers  and  of  which  retinyl  palmitate  is  the 
major species in human skin (11,12). Recent work has identified 
the  neutral  lipid  synthesis  enzyme  acyl-CoA:diacylglycerol 
acyltransferase  1  (DGAT1)  as  a  novel  ARAT  enzyme  present 
in murine skin that regulates retinol oxidation to retinoic acid 
(13).  Additionally,  retinyl  stearate  has  been  identified  as  the 
major form that is present in circulating serum in mammalian 
systems (14). This multi-step processing of retinyl esters serves 
as a point of regulation to control the level of active retinoid in 
the skin and may thus contribute to the lower irritation poten-
tial of these derivatives.

The  molecular  mechanistic  route  that  tRA  follows  in 
skin  is  via  its  function  as  an  agonist  for  binding  to  a  family 
of  nuclear  receptors  called  the  retinoic  acid  receptors  (RAR) 
and  which  also  includes  the  retinoid  X  receptors  (RXR).  In 
each of these two families, three isoforms exist and interact to 
form heterodimers as the functionally active form. Significant 
research  has  gone  into  understanding  these  various  dimer 
combinations, including agonist binding as related to various 
tissues and cells. Upon binding of tRA by RAR and dimeriza-
tion  with  a  member  of  RXR,  this  active  complex  becomes  a 
transcriptional regulator that binds to select sequences in pro-
moter regions of select genes, termed retinoic acid responsive 
elements, or RARE (15).

As  with  most  biological  processes  that  involve  highly 
potent  agents,  the  retinoid  pathway  has  several  regulatory 

72 

 TEXTBOOK OF COSMETIC DERMATOLOGY

feedback loops that help maintain an optimal level of tRA. One 
of  the  most  important  ones  is  depicted  in  Figure  7.2b,  which 
shows the degradation of tRA to the less active metabolites via 
hydroxylation  to  4-hydroxy-retinoic  acid  and  4-oxo-retinoic 
acid, catalyzed by members of the CYP26 family (16). As tRA 
levels  become  temporarily  elevated,  increased  hydroxylase 
activity  via  higher  expression  levels  leads  to  a  decrease  to 
steady state levels.

In  summary,  the  biochemical  confirmation  that  topical 
retinol and retinyl esters can be metabolized to the more active 
form of tRA in skin cells has provided a richer understanding 

Retinoid

retinol

retinyl acetate

retinyl propionate

retinyl palmitate

Structure

CH2OH

O

C

CH3

CH2O

O
CH2O C CH2CH3

O

CH2O C (CH2)14CH3

Figure 7.1  Chemical structures of retinol and retinyl esters.

of how cosmetic retinoids are capable of having subtle effects 
upon photodamaged skin. As we begin to understand deeper 
the molecular biology changes that are caused via tRA bind-
ing to RAR/RXR, novel mechanistic insights into the efficacy 
as well as the negative irritation side effects could allow for an 
improvement in current commercialized products.

Potential to Break the Retinoid Efficacy to 
Irritation Correlation with Retinyl Esters
Over the past few decades, retinol has been used extensively in 
cosmetic products, with the levels of retinol ranging from barely 
detectable to upwards of 0.5%. The relative dosage levels vary in 
part due to intolerance among consumers of irritation side effects 
that is connected in part by a sensitivity to formulation differ-
ences. One approach to reduce retinoid-induced inflammation is 
to  attempt  to  regulate  skin  penetration  and  delivery  rates  into 
the skin via usage of nanoparticles and sponges (17). It is unclear 
yet  whether  this  provides  an  advantage  versus  merely  reduc-
ing delivery loads and reducing efficacy as well. As highlighted 
above, it has been generally assumed that any efficacy from topi-
cally delivered retinol occurs via its sequential conversion via the 
intermediate retinal to tRA (8). For example, it has been shown 
that  0.4%  retinol  can  significantly  improve  the  appearance  of 
wrinkles  on  the  surface  of  skin  but  histological  changes  have 
also  been  measured  in  the  extracellular  matrix  components  of 
epidermal glycosaminoglycans and dermal collagen Type I (18). 
The  authors  also  speculated  that  retinol-treated  skin  would  be 
more resistant to future skin injury, including ulcer formation, 
among elderly consumers. These reported effects are hallmark 
responses associated with topical tRA.

Several natural and synthetic esters of retinol have been 
evaluated  for  retinoid-like  effects,  including  acetate,  pro-
pionate,  palmitate,  ascorbate,  beta-glucuronide,  and  retinyl 

(a)

trans-RA

trans-retinal

RAR/RXR

COOH

gene
expression

NADPH

NADP+

retinal
dehydrogenase

COH

NADPH

NADP+

retinol
dehydrogenase

hydrolase

trans-retinol

OH

LRAT

OCOR

trans-retinyl ester

(b)

active

inactive/less active

COOH

COOH

COOH

RA 4-hydroxylase
(P450-dependent)

trans-RA

OH

trans-4-hydroxyRA

O

trans-4-oxoRA

Figure 7.2  Retinoid metabolic pathways in skin.

 
N-formyl aspartamate. While the chemical structure of retinol 
is conducive to being esterified via the alcohol group, the abil-
ity for retinyl esters to deliver efficacy that approaches retinol 
becomes limited by variables such as skin penetration, cellular 
uptake, hydrolase active site binding, re-esterification via acyl 
transferases, and general pharmacokinetics. As with most reti-
noid analogue work, the objective of evaluating retinyl esters 
is to be able to provide a retinoid-like response on facial skin 
but without the negatives of irritation associated with topical 
usage.

Since  retinyl  esters  are  dependent  upon  an  additional 
biochemical  processing  step  before  releasing  a  free  form  of 
retinol (Figure 7.2a), it is anticipated that topical retinyl esters 
would  have  a  weaker  retinoid  responsiveness  range  when 
compared  with  retinol.  A  human  forearm  biopsy  study  was 
performed that evaluated via histology the effect of tRA, reti-
nol, and three retinyl esters (acetate, propionate, and palmitate) 
for the effects upon changes in epidermal and granular layer 
thickness compared to a placebo control (Table 7.1). Both retinyl 
acetate and retinyl propionate were able to show a significant 
increase in both thickness measures as compared to the placebo 
control. The results with retinyl propionate are similar to what 
has been previously reported (19). These results also highlight 
that  there  is  a  relative  rank  ordering  based  on  the  biochemi-
cal processing steps amongst the retinoids tested. In compar-
ing  the  retinyl  esters,  there  also  appears  a  ranking  in  terms 
of chain length from shortest to longest, with shorter chained 
esters being more potent than longer chained esters. While less 
intuitive, the potential that shorter chained retinyl esters can 
be acted upon by other esterases could partially explain their 
enhanced retinoid response profile compared with retinyl pal-
mitate,  the  endogenous  storage  form.  Since  the  experimental 
data  in  the  table  was  performed  under  semi-occlusive  patch, 
the ability of the retinoids to penetrate into the viable cell lay-
ers is lessened as a variable for this comparison but may not 
explain the complete story for retinyl palmitate (20).

As  would  be  suspected,  this  rank  ordering  of  retinoid-
based  activity  (efficacy)  is  also  indirectly  proportional  to  the 
level  of  irritation  that  some  topical  retinoids  can  induce  on 
skin (20, Oblong, unpublished data). A comparison of human 
retinoid activity data from Table 7.1 with irritation date from a 
human back cumulative irritation protocol using nearly identi-
cal formulations, one can see that there is a general correlation 
among  the  esters  and  retinol  between  retinoid  activity  and 

RETINYL PROPIONATE AND RELATED RETINOIDS 

  73

irritation with the one exception of retinyl propionate at 0.18% 
levels (Figure 7.3). This supports in-house clinical findings that 
retinyl  propionate  does  not  cause  as  much  irritation  as  reti-
nol and still is able to positively impact the appearance of fine 
lines and wrinkles in 12-week human facial studies (21). While 
additional data would be required around the doses tested to 
confirm, these results support the suggestion that retinyl pro-
pionate  is  capable  of  eliciting  a  retinoid  response  in  human 
skin but with a weaker overall retinoid irritation profile.

In  terms  of  application  to  photodamaged  skin,  retinyl 
propionate  has  recently  become  of  interest  since  it  is  capable 
of  affecting  human  skin  much  like  retinol  but  with  a  lower 
irritation  profile  than  other  retinoids  (21,22,  and  Figure  7.3). 
While the relative activity of retinyl propionate on photodam-
aged  skin  is  weaker  than  retinol  (23),  it  is  clear  that  some  of 
the effects are still significant (21,22). More recently, a retinyl 

)
s
n
o
r
c
i
m

(

l
a
m
r
e
d
p
E

i

85

80

75

70

65

60

55

50

45

0.075% retinol

0.3% retinyl acetate

0.18% retinyl propionate

0.172% retinyl acetate

0.3% retinyl propionate

vehicle

0

20

40

60

80

100 120 140 160 180

Back Scores (Redness Grades)

Figure 7.3 Correlation between human irritation measures and 
epidermal  thickening  for  retinyl  acetate,  retinyl  propionate,  and 
retinol.

Table 7.1 Changes in Epidermal and Granular Layer Thicknesses in Forearm Skin due to Retinoid Treatment

Topical treatment

Emulsion control

1.0% retinyl palmitate

0.172% retinyl acetate

0.30% retinyl acetate

0.18% retinyl propionate

0.30% retinyl propionate

0.075% retinol

0.15% retinol

0.025% t-retinoic acid

Code

A

B

C

D

E

F

G

H
I

Epidermal 
thickness 
(microns)

Significance vs. 
control and other 
treatments*

Granular layer 
thickness 
(microns)

Significance vs. 
control and other 
treatments*

50.75

52.07

65.45

79.00

68.83

64.87

80.13

85.66
80.64

–

ns

ABGHI

ABCeF

ABGHI

ABGHI

ABCEF

ABCEF
ABCEF

3.03

4.88

10.73

12.34

10.61

10.73

14.06

17.44
14.72

–

ns

ABH

ABH

ABH

ABH

AB

ABCDEF
AB

*Upper  case  letters  denote  significant  differences  ( p  <  0.05),  while  lower  case  letters  denote  directional  differences  ( p  <  0.10);  ns  =  not 
significant.

 
 
74 

 TEXTBOOK OF COSMETIC DERMATOLOGY

propionate  formulation  that  also  contained  niacinamide  and 
collagen  fragment  peptides  showed  an  equivalent  level  of 
efficacy  compared  with  0.02%  tRA  (24).  This  combination  of 
significant efficacy with an overall lower irritation profile has 
been noted in cross-comparison of human biopsy studies, back 
cumulative  irritation,  and  human  facial  skin  clinicals  (21). 
While less critical than its overall efficacy and irritation profile, 
retinyl propionate has been reported to have a better chemical 
stability  profile  compared  to  other  esters,  thereby  increasing 
half-life upon skin during topical delivery (25).

The  more  potent  ester  retinyl  acetate  has  been  shown  in 
in  vivo  models  as  being  able  to  induce  a  retinoid-like  response 
as measured by epidermal thickening as well as indirect mark-
ers  of  epidermal proliferation (26). Additionally, the kinetics of 
the accommodation response to retinyl acetate as measured by 
erythema has a similar time curve over a 20-day period as has 
been observed in human studies for accommodation to retinol 
(Oblong, unpublished results). Since retinyl acetate has a similar 
pharmaco activity and irritation profile as retinol, there appears 
to be no advantage of this ester over retinol in cosmetic products.
Of  the  retinyl  esters  currently  practiced  in  the  cos-
metic marketplace, retinyl palmitate appears to be one of the 
weaker retinoids in terms of efficacy for generating a retinoid 
response in human skin, including effects on photodamaged 
skin. This is more than likely due to the primary storage role of 
endogenous retinyl palmitate, which is a key regulatory point. 
Although some level of topically applied retinyl palmitate can 
be converted to retinol, the small amount of retinyl palmitate 
that actually penetrates the skin would be expected to become 
accumulated into endogenous storage pools (4). Based on pub-
lished information and historical cosmetic usage, it is accepted 
that retinyl palmitate has at best an overall weak activity pro-
file  and  is  non-irritating  (20).  Evaluation  of  epidermal  and 
granular layer thickening also shows the weak retinoid effect 
in human biopsy studies (Table 7.1).

Finally, it has been observed that there may be a plateau 
of responsiveness among retinyl esters as observed in various 
retinoid-sensitive  models  (Oblong,  unpublished  data).  This 
suggests a threshold level in which excess retinol derived from 
shorter  chain  retinyl  esters  could  be  competitively  targeted 
by  acyl  transferases  over  retinol  dehydrogenases  and  incor-
porated into retinyl palmitate storage pools. Thus, the ability 
to  deliver  greater  efficacy  from  retinyl  esters  in  general  may 
become  dependent  more  upon  optimal  R-groups  or  combi-
nation therapies rather than attempting to elevate the topical 
dose  used.  Examples  include  the  published  clinical  findings 
that  showed  the  photostable  ester  retinyl  N-formyl  asparta-
mate was able to deliver retinoid-like effects on photodamaged 
skin without significant irritation (27).

SUMMARY
Retinoids are a broad family of molecules that can be metabo-
lized via endogenous enzymatic pathways to generate agonists 
for members of the RAR and RXR nuclear receptor family. In 
turn, this denotes their critical role in regulating gene expres-
sion  profiles  via  RAR/RXR  binding  to  RAREs.  In  dermatol-
ogy,  prescription  forms  of  natural  and  synthetic  retinoids 
have  been  shown  to  have  beneficial  effects  upon  acne,  pso-
riasis,  icthyosis,  actinic  keratosis,  and  photodamaged/aging 
skin  attributes.  Relative  to  photodamaged  skin,  the  cosmetic 
industry has been using retinol and various retinyl esters for 
several decades. This class of molecules continues to be one of 
the more efficacious materials available to consumers to help 

combat photoaged skin appearance. While the overall efficacy 
provided by these cosmetic forms of retinoid are generally less 
potent  than  the  prescription  forms  such  as  tRA,  the  knowl-
edge that these forms can be metabolized to more active forms 
supports  the  indirect  mechanism  of  action  that  they  utilize. 
Of  the  retinyl  esters  currently  practiced  in  the  marketplace, 
there appear to be advantages for the usage of retinyl propio-
nate over retinyl acetate in terms of having a similar efficacy 
response range but with an improved irritation profile. In con-
trast, retinyl palmitate has a very low efficacy response range, 
rendering  its  low  irritation  profile  as  moot  in  terms  of  being 
able to have any positive benefits for affecting the appearance 
photodamaged skin.

Future research in better understanding the connections 
between efficacy and retinoid-induced irritation should allow 
for the identification of novel retinyl ester that decouple these 
two phenomena. The results presented with retinyl propionate 
suggest the potential exists. Additionally, there would appear 
to be an opportunity to identify a final solution that combines 
optimized  levels,  formulations,  and  potentially  additional 
materials to maintain or elevate retinoid-like efficacy but with 
a reduced overall irritation profile.

REFERENCES

1. Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin 

for photoaged skin. J Am Acad Dermatol 1986; 15:836–59.

2. Weiss  JS,  Ellis  CN,  Headington  JT,  et  al.  Topical  tretinoin 
improves  photoaged  skin.  A  double-blind  vehicle-controlled 
study. J Am Med Assoc 1988; 259:527–32.

3. Harrison  EH.  Enzymes  catalyzing  the  hydrolysis  of  retinyl 

esters. Biochim Biophys Acta 1993; 1170:99–108.

4. Boehnlein J, Sakr A, Lichtin JL, Bronaugh RL. Characterization 
of  esterase  and  alcohol  dehydrogenase  activity  in  skin. 
Metabolism  of  retinyl  palmitate  to  retinol  (vitamin  A)  during 
percutaneous absorption. Pharm Res 1994; 11:1155–9.

5. Kang  S,  Duell  EA,  Fisher  GJ,  et  al.  Application  of  retinol  to 
human  skin  in  vivo  induces  epidermal  hyperplasia  and  cellu-
lar retinoid binding proteins characteristic of retinoic acid but 
without  measurable  retinoic  acid  levels  of  irritation.  J  Invest 
Dermatol 1995; 105:549–56.

6.  Kurlandsky SB, Xiao J-H, Duell EA, et al. Biological activity of 
all-trans retinol requires metabolic conversion to all-trans reti-
noic acid and is mediated through activation of nuclear retinoid 
receptors in human keratinocytes. J Biol Chem 1994; 269:32821–7.
7.  Bailly  J,  Crettaz  M,  Schifflers  MH,  Marty  JP.  In  vitro  metabo-
lism by human skin and fibroblasts of retinol, retinal and reti-
noic acid. Exp Dermatol 1998; 7:27–34.

8.  Antille C, Tran C, Sorg O, Saurat JH. Penetration and metabo-
lism of topical retinoids in ex vivo organ-cultured full- thickness 
human skin explants. Skin Pharmacol Physiol 2004; 17:124–8.

9.  Napoli 

JL.  Retinol  metabolism 

cells. 
Characterization  of  retinoic  acid  synthesis  by  an  established 
mammalian cell line. J Biol Chem 1986; 261:13592–7.

in  LLC-PK1 

  10.  Kurlandsky SB, Duell EA, Kang S, et al. Auto-regulation of reti-
noic acid biosynthesis through regulation of retinol esterifica-
tion in human keratinocytes. J Biol Chem 1996; 271:15346–52.

  11.  Blomhoff R, Green MH, Norum KR. Vitamin A: Physiological 
and biochemical processing. Ann Rev Nutr 1992; 12:37–57.
  12.  Got L, Gousson T, Delacoux E. Simultaneous determination of 
retinyl  esters  and  retinol  in  human  livers  by  reversed-phase 
high-performance  liquid  chromatography.  J  Chromatography  B 
1995; 668:233–9.

  13.  Shih  MY,  Kane  MA,  Zhou  P,  et  al.  Retinol  esterification  by 
DGAT1  is  essential  for  retinoid  homeostasis  in  murine  skin. 
J Biol Chem 2009; 284:4292–9.

  14.  Ribaya-Mercado JD, Blanco MC, Fox JG, Russell RM. High con-
centrations  of  vitamin  A  esters  circulate  primarily  as  retinyl 

 
 
 
 
 
RETINYL PROPIONATE AND RELATED RETINOIDS 

  75

stearate and are stored primarily as retinyl palmitate in ferret 
tissues. J Am Coll Nutr 1994; 13:83–6.

  15.  Vasios  GW,  Gold  JD,  Petkovich  M,  et  al.  A  retinoic  acid- 
responsive  element  is  present  in  the  5'  flanking  region  of  the 
laminin B1 gene. Proc Natl Acad Sci U S A 1989; 86:9099–103.

  16.  Heise R, Mey J, Neis MM, et al. Skin retinoid concentrations are 
modulated by CYP26AI expression restricted to basal keratino-
cytes in normal human skin and differentiated 3D skin models. 
J Invest Dermatol 2006; 126:2473–80.

  17.  Arayachukeat  S,  Wanichwecharungruang  SP,  Tree-Udom  T. 
Retinyl  acetate-loaded  nanoparticles:  Dermal  penetration  and 
release of the retinyl acetate. Int J Pharm 2011; 404:281–8.
  18.  Kafi R, Kwak HS, Schumacher WE, et al. Improvement of natu-
rally  aged  skin  with  vitamin  A  (retinol).  Arch  Dermatol  2007; 
143:606–12.

  19.  Ridge BD, Batt MD, Palmer HE, Jarrett A. The dansyl chloride 
technique  for  stratum  corneum  renewal  as  an  indicator  of 
changes  in  epidermal  mitotic  activity  following  topical  treat-
ment. Br J Dermatol 1988; 118:167–74.

  20.  Duell EA, Kang S, Voorhees JJ. Unoccluded retinol penetrates 
human  skin  in  vivo  more  effectively  than  unoccluded  retinyl 
palmitate or retinoic acid. J Invest Dermatol 1997; 109:301–5.
  21.  Oblong JE, Saud A, Bissett DL, Zhu C. Topical retinyl propio-
nate achieves skin benefits with favorable irritation profile. In: 

Elsner  P,  Maibach  HI  eds.  Cosmeceuticals  and  Active  Cosmetics: 
Drugs  Versus  Cosmetics  (Cosmetic  Science  and  Technology 
Series). Boca Raton, FL: Taylor and Francis 2005; pp. 441–464.

  22.  Oblong, 

JE,  Bissett  DL.  Retinoids.  In:  Draelos  Z,  ed. 
Cosmeceuticals  (Procedures  in  Cosmetic  Dermatology)  2005;  pp. 
35–42.

  23.  Green C, Orchard G, Cerio R, Hawk JLM. A clinicopathological 
study of the effects of topical retinyl propionate cream in skin 
photoageing. Clin Exp Dermatol 1998; 23:162–67.

  24.  Fu  JJ,  Hillebrand  GG,  Raleigh  P,  et  al.  A  randomized,  con-
trolled comparative study of the wrinkle reduction benefits of 
a  cosmetic  niacinamide/peptide/retinyl  propionate  product 
regimen  vs.  a  prescription  0.02%  tretinoin  product  regimen. 
Br J Dermatol 2010; 162:647–54.

  25.  Semenzato A, Bovenga L, Faiferri L, et al. Stability of vitamin A 

propionate in cosmetic formulations. SÖFW-J 1997; 123:151–4.

  26.  Jarrett  A,  Wrench  R,  Mahmoud  B.  The  effects  of  retinyl  ace-
tate  on  epidermal  proliferation  and  differentiation.  Induced 
enzyme  reactions  in  the  epidermis.  Clin  Exp  Dermatol  1978; 
3:173–88.

  27.  Lee MS, Lee KH, Sin HS, et al. A newly synthesized photostable 
retinol  derivative  (retinyl  N-formyl  aspartamate)  for  photo-
damaged skin: Profilometric evaluation of 24-week study. J Am 
Acad Dermatol 2006; 55:220–4. Epub 2006 Jun 5.

 
8

Idebenone (Hydroxydecyl Ubiquinone)

Birgit A. Neudecker, Falko Diedrich, and Howard I. Maibach

INTRODUCTION
Idebenone is a unique new antioxidant in dermatology used to 
treat the visible and cellular signs of skin aging. This chapter 
reviews the description, uses, functionality, cell biological and 
clinical research, safety, and new improvements of this respi-
ratory chain analog of coenzyme Q10.

DESCRIPTION
Idebenone  is  a  bioengineered  analog,  but  not  a  derivative 
of  ubiquinone  (coenzyme  Q10).  It  belongs  in  the  family  of 
molecules known as quinones; in particular it is a 1,4-benzo-
quinone molecule, as is hydroquinone. Its molecular weight is 
338,  compared  with  coenzyme  Q10  with  a  molecular  weight 
of  860,  and  therefore  in  theory  has  much  greater  skin  pene-
tration  potential.  Idebenone  is  a  potent  antioxidant,  with  the 
ability to operate under low oxygen tension situations, and not 
showing prooxidative metabolites (1,2). Because of its ability to 
inhibit lipid peroxidation, idebenone protects cell membranes 
and mitochondria from oxidative damage caused by free radi-
cals  generated  during  cell  metabolism,  processes  which  are 
also summarized as intrinsic aging (2–4). Ultraviolet radiation 
(UVR)-generated reactive oxygen species (ROS) play a critical 
role  in  the  process  of  photocarcinogenesis  and  environmen-
tally  induced  aging,  also  termed  as  photoaging  or  extrinsic 
aging  (5–9).  Some  studies  claim  that  infrared  radiation  and 
visible light also contribute to a major extend to such kind of 
damage  (10,11).  Although  the  skin  possesses  a  complex  anti-
oxidant  network,  both  intrinsic  and  extrinsic  pathways  can 
provoke  an  imbalance  of  the  fragile  prooxidant-antioxidant 
equilibrium  (12–17)  eventually  leading  to  alteration  of  cells 
and structural macromolecules of the dermal connective tissue 
with its clinical appearance of wrinkle formation, laxity, and 
pigment disorders. In comparison with other antioxidants, ide-
benone shows in vitro studies as well as in vivo studies unique 
properties  providing  protection  regarding  both  intrinsic  and 
extrinsic processes of aging (18–20).

HISTORY AND USES
Idebenone has a history in medical applications dating back to 
1982, with its initial introduction to the scientific community in 
papers published by Shimamoto et al. (21–23) citing its poten-
tial  applications  in  the  energy  metabolism  of  red  blood  cells 
and myocardial tissue. Additional research over the next few 
years lead to the first phase I study to determine the tolerance, 
safety,  and  pharmacokinetics  of  idebenone  (24)  followed  by 
clinical studies in the early 1990s in subjects with Alzheimer's 
disease  (25,26).  It  has  since  been  researched  extensively  for  a 
variety of applications related to the treatment of various age-
related disorders of the human body, including cerebrovascu-
lar  and  Alzheimer's  disease,  Friedreich's  ataxia,  and  showed 

protective properties in organ preservation solutions (2). Until 
2009  over  270  articles  have  been  published,  mostly  related 
to  the  health  benefits  of  idebenone  as  an  antiaging  modality 
(27–32). The potential benefits of idebenone fall into five catego-
ries: antiaging, energy enhancement, cognition enhancement, 
organ protection, and protection against excitatory amino acid 
neurotoxicity.  Its  introduction  in  the  field  of  dermatology  in 
2003  as  a  compound  purported  to  be  beneficial  in  the  treat-
ment of many skin changes associated with acute and chronic 
skin aging.

As with other antioxidants, idebenone exists in a reduced 
and an oxidized state. In a study of its effect on astroglial cells, 
idebenone,  in  either  redox  state,  significantly  inhibited  the 
enzymatic metabolism of arachidonic acid by cyclooxygenase 
and  lipoxygenase.  This  effect  was  stronger  with  the  reduced 
form,  and  showed  potential  central  nervous  system  anti-
inflammatory activity (27).

In another study, synaptosomes isolated from rat brain 
cortex  were  treated  with  iron  and  ascorbate,  establishing 
experimental  cellular  oxidant  injury.  Idebenone  prevented 
both the formation of ROS in the cytosol and mitochondria, as 
well as a decrease in proteinsulfhydryl content (an indicator of 
protein oxidation), compared with controls (28).

In addition to its function as an antioxidant, idebenone 
works as an electron carrier in the electron transfer chain, sim-
ilar to coenzyme Q10. Idebenone was introduced into a canine 
coenzyme  Q10–depleted  brain  mitochondrial  preparation, 
which  prevented  the  loss  of  electron  chain  transfer  activity 
normally seen with coenzyme Q10 depletion (3).

Idebenone  also 

inhibited  mitochondrial 

lipid  per-
oxidation  (4),  which  can  be  interpreted  as  protecting  against 
mitochondrial damage. Other animal studies confirm the mito-
chondrial membrane protective effects of idebenone (29,30).

FUNCTIONALITY
According  to  the  mitochondrial  theory  of  aging,  nonrepaired 
damage  of  mitochondrial  DNA  and  unstable  electron  transfer 
cause an important loss of mitochondrial function in correlation 
with progression of age (6). Mitochondria are the sites of cellular 
metabolic  energy  production  where  oxygen  is  used  to  convert 
carbohydrates  into  ATP  to  power  and  enable  all  cellular  meta-
bolic activity. The process itself produces toxic free radicals as the 
result of electron transfer, which can result in cellular damage 
if  uncontrolled  (33,34).  Therefore  cells  have  developed  defense 
mechanisms, including essential enzymes and coenzymes such 
as coenzyme Q10, SOD, and catalase that are capable of reduc-
ing radical by-products of cellular energy production eventually 
into water (12,35). Unfortunately, these defense mechanisms are 
efficient only to a certain degree, and liberated free radicals such 
as  superoxide  radicals  can  react  with  cellular  organelles  and 

molecules as, for example, DNA, lipids, sugars, and proteins to 
cause cellular damage, which expresses itself as aging (6,8,9,12). 
Mitochondria  possess  the  ability  to  replicate  containing  their 
own DNA but have far fewer repair mechanisms than nuclear 
DNA  despite  the  fact  that  they  are  the  sites  where  most  inter-
nal free radicals are formed. The result is cellular aging directly 
associated with metabolic energy production (33). For this rea-
son,  mitochondria  require  potent  free  radical  scavenging  anti-
oxidants to prevent the early onset of cellular aging. Coenzyme 
Q10  protects  mitochondria  from  oxidant  decay.  As  mentioned 
above, the function of idebenone as an electron transfer respira-
tory chain antioxidant is closely related to that of coenzyme Q10, 
which itself is a vital biochemical found in cellular and mitochon-
drial membranes and plays a critical role in the electron trans-
port chain during the production of energy in the mitochondria. 
However,  unlike  coenzyme  Q10,  idebenone  lacks  the  potential 
downside of a degradative prooxidative effect, especially under 
hypoxic  cellular  conditions,  such  as  those  found  after  stroke, 
heart attack, excessive exercise, or other conditions that lead to 
poor tissue oxygenation. Idebenone appears to be able to tightly 
couple oxygen to the electron transport chain and thus prevent 
toxic oxygen radical production far better than coenzyme Q10 (3).

DERMATOLOGY: CELL BIOLOGICAL 
AND CLINICAL RESEARCH
It is important not to confuse idebenone with other commonly 
used antioxidants in skincare such as vitamin antioxidants like 
vitamin C and vitamin E or botanical antioxidants such as poly-
phenols, flavonoids, and proanthocynidins. Idebenone differs 
from  these  other  types  of  antioxidants  in  that  it  is  a  respira-
tory chain antioxidant that targets aging at the mitochondria. 
In 2003 and 2005, the first cell biological in vitro and in vivo 
clinical studies were published (18–20) that demonstrated that 
idebenone  had  a  potent  ability  to  protect  cellular  lipids,  cell 
membranes, and DNA from oxidative stress and prevent sun-
burn cell (SBC) formation post ultraviolet (UV) exposure, and 
thus could have a significant protective and corrective effect on 
skin aging. In a multistep protocol, a series of five different cell 
biological in vitro and clinical in vivo methods were combined 
to compare the antioxidative  capacities of the following anti-
oxidants:  vitamin  C,  vitamin  E,  a-lipoic  acid,  coenzyme  Q10, 
kinetin, and idebenone. The studies included measurement of 
the ability of the antioxidant to

1.  Scavenge  free  radicals  produced  in  a  reaction  chamber 

using instrumental analysis (Photochem1),

IDEBENONE (HYDROXYDECYL UBIQUINONE) 

 77

2.  Protect against low-density lipoprotein (LDL) oxidation as 

a marker of lipid peroxidation,

3.  Protect against cell membrane oxidation,
4.  Protect against DNA cross-linking post UV exposure, and
5.  Protect human skin from SBC formation post UV exposure.

In  a  scoring  system,  which  was  based  on  a  maximum 
score of 100, idebenone was found to be the most efficient anti-
oxidant tested at the time. Since that time idebenone has been 
researched  in  further  clinical  studies  measuring  the  effects 
at  various  concentrations  to  reduce  the  overall  appearance 
of  fine  lines,  wrinkles,  hyperpigmentation,  and  other  skin 
changes associated with photo-damage and global skin aging. 
The results of these studies (unpublished) are outlined below.
Forty subjects, 6 weeks, b.i.d., double blind, global assess-
ment of 0.5% (20 subjects) and 1.0% (20 subjects) idebenone in 
the  treatment  of  photodamaged  skin  with  measurements  for 
skin  roughness/dryness,  fine  lines/wrinkles,  skin  hydration 
and  global  assessment  by  expert  dermatologist  grader.  The 
results are given in Figure 8.1. In this study, punch biopsies of 
several patients were taken and stained for collagen 1, MMP- 1, 
IL-1,  and  IL-6.  The  results  demonstrated  that  idebenone  was 
able to suppress formation of MMP, IL-1, and IL-6, and increase 
deposition of collagen.

Low  concentrations  of  idebenone  have  been  shown  to 
upregulate certain important genes to suppress MMPs and inter-
leukins  and  increase  expression  of  certain  structural  proteins 
for  collagen  (personal  communication  with  Dr  D.  McDaniel). 
Additionally,  lifespan  extension  studies  using  Drosophila 
have demonstrated the ability of idebenone to extend the lifes-
pan of fruit flies under oxidative stress conditions (36). Similar 
results were found in knockout mouse models of Friedreich's 
ataxia (37).

SAFETY
As previously reviewed, sufficient preclinical and clinical data 
is  available  to  demonstrate  both  cell  biological  and  clinical 
antiaging  benefits  of  idebenone.  Consultations  with  several 
companies that market idebenone in topical skincare formula-
tions also indicate that premarket safety HIRPT studies did not 
indicate  any  skin  sensitivity  concerns.  However,  post-market 
surveillance  (various  formulations  have  been  on  the  market 
since 2004, including Prevage MD, Prevage, and PRIORI) sug-
gests that there have been a few reported cases of skin sensitiv-
ity to the molecule, in most cases immediate and cumulative 
irritation reactions that can include skin redness, itching, and 

27

29

33

30

37

37

26

23

40

30

20

10

0

Roughness/Dryness Fine Lines/Wrinkles

Global Improvement

Skin Hydration

n = 40

0.5% Idebenone

1% Idebenone

Figure 8.1  Percent increase/decrease after 6-week use.

 
78 

 TEXTBOOK OF COSMETIC DERMATOLOGY

folliculitis,  but  in  more  severe  cases,  what  appear  to  be  clas-
sic allergic type reactions (38–40). Since the use of idebenone 
is new in skincare so it is in the general population, consum-
ers  reporting  allergic-type  reactions  on  first  use  can  only  be 
explained via a cross-sensitivity type model. Because the com-
pound is a 1,4-benzoquinone, consumers who exhibit allergy 
to  para-phenylenediamine,  hydroquinone,  evening  primrose 
oil,  and  other  similar  compounds  may  exhibit  the  same  sen-
sitivity  to  idebenone.  For  this  reason,  products  should  carry 
a caution to “patch test” products with idebenone and to wait 
at least 24 hours prior to commencing regular use. If sensitiv-
ity occurs, consumers should not use products containing ide-
benone.  It  is  worthy  of  note  here  that  there  has  never  been  a 
recorded allergic reaction to the internal consumption of ide-
benone in spite of its wide availability as a dietary supplement 
in many markets around the world.

NEW IDEBENONE DERIVATIVE MOLECULES
Improvements  in  the  topical  skincare  delivery  of  idebenone 
include  the  development  of  new  synthetic  molecular  deriva-
tives, which seem to have the capability to enhance efficacy and 
safety of this new antioxidant technology. Specifically, various 
water  and  oil  soluble  esters  of  idebenone  were  synthesized 
and  tested  for  their  ability  to  inhibit  SBC  formation  post-
UV  irradiation,  and  the  first  clinical  studies  were  conducted 
with  assessments  for  known  antiaging  parameters  including 
red  and  brown  pigmentation,  fine  lines  and  wrinkles,  and 
global improvement in photodamage. Finally, skin maximiza-
tion  studies  were  conducted  to  asses  skin  tolerance.  In  these 
pilot  studies  the  dipalmitic  glyceric  acid  ester  of  idebenone 
(hydroxydecyl ubiquinoyl dipalmitoyl glycerate) was found to 
be the most efficient new idebenone derivative molecule across 
all test parameters (unpublished study, personal communica-
tion with Dr. D. McDaniel).

It  is  believed  that  the  improved  antioxidant  and  anti-
aging efficiency of the new derivative is a result of increased 
skin  and  cell  permeability,  improved  time-released  action  of 
idebenone based on rate constant enzymatic hydrolysis in the 
skin, leading to broader skin compatibility, and more efficient 
antioxidant capacity.

CONCLUSION
Idebenone is a very promising new unique respiratory chain 
antioxidant for topical skincare use in treating various signs 
of skin aging. In cell biological studies it has been shown to 
protect cellular lipoproteins, cell membranes, and DNA from 
damage caused by oxidative stress. Clinically it has an anti-
inflammatory effect, the ability to reduce SBCs post UV expo-
sure, and the ability to diminish the visible signs of skin aging 
including fine lines, wrinkles, hyperpigmentation, and over-
all improvement in photodamaged skin. Improvements in the 
technology  have  produced  new  idebenone  derivative  mole-
cules; in particular, dipalmitic glyceric acid, which seems to 
improve the delivery of the molecule and its efficacy but also 
significantly decreases the potential for skin sensitivity.

REFERENCES

1.  Mordente  A,  Martorana  GE,  Minotti  G,  et  al.  Antioxidant 
properties  of  2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-
(idebenone).  Chem  Res  Toxicol  1998; 
1,4-benzoquinone 
11(1):54–63.

2.  Wieland  E,  Schutz  E,  Armstrong  VW,  et  al.  Idebenone  pro-
tects  hepatic  microsomes  against  oxygen  radical-mediated 

damage  in  organ  preservation  solutions.  Transplantation  1995; 
15:60(5):444–51.

3.  Imada  I,  Sato  EF,  Kira  Y,  et  al.  Effect  of  CoQ  homologues  on 
reactive  oxygen  generation  by  mitochondria.  Biofactors  2008; 
32(1–4):41–8.

4.  Imada  I,  Fujita  T,  Sugiyama  Y,  et  al.  Effects  of  idebenone  and 
related  compounds  on  respiratory  activities  of  brain  mito-
chondria, and on lipid peroxidation of their membranes. Arch 
Gerontol Geriatr 1989; 8(3):323–41.

5.  Berneburg  MH,  Plettenberg  J,  Krutmann  J.  Photoaging  of 
human  skin.  Photodermatol  Photoimmunol  Photomed  2000; 
16:239–44.

6.  Scharfetter-Kochanek K, Brenneisen P, Wenk J, et al. Photoaging 
of the skin from phenotype to mechanisms. Exp Gerontol 2000; 
35:307–16.

7.  Berneburg  M,  Grether-Beck  S,  Kurten  V,  et  al.  Singlet  oxy-
gen  mediates  the  UV-induced  generation  of  the  photoaging 
associated  mitochondrial  common  deletion.  J  Biol  Chem  1999; 
274:15345–9.

8.  Gilchrest BA. A review of skin aging and its medical therapy. 

Br J Dermatol 1996; 135(6):867–75.

9.  Hadshiew IM, Eller MS, Gilchrest BA. Skin aging and photoag-
ing: The role of DNA damage and repair. Am J Contact Dermatol 
2000; 11:19–25.

  10.  Schieke  SM,  Schroeder  P,  Krutmann  J.  Cutaneous  effects  of 
infrared  radiation:  From  clinical  observations  to  molecular 
response  mechanisms.  Photodermatol  Photoimmunol  Photomed 
2003; 19(5):228–34.

  11.  Cho S, Shin MH, Kim YK, et al. Effects of infrared radiation and 
heat on human skin aging in vivo. J Investig Dermatol Symp Proc 
2009; 14(1):15–19.

  12.  Thiele JJ, Schroeter C, Hsieh SN, et al. The antioxidant network 

of the stratum corneum. Curr Probl Dermatol 2001; 29:26–42.

  13.  Podda  M,  Traber  MG,  Weber  C,  et  al.  UV-irradiation  depletes 
antioxidants and causes oxidative damage in a model of human 
skin. Free Radic Biol Med 1998; 24(1):55–65.

  14.  Wenk  J,  Brenneisen  P,  Meewes  C,  et  al.  UV-induced  oxidative 
stress and photoaging. Curr Probl Dermatol 2001; 29:83–94.
  15.  Darr  D,  Pinell  SR.  Reactive  oxygen  species  and  antioxidative 
protection  in  photodermatology.  In:  Lowe  NJ,  Shaath  NA, 
Oathak  MA,  eds.  Sunscreens  -  Development,  Evaluation,  and 
Regulatory Aspects. 2nd ed. New York: Dekker 1997; pp. 155–173.
  16.  Fuchs  J,  Packer  L.  Oxidative  Stress  in  Dermatology.  New  York, 

Basel: Dekker 1993; pp. 55–73.

  17.  Sander  CS,  Chang  H,  Salzmann  S,  et  al.  Photoaging  is  asso-
ciated  with  protein  oxidation  in  human  skin  in  vivo.  J  Invest 
Dermatol 2002; 118(4):618–25.

  18.  Neudecker  BA,  Bekyarov  D,  Diedrich  FK,  et  al.  Antioxidants 
compared in a multiphasic protocol to measure to measure pro-
tective  capacity  against  oxidative  stress.  Poster  presentation, 
American Academy of Dermatology, San Francisco, 2003.
  19.  McDaniel DH, Neudecker BA, Dinardo JC, et al. Idebenone: A 
new antioxidant - part I. Relative assessment of oxidative stress 
protection  capacity  compared  to  commonly  known  antioxi-
dants. J Cosmet Dermatol 2005; 4(1):10–17.

  20.  McDaniel  D,  Neudecker  B,  Dinardo  J,  et  al.  Clinical  efficacy 
assessment in photodamaged skin of 0.5% and 1.0% idebenone. 
J Cosmet Dermatol 2005; 4(3):167–73.

  21.  Shimamoto  N,  Goto  N,  Hirata  M.  Effects  of  2,3-dimethoxy-
5-methyl-6-(100-hydroxydecyl)-1,4-benzoquinone 
(CV-2619) 
on  the  energy  metabolism  of  red  blood  cells  of  rats.  Nippon 
Yakurigaku Zasshi 1982; 80(2):137–45.

  22.  Shimamoto  N,  Tanabe  M,  Imamoto  T,  et  al.  Effects  of  2,3- 
dimethoxy-5-methyl-6-(100-hydroxydecyl)-1,4-benzoquinone 
(CV-  2619)  on  myocardial  energy  metabolism  in  the  hyper-
trophied  heart  of  spontaneously  hypertensive  rats.  Nippon 
Yakurigaku Zasshi 1982; 80(4):299–306.

  23.  Shimamoto N, Tanabe M, Hirata M. Effects of 2,3-dimethoxy- 
5-methyl-6-(100 
(CV-2619) 
on  adriamycin-induced  ECG  abnormalities  and  myocardial 

-hydroxydecyl)-1,4-benzoquinone 

 
 
 
 
 
 
 
 
 
 
IDEBENONE (HYDROXYDECYL UBIQUINONE) 

 79

energy metabolism in spontaneously hypertensive rats. Nippon 
Yakurigaku Zasshi 1982; 80(4):307–15.

metabolites  in  the  brains  of  rats  with  cerebral  ischemia.  Arch 
Gerontol Geriatr 1989; 8(3):247–56.

  24.  Barkworth MF, Dyde CJ, Johnson KI, et al. An early phase I study 
to  determine  the  tolerance,  safety  and  pharmacokinetics  of 
idebenone following multiple oral doses. Arzneimittelforschung 
1985; 35(11):1704–7.

  25.  Marigliano  V,  Abate  G,  Barbagallo-Sangiorgi  G,  et  al. 
Randomized,  double-blind,  placebo  controlled,  multicentre 
study  of  idebenone  in  patients  suffering  from  multi-infarct 
dementia. Arch Gerontol Geriatr 1992; 15(3):239–48.

  26.  Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al. Idebenone in 
senile dementia of Alzheimer type: A multicentre study. Arch 
Gerontol Geriatr 1992; 15(3):249–60.

  27.  Civenni G, Bezzi P, Trotti D, et al. Inhibitory effect of the neuro-
protective agent idebenone on arachidonic acid metabolism in 
astrocytes. Eur J Pharm 1999; 370:161–7.

  28.  Cardoso  SM,  Pereira  C,  Oliveira  CR.  The  protective  effect  of 
vitamin E, idebenone and reduced glutathione on free radical 
mediated injury in rat brain synaptosomes. Biochem Biophys Res 
Commun 1998; 246(3):703–10.

  29.  Nagaoka  A,  Kakihana  M,  Fujiwara  K.  Effects  of  idebenone 
on  neurological  deficits  following  cerebrovascular  lesions  in 
stroke-prone  spontaneously  hypertensive  rats.  Arch  Gerontol 
Geriatr 1989; 8(3):203–12.

  30.  Nagaoka  A,  Suno  M,  Shibota  M,  et  al.  Effects  of  idebenone 
on neurological deficits, local cerebral blood flow, and energy 
metabolism in rats with experimental cerebral ischemia.  Arch 
Gerontol Geriatr 1989; 8(3):193–202.

  31.  Kakihana M, Yamazaki N, Nagaoka A. Effects of idebenone on 
the levels of acetylcholine, choline, free fatty acids, and energy 

  32.  Kakihana  M,  Yamazaki  N,  Nagaoka  A.  Effects  of  idebenone 
(CV-  2619)  on  the  concentrations  of  acetylcholine  and  choline 
in  various  brain  regions  of  rats  with  cerebral  ischemia.  Jpn  J 
Pharmacol 1984; 36(3):357–63.

  33.  Krutmann  J,  Schroeder  P.  Role  of  mitochondria  in  photoag-
ing of human skin: The defective powerhouse model. J Investig 
Dermatol Symp Proc 2009; 14(1):44–9.

  34.  Cardoso  SM,  Pereira  C,  Oliveira  R.  Mitochondrial  function  is 
differentially affected upon oxidative stress. Free Radic Biol Med 
1999; 26(1–2):3–13.

  35.  Shindo Y, Witte E, Han D, et al. Enzymatic and nonenzymatic 
antioxidants in epidermis and dermis  of  human  skin.  J  Invest 
Dermatol 1994; 102:122–4.

  36.  Seznec  H,  Simon  D,  Monassier  L,  et  al.  Idebenone  delays  the 
onset of cardiac functional alteration without correction of Fe-S 
enzymes  deficit  in  a  mouse  model  for  Friedreich  ataxia.  Hum 
Mol Genet 2004; 13(10):1017–24.

  37.  Puccio  H.  Multicellular  models  of  Friedreich  ataxia.  J  Neurol 

2009; 256(suppl 1):18–24.

  38.  McAleer  MA,  Collins  P.  Allergic  contact  dermatitis  to 
hydroxydecyl ubiquinone (idebenone) following application of 
antiageing cosmetic cream. Contact Dermatitis 2008; 59(3):178–9.
  39.  Natkunarajah  J,  Ostlere  L.  Allergic  contact  dermatitis  to  ide-
benone  in  an  over-the-counter  anti-ageing  cream.  Contact 
Dermatitis 2008; 58(4):239.

  40.  Sasseville  D,  Moreau  L,  Al-Sowaidi  M.  Allergic  contact  der-
matitis to idebenone used as an antioxidant in an anti-wrinkle 
cream. Contact Dermatitis 2007; 56(2):117–8.

 
9

Antioxidants

Frank Dreher

INTRODUCTION
The  skin  forms  an  efficient  barrier  limiting  chemicals  from 
entering our body and protects from the harmful environment 
encompassing  exposure  to  solar  ultraviolet  radiation  (UVR) 
and air pollutants. Such an exposure results in the formation 
of reactive oxygen (ROS) and reactive nitrogen species (RNS). 
As  oxidative  stress-promoting  chemicals,  those  species  can 
react with skin biomolecules what may ultimately lead to skin 
damage  (1,2).  To  counteract  ROS-  and  RNS-induced  oxida-
tive stress, the skin is equipped with a variety of antioxidants 
forming  an  antioxidant  network.  The  antioxidants  intervene 
at  different  levels  of  oxidative  processes  by  scavenging  and 
removing free radicals or oxidatively damaged biomolecules. 
However, the antioxidant defense in skin can be overwhelmed 
by an increased exposure to oxidative stress, or may be com-
promised due to malnutrition or certain health conditions.

Well  documented  solar  UVR-induced  skin  damage 
includes  acute  reactions  including  sunburn.  Premature  skin 
aging  (photoaging)  and  photocarcinogenesis  are  the  conse-
quences of chronic UVR exposure. Terrestrial solar UVR con-
sists of UVB (290–320 nm) and UVA (UVA II: 320–340 nm, UVA 
I:  340–400  nm).  Radiation  less  than  290  nm  (UVC)  does  not 
reach the earth's surface, since these wavelengths are absorbed 
by  stratosperic  ozone.  While  ozone  in  the  upper  atmosphere 
occurs  naturally  and  protects  skin  by  filtering  out  harmful 
solar  UVR,  ozone  at  ground  level  (troposphere)  is  a  noxious, 
highly reactive oxidant pollutant. Besides UVR and air pollut-
ants  such  as  tropospheric  ozone,  the  presence  of  chemically 
unstable and ROS/RNS-forming drugs as well as the exposure 
of  skin  to  photoreactive  chemicals  may  be  other  sources  of 
cutaneous oxidative stress. Recently, it was found that also the 
visible light and infrared parts of the sun spectrum appear to 
contribute to oxidative stress in skin.

REACTIVE OXYGEN SPECIES
Several steps lead to the formation of ROS during UVR expo-
sure, which represents a well characterized source of oxidative 
stress in skin (1,2). The cascade of ROS formation is initiated by 
UVA  absorption  of  endogenous  or  exogenous  chromophores 
present in the skin. Of the many skin constituents capable of 
absorbing  UVA,  trans-urocanic  acid,  melanins,  flavins,  por-
phyrins,  protein-bound  tryptophan,  or  advanced  glycation 
end products are believed to be relevant chromophores initi-
ating the ROS formation cascade. Following UVR absorption, 
the  activated  chromophore  may  react  in  two  ways.  In  type  I 
photoreactions, the excited chromophore directly reacts with a 
substrate molecule via electron or hydrogen atom transfer and 
gives rise to free radical formation. In the presence of molecu-
lar oxygen (minor type II reaction), this reaction may lead to 
−  Subsequently, 
the  formation  of  superoxide  anion  radical  ⦁O2

− gives hydrogen peroxide (H2O2) by a dismutation reaction 
⦁O2
either  spontaneously  or  catalyzed  by  cutaneous  superoxide 
dismutase (SOD). Further, in the presence of metal ions such 
as  Fe(II)  or  Cu(II),  H2O2  can  be  converted  to  the  highly  reac-
tive hydroxyl radical ⦁OH. Otherwise (major type II reaction), 
electronically excited and reactive singlet oxygen 1O2 is formed 
by  photoenergy  transfer  from  UVR-excited  chromophores  in 
the  presence  of  triplet  oxygen  3O2  (molecular  oxygen  in  its 
ground state). Following their formation, ROS species includ-
−,  ⦁OH,  and  H2O2  react  with  an  array  of  skin  bio-
ing  1O2,  ⦁O2
molecules including lipids, proteins, DNA, and carbohydrates. 
For  instance,  (poly)unsaturated  lipids  (LH)  may  react  with 
ROS forming lipid peroxyl (LOO⦁) and alkoxyl radicals (LO⦁), 
which may initiate a chain-propagating autocatalytic reaction. 
ROS  can  also  cause  modifications  of  amino  acids  of  proteins 
resulting in functional changes of structural or enzymatic pro-
teins.  Besides  a  multitude  of  ROS-mediated  DNA  damages, 
reaction of singlet oxygen with DNA results in the formation 
of 8-hydroxy-deoxyguanosine. Since DNA absorbs strongly in 
the UVB region and is only a weak chromophore in the UVA 
region, UVB is largely considered as a direct, ROS-independent 
inducer  of  DNA  damage.  UVB  absorption  of  DNA  leads  to 
major  base  modifications  such  as  pyrimidine  dimer  or  (6–4) 
photo-adduct  formation.  These  modifications  together  with 
indirect  DNA  damage  induced  by  ROS  are  involved  in  solar 
genotoxicity.

Additionally,  oxidative  damage  to  mitochondrial  DNA 
(mtDNA) has been described to play a major role in photoag-
ing (3). Studies have shown that a common deletion of mtDNA 
is  increased  about  10-fold  in  photoaged  skin  as  compared  to 
sun-protected  skin  in  the  same  individual  (4).  Although  nor-
mal ATP production in the mitochondria results in some level 
of oxidative stress, it is thought that UVA exposure increases 
oxidative  stress  in  the  mitochondria  what  leads  to  mutations 
of mtDNA and consequently to a defective respiratory chain. 
The defective respiratory chain results in reduced energy pro-
duction by the mitochondria and increased production of ROS 
(5–8).  This  increase  in  ROS  leads  to  more  mtDNA  mutations 
which further perpetuate the production of ROS. As a conse-
quence, mtDNA mutations will increase even in the absence of 
UV exposure (3,9). This hypothesis has been termed “the defec-
tive powerhouse model of premature skin aging” (3).

CONSTITUTIVE SKIN ANTIOXIDANT NETWORK
To  protect  against  oxidative  stress,  skin  is  equipped  with  a 
complex  network  of  enzymatic  and  nonenzymatic  antioxi-
dants  (1,2).  Antioxidant  enzymes  such  as  SOD,  catalase,  glu-
tathione  reductase  and  peroxidase,  glutathion-S-transferase 
and  thioredoxin  reductase,  and  peroxidase  interact  with  low 
molecular  weight  lipophilic  antioxidants  including  vitamin  E 

ANTIOXIDANTS 

  81

homologues  (tocopherols  and  tocotrienols)  and  ubiquinols 
(coenzyme  Q)  as  well  as  hydrophilic  antioxidants  such  as 
vitamin  C  (ascorbic  acid  or  ascorbate)  and  glutathione  (GSH) 
(Figure 9.1). Carotenoids, retinoids, and uric acid, also possess-
ing  antioxidant  activity,  were  also  found  in  skin.  Their  role 
within  the  cutaneous  antioxidant  network  is,  however,  less 
well understood.

α-Tocopherol,  the  predominant  vitamin  E  homologue 
in skin, is known to efficiently scavenge lipid peroxyl and alk-
oxyl radicals by intercepting lipid chain propagation, which 
results in the formation of the metastable tocopheroxyl radi-
cal. This radical then either reacts with another lipid radical, 
leading  to  α-tocopherol  consumption,  or  abstracts  a  hydro-
gen  atom  from  polyunsaturated  lipids  to  give  α-tocopherol 
and lipid radical. In the latter case, occurring preferentially 
at low lipid radical concentration, the lipid radical may later 
react with oxygen to form a lipid peroxyl radical. This reac-
tion  consequently  induces  the  α-tocopherol–mediated  lipid 
peroxidation  chain  reaction.  Formation  of  one  molecule  of 
α-tocopherol  radical  results  in  the  formation  of  many  lipid 
hydroperoxides. However, as demonstrated in vitro in lipid 
and  cellular  systems,  when  ascorbic  acid  or  ubiquinol  are 
present,  the  tocopheroxyl  radical  is  rapidly  reduced,  regen-
erating  α-tocopherol.  The  α-tocopherol–mediated  lipid  per-
oxidation chain reaction is thereby terminated. In addition, 
because  of  its  high  reduction  potential,  ascorbic  acid  is  an 
efficient  scavenger  of  a  series  of  ROS  such  as  superoxide 
anion radicals, hydroxyl radicals, singlet oxygen, as well as 
water-soluble  peroxyl  radicals.  The  resulting  ascorbic  acid 
radical can be either recycled to ascorbic acid by co-antioxi-
dants such as glutathione or, respectively, is further oxidized 

to  dehydroascorbic  acid  and  then  irreversibly  decomposed. 
Glutathione  also  reacts  with  singlet  oxygen,  superoxide 
anion radicals, and hydroxyl radicals resulting in the forma-
tion  of  the  thiyl  radical  GS⦁  and  subsequently  glutathione 
disulfide  GSSG.  The  latter  can  be  recycled  to  GSH  by  the 
NAD(P)H-dependent enzyme glutathione reductase.

GSH  is  also  a  cofactor  for  a  few  reducing  enzymes, 
among them glutathione peroxidases. Glutathion peroxidase 
utilizes lipid peroxides as substrate and converts them into 
hydroxy fatty acids. Glutathion peroxidase also catalyzes the 
conversion  of  H2O2  into  water  and  oxygen.  As  mentioned, 
less reactive H2O2 is produced by SOD catalyzing the dismu-
tation reaction of superoxide anion radicals. SOD is present 
in  skin  as  Cu/Zn-  and  Mn-SOD.  GSH  is  likewise  used  by 
glutathion-S-transferases, which catalyze the conjugation of 
GSH  to  a  variety  of  electrophils,  including  oxidized  lipids, 
DNA, and other molecules. Glutathion-S-transferases there-
fore  play  an  important  role  in  removing  products  of  oxida-
tive stress.

Skin  also  contains  catalase,  which  is  similar  to  gluta-
thione  peroxidase  and  eliminates  H2O2.  However,  catalase 
contributes  to  scavenging  H2O2  differently  than  glutathione 
peroxidase  with  respect  to  its  cellular  distribution,  enzyme 
stability,  and  reaction  rate.  The  enzymatic  activity  of  cata-
lase  is  much  higher  than  that  of  glutathione  peroxidase  in 
human epidermis (10). Besides GSH peroxidase, skin contains 
another  selenium-dependent  enzyme,  thioredoxin  reductase 
(11).  Thioredoxin  reductase,  together  with  its  electron  accep-
tor thioredoxin and thioredoxin peroxidase, participates in the 
cutaneous H2O2 turnover similarly to the enzymic thiol redox 
couple GSH reductase/peroxidase.

LOOH,
LOH

LOC,
LO•

α-Tocopheroxyl
radical

Vitamin E
Cycle

α-Tocopherol

Lipids
(LH )

Singlet oxygen,
Hydroxyl radical,
Superoxide radical

Superoxide 
dismutase

H2O  + 
1/2O2

Catalase

GSH-peroxidase

H2O2

NAD(P)H

Glutathione
disulfide,
Thioredoxin (ox),
α-Lipoic acid

GSH or
Thioredoxin-
reductase

NAD(P)+

lipid-water
interface

Ascorbic
acid

Vitamin C
Cycle

Thiol
Cycle

Glutathione,
Thioredoxin (red),
Dihydrolipoic acid,

Ascorbyl
radical

Oxidative stressors
(UVA,  UVB, ozone, etc.)

Figure 9.1  Postulated activation of interactive network of antioxidants and antioxidant enzymes by oxidative stress in skin; note that 
some of the depicted antioxidant recycling mechanisms have been found in vitro and in other than cutaneous systems.

 
 
82 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Along  with  skin's  “interceptive”  antioxidant  network 
that scavenges ROS and RNS, skin also possesses a mecha-
nism of “antioxidant repair” that is able to reverse oxidatively 
damaged  proteins  (12).  In  general,  nonenzymic  antioxidant 
concentrations as well as enzymic antioxidant activities are 
significantly  higher  in  the  epidermis  as  compared  to  the 
dermis. This probably reflects the fact that the epidermis is 
directly  exposed  to  various  exogenous  sources  of  oxidative 
stress  and  might  have  therefore  evolved  to  possess  a  more 
pronounced  antioxidant  defense  capacity  than  the  dermis. 
On  a  molar  basis,  hydrophilic  nonenzymatic  antioxidants 
including  L-ascorbic  acid,  GSH,  and  uric  acid  appear  to  be 
the predominant antioxidants in human skin. Their dermal 
and epidermal overall concentrations are more than approxi-
mately  10-  to  100-fold  greater  than  found  for  vitamin  E  or 
ubiquinol/ubiquinone.  Ascorbic  acid,  GSH,  uric  acid  (13), 
and vitamin E (14) as well as catalase and SOD (15,16) were 
also  detected  in  the  outermost  epidermal  layer,  the  human 
stratum  corneum.  On  the  other  hand,  glutathione  peroxi-
dase  activity  seems  not  to  be  detectable  in  human  stratum 
corneum  (16).  It  was  found  that  the  distribution  of  antioxi-
dants in stratum corneum is not homogeneous, but follows a 
gradient with lower concentrations toward the skin surface 
(14).  Such  a  gradient  may  be  explained  by  the  fact  that  the 
outer skin layers are more directly exposed to environmental 
sources of ROS. A second reason may be related to the longer 
exposure of the superficial stratum corneum layers to oxida-
tive stress as compared to the lower layers, as a consequence 
of  the  physiological  turnover  of  keratinocytes  during  their 
differentiation  process.  Interestingly,  while  human  stratum 
corneum concentrations of vitamin E are as high as in lower 
epidermal layers, concentrations of hydrophilic antioxidants 
ascorbic  acid  and  uric  acid  are  in  the  range  of  one  to  two 
orders  of  magnitude  lower.  This  is  most  likely  due  to  the 
decreased  water  content  of  the  human  stratum  corneum  as 
compared with less keratinized epidermal layers. In contrast 
to uric acid, GSH, and ubiquinol, ascorbic acid and the vita-
min  E  homologues  cannot  be  synthesized  by  humans  and 
must be taken up by the diet. Consequently, the skin's antiox-
idant defense is dependent  on nutritive factors. Knowledge 
of the physiological regulation of ascorbic acid and vitamin E 
in skin is emerging. For instance, once ascorbic acid reaches 
skin via dermal blood vessels, it eventually enters the dermis 
where it is taken up by fibroblasts using a specific, sodium-
dependent  vitamin  C  transporter  (SVCT)  2,  or  further  dif-
fuses through the dermis, finally reaching the epidermis and 
supplying keratinocytes mainly via SVCT1 (17).

α-Tocopherol is known to be a significant constituent of 
human sebum and is continuously secreted to the skin surface 
(18).  Similarly  as  for  carotenoids  (19),  sebaceous  gland  secre-
tion is believed to be a relevant physiological delivery pathway 
of α-tocopherol to sebaceous gland-rich skin regions, such as 
the  well-exposed  facial  skin.  This  may  explain  the  increased 
level of α-tocopherol detected in the upper stratum corneum of 
facial skin as compared to upper arm skin. The physiological 
role of vitamin E in human sebum may be to particularly limit 
the formation of toxic skin surface lipid photooxidation prod-
ucts, such as squalene mono-hydroperoxides (20). In addition 
to its antioxidant activity, L-ascorbic acid acts as cofactor in a 
multitude of metabolic processes involved in skin formation. 
For example, it is required in hydroxylation reactions during 
collagen  synthesis  to  form  connective  tissue  (21)  and  partici-
pates in biosynthesis of epidermal barrier lipids (22).

EFFECTS OF ENVIRONMENTAL 
STRESSORS ON SKIN ANTIOXIDANTS
Numerous  studies  have  documented  the  effects  of  UVR  on 
cutaneous antioxidants after acute or chronic exposure using 
different  animal  models,  but  fewer  studies  exist  that  inves-
tigate  the  mechanisms  and  consequences  of  such  effects  in 
humans  (1,2).  The  antioxidants  contained  in  the  stratum  cor-
neum have been demonstrated to be susceptible to UVR. For 
example, a single suberythemal dose of solar-simulated UVR 
depleted human stratum corneum α-tocopherol by almost half, 
while dermal and epidermal α-tocopherol were only depleted 
at much higher doses (14). The high susceptibility of stratum 
corneum vitamin E to UVR may be, at least in part, due to a lack 
of  co-antioxidants  in  the  outermost  skin  layer.  The  lipophilic 
antioxidant ubiquinone-10 (oxidized form of ubiquinol-10), the 
most  abundant  ubiquinol/ubiquinone  found  in  human  skin, 
was undetectable in human stratum corneum.

Additionally,  ascorbic  acid,  the  major  hydrophilic 
co-antioxidant that is also capable of recycling photooxidized 
α-tocopherol, is present at lower levels in human stratum cor-
neum  than  in  other  skin  tissues.  Because  stratum  corneum 
represents  a  compartmentalized  structure,  the  antioxidants 
are probably not homogeneously distributed. This may further 
affect their interactions and thus limit the recycling capacity of 
α-tocopherol. The hydrophilic antioxidants were also shown to 
be sensitive to UVR. Direct depletion of α-tocopherol and for-
mation of its radical may further affect these endogenous anti-
oxidant pools. However, it seems that ascorbic and uric acid are 
less  susceptible  to  solar-simulated  UVR  than  α-tocopherol  or 
ubiquinol-10, as shown with cultured human skin models (23). 
In  full  thickness  epidermis  of  hairless  mice,  however,  ascor-
bic acid was depleted at lower solar-simulated UV doses than 
those needed to deplete lipophilic antioxidants or GSH (24). In 
another study, murine epidermal GSH levels were significantly 
depleted within minutes after UVB exposure but returned to 
normal  levels  after  half  an  hour  (25).  Moreover,  exposures 
of  hairless  mice  to  solar  simulated  UVR  demonstrated  that 
dermal  and  epidermal  catalase  is  more  susceptible  to  photo-
inactivation than SOD, and far more than GSH peroxidase and 
GSSG reductase (26,27).

Effects  of  the  air  pollutant  ozone  on  skin  antioxidants 
have  also  been  reported  (1,2).  Similarly,  as  found  for  UVR 
exposure,  the  stratum  corneum  is  the  most  susceptible  skin 
layer  for  ozone-induced  depletion  of  lipophilic  and  hydro-
philic antioxidants, as was demonstrated using hairless mice. 
Ozone itself is too reactive to penetrate deeply into the skin and 
reacts therefore predominantly with the skin barrier lipids and 
proteins in the outermost epidermis. Based on transepidermal 
water loss changes measured in hairless mice after exposure to 
either solar-simulated UVR or repetitive high doses of ozone, 
UVR appears a more damaging source of oxidative stress than 
ozone for skin (28).

A complex regulation in the antioxidant system of human 
skin was revealed during aging processes (15,29). α-Tocopherol 
concentrations  were  significantly  lower  in  the  epidermis  of 
aged  skin  but  not  for  the  dermis.  Ascorbic  acid  levels  were 
lower in both epidermis and dermis of aged skin. Total gluta-
thione levels were also lower, whereas uric acid concentrations 
were constant in the epidermis and dermis. Moreover, protein 
oxidation is increased in intrinsically aged, and, most signifi-
cantly, in photoaged human skin. Here, the oxidative damage 
is most pronounced in the papillary dermis and correlates well 
with solar elastosis. Remarkably, both protein oxidation as well 

 
a  sharp  decline  in  catalase  protein  levels  were  also  found  in 
the stratum corneum; however, not in the lower epidermal lay-
ers, where antioxidant protection is overall higher than in der-
mal and stratum corneum layers (15). Accordingly, an age- and 
UVR-dependent decline of stratum corneum catalase enzyme 
activity was later demonstrated (16).

PHOTOPROTECTION OF HUMAN SKIN 
BY TOPICAL ANTIOXIDANTS
Apart from using sunscreens to diminish the intensity of UVR 
reaching  the  deeper  skin  layers,  supplementation  of  the  skin 
with topically applied antioxidants and thereby strengthening 
its  antioxidative  capacity  is  an  established  approach  in  limit-
ing oxidative stress–induced skin damage (1,2,30). Oral supple-
mentation of antioxidants, which is another strategy to prevent 
photodamage of skin, is not the subject of this chapter and has 
been  reviewed  elsewhere  (31–33).  Topical  application  of  anti-
oxidants provides an efficient means of increasing antioxidant 
tissue levels in human skin. As the most susceptible skin layer 
for  UVR-  and  ozone-induced  depletion  of  cutaneous  antioxi-
dants, the stratum corneum may particularly benefit from an 
enhanced antioxidant capacity after topical supplementation.

Vitamin E
The  photoprotective  effects  of  vitamin  E  (α-tocopherol)  have 
been  studied  extensively.  Most  studies  were  performed  in 
animals,  but  several  studies  also  exist  investigating  the  pho-
toprotective effects of topically applied vitamin E in humans 
(1,2,34). Significantly reduced acute skin responses such as ery-
thema and edema, sunburn cell formation, lipid peroxidation, 
DNA adduct formation, immunosuppression, as well as UVA-
induced binding of photosensitizers was demonstrated when 
vitamin E was applied before UVR exposure. As shown in ani-
mal studies, skin wrinkling and skin tumor incidence due to 
chronic UVR exposure seem also to be diminished by topical 
vitamin E. A human study proved that an alcoholic lotion con-
taining  2%  α-tocopherol  significantly  diminished  the  erythe-
mal responses when applied 30 minutes before UVR exposure 
(35).  While  this  lotion  had  no  sunscreening  properties,  some 
α-tocopherol preparations may also act as sunscreens (36).

Diverse  vitamin  E  esters,  in  particular  vitamin  E  ace-
tate,  were  also  shown  to  reduce  UVR-induced  skin  damage. 
However,  their  photoprotective  effects  are  less  pronounced 
as compared to vitamin E. Vitamin E esters need to be hydro-
lyzed during skin absorption to show antioxidant activity. For 
instance, bioconversion of vitamin E acetate into α-tocopherol, 
its  active  antioxidant  form,  seems  slow  and  occurs  only  to 
some  extent.  There  is  evidence  that  vitamin  E  acetate  is  not 
hydrolyzed in the stratum corneum and that its bioconversion 
into α-tocopherol only occurs after penetration into the nucle-
ated epidermis (37). Consequently, the controversial observa-
tions  of  photoprotective  effects  of  topically  applied  vitamin 
E acetate may be explained by a limited bioavailability of the 
active, ester-cleaved form during oxidative stress at the site of 
action. Intriguingly, the bioconversion of vitamin E acetate into 
its active form can be enhanced when skin is exposed to sun, 
possibly by an UVB dependent increase in esterase activity as 
demonstrated in murine epidermis (38).

Vitamin C
Several studies investigated the photoprotective effects of topi-
cal vitamin C (L-ascorbic acid). Using a porcine skin model, top-
ically applied vitamin C protects from UVB-induced erythema 

ANTIOXIDANTS 

  83

and sunburn cell formation when formulated at higher concen-
trations (e.g., 15%) in an appropriate vehicle at low pH (e.g., pH 
3.2) (39,40). In a human study, however, a hydroalcoholic lotion 
with 5% vitamin C was unable to induce any significant photo-
protective effects when applied once 30 minutes before irradia-
tion at a dose of 2mg/cm2 (35). Besides differences between pig 
and human skin responses, differences in vitamin C concen-
tration, mode of application including applied dose and vehi-
cle composition, as well as other experimental parameters may 
explain this difference in the reported photoprotective efficacy 
of the vitamin C formulations.

The  development  of  a  stable  formulation  containing 
vitamin  C  is  challenging  since  vitamin  C  is  easily  oxidized. 
Vitamin  C  can  be  stabilized  in  an  aqueous  formulation  at 
low  pH  when  kept  under  oxygen  exclusion  (41).  Newly,  spe-
cial  water-free,  silicon-based  preparations  allow  stabilizing 
vitamin C over a prolonged period of time (42). Additionally, 
esterified vitamin C derivatives such as magnesium or sodium 
ascorbyl phosphate, aminopropyl ascorbyl phosphate, and tet-
rahexyldecyl ascorbate (tetra-isopalmitate ascorbate) are stable 
alternatives  to  vitamin  C  (43,44).  However,  as  described  for 
vitamin E esters, these esters must be hydrolyzed to vitamin C 
to reveal antioxidant properties. This will take time and may 
occur  only  to  a  limited  extent.  Furthermore,  some  of  those 
derivatives (e.g., tetrahexyldecyl ascorbate) are of significantly 
higher  molecular  weight  as  compared  to  vitamin  C,  that  can 
lower their skin permeability and consequently also their anti-
oxidant efficacy after topical application.

Vitamin C does not act as sunscreen, nor does it absorb 
UVA. In addition to its antioxidant properties, vitamin C par-
ticipates in the formation of collagen fibers as a cofactor of pro-
lyl and lysyl hydroxylase, enzymes essential for the stabilizing 
and cross-linking of newly synthesized collagen molecules. A 
human placebo-controlled study demonstrated that the use of 
a 5% vitamin C cream resulted in significantly improved skin 
relief and a decrease in deep furrows after 6 months of use (45).

Polyphenols
Compounds from dietary and medical plants and vegetables 
have  gained  considerable  attention  as  promising  agents  in 
protecting skin from UVR-induced photodamage after topical 
application (46–49). Extracts from green tea, wine grapes, cof-
fee  berry,  feverfew,  milk  thistle,  pomegranate,  tropical  ferns, 
and  turmeric  were  particularly  well  studied.  They  contain  a 
wide  variety  of  polyphenols  known  as  flavonoids,  which  are 
divided into flavonols, flavones, catechins, flavanones, antho-
cyanidins, and isoflavonoids. They are synthesized conjointly 
with ascorbic acid, vitamin E, and GSH by plants as a response 
to mitigate cellular damage under oxidative conditions. Their 
antioxidant  properties  arise  from  their  high  reactivity  as 
hydrogen or electron donors, from the ability of the polyphe-
nol-derived radical to stabilize the unpaired electron, as well 
as  from  their  ability  to  chelate  transition  metal  ions  such  as 
Fe(II),  thereby  interfering  with  hydroxyl  radical  production. 
Besides hydroxyl radicals, polyphenols are believed to quench 
singlet  oxygen,  superoxide  anion  radicals,  and  peroxyl  radi-
cals. Polyphenolic compounds also possess anti-inflammatory 
and other properties beneficial for skin.

Green tea (Camellia sinensis) extracts are the best studied 
plant-derived antioxidants for skin (50). In contrast to black tea, 
which is fermented, green tea leaves contain a high concentra-
tions of polyphenols such as epigallocatechin gallate (EGCG). 
Green tea polyphenols act as antioxidants by scavenging ROS/

 
84 

 TEXTBOOK OF COSMETIC DERMATOLOGY

RNS, by sequestering metal ions, and act indirectly as antioxi-
dants  through  inhibition  of  “pro-oxidant”  enzymes  such  as 
inducible  nitric  oxide  synthase,  lipoxygenases,  and  cycloxy-
genases, and further induce the antioxidant enzymes GSH-S-
transferases and SOD (51). Protective effects of green tea extract 
and its major polyphenolic constituent EGCG on UVR-induced 
skin  damage  after  topical  application  were  first  observed  in 
animals  (50).  These  effects  were  later  confirmed  in  humans, 
where  topical  application  of  green  tea  extracts  or  EGCG  sig-
nificantly  decreased  erythema  responses,  lipid  peroxidation, 
and DNA damage (52,53). More recently, a placebo-controlled 
study demonstrated that the combined use of a 10% green tea 
cream and oral green tea supplementation for 8 weeks resulted 
in  a  significant  improvement  in  elastic  tissue  (54).  A  trend 
toward improvement but no significant differences in clinical 
grading  were  found  between  the  green  tea–treated  and  the 
placebo group, indicating that a longer treatment period may 
be  required  for  clinically  relevant  improvements.  In  another 
placebo-controlled study, topical application of a green tea pro-
tected human skin from solar-simulated ultraviolet light when 
applied 15 minutes prior to exposure and reapplied immedi-
ately  after  exposure  to  two  minimum  erythema  doses  (55). 
A  further  study  showed  that  three-time  daily  use  of  a  lotion 
containing  0.4%  of  a  green  tea  extract  with  40%  to  50%  total 
polyphenol content helped to reduce UVB-mediated increase 
in sunburn cell formation and p53 expression in keratinocytes, 
but did not reduce erythema or formation of thymidine dimers 
(56). This study indicated that formulations with relatively low 
concentrations of green tea extracts can be sufficient for pro-
viding  photoprotection.  Green  tea  extracts  and  EGCG  were 
further shown to have chemopreventive effects in rodents, and 
limit cancer formation. However, epidemiological studies with 
green tea are so far not conclusive (50,57).

Numerous  other  polyphenols  have  also  been  studied. 
For  instance,  a  milk  thistle  extract  containing  silibinin  as 
predominant polyphenol was shown to inhibit UVB-induced 
immunosuppression,  reduce  UVB-induced  sunburn  cell  for-
mation, prevent DNA adduct formation, and prevent photocar-
cinogenesis after topical application in mice (58,59). In another 
study, topical administration of genistein substantially inhib-
ited UVR-induced hydrogen peroxide formation, lipid peroxi-
dation, and DNA damage in mice, and protected human skin 
against  UVB-induced  erythema  (60).  Furthermore,  topical 
application of a tropical fern extract reduced erythema when 
applied  before  UVR  exposure  as  shown  in  humans  (61).  In  a 
clinical study, 1% coffee berry extract (containing diverse (poly)
phenolic  compounds  including  chlorogenic  acid,  quinic  acid, 
and ferulic acid) resulted in a significant improvement in signs 
of  skin  aging  when  compared  to  vehicle  (62).  Pomegranate 
fruit extract, comprising the polyphenol ellagic acid, possesses 
strong antioxidant and anti-inflammatory properties, and lim-
ited  UVB-mediated  damage  in  a  human  reconstituted  skin 
model  (63).  Another  natural  extract,  a  parthenolide-depleted 
extract  of  feverfew,  significantly  reduced  UV-induced  ery-
thema in humans (64).

Additional  studies  are  warranted  to  further  clarify 
whether  the  observed  beneficial  effects  of  those  extracts  or 
their constituents cannot be at least partially attributed to their 
potential sun-screening properties after topical application.

Thiol Antioxidants
Thiol antioxidants, such as GSH, N-acetylcysteine, lipoic acid, 
and  their  derivatives  are  another  important  group  of  radical 
scavengers  (1,2).  Topical  administration  of  GSH,  GSH-ethyl 

ester,  and  N-acetylcysteine,  respectively,  efficiently  protected 
against UVB radiation–induced epidermal lipid peroxidation, 
cytotoxicity,  and  apoptosis  using  pig  skin  ex  vivo  as  a  skin 
model  (65).  However,  their  photoprotective  effects  have  been 
reported in only a few clinical studies. Topical treatment with 
N-acetylcysteine  under  occlusion  resulted  in  an  increased 
GSH level and eliminated its oxidized form (GSSG) in humans 
(66).  Thus,  the  additional  stimulation  of  GSH  biosynthesis 
might be a key mechanism accounting for the observed photo-
protective  effects  of  N-acetylcysteine.  Dihydrolipoic  acid,  the 
reduced and primarily active antioxidant form of α-lipoic acid, 
is another promising thiol antioxidant (67).

Other Antioxidants
The  pineal  hormone  melatonin  has  antioxidant  properties.  It 
has been shown to significantly reduce UVR-induced erythema 
in  humans,  although  its  potential  sunscreening  properties 
as  well  as  its  immunomodulatory  function  may  have  contrib-
uted  to  the  observed  photoprotective  effects  (35).  In  addition, 
L-ergothioneine,  a  thiourea  derivative  of  histidine  found  in 
food plants and mushrooms, is another potent antioxidant suit-
able for topical application (68). Idebenone, a synthetic analogue 
of  coenzyme  Q,  is  another  interesting  agent  with  antioxidant 
properties  (69).  Whereas  a  clinical  study  with  a  1%  idebenone 
formulation  demonstrated  a  reduction  in  wrinkles  in  females 
with moderate photodamage (70), a study in pigs revealed that 
idebenone seems to offer little to no photoprotective effects (71).

Antioxidant Combinations
Antioxidants  interact  when  combined  and  emanating  radi-
cal or oxidized forms of antioxidants after ROS scavenging 
may  be  quickly  regenerated  in  the  presence  of  appropriate 
co-antioxidants.  Accordingly,  an  enhanced  photoprotective 
effect  may  be  obtained  by  applying  distinct  combinations 
of  antioxidants.  Ample  evidence  exists  about  the  interac-
tive dependence of vitamins C and E in diminishing photo-
damage. A single topical application of a combination of 2% 
vitamin E and 5% vitamin C resulted in a significantly more 
pronounced photoprotective effect as compared to the appli-
cation of either antioxidant alone in the identical vehicle (35). 
As  demonstrated  in  the  same  clinical  study,  the  most  dra-
matic improvement resulted from the combination of mela-
tonin with α-tocopherol and ascorbic acid. Other mixtures of 
topically  applied  antioxidants  were  also  shown  to  be  more 
effective in reducing photodamage than single antioxidants. 
Adding  0.5%  ferulic  acid  (a  phenolic  antioxidant  found  in 
plants)  to  a  solution  of  1%  α-tocopherol  and  15%  ascorbic 
acid  doubled  photoprotection  to  solar-simulated  irradia-
tion as measured by both erythema and sunburn cell forma-
tion  in  pigs  (72).  Another  combination  consisting  of  ferulic 
acid  with  tocopheryl  acetate  and  α-glycosylrutin  limited 
the severity of experimentally induced polymorphous light 
eruptions  when  applied  1  week  prior  to  photoprovocation 
with  UVA  in  humans  (73).  However,  since  ferulic  acid  sig-
nificantly  absorbs  in  the  UVB/A-range,  the  photoprotection 
observed in those studies can likely not be attributed solely 
to  its  antioxidant  properties  (74).  A  significantly  enhanced 
antioxidative efficacy was also found for the combination of 
α-tocopherol,  ascorbic  acid,  and  green  tea  polyphenols  (75). 
Studies revealed that the antioxidant synergism of this com-
bination might be due to the regeneration of α-tocopherol by 
the  green  tea  polyphenols,  while  the  latter  are  regenerated 
by ascorbic acid.

 
Using  an  electron  spin  resonance  spectroscopy–based 
antioxidant  assay  (see  next  paragraph),  a  novel  silicon-oil 
based  preparation  comprising  15%  L-ascorbic  acid  and  1% 
α-tocopherol  combined  with  EGCG,  the  synthetic  vitamin 
E  analogue  dimethylmethoxy  chromanol,  and  creatine  was 
shown  to  be  significantly  more  effective  in  neutralizing  free 
radicals  in  vitro  as  compared  to  a  solution  of  15%  L-ascorbic 
acid, 1% α-tocopherol, and 0.5% ferulic acid (76).

EVALUATING ANTIOXIDANTS
How to determine the capacity of antioxidants or antioxidant 
combinations  to  eliminate  ROS/RNS  is  an  important  ques-
tion when studying antioxidants. Accurate quantification of 
antioxidant capacity is, however, challenging (77). Currently, 
there  is  no  single  assay  available  that  can  sufficiently  meet 
this  task.  Oxygen  radical  absorbance  capacity  (ORAC)  is  a 
frequently used antioxidant assay to determine the strength 
of antioxidants in skin care products. The assay uses a fluo-
rescence probe that is susceptible to oxidation by free radi-
cals. Despite being widely used, this method has significant 
limitations.  In  contrast  to  ORAC  and  other  assays,  electron 
spin  resonance  (ESR)  spectroscopy  based  assays  have  sev-
eral  important  advantages  (77,78).  For  instance,  ESR  allows 
directly  detecting  and  quantifying  free  radicals.  ORAC 
requires  the  addition  of  a  fluorescent  probe  and  therefore 
quantifies radicals only indirectly (similarly to other decol-
orization assays). ESR methods therefore provide more accu-
rate  measures  of  the  antioxidant  capacity  of  antioxidants 
or  antioxidant-containing  formulations.  In  addition,  only 
ESR  methods  can  be  accurately  performed  with  colored  or 
opaque formulations and in skin (77,78).

CONCLUDING COMMENTS
Animal and human studies have convincingly demonstrated 
that  topical  antioxidants  can  limit  UV-induced  skin  damage. 
In humans, the protective effects were well demonstrated for 
ascorbic acid, tocopherol, ferulic acid, and a few natural poly-
phenolic  antioxidant  mixtures  including  green  tea  extract, 
which is rich in EGCG. The efficacy of those antioxidants can 
be significantly increased when they are combined.

However,  formulating  products  with  antioxidants  is 
not  simple  and  a  number  of  technical  requirements  must  be 
fulfilled for an efficient product. First, antioxidants should be 
present  in  a  product  at  high  concentrations.  Second,  antioxi-
dants need to be kept stable in the formulation. Third, antioxi-
dants should be able to penetrate into and through the stratum 
corneum to provide adequate concentrations in lower skin lay-
ers  for  biologically  relevant  antioxidant  effects.  Furthermore, 
efficacy  determination  of  antioxidant  products  should  be 
preferentially based on clinical data and ESR-based methods 
because most other tests, including ORAC, provide only lim-
ited and possibly inaccurate information.

Since sunlight-induced skin damage occurs also through 
nonoxidative  mechanisms,  antioxidant  supplementation  will 
not provide complete photoprotection. In fact, photoprotective 
effects  of  antioxidants  are  relatively  modest  as  compared  to 
broadband  sunscreens.  Therefore,  sunscreens  are  indispens-
able  in  the  effective  prevention  of  skin  photodamage,  while 
the antioxidants will provide additional benefits to sunscreen 
products (79,80).

Finally, it is important to keep in mind that antioxidants 
are of protective nature (i.e., from oxidative stress) and gener-
ally have no effect in reversing existing skin damage, including 

ANTIOXIDANTS 

  85

wrinkles.  Only  agents  which  promote  collagen,  elastin,  and 
hyaluronic acid formation such as retinoic acid, human growth 
factors, and a few distinct peptides, have been shown to help 
reverse the signs of skin aging.

REFERENCES

1. Thiele  JJ,  Dreher  F,  Packer  L.  Antioxidant  defense  systems  in 
skin.  In:  Elsner  P,  Maibach  HI,  eds,  Cosmeceuticals—Drugs  vs. 
Cosmetics. New York: Dekker 2000;145–87.

2. Thiele J, Elsner P. Oxidants and antioxidants in cutaneous biol-
ogy. In: Burg G, ed. Current Problems in Dermatology. Volume 29. 
Basel: Karger, 2001.

3.  Krutmann  J,  Schroeder  P:  Role  of  mitochondria  in  photoag-
ing  of  human  skin:  The  defective  powerhouse  model.  J  Invest 
Dermatol Symp Proc 2009; 14:44–9.

4.  Berneburg M, Gattermann N, Stege H, et al. Chronically ultra-
violet-exposed human skin shows a higher mutation frequency 
of mitochondrial DNA as compared to unexposed skin and the 
hematopoietic system. Photochem Photobiol 1997; 66:271–5.

5.  Lenaz G. Role of mitochondria in oxidative stress and ageing. 

Biochim Biophys Acta 1998; 1366:53–67.

6.  DiMauro S, Tanji K, Bonilla E, et al. Mitochondrial abnormali-
ties in muscle and other aging cells: Classification, causes, and 
effects. Muscle Nerve 2002; 26:597–607.

7.  Jacobs HT. The mitochondrial theory of aging: Dead or alive? 

Aging Cell (2003; 2:11–17.

8.  Pak JW, Herbst A, Bua E, et al. Rebuttal to Jacobs: The mitochon-
drial theory of aging: Alive and well. Aging Cell 2003; 2:9–10.
9.  Berneburg M, Gremmel T, Kürten V, et al. Creatine supplemen-
tation normalizes mutagenesis of mitochondrial DNA as well 
as functional consequences. J Invest Dermatol 2005; 125:213–20.

  10.  Shindo  Y,  Witt  E,  Han  D,  et  al.  Enzymic  and  non-enzymic 
antioxidants in epidermis and dermis of human skin.  J  Invest 
Dermatol 1994; 102:122–4.

  11.  Schallreuter  KU,  Wood  JM.  Thioredoxin  reductase  –  its 
role  in  epidermal  redox  status.  J  Photochem  Photobiol  B  2001; 
64:179–84.

  12.  Taungjaruwinai  WM,  Bhawan  J,  Keady  M,  et  al.  Differential 
expression  of  the  antioxidant  repair  enzyme  methionine 
sulfoxide  reductase  (MSRA  and  MSRB)  in  human  skin.  Am  J 
Dermatopathol 2009; 31:427–31.

  13.  Weber  SU,  Thiele  JJ,  Cross  CE,  et  al.  Vitamin  C,  uric  acid 
and  glutathione  gradients  in  murine  stratum  corneum  and 
their  susceptibility  to  ozone  exposure.  J  Invest  Dermatol  1999; 
113:1128–32.

  14.  Thiele  JJ,  Traber  MG,  Packer  L.  Depletion  of  human  stratum 
corneum  vitamin  E:  An  early  and  sensitive  in  vivo  marker  of 
UV-induced photooxidation. J Invest Dermatol 1998; 110:756–61.
  15.  Sander  CS,  Chang  H,  Salzmann  S,  et  al.  Photoaging  is  asso-
ciated  with  protein  oxidation  in  human  skin  in  vivo.  J  Invest 
Dermatol 2002; 118:618–25.

  16.  Hellemans L, Corstjens H, Neven A, et al. Antioxidant enzyme 
activity  in  human  stratum  corneum  shows  seasonal  varia-
tion  with  an  age-dependent  recovery.  J  Invest  Dermatol  2003; 
120:434–9.

17. Steiling H, Longet K, Moodycliffe A, et al. Sodium-dependent 
vitamin C transporter isoforms in skin: Distribution, kinetics, 
and effect of UVB-induced oxidative stress. Free Radic Biol Med 
2007; 43:752–62.

18. Thiele  JJ,  Weber  SU,  Packer  L.  Sebaceous  gland  secretion  is  a 
major physiological route of vitamin E delivery to skin. J Invest 
Dermatol 1999; 113:1006–10.

19. Darvin ME, Fluhr JW, Caspers P, et al. In vivo distribution of 
carotenoids  in  different  anatomical  locations  of  human  skin: 
Comparative  assessment  with  two  different  Raman  spectros-
copy methods. Exp Dermatol 2009; 18:1060–3.

  20.  Ekanayake  Mudiyanselage  S,  Hamburger  M,  Elsner  P,  et  al. 
Ultraviolet A induces generation of squalene. J Invest Dermatol 
2003; 120:915–22.

 
 
 
 
 
 
 
 
86 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  21.  Davidson JM, LuValle PA, Zoia O, et al. Ascorbate differentially 
regulates elastin and collagen biosynthesis in vascular smooth 
muscle  cells  and  skin  fibroblasts  by  pretranslational  mecha-
nisms. J Biol Chem 1997; 272:345–52.

  22.  Ponec  M,  Weerheim  A,  Kempenmaar  J,  et  al.  The  formation 
of  competent  barrier  lipids  in  reconstructed  human  epider-
mis requires the presence of vitamin C. J Invest Dermatol 1997; 
109:348–55.

  23.  Podda  M,  Traber  MG,  Weber  C,  et  al.  UV-irradiation  depletes 
antioxidants and causes oxidative damage in a model of human 
skin. Free Radic Biol Med 1998; 24:55–65.

  24.  Shindo  Y,  Witt  E,  Han  D,  et  al.  Recovery  of  antioxidants  and 
reduction  in  lipid  hydroperoxides  in  murine  epidermis  and 
dermis after acute ultraviolet radiation exposure. Photodermatol 
Photoimmunol Photomed 1994; 10:183–91.

  25.  Connor MJ, Wheeler LA. Depletion of cutaneous glutathione by 
ultraviolet radiation. Photochem Photobiol 1987; 46:239–45.
  26.  Shindo Y, Witt E, Packer L, et al. Antioxidant defense mecha-
nisms in murine epidermis and dermis and their responses to 
ultraviolet light. J Invest Dermatol 1993; 100:260–5.

  27.  Shindo Y, Witt E, Han D, et al. Dose-response effects of acute 
ultraviolet irradiation on ultraviolet irradiation on antioxidants 
and molecular markers of oxidation in murine epidermis and 
dermis. J Invest Dermatol 1994; 102:470–5.

  28.  Thiele  JJ,  Dreher  F,  Maibach  HI,  et  al.  Impact  of  ultraviolet 
radiation and ozone on transepidermal water loss as a function 
of skin temperature in hairless mice. Skin Pharmacol Appl Skin 
Physiol 2003; 16(5):283–90.

  29.  Rhie  G,  Shin  MH,  Seo  JY,  et  al.  Aging-  and  photoaging- 
dependent changes of enzymic and nonenzymic antioxidants 
in the epidermis and dermis of human skin in vivo. J Invest 
Dermatol 2001; 117:1212–7.

  30.  Pinnell SR. Cutaneous photodamage, oxidative stress, and topi-

cal antioxidant protection. J Am Acad Dermatol 2003; 48:1–19.

  31.  Fuchs J. Potentials and limitations of the natural antioxidants 
RRR-α-tocopherol, L-ascorbic acid and β-carotene in cutaneous 
photoprotection. Free Radic Biol Med 1998; 25:848–73.

  32.  Boelsma E, Hendriks HFJ, Roza L. Nutritional skin care: Health 
effects of micronutrients and fatty acids.  Am J Clin Nutr 2001; 
73:853–64.

  33.  Bialy TL, Rothe MJ, Grant-Kels JM. Dietary factors in the pre-
vention and treatment of nonmelanoma skin cancer and mela-
noma. Dermatol Surg 2002; 28:1143–52.

  43.  Stamford  NP.  Stability,  transdermal  penetration,  and  cutane-
ous effects of ascorbic acid and its derivatives. J Cosmet Dermatol 
2012; 11:310–17. 

  44.  Farris PK. Topical vitamin C: A useful agent for treating pho-
toaging and other dermatologic conditions. Dermatol Surg 2005; 
31:814–17.

  45.  Humbert  PG,  Haftek  M,  Creidi  P,  et  al.  Topical  ascorbic  acid 
on photoaged skin. Clinical, topographical and ultrastructural 
evaluation: Double-blind study vs. placebo. Exp Dermatol 2003; 
12:237–44.

  46.  Afaq F, Mukhtar H. Photochemoprevention by botanical anti-
oxidants. Skin Pharmacol Appl Skin Physiol 2002; 15:297–306.
  47.  Berson  DS.  Natural  antioxidants.  J  Drugs  Dermatol  2008;  7(7 

suppl):s7–s12.

  48.  Baumann  L,  Woolery-Lloyd  H,  Friedman  A.  “Natural”  ingre-
dients  in  cosmetic  dermatology.  J  Drugs  Dermatol  2009;  8(6 
suppl):s5–s9.

  49.  Ditre C, Wu J, Baumann LS, et al. Innovations in natural antioxi-
dants and their role in dermatology. Cutis 2008; 82(6 suppl):2–16.
  50.  Hsu  S.  Green  tea  and  the  skin.  J  Am  Acad  Dermatol  2005; 

52:1049–59.

  51.  Frei  B,  Higdon  JV.  Antioxidant  activity  of  tea  polyphe-
nols  in  vivo:  Evidence  from  animal  studies.  J  Nutr  2003; 
133:3275S–84S.

  52.  Katiyar  SK,  Afaq  F,  Perez  A,  et  al.  Green  tea  polyphenol 
(-)- epigallocatechin-3-gallate treatment of human skin inhibits 
ultraviolet  radiation-induced  oxidative  stress.  Carcinogenesis 
2001; 22:287–94.

  53.  Elmets CA, Singh D, Tubesing K, et al. Cutaneous photoprotec-
tion from ultraviolet injury by green tea polyphenols. J Am Acad 
Dermatol 2001; 44:425–32.

  54.  Chiu  AE,  Chan  JL,  Kern  DF,  et  al.  Double-blinded,  placebo-
controlled  trial  of  green  tea  extracts  in  the  clinical  and  his-
tologic  appearance  of  photoaging  skin.  Dermatol  Surg  2005; 
3:855–60.

  55.  Camouse MM, Domingo DS, Swain FR, et al. Topical applica-
tion of green and white tea extracts provides protection from 
solarsimulated  ultraviolet  light  in  human  skin.  Exp  Dermatol 
2009; 18:522–6.

  56.  Mnich CD, Hoek KS, Virkki LV, et al. Green tea extract reduces 
induction of p53 and apoptosis in UVB-irradiated human skin 
independent  of  transcriptional  controls.  Exp  Dermatol  2009; 
18:69–77.

  34.  Thiele  JJ,  Ekanayake-Mudiyanselage  S.  Vitamin  E  in  human 
skin: Organ-specific physiology and considerations for its use 
in dermatology. Mol Aspects Med 2007; 28:646–67.

  57.  Boehm K, Borrelli F, Ernst E, et al. Green tea (Camellia sinensis) 
for  the  prevention  of  cancer.  Cochrane  Database  Syst  Rev  2009; 
8(3):CD005004.

  35.  Dreher  F,  Gabard  B,  Schwindt  DA,  et  al.  Topical  melatonin  in 
combination  with  vitamins  E  and  C  protects  skin  from  with 
vitamins E and C protects skin from UV-induced erythema: A 
human study in vivo. Br J Dermatol 1998; 139:332–9. 

  36.  Kramer KA, Liebler DC. UVB induced photooxidation of vita-

  58.  Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin 

cancer. Antioxid Redox Signal 2002; 4:655–63.

  59.  Saller  R,  Melzer  J,  Reichling  J,  et  al.  An  updated  systematic 
review of the pharmacology of silymarin. Forsch Komplementmed 
2007; 14:70–80.

min E. Chem Res Toxicol 1997; 10:219–24.

  37.  Baschong W, Artmann C, Hueglin D, et al. Direct evidence for 
bioconversion of vitamin E acetate into vitamin E: An ex vivo 
study in viable human skin. J Cosmet Sci 2001; 52:155–61.
  38.  Kramer-Stickland KA, Liebler DC. Effect of UVB on hydrolysis 
of α-tocopherol acetate to α-tocopherol in mouse skin. J Invest 
Dermatol 1998; 111:302–7.

  39.  Darr D, Combs S, Dunston S, et al. Topical vitamin C protects 
porcine  skin  from  ultraviolet  radiation-induced  damage.  Br  J 
Dermatol 1992; 127:247–53.

  40.  Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combi-
nation topical antioxidants vitamin C and vitamin E. J Am Acad 
Dermatol 2003; 48:866–74.

  60.  Wei H, Saladi R, Lu Y, et al. Isoflavone genistein: Photoprotection 
in  dermatology.  J  Nutr  2003; 

implications 

and  clinical 
133:3811S–19S.

  61.  Gonzàlez S, Pathak MA, Cuevas J, et al. Topical or oral admin-
istration  with  an  extract  of  Polypodium  leucotomos  prevents 
acute  sunburn  and  psoralen-induced  phototoxic  reactions 
as  well  as  depletion  of  Langerhans  cells.  Photodermatol 
Photoimmunol Photomed 1997; 13:50–60.

  62.  Farris P. Idebenone, green tea, and Coffeeberry® extract: New 
and innovative antioxidants. Dermatol Ther 2007; 20:322–9.
  63.  Afaq F, Zaid MA, Khan N, et al. Protective effect of pomegran-
ate  derived  products  on  UVB-mediated  damage  in  human 
reconstituted skin. Exp Dermatol 2009; 18:553–61.

  41.  Gallarate  M,  Carlotti  ME,  Trotta  M,  et  al.  On  the  stability  of 
ascorbic  acid  in  emulsified  systems  for  topical  and  cosmetic 
use. Int J Pharm 1999; 188:233–41.

  64.  Martin K, Sur R, Liebel F, et al. Parthenolide-depleted Feverfew 
(Tanacetum  parthenium)  protects  skin  from  UV  irradiation 
and external aggression. Arch Dermatol Res 2008; 300:69–80.

  42.  Topical  cosmetic  composition  containing  hybrid  silicone 
composite  powder.  United  States  Patent  Application  U.S. 
2005-0112072.

  65.  Rijnkels JM, Moison RMW, Podda E, et al. Photoprotection by 
antioxidants  against  UVB-radiation-induced  damage  in  pig 
skin organ culture. Radiat Res 2003; 159:210–17.

 
ANTIOXIDANTS 

  87

  66.  Kang S, Chung JH, Lee JH, et al. Topical N-acetyl cysteine and 
genistein prevent ultraviolet-light-induced signaling that leads 
to  photoaging  in  human  skin  in  vivo.  J  Invest  Dermatol  2003; 
120:835–41.

  67.  Beitner H. Randomized, placebo-controlled, double blind study 
on the clinical efficacy of a cream containing 5% alpha-lipoic acid 
related to photoageing of facial skin. Br J Dermatol 2003; 149:841–9.
  68.  Dong  KK,  Damaghi  N,  Kibitel  J,  et  al.  A  comparison  of 
the  relative  antioxidant  potency  of  L-ergothioneine  and 
idebenone. J Cosmet Dermatol 2007; 6:183–8.

  69.  McDaniel DH, Neudecker BA, Dinardo JC, et al. Idebenone: A 
new antioxidant - part I. Relative assessment of oxidative stress 
protection  capacity  compared  to  commonly  known  antioxi-
dants. J Cosmet Dermatol 2005; 4:10–17.

  70.  McDaniel  D,  Neudecker  B,  Dinardo  J,  et  al.  Clinical  efficacy 
assessment in photodamaged skin of 0.5% and 1% idebenone. 
J Cosmet Dermatol 2005; 4:167–73.

  71.  Tournas  JA,  Lin  FH,  Burch  JA,  et  al.  Ubiquinone,  idebenone, 
and  kinetin  provide  ineffective  photoprotection  to  skin  when 
compared  to  a  topical  antioxidant  combination  of  vitamins  C 
and E with ferulic acid. J Invest Dermatol 2006; 126:1185–7.
  72.  Lin FH, Lin JY, Gupta RD, et al. Ferulic acid stabilizes a solution 
of  vitamins  C  and  E  and  doubles  its  photoprotection  of  skin. 
J Invest Dermatol 2005; 125:826–32.

  73.  Hadshiew I, Stäb F, Untiedt S, et al. Effects of topically applied 
antioxidants  in  experimentally  provoked  polymorphous  light 
eruption. Dermatology 1997; 195:362–8.

  74.  Graf E. Antioxidant potential of ferulic acid. Free Radic Biol Med 

1992; 13:435–48.

  75.  Dai  F,  Chen  WF,  Zhou  B.  Antioxidant  synergism  of  green  tea 
polyphenols  with  α-tocopherol  and  L-ascorbic  acid  in  SDS 
micelles. Biochemie 2008; 90:1499–1505.

  76.  Dreher  F,  Olansky  A,  Thiele  J.  Novel  antioxidant  serum  with 
high  antioxidant  capacity  -  an  ESR-based  study.  Poster  8132. 
American Academy of Dermatology - Annual Meeting, Denver 
2014.

  77.  Chen LL, Wang SQ. From the bottle to the skin: Challenges in 
evaluating  antioxidants.  Photodermatol  Photoimmunol  Photomed 
2012; 28:228–34. 

  78.  Herrling  T,  Jung  K.  The  Radical  Status  Factor  (RSF):  A  novel 
metric  to  characterize  skin  products.  Int  J  Cosmet  Sci  2012; 
34:285–90.

  79.  Darr D, Dunston S, Faust H, et al. Effectiveness of antioxidants 
(vitamin C and E) with and without sunscreens as topical pho-
toprotectants. Acta Derm Venereol 1996; 76:264–8.

  80.  Matsui  MS,  Hsia  A,  Miller  JD,  et  al.  Non-sunscreen  photo-
protection:  Antioxidants  add  value  to  a  sunscreen.  J  Investig 
Dermatol Symp Proc 2009; 14:56–9.

 
10

Topical Retinol: An Efficacious Solution for 
Improvement of Main Photodamage Signs

Christiane Bertin and Thierry Oddos

INTRODUCTION
Clinically,  skin  aging  is  associated  with  a  variety  of  signs 
such as wrinkles, uneven pigmentation, skin roughness, skin 
color and laxity. These clinical features are consecutive to the 
structural  and  metabolic  changes  that  occur  during  the  pas-
sage  of  time  (chronological  aging).  However,  external  factors 
such as repeated skin exposure to solar ultraviolet (UV) radia-
tion  can  induce  premature  or  photoaging  of  the  skin.  These 
changes  are  consecutive  to  a  decrease  in  fibroblast  number 
as  well  as  collagen  synthesis  and  an  increase  in  UV-induced 
collagen  degradation  by  matrix  metalloproteinases  (MMPs). 
An accumulation of non-functional elastin is also observed in 
the dermis, leading to a loss of skin elasticity and firmness. In 
addition, a constant hallmark of skin aging and photoaging is 
epidermal thinning, which is triggered by a decrease in kera-
tinocyte  turnover  rate  (1).  Photoaging  is  also  associated  with 
a  dysregulation  in  melanin  synthesis  and  distribution  and  a 
general increase in the inflammatory status of the skin leading 
to the appearance of brown spots, a global increase in skin red-
ness, and telangectasia.

Retinoids have shown beneficial effects in reducing skin 
photoaging.  For  instance,  it  has  been  demonstrated  that  all-
trans  retinoic  acid  (ATRA)  improves  skin  photoaging  signs 
(2). This clinical efficacy was mainly attributed to the effect of 
ATRA  on  collagen  metabolism  by  stimulation  of  the  collagen 
synthesis that ultimately accumulates in the upper part of the 
papillary dermis. Moreover ATRA downregulates UV-induced 
MMP1 and MMP9 expression (3), thereby replenishing collagen 
levels. Although ATRA is recognized as an effective therapy for 
the treatment of photoaged skin through its regulatory effect on 
collagen metabolism, it has been suggested that retinol (ROL), 
known  as  vitamin  A,  may  also  alleviate  some  major  signs  of 
photoaging with a better irritation profile.

Retinoids  are  all  derived  from  the  naturally  occurring 
all-trans  retinol.  This  molecule  is  composed  of  15  carbons. 
Three  parts  of  the  molecule  can  be  distinguished:  a  cyclic 
group,  a  polyene  group,  and  a  polar  group  (primary  alcohol 
for  retinol  –CH2OH,  and  aldehyde  –CHO  for  retinaldehyde 
and  a  carboxylic  function  –COOH  for  retinoic  acid,  the  two 
latter compounds being obtained from the previous by oxida-
tion [Figure 10.1]). Natural isomers carrying specific biological 
activities have also been described as 11-cis retinaldehyde and 
9-cis retinoic acid.

Metabolism of Retinol
Diet  is  the  normal  source  of  retinol  in  the  body.  It  origi-
nates  from  carotenoids  in  plants  and  of  the  long-chain  fatty 
acid  esters  of  retinol  (as  retinyl  palmitate)  in  animal  tissue. 
Carotenoids are split, in the intestine epithelium, in the middle 

of  the  molecule  to  form  retinal,  which  is  in  turn  reduced  to 
retinol and esterified into retinyl ester. Retinyl esters are trans-
ported and stored in the liver, which is the main storage site in 
the body. The retinol is then delivered in the bloodstream asso-
ciated with a specific transporter, the retinol-binding protein 
(RBP). In normal conditions, most of the circulating retinol is 
associated with RBP and the level of retinol in healthy volun-
teers fluctuates above 30 µg/mL (4).

In  the  skin,  at  the  keratinocyte  level,  retinol  uptake  is 
mediated through the binding of RBP-retinol complex to spe-
cific receptor(s), such as the 61 Kd RPE protein (retinal pigment 
epithelium protein) and internalization (5,6,7).

In keratinocytes, retinol is stored in the form of retinyl 
esters  (i.e.,  mainly  palmitate,  oleate,  and  acetate  esters)  (8,9) 
primarily through the action of lecithin-retinolacyl transferase 
(10).  It  is  then  oxidized  into  retinal  and  retinoic  acid  by  dif-
ferent alcohol dehydrogenases (11). Two other proteins respon-
sible for retinol transportation play an important role in retinol 
metabolism.  The  first  is  the  cellular  retinol-binding  protein 
(CRBP), which shows a high affinity for all-trans retinol. The 
second  is  the  cellular  retinoic  acid  binding  proteins  (CRABP 
I  and  CRABP  II)  that  bind  specifically  retinoic  acid.  In  skin, 
CRABPII is the predominant retinoic acid binding protein and 
its expression is enhanced by keratinocyte differentiation and 
treatment with retinoids. The role of these proteins is not com-
pletely clarified. CRBP could play a role in presenting the reti-
nol in the adequate conformation to the dehydrogenase. They 
are  also  believed  to  control  the  level  of  free  retinol  and  free 
retinoic  acid  and  the  translocation  of  these  two  molecules  in 
specific cellular compartments such as translocation of retinoic 
acid in the nucleus for CRABPII (12).

Biological Effect on Skin Including 
on Different Cell Types
Retinol plays a major role in the skin, as it is essential for regu-
lating  keratinocyte  differentiation  as  suggested  by  the  early 
observation of abnormal keratinization in vitamin A–deficient 
rats  (13)  and  humans  (14).  Topically,  retinol  stimulates  the 
proliferation  of  the  basal  keratinocytes  through  the  release 
of  heparin-binding–epidermal  growth  factor  (HB-EGF)  from 
suprabasal  keratinocytes  (15,16).  The  influence  of  retinol  on 
keratinocyte differentiation is shown by the increase of some 
differentiation  markers  such  as  keratins  (keratin  4,  keratin 
10, keratin 13, and cytokeratin 19) while others like fillagrine, 
transglutaminase, or loricrine are decreased.

The overall effect on the epidermis is a stimulation of the 
cell proliferation in basal and suprabasal layers and an inhibi-
tion of the terminal differentiation of the keratinocytes. Taken 
together, this leads to a general thickening of the epidermis (8).

TOPICAL RETINOL: AN EFFICACIOUS SOLUTION FOR IMPROVEMENT OF MAIN PHOTODAMAGE SIGNS 

 89

OH

H

OH

O

O

(a) Retinol 

(b) Retinaldehyde

(c) Retinoic acid

Figure  10.1  Structure  of  most  common  retinoids  (all  trans 
conformation).

On  dermal  fibroblasts,  retinol  showed  a  potent  stimu-
lation  of  the  growth  of  fibroblasts  from  aged  donors  and  a 
stimulation of the synthesis of procollagen I and procollagen III 
(17). A suggested mechanism for the improvement of collagen 
synthesis by retinol involves the negative regulator of collagen 
homeostasis, the cysteine-rich protein 61 (CCN1). Topical treat-
ment with retinol for 7 days significantly reduced CCN1 mRNA 
and protein expression in both chronologically and photoaged 
human skin in vivo (18). It has been shown that retinol could 
act  also  on  elastin  synthesis  and  elastin  fiber  formation  (19). 
Indeed,  retinol  treatment  on  dermal  fibroblasts  cultures  as 
well as topical treatment on human skin explants resulted in 
tropoelastin  and  fibrillin-1  gene  expression  and  elastin  fiber 
formation as measured by qPCR and immunohistochemistry.

Retinol  represses  the  overexpression  of  UV-induced 
MMP1  and  MMP9,  two  enzymes  involved  in  the  degrada-
tion of collagen molecules. The underlying mechanism is the 
repression  by  activated  retinoic  receptor  of  the  of  AP1  tran-
scriptional activity that drives the expression of MMP1, MMP3, 
and MMP9. Skin exposure to UV light leads to the stimulation 
of the MAP kinases such as ERK, JNK, or P38 and then to the 
overexpression  of  the  Jun  protein  which  controls  the  level  of 
AP1 in the cell. Thus retinol is able to decrease the UV-induced 
overexpression of MMPs and increase collagen synthesis, two 
mechanisms that could explain in part its potential to protect 
the skin against photodamage (3).

CLINICAL ASPECTS
Retinoids have been widely studied during the past 20 years 
for their activity on human skin. In 1969, Kligman proved the 
therapeutic efficacy of topical tretinoin (all-trans retinoic acid) 
in  acne  vulgaris  and  later  in  1986  pioneered  the  use  of  reti-
noids in cosmetic dermatology by demonstrating its effects on 
photoaged skin. He conducted an open study on eight elderly 
patients  receiving  0.05%  tretinoin  cream  on  the  face  for  6  to 
12 months, while six other patients received the vehicle alone. 

Although only slight clinical differences were observed, histol-
ogy showed a thickening of the previously atrophic epidermis, 
decrease of keratinocyte dysplasia and atypia, more even dis-
persion of melanin, and formation of new dermal collagen and 
blood vessels.

Since then, several clinical studies have been performed 
to  assess  the  activity  of  tretinoin  on  humans,  especially  in 
the  treatment  of  photoaging  signs.  Weiss  and  Voorhees  in 
1988 performed the first double-blind randomized placebo-
controlled  study  by  applying  0.1%  tretinoin  on  the  forearm 
and face of 30 patients for 16 weeks. They demonstrated a sig-
nificant improvement of photoaging in the tretinoin-treated 
areas. The greatest improvement was in the reduction of fine 
wrinkles, with a statistically significant difference occurring 
8  weeks  after  beginning  the  study.  Other  features  such  as 
coarse wrinkles, roughness, and sallowness also showed an 
improvement,  but  to  a  lesser  degree.  Lever,  in  1990,  using 
a  preparation  containing  0.05%  tretinoin  during  12  weeks, 
observed an improvement in clinical grading of photoaging 
(fine lines and wrinkles). Grove again in 1991, assessing dif-
ferent concentrations of tretinoin (from 0.05 to 0.001%) over 
24  weeks,  demonstrated  a  better  efficacy  of  the  dose  activ-
ity  with  the  highest  concentration  (0.05%)  of  the  ingredient 
on the Rz parameter (local mean amplitude) on skin replicas 
(20).  Olsen  in  1992  on  296  subjects,  with  the  same  ranking 
of  concentrations  as  Grove,  over  a  24-week  period  showed 
a  decrease  of  skin  roughness,  hyperpigmentation,  and  fine 
wrinkling (21).

Unfortunately, tretinoin tends to be irritating, with many 
patients experiencing redness, flaking, and increased skin sen-
sitivity. Some patients also reported increased sun sensitivity 
during tretinoin therapy (22).

Retinol, an alternative to tretinoin, has fewer side effects 
and is a better tolerated additive in cosmetic preparations for 
the  improvement  of  photodamage  signs.  In  1995,  Kang  et  al. 
demonstrated  that  the  application  of  retinol  up  to  1.6%,  on 
human  skin  under  an  occlusive  patch,  was  unable  to  induce 
significant erythemal reaction versus vehicle (8). It also evokes 
the  same  physiological  response  as  the  0.025%  erythemato-
genic  concentration  of  retinoic  acid  as  demonstrated  by  epi-
dermal  thickening  and  the  enhancement  of  CRAPBII  mRNA 
and  protein  expression.  This  retinoid  activity  of  retinol  was 
obtained without a detectable increase of retinoic acid in the 
epidermis.  Duell  et  al.  (23)  showed  that  topical  retinol  pene-
trated  the  epidermis  more  and  produced  less  irritation  than 
the acid form. Finally, Goffin in 1997 tested 0.075% of retinol for 
8  weeks  with  corneosurfametry  and  demonstrated  its  better 
tolerance versus tretinoin (24).

Clinical Efficacy of Retinol
Although  retinol  was  demonstrated  to  induce  in  human 
skin  a  physiological  response  typical  of  retinoids,  only  a 
few  clinical  studies  were  published  demonstrating  its  effi-
cacy in improving the signs of skin aging. In 2007, Kafi et al. 
reported a clinical study to demonstrate the beneficial effect 
of  retinol  on  the  skin  signs  associated  with  chronological 
aging  (25).  This  randomized  study  versus  vehicle  was  per-
formed  on  23  elderly  subjects  over  80  years  old  (average  87 
years  old).  Retinol  0.4%  and  vehicle  were  topically  applied 
on the upper inner arm for 6 months. The results showed a 
significant improvement in fine wrinkles versus vehicle after 
2  months  of  application.  This  improvement  increased  with 
the continued application of retinol and was associated with 
a  significant  better  tactile  roughness  and  overall  severity 

 
90 

 TEXTBOOK OF COSMETIC DERMATOLOGY

in  chronologically  aged  skin.  Skin  biopsies  demonstrated 
a  thickening  of  the  epidermis  and  a  significant  increase 
in  GAG  expression  and  procollagen  I  accumulation  in  the 
dermis  compared  to  the  vehicle-treated  arm.  In  this  study, 
although rated as mild, adverse reactions were reported by 
most  subjects  including  erythema,  peeling,  pruritus,  dry-
ness, and burning or stinging, with the withdrawal of three 
subjects following severe enough symptoms (25).

We explored the action of retinol at a lower concentra-
tion (0.1%) on a photoexposed area in order to investigate the 
anti-aging effect of retinol at more tolerated doses on the pho-
toaging signs. In a first blind randomized vehicle-controlled 
study, 48 volunteers (41–60 years old) topically applied to the 
face either the retinol 0.1% containing product or the vehicle, 
every day for 56 weeks. The clinical evaluation, performed 
by an expert grader after 12, 24, and 56 weeks of application, 
showed that wrinkles under the eyes, fine lines at the crow’s 
feet  area,  and  skin  tone  evenness  significantly  improved 
versus  both  baseline  and  vehicle.  The  improvement  of  the 
fine lines in the crow’s feet area was also demonstrated with 
digital  imaging  and  with  surface  profilometry.  A  progres-
sive  improvement  was  seen  between  baseline  and  after  24 
and  36  weeks  of  treatment  (Figure  10.2).  The  improvement 
in  fine  lines  was  also  documented  by  surface  profilometry, 
and  a  progressive  disappearance  of  the  fine  lines  in  the 
crow’s feet area was observed. Moreover, we demonstrated 
that  retinol  stimulates  epidermal  cell  proliferation  along 
with  the  treatment.  The  epidermal  cell  turnover  rate  was 
evaluated  using  in  vivo  fluorescence  spectroscopy  by  mea-
suring the fluorescence maximum attributed to tryptophan 
moieties.  The  placebo-treated  group  did  not  show  any  sig-
nificant change from baseline for any time point. In contrast, 
the  intensity  of  tryptophan  fluorescence  increased  for  the 
actively  treated  group  evident  from  the  first  time  point  (12 

weeks vs. baseline) and then it appeared to reach a plateau. 
Most  importantly,  the  change  in  the  fluorescence  intensity 
from baseline was significantly higher for the active-treated 
group  than  for  the  placebo-treated  group  at  the  36-week 
time point (26). These anti-aging effects of retinol were con-
firmed in two other shorter term double-blind randomized 
studies  performed  with  moisturizing  product  containing 
0.1%  retinol.  In  the  first  study  the  retinol- containing  prod-
uct  was  topically  applied  on  40  subjects  (40–60  years  old) 
once a day for 8 weeks. The effect of the product was com-
pared to the  effect  of  its  vehicle  on  41 subjects. The results 
presented  in  Table  10.1  showed  that  the  application  of  the 
retinol  0.1%  significantly  improved  the  facial  features  of 
photodamaged  areas  as  early  as  4  weeks  of  use.  Results 
from the second study have been published. In this 8-week, 
split-face,  double-blind  randomized  clinical  study,  a  0.1% 
retinol- containing moisturizer was tested (36 subjects) ver-
sus  placebo  (28  subjects)  in  women  with  moderate  facial 
photodamage. Clinical evaluation of photodamage signs by 
a dermatologist demonstrated significant improvement ver-
sus  placebo  of  fine  lines,  wrinkles,  elasticity,  firmness,  and 
overall photodamage after 4 weeks. Thus, using a low level 
of retinol (e.g. 0.1%) could still deliver a significant and rapid 
anti-aging efficacy while maintaining a good tolerance pro-
file, as only a few subjects experienced a slight adverse skin 
reaction without any withdrawal with the retinol product. In 
the  two  studies,  the  number  of  adverse  reactions  observed 
with  the  retinol  product  was  not  significantly  higher  than 
with the vehicle. These clinical results were later confirmed 
by  two  other  clinical  studies  performed  on  middle-aged 
Japanese  females  (27).  Both  studies  included  57  volunteers 
and were performed with 0.075% and 0.04% retinol creams 
during  26  and  13  weeks,  respectively.  Both  trials  revealed 
significant  improvement,  especially  on  fine  wrinkles,  with 

Figure 10.2  Example of improvement of crow’s feet area by retinol 0.1% product treatment.

Table 10.1  Clinical Assessment of Retinol Anti-Aging Efficacy

Vehicle

Retinol 0.1%

Parameter

Under-eye wrinkles
Crow’s feet fine lines
Crow’s feet wrinkles
Forehead wrinkles
Skin radiance
Cheek wrinkles
Overall photodamage

4 weeks

0%
8.1%*
0%
0%
16.7%*
0%
3.8%*

8 weeks

2.2%
10.8%*
0%
0%
20.8%*
0%
3.8%*

4 weeks

4.3%*†
29.7%*†
2.8%*
6.4%*†
34.8%*†
7.3%*†
17.3%*†

8 weeks

6.5%*†
35.1%*†
8.3%*†
6.4%*†
43.5%*†
9.8%*†
19.2%*†

Note: Values represent the percentage of improvement versus baseline.
*Statistical significance versus baseline (p < 0.05).
†Statistical significance versus vehicle (p < 0.05).

 
TOPICAL RETINOL: AN EFFICACIOUS SOLUTION FOR IMPROVEMENT OF MAIN PHOTODAMAGE SIGNS 

 91

minimal irritation. These results are very promising as they 
demonstrate that retinol could be efficient at lower concen-
tration, thus decreasing irritation risks.

Recently,  we  also  demonstrated  that  prolonged  use  of 
topical  retinol  (0.1%)  significantly  improved  clinical  signs  of 
photoaging  on  two  52-week,  double-blind  vehicle-controlled 
studies  (28).  In  the  main  study,  62  volunteers  applied  either 
a  stabilized  retinol  formulation  or  its  vehicle  to  the  full  face, 
while  the  second  study  evaluated  histological/histochemical 
markers in 12 subjects after 52 weeks of either retinol or vehicle 
use on contralateral dorsal forearms. The retinol group showed 
significant photodamage improvement over vehicle at all time-
points during the study. After 52 weeks, retinol had improved 
crow’s feet fine lines by 44% and mottled pigmentation by 84%, 
with over 50% of subjects showing +2 grades of improvement 
in  many  parameters.  Additionally,  at  week  52,  histochemical 
data confirmed the clinical results, showing increased expres-
sion of type I procollagen, hyaluronan, and Ki67 expression (a 
maker of cell proliferation) in basal keratinocytes as compared 
to vehicle.

CONCLUSION
Skin aging is a complex process involving numerous differ-
ent mechanisms such as loss of cell proliferation, decreased 
potential  of  extracellular  matrix  synthesis,  and  overex-
pression  of  matrix-degrading  proteinases.  Retinoids  are 
naturally  present  in  the  skin  and  regulate  epidermal  cell 
differentiation,  activate  collagen  synthesis,  and  attenuate 
the  UV-induced  overexpression  of  MMPs.  The  potential  of 
regulating  several  pathways  involved  in  skin  chronologi-
cal  and  photoaging  makes  them  good  candidates  as  active 
ingredients to alleviate facial aging signs. Although retinoic 
acid has been the first retinoid to demonstrate an efficacious 
wrinkle improvement, the severe side effects induced by its 
topical  application  warrant  the  identification  of  other  reti-
noids  for  this  benefit.  Therefore  retinol  was  identified  as  a 
good  alternative  to  retinoic  acid,  as  its  topical  application 
induces a low level of skin adverse reaction while delivering 
physiological skin responses similar to those induced by ret-
inoic acid. Moreover, the retinoic acid level in the epidermis 
observed  after  topical  application  of  retinol  is  extremely 
low  or  undetectable  and  thus  provides  a  substantial  mar-
gin of safety with respect to possible systemic effect. Results 
presented here focus preferentially on the clinical efficacy of 
well-tolerated doses of retinol. Indeed, in two double-blind 
randomized placebo-controlled studies, retinol at 0.1% dem-
onstrated  a  significant  visible  improvement  of  facial  aging 
features  such  as  fines  lines  and  wrinkles  within  1  month’s 
time.

REFERENCES

1.  Baumann  L.  Skin  ageing  and  its  treatment.  J  Pathol  2007; 

211:241–51.

2.  Griffiths  CE,  Russman  AN,  Majmudar  G,  et  al.  Restoration  of 
collagen formation in photodamaged human skin by tretinoin 
(retinoic acid). N Engl J Med 1993; 329:530–5.

3.  Fisher  GJ,  Datta  SC,  Talwar  HS,  et  al.  Molecular  basis  of  sun-
induced  premature  skin  ageing  and  retinoid  antagonism. 
Nature 1996; 379:335–9.

4.  Rask L, Anundi H, Böhme J, et al. The retinol-binding protein. 

Scand J Clin Lab Invest 1980; 154:45–61.

5.  Båvik  CO,  Peterson  A,  Eriksson  U.  Retinol-binding  protein 
mediates  uptake  of  retinol  to  cultured  human  keratinocytes. 
Exp Cell Res 1995; 216:358–62.

6.  Hinterhuber  G,  Cauza  K,  Brugger  K,  Dingelmaier-Hovorka  et 
al.  RPE65  of  retinal  pigment  epithelium,  a  putative  receptor 
molecule  for  plasma  retinol-binding  protein,  is  expressed  in 
human keratinocytes. J Invest Dermatol 2004; 122:406–13.

7.  Huang J, Vieira A. Evidence for a specific cell membrane reti-
nol-binding  protein  transport  mechanism  in  a  human  kerati-
nocyte line. Int J Mol Med 2006; 17:627–31.

8.  Kang  S,  Duell  EA,  Fisher  GJ,  et  al.  Application  of  retinol  to 
human skin in vivo induces epidermal hyperplasia and cellu-
lar retinoid binding proteins characteristic of retinoic acid but 
without  measurable  retinoic  acid  levels  or  irritation.  J  Invest 
Dermatol 1995; 105:549–56.

9.  Antille C, Tran C, Sorg O, Saurat JH. Penetration and metabo-
lism of topical retinoids in ex vivo organ-cultured full-thickness 
human skin explants. Skin Pharmacol Physiol 2004; 17:124–8.
  10.  Törmä  H,  Vahlquist  A.  Vitamin  A  esterification  in  human 
epidermis:  A  relation  to  keratinocyte  differentiation.  J  Invest 
Dermatol 1990; 94:132–8.

  11.  Yin  SJ,  Han  CL,  Lee  AI,  Wu  CW.  Human  alcohol  dehydroge-
nase family? Functional classification, ethanol/retinol metabo-
lism and medical implication. In: Weiner et al., eds. Enzymology 
and Molecular Biology of Carbonyl Metabolism. New York: Kluwer 
Academics/Plenum 1999; pp. 265–74.

  12.  Roos TC, Jugert FK, Merk HF, Bickers DR. Retinoid metabolism 

in the skin. Pharmacologica Rev 1998; 50:315–33.

  13.  Wolbach SB, Howe PR. Tissue changes following deprivation of 

fat soluble A vitamin. J Exp Med 1925; 42:753–77.

  14.  Frazier  CN  and  CK  Hu.  Cutaneous  lesion  associated  with 

Vitamin A deficiency in man. Arch Intern Med 1931; 48:507–14.

  15.  Chapellier  B,  Mark  M,  Messaddeq  N,  et  al.  Physiological  and 
retinoid-induced  proliferations  of  epidermis  basal  keratino-
cytes are differently controlled. EMBO J 2002; 21:3402–13.
  16.  Rittié  L,  Varani  J,  Kang  S,  et  al.  Retinoid-induced  epidermal 
hyperplasia  is  mediated  by  epidermal  growth  factor  receptor 
activation via specific induction of its ligands heparin-binding 
EGF and amphiregulin in human skin in vivo. J Invest Dermatol 
2006; 126:732–9.

  17.  Varani  J,  Warner  RL,  Gharaee-Kermani  M,  et  al.  Vitamin  A 
antagonizes  decreased  cell  growth  and  elevated  collagen-
degrading  matrix  metalloproteinases  and  stimulates  collagen 
accumulation in naturally aged human skin. J Invest Dermatol 
2000; 114:480–6.

  18.  Quan T, Qin Z, Shao Y, et al. Retinoids suppress cysteine-rich 
protein 61 (CCN1), a negative regulator of collagen homeostasis, 
in skin equivalent cultures and aged human skin in vivo. Exp 
Dermatol 2011; 20:572–6.

  19.  Rossetti D, Kielmanowicz MG, Vigodman S, et al. A novel anti-
ageing mechanism for retinol: Induction of dermal elastin syn-
thesis and elastin fibre formation. Int J Cosmet Sci 2011; 33:62–9.
  20.  Grove  GL,  Grove  MJ,  Leyden  JJ,  et  al.  Skin  replica  analysis  of 
photodamaged  skin  after  therapy  with  tretinoin  emollient 
cream. J Am Acad Dermatol 1991; 25:231–7.

  21.  Olsen EA, Katz HI, Levine N, et al. Tretinoin emollient cream: A 
new therapy for photodamaged skin. J Am Acad Dermatol 1992; 
26:215–24.

  22.  Effendy  I,  Weltfriend  S,  Patil  S,  Maibach  HI.  Differential  irri-
tant skin responses to topical retinoic acid and sodium lauryl 
sulphate:  Alone  and  in  crossover  design.  Br  J  Dermatol  1996; 
134:424–30.

  23.  Duell EA, Kang S, Voorhees JJ. Unoccluded retinol penetrates 
human  skin  in  vivo  more  effectively  than  unoccluded  retinyl 
palmitate or retinoic acid. J Invest Dermatol 1997; 109:301–5.
  24.  Goffin V, Henry F, Piérard-Franchimont C, Piérard GE. Topical 
retinol and the stratum corneum response to an environmental 
threat. Skin Pharmacol 1997; 10:85–9.

 
 
 
 
 
 
 
 
 
 
92 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  25.  Kafi R, Kwak HS, Schumacher WE, et al. Improvement of natu-
rally  aged  skin  with  vitamin  A  (retinol).  Arch  Dermatol  2007; 
143:606–12.

  26.  Bellemère G, Stamatas GN, Bruère V, et al. Antiaging action of 
retinol: From molecular to clinical. Skin Pharmacol Physiol 2009; 
22:200–9.

  27.  Kikuchi  K,  Suetake  T,  Kumasaka  N,  Tagami  H.  Improvement 
of  photoaged  facial  skin  in  middle-aged  Japanese  females 

by  topical  retinol  (vitamin  A  alcohol):  A  vehicle-controlled, 
double-blind study. J Dermatolog Treat 2009; 20:276–81.

  28.  Randhawa  M,  Rossetti  D,  Leyden  JJ,  et  al.  One-year  topical 
stabilized  retinol  treatment  improves  photodamaged  skin  in 
a double-blind, vehicle-controlled trial. J Drugs Dermatol 2015; 
14:271–6.

 
11

Applications of Non-Denatured Soy in Skin Care

Jue-Chen Liu, Jeff Wu, and Miri Seiberg

INTRODUCTION
The  soybean  plant  belongs  to  the  pea  family,  Leguminosae, 
subfamily  Papilionoidezae,  and  the  genus  Glycine.  The  culti-
vated form is named Glycine max (L.) Merr. It is one of the old-
est annual crops of the Far East. Dietary soy has been known 
for centuries to provide nutritional, medicinal, and health ben-
efits. Because of the nutritional value of soybeans, there is an 
inherited value for skin care applications. In fact, the use of soy 
to treat skin conditions has a long history. It was first reported 
in  Traditional  Chinese  Medicine  Encyclopedia  (1)  that  soy-
beans  provided  therapeutic  efficacy  against  skin  conditions 
including hyperpigmented lesions and dry skin. Additionally, 
Chinese folklore has it that women workers in tofu industries 
have the most beautiful skin, i.e., fair, smooth and porcelain-
like fine skin. For a very long time, soy or components of soy 
for topical applications have been limited to functional appli-
cations  such  as  emollient  and  skin  conditioning  agents.  The 
scientific fundamentals and clinical efficacy of soy for skin ben-
efits have not been proven until recent years. It was reported 
that soy isoflavones possess phytoestrogenic properties which 
may play a role in the skin of menopausal women (2). Specific 
protein components in soybeans were identified for inhibition 
of melanosome transfer resulting in pigment reduction (3–5). 
Other  soybean  components  such  as  lipids,  oligosaccharides, 
and saponins can also provide skin benefits. Such new knowl-
edge and findings have been implemented into dermatological 
and cosmeceutical products for broader skin applications. This 
chapter reviews the components of soy and their clinical uses 
in improving skin conditions.

SOY IN HUMAN HEALTH
Soybeans  originate  from  China.  In  2853  BC,  Emperor  Sheng-
Nung  of  China  named  five  sacred  plants—soybeans,  rice, 
wheat, barley, and millet. Soybean plants were then domesti-
cated and cultivated into a food crop for everyday diet (6–7). 
The soybean has blossomed from legendary Chinese origins to 
the “miracle crop” vastly produced on modern-day American 
farms since its first introduction into the United States in the 
early 1800s (7).

From about the first century AC to the Age of Discovery 
(15th to 16th century), soybeans were introduced into several 
countries such as Japan, Indonesia, the Philippines, Vietnam, 
Thailand,  Malaysia,  Burma,  Nepal,  and  India.  The  first  soy-
beans  arrived  in  America  in  the  early  1800s  and  since  then 
have  played  an  increasingly  important  role  for  human  nutri-
tion and health.

Soybeans  with  their  valuable  proteins  and  oil  are  an 
important  source  of  nutrition.  The  soybean  is  rich  in  miner-
als including calcium, iron, and potassium, amino acids, and 
vitamins. It is also a good fiber source (8–9). They can be used 

as  meat  and  dairy  substitutes  in  various  items.  Today,  most 
people  are  aware  of  the  use  of  soy  proteins  in  baby  formula, 
weight-loss  drinks,  sport  drinks,  and  as  a  low-fat  substitute 
for  hamburger.  Soybeans  are  also  valued  for  their  medicinal 
qualities.  Epidemiological  data  indicates  that  people  from 
Asian  cultures  have  lower  rates  of  certain  cancers,  including 
cancers  of  the  breast,  prostate,  and  colon,  and  lower  rates  of 
cardiovascular  disease,  osteoporosis,  and  postmenopausal 
symptoms (10–16). In the past decade, studies on soy’s health 
benefits have dramatically increased in these areas, and more 
systematic and controlled clinical studies have been presented 
on its health benefits (17–18). In 1999, the U.S. Food and Drug 
Administration  (FDA)  approved  a  healthy  claim  for  soy  pro-
tein  that  associated  with  reduced  risk  of  coronary  heart  dis-
ease (19). This ruling is based on the FDA’s decision that foods 
containing soy protein included in a diet low in saturated fat 
and cholesterol may reduce the risk of coronary heart disease 
by lowering blood cholesterol levels.

EARLY UTILIZATION OF SOY IN 
TOPICAL APPLICATION
For  many  years,  due  to  the  lack  of  basic  research  in  under-
standing  the  fundamental  mechanisms  of  soy  on  skin,  soy’s 
nutritional components were used mainly as functional ingre-
dients in the cosmetic industry (20) and mostly have remained 
so  until  today.  The  most  frequently  used  soy  components 
include  soybean  oil,  soy  protein  isolates,  and  soy  lecithin  
as  shown  in  Table  11.1.  Soybean  oil  is  one  of  the  valuable 
materials  used  to  adjust  the  rheology  of  cosmetic  emulsions. 
Examples  of  soy  oil  as  an  emollient  and  moisturizer  include 
baby  oil  and  moisturizing  lotion.  Soy  protein  isolate/hydro-
lysate  has  been  formulated  as  an  emulsifier  and  foaming 
enhancer  into  a  wide  variety  of  products,  including  laundry 
detergent,  bath  products,  shampoos,  and  skin  cleansers  (21). 
The  lecithin  fraction  of  crude  soybean  oil  has  found  applica-
tion as an emulsifying, surface active agent, and a stabilizing 
agent in industrial products such as paint, ink, soap, and cos-
metics (22). Soy sterols are employed as skin conditioners for 
lotion, creams, and cleansers (23).

In  the  early  1990s,  soy  extracts  or  soy  germ  extracts 
that  claimed  to  provide  specific  biological  activities  started 
to appear in skin care products. These soy extracts, although 
defined  vaguely  as  soy  (soja)  concentrates  or  soy  proteins, 
were  actually  produced  using  different  chemical  extraction 
conditions  and  could  result  in  dissimilar  compositions  and 
skin  effects.  Such  soy  extracts  often  had  too  small  a  fraction 
of the original soy components to provide the desired biologi-
cal activities to keep the bioactivities for skin efficacy, or were 
processed excessively under harsh extraction conditions such 
as  extreme  pH,  strong  solvents,  and  elevated  temperatures. 

94 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 11.1  Traditional Use of Soy in Skin and Hair Care

Functionality

Applications

Reference

Soy components

Soybean oil

Skin conditioner/ emollient

Baby oil,

Soy protein Isolate/hydrolyzate

Emulsifier

moisturizer

Bath products, cleansers, 

shampoos

Soy lecithin
/phospholipids

Soy sterol

Surface active, emulsifier, 

Liposome

stabilizing agent

Skin conditioner

Lotion /cream/cleanser

(22)

(21)

(60)

(20)

Few clinical reports or publications were available for cosmetic 
products spiked with such soy extracts. The use of these soy 
extracts has been limited to product marketing claims.

SCIENTIFIC ADVANCES IN THE USE 
OF SOYBEANS FOR SKIN CARE
Soy Proteins, Non-Denatured Soybean 
Extracts, and Depigmentation
There is an increasing global desire for skin care products to 
induce  fair  skin  and  even  skin  tone.  In  addition,  hyperpig-
mented  spots  including  mottled  hyperpigmentation,  solar 
lentigines, and melasma are key concerns for the aging popu-
lation and pregnant women. The most frequently used topical 
treatment agents for depigmentation are tyrosinase inhibitors, 
hydroxyacids,  retinoids,  hydroquinones,  anti-inflammatory 
agents, and their combinations. Treatment with these agents is 
not always satisfactory and may result in irritation, sun sensi-
tivity, or toxicity (24). In its proposal published in the U.S. gov-
ernment’s Federal Register, U.S. FDA notes: “The actual risk to 
humans  from  use  of  hydroquinone  has  yet  to  be  fully  deter-
mined…. We’re acting for safety reasons. There is a potential 
for hydroquinone to be a carcinogen in humans.” In December 
2009, U.S. FDA nominated hydroquinone for further study by 
the National Toxicology Program (NTP). FDA believed that the 
NTP  studies  are  necessary  before  it  can  determine  whether 
hydroquinone  is  generally  recognized  as  safe  (GRAS)  when 
used in over-the-counter (OTC) skin bleaching drug products. 
Therefore,  safer  and  more  effective  depigmenting  agents  are 
needed  to  address  consumer  needs  for  fair  skin,  even  tone, 
and  spot  reduction.  Moreover,  a  move  toward  “green”  thera-
pies has led to a demand for natural, safe, and efficacious skin-
lightening agents.

Soybeans  contain  two  proteins,  which  are  reported  to 
inhibit  the  protease-activated  receptor-2  (PAR-2)  pathway, 
leading  to  reduced  melanosome  transfer  from  melanocyte  to 
keratinocyte  and  resulting  in  pigmentation  reduction.  These 
two  proteins  are  serine  proteinase  inhibitors:  the  Kunitz-
type  trypsin  inhibitor  (soybean  trypsin  inhibitor  [STI]),  and 
the  Bowman-Birk  protease  inhibitor  (BBI)  (25–26).  STI  has  a 
molecular weight of 20 k daltons (k-Da), consists of 181 amino 
acid residues with two disulfide bridges, and is roughly spher-
ically shaped (27). BBI is an 8 k-Da protein that inhibits the pro-
teases trypsin and chymotrypsin at separate reactive sites (28). 
PAR-2  is  a  G-protein-coupled  receptor  activated  by  a  serine 
protease cleavage (29–31). Trypsin, mast cell tryptase, and kal-
likrein are the only known natural serine proteases that acti-
vate PAR-2 (32–34). PAR-2 is expressed in keratinocytes (35–36), 
but not in melanocytes (3) and is involved in the regulation of 
pigmentation  (3,37–38).  It  was  reported  that  the  inhibition  of 
PAR-2 activation by serine protease inhibitors reduces pigment 

deposition.  This  effect  is  possible  only  when  keratinocyte-
melanocyte contact is established (see Figure 11.1, top panel). 
Melanocytes alone do not respond to PAR-2 modulating agents 
with pigmentary changes (3). When serine protease inhibitors 
interfere with PAR-2 activation, melanosome transfer from the 
melanocytes  to  the  keratinocytes  is  inhibited.  The  reduced 
melanosome ingestion by keratinocytes results in depigmenta-
tion both in vitro and in vivo (3,38). This depigmenting effect 
caused by serine protease inhibitors is reversible in vivo (3,38), 
therefore excluding the possibility of melanocyte death follow-
ing such treatments.

In soy foods, STI and BBI are inactivated and denatured 
by heat and pressure or by fermentation to prevent the block-
ing  of  trypsin  activity  in  the  digestive  system  for  human, 
which would cause gastrointestinal adverse effects.

It was found that non-denatured soybean extracts, non-
denatured soy, and the isolated soy- derived proteins STI and 
BBI  inhibit  PAR-2  activation,  resulting  in  skin  depigmenta-
tion  (5).  As  shown  in  Figure  11.1,  keratinocyte-melanocyte 
co-cultures  treated  with  the  soy  protein  STI  have  reduced 
tyrosinase  activity,  documented  by  DOPA  staining  (upper 
panel).  Darkly-pigmented  human  skin  grafted  on  immuno-
deficient mice and treated with STI showed reduced pigment 
deposition,  as  demonstrated  by  Fontana-Mason  (F&M)  stain-
ing of histological sections after five weeks of topical treatment 
(middle panel). F&M staining identifies silver nitrate–reducing 
molecules.  In  skin,  this  nonspecific  stain  identifies  primarily 
melanin. Dark-skinned swine treated with the non-denatured 
soy extract displayed visible skin lightening following 8 weeks 
of treatment (lower panel). Therefore, agents such as STI, BBI, 
or  non-denatured  soybean  extracts  may  serve  as  alternative, 
natural treatments for skin lightening or hyperpigmentation.

Non-Denatured Soybean Extracts 
and Delayed Hair Growth
Mammalian hair provides environmental protection, but this 
function has been lost in humans, who keep or remove their 
hair  at  different  body  locations  for  social  and  cosmetic  pur-
poses.  Many  procedures  are  used  to  remove  unwanted  hair, 
ranging from simple and inexpensive treatments like shaving 
to costly and time-consuming methods such as electrolysis and 
laser therapies. Hair removal methods differ in the duration of 
the effect, pain and discomfort levels, and possible undesired 
side effects (39).

The hair follicle undergoes cycles of active growth (ana-
gen),  regression  (catagen)  and  rest  (telogen)  (40).  While  the 
morphological changes throughout the hair cycle are well doc-
umented (41), the regulation of the different phases of this cycle 
is  not  completely  understood.  It  was  recently  demonstrated 
that non-denatured soybean extracts and the soybean-derived 

 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 95

(a)

(c)

(b)

(d)

Figure  11.1  The  inhibition  of  PAR-2  activation  by  serine  protease  inhibitors  results  in  reduced  pigment  deposition.  Keratinocyte-
melanocyte co-cultures treated with the soy protein STI have reduced tyrosinase activity, documented by DOPA staining (Top panels 
(a) Control vs. (b) Treated). Hyperpigmented human skin grafted on immunodeficient mice and treated with STI showed reduced pigment 
deposition, demonstrated by F&M staining of histological sections after 5 weeks of treatment ([c] control vs. [d] treated). Dark-skinned 
swine treated with a non-denatured soy extract demonstrates visible skin lightening following 8 weeks of treatment (e).

(e)

 
 
 
 
 
96 

 TEXTBOOK OF COSMETIC DERMATOLOGY

proteins  STI  and  BBI  reduce  not  only  hair  pigmentation  but 
also  the  rate  of  hair  growth  and  the  final  dimensions  of  the 
hair  shaft  (5).  Following  non-denatured  soy  treatment,  the 
onset of anagen was delayed, the duration of the hair cycle was 
reduced,  and  the  resulting  hair  shafts  were  shorter,  thinner, 
and softer. As shown in Figure 11.2, mouse hair treated with 
non-denatured soy showed reduction in the length of the hair 
shafts  (upper  panel).  Hair  follicle  development  (anagen)  was 
delayed as seen following 7 days of treatment (middle panel). 
While  the  untreated  follicles  were  completely  developed,  at 
this time point the soy-treated follicles were smaller and con-
tained reduced levels of pigment. At day 15 of treatment, when 
all follicles had reached their final dimensions, the soy-treated 
follicles were significantly smaller (lower panel). While the soy 
isoflavones may play some role in the delayed hair growth by 
the non-denatured soy lotion, the ability of the non-denatured 
soy  product  to  thin  the  hair  and  facilitate  less-frequent  hair 
removal seems to result primarily from the actions of two the 
soy-derived  proteins  STI  and  BBI  (5).  These  results  indicate 
that  agents  such  as  non-denatured  soy  extracts  may  serve  as 
an  inexpensive,  natural  alternative  treatment  for  undesired 
hair growth.

Non-Denatured Soybean Extracts 
and Dermal Matrix Enhancement
Skin  elasticity  and  elastin  fiber  production  are  reduced  with 
aging (42–44) as elastin synthesis decreases and the secretion 
of elastases increases. UV exposure induces extensive elastin 
synthesis  and  crosslinking  (“solar  elastosis”),  which  add  to 
skin’s rigidity. Sunscreens, antioxidants, and retinoids are pro-
moted as “antiaging” agents, however they are not specific for 
repairing or enhancing skin elasticity. Inhibiting UV-induced 
fibroblast-derived  elastases  protected  the  dermal  elastic  net-
work and reduced wrinkle formation in rodents (45–46). The 
non-denatured soybean extracts were found to have elastase-
inhibitory  activities  (47),  to  induce  the  synthesis  of  both  col-
lagen  and  elastin,  and  to  promote  the  correct  assembly  of 
newly-synthesized elastin fibers, suggesting both dermal pro-
tection and restoration of the dermal extracellular matrix.

Human  skin,  transplanted  onto  immunodeficient  mice 
and topically treated with these extracts, showed an increase 
in  the  expression  of  elastin,  elastin-accessory  proteins,  and 
collagen (47). Human skin explants treated ex-vivo with non-
denatured  soybean  extracts  showed  an  increase  in  collagen, 
elastin, and fibrilin-1 production by histological staining and 
immunohistochemistry  (see  Figure  11.3).  These  data  suggest 
that  non-denatured  soybean  extracts  could  induce  collagen 
and  elastin  synthesis  in  human  skin  and  provide  cosmetic 
antiaging effects.

Non-Denatured Soybean Extracts May 
Reduce the Risk of Non-Melanoma 
Skin Cancer Development
Non-Denatured Soybean Extracts Inhibit the COX-2 Pathway
Chronic inflammation is associated with numerous skin con-
ditions  and  diseases,  ranging  from  skin  aging  to  epithelial 
skin tumors (reviewed in 48, 49). Cyclooxygenase-2 (COX-2) is 
involved  in  UV-induced  skin  inflammation  and  carcinogen-
esis (reviewed in 50,51), and in UV-induced edema, epidermal 
hyperplasia,  and  the  generation  of  oxidative  DNA  damage. 
Repeated  UV  exposure  results  in  chronic  upregulation  of 
COX-2 expression and chronic inflammation, which accelerate 
skin aging and increase skin cancer risk. Indeed, aged human 

skin produces higher amounts of prostaglandin E2 (PGE2, the 
product of the COX-2 pathway) relative to young skin (52). In 
animal models, oral and topical COX-2 inhibitors have chemo-
preventive activity against UV-induced skin cancer (reviewed 
in 50, 51). COX-2 expression is reduced in mouse skins upon the 
topical applications of soy isoflavones (53).

Non-denatured soybean extracts inhibit the COX-2 path-
way  (54).  Cultured  keratinocytes  or  epidermal  equivalents 
were pretreated with non-denatured soybean extracts, washed, 
and  then  UV-exposed.  As  shown  in  Figure  11.4,  UV  irradia-
tion induced COX-2 expression and PGE2 secretion, which were 
reduced upon pretreatment with the soy extracts (54). When mice 
were  topically  treated  with  non-denatured  soybean  extracts, 
then washed and then UV-exposed, they had reduced levels of 
COX-2  expression  in  their  skins  as  compared  to  mice  exposed 
to UVB without soy pre-treatment (54). These data confirm the 
COX-2 inhibitory activity of the non-denatured soybean extracts 
in vivo and suggest their possible activity in delaying photoag-
ing symptoms and skin cancer processes in human skin.

Non-Denatured Soybean Extracts Reduce Skin 
Cancer Progression in High-Risk Mice
Polyphenols,  including  green  tea  polyphenols,  resveratrol,  and 
soy  isoflavones  like  genistein,  have  a  photoprotective  effect  on 
UV-induced skin inflammation, oxidative stress, and DNA dam-
age (55). The soy protein BBI is chemoprotective, and an organic 
extract of soybeans enriched in BBI has been evaluated in clini-
cal  studies  (26).  Mice  fed  with  a  non-denatured  soymilk  pro-
tein  supplement  had  a  reduction  in  the  numbers  and  volumes 
of  experimentally-induced  skin  tumors  (56),  however  this  was 
accompanied with undesired gastrointestinal effects. Since non-
denatured  soybean  extracts  contain  isoflavones  and  BBI,  and 
since  they  possess  COX-2  inhibitory  activity,  the  use  of  these 
extracts as topical chemopreventive agents was evaluated.

Hairless mice exposed to chronic low UV levels become 
“high-risk mice.” They are tumor-free, but with a high risk of 
developing skin tumors in the absence of additional UV expo-
sure. High-risk mice were topically treated with non-denatured 
soymilk, heat-denatured soymilk, STI, or BBI, or with water or 
BSA as controls (57). Non-denatured soybean extracts, but not 
heat-denatured  soybean  extracts,  reduced  the  incidence  and 
slowed the growth and progression of skin tumors (see Figure 
11.5). STI and BBI had a similar but reduced effect, suggesting 
that  other  components  of  the  non-denatured  extract  provide 
additional  protection.  The  number  of  tumor-bearing  mice, 
tumors  per  mouse,  and  the  volume  of  the  visible  part  of  the 
tumors were all markedly reduced upon the topical treatment 
of  non-denatured  soybean  extracts  (57).  Histopathological 
examination  documented  numerous  squamous  cell  carci-
noma  (SCC)  lesions  in  the  UV-exposed  mice.  The  non-dena-
tured  soybean  extracts-treated  skins,  in  contrast,  had  very 
small lesions, with no dysplasia or carcinoma, which were not 
classified as SCC (Figure 11.5). These data might suggest that 
non-denatured soybean extracts could be topically applied to 
humans to reduce or prevent UV-induced skin damage and to 
reduce the risk of skin tumor formation and progression.

NON-DENATURED SOY FOR COSMETIC 
DERMATOLOGY APPLICATIONS
Non-Denatured Soy Composition
While  the  compositions  of  natural  soybeans  can  inevitably 
be subject to variations, depending on the particular harvest, 
soil/region, and species variation, the basic chemical composi-
tion is similar, as illustrated in Table 11.2 (58). Mature soybeans 

 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 97

(a)

(c)

(e)

(b)

(d)

(f )

Images of hair growth patterns under different conditions. (a) Untreated control and (b) treated illustrate reduction in the 
Figure 11.2 
length of the mouse hair shafts treated with a non-denatured soy extract. (c) and (d) show delayed hair follicle development anagen) as 
seen following 7 days of treatment. While the untreated follicles (c) were completely developed, at this time point the soy-treated follicles 
(d) were smaller and contained reduced levels of pigment. At day 15 of treatment, when all follicles had reached their final dimensions, 
the soy-treated follicles were significantly smaller (e and f).

 
 
 
 
 
 
 
98 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(c)

(e)

(b)

(d)

(f )

Figure  11.3  Non-denatured  soybean  extracts  induce  collagen  and  elastin  synthesis.  Human  skin  explants  (obtained  from  surgical 
procedures with informed consent and institutional board approval) were maintained in culture for 8 days, with or without topical daily 
treatment,  5  days/week,  using  a  base  formulation  with  2.5%  non-denatured  soybean  extract.  (a)  Untreated  control  versus  (b)  treated  
Herovici  staining  documents  mature  collagen  fibers  (magenta-red).  Topical  treatment  with  non-denatured  soybean  extracts  induces 
the  production  of  collagen  fibers.  (c,  d)  Luna  elastin  staining  documents  mature  elastin  fibers  (purple-brown).  Topical  treatment  with 
non-denatured soybean extracts enhanced the ewlastic fiber network. (e, f) Immunohistochemical staining documents tropoelastin (the 
elastin fiber monomer, green) and fibrillin-1 (an elastin-accessory protein, red). Non-denatured soybean extracts induce tropoelastin and 
fibrillin-1 synthesis, and their co-localization (yellow) documents the site of elastin fiber formation. ([a,b] Images courtesy of Dr. CB Lin 
and D. Rossetti.)

 
 
 
 
 
 
 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 99

)
L
m
/
g
p

(

2
E
G
P

150

100

50

0

Control

UVB

(a)

Soy+UVB

(c)

(b)

(d)

Figure 11.4  Non-denatured soybean extracts inhibit the COX-2 pathway. Epidermal equivalents were topically treated for 24 hours with 
2% non-denatured soybean extracts in PBS or with PBS alone, and then UVB-exposed (100 mJ/cm2) as in (ref. 54). Samples were col-
lected at 24 hours post UVB exposure for analysis. (a) Culture media were analyzed for PGE2 secretion. Non-denatured soybean extracts 
inhibited the UV-induced secretion of the inflammatory mediator PGE2. (b–d) COX-2 staining of the treated equivalents: (b) PBS, (c) PBS 
followed by UVB, (d) 2% non-denatured soybean extracts followed by UVB. Non-denatured soybean extracts led to reduced COX-2 pro-
tein levels after UV exposure.

are composed of up to 36% proteins, 30% carbohydrates, and 
20% lipids. The highly innovative non-denatured soy technol-
ogy  was  created  based  on  scientific  findings.  The  non-dena-
tured  soy  raw  material  was  created  from  whole  soybeans 
without using either chemicals or chemical solvents. The novel 
standardization  of  the  manufacturing  process  results  in  a 
blend of balanced non-denatured components including active 
proteins,  essential  lipids,  oligosaccharides,  and  other  soy 
ingredients, which are in a similar proportion to that naturally 
present in the soybeans. The standardization process includes 
quality control such as measurements and lower limits of bio-
chemical activities, of serine protease inhibitory activities.

It  is  well  known  that  due  to  its  natural  origin,  high 
levels of microorganisms are commonly associated with soy-
beans and soy products. Consequently, decontamination pro-
cesses  such  as  heat,  organic/aqueous  solvent  extraction,  and 
high shear purification are used to reduce microorganism con-
centrations in soy products, to allow soy ingredients to be safe 

for  human  skin  care  applications.  However,  these  processes 
frequently denature the active proteins in the soy, resulting in 
a  compromised  biological  efficacy,  e.g.,  a  reduction  in  prote-
ase  inhibitory  activity.  Furthermore,  such  processes  also  can 
lead to instability of the soy product as well as to an undesir-
able  odor  and  color  generation.  A  novel  manufacturing  pro-
cess was developed for the non-denatured soy technology to 
reduce the levels of microbial contamination in non-denatured 
soy and maintain its protease (trypsin) inhibitory activity and 
preserve stability. This proprietary gamma irradiation process 
with optimized intensity and duration enabled reducing bio-
burden  to  attain  safe  levels  while  maintaining  a  stable  non-
denatured  composition  with  full  protease  inhibitory  activity, 
and with no color or odor changes.

Table 11.3 illustrates the non-denatured soy components 
and  their  potential  applications  in  skin  care.  Non-denatured 
soy contains both non-denatured small and large soy proteins. 
The small soy proteins include STI, BBI, and lunasin, with their 

 
 
 
 
 
 
 
100 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Control

Largest soy-treated lesion

(a)

(b)

SCC

8

7

6

5

4

3

2

1

0

e
s
u
o
m

r
e
p
s
r
o
m
u
T

Heated soymilk

Water control

Untreated
control

Soymilk

0

6

9

12
Weeks
(d)

15

18

21

Average untreated tumor

(c)

Figure 11.5  Non-denatured soybean extracts slow the progression of skin cancer in high-risk mice. SKH-1 mice were irradiated with 
UVB (30 mJ/cm2) twice weekly for 20 weeks and then UVB irradiation was stopped (as in ref. 57). Three weeks later, the mice were topi-
cally treated once a day, 5 days/week, for 21 weeks, with non-denatured soymilk, heat-denatured soymilk, or water control. (a) H&E stain-
ing of visible skin lesions and visually unaffected skins (same magnification): Control skin (not exposed to UV and not treated). (b) Largest 
visible lesion of a non-denatured soymilk-treated skins. (c) An average lesion in the high-risk, UV-exposed and untreated group shows a 
well-differentiated SCC. Topical treatment with non-denatured soymilk significantly reduced the severity of the developing skin lesions. 
(d) The number of visible lesions per mouse was determined every 3 weeks. Topical treatment with non-denatured soymilk, but not with 
heat-denatured soymilk, led to a marked reduction in the number of tumors per mouse. (Images courtesy of C. Paine.) 

 
 
 
 
 
 
 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 101

Table 11.2  Soybean Composition Characteristics

Major components

Water
Proteins
Lipids
Carbohydrates
Fiber

Green/Raw % wt/wt

Mature seeds % wt/wt

67
12
  6
11
  4

  8
36
19
29
  8

Source: USDA National Nutrient Database for Standard Reference, 1999. Available at: http://www.nal.usda.gov/fnic/foodcomp/search/.

Table 11.3  Non-Denatured Soy Components with Potential Applications in Skin Care

Soy components

Skin care applications

Small soy proteins (STI, BBI, 

Depigmenting and delay hair 

Lunasin)

growth

Reference(s)

(3–5, 37–38, 63)

Skin softening and smoothing

(60)

Proteins
30%–50%

Lipids
10%–30%

Carbohydrates

Minor components

Others

Large soy proteins (e.g. 
glycinin 360 k-Da, 
β-conglycinin 180 k-Da)
Essential fatty acids (linoleic, 

linolenic, oleic acids)

Antioxidant protection, skin 
lightening, restore barrier 
function

Lecithins/ phospholipids
Di- and oligosaccharides and 

Skin moisture, cleansing
Skin hydration

polysaccharides

Soy flavones
(e.g. Daidzein, genistein, 

daidzin, genistin

Phytosterols

Vitamins (tocopherols)
Minerals

Saponins
Phytic acid

Weak antioxidant and anti-

inflammatory, inhibition of 
tyrosine

Skin moisture, 

anti-inflammatory

Antioxidant
Deficient can cause untoward 

effects
Cleansing
Depigmentating

(60–62)

(60)
(60)

(64–67)

(68–69)

(60)
(71)

(60, 72)
(60)

depigmenting  activity  retained  and  quantified  (3–4).  Unlike 
trypsin inhibitors of soy protein nature, the non-protein tryp-
sin  inhibitors  lack  specificity  and  are  very  susceptible  to  cat-
ionic suppression (59). The large proteins of the non-denatured 
soy extract include hundreds of proteins with varying molecu-
lar weight up to millions Daltons. The most abundant proteins 
are  glycinin  and  conglycinin,  with  molecular  weight  around 
180  k-Da  and  360  k-Da  (60).  Each  protein  group  precipitates 
at  different  pH  values,  which  may  affect  topical  formulation 
preparations.  Non-denatured  soy  contains  essential  fatty 
acids,  including  linoleic  acid  and  linolenic  acids,  which  are 
essential  to  restore  stratum  corneum  barrier  functions  and 
may potentially help acne resolution. These unsaturated fatty 
acids may also provide antioxidant properties (61). In addition, 
linoleic acid is known to enhance skin penetration of various 
compounds (62). Crude soybean oil contains 1%–3% phospho-
lipids, which are the major components of cell membranes (63). 
Phospholipids can also form liposome, a vesicle delivery sys-
tem that could enhance skin penetration for both hydrophilic 
and  lipophilic  large  molecules  such  as  proteins,  and  small 
such  as  alpha-hydroxy  acids.  Non-denatured  soy  contains 
about  30%  carbohydrates,  which  can  provide  skin  hydration 
properties.

Non-denatured  soy  also  contains  minor  components 
like  isoflavones,  vitamins,  and  minerals,  which  could  offer 
important skin care benefits. Isoflavones have been reported 
to  provide  a  number  of  skin  care  benefits.  They  have  weak 
antioxidant  and  anti-inflammatory  activities,  which  are 
important to combat oxidative stresses induced by the sun. 
A number of studies have indicated isoflavones can prevent 
and  treat  sun-induced  cancer  (64–65).  Isoflavones  such  as 
genistein  and  daidzein,  normally  classified  as  phytoestro-
gens, originate in plants, unlike estrogens, which are of ani-
mal origin. The isoflavone structures are nonsteroidal, while 
all estrogenic hormones are steroidal (66–67). Soybean oil can 
contain as much as 0.37% of phytosterols, which are mostly 
in  unsaponifiable  forms  (68).  The  most  significant  phytos-
terols  found  in  oils  and  fats  are  campesterol,  stigmasterol, 
beta-sitosterol, delta 5-avennasterol, and delta7-stigmasterol. 
Phytosterols  are  reported  to  provide  anti-inflammatory 
effects  via  the  arachidonic  cascade.  Clinical  applications 
can  be  found  for  antipruritic  effects,  reducing  sun-induced 
erythema,  and  diaper  dermatitis  (68–69).  Such  characteris-
tics combined with the conditioned use make them possible 
alternatives  to  cortisone  and  corticosteroids,  as  well  as  sili-
cone replacement. Soybeans contain both water-soluble and 
oil-soluble  vitamins.  The  water-soluble  vitamins  present  in 

 
102 

 TEXTBOOK OF COSMETIC DERMATOLOGY

soybeans  mainly  include  thiamin,  riboflavin,  niacin,  pan-
tothenic acid, and folic acid. The oil-soluble vitamins found 
in  soybeans  are  vitamin  A  and  E.  Soybean  oil  contains  a 
substantial  amount  of  vitamin  E,  which  provides  effective 
natural  antioxidant  and  nutrition  values  (70).  Soy  contains 
relatively high levels of desired metal ions such as iron, zinc, 
manganese, magnesium, and calcium that are important in 
skin health. Metal ions play an important role in skin health. 
Deficiency  in  certain  metal  ions  in  the  skin  will  result  in 
unwanted  effects  such  as  dermatitis,  discoloration  of  hair, 
and  retardation  of  hair  growth.  Optimal  metal  ions  such 
as  manganese,  magnesium,  calcium,  and  zinc  are  needed 
to  maintain  skin  health  (71).  Soy  saponins  (2,3-dihydro-2, 
5-dihydroxy-6-methyl-4H-pyran-one) 
carboxyl 
groups,  which  have  surface  activity  for  foaming  and  emul-
sifying  power  in  cosmetic  formulation  (72),  and  are  also 
reported  to  provide  an  active  oxygen-scavenging  effect  in 
the skin and maintain healthy epidermal conditions (73).

contain 

Safety of Non-Denatured Soy for 
Human Topical Applications
It is known that some naturally derived ingredients can elicit 
irritant or allergic responses. Soy has been used for centuries 
and  is  well  known  to  be  safe  for  human  use.  A  systematical 
safety  evaluation  has  been  completed  to  determine  the  clini-
cal topical profiles of the non-denatured soy raw material and 
the non-denatured soy-containing skin care formulations (74). 
Clinical  cumulative  irritation  evaluations  utilized  two  dif-
ferent  methodologies  that  consisted  of  patching  the  subject 
with the formulation over a 2–3 week time period. Method A 
was conducted to assess irritancy, in which a minimum of 25 
subjects  was  patched  continuously  for  a  total  of  six  applica-
tions over a 2-week period. Method B was conducted to assess 
comparative irritation potential of the formulations, in which 
approximately  200  subjects  were  patched  intermittently  with 
the  formulation  three  times  a  week  for  a  total  of  nine  appli-
cations over a 3-week period. All test sites were graded three 
times  a  week  after  patch  removal.  Using  a  scale  of  potential 
total  irritation  score  of  660,  both  non-denatured  soy  and  all 
skin care formulations with soy resulted in negligible cumula-
tive irritation score <10. Comparative cumulative irritation of 
non-denatured  soy  and  vitamin  formulas  also  demonstrated 
negligible  irritation.  Non-denatured  soy  formulations  were 
clinically evaluated with the repeated insult patch test (RIPT). 
These  studies  demonstrated  that  specific  topical  formula-
tions  containing  the  non-denatured  soy  alone,  soy  extract, 
or soy extract in combination with vitamins A and C did not 
induce contact dermal sensitization. Photosensitivity was also 
assessed  by  photoallergy  and  phototoxicity  tests,  which  did 
not  find  any  photosensitivity  when  non-denatured  soy  was 
applied.  Recently,  soy  isoflavones  have  drawn  attention  for 
their  potential  phytoestrogenic  effects.  Soy  isoflavones  differ 
significantly in terms of their molecular structure from estro-
gens, such as estradiol, and they are not metabolized to these 
estrogens. Experimental data suggest that isoflavones exhibit 
an estrogenic-like potency of between 1000 and 100,000 times 
lower  than  estradiol,  depending  on  the  nature  of  the  assay 
used. (75–77). Largely as a result of research in in-vitro or in 
animal  models,  concerns  have  been  voiced  regarding  isofla-
vone use in soy products and soy infant formulas in relation 
to  nutritional  adequacy,  sexual  development,  neurobehav-
ioral  development,  immune  function,  and  thyroid  disease. 
Available evidence from adult human and infant populations 
indicates  that  dietary  isoflavone  consumption  in  soy  infant 

formulas  does  not  adversely  affect  human  growth,  develop-
ment, or reproduction (78).

The  non-denatured  soy  products  contain  much  lower 
concentrations  of  isoflavones,  typically  less  than  0.01%  soy 
isoflavones, which is negligible compared to the level of phy-
toestrogen  intake  by  average  consumers  in  most  Western 
countries. By way of example, following European guidelines, 
the  estimated  maximum  exaggerated  topical  exposure  from 
non-denatured  soy  products  (0.96  mg/day)  is  considerably 
lower than the measured dietary intake for mid-life Australian 
women  (~  17  mg/day)  (79),  which  is,  in  turn,  less  than  the 
exposure  by  infants  fed  soy-based  formula  milk  (22–45  mg 
/day)  (80).  Moreover,  the  potential  systemic  isoflavone  expo-
sure  from  the  non-denatured  soy  products  (assuming  60  kg 
body weight, 0.00208 mg/kg/day = 2.08 ng/g/day) is insignifi-
cant  when  compared  to  typical  systemic  concentrations.  For 
example, the endogenous systemic plasma baseline concentra-
tion for U.S. adult women is 7.94–34.54 ng/mL (81) and for UK 
adult  women  consuming  20  g  roasted  soybean  products,  the 
systemic concentration is 540ng/mL genistein (82).

Broadly speaking, however, a rank order may be deter-
mined  of  daily  isoflavone  intake:  soy  formula  fed  infant 
(approximately  40  mg/day),  average  Japanese  consumer 
(approximately 25–100 mg/day), vegetarian consumer (approx-
imately  3  mg/day),  average  consumer  (approximately  1  mg 
/day) (109). There is no data documenting that soy extract or 
soy  oil  has  estrogenic  effects  when  applied  to  the  skin  as  it 
might when taken orally at high doses (83).

A  new  longer-term  (2  years),  multicenter,  randomized, 
double-blind,  placebo-controlled  clinical  trial  assessed  the 
effects of daily high level of supplementation with 80 or 120 mg 
aglycone  equivalent  soy  hypocotyl  isoflavones  plus  calcium 
and  vitamin  D  on  the  health  of  403  postmenopausal  women 
(84). At baseline and after 1 and 2 y, clinical blood chemistry 
values  were  measured  and  a  well-woman  examination  was 
conducted, which included a mammogram and a Papanicolaou 
test.  A  cohort  also  underwent  transvaginal  ultrasound  mea-
surements  to  assess  endometrial  thickness  and  fibroids.  The 
baseline  characteristics  of  the  groups  were  similar.  After  2  y 
of  daily  isoflavone  exposure,  all  clinical  chemistry  values 
remained  within  the  normal  range.  Isoflavone  supplementa-
tion  did  not  affect  blood  lymphocyte  or  serum  free  thyrox-
ine  concentrations.  No  significant  differences  in  endometrial 
thickness  or  fibroids  were  observed  between  the  groups.  It 
concluded that daily supplementation for 2 y with 80–120 mg 
soy hypocotyl isoflavones has minimal risk in healthy meno-
pausal women.

A placebo controlled in-vitro dermal absorption study 
using human cadaver skin found that the potential systemic 
soy isoflavones absorption from topical applications of non-
denatured  soy  products  is  below  the  detection  limits  of  the 
current  state-of-the-art  analytical  instrumentation  and  neg-
ligible  compared  to  any  endogenous  levels  of  isoflavones 
resulting from dietary soy consumptions or supplement con-
sumptions of infant soy milk. The potential local epidermal 
and dermal accumulations for soy isoflavones are estimated 
to be at least 2500 times lower than the no-observed adverse 
effect  level  (NOAEL)  limit.  In  summary,  soy  isoflavones  are 
naturally occurring in non-denatured soy at trace levels, and 
their potential systemic absorption is negligible and presents 
no harmful risks to human health.

Council  of  Europe  guidance  on  the  use  of  plants  in 
cosmetics  specifically  endorses  the  use  of  soy  extracts.  With 
particular  reference  to  phytoestrogens,  guidance  from  1994 

 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 103

provides that “the use of a natural ingredient in cosmetic prod-
ucts is recommended only if the finished products are free of 
estrogenic activity” (85). More recent guidance explicitly con-
firms that glycine soja (soy) ingredients including soy extracts 
containing isoflavones and phytoestrogens, can be used in cos-
metics. It classifies them as “category A” ingredients (i.e. ingre-
dients that are considered to be safe) and specifically envisages 
their use in concentrations up to 5%.

The  official  International  Nomenclature  of  Cosmetic 
Ingredients (INCI) confirms that soy extracts may be used in cos-
metics 
(http://www.cosmeticsinfo.org/ingredient/glycine- 
soja-soybean-protein-and-related-ingredients).  The  entry  for 
glycine  soja  covers  the  following:  “Soybean  oil.  Extractives 
and their physically modified derivatives. It consists primar-
ily of the glycerides of the fatty acids linoleic, oleic, palmitic 
and  stearic.  (Soja  hispida,  Leguminosae).”  The  official  INCI 
list  also  lists  other  permitted  plants  and  their  extracts  that 
are known to contain phytoestrogens, such as Daucus carota, 
Hederal helix, and Humulus lupulus. All four plants are also 
referred to by the Council of Europe as containing phytoes-
trogens (85).

There  is  an  increasing  public  concern  that  genetically 
modified  (GMO)  plants  may  be  harmful,  and  some  scientific 
publications  claiming  danger  have  received  attention  in  the 
media. However, there is a broad scientific consensus that GMO 
plants  on  the  market  poses  no  greater  risk  to  human  health 
than conventional plants. Nevertheless, consumer prefers non-
GMO  soybean  or  conventional  harvested  soybean–derived 
products.  Non-denatured  soy  uses  high  quality  non-GMO 
soybean to address consumer’s needs.

Preclinical Results of Non-Denatured Soy
Non-denatured  soy  has  been  found  to  show  multiple  bioac-
tivities  including  trypsin-inhibitory  activity,  stimulating  col-
lagen and elastin production, anti-inflammatory, antioxidant, 
anti-stress/thiol  retention,  and  anti-UVB  damage  activity.  A 
summary of the biological activities of non-denatured soybean 
extracts and their relevance to skin health and beautify can be 
found in reference 86.

Trypsin Inhibitory Activity of Non-Denatured Soy
Soy preparations containing various levels of non-denatured 
soymilk  resulted  in  a  dose-dependent  inhibition  of  trypsin 
activity, measured by an in-vitro fluorescence assay. A stabi-
lized soy formulation containing non-denatured soy protein 
STI was developed (87). The stability of the STI was monitored 
by  enzyme  inhibition  assay  and  Western  blot.  The  results 
illustrate that the soy formulation retained the serine prote-
ase inhibitory activity. The STI protein was shown to be intact 
by  Western  blot  analysis  after  1  year  at  room  temperature 
(Figure 11.6).

Collagen Production
Preclinical  studies  of  a  non-denatured  soy  composition  were 
investigated  for  in-vitro  collagen  production  via  monitoring 
normal  human  dermal  fibroblast  synthesis  method.  Table  11.4 
shows that non-denatured soy could stimulate collagen synthe-
sis (88–89). For a non-denatured soy concentration as low as 0.01 
mg/mL, the increase rate in the fibroblasts was found to be 33% 
after 72 hours of non-denatured soy action at 37oC in a humidi-
fied atmosphere.

Elastin Enhancement
The  effect  of  non-denatured  soy  on  elastin  production  was  
evaluated  preclinically  on  swine  skin  (88).  The  histologi-
cal  analysis  from  these  elastin  evaluations  demonstrates 
an  increase  in  fine  and  highly  branched  elastin  fibers  after 
non-denatured  soy  composition  applications,  as  shown  in 
Figure 11.7, suggesting the capability of non-denatured soy to 
enhance skin elasticity. Swine studies with the application of 
non-denatured soy composition, twice a day, 5 days/week, for 
9 weeks showed no visual irritation, and histological analyses 
revealed  no  markers  of  irritation  or  other  pathological  signs. 
Sections from biopsies were stained with Luna stain, to docu-
ment elastin fibers. At least three sections per biopsy, two sites 
per  swine  were  processed.  Each  experiment  was  repeated  at 
least  three  times.  Histological  analysis  of  Luna-stained  sec-
tions  demonstrates  an  increase  in  fine  and  highly  branched 
elastin  fibers  at  the  upper  part  of  the  dermis  following  soy 
treatments  as  shown  in  Figure  11.7.  This  increase  in  elastin 

Western bolt of STI in cosmetic formulations

1

2

3

4

5

6

1, 2 – size markers
3 – STI  markers
4 – Ess-23
5 – Ess-23 placebo
6 – Future white essence HR

Figure  11.6  Western  blots  comparing  a  non-denaturing  soy 
(Total  Soy)  product  to  a  soy  product  using  a  single  soy  compo-
nent. According to Western blot analysis, the STI protein was com-
promised for soy products using a single soy component. The STI 
protein  was  intact  after  1  year  at  room  temperature  for  the  non-
denatured soy preparation.

Table 11.4  Effect of Non-Denatured Soy Complex on Extracellular Collagen Synthesis in Normal Human Dermal Fibroblasts

Collagen synthesis

(dpm/cell) ×1000*1000

Stimulation

Control

11.26 ± 1.62

Non-denatured soy (µg/mL)

0.01

15.0 ± 1.46
NS
+ 33 %

0.1

13.68 ± 2.51
NS
+ 21 %

1

17.80 ± 2.01
P < 0.05
+ 58 %

Abbreviation: NS: nonsignificant
* dpm = disintegration per minute, a unit measuring radioactivity level. The collagen synthesis assay uses a radioactive precursor and measures 
radioactivity of the collagen product.

 
104 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(a, b) Histological analysis of Luna-stained sections 
Figure 11.7 
demonstrates  an  increase  in  fine  and  highly  branched  elastin 
fibers at the upper part of the dermis following soy treatments as 
displayed.

staining  resembles  a  “repair  zone,”  as  documented  for  the 
effect of retinoids on UV-damaged skin (90).

 Anti-Inflammatory and Antioxidant Activities
The  non-denatured  soy  extract  was  found  to  be  active  against 
the  acute  oxazolone  application  on  mouse  ear  edema  (91). 
Oxazalone was used to induce contact hypersensitivity or edema 
in mouse ear and the inhibition of edema was used to determine 
the degree of anti-inflammation activity. The studies showed that 
a 2% non-denatured soy lotion induced about 56% edema inhibi-
tion vs. 8% for its placebo control. As a comparison, 0.1% hydro-
cortisone induced an inhibition of 86%. The non-denatured soy 
extract was also found to have antioxidant activity.

Anti-Stress/Thiol Retention Activity
Non-denatured soy was found to maintain normal cell metabo-
lism, even when exposed to a harsh environments such as envi-
ronmental pollution, e.g. smoke-induced loss of thiols (92). The 
ability  of  non-denatured  soy  to  prevent  smoke-induced  loss 
of  thiols  was  evaluated  in  normal  human  dermal  fibroblasts 
(Clonetics,  San  Diego,  CA).  Thiols,  chiefly  glutathione  (GSH), 
are  part  of  the  endogenous  cellular  antioxidant  defense  sys-
tem.  GSH  serves  as  a  redox  buffer,  thereby  maintaining  the 
balance  between  oxidants  and  antioxidants  (93).  GSH  is  also 
the preferred substrate for several enzymes such as the GSH 
peroxidases  (decomposing  peroxides)  and  the  glutathione-S-
transferases (a major group of detoxification enzymes) (94).

Cutaneous  antioxidants  (both  enzymatic  and  non-
enzymatic),  including  GSH,  are  depleted  after  UV  or  ozone 
exposure (95–96). In cell culture models, low intracellular GHS 
levels  lead  to  a  higher  UV  radiation  sensitivity.  Glucothione 
is a major endogenous antioxidant, highly responsive against 
environmental  challenges,  able  to  regulate  the  tone  and  the 
wrinkling of skin, as well as treat external aggression.

The effects of non-denatured soy in preventing smoke-
induced stress are displayed in Table 11.5. The results indicate 
that  non-denatured  soy  afforded  protection  against  smoke-
induced loss of thiols or thiol retention activity. Data represent 
the mean ± standard of the mean of replicates from three inde-
pendent experiments. Thiol retention activity is the ability of 
the non-denatured soy at a concentration of 1%( w/v) to inhibit 
smoke-induced loss of thiols, as measured by the above assay.

Reduction in UVB-Induced Skin Damage
The incidence of non-melanoma skin cancers is increasing, and 
agents that can prevent or reduce UVB-induced skin cancer are 

Table 11.5  Thiol Retention Activity Measurement for Non-
Denatured Soy

Environmental 
stress

Non-
denatured soy 
complex 
concentration 
(weight %)

Thiol retention activity %*

No Smoke
Smoke (10 min.)

0
0
0.5
1
2

100 ± 6.71
65.38 ± 7.16
91.24 ± 14.25
95.39 ± 4.52
106.92 ± 17.06

*Thiol  retention  activity  %  (%  thiols  contained  in  No  Smoke  Group; 
mean ± S.E.M.)

desired. The BBI protein is a known cancer suppressive agent 
that is effective in many different species, in different organs 
and tissues, and when given via different routes of adminis-
tration  (26).  Recent  studies  showed  that  pretreatment  with 
non-denatured  soy  extracts,  BBI,  and  STI  proteins  reduced 
UVB-induced skin tumor formation and progression in high-
risk  hairless  mice  with  low  dose  of  UVB  pretreatment  for  a 
long time (58). In contrast, denatured soy extracts were found 
to have no effects on skin tumor formation and progression.

Multiple mechanisms of action were identified for non-
denatured soybean extracts. In vitro, non-denatured soybean 
extracts  enhanced  UVB-induced  checkpoint  kinase-1  (Ck1) 
activation,  suggesting  a  delay  in  cell  cycle  progression  that 
enables longer time for DNA repair. Non-denatured soybean 
extracts display anti-inflammatory activity via reduced UVB-
induced  COX-2  expression  and  prostaglandin  E2  secretion, 
and  inhibited  p-38  MAP  kinase  activation.  Mice  pretreated 
topically  with  non-denatured  soybean  extracts  had  reduced 
levels  of  UVB-induced  TT  dimers  and  COX-2  expression  in 
their  skins  compared  with  UVB  alone.  Non-denatured  soy-
bean extracts also inhibited vascular endothelial growth fac-
tor  (VEGF)-induced  endothelial  tube  formation  in  Matrigel, 
suggesting  a  possible  inhibitory  effect  on  angiogenesis  and 
tumor progression. These findings suggest that topical appli-
cation  of  non-denatured  soybean  extracts  could  potentially 
reduce  the  incidence  of  skin  cancer,  via  multiple  molecular 
mechanisms, at both the tumor initiation and tumor progres-
sion stages (54).

Non-Denatured Soybean Extracts Reduce Skin 
Cancer Risk by Multiple Mechanisms
Non-denatured  soybean  extracts  contain  multiple  agents 
and  are  expected  therefore  to  act  by  multiple  mechanisms. 
Mechanism-of-action studies identified effects of these extracts 
both at the initiation stage and during the progression of skin 
tumors,  with  multiple  mechanisms  affecting  the  tumor  and 
the microenvironment (54). Hairless mice and Yucatan swine 
were  topically  treated  with  non-denatured  soybean  extracts 
for several days prior to UVB exposure. Histochemical stain-
ing  documented  reduced  formation  of  UVB-induced  DNA 
damage (T-T dimers) and reduced numbers of apoptotic cells. 
Non-denatured  soybean  extracts  inhibited  matrix  metallo-
proteinase  (MMP)  expression  in  vivo,  suggesting  the  inhibi-
tion  of  dermal  ECM  degradation  and  remodeling,  which  are 
required for tumor progression. In vitro, these extracts inhib-
ited  VEGF-induced  endothelial  tube  formation  in  Matrigel, 

 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 105

suggesting  a  possible  inhibitory  effect  on  angiogenesis  and 
tumor  progression.  The  ability  to  inhibit  multiple  proteases 
and to enhance elastin and collagen production (47), the ability 
to inhibit the COX-2 pathway (54), and the content of intact STI 
and  BBI  suggest  that  non-denatured  soybean  extracts  could 
affect the tumor and the microenvironment at multiple stages 
of  skin  cancer  initiation  and  development.  Topical  treatment 
with  non-denatured  soybean  extracts  could  therefore  reduce 
UVB-induced DNA and cellular damage, and reduce microen-
vironment processes affecting tumor progression, suggesting 
that daily topical treatment could reduce the risk of skin cancer 
development.

Reduction in Visible Light–Induced Skin Oxidative Stress
A new study (97) demonstrated that irradiation of human skin 
equivalents  with  visible  light  (400–700 nm)  could  induce  the 
production of reactive oxygen species (ROS), pro-inflammatory 
cytokines,  and  MMP-1  expression.  Human  subjects  were 
exposed  to  visible  light,  and  chemiluminescence  was  mea-
sured  as  a  marker  of  ROS.  A  50  Jcm−2  dose  of  visible  light  at 
150  mW cm−2  significantly  increased  free-radical  production 
(p < 0.05), compared with untreated skin (N = 40). Commercially 
available  sunscreens  were  found  to  have  minimal  effects  on 
reducing  visible  light–induced  ROS,  suggesting  that  UVA 
/UVB  sunscreens  do  not  protect  the  skin  from  visible  light–
induced responses. However, pretreatment with a photo-stable 
UVA/UVB sunscreen containing an antioxidant combination 
of  non-denatured  soy  extract,  feverfew  (Tanacetum  parthe-
nium) extract, and Gamma tocopherol, compared to the sun-
screen  alone  (N = 12  per  group  of  sunscreens),  significantly 
reduced the production of ROS, cytokines, and MMP expres-
sion in vitro, and decreased oxidative stress in human subjects 
after visible light irradiation at 65 J/cm2.

Clinical Efficacy of Non-Denatured Soy
Reduction of Hyperpigmented Spots
A  stabilized  non-denatured  soy  formulation  was  tested  on  a 
Caucasian  male  population  with  solar  lentigine  hyperpig-
mented lesions (98). The effect of stabilized non-denatured soy 
formulation was compared with that of 15% azelaic acid or 12% 
glycolic  acid.  After  3  weeks  of  once-daily  treatment,  the  pig-
mented lesions were significantly lightened. The effect of stabi-
lized non-denatured soy formulation is comparable to or better 
than either to 15% azelaic acid or 12% glycolic acid according 

to dermatological grading. In another open-label clinical study 
on  a  Caucasian  population  with  various  types  of  pigmented 
lesions,  the  stabilized  non-denatured  soy  formulation  was 
found to improve 78% tested subjects in dermatological grad-
ing (Figure 11.8).

Reduction of Facial Lengtigines (Age Spots)
Manifestations of photodamage are multidimensional, includ-
ing  facial  lentigines,  mottled  hyperpigmentation,  skin  tone 
deterioration (sallowness), and skin texture deterioration with 
the appearance of fine lines, coarse and fine wrinkles, and skin 
roughness. Overall, photodamage has many visible character-
istics.  There  are  numerous  prescription  and  OTC  cosmetics 
that  target  photodamage.  Certain  prescription  products  such 
as  hydroquinone  are  effective  in  targeting  hyperpigmented 
legions  but  result  in  unknown  side  effects.  There  is  a  strong 
need for products which are effective over a broader range of 
photodamage  symptoms  as  well  as  being  gentle  to  the  pho-
todamaged  skin.  The  non-denatured  soy  preparation  was 
proven to reduce the appearance of solar lentigines. A 12-week 
randomized,  blind,  half-face  benchmark-controlled  clinical 
study was conducted on N = 52 skin Type I-III healthy subjects 
with solar lentigines/mild-moderate photodamage (2–5 on a 9 
scale)  to  evaluate  the  clinical  efficacy  of  a  moisturizer  lotion 
containing 2% non-denatured soy in reducing the appearance 
of solar lentigines (99). Melanex (3% hydroquinone) was used 
as a benchmark. Negligible signs of irritation (rash, erythema, 
edema,  stinging,  burning,  and  itching)  or  sensitization  were 
reported  in  the  non-denatured  soy–treated  population.  Non-
denatured soy lotion had significant (p < 0.01) improvement in 
facial lentigines, overall photodamage, mottled hyperpigmen-
tation, and skin sallowness from week 4 vs. baseline. The non-
denatured  soy  lotion  had  no  significant  difference  in  overall 
photodamage (p>0.71) vs. Melanex. At 8 weeks, facial age spot 
and brown spot reduction was observed by 48% of the subjects 
for non-denatured soy lotion. In the same clinical study, non-
denatured  soy  also  had  a  significant  improvement  in  coarse 
wrinkles from week 8 (p = 0.057) and significant improvement 
in  laxity  (p = 0.057)  at  week  12  vs.  baseline.  Non-denatured 
soy  was  significantly  superior  to  Melanex  in  surface  rough-
ness  reduction  (p < 0.056)  and  in  facial  sallowness  reduction 
(p < 0.02) at the end of the study (week 12). These results sug-
gest  that  the  non-denatured  soy  formulation  may  be  consid-
ered for reducing lentigenes or age spots.

(a)

(b)

(a) A non-denatured soy formulation containing STI was tested on a female population with hyperpigmented lesions (n = 42). 
Figure 11.8 
(b) After 8 weeks of once-daily treatment on the selected lesions, the pigmented lesions were significantly lightened, thereby evening the 
appearance of skin tone.

 
106 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 11.9 
The measurement was conducted at 24 hours post exposure.

(a) A Caucasian male volunteer treated half of his face with soy once daily for 6 weeks followed by an 8-hour exposure (b). 

(a)

(b)

Reduction of Ultraviolet-Induced Damage
Other proven benefits include reducing UV-induced erythema 
and flakiness (100–101) (Figure 11.9). Based upon the preclini-
cal learning of non-denatured soy in preventing UV-induced 
pigmentation,  a  topical  non-denatured  soy  formulation  was 
tested  in  a  placebo  controlled  clinical  study  on  Type  I  and 
III  skins  with  0.8–2  MED  UV  irradiation.  Both  pretreatment 
and post treatment were performed on six different subjects, 
each for 5 consecutive days. Evaluation techniques employed 
to  determine  the  effect  of  non-denatured  soy  on  the  irradia-
tion  included  visual  clinical  assessment,  diffused  reflectance 
spectroscopy,  photo  imaging,  and  desquamation  taping. 
Observations  were  made  at  24  hours  and  7  days  post  treat-
ment.  Dermatologists’  clinical  assessment  displayed  that  an 
immediate application of non-denatured soy reduced redness 
induced  by  UV  irradiation  at  0.8–1.5  MED.  Clinical  assess-
ment  also  indicated  that  a  consecutive  5-day  application  of 
non-denatured  soy  protected  skin  from  UV-induced  red-
ness. Diffuse reflectance spectroscopy further illustrated that 
reduction of redness occurred at the highest irradiation dose 
(2 MEDs) in this clinical study. In follow-up measurements at 
7 days post irradiation, it was found that flakiness existed for 
some of the control sites (placebo or untreated), however none 
was  found  in  both  preventive  treatment  and  post  treatment. 
The  study  clearly  demonstrates  the  usefulness  and  potential 
of non-denatured soy for daily defense against sun irradiation.

Non-Denatured Soy and UVA/UVB Protection
A double-blind, placebo-controlled clinical study was performed 
to  determine  the  benefits  of  using  a  daily  non-denatured  soy 
facial preparation with broad spectrum SPF 30 in improving var-
ious skin tone and textural parameters (102–104). Sixty-three pan-
elists between the ages of 30 and 50 exhibiting moderate levels 
of skin roughness, blotchiness, and mottled hyperpigmentation 
were enrolled into the 12-week study. Dermatologist evaluations, 
self-assessments,  and  instrumental  analysis  were  completed 
at  various  time  points  during  the  study.  Dermatologist  evalu-
ations  demonstrated  significant  improvements  (p < 0.05)  in 
skin  roughness,  clarity,  and  mottled  hyperpigmentation  after 
2  weeks’  use  of  the  non-denatured  soy  facial  preparation  con-
taining  SPF  30.  Significant  improvements  (p < 0.05)  in  mottled 

hyperpigmentation,  blotchiness,  appearance  of  fine  lines,  and 
overall skin tone and texture were observed vs. the placebo con-
trol group after only 2 weeks of use. Non-denatured soy showed 
improvements  in  mottled  hyperpigmentation,  blotchiness,  and 
fine  lines  when  compared  to  the  placebo  control  group  and 
baseline mean values. After 4 weeks of use there was over a 35% 
mean  improvement  in  skin  blotchiness  and  clarity  of  the  skin. 
Colorimetry showed a significant increase (p < 0.05) in skin lumi-
nosity  with  a  significant  decrease  (p < 0.05)  in  yellowness,  cor-
relating to an improvement in skin brightness and overall skin 
tone.  Self-assessments  showed  that  subjects  began  to  perceive 
significant improvements (p < 0.05) in various skin tone, texture, 
and brightness parameters as early as 1 week of using the non-
denatured  soy  and  SPF  30  facial  moisturizer.  Additional  stud-
ies showed that the non-denatured soy and SPF 30 moisturizer 
was noncomedogenic, gentle to the skin, and did not induce der-
mal  sensitization.  The  sunscreens  used  in  this  non-denatured 
soy  moisturizer  have  been  shown  to  be  compatible  with  non-
denatured  soy  and  photostable  in  both  clinical  and  scientific 
studies (102–103).

Delay in Hair Regrowth
A  double-blind,  placebo  controlled  study  examining  leg 
hair  regrowth  enrolled  20  women  aged  29  to  55.  All  subjects 
shaved  immediately  before  the  baseline  randomization  visit 
and then just once a week prior to returning for the follow-up 
assessments.  Evaluations  consisted  of  patient  and  investiga-
tor ratings of hair growth and adverse events. In addition, the 
treatment effects were quantified in terms of hair counts and 
hair growth rates through digital analysis of video microscope 
images  taken  of  two  areas  of  each  leg—one  toward  the  knee 
and the other close to the ankle. All of the women completed 
the study, and the only adverse effect reported was mild dry-
ness. The digital analyses showed that mean hair regrowth rate 
was  unchanged  on  the  placebo-treated  leg  but  progressively 
decreased with application of the non-denatured soy-based gel 
(Figure 11.10). As a result, the mean regrowth rate was consis-
tently  reduced  on  the  treated  leg  for  both  areas  measured  at 
each weekly visit. By study end, the between-group difference 
for the effects on the lower portion of the leg achieved statisti-
cal significance.

 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 107

Hair  counts,  which  included  any  stubble,  were  consis-
tently  lower  on  the  soy-treated  leg  compared  with  placebo 
beginning  by  week  2.  However,  there  were  large  standard 
deviations  in  the  means  and  the  differences  between  treat-
ments  did  not  achieve  statistical  significance.  The  subjective 
evaluations  from  the  study  participants  indicated  the  treat-
ment caused the hair to regrow more slowly and that the hair 
present  was  softer.  The  proportion  of  women  noting  both  of 
those outcomes increased over time was significant. At week 1, 
about 40% of women noted the hair on the soy-treated leg was 
softer  and  about  35%  noticed  the  growth  rate  was  reduced. 
At week 4, about two-thirds of the participants indicated that 
the hair on the soy-treated leg was softer and showed a reduced 

growth rate. For the weekly assessments of the placebo-treated 
leg, between 5% and 22% of women considered the hair that 
regrew to feel softer, while 12% to 28% remarked that the hair 
growth rate was reduced. The results of self-assessments were 
consistent with investigator ratings that noted beneficial differ-
ences in hair appearance and quality favoring the soy-treated 
leg.  Two-thirds  of  the  study  participants  documented  delay-
ing  hair  regrowth,  and  smoothing  and  moisturizing  of  the 
skin  (106–107).  The non-denatured soy lotion  was  also  found 
to reduce the facial hair area, length, and width for a male sub-
ject of Fitzpatrick skin type II, who shaved daily followed by 
applying a soy preparation daily for 4 weeks as illustrated in 
Figure 11.11.

(a)

(b)

(a) A double-blind, placebo-controlled study examining leg hair regrowth comparing soy formula vs placebo. (b) Mean hair 
Figure 11.10 
regrowth rate was stable on the placebo-treated leg but progressively decreased with application of the soy-based gel (active) after 2 
weeks of the application of soy preparation.

Control

Soymilk

(a)

(b)

i

e
d
S
r
e
p
d
e
t
n
u
o
C
s
r
i
a
H
0
8
1
f
o
e
g
a
r
e
v
a

l

a
t
o
T

80

70

60

50

40

30

20

10

0

Soymilk Facial Hair Study
Image analysis of one image from each side of the face
(treated side and untreated side)

Area

Length

Width

(c)

Figure 11.11  Three Caucasian male volunteers, Fizpatrick skin type II, who shaved daily followed by application of a soy preparation 
daily for 4 weeks. (a) Shows the control and (b) the soymilk results for the shaved areas. (c) Average hair area, length, and width at the 
end of the study.

 
 
 
 
 
 
 
 
108 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 11.12  Caucasian female subject (a) before and (b) after using non-denatured soy preparation. After 45 days of non-denatured 
soy product application, there was a statistically significant reduction in erythema and inflammatory papules (p < 0.001).

Improvement of Acneic Inflammatory Lesions
The soy preparation was also proven to reduce acne-related 
blotchiness  and  erythema.  A  pilot  clinical  study  was  con-
ducted  to  evaluate  the  potential  of  a  non-denatured  soy 
formulation  to  reduce  erythema  and  acne  lesions  in  acne 
sufferers  and  to  look  at  the  potential  of  this  formulation 
to induce acne lesions in normal subjects. In the mild acne 
group, there was a statistically significant reduction in ery-
thema  and  inflammatory  papules  after  treatment  with  the 
soy  preparation  (p < 0.001).  There  was  a  statistical  trend 
in  the  reduction  of  the  number  of  non-inflammatory  com-
edones (Figure 11.12) (108). There was no incidence of acne 
induction  by  the  treatment.  Twenty-six  subjects  with  mild 
acne  and  29  subjects  with  no  acne  were  entered  into  this 
open  label  study  after  Institutional  Review  Board  (IRB) 
approval and informed consents. All subjects were female, 
64%  were  Caucasian  and  36%  were  black.  Subjects  applied 
the test product twice daily. Clinical safety evaluations were 
made on days 3, 7, 14, 21, 28, and 35. Dermatologist evalua-
tions were made on day 0 (baseline) and day 45. In subjects 
with no acne, there was no statistically significant increase 
in  comedones  or  papules  and  pustules.  For  those  subjects 
with mild acne, a highly significant decrease from baseline 
in  the  number  of  inflammatory  papules  (p = 0.001),  a  41.9% 
decrease, was noted after 45 days of treatment with the soy 
preparation  (79).  This  soy  product  was  exceptionally  well 
tolerated  with  no  reports  of  stinging,  burning,  or  itching 
at any time point evaluated. These results suggest that this 
non-denatured soy formulation may be considered as non-
comedogenic and may be utilized as an important therapeu-
tic option in acne sufferers.

Enhancement in Skin Firming
In  addition  to  the  enhancement  in  skin  collagen  production 
and  elastin  repair  discussed  in  the  section  of  “Preclinical 
Results  of  Non-Denatured  Soy,”  clinical  studies  have  further 
indicated that a soy composition containing a complete spec-
trum  of  soy  components  can  improve  skin  firming  and  elas-
ticity. In a 12-week double-blind randomized clinical study of 
skin aging, using a full-face design with twice daily applica-
tions, the non-denatured soy composition provided significant 
improvement in skin laxity versus baseline as early as week 4. 
Cutometer measurements further supported the dermatologist 
assessment in that 100% of the non-denatured soy–treated sub-
jects showed improvement in skin firmness and distensibility.

Sebum Production and Moisturization Balance 
in Combination Skin
A  5-week,  half-face,  double  blind  placebo-controlled  clinical 
study was performed in 23 female subjects of ages 20 to 35 years 
with  combination  skin  (Fitzpatrick  type  I–II).  Combination 
skin  was  defined  as  facial  skin  having  at  least  one  oily  area 
and  one  dry  area  on  each  of  the  half  face.  The  oily  and  dry 
areas were determined by sebumeter reading at >200 mg/cm2 
and  <66  mg/cm2,  respectively.  Subjects  applied  soy  prepara-
tion  or  placebo  on  the  designated  side  of  the  face  daily  for  5 
weeks. Measurements were taken at baseline and weeks 1, 3, 
and  5  on  the  forehead,  cheek,  and  chin.  Scaling,  moisturiza-
tion, oiliness, and smoothness were evaluated by instrumental 
measurements and digital photography. The results indicated 
this  non-denatured  soy  preparation  significantly  reduced 
sebum in oily patches (p < 0.05 for chin areas, as displayed in 
Figure 11.13) and enhanced moisturization for dry patches as 

 
APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 109

compared to placebo (p < 0.05). Subject self-assessments dem-
onstrated enhanced skin smoothness and oil reduction, which 
correlated  with  the  instrumental  results.  Approximately  70% 
of  the  subjects  noted  improvement  on  the  soy  treated  side 
while only 17% on placebo treated side noted improvement in 
overall tone and texture.

formulations. The skin care formulas prepared from non-dena-
tured soy are stable throughout their shelf life, and possess the 
key bioactivities summarized in Table 11.6. These bioactivities 
were then proven in clinical studies to improve the skin condi-
tion, including reduction in hyperpigmentation, sun damage, 
unwanted hair, overly oily and dry skin, and acne.

Effects on Ethnic Skin
Skin  color  is  the  most  noticeable  difference  among  different 
ethnic  skins.  Post-inflammatory  hyperpigmentation  (PIH)  is 
of major concern to dark-skinned individuals. Non-denatured 
soy lotion combined with retinol and salicylic  acid  has  clini-
cally proven to reduce incidence and severity of PIH in as early 
as 1 week (108).

A 4-month double-blind, placebo controlled, randomized 
clinical study was conducted to evaluate the efficacy of a topi-
cal non-denatured soy formulation in improving the appear-
ance of acne and post-acne PIH in 41 male and female Asian, 
African-American,  and  Hispanic  subjects  with  Fitzpatrick 
skin type III–V and mild acne vulgaris (10–50 total facial acne 
lesions), 12 to 45 years of age. Subjects had physically distinct 
recent facial PIH acne marks. Subjects were asked to apply the 
test preparation twice daily (a.m. and p.m.) on the face.

The non-denatured soy composition led to a significant 
decrease in darkness, roughness, and erythema compared to 
baseline at week 4 and continued at weeks 8, 12, and 16, with 
reduction in darkness seen as early as week 1. Clinical expert 
grading  of  photos  showed  that  the  non-denatured  soy  lotion 
induced average improvements in PIH size of 41% at week 4, 
68% at week 8, 82% at week 12, and 92% at week 16. This was 
statistically significantly more effective than the placebo com-
position at weeks 4, 8, 12, and 16. This composition was effec-
tive  on  91%  of  subjects  at  week  4  and  on  100%  of  subjects  at 
weeks 8, 12, and 16.

Further statistical analysis of the data also showed that 
the  non-denatured  soy  composition  worked  faster  than  the 
placebo in reducing the size and darkness of PIH marks.

Non-denatured soy also addressed the important issues 
of using natural ingredients for skin care, including being free 
of any trace pesticides/herbicides and any toxic heavy metals, 
e.g.  lead  and  arsenic,  being  produced  from  non-GMO  beans, 
and having very low microbial contents adequate for cosmetic 

CONCLUDING REMARKS
Fundamental  understanding  of  the  mechanisms  of  action  of 
soy actives led to the discovery of a new depigmenting option. 
Additional scientific studies demonstrated that non-denatured 
soy,  which  contains  a  complete  spectrum  of  non-denatured 
soy components, provides broad skin care benefits. Thorough 
studies and safety reviews supported non-denatured soy as a 
long-term solution to skincare.

ACKNOWLEDGEMENT
The authors thank Dr. Ying Sun for valuable scientific input.

e
g
n
a
h
C
%

0

-5

-10

-15

-20

-25

-30

-35

-40

Soy

Placebo

Week 0

Week 3

Week 5

Time after product use

Figure  11.13  The  non-denatured  soy  preparation  significantly 
reduced sebum production in oily patches (p < 0.05 for chin areas) 
versus placebo.

Table 11.6  Summary of Recent Results in Understanding Soy’s Bioactivity and Its Therapeutic Effects on Human Skin

In-vitro tests

Non-denatured soy’s bioactivity/therapeutic 
effects on human skin

Thiol retention activity antioxidant

Maintain the normal skin cell metabolism 

Reference(s)

73,83

Soybean trypsin inhibition activity

Collagen synthesis
Elastin
Anti-inflammation

even when exposed to a harsh 
environment (e.g., smoke-induced loss of 
thiols)

Protease-activated recptor-2 (PAR-2) in skin 
depigmentation (e.g., freckles, mottled 
hyperpigmentation, age spots) and delay 
hair regrowth

Enhance skin firming
Enhance skin elasticity
Reduce skin scaliness, erythema, and pain 
associated with sun exposure; reduce 
number of inflammatory papules 
( p < 0.001 vs baseline) in mild acne 
subjects

3–5, 37–38, 47, 90–92

86
86
47, 99–101

 
 
110 

 TEXTBOOK OF COSMETIC DERMATOLOGY

REFERENCES

1.  Chen  KT,  ed.  General  Explanation  of  Compendium  of  Materia 

Medica, Xue Yuan, 1992:1255–8.

2.  Scambia G, Mango D, Signorile, PG, et al. Clinical effects of a 
standared soy extract in postmenopausal women: A pilot study. 
Menopause 2000; 7:105–11.

3.  Seiberg  M,  Paine  C,  Sharlow  E,  et  al.  The  protease-activated 
receptor-2 regulates pigmentation via keratinocyte-melanocyte 
interactions. Exp Cell Res 2000; 254:25–32.

4.  Paine C, Sharlow E, Liebel F, et al. An alternative approach to 
depigmentation by soybean extracts via inhibition of the PAR-2 
pathway. J Invest Dermatol 2001; 116:587–95.

5.  Seiberg  M,  Liu  J-C,  Sharlow  E,  Shapiro  S.  Soymilk  reduces 
hair  growth  and  hair  follicle  dimensions.  Exp  Dermatol  2000; 
10:405–13.

6.  Ho PT. The loss and the origin of Chinese agriculture. Am Hist 

Rev 1969; 75:1–36.

7.  Hymowitz  T.  On  the  domestication  of  the  soybean.  Economic 

Botany 1970; 24:408–21.

8.  Ensminger  A,  Konland  JL,  Robson  J.  Concise  Encyclopedia  of 
Foods  and  Nutrition,  2nd  edition.  Boca  Raton,  FL:  CRC  Press 
1994; pp. 2017–35.

9.  Polunin  M,  Healing  Foods,  1st  edition.  New  York,  NY:  DK 

Publishing 1997; p. 70.

  10.  Cassidy A, Bingham S, Setchell KD. Biological effects of a diet of 
soy protein rich in isoflavones on menstrual cycle of premeno-
pausal women. Am J Clin Nutr 1994; 60:333–40.

  11.  Barnes S. The chemopreventive properties of soy isoflavonoids 
in animal models of breast cancer. Breast Cancer Res Treat 1997; 
46:169–79.

  12.  Stoll B. Eating to beat breast cancer: Potential role for soy sup-

plements. Ann Oncol 1997; 8:223–5.

  13.  Goodman  M,  et  al.  Association  of  soy  and  fiber  consump-
tion  with  the  risk  of  endometrial  cancer.  Am  J  Epidemiol  1997; 
146:294–306.

  14.  Morton M, et al. Measurement and metabolism of isoflavonoids 
and ligans in the human male. Cancer Lett 1997; 114:145–51.
  15.  Barnes S.Evolution of the health benefits of soy isoflavones. Proc 

Soc Exp Biol Med 1998; 217:386–92.

  16.  Anonymous.  The  Soy  Connection,  United  Soy  Board. 

Chesterfield, MO. Vol. 6, #2, Spring 1998.

  17.  Messina  M,  Gardner  C,  Barnes  S.  Gaining  insight  into  the 
health  effects  of  soy  but  a  long  way  still  to  go:  Commentary 
on  the  Fourth  International  Symposium  on  the  Role  of  Soy 
in  Preventing  and  Treating  Chronic  Disease.  J  Nutr  2002; 
132:547S–51S.

  18.  Barnes  S,  Messina  M.  Introduction  and  satellite  session  at 
the  Fourth  International  Symposium  on  the  Role  of  Soy 
in  Preventing  and  Treating  Chronic  Disease,  J  Nutr  2002; 
132:545S–6S.

  19.  Food and Drug Administration. Food labeling, health claims, 
soy  protein,  and  coronary  heart  disease.  Fed  Regist  1999; 
57:699–733.

  20.  Cosmetics & Toiletries. Cosmetic Bench Reference 1996. Available 
at:  http://dir.cosmeticsandtoiletries.com/main/login.html;jsessi
onid = C28BE4123C5726EB30288A54F1C8CF4C

  21.  Wu W, Hettiarachchy NS. Foaming and emulsifying properties 
of soy protein isolate and hydrolyzates in skin and hair prod-
ucts. J Surfact Deterg 1998; 1:241–6.

  22.  Bradley TF. Nonedible soybean oil products. In: Markley KS, ed. 
Soybeans  and  Soybean  Products.  Vol.  II.  New  York:  Interscience; 
2000 pp. 3–59.

  23.  Lanigan, RS. Cosmetic Ingredient Review Expert Panel, “Final 
report on the safety assessment of PEG-5, −10, −16, −25, −30, and 
−40 soy sterol.” Int J Toxicol 2000; 19(Suppl. 1):29–46.

  24.  Jimbow  K,  Jimbow  M.  Chemical,  pharmacologic  and  physical 
agents  causing  hypomelanoses.  In:  Nordlund  JJ,  Boissy  RE, 
Hearing VJ et al, eds. The Pigmentary System. Oxford University 
Press, 1998; pp. 621–7.

  25.  Birk Y. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-

inhibitor from soybeans. Int J Pept Protein Res 1985; 25:113–31.
  26.  Kennedy AR. The Bowman-Birk inhibitor from soybeans as an 
anticarcinogenic agent. Am J Clin Nutr 1998; 68:1406S–12S.
  27.  Billings  PC,  Habres  JM.  A  growth-regulated  protease  activity 
that is inhibited by the anticarcinogenic Bowman-Birk protease 
inhibitor. Proc Natl Acad Sci 1992; 89:3120–4.

  28.  Sessa  DJ,  Wolf  WJ.  Bowman-Birk  inhibitors  in  soybean  seed 

coats. Industrial Crops Products 2001; 14:73–83.

  29.  Nystedt  S,  Emilsson  K,  Wahlestedt  C,  Sundelin  J.  Molecular 
cloning  of  a  potential  proteinase  activated  receptor.  Proc  Natl 
Acad Sci U S A 1994; 91:9208–12..

  30.  Nystedt  S,  Emilsson  K,  Larsson  AK,  et  al.  Molecular  cloning 
and  functional  expression  of  the  gene  encoding  the  human 
proteinase-activated receptor 2. Eur J Biochem 1995, 232:84–9.

  31.  Nystedt  S,  Larsson  AK,  Aberg  H,  Sundelin  J.  The  mouse 
proteinase-activated  receptor-2  cDNA  and  gene.  Molecular 
cloning and functional expression. J Biol Chem 1995; 270:5950–5.
  32.  Déry O, Bunnett NW. Proteinase-activated receptors: A grow-
ing family of heptahelical receptors for thrombin, trypsin and 
tryptase. Biochem Soc Trans 1999; 27: 246–54.

  33.  Déry  O,  Corvera  CU,  Steinhoff  M,  Bunnett  NW.  Proteinase-
activated receptors: Novel mechanisms of signaling by serine 
proteases. Am J Physiol 1998; 247:C1429–52.

  34.  Stefansson K, Brattsand M, Roosterman D, et al. Activation of 
proteinase-activated  receptor-2  by  human  kallikrein-related 
peptidases.  J  Invest  Dermatol  2008  Jan;  128(1):18–25.  Epub  2007 
Jul 12.

  35.  Marthinuss  J,  Andrade-Gordon  P,  Seiberg  M.  A  secreted  ser-
ine protease can induce apoptosis in pam12 keratinocytes. Cell 
Grow Differ 1995; 6:807–16.

  36.  Santulli RJ, Derian CK, Darrow AL, et al. Evidence for the presence 
of a protease-activated receptor distinct from thrombin receptor 
in human keratinocytes. Proc Natl Acad Sci 1995; 92:9151–5.
  37.  Sharlow  ER,  Paine  C,  Babiarz  L,  et  al.  The  protease  activated 
receptor-2  upregulates  keratinocyte  phagocytosis.  J  Cell  Sci 
2000; 113:3093–101.

  38.  Seiberg  M,  Paine  C,  Sharlow  E,  et  al.  Inhibition  of  melano-
some transfer results in skin lightening. J Invest Dermatol 2000; 
115:162–7.

  39.  Olsen EA. Methods of hair removal. J Am Acad Dermatol 1999; 

40:143–55; quiz 156–7.

  40.  Panaretto BA. Gene expression of potential morphogenes dur-
ing hair follicle and tooth formation: A review. Reprod Fertil Dev 
1993; 5:345–60.

  41.  Chase HB. Growth of the hair. Physiol Rev 1954; 34:113–26.
  42.  Uitto  J.  Connective  tissue  biochemistry  of  the  aging  dermis. 
Age-related  alterations  in  collagen  and  elastin.  Dermatol  Clin 
1986; 4:433–46.

  43.  Uitto  J.  The  role  of  elastin  and  collagen  in  cutaneous  aging: 
Intrinsic  aging  versus  photoexposure.  J  Drugs  Dermatol  2008; 
7:s12–16

  44.  Pasquali-Ronchetti  I,  Baccarani-Contri  M.  Elastic  fiber  during 
development and aging. Microsc Res Tech 1997; 38:428–35
  45.  Tsukahara  K,  Moriwaki  S,  Fujimura  T,  Takema  Y.  Inhibitory 
effect  of  an  extract  of  Sanguisorba  officinalis  L.  on  ultraviolet-
B-induced  photodamage  of  rat  skin.  Biol  Pharm  Bull  2001a; 
24:998–1003.

  46.  Tsukahara K, Takema Y, Moriwaki S, et al. Selective inhibition 
of  skin  fibroblast  elastase  elicits  a  concentration-dependent 
prevention of ultraviolet B-induced wrinkle formation. J Invest 
Dermatol 2001b; 117:671–7.

  47.  Zhao,  R,  Bruning,  E,  Rossetti,  D,  et  al.  Extracts  from  glycine 
max  (soybean)  induce  elastin  synthesis  and  inhibit  elastase 
activity. Exp Dermatol 2009; 18(10):883–6.

  48.  Thornfeldt  CR.  Chronic  inflammation  is  etiology  of  extrinsic 

aging. J Cosmet Dermatol 2008 Mar; 7(1):78–82.

  49.  Mueller MM. Inflammation in epithelial skin tumours: Old sto-

ries and new ideas. Eur J Cancer 2006; 42(6):735–44.

 
 
 
 
 
 
 
 
 
 
  50.  Zhan  H,  Zheng  H.  The  role  of  topical  cyclo-oxygenase-2 
inhibitors in skin cancer: Treatment and prevention. Am J Clin 
Dermatol 2007; 8(4):195–200.

  75.  L Markiewicz, Garey H, Adlercreutz E, et al. In vitro bioassays 
of non-steroidal phytestrogens. J Steroid Biochem Molec Biol 1993; 
45:399–405.

APPLICATIONS OF NON-DENATURED SOY IN SKIN CARE 

 111

  51.  Rundhaug  JE,  Mikulec  C,  Pavone  A,  Fischer  SM.  A  role  for 
cyclooxygenase-2 in ultraviolet light-induced skin carcinogen-
esis. Mol Carcinog 2007; 46(8):692–8.

  52.  Seo JY, Kim EK, Lee SH, et al. Enhanced expression of cylooxy-
genase-2 by UV in aged human skin in vivo. Mech Ageing Dev 
2003; 124(8–9):903–10.

  53.  Chiu  TM,  Huang  CC,  Lin  TJ,  et  al.  In  vitro  and  in  vivo  anti-
photoaging  effects  of  an  isoflavone  extract  from  soybean 
cake. J Ethnopharmacol 2009 Oct 29; 126(1):108–13. doi: 10.1016/j.
jep.2009.07.039. Epub 2009 Aug 11.

  54.  Chen N, Scarpa R, Zhang L, et al. Non-denatured soy extracts 
reduce  UVB-induced  skin  damage  via  multiple  mechanisms. 
Photochem Photobiol 2008; 84:1551–9.

  55.  Nichols JA, Katiyar SK. Skin photoprotection by natural poly-
phenols:  Anti-inflammatory,  antioxidant  and  DNA  repair 
mechanisms. Arch Dermatol Res 2010; 302(2):71–83.

  56.  Limtrakul  P,  Suttajit  M,  Semura  R,  et  al.  Suppressive  effect  of 
soybean milk protein on experimentally induced skin tumor in 
mice. Life Sci 1993; 53(21):1591–6.

  57.  Huang  MT,  Xie  JG,  Lin  CB,  et  al.  Inhibitory  effect  of  topi-
cal  applications  of  non-denatured  soymilk  on  the  formation 
and  growth  of  UVB-induced  skin  tumors.  Oncology  Res  2004; 
14(7–8):387–97.

  58.  USDA National Nutrient Database for Standard Reference, 1999. 

Available at: http://www.nal.usda.gov/fnic/foodcomp/search/

  59.  Liu  KS,  Markakis  P,  Smith  D.  Trypsin  inhibition  by  free  fatty 
acids and stearoyl-CoA. J Agric Food Chem 1990; 38:1475–8.
  60.  Liu  K.  Soybeans,  Chemistry,  Technology  and  Utilization. 

Gaithersburg, Maryland: Aspen, 1999.

  61.  Ando H, Ryu A, Hashimoto A, et al. Linoleic acid and alpha-
linolenic  acid  lightens  ultraviolet-induced  hyperpigmentation 
of the skin. Arch Dermatol Res 1998; 290:375–81.

  62.  Tanojo  H,  Junginger  HE.  Skin  permeation  enhancement  by 

fatty acids. J Dispers Sci Technol 1999; 20(1 2):127–38.

  63.  Galvez,  AF,  Chen  N,  Macasieb  J,  Lumen  B.  Chemopreventive 
property of a soybean peptide (Lunasin) that binds to deacet-
ylated  histones  and  inhibits  acetylation.  Cancer  Res  2001; 
61:7473–8.

  64.  Wei H, Bowen R, Cai Q, et al. Antioxidant and antiprotection 
effects  of  soybean  isoflavone  genistein.  Proc  Soc  Exp  Biol  Med 
1995 Jan; 208(1):124–30.

  65.  Widyarini  S,  Spinks  N,  Reeve  VE.  Protective  effect  of  iso-
flavones  derivative  against  photocarcinogenesis  in  a  mouse 
model. Redox Rep 2000; 5(2–3):156–8.

  66.  Merck Index. 13th edition. Whitehouse Station, NJ: Merck 2001. 

Available at: https://www.rsc.org/Merck-Index/)

  67.  Brincat  MP.  Hormone  replacement  therapy  and  the  skin. 

Maturitas 2000; 35:107–17.

  68.  Wachter  R,  Salka  B,  Magnet  A.  Phytosterols.  Cosmet  Toiletries 

1995; 110:72–82.

  69.  Corbella  A.  Applications  of  phytosterols  as  active  principles. 

Cosmet News 1997; 20(117):419–21 [Italian].

  76.  Jefferson WN, Newbold RR. Potential endocrine-modulating effect 
of various phytoestrogen in the diet. Nutrition 2000; 16, 658–62, 2000
  77.  Farnswoth  NR,  Bingel  AS,  Cordell  GA.  Potential  value  of 
plants as sources of new antifertility agents. J Pharm Sci 1975; 
64:717–52.

  78.  Merritt RJ, Jenks BH. Safety of soy-based infant formulas con-
taining  isoflavones:  The  clinical  evidence.  Supplement:  Fifth 
International Symposium on the Role of Soy in Preventing and 
Treating Chronic Disease. J Nutrition 2004; 134:1220S–4S.
  79.  Guthrie JR, Ball M, Murkies A, Dennerstein L. Dietary phytoes-
trogen intake in mid-life Australia-born women: Relationship 
to health variables. Climacteric Dec. 2000; (3)4:254–61,

  80.  Setchell  KD,  Zimmer-Nechemias  L,  Cai 

JE. 
Isoflavone  content  of  infant  formulas  and  the  metabolic  fate 
of these phytoetrogens in early life. Am J Clin Nutr Dec. 1998; 
68:6(Suppl)1453S–61S,.

J,  Heubi 

  81.  Soy  Dietary  Supplement  Study,  J&J  Advanced  Care  Products, 

Research Report 98-003-CR82, p. 10.

  82.  Franke  AA,  Custer  LJ,  Tanaka  Y.  Isoflavones  in  human  breast 
milk  and  other  biological  fluids.  Am  J  Clin  Nutr  Dec.  1998; 
68:6(Suppl)1466S–73S,.

  83.  Final report of the amended safety assessment of PEG-5, -10, -16, 

-25, -30, and -40 soy sterol. Int J Toxicol 2004; 23(Suppl2):23–47

  84.  Steinberg, FM, et al. Clinical outcomes of a 2-y soy isoflavone 
supplementation  in  menopausal  women.  Am  J  Clin  Nutr  2011; 
93(2):356–67

  85.  Plants in Cosmetics, Volume I, 1994, republished in January 2002.
  86.  Seiberg  M.  Non-denatured  soybean  extracts  in  skin  care: 
Multiple  anti  aging  effects.  In:  Tzi-Bun  Ng,  ed.  Soybean  - 
Biochemistry, Chemistry and Physiology. InTech 2011.

  87.  Liu  J-C.  Applications  of  soy  in  skin  care.  J  Nutrition  2002; 

132:574.

  88.  Liu  J-C,  Seiberg  M,  Liebel  F,  et  al.  Preclinical  and  clinical 
evaluation of total soy preparation in improving skin physical 
tone  parameters,  Poster  182,  presented  at  American  Academy 
of  Dermatology  60th  Annual  Meeting,  New  Orleans,  LA, 
February 22–27, 2002.

  89.  Bauer  EA,  Uitto  J.  Special  tissue  collagen:  Skin.  In:  Jayson  M, 
Weiss J eds. Collagen in Health and Disease, Churchill Livingstone: 
Edinburgh, 1982; pp. 474–87.

  90.  Kligman LH. Effects of all-trans-retinoic acid on the dermis of 
hairless  mice.  J  Am  Acad  Dermatol  1986  Oct;,  15(4  Pt  2):779–85, 
884–7.

  91.  Young JM, De Young CM. Cutaneous models of inflammation for 
the evaluation of topical and systemic pharmaceutical agents. In: 
Spector J, Back N, eds., New York: Alan R. Liss, 1989; pp. 215–31.

  92.  Saliou C, Seiberg M, Liu J-C et al. Use of legume products for 
the  treatment  of  external  aggressions.  U.S.  Pat.  Appl.  Publ. 
(2002), Cont.-in-part of Ser. No. U.S. 2001-795762.

  93.  Davis  W  Jr,  Ronai  Z,  Tew,  KD.  Cellular  thiols  and  reactive 
oxygen  species  in  drug-induced  apoptosis.  J  Pharmacol  Exper 
Therapeut 2001; 296(1):1–6.

  70.  Pinnell  SR.  Cutaneous  photodamage,  oxidative  stress,  and 
topical  antioxidant  protection.  J  Am  Acad  Dermatol  2003  Jan; 
48(1):1–19.

  94.  Hayes JD, McLellan LI. Glutathione and glutathione-dependent 
enzymes  represent  a  co-ordinately  regulated  defense  against 
oxidative stress. Free Radical Res 1999; 31(4):273–300.

  71.  Guy RH, Hostynek JJ, Hinz RS, Lorence CR. Metals and the Skin: 
Topical Effects and Systemic Absorption, Illustrated edition. New 
York: Dekker, 1999.

  72.  Gohtani  S,  Yamano  Y.  Soybean  saponin  and  natural  surfac-

tants. Hyomen 1991; 29(7):559–70.

  73.  Yoshiki Y, Okubo K. Active oxygen-scavenging effects of soy-
bean  studied  by  luminescence  method.  BRAIN  Techno  News 
1999; 75:8–11.

  74.  Kurtz E, Nebus J, Walczak V. The essence of safety testing on 
soy  extract  formulations,  Poster  139,  presented  at  American 
Academy  of  Dermatology  59th  Annual  Meeting,  Washington 
DC March 2–7, 2001.

  95.  Connor MJ, Wheeler LA. Depletion of cutaneous glutathione by 
ultraviolet radiation. Photochem Photobiol 1987; 46:239–46
  96.  Tyrrell RM, Pidoux M. Correlation between endogenous gluta-
thione content and sensitivity of cultured human skin cells to 
radiation at defined wavelengths in the solar ultraviolet range. 
Photochem Photobiol 1988; 47:405–12.

  97.  Liebel F, et al. Irradiation of skin with visible light induces reac-
tive  oxygen  species  and  matrix-degrading  enzymes.  J  Invest 
Dermatol 2012; 132(7):1901–7.

  98.  Hermanns JF, Petit L, Martalo O, et al. Unraveling the patterns 
of subclinical pheomelanin-enriched facial hyperpigmentation: 
Effect of depigmenting agents. Belgium Dermatol 2000; 201:118–22.

 
112 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  99.  Wu  J,  Kollis  K,  Liu  J-C.  Total  soy  to  diminish  wrinkles  and 
hyperpigmentation 
in  photoaged  population.  Poster  101. 
American  Academy  of  Dermatology,  59th  Annual  Meeting, 
Washington DC, February2005.

  100.  Wu J, Stamatas G, Kollias N, Liu, JC. Soy application for daily 
defense against sun irradiation, In: Ring J, Weidinger S, Darsow 
U,  eds.  Skin  and  Environment  –  Perception  and  Protection.  10th 
EADV Congress, Munich, 2001. Mondond: Bologna, Italy, 2001; 
pp. 869–73.

  101.  Liu  J-C,  Seiberg  M,  Miller  J,  Wu  J.  Applications  of  soy  in 
skin  care.  In:  Ring  J,  Weidinger  S,  Darsow  U,  eds.  Skin  and 
Environment  –  Perception  and  Protection.  10th  EADV  Congress, 
Munich, 2001. Mondond: Bologna, Italy, 2001; pp. 881–4.
  102.  Nebus J, Costes F, Wallo W, et al. Clinical improvements in skin 
tone and texture using a facial moisturizer with a combination 
of total soy and SPF 30 UVA/UVB protection. AAD 2006.

  103.  Wallo  W,  Nebus  J,  Leyden  JJ.  Efficacy  of  a  soy  moisturizer  in 
photoaging: A double-blind, vehicle controlled, 12-week study. 
J Drugs Dermatol 2007; 6:917–22.

  104.  Leyden, J, Wallo W. The mechanism of action and clinical bene-
fits of soy for the treatment of hyperpigmentation. Int J Dermatol 
2011; 50(4):470–7

  105.  Lyden JJ, et al. Natural options for the management of hyper-

pigmentation. J Eur Acad Dermatol Venereol 2011; 25(10):1140–5.
  106.  Guttman C, Liu J-C, Seiberg M. Dermatology Times 2001; 22:24.
  107.  Au  Ghyczy  M,  Nissen  HP.  Montecatini  Terme  Italy,  J  Appl 

Cosmetol 1995; 13:109.

  108.  Archana S, Victoria D, Glenn N. Compositions and methods for 

treating skin conditions. U.S. patent application. US8106094.

  109.  Committee  on  Toxicity  of  Chemicals  in  Food,  Consumer 
Products and the Environment. Phytoestrogens and Health, Food 
Standards Agency, FSA/0826/0503, London, 2003.

 
12

Kinetin

Stanley B. Levy

INTRODUCTION
The success of retinoids and hydroxy acids as active ingredi-
ents  in  skin  care  products  designed  to  improve  the  appear-
ance  of  aging  skin  has  stimulated  the  search  for  additional 
compounds. The use of both retinoids and hydroxy acids may 
be  associated  with  skin  irritation,  further  encouraging  inter-
est in alternatives. A possible addition to this armamentarium 
is  kinetin  (N6-furfuryladenine).  Kinetin  is  a  member  of  the 
plant growth hormone family cytokinins, known for growth-
promoting  and  antiaging  effects  in  plants.  Zeatin  is  another 
cytokinin  that  has  been  incorporated  into  skin  care,  as  has 
Pyratine-6  (furfurylaminotetrahydropyranyladenine),  a  syn-
thetic analogue. The incorporation of these materials into cos-
meceuticals has prompted a more detailed review.

CHEMISTRY
Kinetin was first isolated from autoclaved herring sperm DNA 
in 1955 (1,2). It is a derivative of one of the nucleic acid purine 
bases, adenine. Kinetin has been reported to be present in vari-
ous plants (3,4) and human cell extracts (5). It has been identi-
fied as a naturally occurring base modification of DNA (6). The 
chemical  structure  of  kinetin  suggests  that  it  can  be  formed 
from adenine and furfuryl (Figure 12.1). The latter is a primary 
oxidation product of the deoxyribose moiety of DNA (7). It is 
not known if DNA repair enzymes remove this modified base 
from the DNA and make it available as free kinetin. Zeatin also 
contains adenine with the addition of an hydroxy-methylbutyl 
group (Figure 12.2). Pyratine-6 is structurally similar to kine-
tin except for the addition of a tetrahydropyranyl group.

BIOLOGY
Kinetin  was  the  first  cytokinin  identified  (1,2)  and  the  most 
studied. Cytokinins are plant growth substances that promote 
cell  division  and  may  play  roles  in  cell  differentiation.  Most 
of the data for the biological properties of kinetin come from 
plant studies. Kinetin has been shown in plant systems to stim-
ulate tRNA synthesis (8) and cell cycle progression (9). Calcium 
influx through the plasma membrane calcium channel in plant 
cells is stimulated by low levels of kinetin (10). More directly 
linked or related to antiaging, kinetin is known to prevent yel-
lowing and senescence of leaves and slow down over ripening 
and degeneration of fruits (11).

Rattan and Clark (12) have reported the antiaging effect 
of  kinetin  on  human  skin  cells  and  fruit  flies.  As  little  as  10 
to 20 ppm of kinetin delay the onset of some biochemical and 
cellular changes associated with cellular aging in cell culture. 
Human  skin  fibroblast  cell  cultures  of  both  young  cells  that 
had completed less than 20% of their potential in vitro life span 
and  older  cells  that  had  completed  90%  or  more  of  their  life 

span were studied. Results were compared with cell cultures 
receiving no treatment (Table 12.1). Cytological manifestations 
of in vitro aging including cell enlargement, presence of multi-
nucleated giant cells, accumulation of cellular debris and lipo-
fuscin, and changes in actin filaments and microtubules were 
attenuated by the addition of kinetin. The number of cells per 
unit  area  in  a  confluent  layer  also  markedly  diminishes  as  a 
function of age. Kinetin treatment significantly diminished the 
age-associated reduction in cell yield (Figure 12.3). Kinetin did 
not affect the longevity of culture cells or their ability to mul-
tiply. Zeatin produced similar results in cell culture with less 
toxicity at higher concentrations (13).

A diet containing 20 to 50 ppm kinetin fed to fruit flies 
slowed down aging and development and prolonged  average 
and  maximum  life  span  by  65%  and  35%,  respectively  (14). 
The  increase  in  life  span  was  accompanied  by  a  55%  to  60% 
increase  in  the  antioxidant  enzyme  catalase  (15).  Catalase 
breaks down hydrogen peroxide associated with cell toxicity.

Kinetin has been demonstrated to have inhibitory activ-
ity  on  free  radical  formation  of  active  platelets  in  vitro  and 
thrombus  formation  in  vivo  (16).  Kinetin  may  therefore  be  a 
potential  therapeutic  agent  for  arterial  thrombosis.  A  cytoki-
nin nucleoside, N6-fufuryladenosine, has been shown to have 
antiproliferative  and  apoptogenic  activity  against  various 
human cancer cell lines, suggesting potential anticancer activ-
ity (17). This activity has not been shown with kinetin.

MECHANISM OF ACTION
The exact mechanism by which kinetin acts to exert its effects 
is unknown. Kinetin may act directly as a signaling molecule, 
involved in signal transduction, stimulating defense pathways 
such  as  DNA  repair  (18).  Kinetin  modulates  and  promotes 
calcium-induced  differentiation  of  normal  human  keratino-
cytes that becomes progressively delayed during aging (19,20).
Kinetin may also act indirectly as a natural antoxidant 
(21),  preventing  the  formation  of  reactive  oxygen  species  or 
as  a  direct  free  radical  scavenger  (22).  Oxygen  radicals  could 
abstract  hydrogen  from  the  α-carbon  of  the  amine  bond 
N6-furfuryladenine (23). Oxygen radicals undergo a faster dis-
mutation reaction when kinetin is complexed with copper. A 
direct  effect  of  kinetin  on  superoxide  dismutase  activity  has 
been observed in plants (21). Kinetin has also been shown to 
protect  against  oxidative  and  glycoxidative  protein  damage 
generated in vitro by sugars and an iron/ascorbate system (22).
The  biological  significance  of  kinetin's  interaction  with 
DNA  or  its  antioxidant  properties  are  unknown.  However, 
pluripotency  may  be  a  necessary  prerequisite  for  effective 
antiaging activity (24). A multistep protocol utilizing in vitro 
and in vivo studies designed to compare the oxidative stress 

114 

 TEXTBOOK OF COSMETIC DERMATOLOGY

capacity  or  various  antioxidants  demonstrated  that  kinetin 
performed  favorably  relative  to  other  known  antioxidants 
including tocopherol, ascorbic acid, and lipoic acid (25).

The  activity  of  zeatin  is  attributable  to  its  more  stable 
trans  form  (26).  Trans-zeatin  inhibits  UVB-induced  matrix 
metalloproteinase-1  expression  via  MAP  kinase  signaling  in 
human skin fibroblasts (27). It also has been shown to attenu-
ate  ultraviolet-induced  down  regulation  of  aquaporin-3  in 
cell-cultured  keratinocytes,  also  attenuating  delayed  wound 
healing  and  decreased  water  permeability  (28).  Therefore, 
trans-zeatin and might have protective effects on photoaging.

NH2

N

H

N

(a)

CH

N

N
H

O

H

C

O

(b)

HC

CH

NH

CH2

C

CH

N

H

N

O

CH

N

N
H
(c)

CLINICAL STUDIES
Percutaneous absorption studies of kinetin with human cadaver 
skin  demonstrate  significant  skin  penetration  (McCullough, 
unpublished study). A dose-response was shown with 0.01% ver-
sus  0.05%  kinetin  with  tissue  levels  for  both  serum  and  lotion 
formulations. There was no significant difference in transdermal 
absorption  with  the  two  test  formulations.  Topical  treatment 
with low-concentration kinetin normalized hyperpigmentation 
and  improved  age-related  skin  structure  changes  in  hairless 
dogs (29). Although cosmetic formulations containing a disper-
sion  of  liposomes  with  magnesium  ascorbyl  phosphate,  alpha 
lipoic acid, and kinetin showed photoprotective effects (30), an 
0.5% kinetin solution and 0.1% kinetin cream showed no photo-
protective effects by themselves (31).

Thirty  subjects  with  mild  to  moderate  photodamaged 
facial  skin  were  treated  with  topical  kinetin  0.1%  twice  daily 
for 24 weeks (32). Significant improvements were seen in tac-
tile roughness, mottled hyperpigmentation, and fine wrinkles 
at both 12 and 24 weeks. Overall photodamage was reported 
improved  by  both  self-assessment  and  dermatologist  grad-
ing. Transepidermal water loss decreased after 24 weeks, con-
sistent  with  skin  barrier  function  improvement.  Other  than 
some   initial  contact  folliculitis,  no  significant  skin  irritation 
was seen.

Ninety-eight subjects with mild to moderate photodam-
aged facial skin each applied a kinetin-containing lotion and 

Figure  12.1  Chemical  structure  of  (a)  adenine,  (b)  furan,  and 
(c) kinetin.

)
2

m
c
/
s
l
l

Untreated

Treated

5

4

3

2

1

0

e
c
4
0
1
(
d
e
Y

l

i

l
l

e
C

Young

Old

Figure  12.3  Cell  yield  in  untreated  and  kinetin-treated  young 
and old cells. (From Rattan SI, Clark BF, Biochem Biophys Res 
Commun; 201(2):665–72, 1994. With permission).

HO

N

NH

N

H
N

N

Figure 12.2  Chemical structure of zeatin.

Table 12.1  Kinetin’s Effects on the Cytological Manifestations of In Vitro Aging

Characteristic

Cell enlargement
Multinucleate cells
Cellular debris
Lipofusein
Actin filaments
Microturbules

Young

None
None
Minimal
Low
Diffuse
Orderly

Untreated

Old

Significant
Present
Significant
High
Highly polymerized
Disorganized

Young

None
None
Minimal
Low
Diffuse
Orderly

Kinetin

Old

Insignificant
None
Minimal
Low
Less polymerized
Orderly

Source: Rattan SI, Clark BF, Biochem Biophys Res Commun; 201(2):665–72, 1994. With permission.

 
 
 
 
 
 
 
 
creams  for  10  weeks  (Revlon  Research  Center,  unpublished 
studies).  All  subjects  were  assessed  at  baseline  4,  8,  and  10 
weeks  for  photodamage  parameters.  Statistically  significant 
improvements  were  noted  in  all  parameters,  greatest  with 
texture,  skin  clarity,  discrete  and  mottled  pigmentation,  fine 
wrinkling,  and  global  appearance.  No  significant  irritation 
was noted.

Forty female subjects, ages 22 to 57, having mild to mod-
erate  facial  skin  photodamage,  underwent  a  12-week  split 
face, double-blind, controlled and randomized study compar-
ing a topically applied kinetin-containing lotion twice daily 
on  one  side  and  retinol  containing  lotion  on  the  other  (33). 
Evaluations  at  4-week  intervals  demonstrated  significant 
improvements  for  all  attributes  graded  including  discrete 
and mottled pigmentation, fine wrinkling, and overall photo-
damage.  The  kinetin  lotion  produced  greater  improvements 
in texture and clarity.

Another  non-placebo  controlled  trial  demonstrated  a 
beneficial effect of topical kinetin 0.1% lotion in reducing ery-
thema  and  overall  clinical  scores  in  17  subjects  with  mild  to 
moderate  rosacea  (34).  A  study  of  topical  kinetin  0.03%  with 
niacinamide  4%  in  52  Asian  subjects  over  a  12-week  period 
suggested some synergistic cosmetic benefits to the combina-
tion (35).

Nine  kinetin-containing  products  in  200  subjects  each 
were subject to modified Draize repeat insult patch tests. No 
instances  of  sensitization  were  seen  in  the  challenge  phase. 
In  addition,  controlled  use  testing  for  up  to  6  weeks  demon-
strated  no  significant  irritation  (Almay  Research  and  Testing 
Corp., Edison, NJ, unpublished studies). Six kinetin-containing 
products were tested in 10 subjects each with skin phototypes 
I–III  for  UV  sensitivity  with  a  solar  simulator  (Ivy  Research 
Laboratory  Inc.,  Philadelphia,  Pennsylvania,  unpublished 
study). Panelists were treated with once-daily applications of 
2  mg/cm2  to  the  mid-back  for  2  weeks  at  six  sites.  After  the 
final  applications,  no  difference  in  minimal  erythema  dose 
was  noted  between  untreated  control  and  treated  sites.  The 
above  studies  and  clinical  experience  to  date  would  suggest 
that  kinetin  has  minimal  or  no  potential  to  cause  irritation, 
allergy, or photosensitization.

Furfuryl tetrahydropyranyladenine (Pyratine-6), a kine-
tin analogue, was utilized as a topical agent in a single 12-week 
open  label  photoaging  study.  Improvement  in  skin  rough-
ness,  moisturization,  hyperpigmentation,  and  fine  wrinkling 
was  noted  (36).  The  same  analogue  showed  some  efficacy  in 
a 48-week open label study in subjects with mild to moderate 
rosacea (37).

CONCLUSION
Kinetin  (N6-furfuryladenine),  a  plant  growth  regulator, 
has been demonstrated to delay a range of cellular changes 
associated  with  the  aging  of  human  skin  cells  in  vitro.  In 
addition,  kinetin  has  antioxidant  properties,  formed  as  a 
response to free radical damage in human DNA. Before-and-
after  clinical  studies  have  demonstrated  improvements  in 
photodamaged  skin.  As  is  very  often  the  case  with  cosme-
ceutical ingredients, active to vehicle comparison studies are 
not  available  (38).  Studies  have  clearly  shown  that  the  use 
of kinetin is not associated with significant irritation and is 
a  potential  alternative  for  individuals  sensitive  to  retinoids 
and hydroxy acids. Analogues of kinetin may also prove use-
ful in the future.

KINETIN 

  115

REFERENCES

1. Miller CO, Skoog F, Von Saltza MH, et al. Kinetin, a cell divi-
sion  factor  from  deoxyribonucleic  acid.  J  Am  Chem  Soc  1955; 
77:1392.

2.  Miller CO, Skoog F, Okumura FS, et al. Isolation, structure, and 
synthesis of kinetin, a substance promoting cell division. J Am 
Chem Soc 1956; 78:1375–80.

3.  Ramman N, Elumalai S. Presence of cytokinin in the root nod-
ules of Casuarina equisetifolia. Ind J Exp Biol 1996; 34:577–9.
4.  Ratti  N,  Janardhanan  KK.  Effect  on  growth  of  and  cytokinin 
contents  of  palmrosa  (Cymbopogon  martinii  var.  motia)  by 
Glomus inoculation. Ind J Exp Biol 1996; 34:1126–8.

5.  Barciszewski J, Siboska GE, Pedersen BO, et al. Evidence for the 
presence  of  kinetin  in  DNA  and  cell  extracts.  FEBS  Lett  1996; 
393:197–200.

6. Barciszewski J, Siboska GE, Pedersen BO, et al. A mechanism 
for  the  in  vivo  formation  of  N6-furfuryladenine,  kinetin  as  a 
secondary oxidative damage product in DNA. FEBS Lett 1997; 
414:457–60.

7. Kahn QA, Hadi SM. Effect of furfural on plasmid DNA. Biochem 

Mol Biol Int 1993; 29:1153–60.

8. Guadino  RJ.  Cytokinin  induction  of  RNA  polymerase  I  tran-
scription in Arabidopsis thaliana. J Biol Chem 1997; 272:6799–804.
9.  Zhang K, Letham DS, John PC. Cytokinin controls the cell cycle  
of  at  mitosis  by  stimulating  the  tyrosine  dephophorylation  and 
activation of p34cdc-2-like H1 histone kinase. Planta 1996;200:2–12.
10. Shumaker KS, Gizinski MJ. Cytokinin stimulates dihydropyr-
idine-sensitive  calcium  uptake  in  moss  protoplasts.  Proc  Natl 
Acad Sci U S A 1993; 90:10937–41.

11. McFarland GA, Holliday R. Retardation of the senescense of cul-

tured human diploid fibroblasts. Exp Cell Res 1994; 212:167–75.

  12.  Rattan  SI,  Clark  BF.  Kinetin  delays  the  onset  of  ageing  char-
acteristics  in  human  fibroblasts.  Biochem  Biophys  Res  Commun 
1994; 201(2):665–72.

  13.  Rattan SI, Sodagam L. Genomodulatory and youth-preserving 
effects of zeatin on human skin fibroblasts undergoing aging in 
vitro. Rejuvenation Res 2005: 8(1):46–57.

  14.  Sharma  SP,  Kaur  P,  Rattan  SI.  Plant  growth  hormone  kinetin 
delays ageing, prolongs the lifespan and slows down develop-
ment of the fruitfly Zaprionus parvittiger. Biochem Biophys Res 
Commun 1995; 216(3):1067–71.

  15.  Sharma  SP,  Kaur  J,  Rattan  SI.  Increased  longevity  of  kinetin-
fed Zaprionus fruitflies is accompanied by their reduced fecun-
dity and enhanced catalase activity. Biochem Mol Biol Int 1997; 
41(5):869–75.

  16.  Hsiao  G,  Shen  MY,  Lin  KH,  et  al.  Inhibitory  acticity  of  kine-
tin on free radical formation of active platelets in vitro and on 
thrombus formation in vivo. Eur J Pharmacol 2003; 465(3):281–7.
  17.  Cabello  CM,  Bair  WB,  Ley  S,  et  al.  The  experimental  chemo-
therapeutic  N6-furfuryladenosine  (kinetin-riboside)  induces 
rapid  ATP  depletion,  genotoxic  stress,  and  CDKN1A  (p21) 
upregulation  in  human  cancer  cell  lines.  Biochem  Pharmacol 
2009; 77:1125–38.

  18.  Barciszewski  J,  Massimo  F,  Clark  BFC.  Kinetin-A  multiactive 

molecule. Int J Biol Macromol 2007; 40:182–92.

  19.  Berge  U,  Kristensen  P,  Rattan  SI.  Kinetin-induced  premature 
aging and altered differentiation of normal human epidermal 
keratinocytes undergoing aging in vitro. Ann N Y Acad Sci 2006; 
1067:332–6.

  20.  Berge  U,  Kristensen  P,  Rattan  SI.  Hormetic  modulation  of 
differentiation  of  normal  human  epidermal  keratinocytes 
undergoing  replicative  senescence  in  vitro.  Exp  Gerentol  2008; 
43(7):658–62.

  21.  Olsen  A,  Siboska  GE,  Clark  BFC,  et  al.  N6-furfuryladenine, 
kinetin  protects  against  Fenton  reaction-mediated  oxidative 
damage to DNA. Biochem Biophys Res Commun 1999; 265:499–502.
  22.  Verbeke  P,  Siboska  GE,  Clark  BFC,  et  al.  Kinetin  inhibits  pro-
tein  oxidation  and  glyoxidation  in  vitro.  Biochem  Biophys  Res 
Commun 2000; 276:1265–70.

 
 
 
 
 
 
116 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  23.  Rattan  SI.  N6-furfuryladenine  (kinetin)  as  a  potential  anti-

aging molecule. J Anti-Aging Med 2002; 5:113–6.

  24.  Hipkiss AR. On the “struggle between chemistry and biology 
during  aging”—implications  for  DNA  repair,  apoptosis  and 
proteolysis,  and  a  novel  route  of  intervention.  Biogerontology 
2001; 2 (3):173–8.

  25.  McDaniel  DH,  Neudecker  BA,  DiNardo  JC.  Idebenone:  a  new 
antioxidant—Part I. Relative assessment of oxidative stress pro-
tection  capacity  compared  to  commonly  known  antioxidants. 
J Cosmet Dermatol 2005; 4:10–17.

  26.  Kulaeva  ON,  Karavaikpo  NN,  Selvinkina  S,  et  al.  Receptor  of 
trans-zeatin involved in transcription activation by cytokinin. 
FEBS Lett 1995: 366:26–8.

  27.  Yang  BO,  Chao  JL,  Chen  W,  et  al.  Trans-zeatin  inhibits  UVB-
induced  matrix  metalloproteinase-1  expression  via  MAP 
kinase signaling in human skin fibroblasts. Int J Mol Med 2009; 
23:550–60.

  28.  Chao JL, Yangli Y, Yang BO, et.al. Trans-zeatin attenuates ultra-
violet  induced  down-regulation  of  aquaporing-3  in  cultured 
human skin keratinocytes. Int J Mol Med 2010; 26:257–63.
  29.  Kimura  T,  Kunio  D.  Depigmentation  and  rejuvenation  effects 
of kinetin on the aged skin of hairless descendents of Mexican 
hairless dogs. Rejuvenation Res 2004; 7:32–9.

  30.  Campos  PM,  de  Carmago  FB,  de  Andrade,  Gaspar  JP,  et.  al. 
Efficacy of cosmetic formulations containing dispersion of lipo-
some  with  magnesium  ascorbyl  phosphate,  alpha-lipoic  acid 
and kinetin. Photochem Photobiol 2012; 66:748–52.

  31.  Tourna JA, Lin FH, Selim MA, et. al. Ubiquinone, idenone, and 
kinetin provide ineffective protection to skin when compared 
to a topical antioxidant combination of viramins C and E with 
ferulic acid. J Invest Dermatol 2006; 126:1185–7.

  32.  McCullough JL, Weinstein GD. Clinical study of safety and effi-
cacy of using topical kinetin 0.1% (Kinerase) to treat photodam-
aged skin. Cosmet Dermatol 2002; 15:29–32.

  33.  Dickens MS, Levy SB, Helman MS, Nucci JE. Kinetin contain-
ing lotion compared with retinol containing lotion: Comparable 
improvements in the signs of photoaging. 60th Annual American 
Academy  of  Dermatology  Meeting  New  Orleans,  Louisiana. 
February 22–27, 2002.

  34.  Wu  JJ,  Weinstein  GD,  Kricorian  GJ,  et  al.  Topical  kinetin  0.1% 
lotion for improving the signs and symptoms of rosacea. Clin 
Exp Dermatol 2007; 32:693–5.

  35.  Chiu PC, Chan CC, Lin HM, et al. The clinical antiaging-aging 
effects of topical kinetin and niacinamide in Asians: a random-
ized,  double-blind,  placebo-controlled,  split-face  comparative 
trial. J Cosmet Dermatol 2007; 6:243–9.

  36.  McCullough  JL,  Garcia  RL,  Reece  B.  A  clinical  study  of  topi-
cal pyratine 6 for improving the appearance of photodamaged 
skin. J Drugs Dermatol 2008; 7:131–5.

  37.  Tremaine AM, Ortiz A, Eikeeb L, et. al. Long-term efficacy and 
safety  of  topical  PRK  124  (0.125%)  lotion  (Pyratine-XR)  in  the 
treatment of mild-to moderate rosacea. J Drugs Dermatol 2010; 
6:647–50.

  38.  Kligman C. Cosmeceuticals. Dermatol Clin 2000; 18:609–15.

 
13

Urokinase and Plasmin in Dry Skin and Skin Aging

Yuji Katsuta

INTRODUCTION
Urokinase  (urokinase-type  plasminogen  activator,  uPA) 
belongs to trypsin-like serine protease family and activates 
inactive  plasminogen  into  its  active  form  plasmin.  Because 
plasmin  degrades  fibrin  clots,  urokinase  and  plasmin  are 
called  fibrinolytic  enzymes.  These  fibrinolytic  enzymes 
function  not  only  in  the  blood  systems  but  also  in  other 
organs,  including  the  epidermis.  They  function  in  wound 
repair and in many disorders such as psoriasis and pemphi-
gus.  From  the  cosmetic  point  of  view,  urokinase  and  plasi-
min  are  involved  in  dry  skin  and  skin  aging.  This  chapter 
reviews the roles of urokinase and plasmin in dry skin and 
skin aging.

UROKINASE AND PLASMIN IN DRY SKIN
Dry Skin
Dry  skin  is  visually  characterized  by  dryness,  scaling,  and 
rough  texture  (1,2).  This  condition  can  be  experienced  by 
any  healthy  person,  especially  in  a  dry,  cold  season.  There 
are  many  external  and  internal  factors  that  change  the  skin 
surface morphology and cause dry skin. The external factors 
include exposure to extremes of climate (cold, wind, dryness) 
and chemicals (detergents, solvents), and ultraviolet radiation. 
The  internal  factors  include  various  abnormalities  in  physi-
ologic functions, illness, and mental stress. The effects of dry 
skin are not limited to the appearance. The barrier function of 
the stratum corneum is reduced. Proliferation of keratinocytes 
is accelerated and turnover of the epidermis is increased. The 
epidermis becomes hypertrophic. The differentiation of kerati-
nocytes is also abnormal in dry skin, leading to the incomplete 
formation of the stratum corneum.

For these reasons, supplying moisture to the skin surface 
is  not  sufficient  to  prevent  and  improve  dry  skin.  Applying 
creams  topically  for  the  purpose  of  occluding  the  skin  sur-
face  is  effective  in  improving  the  damaged  barrier  function, 
but this is not a fundamental treatment. To maintain the skin 
in a healthy state, it is essential to protect the epidermis from 
inside. Maintaining the normal proliferation of keratinocytes 
and  keeping  epidermal  differentiation  normal  are  important 
requirements for preventing dry skin.

Approach to Finding Intra-Epidermal 
Secondary Factors That Cause Dry Skin
To  elucidate  the  mechanism  of  dry  skin  occurrence  and 
develop effective compounds for preventing dry skin, attempts 
have  been  made  to  identify  intra-epidermal  secondary  fac-
tors that cause dry skin (1,3,4). These putative secondary fac-
tors are thought to respond to primary factors, such as a dry 
environment, and cause further changes in dry skin. Plasmin 

is  identified  as  one  of  the  secondary  factors  by  means  of  the 
following approach.

Detergent is a well-known cause of dry skin and is often 
used for an experimental dry skin model. Topical application 
of sodium lauryl sulfate (SLS) induces the features of dry skin, 
such as dryness, scaling, and rough texture. Physiologic values 
are also changed in the SLS-treated area. The water content of 
the stratum corneum is reduced and the transepidermal water 
loss (TEWL) values are increased. These physiologic features 
of the SLS-induced dry skin model resemble those of naturally 
occurring dry skin. This model was used in the screening for 
the secondary factors.

The  barrier  recovery  test  was  also  used,  because  the 
decrease of barrier function is one of the most important phe-
nomena  associated  with  dry  skin  (4).  The  barrier  function  of 
the stratum corneum was destroyed by tape-stripping or the 
application of a detergent or a solvent. Then the time course of 
TEWL was measured.

Many kinds of compounds were assayed in the exper-
imentally  dry  skin  model  and  the  barrier  recovery  test. 
Nonsteroidal anti-inflammatory agents such as acetylsalicylic 
acid, indomethacin, mefenamic acid, ibuprofen, and sodium 
diclofenac were tested, but these compounds did not exhibit 
suppressive effects. Then protease inhibitors were tested and 
tranexamic  acid  [trans-4-(aminomethyl)  cyclohexane  carbox-
ylic acid (t-AMCHA)] prevented epidermal hypertrophy and 
suppressed the appearance of dry skin. This compound is an 
inhibitor of plasmin. In contrast, ethylenediaminetetraacetic 
acid (EDTA; a metalloprotease inhibitor), pepstatin (an aspar-
tate  protease  inhibitor)  and  chymostatin  (a  chymotrypsin-
type serine protease inhibitor) had no beneficial effect.

Because  t-AMCHA,  a  plasmin  inhibitor,  was  effective 
in  ameliorating  dry  skin,  plasmin  was  the  candidate  for  the 
secondary factor that causes dry skin. To confirm this, immu-
nohistochemistry  was  performed.  As  shown  in  Figure  13.1, 
the  localization  of  plasmin  was  localized  is  restricted  to  the 
basal layer in the intact skin of the inner forearm. On the other 
hand,  plasmin  was  localized  throughout  the  epidermis  of 
experimentally  induced  dry  skin  on  the  inner  forearm.  This 
result shows that the amount of plasmin was increased with 
the induction of dry skin, suggesting that plasmin is one of the 
secondary factors of dry skin. Treatment with t-AMCHA was 
effective in preventing changes in the intra-epidermal distri-
bution of plasmin associated with dry skin as well as in sup-
pressing epidermal hypertrophy.

Efficacy  of  t-AMCHA  was  also  shown  in  naturally 
occurring  dry  skin.  A  double-masked  clinical  test  was  car-
ried out in the dry, cold winter season in Japan. The texture 
of  the  facial  skin  treated  with  t-AMCHA  was  significantly 
improved.

118 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(c)

Figure 13.1  Localization of plasmin in intact skin (a), in experi-
mentally induced dry skin (b), and in experimentally-induced dry 
skin  treated  with  t-AMCHA  (c).  (From  Kitamura  K  et  al.,  J  Soc 
Cosmet Chem Jpn; 29:133–45, 1995.)

Involvement of Plasmin in Skin Diseases
Plasmin  is  a  trypsin-like  serine  protease  that  is  distributed 
mainly in plasma. Although its main function is fibrinolysis in 
coagulated fibrin clots, plasmin is also exists in adrenal, kid-
ney, testis, heart, lung, uterus, spleen, thymus, and gut (5).

Plasmin  exists  in  the  epidermis  as  well.  It  is  known  to 
be  expressed  in  diseases  such  psoriasis  (6).  The  epidermis 
of  psoriatic  skin  is  extremely  hypertrophic,  and  the  prolif-
eration of keratinocyte is rapid. The expression of plasmin is 
scattered throughout the epidermis in lesional psoriatic skin. 
The increased plasmin activity may contribute to the disease 
manifestation.

Wounding epidermis also increases plasmin (7). At the 
wound edge, keratinocytes proliferate and migrate rapidly to 
cover  the  wounded  area.  Plasmin  degrades  the  extracellular 
matrix  at  the  wound  edge  to  aid  proliferation  and  migration 
of keratinocytes.

Epidermal hypertrophy is common in psoriasis, wound-
ing, and dry skin. Plasmin may be involved in promoting the 
proliferation and migration of keratinocytes, resulting in epi-
dermal hypertrophy.

Urokinase in Dry Skin
Plasmin is biosynthesized as an inactive precursor called plas-
minogen.  The  cleavage  of  Arg560-Val561  of  plasminogen  acti-
vates this precursor molecule. Two major proteases are involved 
in plasminogen activation. One of them is urokinase-type plas-
minogen activator (uPA) and the other is tissue-type plasmino-
gen activator (tPA). These plasminogen activators also belong to 
the trypsin-like serine protease family, as well as plasmin.

Aberrant plasmin activity in the epidermis may require 
increased  levels  of  plasminogen  activators.  The  lesional  epi-
dermis from patients with psoriasis contains elevated levels of 
plasminogen activators compared with nonlesional epidermis 
or  epidermis  from  normal  individuals  (8,9).  In  psoriasis,  tPA 
is thought to be the major plasminogen activator (10), whereas 
urokinase may be predominant in wounding.

The activity of plasminogen activator was detected in dry 
skin.  Stratum  corneum  obtained  from  dry  skin  by  tape  strip-
ping had the activity of lysing fibrin in vitro. Because this lysis 
was  completely  inhibited  when  antibody  against  urokinase 
was added, the major plasminogen activator in dry skin might 
be  urokinase.  In  situ  zymography  was  carried  out  to  confirm 
the  presence  of  plasminogen  activator  activity.  The  activity  of 
plasminogen activator was detected in the epidermis of the SLS-
treated skin, whereas little activity was seen in the control skin (4).

Urokinase Activity in Stratum 
Corneum of Dry Skin
Urokinase is produced and secreted as an inactive single-chain 
precursor called pro-uPA. Cleavage of Lys158-Ile159 is essential 
for its activation. It was found that urokinase is activated in stra-
tum corneum after barrier disruption (11). As a result of in situ 
zymography, plasminogen activator activity was detected in the 
stratum  corneum  1  hour  after  barrier  disruption  (Figure  13.2). 
This indicated that urokinase is activated in the stratum corneum 
at  an  early  stage  of  dry  skin  formation.  The  stratum  corneum 
forms the surface layer of our bodies and is always exposed to 
the environment. This activation of urokinase in the stratum cor-
neum might be the trigger process in dry skin formation.

The activation of urokinase in the stratum corneum was 
also  tested  in  vitro.  Human  stratum  corneum  was  homog-
enized in a glass homogenizer. The homogenate was washed 
with glycine buffer to remove endogenous urokinase. Pro-uPA 
was activated after the incubation with the insoluble compo-
nents of the stratum corneum homogenate.

Pro-uPA activation must have taken place on the surface of 
solid stratum corneum, because only the insoluble components 
were used in the in vitro urokinase activation assay. To estimate 
the physical interaction of pro-uPA and the insoluble components 
of the stratum corneum homogenate, the mixture was filtrated to 
divide the soluble and insoluble components. Then the amounts 
of urokinase in both soluble and insoluble components were eval-
uated. Pro-uPA was found to bind to the insoluble components of 
stratum corneum homogenate in this assay. The physical interac-
tion is likely to be important for the activation of urokinase.

 
UROKINASE AND PLASMIN IN DRY SKIN AND SKIN AGING 

 119

t-AMCHA Methylamide is Effective 
for Preventing Dry Skin
The  methylamide  derivative  of  t-AMCHA  (Figure  13.3)  has 
less  inhibitory  activity  against  fibrinolysis  than  t-AMCHA 
(Figure  13.4a).  However,  t-AMCHA  methylamide  strongly 
inhibited  the  physical  interaction  between  urokinase  and  the 
insoluble  components  of  the  stratum  corneum  homogenate  in 
vitro (Figure 13.4b).

The  effectiveness  of  t-AMCHA  and  t-AMCHA  methyl-
amide in preventing dry skin was compared in experimentally 
induced dry skin (Figure 13.4c). t-AMCHA methylamide sup-
pressed  dry  skin  more  potently  than  t-AMCHA  at  the  same 

concentration.  This  result  suggests  that  inhibiting  the  physi-
cal interaction between urokinase and the stratum corneum is 
more effective in preventing dry skin than inhibiting plasmin 
activity. Inhibition of urokinase activation in stratum corneum 
by t-AMCHA methylamide in vivo was confirmed by using in 
situ zymography (12).

Efficacy  of  t-AMCHA  methylamide  in  ameliorating 
naturally  occurring  dry  skin  was  demonstrated  in  a  double-
masked clinical test. After 1 month’s efficacy test in dry, cold 
winter in Japan, lotion containing t-AMCHA methyamide sig-
nificantly improved dry skin. The skin surface texture of two 
cases  before  and  after  the  treatment  is  shown  in  Figure  13.5. 

100

80

60

40

20

0

100

80

60

40

20

0

t–AMCHA

t–AMCHA
methylamide

(a)

t–AMCHA

t–AMCHA
methylamide

(b)

*p < 0.05

)

%

(
e
t
a
r
n
o
i
t
i
b
h
n

i

I

)

%

(
e
t
a
r
n
o
i
t
i
b
h
n

i

I

)
r
h
r
e
p
2

m
/
g
(
L
W
E
T
Δ

12

10

8

6

4

2

0

Control

t–AMCHA

t–AMCHA
methylamide

(c)

(a) Inhibition of fibrinolysis by t-AMCHA and t-AMCHA 
Figure 13.4 
methylamide.  t-AMCHA  methylamide  (1  mol/L)  had  less  inhibitory 
effect  on  fibrinolysis  than  t-AMCHA  in  vitro.  ±S.D.  (b)  Inhibition  of 
physical  interaction  between  urokinase  and  stratum  corneum. 
t-AMCHA  methylamide  inhibited  (1%  solution)  the  attachment  of 
urokinase to the insoluble components of stratum corneum homog-
enate  more  potently  than  t-AMCHA.  ±S.D.  (c)  Inhibition  of  experi-
mentally dry skin by application of SLS. t-AMCHA methylamide (1% 
solution) suppressed the increasment of TEWL than t-AMCHA ±S.E.

(a)

(b)

Figure  13.2  Detection  of  plasminogen  activator  activity  in  intact 
skin (a) and skin after barrier disruption (b). Loss of fluorescence indi-
cates plasminogen activator activity. Plasminogen activator activity 
was detected in stratum corneum after barrier disruption (arrow).

H2 H2N C

COOH

H

(a)

H

H2

2NH C

CONHCH3

H

H 

(b)

Figure 13.3  Molecular structures of t-AMCHA (a) and t-AMCHA 
methylamide (b).

 
 
 
 
 
 
 
 
120 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(c)

(b)

(d)

Figure  13.5  The  improvement  of  skin  surface  texture  after  one  month’s  treatment  with  t-AMCHA  methyamide.  Skin  surface  texture 
before treatment (a,c) and after treatment (b,d).

The efficacy of  t-AMCHA methyamide indicates that inhibit-
ing  the  physical  interaction  between  urokinase  and  stratum 
corneum is a useful approach for preventing dry skin.

UROKINASE AND PLASMIN IN SKIN AGING
Basement Membrane in Photo-Aged Skin
The  epidermal  basement  membrane  (BM),  located  at  the 
dermal-epidermal junction, plays several important roles in 
controlling  skin  functions.  It  links  the  epidermis  and  der-
mis  tightly,  and  determines  the  polarity  of  keratinocytes 
(13). The proliferating keratinocytes remain attached to the 
BM and the daughter cells migrate into the upper layers and 
differentiate (14–16). The BM is mainly composed of type IV 
and VII collagens, laminins (laminin 332, 331 and 511), nido-
gen,  and  perlcan  (17–19).  Laminin  322,  α2β4  integrin,  type 
XVII collagen, and type VII collagen are essential to epider-
mal attachment, and mutations in the genes encoding these 
proteins lead to blistering at the dermal-epidermal junction 
(20–22).

Skin aging can be classified as intrinsic aging or photo-
aging (23). Photo-aging is caused by chronic exposure of skin 
to  ultraviolet  radiation.  Photo-aged  skin  is  characterized  by 
several clinical features such as wrinkling, laxity, roughness, 
sallowness, pigments, telangiectasis, and neoplasia (24,25). The 
histological  changes  of  photo-aged  skin  include  decrease  in 

collagen, dermal elastosis, loss of polarity, and flattening of the 
dermal-epidermal  junction  (26,27).  Another  feature  of  photo-
aged skin is disrupted BM structure. As shown in Figure 13.6, 
the BM is a single-layer sheet in the sun-protected skin, but it 
changes to multilayer in the sun-exposed skin (27–29).

Involvement of Urokinase and 
Plasmin in the Disruption of BM
Ultraviolet exposure increases proteases such as matrix metal-
loproteinases (MMPs) and urokinase (30–33). These enzymes 
were reported to damage the BM. These enzymes were also con-
firmed in in vitro skin-equivalent models (34). Skin-equivalent 
models  show  only  a  faint  BM  because  BM  components  were 
degraded  by  MMPs.  In  addition  to  MMPs,  urokinase  was 
detected in the condition medium by ELISA assay. The condi-
tion medium of the skin-equivalent model showed fibrinolytic 
activity in the presence of additional plasminogen. It indicated 
that the added plasminogen was activated by the urokinase in 
the skin-equivalent model.

BM  in  the  skin-equivalent  model  is  degraded  in  the 
presence  of  plasmin.  The  addition  of  plasminogen  disrupted 
the  deposition  of  the  BM  components  such  as  laminin  332, 
type  IV  collagen,  and  type  VII  collagen.  The  depositions  of 
these  BM  components  are  reduced  and  discontinuous  at  the 

 
 
 
 
 
UROKINASE AND PLASMIN IN DRY SKIN AND SKIN AGING 

 121

(a)

(b)

Figure  13.6  Transmission  electron  microscopic  images  of  the  basement  membrane  (BM)  of  human  skin.  (a)  Neither  disruption  nor 
duplication is observed in the sun-protected abdomen skin of a 34-year-old woman, but (b) disruption and reduplication of the BM are 
observed in the sun-exposed cheek skin of a 30-year-old woman (b).

Control

Palsminogen

Palsminogen
+ t-AMCHA

HE

Laminin 332

Type IV
collagen

Type VII
collagen

(a)

(b)

(c)

(d)

(e)

(f )

(g)

(h)

(i)

(j)

(k)

(l)

Figure 13.7  Disassembly of BM at the dermal-epidermal junction in the presence of plasmin, and the recovery of BM assembly by the 
addition of t-AMCHA. Skin equivalents (SEs) were cultured in the absence (a–d) or presence of plasminogen (e–l). The contro SE showed 
linear and sharply defined deposition of laminin 332, type IV collagen, and type VII collagen (b–d). In the presence of human plasmino-
gen, impaired deposition of BM components is observed (f–h). The impairment of BM assembly is blocked in the presence of t-AMCHA 
(j–l). HE, hematoxylin and eosin staining (a,e,i).

dermal-epidermal  junctions  (Figure  13.7).  Furthermore,  the 
epidermis showed abnormal differentiation without filaggrin 
expression.  The  urokinase  inhibitor  t-AMCHA  improved  the 
deposition of these BM components, and the epidermis recov-
ered to a normal differentiation state.

Laminin 332 is Degraded by Plasmin
Because  the  deposition  of  laminin  332  was  reduced  by  the 
addition  of  plasminogen,  the  degradation  of  laminin  332  by 
plasmin  was  analyzed  by  means  of  Western  blotting.  The 
processed  form  of  laminin  332  is  composed  of  two  160-  and 

 
122 

 TEXTBOOK OF COSMETIC DERMATOLOGY

150-kDa α3 chains, a 140-kDa β3 chain and a 105-kDa γ2 chain. 
On the other hand, the plasmin-treated laminin 332 was com-
posed of two 140- and 145- kDa α3 chains, a 110-kDa β3 chain 
and  a  105-kDa  γ2  chain.  These  chains  were  presumably  gen-
erated  by  the  cleavage  of  a  5-  or  10-  kDa  fragment  from  the 
carboxyterminal end.

CONCLUSION
Urokinase and plasmin are activated in the process of dry skin. 
Inhibiting  these  enzymes  is  a  useful  approach  for  prevent-
ing dry skin. t-AMCHA and its methylamide derivative were 
effective in clinical tests.

The BM is located at the dermal-epidermal junction and 
is important for controlling skin functions. It is known to be 
degraded with photo-aging. In skin-equivalent models, uroki-
nase and plasmin disrupted the BM structure and t-AMCHA 
improved the deposition of the BM components. It suggested 
that inhibiting these enzymes is also useful in anti-aging treat-
ments of skin.

REFERENCES

1.  Kitamura  K,  Ito  A,  Yamada  K,  et  al.  Potential  medication  for 
skin care – focusing on the development of a new effective com-
pound for dry skin. In: Tagami H, Parrish JA, Ozawa T, eds. Skin: 
Interface of a Living System. Elsevier Science 1998; pp. 151–66.
2.  Gall  Y,  Chappuis  JP.  Skin  care  products  for  normal,  dry  and 
greasy skin. In: Baran R, Mainbach H, eds. Cosmetic Dermatology, 
London: Martin Dunitz 1994; pp. 89–111.

3.  Kitamura K, Yamada K, Ito A, et al. Research on the mechanism 
by  which  dry  skin  occurs  and  the  development  of  an  effec-
tive  compound  for  its  treatment.  J  Soc  Cosmet  Chem  Jpn  1995; 
29:133–45.

4.  Denda M, Kitamura K, Elias PM, et al. Trans-4-(aminomethyl) 
cyclohexane  carboyxylic  acid  (t-AMCHA),  an  anti-fibrinolytic 
agent, accelerates barrier recovery and prevents the epidermal 
hyperplasia induced by epidermal injury in hairless mice and 
humans. J Invest Dermatol 1997; 109:84–90.

5.  Zhang L, Seiffert D, Fowler BJ, et al. Plasminogen has a broad 
extrahepatic distribution. Thromb Haemost 2002; 87:493–501.
6.  Justus C, Muller S, Kramer MD. A monoclonal antibody recog-
nizing plasminogen and plasmin-altered reactivity in psoriatic 
lesions. Br J Dermatol 1987; 117:687–94.

7.  Schafer BM, Maier K, Eickhoff U, et al. Plasminogen activation 

in healing human wounds. Am J Pathol 1994; 144:1269–80.

8.  Jensen PJ, Baird J, Belin D, et al. Tissue plasminogen activator in 

psoriasis. J Invest Dermatol 1990; 95:13S–14S.

9.  Spiers EM, Lazarus GS, Lyons-Giordano B. Expression of plas-
minogen  activator  enzymes  in  psoriatic  epidermis.  J  Invest 
Dermatol 1994; 102:333–8.

  10.  Grondahl-Hansen J, Lund LR, Ralfkaier E, et al. Urokinase- and 
tissue-type  plasminogen  activators  in  keratinocytes  during 
wound reepithelialization in vivo. J Invest Dermatol 1988; 90:790–5.
  11.  Katsuta Y, Yoshida Y, Kawai E, et al. Urokinase-type plasmino-
gen activator is activated in stratum corneum after barrier dis-
ruption. J Dermatol Sci 2003; 32:55–7.

  12.  Katsuta  Y,  Yoshida  Y,  Kawai  E,  et  al.  trans-4-(Aminomethyl) 
cyclohexane  carboxylic  acid  methylamide  (t-AMCHA  methyl-
amide) inhibits the physical interaction between urokinase-type 
plasminogen activator and stratum corneum, and accelerates the 
recovery of barrier function. J Dermatol Sci 2005; 40:218–20.
  13.  De  Arcangelis  A,  Neuville  P,  Boukamel  R,  et  al.  Inhibition  of 
laminin  alpha  1-chain  expression  leads  to  alteration  of  base-
ment  membrane  assembly  and  cell  differentiation.  J  Cell  Biol 
1996; 133:417–30.

  14.  Watt FM. Selective migration of terminally differentiating cells 
from  the  basal  layer  of  cultured  human  epidermis.  J  Cell  Biol 
1984; 98:16–21.

  15.  Bohnert  A,  Hornung  J,  Mackenzie  IC,  et  al.  Epithelial  mesen-
chymal  interactions  control  basement  membrane  production 
and differentiation in cultured and transplanted mouse kera-
tinocytes. Cell Tissue Res 1986; 244:413–49.

  16.  Barrandon Y, Green H. Three clonal types of keratinocyte with 
different capacities for multiplication. Proc Natl Acad Sci U S A 
1987; 84:2302–6.

  17.  Marinkovich MP, Keene DR, Rimberg CS, et al. Celluar origin 
of  the  dermal-epidermal  basement  membrane.  Dev  Dyn  1993; 
197:255–67.

  18.  Kikkawa Y, Sanzen N, Sekiguchi K. Isolation and characteriza-
tion of laminin-10/11 mediates cell adhesion through integrin 
alpha 3 beta 1. J Biol Chem 1998; 273:15854–9.

  19.  Kikkawa Y, Sanzen N, Fujiwara H, et al. Integrin binding speci-
ficity of laminin-10/11: Laminin-10/11 are recognized by alpha 
3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. J Cell Sci 
2000; 113(Pt 5):869–76.

  20.  Uitto  J,  Pulkkinen  L,  Christiano  AM.  Molecular  basis  of  the 
dystrophic  and  junctional  forms  of  epidermolysis  bullosa: 
Mutations  in  the  type  VII  collagen  and  Kalinin  (laminin  5) 
genes. J Invest Dermatol 1994; 103:S39–46.

  21.  Niessen  CM,  van  der  Raaij-Helmer  MH,  Hulsman  EH,  et  al. 
Deficiency  of  the  integrin  beta  4  subunit  in  junctional  epi-
dermolysis  bullosa  with  pyloric  atresia:  Consequences  for 
hemidesmosome formation and adhesion properties. J Cell Sci 
1996; 109:1695–1706.

  22.  McGrath JA, Gatalica B, Christiano AM, et al. Mutations in the 
180-kD  bullous  pemphigoid  antigen  (BPAG2),  a  hemidesmo-
somal transmembrane collagen (COL17A1), in generalized atro-
phic benign epidermolysis bullosa. Nat Genet 1995; 11:83–6.
  23.  Tagami  H.  Functional  characteristics  of  the  stratum  corneum 
in photoaged skin in comparison with those found in intrinsic 
aging. Arch Dermatol Res 2008; 300(Suppl 1):S1–6.

  24.  Gilchrest  BA.  Skin  aging  and  photoaging:  An  overview.  J  Am 

Acad Dermatol 1989; 21:610–13.

  25.  Griffiths  CE.  The  clinical  identification  and  quantification  of 

photodamage. Br J Dermatol 1992; 127(Suppl 41):37–42

  26.  Kligman  AM,  Grove  GL,  Hirose  R,  et  al.  Topical  tretinoin  for 

photoaged skin. J Am Acad Dermatol 1986; 15:836–59.

  27.  Lavker  RM.  Structual  alterations  in  exposed  and  unexposed 

aged skin. J Invest Dermatol 1979; 73:59–66.

  28.  Lavker  RM,  Zheng  PS,  Dong  G.  Aged  skin:  A  study  by  light, 
transmission  electron,  and  scanning  electron  microscopy. 
J Invest Dermatol 1987; 88:S44–51.

  29.  Amano S, Matsunaga Y, Akutsu N, et al. Basement membrane 
damage, a sign of skin early aging, and laminin 5, a key player 
in basement membrane care. IFSCC Magazine 2000; 3:15–23.

  30.  Fisher  GJ,  Datta  SC,  Talwar  HS,  et  al.  Molecular  basis  of  sun-
induced  premature  skin  ageing  and  retinoid  antagonisim. 
Nature 1996; 379:335–9.

  31.  Scharffetter  K,  Wlaschek  M,  Hogg  A,  et  al.  UVA  irradiation 
induces collagenase in human dermal fibroblasts in vitro and 
in vivo. Arch Dermatol Res 1991; 283:506–11.

  32.  Miralles  C,  Parra  M,  Caelles  C,  et  al.  UV  irradiation  induces 
the murine urokinase-type plasminogen activator gene via the 
c-Jun N-terminal kinase signaling pathway: Requirement of an 
AP1 enhancer element. Mol Cell Biol 1998; 18:4537–47.

  33.  Marschall C, Lengyel E, Nobutoh T, et al. UVB increases uroki-
nase-type plasminogen activator receptor (uPAR) expression. J 
Invest Dermatol 1999; 113:69–76.

  34.  Ogura  Y,  Matsunaga  Y,  Nishiyama  T,  et  al.  Plasmin  induces 
degradation  and  dysfunction  of  laminin  332  (laminin  5)  and 
impaired assembly of basement membrane at the dermal-epi-
dermal junction. Br J Dermatol 2008.; 159:49–60.

 
 
 
 
 
 
 
 
 
 
14

Ceramides and the Skin

David J. Moore, Clive R. Harding, and Anthony V. Rawlings

INTRODUCTION
Prevention of desiccation of the body is a major function of the 
skin.  This  function  is  performed  for  the  most  part  by  skin’s 
epidermis, with a particularly crucial contribution by the out-
ermost layers, the stratum corneum (SC). At the skin’s surface 
there is a delicate balance between the water content of the SC 
and the environment, and although the SC contains relatively 
little water, a critical level of moisturization is essential for the 
normal  barrier  function  and  health  of  the  skin.  To  maintain 
the  proper  level  of  moisturization,  the  skin’s  epidermis  has 
evolved  a  finely  tuned  differentiation  program  which  gener-
ates  and  maintains  an  SC  composed  of  cellular  and  macro-
molecular  components  that  provide  the  required  structure, 
humectancy,  and  barrier  to  water  loss  (1).  The  SC  consists  of 
three basic components: corneocytes (terminally differentiated 
keratinocytes), corneodesmosomes (proteinaceous rivets hold-
ing  corneocytes  together),  and  lipids.  A  widely  employed,  if 
oversimplified analogy of SC structural organization is a brick 
wall (2,3). This analogy provides an image of a heterogeneous 
structure of two major components: bricks and mortar (Figure 
14.1). In this model, the corneocyte ‘bricks’ occupy most of the 
volume of the SC wall and are surrounded by a lipid “mortar.” 
It  is  now  recognized  that  the  corneodesmosomes  are  a  vital 
element  of  the  mortar,  ensuring  structural  integrity.  Equally, 
the  size  and  shape  of  the  corneocytes  influence  skin  barrier 
function as well as the total thickness of the SC. One must also 
not forget the role of filaggrin and its degraded components in 
SC functioning (1).

The lipid matrix constitutes approximately 20% of the SC 
volume  (about  15%  of  the  dry  weight)  and  is  the  continuous 
phase of the skin barrier (4,5). The lamellar bilayer organiza-
tion of this lipid matrix was first observed clearly using elec-
tron microscopy to examine ruthenium tetroxide (RuO4)–fixed 
samples (6) (typical examples are shown in Figure 14.2a and b). 
It has now been well established, using a variety of tape strip-
ping  and  lipid  extraction  experiments,  that  the  hydrophobic 
epidermal  permeability  barrier  resides  primarily  in  the  lipid 
bilayers  of  the  SC  with  the  corneocytes  and  thickness  of  the 
SC dictating the tortuosity and thereby increased path length 
for the diffusion of water through the SC. Consistent with the 
“mortar”  analogy,  however,  there  is  good  evidence  to  indi-
cate that the lipids also contribute to the intercellular cement, 
which helps to maintain the integrity of the tissue (7,8).

The  SC  lipid  bilayers  are  unique  among  biological 
membranes in terms of composition, organization, and physi-
cal  properties.  The  major  lipid  species  of  the  SC  are  cerami-
des (about 50% by mass), fatty acids (10%–20% by mass), and 
cholesterol  (25%  by  mass)  (4,5,9).  In  addition,  there  are  small 
amounts  of  cholesterol  esters  and  cholesterol  sulfate  which, 
in  particular,  seems  to  play  a  critical  role  in  normal  barrier 

function  (10).  There  are  no  phospholipids  in  healthy  SC  (5). 
Many of the lipids of the SC are derived from the contents of 
the  membrane-coating  granules  (MCG)  (also  called  lamellar 
bodies  or  keratinosomes)  formed  in  the  keratinocytes  of  the 
stratum granulosum, the uppermost layer of the viable epider-
mis. At the interface between the stratum granulosum and SC 
the extruded phospholipids, sphingolipids, and plasma mem-
brane constituents are enzymatically cleaved as they enter the 
SC to generate free fatty acids and ceramides (11). These com-
ponents  then  fuse  together  to  form  the  continuous  lamellar 
bilayers characteristic of the SC (Figure 14.2a and b). It is esti-
mated  that  the  skin  must  synthesize  approximately  100–150 
mg of lipid per day to replace that lost in normal desquama-
tion. The skin is therefore one of the most active sites of lipid 
synthesis in the body (9,12).

This chapter reviews developments in our understand-
ing  of  the  biological  functions  of  ceramides,  the  major  polar 
species  from  which  the  extracellular  lipids  of  the  SC  are 
organized.

THE STRUCTURE OF STRATUM 
CORNEUM CERAMIDES
As noted in the last edition of this chapter, our understanding 
of the heterogeneity of SC ceramides continues to increase in 
parallel with the development of new, highly sensitive analyti-
cal methodologies for their detection and measurement (13,14) 
and even visualization using specific antilipid antibodies (15). 
The previously described studies by Masukawa and colleagues 
employing normal-phase liquid chromatography (NPLC) con-
nected to electrospray ionization-mass spectrometry (ESI-MS) 
which  provided  new  quantitative  insights  into  the  diversity 
of  ceramide  classes  and  species  in  human  stratum  corneum 
(16,17)  have  been  further  advanced  by  several  groups  in  The 
Netherlands, Belgium, and Germany (18–20).

At  the  time  of  writing  this  chapter  (December  2014), 
15  classes  of  free  ceramides  (Figure  14.3;  non  corneocyte–
bound)  have  been  identified  including  the  newly  identified 
and  classified  1-O-acyceramides  which  contain  long  acyl 
chains  in  both  the  N-  and  O-positions  (20,21).  In  addition, 
three classes of covalently bound ceramide (Figure 14.4) spe-
cies  have  been  identified  (22–25).  Collectively  these  cerami-
des  are  derived  from  three  distinct  lipid  precursor  pools 
synthesized  in  the  underlying  epidermis:  epidermosides, 
glucosylceramides,  and  sphingomyelin.  Epidermosides  are 
glycated precursors of omega- hydroxyl–containing cerami-
des  (26).  Studies  have  shown  that  both  glucosylceramides 
(MCG-content  derived)  and  sphingomyelin  (plasma  mem-
brane  and  MCG-membrane  derived)  can  contribute  to  the 
formation of SC ceramides (27), although evidence suggests 
that  glucosylceramides  may  represent  the  major  source  of 

124 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Cornifted protein and lipid envelope

NMF

Filaggrin crosslinked keratin filaents

Lipid lamellae

Corneodestmosome

Tight jnction

Protease

Protease inhibitor

Figure 14.1  Schematic representation of the stratum corneum 
“bricks and mortar” structure depicting the major structural com-
ponents responsible for the water barrier function and overall tis-
sue  integrity.  (From  Rawlings  AV,  Br  J  Dermatol,  2014  Sep;171 
Suppl 3:19-28.)

ceramide  synthesis  (28).  The  epidermosides  are  precursors 
to  the  covalently  bound  ceramides  together  with  omega-
hydroxy–containing  ceramides  (26).  The  general  pathway 

of ceramide synthesis is illustrated in Figure 14.5. At an ini-
tial  glance  the  pathways  of  ceramide  synthesis  transporta-
tion  and  metabolism  appears  unduly  complex  and  heavily 
dependent  on  metabolic  resources  and  energy.  However, 
the  intrinsic  insolubility  of  crystalline,  high  melting  point 
ceramides, critical for barrier integrity, dictates initially their 
modification to facilitate transport and delivery to the stra-
tum granulosum: the SC interface. This is achieved through 
their  glycosylation  (glucosylceramide  synthetase),  or  con-
version  into  sphingomyelin  (sphingolipid  synthetase)  and 
transportation  within  MCGs.  Once  extruded  into  the  inter-
corneocyte  space  the  mature  ceramides  must  subsequently 
be “regenerated” through a number of enzymatic processes. 
The integrity of the barrier function of the stratum corneum 
is  therefore  critically  dependent  on  glucosylceramide  and 
sphingomyelin  synthesis  (29).  Ceramide  synthesis  in  the 
epidermis,  including  the  newly  identified  pathways  for  the 
1-O-acyceramides,  has  been  reviewed  by  Sandhoff  and  col-
leagues (21).

The chemical structures of the 15 free ceramides classes 
currently resolved are shown in Figure 14.3, where they are 
labeled  according  to  the  nomenclature  system  described 
below.

The old numerical ceramide nomenclature discussed in 
the earlier editions of this chapter has thankfully now largely 
been replaced by a nomenclature based upon chemical struc-
ture. Readers of older papers are cautioned to check the chemi-
cal structures of ceramides identified by either Arabic or Roman 
numerals as there is confusion and nomenclature inconsistency 
in regard to studies with ceramides isolated from porcine and 
human  stratum  corneum,  and  bovine  brain–derived  cerami-
des. The preferred ceramide nomenclature was first suggested 
some  years  ago  (23,30)  and  is  based  on  the  molecular  struc-
tures corresponding to the sphingoid base chains sphingosine 

(a)

(d)

(b)

(c)

(e)

(f )

Figure 14.2  Electron micrographs of lipid organization in tape strippings of normal (a–c) and xerotic (d–f) stratum corneum. Each 
case shows the first (a,d), second (b,e), and third (c,f) strippings. Normal lipid lamellae can see seen in the third strippings but loss of 
lipid organization is seen in the first for normal SC, whereas a totally disrupted structure is observed in xerotic skin (×200,000; bar 0.05 
µm). (From Rawlings AV et al., J Soc Cosmet Chem, 1994; 45:203–20.)

 
 
 
   
 
 
CERAMIDES AND THE SKIN 

 125

CER[NT]

CER[AP]

CER[AdS]

CER[NS]

CER[NH]

CER[AH]

CER[NP]

CER[AS]

CER[NdS]

CER[EOP]

CER[EOS]

CER[EOH]

CER[EOdS]

CER[1-O-EAS]

CER[1-O-ENS]

Figure 14.3  Structures of the major free ceramide classes of human SC.

O

H HN

HO

HO

H

CER[POS]

O

H HN

OH

HO

HO

H

CER[POH]

O

H HN

OH

HO

HO

H

CER[POP]

O

Corneocyte envelope

O

O

Corneocyte envelope

O

O

Corneocyte envelope

O

Figure 14.4  Structures of the major covalentlybound ceramides of human SC.

(S), 6-hydroxy sphingosine (H), dihydrosphingosine (DS), phy-
tosphingosine  (P),  dihydroxy  sphinganine  (T),  and  the  fatty 
acid chains alpha-hydroxy acid (A), nonhydroxy fatty acid (N) 
and  omega-hydroxy  fatty  acid  (O).  The  complete  molecule  is 

designated by “ceramide-acid-base,” i.e., the acid chain abbre-
viation precedes the base chain. In the case of ceramides esteri-
fied with an additional fatty acid, the letter E precedes the base 
and fatty acid chains. For ceramides covalently bonded to the 

 
126 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Fatty acid
elongase
(ELOVL 1-7)

Fatty acid
Fatty acid
2-hydroxylase
(FA2H) & ω-hydroxylase
& esterification with linoleate

AcylCoA

L-serine + palmitoyl CoA

Serine palmitoyltransferase (SPT 1-3)

Sphingoid base

Ceramide synthase
Dihydroceramide desaturase (DES1):sphinganine
Dihydroceramide hydroxylase (DES2):phytosphingosine

Acylceramides

Ceramides

UDP-glucose

UDP

Glucosylceramide
synthase

UDP-glucose

UDP

Sphingomyelin
synthase

PC

DG

Epidermosides
(acylglucosylceramides)

Glucosylceramides

Sphingomyelins

Lipoxygenase
Hydrolase
Transglutaminase

Beta-
glucocerebrosidase

Covalently bound
ceramides

Intercellular lipid
lamellae

e
s
a
l
y
c
a
e
d

Sphingomyelinase

Ceramides
(primarily CER NS
and CER AS)

n

i
l
e
y
m
o
g
h
p
S

i

n

i
l
e
y
m
o
g
n
h
p
S

i

i

e
d
m
a
r
e
c
l
y
s
o
c
u
G

l

i

e
d
m
a
r
e
c
l
y
s
o
c
u
G

l

e
s
a
l
y
c
a
e
d

Glucosyl
sphingosine
in atopics

Ceramidase

Free fatty acid and sphingoid base

SPC
in atopics

Figure 14.5  Summary of the proposed pathways leading to synthesis of SC ceramides. Enzymes are shown in bold italics. PC, phosphati-
dylcholine; DG, diacylglycerol; UDP, uridine diphosphate, SPC, sphingosylphosphorylcholine. (From Wollenweber U  et al., SOFA. 2004; 130.)

corneocyte protein envelope via the omega-hydroxy fatty acid 
the letter P precedes the base and fatty acid chain letters. For 
example, a 6-hydroxy sphingosine with an alpha-hydroxy fatty 
acid chain is denoted as CER[AH]. The free ceramide classes 
possible  from  the  above  combinations  of  acid  and  bases  are 
shown in Figure 14.3 while the relative concentration of each 
class is listed in Table 14.1, based upon the work of t’Kindt et 
al (19).

Human  SC  ceramide  base  chains  range  from  18  to  22 
carbons  in  length  (12,22,31).  For  the  non-hydroxy  fatty  acid 
ceramides the amide-linked fatty acid chains range from 16 
to  32  carbons  in  length,  with  the  major  chain  species  being 
either 24 or 26 carbons (22,30). For the omega-hydroxy cerami-
des the fatty acid chains range from 30 to 34 carbons in length 
with  linoleic  acid  (C18:2)  esterified  to  the  omegahydroxy 
group  (22,32).  The  pioneering  analytical  work  of  Masukawa 
and  colleagues  in  evaluating  SC  ceramides  was  in  general 
agreement  (16,17)  with  the  above  and  has  been  significantly 
added  to  by  the  work  cited  above  (18–20).  Furthermore,  the 
identification  of  several  odd-numbered  fatty  acid  chains  in 
SC  ceramides  has  been  confirmed  in  these  studies  (22,33). 
Table  14.2  lists  the  relative  distribution  of  total  ceramide 
carbon atoms as described by Bouwstra and colleagues (18). 
Using  NPLC-ESI-MS  methods,  over  300  ceramide  species 
had  been  to  which  approximately  100  new  molecules  are 
added with the identification of the 1-O-acylceramides (17,21). 
Further improvements in these techniques appear set to her-
ald  in  the  dawn  of  epidermal  sphingolipid  and  ceramide 
lipidomics,  defining  precise  changes  in  these  species  asso-
ciated  with  body  site,  increasing  age,  gender,  ethnic  differ-
ences,  and  varying  skin  conditions.  No  doubt  portending 

Table 14.1  Approximate Percentage of Major Free Ceramide 
Species to Total Ceramide Pool in The Stratum Corneum

Ceramide Nomenclature

Percent of Total Ceramide

Ceramide [NS]
Ceramide [NDS]
Ceramide [NP]
Ceramide [NH]
Ceramide [NT]
Ceramide [AS]
Ceramide [ADS]
Ceramide [AP]
Ceramide [AH]
Ceramide [EOS]
Ceramide [EOP]
Ceramide [EOH]
Ceramide [EODS]
Ceramide [1-O-ENS]
Ceramide [1-O-EAS]

  7.4
  9.8
22.1
14.5
  1.7
  9.6
  1.6
  8.8
10.8
  6.5
  1.1
  4.3
  0.4
<2.0
<2.0

the  widespread  application  of  such  methods,  a  study  from 
Kao’s laboratories identified several significant differences in 
the profiles of 12 ceramide classes as a function of anatomi-
cal  site  and  season.  Changes  in  ceramide  class  and  species 
(i.e., specific chain lengths) were correlated to skin properties 
such as barrier function and capacitance (34).

Analytical  platforms  now  exist  which  allow  for  semi-
quantitative  analyses  of  all  stratum  corneum  lipids.  Thus, 
although  not  a  focus  of  this  chapter,  it  is  worth  noting  that 
the development and application of increasingly sensitive lip-
idomic methods has increased our understanding of the free 

 
Table 14.2  Relative Distribution of Total Carbon Atoms (Both 
Chains) in the Ceramides of Human Stratum Corneum

Table 14.3  Relative Abundance of Free Fatty Acids in Human 
Stratum Corneum

Ceramide Chain Length (total 
carbon atoms)

Percent
Abundance

FFA Carbon Chain 
Length

Saturated Chains 
(%)

Unsaturated 
Chains (%)

CERAMIDES AND THE SKIN 

 127

34

40
41
42
43
44
45
46
47
48
49
50
51
52
66
68
70

2

3
4
9
6
13
6
14
5
10
3
5
2
2
2
2
2

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
>30

4.0
0.1
5.6
0.1
0.7
0.1
3.8
2.8
33.7
8.0
25.2
2.3
7.1
0.7
1.0
0.1

0.2
0.1
2.3
<0.1
0.1
<0.1
<0.1
<0.1
0.1
0.1
0.1
<0.1
<0.1
<0.1
0.2
0.2

Table lists only species contributing >2%. It is noted that many minor 
species exist and have been quantified.

fatty  acids  in  the  stratum  corneum.  The  relative  concentra-
tions of free fatty acids are listed in Table 14.3, showing that 
saturated  fatty  acids  make  up  some  95%  of  free  fatty  acids. 
Confirming earlier studies, C24 and C26 saturated chains are 
the major free fatty acid species (35). However, of note is the 
identification of several odd-numbered fatty acids as well as 
long-chain  hydroxy  free  fatty  acids  such  as  C22:0-OH  (18). 
The unusual physical properties of the SC lipid bilayers, com-
pared  to  other  biological  membranes,  are  in  large  part  due 
to  these  long,  primarily  unsaturated,  hydrocarbon  chains 
that characterize both the ceramides and the fatty acids. The 
critical importance of very long chain fatty acids (VLCFA) is 
emphasized by mutations in the enzymes (elongases) respon-
sible for their synthesis. Mutations in the elongase, ELOVL4, 
are associated with the Stargardt-like macular degeneration. 
Deliberate deletion of ELOVL4 in murine models led to pro-
found  barrier  defects  characterized  by  a  global  decrease  in 
VLCFA in the free fatty acid, ceramide, and glucosylceramide 
fractions (36,37). Strikingly, the SC is devoid of CER[EOS] and 
CER[EOH]. Similarly, synthetic short-chain ceramides (based 
on CER[NS]) with a 4 to 8 carbon acyl chain have been shown 
to  dramatically  increase  SC  permeability.  The  disruption  to 
barrier was maximal with a C 6 acyl chain, whereas C2 and 
C12  ceramides  did  not  increase  permeability  (38).  In  con-
trast,  others  have  demonstrated  that  short-chain  ceramides, 
including  those  with  a  C6  acyl  chain,  increase  keratinocyte 
differentiation. (39,40).

Certain ceramides are covalently bonded to the outside 
aspect of the corneocyte protein envelope via the formation 
of  ester  linkages  between  hydroxyl  groups  on  the  cerami-
des and carbonyls of the beta-sheet proteins of the cornified 
cell envelope (41,42). This process appears to be catalyzed by 
transglutaminase  1  (43),  a  calcium-requiring  enzyme  previ-
ously  thought  to  be  involved  solely  with  protein  crosslink-
ing  within  the  cornified  envelope.  Lipoxygenases  and  an 
unknown  hydrolase  is  also  now  known  to  be  involved  in 
this  sequence  of  events  prior  to  attachment  to  the  corneo-
cyte envelope via transglutaminase (44). Two novel species of 

covalently  bound  ceramides  have  been  identified—one  con-
sisting of a sphinganine base (C17-22), the other displaying a 
phytosphingosine  base,  and  both  linked  to  omega-hydroxy 
acid, designated CER[POS], and CER[POP], respectively (21). 
Downing  suggests  that  all  the  omega-hydroxyceramides  of 
corneocyte lipid envelopes are attached to proteins through 
their  omega-hydroxyl  groups  (45).  Clement  et  al.  (46)  found 
five classes of covalently bound ceramides in sparrows. Their 
structure awaits confirmation and their presence in humans 
needs to be identified.

It has been determined that there is enough lipid cova-
lently  attached  to  the  corneocyte  protein  envelope  to  form  a 
complete  lipid  monolayer  over  the  surface  of  each  cell  (5,41). 
The  very  long  chains  of  the  envelope  ceramides  lipids  will 
be  conformationally  ordered,  thereby  forming  a  water  bar-
rier around each corneocyte (41), and studies in mice suggest 
that  the  amount  of  covalently  bound  ceramide  is  highly  cor-
related with the barrier function of the skin (47). A proposed 
critical function of this layer is to cover the corneocytes with 
a  lipophilic  coating  and  thereby  act  as  a  template  or  scaffold 
to  direct  the  assembly  of  the  extruded  lamellar  body  lipids 
into lamellar bilayers (4,5). It has also been proposed that the 
corneocyte envelope may function as a semipermeable mem-
brane permitting water transport but preventing the transport 
of  natural  moisturizing  factor  (NMF)  out  of  corneocytes  (1). 
Severe  abnormalities  to  MCG  formation,  lipid  organization, 
and  barrier  function  result  from  the  topical  application  of  a 
specific  inhibitor  of  omega-hydroxylation,  emphasizing  the 
important role this class of ceramides plays in barrier forma-
tion and integrity (48).

Although the majority of ceramides with the SC remain 
intact during SC maturation, ceramide-hydrolyzing enzymes 
have been identified in the SC, and these may be responsible 
for  the  formation  of  ceramide  degradation  products  readily 
identified  within  the  tissue  (49).  A  lipid  species  called  acyl 
acid,  which  appears  to  be  the  omega-esterified  N-acyl  fatty 
acid  portion  of  CER[EOS],  and  free  sphingoid  bases  were 
shown to be present in human epidermis (50–52). It is possible 

 
128 

 TEXTBOOK OF COSMETIC DERMATOLOGY

that both of these lipid species could be derived from hydroly-
sis of CER[EOS] or acylglucosylceramides. Although the role 
of these degradation products is uncertain, sphingosine and 
other  sphingoid  bases  may  be  involved  in  an  SC–epidermis 
signaling  function,  as  these  have  been  reported  to  inhibit 
keratinocyte  proliferation  (53).  It  has  been  shown  also  that 
sphingosine is a potent anti-microbial and its presence in the 
SC may well form part of the skin’s defense against invading 
microorganisms (54). Similarly, it has been reported that phy-
tosphingosine has both antimicrobial and anti-inflammatory 
properties and has demonstrated potential to enhance exist-
ing  anti-acne  therapies.  (55).  The  acyl  acids  may  have  addi-
tional lamellar lipid-structuring roles as has been shown for 
other esters (56–60).

As can be seen in Figure 14.5, the first step in the synthe-
sis of ceramides is via condensation of serine and palmitoyl-
CoA  to  form  3-ketodihydrosphingosine  (not  shown),  which 
in  turn  is  reduced  by  a  reductase  to  dihydrosphingosine 
before being N-acylated by dihydro-CER synthase (CER syn-
thase).  Dihydro  CER  desaturase  (DES1)  produces  ceramides 
whereas  dihydro  CER  hydroxylase  (DES2)  produces  phyto-
ceramides.  There  are  six  CER  synthases  with  specific  fatty 
acyl-CoA  preferences.  CER  S2  and  S3  have  the  longest  acyl 
chain length preferences. Once formed, these ceramides are 
converted to glucosylceramides and sphingomyelin and after 
secretion  into  the  intercellular  spaces  are  reconverted  back 
to  ceramides  via  beta-glucocerebrosidase  and  sphingomy-
elinase. CER[NS] and CER[AS] are primarily formed via the 
sphingomyelin pathway (61).

LIPID ORGANIZATION IN THE 
STRATUM CORNEUM
The lamellar bilayer of most biological membranes consists of 
lipids in the liquid crystalline (Lα) state. In this state the lipid 
chains  have  considerable  intramolecular  conformational  dis-
order.  Aliphatic  liquid  crystal-forming  lipids  can  undergo 
reversible transitions between the lamellar gel phase (Lβ) and 
the lamellar Lα phase. In the Lβ phase, hydrocarbon chains are 
in a fully extended all-trans conformation and the chains are 
packed in a two-dimensional hexagonal array which allows for 
some limited rotational freedom along the axes of the chains. 
Saturated long-chain lipids can also pack in lamellar bilayers 
in  which  the  chains  are  packed  in  a  two-dimensional  ortho-
rhombic  array.  In  this  phase  the  chains  are  conformationally 
ordered, packed in a very tight crystalline array, and have no 
rotational freedom (62).

Our understanding of biological membranes continues 
to advance as ever more sensitive analytical and biophysical 
techniques shed light on the molecular details of membrane 
lipid composition, organization, and dynamics. As discussed 
in  the  previous  edition  of  this  chapter  there  has  been  con-
siderable  modification  of  the  original  “fluid  mosaic”  model 
of  cell  membrane  organization  as  lipid  domains  across  cell 
membrane  bilayers  and  within  the  plane  of  membrane  leaf-
lets have been observed in a variety of biological membranes 
(63–66).  The  complexity  of  the  lipid  composition  of  the  SC, 
its unusual composition and unique physical properties, sug-
gest the likelihood of a unique molecular organization. The 
very long carbon chain lengths of SC ceramides and free fatty 
acids  (see  Tables  14.2  and  14.3)  along  with  the  small  polar 
headgroups of these lipids determine the unusual and highly 
specialized  physical  properties  of  the  SC  lipid  lamellae. 

A  variety  of  biophysical  techniques  including  nuclear  mag-
netic  resonance  (NMR),  wide-angle  and  small-angle  x-ray 
diffraction, differential scanning calorimetry (DSC), Fourier 
transform  infrared  (FTIR)  spectroscopy,  and  Raman  spec-
troscopy have presented a detailed molecular level picture of 
lipid organization in the SC.

A  variety  of  published  reports  have  established  that 
the  hydrocarbon  chains  of  SC  lipids  are  highly  ordered. 
McIntosh and co-workers, in x-ray studies of mixtures con-
taining  ceramides,  fatty  acids,  and  cholesterol,  observed 
ordered gel phase lipids at 25 mole % cholesterol, which did 
not depend on the amount of water present or on the pres-
ence of protein (67). The repeat unit of 130 angstroms in these 
studies  was  postulated  to  arise  from  two  bilayers.  In  early 
wide-angle x-ray studies of murine SC, White and colleagues 
reported  the  presence  of  some  crystalline  orthorhombic 
lipids  at  physiological  temperature  (68).  Seminal  studies 
by  Bouwstra  and  colleagues  utilizing  x-ray  diffraction  and 
electron  diffraction  techniques  demonstrated  the  presence 
of  orthorhombic  phase  lipids  in  isolated  human  SC  as  well 
as  ceramide/cholesterol/fatty  acid  models  of  SC  (69–71).  In 
addition,  Bouwstra  and  colleagues  have  demonstrated  the 
importance  of  CER[EOS]  in  producing  the  intermolecular 
organization necessary for healthy skin barrier function (72). 
Since  the  above-mentioned  studies,  many  further  studies 
have  confirmed  the  presence  of  orthorhombic  and  hexago-
nally packed lipids in isolated human SC and in a range of 
ceramide-containing SC lipid models. Biophysical studies of 
complex mixtures of SC lipids, isolated SC, and even in vivo 
SC lipids is a vast topic well beyond the ceramide focus of the 
current chapter.

In  one  of  the  authors’  laboratories  (DJM),  experimental 
infrared spectroscopy techniques were developed to measure 
lipid  organization  in  lipid  bilayers,  cell  membranes,  and  liv-
ing cells (73–75) to explore the molecular behavior of diverse 
ceramide  species,  both  alone  and  in  lipid  models  of  the  SC 
(76–79). This work demonstrated that distinct ceramide species 
organize  differently,  reflecting  distinct  intermolecular  inter-
actions between their hydrocarbon chains and distinct head-
group hydrogen bonding interactions. It is quite feasible that 
good  overall  cohesion  in  the  SC,  and  therefore  good  barrier 
function,  relies  upon  the  diverse  physical  properties  of  these 
heterogeneous species.

CER[EOS]  is  worthy  of  particular  mention.  This  is  the 
predominant  ceramide  containing  unsaturated  fatty  acids  in 
the  SC  and  it  is  remarkably  enriched  in  linoleic  acid,  which 
comprises  a  minimum  of  20%–30%  of  the  omega-esterified 
fatty acid. The epidermis has an absolute requirement for lin-
oleic acid in order to maintain a correctly functioning barrier 
and  its  absence  leads  directly  to  the  dramatically  perturbed 
barrier found in EFAD animals. The characteristic hyperpro-
liferation seen in this condition may also reflect further pertur-
bation in linoleic acid metabolism (80).

As the work of Bouwstra and co-workers and others has 
suggested,  this  particular  ceramide  species  provides  unique 
physical properties to the stratum corneum (72,81) that simply 
cannot be compensated for by the esterification of other unsat-
urated fatty acids within the CER[EOS] fraction. As we discuss 
later  in  this  chapter,  reduced  levels  of  CER[EOS]-containing 
linoleic  acid  is  a  feature  common  to  many  skin  disorders 
including acne, atopic dermatitis (AD), and winter xerosis.

In  contrast,  increases  in  CER[EOS]  are  a  feature  of  the 
response of skin to repeated surfactant challenge (the so-called 

 
“hardening  phenomenon”),  again  emphasizing  the  key  role 
this ceramide plays in skin protection (82).

The careful interpretation of many in vitro and in vivo 
investigations on lipid behaviour in the SC has led to several 
models being proposed to describe lipid organization in this 
structure.  Some  models  are  more  theoretical/hypothetical, 
such  as  Forslind’s  “domain  mosaic”  model  (83)  and  Norlen’s 
related “single gel phase” model (84), whereas others are based 
on selected empirical data, such as Bouwstra’s sandwich model 
that relies primarily on x-ray diffraction data (69). Over the last 
decade no significant new models have been proposed for SC 
lipid  organization,  while  the  presence  of  orthorhombic  lipid 
organization in both ex vivo and in vivo SC measurements has 
been repeatedly confirmed (85–89). Nevertheless, Iwai et al. (90) 
reported that the barrier is organized of fully extended cerami-
des with cholesterol molecules associated with the sphingoid 
moiety.

Although the prime function of lipids in the SC is that 
of providing the water barrier, lipid abnormalities associated 
with  altered  cornification  have  been  reported  in  many  com-
mon dermatological disorders (psoriasis and atopic dermatitis) 
(91).  However,  at  present  there  is  not  a  detailed  understand-
ing of how changes in the lipid composition, or specifically the 
ceramide composition, influence corneocyte cohesion and ulti-
mately desquamation. There is indirect evidence for SC lipids 
being involved in cell cohesion from corneocyte re-aggregation 
studies in vitro. Numerous workers have re-aggregated previ-
ously dispersed corneocytes in the presence of SC lipids and 
found the physical properties of the reconstituted SC lipid-cell 
films to be similar to the intact tissue (92,93). In marked con-
trast, Chapman et al. (94) suggested intercellular lipids might 
actually have an anticohesive role, preventing close opposition 
of adjacent corneocytes. In those particular studies, when SC 
lipids  were  completely  extracted,  the  intercorneocyte  forces 
were  dramatically  increased,  primarily  due  to  the  juxtaposi-
tion  of  the  covalently  bound  lipids,  and  corneocytes  became 
tightly  cohesive.  Taken  together,  these  observations  indicate 
that  both  the  intercellular  and  covalently  bound  lipids  may 
have a role in SC integrity.

Changes  in  physical  properties  of  the  SC  ceramide  lip-
ids may also be important in promoting cell dyshesion toward 
the  skin  surface.  It  is  known  that  the  fine  ultrastructure  of 
the  ceramide  bilayers  is  disturbed  in  the  superficial  layers 
in normal skin (95). This loss of structure, critical for normal 
desquamation,  may  reflect  hydrolysis  by  ceramidases  (49). 
Alternatively, there is evidence that surfactant-like sebaceous 
fatty acids may lead to bilayer disruption (96) and the induc-
tion  of  an  orthorhombic-to-hexagonal  structure  transition  at 
the surface of the SC (97).

Ultimately,  however,  it  is  the  corneodesmosome  which 
is primarily responsible for inter-corneocyte cohesion (95–99), 
and it is this structure which must be effectively hydrolyzed 
to ensure desquamation. Ceramides, together with other lipid 
species, may play an important role in this process. Although 
the  precise  mechanism  is  far  from  understood,  the  phase 
behavior  and  organization  of  the  intercellular  lipids  controls 
the water content in the SC and may influence the activity of 
the  hydrolytic  enzymes  (100)  present  within  the  intercellular 
space  which  are  responsible  for  corneodesmosomal  degra-
dation.  In  this  respect  it  is  of  interest  to  note  that  the  action 
of  ceramidase  in  releasing  free  fatty  acids  may  also  contrib-
ute to the acidification of the stratum corneum that is critical 
for  enzymatic  regulation,  normal  desquamation,  and  barrier 
function (101).

CERAMIDES AND THE SKIN 

 129

VARIATIONS IN SC CERAMIDE LEVELS
The  total  amount  of  ceramides  in  SC,  as  well  as  individual 
ceramide species, are influenced by disease and hormonal sta-
tus,  diet,  age,  race,  external  environment,  and  by  circannual 
variation. Ultimately, it is the ratio of the different lipid classes 
as well as  the levels of individual lipids  in  the SC  that  influ-
ence  the  physical  properties  of  the  extracellular  lipid  matrix 
and  thereby  barrier  function,  water  content,  and  skin  condi-
tion. These differences can be subtle; i.e., changes in the cru-
cial ceramide:cholesterol ratio may explain the altered barrier 
characteristics in axillary skin (102). In this section we review 
specifically the changes in ceramide composition characteristic 
of various skin disorders.

Psoriasis and Ichthyoses
Of the genetic diseases impacting skin condition, only lamel-
lar  ichthyosis  and  psoriasis  have  been  investigated  in  any 
detail  in  relation  to  the  levels  of  SC  ceramides.  In  both  of 
these  conditions  dramatic  changes  in  SC  lipid  structure  is 
observed,  reflecting  changes  in  lipid  composition  (103–105). 
These changes include increases in CER[NS] and CER[EOH], 
and  decreases  in  CER[AS].  Together  with  the  altered  choles-
terol and fatty acid levels, these alterations contribute toward 
some  of  the  aberrations  in  SC  function  which  are  character-
istic  of  these  conditions,  including  corneocyte  cohesion  and 
faulty desquamation. Individuals suffering from lamellar ich-
thyosis  have  a  defective  gene  for  transglutaminase  1.  As  we 
have seen earlier, the inability to link ceramides to the corni-
fied envelope has dramatic consequences for the skin, and the 
loss of this enzymatic function explains in part the dramatic 
skin phenotype seen in ichthyotic individuals. It has also been 
reported  that  the  composition  of  the  covalently  bound  lipids 
differs  in  psoriatic  SC  compared  with  healthy  SC.  In  psori-
atic skin, CER[OH] decreases while other components such as 
ω-hydroxy  acids  and  fatty  acids,  particularly  the  covalently-
bound oleate and linoleate, are seen to increase (106). Focused 
studies on the discrete enzymes involved in the synthesis and 
degradation  of  ceramide  have  suggested  that  serine  palmi-
toyl  transferase  (SPT),  the  rate-limiting  enzyme  in  ceramide 
biosynthesis, is significantly decreased in lesional and nonle-
sional sites, whereas the levels of ceramidase were unchanged 
(106).  The  same  authors  also  report  on  a  negative  correlation 
between the levels of this enzyme and the psoriasis area sever-
ity  index  score.  The  data  on  changes  in  ceramide  levels  in 
psoriasis were reviewed by Feingold (107) and indicate a short-
ening  of  ceramide  chain  length  being  dictated  by  the  chain 
length of the amidated fatty acid. The proportion of CER[NH] 
with  total  higher  carbon  number  between  40–43  was  higher, 
whereas  C47-50  was  lower  compared  to  healthy  controls. 
Similar  changes  were  observed  for  CER[AdS],  CER[NP],  and 
CER[AP]. Tawada et al. suggest that interferon gamma caused 
the effects, as in vitro it reduced the expression of ELOVL1, 4, 
5, 6, 7, and CerS3, 4, and 6 (108). Ye et al. (109) have shown that 
the barrier recovery rates in uninvolved psoriatic skin are less 
compared with healthy skin.

Over  the  past  5  years  the  genetic  basis  of  the  congeni-
tal scaling syndrome harlequin ichthyosis has pointed to the 
importance  of  mutations  in  a  member  of  the  ABCA  trans-
porter  family:  ABCA12.  Mutations  in  this  gene  lead  to  an 
abnormality  in  lamellar  body  formation,  perturbed  lamel-
lar  lipid  organization  in  the  SC,  and  loss  of  barrier  function 
(110).  These  barrier  perturbations  are  associated  with  pro-
found  decreases  in  the  long-chain  omega-hydroxyceramides 

 
130 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(CER[EOS])  and  a  corresponding  increase  in  glucosylcerami-
des  (111).  Understanding  of  molecular  mechanisms  indicates 
that epidermal ceramides may regulate ABCA12 gene expres-
sion through a PPAR delta–mediated signaling pathway (112). 
Although the SC lipid profiles in other ichthyotic diseases have 
not been fully determined, reduced levels of sphingosine have 
been  found  in  a  variety  of  subjects  with  various  ichthyoses 
(113). This decrease in sphingosine may in part explain the cel-
lular hyperproliferation observed in these conditions as sphin-
gosine  has  been  proposed  to  feedback  to  the  epidermis  and 
down-regulate keratinocyte turnover (53).

Refsum disease is a rare disorder of peroxisome metab-
olism  due  to  a  defect  in  the  oxidation  of  phytanic  acid,  and 
Menon et al. (114) examined the barrier lipid structural orga-
nization in these patients. The SC intercorneocyte space were 
nonuniform,  with  some  areas  having  appropriate  lamellar 
structures and others completely lacking them. In many cases 
complete absence of corneocyte lipid envelopes was observed.
Sjögren-Larsson syndrome is caused by mutations in the 
fatty  aldehyde  dehydrogenase  gene  (ALDH3A2)  which  oxi-
dizes medium- to long-chain fatty acids. Nakajima et al. (115) 
have reported that a patient had no difference in the quantity of 
SC-derived cholesterol but the fatty acids were increased two-
fold while CER[EOS], CER[AP], and CER[AH] were decreased 
and membrane-bound ceramide as increased.

Dorfman-Charainin syndrome is a neutral lipid storage 
disorder  in  a  gene  that  activates  triglyceride  lipases,  yet  acyl 
ceramides have been reported to be deficient in these subjects 
(116).  Equally,  reduced  levels  of  corneocyte-bound  omega-
hydroxy  ceramides  and  fatty  acids  were  observed.  It  is  pro-
posed  that  the  CGI-58  the  protein  that  activates  triglyceride 
hydrolysis also provides fatty acids for the omega-esterification 
of ceramides leading to acyl ceramides. Goto-Inoue et al. (117) 
also  reported  on  the  ceramide  abnormalities  in  Dorfman-
Chanarin  syndrome  using  imaging  mass  spectrometry,  con-
firming the trace levels of acyl ceramides in these patients.

Chan et al. (118) highlighted the diagnostic implications 
of the skin ultrastructural changes in type 2 Gaucher disease, a 
disease lacking beta-glucosylcerebrosidase. Types 1 and 3 had 
normal lamellae due to low levels of the enzyme.

Atopic Dermatitis and Netherton Syndrome
Atopic dermatitis (AD) is characterized by xerosis and reduced 
barrier  function  as  measured  by  transepidermal  water  loss 
(TEWL)  and  corneosurfametry.  This  condition  is  also  associ-
ated with a significant decrease in SC ceramide levels (119,120)—
particularly CER[EOS]–containing linoleic acid (121)—and the 
presence  of  unusual,  possibly  diagnostic  ceramide  species 
(122).  Research  over  the  past  15  years  has  emphasized  that 
many aspects of lipid metabolism are deranged in this condi-
tion; AD patients have significantly depleted covalently-bound 
ω-hydroxyceramides  (123)  and  reduced  levels  of  prosaposin, 
an important regulator of sphingolipid metabolism (124).

Ishikawa  et  al.  (125)  observed  increased  levels  of 
Cer[AS]  in  AD  patients  and  that  the  larger  ceramide  spe-
cies  (>50  carbons)  was  expressed  at  lower  levels  in  CER[NS], 
CER[NdS],  CER[NH],  CER[AS],  and  CER[AH],  whereas  the 
smaller  species  (<40  carbons)  were  observed  at  higher  levels 
in  CER[NS],  CER[NdS],  and  CER[AS].  CER[EOS],  CER[EOP], 
and  CER[EOH]  were  all  at  lower  levels.  Janssens  et  al.  (126) 
also observed decreased levels of the EO species of ceramides 
including CER[EOdS] but increased levels of CER[NP] and of 
elevated C34 fatty acid chain length species in ceramide sub-
classes  CER[AS],  CER[AH],  CER[NS],  and  CER[NH]  (91,127). 

Overall,  the  average  ceramide  chain  length  was  significantly 
decreased by 0.64 ± 0.23 total carbon atoms in atopic eczema 
patients, and no difference was observed between carriers and 
noncarriers  of  FLG  mutations.  When  focusing  on  the  lateral 
organization,  atopic  eczema  patients  show  a  less  dense  lipid 
packing  compared  with  controls,  which  correlates  strongly 
with a higher level of C34 ceramides. This finding shows that 
ceramide chain length is also an important determinant of the 
lateral  lipid  organization  in  SC.  van  Smeden  et  al.  (128)  also 
showed that a reduction in fatty acid chain length associates 
with a reduced ceramide chain length. An increase in unsatu-
rated  fatty  acids  is  also  observed  in  atopic  eczema.  Joo  et  al. 
(129) reported that representing lipids as a ratio to cholesterol 
rather  than  protein  might  be  more  sensitive  for  discrimina-
tion between AD patients and healthy controls. Nevertheless, 
Janssens  et  al.  (130)  observed  a  reduction  in  the  lipid:protein 
ratio  together  with  a  thinner  SC  in  both  lesional  and  nonle-
sional  skin.  Angelova-Fischer  et  al.  (131)  observed  that  SC 
integrity was weaker in subjects with AD and filaggrin muta-
tions  but  AD  without  filaggrin  mutations  was  not  different 
from  healthy  controls.  Nevertheless,  there  was  no  difference 
in barrier recovery. Furthermore, the AD subjects with at least 
one  filaggrin  mutation  had  a  lower  ceramide-to-cholesterol 
ratio and reduced CER[EOH].

The  total  amount  of  ceramides  is  also  reduced  in 
Netherton syndrome while the amount of shorter chain cerami-
des (C30-40) is increased, much like the diseases reported pre-
viously  (132).  Of  all  the  ceramide  subclasses,  CER[NP]  was 
the  most  significantly  reduced  whereas  CER[AS],  CER[NS], 
and  CER[AH]  were  the  least  affected.  Equally,  the  levels  of 
acyl-ceramides  are  dramatically  decreased  yet  their  glycated 
variants  are  not.  Moreover,  ceramides  containing  monoun-
saturated  fatty  acids  were  observed  which  lead  to  an  altered 
lamellar lipid organisation with a high degree of disorder.

The  lowered  level  of  ceramides  in  AD  has  been  linked 
to  reduced  activity  of  sphingomyelinase  (133)  and  an  altered 
(increased)  expression  of  the  enzyme  sphingomyelin  deacyl-
ase  (134,135).  This  enzyme  competes  with  sphingomyelinase 
for  the  ceramide  precursor  sphingomyelin.  Although  sphin-
gomyelinase  remains  active  in  AD  (136),  significant  levels  of 
sphingomyelin  are  hydrolyzed  by  this  alternative  pathway 
to  release  free  fatty  acid  and  sphingosyl  phosphoryl  choline 
(SPC), The same enzyme can also degrade glucosylceramides 
to release glucosylsphingosine (GS) i.e. it also possess glucosyl-
ceramide deacylase activity (137).

The  presence  of  SPC  may  partially  explain  the  inflam-
mation associated with this disorder as it is a potent modulator 
of  epidermal  function,  stimulating  proliferation  and  upregu-
lating plasminogen activator (138). The vulnerability of the SC 
of  AD  patients  to  colonization  by  Staphylococcus  aureus  may 
reflect the reduced levels of sphingosine present in the tissue, 
in turn reflecting the decreased levels of ceramide (substrate) 
and  the  diminished  activity  of  its  metabolic  enzyme  acid 
ceramidase (139).

The  shorter  chain  species  identified  in  Netherton  syn-
drome  as  related  to  reduced  levels  of  ELVOVL1  and  6  and 
altered  expression  of  glucosylcerebrosidase  and  sphingomy-
elinase was noted (132).

Acne
Alterations  in  lipid  species  are  evident  in  acne.  Downing 
et  al.  (140)  found  reduced  proportions  of  linoleate  bound  to 
CER[EOS]  in  acne  patients  and  postulated  that  this  reflected 
a localized decrease in the bioavailability of the essential fatty 

 
acid  due  to  a  dilution  effect  of  increased  sebum  production. 
Yamamoto  et  al.  (141)  have  shown  that  the  general  decreases 
in  both  ceramides  and  free  sphingosine  in  acne  patients  cor-
relates to diminished water barrier function. Therefore, altered 
barrier  functionality  leading  to  epidermal  hyperkeratiniza-
tion and poor desquamation within the follicular epithelium 
may  be  responsible  for  comedone  formation  in  susceptible 
individuals.

Dandruff
Harding et al. have demonstrated (142) that in dandruff suffer-
ers the intercellular lipid content of scalp SC, including cerami-
des,  is  dramatically  reduced  compared  to  healthy  subjects. 
This  depletion  is  associated  with  reduced  barrier  function, 
which may leave dandruff sufferers more prone to the adverse 
irritant effects of microbial metabolites, surfactants, or pollut-
ants present on the scalp surface. These observations are con-
sistent with studies that indicate the presence of a perturbed 
lipid  ultrastructure  in  dandruff  sufferers  (143).  Effective  use 
of antidandruff treatments is accompanied by increased lipid 
levels, including ceramides (144).

Senile Xerosis
It is widely experienced that as we age we suffer from more 
skin  problems.  Although  these  problems  arise  from  a  com-
bination  of  many  factors,  an  age-related  reduction  in  the 
levels of SC ceramides may contribute to senile xerosis and 
other  skin  conditions.  Age-related  declines  in  SC  ceramide 
have  been  reported  in  both  Japanese  (145)  and  Caucasian 
subjects  (146–147).  In  the  latter  study,  although  the  relative 
levels of the main ceramide subtypes did not change, over-
all  SC  lipid  levels  diminished  with  increasing  age  on  face, 
leg,  and  hand  skin.  In  addition,  the  same  group  reported 
an  age-related  decline  in  CER[EOS]  linoleate  levels,  which 
may  have  a  dramatic  effect  on  SC  barrier  function  (146).  In 
another  study  with  French  Caucasians,  a  selective  deple-
tion of sterol esters and triglycerides, but not ceramides, was 
reported  in  aging  leg  SC  (147).  Researchers  at  L’Oreal  have 
used  high-performance  liquid  chromatography  coupled 
with electrospray ionization mass spectrometry to elucidate 
ceramide change in dry skin. They report that phytosphin-
gosine-containing  ceramides  are  particularly  depleted  in 
dry  skin  compared  with  sphingosine-containing  ceramide 
species  (148).  Moreover,  shortening  and  lengthening  of  the 
acyl sphingoid bases sphingosine and 6-hydroxysphingosine 
have been reported in dry skin (148).

Ceramide subtypes have also been reported to change 
with  age  in  Japanese  women  (145).  Surprisingly,  increases 
in  CER[EOS]  but  decreases  in  CER[NP]  and  CER[AP]  were 
found  going  from  prepuberty  to  adulthood.  These  studies 
and others suggest that the impact of age on ceramide levels 
is likely to be influenced by ethnic background. For instance, 
in comparing SC lipid levels in several racial groups, Sugino 
and  coworkers  (149)  reported  that  SC  ceramide  levels  were 
lowest  in  African  Americans  compared  with  other  racial 
types. Paradoxically, African-American skin is often viewed 
as being relatively resistant to damage, emphasizing the fact 
that the resilience of the skin barrier is determined by many 
factors  including  the  size  of  the  corneocytes  and  the  thick-
ness and integrity of the SC, although these factors were not 
discussed by these authors (150).

The most likely cause of an age-related decline in lipid 
levels  is  a  reduced  epidermal  lipid  biosynthesis  capability, 

CERAMIDES AND THE SKIN 

 131

as  reported  by  Ghadially  et  al.  (151).  The  increased  activ-
ity  of  ceramidase  reported  by  Akimoto  may  also  contribute 
to  declining  ceramide  levels  (152).  Studies  in  aged  mice  have 
shown  reduced  levels  of  epidermal  acid  sphingomyelinase 
and ceramide synthase consistent with a reduced age-related 
capacity to repair the barrier. In this study ceramidase did not 
show any age-related change (153). Further work is needed to 
extend and confirm these changes in man.

Although  considerable  progress  has  been  made,  our 
understanding  of  the  influences  of  race,  gender,  and  age  on 
SC lipids remains incomplete. There is a large intra-individual 
difference in lipid levels without obvious physical manifesta-
tions of dryness (154). Similarly, in aged dry skin the demon-
stration of an altered lipid composition or differing molecular 
organization is not always apparent. Clearly, clinical dry skin 
is  not  monocausal  and  many  other  factors  contribute  to  the 
phenotype (1). Nevertheless, and once again emphasizing the 
importance  of  the  omega-hydroxy  fatty  acids,  a  deficiency  of 
CER[EOS]  and  CER[EOH]  is  frequently  correlated  with  an 
absence of the long periodicity phase as examined by x-ray dif-
fraction in the dry skin disorder (81).

Effects of Environmental Factors on 
The Expression of Winter Xerosis
It has become apparent that many factors influence the levels 
and types of  SC lipids,  and it  is possible  that  their reduction 
leads directly to poor skin condition. Levels of lipids differ on 
different body sites, which may make some sites more or less 
prone  to  environmental  damage  (34,155).  For  instance,  lower 
levels of SC lipids will be more susceptible to extraction (e.g. 
during hand washing) or perturbation of their structural orga-
nization  which  could  lead  to  abnormalities  in  SC  function 
and overall skin condition, leading to a visibly dry and flaky 
skin  surface.  Indeed,  a  picture  is  emerging  that  lipids  influ-
ence the expression of this common problem. Lipids are easily 
extracted from the SC by solvents (156) and surfactants (157), 
leading to their depletion from the intercellular spaces of the 
SC, and resulting in skin scaling. In studies employing aggres-
sive acute treatment regimes, solvent and surfactant extraction 
leads to changes in the relative amounts of the different lipid 
species in the outer layers of the skin, due to selective removal 
of  lipids.  However,  during  chronic  treatments,  particularly 
with surfactants, differences in SC lipid composition, but not 
total lipid levels, have been reported (158). Following chronic 
exposure to surfactants increases in CER[EOS], CER[NS], and 
cholesterol were observed, whereas the remaining ceramides, 
cholesterol esters, and long-chain fatty acids all decreased in 
concentration.  Similar  changes  in  SC  ceramide  profiles  have 
been reported in other experimental models for scaly skin (e.g. 
tape-stripping),  indicating  that  the  changes  in  SC  lipid  com-
position are related to changes in epidermal lipid biosynthesis 
rather  than  lipid  extraction  from  the  SC  (159).  In  skin  suffer-
ing  from  soap-induced  winter  xerosis,  the  total  levels  of  SC 
ceramides are decreased (160) and the levels of fatty acids are 
increased  (160,161)  leading  to  aberrations  in  the  SC  lamellar 
organization (Table 14.4 and Figure 14.2). Ishikawa et al. (162) 
demonstrated  that  all  ceramide  species  negatively  correlated 
with skin dryness, roughness, and scaliness.

Although  the  effects  of  climate  on  skin  condition  are 
well known, there have been very few studies examining circ-
annual variation in SC lipids. An early study has shown a gen-
eral  decrease  in  epidermal  cerebrosides  in  winter  compared 
with  summer  (163).  Following  the  analysis  of  SC  lipids  from 
the face, hand, and leg skin of female Caucasians in the winter, 

 
132 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 14.4  Relationship of Skin Xerosis and Stratum Corneum Lipid Composition

Skin Xerosis Grade

Lipid Species

Grade 1

Grade 2

Grade 3

Grade 4

Lipid Levels (ng lipid/μg protein)
Ceramides
Free acids
Cholesterol
Relative Lipid Levels (% of total lipids)
Ceramide
Fatty acid
Cholesterol

64.9 ± 34.4
62.1 ± 34.6
3.9 ± 2.1

47.1 ± 17.4
49.7 ± 18.6
2.0 ± 1.9

68.6 ± 30.4
67.4 ± 32.7
7.7 ± 4.2

48.3 ± 8.6
46.2 ± 9.8
5.5 ± 2.6

39.2 ± 14.9*
60.5 ± 37.0
4.4 ± 2.0

40.2 ± 13.2
55.0 ± 12.0
4.8 ± 2.4

37.5 ± 14.1*
54.9 ± 28.2
4.6 ± 2.3

38.3 ± 11.2
56.0 ± 10.8
5.2 ± 3.2

Source: Rawlings AV et al., J Soc Cosmet Chem, 1994; 45:203–20.
Notes: Note reductions in ceramide levels with increasing skin xerosis. Values represent mean ± standard deviation. Grade 1, n = 8; grade 2, n = 8; 
grade 3, n = 12; grade 4, n = 12.
*Significantly different from grade 1 ( p, 0.05).

summer, and spring months of the year, Rogers et al. reported 
decreases  in  all  major  lipid  classes  on  all  body  sites  during 
the winter months (146). Although the levels of ceramide sub-
types  were  unchanged,  the  amount  of  linoleate  esterified  to 
CER[EOS] was reduced. These changes are likely to result in 
reduced barrier function. For instance, an increased suscepti-
bility to treatment with SLS has been reported for the winter 
months of the year (164), and an inverse correlation has been 
shown between ceramide levels and TEWL following an SLS 
patch (165).

Xerosis is not confined to winter, and studies conducted 
almost  20  years  ago  reported  that  there  were  changes  in 
ceramides  associated  with  UV  damage.  Murine  studies  have 
indicated  that  there  are  dramatic  differences  in  ceramide-
relevant enzymatic activity during the early response to UV-B. 
Glucosylceramides  accumulate  in  the  SC  due  to  attenuated 
activity  of  beta-glucocerebrosidase  (166),  and  decreased  lev-
els  of  covalently  bound  lipids  are  measured  potentially  due 
to  down-regulation  of  transglutaminase  1  (167).  These  and 
changes in other enzymes associated with lamellar body for-
mation  and  organization  will  contribute  to  the  reduced  bar-
rier  function  and  scaly  skin  characteristically  seen  post  UV 
irradiation.

During the past 15 years the pioneering studies by Denda 
and co-workers have begun to elucidate just how seasonal low 
humidity  can  influence  epidermal  processes  and  lead  to  dis-
turbances in barrier function. The observation that low envi-
ronmental humidity stimulates epidermal DNA synthesis and 
amplifies the hyperplasia associated with barrier damage (168) 
has helped to rationalize the characteristic seasonal exacerba-
tion  of  inflammatory  dermatoses.  Perturbations  to  mast  cell 
physiology  have  suggested  the  use  of  H1  and  H2  histamine 
receptor  antagonists  to  improve  overall  skin  condition  (169). 
The reader is referred to reviews by Denda (170) and Feingold 
and Denda (171) that explore several new strategies to improve 
barrier homeostasis.

Many studies only evaluate forearm or leg stratum cor-
neum, and few have considered facial skin. Ishikawa et al. (34), 
however, examined the ceramide composition for a variety of 
body sites and observed that the skin on the lower legs, fore-
arm,  head,  upper  arm,  buttock,  and  scalp  have  higher  total 
ceramides compared with that of the palm, finger, lip, back of 
the hand, and cheek. The palm, finger, lip, and cheek showed 
a  lower  percentage  of  CER[NP],  CER[EOS],  CER[EOH],  and 
CER[EOP] and a higher percentage of CER[NS] and CER[AS]. 
The skin on the scalp had the highest percentage of CER[NdS] 

and CER[EOP], and the skin on the palm had the lowest per-
centage of CER[EOS], CER[EOH], and CER[EOP]. Equally, the 
average  carbon  numbers  of  CER[NS]  were  shorter  on  the  lip, 
palm, cheek, and fingers compared with other body sites. C34-
CER NS was higher on the scalp, forehead, cheek, and lip com-
pared  with  the  other  body  sites.  Seasonal  variations  in  these 
body comparisons were observed, and all studies need to con-
sider this.

Ethnicity
Muizzuddin et al. (172) compared  the  levels of  SC ceramides 
in African-American, Caucasian, and East Asian skin. African-
American skin had the lowest ceramide-to-protein ratio, with 
the  East  Asians  being  identical  to  the  Caucasians.  However, 
Jungersted  et  al.  (173)  found  increased  ceramide:cholesterol 
ratios  for  Asian  subjects  compared  with  Africans  and 
Caucasians, with the Africans having the lowest values. Much 
more work is needed in this area to understand the importance 
of  these  differences  to  the  known  differences  in  skin  barrier 
function.

BIOSYNTHESIS OF SC CERAMIDES 
AND BARRIER REPAIR
Endogenous Regulation of Ceramide 
Synthesis and Barrier Function
Elias  and  co-workers  developed  several  models  of  barrier 
repair in order to decipher the biochemical control mechanisms 
of barrier homeostasis (reviewed in 174). When the SC barrier 
is damaged, a series of homeostatic processes are immediately 
accelerated, and in the absence of further damage, the barrier 
recovers to its original level. These processes include lipid bio-
synthesis, lipid processing, and the acceleration of the exocy-
tosis of lamellar bodies. Although altered water flux is a key 
factor  in  initiating  barrier  repair  following  SC  perturbation 
(175), the precise signal is not understood. Moreover, it should 
be noted that many of these studies were conducted on murine 
models and may not necessarily reflect the situation in human 
skin (176).

Studies using inhibitors to the key rate-limiting enzymes 
have indicated that all major species of SC lipids are synthe-
sized  during  barrier  repair  and  all  are  required  for  full  bar-
rier homeostasis. In contrast to the synthesis of cholesterol and 
fatty  acids,  which  increase  almost  immediately  after  barrier 
disruption,  synthesis  of  glucosylceramides,  the  precursors  of 
the SC ceramides, is delayed until approximately 7 hours later 
(177). It is possible that the synthesis of the other lipids occurs 

 
more  quickly,  as  the  rate-limiting  enzymes  (hydroxymethyl-
glutaryl CoA reductase and fatty acid synthetase) involved in 
their synthesis are subjected to acute metabolic control mecha-
nisms, such as phosphorylation. SPT (see earlier section) is not 
subjected  to  such  control  and  requires  the  transcription  and 
translation  of  further  enzyme  (178).  Furthermore,  studies  on 
transcriptional  control  of  lipid  synthesis  in  mammalian  cells 
have  shown  that  the  expression  of  genes  involved  in  choles-
terol  and  fatty  acid  synthesis  and  uptake  is  regulated  by  the 
sterol regulatory binding proteins (SREBP 1 and 2). In contrast, 
ceramide synthetic machinery does not appear to be regulated 
by this system (179).

Studies  on  animal  models  (48)  have  emphasized  that 
hydrolysis  of  the  glycosylated  ceramide  precursors  by  beta-
glucocerebrosidase  is  a  critical  step  in  correct  barrier  for-
mation  and  repair,  and  once  again  activity  of  this  enzyme 
is  regulated  by  barrier  permeability  (180).  Although  factors 
controlling  the  synthesis  and  activity  of  this  enzyme  are 
poorly understood, there is evidence emerging that the sapo-
sins (sphingolipid activator proteins) are intimately involved. 
This  class  of  proteins  stimulates  enzymatic  hydrolysis  of 
sphingolipids including glucosylceramide and is essential for 
epidermal barrier permeability barrier formation and main-
tenance (181). Prosaposin is reported to be depleted in certain 
skin disorders (132,182). Many studies have indicated that ion 
flux plays a critical role in barrier homeostasis, and there is a 
drastic alteration of calcium gradient following barrier insult 
(183).  It  is  possible  that  regulation  of  calcium  ion  dynam-
ics  after  the  barrier  damage  might  control  the  skin  barrier 
homeostasis (184). Mixtures of magnesium and calcium salts 
have  been  shown  to  accelerate  skin  barrier  recovery  and 
improve  surfactant-induced  or  tape-stripping–induced  dry 
skin (185). Although such studies indicate the importance of 
these  ions  for  epidermal  homeostasis,  more  work  is  needed 
with  cosmetic  formulations.  Nevertheless,  based  on  these 
observations  some  work  has  demonstrated  that  manipula-
tion of ligand-gated ion channels can influence barrier recov-
ery. Gamma-aminobutyric (GABA) type A receptor agonists 
musimol and isoguvacine accelerate barrier recovery follow-
ing  barrier  disruption  (186).  Conversely,  ATP  (purinergic) 
receptor  (P2X)  agonists  delay  barrier  recovery  whereas  P2Y 
antagonists accelerate it (187). These molecules also reduced 
the  epidermal  hyperproliferative  response  induced  by  ace-
tone treatment under low environmental humidity.

Importantly, a variety of cytokines are released/secreted 
by the epidermis during barrier repair and they equally may 
contribute as key lipid biosynthetic switches in barrier devel-
opment and barrier homeostasis (188–190). Readers are referred 
to the reviews of Denda together with Feingold and Denda for 
additional information (170,171).

Influence of Topically Applied of 
Ceramides on SC Barrier Function
Imokawa  and  co-workers  were  the  first  to  investigate  the 
effects  of  topical  application  of  human  SC  ceramides  to  sol-
vent  and  surfactant-induced  scaly  skin  (156,157).  When  the 
extracted lipids, and in particular the ceramide fraction, were 
applied  back  to  the  damaged  skin,  reductions  in  scaling  and 
improvements  in  skin  moisturization,  as  measured  by  skin 
conductance, were observed. This amelioration of skin condi-
tion was superior to placebo and corresponding formulations 
containing  sebaceous  lipids.  In  these  studies  the  ceramides 
were  either  solubilized  in  squalene  or  emulsified  in  water  in 

CERAMIDES AND THE SKIN 

 133

oil  cream  containing  monomethylheptadecylglyceryl  ether. 
Interestingly, these effects were not observed without the glyc-
eryl ether. The glyceryl ether may be aiding penetration of the 
influencing  SC  lipid  phase  behavior.  Agents  such  as  glycerol 
and glyceridacid are known to influence the physical proper-
ties of the ceramide-containing SC lipids.

Beradesca  et  al.  (191)  and  Lintner  et  al.  (192)  have  dem-
onstrated  that  exogenously  supplied  CER[EOS]  and  CER[NS] 
respectively reduced the detrimental effects of SLS on disturbing 
skin barrier function. Chamlin et al. (193) reported that a ceramide 
dominant  barrier  repair  cream  helped  to  alleviate  AD  over  a 
6-week  period.  However,  the  title  was  incorrect  in  this  paper, 
as  a  pseudoceramide  was  actually  used  (N-(2-hydroxyethyl)-
2-pentadecanoylhexadecanamide 
communication 
Y. Uchida). Studies by Imokawa and co-workers have reported 
on  the  skin  condition  benefits  derived  from  topical  application 
of  formulations  containing  5%–8%  synthetic  ceramides  (so-
called  pseudoceramides)  that  mimic  the  physical  properties  of 
SC ceramides (194). Many laboratories continue to examine novel 
synthetic  ceramide  structures  for  both  improved  keratinocyte 
differentiation and impact upon barrier repair (195,196)

(personal 

Invariably,  optimal  improvements  in  dry  and  dam-
aged SC are observed when complete lipid mixtures are topi-
cally applied. De Paepe observed that a mixture of ceramides 
(CER[NP] and CER[AS], together with cholesterol, linoleic acid, 
and  phytosphingosine  provided  significant  improvements  in 
barrier  function  and  hydration  over  use  of  ceramides  alone 
(197).  Elias  and  co-workers  have  also  focused  on  the  use  of 
exogenously  supplied  lipids  to  repair  water  barrier  function 
(198,199).  Although  equimolar  mixtures  of  ceramides,  choles-
terol, and fatty acids allow the barrier to repair at normal rates, 
an  optimized  mixture  (cholesterol,  ceramide,  palmitate,  and 
linoleate:  4.3:2.3:1:1.08)  was  noted  to  accelerate  barrier  repair 
following  disruption  of  the  murine  water  barrier  by  acetone. 
Although  this  mixture  was  seen  to  accelerate  barrier  repair 
following a range of barrier insults (tape-stripping, treatment 
with  N-laurosarcosine  or  dodecylbenzene  sulphonic  acid), 
the  mixture  was  not  effective  after  barrier  damage  with  SLS 
or ammoniumlaurylsulphosuccinate (200). These studies sug-
gest that customized mixtures of the critical lipid species may 
be required to repair barrier damage resulting from differing 
insults. Further studies are required to relate the significance 
of these observations to human skin.

So  called  “ceramide-based”  emulsions  such  as 
EpiCeram  and  TriCeram  are  based  upon  the  physiological 
3:1:1  molar  ratio  although  they  contain  pseudoceramides. 
Other pseudoceramides have also been used topically (201–
203). Many of the studies conducted with these formulations 
suffer from not having an appropriate vehicle control but at 
the same mass level in a product they should be superior to a 
non bilayer forming ingredients (204,205). However, if a non-
bilayer–forming ingredient can be formulated into a product 
at much higher concentration because it is less expensive (e.g. 
petrolatum),  then  this  will  give  a  superior  clinical  benefit 
(206).  These  types  of  products  may,  however,  be  inferior  in 
terms of product aesthetics.

Huang  et  al.  (207),  however,  reported  that  CER[EOS] 
and  CER[NS]  act  synergistically  on  skin  hydration  and  tran-
sepidermal water loss of SLS-irritated skin relative to a control 
non-ceramide–containing vehicle. This is the best comparison 
potentially  demonstrating  the  effects  of  ceramides  but  the 
vehicle simply had less “emollient” in the formulation. To be 
confident of these effects, further studies need to be conducted 

 
134 

 TEXTBOOK OF COSMETIC DERMATOLOGY

with the same mass level of emollients and barrier lipids in the 
products.

It  is  also  becoming  apparent  that  in  order  to  optimize 
barrier integrity through the topical application of ceramides 
that the correct stereochemistry of these lipids is considered. 
X-ray  diffraction  studies  have  reported  that  chiral  CER[NP] 
forms  the  characteristic  short  (SPP)  and  long  periodicity 
phases  (LPP),  while  a  racemic  CER[NP]  mix  prevented  for-
mation of the LPP, resulting in a disrupted lipid matrix (208). 
Moreover, one of the big problems in interpreting the clinical 
data on use of ceramides is the lack of vehicle-controlled stud-
ies. Nevertheless, amphiphiles that mimic their behavior have 
been  shown  to  be  clinically  very  effective  compared  to  non-
bilayer–forming species (204,205).

Enhanced Ceramide Synthesis through 
Delivery of Ceramide Precursors
Given the critical importance of ceramides to the barrier func-
tion, many researchers have sought routes to increase the syn-
thesis of ceramides within the skin using lipid precursors. The 
earliest  work  relates  to  the  correction  of  ceramide  levels  and 
barrier function in essential fatty acid deficiency by the appli-
cation of linoleic and linolenic acid (209). Similarly, it has also 
been  demonstrated  that  the  low  ratio  of  CER[EOS]  linoleate 
to CER[EOS] oleate which is characteristically seen in skin in 
the  winter  months,  and  which  may  predispose  such  skin  to 
winter  xerosis,  can  be  improved  by  up  to  85%,  through  topi-
cal application of formulations containing linoleic acid in the 
form of natural oils (210). Brod et al. have also demonstrated 
similar effects on dry skin (211). Thus, increasing the propor-
tion of CER[EOS] linoleate may improve SC function in such 
conditions.

Lactic  acid,  especially  L-lactic  acid,  can  also  function 
as a general precursor to ceramides and this may explain the 
improvements  in  SC  resilience  observed  following  treatment 
with  this  alpha-hydroxy  acid.  The  L-chiral  isomer  improved 
SC barrier function, as measured by both reduction in TEWL 
values following a challenge with SLS, and by improved resis-
tance to the appearance of dry skin in moisturization efficacy 
studies  (212).  These  improvements  were  related  to  the  over-
all  increase  in  SC  ceramide  levels  and  especially  ceramide 
1-linoleate  levels  following  use  of  the  prototype  formulation. 
Furthermore,  in  vitro  studies  with  keratinocytes  established 
that lactic acid was utilized for lipid biosynthesis and it is pos-
sible  that  this  also  takes  place  in  vivo,  leading  to  increased 
ceramide levels and a more effective barrier.

Other  precursors  such  as  serine,  the  primary  substrate 
for SPT, are utilized by keratinocytes in the presence of thiols 
(lipoic  acid  and  n-acetylcysteine)  to  stimulate  ceramide  bio-
synthesis (213). These thiols presumably activate SPT by thiol 
disulphide  exchange  mechanisms,  and  might  be  expected  to 
provide benefit to the skin of subjects with a perturbed barrier.
Another option for enhancing ceramide biosyntheses is 
to use substrates, which can feed into the ceramide biosynthe-
sis pathway beyond the rate-limiting enzyme. Carlomusto et al. 
have  shown  that  the  modified  sphingoid  base  tetracetylphy-
tosphingosine (TAPS) is a substrate for ceramide biosynthesis 
in  vitro  (214).  In  vivo  topical  application  of  TAPs  lead  to  an 
increase in ceramide biosynthesis in vivo as measured by lipid 
analysis of tape-stripped SC and a corresponding increase in 
resistance to surfactant damage (215). In further studies, a syn-
ergistic improvement in SC ceramide levels and a correspond-
ing increase in barrier function was achieved when TAPS was 

combined  with  omega-hydroxy  acids  and  linoleic  acid.  This 
triple  lipid  combination  preferentially  increased  CER[EOS] 
level above other ceramides, supporting its proposed mode of 
action as a CER[EOS] precursor (215).

Activation  of  key  enzymes  is  a  promising  route  to 
increase  lipid  biosynthesis.  Studies  by  Tanno  and  coworkers 
(216)  have  shown  that  nicotinamide  can  increase  synthesis 
of ceramide and free fatty acid levels in the SC and decrease 
TEWL  in  dry  skin.  The  mechanism  of  this  action  involves 
increased synthesis of acetyl CoA (as a general precursor for 
both  lipid  species)  and  of  mRNA  for  SPT  with  an  associated 
increases in enzyme activity.

Peroxisome  proliferator-activated  receptors  (PPAR)  are 
nuclear  receptors  that  belong  to  the  steroid/thyroid/retinoid 
receptor  superfamily  and  are  specifically  involved  in  lipid 
homeostasis. Evidence suggests that activation of these recep-
tors by specific ligands can also increase the mRNA expression 
of  several  key  enzymes  involved  in  ceramide  (SPT  and  beta-
glucocerebrosidase)  and  cholesterol  (HMG  CoA  reductase) 
synthesis. (217). It is of interest to note that expression of PPAR 
alpha is down-regulated in involved regions of psoriatic skin 
(218). Studies by Hara and coworkers have suggested that cer-
tain glycosphingolipids may also improve dry skin condition 
through  activation  of  beta-glucocerebrosidase  (219).  There  is 
also an indication that, in vitro at least, vitamin C can influence 
the hydroxylation and synthesis of specific ceramides, notably 
CER[AP]  and  CER[AH],  to  improve  the  overall  organization 
and  water-retaining  properties  of  these  model  systems  (220). 
Whether  vitamin  C  can  influence  the  spectrum  of  ceramides 
synthesized in vivo remains to be established.

Novel  routes  to  enhancing  ceramide 

levels  have 
appeared  in  the  literature;  increased  levels  of  ceramides  are 
reported in the skin of elderly subjects following topical appli-
cation of a preparation of Streptococcus thermophilus containing 
sphingomyelinase (221), and the potential of dietary manipula-
tion leading to increased barrier function has been shown in 
mice following dietary supplementation of glucosylceramides 
obtained from rice bran and germ (222). Dietary supplementa-
tion with wheat germ extracts are also claimed to improve bar-
rier function in humans. Peptides from potato hydrolysate have 
also been shown to increase ceramide synthesis (223), as well 
as eucalyptus extract, with macrocarpal A being the key com-
ponent, which also increases the expression of the ceramide-
generating  epidermal  enzymes  (224).  Moreover,  Kato  and 
Takahashi  (225)  reported  that  sodium  alpha-tocopheryl-6-o-
phosphate  increases  ceramide  biosynthesis.  In  addition, 
Hashizume et al. (226) found that N-acetyl-L-hydroxyproline 
increased ceramide synthesis and expression of SPT.

Influence of Ceramides on 
Keratinocyte Differentiation
In this review we have been concerned primarily with the role 
of  ceramide  in  barrier  function.  Extracellular  or  exogenously 
added  ceramides  may  play  an  important  pro-differentiation 
role, indirectly leading to improved SC resilience. For instance, 
exogenously supplied short chain ceramides, and certain pseu-
doceramides, are known to induce keratinocyte differentiation 
in vitro (39,195). Short-chain ceramides and pseudoceramides 
also potentiate the effects of vitamin D, which is essential for 
keratinocyte differentiation (214).

Moreover,  sphingolipids  act  as  potent  second  mes-
sengers  in  diverse  cellular  signaling  pathways  (227–230). 
Ceramides  are  intimately  involved  in  cellular  decisions  on 

 
proliferation (231), differentiation (39,40,214,232), and apoptosis 
(233), and ultimately the ubiquitous roles fulfilled by cerami-
des  impact  skin  condition  at  many  different  levels.  Much  of 
the initiation of mammalian apoptosis and epidermal differen-
tiation takes place at the mitochondrial level where the physi-
cochemical properties and integrity of the membrane plays a 
critical role. Mitochondria are essentially sensors of sphingo-
lipids,  and  ceramides  can  influence  membrane  permeability, 
effecting activation of the critical proteases (caspases) that can 
initiate  apoptosis  or  differentiation  (234).  The  mitochondrial 
membrane appears to represent a common destination where 
mediators of stress converge and where critical decisions about 
cellular adaptation or apoptosis are taken. It is becoming clear 
that  ceramides  directly  or  indirectly  profoundly  affect  mito-
chondrial functions but it must be remembered that this is also 
necessary  for  epidermal  differentiation.  (235,236).  The  most 
compelling  evidence  for  a  lack  of  effect  of  these  compounds 
on apoptosis comes from in vivo studies. In humans Jatoi et al. 
find no effects of C2 and C6 ceramides on apoptosis (237). In 
light of these studies and in vitro studies, using realistic dose 
levels  of  short-chain  ceramides  can  clearly  induce  epider-
mal  differentiation  by  up-regulating  ABCA12  expression  via 
the  PPAR  delta–mediated  signaling  pathway,  which  are  both 
important  for  epidermal  differentiation  and  lipogenesis  (112) 
These  studies  are  consistent  with  the  earlier  investigations 
reported by Pillai et al. (39) and Paragh et al. (40).

There  is  a  lot  of  confusion  in  the  literature  on  whether 
ceramide or pseudoceramides and especially their short chain 
variants  cause  keratinocyte  apoptosis  or  induce  keratinocyte 
differentiation.  This  has  been  fueled  by  the  studies  of  Uchida 
et  al.  (195)  who  showed  that  cell  permeant  C-2  ceramides  and 
natural  ceramides  decreased  mitochondrial  membrane  poten-
tial but pseudoceramides PC104 and BIO301 did not. The authors 
then emphasized the safety of the latter but not the former. This 
was  despite  earlier  studies  demonstrating  the  keratinocyte 
prodifferentiation benefits of short chain ceramides and pesu-
doceramides (39,40,214,232). Kim et al. (238) also demonstrated 
the apoptotic effects of tetraacetyl phytosphingosine in HaCat 
cells which was enhanced in the presence of UVB light. Takeda 
et al. (239), however, found that only C6 and not C2-ceramides 
induced apoptosis in HaCat cells. Conversely, Kwon et al. (196) 
established that the pseudoceramides K6PC-4, 5, and 9 induced 
differentiation of primary keratinocytes. Philips et al. (240) how-
ever, found that C-2 ceramides increased caspase-3 expression 
in primary keratinocytes. Nevertheless, Jiang et al. (112) found 
that  short-chain  ceramides  increased  ABCA12  expression  via 
stimulation  of  PPAR  delta  expression,  indicating  the  role  of 
short chain ceramides in epidermal differentiation that was long 
established  (39,40,214,232).  Murakami  et  al.  (241)  later  showed 
that phytoceramide and sphingolipid bases derived from brew-
er’s yeast activated PPAR, which was followed by a study of the 
effects of sphingoid bases in keratinocytes (242) and the effects 
phytosphingosine-1-phosphate  inducing  EGF-dependent  der-
mal  fibroblast  proliferation  together  with  phytosphingosine 
ameliorating  skin  inflammation  (243).  Farwick  and  Rawlings 
reviewed the effect of sphingoid bases as PPAR agonists (244). 
Thus on balance, despite the earlier study of Uchida et al. (195) 
demonstrating the pro-apoptotic effects of ceramides, this class 
of lipids would appear to induce keratinocyte differentiation. In 
support of this, Jiang et al. (245) demonstrated that C2 and C6 
ceramides (but not C8 glucosyl ceramides) increased caspase-14 
expression.  Nevertheless,  the  most  compelling  evidence  for 
a  lack  of  effect  of  these  compounds  on  apoptosis  comes  from 

CERAMIDES AND THE SKIN 

 135

in vivo studies described above (237). Additionally, a study by 
Grether-Beck et al. (246) confirmed the lack of effect of phyto-
sphingosine,  N-hexanoyl  phytosphingosine,  and  N-stearoyl 
phytosphingosine  on  UVB-induced  apoptosis.  Increased  cas-
pase-3 activity was observed in basal and differentiating kera-
tinocytes  with  UVB,  but  co-stimulation  with  the  ceramides 
did  not  further  increase  caspase-3  activity  and  nucleosomal 
fragmentation,  corroborating  the  safety  of  these  ceramides. 
Moreover,  Janusova  et  al.  (247)  found  that  medium-  to  long-
chain  ceramides  (C8–24)  had  no  detrimental  effect  on  barrier 
function, whereas short-chain ceramides adversely affected the 
physical  properties  of  the  barrier.  This  is  similar  to  the  stud-
ies of Novotny et al. (38). Thus the short-chain ceramides may 
enhance their own delivery.

In support of this, several dietary studies have also con-
firmed  the  effects  of  dietary  sphingolipids  on  keratinocyte 
differentiation.  Hasegawa  et  al.  (248)  showed  that  glucosyl-
ceramide  enhances  corneocyte envelope  formation  via  trans-
glutaminase expression and involucrin production in hairless 
mice  irradiated  by  UVB.  Ideta  et  al.  (249)  showed  that  orally 
administered glucosylceramide improves epidermal tight junc-
tion and corneocyte envelope expression in SDS-treated mice. 
Duan et al. (250) showed that glucosyl ceramide and sphingo-
myelin increased the expression of ceramide synthases 3 and 4 
in the epidermis of an AD-like skin model, and Kawada et al. 
(251)  demonstrated  that  dietary  glucosyl  ceramide  enhanced 
the expression of claudin-1 in UVB-irradiated mice.

CONCLUSIONS
Research  into  the  structure  and  function  of  skin  ceramides 
has  increased  dramatically  over  the  past  20  years.  These 
complex  lipids  have  been  shown  to  influence  many  aspects 
of  cutaneous  biology,  including  the  barrier,  mechanical, 
and desquamatory properties of the SC. In this respect our 
understanding  of  the  relationship  between  SC  lipids  and 
cosmetic  and  pathological  skin  conditions  has  been  essen-
tial in our continued desire to improve these abnormal skin 
conditions,  through  the  use  of  either  defined  barrier  lipid 
species or their biosynthetic precursors. Nevertheless, as our 
techniques  of  investigation  become  more  sophisticated  it  is 
becoming  increasingly  evident  that  our  understanding  of 
these molecules remains in its infancy. The observations that 
the SC contains over 300 distinct ceramide species, derived 
from  13  classes,  suggests  an  exquisitely  subtle  relationship 
between  the  types  of  ceramides  and  their  correct  physical 
and chemical characteristics and the essential barrier func-
tion  of  the  skin.  There  is  much  to  learn  about  the  critical 
role  that  ceramides  play  in  epidermal  signaling  and  differ-
entiation, the factors that control their biosynthesis, and not 
least,  the  subtleties  of  their  organization  that  maintain  the 
essential barrier function. Moreover, the safety of ceramides, 
whether short or long and in the presence of UV or not, has 
now  been  completely  established  through  the  exhaustive 
studies  conducted  over  the  last  two  decades  both  in  vitro 
and in vivo.

REFERENCES

1. Rawlings AV. Molecular basis for stratum corneum maturation 
and moisturization. Br J Dermatol. 2014 Sep;171 Suppl 3:19-28.
2. Elias  PM.  Epidermal  lipids,  barrier  function,  and  desquama-

tion. J Invest Dermatol. 1983; 80 Suppl:44s–9s.

 
136 

 TEXTBOOK OF COSMETIC DERMATOLOGY

3.  Williams  ML,  Elias  PM.  The  extracellular  matrix  of  stratum 
corneum:  Role  of  lipids  in  normal  and  pathological  function. 
Crit Rev Ther Drug Carrier Syst. 1987; 3(2):95–122.

4.  Schaefer H, Redelmeier TE. Skin Barrier: Principles of Percutaneous 

Absorption. Basel: Karger. 1996.

5.  Wertz PW, van den Bergh B. The physical, chemical and func-
tional properties of lipids in the skin and other biological barri-
ers. Chem Physics Lipids. 1998; 91(2):85–96.

6.  Madison  KC,  Swartzendruber  DC,  Wertz  PW,  Downing  DT. 
Presence of intact intercellular lipid lamellae in the upper lay-
ers of the stratum corneum. J Invest Dermatol. 1987; 88(6):714–8.
7.  Epstein  EH  Jr,  Williams  ML,  Elias  PM.  Steroid  sulfatase, 
X-linked  ichthyosis,  and  stratum  corneum  cell  cohesion.  Arch 
Dermatol. 1981; 117(12):761–3.

8.  Ranasinghe AW, Wertz PW, Downing DT, Mackenzie IC. Lipid 
composition  of  cohesive  and  desquamated  corneocytes  from 
mouse ear skin. J Invest Dermatol. 1986; 86(2):187–90.

9.  Elias  PM.  Epidermal  barrier  function:  Intercellular  lamellar 
lipid structures, origin, composition and metabolism. J Control 
Release 1991; 15:199–208.

  10.  Williams ML. Lipids in Normal and Pathological Desquamation. 
In:  Elias  PM,  ed.  Skin  Lipids.  New  York:  Academic  Press  1991; 
pp. 211–62.

  11.  Mao-Qiang  M,  Feingold  KR,  Jain  M,  Elias  PM.  Extracellular 
processing  of  phospholipids  is  required  for  permeability  bar-
rier homeostasis. J Lipid Res. 1995; 36(9):1925–35.

  12.  Rawlings A. Skin waxes. Their composition, properties, struc-
tures  and  biological  significance.  In:  Hamilton  R,  Christie  W, 
eds. Skin Waxes. Dundee: Oily Press, 1995; pp. 223–56.

  13.  Han  X.  Characterization  and  direct  quantitation  of  ceramide 
molecular  species  from  lipid  extracts  of  biological  samples 
by  electrospray  ionization  tandem  mass  spectrometry.  Anal 
Biochem. 2002; 302(2):199–212.

  14.  Vietzke  JP,  Strassner  M,  Hintze  U.  Separation  and  identi-
fication  of  ceramides  in  the  human  stratum  corneum  by 
high-performance 
liquid  chromatography  coupled  with 
electrospray  ionisation  mass  spectrometry  and  electrospray 
multiple stage mass spectrometry profiling. Chromatographia. 
1999; 50:15–29.

  15.  Vielhaber  G,  Pfeiffer  S,  Brade  L,  Lindner  B,  Goldmann  T, 
Vollmer E, et al. Localization of ceramide and glucosylceramide 
in  human  epidermis  by  immunogold  electron  microscopy. 
J Invest Dermatol. 2001; 117(5):1126–36.

  16.  Masukawa  Y,  Narita  H,  Sato  H,  Naoe  A,  Kondo  N,  Sugai  Y, 
et  al.  Comprehensive  quantification  of  ceramide  species  in 
human stratum corneum. J Lipid Res. 2009; 50(8):1708–19.
  17.  Masukawa Y, Narita H, Shimizu E, Kondo N, Sugai Y, Oba T, 
et  al.  Characterization  of  overall  ceramide  species  in  human 
stratum corneum. J Lipid Res. 2008; 49(7):1466–76.

  18.  van Smeden J, Boiten WA, Hankemeier T, Rissmann R, Bouwstra 
JA, Vreeken RJ. Combined LC/MS-platform for analysis of all 
major stratum corneum lipids, and the profiling of skin substi-
tutes. Biochim Biophys Acta. 2014; 1841(1):70–9.

  19.  t’Kindt R, Jorge L, Dumont E, Couturon P, David F, Sandra P, 
  et al. Profiling and characterizing skin ceramides using reversed-
phase  liquid  chromatography-quadrupole  time-of-flight  mass 
spectrometry. Anal Chem. 2012; 84(1):403–11.

  20.  Rabionet M, Bayerle A, Marsching C, Jennemann R, Grone HJ, 
Yildiz  Y,  et  al.  1-O-acylceramides  are  natural  components  of 
human and mouse epidermis. J Lipid Res. 2013; 54(12):3312–21.

  21.  Rabionet M, Gorgas K, Sandhoff R. Ceramide synthesis in the 

epidermis. Biochim Biophys Acta. 2014; 1841(3):422–34.

  22.  Wertz PW, Miethke MC, Long SA, Strauss JS, Downing DT. The 
composition  of  the  ceramides  from  human  stratum  corneum 
and from comedones. J Invest Dermatol. 1985; 84(5):410–2.
  23.  Robson KJ, Stewart ME, Michelsen S, Lazo ND, Downing DT. 
6-Hydroxy-4-sphingenine  in  human  epidermal  ceramides. 
J Lipid Res. 1994; 35(11):2060–8.

  24.  Chopart  M,  Castiel  I,  Arbey  E,  Schmidt  R.  A  new  type  of 
covalently  bound  ceramide  in  human  epithelia.  In:  Marks  R, 

Leveque  JL,  Voegeli  R,  eds.  The  Essential  Stratum  Corneum. 
London: Dunitz 2002; pp. 331–4.

  25.  Hill J, Paslin D, Wertz PW. A new covalently bound ceramide 
from  human  stratum  corneum  -omega-hydroxyacylphyto-
sphingosine. Int J Cosmet Sci. 2006; 28(3):225–30.

  26.  Hamanaka  S.  [Epidermosides—epidermal  acylsphingoglyco-
lipids and their barrier function]. Seikagaku. 1991; 63(5):366–70.

  27.  Uchida  Y,  Hara  M,  Nishio  H,  Sidransky  E,  Inoue  S,  Otsuka  F, 
et  al.  Epidermal  sphingomyelins  are  precursors  for  selected 
stratum corneum ceramides. J Lipid Res. 2000; 41(12):2071–82.

  28.  Hamanaka S, Hara M, Nishio H, Otsuka F, Suzuki A, Uchida Y.  
Human  epidermal  glucosylceramides  are  major  precursors 
of  stratum  corneum  ceramides.  J  Invest  Dermatol.  2002; 
119(2):416–23.

  29.  Jennemann R, Sandhoff R, Langbein L, Kaden S, Rothermel U, 
Gallala H, et al. Integrity and barrier function of the epidermis 
critically  depend  on  glucosylceramide  synthesis.  J  Biol  Chem. 
2007; 282(5):3083–94.

  30.  Motta  S,  Monti  M,  Sesana  S,  Caputo  R,  Carelli  S,  Ghidoni  R. 
Ceramide  composition  of  the  psoriatic  scale.  Biochim  Biophys 
Acta. 1993; 1182(2):147–51.

  31.  Wertz PW. Lipids and barrier function of the skin.  Acta Derm 

Venereol Suppl. 2000; 208:7–11.

  32.  Wertz PW, Madison KC, Downing DT. Covalently bound lipids 
of human stratum corneum. J Invest Dermatol. 1989; 92(1):109–11.
  33.  Hinder  A,  Schmelzer  CE,  Rawlings  AV,  Neubert  RH.  Inves-
tigation of the molecular structure of the human stratum cor-
neum  ceramides  [NP]  and  [EOS]  by  mass  spectrometry.  Skin 
Pharmacol Physiol. 2011; 24(3):127–35.

  34.  Ishikawa  J,  Shimotoyodome  Y,  Ito  S,  Miyauchi  Y,  Fujimura  T, 
Kitahara T, et al. Variations in the ceramide profile in different 
seasons and regions of the body contribute to stratum corneum 
functions. Arch Dermatol Res. 2013; 305(2):151–62.

  35.  Norlen L, Nicander I, Lundsjo A, Cronholm T, Forslind B. A new 
HPLC-based method for the quantitative analysis of inner stra-
tum corneum lipids with special reference to the free fatty acid 
fraction. Arch Dermatol Res. 1998; 290(9):508–16.

  36.  Vasireddy  V,  Uchida  Y,  Salem  N  Jr,  Kim  SY,  Mandal  MN, 
Reddy  GB,  et  al.  Loss  of  functional  ELOVL4  depletes  very 
long-chain  fatty  acids  (>  or  =C28)  and  the  unique  omega-O-
acylceramides in skin leading to neonatal death. Hum Mol Gen. 
2007; 16(5):471–82.

  37.  Li W, Sandhoff R, Kono M, Zerfas P, Hoffmann V, Ding BC, et al. 
Depletion of ceramides with very long chain fatty acids causes 
defective  skin  permeability  barrier  function,  and  neonatal 
lethality in ELOVL4 deficient mice. Int J Biol Sci. 2007; 3(2):120–8.
  38.  Novotny  J,  Janusova  B,  Novotny  M,  Hrabalek  A,  Vavrova  K. 
Short-chain  ceramides  decrease  skin  barrier  properties.  Skin 
Pharmacol Physiol. 2009; 22(1):22–30.

  39.  Pillai  S,  Cho  S,  Mahajan  M,  Frew  L,  Rawlings  AV.  Synergy 
between vitamin D precursor 25-hydroxyvitamin D and short 
chain ceramides on keratinocyte proliferation and differentia-
tion. J Invest Dermatol Symp Proc. 1996; 1(1):39–43.

  40.  Paragh G, Schling P, Ugocsai P, Kel AE, Liebisch G, Heimerl S, 
et al. Novel sphingolipid derivatives promote keratinocyte dif-
ferentiation. Exper Dermatol. 2008; 17(12):1004–16.

  41.  Swartzendruber  DC,  Wertz  PW,  Madison  KC,  Downing  DT. 
Evidence  that  the  corneocyte  has  a  chemically  bound  lipid 
envelope. J Invest Dermatol. 1987; 88(6):709–13.

  42.  Lazo ND, Meine JG, Downing DT. Lipids are covalently attached 
to rigid corneocyte protein envelopes existing predominantly 
as beta-sheets: A solid-state nuclear magnetic resonance study. 
J Invest Dermatol. 1995; 105(2):296–300.

  43.  Nemes  Z,  Marekov  LN,  Fesus  L,  Steinert  PM.  A  novel  func-
tion for transglutaminase 1: Attachment of long-chain omega-
hydroxyceramides to involucrin by ester bond formation. Proc 
Nat Acad Sci U S A. 1999; 96(15):8402–7.

  44.  Zheng  Y,  Yin  H,  Boeglin  WE,  Elias  PM,  Crumrine  D,  Beier 
DR,  et  al.  Lipoxygenases  mediate  the  effect  of  essential  fatty 
acid  in  skin  barrier  formation:  A  proposed  role  in  releasing 

 
 
 
 
 
 
 
 
 
omega-hydroxyceramide  for  construction  of  the  corneocyte 
lipid envelope. J Biol Chem. 2011; 286(27):24046–56.

  45.  Stewart ME, Downing DT. The omega-hydroxyceramides of pig 
epidermis  are  attached  to  corneocytes  solely  through  omega-
hydroxyl groups. J Lipid Res. 2001; 42(7):1105–10.

  46.  Clement ME, Munoz-Garcia A, Williams JB. Cutaneous water 
loss  and  covalently  bound  lipids  of  the  stratum  corneum  in 
nestling  house  sparrows  (Passer  domesticus  L.)  from  desert 
and mesic habitats. J Exper Biol. 2012; 215(Pt 7):1170–7.

  47.  Meguro S, Arai Y, Masukawa Y, Uie K, Tokimitsu I. Relationship 
between  covalently  bound  ceramides  and  transepidermal 
water loss (TEWL). Arch Dermatol Res. 2000; 292(9):463–8.
  48.  Behne M, Uchida Y, Seki T, de Montellano PO, Elias PM, Holleran 
WM. Omega-hydroxyceramides are required for corneocyte lipid 
envelope  (CLE)  formation  and  normal  epidermal  permeability 
barrier function. J Invest Dermatol. 2000; 114(1):185–92.

  49.  Wertz  PW,  Downing  DT.  Ceramidase  activity  in  porcine  epi-

dermis. FEBS Lett. 1990; 268(1):110–2.

  50.  Bowser PA, Nugteren DH, White RJ, Houtsmuller UM, Prottey C.  
Identification,  isolation  and  characterization  of  epidermal 
lipids  containing  linoleic  acid.  Biochim  Biophys  Acta.  1985; 
834(3):419–28 (1985).

  51.  Wertz  PW,  Downing  DT.  Free  sphingosine  in  human  epider-

mis. J Invest Dermatol. 94(2):159–61.

  52.  Wertz  PW,  Downing  DT.  Hydroxyacid  derivatives  in  human 

epidermis. Lipids. 1988; 23(5):415–8.

  53.  Gupta  AK,  Fisher  GJ,  Elder  JT,  Nickoloff  BJ,  Voorhees  JJ. 
Sphingosine  inhibits  phorbol  ester-induced  inflammation, 
ornithine  decarboxylase  activity,  and  activation  of  protein 
kinase C in mouse skin. J Invest Dermatol. 1988; 91(5):486–91.

  54.  Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphin-

gosines. J Invest Dermatol. 1992; 98(3):269–73.

  55.  Pavicic  T,  Wollenweber  U,  Farwick  M,  Korting  HC.  Anti-
microbial  and  -inflammatory  activity  and  efficacy  of  phyto-
sphingosine:  An  in  vitro  and  in  vivo  study  addressing  acne 
vulgaris. Int J Cosmet Sci. 2007; 29(3):181–90.

  56.  Pennick  G,  Harrison  S,  Jones  D,  Rawlings  AV.  Superior  effect 
of  isostearyl  isostearate  on  improvement  in  stratum  corneum 
water permeability barrier function as examined by the plastic 
occlusion stress test. Int J Cosmet Sci. 2010; 32(4):304–12.

  57.  Dederen JC, Chavan B, Rawlings AV. Emollients are more than 
sensory  ingredients:  The  case  of  isostearyl  isostearate.  Int  J 
Cosmet Sci. 2012; 34(6):502–10.

  58.  Caussin  J,  Gooris  GS,  Groenink  HW,  Wiechers  JW,  Bouwstra 
JA. Interaction of lipophilic moisturizers on stratum corneum 
lipid domains in vitro and in vivo. Skin Pharmacol Physiol. 2007; 
20(4):175–86.

  59.  Caussin J, Groenink HW, de Graaff AM, Gooris GS, Wiechers 
JW, van Aelst AC, et al. Lipophilic and hydrophilic moisturizers 
show different actions on human skin as revealed by cryo scan-
ning electron microscopy. Exper Dermatol. 2007; 16(11):891–8.

  60.  Bouwstra  JA,  Nahmoed  N,  Groenink  HW,  Ponec  M.  Human 
skin equivalents are an excellent tool to study the effect of mois-
turizers on the water distribution in the stratum corneum. Int J 
Cosmet Sci. 2012; 34(6):560–6.

  61.  Mizutani  Y,  Mitsutake  S,  Tsuji  K,  Kihara  A,  Igarashi  Y. 
Ceramide biosynthesis in keratinocyte and its role in skin func-
tion. Biochimie. 2009; 91(6):784–90.

  62.  Small DM. The Physical Chemistry of Lipids. In: Hanahan DJ, 
ed.  Handbook  of  Lipid  Research.  New  York:  Plenum  Press,  1986; 
p.  672.

  63.  Singer SJ, Nicolson GL. The fluid mosaic model of the structure 
of cell membranes. Science. 1972; 175(4023):720–31 (1972).
  64.  Welti R, Glaser M. Lipid domains in model and biological mem-

CERAMIDES AND THE SKIN 

 137

  67.  McIntosh TJ, Stewart ME, Downing DT. X-ray diffraction analy-
sis  of  isolated  skin  lipids:  Reconstitution  of  intercellular  lipid 
domains. Biochemistry. 1996; 35(12):3649–53.

  68.  White  SH,  Mirejovsky  D,  King  GI.  Structure  of  lamellar  lipid 
domains and corneocyte envelopes of murine stratum corneum. 
An X-ray diffraction study. Biochemistry. 1988; 27(10):3725–32.

  69.  Bouwstra  JA,  Gooris  GS,  Weerheim  A,  Kempenaar  J,  Ponec 
M.  Characterization  of  stratum  corneum  structure  in  recon-
structed  epidermis  by  X-ray  diffraction.  J  Lipid  Res.  1995; 
36(3):496–504.

  70.  Bouwstra JA, Gooris GS, Salomons-de Vries MA, et al. Structure 
of  human  stratum  corneum  as  a  function  of  temperature 
and  hydration:  A  wide-angle  X-ray  diffraction  study.  Int  J 
Pharmaceut. 1992; 84:205–16.

  71.  Pilgram  GS,  Van  Pelt  AM,  Spies  F,  Bouwstra  JA,  Koerten  HK. 
Cryo-electron diffraction as a tool to study local variations in 
the lipid organization of human stratum corneum. J Microscopy. 
1998; 189(Pt 1):71–8.

  72.  Bouwstra  JA,  Gooris  GS,  Dubbelaar  FE,  Ponec  M.  Phase 
behavior of stratum corneum lipid mixtures based on human 
ceramides: The role of natural and synthetic ceramide 1. J Invest 
Dermatol. 2002; 118(4):606–17.

  73.  Moore  DJ,  Mendelsohn  R.  Adaptation  to  altered  growth  tem-
peratures  in  Acholeplasma  laidlawii  B:  Fourier  transform 
infrared studies of acyl chain conformational order in live cells. 
Biochemistry. 1994; 33(13):4080–5.

  74.  Moore  DJ,  Sills  RH,  Mendelsohn  R.  Conformational  order  of 
specific  phospholipids  in  human  erythrocytes:  Correlations 
with changes in cell shape. Biochemistry. 1997; 36(3):660–4.
  75.  Mendelsohn R, Moore DJ. Vibrational spectroscopic studies of 
lipid domains in biomembranes and model systems. Chem Phys 
Lipids. 1998; 96(1–2):141–57.

  76.  Moore  DJ.  Stratum  corneum  lipids  and  barrier  function: 
Biophysical  studies  of  molecular  organisation  in  sphingomy-
elin and ceramide [NS] Bilayers. Recent Res Devel Lipids. 2002; 
6:55–63.

  77.  Chen H, Mendelsohn R, Rerek ME, Moore DJ. Effect of choles-
terol on miscibility and phase behavior in binary mixtures with 
synthetic  ceramide  2  and  octadecanoic  acid.  Infrared  studies. 
Biochim Biophys Acta. 2001; 1512(2):345–56.

  78.  Rerek  ME,  Chen  HC,  Markovic  B,  et  al.  Phytosphingosine 
and  sphingosine  ceramide  headgroup  hydrogen  bonding: 
Structural insights through thermotropic hydrogen/deuterium 
exchange. J Phys Chem. 2001; 105:9355–63.

  79.  Mendelsohn R, Moore DJ. IR determination of conformational 
order and phase behavior in ceramides and stratum corneum 
models. Methods Enzymol. 2001; 312:228–47.

  80.  Ziboh  VA,  Miller  CC,  Cho  Y.  Metabolism  of  polyunsaturated 
fatty  acids  by  skin  epidermal  enzymes:  Generation  of  antiin-
flammatory  and  antiproliferative  metabolites.  Am  J  Clin  Nutr. 
2000; 71(1 Suppl):361S–6S.

  81.  Schreiner V, Gooris GS, Pfeiffer S, Lanzendorfer  G, Wenck H, 
Diembeck  W,  et  al.  Barrier  characteristics  of  different  human 
skin  types  investigated  with  X-ray  diffraction,  lipid  analy-
sis,  and  electron  microscopy  imaging.  J  Invest  Dermatol.  2000; 
114(4):654–60.

  82.  Heinemann  C,  Paschold  C,  Fluhr  J,  Wigger-Alberti  W, 
Schliemann-Willers S, Farwanah H, et al. Induction of a hard-
ening phenomenon by repeated application of SLS: Analysis of 
lipid changes in the stratum corneum. Acta Derm Venereol. 2005; 
85(4):290–5.

  83.  Forslind  B.  A  domain  mosaic  model  of  the  skin  barrier.  Acta 

Derm Venereol. 1994; 74(1):1–6.

  84.  Norlen  L.  Skin  barrier  structure  and  function:  The  single  gel 

branes. Chem Phys Lipids. 1994; 73(1–2):121–37.

phase model. J Invest Dermatol. 2001; 117(4):830–6.

  65.  Devaux  PF,  Zachowski  A.  Maintenance  and  consequences  of 
membrane  phospholipid  asymmetry.  Chem  Phys  Lipids.  1994; 
73:107–20.

  85.  Bouwstra  JA,  Dubbelaar  FE,  Gooris  GS,  Ponec  M.  The  lipid 
organisation in the skin barrier. Acta Derm Venereol Suppl. 2000; 
208:23–30.

  66.  Mouritsen OG, Jorgensen K. Dynamical order and disorder in 

lipid bilayers. Chem Phys Lipids. 1994; 73(1–2):3–25.

  86.  Pensack RD, Michniak BB, Moore DJ, Mendelsohn R. Infrared 
kinetic/structural  studies  of  barrier  reformation  in  intact 

 
138 

 TEXTBOOK OF COSMETIC DERMATOLOGY

stratum  corneum 
following 
Spectrosc. 2006; 60(12):1399–404.

thermal  perturbation.  Appl 

  87.  Damien F, Boncheva M. The extent of orthorhombic lipid phases 
in  the  stratum  corneum  determines  the  barrier  efficiency  of 
human skin in vivo. J Invest Dermatol. 2010; 130(2):611–4.
  88.  Groen D, Poole DS, Gooris GS, Bouwstra JA. Is an orthorhom-
bic lateral packing and a proper lamellar organization impor-
tant  for  the  skin  barrier  function?  Biochim  Biophys  Acta.  2011; 
1808(6):1529–37.

  89.  Mojumdar  EH,  Kariman  Z,  van  Kerckhove  L,  Gooris  GS, 
Bouwstra  JA.  The  role  of  ceramide  chain  length  distribution 
on the barrier properties of the skin lipid membranes. Biochim 
Biophys Acta. 2014; 1838(10):2473–83.

  90.  Iwai  I,  Han  H,  den  Hollander  L,  Svensson  S,  Ofverstedt  LG, 
Anwar J, et al. The human skin barrier is organized as stacked 
bilayers  of  fully  extended  ceramides  with  cholesterol  mol-
ecules associated with the ceramide sphingoid moiety. J Invest 
Dermatol. 2012; 132(9):2215–25.

  91.  Janssens  M,  van  Smeden  J,  Gooris  GS,  Bras  W,  Portale  G, 
Caspers  PJ,  et  al.  Increase  in  short-chain  ceramides  corre-
lates  with  an  altered  lipid  organization  and  decreased  bar-
rier  function  in  atopic  eczema  patients.  J  Lipid  Res.  2012; 
53(12):2755–66.

  92.  Abraham  W,  Downing  DT.  Interaction  between  corneocytes 
and stratum corneum lipid liposomes in vitro. Biochim Biophys 
Acta. 1990; 1021(2):119–25.

  106.  Hong KK, Cho HR, Ju WC, Cho Y, Kim NI. A study on altered 
expression  of  serine  palmitoyltransferase  and  ceramidase  in 
psoriatic skin lesion. J Korean Med Sci. 2007; 22(5):862–7.
  107.  Feingold KR. The adverse effect of IFN gamma on stratum cor-
neum structure and function in psoriasis and atopic dermatitis. 
J Invest Dermatol. 2014; 134(3):597–600.

  108.  Tawada  C,  Kanoh  H,  Nakamura  M,  Mizutani  Y,  Fujisawa  T, 
Banno  Y,  et  al.  Interferon-gamma  decreases  ceramides  with 
long-chain fatty acids: Possible involvement in atopic dermati-
tis and psoriasis. J Invest Dermatol. 2014; 134(3):712–8.

  109.  Ye L, Lv C, Man G, Song S, Elias PM, Man MQ. Abnormal epi-
dermal barrier recovery in uninvolved skin supports the notion 
of  an  epidermal  pathogenesis  of  psoriasis.  J  Invest  Dermatol. 
2014; 134(11):2843–6.

  110.  Kelsell  DP,  Norgett  EE,  Unsworth  H,  Teh  MT,  Cullup  T,  Mein 
CA,  et  al.  Mutations  in  ABCA12  underlie  the  severe  congeni-
tal  skin  disease  harlequin  ichthyosis.  Am  J  Hum  Genet.  2005; 
76(5):794–803.

  111.  Zuo  Y,  Zhuang  DZ,  Han  R,  Isaac  G,  Tobi  JJ,  McKee  M,  et  al. 
ABCA12 maintains the epidermal lipid permeability barrier by 
facilitating  formation  of  ceramide  linoleic  esters.  J  Biol  Chem. 
2008; 283(52):36624–35.

  112.  Jiang  YJ,  Uchida  Y,  Lu  B,  Kim  P,  Mao  C,  Akiyama  M,  et  al. 
Ceramide  stimulates  ABCA12  expression  via  peroxisome 
proliferator-activated receptor {delta} in human keratinocytes. 
J Biol Chem. 2009; 284(28):18942–52.

  93.  Smith WP, Christensen MS, Nacht S, Gans EH. Effect of lipids 
on  the  aggregation  and  permeability  of  human  stratum  cor-
neum. J Invest Dermatol. 1982; 78(1):7–11.

  113.  Paige DG, Morse-Fisher N, Harper JI. Quantification of stratum 
corneum ceramides and lipid envelope ceramides in the heredi-
tary ichthyoses. Brit J Dermatol. 1994; 131(1):23–7.

  94.  Chapman  SJ,  Walsh  A,  Jackson  SM,  Friedmann  PS.  Lipids, 
proteins  and  corneocyte  adhesion.  Arch  Dermatol  Res.  1991; 
283(3):167–73.

  95.  Rawlings  A,  Hope  J,  Rogers  J,  et  al.  Skin  dryness-what  is  it? 

J Invest Dermatol. 1993; 100:510.

  96.  Sheu HM, Chao SC, Wong TW, Yu-Yun Lee J, Tsai JC. Human 
skin surface lipid film: An ultrastructural study and interaction 
with corneocytes and intercellular lipid lamellae of the stratum 
corneum. Brit J Dermatol. 1999; 140(3):385–91.

  97.  Pilgram  GS,  van  der  Meulen  J,  Gooris  GS,  Koerten  HK, 
Bouwstra JA. The influence of two azones and sebaceous lipids 
on the lateral organization of lipids isolated from human stra-
tum corneum. Biochim Biophys Acta. 2001; 1511(2):244–54.
  98.  Menon GK, Ghadially R, Williams ML, Elias PM. Lamellar bod-
ies as delivery systems of hydrolytic enzymes: Implications for 
normal and abnormal desquamation. The Brit J Dermatol. 1992; 
126(4):337–45.

  99.  Skerrow CJ, Clelland DG, Skerrow D. Changes to desmosomal 
antigens and lectin-binding sites during differentiation in nor-
mal  human  epidermis:  A  quantitative  ultrastructural  study. 
J Cell Sci. 1989; 92(Pt 4):667–77.

  100.  Rawlings  AV,  Voegeli  R.  Stratum  corneum  proteases  and  dry 

skin conditions. Cell Tiss Res. 2013; 351(2):217–35.

  101.  Houben  E,  Hachem  JP,  De  Paepe  K,  Rogiers,  V.  Epidermal 
ceramidase  activity  regulates  epidermal  desquamation  via 
stratum  corneum  acidification.  Skin  Pharmacol  Physiol.  2008; 
21(2):111–8.

  102.  Watkinson  A,  Lee  RS,  Moore  AE,  Pudney  PD,  Paterson  SE, 
Rawlings  AV.  Reduced  barrier  efficiency  in  axillary  stratum 
corneum. Int J Cosmet Sci. 2002; 24(3):151–61.

  103.  Lavrijsen,  A.P.,  Bouwstra,  J.A.,  Gooris,  G.S.,  Weerheim,  A., 
Bodde,  H.E.  and  Ponec,  M.  Reduced  skin  barrier  function 
parallels  abnormal  stratum  corneum  lipid  organization  in 
patients  with  lamellar  ichthyosis.  J  Invest  Dermatol.  1995; 
105(4):619–24.

  104.  Menon G, Ghadially R. Morphology of lipid alterations in the 
epidermis: A review. Microsc Res Tech. 1997; 37(3):180–92.
  105.  Pilgram GS, Vissers DC, van der Meulen H, Pavel S, Lavrijsen 
SP, Bouwstra JA, et al. Aberrant lipid organization in stratum 
corneum  of  patients  with  atopic  dermatitis  and  lamellar  ich-
thyosis. J Invest Dermatol. 2001; 117(3):710–7.

  114.  Menon GK, Orso E, Aslanidis C, Crumrine D, Schmitz G, Elias 
PM. Ultrastructure of skin from Refsum disease with empha-
sis on epidermal lamellar bodies and stratum corneum barrier 
lipid organization. Arch Dermatol Res. 2014; 306(8):731–7.
  115.  Nakajima K, Sano S, Uchida Y, Akiyama M, Morita Y, Shimizu 
H.  Altered  lipid  profiles  in  the  stratum  corneum  of  Sjogren-
Larsson syndrome. J Dermatol Sci. 2011; 63(1):64–6.

  116.  Uchida  Y,  Cho  Y,  Moradian  S,  Kim  J,  Nakajima  K,  Crumrine 
D, et al. Neutral lipid storage leads to acylceramide deficiency, 
likely  contributing  to  the  pathogenesis  of  Dorfman-Chanarin 
syndrome. J Invest Dermatol. 2010; 130(10):2497–9.

  117.  Goto-Inoue, N., Hayasaka, T., Zaima, N., Nakajima, K., Holleran, 
W.M.,  Sano,  S.,  et  al.  Imaging  mass  spectrometry  visualizes 
ceramides  and  the  pathogenesis  of  dorfman-chanarin  syn-
drome due to ceramide metabolic abnormality in the skin. PloS 
One. 2012; 7(11):e49519.

  118.  Chan A, Holleran WM, Ferguson T, Crumrine D, Goker-Alpan 
O,  Schiffmann  R,  et  al.  Skin  ultrastructural  findings  in  type 
2  Gaucher  disease:  Diagnostic  implications.  Mol  Genet  Metab. 
2011; 104(4):631–6.

  119.  Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. 
Decreased level of ceramides in stratum corneum of atopic der-
matitis: An etiologic factor in atopic dry skin? J Invest Dermatol. 
1991; 96(4):523–6.

  120.  Matsumoto M, Umemoto N, Sugiura H, Uehara M. Difference 
in  ceramide  composition  between  “dry”  and  “normal”  skin 
in  patients  with  atopic  dermatitis.  Acta  Derm  Venereol.  1999; 
79(3):246–7.

  121.  Yamamoto A, Serizawa S, Ito M,Sato Y. Stratum corneum lipid 
abnormalities  in  atopic  dermatitis.  Arch  Dermatol  Res.  1991; 
283(4):219–23.

  122.  Bleck O, Abeck D, Ring J, Hoppe U, Vietzke JP, Wolber R, et al. 
Two  ceramide  subfractions  detectable  in  Cer(AS)  position  by 
HPTLC  in  skin  surface  lipids  of  non-lesional  skin  of  atopic 
eczema. J Invest Dermatol. 1999; 113(6):894–900.

  123.  Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal 
protein-bound  omega-hydroxyceramides  in  atopic  dermatitis. 
J Invest Dermatol. 2002; 119(1):166–73.

  124.  Cui CY, Kusuda S, Seguchi T, Takahashi M, Aisu K, Tezuka T. 
Decreased level of prosaposin in atopic skin. J Invest Dermatol. 
1997; 109(3):319–23.

 
  125.  Ishikawa J, Narita H, Kondo N, Hotta M, Takagi Y, Masukawa Y,  
et al. Changes in the ceramide profile of atopic dermatitis patients. 
J Invest Dermatol. 2010; 130(10):2511–4.

  126.  Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers 
PJ, et al. Lamellar lipid organization and ceramide composition 
in the stratum corneum of patients with atopic eczema. J Invest 
Dermatol. 2011; 131(10):2136–8.

  127.  van  Smeden  J,  Janssens  M,  Lavrijsen  AP,  Kezic  S,  Vreeken  RJ, 
Bouwstra  JA.  Skin  barrier  dysfunction  in  non-lesional  atopic 
eczema: The role of stratum corneum lipids. Eur J Dermatol. 2013.
  128.  van Smeden J, Janssens M, Kaye EC, Caspers PJ, Lavrijsen AP, 
Vreeken RJ, et al. The importance of free fatty acid chain length 
for  the  skin  barrier  function  in  atopic  eczema  patients.  Exper 
Dermatol. 2014; 23(1):45–52.

  129.  Joo  KM,  Hwang  JH,  Bae  S,  Nahm  DH,  Park  HS,  Ye  YM,  et  al. 
Relationship of ceramide-, and free fatty acid-cholesterol ratios in 
the stratum corneum with skin barrier function of normal, atopic 
dermatitis lesional and non-lesional skins. J Dermatol Sci. 2014.

  130.  Janssens M, van Smeden J, Puppels GJ, Lavrijsen AP, Caspers 
PJ, Bouwstra JA. Lipid to protein ratio plays an important role 
in the skin barrier function in patients with atopic eczema. Brit 
J Dermatol. 2014; 170(6):1248–55.

  131.  Angelova-Fischer  I,  Mannheimer  AC,  Hinder  A,  Ruether  A, 
Franke  A,  Neubert  RH,  et  al.  Distinct  barrier  integrity  pheno-
types in filaggrin-related atopic eczema following sequential tape 
stripping and lipid profiling. Exper Dermatol. 2011; 20(4):351–6.

  132.  van Smeden J, Janssens M, Boiten WA, van Drongelen V, Furio L, 
Vreeken RJ, et al. Intercellular skin barrier lipid composition and 
organization in Netherton syndrome patients. J Invest Dermatol. 
2014; 134(5):1238–45.

  133.  Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-
Morbach  S,  Neumann  C,  et  al.  Impaired  sphingomyelinase 
activity  and  epidermal  differentiation  in  atopic  dermatitis. 
J Invest Dermatol. 2004; 122(6):1423–31.

  134.  Murata Y, Ogata J, Higaki Y, Kawashima M, Yada Y, Higuchi K, 
et al. Abnormal expression of sphingomyelin acylase in atopic 
dermatitis: An etiologic factor for ceramide deficiency? J Invest 
Dermatol. 1996; 106(6):1242–9.

  135.  Hara  J,  Higuchi  K,  Okamoto  R,  Kawashima  M,  Imokawa  G. 
High-expression  of  sphingomyelin  deacylase  is  an  important 
determinant of ceramide deficiency leading to barrier disrup-
tion in atopic dermatitis. J Invest Dermatol. 2000; 115(3):406–13.

  136.  Kusuda  S,  Cui  CY,  Takahashi  M,  Tezuka,  T.  Localization  of 
sphingomyelinase in lesional skin of atopic dermatitis patients. 
J Invest Dermatol. 1998; 111(5):733–8.

  137.  Imokawa  G.  A  possible  mechanism  underlying  the  ceramide 
deficiency  in  atopic  dermatitis:  Expression  of  a  deacylase 
enzyme that cleaves the N-acyl linkage of sphingomyelin and 
glucosylceramide. J Dermatol Sci. 2009; 55(1):1–9.

  138.  Wakita H, Matsushita K, Nishimura K, Tokura Y, Furukawa F, 
Takigawa  M.  Sphingosylphosphorylcholine  stimulates  prolif-
eration  and  upregulates  cell  surface-associated  plasminogen 
activator  activity  in  cultured  human  keratinocytes.  J  Invest 
Dermatol. 1998; 110(3):253–8.

  139.  Arikawa  J,  Ishibashi  M,  Kawashima  M,  Takagi  Y,  Ichikawa  Y, 
Imokawa  G.  Decreased  levels  of  sphingosine,  a  natural  antimi-
crobial agent, may be associated with vulnerability of the stratum 
corneum from patients with atopic dermatitis to colonization by 
Staphylococcus aureus. J Invest Dermatol. 2002; 119(2):433–9.
  140.  Downing DT, Stewart ME, Wertz PW, Strauss JS. Essential fatty 
acids and acne. J Am Acad Dermatol. 1986; 14(2 Pt 1):221–5.
  141.  Yamamoto  A,  Takenouchi  K,  Ito  M.  Impaired  water  barrier 
function in acne vulgaris. Arch Dermatol Res. 1995; 287(2):214–8.
  142.  Harding  CR,  Moore  AE,  Rogers  JS,  Meldrum  H,  Scott 
AE,  McGlone  FP.  Dandruff:  A  condition  characterized  by 
decreased  levels  of  intercellular  lipids  in  scalp  stratum  cor-
neum and impaired barrier function. Arch Dermatol Res. 2002; 
294(5):221–30.

  143.  Warner RR, Schwartz JR, Boissy Y, Dawson TL Jr. Dandruff has 
an  altered  stratum  corneum  ultrastructure  that  is  improved 

CERAMIDES AND THE SKIN 

 139

with  zinc  pyrithione  shampoo.  J  Am  Acad  Dermatol.  2001; 
45(6):897–903.

  144.  Rogers JS, Moore AE, Meldrum H, Harding CR. Increased scalp 
skin  lipids  in  response  to  antidandruff  treatment  containing 
zinc pyrithione. Arch Dermatol Res. 2003; 295(3):127–9.

  145.  Denda M, Koyama J, Hori J, Horii I, Takahashi M, Hara M, et al. 
Age- and sex-dependent change in stratum corneum sphingo-
lipids. Arch Dermatol Res. 1993; 285(7):415–7.

  146.  Rogers J, Harding C, Mayo A, Banks J, Rawlings A. Stratum cor-
neum lipids: The effect of ageing and the seasons. Arch Dermatol 
Res. 1996; 288(12):765–70.

  147.  Saint-Leger  D,  Francois  AM,  Leveque  JL,  Stoudemayer  TJ, 
Kligman AM, Grove G. Stratum corneum lipids in skin xerosis. 
Dermatologica. 1989; 178(3):151–5.

  148.  Chopart  M,  Castiel-Higounen  I,  Arbey  E,  et  al.  Quantitative 
and qualitative analysis of ceramides in the stratum corneum 
of normal & dry skin. In: Marks R, Leveque JL, Voegeli R, eds. 
The Essential Stratum Corneum. London: Dunitz 2002.

  149.  Sugino K, Imokawa G, Maibach HI. Ethnic differences of varied 
stratum corneum function in relation to stratum corneum lip-
ids. J Invest Dermatol. 1993; 102:482.

  150.  Rawlings  AV.  Ethnic  skin  types:  Sre  there  differences  in  skin 
structure and function? Int J Cosmet Sci. 2006; 28(2):79–93.
  151.  Ghadially  R,  Brown  BE,  Sequeira-Martin  SM,  Feingold  KR, 
Elias PM. The aged epidermal permeability barrier. Structural, 
functional, and lipid biochemical abnormalities in humans and 
a senescent murine model. J Clin Invest. 1995; 95(5):2281–90.
  152.  Akimoto K, Yoshikawa N, Higaki Y, Kawashima M, Imokawa 
G.  Quantitative  analysis  of  stratum  corneum  lipids  in  xerosis 
and asteatotic eczema. J Dermatol. 1993; 20(1):1–6.

  153.  Jensen  JM,  Forl  M,  Winoto-Morbach  S,  Seite  S,  Schunck  M, 
Proksch E, et al. Acid and neutral sphingomyelinase, ceramide 
synthase,  and  acid  ceramidase  activities  in  cutaneous  aging. 
Exper Dermatol. 2005; 14(8):609–18.

  154.  Norlen  L,  Nicander  I,  Lundh  Rozell  B,  Ollmar  S,  Forslind  B. 
Inter- and intra-individual differences in human stratum cor-
neum lipid content related to physical parameters of skin bar-
rier function in vivo. J Invest Dermatol. 1999; 112(1):72–7.
  155.  Lampe  MA,  Burlingame  AL,  Whitney  J,  Williams  ML, 
Brown  BE,  Roitman  E,  et  al.  Human  stratum  corneum  lipids: 
Characterization  and  regional  variations.  J  Lipid  Res.  1983; 
24(2):120–30.

  156.  Imokawa G, Akasaki S, Minematsu Y, Kawai M. Importance of 
intercellular lipids in water-retention properties of the stratum 
corneum: Induction and recovery study of surfactant dry skin. 
Arch Dermatol Res. 1989; 281(1):45–51.

  157.  Imokawa  G,  Akasaki  S,  Hattori  M,  Yoshizuka  N.  Selective 
recovery of deranged water-holding properties by stratum cor-
neum lipids. J Invest Dermatol. 1986; 87(6):758–61.

  158.  Fulmer  AW,  Kramer  GJ  Stratum  corneum  lipid  abnormalities 
in  surfactant-induced  dry  scaly  skin.  J  Invest  Dermatol.  1986; 
86(5):598–602.

  159.  Denda M, Hori J, Koyama J, Yoshida S, Nanba R, Takahashi M, 
et al. Stratum corneum sphingolipids and free amino acids in 
experimentally-induced  scaly  skin.  Arch  Dermatol  Res.  1992; 
284(6):363–7.

  160.  Rawlings AV, Hope J, Rogers J, et al. Abnormalities in stratum 
corneum structure, lipid composition and desmosomal degra-
dation in soap-induced winter xerosis. J Soc Cosmet Chem. 1994; 
45:203–20.

  161.  Nappe C, Delesalle G. Jansen A, et al. Decrease in ceramide II in 

skin xerosis. J Invest Dermatol. 1993; 100:530.

  162.  Ishikawa  J,  Yoshida  H,  Ito  S,  Naoe  A,  Fujimura  T,  Kitahara  T, 
et al. Dry skin in the winter is related to the ceramide profile in 
the stratum corneum and can be improved by treatment with a 
Eucalyptus extract. J Cosmet Dermatol. 2013; 12(1):3–11.

  163.  Nieminen E, Leikola E, Koljonen M, Kiistala U, Mustakallio KK. 
Quantitative analysis of epidermal lipids by thin-layer chroma-
tography with special reference to seasonal and age variation. 
Acta Dermat Venereol. 1967; 47(5):327–38.

 
140 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  164.  Agner T, Serup J. Seasonal variation of skin resistance to irri-

tants. Brit J Dermatol. 1989; 121(3):323–8.

  165.  di Nardo A, Sugino K, Wertz P, Ademola J, Maibach HI. Sodium 
lauryl sulfate (SLS) induced irritant contact dermatitis: A cor-
relation  study  between  ceramides  and  in  vivo  parameters  of 
irritation. Contact Dermatitis. 1996; 35(2):86–91.

  166.  Takagi Y, Nakagawa H, Yaginuma T, Takema Y, Imokawa G. An 
accumulation of glucosylceramide in the stratum corneum due 
to attenuated activity of beta-glucocerebrosidase is associated 
with  the  early  phase  of  UVB-induced  alteration  in  cutaneous 
barrier function. Arch Dermatol Res. 2005; 297(1):18–25.

  167.  Takagi  Y,  Nakagawa  H,  Kondo  H,  Takema  Y,  Imokawa  G. 
Decreased levels of covalently bound ceramide are associated 
with  ultraviolet  B-induced  perturbation  of  the  skin  barrier. 
J Invest Dermatol. 2004; 123(6):1102–9.

  168.  Denda  M,  Sato  J,  Tsuchiya  T,  Elias  PM,  Feingold  KR.  Low 
humidity  stimulates  epidermal  DNA  synthesis  and  ampli-
fies  the  hyperproliferative  response  to  barrier  disruption: 
Implication for seasonal exacerbations of inflammatory derma-
toses. J Invest Dermatol. 1998; 111(5):873–8.

  169.  Ashida  Y,  Denda  M,  Hirao  T.  Histamine  H1  and  H2  receptor 
antagonists  accelerate  skin  barrier  repair  and  prevent  epider-
mal  hyperplasia  induced  by  barrier  disruption  in  a  dry  envi-
ronment. J Invest Dermatol. 2001; 116(2):261–5.

  170.  Denda M. New strategies to improve skin barrier homeostasis. 

Adv Drug Deliv Rev. 52002; 4 Suppl 1:S123–30.

  171.  Feingold  KR,  Denda  M.  Regulation  of  permeability  barrier 

homeostasis. Clinics Dermatol. 2012; 30(3):263–8.

  172.  Muizzuddin  N,  Hellemans  L,  Van  Overloop  L,  Corstjens  H, 
Declercq  L,  Maes  D.  Structural  and  functional  differences  in 
barrier  properties  of  African  American,  Caucasian  and  East 
Asian skin. J Dermatol Sci. 2010; 59(2):123–8.

  173.  Jungersted  JM,  Hogh  JK,  Hellgren  LI,  Jemec  GB,  Agner  T. 
Ethnicity and stratum corneum ceramides. Brit J Dermatol. 2010; 
163(6):1169–73.

  174.  Feingold KR. Permeability barrier homeostasis; its biochemical 

basis and regulation. Cosmet Toiletries. 1997; 112:49–59.

  175.  Grubauer G, Elias PM, Feingold KR. Transepidermal water loss: 
The signal for recovery of barrier structure and function. J Lipid 
Res. 1989; 30(3):323–33.

  176.  Welzel J, Wilhelm KP, Wolff HH. Skin permeability barrier and 
occlusion: No delay of repair in irritated human skin. Contact 
Dermatitis. 1996; 35(3):163–8.

  177.  Holleran  WM,  Man  MQ,  Gao  WN,  Menon  GK,  Elias  PM, 
Feingold  KR.  Sphingolipids  are  required  for  mammalian  epi-
dermal  barrier  function.  Inhibition  of  sphingolipid  synthesis 
delays  barrier  recovery  after  acute  perturbation.  J  Clin  Invest. 
1991; 88(4):1338–45.

  178.  Stachowitz  S,  Alessandrini  F,  Abeck  D,  Ring  J,  Behrendt  H. 
Permeability  barrier  disruption  increases  the  level  of  serine 
palmitoyltransferase  in  human  epidermis.  J  Invest  Dermatol. 
2002; 119(5):1048–52.

  179.  Harris  IR,  Farrell  AM,  Holleran,  WM,  Jackson  S,  Grunfeld  C, 
Elias PM, et al. Parallel regulation of sterol regulatory element 
binding protein-2 and the enzymes of cholesterol and fatty acid 
synthesis but not ceramide synthesis in cultured human kerati-
nocytes and murine epidermis. J Lipid Res. 1998; 39(2):412–22.

  180.  Holleran  WM,  Takagi  Y,  Menon  GK,  Jackson  SM,  Lee  JM, 
Feingold  KR,  et  al.  Permeability  barrier  requirements  regu-
late  epidermal  beta-glucocerebrosidase.  J  Lipid  Res.  1994; 
35(5):905–12.

  181.  Doering  T,  Holleran  WM,  Potratz  A,  Vielhaber  G,  Elias  PM, 
Suzuki  K,  et  al.  Sphingolipid  activator  proteins  are  required 
for epidermal permeability barrier formation. J Biol Chem. 1999; 
274(16):11038–45.

  182.  Alessandrini F, Stachowitz S, Ring J, Behrendt H. The level of 
prosaposin  is  decreased  in  the  skin  of  patients  with  psoriasis 
vulgaris. J Invest Dermatol. 2001; 116(3):394–400.

  183.  Menon  GK,  Price  LF,  Bommannan  B,  Elias  PM,  Feingold  KR. 
Selective  obliteration  of  the  epidermal  calcium  gradient  leads 

to  enhanced  lamellar  body  secretion.  J  Invest  Dermatol.  1994; 
102(5):789–95.

  184.  Elias PM, Ahn SK, Denda M, Brown BE, Crumrine D, Kimutai 
LK,  et  al.  Modulations  in  epidermal  calcium  regulate  the 
expression of differentiation-specific markers. J Invest Dermatol. 
2002; 119(5):1128–36.

  185.  Denda  M,  Katagiri  C,  Hirao  T,  Maruyama  N,  Takahashi  M. 
Some magnesium salts and a mixture of magnesium and cal-
cium  salts  accelerate  skin  barrier  recovery.  Arch  Dermatol  Res. 
1999; 291(10):560–3.

  186.  Denda M, Inoue K, Inomata S, Denda S. gamma-Aminobutyric 
acid (A) receptor agonists accelerate cutaneous barrier recovery 
and prevent epidermal hyperplasia induced by barrier disrup-
tion. J Invest Dermatol. 2002; 119(5):1041–7.

  187.  Denda M, Inoue K, Fuziwara S, Denda S. P2X purinergic recep-
tor antagonist accelerates skin barrier repair and prevents epi-
dermal hyperplasia induced by skin barrier disruption. J Invest 
Dermatol. 2002; 119(5):1034–40.

  188.  Wood  LC,  Jackson  SM,  Elias  PM,  Grunfeld  C,  Feingold  KR. 
Cutaneous barrier perturbation stimulates cytokine production 
in the epidermis of mice. J Clin Invest. 1992; 90(2):482–7.
  189.  Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier func-
tion  correlates  with  initiation  of  cytokine  cascade  in  human 
skin. J Am Acad Dermatol. 1994; 30(4):535–46.

  190.  Williams ML, Elias PM, Feingold KR. Regulation and differen-
tiation in newborn human keratinocytes by endogenous ligands 
of nuclear hormone receptors. J Skin Barr Res. 2000; 2:3–26.
  191.  Beradesca  E,  Vignoli  GP,  Oresago  C,  et  al.  Prevention  of  bar-
rier function damage by topically applied ceramides. Proc 17th 
IFSCC, 1992; 881–89.

  192.  Lintner K, Mondon P, Girard F, Gibaud C. The effect of a syn-
thetic  ceramide–2  on  transepidermal  water  loss  after  strip-
ping or sodium lauryl sulfate treatment: An in vivo study. Int J 
Cosmet Sci. 1997; 19(1):15–26.

  193.  Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, 
et al. Ceramide-dominant barrier repair lipids alleviate child-
hood atopic dermatitis: Changes in barrier function provide a 
sensitive indicator of disease activity. J Am Acad Dermatol. 2002; 
47(2):198–208.

  194.  Imokawa  G.  Ceramides  as  natural  Moisturizing  factors  and 
their efficacy in dry skin. In: Leyden JJ, Rawlings AV, eds. Skin 
Moisturization. New York: Dekker, 2002; pp. 267–302.

  195.  Uchida  Y,  Holleran  WM,  Elias  PM.  On  the  effects  of  topical 
synthetic  pseudoceramides:  Comparison  of  possible  kerati-
nocyte  toxicities  provoked  by  the  pseudoceramides,  PC104 
and  BIO391,  and  natural  ceramides.  J  Dermatol  Sci.  2008; 
51(1):37–43.

  196.  Kwon YB, Kim CD, Youm JK, Gwak HS, Park BD, Lee SH, et al. 
Novel synthetic ceramide derivatives increase intracellular cal-
cium  levels  and  promote  epidermal  keratinocyte  differentia-
tion. J Lipid Res. 2007; 48(9):1936–43.

  197.  De  Paepe  K,  Roseeuw  D,  Rogiers  V.  Repair  of  acetone-  and 
sodium lauryl sulphate-damaged human skin barrier function 
using  topically  applied  emulsions  containing  barrier  lipids. 
J Eur Acad Dermatol Venereol. 2002; 16(6):587–94.

  198.  Man  MQ,  Feingold  KR,  Elias  PM.  Exogenous  lipids  influence 
permeability  barrier  recovery  in  acetone-treated  murine  skin. 
Arch Dermatol. 1993; 129(6):728–38.

  199.  Zettersten  EM,  Ghadially  R,  Feingold  KR,  Crumrine  D,  Elias 
PM. Optimal ratios of topical stratum corneum lipids improve 
barrier  recovery  in  chronologically  aged  skin.  J  Am  Acad 
Dermatol. 1997; 37(3 Pt 1):403–8.

  200.  Yang  L,  Mao-Qiang  M,  Taljebini  M,  Elias  PM,  Feingold  KR. 
Topical  stratum  corneum  lipids  accelerate  barrier  repair  after 
tape stripping, solvent treatment and some but not all types of 
detergent treatment. Brit J Dermatol. 1995; 133(5):679–85.
  201.  Lowe AJ, Tang ML, Dharmage SC, Varigos G, Forster D, Gurrin 
LC, et al. A phase I study of daily treatment with a ceramide-
dominant  triple  lipid  mixture  commencing  in  neonates.  BMC 
Dermatol. 2012; 12:3.

 
  202.  Sahle  FF,  Gebre-Mariam  T,  Dobner  B,  Wohlrab  J,  Neubert 
RH.  Skin  Diseases  Associated  with  the  Depletion  of  Stratum 
Corneum  Lipids  and  Stratum  Corneum  Lipid  Substitution 
Therapy. Skin Pharmacol Physiol. 2014; 28(1):42–55.

  203.  Sajic  D,  Asiniwasis  R,  Skotnicki-Grant  S.  A  look  at  epidermal 
barrier function in atopic dermatitis: Physiologic lipid replace-
ment and the role of ceramides. Skin Ther Lett. 2012; 17(7):6–9.

  204.  Summers  RS,  Summers  B,  Chandar  P,  Feinberg  C,  Gursky  R, 
Rawlings AV. The effect of lipids with and without humectant 
on skin xerosis. J Soc Cosmet Chem. 1996; 47:27–39.

  205.  Pennick G, Chavan B, Summers B, Rawlings AV. The effect of an 
amphiphilic self-assembled lipid lamellar phase on the relief of 
dry skin. Int J Cosmet Sci. 2012; 34(6):567–74.

  206.  Miller DW, Koch SB, Yentzer BA, Clark AR, O’Neill JR, Fountain J, 
et al. An over-the-counter moisturizer is as clinically effective as, 
and more cost-effective than, prescription barrier creams in the 
treatment of children with mild-to-moderate atopic dermatitis: A 
randomized, controlled trial. J Drugs Dermatol. 2011; 10(5):531–7.

  207.  Huang  HC,  Chang  TM.  Ceramide  1  and  ceramide  3  act  syn-
ergistically  on  skin  hydration  and  the  transepidermal  water 
loss of sodium lauryl sulfate-irritated skin. Int J Dermatol. 2008; 
47(8):812–9.

  208.  Wollenweber U, Rawlings AV, et al. Application of a skin identi-
cal lipid concentrate for enhanced skin moisturisation and pro-
tection. SOFA. 2004; 130.

  209.  Prottey  C,  Hartop  PJ,  Press  M.  Correction  of  the  cutaneous 
manifestations  of  essential  fatty  acid  deficiency  in  man  by 
application of sunflower-seed oil to the skin. J Invest Dermatol. 
1975; 64(4):228–34.

  210.  Conti A, Rogers J, Verdejo P, Harding CR, Rawlings AV. Seasonal 
influences on stratum corneum ceramide 1 fatty acids and the 
influence of topical essential fatty acids. Int J Cosmet Sci. 1996; 
18(1):1–12.

  211.  Brod  J,  Traitler  H,  Studer  A,  Lacharriere  O.  Evolution  of  lipid 
composition  in  skin  treated  with  blackcurrant  seed  oil.  Int  J 
Cosmet Sci. 1988; 10(4):149–59.

  212.  Rawlings  AV,  Davies  A,  Carlomusto  M,  Pillai  S,  Zhang  K, 
Kosturko  R,  et  al.  Effect  of  lactic  acid  isomers  on  keratino-
cyte  ceramide  synthesis,  stratum  corneum  lipid  levels  and 
stratum  corneum  barrier  function.  Arch  Dermatol  Res.  1996; 
288(7):383–90.

  213.  Zhang K, Kosturko R, Rawlings AV. The effect of thiols on epi-
dermal lipid biosynthesis. J Invest Dermatol. 1995; 104:687.
  214.  Carlomusto M, Pillai K, Rawlings AV. Human keratinocytes in 
vitro can utilise exogenously supplied sphingolipid analogues 
for keratinocyte ceramide biosynthesis. J Invest Dermatol. 1996; 
106:919.

  215.  Davies A, Verdejo P, Feinberg C, Rawlings AV. Increased stra-
tum  corneum  ceramide  levels  and  improved  barrier  function 
following treatment with tetraacetylphytosphingosine. J Invest 
Dermatol. 1996; 106:918.

  216.  Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide 
increases  biosynthesis  of  ceramides  as  well  as  other  stratum 
corneum lipids to improve the epidermal permeability barrier. 
Brit J Dermatol. 2000; 143(3):524–31.

  217.  Rivier M, Castiel I, Safonova I, Ailhaud G, Michel, S. Peroxisome 
proliferator-activated receptor-alpha enhances lipid metabolism 
in a skin equivalent model. J Invest Dermatol. 2000; 114(4):681–7.

  218.  Rivier M, Safonova I, Lebrun P, Griffiths CE, Ailhaud G, Michel 
S. Differential expression of peroxisome proliferator-activated 
receptor subtypes during the differentiation of human kerati-
nocytes. J Invest Dermatol. 1998; 111(6):1116–21.

  219.  Hara  M,  Uchida  Y,  Haratake  A,  Mimura  K,  Hamanaka  S. 
Galactocerebroside and not glucocerebroside or ceramide stim-
ulate epidermal beta-glucocerebrosidase activity. J Dermatol Sci. 
1998;16(2):111–9.

  220.  Ponec  M,  Weerheim  A,  Kempenaar  J,  Mulder  A,  Gooris  GS, 
Bouwstra J, et al. The formation of competent barrier lipids in 
reconstructed human epidermis requires the presence of vita-
min C. J Invest Dermatol. 1997;109(3):348–55.

CERAMIDES AND THE SKIN 

 141

  221.  Di  Marzio  L,  Cinque  B,  Cupelli  F,  De  Simone  C,  Cifone  MG, 
Giuliani  M.  Increase  of  skin-ceramide  levels  in  aged  subjects 
following a short-term topical application of bacterial sphingo-
myelinase from Streptococcus thermophilus. Int J Immunopathol 
Pharmacol. 2008; 21(1):137–43.

  222.  Tsuji K, Mitsutake S, Ishikawa J, Takagi Y, Akiyama M, Shimizu 
H, et al. Dietary glucosylceramide improves skin barrier func-
tion in hairless mice. J Dermatol Sci. 2006; 44(2):101–7.

  223.  Popa I, Abdul-Malak N, Portoukalian J. The weak rate of sphin-
golipid  biosynthesis  shown  by  basal  keratinocytes  isolated 
from aged vs. young donors is fully rejuvenated after treatment 
with  peptides  of  a  potato  hydrolysate.  Int  J  Cosmet  Sci.  2010; 
32(3):225–32.

  224.  Ishikawa  J,  Shimotoyodome  Y,  Chen  S,  Ohkubo  K,  Takagi  Y, 
Fujimura T, et al. Eucalyptus increases ceramide levels in kera-
tinocytes and improves stratum corneum function. Int J Cosmet 
Sci. 2012; 34(1):17–22.

  225.  Kato  E,  Takahashi  N.  Improvement  by  sodium  dl-alpha-
tocopheryl-6-O-phosphate  treatment  of  moisture-retaining 
ability in stratum corneum through increased ceramide levels. 
Bioorganic Medicinal Chem. 2012; 20(12):3837–42.

  226.  Hashizume  E,  Nakano  T,  Kamimura  A,  Morishita  K.  Topical 
effects of N-acetyl-L-hydroxyproline on ceramide synthesis and 
alleviation of pruritus. Clin Cosmet Invest Dermatol. 2013; 6:43–9.

  227.  Spiegel  S,  Merrill  AH  Jr.  Sphingolipid  metabolism  and  cell 

growth regulation. FASEB J. 1996; 10(12):1388–97.

  228.  Hannun  YA.  Functions  of  ceramide  in  coordinating  cellular 

responses to stress. Science. 1996; 274(5294):1855–9.

  229.  Merrill  AH  Jr,  Schmelz  EM,  Dillehay  DL,  Spiegel  S,  Shayman 
JA, Schroeder JJ, et al. Sphingolipids—the enigmatic lipid class: 
Biochemistry,  physiology,  and  pathophysiology.  Toxicol  Appl 
Pharmacol. 1997; 142(1):208–25.

  230.  Uchida  Y.  Ceramide  signaling  in  mammalian  epidermis. 

Biochim Biophys Acta. 2014; 1841(3):453–62.

  231.  Jung EM, Griner RD, Mann-Blakeney R, Bollag WB. A potential 
role for ceramide in the regulation of mouse epidermal kerati-
nocyte proliferation and differentiation. J Invest Dermatol. 1998; 
110(4):318–23.

  232.  Wakita  H,  Tokura  Y,  Yagi  H,  Nishimura  K,  Furukawa  F, 
Takigawa  M.  Keratinocyte  differentiation  is  induced  by  cell-
permeant ceramides and its proliferation is promoted by sphin-
gosine. Arch Dermatol Res. 1994; 286(6):350–4.

  233.  Allan  D,  Shawyer  A,  Taylor  A.  Mechanisms  by  which  short-
chain  ceramides  cause  apoptosis.  Biocheml  Soc  Trans.  1999; 
27(4):428–32.

  234.  Tomassini B, Testi R. Mitochondria as sensors of sphingolipids. 

Biochimie. 2002; 84(2–3):123–9.

  235.  Siskind  LJ,  Kolesnick  RN,  Colombini  M.  Ceramide  channels 
increase  the  permeability  of  the  mitochondrial  outer  mem-
brane to small proteins. J Biol Chem. 2002; 277(30):26796–803.

  236.  Wieder  T,  Orfanos  CE,  Geilen,  CC.  Induction  of  ceramide-
mediated  apoptosis  by  the  anticancer  phospholipid  analog, 
hexadecylphosphocholine. J Biol Chem. 1998; 273(18):11025–31.

  237.  Jatoi  A,  Suman  VJ,  Schaefer  P,  Block  M,  Loprinzi  C,  Roche  P, 
et al. A phase II study of topical ceramides for cutaneous breast 
cancer. Breast Cancer Res Treat. 2003; 80(1):99–104.

  238.  Kim HJ, Kim HJ, Kim SH, Kim TY. Tetraacetyl phytosphingo-
sine-induced  caspase  activation  and  apoptosis  occur  through 
G2 arrest in human keratinocyte HaCaT cells. J Invest Dermatol. 
2003; 121(5):1135–7.

  239.  Takeda S, Mitsutake S, Tsuji K, Igarashi Y. Apoptosis occurs via 
the  ceramide  recycling  pathway  in  human  HaCaT  keratino-
cytes. J Biochem. 2006; 139(2):255–62.

  240.  Philips N, Tuason M, Chang T, Lin Y, Tahir M, Rodriguez SG. 
Differential  effects  of  ceramide  on  cell  viability  and  extracel-
lular matrix remodeling in keratinocytes and fibroblasts. Skin 
Pharmacol Physiol. 2009; 22(3):151–7.

  241.  Murakami  I,  Wakasa  Y,  Yamashita  S,  Kurihara  T,  Zama  K, 
Kobayashi N, et al. Phytoceramide and sphingoid bases derived 
from  brewer’s  yeast  Saccharomyces  pastorianus  activate 

 
142 

 TEXTBOOK OF COSMETIC DERMATOLOGY

peroxisome  proliferator-activated  receptors.  Lipids  Health  Dis. 
2011; 10:150.

  242.  Cha  HJ,  Lee  JP,  Lee  KS,  Lee  KK,  Choi  MJ,  Lee  DK,  et  al. 
Phytosphigosine-1-phosphate  increases  sensitivity  of  EGF-
dependent cell proliferation. Int J Molec Med. 2014; 33(3):649–53.
  243.  Kim BH, Lee JM, Jung YG, Kim S, Kim TY. Phytosphingosine 
derivatives  ameliorate  skin 
inhibiting 
NF-kappaB  and  JAK/STAT  signaling  in  keratinocytes  and 
mice. J Invest Dermatol. 2014; 134(4):1023–32.

inflammation  by 

  244.  Farwick M, Rawlings A. Phytosphingosine: A nature-inspired 
sphingoid  base  with  multiple  skin  benefits.  Cosmet  Toiletries. 
2011; 126(5):336–47.

  245.  Jiang YJ, Kim P, Uchida Y, Elias PM, Bikle DD, Grunfeld C, et al. 
Ceramides stimulate caspase-14 expression in human keratino-
cytes. Exper Dermatol. 2013; 22(2):113–8.

  246.  Grether-Beck  S,  Felsner  I,  Koehler  T,  Farwick  M,  Lersch  P, 
Rawlings  AV,  et  al.  Topical  ceramides  neither  enhance  UVB-
induced  apoptosis  in  normal  human  keratinocytes  nor  affect 
viability  in  UVB-irradiated  reconstructed  human  epidermis. 
Exper Dermatol. 2014; 23(11):853–5.

  247.  Janusova B, Zbytovska J, Lorenc P, Vavrysova H, Palat K, Hrabalek 
A, et al. Effect of ceramide acyl chain length on skin permeabil-
ity and thermotropic phase behavior of model stratum corneum 
lipid membranes. Biochim Biophys Acta. 2011; 1811(3):129–37.
  248.  Hasegawa  T,  Shimada  H,  Uchiyama  T,  Ueda  O,  Nakashima 
M,  Matsuoka  Y.  Dietary  glucosylceramide  enhances  cornified 
envelope formation via transglutaminase expression and invo-
lucrin production. Lipids. 2011; 46(6):529–35.

  249.  Ideta R, Sakuta T, Nakano Y, Uchiyama T. Orally administered 
glucosylceramide improves the skin barrier function by upreg-
ulating genes associated with the tight junction and cornified 
envelope formation. Biosci Biotech Biochem. 2011; 75(8):1516–23.

  250.  Duan J, Sugawara T, Hirose M, Aida K, Sakai S, Fujii A, et al. 
Dietary  sphingolipids  improve  skin  barrier  functions  via  the 
upregulation  of  ceramide  synthases  in  the  epidermis.  Exper 
Dermatol. 2012; 21(6):448–52.

  251.  Kawada C, Hasegawa T, Watanabe M, Nomura Y. Dietary glu-
cosylceramide enhances tight junction function in skin epider-
mis via induction of claudin-1. Bioscience, Biotech Biochem. 2013; 
77(4):867–9.

 
15

4-Hexyl-1,3-Phenylenediol, an NF-κB Inhibitor, 
Improving Clinical Signs of Aging

Cécilia Brun, Simarna Kaur, Michael D Southall, Christiane Bertin, and Thierry Oddos

INTRODUCTION
Aging can be defined as a physiological process that is charac-
terized by an alteration of the physical and intellectual abilities 
of  the  human  body,  the  fight  against  aging  being  one  of  the 
major challenges of the twenty-first century.

Skin aging could be considered as a reflection of the over-
all aging of the human body. Indeed, the appearance of wrin-
kles  is  one  of  the  first  visible  signs  of  aging.  Among  several 
features, skin aging can be characterized by the appearance of 
wrinkles but also an emergence of brown spots, loss of skin tis-
sue, or reduced wound healing capacity. Cosmetic industries 
through  their  “anti-aging”  product  lines  attempt  to  mitigate 
the appearance of these signs of aging. Therefore, the develop-
ment of these products requires prior knowledge of skin aging 
mechanisms and many research teams try to identify markers 
of  aging  and  evaluate  the  cellular  and  molecular  alterations 
responsible for these skin changes. Briefly, skin aging is associ-
ated with epidermal atrophy, decreased proliferative capacity 
of skin cells, and loss and/or alterations of dermal extracellular 
matrix (ECM) protein expression.

At  the  cellular  level,  the  aging  process,  also  called  cel-
lular senescence, involves a cell cycle arrest accompanied by a 
certain loss of function and an alteration of the gene expression 
pattern. Over the past 20 years, NFκB (nuclear factor kappa B) 
activation has been recognized as a hallmark of the aging pro-
cess as it regulates the expression of numerous genes, some of 
which are involved in senescence entry and maintenance.

NFκB SIGNALING
First  described  in  1986  by  Sen  and  Baltimore  (1),  NFκB  is  a 
well-known transcription factor involved in the regulation of 
numerous target genes related to innate and adaptative immu-
nity,  inflammation,  apoptosis,  or  cellular  growth  (2,3).  NFκB 
was  also  shown  to  be  involved  in  several  diseases  including 
arthritis, asthma, and cancers (4).

The NFκB family members such as p50, p52, p65, c-Rel, 
and  RelB  are  found  as  homodimers  or  heterodimers  in  the 
cytoplasm of unstimulated cells, the most common form being 
a  heterodimer  of  p65  and  p50.  These  proteins  share  highly 
conserved sequences of amino acids known as the Rel homol-
ogy  domain,  containing  a  DNA-binding  site,  a  dimerization 
domain, and a nuclear localization domain.

Both homodimers and heterodimers are sequestered in 
the cytoplasm in an inactive form due to their association with 
a  member  of  the  IκB  family  of  inhibitory  proteins  masking 
their nuclear localization domain and preventing their trans-
location  to  the  nucleus  (5).  Activation  of  the  dimers  requires 
the  activity  of  IκB  kinases  (IKK)  which  phosphorylate  two 

serine  residues  (Ser32  and  Ser36)  on  IκB  proteins  leading  to 
their  ubiquitination  and  degradation  in  the  proteasome.  The 
degradation of IκB proteins unmasks the nuclear localization 
sequence  of  NFκB  which  can  translocate  to  the  nucleus  and 
finally  bind  to  specific  sequences  on  the  promoter  region  of 
various target genes (6).

NFκB AND SKIN HOMEOSTASIS
NFκB pathway was first studied for its role in the development 
and function of immune cells (7). More recently, its implication 
in non-immune cell growth and function regulation has been 
largely investigated, especially for skin homeostasis. More spe-
cifically, several studies have shown that NFκB signaling had 
a particularly important role for the maintenance of immune 
homeostasis in epithelial tissues (8).

The skin is comprised of two major compartments, the 
epidermis and the dermis. The latter is mainly composed of 
fibroblasts surrounded by ECM proteins such as collagen and 
elastin.  The  epidermis  is  a  stratified  epithelium  containing 
various layers of keratinocytes. The basal layer is mitotically 
active  and  contributes  to  cell  renewal,  whereas  in  the  upper 
layers, proliferation stops and cells migrate and undergo ter-
minal differentiation.

Khavari’s  team  has  evidenced  a  critical  role  of  NFκB 
in  epidermis  homeostasis.  They  observed  a  cytoplasmic 
localization  of  NFκB  proteins  within  cells  of  the  basal  layer 
and  a  nucleic  localization  in  non-proliferating  cells  of  the 
upper  layers,  suggesting  that  NFκB  activation  plays  a  role  in 
the  switch  from  the  proliferative  basal  cell  phenotype  to  the 
non-proliferative  one  of  suprabasal  layers  (9).  Furthermore, 
blockade  of  NFκB  function  resulted  in  epithelial  hyperplasia 
demonstrating a potential role for NFκB activation in negative 
growth  regulation,  in  contrast  to  other  tissues.  In  vitro  over-
expression of active  NFκB subunits  in normal epithelial  cells 
inhibits  cell  cycle  progression  and  favors  cell  cycle  inhibitor 
expression such as p21 (10). Likewise, IKK deficient mice dis-
play abnormal skin development with thicker epidermis asso-
ciated  with  hyper-proliferation  and  defects  in  keratinocyte 
terminal differentiation (11).

The  epidermis  is  perpetually  subjected  to  harmful  UV 
radiation. In this context, NFκB binding activity was shown to 
be rapidly induced in nuclear extracts from skin submitted to 
UV radiation, suggesting a role for the transcription factor in 
keratinocyte protection and survival (12).

At  the  dermis  level,  NFκB  was  shown  to  inhibit  the 
expression of collagen 1 alpha 1 (COL1A1) gene (13). This inhibi-
tion is mediated through the recruitment of p65 subunit to the 
COL1A1 gene promoter by physical interaction with COL1A1 

144 

 TEXTBOOK OF COSMETIC DERMATOLOGY

transcription activators c-Krox, Sp1, and Sp3 (14). NFκB is thus 
a potent negative regulator of dermal ECM homeostasis.

Furthermore,  overexpressing  an  NFκB  super-repressor 
in adult mice resulted in defective morphogenesis of hair folli-
cle and other appendices (15), confirming important functions 
of NFκB in skin biology. Altogether, these data clearly indicate 
that NFκB proteins are strongly involved in skin homeostasis.

NFκB ACTIVATION UNDER (SKIN) AGING
There is now growing evidence for an increased NFκB activity 
during aging. This alteration was first observed on rodents by 
Salimen’s group, which demonstrated an age-related increase 
in  NFκB  binding  activity  in  mouse  cardiac  muscle  and  rat 
brain (16,17). However, neither IκB inhibitor protein levels nor 
IKK protein levels and phosphorylation activity were affected 
by  aging  (18),  suggesting  a  potential  retention  of  the  tran-
scription  factor  into  the  nucleus.  The  role  of  NFκB  signaling 
during aging was further investigated by motif module map-
ping  technique.  These  experiments  on  various  tissues  from 
mice and humans revealed that the NFκB motif was the motif 
most strongly associated with aging (19). Another study sug-
gested  that  NFκB  might  be  activated  upon  senescence  (20). 
More recently, a genome-wide expression profiling identified 
various  up-regulated  and  down-regulated  genes  during  cel-
lular senescence as downstream targets of NFκB. Reversion of 
senescence  by  abrogation  of  p53/p21  and  p16/pRb  pathways 
reversed up-regulation of these NFκB target genes as well as 
silencing  of  NFκB  subunits  did  manage  to  overcome  growth 
arrest. This suggests that NFκB signaling has a causal role in 
promoting senescence (21).

Of  interest,  various  studies  demonstrated  an  associa-
tion  between  NFκB  signaling  and  skin  aging.  Indeed,  senes-
cent  keratinocytes  were  shown  to  display  higher  NFκB  DNA 
binding  activity  than  young  ones  and  inhibiting  its  activity 
resulted  in  decreased  senescence-associated  β-galactosidase 
(SA-βGal)  staining  in  old  cells.  Also,  overexpression  of  NFκB 
subunits  in  normal  young  keratinocytes  induced  premature 
senescence  of  these  cells  (22).  Likewise,  Bigot  et  al.  observed 
elevated amounts and binding activities of p65 and p50 NFκB 
subunits  in  dermal  fibroblasts  isolated  from  aged  skins  (23). 
This alteration is associated with a significant loss of COL1A1 
expression  in  older  cells  compared  to  younger  ones.  NFκB 
was  previously  shown  to  inhibit  the  transcription  COL1A1 
gene  (13,14);  thus,  as  expected,  forced  expression  of  p65  and 
p50  NFκB  subunits  in  young  cells  resulted  in  significantly 
lower expression of COL1A1. Also, overexpression of p65 did 
induce senescence in fibroblasts from young and old donors. 
Altogether,  this  set  of  data  strongly  suggest  that  NFκB  sig-
naling might be involved in the skin aging process by favor-
ing  skin  cell  senescence  and  preventing  collagen  synthesis, 
both  features  leading  to  the  appearance  of  the  clinical  signs 
of aging. Supporting this hypothesis, the work of Adler et al. 
revealed that tissue-specific NFκB blockade in mice did reverse 
key  features  of  epidermal  aging  such  as  loss  of  proliferative 
potential of keratinocyte from the basal layer, p16 expression, 
and SA-βGal-positive staining (19).

NFκB pathway can also be activated in response to oxi-
dative  stress  triggered  by  ionizing  radiation  or  ultraviolet 
exposure with a subsequent enhanced DNA binding activity 
and  NFκB  protein  expression  (24,  25).  Skin  being  chronically 
exposed  to  sun  radiation  along  life,  enhanced  NFκB  activity 
might favor cellular senescence and participate to skin aging, 
in particular photo-aging.

UV  radiation  and  photo-aging  are  often  associated 
with an accumulation of DNA damage through the oxidative 
metabolism  of  reactive  oxygen  species  (ROS)  (26).  Our 
preliminary experiments suggest that NFκB might favor DNA 
damage accumulation after UV exposure (27). Indeed, topical 
pretreatment  of  skin  equivalents  with  an  NFκB  inhibitor 
(4-hexyl-1,3-phenylenediol)  significantly  reduced  UV-induced 
DNA  damage  as  determined  by  T-T  dimer  formation  in  skin 
cells. However, NFκB was also shown to be involved in double 
strand  break  removal  and  repair  by  stimulating  homologous 
recombination, potentially through BRCA2 which expression 
can be induced by NFκB (28,29). Conversely, our experiments, 
where human primary keratinocytes were treated with NFκB 
inhibitors (Bay-11-7082 and 4-hexyl-1,3-phenylenediol) after UV 
exposure, indicate that NFκB activity could delay DNA repair 
capacities  of  keratinocytes  (27).  Cells  immediately  treated 
with  NFκB  inhibitors  (0.1µg/mL  and  1µg/mL)  displayed  sig-
nificantly lower DNA damage after 1 or 2 hours of treatment 
as  measured  by  Comet  assay  compared  to  untreated  cells, 
strongly suggesting improved DNA repair capacity with NFκB 
inhibition. Sauvaigo and her team recently demonstrated that 
both base excision repair and nucleotide excision repair were 
significantly  reduced  in  human  skin  fibroblasts  under  aging 
(30,31). As previously mentioned, NFκB binding activity is sig-
nificantly  increased  in  dermal  fibroblasts  from  older  donors 
compared with younger ones (23). Taken together, these data 
clearly  suggest  that  elevation  of  NFκB  transcriptional  activ-
ity might contribute to the decrease in DNA repair capacity of 
skin cells under aging.

A NEW TARGET FOR SKIN AGING?
Since NFκB is now clearly associated with skin aging, it appears 
as a promising target. As mentioned, the work of Adler et al. 
clearly supports the idea that NFκB blockade could reverse the 
skin aging phenotype (19). Indeed, tissue specific blockade of 
NFκB in the epidermis by using a mutant of p50 unable to bind 
DNA under control of the keratin 14 promoter did reduce gene 
expression of 225 genes in older skins to gene expression levels 
observed in younger ones. It also reversed key features of epi-
dermal aging such as loss of proliferative potential of keratino-
cyte from the basal layer, p16 expression, and SA-βGal-positive 
staining (19).

NFκB inhibitors are also frequently investigated for their 
protective  effects  against  skin  aging.  For  example,  Tanaka 
and his colleagues have widely explored this topic and dem-
onstrated that some plant extracts such as parthenolide (from 
Tanacetum  parthenium),  magnolol  (from  Magnolia  ovovata)  or 
cynaropicrin  (from  Cynara  scolymus  L.)  efficiently  protected 
skin  cells  from  photo-aging  (32,33,34).  Likewise,  our  results 
strongly  indicate  that  the  NFκB  inhibitor  4-hexyl-1,3-phenyl-
enediol, also known as HEXINOL™, can protect skin cells from 
UV-induced DNA damages and increase DNA repair capacity, 
thus preventing the photo-aging process (27).

4-Hexyl-1,3-Phenylenediol: A New 
Technology against Skin Aging?
4-hexyl-1,3-phenylenediol is commonly used in food process-
ing  (35)  and  has  a  long  history  of  use  in  topical  disinfectant 
and  throat  lozenges  for  its  antioxidative  and  antimicrobial 
properties (36,37,38). It contains a 4-substituted phenylenediol 
motif, and compounds with such chemical moiety are known 
as  potent  inhibitors  of  tyrosinase  activity  in  vitro  (39,40),  an 
enzyme  involved  in  melanin  synthesis.  Our  recent  study 

 
4-HEXYL-1,3-PHENYLENEDIOL, AN NF-κB INHIBITOR, IMPROVING CLINICAL SIGNS OF AGING 

 145

described that 4-hexyl-1,3-phenylenediol significantly reduced 
melanogenesis  in  primary  human  melanocytes,  murine  mel-
anoma  cells,  and  pigmented  human  epidermal  equivalents 
through inhibition of tyrosinase enzyme activity and protein 
expression  (41).  A  double-blinded,  randomized  controlled 
clinical study confirmed that topical application of a formula 
containing  4-hexyl-1,3-phenylenediol  significantly  reduced 
skin  hyperpigmentation  (41).  These  findings  clearly  establish 
4-hexyl-1,3-phenylenediol  as  an  effective  agent  for  the  treat-
ment  of  undesirable  human  skin  hyperpigmentation  such  as 
the appearance of brown spots, one of the key features of skin 
aging process.

4-hexyl-1,3-phenylenediol  is  also  known  as  a  potent 
inhibitor  of  NFκB  (42).  Given  the  prominent  role  of  the 
transcription  factor  in  aging  and  in  particular  during  skin 
aging,  we  investigated  whether  NFκB  inhibition  through 
4-hexyl-1,3-phenylenediol  could  improve  photo-damaged 
skin  and  clinical  signs  of  aging.  Our  recent  results  (43)  first 
confirmed  an  increased  NFκB  transcription  activity  in  cells 
from  older  skins  compared  with  younger  cells,  activity  that 
was dose-dependently inhibited with 4-hexyl-1,3-phenylene-
diol. Furthermore, treatment with 4-hexyl-1,3-phenylenediol 
restored collagen and elastin synthesis that had been inhib-
ited  by  NFκB  signaling  enhancement.  At  the  clinical  level, 
an  8-week,  double  blinded,  placebo-controlled,  randomized 
controlled  study  demonstrated  significant  improvements 
regarding crow’s feet fine lines, cheek wrinkles, and forehead 
wrinkles  in  females  treated  with  4-hexyl-1,3-phenylenediol 
compared  with  those  treated  with  placebo.  Skin  radiance, 
mottled pigmentation, and age spots were also significantly 
improved (43). These results are in accordance with the anti-
tyrosinase  activity  of  4-hexyl-1,3-phenylenediol,  as  previ-
ously described (41).

This set of data strongly indicate that 4-hexyl-1,3-phen-
ylenediol, by reducing skin hyperpigmentation and inhibiting 
NFκB-mediated skin damage such as reduced ECM expression 
or  decreased  DNA  repair  capacity,  is  a  potent  tool  for  anti-
aging strategies.

Clinical Study
To further investigate the effects of HEXINOL technology on 
skin aging, we performed a clinical study on 42 female volun-
teers from 45 to 70 years old. A product containing the 4-hexyl-
1,3-phenylenediol (1%) or a placebo was applied by the subjects 
on half face and neck for 12 weeks, twice a day. Enrolled vol-
unteers presented wrinkles to the forehead, in crow’s feet area, 
underneath eyes, in cheeks and nasolabial folds, and to the cor-
ner of the lips. They also displayed pigmented spots to the face 
(at  least  one  of  3  mm  in  diameter  on  each  half-face),  tonicity 
problems, and dull complexion.

Skin  aging  features  were  clinically  assessed  by  a  der-
matologist using a visual analog scale. Brown spots were also 
characterized  using  a  colorimeter,  and  viscoelasticity  of  the 
skin  was  measured.  Assessments  were  performed  before  the 
first application (T0), then after 4 weeks (T4), 8 weeks (T8), and 
12 weeks (T12) of product application.

Results of the clinical grading are presented in Table 15.1. 
For nearly each parameter, there was a significant improvement 
after  treatment  with  both  the  product  and  the  placebo  at  T8 
and  T12.  Moreover,  for  almost  all  improved  parameters,  the 
improvement  was  significantly  higher  in  the  tested  product 
when  compared  with  placebo.  At  T4,  no  improvements  were 
observed with both tested products. Regarding skin viscoelas-
ticity, as measured by a cutometer, both placebo and product 
significantly improved skin elasticity. However, no significant 
differences were observed between the two products. This set 
of data clearly indicate that HEXINOL technology contributes 
to the reduction of wrinkles and fine lines, favors skin firmness 
and  elasticity  as  well  as  skin  softness  and  smoothness,  and 
improves skin radiance and complexion.

Colorimetric  assay  results  on  brown  spots  are  consistent 
with the clinical grading performed by the dermatologist (Figure 
15.1). After 8 weeks and 12 weeks of treatment, individual typo-
logical angle (ITA°) values, which define the skin pigmentation 
degree of a subject and the L* values, were significantly increased, 
indicating a decrease in the spots’ darkness with both product 
and placebo. Of note, at T8 the tested product had a significantly 

Table 15.1  Percentage of Improvement for Each Parameter with The Tested Product at T8 and T12

T8

T12

% Improvement

Significance vs Placebo % Improvement

Significance vs Placebo

Forehead wrinkles
Crow’s feet wrinkles
Under the eye wrinkles
Cheek wrinkles
Marionette wrinkles
Nasolabial fold
Crow’s feet fine lines
Under the eye fine lines
Color intensity of pigmented spots
Size of the pigmented spots
Number of pigmented spots
Overall photodamage
Skin brightness
Complexion homogeneity
Skin firmness
Skin elasticity
Softness
Smoothness

5,00
17,00
19,00
10,00
5,00
4,00
9,00
13,00
11,00
3,60
8,00
9,00
18,00
26,00
26,00
21,00
21,00
32,00

*
*
*
*
NS
*
*
*
*
NS
*
*
NS
*
*
*
*
*

8,00
25,00
29,00
18,00
7,00
7,00
13,00
21,00
24,00
6,00
16,00
16,00
26,00
33,00
35,00
28,00
30,00
46,00

*
*
*
*
NS
*
*
*
*
NS
*
*
NS
*
*
*
*
*

Note: Results are presented as percentage of improvement as compared to T0. *p < 0.05 versus placebo, NS: Non significant.

 
146 

 TEXTBOOK OF COSMETIC DERMATOLOGY

60

50

40

30

20

10

0

0
T
s
u
s
r
e
v
e
g
n
a
h
c
f
o
%

–10

70

60

50

40

30

20

10

0

–10

–20

0
T
s
u
s
r
e
v
e
g
n
a
h
c
f
o
%

Tested product
Placebo

#

**

**

L*

Tested product
Placebo

**
**

**

L*

#

*

**

b*
(a)

#

*

**

b*
(b)

#

**

**

ITAº

**

**

ITAº

Figure  15.1  Percentage  of  change  of  L*,  b*,  and  ITA°  val-
ues  at  (a)  T8  and  (b)  T12  versus  T0.  Color  is  expressed  in 
a  three-dimensional  coordinate  system,  in  terms  of  three 
units: L* (black-white), a* (green-red) and b* (blue-yellow). The 
skin  color  is  an  admixture  of  the  L*  a*  b*-values.  Individual 
Typological Angle (ITA°) defines the skin pigmentation degree 
of  a  subject,  ITA°  =  (arctan(L*  −  50/b*))  × 180/π.  The  higher 
the  ITA°  and  L*,  the  lighter  the  skin  is,  and  the  lower  the  b* 
parameter, the less yellow/brown the skin is. **p < 0.001 vs T0; 
*p < 0.05 vs T0; # p < 0.05 between products.

higher  activity  as  compared  with  placebo.  Moreover,  b*  values 
were  significantly  reduced  by  both  treatments,  indicating  a 
decrease  in  spot  coloration.  The  tested  product  also  had  a  sig-
nificantly higher activity on b* values as compared with placebo. 
Altogether, these data strongly demonstrate that HEXINOL tech-
nology is effective in reducing age-induced brown spots.

Finally,  the  clinical  study  performed  on  a  product  that 
contains the active ingredient 4-hexyl-1,3-phenylenediol clearly 
confirms the anti-aging properties of 4-hexyl-1,3-phenylenediol 
and validates the NFκB pathway as a promising target to fight 
skin aging.

REFERENCES

1.  Sen  R,  Baltimore  D.  Inducibility  of  kappa  immunoglobulin 
enhancer-binding  protein  Nf-kappa  B  by  a  posttranslational 
mechanism. Cell 1986; 47:921–8.

2.  Baeuerle  PA,  Baltimore  D.  NF-kappa  B:  Ten  years  after.  Cell 

1996; 87:13–20.

3.  Perkins  ND. 

Integrating  cell-signaling  pathways  with 
NF-kappaB  and  IKK  function.  Nat  Rev  Mol  Cell  Biol  2007; 
8:49–62.

4.  Karin  M.  Nuclear  factor-kappaB  in  cancer  development  and 

progression. Nature 2006; 441:431–6.

5.  Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: 
The  control  of  NF-[kappa]B  activity.  Annu  Rev  Immunol  2000; 
18:621–63.

6.  DiDonato  JA,  Hayakawa  M,  Rothwarf  DM,  et  al.  A  cytokine-
responsive IkappaB kinase that activates the transcription fac-
tor NF-kappaB. Nature 1997; 388:548–54.

7.  Baeuerle PA, Henkel T. Function and activation of NF-kappa B 

in the immune system. Annu Rev Immunol 1994; 12:141–79.
8.  Wullaert  A,  Bonnet  MC,  Pasparakis  M.  NF-κB  in  the  regula-
tion of epithelial homeostasis and inflammation. Cell Res 2011; 
21:146–58. 

9.  Seitz CS, Lin Q, Deng H, et al. Alterations in NF-kappaB func-
tion  in  transgenic  epithelial  tissue  demonstrate  a  growth 
inhibitory  role  for  NF-kappaB.  Proc  Natl  Acad  Sci  U  S  A  1998; 
95:2307–12.

  10.  Seitz CS, Deng H, Hinata K, et al. Nuclear factor kappaB sub-
units  induce  epithelial  cell  growth  arrest.  Cancer  Res  2000; 
60:4085–92.

  11.  Li  Q,  Lu  Q,  Hwang  JY,  et  al.  IKK1-deficient  mice  exhibit 
abnormal  development  of  skin  and  skeleton.  Genes  Dev  1999; 
13:1322–8.

  12.  Fisher  GJ,  Datta  SC,  Talwar  HS,  et  al.  Molecular  basis  of  sun-
induced  premature  skin  ageing  and  retinoid  antagonism. 
Nature 1996; 379:335–9.

  13.  Rippe RA, Schrum LW, Stefanovic B, et al. NF-kappaB inhibits 
expression  of  the  alpha1(I)  collagen  gene.  DNA  Cell  Biol  1999; 
18:751–61.

  14.  Beauchef  G,  Bigot  N,  Kypriotou  M,  et  al.  The  p65  subunit  of 
NF-κB  inhibits  COL1A1  gene  transcription  in  human  dermal 
and  scleroderma  fibroblasts  through  its  recruitment  on  pro-
moter  by  protein  interaction  with  transcriptional  activators 
(c-Krox, Sp1, and Sp3). J Biol Chem 2012; 287:3462–78.

  15.  Schmidt-Ullrich R, Aebischer T, Hülsken J, et al. Requirement 
of  NF-kappaB/Rel  for  the  development  of  hair  follicles  and 
other epidermal appendices. Development 2001; 128:3843–53.

  16.  Helenius  M,  Hänninen  M,  Lehtinen  SK,  et  al.  Aging-induced 
up-regulation  of  nuclear  binding  activities  of  oxidative  stress 
responsive NF-kB transcription factor in mouse cardiac muscle. 
J Mol Cell Cardiol 1996; 28:487–98.

  17.  Korhonen P, Helenius M, Salminen A. Age-related changes in 
the regulation of transcription factor NF-kappa B in rat brain. 
Neurosci Lett 1997; 225:61–4.

  18.  Helenius M, Kyrylenko S, Vehviläinen P, et al. Characterization 
of aging-associated up-regulation of constitutive nuclear factor-
kappa B binding activity. Antioxid Redox Signal 2001; 3:147–56.

  19.  Adler  AS,  Sinha  S,  Kawahara  TL,  et  al.  Motif  module  map 
reveals enforcement of aging by continual NF-kappaB activity. 
Genes Dev 2007; 21:3244–57.

  20.  Hardy  K,  Mansfield  L,  Mackay  A,  et  al.  Transcriptional  net-
works and cellular senescence in human mammary fibroblasts. 
Mol Biol Cell 2005; 16:943–953.

  21.  Rovillain E, Mansfield L, Caetano C, et al. Activation of nuclear 
factor-kappa  B  signalling  promotes  cellular  senescence. 
Oncogene 2011; 30:2356–66.

  22.  Bernard  D,  Gosselin  K,  Monte  D,  et  al.  Involvement  of  Rel/
nuclear  factor-kappaB  transcription  factors  in  keratinocyte 
senescence. Cancer Res 2004; 64:472–81.

  23.  Bigot  N,  Beauchef  G,  Hervieu  M,  et  al.  NF-κB  accumulation 
associated with COL1A1 transactivators defects during chron-
ological  aging  represses  type  I  collagen  expression  through 
a  -112/-61-bp  region  of  the  COL1A1  promoter  in  human  skin 
fibroblasts. J Invest Dermatol 2012; 132:2360–7.

  24.  Brach  MA,  Hass  R,  Sherman  ML,  et  al.  Ionizing  radiation 
induces  expression  and  binding  activity  of  the  nuclear  factor 
kappa B. J Clin Invest 1991; 88:691–5.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4-HEXYL-1,3-PHENYLENEDIOL, AN NF-κB INHIBITOR, IMPROVING CLINICAL SIGNS OF AGING 

 147

  25.  Muthusamy V, Piva TJ. The UV response of the skin: A review 
of  the  MAPK,  NFkappaB  and  TNFalpha  signal  transduction 
pathways. Arch Dermatol Res 2010; 302:5–17.

  26.  Moriwaki  S,  Takahashi  Y.  Photoaging  and  DNA  repair. 

J Dermatol Sci 2008; 50:169–76.

  27.  Kaur S, Oddos T, Tucker-Samaras S, et al. Regulation of DNA 
repair  process  by  the  pro-inflammatory  NF-κB  pathway.  In 
Chen, C., ed. New Research Directions in DNA Repair, Intech, 2013.
  28.  Volcic  M,  Karl  S,  Baumann  B,  et  al.  NF-κB  regulates  DNA 
double-strand  break  repair  in  conjunction  with  BRCA1-CtIP 
complexes. Nucleic Acids Res 2012; 40:181–95.

  29.  Wu  K,  Jiang  SW,  Thangaraju  M,  et  al.  Induction  of  the 
BRCA2  promoter  by  nuclear  factor-kappa  B.  J  Biol  Chem  2000; 
275:35548–56.

  30.  Sauvaigo  S,  Caillat  S,  Odin  F,  et  al.  Effect  of  aging  on  DNA 
excision/synthesis repair capacities of human skin fibroblasts. 
J Invest Dermatol 2010; 130:1739–41.

  31.  Pons B, Belmont AS, Masson-Genteuil G, et al. Age-associated 
modifications of Base Excision Repair activities in human skin 
fibroblast extracts. Mech Ageing Dev 2010; 131:661–5.

  32.  Tanaka K, Hasegawa J, Asamitsu K, et al. Prevention of the ultra-
violet  B-mediated  skin  photoaging  by  a  nuclear  factor  kappaB 
inhibitor, parthenolide. J Pharmacol Exp Ther 2005; 315:624–30.

  33.  Tanaka  K,  Hasegawa  J,  Asamitsu  K,  et  al.  Magnolia  ovovata 
extract and its active component magnolol prevent skin photo-
aging via inhibition of nuclear factor kappaB. Eur J Pharmacol 
2007; 565:212–9.

  34.  Tanaka  YT,  Tanaka  K,  Kojima  H,  et  al.  Cynaropicrin  from 
Cynara scolymus L. suppresses photoaging of skin by inhibit-
ing the transcription activity of nuclear factor-kappa B. Bioorg 
Med Chem Lett 2013; 23:518-23.

  35.  Frankos  VH,  Schmitt  DF,  Haws  LC,  et  al.  Generally  recog-
nized as safe (GRAS) evaluation of 4-hexylresorcinol for use as 

a processing aid for prevention of melanosis in shrimp. Regul 
Toxicol Pharmacol 1991; 14:202–212.

  36.  Kraal JH, Hussain AA, Gregorio SB, et al. Exposure time and 
the effect of hexylresorcinol on bacterial aggregates. J Dent Res 
1979; 58:2125–2131.

  37.  Rabbani  GH,  Gilman  RH,  Kabir  I,  et  al.  The  treatment  of 
Fasciolopsis buski infection in children: A comparison of thia-
bendazole, mebendazole, levamisole, pyrantel pamoate, hexyl-
resorcinol  and  tetrachloroethylene.  Trans  R  Soc  Trop  Med  Hyg 
1985; 79:513–515.

  38.  McNally  D,  Shephard  A,  Field  E.  Randomised,  double-
blind,  placebo-controlled  study  of  a  single  dose  of  an 
amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine loz-
enge or a hexylresorcinol lozenge for the treatment of acute sore 
throat due to upper respiratory tract infection. J Pharm Pharm 
Sci 2012; 15:281–294.

  39.  Chen QX, Ke LN, Song KK, et al. Inhibitory effects of hexylres-
orcinol and dodecylresorcinol on mushroom (Agaricus bispo-
rus) tyrosinase. Protein J 2004; 23:135–141.

  40.  Kolbe  L,  Mann  T,  Gerwat  W,  et  al.  4-n-butylresorcinol,  a 
highly  effective  tyrosinase  inhibitor  for  the  topical  treatment 
of  hyperpigmentation.  J  Eur  Acad  Dermatol  Venereol  2013; 
27(Suppl 1):19–23.

  41.  Won YK, Loy CJ, Randhawa M, et al. Clinical efficacy and safety 
of 4-hexyl-1,3-phenylenediol for improving skin hyperpigmen-
tation. Arch Dermatol Res 2014; 306:455–65.

  42.  Kim  SG,  Lee  SW,  Park  YW,  et  al.  4-hexylresorcinol  inhibits 
NF-κB phosphorylation and has a synergistic effect with cispla-
tin in KB cells. Oncol Rep 2011; 26:1527–32.

  43.  Kaur S, Kizoulis M, Fantasia J, et al. 4-Hexyl-1,3-phenylenediol, 
an NF-kB inhibitor, improves photodamaged skin and clinical 
signs of aging in a double-blinded, randomized controlled trial. 
Br J Dermatol. 2015;173:218–26.

 
16

Perfumes

Jeanne Duus Johansen

DEFINITIONS
A fragrance ingredient is any basic substance used for its odor-
ous,  odor-enhancing,  or  blending  properties  in  the  composi-
tion of perfumes. A perfume is a blend of fragrance ingredients 
diluted in ethanol and experienced over a certain time frame. 
It is also named the fragrance formula and may consist of 10 to 
several  hundred  ingredients.  A  fragrance  ingredient  may  be 
either a chemical or a natural product (1).

Natural fragrance ingredients are produced from natu-
ral  products  such  as  plant  parts—for  example,  petals,  leaves, 
bark,  roots,  or  fruits  from  certain  plant  families  (1).  Animal 
secretions such as musk from the male musk deer have been 
used for their odoriferous properties, but are now replaced by 
blends  of  chemicals  for  the  reason  of  animal  welfare  protec-
tion. The fragrance ingredients are extracted from the plants 
by processes such as distillation, extraction, or expression.

The  resulting  natural  products  are  often  complex  mix-
tures  consisting  of  numerous  ingredients.  In  some  cases,  the 
characteristic  odor  is  due  to  a  particular  ingredient,  and  the 
isolation  of  these  odor  determinants  is  the  original  basis  of 
production of chemical ingredients. Fragrance chemicals may 
be  isolated  from  the  natural  products  or  synthesized  from 
basic  organic  chemicals.  The  synthesized  chemicals  may  be 
nature-identical; that is, imitations of naturally occurring sub-
stances  or  entirely  new  chemicals  never  identified  in  nature. 
Most fragrance ingredients are natural or nature-identical (1). 
About 2500 fragrance ingredients are in current use for com-
pounding perfumes.

APPLICATIONS OF PERFUMES
Perfumes  are  added  to  many  types  of  consumer  products 
such  as  cosmetics,  detergents,  air  fresheners,  sanitary  nap-
kins, and toys. Perfumes are also used in aromatherapy and 
herbal remedies as well as industrial settings. Perfumes are 
products  in  themselves  sold  as  parfum,  eau  de  toilette,  and 
eau  de  cologne.  A  perfume  is  developed  for  one  particular 
type of product, and the composition may have to be changed 
to  retain  the  same  odor  if  it  is  incorporated  into  a  different 
type of product.

Perfumes may be used to mask unpleasant odors from 
the basic ingredients, for example, in skin care products. If a 
perfume is added for this purpose only, it is termed a masking 
perfume and is usually of a simple composition, consisting of 
few ingredients. Certain fragrance ingredients such as farne-
sol and geraniol have antibacterial properties and may be used 
as preservatives.

Plant extracts are regarded by some as functional ingre-
dients, claimed to act as, for example, anti-irritants. The same 
ingredients may in other cases be used just to provide a pleas-
ant odor.

Perfumes  are  part  of  daily  life  in  modern  society  as  it 
was  in  ancient  times.  The  most  intense  skin  exposure  comes 
from cosmetic products, especially stay-on cosmetics, which is 
also the cause of most contact allergic reactions.

ADVERSE REACTIONS TO 
FRAGRANCE INGREDIENTS
A few fragrance ingredients are banned by industry because 
of their neurotoxicity or carcinogenic properties (www.ifraorg.
org),  but  the  majority  of  fragrance  ingredients  have  not  been 
evaluated  at  all  for  systemic  effects  or  poorly  so.  Effects  on 
the respiratory organs from inhalation of perfumes have been 
described,  mediated  by  sensory  or  irritant  mechanisms  (2). 
Skin  reactions  as  contact  urticaria,  photoallergy,  and  photo-
toxicity  are  well  recognized  but  infrequent  skin  side  effects. 
Psoralens  in  naturally  occurring  fragrance  ingredients  were 
previously the cause of phototoxic reactions giving rise to acute 
erythema and followed by long-standing hyperpigmentation. 
The content of the light sensitivity–inducing substances is now 
regulated  and  the  problem  has  diminished.  In  the  1970s,  the 
fragrance ingredient musk ambrette was the cause of an epi-
demic  of  photoallergy,  particularly  in  men  following  the  use 
of after-shave. The usage of musk ambrette was reduced and 
in 1995 the substance was prohibited from use in cosmetics in 
Europe (http://ec.europa.eu/enterprise/cosmetics/cosing).

Immediate  contact  reaction  to  fragrance  ingredients 
is  often  of  the  nonimmunological  type  (3).  This  means  that 
most  individuals  will  react  with  local  erythema  and  edema 
if  exposed  to  the  substance  in  a  sufficient  concentration.  The 
fragrance ingredient cinnamal is capable of producing nonim-
munological contact urticarial reactions, as are Balsam of Peru 
and cinnamic acid (3). Allergic contact dermatitis is the most 
frequently  reported  adverse  reaction  in  relation  to  fragrance 
ingredients (4).

ALLERGIC CONTACT DERMATITIS
Fragrance  ingredients  are  low  molecular  weight  substances, 
which easily penetrate intact skin. About 100 of the 2500 ingre-
dients used for compounding perfumes have been described as 
capable of inducing contact allergy in humans (4,5). Fragrance 
ingredients are the most common cause of allergic contact der-
matitis because of cosmetics, being responsible for 25% to 45% 
of  the  allergic  reactions  depending  on  the  population  under 
study,  closely followed  by  the preservatives  (5).  Allergic  con-
tact  dermatitis  due  to  fragrance  ingredients  may  involve  the 
face,  hands,  the  axilla,  or  be  generalized.  depending  on  the 
causative products (4).

Contact allergy to fragrance ingredients is diagnosed in 
10% to 15% of eczema patients in Europe and North America 
(4). Estimates show that in terms of population frequencies, it 

can be translated into 1.7% to 4.2% of the general population 
with  either  a  high  or  low  degree  of  sensitivity  to  fragrance 
ingredients. In Germany, this corresponds to at least 1.4 to 3.4 
million people (6).

In Denmark, the frequency of contact allergy to the fra-
grance ingredients in a sample of women aged 18 to 41 years 
recruited from the general population rose from 0.7% in 1990 to 
3.9% in 1998 and decreased again to 2.3% in 2006 (7). A statisti-
cal significant relationship between fragrance allergy, cosmetic 
dermatitis within the past 12 months, and seeing a doctor for 
this condition was established in the population (7).

While contact allergy in children to cosmetic ingredients 
previously was rare, allergy to fragrance ingredients is seen in 
about 2% of children 12 to 16 years of age with almost equal 
frequency in boys and girls (8). Furthermore, fragrance ingre-
dients are among the most common causes of allergic contact 
dermatitis in the pediatric population, when patch tested (9). 
Investigations  in  the  general  population  are  in  the  pipeline 
concerning  the  newer  marker  of  fragrance  allergy,  fragrance 
mix II (see later in the chapter), which may add to the preva-
lence of fragrance allergy.

CAUSATIVE INGREDIENTS AND DIAGNOSIS
Since the beginning of the 1980s, a mixture of eight fragrance 
ingredients,  named  fragrance  mix  I,  has  been  used  for 
screening  purposes  in  the  routine  investigation  of  allergic 
contact  dermatitis  (Table  16.1).  The  mixture  has  been  valu-
able  in  diagnosing  fragrance  contact  allergy,  and  only  few 
modifications  have  been  made  to  its  original  composition 
over the years. In 1984 the initial patch test concentration of 
16%  was  reduced  to  8%  because  of  many  irritant  reactions, 
which seemed to be caused mainly by the presence of cinna-
mal. As many fragrance ingredients are used in composing 
perfumes,  investigations  have  been  conducted  to  identify 
significant fragrance ingredients not present in the fragrance 
mix I (10,11,13,14). From this knowledge base a new test has 
been designed, fragrance mix II, which contains six fragrance 
chemicals (15–17) (Table 16.1), compiled to a test concentration 
of 14% in pet. This has also been included in the European 
baseline series together with its main ingredient hydroxyiso-
hexyl 3-cyclohexenecarboxaldehyde (Lyral) (18). In a Belgian 
investigation, fragrance mix I gave positive reactions in 9.0%; 
fragrance mix II and hydroxyisohexyl 3-cyclohexenecarbox-
aldehyde in 2.1% of patch tested eczema patients (19). Contact 
allergy to hydroxyisohexyl 3-cyclohexenecarboxaldehyde is 
much  less  frequent  in  North  America  than  in  Europe  (20), 
where a positive reaction to the substance in 0.4% of consecu-
tively  patch  tested  patients  was  seen.  The  reason  could  be 
that  hydroxyisohexyl  3-cyclohexene  carboxaldehyde  is  not 
used to the same extent in underarm preparations in North 
America as in Europe. Deodorants/antiperspirants are prod-
uct  types  carrying  a  high  risk  of  sensitization  to  fragrance 
ingredients (21–23).

The ingredients of fragrance mix I and II are present in 
most consumer products in combinations and not infrequently 
in concentrations capable of eliciting allergic contact dermatitis 
(24). This explains the value of the two fragrance mixes as diag-
nostic tools and links the patch test reactions to exposure and 
clinical disease. A natural Myroxylon pereirae is also part of the 
European baseline series and is used in some countries in topi-
cal medicaments and also in the form of extracts and distillates 
in fragrances (25). Work has been done to optimize the identi-
fication of contact allergy caused by natural extracts (10,11,26) 

PERFUMES 

 149

(Table 16.2). Some natural extracts have a simple composition, 
consisting of only a few chemicals; an example is clove oil, that 
contains  up  to  80%  geraniol,  a  well-known  allergen.  Other 
extracts  have  a  very  complex  composition,  and  even  though 
they  are  well  recognized  as  causes  of  allergic  reactions,  the 
allergens in the extracts are not known. An example is Evernia 
prunastri (oakmoss absolute). As E. prunastri is a major cause of 
allergic reactions, investigations have been undertaken to pin-
point the major allergens, chloroatranol and atranol; still other 
less important allergens exist in the mixture (27). This opens 
up the possibility of producing extracts of E. prunastri with no 
or low levels of these two strong allergens (28).

Some  natural  products  from  the  terpene  family,  such 
as limonene and linalool, will form allergens when oxidized, 
but while they in their unoxidized state have only weak or no 
allergenic properties. The allergens formed are mainly hydro-
peroxides  with  strong  allergenic  potential  (30).  These  oxi-
dized  terpenes  are  major  causes  of  fragrance  contact  allergy 
and  should  be  included  in  the  test  series  for  fragrance  con-
tact allergy (31). Antioxidants can prevent oxidation for some 
time, but when the antioxidant is consumed, oxidation starts 
immediately.

COSMETIC PRODUCTS AND 
ALLERGIC CONTACT DERMATITIS 
TO FRAGRANCE INGREDIENTS
Investigations of fragrance-allergic individuals have shown that 
initiation of disease typically is caused by a fragranced deodor-
ant, a cologne/perfume, or both (21). High levels of well-known 
allergens  have  been  shown  particularity  in  fine  fragrances.  A 
parfum may contain up to 30% of fragrance ingredients, while 
1%  is  typical  for  deodorants.  This  means  that  the  individual 
ingredients  are  present  in  much  higher  concentrations  in  par-
fums  than  in  other  products.  The  same  allergens  have  been 
found also in significant concentrations in naturally based per-
fumes, deodorants, and toy perfumes (4).

The  risk  of  sensitization  will  depend  primarily  on 
exposure  concentration.  The  exposures  as  well  as  the  sen-
sitivity  of  the  individual  are  decisive  factors  in  whether 
eczema develops in a sensitized individual. A key determi-
nant  in  exposure  is  the  concentration  of  allergen  per  unit 
of skin surface. However, the formulation of a product also 
influences the risk of elicitation of allergy; for example, from 
experiments it seems that deodorant sprays are more likely 
to provoke reactions, given the same conditions and contents 
of allergens, as deodorant sticks. Other factors that affect the 
risk of elicitation in humans are the number of allergens in 
a product, frequency of exposure, region of application, the 
skin condition (4). The intensity of skin contact is important, 
which  means  that  stay-on  products  generally  give  a  higher 
risk  of  sensitization  and  elicitation  than  wash-off  products 
given  the  same  concentrations  of  allergens.  However,  fre-
quent  use  of  a  product  such  as  a  liquid  soap  may  compen-
sate and cause the same risk as a stay-on cosmetic product. 
Another frequent cause of fragrance contact allergy is topical 
medicaments in some countries (32).

THE FRAGRANCE ALLERGIC PATIENT
There is considerable inter-individual variation in the sensitiv-
ity of fragrance-allergic individuals. Some cannot tolerate any 
fragrance products at all; others may be able to use some type 
of products such as shampoos without problems because of the 

 
150 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 16.1  Fragrance Ingredients Included in the List of Substances to be Labeled as Ingredients If Present in Cosmetics in Europe 
and Their Inclusion in Diagnostic Test Preparations

Name (INCI)

Amyl cinnamal
Benzyl alcohol
Cinnamyl alcohol
Citral
Eugenol
Hydroxycitronellal
Isoeugenol
Amylcinnamyl alcohol
Benzyl salicylate
Cinnamal
Coumarin
Geraniol
Hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyral)
Anisyl alcohol
Benzyl cinnamate
Farnesol
Butylphenyl methylpropional
Linalool
Benzyl benzoate
Citronellol
Hexyl cinnamal
D-Limonene
Methyl 2-octynoate
Alpha isomethyl ionone
Evernia prunastri (oakmoss extract)
Evernia furfuracea (treemoss extract)

CAS no.

122-40-7
100-51-6
104-54-1
5392-40-5
97-53-0
107-75-5
97-54-1
101-85-9
118-58-1
104-55-2
91-64-5
106-24-1
31906-04-4
105-13-5
103-41-3
4602-84-0
80-54-6
78-70-6
120-51-4
106-22-9
101-86-0
5989-27-5
111-12-6
127-51-5
90028-68-5
90028-67-4

In FM I

In FM II

X

X
X
X
X

X

X

X

X

X

X

X

X
X

Abbreviations:  INCI,  International  Nomenclature  of  Cosmetic  Ingredients;  FM,  mixture  of  fragrance  ingredients  used  for  diagnosing  fragrance 
allergy.
Note: The presence of the substance must be indicated in the list of ingredients when its concentration exceeds 0.001% in leave-on products and 
0.01% in rinse-off products according to the Cosmetic Directive in EU (http://ec.europa.eu/enterprise/cosmetics/cosing). Information regarding the 
presence of other fragrance ingredients in cosmetics may be made available by fragrance industry on a case-by-case basis (38).

Table 16.2  Natural Extracts Frequently Reported as Causing 
Positive Patch Tests in Eczema Patients

Cedarwood oil
Clove bud oil
Dwarf pine needle oil
Eucalyptus oil
Evernia furfuracea (treemoss abs)
Evernia prunastri (oakmoss abs)
Geranium oil bourbon
Jasmine abs
Lavender oil
Lemongrass oil
Lemon oil
Myroxylon pereirae (Balsam of Peru)
Narcissus abs
Neroli oil
Orange oil
Patchouli oil
Peppermint oil
Sandalwood oil
Spearmint oil
Ylang-ylang oil I
Ylang-ylang oil II

Sources: Simonsen AB et al., Contact Dermatitis; 65:254–65, 2011; 
Larsen W et al., Am J Contact Dermatitis; 9:202–6, 1998; Frosch PJ 
et  al.,  Contact  Dermatitis;  47:279–87,  2002;  Uter  W  et  al.,  Contact 
Dermatitis; 63:277–83, 2010.
Note: A more extensive list can be found in ref. 4.

short contact time and the dilution factor, and may even tolerate 
some stay-on products. The products most difficult to tolerate 
on the skin are perfumed deodorants, perfumes/colognes, and 
skin care products. In a questionnaire study of the strategies of 

fragrance-allergic eczema patients in their choice of cosmetic 
products,  45.3%  answered  that  they  had  found  some  scented 
products  that  they  could  tolerate,  31.6%  had  not  tried  to  find 
any  scented  products,  and  22%  had  tried  but  could  not  find 
any (30). The methods  most often used  were trying  different 
products and reading the ingredient label. The quality of life 
in patients, especially younger women with fragrance allergy, 
has been shown to be severely affected (33).

Indicative of the clinical problems the fragrance-allergic 
individual may have is their level of sensitivity at patch test-
ing with standard test concentrations. It has been shown that 
patients giving a +++ or ++ grading at patch testing with the 
fragrance mix or one of its ingredients are very sensitive and 
likely to react to normal use of cosmetics containing the aller-
gen they cannot tolerate.

A  total  82.1%  of  a  group  of  eczema  patients  who  had 
been diagnosed with fragrance contact allergy within the past 
2 years reported some degree of eczema presently. Most had 
hand  eczema  (55.5%),  followed  by  facial  eczema  (33.3%),  and 
42.7% had eczema at multiple locations (30).

Fragrance-allergic patients are advised to avoid the spe-
cific fragrance ingredient(s) they cannot tolerate according to 
the patch test results. However, if they are allergic to multiple 
fragrance  ingredients,  fragrance  ingredients  not  obligatorily 
declared on the label, or if they have no interest in using fra-
granced products, they are advised to use fragrance-free prod-
ucts  only.  They  should  be  made  aware  that  some  products 
marketed as fragrance-free may contain fragrance ingredients 
in spite of this marketing. Various flower or plant extracts or 
chemicals are often used as preservatives (34). Such products 
may cause adverse reactions in the perfume-allergic patient. It 

 
is often possible to tell if a product contains fragrance ingredi-
ents by the (pleasant) scent.

INTERVENTIONS AND REGULATIONS
The International Fragrance Association (IFRA) was founded 
in  1973  by  fragrance  manufacturers  and  has  since  issued 
recommendations  for  the  safe  use  of  fragrance  ingredients. 
Guidelines for more than 100 ingredients are published (www.
ifraorg.org).  Most  recommendations  are  due  to  skin  effects, 
especially allergic contact dermatitis. In spite of these guide-
lines, fragrance ingredients still are one of the most frequent 
causes  of  allergic  contact  dermatitis.  The  fragrance  industry 
has  developed  new  models  for  estimation  of  exposure  levels 
which are not expected to sensitize (35). The efficacy of these 
models  is  unknown,  and  already-sensitized  consumers  will 
not be protected.

In  Europe,  ingredient  labeling  of  cosmetics  was  intro-
duced in 1997, while it has been in force in the United States for 
decades. In both cases, fragrance compositions were referred 
to  as  “parfum,”  and  disclosure  of  the  individual  fragrance 
ingredients was not given. By the amendment of the Cosmetic 
Directive in Europe (2003), labeling of certain fragrance ingre-
dients  recognized  for  their  sensitizing  potential  has  been 
introduced  (Table  16.1)  to  improve  diagnostics  and  help  the 
sensitized  consumer  to  avoid  relevant  allergens.  The  list  has 
been proposed to be expanded to more than 100 substances in 
a 2012 (4) revision of the original opinion from 1997. Whether 
this will be implemented in practice is not known. A number 
of  other  fragrance  ingredients  have  been  restricted  or  have 
been  banned  from  use  in  cosmetic  products  mainly  because 
of their sensitizing properties (http://ec.europa.eu/enterprise/
cosmetics/cosing).  The  fragrance  ingredient  hydroxyisohexyl 
3-cyclohexene  carboxaldehyde  as  well  as  the  main  allergens 
in E. prunastri (oak moss absolute) are under consideration for 
ban  in  cosmetic  products  in  Europe  due  to  their  sensitizing 
properties.

A  decline  in  contact  allergy  to  FMI  and  MP  has  been 
noted (7,19,36), which may to some extent be an effect of these 
actions,  change  in  fashion,  and  other  initiatives;  however,  as 
new causative ingredients have been identified (FMII/HICC), 
the  collective  sum  of  fragrance  allergy  seems  unchanged  or 
even increasing, as recently shown in Germany (37).

REFERENCES

1.  Harder U. The art of creating a perfume. In: Frosch PJ, Johansen 
JD,  White  IR,  eds.  Fragrances-Beneficial  and  Adverse  Effects. 
Berlin: Springer-Verlag, 1998:3–5.

2.  Elberling J, Dirksen A, Johansen JD, et al. The capsaicin cough 
reflex in eczema patients with respiratory symptoms elicited by 
perfume. Contact Dermatitis 2006; 54(3):158–64.

3.  Tanaka S, Matsumoto Y, Dlova N, et al. Immediate contact reac-
tions  to  fragrance  mix  constituents  and  Myroxylon  pereirae 
resin. Contact Dermatitis 2004; 51(1):20–1.

4.  Uter W, Johansen JD, Börje A, et al. Categorization of fragrance 
contact  allergens  for  prioritization  of  preventive  measures: 
Clinical and experimental data and consideration of structure–
activity relationships. Contact Dermatitis 2013; 69:196–230.

5.  Travassos  AR,  Claes  L,  Boey  L,  Drieghe  J,  Goossens  A.  Non-
fragrance  allergens  in  specific  cosmetic  products.  Contact 
Dermatitis 2011; 65:276–85.

6.  Schnuch  A,  Uter  W,  Geier  J,  et  al.  Epidemiology  of  contact 
allergy: An estimation of morbidity employing the clinical epi-
demiology and drug utilization research (CE-DUR) approach. 
Contact Dermatitis 2002; 47:32–9.

PERFUMES 

 151

7.  Thyssen  JP,  Linneberg  A,  Menné  T,  et  al.  The  prevalence  and 
morbidity of sensitization to fragrance mix I in the general pop-
ulation. Br J Dermatol 2009; 161(1):95–101. [Epub April 24, 2009].
8.  Mortz CG, Lauritsen JM, Bindslev-Jensen C, et al. Contact allergy 
and allergic contact dermatitis in adolescents: Prevalence mea-
sures and associations. Acta Derm Venereol 2002; 82:352–8.

9.  Simonsen  AB,  Deleuran  M,  Johansen  JD,  Sommerlund  M. 
Contact allergy and allergic contact dermatitis in children—A 
review of current data. Contact Dermatitis 2011; 65:254–65.
  10.  Larsen  W,  Nakayama  H,  Fischer  T,  et  al.  A  study  of  new  fra-
grance mixtures. Am J Contact Dermatitis 1998; 9:202–6.
  11.  Frosch PJ, Johansen JD, Menné T, et al. Further important sensi-
tizers in patients sensitive to fragrances. II. Reactivity to essen-
tial oils. Contact Dermatitis 2002; 47:279–87.

  12.  Larsen W, Nakayama H, Lindberg M, et al. Fragrance contact 
dermatitis: A worldwide multicenter investigation, part I. Am J 
Contact Dermatitis 1996; 7:77–83.

  13.  Larsen  WG.  How  to  test  for  fragrance  allergy.  Cutis  2000; 

65:39–41.

  14.  Frosch PJ, Johansen JD, Menné T, et al. Further important sensi-
tizers in patients sensitive to fragrances. I. Reactivity to 14 fre-
quently used chemicals. Contact Dermatitis 2002; 47:78–85.
  15.  Frosch PJ, Pirker C, Rastogi SC, et al. Patch testing with a new 
fragrance mix detects additional patients sensitive to perfumes 
and  missed  by  the  current  fragrance  mix.  Contact  Dermatitis 
2005; 52:207–15.

  16.  Frosch PJ, Rastogi SC, Pirker C, et al. Patch testing with a new 
fragrance mix–reactivity to the single constituents and chemi-
cal detection in relevant cosmetic products. Contact Dermatitis 
2005; 52:216–25.

  17.  Frosch PJ, Johansen JD, Menné T, et al. Lyral1 is an important 
sensitizer in patients sensitive to fragrances. Br J Dermatol 1999; 
141:1076–83.

  18.  Bruze  M,  Andersen  KE,  Goossens  A.  Recommendation  to 
include  fragrance  mix  2  and  hydroxyisohexyl  3-cyclohexene 
carboxaldehyde  (Lyral1)  in  the  European  Baseline  patch  test 
series. Contact Dermatitis 2008; 58:129–33.

  19.  Nardelli A, Carbonez A, Ottoy W, et al. Frequency of and trends 
in  fragrance  allergy  over  a  15-year  period.  Contact  Dermatitis 
2008; 58(3):134–41.

  20.  Belsito DV, Fowler JF Jr, Sasseville D, et al. Delayed-type hyper-
sensitivity  to  fragrance  materials  in  a  select  North  American 
population. Dermatitis 2006; 17(1):23–8.

  21.  Johansen  JD,  Andersen  TF,  Kjøller  M,  et  al.  Identification  of 
risk  products  for  fragrance  contact  allergy.  A  case-referent 
study  based  on  patients’  histories.  Am  J  Contact  Dermatitis 
1998; 2:80–7.

  22.  Uter W, Geier J, Schnuch A, et al. Patch test results with patients’ 
own perfumes, deodorants and shaving lotions: Results of the 
IVDK 1998-2002. J Eur Acad Dermatol Venereol 2007; 21(3):374–9.

  23.  Heisterberg  MV,  Menné  T,  Andersen  KE,  Avnstorp  C  et  al. 
Deodorants are the leading cause of allergic contact dermatitis 
to fragrance ingredients. Contact Dermatitis 2011; 64:258–64.

  24.  Buckley DA. Fragrance ingredient labelling in products on sale 

in the U.K. Br J Dermatol 2007; 157(2):295–300.

  25.  Api  AM.  Only  Peru  Balsam  extracts  or  distillates  are  used  in 

perfumery. Contact Dermatitis 2006; 54(3):179.

  26.  Uter W, Schmidt E, Geier J, Lessmann H et al. Contact allergy 
to essential oils: Current patch test results (2000–2008) from the 
Information Network of Departments of Dermatology (IVDK). 
Contact Dermatitis 2010; 63:277–83.

  27.  Bernard  G,  Giménez-Arnau  E,  Rastogi  SC,  et  al.  Contact 
allergy  to  oak  moss:  Search  for  sensitizing  molecules  using 
combined  bioassayguided  chemical  fractionation,  GC-MS, 
and  structure–activity  relationship  analysis.  Arch  Dermatol 
Res 2003; 295:229–35.

  28.  Andersen F, Andersen KH, Bernois A, Brault C, et al. Reduced 
content of chloroatranol and atranol in oak moss absolute sig-
nificantly  reduces  the  elicitation  potential  of  this  fragrance 
material. Contact Dermatitis 2015;72:75–83.

 
 
 
 
 
 
 
 
 
 
152 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  29.  Hagvall L, Bäcktorp C, Svensson S, et al. Fragrance compound 
geraniol forms contact allergens on air exposure. Identification 
and quantification of oxidation products and effect on skin sen-
sitization. Chem Res Toxicol 2007; 20:807–14.

  30.  Lysdal SH, Johansen JD. Fragrance allergic patients—Strategies 
for use of cosmetic products and perceived impact on life situa-
tion. Contact Dermatitis 2009; 61:320–4.

  31.  Karlberg  AT,  Börje  A,  Johansen  JD,  Lidén  C  et  al.  Activation 
of  non-sensitizing  or  low-sensitizing  fragrance  substances 
into  potent  sensitizers—Prehaptens  and  prohaptens.  Contact 
Dermatitis 2013; 69:323–34.

  32.  Nardelli  A,  d’hooghe  E,  Drieghe  J,  Dooms  M,  Goossens  A. 
Allergic  contact  dermatitis  from  fragrance  components  in 
specific  topical  pharmaceutical  products  in  Belgium.  Contact 
Dermatitis 2009; 60:303–13.

  34.  Scheinman PL. The foul side of fragrance-free products: What 
every clinician should know about managing patients with fra-
grance allergy. J Am Acad Dermatol 1999; 41:1020–4.

  35.  Api AM, Basketter DA, Cadby PA, Cano MF et al. Dermal sensi-
tization quantitative risk assessment (QRA) for fragrance ingre-
dients. Regul Toxicol Pharmacol. 2008 Oct;52(1):3-23.

  36.  Thyssen  JP,  Carlsen  BC,  Menné  T,  et  al.  Trends  of  contact 
allergy  to  fragrance  mix  I  and  Myroxylon  pereirae  among 
Danish eczema patients tested between 1985 and 2007. Contact 
Dermatitis 2008; 59(4):238–44.

  37.  Mahler  V,  Geier  J,  Schnuch  A.  Current  trends  in  patch 
testing—New  data  from  the  German  Contact  Dermatitis 
Research  Group  (DKG)  and  the  Information  Network  of 
Departments  of  Dermatology  (IVDK).  J  Dtsch  Dermatol  Ges 
2014;12:583–92.

  33.  Heisterberg MV, Menné T, Johansen JD. Fragrance allergy and 
quality  of  life—A  case–control  study.  Contact  Dermatitis  2014; 
70:81–89.

  38.  Roberts G. Procedures for supplying fragrance information to 
dermatologists. Letter to the editor. Am J Contact Dermat 2002; 
13:206–7.

 
17

Alternative and natural treatments in dermatology

Daniel Oxman and Cheryl Levin

Supplementation  to  traditional  drugs  has  gained  popularity 
in  recent  years,  particularly  within  the  field  of  dermatology 
where  diseases  are  often  chronic  and  treatments  may  at 
times  be  frustrating  (1,2).  The  intent  of  this  review  is  to 
survey  some  of  the  more  recently  reported  alternative  and 
complementary  dermatologic  treatments,  with  an  emphasis 
on  those  that  follow  evidence-based  dermatology  guidelines 
(3,4). Specifically, this review focuses on those difficult to treat 
skin conditions in which significant developments have been 
made, including skin pigmentation disorders, onychomycosis, 
psoriasis, and atopic dermatitis.

HYPERPIGMENTATION
Melanin is produced by melanocytes in the basal layer of the skin 
and  is  primarily  responsible  for  skin  pigmentation.  Humans 
all  have  approximately  the  same  number  of  melanocytes, 
implying that variation in skin color is attributable to a variety 
of other factors, such as the number and size of melanosomes 
within each melanocyte, the ratio of different types of melanin 
produced,* degree of melanocyte activity, and environmental 
factors.  From  a  biochemical  standpoint,  tyrosinase  catalyzes 
three  reactions  in  melanin  formation:  hydroxylation  of 
tyrosine  to  DOPA,  oxidation  of  DOPA  to  DOPAquinone,  and 
oxidation of DHI to indolequinone. Consequently, this enzyme 
is  a  popular  target  for  inhibition  in  treating  subjects  with 
hyperpigmentation (5).

Melasma is quite common, yet the precise pathogenesis 
is not fully understood. It is thought that sun exposure is the 
most  common  trigger.  Mechanistically,  the  thought  is  that 
sunlight  stimulates  nitric  oxide  production,  which  increases 
melanocyte  tyrosinase  activity,  thereby  increasing  melanin 
production, resulting in patches of hyperpigmentation in sun-
exposed skin. The second most common trigger is believed to 
be estrogen, with a predilection often observed in pregnancy, 
oral  contraceptive  use,  or  hormone  replacement  therapy. 
Pregnancy-associated  melasma  often  clears  within  several 
months postpartum, whereas the other forms may take years (6). 
Topical hydroquinone is the gold standard treatment. A novel 
formulation, described by Kligman and Willis in 1975, utilizes 
hydroquinone  in  combination  with  a  topical  corticosteroid 
and topical retinoid to provide additional depigmentation (7). 
Many alternative therapies have been investigated, including 
kojic acid, azelaic acid, and glycolic acid (8).

Ascorbic  acid  is  a  known  tyrosinase  inhibitor.  It  also  is 
known to prevent the absorption of UV light. Finally, it acts as 
an antioxidant, preventing free radical generation and thereby 
preventing  increased  melanin  production  (9).  Espinal-Perez 
et al. conducted a double-blind randomized trial that assessed 
the  efficacy  of  5%  ascorbic  acid  versus  4%  hydroquinone  in 

* Eumelanin and pheomelanin.

treating 16 women with melasma. Participants included in the 
study  had  bilateral  and  symmetric  facial  melasma,  and  were 
instructed  to  apply  hydroquinone  to  one  side  of  the  face  and 
ascorbic acid to the other side daily for 16 weeks. Endpoints of the 
study were subjective assessment by the patient† and objective 
colorimetric assessment. Of the participants, 62.5% rated their 
response  to  ascorbic  acid  as  “very  good”  or  “good,”  whereas, 
93.75% rated their responses to hydroquinone as “very good” 
or “good.” Objective colorimetry found no difference in success 
rates between the two compounds. However, this may be due 
to several factors including the small sample size or the short 
16-week endpoint. Notably, positive results from hydroquinone 
were  visible  within  the  first  month  of  treatment,  while  posi-
tive  results  from  ascorbic  acid  were  not  noticeable  until 
month  three.  Greater  than  two-thirds  of  patients  experienced 
skin  irritation  from  the  hydroquinone,  and  only  one  patient 
experienced  irritation  from  the  ascorbic  acid.  The  authors 
propose  that  a  higher  percentage  ascorbic  acid  solution  will 
likely produce more dramatic results. Ascorbic acid is known 
to be an unstable molecule. It is possible that as ascorbic acid is 
better stabilized in cream or solution formulation, it will have a 
greater efficacy. Hakozaki et al. conducted several in vitro and 
in vivo studies assessing the impact of niacinamide‡ on mela-
nin  and  hyperpigmentation.  Regarding  the  in  vivo  studies, 
investigators determined that niacinamide does not impact the 
activity of mushroom tyrosinase,§ nor does it impact melanocyte 
production  of  melanin.  Interestingly,  the  final  in  vivo  study 
demonstrated  that  niacinamide  inhibits  transfer  of  melano-
some  from  melanocytes  to  keratinocytes,  when  melanocytes, 
keratinocytes,  and  niacinamide  are  cultured  together.  Two 
keratinocyte  cell  lines  were  used  and  melanin  transfer  was 
inhibited by 35% in one cell line and 68% in the other. Two in 
vivo  clinical  studies  were  conducted  assessing  the  efficacy  of 
niacinamide at reducing hyperpigmentation. Study 1 involved 
18  Japanese  women  with  areas  of  facial  hyperpigmentation—
slight–moderate  solar  lentigines,  melasma,  or  freckles—who 
applied 5% niacinamide moisturizer to one side of the face and 
the vehicle to the other side, for 8 weeks. Study 2 included 120 
Japanese women with “moderate to deep facial tan,” randomized 
to one of three groups. Group 1 members applied the vehicle to 
one side of the face and sunscreen to the other. Group 2 mem-
bers applied sunscreen to one side of the face and 2% niacina-
mide + sunscreen to the other side. Group 3 members applied 
the vehicle to one side of the face and 2% niacinamide + sun-
screen to the other. Outcome measures included objective imag-
ing with computer analysis of percent change in pigmentation, 

† Subjectively rated as “very good,” “good,” “moderate,” and “mild” in 
terms of improvement.
‡ Activated vitamin B3.
§ Enzyme responsible for the rate limiting step in melanin formation.

154 

 TEXTBOOK OF COSMETIC DERMATOLOGY

visual  assessment  by  blinded  judges,  and  self-assessment.  In 
study  1,  all  three  outcome  measures  demonstrated  a  greater 
reduction  in  pigmentation  with  niacinamide  as  compared  to 
the vehicle, with the greatest difference observed with objective 
image analysis. In study 2, the lightening ability of niacinamide 
+ sunscreen compared to sunscreen alone on “tan” skin was less 
conclusive. Self-assessments did not demonstrate a significant 
difference  between  the  two  arms  of  the  study.  However, 
imaging  with  objective  computer  analysis  did  demonstrate  a 
statistically  significant  difference  between  sunscreen  +  nia-
cinamide  and  sunscreen  alone  in  lightening  capacity  at  4 
weeks; however, at 8 weeks, the difference between these two 
categories were no longer significant. Both the niacinamide + 
sunscreen and sunscreen alone showed significant lightening 
capacity compared to the vehicle alone at 4 and 8 weeks (10).

Hakozaki et al. performed a subsequent in vivo clinical 
trial that explored the efficacy of ascorbyl gluocoside (AG)* plus 
niacinamide,  in  conjunction  with  sonophoresis,  in  treating 
hyperpigmentation.  The  subjects  were  60  Japanese  women 
with  bilateral  facial  hyperpigmentation—solar  lentigines, 
melasma,  or  freckles.  A  5  MHz  ultrasound  device  set  at  an 
intensity of 0.7 W/cm2 and the gel containing 2 AG and 3.5% 
niacinamide  were  used.  The  subjects  were  divided  into  two 
groups of 30. Group 1 applied 2.6 mL of the gel to one side of 
their face and used the ultrasound for 10 minutes nightly, and 
applied  nothing  to  the  other  side  of  their  face.  Group  2  used 
the gel and ultrasound on one side as described above, and gel 
only on the other side. The duration of the study was 4 weeks. 
Results of the study were measured in a variety of manners, 
though  most  telling  was  the  high  resolution  digital  imaging 
with  computer  quantification  of  pigmentation  reduction.  In 
group  1,  the  side  of  the  face  treated  with  ultrasound  and  gel 
showed  a  9.4%  greater  reduction  in  pigmentation  compared 
to  the  no-treatment  side.  In  group  2,  the  ultrasound  plus 
gel  demonstrated  a  4.8%  greater  reduction  in  pigmentation 
when  compared  to  gel  alone.  This  implies  that  not  only  are 
niacinamide and AG effective at reducing hyperpigmentation, 
but  that  ultrasound  is  likely  responsible  for  approximately 
half of the efficacy.† No adverse effects were reported by any 
subjects during the study (11). Interestingly, there is a cream, 
Fair & Lovely, that was launched in Kenya, and is now avail-
able worldwide, that contains niacinamide and ascorbyl phos-
phate, among other ingredients (8).

Assorted plant extracts are potent inhibitors of melanin 
formation  and  many  have  been  investigated  as  potential 
depigmenting  agents.  The  bioflavonoids  as  a  class,  and 
specifically  the  flavanones,  have  been  identified  as  potent 
tyrosinase  inhibitors  (12).  Flavanones,  including  hesperidin, 
eriodictyol, and naringenin, have a chemical structure similar 
to hydroquinone. In a study by Zhang et al., hesperidin, found 
in  the  peel  and  membranes  of  citrus  fruits,  was  applied  to 
melanoma B16 cells and human primary melanocytes. A dose-
dependent  inhibition  of  tyrosinase  activity  versus  control 
was  observed  (13,14).  Flavonoids  from  licorice  roots,  such  as 
glabrene, glabridin, and isoliquiritigenin, have also been found 
to  inhibit  tyrosinase  (15).  In  one  study,  glabridin  applied  to 
cultured B16 murine melanoma cells at concentrations from 0.1 
to 1.0 µg/mL-1 inhibited tyrosinase activity without affecting 
DNA synthesis (16,14).

The licorice extract liquiritin, another flavonoid, was also 
found to be effective in decreasing skin pigmentation. In a clinical 
trial, 2% liquirtin cream at a dose of 1 g day-1 was applied to 20 
women with melasma for 4 weeks. Eighty percent of the treated 
cases had a reported excellent response (17). Of note, liquiritin 
does not inhibit tyrosinase activity. Depigmentation is thought 
to be secondary to melanin dispersibility and epidermal stain-
removing  property.  Pycnogenol,  a  flavonoid-containing  bark 
extract, has also decreased pigmentation in melasma patients. 
In  a  study  of  30  women  with  melasma,  a  25-mg  pycnogenol 
tablet  taken  three  times  daily  led  to  a  statistically  significant 
decrease in melasma pigmentation, as measured by the average 
pigment intensity and average melasma area (18).

in 

A  recent  study  by  Yamakoshi  et  al.  studied  the  effects 
of  grape  seed  extract 
treating  melasma-associated 
hyperpigmentation.  Twelve  Japanese  women  with  melasma 
took  proanthocyanidin-rich  grape  seed  extract  three  times 
daily for between 6 and 12 months while not using any other 
treatments for their melasma. There was a significant decrease 
in their melasma as measured by reflectance spectrophotometry 
and clinical parameters as compared to baseline (19).

Arbutin,  a  hydroquinone  derivative  found  in  the 
bearberry  plant,  has  been  found  to  inhibit  tyrosinase  and 
DHICA  (5,6-dihydroxyindole-2-carboxylic  acid)  polymerase 
activities  (20),  possibly  through  competitive  inhibition  (14). 
A clinical trial of topical deoxyarbutin (dA,4-[tetrahydrofuran-
2-yl-oxy]-phenol)  applied  to  solar  lentigines  for  12  weeks  led 
to  significant  lightening  in  light-skinned  individuals  and 
minimal  lightening  in  dark-skinned  individuals  (21).  Alpha-
arbutin  (4-hydroxyphenyl  alpha-glucopyranoside)  exhibits 
greater chemical stability and stronger inhibition of tyrosinase 
when compared to arbutin (22).

Multiple  in  vitro  studies  were  conducted  to  investigate 
the inhibitory capacity of aloesin, an aloe extract, on tyrosinase. 
First,  experimenters  looked  at  aloesin’s  inhibitory  capacity 
on  fungal,  murine,  and  human  tyrosinase,  and  compared 
to  it  to  two  well-known  tyrosinase  inhibitors,  arbutin  and 
kojic acid. Aloesin was consistently shown to be a less potent 
inhibitor  than  kojic  acid  and  a  more  potent  inhibitor  than 
arbutin.  Additionally,  aloesin  was  shown  to  inhibit  melanin 
production in a dose-dependent fashion in murine melanoma 
cells,  stimulated  with  alpha-MSH.  Specifically,  aloesin  was 
shown  to  inhibit  both  the  tyrosine  hydroxylase  and  DOPA 
oxidase reactions. However, aloesin dissolved in ethanol when 
applied to cadaveric skin was found to have poor penetration. 
Subsequently, the authors conducted a preliminary trial‡ that 
demonstrated  a  localized  decrease  in  melanin  production 
when  a  hydrophilic  patch  impregnated  with  1%  aloesin  was 
applied to human volunteers’ skin (5).

Khan  et  al.  conducted  in  vivo  and  in  vitro  studies 
exploring the efficacy of extracts from two plants known to have 
medicinal  properties.  Cassia  fistula,  also  known  as  the  golden 
shower tree, is a yellow-flowering tree, previously described in 
Indian literature in the treatment of a variety of skin conditions, 
including boils, leprosy, ringworm, and burning skin sensation. 
Hippophae  rhamnoides,  common  sea- buckthorn,  is  a  berry-pro-
ducing shrub found throughout Europe whose medicinal prop-
erties were discovered over 1000 years ago. Extracts from both of 
these plants—found to be rich in the antioxidant catechin, part 
of the flavenoid  family, were tested.§ This was a single-blinded, 

* Vitamin C derivative.
† Group 1: 9.4% difference between gel+US and no treatment. Group 
2:  4.8%  difference  between  gel+US  and  gel  alone.  Efficacy  of  gel  is 
9.4% – 4.8% = 4.6%.

‡ Data not available in this study.
§  Formulation  1  (F1)  =  H.  rhamnoides  extract,  F2  =  C.  fistula  extract, 
F3 = placebo.

 
ALTERNATIVE AND NATURAL TREATMENTS IN DERMATOLOGY 

  155

12 week study that involved 50 Asian subjects with melasma, 
divided into two groups of 25 subjects each. One group applied 
H. rhamnoides to one cheek (referred to as F1) and C.  fistula (F2) 
to  the  opposite  cheek,  while  the  other  group  applied  F2  to 
one  cheek  and  placebo  to  the  other;  both  groups  applied  the 
formulation  twice  daily.  Skin  pigmentation  was  measured 
objectively by the Mexameter®, a spectrophotometer sensitive 
to the presence of melanin. Results at 12 weeks were significant 
for a mean melanin reduction of 16.35% in those using F1, the 
H.  rhamnoides  formulation,  and  a  reduction  of  13.0%  in  those 
using F2, the C. fistula formulation. The side of the face receiv-
ing F3, the placebo, actually showed mild increases in melanin. 
Side effects of F1 and F2 were limited to mild to moderate itch-
ing  and  skin  irritation  experienced  by  approximately  10%  of 
patients (23).

Just as the golden shower tree and common sea-buckthorn 
are known to be rich in tyrosinase-inhibitory catechins, Acacia 
nilotica,  a  tree  long  reputed  for  its  medicinal  properties,  is 
known  to  possess  similar  phenolic  catechin  compounds.  Ali 
et al. conducted a 12-week, blinded, controlled study assessing 
the efficacy of Acacia bark extract in reducing skin pigmentation 
and erythema content in 11 subjects. Subjects applied the vehicle 
to one side of the face and the experimental cream to the other 
twice daily. Skin melanin and erythema content were measured 
using  the  Mexameter  spectrophotometer  every  other  week. 
Throughout the study, the Acacia extract cream produced con-
tinuous reduction in erythema and melanin content, while the 
control cream did not. At the conclusion of the study, there was a 
statistically significant reduction in skin melanin and erythema 
content  when  the  active  cream  was  used  and  insignificant 
reductions when the control cream was used (24).

Keratinocyte phagocytosis of melanosomes, regulated by 
protease-activated receptor 2 (PAR-2), has been confirmed to be 
an important biochemical pathway in pigmentation regulation. 
Serine  protease  inhibitors  found  in  soybeans—soybean  tryp-
sin inhibitor (STI) and Bowman-Birk protease inhibitor (BBI)—
modulate this pathway, potentially resulting in depigmentation. 
Wallo et al. conducted a 12-week, parallel, randomized, double-
blind,  and  vehicle-controlled  study  involving  63  subjects  with 
evidence of photoaging, and compared the effects of a facial mois-
turizer with sunscreen, STI, and BBI to one with only sunscreen 
when applied twice daily. The study endpoint was improvement 
in  skin  tone*  and  texture,†  as  evaluated  by  the  patient,  derma-
tologist, and digital photography with colorimetry. While both 
groups  showed  clinical  improvement,  the  experimental  group 
showed a statistically significant greater improvement than the 
control group in skin tone and texture as per dermatologist eval-
uation. However, objective colorimetry found no significant dif-
ference (25). See Table 17.1 for alternative treatments.

ONYCHOMYCOSIS
Onychomycosis is a condition that results in disfigurement of 
the  nails,  and  can  often  be  embarrassing  (26).  In  addition  to 
social and emotional ramifications, there are medical concerns, 
including  secondary  bacterial  infection,  pain,  and  spread  of 
infection to others (27). Onychomycosis is responsible for one-
third of all fungal skin infections and approximately one-half of 
all nail disease. Trichophyton rubrum is the most common caus-
ative organism, primarily infecting the nail bed and underside 

of  the  nail  plate  (26).  While  oral  systemic  treatments  have 
been the traditional choice and are among the most effective 
in  treating  this  condition,  they  are  associated  with  a  higher 
rate of adverse effects and drug–drug interactions than other 
treatment  modalities  (28).  This  section  addresses  the  alterna-
tive therapies that can be used in managing onychomycosis.

Ciclopirox
Ciclopirox is a “substituted pyridone” topical agent with broad 
antifungal activity. Its exact mechanism of action is unknown; 
however, it is thought to exert its antifungal effects by interfer-
ing with fungal transmembrane transport as well as DNA and 
RNA synthesis (29).

Two  U.S.,  multicenter,  randomized,  double-blind,  vehicle 
controlled studies, conducted with similar protocols, were per-
formed  to  assess  the  efficacy  of  Ciclopirox  8%  lacquer  in  the 
treatment of toenail onychomycosis. Four hundred sixty subjects 
with 20%–65% involvement of the target nail were included in 
the study and randomized to apply the Ciclopirox or vehicle to 
all nails daily for 48 weeks. The mycological cure, defined as neg-
ative culture and KOH stain, was 34% for the Ciclopirox group 
and 10% for the vehicle group. Treatment cure rate, defined as 
100%  clearance  of  clinical  signs  of  fungal  infection  as  well  as 
negative culture and KOH, was 7% for the Ciclopirox group com-
pared to less than 1% in the vehicle group (30).

Friedlander et al. conducted a prospective, randomized, 
double-blinded, vehicle-controlled study assessing the efficacy 
of Ciclopirox 8% nail lacquer in treating toenail onychomycosis 
without matrix involvement, in a pediatric population. Of the 
40 subjects enrolled in the study, 30 were assigned to the exper-
imental  arm  and  10  were  assigned  to  the  vehicle  arm  of  the 
study.  Subjects  applied  their  assigned  lacquer  to  all  toenails 
daily for 32 weeks, and 7/9 of the subjects in the vehicle arm 
were crossed over to the experimental arm at week 12, for lack 
of noticeable improvement. Results at 32 weeks were as follows: 
34% of the Ciclopirox group achieved complete cure,‡ 71.4% of 
the Ciclopirox group achieved effective treatment (defined as 
>50%  clearance  and  negative  culture),§  none  of  the  crossover 
subjects achieved complete cure, and the two subjects remain-
ing in the vehicle group achieved complete cure. Of those who 
achieved complete cure at 32 weeks, 92% remained disease free 
at 1 year follow-up. Authors of the study suggest that the thin-
ner and potentially faster growth rate of nails in the pediatric 
population may be part of the explanation for the higher effi-
cacy in this treatment population than in adults. Additionally, 
given the two children achieving complete cure in the vehicle 
arm, watchful waiting may be a feasible option in the pediat-
ric population. Interestingly, T. rubrum was found to be more 
resistant to treatment than other infectious fungi (31).

Tea Tree Oil
Several studies have been performed to assess the efficacy of 
tea  tree  oil  in  the  treatment  of  onychomycosis.  Tea  tree  oil  is 
derived  from  the  Australian  tree  Melaleuca  alternifolia,  and 
the active ingredient is Terpinen-4-ol (32).

A double-blind, multicenter, randomized controlled trial 
involving  117  subjects  with  distal  subungual  onychomycosis 
compared the efficacy of 1% clotrimazole solution to 100% tea 

*  Improvement  in  skin  tone  defined  as  reduction  in  mottled  hyper-
pigmentation, lentigines, and blotchiness with increase in brightness.
† Improvement in skin texture defined as reduction in surface rough-
ness or improvement in fine lines and wrinkling.

‡ Complete cure is defined as IGA (Investigator’s Global Assessment) 
score of 0 and negative culture. IGA ranges are: 0 (complete clearance); 
1 (75%–99% clearance); 2 (50%–74% clearance); 3 (<50% clearance); 4 (no 
change); and 5 (worsening).
§ Effective treatment is defined as IGA score <2 and negative culture.

 
156 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 17.1  Alternative Treatments for Hyperpigmentation

Alternative Medication

Study Type

Experimental Result

Source

Acacia bark extract

In vivo, blinded, controlled

In vivo - double-blind, 
randomized

Decrease melasma 
pigmentation

(Espinal-Perez et al. 2004)

Aloesin

Arbutin

Ascorbic acid

Ascorbyl glucoside with 
sonophoresis
Deoxyarbutin

Glabridin

C. fistula and H. rhamnoides

Grape seed extract

Hesperidin

Liquirtin

Niacinamide

In vitro

In vitro

In vivo

In vivo

In vitro

In vitro and in vivo (single 
blinded)

In vivo—open design study

In vitro

In vivo—clinical trial

In vitro and in vivo

Decrease melanin and 
erythema

(Ali, Akhtar et al. 2012)

Decrease tyrosinase activity

(Jones et al. 2002)

Decrease tyrosinase and 
DHICA

(Chakraborty, Funasaka et al. 
1998)

Decreases hyperpigmentation

(Hakozaki et al. 2006)

Decreases solar lentigines

(Boissy, Visscher et al. 2005)

Inhibit tyrosinase

Tyrosinase inhibition (in vitro)
Reduction in melanin (in vivo)

(Fu, Li et al. 2005)

(Khan et al. 2013)

Decrease melasma 
pigmentation

Inhibit tyrosinase

Decrease melasma 
pigmentation

Inhibition of melanosome 
transfer from melanocytes to 
keratinocytes (in vitro)
Pigmentation reduction (in 
vivo)

Decrease melasma 
pigmentation

(Yamakoshi, Sano et al. 2004)

(Zhang, Zhu et al. 2008)

(Amer and Metwalli 2000)

(Hakozaki et al. 2002)

(Ni, Mu et al. 2002)

Pycogenol

In vivo

Soybean—soybean trypsin 
inhibitor and Bowman-Birk 
protease inhibitor

In vivo—parallel, randomized, 
double-blind, vehicle 
controlled

Improvement in skin tone and 
texture

(Wallo et al. 2007)

Another 

tree oil in treating this condition. Patients were instructed to 
apply  the  assigned  solution  to  the  affected  nails  twice  daily 
for  6  months,  with  follow  up  at  1-,  3-,  and  6-month  intervals 
for clipping and debridement. Outcome measures were fungal 
culture,  clinical  appearance,  and  subjects’  perception  of 
appearance and symptoms at 9 months after initiation. Of the 
108  participants  to  complete  the  trial,  one-half  to  two-thirds 
demonstrated  clinical  improvement  or  reported  subjective 
improvement of their fungal nail infection, without statistically 
significant  differences  between  the  two  groups.  Analysis  of 
fungal  culture  results  was  limited  due  to  35%  dropout  at  6 
months, when the culture was to be performed (32).
double-blinded, 
randomized, 

placebo-
controlled study involving 60 patients compared the efficacy 
of  5%  tea  tree  oil  with  2%  butenafine,  a  phenol-substituted 
benzylamine derivative, which has been shown in prior stud-
ies  to  have  fungicidal  effects  vs.  5%  tea  tree  oil  alone  in  the 
treatment of toenail fungal infections. Mycological cure was 
defined as negative fungal culture and potassium hydroxide 
stain,  clinical  cure  was  defined  as  100%  remission  or  >  90% 
improvement, and overall cure was defined as both mycologi-
cal  and  clinical  cure.  Patients  applied  their  assigned  cream 
three  times  daily  to  the  affected  toenail  for  8  weeks,  with 
debridement  of  the  nails  occurring  as  deemed  necessary  by 
the  examiners.  They  were  evaluated  on  a  weekly  basis  for 
the  first  16  weeks,  then  monthly  until  week  36.  Eighty  per-
cent  (32/40)  of  the  experimental  group  achieved  overall 
cure,  while  none  of  the  control  group  (0/20)  achieved  over-
all cure. Mild inflammation was the only reported side effect. 

The investigators suggested that 8 weeks may not have been a 
long enough duration for tea tree oil to achieve its full effect, 
explaining its lack of efficacy in this study (33).

Vicks® VapoRub
Vicks  VapoRub  has  been  reported  as  a  folk  remedy  for 
onychomycosis. Ramsewak et al. conducted an in vitro study 
investigating  the  inhibitory  activity  of  both  the  active  and 
inactive ingredients found in VapoRub on fungal  pathogens 
which  cause  onychomycosis.  The  study  demonstrated  that 
camphor,  menthol,  thymol,  and  Eucalyptus  citriodora  oil 
( composed  of  monoterpenes)  are  all  effective  inhibitors 
when used singly as well as when used in combination (34). 
Disruption  of  the  fungal  cell  membranes  and  inhibition 
of  ergosterol  synthesis  by  thymol  and  monoterpenes  has 
been  suggested  as  the  mechanism  of  action  in  laboratory 
studies (35,36).

A  clinical  case  series  examined  the  effect  of  daily 
topical  application  of  VapoRub  in  18  human  subjects  with 
clinically  confirmed  and  culture-positive  fungal  nail  infec-
tions.  Outcome  measures  at  the  study  endpoint  of  48  weeks 
were defined as “mycological cure,” based on KOH and nail 
sample  cultures,  and  “clinical  cure,”  which  could  be  either 
“complete,”  “partial,”  or  “no  change,”  dependent  on  the 
appearance of the nail. Five subjects experienced mycological 
cure, ten demonstrated partial clinical cure, and three showed 
no  significant  change.  Interestingly,  the  six  subjects  who 
were  culture-positive  for  T.  rubrum,  the  most  common  caus-
ative pathogen of onychomycosis, had only “partial cure” or 

 
ALTERNATIVE AND NATURAL TREATMENTS IN DERMATOLOGY 

  157

“no change,” whereas the five individuals who demonstrated 
“complete cure” were culture-positive for either Candida para-
silosis or Trichophyton mentagrophytes (37).

Tavaborole
Tavaborole  is  a  boron-containing  compound  developed  by 
Anacor Pharmaceuticals (Palo Alto, CA) that has been shown 
to inhibit a fungal enzyme needed for fungal protein synthesis. 
Two  phase  III  trials—approximately  600  subjects  per  trial—
assessing  the  efficacy  of  topical  application  of  tavaborole  in 
treating onychomycosis were recently completed and demon-
strated promising results (38). Primary publication data could 
not be found with a Pubmed search for “Tavaborole,” however, 
a recent review article quoted complete cure* rate of 6.5% in the 
treatment arm versus 0.5% in the vehicle arm (39).

Efinaconazole
Efinaconazole  is  the  first  triazole  antifungal  developed  for  the 
treatment of onychomycosis. Two identical multicenter, random-
ized,  double-blind,  vehicle-controlled  studies  involving  a  total 
of 1655 subjects were conducted to assess the efficacy of topical 
efinaconazole  10%  solution  in  treating  onychomycosis.  Subjects 
were  randomized  to  efinaconazole  or  vehicle  and  applied  the 
assigned  solution  daily  for  48  weeks  and  were  evaluated  at  52 
weeks, with endpoints defined as complete cure† or treatment suc-
cess.‡ In studies 1 and 2, 18% and 15% of subjects in the treatment 
arm achieved complete cure, respectively. Complete cure rate was 
only 3% and 6% in the vehicle arm in studies 1 and 2, respectively. 
For  those  treated  with  efinaconazole,  treatment  success  was 
achieved in 45% and 40% in studies 1 and 2, respectively, whereas 
only 17% (study 1) and 15% (study 2) reached treatment success in 
the vehicle arm. Given the high treatment success rate achieved 
with efinaconazole at 48 weeks and that toenails may take up to 
78  weeks  for  completely  new  growth,  the  authors  suggest  that 
longer  treatment  duration  may  increase  complete  cure  rates. 
Additionally, the authors commented that given the minimal side 
effect profile of efinaconazole, it could be used as a maintenance 
medication or adjunct to prevent recurrence of onychomycosis in 
those previously treated with systemic therapy (40).

Photodynamic Therapy
Photodynamic therapy (PDT) refers to the use of light-activated 
compounds that react with a certain wavelength of light to pro-
duce oxygen free radicals which interact with cells, resulting in 
cell damage and/or death (41). While the U.S. Food and Drug 
Administration (FDA) has not approved PDT for the treatment 
of  onychomycosis  (42),  there  is  evidence  to  suggest  that  PDT 
likely has a role and can be used in treating this condition.

An in vitro study by Smijs’ et al. demonstrated the fungi-
cidal activity of certain photosensitizing porphyrin molecules 
when  exposed  to  wavelengths  of  light  in  the  red  spectrum. 
Notably, PDT was demonstrated to not only eradicate the fun-
gal hyphae, but to also inactivate the T. rubrum spores, which 
have  been  implicated  in  the  recurrence  of  tinea  unguium 
infections after treatment with traditional oral agents. Use of 
red  light  has  the  additional  benefit  of  increased  tissue  pene-
tration when compared to white light, making it an attractive 
agent for treating fungal nail, which requires adequate tissue 
penetration (41).

* See footnote 14.
† Complete cure defined as 0% clinical involvement of the nail, as well 
as negative culture and KOH stain.
‡ Treatment success defined as <10% clinical involvement of the nail.

A subsequent in vitro study demonstrated that T. rubrum, 
when  exposed  to  5-aminolevulinic  acid  (5-ALA),  generates 
the  photosensitizing  molecule  protoporphyrin  IX,  which  can 
be  irradiated  with  red  wavelengths  of  light—636nm  and 
708nm—resulting in a nearly 50% inhibition of fungal growth 
compared to control (43).

Utilizing  the  technology  discussed  above,  there  have 
been several in vivo case reports of successfully treated ony-
chomycosis  using  PDT.  One  case  was  that  of  a  78-year-old 
woman  with  onychomycosis  of  the  bilateral  great  toenails. 
Treatment  included  removal  of  the  affected  nails  after  soft-
ening with 40% urea ointment, application of 5-ALA (Metvix 
160 mg/g) cream, and irradiation with 37 J/cm2 light-emitting 
diodes in the red spectrum—630nm wavelength. This regimen 
was  repeated  every  15  days  for  45  days,  totaling  three  treat-
ment  sessions.  While  KOH  stain  and  cultures  were  positive 
immediately after the last session, follow-up at months three 
through month 24 demonstrated complete mycologic and clini-
cal resolution of the infection (44).

Additionally,  two  case  reports  of  successfully  treated 
onychomycosis  involving  urea,  5-ALA,  and  irradiation  with 
red  light  have  been  described  by  Watanabe  et  al.  However, 
in  these  cases,  20%  urea  was  used  to  soften  the  nail  without 
subsequent  removal  and  an  excimer-dye  laser  with  a  fluence 
of  100  J/cm2  at  630nm  wavelength  was  used.  While  the  laser 
caused “some pain” for the patients during treatments, it was 
temporary  in  nature,  and  the  laser  was  chosen  as  the  light 
source  due  to  its  greater  tissue-penetrating  capabilities  than 
other light sources. One patient required seven treatments and 
the other required six treatments with no recurrence of infec-
tion recorded at 6-month and 3-month follow-ups, respectively 
(45).

Sotiriou et al. conducted a single-center open trial involv-
ing  30  Caucasian  subjects  with  diagnosed  toenail  onycho-
mycosis.  Therapeutic  regimen  included  treatment  with  20% 
topical  urea  cream  with  subsequent  removal  of  the  affected 
nail, 3-hour treatment with 20% 5-ALA, and irradiation with a 
noncoherent, 40 J/cm2 dose of red light ranging in wavelength 
from 570–670nm. Three treatments were performed at 2-week 
intervals for 6 weeks. During irradiation, approximately one-
third  of  patients  endorsed  pain  or  burning  requiring  a  brief 
interruption, and almost all patients experienced other minor 
side  effects  such  as  erythema,  edema,  and  blistering  around 
the  site.  Cure  at  12  and  18  month  follow-up  was  defined  as 
“100%  absence  of  clinical  signs”  or  “subungual  hyperkerato-
sis”  affecting  less  than  10%  of  the  nail  plate  with  “negative 
mycological  laboratory  results.”  This  study  demonstrated  a 
cure rate of 43.3% (13/30) at 12 months and 36.6% (11/30) at 18 
months, suggesting that PDT is somewhat efficacious, though 
room for improvement exists (46).

Laser Therapy
In  addition  to  PDT,  many  studies  have  begun  exploring  the 
therapeutic  effect  of  lasers  on  onychomycosis.  The  following 
in vitro study by Vural et al. investigated the effects of a vari-
ety  of  laser  systems,  wavelengths,  and  fluences  on  T.  rubrum 
growth  inhibition.  T.  rubrum  colonies  were  grown  on  culture 
plates  and  irradiated  by  a  variety  of  lasers,  with  fungal  col-
ony  size  and  growth  rate  measured  on  days  1,  3,  and  6  post-
irradiation.  While  a  majority  of  the  lasers  were  ineffective  at 
inhibiting growth, the Q-switched Nd:YAG laser used at inde-
pendent wavelengths of 532nm and 1064nm, with varying flu-
ences, both retarded fungal growth. The authors suggest that 
the  growth  retardation  observed  with  532nm  irradiation  is 

 
158 

 TEXTBOOK OF COSMETIC DERMATOLOGY

likely due to xanthomegnin, a T. rubrum pigment that absorbs 
in that spectrum, leading to “photothermolysis,” as opposed to 
“nonspecific thermal damage.” Similarly, irradiation with the 
1064nm  wavelength  is  postulated  to  cause  its  “photothermo-
lytic” damage due to absorption by melanin, a pigment found 
in the cell walls of T. rubrum. The Q-switched Nd:YAG laser’s 
“short pulse width” adds to its inhibitory effects on T. rubrum 
growth by inducing thermal and mechanical damage via rapid 
heating and cooling, as well as “acoustic shock wave” produc-
tion, respectively. Fluences chosen in this study were similar in 
energy to fluences used in other dermatologic procedures, such 
as port-wine stain and unwanted hair or  tattoo removal (47).

A subsequent clinical study demonstrated strong efficacy 
of the VSP long pulse Nd:YAG 1064nm laser therapy in treat-
ing  four  different  types  of  onychomycosis—total  dystrophic 
form, distal, proximal, and endonyx—in 72 patients with 194 
affected nails caused by T. rubrum, T. mentagrophytes, Candida, or 
Aspergilus niger. After microscopic and culture confirmation of 
positive fungal infection, subjects underwent four sessions—
three irradiations during each session—at 1-week intervals, in 
which affected nails were irradiated at fluences of 35–40 J/cm2, 
pulse  duration  35ms,  and  rate  1Hz.  Variation  in  fluence  was 
due to variations in nail thickness, with thicker nails requiring 
higher fluence. Three participants had particularly thick nails, 
which were pretreated with a urea preparation to improve laser 
penetration.  Nail  plate  temperatures  were  raised  to  45+5oC, 
with cold air cooling used during treatments, with the majority 
of patients rating their pain as “mild,” none rating their pain as 
“severe” or “intolerable.” At 3-month follow-up, 69/72 subjects 
were cleared of fungal infection and the three affected subjects 
repeated the therapeutic protocol. All 72 subjects were free of 
infection  at  6-  and  12-month  follow-ups.  The  mechanism  of 
action  underlying  this  therapy  is  in  line  with  the  previously 
discussed  theory  that  1064nm  wavelengths  are  absorbed  by 
fungal cell wall melanin, leading to “local hyperthermia,” and 
consequent fungal destruction. This study extrapolates on the 
“local hyperthermia” and destruction, suggesting that thermal 
injury likely results in a combination of fungal DNA damage, 
production  of  reactive  oxygen  species,  and  protein  denatur-
ation, all triggering fungal cell apoptosis, leading to mycologi-
cal cure (48).

Kalokasidas  et  al.  conducted  a  clinical  study  involving 
131  subjects,  investigating  the  inhibitory  effects  when  both 
1032nm  and  532nm  wavelengths  are  used  together.  Prior  to 
irradiation,  the  severity  of  onychomycosis  was  graded  and 
subjects’  affected  nails  were  mechanically  debrided  with  a 
nail file. Using the Q-switched Nd:YAG 1064nm/532nm laser, 
affected nails were first irradiated with a 1064nm wavelength 
laser,  received  a  2-minute  break,  and  then  irradiated  with  a 
532nm wavelength laser. Participants attended two treatment 
sessions—on days 0 and 30—and the above regimen was con-
ducted  during  each  session.  The  results  of  this  study  reflect 
that  of  the  prior  study,  with  125/131  subjects  demonstrating 
mycological cure (negative microscopy and culture) at 3-month 
follow-up. Notably, of the types of onychomycosis, “distal sub-
ungual”  demonstrated  the  best  response  to  treatment  and  of 
the  infecting  organisms,  T.  rubrum  showed  the  most  prompt 
response.  Given  the  promising  results,  if  laser  therapy  does 
not supplant systemic therapy, it could potentially be used in 
conjunction with it, reducing treatment duration. This study’s 
clinical  outcomes  have  yet  to  be  fully  assessed  at  12-month 
follow-up,  and  as  the  authors  point  out,  negative  cultures  do 
not always equate with mycological cure, as there is high false 
negative rate (27).

While  many  studies  have  shown  laser  therapy  to  be 
efficacious  in  the  treatment  of  onychomycosis,  a  recent  in 
vitro  and  in  vivo  study  by  Carney  et  al.  brings  the  efficacy 
of  Nd:YAG  1064nm  laser  therapy  into  question.  A  few  com-
mon  nail  dermatophytes,  including  T.  rubrum,  were  chosen 
for  the  in  vitro  portions  of  the  study.  In  phase  one  of  the  in 
vitro portion, suspensions of the fungi were heated to varying 
temperatures—45oC,  50oC,  and  55oC—for  varying  durations, 
then  plated  on  agar  and  monitored  for  growth.  T.  rubrum 
growth was retarded when exposed to 50oC for 5 minutes and 
a fungicidal effect was observed when exposed for 15 minutes. 
In phase two, T. rubrum suspensions were plated on agar, then 
irradiated  with  the  laser  at  varying  combinations  of  fluence, 
pulse width, and Hz, and temperature was recorded. In phase 
3, T. rubrum was grown on an agar plate until red pigmenta-
tion was visible; 3-mm punch biopsies of mycelium were taken 
and  transplanted  to  another  plate,  which  was  subsequently 
irradiated with the same variations as used in phase 2. In both 
phases 2 and 3, no growth inhibition of T. rubrum was noted 
after irradiation and temperatures only reached 40oC in phase 
2,  suggesting  that  prior  clinical  trials  proposing  fungicidal 
effects due to thermal destruction is unlikely. Phase 4 was the 
24-week in vivo portion of the study in which five laser treat-
ments  were  performed  on  eight  individuals  with  14  affected 
nails over the course of the initial 7 weeks. Nail assessments, 
microscopic and culture evaluation were performed intermit-
tently  throughout  the  study.  Notably,  eight  of  the  14  affected 
nails showed only mild clinical improvement, though this did 
not correlate with microscopic or culture findings, and notably, 
two  subjects  changed  Onychomycosis  Severity  Index  (OSI)* 
categories, both of which increased in disease severity. While 
recognizing  differences  in  study  protocols,  particularly  the 
wide variation in laser settings, the results of this study have 
compelled  the  authors  to  conclude  that  laser  therapy  is  thus 
far  not  a  reliable  treatment  modality  for  onychomycosis  and 
thermal damage is unlikely the mechanism underlying clini-
cal improvement when laser therapy is performed (49).

See also Table 17.2.

ATOPIC DERMATITIS
Atopic  dermatitis  is  a  common  disease  affecting  up  to  20% 
of the pediatric population and about 1%–3% of adults in the 
industrialized  world.  The  disease  is  characterized  by  pru-
ritus,  rash  on  the  extensor  surfaces  and  face  of  young  chil-
dren, lichenification of the flexural surfaces of older children, 
recurrent  skin  infections,  and  personal  or  family  history  of 
atopic disease. The pathogenesis of the disease is complex and 
multifactorial,  involving  interplay  of  genetic  susceptibility 
resulting  in  decreased  skin  barrier  and  immune  system  dys-
regulation  and  hyper-reactivity  (50).  Many  traditional  thera-
pies exist; however, side effects may limit their use (51). This 
has  prompted  a  search  for  additional,  alternative  treatment 
modalities for this condition.

Pruritus  is  a  common  symptom  of  atopic  dermatitis 
and  is  thought  to  be  due  to  increased  nitric  oxide  and  cyto-
kines. Vitamin B12 is a nitric oxide scavenger, thereby reduc-
ing  pruritic  symptoms  through  reduction  of  nitric  oxide 
levels.  A  double-blinded,  randomized,  placebo-controlled, 

*  OSI:  Area  of  involvement  is  rated  from  1–5.  Proximity  of  disease 
to  the  nail  matrix  is  rated  from  1–5.  The  two  values  are  multiplied. 
Ten points are added if a longitudinal patch or streak is present or if 
 subungual  hyperkeratosis  greater  than  2  mm  is  present.  Categories: 
Mild = 1–5, Moderate = 6–15, Severe = 16–35

 
ALTERNATIVE AND NATURAL TREATMENTS IN DERMATOLOGY 

  159

Table 17.2  Alternative Treatments for Onychomycosis

Alternative Medication

Study Type

Experimental Result

Source

Ciclopirox

Ciclopirox

Efinaconazole

Multicenter, randomized, 
double-blind, vehicle-
controlled in vivo

34% mycological cure rate; 7% 
clinical cure rate

(Gupta and Joseph 2000)

Randomized, double-blinded, 
vehicle-controlled, crossover, 
in pediatric population in vivo

34% achieved complete cure; 
72% with greater than 50% 
clearance

Multicenter, randomized, 
double-blind, vehicle-
controlled in vivo

15%–18% complete cure rate 
and 40%–45% with <10% 
clinical involvement

(Friedlander et al., 2013)

(Elewski et al., 2013c)

Laser therapy: 
Q-switched Nd: YAG
Laser therapy: 
VSP long pulse Nd: YAG
Laser therapy: 
Q-switched Nd: YAG

In vitro

In vivo

In vivo

Laser therapy: long pulsed 
Nd:YAG

In vivo and in vitro

Retardation of fungal growth

(Vural et al., 2008)

100% cure rate

(Kozarev and Vizintin, 2010)

(Kalokasidis et al., 2013)

(Carney et al., 2013)

9% with excellent clinical 
improvement and 95% 
mycological cure rate

In vitro demonstrated no fungal 
growth inhibition
In vivo showed 57% with 
clinical improvement and 43% 
without clinical improvement 
or worsening

Photodynamic therapy

Photodynamic therapy

Photodynamic therapy

Photodynamic therapy

In vitro

In vitro

Eradication of fungus

(Smijs et al., 2004)

50% Inhibition of fungal growth

(Kamp et al., 2005)

Single case report in vivo

Clinical and mycological cure

(Piraccini et al., 2008)

2 case reports in vivo

Clinical improvement and 
mycological cure

(Watanabe et al., 2008)

Photodynamic therapy

Single-center open trial in vivo

36.6% Cure rate

(Sotiriou et al., 2010)

Phase 3 clinical trials in vivo

6.5% Complete cure rate

(Anacor Pharmaceuticals)

Tavaborole

Tea tree oil (100%)

Tea tree oil (5%)

Multicenter, double-blind, 
randomized in vivo

Randomized, double-blinded, 
placebo-controlled in vivo

Improvement in 
onychomycosis

No improvement

Vick’s Vapo Rub

In vitro

Vick’s Vapo Rub

Clinical case series in vivo

Effective inhibition of fungal 
growth

28% mycological cure rate and 
55.5% partial clinical cure 
rate

(Addino et al., 1994)

(Syed et al., 1999)

(Ramesewak et al., 2003)

(Derby et al., 2011)

intra-individual study conducted in 2009 examined the effects 
of  topical  vitamin  B12  on  atopic  dermatitis  in  the  pediatric 
population.  Participants’  ages  ranged  from  6  months  to  14 
years  old.  Parents  were  instructed  to  apply  the  vitamin  B12 
cream to one side of their child’s body and the vehicle to the 
other twice daily for 4 weeks, the study duration. Efficacy of 
the creams was evaluated using the modified SCORAD scale.*
At the study’s completion, there was a statistically significant 
difference between SCORADs. When B12 was used, the aver-
age baseline SCORAD value of 13.19 decreased by 4.52 points, 
whereas  the  controls’  baseline  SCORAD  value  of  12.57  only 
decreased by 1.61 points. Side effects were minimal; 22 subjects 
started the 4-week study and 21 subjects completed the study, 

* SCORAD (SCORing for Atopic Dermatitis) scale. This is the gold stan-
dard for evaluation of atopic dermatitis disease severity. The modified 
SCORAD scale contains six objective items (erythema, edema, excoria-
tion, oozing, lichenification, and dryness) and three subjective items 
(pruritus, sleep loss, and overall parental rating), each rated from 0–3.

with one subject experiencing side effects to both the experi-
mental  and  control  creams.  A  similar  study  had  previously 
been conducted in adults. This was the first to be conducted in 
the pediatric population (51).

Oats, a secondary crop derived from a weed of the pri-
mary cereal domesticates wheat and barley (52), are commonly 
used to treat skin conditions such as atopic dermatitis. In fact, 
oatmeal has been deemed an effective skin protectant by the 
FDA (53).  In an assessor-blind study of 35 burn  wound heal-
ing patients, 5% colloidal oatmeal in a liquid paraffin suspen-
sion applied twice daily was compared to liquid paraffin alone. 
Patients applying colloidal oatmeal reported significantly less 
itch  and  required  significantly  less  antihistamine  than  those 
applying vehicle alone (54).

Essential  fatty  acids  (EFAs)  are  fatty  acids  that  need  to 
be  obtained  through  the  diet,  because  the  body  cannot  syn-
thesize  them.  As  noted  above,  immune  system  dysregula-
tion  is  thought  to  play  a  role  in  atopy,  and  it  is  known  that 
EFAs—notably  n-3  and  n-6  fatty  acids—have  a  role  both  in 

 
160 

 TEXTBOOK OF COSMETIC DERMATOLOGY

inducing  inflammation  and  modulating  it.  Previous  studies 
have suggested that having an optimal ratio of n-3 fatty acids 
to n-6 fatty acids* plays an important role in properly program-
ming the fetal and infant immune system.

Blackcurrant is a commonly cultivated berry in Europe, 
and blackcurrant seed oil (BCSO) possesses the optimal ratio 
of these EFAs. Therefore, Linnamaa et al. conducted a double-
blind, placebo-controlled trial assessing the efficacy of BCSO 
dietary  supplementation  in  preventing  the  development  of 
atopic dermatitis in infants. Pregnant women were randomly 
assigned to receive 3 g† of either BCSO or olive oil, the control. 
The pregnant women received their first dose at 8 weeks’ and 
16 weeks’ gestation, then daily through the end of the exclusive 
breastfeeding phase. After breastfeeding was complete, infants 
received the oils orally, in the form of drops, until 2 years of 
age. Infants were evaluated for atopic dermatitis at 3, 12, and 
24 months of age, and the SCORAD scale—mentioned above—
was used to assess severity. Interestingly, 81.7% of the infants 
in  this  study  had  either  one  or  two  parents  with  a  personal 
history of atopy, thereby increasing the infants’ predisposition 
to atopy. At both 3 months and 24 months of age, there was no 
statistically  significant  difference  between  the  two  treatment 
groups with regard to the atopic dermatitis rates. However, at 
12 months of age there was a statistically significant difference 
between  the  two  study  groups,  33%  and  47.3%  with  atopic 
dermatitis  in  the  BCSO  and  olive  oil  groups,  respectively. 
Additionally, according to the SCORAD, those with atopic der-
matitis  in  the  BCOS  group  had  statistically  significantly  less 
severe disease than those in the placebo group. The lack of sta-
tistically significant differences at ages 3 and 24 months may 
be explained by the general low prevalence and adoption of a 
less  healthy  diet  at  those  ages,  respectively.  Previous  studies 
have shown no side effects to blackcurrant supplements, mak-
ing this a viable option for preventing and reducing the sever-
ity of atopic dermatitis early in life (55).

Chronic inflammation associated with atopic dermatitis 
is in part thought to be associated Staphylococcus aureus coloni-
zation, and the S. aureus burden has been shown to correlate 
with eczema severity.‡ Gentian violet (GV) is a known antimi-
crobial agent, and Brockow et al. performed a study assessing 
the efficacy of topical GV, diflucortolone-21-valerate (DC),§ and 
liquor carbonis detergens (LCD)¶ in treating S. aureus–colonized 
atopic dermatitis. Twenty-one adults with S. aureus–colonized 
atopic  dermatitis  were  assigned  to  one  of  three  groups—GV, 
DC, or LCD—and were instructed to apply their assigned topi-
cal agents—active and vehicle—to both eczematous and nor-
mal skin twice daily for 4 days. The severity of the eczematous 
lesions was evaluated prior to and 2 days after completing the 
treatment  regimen  using  the  modified  SCORAD  scale,  and 
S. aureus burden was quantified daily. In patients treated with 
GV, both unaffected and eczematous skin showed statistically 
significant decreases in S. aureus density and there was a statis-
tically significant difference between those areas treated with 
GV and those treated with control. Two days after treatment, S. 
aureus density returned to pretreatment baseline. Eczematous 
patches showed statistically significant reductions in SCORAD 
values during treatment with GV, as well as control. Subjects 
treated with DC and LCD did not show significant reductions 

* Optimal n-3:n-6 is 1:3 to 1:4.
† 3 g of the oils, administered in capsule form; 6 capsules = 3 grams.
‡ Confirmed in this study as well.
§ Potent steroid.
¶ Tar solution.

in S. aureus colonization in either affected or unaffected skin 
during  the  treatment  phase,  though  interestingly,  S.  aureus 
density  decreased  2  days  following  treatment.  SCORAD  val-
ues  improved  for  the  eczematous  lesions  treated  with  DC 
and  LCD,  as  well  as  their  associated  controls;  however,  the 
improvement was more dramatic when the active agents were 
used. The in vitro portion of the study demonstrated the bac-
tericidal effect of GV on S. aureus and DC’s and LCD’s lack of 
antibacterial effects (56). Notably, a more recent case report of 
group A Streptococcus impetiginized atopic dermatitis treated 
with topical 1% GV and oral doxycycline was presented in the 
Journal of the American Academy of Dermatology. Not only did the 
GV  successfully  treat  the  infection  and  dermatitis,  it  offered 
almost instantaneous relief of the associated discomfort. The 
authors suggest that it is often difficult to distinguish whether 
or  not  the  underlying  process  is  inflammatory,  infectious,  or 
both, and GV is a viable option for treating both (57).

Evening  primrose  is  a  tall  herbal  plant  with  yellow 
flowers  that  bloom  in  the  evening.  It  was  first  described  by 
the  Native  Americans  in  17th  century  as  being  used  to  treat 
“swelling  in  the  body.”  Evening  primrose  oil  (EPO)  contains 
8%–10%  gamma-linolenic  acid  (GLA)—n-6  EFA—  and  can 
be  used  as  an  alternative  or  adjunctive  treatment  for  atopic 
dermatitis. Senapati et al. carried out a randomized, placebo-
controlled study assessing the efficacy of oral EPO in treating 
atopic  dermatitis  in  an  Indian  population.  Twenty-five  sub-
jects were enrolled in both the experimental and placebo arms 
and  instructed  to  take  age-dependent  oral  doses—in  capsule 
form—of  either  EPO  or  sunflower  oil,  respectively.  Patients 
were  followed  for  5  months  and  investigators  evaluated  par-
ticipants’  disease  monthly,  based  on  four  parameters:  extent, 
intensity,  dryness,  and  itching.  On  average,  subjects  treated 
with EPO gradually and progressively improved in all param-
eters during the course of the study, while those in the placebo 
group  on  average  demonstrated  inconsistent  improvement. 
Based on the four parameters, subjects were given a numeric 
score, and improvement was defined as receiving a score up to 
75% of baseline. At the study’s end, 96% of participants in the 
experimental arm and 32% in the placebo arm demonstrated 
improvement, which was statistically significant (58).

Despite the promising findings of PMO in the Senapati 
et al. study, a recent Cochrane Review suggests the contrary. This 
review of 19 studies, including two meta-analyses—one with 
seven  studies  and  other  with  eight  studies—concluded  that 
there  was  no  statistically  significant  difference  in  improve-
ment between those treated with oral EPO and those treated 
with  placebo.  Additionally,  side  effects  of  EPO  noted  in  the 
report were predominantly GI upset and EPO’s anticoagulant 
effects.  Therefore,  Cochrane’s  recommendation  is  that  EPO 
not be used in treating atopic dermatitis, and further studies 
evaluating the effects of EPO on atopic dermatitis “would be 
hard to justify” (59).

In  addition,  the  Cochrane  Report  reviewed  the  efficacy 
of  borage  oil  (BO)  versus  placebo  in  treating  atopic  dermati-
tis. While no meta-analysis was performed for the BO studies, 
Cochrane reviewed eight studies and concluded that BO is not 
efficacious in treating eczema (59).

Although the Cochrane Review suggests that oral supple-
mentation with BO does not improve atopic dermatitis, the fol-
lowing study suggests that topical BO likely has a role. While 
EPO contains 8%–10% GLA, BO (also known as starflower oil) 
(60),  contains  24%  GLA,  making  it  a  suitable  consideration 
for  the  treatment  of  atopic  dermatitis.  Kanehara  et  al.  con-
ducted  a  double-blind,  placebo-controlled  trial  assessing  the 

 
ALTERNATIVE AND NATURAL TREATMENTS IN DERMATOLOGY 

  161

efficacy of BO-coated undershirts in treating atopic dermatitis. 
Investigators had BO chemically bonded to cotton undershirts, 
which would be gradually released; BO remained on the shirts 
after  60  washings.  Thirty-two  pediatric  subjects  participated 
in  the  study,  with  16  assigned  to  the  BO-coated  undershirt 
group and 16 to the uncoated group. Subjects were evaluated 
by a single clinician at baseline for a variety of signs and symp-
toms  associated  with  atopic  dermatitis,*  instructed  to  wear 
the  undershirts  daily,  and  were  reassessed  2  weeks  later  for 
the same signs and symptoms. As evaluated by the clinician, 
participants in the BO group showed a statistically significant 
improvement  in  symptoms  of  “itch”  and  “erythema”  after  2 
weeks, while those in the placebo did not show statistically sig-
nificant improvement in any signs or symptoms. Notably, 75% 
of parents of children in the BO group reported symptomatic 
improvement, while 56.2% in the placebo also reported symp-
tomatic improvement. Authors speculate that the symptomatic 
improvement  observed  by  parents  in  the  placebo  group  may 
be  due  to  high  quality,  pure,  organic  undershirts  that  their 
children were wearing. Of note, those in the BO group showed 
a statistically significant decrease in transepidermal water loss 
(TEWL)  after  2  weeks  of  treatment,  while  the  placebo  group 
did not. Individuals with atopic dermatitis have defective epi-
dermal function, leading to increased TEWL and subsequent 
dry skin and associated symptoms. Therefore, the implications 
of topical BO in treating atopic dermatitis are twofold: decreas-
ing inflammation and restoring epidermal structure and func-
tion, thereby decreasing water loss (61).

Another topical agent studied for the treatment of atopic 
dermatitis  is  extract  from  Mahonia  aquifolium,  an  evergreen 
shrub  related  to  the  barberry.  In  one  study,  30  patients  with 
atopic dermatitis were treated with three times daily applica-
tion of Relieva cream, a homeopathic product containing a pro-
prietary  10%  M.  aquifolium  extract.  Eczema  area  and  severity 
index (EASI) scoring revealed significant improvement in both 
short-term (4-week) and long-term (12-week) improvement as 
compared  to  baseline  (62).  However,  no  placebo  control  was 
utilized in this study.

Traditional  Chinese  herbal  medicine  (TCHM),  also 
known as the PentaHerbs (PTH) formulation, is a “widely used 
ancestral  Chinese  concoction”  of  five  herbal  extracts,  which 
includes  Flos  lonicerae,  Herba  menthae  (HM),  Cortex  moutan, 
Rhizoma atractylodis, C. phellodendri in the quantities of 2g, 1g, 
2g, 2g, and 2g, respectively. It is quite commonly used in Asia 
and China to treat children with atopic dermatitis. Hon et al. 
conducted  a  randomized,  double-blind,  placebo-controlled 
trial  assessing  the  efficacy  of  oral  TCHM  in  treating  atopic 
dermatitis.  Eighty-five  subjects  were  enrolled—42  TCHM,  43 
placebo—and instructed to take three capsules twice daily for 
12 weeks. Participants were assessed every 4 weeks† using the 
SCORAD  scale  and  the  Children’s  Dermatology  Life  Quality 
Index (CDLQI),‡ as well as the Allergic Rhinitis Score (ARS)§. 
Subjects were instructed to continue using prior medications 

* Specifically—erythema, itch, papules, erosion, scaling, and lichenifi-
cation. These were rated as 0–3, correlating to “none,” “mild,” “moder-
ate,” and “severe.”
†  Study  duration  was  16  weeks.  Patients  were  not  taking  TCHM  or 
 placebo from week 12 to week 16.
‡  CDLQI  contains  ten  questions  relating  to  six  categories:  symp-
toms and feeling, daily activities, leisure, work and school, personal 
 relationships, and treatment.
§  ARS  evaluates  symptoms  of  sneezing,  watery  rhinorrhea,  nasal 
 congestion, itching nose, itching eyes, and watering eyes.

and  amount  of  topical  corticosteroids—0.1%  mometasone 
furoate—were weighed during visits. Analysis of the data after 
16  weeks  demonstrated  statistically  significant  improvement 
in the SCORAD scores in both the TCHM and placebo groups. 
However,  there  was  not  a  statistically  significant  difference 
between the two groups. While SCORAD values did not differ, 
the TCHM group showed a greater than 30% improvement in 
CDLQI  scores,  while  the  placebo  group  showed  no  improve-
ment  at  the  study’s  end;  TCHM’s  improvement  compared  to 
baseline and compared to the placebo group were both statis-
tically  significant.  In  addition  to  an  improvement  in  CDLQI 
scores,  those  in  the  TCHM  group  demonstrated  statistically 
significant  decrease  in  the  number  of  days  topical  cortico-
steroids  were  used  per  month,  when  compared  to  baseline. 
Additionally, the quantity of steroid used by the TCHM group 
was statistically significantly less than both the amounts used 
at  their  baseline  and  the  amount  used  by  the  placebo  group 
during  the  study.  Interestingly,  prior  studies  evaluating  the 
chemical  makeup  of  the  TCHM  have  shown  it  to  have  no 
chemical similarity to corticosteroids. Side effects of TCHM in 
this study were “generally mild and self-limiting” (63).

Mast cells are known to play a role in allergic processes. 
In  response  to  triggers,¶  mast  cells  release  pro-inflammatory 
mediators such as histamine, cytokines, and prostaglandin D2 
(PGD2). Subsequent to the 2007 Hon et al. study, several inves-
tigators  from  the  same  research  group  conducted  an  in  vivo 
study  exploring  the  effects  of  the  five  substances  in  the  PTH 
formula on mast cells in an attempt to explain PTH’s modula-
tory  effect  on  atopic  dermatitis.  In  part  one  of  the  study,  rat 
peritoneal  mast  cells  (RPMCs)  were  incubated  with  each  of 
the five herbal components and then triggered to release pro-
inflammatory  mediators.  In  part  two  of  the  study,  Human 
mast  cells  (HMC-1)  were  incubated  with  either  dexametha-
sone,  PTH  formula,  or  one  of  the  five  components,  and  then 
triggered,** and cytokine†† production was measured. PHF as 
well  as  one  component  of  PHF,  namely  Cortex  moutan  (CM) 
alone,  demonstrated  statistically  significant  decreases  in  his-
tamine concentrations from RPMCs as compared to controls. 
Likewise,  statistically  significant  reductions  in  PGD2  concen-
trations  were  observed  upon  exposure  to  PHF,  CM,  and  Flos 
lonicerae  (FL).  One  component  of  PHF,  namely  C.  phellodendri 
(CP) seemed to increase histamine response and PGD2 release. 
While the aforementioned 2007 Hon et al. study demonstrated 
no  improvement  in  the  severity  of  atopic  dermatitis  when 
treated with TCHM, authors suggest in this report that propor-
tions of the individual components may have been subthera-
peutic or an optimal ratio of the components was not present. 
Researchers recommend that increasing the ratio of CM or HM 
and  decreasing  CP  could  potentially  increase  the  efficacy  of 
PTH in lessening the severity of atopic dermatitis (64).

Psoriasis
Among  dermatologic  conditions,  psoriasis  carries  significant 
psychological burden and is associated with widespread treat-
ment  dissatisfaction  (65,66).  Patients  with  psoriasis  therefore 
often turn to alternative therapies to complement their medical 
treatments.

¶ Compound 48/80 is polycationic compound, similar to Substance P 
in that it is a secretagogue. Substance P serum levels have previously 
been shown to be associated with disease severity in atopic dermatitis.
** Triggered with a substance known as A23187+PMA.
†† Cytokines that were measured included: GM-CSF, IL-6, IL-8, IL-10, 
TNF-alpha.

 
162 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Aloe vera, a succulent plant that probably originated in 
Northern Africa, the Canary islands, and Cape Verde, is a com-
monly  used  herbal  medicine.  Conflicting  results  have  been 
observed  in  the  treatment  of  psoriasis.  In  one  study  by  Syed 
et al., aloe vera cream applied three times daily to 60 patients 
with slight to moderate psoriasis showed improvement as com-
pared to placebo. Improvement was determined by a “positive 
response,”  measured  as  a  composite  of  decreased  erythema, 
infiltration,  reductions  of  lesions,  desquamation,  and  lower 
psoriasis-associated  severity  index  (PASI)  score  (67).  A  more 
recent investigation of aloe vera gel applied twice daily for 4 
weeks to 41 patients with slight to moderate psoriasis vulgaris 
showed a greater improvement in placebo-treated patients as 
compared to those with aloe vera. Efficacy was measured uti-
lizing a modified PASI score (68).

The  Dead  Sea,  a  salt  lake  bordering  Jordan,  the  West 
Bank, and Israel, is the deepest hypersaline lake in the world, 
and with 33.7% salinity is one of the world’s saltiest bodies. It is 
purported to have many health benefits and has been investi-
gated in the treatment of psoriasis. In a double-blind, random-
ized  control  clinical  trial  by  Cheesbrough  et  al.,  24  patients 
were treated with either a 30% Dead Sea salt lotion or placebo 
for  a  total  of  12  weeks.  There  was  no  statistically  significant 
improvement in either the Dead Sea salt lotion or vehicle dur-
ing  the  treatment  period  (69).  A  more  recent  study  by  Dawe 
et  al.  investigated  Dead  Sea  salt  (DSS)  soaks  plus  NB-UVB 

versus NB-UVB alone in the treatment of plaque psoriasis in 
a randomized, single-blind, controlled, right/left comparison 
study.  Sixty-six  patients  pretreated  one  limb  with  DSS  soaks 
and then underwent NB-UVB for 12 weeks. There was no sig-
nificant difference between the DSS soaks plus NB-UVB when 
compared to NB-UVB alone (70).

Indigo naturalis, derived from the leaves of plants such 
as Baphicacavthus cusia, has been investigated in the treatment 
of  psoriasis.  A  recent  randomized,  observer-blind,  vehicle-
controlled, intrapatient comparison study by Lin et al. evalu-
ated the efficacy of a topical indigo naturalis ointment versus 
vehicle  in  the  treatment  of  recalcitrant  plaque-type  psoriasis 
in  42  patients.  Statistically  significant  reductions  in  the  sum 
of scaling, erythema, and induration scores were observed in 
indigo naturalis–treated patients as compared to controls (71). 
A  follow-up  study  in  the Journal  of  Investigative  Science  found 
that the antipsoriatic effects of indigo naturalis involve, at least 
partially,  modulating  the  proliferation  and  differentiation  of 
keratinocytes (72).

Finally,  just  as  M.  aquifolium  has  been  studied  for  the 
treatment of atopic dermatitis, so too, it has been investigated 
for  its  use  in  treating  psoriasis.  The  study  consisted  of  200 
patients  treating  one  plaque  of  psoriasis  with  Relieva  twice 
daily for 12 weeks. PASI scores were significantly improved in 
the Relieva-treated patients as compared to placebo (73,74). See 
further Table 17.3.

Table 17.3  Alternative Treatments for Atopic Dermatitis, Psoriasis, Pruritus

Alternative Medication

Study Type

Aloe vera

Aloe vera

Blackcurrant seed oil, oral

Double-blind, placebo-
controlled (in vivo)

Double-blind, placebo-
controlled (in vivo)

Double-blind, placebo-
controlled (in vivo)

Experimental Result

Slight to moderate 

improvement in psoriasis

Source

(Syed, Ahmad et al. 1996)

No improvement in psoriasis

(Paulsen, Korsholm et al. 2005)

Improvement in atopic 
dermatitis in infants

(Linnamaa, Savolainen et al. 

2010)

Borage oil, oral

Cochrane Review (in vivo)

Improvement of atopic 

(Bamford, Ray et al. 2013)

Borage oil, topical

Double-blind, placebo-
controlled (in vivo)

Traditional Chinese herbal 

medicine, oral

Randomized, double-blind, 

placebo-controlled (in vivo)

Traditional Chinese herbal 
medicine (PentaHerbs 
formula)

In vitro

dermatitis is no greater than 
placebo

Symptomatic improvement in 

(Kanehara, Ohtani et al. 2007)

atopic dermatitis

Overall improvement of atopic 
dermatitis no greater than 
placebo

Improvement in quality of life 
and decreased amount of 
topical steroid needed to 
treat

Reduction in rat peritoneal 
mast cell release of pro-
inflammatory mediators of 
atopic dermatitis

(Hon, Leung et al. 2007)

(Chan, Hon et al. 2008)

Colloidal oatmeal suspension

Alternating assignment, 

Improvement in pruritus in burn 

(Matheson, Clayton et al. 2001)

Dead sea salt lotion

Dead Sea salt soaks (with 

NB-UVB)

Evening primrose oil, oral

assessor-blinded (in vivo)

wound healing patients

Placebo-controlled (in vivo)

No improvement in psoriasis

(Cheesbrough 1992)

Randomized, observer-blinded, 
paired comparison (in vivo)

No additional improvement in 
psoriasis as compared to 
NB-UVB alone

(Dawe, Yule et al. 2005)

Cochrane Review and 

meta-analyses (in vivo)

Improvement of atopic 

(Bamford, Ray et al. 2013)

dermatitis is no greater than 
placebo

(Continued)

 
ALTERNATIVE AND NATURAL TREATMENTS IN DERMATOLOGY 

  163

Table 17.3 (Conitnued)  Alternative Treatments for Atopic Dermatitis, Psoriasis, Pruritus

Alternative Medication
Evening primrose oil, oral

Study Type

Experimental Result

Source

Randomized, placebo-
controlled (in vivo)

Improvement in atopic 

(Senapati, Sabyasachi et al. 

dermatitis

2008)

Gentian violet

Case report

Improvement of Streptococcus 

(Stoff, MacKelfresh et al. 2010)

impetiginized atopic 
dermatitis

Gentian violet

Placebo-controlled trial (in vivo; 

Reduces S. aureus skin burden 

(Brockow, Grabenhorst et al. 

in vitro)

and improves atopic 
dermatitis that is colonized 
with S. aureus

1999)

Indigo naturalis ointment

Randomized, observer-blinded, 
vehicle-controlled (in vivo)

Improvement in psoriasis

(YK, CJ et al. 2008)

Mahonia aquifolium

In vivo

Improvement in psoriasis

(Bernstein et al 2006; Smith et al 

2009)

Vitamin B12, topical

Double-blind, randomized, 

Improvement in atopic 

(Januchowski, 2011)

placebo-controlled (in vivo)

dermatitis

REFERENCES

1.  Chen  Y,  Chang  J.  Complementary  and  alternative  medicine 
among  patients  attending  a  hospital  dermatology  clinic  in 
Taiwan. Intl J Dermatol. 2003;42:616–21.

2.  Fleisher AJ, Feldman S, Rapp S, Reboussin D, Exum M, Clark A. 
Alternative  therapies  commonly  used  within  a  population  of 
patients with psoriasis. Cutis 1996; 158:216–20.

3.  Bigby  M.  Evidence-based  medicine  in  dermatology.  Dermatol 

Clin 2000; 18:261–76.

4.  Maibach H, Bashir S, McKibbon A. Evidence-Based Dermat ology. 

Toronto, Ontario: Dekker; 2002.

5.  Jones  K,  Hughes  J,  Hong  M,  Jia  Q,  Orndorff  S.  Modulation  of 
melanogenesis  by  aloesin:  A  competitive  inhibitor  of  tyrosi-
nase. Pigment Cell Res 2002; 15:335–40.

6.  James W, Berger T, Elston D. Andrews’ Diseases of the Skin: Clinical 

Dermatology, 11th edn., Saunders, 2011.

7.  Kligman A, Willis I. A new formula for depigmentating human 

skin. Arch Dermatol 1975; 111:40–48. 

8.  Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmenta-

tion: What is available? J Cutan Aesthet Surg 2013; 6:4–11.

9.  Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-
blinded randomized trial of 5% ascorbic acid vs. hydroquinone 
in melasma. Intl J Dermatol 2004; 43:604–7.

  10.  Hakozaki  T,  Minwalla  L,  Zhuang  J,  Chhoa  M,  Matsubara  A, 
Miyamoto K, et al. The effect of niacinamide on reducing cuta-
neous pigmentation and suppression of melanosome transfer. 
Br J Dermatol 2002; 147:20–31.

  11.  Hakozaki  T,  Takiwaki  H,  Miyamoto  K,  Sato  Y,  Arase  S. 
Ultrasound enhanced skin-lightening effect of vitamin C and 
niacinamide. Skin Res Technol 2006; 12:105–13.

  12.  Tiedtke 

J,  Morel 

factor. 
Bioflavonoids  -  a  safe  and  effective  skin  lightener  based  on 
encapsulated citrus bioflavonoids. Cosmetochem 2004; 12–17.

J,  Marks  O.  Depigmentation 

  13.  Zhang R, Zhu W, Xie F. Effect of hesperidin on B16 and HaCaT 
cell lines irradiated by narrowband-UVB light. J Clin Dermatol 
(China) 2008.

  14.  Zhu  W,  Gao  J.  The  use  of  botanical  extracts  as  topical  skin-
lightening  agents  for  the  improvement  of  skin  pigmentation 
disorders. J Invest Dermatol 2008; 13:20–4.

  15.  Nerya O, Vaya J, Musa R, Izrael S, Arie RB, Tamir S. Glabrene 
and  isoliquiritigenin  as  tyrosinase  inhibitors  from  licorice 
roots. J Agric Food Chem, 2003; 51:1201–7.

  16.  Fu B, Li H, Wang X, Lee F, Cui S. Isolation and identification of 
flavonoids in licorice and a study of their inhibitory effects on 
tyrosinase. J Agric Food Chem 2005; 53:7408–14.

  17.  Amer M, Metwalli M. Topical liquiritin improves melasma. Intl 

J Dermatol 2000; 39:299–301.

  18.  Ni Z, Mu Y, Gulati O. Treatment of melasma with pycnogenol. 

Phytother Res 2002; 16:567–71.

  19.  Yamakoshi J, Sano A, Tokutake S, Saito M, Kikuchi M, Kubota Y. 
Oral intake of proanthocyanidin-rich extract from grape seeds 
improves chloasma. Phytother Res 2004; 18:895–9.

  20.  Chakraborty  A,  Funasaka  Y,  Komoto  M,  Ichihashi  M.  Effect 
of  arbutin  on  melanogenic  proteins  in  human  melanocytes. 
Pigment Cell Res 1998; 11:206–12.

  21.  Boissy  R,  Visscher  M,  DeLong  M.  DeoxyArbutine:  A  novel 
reversible tyrosinase inhibitor with effective in vivo skin light-
ening potency. Exp Dermatol 2005; 14:601–8.

  22.  Sugimoto  K,  Nishimura  T,  Nomura  K,  Sugimoto  K,  Kuriki  T. 
Inhibitory  effects  of  alpha-arbutin  on  melanin  synthesis  in 
 cultured  human  melanoma  cells  and  a  three-dimensional 
human skin model. Biol Pharm Bull. 2004; 27:510–14.

  23.  Khan BA, Akhtar N, Hussain I, Abbas KA, Rasul A. Whitening 
efficacy  of  plant  extracts  including  Hippophae  rhamnoides 
and  Cassia  fistula  extracts  on  the  skin  of  Asian  patients  with 
melasma. Adv Dermatol Alergol 2013; 4:226–32.

  24.  Ali A, Akhtar N, Khan MS. In vivo evaluation: The effects of a 
cream containing Acacia bark extract on skin melanin and ery-
thema content. Adv Dermatol Allergol 2012; 5:369–72.

  25.  Wallo  W,  Nebus  J,  Leyden  JJ.  Efficacy  of  a  soy  moisturizer  in 
photaging: A double-blind, vehicle-controlled, 12-week study. J 
Drug Dermatol 2007; 6:917–22.

  26.  Rodgers  P,  Bassler  M.  Treating  onychomycosis.  Am  Fam 

Physician 2001; 63:663–72.

  27.  Kalokasidis K, Meldem O, Trakatelli M-G, Richert B, Fritz K. The 
effect  of  Q-switched  Nd:YAG  1064nm532nm  laser  in  the  treat-
ment of onychomycosis on vivo. Dermatol Res Pract 2013; 2013:1–10.
  28.  Gupta A, Pacquet M, Simpson F. Therapies for the treatment of 

onychomycosis. Clin Dermatol 2013; 31:544–54.

  29.  Elsevier,  Drug  Monograph.  Ciclopirox,  Clinical  Key,  Elsevier, 

2014.

  30.  Gupta A, Joseph W. Ciclopirox 8% nail lacquer in the treatment 
of  onychomycosis  of  the  toenails  in  the  United  States.  J  Am 
Podiatr Med Assoc 2000; 90:495–501.

  31.  Friedlander S, Chan Y, Chan Y, Eichenfield L. Onychomycosis 
does  not  always  require  systemic  treatment  for  cure:  A  trial 
using topical therapy. Pediatr Dermatol 2013; 30:316–22.

  32.  Addino J, Buck D, Nidorf D. Comparison of two topical prepa-
rations for the treatment of onychomycosis: Melaleuca alterni-
folia (tea tree) oil and clotrimazol. J Fam Practice 1994; 38.
  33.  Syed TA, Qureshi ZA, Ali SM, Ahmad S, Ahmad SA. Treatment 
of toenal onychomycosis with 2% butenafine and 5% Melaleuca 
alternifolia (tea opicee) oil in cream. Trop Med Intl Health 1999; 
4:284–7.

 
 
 
 
 
 
 
 
 
 
164 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  34.  Ramesewak R, Muraleedharan N, Stommel M, Selanders L. In 
vitro antagonistic activity of monoterpenes and their mixtures 
against ‘toe nail fungus’ pathogens. Phytother Res 2003; 17:376-9.
  35.  Pinto  E,  Pina-Vaz  C,  Salgueiro  L,  Goncalves  MJ,  Costa-de-
Oliveira S, Cavaleiro C, et al. Antifungal activity of the essential 
oil of Thymus pulegioides on Candida, Aspergillus and dermato-
phyte species. J Med Microbiol 2006; 55:1367–73.

  36.  Pina-Vaz  C,  Goncalves  Rodriguez  A,  Costa-de-Oliveira  S, 
Tavares  C,  Salgueiro  L,  Goncalves  M,  Martinez-de-Oliveira  J. 
Antifungal activity of Thymus oils and their major compounds. 
J Eur Acad Dermatol Venereol 2004; 18:73–8.

  37.  Derby R, Robal P, Jackson C, Beutler A, Olsen C. Novel treatment 
of onychomycosis using over-the-counter mentholated ointment: 
A clinical case series. J Am Board Fam Med 2011; 24:69–74.
  38.  Anacor Pharmaceuticals, Pipeline > Tavaborole (AN2690) 2013. 

  56.  Brockow  K,  Grabenhorst  P,  Abeck  D,  Traupe  B,  Ring  J,  Hoppe 
U,  Wolf  F.  Effect  of  gentian  violet,  corticosteroid  and  tar  prep-
arations  in  Staphylococcus  aureus-colonized  atopic  eczema. 
Dermatology1999;  199:231–6.

  57.  Stoff  B,  MacKelfresh  J,  Fried  L,  Cohen  C,  Arbiser  J.  A  nonste-
roidal  alternative  to  impetiginized  eczema  in  the  emergency 
room. J Am Acad Dermatol 2010; 63:537–9.

  58.  Senapati  S,  Sabyasachi  B,  Gangopadhyay  DN.  Evening 
primrose  oil  is  effective  in  atopic  dermatitis:  A  randomized 
placebo-controlled trial. Indian J Dermatol Venereol Leprol 2008; 
74:447–52.

  59.  Bamford  J,  Ray  S,  Musekiwa  A,  van  Gool  C,  Humphreys  R, 
Ernst E. Oral evening primrose oil and borage oil for eczema. 
Cochrane Database Syst Rev 2013.

  60.  Foster R, Hardy G, Alany R. Borage oil in the treatment of atopic 

Available at: http://www.anacor.com/an2690.php

dermatitis. Nutrition 2010; 26:708–18.

  39.  Elewski  B,  Pariser  D,  Rich  P,  Scher  R.  Current  and  emerging 
options  in  the  treatment  of  onychomycosis.  Semin  Cutan  Med 
Surg 2013a; 32: S9–12.

  40.  Elewski  B,  Rich  P,  Pollak  R,  Pariser  D,  Watanabe  S,  Senda  H, 
et  al.  Efinaconazole  10%  solution  in  the  treatment  of  toenail 
onychomycosis:  Two  phase  III  multicenter,  randomized,  dou-
ble-blind studies. J Am Acad Dermatol 2013c; 68:600–8.

  41.  Smijs  TGM,  van  der  Haas  RNS,  Lugtenburg  J,  Liu  Y,  de  Jong 
RLP, Schuitmaker HJ. Photodynamic treatment of the dermato-
phyte Trychophyton rubrum and its microconidia with porphy-
rin photosensitizers. Photochem Photobiol 2004; 80:197–2002.
  42.  Elewski B, Parisner D, Rich P, Scher R. Current and emerging 
options  in  the  treatment  of  onychomycosis.  Semin  Cutan  Med 
Surg 2013b; 32:S9–12.

  43.  Kamp H, Tietz HJ, Lutz M, Piazena P, Sowyrda J, Blume-Peytavi U. 
Antifungal effect of 5-aminolevulinic acid in Trichophyton rubrum. 
Mycoses 2005; 48:101–7.

  44.  Piraccini BM, Rech G, Tosti A. Photodynamic therapy of ony-
chomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 
2008; 59:S75–6.

  45.  Watanabe  D,  Chiharu  K,  Masuda  Y,  Akita  Y,  Tamada  Y, 
Matsumoto  Y.  Successful  treatment  of  toenail  onychomycosis 
with photodynamic therapy. Arch Dermatol 2008; 144:19–21.
  46.  Sotiriou E, Koussidou-Ermonti T, Chaidemenos G, Ionnides D. 
Photodynamic therapy for distal and lateral subungual toenail 
onychomycosis  caused  by  Trichophyton  rubrum:  Preliminary 
results of a single-centre open trial. Acta Dermatol Venereol 2010; 
90:216–17.

  47.  Vural E, Winfield H, Shingleton A, Horn T, Shafirstein G. The 
effects  of  laser  irradiation  on  Trichophyton  rubrum  growth. 
Lasers Med Sci 2008; 23:349–53.

  48.  Kozarev J, Vizintin Z. Novel laser therapy in treatment of ony-

chomycosis. J Laser Health Acad 2010; 2010:1–8.

  49.  Carney C, Cantrell W, Warner J, Elewski B. Treatment of onycho-
mycosis using a submillisecond 1064-nm neodymium:yttrium-
aluminum-garnet laser. J Am Acad Dermatol 2013; 69:578–582.

  50.  Goldsmith  L,  Katz  S,  Gilchrest  B,  Paller  A,  Leffell  D,  Wolff  K. 
Fitzpatrick’s Dermatology in General Medicine, 8th edn., McGraw-
Hill 2012.

  51.  Januchowski R. Evaluation of topical vitamin B12 for the treat-

ment of childhood eczema. J Altern Compl Med 2011; 15:387–9.

  52.  Zhao X, Jellen E, Murphy J. Progenitor germplasm of domesti-

cated hexaploid oat. Crop Science 1999; 39:1208–14.

  53.  Baumann  LS.  Less-known  botanical  cosmeceuticals.  Dermatol 

Ther 2007; 20:330–42.

  54.  Matheson J, Clayton J, Muller M. The reduction of itch during 
burn wound healing. J Burn Care Rehabil 2001; 22:76–81.
  55.  Linnamaa  P,  Savolainen  J,  Koulu  L,  Tuomasjukka  S,  Kallio  H, 
Yang  B,  et  al.  Blackcurrant  seed  oil  for  prevention  of  atopic 
dermatitis in newborns: A randomized, double-blind, placebo-
controlled trial. Clin Exp Allergy 2010; 40:1247–55.

  61.  Kanehara  S,  Ohtani  T,  Uede  K,  Furukawa  F.  Clinical  effects 
of undershirts coated with borage oil on  children  with atopic 
dermatitis:  A  double-blind,  placebo-controlled  clinical  trial. 
J Dermatol 2007; 34:811–5.

  62.  Donsky H, Clarke D. Relieva, a Mahonia Aquifolium extract for 
the treatment of adult patients with atopic dermatitis. Am J Ther 
2007; 14:442–6.

  63.  Hon KLE, Leung PC, Ng MCA, Kam WYC, Wong KY, Lee KCK, 
et  al.  Efficacy  and  tolerability  of  a  Chinese  herbal  medicine 
concoction  for  treatment  of  atopic  dermatitis:  A  randomized, 
double-blind,  placebo-controlled  study.  Br  J  Dermatol,  2007; 
157:357–63.

formula  suppresses 

  64.  Chan BCL, Hon KLE, Leung PC, Sam SW, Fung KP, Lee MYH, 
Lau  HYA.  Traditional  Chinese  medicine  for  atopic  eczema: 
Pentaherbs 
inflammatory  mediators 
release from mast cells. J Ethnopharmacol 2008; 120:85–91.
  65.  Lebwohl M, Tan M-H. Psoriasis and stress. Lancet 1998; 351:82.
  66.  Stern R, Nijsten T, Feldman S, Margolis D, Rolstad T. Psoriasis is 
common, carries a substantial burden even when not extensive, 
and  is  associated  with  widespread  treatment  dissatisfaction. 
J Invest Dermatol Symp Proc, 2004; 9:136–9.

  67.  Syed  T,  Ahmad  S,  Holt  A,  Ahmad  S,  Ahmad  S,  Afzal  M. 
Management of psoriasis with aloe vera extract in a hydrophilic 
cream: A placebo-controlled, double-blind study. Trop Med Int 
Health 1996; 1:505–9.

  68.  Paulsen E, Korsholm L, Brandrup  F.  A  double-blind,  placebo-
controlled study of a commercial aleo vera gel in the treatment 
of  slight  to  moderate  psoriasis  vulgaris.  J  Eur  Acad  Dermatol 
Venereol, 2005;19:326–31.

  69.  Cheesbrough M. Treatment of psoriasis with 30% Dead Sea salt 

lotion. J Dermatol Treat 1992; 3:201–3.

  70.  Dawe R, Yule S, Cameron H, Moseley H, Ibboston S, Ferguson J. 
A  randomized  controleed  comparison  of  the  efficacy  of  Dead 
Sea  salt  balneophototherapy  vs  narrownand  ultraviolet  BH 
monotherapy for chronic plaque psoriasis. Br J Dermatol 2005; 
153:613–19.

  71.  YK  L,  CJ  C,  YC  C,  WR  W,  SC  C,  JH  P.  Clinical  assessment  of 
patients with recalcitrant psoriasis in a randomized, observer-
blind,  vehicle-controlled  trial  using  indigo  naturalis.  Arch 
Dermatol. 2008;144:1457–64.

  72.  Lin Y-K, Leu Y-L, Yang S-H, Chen H-W, Wang C-T, Pang J-HS. 
Anti-psoriatic  effects  of  indigo  naturalis  on  the  proliferation 
and differentiation of keratinocytes with indirubin as the actice 
component. J Dermatol Sci 2009; 54:168–74.

  73.  Bernstein  S,  Donsky  H,  Gulliver  W,  Hamilton  D,  Nobel  S, 
Norman  R.  Treatment  of  mild  to  moderate  psoriasis  withRe-
lieva, a Mohonia aquifolium extract: A double-blind, placebo-
controlled study. Am J Ther 2006; 13:121–6.

  74.  Smith N, Weymann A, Tausk FA, Gelfand JM. Complementary 
and alternative medicine for psoriasis: a qualitative review of 
the clinical trial literature. JAAD 2009; 61:841–6.

 
Section III

Non-Pathological Skin Treatments

18

Skin Care Products for Normal, Dry, and Greasy Skin

Christine Lafforgue, Céline Try, Laurence Nicod, and Philippe Humbert

INTRODUCTION
Skin  care  products  have  biologically  active  ingredients  with 
medicinal  or  druglike  benefits.  Furthermore,  they  satisfy  the 
needs  of  beauty  and  health.  Many  substances,  either  chemi-
cally synthesized or extracted from plants or animals, can be 
used  as  functional  ingredients.  Nowadays,  many  products 
with biologically active ingredients have been developed and 
marketed.  They  are  intended  to  carry  out  their  functions  as 
protection,  whitening,  tanning,  antiwrinkling,  deodorants, 
antiaging,  and  nail  and  hair  care.  Skin  care  products  may, 
however, cause some unwanted problems. The common ones 
are irritability to the skin, contact dermatitis, photosensitivity, 
comedogenicity, hair and nail damage, hyper- or hypopigmen-
tation, infectivity, carcinogenicity, and even systemic adverse 
effects.

Advances in electronics and computing have allowed the 
development of instruments for measuring certain parameters 
of the skin. Quantification of these parameters has enabled the 
evaluation,  comparison,  and  hence  improvement  of  the  effi-
cacy of skin care products.

THE DIFFERENT TYPES OF SKIN
Normal Skin
Normal  skin  is  defined  as  having  no  visible  lesions  or 
 sensations  of  discomfort.  It  results  from  an  equilibrium 
of   various  continuous  biologic  processes  including  kerati-
nization,  desquamation,  water  loss,  sebum  excretion,  and 
sweating.  In  situations  of  perfect  balance  between  sebum 
production  and  requirements,  the  skin  is  comfortable,  well 
moisturized, supple, elastic, clean, easy to decorate, and not 
so easy to irritate.

During  aging,  the  skin  undergoes  certain  changes 
 arising  from  external  causes,  in  particular  ultraviolet  (UV) 
radiation  as  well  as  the  general  aging  process  that  affects 
the  entire  organism.  According  to  certain  authors,  these 
changes  with  age  are  manifested  as  changes  in  the  chemi-
cal structure, the quality and quantity of structural proteins, 
 proteoglycans and hyaluronic acid (1). Also, during adult life, 
dermal   collagen  content  progressively  decreases,  correlat-
ing  with  a  reduction  in  skin  thickness  (2).  A  simultaneous 
decrease in the amount of proteoglycans and hyaluronic acid 
is also seen (1).

Elsewhere, hormonal changes occurring during adoles-
cence and then aging account for the respective increases in 
sebum secretion seen in puberty, then its progressive decrease 
during adult life, declining considerably in postmenopausal 
women  (3).  With  aging,  a  decrease  in  the  rate  of  corneocyte 
desquamation is also seen (4).

Dry Skin
The term dry skin or xerosis describes an integument with a 
dry, rough, or scaly appearance with the possible presence of 
reddening,  cracking,  or  itching.  The  skin  is  less  flexible  than 
normal, contributing to the irregular feel to the touch (5,6).

Dry skin results from many factors: 

•  The water content of stratum corneum is reduced (13% of 

water for normal skin and less of 10% for dry skin).

•  An  abnormal  keratinization  modifying  the  stratum 
 corneum  equilibrium 
(between  desquamation  and 
proliferation)  and  corneocytes  cohesion  (abnormal  lipid 
compartment).

•  A decrease in barrier function, which increases in the pas-

sive rate of transepidermal water loss.

Two types of dry skin can be distinguished (7): acquired 
dry skin and constitutional dry skin. Acquired dry skin may 
arise  from  normal,  or  sometimes  even  greasy  skin,  which  is 
rendered temporarily and locally dry by external factors such 
as  solar  radiation,  exposure  to  extreme  climate  (cold,  heat, 
wind, dryness), exposure to chemicals, or various therapeutic 
measures  (lithium,  retinoids).  Constitutional  dry  skin  can  be 
nonpathologic (senile skin, fragile skin) or pathologic (ichtyo-
ses, dry skin of atopic dermatitis, hypothyroidism, uremia).

Greasy Skin
Greasy skin mainly involves the upper part of the body, where 
greater numbers of sebaceous gland are found. Simple greasy 
skin is common in adolescents and young adults. It is charac-
terized by skin thickening and an increase in sebaceous excre-
tion, giving the face a shiny appearance, especially on the nose 
and  forehead,  with  an  unclean  appearance  and  rancid  smell. 
In extreme cases, the follicular ducts are often dilated (kerosis). 
However, they can also plug by minuscule cornified spicules, 
which protrude and give a sensation of roughness to the touch.
Several parameters induce production of sebum by seba-
ceous glands, notably by the main stimulus, circulating andro-
gen levels. In men, the sebum causal level is higher from birth 
and is temporarily inverted during prepuberty, which occurs 
earlier  in  girls.  In  females,  a  decrease  during  the  estrogenic 
phase of the menstrual cycle and an increase during the luteal 
phase are observed (8).

Several  types  of  complications  can  be  associated  with 

greasy skin, especially the following:

Acne
This  complication  is  characterized  by  the  presence  of  com-
edones  (blackheads)  and  closed  comedones  (microcysts). 
Causes can include excessive proliferation of Propionibacterium 
acnes,  which  produces  free  acids  by  enzymatic  hydrolysis  of 

168 

 TEXTBOOK OF COSMETIC DERMATOLOGY

triglycerides; irritation of the dermis by keratin and free fatty 
acids  released  by  comedones;  and  immune  reactions  with 
 sensitization of acne subjects to P. acnes.

Seborrheic Dermatitis
This  is  also  a  frequent  problem,  the  cause  of  which  is  still 
unknown but may include Malassezia yeast (Malassezia globosa 
and M. fufur), chemical agents (detergents), or nervous factors 
(stress, anxiety). It is characterized by the presence of erythe-
matosquamous plaques, made up of greasy squames, localized 
mainly  on  the  hairline  and  eyebrows,  nasal  folds,  chin,  and 
presternal region. The scalp is often affected, with the forma-
tion  of  crusty  plaques  covering  the  bases  of  the  hair  shafts. 
These lesions are often slightly pruritic.

METHODS FOR EVALUATING SKIN 
CHARACTERISTICS (BIOENGINEERING)
The main parameters of different skin types that can be used 
to evaluate products efficacy are those related to skin surface 
morphology,  stratum  corneum  hydration,  and  sebum  excre-
tion. Because of parameter variation between different anatom-
ical zones on the same subject and between different subjects, 
these techniques are used mainly to measure the change in a 
parameter with time, on the same zone. For example, a com-
parison  can  be  made  between  the  initial  state  (pretreatment) 
and the final state (post-treatment).

Evaluation of Skin Surface Morphology
D-Squames  and  Corneofix  F20  (9,10)  are  used  to  detect  and 
assess  some  damage  of  the  horny  layer  and  alteration  of  the 
viable  epidermis  behavior.  The  principles  of  measure  con-
sist  of  a  special  transparent  adhesive  tape,  which  collects 
corneocytes from the top layer of the skin for 5 seconds. The 
tape is removed, stuck on a glass slide, inserted into a micro-
film viewer, and its optical density is measured. The latter is 
inversely proportional to the amount of scales per unit area.

With  the  probe,  precise  information  regarding  desqua-
mation can be obtained: the number, size and thickness of the 
corneocytes or the roughness of the stratum corneum can be 
evaluated.

Other Probes
The  Visioscan  VC98  device  (Courage  and  Khazaka,  Kö  ln, 
Germany) is a video camera that monitors the skin surface illu-
minated under a UVA light source. Interpretation of the image 
by the supplied software gives information about skin rough-
ness, smoothness, scaliness, and wrinkles.

Optical  coherence  tomography  (OCT)  was  originally 
used for ophthalmologic diagnosis but has found applications 
in dermatologic investigation (11). OCT is based on the princi-
ple of Michelson interferometry and uses a light source with a 
short coherence length. The light source is split into a reference, 
and a sample beam is focused on the skin. Structural informa-
tion on morphology and thickness can be easily obtained, and 
information on water content or hydration is also available via 
the calculation of refractive index profiles.

Confocal  laser  scanning  microscopy  (Vivascope  1500) 
(12)  enables  instant  visualization  of  skin  structures  at  a  his-
tolopathologic  resolution  and  represents  a  new  noninvasive 
approach  for  the  in  vivo  study  of  physiologic  and  pathologic 
conditions of the skin.

The  confocal  microscope  consists  of  a  small  source  of 
light, which illuminates a small spot within the object; the illu-
minated spots are then imaged onto a detector through a small 
aperture. The source, illuminated spot, and detector aperture 
are placed in optically conjugate focal planes. The images are 
obtained  with  a  defined  horizontal  layer  of  5-mm  thickness, 
thus eliminating reflected light from other skin layers as well 
as aberrations.

A near infrared laser wavelength (830 nm) is absolutely 

harmless for user and patient.

Skin Hydration Measurements
Objective  assessment  of  skin  hydration  remains  the  preoc-
cupation  of  most  cosmetic  scientists  and  dermatologists.  The 
methods  and  techniques  used  vary  in  complexity  and  have 
been fully described elsewhere (13).

Measurement of Electrical 
Properties of the Skin
The  dielectric  constants  of  keratin  and  epidermal  lipids  are 
very  small  as  compared  with  that  of  water.  Therefore,  the 
dielectric constant of the stratum corneum is principally deter-
mined by its level of hydration: the greater the water content, 
the larger the dielectric constant.

The  Corneometer  CM  825  (Courage  and  Khazaka,  Kö 
ln, Germany) (14) is an apparatus with a probe that is placed 
in  contact  with  the  skin.  The  probe  acts  as  a  capacitor.  The 
capacitance  thus  measured  is  proportional  to  the  dielectric 
constant  of  the  skin,  varies  according  to  its  state  of  hydra-
tion, and is expressed in arbitrary units. The device measures 
capacitance,  which  is  proportional  to  the  dielectric  constant 
of the skin, and varies according to its state of hydration. On 
the forearm the following data are obtained (15):

•  <75: dehydrated skin
•  75–90: skin with a tendency to dehydration
•  >90: normal skin

Other instruments can evaluate the hydration state of the 

skin by assessing electrical properties (16):

•  The  DermaLab  (Cortex  Technology,  Hadsund,  Denmark) 

measures the impedance of the skin.

•  The  MoistureMeter  SC-4  (Delfin  Technology,  Kuopio, 
Finland)  is  a  novel  capacitive  device.  The  instrument 
shows arbitrary capacitance units.

•  The Nova Dermal Phase Meter DPM 9003 (Nova
•  Technology  Corporation,  Portsmouth,  New  Hampshire) 
measures  impedance-based  capacitive  reactance  of  the 
skin.  The  final  readout  is  given  in  arbitrary  DPM  units, 
which are related to the capacitance.

•  The Skicon 200, based on the experimental device developed 
by  Tagami  and  coworkers  (ISBS  Company,  Hamamatsu, 
Japan) measures the conductance in micro-siemens.

Infrared Spectroscopy (17)
Water  absorbs  infrared  radiation.  Because  of  this  prop-
erty, it’s possible to quantify the water content of stratum 
corneum  using  attenuated  total  reflectance  infrared  spec-
troscopy.  It  has  been  shown  that  absorbance  at  3400/cm 
characteristic of OH stretching vibrations increases in the 
deeper layers of the stratum corneum, suggesting a corre-
sponding increase in water content as a function of stratum 
corneum depth.

 
SKIN CARE PRODUCTS FOR NORMAL, DRY, AND GREASY SKIN 

 1 69

Measurement of Passive Transepidermal 
Water Loss (18,19)
Measurement of transepidermal water loss (TEWL) (18,19) deter-
mines the continual flux of water vapor diffusing across the stra-
tum corneum. It does not measure skin hydration, but does allow 
evaluation of the barrier function and efficacy of hydrating prod-
ucts whose mode of action relies on  occlusivity. TEWL is mea-
sured using an evaporimeter (Servo Med Evaporimeter, Kinna, 
Sweden).  This  device  is  applied  on  the  skin  surface,  built  as  a 
cylindrical chamber open to the surrounding air, and determines 
the  continual  flux  of  water  vapor  diffusing  across  the  stratum 
corneum. The process measures the partial water vapor pressure 
at two points 3 and 9 mm above the skin surface, respectively, 
with the aid of two pairs of humidity transducers and thermis-
tors. Normal TEWL values are between 2 and 5 g/m2/hr.

Measurement of Wettability (20–25)
Wettability results from the interactions between a fluid and the 
skin. A drop of water is placed on the skin and forms with the 
skin a semi-hydrophobic contact angle. The drop is observed 
with  an  operating  microscope  equipped  with  a  slanted  mir-
ror,  which  gives  a  view  of  the  profile  of  the  drop,  recording 
the image of the profile using a video camera connected to a 
computer. The water contact angle y can be measured and is 
used as an indicator of hydrophobic or hydrophilic tendency 
of the skin or to see the effect of products in the greasy or dry 
skin. For normal skin, y (forehead) is between 578 and 738. In 
the case of dry skin, the affinity with water decreases, and the 
contact angle between skin and water increases.

Evaluation of Friction Coefficient
Friction  is  an  interaction  between  two  surfaces.  Many  factors 
influence  the  friction  coefficient  value  as  hydration  or  sebum. 
Hydration  studies  have  correlated  increases  and  decreases  in 
skin hydration with the changes in the friction coefficient (26–28).

Sebum Measurement
Measurement of Sebum Excretion (29,30)
The Sebumeter SM 810 (Courage and Khazaka, Kö ln, Germany) 
uses a plastic tape which is applied on the skin for 30 seconds. The 
sebum lipids are adsorbed on the film and render it transparent. 
Next, the probe is inserted into the Sebumeter, which shines a light 
beam onto the film. A reflective metal plate behind the film reflects 
the light back, passing a second time through the film before enter-
ing a photomultiplier. The device automatically determines the 
increase in film transparency as a function of skin surface sebum 
and gives the lipid index in micrograms per square centimeter.

The Lipometer (L’Oréal, Paris) functions in a similar way 

to the Sebumeter. Its principal differences are:

•  The plastic film is replaced by a ground-glass disc mounted 
on a dynamometer to standardize the application pressure
•  A series of standard calibrated values are used to convert 

readings into absolute data (e.g., mg lipid/cm2)

Quantification of Sebum Output, Density, and 
Activity of Sebaceous Glands (31)
The main component of Sebutape (Cutoderm, Dallas, Texas, U.S.) is 
a microporous hydrophobic polymer film, which becomes trans-
lucent and then transparent when impregnated with oil. It can be 
stuck on the skin as it has an adhesive coating, or simply applied 
(Sebufix F16). The film absorbs the sebum originating from the 
follicular openings, which forms transparent spots that are eas-
ily visible on a dark background and whose area is proportional 

to the collected volume. This method quantified the topographi-
cal distribution of functional glands and their output on the skin 
surface using computerized image analysis. The size of the spot is 
proportional to follicular excretion activity. With sustained appli-
cation of Sebufix F16, the progressive enlargement of sebum spots 
can be monitored using a UV light video camera (Visioscan VC98, 
Courage and Khazaka) and 3D images obtained at will.

Skin Brightness Measurement
The  glossmeter  is  a  new  instrumentation  to  measure  the 
speculary reflecting light from the skin. It can be used to evalu-
ate the skin care including the brightness of the skin. It could be 
used to evaluate the effect of matting products or  hydrating prod-
ucts. Two glossmeters were developed in 2009: the Glossymeter 
GL  200  (Courage  and  Khazaka,  Kö  ln,  Germany)  and  the 
Skinglossmeter (Delphin Technologies, Kuopio, Finland) (32).

SKIN CARE PRODUCTS
Care of Normal Skin (33)
The  stratum  corneum  matrix  is  rich  in  ceramides,  free  fatty 
acids, and cholesterol, which serve to repel water and provide 
an effective barrier. The integrity of the stratum corneum is also 
promoted by substances in the corneocytes known as natural 
moisturizing factors (NMFs), a complex mixture of free amino 
acids, amino acid derivatives, and salts, which attract and hold 
water. This also helps to maintain skin flexibility and elasticity 
by  absorbing  water  from  the  atmosphere,  which  enables  the 
outermost  layers  of  the  skin  to  remain  hydrated  despite  the 
drying action of the environment. Fundamental skin care con-
sists mainly of cleansing, moisturizing, and protection.

Cleansing Products
Washing removes debris from the skin surface, and soap and 
water are frequently used together for this purpose because of 
convenience and perceived cost-effectiveness. Soaps are made 
by  hydrolysis  of  natural  triglycerides  and  neutralization  of 
fatty acids released by sodium. They are good emulsifiers, hav-
ing emollient action and increased lathering power. However, 
two problems are associated with them:

•  Their powerful detergent action may completely eliminate 
the  protective  surface  lipid  film,  which  helps  maintain 
the  skin’s  physiological  balance,  and  thus  may  engender 
irritation.

•  Soaps  have  highly  alkaline  nature  (pH  around  10).  The 
repeated use of soap may shift the pH of the skin surface, 
making  it  more  alkaline,  thereby  negating  the  protective 
influence of the acid mantle and upsetting the balance of 
resident flora on the skin (34).

All  surfactants  interact  with  skin  lipids  and  also  with 
cutaneous  proteins,  thus  use  of  a  mild  or  lipid-rich  cleanser 
permits washing and avoids damage to the skin barrier (35).

Hydrating Products
Current emollients are available in the form of sprays, lotions, 
creams,  and  ointments.  Although  the  development  and 
formulation of emollients has moved forward, the basic principle 
remains the same—they are all variations of an oil (lipid) and 
water  emulsion.  Technically  these  emulsions  may  take  the 
form of oil-in-water or water-in-oil emulsions, with oil-in-water 
emulsions  being  the  most  common.  Thus,  modern  emollients 
can not only help to maintain skin hydration, but can also help 
to replenish skin barrier lipids. The characteristics of emollients 
are described below in the section “Care of Dry Skin.”

 
170 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Photoprotective Products
Ultraviolet  radiation  can  cause  inflammatory  changes,  ery-
thema,  and  subsequently  pigmentation,  inducing  premature 
skin aging and risk of cancer. Throughout the seasons, photo-
protection has an important role for all skin types, including 
normal skin. The ideal photoprotector must effectively absorb, 
diffract, or reflect noxious radiation (UVB and UVA), be sub-
stantive to the stratum corneum and be water and sweat resis-
tant, be stable in daylight and in air and to heat and water, and 
be totally innocuous.

A  proper  sunscreen  product  must  provide  protection 
against acute and long-term UV–induced skin damage and be 
stable  to  heat  and  UV  radiation.  The  degree  to  which  a  sun-
screen protects the skin from UV rays is given as its sun pro-
tection factor (SPF). The SPF can be used as a guide to select 
sunscreen to avoid sunburn. The SPF indicates the time a per-
son with sunscreen applied can be exposed to sunlight before 
getting  sunburn  relative  to  the  time  a  person  without  sun-
screen can be exposed. The SPF value concerns protection in 
front of UVB and UVA radiation with a minimum balance of 
1 UVA for 3 UVB for Europe legislation.

The photoprotective ability of sun products is determined 
by two types of substance: chemical filters and physical screens.
Chemical  filters  (36)  are  synthetic  chemical  substances 

with the following properties:

•  Powerful absorption of UV radiation owing to the measure 

of double bonds

•  Relative stability when excited, so the absorbed energy is 

released slowly

Physical screens are mineral particles that in addition to 
absorbing UV rays reflect and diffract them like a mirror. The 
main  type  used  is  ultrafine  titanium  dioxide  (TiO2),  made  up 
of particles of 20–30 nm in size (37). The reduced size of ultra-
fine particles confers better reflection in the UVB and short UVA 
wavelengths, and better transparency in the visible wavelengths.
Consumers  are  more  aware  of  unnatural  chemicals  and 
other toxins and are searching for natural products to use on their 
skin. Antioxidants can have profound effects on the intracellular 
signaling pathways involved in skin damage and thus may be 
protective against photodamage as well as may prevent wrinkles 
and inflammation. The body has physiologic antioxidants, such 
as vitamins, glutathione, ubiquinon 10 (CoQ10), and lipoic acid. 
The use of exogenous antioxidants can add to the body’s physi-
ologic  reservoir  of  endogenous  antioxidants  and  enhance  the 
enzymatic clearance of reactive oxygen species (ROS) (38).

Following, there are many examples of natural compo-
nents which have antioxidant properties. Some of them can be 
found in skin care.

Vitamins  A,  C,  and  E  are  naturally  present  in  human 
skin.  These  vitamins  are  part  of  a  complex  system  of  enzy-
matic  and  nonenzymatic  antioxidants  that  protect  the  skin 
from  harmful  ROS  (39,40).  However,  the  skin  is  subjected  to 
substantial  environmental  free  radical  stress  from  sunlight, 
pollution, and smoking that can deplete dermal stores of natu-
rally  occurring  antioxidants.  To  remedy  vitamin  deficiency, 
many topical products contain vitamins (41).

Soy contains active ingredients: phytosterols and small 
protein  serine  protease  inhibitors  (Bowman-Birk  inhibitor 
and soybean trypsin inhibitor). Soy has antioxidant and anti-
inflammatory  effects  (42,43).  It  stimulates  collagen  synthesis, 
initiates the skin elastin repair process, inhibits pigmentation, 
controls oil production, and moisturizes the skin.

White,  green,  oolong,  and  black  tea  are  derived  from 
the leaves and buds of the tea plants (Camellia sinensis), with 
the  different  varieties  dependent  on  the  type  of  processing 
and  oxidation  or  fermentation.  The  main  active  ingredients 
are  polyphenols  that  include  catechin,  epicatechin-3-gallate, 
epigallocatechin,  and  epigallocatechin-3-gallate.  These  poly-
phenols have very potent antioxidant, anti-inflammatory, and 
anticarcinogenic properties, making teas useful in the preven-
tion and treatment of photodamage (44,45).

Pomegranate extract (Punica granatum) is primarily com-
posed of alkaloids and polyphenols, the active constituent being 
ellagic acid. It has demonstrated a variety of beneficial functions 
including antioxidative and antiviral activity. Pomegranate seed 
oil fractions may facilitate epidermal regeneration (30).

Ectoin,  a  natural,  vital  substance,  was  developed  for 
use  in  cosmetic  applications.  It  was  discovered  in  halophilic 
bacteria,  which  survive  and  grow  under  extreme  conditions 
in salt lakes, sea water, and saline deserts. Efficacy studies in 
vitro demonstrated that ectoin counteracts the effects of UVA-
induced and UVA-accelerated skin aging at different cell levels. 
Ectoin protects the skin from the effects of UVA-induced cell 
damage  in  a  number  of  different  ways  and  has  the  potential 
to protect mitochondria of human fibroblasts in vitro against 
UVA radiation–induced mutagenis (46).

Sesamol  (47)  is  a  highly  acclaimed  antioxidant.  An 
experiment  on  mouse  skin  showed  that  it  has  a  good  effect 
on prevention on photodamage, observed on biochemical and 
histopathologic changes.

Resveratrol,  or  polydatin,  is  now  used  because  it  pro-
motes  modulation  of  epidermal  cytokines  and  proteins 
engaged in cell repair (48,49).

Care of Dry Skin (50–52)
Treatment of dry skin is aimed at restoration of the epidermal 
water barrier. This is accomplished with moisturizing agents 
that are topically applied to the skin.

Excessive  bathing  or  the  use  of  hot  baths  or  showers 
should be discouraged and the use of mild soaps rather than 
harsh soaps or detergents should be encouraged.

Soap  substitutes  such  as  cetyl  alcohol  preparations  can 
be helpful for dry skin. Hydration of the stratum corneum by 
balneotherapy  followed  by  either  addition  of  oil  to  the  bath 
water  or  rapid  application  of  emollients  (occlusive  agents)  to 
the  skin  on  exit  from  the  bath  can  improve  hydration  of  the 
stratum corneum.

Hydratation can be done in two ways:

•  By the input of external water, which is retained in the stra-

tum corneum by addition of humectants

•  By the slowing down of stratum corneum water loss due 
to evaporation (reducing TEWL), by means of an occlusive 
lipid film

The lipids in the latter can combat the delipidization associated 
with dry skin and protect against external agents. Formulation 
of  a  hydrating  product  involves  both  of  these  principles,  but 
with  different  emphasis  placed  on  them  depending  on  the 
type  of  skin  (dehydrated  skin  or  dry  skin)  and  conditions  of 
use envisaged.

Humectant Moisturizing Ingredients
Humectants are compounds that attract water from the dermis 
into  the  stratum  corneum.  They  are  many  and  varied.  When 
humidity is higher than 70%, humectants can also attract water 
from  the  atmosphere  into  the  epidermis.  Humectants  can  be 

 
SKIN CARE PRODUCTS FOR NORMAL, DRY, AND GREASY SKIN 

 1 71

thought of as the cosmetic equivalents of NMF. NMFs are natural 
components including hygroscopic and hydrosoluble substances 
in the stratum corneum which are most likely to be enveloped by 
cell membrane lipids. These substances play an important role 
in water retention, since it has been shown that their extraction 
results in a 25% loss in stratum corneum water content and 66% 
loss in elasticity (53). NMF agents include the following:

Polyols  are  molecules  with  numerous  hydroxyl  groups 
(hydrophilic and hygroscopic substances). Glycerol and sorbitol 
are excellent humectants and are used at concentration between 
2%  and  10%.  Propylene  glycol  has  good  hydrating  ability  at 
low concentrations (inferior to 10%) and keratolytic activity at 
high concentrations (superior to 40%). Other polyols are used 
like mannitol but there are less hydrating.

Pyrrolidone carboxylic acid is the one of principal com-
ponents of NMF (about 12%). It is found in salt form and has a 
hydrating effect at concentration of 3% to 5%.

Urea  hydrates  at  concentration  at  less  than  10%.  Over 
this concentration, urea has keratolytic power. This molecule 
has  a  high  solubility  in  water  and  is  rapidly  hydrolyzed  and 
decomposed.

Lactic acid and  sodium lactate can  capture a  high  con-
centration of water and participate in maintaining acid mantle 
and NMF efficacy on the skin surface. It has an effect from con-
centration of 3%.

Certain  macromolecules  of  biologic  origin,  such  as 
hydrolyzed wheat proteins, have a high content of hydrophilic 
groups, but with their large size, they cannot penetrate the stra-
tum corneum and they form a hygroscopic film at the surface.
Certain  macromolecules  of  biologic  origin  have  a  high 
content  of  hydrophilic  groups,  but  with  their  large  size,  they 
cannot penetrate the stratum corneum and they form a hygro-
scopic film at the surface. This category includes the following:

•  Glycosaminoglycans  such  as  hyaluronic  acid  and  chon-
droitin  sulphate  are  polysaccharides.  These  compounds 
are found in the ground substance of all connective tissue 
and  possess  a  considerable  water  sorption  and  retention, 
owing the large number of hydroxyl groups.

•  Collagen and elastin are the two main structural proteins 
of the connective tissue and have hygroscopic property. 
With water, they form an aqueous gel. These proteins are 
generally used in denatured or hydrolyzed form.

•  DNA  has  a  large  number  of  phosphate  groups  and  pos-
sesses a good hygroscopic property. It used in a denatured 
and partially hydrolyzed form in cosmetology.

Occlusive Moisturizing Ingredients (51)
Occlusives  increase  the  water  content  of  the  skin  by  slowing 
the  evaporation  of  water  from  the  surface  of  the  skin.  These 
ingredients  are  often  greasy  and  are  most  effective  when 
applied to damp skin. Mineral oil is often used because of its 
favorable texture, but it is not as effective at preventing evapo-
ration of water as many other occlusives.

Actually,  filmogenic  products  compose  the  emulsion. 
Water-in-oil emulsion is very occlusive. Petrolatum, an hydro-
carbon oil, is the most effective occlusive moisturizer.

Other  hydrocarbons  include  mineral  oil,  paraffin,  and 
squalene.  In  occlusive  moisturizing  ingredients,  other  cat-
egories  of  compounds  exist  and  include  vegetable  fats,  fatty 
alcohols,  wax  esters,  vegetable  waxes,  phospholipids,  sterols, 
silicones, and oils rich in polyunsaturated fatty acids (PUFAs).
Oils rich in PUFAs (52) occupy a particular place in cos-
metology.  They  are  occlusive  but  their  potential  lies  in  their 

high PUFA content. PUFAs are long-chain fatty acids, unsatu-
rated at o-3 or o-6, of which some are classed among the essen-
tial fatty acids (linoleic acid, arachidonic acid, linolenic acid). 
These  PUFAs  are  found  in  large  quantities  in  certain  animal 
oils  (fish  oil)  and  plants  (evening  primrose,  borage,  grape 
seed). They are involved in several important physiologic func-
tions such as metabolism of prostaglandins and leukotrienes, 
inflammation, and hence the maintenance of stratum corneum 
hydration.

Additives to Moisturizer
Other  agents  are  now  included  in  moisturization  products. 
These  agents  have  different  functions  than  simply  reducing 
TEWL  or  reconstituting  the  lipid  components  of  the  stratum 
corneum. Special moisturizing agents such as α- or β-hydroxy 
acids can help promote corneocyte desquamation and decrease 
roughness.  α-Hydroxy  acids  (52)  (lactic,  glycolic,  malic,  tartric, 
citric, gluconic, and mandelic acids) have been shown to improve 
the  appearance  of  photodamaged  skin  and  are  an  effective 
keratolytic in concentration as low as 10%, and have a tendency to 
reduce corneocyte cohesion at the base of the stratum corneum. 
At  high  concentration  (30%–70%),  their  keratolytic  action  pre-
dominates:  they  act  on  the  deeper  epidermal  layers,  and  even 
the papillary and reticular dermis. At these concentrations they 
are suggested for the treatment of hyperkeratosis.

Salicylic acid is the only β-hydroxy acid. Its mechanism 
of  action  is  supposed  on  the  dissolution  of  the  intercellular 
cement  between  adjacent  corneocytes,  reducing  corneocyte 
adhesion. It is unique in that it can enter the pilosebaceous unit 
and increase exfoliation in the oily areas of the face. Because of 
its exfoliating effects, salicylic acid is beneficial in aging skin 
because of increased desquamation of the stratum corneum.

Urea (51) can also be added to moisturizers and enhances 
the water-binding capacity of the stratum corneum by disrupt-
ing  hydrogen  bonding.  Urea  exposes  water-binding  sites  on 
corneocytes  and  promotes  desquamation  by  decreasing  the 
intercellular  cementing  substance  between  the  corneocytes. 
Also, long-term treatment with urea has been demonstrated to 
decrease TEWL.

Care of Greasy Skin (54)
The  essential  requirement  is  to  reduce  excess  skin  surface 
sebum  without  total  delipidization.  Severe  degreasing  treat-
ment can lead to an exacerbation of sebaceous secretion.

Facial  washing  may  be  carried  out  with  either  a  mild 
soap or a lipid-rich soap. This must be followed by copious rins-
ing. In cold weather, the protection afforded by a continuous 
aqueous phase, light emulsion (oil in water) suffices. However, 
products used for this type of skin must be noncomedogenic.

Acne Treatment
Comedolytic Agents
Salicylic  acid,  lactic  acid,  glycolic  acid,  and  benzoyl  peroxide 
may  all  decrease  follicular  impaction  and  have  been  proved 
in both human and animal use. Of these compounds, salicylic 
acid is the most widely used. It has been shown to be safe and 
effective in reducing comedones when applied in 0.5% and 2% 
solutions.

The use of topical benzoyl peroxide does have some lim-
itations.  It  is  not  effective  as  a  monotherapy  for  severe  acne. 
Leave-on benzoyl peroxide creams and gels have the potential 
to bleach clothes and bed linens, and like all topical medica-
tions have the risk of causing an allergic contact dermatitis.

 
172 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Some more recent innovations in benzoyl peroxide for-
mulations  include  microsphere  technology,  aqueous-based 
gel, liposomal delivery, and microemulsion. The latest innova-
tion involves the use of micronization to produce solubilized 
benzoyl  peroxide  particles,  which  allows  the  smaller-sized 
particles to penetrate down into the follicle.

Moreover,  irritation  associated  with  benzoyl  peroxide 
can be minimized, while maintaining equal efficacy, by using 
the 2.5% formulation of benzoyl peroxide and vehicle such as 
the dimethyl isosorbide–containing hydrophase base and 10% 
urea (55).

As  benzoyl  peroxide  treatment  technology  advances,  it 
should become an even more useful treatment, as monother-
apy or adjunct, for mild to moderate acne vulgaris.

Topical Antibiotics
The  use  of  topical  antibiotics  (macrolide  as  clindamycin  or 
erythromycin)  is  frequent.  Its  bactericidal  action  on  P.  acnes 
inhibits bacterial protein synthesis.

The  problem  of  the  emergence  of  antibiotic-resistant 
P.  acnes  encountered  with  topical  clindamycin  monotherapy 
is  markedly  reduced  by  the  addition  of  benzoyl  peroxide  as 
a  combination  formulation.  Fixed  combination  products  of 
clindamycin 1% and benzoyl peroxide 5% are commonly used 
in the treatment of acne vulgaris. Although any given topical 
acne product may be therapeutically effective, signs and symp-
toms of cutaneous tolerability may lead to missed applications 
by the patient, thus limiting adherence to therapy. Benzoyl per-
oxide  can  cause  cutaneous  irritation  and  dryness,  which  are 
dose-dependent.  Recently,  clindamycin  and  benzoyl  perox-
ide 2.5% gel appears to provide efficacy comparable to that of 
higher concentration (5%) fixed clindamycin-benzoyl peroxide 
combination products and should optimize patient compliance 
as a result of the reduction in cutaneous tolerability reactions, 
including signs of skin irritation or dryness (56).

 Azelaic Acid
This  is  a  naturally  occurring  dicarboxylic  acid  produced  by 
yeasts of the Pityrosporum genus. It is a compound with sig-
nificant direct anti–P. acnes activity and some anticomedonal 
activity. The compound has no effect on sebaceous gland size, 
sebum production, or sebum composition, even after long-term 
application. Azelaic acid is bacteriostatic at low concentrations 
and bactericidal at higher levels.

Topical Tretinoin
Tretinoin,  which  is  the  acid  form  of  vitamin  A  (also  known 
as all-trans retinoic acid), works both by comedolysis and by 
normalizing  the  maturation  of  follicular  epithelium  so  that 
comedon  formation  ceases.  It  has  no  antiseborrheic  or  bacte-
ricidal  activity.  All  concentrations  of  tretinoin  are  useful  in 
comedonal and inflammatory acne (0.05% or 0.1% cream is the 
maximal benefit).

Despite  its  benefits,  tretinoin,  as  with  other  topical 
retinoids,  has  the  potential  to  cause  localized  irritation.  To 
minimize  this  response  while  maintaining  clinical  efficacy, 
tretinoin has been formulated in sponge-like polymeric micro-
spheres  that  encapsulate  the  active  ingredient  and  deliver 
gradually and relatively selectively to the follicle. In compari-
son with a standard 0.025% cream, a tretinoin microsphere gel 
0.1% formulation has been shown to be less irritating to normal 
skin and to cause significantly less erythema and dryness in 
patients with mild to moderate facial acne over a period of 12 
weeks (57,58).

Sebum Regulator
Intradermal Botulinum Toxin
The use of intradermal botulinum toxin type A is a new tech-
nique. The purported mechanism of action of botulinum pore 
reduction can be postulated on the basis of its known neuro-
modulatory effects. A. Shah shows that intradermal botulinum 
toxin can be injected safely in the area of the forehead, medial 
cheek, and nose without complications. A treatment of intra-
dermal botulinum toxin subjectively reduced skin oiliness and 
pore size in 17/20 patients at 1 month after injection (59).

The role of botulinum toxin in targeted therapy without 
systemic consequences may eventually make it an alternative to 
isotretinoin in the treatment of oily skin and acne-prone skin.

Seborrheic Dermatitis Treatment
Essentially,  treatment  consists  of  daily  application  of  topical 
antifungals  (topical  imidazoles),  which  act  on  Pityrosporum. 
Treatments using products with 5-α reductase inhibitors (acet-
amide and unsaponifiable plant oils) may also be used to com-
bat seborrhoea. In parallel, treatments for greasy skin will also 
be used.

CONCLUSION
In  recent  years,  considerable  progress  has  been  made  in  the 
cosmetics  industry,  which  was  originally  mainly  concerned 
with perfume and makeup. Today the emphasis is much more 
on the development of veritable medical cosmetics of increas-
ingly  high  performance,  specifically  adapted  for  all  kinds  of 
skin  types,  and  backed  up  by  rigorous  scientific  testing  pro-
cedures for efficacy and tolerance. Whether one considers the 
various  protective  roles  of  all  these  products  or  looks  more 
specifically  at,  say,  the  corrective  properties  of  treatment  for 
dry or greasy skin, all have the common aim of maintaining or 
restoring the skin to its “normal” state. At the same time, these 
products  can  also  be  used  as  complementary  treatments  for 
more classical therapy, particularly where side effects occur.

REFERENCES

1. Pierard  GE,  Lapiere  CM.  Structures  et  fonction  du  derme 
et  de  l’hypoderme.  In:  Prunieras  M,  ed.  Précis  de  Cosmétologie 
Dermatologique. Paris: Masson 1989; pp. 37–50.

2. Shuster S, Black MM, McVitie E. The influence of age and sex 
on skin thickness, skin collagen and density. Br J Dermatol 1975; 
93:639–43.

3. Agache  P.  Seborrhea.  In:  Zviak  C,  ed.  The  Science  of  Hair  Care. 

New York: Marcel Dekker 1986; pp. 469–499.

4. Roberts  D,  Marks  R.  The  determination  of  regional  and  age 
variations  in  the  rate  of  desquamation:  A  comparison  of  four 
techniques. J Invest Dermatol 1980; 74:13–16.

5. Chernosky ME. Clinical aspects of dry skin. J Soc Cosmet Chem 

1976; 27:24–28.

6. Seitz JC, Rizer RL, Spencer TS. Photographic standardization of 

dry skin. J Soc Cosmet Chem 1984; 35:423–37.

7. Curtil  L.  Améliorer  les  peaux  se`ches.  Rev  Eur  Dermatol  MST 

1992; 4:75–82.

8. Agache  P.  Sebaceous  physiology.  In:  Agache  P,  Humbert  PH, 

eds. Measuring the Skin. Berlin: Springer 2004; pp. 271–280.

9. Agache  P.  Metrology  of  the  stratum  corneum.  In:  Agache  P, 
Humbert PH, eds. Measuring the Skin. Berlin: Springer 2004;  
pp. 101–111.

10. Schatz H, Kligman AM, Manning S, et al. Quantification of dry 
(xerotic) skin by image analysis of scales removed by adhesive 
discs (D-Squames). J Soc Cosmet Chem 1993; 44:53–63.

11. Welzel  J.  Optical  coherence  tomography  in  dermatology. 

J Biomed Optics 2000; 5:83–92.

 
SKIN CARE PRODUCTS FOR NORMAL, DRY, AND GREASY SKIN 

 1 73

  12.  Corcuff P, Gonnard G, Pierard GE, et al. In vivo confocal micros-
copy scanning laser microscopy: A new design for cosmetology 
and dermatology. Scanning 1996; 18:351–5.

  13.  Elsner  P,  Berardesca  E,  Maibach  HI,  eds.  Bioengineering  of  the 
Skin: Water and the Stratum Corneum. Boca Raton, FL: CRC Press 
1994.

  14.  Courage W. Hardware and measuring principle: Corneometer. 
In: Elsner P, Berardesca E, Maibach HI, eds. Bioengineering of the 
Skin: Water and the Stratum Corneum. Boca Raton, FL: CRC Press 
1994; pp. 171–5.

  15.  Marty  JP,  Vincent  CM,  Fiquet  E.  Etude  des  propriétés 
hydratantes  de  la  cre`me  hydratante  visage  Neutrogena. 
Réalités Ther Dermatovenerol 1992; 15:37–40.

  16.  Gabard B, Clarys P, Barel AO. Comparison of commercial elec-
trical  measurement  instruments  for  assessing  the  hydration 
state  of  the  stratum  corneum.  In:  Serup  J,  Jemec  G,  Grove  G, 
eds. Handbook of Non-Invasive Methods and the Skin. 2nd edition. 
Boca Raton, FL: CRC Press 2006.

  17.  Triebskorn  A,  Gloor  M.  Infrared  spectroscopy.  A  method  for 
measurement of moisture in the stratum corneum using the ATR 
method. 16e`mes Journées Internationales de Dermocosmétologie de 
Lyon 1988; 47–55.

  18.  Wilson DR, Maibach HI. Transepidermal water loss: A review. 
In: Lévêque JL, ed. Cutaneous Investigation in Health and Disease. 
New York: Marcel Dekker 1989; pp. 113–33.

  19.  Gabard  B,  Treffel  P.  Transepidermal  water  loss.  In:  Agache  P, 
Humbert  PH,  eds.  Measuring  the  Skin.  Berlin:  Springer  2004; 
553–64.

  20.  Agache P, Elkyhyat A, Mavon A. Measurement of skin surface 
wettability. In: Agache P, Humbert PH, eds. Measuring the Skin. 
Berlin: Springer 2004; pp. 87–94.

  21.  Mavon A, Zahouani H, Redoules D, et al. Sebum and stratum 
corneum  lipids  increase  human  skin  surface  free  energy  as 
determined from contact angle measurements: A study on two 
anatomical sites. Coll Surf B Biointerface 1997; 8:147–55.

  22.  Elkhyat A, Courderot-Masuyer C, Mac-Mary S, et al. Assessment 
of spray application of Saint Gervais water effects on skin wet-
tability by contact angle measurement comparison with bidis-
tilled water. Skin Res Technol 2004; 10:283–6.

  23.  Elkhyat A, Courderot-Masuyer C, Gharbi T, et al. Influence of 
the hydrophobic and hydrophilic characteristics of sliding and 
slider surfaces on friction coefficient: In vivo human skin fric-
tion  human  skin  friction  comparison.  Skin  Res  Technol  2004; 
10:215–21.

  24.  Elkhyat  A,  Mac-Mary  S,  Humbert  PH.  Skin  wettability  and 
friction.  In:  Barel  AO,  Paye  M,  Maibach  HI,  eds.  Handbook  of 
Cosmetic Science and Technology. 3rd edition. New York: Taylor & 
Francis 2009; pp. 427–36.

  25.  Mavon A, Redoules D, Humbert PH, et al. Changes in sebum 
levels and skin surface free energy components following skin 
surface washing. Coll Surf B Biointerface 1998; 10:243–50.
  26.  Sivamani RK, Wu G, Maibach HI. Tribological studies on skin: 
Measurement of the coefficient of friction. In: Barel AO, Paye M, 
Maibach HI, eds. Handbook of Cosmetic Science and Technology, 3rd 
edition. New York: Taylor & Francis 2009; pp. 415–25.

  27.  Cua  AB,  Wilhelm  KP,  Maibach  HI.  Frictional  properties  of 
human  skin:  Relation  to  age,  sex  and  anatomical  region,  stra-
tum  corneum  hydration  and  transepidermal  water  loss.  Br  J 
Dermatol 1990; 123:473–9.

  28.  Elkhyat A, Courderot-Masuyer1 C, Gharbi T, et al. Influence of 
the hydrophobic and hydrophilic characteristics of sliding and 
slider surfaces on friction coefficient: In vivo human skin fric-
tion comparison. Skin Res Technol 2004; 10:215–21.

  29.  Agache  P.  Sebaceous  function  assessment.  In:  Agache  P, 
Humbert  PH,  eds.  Measuring  the  Skin.  Berlin:  Springer  2004; 
pp. 281–289.

  30.  Agache  P.  Evaluation  de  la  production  sébacée.  In:  Thivolet  J, 
Schmitt D, eds. Biologie de la Peau. Séminaire INSERM. Vol 148, 
1987; pp. 93–100.

  31.  Pierard GE, Pierard-Franchimont C, Lê T, et al. Patterns of fol-
licular sebum excretion rate during lifetime. Arch Dermatol Res 
1987; 279:S104–7.

  32.  Petitjean  A,  Sainthillier  JM,  Mac-Mary  S,  et  al.  Skin  radiance: 
How  to  quantify?  Validation  of  an  optical  method.  Skin  Res 
Technol 2007; 13(1):2–8.

  33.  Curtil L, Richard A. Maintenir en bon état les peaux normales. 

Rev Eur Dermatol MST 1991; 3:403–10.

  34.  Korting HC, Kober M, Mueller M, et al. Influence of repeated 
washings  with  soap  and  synthetic  detergents  on  pH  and 
resident  flora  of  forehead  and  forearm.  Acta  Derm  Venereol 
(Stockh) 1987; 67:41–7.

  35.  Ananthapadmanabhan  KP,  Moore  DJ,  Subramanyan  K.  et  al. 
Cleansing without compromise: The impact of cleansers on the 
skin  barrier  and  technology  of  mild  cleansing  Dermatol  Ther 
2004; 17;16–25.

  36.  Jeanmougin  M.  Filtres  et  écrans  solaires.  Bull  Esthet  Dermatol 

Cosmetol 1983; 7:11–21.

  37.  Msika  PH,  Boyer  F.  Efficacité  et  sécurité  de  l’oxyde  de  titane 
ultrafin en photoprotection. Bull Esthet Dermatol Cosmetol 1993; 
1:231–40.

  38.  Ditre  C,  Wu  J,  Baumann  LS,  et  al.  Innovations  in  natural 
antioxidants  and  their  role  in  dermatology.  Cutis  2008;  82(6 
Suppl):2–16.

  39.  Thiele  JJ,  Hsieh  SN,  Ekanayake  Mudiyanselage  S.  Vitamin  E: 
Critical review of its current use in cosmetic and clinical der-
matology. Dermatol Surg 2005; 31:805–13.

  40.  Farris PK. Topical vitamin C: A useful agent for treating photo-
aging  and  other  dermatologic  conditions.  Dermatol  Surg  2005; 
31:814–18.

  41.  Burke  KE.  Photodamage  of  the  skin:  Protection  and  reversal 
with topical antioxidants. J Cosmet Dermatol 2004; 3:149–55.
  42.  Wallo W, Nebus J, Leyeden JJ. Efficacy of a soy moisturizer in 
photoaging: A double-blind, vehicle controlled, 12-week study. 
J Drugs Dermatol 2007; 6:917–22.

  43.  Bonina  F,  Puglia  C,  Avogadro  M,  et  al.  The  topical  pro-
tective  effect  of  soybean  germ  oil  against  UVB-induced 
 cutaneous  erythema: An in vivo evaluation. Arch Pharm 2005; 
338:598–601.

  44.  Camouse  MM,  Hannelan  KK,  Conrad  EP,  et  al.  Protective 
effects  of  tea  polyphenols  and  caffeine.  Expert  Rev  Anticancer 
Ther 2005; 5:1061–8.

  45.  Katiyar  S,  Elmets  CA,  Katiyar  SK.  Green  tea  and  skin  can-
cer:  Photoimmunology,  angiogenesis  and  DNA  repair.  J  Nutr 
Biochem 2007; 18:287–96.

  46.  Heinrich U, Barbe B, Tronnier H. In vivo assessment of ectoin: 
A randomized, vehicle-controlled clinical trial. Skin Pharmacol 
Physiol 2007; 20(4):211–18.

  47.  Sharma S, Kaur IP. Development and evaluation of sesamol as 

an antiaging agent. Int J Dermatol 2006; 45:200–8.

  48.  Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The 

in vivo evidence. Nat Rev Drug Discov 2006; 5:493–506.

  49.  Ravagnan  G,  De  Filippis  A,  Carteni  M,  et  al.  Polytadin,  a 
natural  precursor  of  resveratrol,  induces  β  defensin  produc-
tion  and  reduces  inflammatory  response.  Inflammation  2013; 
36;26–34.

  50.  Proksch E. Protection against dryness of facial skin: A rational 

approach. Skin Pharmacol Physiol 2009; 22:3–7.

  51.  Curtil  L.  Améliorer  les  peaux  se`ches.  Rev  Eur  Dermatol  MST 

1991; 3:457–64.

  52.  Gougerot  A,  Enjolras  O.  Améliorer 

les  peaux  se`ches 

pathologiques. Rev Eur Dermatol MST 1992; 4:75–82.

  53.  Ramette G. Produits cosmétiques de protection et de correction. 
In: Prunieras M, ed. Précis de cosmétologie dermatologique. Paris: 
Masson 1981; 103–22.

  54.  Roger F. Les cosmétiques de la peau grasse. Bull Esthet Dermatol 

Cosmetol 1985; 5:13–18.

  55.  Fakhouri T, Yentzer BA, Feldman SR. Advancement in benzoyl 
peroxide-based acne treatment: Methods to increase both effi-
cacy and tolerability. J Drugs Dermatol 2009; 8:657–61.

  56.  Bucks  D,  Sarpotdar  P,  Yu  K,  et  al.  The  development  and  opti-
mization  of  a  fixed  combination  of  clindamycin  and  benzoyl 
peroxide aqueous gel. J Drugs Dermatol 2009; 8:634–8.

  57.  Nighland  M,  Grossman  R.  Tretinoin  microsphere  gel  in 
facial  acne  vulgaris:  A  meta-analysis.  J  Drugs  Dermatol  2008; 
7(8 suppl):2–8.

  58.  Jorizzo J, Grossman R, Nighland M. Tretinoin microsphere gel 

in younger acne patient. J Drugs Dermatol 2008; 7(8 suppl):9–13.

  59.  Shah  AR.  Use  of  intradermal  botulinum  toxin  to  reduce 
sebum production and facial pore size. J Drugs Dermatol 2008; 
7:847–50.

 
19

Self-Tanning Products

Stanley B. Levy

INTRODUCTION
With improvements in formulation and aesthetics, sunless or 
self-tanning products have become a viable alternative to UV 
tanning.  Public  awareness  as  to  the  hazards  of  both  natural 
and artificial UV tanning has facilitated self-tanners becoming 
a significant component of the overall suncare market. Ten to 
over  20%  of  adolescent  and  young  adults  in  both  the  United 
States  and  Australia  reported  using  these  products  (1–3). 
Individual users were also more likely to have sunburn  con-
sistent with higher use of these products in fairer caucasians. 
In other studies, exclusive users of sunless tanners were more 
likely to practice overall sun protection (4,5) and decrease their 
use of UVL tanning beds (6,7). A randomized trial at the beach 
for skin cancer prevention promoting sunless tanning reduced 
sunbathing and sunburns (8).

Dihydroxyacetone  (DHA),  a  keto-sugar,  is  the  active 
ingredient  in  sunless  or  self-tanners,  and  is  responsible 
for  darkening  the  skin  by  staining.  DHA  is  classified  in  the 
International Cosmetic Ingredient Dictionary and Handbook (9) as a 
colorant or a colorless dye. Other similar sugars such as eryth-
rulose  and  glyceraldehyede  are  occasionally  used.  Products 
containing  DHA  should  not  be  confused  with  bronzers 
intended to produce a darker color on the skin  by the  use  of 
water-soluble  colorants  or  dyes.  Other  agents  that  have  been 
used  to  enhance  skin  pigmentation  with  and  without  stimu-
lation  by  UV  with  varying  degrees  of  success  and  toxicity 
(Table 19.1) will not be discussed in detail here (10,11).

CHEMISTRY
Dihydroxyacetone  (C3H6O3)  is  a  white,  crystalline  hygro-
scopic powder. This 3-carbon sugar forms a dimer in freshly 
prepared aqueous solution (Figure 19.1). With heating to effect 
a solution in alcohol, ether, or acetone it reverts to the mono-
mer. The monomeric form is less stable but more important in 
the  browning  reaction  leading  to  the  skin  color  change  (12). 
DHA is stable between pH 4 to 6, but above pH 7 efficacy is lost 
with the formation of brown colored compounds. A buffered 
mixture at pH 5 is most stable. Heating above 38º C for  long 

Table 19.1  Tanning Product Types

Product Type

Sunless or self-tanner
Bronzer
Tanning simulator
Tanning preparation
Tan accelerator
Tanning promoter
Tanning pill
Hormone

Active Ingedient

Dihydroxyacetone
Dyes
Melanins
UVB sunscreens
Tyrosine
5-Methoxypsoralen
Canthaxanthin
Synthetic analogues α-MSH

periods of time will also effect stability. DHA needs to be stored 
in a cool, dry place, ideally 4º C and low atmospheric humid-
ity (13). Glyceraldehyde, the isomer of DHA, is also present in 
solution. Glyceraldehyde may degrade into formaldehyde and 
formic  acid.  In  acidic  solution  (pH  4),  this  isomerization  and 
therefore these latter undesirable ingredients are minimized. 
Commercially available formulations generally contain 2.5% to 
10% DHA (Figure 19.2).

The  Maillard  or  browning  reaction  has  been  defined 
as the reaction of an amino group of amino acids, peptides, 
or proteins with the glosidic hydroxyl group of sugars. DHA 
in the context of this reaction may be considered a 3-carbon 
sugar,  reacting  with  free  amino  groups  available  as  amino 
acids, peptides, and proteins supplied by the keratin to form 
products  or  chromophores  referred  to  as  melanoidins  (14). 
Melanoidins  have  some  physicochemical  properties  similar 
to  naturally  occuring  melanin  (15).  Electron  spin  resonance 
has  shown  that  free  radicals  are  produced  in  vivo  by  the 
Maillard reaction (16).

MECHANISM OF ACTION
The  site  of  action  of  DHA  is  the  stratum  corneum  (17).  Tape 
stripping  of  the  skin  quickly  removes  the  color  (18),  as  does 
mechanical  rubbing.  Deeper  staining  in  areas  with  thicker 
stratum  corneum  and  no  staining  of  mucous  membranes 
without a stratum corneum is also consistent with this being 
the  site  of  action.  DHA  may  be  used  as  a  substitute  for  dan-
syl  chloride  as  a  measure  of  stratum  corneum  turnover  time 
(19,20). Microscopic studies of stripped stratum corneum and 
hair reveal irregular pigment masses in the keratin layers (21) 
consistent  with  melanoidins.  These  melanoidins  are  formed 

CH2OH

C

O

CH2OH

HOC

CH2

CH2OH

O

O

CH2

COH

CH2OH

Monomer

Dimer

Figure 19.1  Chemical structure of DHA.

SELF-TANNING PRODUCTS 

 175

)
s
e
u
l
a
v
*
E
∆
(

l

r
o
o
c
n

i
e
g
n
a
h
c
l
a
t
o
T

12.00

10.00

8.00

6.00

4.00

2.00

0.00

Figure 19.2  Degree of skin darkening with concentrations of DHA.

2.50%

5%

6.5%

9%

Concentration of DHA

via the Maillard reaction with DHA as a sugar reacting with 
the amino groups supplied by the keratin.

APPLICATION
Following  application  of  a  typical  DHA  containing  self- 
tanning  lotion,  color  change  may  be  observed  within  an 
hour (22). This color change may be seen under Wood's light 
(black light) within 20 minutes. Maximal darkening may take 8 
to 24 hours to develop. Individuals can make several  successive 
applications  every  few  hours  to  achieve  their  desired  color. 
Color may last as long as 5 to 7 days with a single application. 
Depending  on  anatomical  application,  the  same  color  can  be 
maintained with repeat applications every 1 to 4 days. The face 
requires fewer applications but more frequent  reapplication to 
maintain the color than the extremities. Depth of color varies 
with the thickness and compactness of the stratum corneum. 
Palms and soles stain deepest necessitating washing of hands 
after  application  to  avoid  staining.  Hair  and  nails  will  color 
but  not  mucous  membranes  lacking  a  stratum  corneum  or 
 keratin  layer.  Rougher  hyperkeratotic  skin  over  the  knees, 
elbows, and ankles will color more unevenly as will older skin 
with   keratoses  and  mottled  pigmentation.  Color  will  also  be 
 maintained longer in these areas.

As in the formulation, the pH of the skin before applica-
tion may have an effect on  the tonality of the skin  color (12). 
Alkaline residues from soaps or detergents may interfere with 
the  reaction  between  DHA  and  the  amino  acids  on  the  skin 
surface,  resulting  in  a  less  natural  (more  yellow)  appearing 
color.  Wiping  the  skin  surface  with  a  hydroalcoholic,  acidic 
toner  just  prior  to  DHA  application  may  improve  results. 
Ex-vitro epidermal studies suggest that skin hydration (23) and 
relative humidity (24) influence the development of coloration.
Careful  application  is  key  with  using  these  products 
(Table 19.2). The skin may be prepared with a mild form of exfo-
liation.  Even  application  is  required,  with  lighter  application 
around elbows, knees, and ankles to avoid excessive darken-
ing in these areas. Care also needs to taken around the hair-
line where lighter hair may darken. Hands need to be washed 
immediately after use to avoid darkening of the palms, fingers, 
and nails. Skill and experience are necessary with using these 
products resulting in greater user satisfaction.

Spray-on tanning formulations may aid in providing an 
even  application.  Larger  air-operator  assisted  delivery  units 
are available for airbrushing on by a technician (25). Tanning 

booths using sprays are now commonplace in spas and salons. 
This  form  of  application  introduces  the  potential  hazard  of 
inhalation of sprayed material.

Some formulations include colorants as used in bronzers, 
including  dyes  and  caramel,  to  achieve  an  immediate  effect. 
Similarly tinting with iron oxides or titanium titanium can pro-
vide immediate color and allow the user to more easily visu-
alize  the  eveness  of  application.  Metal  oxides  may,  however, 
induce degradation of DHA (26). Vitamins, botanical extracts, 
antioxidants (27), anti-irritants, and even alpha hydroxy acids 
may  be  added  to  broaden  the  manufacturer's  claims  made 
with  a  given  product.  The  addition  of  sunscreen  ingredients 
to self-tanners warrants a more detailed discussion in the next 
section.

SUNSCREEN ACTIVITY
DHA itself has at most a modest effect on SPF (28), providing 
perhaps SPF 3 or 4 protection. SPF increases with DHA concen-
tration and number of applications (29). Low level SPF persists 
for several days, decreasing with loss of color (30). The brown 
color obtained on the skin does absorb in the low end of the 
visible spectrum with overlap into long UVA and may provide 
some UVA I protection (31). Melanoidins can act as free-radical 
scavengers as they demonstrate an electron spin resonance sig-
nal (32). Superficial skin coloration induced by frequent topical 
application of DHA in high concentrations delays skin cancer 
development  in  hairless  mice  irradiated  with  moderate  UV 
doses (33).

Individuals  using  DHA-containing 

tanning  prod-
ucts  need  to  be  cautioned  that  despite  visible  darkening  of 
their  skin,  these  products  provide  minimal  sun  protection. 
Confusion may be compounded by the addition of UV filters 
to  the  formulation  providing  significant  sun  protection.  The 
stated  SPF  for  the  product  is  applicable  for  a  few  hours  after 
application, but not for the days during which the skin color 
change may remain perceptible.

INDICATIONS
Even  with  recent  improvement  in  DHA  formulations,  the 
color  achieved  remains  dependent  on  skin  type.  Individuals 
of medium complexion  with skin  phototypes  II  or III (34),  as 
opposed to those who are lighter or darker, will obtain a more 
pleasing color. Individuals with underlying golden skin tones 

 
 
 
 
 
 
 
176 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 19.2  Application Instructions For Self-Tanners

Prepare skin with mechanical exfoliation
Spot test
Wipe skin with hydroalcoholic acidic toner
Apply carefully and evenly
Apply less to thicker skin
Allow to dry
Reapply regularly
Remember sun protection

will achieve better results than individuals with a rosy, sallow, 
or olive complexion. Older consumers with roughened, hyper-
keratotic skin or mottled pigmentation with freckling may be 
less pleased with their use.

Dermatologists  regularly  recommend  these  products 
for tanning as a safe alternative to UV exposure. They may be 
used to camouflage some skin irregularities such as leg spi-
der veins. Light to medium complected patients with vitiligo 
who show increased contrast with the vitiliginous areas with 
natural or unavoidable tanning in their normal skin may also 
benefit  (35,36).  DHA  provides  some  protection  for  individu-
als  with  certain  photosensitivity  disorders  (37).  Protection 
of  uninvolved  skin  by  DHA  during  psoralen-UVA  (PUVA) 
treatment  allows  higher  UVA  exposures  to  be  tolerated, 
with fewer treatments resulting in faster clearing, known as 
Turbo-PUVA (38).

SAFETY
The  visible  color  change  associated  with  the  use  of  artificial 
tanning products might suggest to some users that these prod-
ucts  are  hazardous.  Based  on  the  chemistry  of  DHA  and  its 
toxicological  profile,  it  can  be  considered  nontoxic.  It  reacts 
quickly in the stratum corneum, minimizing systemic absorp-
tion. The acute toxicity of DHA was investigated for diabetics 
in the 1920s, with oral intake well tolerated (39). The phosphate 
of DHA is found naturally as one of the intermediates in the 
Krebs  cycle.  Toxicity  based  on  inhalation  in  closed  spray-on 
tanning booths is unknown.

Contact dermatitis to DHA has only rarely been reported 
(40,41). As with other topical products with active ingredients, 
such as sunscreens, much of the reported sensitivity is second-
ary to other ingredients in the vehicle (42). Adverse reactions 
are more likely to occur on the basis of irritation and not true 
allergy.  Ultimately  all  claims  related  to  product  safety  are 
based on testing the final formulation.

Although not approved by regulatory agencies, some of 
the alternative agents for increasing skin pigmentation (Table 
19.1)  are  available  to  individuals.  Tanning  pills  containing 
carotenoids such as canthaxanthin have been reported to cause 
retinopathy, urticaria, hepatitis, and aplastic anemia (43). More 
recently,  injections  of  analogues  of  melanocyte-stimulating 
hormone may be gaining in popularity (44). Of potential ben-
efit to individuals with photosensitive disorders (45), synthetic 
analogues  of  α-MSH  may  drive  proliferation  of  neoplastic 
melanocytic cells in the nevi of predisposed individuals (46).

CONCLUSION
Increasing awareness as to the hazards of UV light should fuel 
ongoing  interest  in  self-tanning  products.  It  is  incumbent  on 
dermatologists  to  be  familiar  with  this  category.  The  benign 
toxicologic  profile  of  DHA  reinforces  the  notion  that  these 

products represent a safe alternative to a UV-induced tan. The 
results obtained are dependent on the final formulation, indi-
vidual  application  technique,  and  the  consumer's  skin  type. 
Greater  experience  in  formulation  combined  with  increasing 
sophistication on the part of the consumers has led to increas-
ing satisfaction with the use of these products.

Users  need  to  be  clearly  informed  that  these  products 
do not offer significant protection against UVB. If formulated 
with  standard  sunscreens,  individuals  should  be  cautioned 
that the duration of UV protection is more short-lived than the 
color change.

REFERENCES

1. Brooks  K,  Brooks  D,  Dajani  Z,  et  al.  Use  of  artificial  tanning 
products  among  young  adults.  J  Am  Acad  Dermatol  2006; 
54(6):1060–6.

2. Beckmann KR, Kirke BA, McCaul KA, et al. Use of fake tanning 
lotions  in  the  South  Australian  population.  Med  J  Aust,  2001; 
174(2):75–8.

3. Cokkinides VE, Bandi P, Weinstock MA, Ward E. Use of sunless 
tanning products among U.S. adolescents aged 11 to 18 years. 
Arch Dermatol 2010; 146(9):987–92.

4. Stryker  JE,  Yaroch  AL,  Moser  RP,  et  al.  Prevalence  of  sunless 
tanning  product  use  and  related  behaviors  among  adults  in 
the  United  States:  Results  from  a  national  survey.  J  Am  Acad 
Dermatol 2007; 56(3):387–90.

5. Mahler HI, Kulik JA, Harrell J, et al. Effects or UV photographs, 
photoaging information, and use of sunless tanning lotion on 
sun protection behaviors. Arch Dermatol 2005; 141(3):373–80.
6. Sheehan DJ, Lesher JL. The effect of sunless tanning on behav-
ior in the sun: A pilot study. South Med J 2005; 98(12):1192–5.
7.  Sahn RE, McIlwain MJ, Mager KH, et al. A cross-sectional study 
examining  the  correlation  between  sunless  taninng  product 
use  and  tanning  belief  and  behaviors.  Arch  Dermatol  2012; 
148(4):448–54.

8.  Pogato SL, Schneider KL, Oleski J, et al. The sunless study: A 
beach rendomized trial of a skin cancer prevention intervention 
promoting sunless tanning. Arch Dermatol 2010; 146(9):979–84.
9. Wenninger  JA,  McEwen  GN  Jr,  eds.  International  Cosmetic 
Ingredient  Dictionary  and  Handbook.  11th  edition.  Washington: 
The Cosmetic, Toiletry, and Fragrance Association, 2006.

10. Brown DA. Skin pigmentation enhancers. J Photochem Photobiol 

2001; 63:148–61.

  11.  O’Leary RE, Diehl J, Levins PC. Update on tanning: More risks: 

Fewer benefits. J Am Acad Dermatol 2014; 70:562–8.

  12.  Maes  DH,  Marenus  KD.  Self-tanning  products.  In  Baran  R, 
Maibach  HI,  ed.  Textbook  of  Cosmetic  Dermatology,  3rd  edition. 
Boca Raton, FL: Taylor & Francis 2005; pp.225–7.

  13.  Aretz C, Buczys R, Buchholz, Driller H. Degradation reactions 

of dihydroxyacetone. Euro Cosmetics 1999; 6:32–6.

  14.  Wittgenstein  E,  Berry  HK.  Reaction  of  dihydroxyacetone 
(DHA) with human skin callus and amino compounds. J Invest 
Dermatol 1961; 36:283–6.

  15.  Meybeck A. A spectroscopic study of the reaction products of 
dihydroxyacetone  with  amino  acids.  J  Soc  Cosmet  Chem  1977; 
28:25–35.

  16.  Lloyd  RV,  Fong  AJ,  Sayre  RM.  In  vivo  formation  of  Maillard 
reaction  free  radicals  in  mouse  skin.  J  Invest  Dermatol  2001; 
117:740–2.

  17.  Goldman L, Barkoff J, Blaney D, Nakai T, Suskind R. The skin 
coloring  agent  dihydroxyacetone.  General  Practitioner  1960; 
12:96–8.

  18.  Maibach  HI,  Kligman  AM.  Dihydroxyacetone:  A  suntan-

simulating agent. Arch Dermatol 1960; 82:505–7.

19. Purcetti G, Leblanc RM. A sunscreen tanning compromise: 3D 
visualization  of  the  actions  of  titanium  dioxide  particles  and 
dihydroxyacetone  on  human  epidermis.  Photochem  Photobiol 
2000; 71:426–30

 
 
 
SELF-TANNING PRODUCTS 

 177

  20.  Pierard  GE,  Pierard-Franchimont  C.  Dihydroxyacetone  test 
as  a  substitute  for  the  dansyl  chloride  test.  Dermatology  1993; 
186(2):133–7.

  21.  Forest SE, Grothaus JT, Ertel KD, Rader C, Plante J. Flourescence 
spectral  imaging  of  dihydroxyacetone  on  skin  in  vivo. 
Photochem Photobiol 2003; 77:524–30.

  22.  Levy SB. Dihydroxyacetone-containing sunless or self-tanning 

lotions. J Am Acad Dermatol 1992; 27:989–93.

  34.  Fitzpatrick TB. The validity and practicality of sunreactive skin 

types I through IV. Arch Dermatol 1988; 124:869–71.

  35.  Rajatanavin  N,  Suwanachote  S,  Kulkolllakarn  S.  Dihydroxy-
acetone:  A  safe  camouflaging  option  in  vitiligo.  Int  J  Dermatol 
2008; 47:402–6.

  36.  Suga Y, Ikejima A, Matsuba S, Ogawa H. Medical pearl: DHA 
application  for  camouflaging  segmental  vitiligo  and  piebald 
lesions. J Am Acad Dermatol 2002; 47:436–8.

  23.  Nguyen BC, Kochevar IE. Influence of hydration on dihydroxy-
acetone-induced  pigmentation  of  stratum  corneum.  J  Invest 
Dermatol 2003; 120:655–61.

  37.  Fusaro  RM,  Johnson  JA.  Photoprotection  of  patients  sensitive 
to short and/or long ultraviolet light with dihydroxyacetone/
naphthoquinone. Dermatologica 1974; 148:224–7.

  24.  Nguyen BC, Kochevar IE. Factors influencing sunless tanning 

with dihydroxyacetone. Br J Dermatol 2003; 149:332–40.
  25.  Rogers CJ. Spray-on tanning. Aesthetic Surg J 2005; 25:413–15.
  26.  Chaudhuri  RK.  Dihydroxyactone:  Chemistry  and  and  appli-
cations  in  self-tanning  products.  In:  Schlossman  ML,  ed.  The 
Chemistry and Manufacture of Cosmetics. Volume III. Carol Stream, 
IL: Allured Publishing 2002; pp. 383–402.

  38.  Taylor  CR,  Kwagsukstith  C,  Wimberly  J,  Kollias  N,  Anderson 
RR.  Turbo-PUVA:  Dihydroxyacetone-enhanced  photochemo-
therapy  for  psoriasis:  A  pilot  study.  Arch  Dermatol  1999; 
135:540–4.

  39.  Guest GM, Cochrane W, Wittgenstein E. Dihydroxyacetone tol-
erance test for glycogen storage disease. Mod Prob Paediat 1959; 
4:169–78.

  27.  Muizzuddin N. Marenus KD, Maes DH. Tonality of suntan vs 
sunless tanning with dihydroxyacetone. Skin Res Technol 2000; 
6(4):199–204

  40.  Bovenschen  HJ,  Korver  JEM,  Van  der  Valk  PGM.  Contact 
dermatitis  to  self-tanning  products.  Contact  Dermatitis  2009; 
60:290–1.

  28.  Muizzuddin N. Marenus KD, Maes DH. UV-A and UV-B pro-
tective  effect  of  melanoids  formed  with  dihydroxyacetone 
and skin. Poster 360 presented at: 55th Annual Meeting of the 
American Academy of Dermatology; 1997; San Francisco, CA.

  29.  Faurschou  A,  Janjua  NR,  Wulf  HC.  Sun  protection  effect  of 

dihydroxyacetone. Arch Dermatol 2004; 140:886–7.

  30.  Faurschou  A,  Wulf  HC.  Durability  of  the  sun  protection  fac-
tor provided by dihydroxyacetone. Photodermatol Photoimmunol 
Photomed 2004; 20:239–42.

  31.  Johnson  JA,  Fusaro  RM.  Protection  against  long  ultravio-
let  radiation:  Topical  browning  agents  and  a  new  outlook. 
Dermatologica 1987; 175:53–7.

  32.  Lloyd  RV,  Fong  AJ,  Sayre  RM.  In  vivo  formation  of  Maillard 
reaction  free  radicals  in  mouse  skin.  J  Invest  Dermatol  2001; 
117:740–2.

  33.  Petersen AB, Na R, Wulf HC. Sunless skin tanning with dihy-
droxyacetone delays broad spectrum ultraviolet photocarcino-
genesis in hairless mice. Mutat Res 2003; 542:129–38.

  41.  Kimura T. Contact dermatitis caused by sunless tanning treat-
ment with dihydroxyacetone in hairless descendants of mexi-
can hairless dogs. Environ Toxicol 2008; 1:1–7.

  42.  Foley  P,  Nixon  R,  Marks  R,  Frowen  K,  Thompson  S.  The  fre-
quency  of  reaction  to  sunscreens:  Results  of  a  longitudinal 
population-based  study  on  the  regular  use  of  sunscreens  in 
Australia. Br J Dermatol 1993; 128:512–18.

  43.  Bluhm  R,  Branch  R,  Johnston  P.  Aplastic  anemia  associated 
with canthaxanthin ingested for tanning purposes. JAMA 1990; 
264:1141–2.

  44.  Langan  EA,  Nie  Z,  Rhodes  LE.  Melanotropic  peptides:  More 
than just ‘Barbie drugs’ and ‘sun-tan jabs’? Br J Dermatol 2013; 
163:451–5.

  45.  Harms  J,  Lautenschlager  S,  Minder  C,  Minder  E.  An 
α-melanocyte-stimulating hormone analogue in erythropoietic 
protoporphyria. NEJM 2009; 360:307–8.

  46.  Carderones  AR,  Grichnik 

JM.  α-melanocytic-stimulating 

hormone-induced eruptive nevi. Arch Derm 2009; 145:441–4.

 
20

Astringents, Masks, and Ancillary Skin Care Products

Zoe Diana Draelos

INTRODUCTION
Ancillary skin care encompasses products designed to supple-
ment basic cleansing and moisturizing of the skin. Frequently, 
these products are recommended as part of a skin care routine 
designed  to  impart  benefits  above  and  beyond  basic  hygiene 
needs or maintenance of the skin barrier. Ancillary skin care 
products  include  astringents,  exfoliants,  facial  scrubs,  epi-
dermabrasion, textured cloths, mechanized skin care devices, 
and  face  masks.  This  chapter  discusses  these  ancillary  skin 
care products and their dermatologic value.

ASTRINGENTS
Astringents are liquids applied to the face following cleansing. 
They  comprise  a  broad  category  of  formulations  known  by 
many terms: toners, clarifying lotions, controlling lotions, pro-
tection  lotions,  skin  fresheners,  toning  lotions,  T-zone  tonics, 
etc. Originally, astringents were developed to remove alkaline 
soap  scum  from  the  face  following  cleansing  with  lye-based 
soaps and high–mineral content well water. The development 
of synthetic detergents (syndets) and public softened water sys-
tems  greatly  decreased  the  amount  of  post-washing  residue. 
A  new  use  for  astringents  was  found  when  cleansing  cream 
became a preferred method of removing facial cosmetics and 
environmental  dirt.  The  astringent  then  became  an  effective 
product  for  removing  the  oily  residue  left  behind  following 
cleansing cream use.

Astringent  formulations  are  presently  available  for  all 
skin types (oily, normal, dry, sensitive, photoaged, etc.), with a 
variety of uses (1). Oily skin astringents contain a high concen-
tration of alcohols, water, and fragrance functioning to remove 
any sebum left behind following cleansing to produce a clean 
feel and to possibly deliver some treatment product to the face. 
For  example,  2%  salicylic  acid  or  witch  hazel  may  be  added 
for  a  keratolytic  and  drying  effect  on  the  facial  skin  of  acne 
patients. Clays, starches, or synthetic polymers may be added 
to  absorb  sebum  and  minimize  the  appearance  of  facial  oil. 
Astringents for normal skin are generally formulated to give 
the  skin  a  clean,  fresh  feeling  without  much  dryness.  They 
may  contain  propylene  glycol  to  function  as  a  humectant,  a 
water-attracting mild moisturizing agent.

Products  formulated  for  dry  or  sensitive  skin  are 
 alcohol-free  and  are  based  on  lightweight  occlusive  mois-
turizers,  such  as  silicone  (dimethicone,  cyclomethicone).  In 
addition, soothing agents such as allantoin, guaiazulene, and 
quaternium-19 may be added. The newest type of astringents 
are  those  designed  for  photoaged  skin  that  contain  salicylic 
acid  (β-hydroxy  acid)  or  glycolic  acid  (α-hydroxy  acid)  to  aid 
in keratinocyte exfoliation and achieve smoother, more evenly 
pigmented skin.

EXFOLIANTS
Exfoliants are solutions, lotions, or creams applied to the face 
following cleansing designed to hasten stratum corneum exfo-
liation.  They  are  similar  in  function  to  the  antiaging  astrin-
gents previously discussed. Their exfoliant effect is based on 
the use of α-, poly-, or β-hydroxy acids, thus inducing chemical 
exfoliation.

Exfoliants  containing  hydroxy  acids  produce  both 
epidermal and dermal changes. The epidermal changes are 
immediate and occur at the junction of the stratum corneum 
and stratum granulosum. They consist of a reduction in the 
thickness  of  the  hyperkeratotic  stratum  corneum  due  to 
decreased corneocyte adhesion (2). The dermal effects, which 
are delayed, consist of increased glycosaminoglycan synthe-
sis (3). These effects are most pronounced with the α-hydroxy 
acids  (glycolic  acid,  lactic  acid,  malic  acid),  which  rapidly 
penetrate  the  epidermis  to  enter  the  dermis.  Individuals 
with  sensitive  skin  may  not  be  able  to  tolerate  the  low  pH 
of  3  required  to  cause  this  epidermal  renewal  (4).  This  has 
led  to  development  of  polyhydroxy  acids  (gluconolactone, 
lactobionic  acid,  ferulic  acid),  which  are  larger  molecular 
weight hydroxy acids that do not penetrate as rapidly to the 
dermis.  This  produces  less  irritation  allowing  polyhydroxy 
acid use by persons with sensitive skin, eczema, and atopic 
dermatitis.

Another  mechanism  for  reducing  the  irritation  of 
chemical  exfoliants  is  through  neutralization  or  buffering. 
Irritation  can  also  be  minimized  by  raising  the  exfoliant 
pH through sodium hydroxide neutralization; however this 
also reduces the exfoliation produced. The use of buffering 
agents, such as phosphoric acid or monosodium phosphate, 
is  preferable  since  the  buffer  maintains  the  product  at  a 
desired pH (5). Ideally, the pH of an exfoliant solution should 
not be lower than 3. More exfoliation is induced with lower 
pH,  since  the  hydroxy  acid  concentration  is  increased,  but 
more  irritation  in  the  form  of  stinging  and  burning  is  also 
expected.

β-Hydroxy acids, such as salicylic acid, may also be used, 
but do not produce dermal penetration. Salicylic acid is techni-
cally  not  a  β-hydroxy  acid,  but  rather  a  phenolic  compound, 
but  the  marketing  nomenclature  has  popularized  this  termi-
nology. Salicylic acid is an oil-soluble acid, as compared to the 
α-hydroxy  acids  that  are  mainly  water  soluble,  and  remains 
on  the  skin  surface.  Since  exfoliation  occurs  on  the  skin  sur-
face, this is a desirable characteristic that minimizes irritation. 
Salicylic acid is also able to exfoliate within the follicular ostia, 
making it the exfoliant of choice in acne patients as well as sen-
sitive skin patients. Salicylic acid is listed on the acne mono-
graph and functions as a keratolytic in many over-the-counter 
acne preparations.

ASTRINGENTS, MASKS, AND ANCILLARY SKIN CARE PRODUCTS 

 179

FACIAL SCRUBS
Facial  scrubs  are  mechanical  exfoliants,  as  opposed  to  the 
chemical  exfoliants  previously  discussed,  employing  small 
granules  in  a  cleansing  base  to  enhance  corneocyte  desqua-
mation.  The  scrubbing  granules  may  be  polyethylene  beads, 
aluminum oxide, ground fruit pits, or sodium tetraborate deca-
hydrate granules aiding in the removal desquamating stratum 
corneum  from  the  face  (6).  Sibley  et  al.  considered  abrasive 
scrubbing  creams  effective  in  controlling  excess  sebum  and 
removing  desquamating  tissue  (7).  However,  they  can  cause 
epithelial damage if used too vigorously. This view is held by 
Mills  and  Kligman,  who  noted  that  the  products  produced 
peeling  and  erythema  without  a  reduction  in  comedones. 
Aluminum oxide and ground fruit pits provide the most abra-
sive scrub because of their rough-edged particles, followed by 
polyethylene beads, which are smoother and produce less stra-
tum corneum removal. Sodium tetraborate decahydrate gran-
ules become softer and dissolve during rubbing, providing the 
least abrasive scrub.

A currently popular trend in facial exfoliant scrubs is the 
production of warmth. These products are labeled as “self-heat-
ing” scrubs. The heat is produced as part of an exothermic reac-
tion resulting in the heat by-product. The heat does not increase 
exfoliant efficacy but is added for consumer comfort and mar-
keting purposes. Sometimes these heated exfoliant scrubs are 
preceded by a self-administered hydroxy acid peel, thus com-
bining both chemical and physical exfoliation into one kit.

Epidermabrasion and Textured Cloths
Another  mechanical  method  of  enhancing  stratum  corneum 
exfoliation  has  been  labeled  epidermabrasion  by  Durr  and 
Orentreich, who examined the use of a nonwoven polyester fiber 
web sponge for the removal of keratin excrescences and trapped 
hairs  in  pilosebaceous  ducts  (8–10).  Other  epidermabrasion 
implements include rubber puffs, sea sponges, loofahs, and the 
most  recent  addition,  textured  fibered  face  cloths.  The  fibered 
face cloths have become a large segment of the current epiderm-
abrasion marketplace and therefore are discussed in detail.

Fibered  cloths  are  extremely  versatile  dermatologic 
devices. They can be premoistened and impregnated with sur-
factants  to  cleanse  the  face,  be  perfumed  containing  volatile 
solvents  to  freshen  the  face,  be  packaged  dry  with  lipids  and 
detergents to clean the face, be covered with a plastic film pouch 
with microscopic holes to time-release an active ingredient onto 
the  skin  surface,  and  be  textured  with  patterns  to  physically 
exfoliate the skin. Even though many of the facial uses of fibered 
cloths are new, the cloths have been around for 30 years.

The first fibered cloths were introduced as baby wipes. 
They  were  made  from  carded  rayon  fibers  that  were  held 
together  by  adhesive  binders.  They  exhibited  wonderful 
strength for their thickness, but were rather coarse and a fre-
quent cause of irritant contact dermatitis due to both the sur-
factants employed and the rough cloth texture. The need for a 
strong but soft cloth led to development of air-laid nonwoven 
fibered cloths in the mid-1970s. These cloths were composed of 
wood pulp, polyester, and adhesive binders. They were thicker 
and softer. The technology was further developed in the 1980s 
by adding both cotton and rayon fibers to improve strength.

Modern fibered cloth technology focused on creating a 
soft wipe with excellent strength to prevent tearing. The fibers 
used are a combination of polyester, rayon, cotton, and cellu-
lose held together via heat through a technique known as ther-
mobonding.  Additional  strength  is  imparted  to  the  wipe  by 

hydroentangling the fibers. This is achieved by entwining the 
individual rayon, polyester, and wood pulp fibers with high-
pressure  jets  of  water.  Thermobonding  and  hydroentangling 
have eliminated the use of adhesive binders, thereby creating 
a soft, strong cloth suitable for facial use.

Face cloths are available both dry and moist. The dry pack-
aged cloths are impregnated with a cleanser that foams modestly 
when the cloth is water moistened. The type of cleanser in the 
cloth  can  produce  aggressive  sebum  removal  for  oily  skin  or 
minimal  sebum  removal  for  dry  skin.  Humectants  and  emol-
lients can also be added to the cloth to decrease barrier damage 
or to smooth xerotic skin scale. Thus, face cloths can be designed 
for normal to oily skin, normal to dry skin, or sensitive skin.

In  addition  to  the  composition  of  the  ingredients  preap-
plied to the dry cloth, the weave of the cloth will also determine 
its  cutaneous  effect.  There  are  two  types  of  fiber  weaves  used 
in facial products: open weave and closed weave. Open weave 
cloths are so named because of the 2- to 3-mm windows in the 
cloth between the adjacent fiber bundles. These cloths are used 
in  persons  with  dry  and/or  sensitive  skin  to  increase  the  soft-
ness of the cloth and decrease the surface area contact between 
the cloth and the skin, yielding a milder exfoliant effect. Closed 
weave  cloths,  on  the  hand,  are  designed  with  a  much  tighter 
weave and are double-sided. One side of the closed weave cloth 
is textured and impregnated with a synthetic detergent cleanser 
designed to optimize the removal of sebum, cosmetics, and envi-
ronmental dirt while providing an exfoliant effect. The opposite 
side of the cloth is smooth and designed for rinsing the face and 
possibly applying skin conditioning or antiaging agents. Some of 
the newer cloths contain a central petrolatum strip designed to 
leave behind a moisturizer on the skin during the rinse process.
The texture of the cloth provides gentle mechanical exfo-
liation  that  may  be  valuable  in  the  patient  who  cannot  toler-
ate  chemical  exfoliation  with  hydroxy  acids.  The  mechanical 
exfoliation  can  be  achieved  on  the  skin  surface  and  around 
the follicular ostia because of the ability of the textured cloth 
to  traverse  the  irregular  topography  of  the  skin  more  effec-
tively than the hands or a washcloth. The degree of exfoliation 
achieved  is  dependent  on  the  cloth  weave,  the  pressure  with 
which the cloth is stroked over the skin surface, and the length 
of time the cloth is applied.

Figure  20.1  provides  a  demonstration  of  the  amount  of 
facial foundation left behind on the skin after cleansing with 
a variety of different techniques. The pads contain unremoved 
cosmetic.  Notice  that  there  is  a  small  amount  of  cosmetic  on 
the  pad  after  using  either  a  closed  weave  or  an  open  weave 
cloth.  More  cosmetic  is  left  behind  after  soap  cleansing  and 
even  more  after  using  a  lipid-free  cleanser.  This  illustration 
demonstrates the cleansing attributes of a face cloth.

(a)

(b)

(c)

(d)

Figure  20.1  Cleansing  cloth:  facial  foundation  removal;  (a) 
normal/dry; (b) normal/oily; (c) syndet bar; (d) lipid free.

 
180 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure  20.2  An  example  of  a  currently  marketed  handheld 
reusable cleansing pad for facial use.

Handheld Reusable Textured Cleansing Pads
The new environmental concerns regarding disposable cleans-
ing  cloths  has  led  to  a  revival  of  the  old-fashioned  cleansing 
pad. Originally, these were textured flat rubber brushes with 
a  ring  on  the  back  for  middle  finger  insertion.  The  pad  had 
numerous tiny rubber bristles to which soap was applied and 
the face was scrubbed with finger pressure on the back of the 
pad.  Similar  devices  were  in  vogue  for  cleansing  the  male 
scalp. These pads have seen a revival in the form of a flexible 
silicone pad with numerous carefully designed fingers that are 
stroked over the face (Figure 20.2). The back of the pad contains 
a suction cup to adhere the pad to the mirror or shower door 
for easy use. These pads are reusable and designed to allow the 
cleansing fingers to adequately clean the skin in and around 
the pores without injury.

MECHANIZED SKIN CARE DEVICES
Mechanization  of  the  epidermabrasion  process  is  known  as 
microdermabrasion. This is a procedure performed by esthe-
ticians  and  paramedical  personnel  where  small  particulates, 
such as aluminum, silica, and baking soda, are sprayed against 
the skin surface and simultaneously removed with a vacuum. 
Microdermabrasion  simply  represents  another  technique  to 
induce  stratum  corneum  exfoliation,  a  natural  body  process 
that slows with advancing age.

A variety of devices are available to exfoliate the facial 
skin. These include rotary brushes that drag synthetic bristles 
across the skin surface to physically remove the stratum cor-
neum. These devices are sold with a special cleanser to remove 
sebum  and  clean  the  bristles  simultaneously.  A  variant  of 
this  technology  used  scrubbing  pads  of  various  roughnesses 
to  produce  exfoliation.  The  scrubbing  pads  were  held  on  the 
device head with adhesive and could be replaced when worn. 
These devices vibrated instead of rotating to remove skin scale.
A third type of facial cleansing device produces a sonicat-
ing motion, similar to the sonicating electric toothbrushes. The 
handheld device runs on a rechargeable battery that is attached 

to  a  miniaturized  motor  creating  an  oscillatory  motion  of  the 
brush head. This oscillatory sonic motion allows the brush bris-
tles to traverse the dermatoglyphics, facial pores, and facial scars 
more adeptly than other mechanized cleansing methods.

FACE MASKS
Face masks are the last ancillary skin care product discussed 
and consist of substances applied to the face for an extended 
time  period  for  therapeutic  and/or  esthetic  purposes.  Masks 
are  available  for  home  purchase  and  professional  use.  They 
may be packaged in a jar or bottle for immediate application 
to  the  face  or  as  dry  ingredients  in  a  pouch  for  mixing  with 
water. Some premixed masks are applied to a disposable cloth, 
similar to the cleansing cloths previously described. The cloth 
is shaped to fit over the face or body area and is removed from 
the pouch moistened with the ingredients and ready for appli-
cation. Once the liquids have evaporated from the mask, it is 
removed and disgarded. These instant masks are very popu-
lar  in  the  Orient,  but  are  quickly  gaining  popularity  around 
the  world  for  their  easy  use  and  efficiency.  Typically,  a  mask 
is applied on a weekly basis to provide a time for relaxation, 
an  esthetically  pleasing  sensation,  and  skin  benefits.  There 
are four basic mask formulations: wax-based, vinyl or rubber-
based, hydrocolloid, and earth-based.

Wax Masks
Wax masks are popular among women who visit professional 
spas for their warm, esthetically pleasing feel. They are com-
posed of beeswax or, more commonly, paraffin wax to which 
petroleum jelly and cetyl or stearyl alcohols have been added 
to provide a soft, pliable material for facial application with a 
soft brush. The wax is heated in a pot placed in a water bath to 
control the temperature and prevent burning. Sometimes the 
wax is dipped from the pot and painted over the face and other 
times  it  may  be  brushed  over  thin  cotton  gauze  draped  over 
the face. Gauze is commonly used to enable the facial techni-
cian to remove the wax in one piece (11). Gauze also prevents 
the  wax  from  sticking  to  the  vellus  hairs  on  the  face,  which 
may be painfully epilated as the wax is peeled from the face.

Wax-based  face  masks  temporarily  impede  cutaneous 
transepidermal water loss. This effect is limited only to the time 
the mask is in direct contact with the face, unless a suitable occlu-
sive moisturizer is applied immediately following mask removal. 
For this reason, they are popular in persons with dry skin.

Vinyl and Rubber-Based Masks
Vinyl  and  rubber-based  masks  are  popular  masks  for  home 
use, since they are easily squeezed from a pouch onto the face 
and  removed  in  one  piece.  Rubber-based  masks  are  usually 
based  on  latex,  while  vinyl-based  masks  are  based  on  film-
forming substances, such as polyvinyl alcohol or vinyl acetate. 
Because  of  the  concern  over  latex  allergy,  there  are  no  true 
rubber-based masks for home use.

Vinyl  masks  are  squeezed  premixed  from  a  tube  or 
pouch and applied with the fingertips or a wooden applicator 
to the face. Upon evaporation of the vehicle, a thin flexible vinyl 
film remains behind on the face. The mask is generally left in 
contact with the skin for 10 to 30 minutes and then peeled in 
one sheet by loosening the edges from the face.

Vinyl  and  rubber  masks  are  appropriate  for  all  skin 
types. The evaporation of the vehicle from the wet mask creates 
a cooling sensation, and the shrinking of the mask with drying 
may  give  the  impression  that  the  skin  is  actually  tightening. 

 
ASTRINGENTS, MASKS, AND ANCILLARY SKIN CARE PRODUCTS 

 181

These  masks  can  temporarily  impede  transepidermal  water 
loss while they are in contact with the skin.

Hydrocolloid Masks
Hydrocolloid masks are used both in professional salons and 
at home. Hydrocolloids are substances such as oatmeal that are 
of large molecular weight and thus interfere with transepider-
mal  water  loss.  These  masks  are  formulated  from  gums  and 
humectants and enjoy tremendous popularity since many spe-
cialty  ingredients  are  easily  incorporated  into  their  formula-
tion.  They  are  marketed  in  the  form  of  dry  ingredients  in  a 
sealed  pouch  that  must  be  mixed  with  warm  water  prior  to 
application. The resulting paste is then smeared over the face 
with the hands or a wooden blade and allowed to dry (12).

Hydrocolloid  masks  leave  the  skin  feeling  smooth  and 
create the sensation of skin tightening as the water evaporates 
and the mask dries. Temporary moisturization can occur while 
the mask is on the skin. Specialty additives such as honey, egg 
whites, chamomile flowers, aloe vera, almond oil, zinc oxide, 
sulfur, avocado, and witch hazel may be used to customize the 
mask. Many spas have their own special concoction. By vary-
ing the ingredients, masks can be created for all skin types. In 
addition, herbal medicine can be practiced by combining vari-
ous healing plants into a poultice for facial application. These 
hydrocolloid ingredients are well suited for the instant mask 
application previously described for home use.

Earth-Based Masks
Earth-based masks, also known as paste masks or mud packs, 
are  formulated  of  absorbent  clays  such  as  bentonite,  kaolin, 
or  china  clay.  The  clays  produce  an  astringent  effect  on  the 
skin  making  this  mask  most  appropriate  for  oily-complected 
patients.  The  astringent  effect  of  the  mask  can  be  enhanced 
through the addition of other substances such as magnesium, 
zinc oxide, and salicylic acid.

SUMMARY
This  chapter  has  discussed  the  various  ancillary  skin  care 
products for purchase in the current marketplace. Astringents 
represent  a  broad  category  and  may  impart  both  cleansing 
and moisturizing effects to the skin, depending on formula-
tion  and  skin  type.  Exfoliants,  which  became  popular  when 
glycolic acid was introduced to the antiaging marketplace, can 
contain both chemical and physical exfoliating ingredients to 
enhance desquamation of the stratum corneum. Physical exfo-
liating  agents  are  commonly  packaged  as  particulate  facial 

scrubs,  woven  sponges,  or  textured  cloths.  Textured  cloths 
and reusable silicone cleansing pads are the newest introduc-
tion  and  can  function  like  washcloths  or  may  leave  behind 
ingredients on the skin surface. Mechanized skin care devices 
attempt  to  deliver  at-home  microdermabrasion  with  rotary, 
vibrating,  or  sonicating  motors.  Finally,  face  masks  deliver 
both esthetic and skin care benefits in a professional or home 
environment.

Ancillary skin care is an interesting area that combines 
devices and products to offer innovative solutions to skin care. 
These products can be used alone or in combination to deliver 
exfoliant, antiaging, moisturizing, astringent, or aesthetic ben-
efits. Most of the new introductions in the commercial skin care 
market have occurred in this arena, since the profit margin is 
high and consumers are now focusing on cleansing as a way of 
enhancing the skin appearance. While cleansing has tradition-
ally been a method to obtain good skin hygiene and minimize 
infection, a new concept in skin care is the expansion of cleans-
ing beyond soap and water to include astringents, exfoliants, 
facial  scrubs,  epidermabrasion,  textured  cloths,  mechanized 
skin care devices, and face masks.

REFERENCES

1. Wilkinson JB, Moore RJ. Astringents and skin toners. In: Harry's 
Cosmeticology.  7th  edition.  New  York:  Chemical  Publishing 
1982; pp. 74–81.

2. Dietre  CM,  Griffin  TD,  Murphy  CF,  et  al.  Effects  of  alpha-
hydroxy  acids  on  photoaged  skin.  J  Am  Acad  Dermatol  1996; 
34:187–95.

3. Van Scott JE, Yu RJ. Hyperkeratinization, corneocyte cohesion 
and alpha hydroxy acids. J Am Acad Dermatol 1984; 11:867–79.
4. Smith  WP.  Hydroxy  acids  and  skin  aging.  Cosmet  Toil  1994; 

109:41–8.

5. Yu RJ, Van Scott EJ. Alpha hydroxy acids: Science and therapeu-

tic use. Cosmet Dermatol 1994; 7(10s):12–20.

6.  Mills OH, Kligman AM. Evaluation of abrasives in acne ther-

apy. Cutis 1979; 23:704–5.

7.  Sibley MJ, Browne RK, Kitzmiller KW. Abradant cleansing aids 

for acne vulgaris. Cutis 1974; 14:269–74.

8.  Durr  NP,  Orentreich  N.  Epidermabrasion  for  acne.  Cutis  1976; 

17:604–8.

9. Mackenzie  A.  Use  of  Buf-Puf  and  mild  cleansing  bar  in  acne. 

Cutis 1977; 20:170–1.

10. Millikan LE, Ameln R. Use of Buf-Puf and benzoyl peroxide in 

the treatment of acne. Cutis 1981; 28:201–205.

11. Gerson J. Milady's Standard Textbook for Professional Estheticians. 

Buffalo, NY: Milady 1992; pp. 240–242.

  12.  Draelos ZD. Cosmetics in Dermatology. 2nd edition. Edinburgh: 

Churchill Livingstone; WB Saunders 1995; p. 213.

 
 
 
 
21

Regulatory Overview of Cosmeceuticals

Lauren A. Hassoun, Howard I. Maibach, and Raja K. Sivamani

Cosmeceuticals are an intriguing and burgeoning field within 
dermatology and the skin care market. This industry was esti-
mated to have generated approximately $8.2 billion in sales in 
2012  (1).  Furthermore,  researchers  focusing  on  cosmeceutical 
products  highlight  strong  growth  perspectives  in  the  com-
ing  years  with  a  rapid  compound  annual  growth  rate  of  7.7% 
and  the  global  cosmeceutical  market  reaching  $42.4  billion  by 
2018 (2). While consumers in the United States spend more on 
cosmeceutical products than all of Europe combined, consum-
ers in France and Germany spend the most within Europe (3). 
Although there is no strict definition for cosmeceuticals within 
the skin care industry or dermatology realm (4), they are typi-
cally considered cosmetic products with components that have 
“drug-like” benefits and properties. Examples of cosmeceuticals 
include  moisturizers,  serums,  topical  antioxidants,  retinoids, 
peptides,  and  botanicals.  As  a  category,  they  are  believed  to 
 contain  either  one  or  a  mix  of  ingredients  that  improve  skin 
 condition  and  appearance  without  making  an  explicit  asser-
tion  on  skin  health.  In  addition  to  their  aesthetic  properties 
which  make  them  desirable  for  both  consumers  and  patients, 
development  of  cosmeceutical  products  has   several  economi-
cal advantages, as the process of marketing them is simpler and 
they require less monetary investment than a drug, which may 
require from $800 million to upward of $1 billion (5).

REGULATORY OVERSIGHT
The  term  “cosmeceuticals”  is  derived  as  an  amalgam  of  cos-
metics and pharmaceuticals. The Food and Drug Association 
(FDA)  does  not  formally  acknowledge  the  term  “cosmeceuti-
cal” but notes that the term is used by the cosmetic industry 
to refer to cosmetic products that have medicinal or drug-like 
benefits (6).

It is necessary to distinguish between cosmetics, drugs, 
and  cosmeceuticals.  Cosmetics  are  defined  as  either  (1) 
 articles intended to be rubbed, poured, sprinkled, or sprayed 
on,   introduced  into,  or  otherwise  applied  to  the  human 
body  or  any  part  thereof  for  cleansing,  beautifying,  promot-
ing   attractiveness,  or  altering  the  appearance,  or  (2)  articles 
intended for use as a component of any such articles. Cosmetics 
are recognized by the FDA, however approval is not required 
for marketing (6).

Drugs are defined as (1) articles recognized in the offi-
cial  United  States  Pharmacopoeia,  official  Homoeopathic 
Pharmacopoeia  of  the  United  States,  or  official  National 
Formulary,  or  any  supplement  to  any  of  them,  (2)  articles 
intended for use in the diagnosis, cure, mitigation, treatment, 
or prevention of disease in man or other animals, (3) articles 
(other than food) intended to affect the structure or any func-
tion  of  the  body  of  man  or  other  animals,  and  (4)  articles 
intended  for  use  as  a  component  of  any  article  specified  in 

clause  (1),  (2),  or  (3).  Drugs  are  recognized  by  the  FDA  and 
unlike cosmetics, approval is required for marketing (6).

Cosmeceuticals are cosmetic products that have medici-
nal or drug-like benefits. They are not recognized by the FDA 
and approval is not required for marketing if pharmaceutical 
claims are not made (5).

In the United States, regulatory oversight for the cosme-
ceutical  industry  is  primarily  provided  by  the  FDA.  As  long 
as no claims that would meet criteria for evaluation as a drug 
are met, cosmeceuticals are regarded as cosmetics for regula-
tory purposes. The FDA does not possess any legal authority 
in the approval of cosmetic products before they are marketed, 
but  if  a  cosmetic  product  is  determined  to  be  misbranded  or 
adulterated, they are able to take legal action. Thus, while cos-
meceuticals  may  contain  drug-like  benefits,  there  is  no  regu-
latory approval mechanism insofar as the cosmeceutical does 
not make a claim that would qualify it as a drug.

The  regulation  of  cosmeceuticals  is  not  well  defined 
outside the United States. For example, in Europe, regulatory 
authorities  consider  many  cosmeceuticals  as  cosmetics  (3) 
while in Japan, they are treated as quasi-drugs (3). Even more 
obscured  is  the  process  in  India,  where  multiple  regulatory 
bodies  may  be  involved  without  guidelines  on  product  aims 
for cosmetics and the term “cosmeceutical” is not included in 
official legal definitions (3).

THE ROLE OF BOTANICALS
Botanicals have an expanding role in cosmeceuticals due to the 
rapidly  growing  demand  for  the  use  of  complementary  and 
alternative  medical  therapies  (7).  Specifically,  several  studies 
have evaluated the ability of whole botanical extracts and spe-
cific  phytochemicals  to  modulate  cellular  functions  (8–10).  In 
this regard, botanicals may have valuable properties in addi-
tion to a cosmetic purpose. Yet despite these encouraging data, 
official claims need to remain guarded to be marketed as cos-
meceuticals rather than a drug.

Some  botanical  products  have  blurred  the  boundar-
ies  of  cosmeceuticals  and  drugs.  For  instance,  two  botani-
cally derived dermatological preparations have received FDA 
approval  as  prescription  drugs.  One  is  an  extract  of  Camellia 
sinensis (green tea) composed of sinecatechins that is used for 
the  topical  treatment  of  external  genital  and  perianal  warts 
(11). The second is a purified proanthocyanidin extracted from 
the  South  American  tree  Croton  lechleri  for  the  treatment  of 
diarrhea associated with anti-HIV drugs (12).

In  recent  years,  there  has  been  greater  demand  for 
“organic”  cosmeceuticals  as  a  result  of  the  growing  demand 
for  natural  and  botanical  alternatives.  In  the  United  States, 
the standards for “organic” are not set by the FDA but by the 
United  States  Department  of  Agriculture  (USDA).  The  FDA 

does  not  have  a  role  in  regulating,  reviewing,  or  enforcing 
these  standards.  Depending  on  the  country  of  origin,  there 
are  several  regulatory  bodies  that  provide  oversight  on  the 
“organic” distinction, as outlined in Table 21.1.

While the FDA regulates cosmetics under the authority 
of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 
the Fair Packaging and Labeling Act (FPLA), the term “organic” 
is not defined in either of these laws. Rather, the Agricultural 
Marketing Service of the USDA, which oversees the National 
Organic Program (NOP), regulates the term “organic.” As out-
lined in Table 21.1, the NOP regulations include a definition of 
“organic” and provide for certification that agricultural ingre-
dients have been produced under conditions that would meet 
the definition.

The USDA requirements for the use of the term “organic” 
are separate from the laws and regulations that FDA enforces 
for  cosmetics.  Cosmetics,  body  care  products,  and  personal 
care products labeled with organic claims must comply with 
both USDA regulations for the organic claim and FDA regula-
tions for labeling and safety requirements for cosmetics.

Importantly,  cosmetics  made  with  “organic”  ingredi-
ents are not necessarily safer for consumers than those made 
with  ingredients  from  other  sources.  Under  the  FD&C  Act, 
all cosmetic products and ingredients are subject to the same 
safety  requirement:  they  must  be  safe  for  consumers  under 
labeled or customary conditions of use. Companies and indi-
viduals who market cosmetics have a legal responsibility to 
ensure  that  their  products  and  ingredients  are  safe  for  the 
intended use.

Notably, the USDA has no authority over the production 
and labeling of cosmetics, body care products, and personal 
care  products  that  are  not  made  up  of  agricultural  ingredi-
ents  or  do  not  make  any  claims  to  meeting  USDA  organic 
standards (13).

In  Europe,  the  Soil  Association  is  the  principal  body 
involved  in  the  inspection  and  organic  certification  of  health 
and beauty products. With regard to the certification process 
of non-food items such as health and beauty products, the Soil 
Association issues an annual certificate of registration, a trad-
ing  schedule,  and  license  to  use  the  Soil  Association  organic 
symbol once the producer or operator has fulfilled the neces-
sary standards of product safety and integrity (14).

REGULATORY OVERVIEW OF COSMECEUTICALS 

 183

The standards set forth by the Soil Association apply to 
health  and  beauty  products  made  from  organic  ingredients, 
and include herbal products, natural and herbal medicine-like 
products,  toiletries,  body  care  products,  and  cosmetics  and 
perfumery  (14).  In  addition,  organic  health  and  beauty  prod-
ucts  are  required  to  fulfill  the  following  principles:  be  fit  for 
their purpose, have as high as possible proportion of organic 
ingredients, be clearly identified, traceable and separate from 
non-organic  products  at  all  stages  of  manufacturing,  not  be 
tested  on  animals,  not  be  harmful  to  human  health  and  the 
environment in manufacture and use, be produced in line with 
ethical trade standards, and be labeled to give clear and accu-
rate information to the consumer (14).

The Soil Association, along with several other European 
organizations,  collaborated  and  introduced  a  new  unified 
standard for organic health and beauty products, the COSMOS 
standard,  effective  since  2015.  This  standard  introduced  the 
concept  of  “green  chemistry,”  defined  as  a  desire  within  the 
cosmetics  sector  to  contribute  to  sustainable  development. 
This principle extends to the requirements expected of manu-
facturers  who  produce  the  chemically  processed  ingredients 
used  in  cosmetic  products.  For  example,  such  manufacturers 
are restricted to a certain list of chemical processes, must use 
renewable resources, and must comply with specific quantita-
tive requirements for their ingredients (14).

COSMETIC LABELING STANDARDS 
The FDA does not have the resources nor authority under the 
law  for  pre-market  approval  of  cosmetic  product  labeling.  It 
is  the  manufacturer's  and/or  distributor's  responsibility  to 
ensure that products are labeled properly. Importantly, organic 
cosmetics cannot be labeled with any therapeutic claims. Any 
assertion  that  a  product  treats  or  prevents  disease  or  affects 
the structure or function of any part of the body may cause the 
product to be considered a drug.

Labeling  information  that  is  required  to  appear  on  the 
principal  display  panel  (the  part  of  the  label  most  likely  dis-
played  or  examined  under  customary  conditions  of  display 
for sale) includes an identity statement and an accurate state-
ment  of  the  net  quantity  of  contents.  An  identity  statement 
indicates the nature or use of the product (by means of either 

Table 21.1  Organic Labeling Standards of International Regulatory Bodies

Regulatory body

United States Department of 
Agriculture National Organic 
Program (United States)

COSMOS (Europe)

Label

Requirement

May Display USDA Organic 
Seal?

100% Organic

Organic

100% organic ingredients

95% organic ingredients

Made with organic ingredients

70% organic ingredients

No organic distinction allowed

<70% organic ingredients

YES

YES

NO

NO

Label

ORGANIC

NATURAL

Requirement

  1) 95% of a product’s “agro-ingredients” and 20% of the entire 

product must be organic

  2) For products that are less than 95% organic, the label may 

make reference to individual organic ingredients

  1) No minimum level of organic ingredients required but the 
label must report organic ingredients on the ingredient list
  2) May report % of organic ingredients to total product or total 

product minus water and minerals

  3) Must not make any organic claim of products or ingredients 

on the front packaging label

 
184 

 TEXTBOOK OF COSMETIC DERMATOLOGY

the  common  or  usual  name,  a  descriptive  name,  a  fanciful 
name understood by the public, or an illustration) and the net 
quantity of contents can be displayed in terms of weight, mea-
sure, numerical count, or combination of numerical count and 
weight or measure.

Additionally, the following must appear on the informa-
tion panel (a panel other than the principal display panel that 
can  accommodate  label  information  where  the  consumer  is 
likely  to  see  it)  of  the  product:  name  and  place  of  business 
(e.g.  manufacturer,  packer,  or  distributor),  distributor  state-
ment,  material  facts  (e.g.  directions  for  safe  use  if  a  product 
could be unsafe if used incorrectly), warning and caution state-
ments, and ingredients.

CONCLUSION
While cosmeceuticals are extensively used and marketed and 
their popularity will undoubtedly continue to soar, with regu-
latory  overview  still  evolving  they  do  not  yet  have  a  widely 
accepted definition (4). Hence it is the responsibility of the skin 
care provider as well as the consumer to understand and criti-
cally evaluate the evidence (15). Additionally, because organic 
regulatory  distinctions  may  be  especially  confusing  for  con-
sumers, skin care providers should be familiar with the topic.

For  today's  consumer,  cosmeceuticals  offer  numerous 
new potentially exciting and favorable skin care products and 
options, and the interest and expansion in botanically derived 
products  has  significantly  increased  these  choices.  However, 
despite this surge in enthusiasm, the multitude of choices can 
also  be  confusing.  As  the  cosmeceutical  industry  continues 
to  expand,  including  those  products  that  are  “natural”  and 
“organic,”  there  will  be  a  greater  need  to  monitor  marketing 
claims and the evidence behind them. Furthermore, with the 
well-being of the consumer and patient in mind, the safety of 
these products will need to be evaluated closely (16).

REFERENCES

1.  Brandt  FS,  Cazzaniga  A,  Hann  M.  Cosmeceuticals:  Current 
Trends and market analysis. Sem Cutan Med Surg 2011; 30:141–3.

2.  Lohani A, Verma A, Joshi H, Yadav N, Karki N. Nanotechnology-

based cosmeceuticals. ISRN Dermatol 2014:843687.

3.  Sharma P. Cosmeceuticals: Regulatory scenario in U.S., Europe 

& India. Intl J PharmTechnol 2011; 3:1512–35.

4.  Draelos  ZD.  Cosmeceuticals:  Undefined,  unclassified,  and 

unregulated. Clin Dermatol 2009; 27:431–4.

5.  DiMasi  JA,  Hansen  RW,  Grabowski  HG.  The  price  of  innova-
tion:  New  estimates  of  drug  development  costs.  J  Health  Econ 
2003; 22:151–85.

6.  Federal  Food,  Drug,  and  Cosmetic  Act,  Subchapter  II, 
Definitions.  U.S.  Government  Publishing  Office.  Available  at: 
http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/
USCODE-2010-title21-chap9-subchapII.htm  (accessed  May  26, 
2013).

7.  Thornfeldt  C.  Cosmeceuticals  containing  herbs:  Fact,  fiction, 

and future. Dermatol Surg 2005; 31:873–80; discussion 880.

8.  Mukherjee  PK,  Maity  N,  Nema  NK,  Sarkar  BK.  Bioactive 
compounds  from  natural  resources  against  skin  aging. 
Phytomedicine 2011; 19:64–73.

9.  Hunt  KJ,  Hung  SK,  Ernst  E.  Botanical  extracts  as  anti-aging 
preparations  for  the  skin:  A  systematic  review.  Drugs  Aging 
2010; 27:973–85.

  10.  Korkina L, De Luca C, Pastore S. Plant polyphenols and human 
skin: Friends or foes. Ann N Y Acad Sci 2012; 1259:77–86.
  11.  Veregen:  A  botanical  for  treatment  of  genital  warts.  Med  Lett 

2008; 50:15–16.

  12.  Yeo  QM,  Crutchley  R,  Cottreau  J,  Tucker  A,  Garey  KW 
Crofelemer.  A  novel  antisecretory  agent  approved  for  the 
treatment of HIV-associated diarrhea. Drugs Today (Barc) 2013; 
49:239–52.

  13.  United States Department of Agriculture. USDA Agricultural 
Marketing  Service.  Available  at:  http://www.ams.usda.gov/
(accessed 
AMSv1.0/getfile?dDocName=STELPRDC5068442 
July 9, 2015).

  14.  Soil  Association.  Available  at:  http://www.soilassociation.org 

(accessed July 6, 2015).

  15.  Levin  J,  Momin  SB  How  much  do  we  really  know  about  our 
favorite cosmeceutical ingredients? J Clin Aesthet Dermatol 2010; 
3:22–41.

  16.  Antignac E, Nohynek GJ, Re T, Clouzeau J, Toutain H. Safety of 
botanical ingredients in personal care products/cosmetics. Food 
Chem Toxicol 2011; 49:324–41.

 
 
 
 
 
 
 
 
 
 
22

Photodamage: Protection

Laurent Meunier

INTRODUCTION
The spectral distribution of the solar energy at the sea level 
comprises  roughly  3%–7%  of  ultraviolet  radiation  (UVR) 
 (290–400 nm),  44%  of  visible  light  (400–700 nm),  and  53%  of 
infrared  (IR)  radiation  (700–1440 nm).  Terrestrial  solar  UVR 
comprises  approximately  5%  UVB  (280–320  nm)  and  95% 
UVA  (320–400  nm),  the  majority  (75%)  of  which  is  UVA1 
(340–400  nm).  Seventy  percent  of  UVB  radiation  that  reaches 
the skin is absorbed by the stratum corneum, 20% reaches via-
ble  epidermis,  and  only  10%  penetrates  the  upper  part  of  the 
 dermis. On the other hand, UVA radiation is partly absorbed 
by the  epidermis, but 20%–30% of it reaches deep dermis. The 
major chromophores that determine the depth of penetration are 
nucleic acids, aromatic amino acids, and melanin. Energy from 
the shorter-wavelength UVB is absorbed in greater amounts by 
the  epidermis  and  by  keratinocyte  DNA,  compared  with  the 
energy from UVA, which penetrates more deeply into the der-
mal layers of the skin. Visible and IR light wavelengths penetrate 
deep into the dermis and produce heat following absorption.

UVR AND PHOTODAMAGE MECHANISMS
UVR photodamage occurs through direct and indirect mecha-
nisms.  Direct  absorption  of  UV  energy  drives  biochemical 
reactions  that  result  in  molecular  changes  and  production  of 
reactive oxygen species (ROS). UVA wavelengths, which pen-
etrate  deeply  into  skin,  induce  formation  of  ROS,  which  act 
as  mediators  of  indirect  photodamage  resulting  in  oxidative 
stress and adduct formation of biomolecules. DNA has absorp-
tion maxima in UV wavelength range and is therefore a direct 
target of UV damage, forming cyclobutane pyrimidine dimers 
(CPDs)  and  6-4  photoproducts  (6-4PPs).  These  DNA  photo-
products are mainly induced by UVB, but with some contribu-
tion  from  UVA  (1,2).  They  interfere  with  biological  processes 
and induce signals that inform cellular decisions for entry into 
one of two main pathways: cell survival through initiation of 
cellular  repair  processes  or  cell  death  by  apoptosis  (3).  ROS 
produced in the skin following UV irradiation are key media-
tors of oxidative damage to the skin. Cell damage from UV also 
occurs through peroxidation of membrane lipids via generation 
of lipid peroxides. UV irradiation results in the rapid depletion 
of several endogenous skin enzymes and antioxidants such as 
glutathione reductase and catalase. Exposure to UV radiation 
suppresses  the  immune  response,  and  UV-induced  immune 
suppression is a major risk factor for skin cancer induction (4). 
Multiple mechanisms are involved depending upon the doses 
and the type of irradiation (acute or chronicle): DNA damage, 
production of cytokines, and inflammatory mediators (5). UV 
exposure affects antigen-presenting cell function and induces 
immune tolerance in part through the induction of regulatory 
T cells (6).

SOLAR EXPOSURE: SHORT- AND 
LONG-TERM EFFECTS 
Erythema  (sunburn)  is  the  most  familiar  symptom  associ-
ated with UVR overexposure. The erythemal reaction to UVR 
depends on the wavelength range, and increasing wavelength 
decreases the erythemal effectiveness considerably. UVB, par-
ticularly  at  307  nm,  is  the  most  effective  waveband  for  elicit-
ing a sunburn reaction, while UVA radiation is 1000-fold less 
potent  in  producing  skin  erythema.  UVB-induced  erythema 
reaches a peak at 6–24 hdepending on the dose, and fades over 
a day or longer. UVA-induced erythema contributes to at least 
15%  of  total  sun-induced  erythema.  The  minimal  erythema 
dose (MED) is defined as the smallest UV dose that produces 
perceptible redness of the skin with clearly defined borders at 
16–24 h after UV exposure.

UVA-induced  changes  in  color  begin  with  an  immedi-
ate pigment darkening (IPD) of the skin due to photooxidation 
of  preexisting  melanin,  and  a  partial  fading  occurs  rapidly 
within  1  h  after  the  end  of  exposure.  Following  exposure  to 
UVA, a stable residual pigmentation is observed after the tran-
sient part of IPD has faded out. This pigmentation (persistent 
pigment darkening or PPD), due also to melanin photooxida-
tion, remains detectable for a few days or weeks, depending on 
the UVA dose. The delayed pigmentation is characterized by a 
visible brown pigmentation in UV-exposed skin, which repre-
sents an increase in epidermal melanin content. It becomes vis-
ible after about 72 h. An acute erythemogenic dose of UVB is 
necessary to induce delayed pigmentation. Both UVA and UVB 
can cause tanning, but UVA is less effective. UVB-induced pig-
mentation can bring some protection but UVA pigmentation is 
not protective.

The  hallmarks  of  long-term  exposure  to  solar  UVR  are 
photoaging and photocarcinogenesis. Photoaging is character-
ized by the induction of extracellular matrix-degrading proteo-
lytic enzymes (matrix metalloproteinases [MMPs]), a family of 
zinc-dependent endopeptidases secreted by  epidermal kerati-
nocytes  and  dermal  fibroblasts,  without  a  parallel  induction 
of inhibitors of proteolysis (tissue inhibitor of metalloprotein-
ases). The resulting pathological remodeling process involves 
the degradation of collagen and the accumulation of abnormal 
elastin  in  the  superficial  dermis,  resulting  in  the  characteris-
tic changes of solar elastosis. Exposure to UV has been shown 
to  induce  proinflammatory  cytokines,  such  as  IL-1α,  and 
MMPs  in  keratinocytes  and  fibroblasts.  The  mechanisms  by 
which UVR induces MMPs are poorly understood. This may 
occur via the generation of ROS or via the formation of CPDs. 
Induction of inflammatory cytokines by UV, leading to over-
all skin inflammation is another significant contributor to the 
photoaging process in skin. It is widely considered that UVA 
has a larger role than UVB in photoaging, both because of the 

186 

 TEXTBOOK OF COSMETIC DERMATOLOGY

deeper penetration of UVA into the dermis and because of the 
sensitivity of fibroblasts to UVA-induced MMPs.

Occupational and recreational exposure to solar radia-
tion  represents  a  major  environmental  risk  factor  for  the 
development  of  skin  cancers.  Epidemiological  studies  have 
shown associations between melanoma incidence and inter-
mittent exposure to solar light during childhood and adoles-
cence. In contrast, squamous cell carcinoma (SCC) is related 
to  cumulative  solar  exposure.  Similar  to  melanoma  and  in 
contrast  to  SCC,  sporadic  basal  cell  carcinoma  (BCC)  may 
occur in individuals with intermittent extreme UV exposure 
behavior  (7).  However,  published  epidemiological  literature 
indicates that outdoor workers are at significantly increased 
risk for BCC (8).

Sunlight overexposure is involved in increasing the risk 
of skin cancer since DNA represents one of its biological tar-
gets. Indeed, DNA alteration can affect many cellular functions 
and can lead to mutations and genetic instability. Unlike UVB, 
which directly impacts DNA, UVA toxicity mainly depends on 
indirect mechanisms in which ROS are generated through the 
activation of endogenous photosensitizers present in skin, trig-
gering the genotoxic effects.

Malignant  melanoma  of  the  skin  (cutaneous  malig-
nant  melanoma  [CMM])  is  associated  with  solar  exposure, 
but  the  mechanisms  involved  are  still  unclear.  By  using  an 
animal  model,  Noonan  and  colleagues  (9)  recently  found 
that  melanoma  induction  by  UVA  requires  the  presence  of 
melanin pigment and is associated with oxidative DNA dam-
age  within  melanocytes,  while  UVB  initiates  melanoma  in  a 
 pigment-independent  manner  associated  with  direct  UVB 
DNA damage.

PREVENTION OF PHOTODAMAGE
Sunscreens
The use of sunscreens should be considered as a part of pho-
toprotection  and  should  always  be  associated  to  appropriate 
physical  measures  (shade,  clothing,  hats,  sunglasses)  espe-
cially in children. An ideal sunscreen should provide uniform 
protection across the range of UVB and UVA, a property which 
assures that the natural spectrum of sunlight is attenuated in 
a  uniform  manner.  It  should  also  have  aesthetically  pleas-
ing  composition  that  enhances  compliance  (10).  Sunscreens 
are composed of excipients and filters that are categorized as 
organic  or  inorganic  (chemical  or  physical).  Organic  (chemi-
cal) UV filters act by absorbing UV radiation and most of them 
are  photostable  under  the  conditions  of  use.  The  sun  protec-
tion factor (SPF) and the UVA protection factor (UVA-PF) are 
the two common indices used to quantify the efficacy of sun-
screens. The measurement of SPF is performed in vivo using a 
panel of volunteers. Sunscreen is applied to the protected test 
sites at a density of 2 mg/cm2 and SPF is then calculated as the 
ratio  of  MED  on  sunscreen-protected  skin  to  that  on  unpro-
tected  skin.  Methods  for  assessment  of  UVA  protection  vary 
by country. Persistent pigment darkening (PPD) measures the 
minimal UVA radiation dose required to induce the first per-
ceptible pigmentation changes (ie, minimal pigmenting dose) 
in  sunscreen-protected  skin  compared  to  unprotected  skin. 
The EU requires UVA-PF to be at least one-third of the labeled 
SPF.  For  example,  a  sunscreen  with  a  SPF  of  30  must  have  a 
UVA-PF of at least 10. In the UK, the ratio of UVA absorbance 
to  mean  UVB  absorbance  is  measured  in  vitro;  a  star  rating 
system is used. Australia adopted the in vitro test procedure 
ISO 24443:2012 for determining broad-spectrum performance, 
which  is  similar  to  the  European  assessment.  In  Europe  and 

in the United States, recommendations include the determina-
tion of the critical wavelength (CW). The CW test is conducted 
by applying the test product to polymethylmethacrylate plates 
and then by measuring UV transmittances 290–400 nm. CW is 
defined as the wavelength at which 90% of the total area under 
the  absorbance  curve  occurs.  The  broad-spectrum  status  is 
admitted when the CW is superior to 370 nm.

Correct  use,  appropriate  amount  of  sunscreen  applied, 
and  reapplication  frequency  are  important  factors  for  the 
effectiveness of sunscreens (11). In practice, most people often 
apply only 25%–50% of the amount used for SPF testing. This 
results in an effective SPF that is less than 33% of the labeled 
SPF.  Recently,  a  modification  of  the  ‘‘teaspoon  rule’’  for  sun-
screen application has been proposed (12). Namely, to achieve 
2 mg/cm2 of density, the following should be done: 1 teaspoon 
of sunscreen to the face/head/neck, 1 teaspoon to each upper 
extremity,  a  total  of  2  teaspoons  to  the  front  and  back  torso, 
and  2  teaspoons  to  each  lower  extremity.  The  reapplication 
frequency is also an important factor. Two applications of sun-
screen, the first 15–30 minutes before sun exposure, followed 
by another application 15–30 minutes later, is recommended to 
obtain adequate amounts of sunscreen on the skin.

Protection Afforded by Sunscreens
The  protective  property  of  sunscreens  against  acute  and 
chronic effects of UV has now been well established (10) and 
only well-balanced UVA-UVB sunscreens, absorbing over the 
entire UV spectrum are able to prevent or significantly reduce 
the associated biological damage (13).

DNA  damage  is  an  important  part  of  the  photoag-
ing process. By using in vitro skin models, Dehaven et al. (14) 
demonstrated that sunscreen application prior to full- spectrum 
solar exposure protects from CPD and SBC formation. In vitro 
experiments showed that UVA-activated synthesis of MMPs is 
prevented by a broad-spectrum sunscreen (15). This is important 
since progressive skin darkening in response to repeated low-
dose UVA1 exposures does not prevent UVA1–induced colla-
genolytic changes (16). A recent randomized controlled trial that 
was conducted in 903 adults younger than 55 years showed that 
regular sunscreen use retards skin photoaging (17). There is also 
evidence suggesting that sunscreens can diminish the appear-
ance of premature aging and prevent exacerbations of photoder-
matoses such as polymorphous light eruption (17–19).

UVB and UVA are both immunosuppressive, and broad-
spectrum sunscreens provide protection against the reduction 
of  human  cutaneous  immunity  induced  by  solar  exposure 
(20,21).  Several  studies  have  explored  the  effect  of  sunscreen 
use  on  the  development  of  actinic  keratosis  (AK).  Thompson 
and  colleagues  (22)  conducted  a  randomized,  controlled  trial 
of the effect on solar keratosis of daily use of an SPF 17 broad-
spectrum sunscreen in 588 subjects. The sunscreen group had 
fewer  new  lesions  and  more  remissions  than  the  base-cream 
group. Darlington and colleagues (23) found that daily use of a 
broad-spectrum, SPF 16 sunscreen resulted in a 24% reduction 
in the average rate of AK development. Thus, promoting regu-
lar sunscreen use can be a safe and cost-effective approach to 
prevent AKs and SCC (24). Indeed, Green and colleagues (25) 
found that the routine use of a SFPF 16 sunscreen for 4.5 years 
resulted  in  a  38%  reduction  in  the  incidence  of  SCC,  while 
there  was  no  beneficial  effect  on  BCC  prevention.  The  same 
investigators  reported  similar  protective  effects  of  daily  sun-
screen use after further follow-up of 8 years (26). The relation-
ship between UV light and BCC development is complex and 
these tumors have a long latency period from the time of UV 

 
damage  to  the  clinical  onset  of  disease.  Thus  longer  periods 
of follow-up may be needed to observe a protective effect and 
further  studies  are  needed.  Nevertheless,  currently  available 
results do no not support a role of sunscreen use in prevention 
of BCC growth.

The  use  of  sunscreen  in  the  prevention  of  melanoma 
has  been  the  subject  of  much  controversy  but  analysis  of 
case-control studies revealed neither a protective nor a harm-
ful association between sunscreen use and melanoma (27,28). 
However,  a  randomized  controlled  study  demonstrated  that 
regular  sunscreen  use  reduces  the  risk  of  developing  mela-
noma (29). Moreover, by using a BRAF (V600E) mouse model, 
Viros and colleagues (30) demonstrated that sunscreen delayed 
UV-driven melanoma in susceptible mice. These data validate 
public health campaigns that promote sunscreen protection for 
individuals at risk of melanoma.

Sunscreen and Vitamin D
Solar UVB converts 7-dehydrocholesterol in the skin to previ-
tamin D3 and is the major source of vitamin D (31). Sufficient 
levels  of  vitamin  D  are  essential  for  bone  development  and 
maintenance and may reduce the risk for certain cancers and 
influence other diseases. Although sunscreens can significantly 
reduce production of vitamin D under strict photoprotection, 
their normal usage, most likely due to inadequate application 
(0.5 mg/cm2), does not result in vitamin D deficiency (31).

PHYSICAL PHOTOPROTECTION
Physical  methods  of  photoprotection  include  glass,  window 
films,  sunglasses,  and  clothing  (32).  Almost  all  glass  blocks 
UVB  radiation,  regardless  of  type  or  properties  of  the  glass. 
However, the transmission of UVA radiation varies according 
to the type, thickness, and color of the glass (33). Mean UVR 
exposure  to  a  car  passenger  is  3%–4%  of  the  ambient  UVR, 
with the highest UV exposure to the left arm and lateral head 
of  the  driver.  Although  windshields  (laminated  glass)  block 
the  majority  of  UVA  radiation,  side  and  back  windows  (tem-
pered  glass)  block  only  20%  of  UVA  radiation.  This  partial 
protection is not sufficient to protect patients with severe pho-
tosensitive  disorders.  The  thickness  of  the  glass  was  shown 
to have a limited effect on the protection. On the other hand, 
the color of the glass plays an important role in UVR protec-
tion and it has been shown that a gray color offered the high-
est  protection.  The  addition  of  window  film  to  glass  used  in 
side and back windows results in 99% reduction in the trans-
mission  of  UVR  and  represents  an  excellent  way  to  increase 
UVA protection. Several data provided arguments supporting 
a  role  of  driving  in  UV-related  skin  damage  and  cutaneous 
carcinogenesis.  A  recent  population-based  study  of  279  head 
and neck melanomas found a sex-related distribution of these 
tumors that may be related to driving (34). The general popula-
tion should be aware that a car window does not totally protect 
against sun-related damage and that protection by clothes and 
sunscreens is still relevant even in a car, especially on sunny 
days.  However,  results  of  a  retrospective  survey  reveal  poor 
patient  awareness  and  compliance  with  sun-protection  mea-
sures while in an automobile (35).

Clothing may offer constant level of protection through-
out the day but several factors affect the UV protection factor 
(UPF) afforded by textiles. The in vitro method using spectro-
photometry is most commonly used to determine the UPF of 
textiles.  UPFs  measured  with  this  method  reflect  mainly  the 
protection  against  UVB  and  are  usually  smaller  than  those 

PHOTODAMAGE: PROTECTION 

  187

occurring  in  real  life.  Several  fabric  characteristics  can  affect 
the  UPF,  such  as  porosity,  weight,  thickness,  type  of  fabric, 
laundering,  hydration,  stretch,  fabric  processing,  UV  absorb-
ers, color, and fabric-to-skin distance. Porosity of the fabric is 
the  most  important  factor  that  affects  UV  transmission  and 
fabrics, with large space between the yarns having  generally 
lower  UPF  values.  Cotton  and  rayon  (cellulosic  fibers)  have 
the  least  UV-absorbing  capacity  (UPF<15),  whereas  polyester 
has  the  highest.  Wool,  silk,  and  nylon  lie  between  these  two 
groups. Colored fabrics have better UV protection than white 
fabrics,  and  darker  colors  have  better  UV  protection  than 
lighter colors, because of increased UV absorption. Hydration 
or  wetting  decreases  the  UPF  for  most  clothing,  because  the 
presence of water eliminates the scattering of UV light at the 
fabric/air  interface  (36).  Adding  broadband  UVR  absorbers 
(e.g.,  Tinosorb  FD)  during  laundry  enhances  UVR  blocking 
properties of fabrics even after several washes. Hats and visors 
provide variable sun protection. Wide-brimmed hats (7.5 cm) 
provide  SPF  7  for  the  nose,  3  for  cheek,  5  for  neck,  and  2  for 
chin, whereas narrow-brimmed hats provide only SPF 1.5 for 
the nose, and minimal, if any, protection for other areas (32). 
Exposure to UVA and UVB can affect the eyes, and in contrast 
to the time of maximum UV exposure to the skin (10 a.m. to 
2 p.m.), the time of maximum UV exposure to the eyes is from 
8 to 10 a.m. and 2 to 4 p.m., when rays of the sun are parallel 
to the eyes. Sunglass standards have been developed to ensure 
quality,  performance,  and  adequate  protection  to  consumers. 
While in Australia and Europe standards are mandatory, the 
U.S.  standard  is  voluntary  and  not  followed  by  all  manufac-
turers. The U.S. standard (ANZI Z80.3) requires less than 1% 
of the wavelengths below 310 nm to be transmitted. The ideal 
sunglass should substantially reduce UV transmission to cor-
nea  and  lens  and  protect  the  retina  against  violet/blue  light. 
Size, style, and position of the sunglasses are other factors that 
should be considered. Small lenses increase the probability of 
UVR reaching the eyes from the side of the lens. Based on this 
factor,  the  Australian  standard  has  a  minimum  requirement 
of lens size, which is 28 mm for adult and 24 mm for children 
(37). Moving the sunglasses a small distance (6 mm) away from 
the forehead results in more than 20% increase in the amount 
of UVR reaching the eyes. Excessively dark tinted sunglasses 
can cause the pupil to dilate, making the eye structures more 
susceptible to UV. The public should be aware to choose sun-
glasses that are in compliance with one of the three national 
standards, choose a wraparound style or sunglasses with side 
shields, and position the sunglasses as close as possible to the 
forehead (37).

ANTIOXIDANTS AND DIETARY AGENTS
Orally  consumed  substances,  either  in  the  diet  or  as  supple-
ments, can modulate cutaneous responses to UV and provide 
additional photoprotection (38).

Nonsteroidal Anti-Inflammatory Drugs 
Regular  users  of  nonsteroidal  anti-inflammatory  drugs 
(NSAIDs) appear to have lower risks of SCC and lower counts of 
AKs than nonusers. The use of NSAIDs in the year prior to skin 
cancer diagnosis may reduce the risk of SCC but the effect on BCC 
is weak (39,40). COX-2 produces prostaglandins such as prosta-
glandin E2 (PGE2) from arachidonic acid. UV-induced PGE2 has 
been  shown  to  contribute  to  UV-induced  immunosuppression 
and to enhance proliferation of keratinocytes (38). Selective oral 
cyclooxygenase (COX-2) inhibitors such as celecoxib are likely to 

 
188 

 TEXTBOOK OF COSMETIC DERMATOLOGY

be useful for protection from sunlight-induced skin cancer and 
recent data indicate that celecoxib may prevent the appearance 
of cutaneous SCCs accelerated by BRAF inhibitors (41). A double-
blind placebo-controlled multicenter randomized trial suggests 
that celecoxib could potentially reduce new non- melanoma skin 
cancers (NMSCs) in patients with extensive actinic damage (42). 
Currently, oral COX-2 inhibitors cannot be recommended on a 
wide population level because of concerns regarding cardiovas-
cular toxicity, and it would be better to evaluate topical inhibi-
tors  (43).  Diclofenac,  a  nonselective  NSAID  that  inhibits  both 
COX-1 and COX-2, is available topically and has been success-
fully used in the treatment of AK (44).

Dietary Components
Several  studies  in  mice  showed  that  fruit  or  plants  rich 
in  antioxidants  might  have  photoprotective  effects  (45). 
Flavonoids  are  well  known  for  their  antioxidant  (or  free 
radical  scavenging)  properties  and  some  of  them  absorb 
UVB rays, hence contributing to their photoprotective effect 
by  behaving  as  UV  filters.  Quercetin,  which  is  the  most 
abundant  flavonol  in  the  human  diet,  has  been  reported 
to  block  UVB  induced  oxidative  stress  and  DNA  damage. 
Epigallocatechin-3-gallate (EGCG) is a member of the group 
of  flavonoids  that  is  mainly  found  in  tea,  red  wine,  straw-
berry,  and  cacao  products.  Many  studies  showed  that  this 
compound  could  prevent  the  skin  from  UV-induced  dam-
age. Polyphenols (green tea polyphenols, pomegranate, fruit 
extract,  grape  seed  proanthocyanidins,  resveratrol,  silyma-
rin, genistein, and delphinidin) are found in a wide variety 
of  fruits  and  vegetables.  Molecular  targets  of  these  com-
pounds include (i) regulation of anti-inflammatory activity, 
(ii)  modulation  of  immunosuppression,  (iii)  prevention  of 
DNA damage and regulation of DNA repair, and (iv) modu-
lation of cell-signaling pathways critically involved in differ-
ent stages of photocarcinogenesis (46,47).

Goji  berries  (Lycium  barbarum)  that  have  been  used  in 
traditional  Chinese  medicine  reduce  UV-induced  immu-
nosuppression  and  lipid  peroxidation  (48).  Pomegranate 
(Punica  granatum)  fruit  possesses  strong  antioxidant,  anti-
inflammatory, and antiproliferative properties (49,50).

Carotenoids are ingested with food components, nota-
bly fruits and vegetables, but also from animal sources. Most 
of  human  intervention  studies  provided  evidence  that  an 
elevated  intake  of  carotenoids  ameliorates  UV-induced  ery-
thema,  the  efficacy  depending  on  the  duration  of  treatment 
before exposure and on the dose (51). However, beta-carotene 
supplementation has not been shown to have any beneficial 
effect  on  photodamage  and  skin  cancer  prevention  (17,25). 
Conversely, it was associated with increased risk not only of 
lung cancer but also of gastric cancer in smokers and asbestos 
workers. Thus, nutritional prevention of skin cancer through 
beta-carotene supplementation should not be recommended 
(52).  Lycopene  is  a  carotenoid  found  at  high  concentrations 
in  tomatoes.  A  randomized  controlled  study  showed  that 
women  whose  diet  is  supplemented  with  tomato  paste  had 
reduced UV-induced erythema and MMP-1 production. The 
mitochondrial DNA deletion following an acute UV-exposure 
was  also  significantly  reduced  after  supplementation  with 
tomato  paste  (53).  Antioxidant  mixture  may  exert  in  vitro 
protective effects against UV-induced lipid peroxidation and 
antioxidant  nutritional  supplement  containing  lycopene, 
beta-carotene, and Lactobacillus johnsonii may provide protec-
tion against the development of UVA-induced protein-losing 
enteropathy (PLE) lesions (54).

Resveratrol  (RES),  a  phytoalexin  antioxidant  found  in 
red  grapes,  has  been  shown  modulate  transcription  factors 
and to have protective effects against UV radiation–mediated 
oxidative stress and cutaneous damage, including skin cancers 
(55–57).  RES  suppresses  UV-induced  malignant  tumor  pro-
gression  in  mice  and  acts  in  part  through  the  Akt-mediated 
downregulation of TGF-beta2 (58).

The  leaves  of  the  fern  Polypodium  leucotomos  (PL)  are 
rich in phenolic compounds such as ferulic and caffeic acids, 
and PL extracts have powerful antioxidant properties (59,60). 
Their  short-term  effects  include  inhibition  of  ROS  produc-
tion  induced  by  UV  radiation,  DNA  damage,  isomeriza-
tion  and  decomposition  of  transurocanic  acid,  prevention  of 
UV-mediated  apoptosis,  and  necrosis  (61).  PL  has  also  been 
shown  to  accelerate  removal  of  UV-induced  photoproducts, 
highlighting its anticarcinogenic role. By reducing UV-induced 
inflammatory  responses  and  inhibiting  extracellular  matrix 
remodeling,  PL  demonstrates  some  protective  effects  against 
photoaging  and  PUVA-induced  phototoxicity.  A  randomized 
clinical  trial  showed  that  in  healthy  volunteers  oral  PL  may 
result  in  a  decrease  of  UVA-induced  mitochondrial  common 
deletion (62). PL may decrease UV-induced erythema and sun-
burn cells (63, 64) and oral PL treatment might be beneficial for 
the prevention of PLE (65).

Caffeine  has  been  shown  to  be  chemopreventive  in 
 non-melamona  skin  cancer  in  mice  and  to  promote  UVB-
induced  apoptosis  in  HaCaT  keratinocytes  (66,67).  However, 
the  results  from  observational  studies  performed  in  humans 
are contradictory (38).

Dietary fish oils that contain omega-3 polyunsaturated 
fatty  acids  (PUFAs)  may  modulate  the  lipid  content  of  the 
cell membrane and modify the cell behavior in response to 
UV  exposure.  These  compounds  may  alter  membrane  lipid 
peroxidation  and  signal  transduction  pathways  that  are 
implicated  in  UV-induced  erythema  and  immunosuppres-
sion.  A  community-based  study  in  Queensland,  Australia, 
examined  the  diets  of  1119  adults  and  found  that  a  moder-
ate intake of oily fish may decrease the acquisition of actinic 
keratosis  (68).  A  randomized  controlled  study  performed 
in  nickel-allergic  women  found  that  supplementation  with 
omega-3  fatty  acids  resulted  in  a  reduction  of  UV-induced 
immunosuppression  (69).  The  results  of  a  cross-sectional 
study conducted on 2919 subjects suggest a  possible benefit 
of PUFAs on skin photoaging (70).

Vitamins and Hormones
Nicotinamide (or niacinamide) is an amide form of vitamin B3 
that  is  highly  photoprotective.  Nicotinamide  partly  prevents 
the loss of cellular energy that occurs after UV exposure and 
patients suffering from a vitamin B3 deficiency (pellagra) fre-
quently have a photosensitive dermatitis (38,71). Nicotinamide 
enhances repair of UV-induced DNA damage in keratinocytes 
and  melanocytes  (72,73),  protects  against  UV-induced  immu-
nosuppression  (74,75),  and  prevents  photocarcinogenesis  in 
animal studies (71).

Activation  of  the  melanocortin  1  receptor  (MC1R)  by 
alpha-MSH  stimulates  eumelanin  synthesis  and  enhances 
repair  of  UV-induced  DNA  damage  (76).  Potent  alpha-MSH 
analogues increase the tanning response after UV light expo-
sure and reduce thymine dimer formation in subjects exposed 
to UV light (77). However, serious concerns exist regarding the 
public's  unrestricted  use  of  untested  alpha-MSH  analogues 
because  of  their  potential  to  induce  malignant  changes  in 
melanocytes (78).

 
PROTECTION FROM VISIBLE LIGHT 
AND INFRARED RADIATION
At least 50% of the total energy that is being emitted by the sun 
and  that  reaches  human  skin  is  in  the  IR  range.  In  addition, 
within the IR range, IRA rays (770–1400 nm), which represent 
one-third of the total solar energy, are capable of penetrating 
human skin and directly affecting cells located in the epider-
mis, dermis, and subcutis. More than 65% of IRA reaches the 
dermis  and  there  is  now  increasing  evidence  that  IRA,  simi-
lar to UVB or UVA, significantly contributes to photoaging of 
human  skin  (79).  Recent  works  demonstrate  that  IR  and  heat 
exposure  each  induce  cutaneous  angiogenesis  and  inflam-
matory  cellular  infiltration,  disrupt  the  dermal  extracellular 
matrix  by  inducing  MMPs,  and  alter  dermal  structural  pro-
teins  (80).  The  recent  analysis  of  IRA-induced  transcriptome 
in primary human skin fibroblasts identifies IRA as an envi-
ronmental factor with relevance for skin homeostasis and pho-
toaging (81). Exposure of human skin fibroblasts in vitro and 
human  skin  in  vivo  to  physiologically  relevant  doses  of  IRA 
causes an increase in MMP-1 without a concomitant upregu-
lation  of  tissue  inhibitor  of  metalloproteinase-1  expression 
(82,83).  The  underlying  mechanisms  responsible  for  UVB-, 
UVA-,  and  IRA-induced  MMP-1  expression  markedly  differ. 
The major chromophores for UVB appear to be nuclear DNA 
and  cytoplasmic-free  tryptophan,  whereas  the  UVA  stress 
response is controlled by the lipid composition of specialized 
membrane  microdomains  (rafts)  (84).  IRA  radiation  is  stron-
gest  absorbed  by  mitochondria  and  the  earliest  biological 
event following IRA irradiation of human skin fibroblasts is an 
increase in mitochondrial production of ROS (85). IRA expo-
sure induces similar biological effects to UV radiation, but the 
underlying  mechanisms  are  substantially  different  since  the 
cellular response to IRA irradiation mostly involves the mito-
chondrial electron transport chain. Thus, effective sun protec-
tion  may  require  specific  strategies  to  prevent  IRA-induced 
skin  damage,  and  mitochondrial-targeted  antioxidants  may 
be used to protect human skin against IRA radiation–induced 
damage (86). Visible light exposure can induce ROS, which can 
lead to the release of proinflammatory cytokines and MMPs in 
the skin, similar to the effects of UV, and therefore visible light 
may  contribute  to  the  signs  of  premature  aging  in  the  skin. 
However,  commercially  available  sunscreens  were  found  to 
have  minimal  effects  on  reducing  visible  light–induced  ROS, 
suggesting that UVA/UVB sunscreens do not protect the skin 
from visible light–induced responses (87).

EDUCATION AND PREVENTION
Indoor  tanning  is  associated  with  an  increased  risk  of 
developing melanoma and cutaneous carcinoma. Exposure to 
indoor  tanning  is  common  in  the  United  States  and  Western 
countries,  especially  among  young  persons  and  high  school 
students  (88,89).  A  recent  meta-analysis  shows  that  use  of 
indoor tanning increases the odds of melanoma after 10 tan-
ning sessions (90). Public health efforts are needed to change 
social norms regarding tanned skin and to increase awareness, 
knowledge,  and  behaviors  related  to  indoor  tanning  among 
adolescents.  Clinicians  should  continue  to  educate  patients 
on  the  harms  of  indoor  tanning  and  encourage  its  cessation. 
Prevention efforts should be also associated with population-
based  interventions  in  the  form  of  legislation  to  discourage 
and decrease access to indoor tanning facilities (91).

Although most vacationers use sunscreen at sunny holi-
day  destinations,  an  alarmingly  high  proportion  experiences 

PHOTODAMAGE: PROTECTION 

  189

sunburn,  and  skin  cancer  prevention  campaigns  should 
emphasize the significance of covering up and seeking shade 
(92).  Clinicians  and  public  health  agencies  should  discour-
age people from prolonging sun exposure through sunscreen 
use in order to acquire a suntan (93). Campaigns designed to 
promote sun protection should focus on specific populations, 
and a large nationwide cross-sectional study showed that fac-
tors  associated  with  low  adherence  to  sun  protection  behav-
ior  were  age  below  20  or  over  64  years,  male  sex,  and  lower 
knowledge  about  accurate  sun  protection  recommendations 
and UV-associated risks (94).

Photoprotection,  including  seeking  shade  when  out-
doors and using sunscreens and protective clothing, is the first 
line  of  defense  against  photoaging.  Primary  prevention  also 
includes avoidance of artificial sources of UV exposure, includ-
ing tanning beds, and judicious use of therapeutic light boxes 
for medical treatment of dermatoses. Topical retinoids are the 
mainstay of treatment of patients with mild to moderate photo-
aging. These compounds increase collagen production, induce 
epidermal hyperplasia, decrease keratinocyte and melanocyte 
atypia, and have been shown to reduce CPDs. Oral retinoids 
likely prevent SCCs, as well as possibly preventing BCCs and 
reducing AKs. However, because of their side effects, their use 
is limited to selected high-risk patients only.

CONCLUSION
Sunscreen  use  alone  will  not  reduce  skin  cancer  and  photo-
aging, but it should be considered as an effective ancillary to 
wearing protective clothing and seeking shade (93). The posi-
tive perceptions of a suntan as healthy and attractive remains a 
challenge, and in a world where fashion is more powerful than 
health it will not be easy to change these perceptions, unless 
fashion changes (95).

REFERENCES

1. Cadet  J,  Mouret  S,  Ravanat  JL,  Douki  T.  Photoinduced  dam-
age  to  cellular  DNA:  Direct  and  photosensitized  reactions. 
Photochem Photobiol 2012 Sep–Oct; 88(5):1048–65.

2. Mouret S, Baudouin C, Charveron M, Favier A, Cadet J, Douki 
T.  Cyclobutane  pyrimidine  dimers  are  predominant  DNA 
lesions  in  whole  human  skin  exposed  to  UVA  radiation.  Proc 
Natl Acad Sci U S A 2006 Sep 12; 103(37):13765–70.

3. Nasti TH, Timares L. Inflammasome activation of IL-1 family 
mediators  in  response  to  cutaneous  photodamage.  Photochem 
Photobiol 2012 Sep–Oct; 88(5):1111–25.

4.  Ullrich  SE,  Byrne  SN.  The  immunologic  revolution:  Photo-
immunology. J Invest Dermatol 2012 Mar; 132(3 Pt 2):896–905.
5.  Halliday GM, Damian DL, Rana S, Byrne SN. The suppressive 
effects  of  ultraviolet  radiation  on  immunity  in  the  skin  and 
internal organs: Implications for autoimmunity. J Dermatol Sci 
2012 Jun; 66(3):176–82.

6.  Schwarz A, Schwarz T. UVR-induced regulatory T cells switch 
antigen-presenting  cells  from  a  stimulatory  to  a  regulatory 
phenotype. J Invest Dermatol 2010 Jul; 130(7):1914–21.

7.  Dessinioti C, Antoniou C, Katsambas A, Stratigos AJ. Basal cell 
carcinoma: What’s new under the sun. Photochem Photobiol 2010 
May–Jun; 86(3):481–91.

8. Bauer A, Diepgen TL, Schmitt J. Is occupational solar ultravio-
let  irradiation  a  relevant  risk  factor  for  basal  cell  carcinoma? 
A systematic review and meta-analysis of the epidemiological 
literature. Br J Dermatol 2011 Sep; 165(3):612–25.

9.  Noonan FP, Zaidi MR, Wolnicka-Glubisz A, Anver MR, Bahn J, 
Wielgus A, et al. Melanoma induction by ultraviolet A but not 
ultraviolet B radiation requires melanin pigment. Nat Commun 
2012; 3:884.

 
 
 
 
 
190 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  10.  Jansen  R,  Osterwalder  U,  Wang  SQ,  Burnett  M,  Lim  HW. 
Photoprotection: Part II. Sunscreen: Development, efficacy, and 
controversies. J Am Acad Dermatol 2013 Dec; 69(6):867 e1–14; quiz 
81–2.

  11.  Loden M, Beitner H, Gonzalez H, Edstrom DW, Akerstrom U, 
Austad  J,  et  al.  Sunscreen  use:  Controversies,  challenges  and 
regulatory aspects. Br J Dermatol 2011 Aug; 165(2):255–62.
  12.  Isedeh  P,  Osterwalder  U,  Lim  HW.  Teaspoon  rule  revis-
ited:  Proper  amount  of  sunscreen  application.  Photodermatol 
Photoimmunol Photomed 2013 Feb; 29(1):55–6.

  13.  Fourtanier  A,  Moyal  D,  Seite  S.  UVA  filters  in  sun-protection 
products: Regulatory and biological aspects. Photochem Photobiol 
Sci 2012 Jan; 11(1):81–9.

  14.  DeHaven  C,  Hayden  PJ,  Armento  A,  Oldach  J.  DNA 
 photoprotection conveyed by sunscreen. J Cosmet Dermatol 2014 
Jun; 13(2):99–102.

  15.  Jean  C,  Bogdanowicz  P,  Haure  MJ,  Castex-Rizzi  N,  Fournie 
JJ,  Laurent  G.  UVA-activated  synthesis  of  metalloprotein-
ases  1,  3  and  9  is  prevented  by  a  broad-spectrum  sunscreen. 
Photodermatol Photoimmunol Photomed 2011 Dec; 27(6):318–24.

  16.  Wang  F,  Smith  NR,  Tran  BA,  Kang  S,  Voorhees  JJ,  Fisher  GJ. 
Dermal damage promoted by repeated low-level UV-A1 expo-
sure despite tanning response in human skin. JAMA Dermatol 
2014 Apr; 150(4):401–6.

  17.  Hughes MC, Williams GM, Baker P, Green AC. Sunscreen and 
prevention  of  skin  aging:  A  randomized  trial.  Ann  Int  Med 
[Randomized  Controlled  Trial  Research  Support,  Non-U.S. 
Govt] 2013 Jun 4; 158(11):781–90.

  18.  Bissonnette R, Nigen S, Bolduc C. Influence of the quantity of sun-
screen applied on the ability to protect against ultraviolet-induced 
light  eruption.  Photodermatol  Photoimmunol 
polymorphous 
Photomed 2012 Oct; 28(5):240–3.

  19.  Medeiros VL, Lim HW. Sunscreens in the management of pho-

todermatoses. Skin Ther Lett 2010 Jun; 15(6):1–3.

  20.  Damian DL, Halliday GM, Barnetson RS. Broad-spectrum sun-
screens  provide  greater  protection  against  ultraviolet-radia-
tion-induced suppression of contact hypersensitivity to a recall 
antigen in humans. J Invest Dermatol 1997 Aug; 109(2):146–51.

  21.  Moyal  DD,  Fourtanier  AM.  Broad-spectrum  sunscreens  pro-
vide better protection from solar ultraviolet-simulated radiation 
and  natural  sunlight-induced  immunosuppression  in  human 
beings. J Am Acad Dermatol 2008 May; 58(5 Suppl 2):S149–54.

  22.  Thompson  SC,  Jolley  D,  Marks  R.  Reduction  of  solar  kera-
toses  by  regular  sunscreen  use.  N  Engl  J  Med  1993  Oct  14; 
329(16):1147–51.

  23.  Darlington  S,  Williams  G,  Neale  R,  Frost  C,  Green  A.  A  ran-
domized  controlled  trial  to  assess  sunscreen  application  and 
beta carotene supplementation in the prevention of solar kera-
toses. Arch Dermatol 2003 Apr; 139(4):451–5.

  24.  Gordon LG, Scuffham PA, van der Pols JC, McBride P, Williams 
GM,  Green  AC.  Regular  sunscreen  use  is  a  cost-effective 
approach  to  skin  cancer  prevention  in  subtropical  settings. 
J Invest Dermatol 2009 Dec; 129(12):2766–71.

  25.  Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. 
Daily  sunscreen  application  and  betacarotene  supplementa-
tion in prevention of basal-cell and squamous-cell carcinomas 
of the skin: A randomised controlled trial. Lancet 1999 Aug 28; 
354(9180):723–9.

  26.  van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. 
Prolonged prevention of squamous cell carcinoma of the skin 
by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006 
Dec; 15(12):2546–8.

  27.  Bastuji-Garin S, Diepgen TL. Cutaneous malignant melanoma, 
sun exposure, and sunscreen use: Epidemiological evidence. Br 
J Dermatol 2002 Apr; 146(Suppl 61):24–30.

  28.  Dennis LK, Beane Freeman LE, VanBeek MJ. Sunscreen use and 
the risk for melanoma: A quantitative review. Ann Int Med 2003 
Dec 16; 139(12):966–78.

J  Clin  Oncol  [Randomized  Controlled  Trial  Research  Support, 
Non-U.S. Govt] 2011 Jan 20; 29(3):257–63.

  30.  Viros  A,  Sanchez-Laorden  B,  Pedersen  M,  Furney  SJ,  Rae  J, 
Hogan  K,  et  al.  Ultraviolet  radiation  accelerates  BRAF-driven 
melanomagenesis  by  targeting  TP53.  Nature  2014  Jul  24; 
511(7510):478–82.

  31.  Kannan  S,  Lim  HW.  Photoprotection  and  vitamin  D: 
A  review.  Photodermatol  Photoimmunol  Photomed  2014  Apr–Jun; 
30(2–3):137–45.

  32.  Jansen  R,  Wang  SQ,  Burnett  M,  Osterwalder  U,  Lim  HW. 
Photoprotection:  Part  I.  Photoprotection  by  naturally  occur-
ring,  physical,  and  systemic  agents.  J  Am  Acad  Dermatol  2013 
Dec; 69(6):853 e1–12; quiz 65–6.

  33.  Almutawa F, Vandal R, Wang SQ, Lim HW. Current status of 
photoprotection  by  window  glass,  automobile  glass,  window 
films,  and  sunglasses.  Photodermatol  Photoimmunol  Photomed 
2013 Apr; 29(2):65–72.

  34.  Lesage C, Barbe C, Le Clainche A, Lesage FX, Bernard P, Grange 
F.  Sex-related  location  of  head  and  neck  melanoma  strongly 
argues for a major role of sun exposure in cars and photopro-
tection by hair. J Invest Dermatol 2013 May; 133(5):1205–11.
  35.  Kim  DP,  Chabra  I,  Chabra  P,  Jones  EC.  Sunscreen  use  while 

driving. J Am Acad Dermatol 2013 Jun; 68(6):952–6.

  36.  Wang  SQ,  Balagula  Y,  Osterwalder  U.  Photoprotection: 
A review of the current and future technologies. Dermatol Ther 
2010 Jan–Feb; 23(1):31–47.

  37.  Almutawa F, Buabbas H. Photoprotection: Clothing and glass. 

Dermatol Clin 2014 Jul; 32(3):439–48, x.

  38.  Chen  AC,  Damian  DL,  Halliday  GM.  Oral  and  systemic 
 photoprotection.  Photodermatol  Photoimmunol  Photomed  2014 
Apr–Jun; 30(2–3):102–11.

  39.  Butler  GJ,  Neale  R,  Green  AC,  Pandeya  N,  Whiteman  DC. 
Nonsteroidal  anti-inflammatory  drugs  and  the  risk  of  actinic 
keratoses  and  squamous  cell  cancers  of  the  skin.  J  Am  Acad 
Dermatol 2005 Dec; 53(6):966–72.

  40.  Grau  MV,  Baron  JA,  Langholz  B,  Karagas  M,  Greenberg  ER, 
Stukel  TA,  et  al.  Effect  of  NSAIDs  on  the  recurrence  of  non-
melanoma skin cancer. Intl J Cancer 2006 Aug 1; 119(3):682–6.

  41.  Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, et al. 
COX-2  inhibition  prevents  the  appearance  of  cutaneous  squa-
mous  cell  carcinomas  accelerated  by  BRAF  inhibitors.  Molec 
Oncol 2014 Mar; 8(2):250–60.

  42.  Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, 
et al. Chemoprevention of nonmelanoma skin cancer with cele-
coxib:  A  randomized,  double-blind,  placebo-controlled  trial. 
J Natl Cancer Inst 2010 Dec 15; 102(24):1835–44.

  43.  Liebman  TN,  Stein  JA,  Polsky  D.  Cyclo-oxygenase-2  inhibi-
tors  for  chemoprevention  of  nonmelanoma  skin  cancer:  Is 
there  a  role  for  these  agents?  J  Am  Acad  Dermatol  2013  Jan; 
68(1):173–6.

  44.  Ulrich  C,  Johannsen  A,  Rowert-Huber  J,  Ulrich  M,  Sterry  W, 
Stockfleth E. Results of a randomized, placebo-controlled safety 
and efficacy study of topical diclofenac 3% gel in organ trans-
plant  patients  with  multiple  actinic  keratoses.  Eur  J  Dermatol 
2010 Jul–Aug; 20(4):482–8.

  45.  Chen  L,  Hu  JY,  Wang  SQ.  The  role  of  antioxidants  in  photo-
protection:  A  critical  review.  J  Am  Acad  Dermatol  2012  Nov; 
67(5):1013–24.

  46.  Afaq  F,  Katiyar  SK.  Polyphenols:  Skin  photoprotection  and 
inhibition of photocarcinogenesis. Mini Rev Med Chem 2011 Dec; 
11(14):1200–15.

  47.  Nichols JA, Katiyar SK. Skin photoprotection by natural poly-
phenols:  Anti-inflammatory,  antioxidant  and  DNA  repair 
mechanisms. Arch Dermatol Res 2010 Mar; 302(2):71–83.

  48.  Reeve VE, Allanson M, Arun SJ, Domanski D, Painter N. Mice 
drinking  goji  berry  juice  (Lycium  barbarum)  are  protected 
from UV radiation-induced skin damage via antioxidant path-
ways. Photochem Photobiol Sci 2010 Apr; 9(4):601–7.

  29.  Green AC, Williams GM, Logan V, Strutton GM. Reduced mela-
noma after regular sunscreen use: Randomized trial follow-up. 

  49.  Afaq  F,  Khan  N,  Syed  DN,  Mukhtar  H.  Oral  feeding  of 
pomegranate  fruit  extract  inhibits  early  biomarkers  of  UVB 

 
radiation-induced carcinogenesis in SKH-1 hairless mouse epi-
dermis. Photochem Photobiol 2010 Nov–Dec; 86(6):1318–26.
  50.  Khan  N,  Syed  DN,  Pal  HC,  Mukhtar  H,  Afaq  F.  Pomegranate 
fruit extract inhibits UVB-induced inflammation and prolifera-
tion by modulating NF-kappaB and MAPK signaling pathways 
in mouse skin. Photochem Photobiol 2012 Sep–Oct; 88(5):1126–34.

  51.  Stahl W, Sies H. beta-Carotene and other carotenoids in protec-

tion from sunlight. Am J Clin Nutr 2012 Nov; 96(5):1179S–84S.

  52.  Druesne-Pecollo  N,  Latino-Martel  P,  Norat  T,  Barrandon  E, 
Bertrais  S,  Galan  P,  et  al.  Beta-carotene  supplementation  and 
cancer risk: A systematic review and metaanalysis of random-
ized controlled trials. Intl J Cancer 2010 Jul 1; 127(1):172–84.
  53.  Rizwan M, Rodriguez-Blanco I, Harbottle A, Birch-Machin MA, 
Watson RE, Rhodes LE. Tomato paste rich in lycopene protects 
against cutaneous photodamage in humans in vivo: A random-
ized controlled trial. Br J Dermatol 2011 Jan; 164(1):154–62.
  54.  Marini A, Jaenicke T, Grether-Beck S, Le Floc’h C, Cheniti A, 
Piccardi N, et al. Prevention of polymorphic light eruption by 
oral  administration  of  a  nutritional  supplement  containing 
lycopene,  beta-carotene,  and  Lactobacillus  johnsonii:  Results 
from a randomized, placebo-controlled, double-blinded study. 
Photodermatol Photoimmunol Photomed 2014 Aug; 30(4):189–94.

  55.  Whitlock  NC,  Baek  SJ.  The  anticancer  effects  of  resvera-
trol:  Modulation  of  transcription  factors.  Nutr  Cancer  2012; 
64(4):493–502.

  56.  Svajger U, Jeras M. Anti-inflammatory effects of resveratrol and 
its potential use in therapy of immune-mediated diseases. Int 
Rev Immunol 2012 Jun; 31(3):202–22.

  57.  Ndiaye M, Philippe C, Mukhtar H, Ahmad N. The grape anti-
oxidant resveratrol for skin disorders: Promise, prospects, and 
challenges. Arch Biochem Biophys 2011 Apr 15; 508(2):164–70.
  58.  Kim  KH,  Back  JH,  Zhu  Y,  Arbesman  J,  Athar  M,  Kopelovich 
L,  et  al.  Resveratrol  targets  transforming  growth  factor-beta2 
signaling  to  block  UV-induced  tumor  progression.  J  Invest 
Dermatol 2011 Jan; 131(1):195–202.

  59.  El-Haj N, Goldstein N. Sun protection in a pill: The photopro-
tective  properties  of  Polypodium  leucotomos  extract.  Intl  J 
Dermatol 2015 Mar; 54(3)362–6.

  60.  Rodriguez-Yanes  E,  Juarranz  A,  Cuevas  J,  Gonzalez  S,  Mallol 
J.  Polypodium  leucotomos  decreases  UV-induced  epidermal 
cell  proliferation  and  enhances  p53  expression  and  plasma 
antioxidant  capacity  in  hairless  mice.  Exp  Dermatol  2012  Aug; 
21(8):638–40.

  61.  Gonzalez  S,  Gilaberte  Y,  Philips  N.  Mechanistic  insights  in 
the  use  of  a  Polypodium  leucotomos  extract  as  an  oral  and 
topical photoprotective agent. Photochem Photobiol Sci 2010 Apr; 
9(4):559–63.

  62.  Villa  A,  Viera  MH,  Amini  S,  Huo  R,  Perez  O,  Ruiz  P,  et  al. 
Decrease of ultraviolet A light-induced “common deletion” in 
healthy  volunteers  after  oral  Polypodium  leucotomos  extract 
supplement in a randomized clinical trial. J Am Acad Dermatol 
2010 Mar; 62(3):511–3.

  63.  Aguilera  P,  Carrera  C,  Puig-Butille  JA,  Badenas  C,  Lecha  M, 
Gonzalez  S,  et  al.  Benefits  of  oral  Polypodium  Leucotomos 
extract in MM high-risk patients. J Eur Acad Dermatol Venereol 
2013 Sep; 27(9):1095–100.

  64.  Middelkamp-Hup  MA,  Pathak  MA,  Parrado  C,  Goukassian 
D, Rius-Diaz F, Mihm MC, et al. Oral Polypodium leucotomos 
extract  decreases  ultraviolet-induced  damage  of  human  skin. 
J Am Acad Dermatol 2004 Dec; 51(6):910–8.

  65.  Tanew  A,  Radakovic  S,  Gonzalez  S,  Venturini  M,  Calzavara-
Pinton  P.  Oral  administration  of  a  hydrophilic  extract  of 
Polypodium  leucotomos  for  the  prevention  of  polymorphic 
light eruption. J Am Acad Dermatol 2012 Jan; 66(1):58–62.
  66.  Han  W,  Ming  M,  He  YY.  Caffeine  promotes  ultraviolet 
B-induced apoptosis in human keratinocytes without complete 
DNA repair. J Biol Chem 2011 Jul 1; 286(26):22825–32.

  67.  Conney  AH,  Lu  YP,  Lou  YR,  Kawasumi  M,  Nghiem  P. 
Mechanisms of caffeine-induced inhibition of UVB carcinogen-
esis. Frontiers Oncol 2013; 3:144.

PHOTODAMAGE: PROTECTION 

  191

  68.  Hughes  MC,  Williams  GM,  Fourtanier  A,  Green  AC.  Food 
intake,  dietary  patterns,  and  actinic  keratoses  of  the  skin: 
A longitudinal study. Am J Clin Nutr 2009 Apr; 89(4):1246–55.

  69.  Pilkington  SM,  Massey  KA,  Bennett  SP,  Al-Aasswad  NM, 
Roshdy K, Gibbs NK, et al. Randomized controlled trial of oral 
omega-3  PUFA  in  solar-simulated  radiation-induced  suppres-
sion  of  human  cutaneous  immune  responses.  Am  J  Clin  Nutr 
2013 Mar; 97(3):646–52.

  70.  Latreille  J,  Kesse-Guyot  E,  Malvy  D,  Andreeva  V,  Galan  P, 
Tschachler  E,  et  al.  Association  between  dietary  intake  of  n-3 
polyunsaturated fatty acids and severity of skin photoaging in 
a middle-aged Caucasian population. J Dermatol Sci 2013 Dec; 
72(3):233–9.

  71.  Park  J,  Halliday  GM,  Surjana  D,  Damian  DL.  Nicotinamide 
prevents  ultraviolet  radiation-induced  cellular  energy  loss. 
Photochem Photobiol 2010 Jul–Aug; 86(4):942–8.

  72.  Surjana D, Halliday GM, Damian DL. Nicotinamide enhances 
repair of ultraviolet radiation-induced DNA damage in human 
keratinocytes  and  ex  vivo  skin.  Carcinogenesis  2013  May; 
34(5):1144–9.

  73.  Thompson  BC,  Surjana  D,  Halliday  GM,  Damian  DL. 
Nicotinamide enhances repair of ultraviolet radiation-induced 
DNA  damage  in  primary  melanocytes.  Exp  Dermatol  2014  Jul; 
23(7):509–11.

  74.  Damian  DL,  Matthews  YJ,  Halliday  GM.  Topical  riboflavin 
attenuates  ultraviolet  B-  and  ultraviolet  A-induced  immuno-
suppression  in  humans.  Photodermatol  Photoimmunol  Photomed 
2010 Apr; 26(2):66–9.

  75.  Damian DL, Patterson CR, Stapelberg M, Park J, Barnetson RS, 
Halliday  GM.  UV  radiation-induced  immunosuppression  is 
greater in men and prevented by topical nicotinamide. J Invest 
Dermatol 2008 Feb; 128(2):447–54.

  76.  Nasti  TH,  Timares  L.  MC1R,  eumelanin  and  pheomelanin: 
Their  role  in  determining  the  susceptibility  to  skin  cancer. 
Photochem Photobiol 2015 Jan-Feb; 91(1):188–200.

  77.  Barnetson  RS,  Ooi  TK,  Zhuang  L,  Halliday  GM,  Reid  CM, 
Walker PC, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating 
hormone  significantly  increased  pigmentation  and  decreased 
UV  damage  in  fair-skinned  Caucasian  volunteers.  J  Invest 
Dermatol 2006 Aug; 126(8):1869–78.

  78.  O’Leary RE, Diehl J, Levins PC. Update on tanning: More risks, 
fewer benefits. J Am Acad Dermatol 2014 Mar; 70(3):562–8.
  79.  Krutmann J, Morita A, Chung JH. Sun exposure: What molec-
ular  photodermatology  tells  us  about  its  good  and  bad  sides. 
J Invest Dermatol 2012 Mar; 132(3 Pt 2):976–84.

  80.  Cho S, Shin MH, Kim YK, Seo JE, Lee YM, Park CH, et al. Effects 
of  infrared  radiation  and  heat  on  human  skin  aging  in  vivo. 
J Invest Dermatol Symp Proc 2009 Aug; 14(1):15–9.

  81.  Calles  C,  Schneider  M,  Macaluso  F,  Benesova  T,  Krutmann  J, 
Schroeder  P.  Infrared  A  radiation  influences  the  skin  fibro-
blast  transcriptome:  Mechanisms  and  consequences.  J  Invest 
Dermatol 2010 Jun; 130(6):1524–36.

  82.  Schieke S, Stege H, Kurten V, Grether-Beck S, Sies H, Krutmann 
J.  Infrared-A  radiation-induced  matrix  metalloproteinase  1 
expression is mediated through extracellular signal-regulated 
kinase  1/2  activation  in  human  dermal  fibroblasts.  J  Invest 
Dermatol 2002 Dec; 119(6):1323–9.

  83.  Schroeder  P,  Haendeler  J,  Krutmann  J.  The  role  of  near  infra-
red radiation in photoaging of the skin. Exp Gerontol 2008 Jul; 
43(7):629–32.

  84.  Grether-Beck  S,  Salahshour-Fard  M,  Timmer  A,  Brenden  H, 
Felsner I, Walli R, et al. Ceramide and raft signaling are linked 
with  each  other  in  UVA  radiation-induced  gene  expression. 
Oncogene 2008 Aug 14; 27(35):4768–78.

  85.  Schroeder  P,  Pohl  C,  Calles  C,  Marks  C,  Wild  S,  Krutmann 
J.  Cellular  response  to  infrared  radiation  involves  retro-
grade  mitochondrial  signaling.  Free  Radic  Biol  Med  2007  Jul  1; 
43(1):128–35.

  86.  Schroeder  P,  Calles  C,  Benesova  T,  Macaluso  F,  Krutmann 
J.  Photoprotection  beyond  ultraviolet  radiation–effective 

 
192 

 TEXTBOOK OF COSMETIC DERMATOLOGY

sun  protection  has  to  include  protection  against  infrared  A 
radiation-induced  skin  damage.  Skin  Pharmacol  Physiol  2010; 
23(1):15–7.

  87.  Liebel F, Kaur S, Ruvolo E, Kollias N, Southall MD. Irradiation 
of  skin  with  visible  light  induces  reactive  oxygen  species 
and  matrix-degrading  enzymes.  J  Invest  Dermatol  2012  Jul; 
132(7):1901–7.

  88.  Wehner  MR,  Chren  MM,  Nameth  D,  Choudhry  A,  Gaskins 
M, Nead KT, et al. International prevalence of indoor tanning: 
A  systematic  review  and  meta-analysis.  JAMA  Dermatol  2014 
Apr; 150(4):390–400.

  89.  Guy  GP,  Jr.  Berkowitz  Z,  Tai  E,  Holman  DM,  Everett  Jones  S, 
Richardson  LC.  Indoor  tanning  among  high  school  students 
in the United States, 2009 and 2011. JAMA Dermatol 2014 May; 
150(5):501–11.

  90.  Colantonio S, Bracken MB, Beecker J. The association of indoor 
tanning and melanoma in adults: Systematic review and meta-
analysis. J Am Acad Dermatol 2014 May; 70(5):847–57 e1–18.

  91.  Holman DM, Fox KA, Glenn JD, Guy GP, Jr. Watson M, Baker 
K, et al. Strategies to reduce indoor tanning: Current research 
gaps and future opportunities for prevention. Am J Prevent Med 
2013 Jun; 44(6):672–81.

  92.  Reinau  D,  Achermann  C,  Arnet  N,  Meier  CR,  Hatz  C, 
Surber C. Sun protective  behaviour  of  vacationers  spending 
 holidays in the tropics and subtropics. Br J Dermatol 2014 Oct; 
171(4):868–74.

  93.  Iannacone  MR,  Hughes  MC,  Green  AC.  Effects  of  sunscreen 
on  skin  cancer  and  photoaging.  Photodermatol  Photoimmunol 
Photomed 2014 Apr–Jun; 30(2–3):55–61.

  94.  Sattler  U,  Thellier  S,  Sibaud  V,  Taieb  C,  Mery  S,  Paul  C,  et  al. 
Factors  associated  with  sun  protection  compliance:  Results 
from  a  nationwide  cross-sectional  evaluation  of  2215  patients 
from  a  dermatological  consultation.  Br  J  Dermatol  2014  Jun; 
170(6):1327–35.

  95.  Roelandts  R.  Determinants  of  personal  ultraviolet  radiation 
exposure  doses  on  a  sun  holiday.  Br  J  Dermatol  2013  May; 
168(5):927.

 
23

Photodamage and Skin Cancer: How Successful 
Are Sunscreens as a Means of Prevention?

Xinyi Du and Douglas Maslin

INTRODUCTION
Sunscreens  were  first  developed  in  the  1930s  as  a  means  of 
protection  from  sunburn,  as  light-skinned  individuals  dem-
onstrated  increasing  sun-seeking  behaviours  in  the  face  of 
tanned  skin  becoming  fashionable  (1).  However,  despite  this 
long  history  sunscreen  uptake  has  been  temperamental,  its 
use sometimes controversial, and the incidence of skin cancers 
within the western hemisphere continues to rise (2). This now 
represents  an  impending  public  health  crisis,  as  there  is  an 
ever-increasing  demand  on  already  stretched  dermatological 
and oncological services.

Sunscreens  have  been  widely  promoted  as  a  success-
ful preventative method, for example in Australia where they 
have  campaigned  to  “slop  on  sunscreen”  as  part  of  the  “slip, 
slop,  slap,  seek  &  slide”  SunSmart  campaign  (3).  However, 
despite  decades  of  such  public  health  messages,  skin  cancer 
remains on the rise overall. So is it fair to say that sunscreen 
has  “failed”  as  a  preventative  measure  against  photodamage 
and skin cancer?

This chapter looks at the scientific evidence behind ultra-
violet (UV) radiation and carcinogenesis and the mechanisms 
of  photoprotection  provided  by  sunscreen,  and  investigates 
the evidence base and controversies surrounding its effective-
ness  as  a  photoprotective  agent.  Why  is  it  that  some  studies 
show, in direct contradiction to scientific logic, that sunscreen 
use is associated with increased skin cancer rates, in particular 
of malignant melanoma (4)? The key behavioral factors so inte-
gral to sunscreen use are thus also analyzed.

It is evident that clear communication and high-quality 
patient education is an integral part of preventing sunlight-
induced  skin  aging  and  more  importantly,  carcinogenesis. 
This chapter looks at the future of preventing photocarcino-
genesis and the role of sunscreen within this, and therefore 
how we may best advise our patients on the key issue of pre-
vention.

ULTRAVIOLET RADIATION AND 
PHOTOCARCINOGENESIS
Epidemiological  studies  from  nearly  50  years  ago  first  dem-
onstrated the link between sun exposure and dermatological 
malignancies. This was deduced from observations that mela-
noma  is  proportionally  more  common  in  those  living  closer 
to  the  equator,  where  UV  exposure  is  higher  (5).  Secondly, 
those  who  have  a  reduced  ability  to  absorb  UV  light  due  to 
possessing  less  melanin,  such  as  those  with  Fitzpatrick  skin 
type I, are statistically more likely to develop skin cancer (6). 
Thirdly,  non-melanoma  skin  malignancies  such  as  basal  cell 
carcinomas (BCCs) and squamous cell carcinomas (SCCs) are 

commonly  found  on  sun-exposed  areas  such  as  the  face  and 
upper chest (7).

Sunlight represents a broad range within the electromag-
netic spectrum; the two types of radiation we notice are visible 
light (wavelength 400–760 nm) and infrared ( 760–106nm) in the 
form of heat. The form of radiation that we are concerned with, 
however,  is  ultraviolet  B  (UVB)  (290–320  nm)  and  ultraviolet 
A  (UVA)  (320–400  nm),  which  are  invisible  but  biologically 
active  components  of  sunlight.  UVB,  for  example,  interacts 
with  7-dehydrocholesterol  in  the  skin  to  produce  cholecalcif-
erol (vitamin D3).

Both  forms  of  UV  are  thought  to  induce  DNA  damage 
and thus genetic mutations, which could lead to the so-called 
“hallmarks of cancer” (8). UVB is thought to cause direct dam-
age  to  cellular  DNA,  leading  to  the  formation  of  pyrimidine 
dimers (Figure 23.1). The importance of this is highlighted by 
the  condition  xeroderma  pigmentosum:  the  resulting  defect 
in  the  nucleotide  excision  repair  pathway  that  repairs  these 
abnormal pyrimidine dimers leads to a skin cancer risk 2000 
times greater than that of the general population (9).

UVA, on the other hand, is thought to penetrate deeper 
into the dermis due to its longer wavelength, and then to cause 
DNA  damage  by  the  production  of  circulating  free  radicals. 
However,  more  recent  research  has  shown  that  this  view  is 
overly  simplistic  and  the  damaging  effects  of  UVA  and  UVB 
are probably more synergistic than previously understood (10). 
Furthermore, there is evidence that radiation within different 
areas of the electromagnetic spectrum also have a role of pho-
todamage and photoaging, in particular infrared (11).

It has also become evident that immunity is a key player 
in dermatological malignancies. The use of immunotherapies 
has changed the landscape of both malignant melanoma and 
solid tumor malignancies. There is now evidence that combi-
nation treatment with the immunomodulatory agents ipilim-
umab  (an  anticytotoxic  T-lymphocyte-4  antigen  monoclonal 
antibody) and nivolumab (an antiprogrammed death-1 recep-
tor antibody) may provide the best outcomes in advanced mel-
anoma. Such agents work by augmenting antitumor immunity 
by blocking checkpoints in the immune pathway by acting on 
antigens and receptors such as CTL4 and PD-1 (12). The rela-
tionship  between  UV  radiation  and  immunity  has  also  been 
studied, and both UVA and UVB are known to cause immu-
nosuppression  (13).  In  addition  to  this,  the  role  of  UVB  in 
generating  vitamin  D3,  which  has  a  multifactorial  impact  on 
immunity  that  is  yet  to  be  fully  understood,  must  also  to  be 
considered (14).

As sun-seeking behaviors and so exposure to UV radia-
tion have increased over the 20th century, so have incidences 

194 

 TEXTBOOK OF COSMETIC DERMATOLOGY

of all types of skin cancer (15). Broadly speaking, these are 
divided into melanoma and non-melanoma skin carcinomas. 
SCCs and BCCs tend to present in sun-exposed areas, with 
SCCs thought to be largely associated with cumulative UVB 
exposure  and  BCCs  with  episodes  of  sunburn.  Although 
there is not a significant risk of mortality (it is greater with 
SCCs  than  BCCs),  they  are  locally  invasive  and  damaging, 
as  well  as  cosmetically  concerning  to  patients.  Melanomas 
are further subdivided into different subtypes with varying 
degrees  of  invasiveness  and  aggression.  Nodular  melano-
mas  are  associated  with  a  poorer  prognosis  than  the  more 
common superficial spreading melanomas. Melanomas tend 
to  present  in  non-sun–exposed  areas  such  as  the  back  and 
lower leg (16). Mutations such as the oncogene braf, which are 
found in around 50% of melanomas, have been suggested to 
be  caused  by  free  radical  damage  caused  by  UVA  (17).  The 
revolutionary  impact  of  braf  inhibitors  on  metastatic  mela-
noma  highlights  the  importance  of  such  a  mutation.  Mela-
noma has a significant mortality rate, and is the cancer which 
causes  the  most  deaths  of  young  adults  worldwide  (18). 
 Figure  23.2  summarizes  the  rising  incidence  of  malignant 
melanoma between 1975 and 2011.

UV

G

C

T

G

G

C

C

A

TT

G

dimer

A A

C

G

C

Figure 23.1  UV light-induced thymine dimer.

SUNSCREEN: HOW DOES IT WORK 
AND HOW IS THIS MEASURED?
The  ideal  sunscreen  would  provide  complete  UV  protection, 
be long-lasting, and be cosmetically acceptable. However, the 
reality is that most sunscreens provide relatively limited pro-
tection across the UV spectrum, require regular reapplication, 
and  can  be  cosmetically  unappealing  due  to  shine  and  com-
edogenic  properties.  Furthermore,  sunscreens  are  costly  and 
the large area to which they need to be applied can mean they 
are unacceptably expensive for individuals to use as their pri-
mary sun protection measure (19).

Sunscreens  are  divided  into  organic  and  inorganic 
agents, which act by providing chemical and physical barriers 
to UV radiation, respectively. The protection given is divided 
into UVB, UVA, or “broad-spectrum” coverage.

Organic  barriers  work  by  absorbing  UV  radiation;  his-
torically they were manufactured to absorb UVB only as this 
was  once  thought  to  be  the  sole  “harmful”  wavelength.  The 
most  commonly  used  organic  agents  are  cinnamates  such  as 
octyl  methoxycinnamate,  which  still  provide  predominantly 
UVB absorption (20). However, more recently developed agents 
provide  cover  for  a  broader  wavelength  including  UVA.  The 
most commonly used UVA-protective agents are benzophones 
such  as  oxybenzone.  However,  oxybenzone,  for  example,  is 
limited  by  a  number  of  factors  including  its  preponderance 
toward  causing  allergic  dermatitis,  and  its  skin  penetration, 
as evidenced by its presence in the urine and bloodstream of 
individuals using the product. Another challenge in the pro-
duction  of  effective  broad-spectrum  sunscreens  is  being  able 
to successfully combine both UVA- and UVB-protective prod-
ucts in an acceptable lotion (21).

Inorganic agents such as titanium dioxide and zinc oxide 
form a physical barrier of inert metal particles, which are able 
to reflect and scatter UV radiation but also visible light. They 
have been assumed to be safer than organic agents, and have 
been advocated for children. Inorganic agents provide varying 
degrees of protection, with titanium dioxide being inferior to 
zinc  in  providing  protection  against  UVA  (22).  These  tend  to 
form thick, shiny lotions that can be cosmetically unappealing 

Male

Female

Combined

20

16

12

8

4

,

0
0
0
0
0
1
r
e
p
e
t
a
R

0
1975 1977

1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011

1998 2000 2002 2004 2006 2008 2010

1976 1978 1980 1982 1984 1986 1988 1990 1992 1994 1996
Year of diagnosis

Figure 23.2  Malignant melanoma 1975–2011 European age-standardized incidence rates per 100,000 population, by sex, Great  Britain. 
(From Cancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/incidence/. Accessed 2015.)

 
 
 
to use. However, new developments in sunscreen technology 
have  resulted  in  the  formulation  of  micro-ionized  particles, 
which are significantly smaller and therefore scatter less vis-
ible light, reducing undesirable shine (23). However, there have 
been suggestions that these micro-ionized particles would be 
absorbed more easily and so result in toxicities.

Over the years, safety concerns have been raised regard-
ing  active  ingredients  within  sunscreen,  leading  to  delays  in 
consumers  being  able  to  access  theoretically  more  effective 
products.  The  proposed  dangers  include  possible  carcinoge-
nicity,  and  that  rather  than  reducing  free  radical  production, 
the  active  products  in  sunscreens  may  even  produce  free 
radicals (24). So far, studies analyzing toxicities related to sun-
screen ingredients such as retinyl palmitate, oxybenzone, zinc 
oxide,  and  titanium  dioxide  have  failed  to  demonstrate  they 
have such harmful effects (25).

A  quirk  of  American  legislation  means  that  sunscreen 
products are classified as drugs, as opposed to cosmetic prod-
ucts as they are in Europe. This means that in order for them 
to be available to consumers, they have to pass far more strin-
gent safety regulations via the Food and Drug Administration 
(FDA). Subsequently, FDA hasn’t approved an over-the-counter 
sunscreen  ingredient  since  1999  (26).  Therefore,  individuals 
using sunscreen in the United States have yet to benefit from 
newer products which provide greater protection against UVA, 
some  of  which  have  been  available  in  Europe  and  Japan  for 
quite some time. However, recent updates in the law may see 
this change (27).

The protection sunscreens provide against UVB is quan-
tified by its sun protection factor (SPF). This is the ratio of the 
amount  of  UV  radiation  required  to  cause  an  erythematous 
reaction with a filter compared to without. For example, apply-
ing SPF2 sunscreen enables an individual to have exposure to 
UV  radiation  twice  as  strong  as  they  would  otherwise  with-
out protection, before erythema is induced. The absorption of 
UVB rays is also influenced by the strength of SPF, but there 
is  an  exponentially  decreasing  return  on  increasing  SPF.  For 
example, whilst SPF2 applied at a rate of 2mg/cm2 absorbs 50% 
of  rays,  SPF15  absorbs  93%,  SPF  30  absorbs  97%,  and  SPF  50 
absorbs  98%.  Therefore,  higher  SPF  sunscreens  may  provide 
a  negligible  difference  in  UV  absorption  while  encouraging 
the user to feel disproportionately more protected against UV. 
As  discussed  below,  this  is  reflected  in  some  studies  of  high 
SPF  sunscreen  use,  which  suggest  that  they  are  not  provid-
ing greater sun protection as one would assume (28). Further-
more, in calculating the SPF, FDA uses a dose of 2.2mg/cm2 of 
exposed  skin.  However,  this  estimated  dose  is  thought  to  be 
up  to  four  times  higher  than  what  individuals  use  in  reality 
(29).  There  is  also  the  big  question  of  whether  SPF  is  even  a 
useful measure of long-term UV damage, as there is evidence 
that  photoaging,  immunosuppression,  gene  mutations,  and 
pyrimidine  dimer  formation  is  induced  by  suberythematous 
UVB radiation (30).

UVA  measurement  techniques  vary  in  not  only  meth-
odology, but also in the generation of rating scales produced. 
A variety of in vivo and in vitro methods are used in Japan, 
Europe,  the  United  Kingdom,  the  United  States,  and  Austra-
lia. FDA, for example, employs an in vitro method which mea-
sures the UV transmittance after radiation is administered to 
a  test  product.  The  critical  wavelength  is  determined  by  the 
wavelength  at  which  90%  of  the  total  area  under  the  absor-
bance curve occurs. Sunscreens which include a critical wave-
length of greater than or equal to 370 nm are defined as “broad 
spectrum.”  In  contrast,  Japan  uses  an  in  vivo  method  with 

PHOTODAMAGE AND SKIN CANCER 

 195

persistent  pigment  darkening  (PPD)  as  the  primary  clinical 
endpoint, where the minimal UVA radiation dose required to 
induce pigmentation is compared when using UVA protection 
versus  without.  This  enables  generation  of  a  UVA  protection 
grade from PA + to PA ++++. The EU also uses PPD as the clini-
cal endpoint but also requires UVA protection as a proportion 
of  UVB  protection  to  be  present,  which  then  generates  a  star 
rating (31).

It can be seen, therefore, that there is considerable varia-
tion in both the ingredients in the products available and the 
protection they subsequently provide. This makes comparing 
studies difficult, and applying the results of many such stud-
ies, often using outdated agents, unhelpful. Therefore, analyz-
ing the efficacy of sunscreen use can be difficult.

SUNSCREEN: DOES IT REALLY WORK 
AND WHAT EVIDENCE IS OUT THERE?
Effects  of  photoaging,  including  pigmentation,  collagen  loss, 
and  blood  vessel  dilatation  have  been  shown  to  be  reduced 
through  the  appropriate  use  of  sunscreen  (32).  In  fact,  an 
Australian  randomized-controlled  trial  of  903  participants 
examined the effects of daily application of broad-spectrum SPF 
15+ sunscreen on a measure of dermal elastosis. After 4 years of 
follow-up, the trial concluded that skin aging was significantly 
less in those using regular sunscreen (33). Although sunscreen 
use logically ought to also reduce the incidence of skin cancers, 
data from clinical trials has been far more conflicting in nature.
Trials  have  demonstrated  that  sunscreens  reduce  the 
incidence of solar keratosis (34) and SCCs, while its effects on 
BCCs have been insignificant or only somewhat effective. The 
primary  example  is  from  another  Australian  randomized-
controlled trial. This involved 1621 participants, beginning in 
1992, and encouraged those in one arm of the study to apply 
SPF  15+  sunscreen  to  specific  areas  at  least  every  morning. 
Follow-up of these participants over 4.5 years led to this same 
conclusion—that such sunscreen use was effective in prevent-
ing SCCs but not BCCs (35).

However, the major controversy undoubtedly surrounds 
the effect that sunscreen use has on the incidence of malignant 
melanoma,  the  most  lethal  skin  cancer.  A  case  control  study 
of 571 melanoma cases and 913 healthy controls, published in 
2000, found a positive association between sunscreen use and 
trunk melanoma formation (4). Of note, the median SPF used 
in this study was 6, and those using sunscreen were also found 
to spend more time in the sun.

A quantitative review of 18 case-control studies did not 
corroborate  these  results,  finding  no  increase  in  melanoma 
associated with sunscreen use (36). Similarly, a meta-analysis 
of  9067  patients  from  11  observational  studies  found  a  rela-
tive  risk  for  melanoma  formation  of  1.01,  when  comparing 
sunscreen use to no use (37). While this may be reassuring to 
a certain extent, they do not show a benefit of sunscreen use 
in  terms  of  melanoma  incidence.  To  this  end,  a  randomized-
controlled  trial  has  shown  that  sunscreen  use  decreases  the 
development of melanocytic nevi in children, which could be 
considered  as  a  surrogate  marker  for  melanoma  risk  (6).  The 
highest-level evidence available is from a 10-year follow-up of 
the  randomized-controlled  trial  mentioned  above,  involving 
1621  participants  in  Australia  (38).  In  this  study,  there  was  a 
marginally statistically significant protection afforded by the 
use  of  regular  sunscreen  against  the  occurrence  of  invasive 
melanoma.  The  secondary  endpoint  outcomes  are,  however, 
small in number: with 3 melanomas classified as invasive out 

 
196 

 TEXTBOOK OF COSMETIC DERMATOLOGY

of 812 individuals on the “treatment” arm (and 11 new primary 
melanomas) versus 11 of 809 in the comparison group (22 new 
primary melanomas).

Numerous  suggestions  have  been  posited  for  explana-
tions regarding this rather equivocal data. As mentioned above, 
the protection afforded especially against UVA by sunscreen 
has historically been poor, such that many of the early studies 
were conducted using sunscreens with only UVB cover. Newer 
trials with modern sunscreens are therefore warranted.

Vitamin D has also been proposed to have a significant 
effect.  Chronic  sun  exposure,  which  would  raise  vitamin  D 
levels, has been associated with melanoma risk reduction (39), 
and it has also been found that greater weekend sun exposure 
(but  not  burning)  may  be  protective  against  melanoma  (40). 
Despite this, current research does not demonstrate that sun-
screen use decreases levels of vitamin D significantly, nor has 
supplementation been shown to reduce risks of melanoma (41). 
A further case-control study has concluded that increased sun 
exposure is correlated with increased melanoma survival (42). 
These results certainly raise the issue that all sunscreen stud-
ies  should  be  looking  not  only  at  melanoma  incidence,  but 
aggressiveness and patient survival as well. Overall, however, 
there is no evidence to establish a clear relationship between 
vitamin  D  and  melanoma  risk,  and  there  is  no  consensus  as 
to  whether  individuals  ought  to  change  their  sun  exposure 
behavior in regard to this (43).

As discussed, it has also been suggested that some of 
the  chemical  products  in  sunscreen  may  be  counteracting 
the benefits it affords in UV protection. Retinyl palmitate, for 
example,  has  previously  been  linked  with  carcinogenesis, 
although there is currently no evidence that it increases the 
risk of skin cancer (44). The formation of damaging free radi-
cals  from  chemicals  in  sunscreen  has  also  been  posited  as 
negating the benefits of reduced free-radical formation from 
UV exposure. If sunscreens are not being applied effectively 
(as discussed below), the balance may tip in favor of excess 
production of reactive oxygen species and thus carcinogen-
esis (45).

In  summary,  there  is  evidence  that  sunscreen  use  pre-
vents photoaging, solar keratoses, and SCC formation but no 
evidence of any benefit (or harm) for BCC. For melanoma, the 
water is a bit murkier, but again there is no clear evidence of 
harm—in fact, the strongest evidence is of a mild benefit. This 
all  being  said,  behavioral  factors  are  the  most  important  fac-
tor in the outcome of sunscreen use, so they must be carefully 
considered in the interpretation of all results.

HUMAN FACTORS IN SUNSCREEN USE
The  use  of  sunscreen  (whether  adequate  or  not)  has  been 
suggested  to  provide  individuals  with  a  sense  of  protection, 
enabling them to indulge in sun-seeking behaviours. There is 
also an (incorrect) assumption that a lack of sunburn is equita-
ble to lack of DNA damage, resulting in a false sense of security. 
Importantly, it has been found that application of sunscreen is 
associated with increased intentional sun exposure (46). Simi-
larly, the use of high SPF sunscreens in particular is associated 
with an increase in sun-seeking behaviors (47), most likely due 
to complacency when using “stronger” sunscreens. Sunscreen 
dosage  and  use,  as  discussed  above,  is  also  frequently  inad-
equate. A survey of 423 individuals found that less than a third 
of respondents knew to apply sunscreen 30 minutes before sun 
exposure,  and  a  similar  minority  knew  how  to  reapply  the 
sunscreen appropriately. A paltry 18% knew the correct dose 

of sunscreen to  apply  (48). Other  studies have drawn similar 
conclusions.  This  usage  of  inadequate  volumes  of  sunscreen 
has been shown to significantly reduce the effective SPF—with 
an exponential  relationship. When  the more commonly used 
amount of 0.5 mg/cm2 is used, SPF 4 becomes 1.4, and SPF 16 
becomes  just  2  (49).  These  behavioral  factors  along  with  oth-
ers, including the fact that fairer-skinned individuals are both 
more likely to use sunscreen and also to develop skin cancer, 
are  strong  confounding  factors  in  the  outcome  of  the  above-
discussed trials.

For  many,  tanned  skin  is  considered  to  be  a  sign  of 
health,  wealth,  and  beauty.  Some  individuals  continue  to 
pursue  this  cosmetic  ideal  despite  awareness  of  health  risks 
of  sun  exposure.  Even  in  the  face  of  well-established  public 
health messages about these serious risks, and thus the need 
for minimizing UV exposure, both tanning beds and holidays 
in  the  sun  remain  widely  popular.  This  persistent  belief  is 
reflected in the results of numerous surveys in different coun-
tries. One international survey of sun protection behaviors of 
8178 individuals showed that a substantial proportion of their 
study group reported “inadequate sun protection behaviours 
resulting in severe sunburn.” Even individuals who have pre-
viously  suffered  with  skin  cancers  and  melanomas  contin-
ued to experience sunburn due to inadequate protection (50). 
Another  recent  survey  of  148,869  Norwegian  women  found 
that although sunscreen use is increasing among Norwegian 
women, this increase has not been accompanied by a decrease 
in sunburn. Results from this survey also show that more than 
two-thirds of Norwegian women are also not protected with 
recommended SPF (51).

Overall it appears that sunscreen use has been increas-
ing  over  the  last  two  decades  with  relatively  poor  improve-
ment  in  rates  of  sunburn.  Sunscreen  persists  in  being  a 
popular method despite the high cost of regular sunscreen use 
and  the  relative  low  cost  of  purchasing  a  wide-brimmed  hat 
or  avoiding  the  sun  altogether.  Sunscreens  are  highly  profit-
able and aggressively marketed by the cosmetic industry, and 
advertisements frequently show children or adults at a sunny 
beach  in  swimwear,  with  no  other  sun  protection.  In  reality, 
such  advertisements  are  promoting  a  behavior  more  harm-
ful to the skin than any sunscreen can realistically counteract. 
Magazines and other media continue to frequently show both 
male  and  female  beauty  ideals  as  sporting  a  tanned  appear-
ance. Unsurprisingly, “positive tan appeal” remains high and 
use  of  indoor  tanning  has  also  increased.  Worryingly,  UV 
exposure from indoor tanning has also been suggested to be 
addictive  (52).  Indeed,  vanity  plays  a  key  role  in  sunscreen 
use, with one study demonstrating that individuals reported 
a more positive response to a sunscreen product when it was 
promoted as preventing skin aging instead of preventing can-
cer (53).

Despite our deeply ingrained cultural appreciation of 
an attractive and “healthy” tan in Western culture, there is 
some  encouraging  evidence  that  the  tide  may  be  turning. 
Recent  epidemiological  studies  of  incidence  of  melanoma 
in  children  and  young  adults  show  some  positive  changes. 
One  study  found  that  overall  trends  have  been  decreasing 
in  the  pediatric  population  in  the  United  States  between 
2000  and  2010,  and  another  found  that  there  is  a  stabiliza-
tion  or  decreasing  trend  in  the  age  group  between  25  and 
44  more  recently  (54,55).  This  may  well  be  attributable  to 
public  health  initiatives  advocating  sun  protection  and 
avoidance, and perhaps also represents a subtle shift in our 

 
sociocultural beliefs and expectations surrounding tanning 
and sun exposure.

CONCLUSION
This chapter has summarized (i) the epidemiology of skin can-
cers, (ii) the role of ultraviolet light in skin aging and carcino-
genesis, (iii) the aims of topical sunscreens as a photoprotective 
tool, (iv) the (somewhat limited) data on outcomes of sunscreen 
use, particularly in regard to melanoma, and (v) the proposed 
reasons for variations within this data, with particular focus 
on the behavioral aspects of sun exposure and sunscreen use. 
But what might one conclude from all this?

Continued  sun-seeking  behaviour  and  a  desire  for  a 
“fashionable” or “healthy” tan has (at least partly) driven the 
rates of both non-melanoma and melanoma skin cancers ever 
higher in the last 50 years. Currently used methods of photo-
protection are proving to be wholly inadequate. However, as 
the  formulations  of  topical  sunscreens  continue  to  improve, 
the main limiting factor of protection is likely to be behavioral.
The public need to be educated on proper sunscreen use 
and  that,  as  stated  by  the  International  Agency  for  Research 
on Cancer, “sunscreens should not be the first choice for skin 
cancer prevention, and should not be the sole agent for protec-
tion against the sun” (56). Further public health initiatives to 
enforce the messages outlined in Table 23.1, while at the same 
time  tackling  the  images  and  misconceptions  promoted  by 
sunscreen marketing and the fashion industry.

Table 23.1  Key behaviors for protection

Seek the shade, especially between 10 a.m. and 4 p.m.
Do not burn.
Avoid tanning and never use UV tanning beds.
Cover up with clothing, including a broad-brimmed hat and 

UV-blocking sunglasses.

Use a broad spectrum (UVA/UVB) sunscreen with an SPF of 
15 or higher every day. For extended outdoor activity, use a 
water-resistant, broad spectrum (UVA/UVB) sunscreen with an 
SPF of 30 or higher.

Apply 1 ounce (2 tablespoons) of sunscreen to your entire body 
30 minutes before going outside. Reapply every 2 hours or 
immediately after swimming or excessive sweating.

Keep newborns out of the sun. Sunscreens should be used 

on babies over the age of 6 months.

Examine your skin head-to-toe every month.
See your physician every year for a professional skin exam.

Source: Skin Cancer Foundation, http://www.skincancer.org/preven-
tion/sun-protection/prevention-guidelines/preventing-skin-cancer. 
With permission.

Table 23.2  Useful tools or protection

SunSmart app to check the daily sun protection times for your 
location each day on the SunSmart app for iPhone, iPad, and 
Android. The app lets you know when you do and don’t need 
sun protection, making it easier than ever to be smart about 
your sun exposure all year.

•  Sunscreen calculator to find out if you are using enough 

sunscreen today.

•  Vitamin D tracker to find out how your UV exposure today 
compares with recommended UV exposure for vitamin D.

Source:  SunSmart,  http://www.sunsmart.com.au/tools/interactive-
tools. With permission.

PHOTODAMAGE AND SKIN CANCER 

 197

Further  large-scale  trials  with  modern  sunscreens  are 
needed  before  we  can  understand  more  closely  their  precise 
effects.  As  newer  products  become  available,  the  overall  pic-
ture  may  become  more  clear.  However,  while  there  remains 
no  convincing  evidence  of  harm,  appropriate  sunscreen  use 
should be encouraged along with covering up and other sun-
avoiding behaviors.

HELPFUL TIPS AND RECOMMENDATIONS
The  Skin  Cancer  Foundation  recommends  the  behaviors  in 
Table 23.1 as being key to preventing skin cancer. Other useful 
tools  to  help  individuals  avoid  dangerous  UV  radiation  and 
protect themselves adequately include the items in Table 23.2. 
The  Cancer  Council  Victoria’s  SunSmart  program  has  pro-
duced  a  free  smartphone  application  which  helps  calculate 
the  above  and  personalizes  sun  protection  recommendation 
according to skin type and exposure risk.

REFERENCES

1. Albert  MR,  Ostheimer  KG.  The  evolution  of  current  medical 
and popular attitudes toward ultraviolet light exposure. Part 3. 
J Am Acad Dermatol 2003; 49(6):1096–106.

2. Skin Cancer Foundation. Skin cancer facts and statistics. Avail-
able  at:  http://www.skincancer.org/skin-cancer-information/
skin-cancer-facts (accessed May 2015).

3.  SunSmart. Slip, slop, slap, seek & slide: Sid Seagull. Available at: 
http://sunsmart.com.au/news_and_media/media_campaigns/
slip-slop-slap-seek-and-slide (accessed April 2015).

4.  Westerdahl  J,  Ingbar  C,  Mâsbäck  A,  et  al.  Sunscreen  use  and 

malignant melanoma. Int J Cancer 2000; 87:145–50.

5.  Elwood JM, Lee JA, Walter SD, et al. Relationship of melanoma 
and  other  skin  cancer  mortality  to  latitude  and  ultraviolet 
radiation in the United States and Canada. Int J Epidemiol 1974; 
3:325–32.

6.  Gallagher RP, Hill G, Bajdik CD, et al. Sunlight exposure, pig-
mentation  factors,  and  risk  of  nonmelanocytic  skin  cancer.  II. 
Squamous cell carcinoma. Arch Dermatol 1995; 131:164–9.

7.  Nalldi, L, Hufford, D, Hall-Jordan, L. Etiological factors in skin 
cancers: Environmental and biological. In Rigell DS, et al., eds. 
Cancer of the Skin 2nd edn. Philadelphia, PA: Elsevier Saunders 
2011.

8.  Hanahan D, Weinbery RA. The hallmarks of cancer. Cell 2000; 

100:57–70.

9. Hoeijmakers, JHJ. DNA damage, aging and cancer. N Engl J Med 

2009; 361:1475–85.

10. Runger TM. C→T transition mutations are not solely UVB sig-
nature  mutations,  because  they  are  also  generated  by  UVA.  J 
Invest Dermatol 2008; 128(9):2137–40.

  11.  Grether-Beck  S,  et  al.  Photoprotection  of  human  skin  beyond 
ultraviolet radiation Photodermatol Photoimmunol Photomed 2014; 
30:167–74.

  12.  Postow  MA,  et  al.  Nivolumab  and  ipilimumab  versus  ipilim-
umab in untreated melanoma. 2015; April 20. nejm.org (accessed 
April 2015).

  13.  Hanneman KK, et al. Ultraviolet immunosuppression: Mecha-
nisms and consequences. Dermatol Clin 2010; 24(1):31–47.
  14.  Miller J, Gallo R. Vitamin D and innate immunity. Dermatologic 

Therapy 2010; 23:13–22.

  15.  Cancer Research UK. Skin cancer incidence statistics. Available 
at: http://www.cancerresearchuk.org/cancer-info/cancerstats/
types/skin/incidence/ (accessed May 2015).

  16.  Elwood JM, Lee JA, Walter SD, et al. Relationship of melanoma 
and  other  skin  cancer  mortality  to  latitude  and  ultraviolet 
radiation in the United States and Canada. Int J Epidemiol 1974; 
3:325–32.

  17.  Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and mela-

noma: A review. J Am Acad Dermatol 2001; 44:837–46.

 
 
 
 
 
 
 
198 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  18.  Miller A, Mihm M. Melanoma. N Engl J Med 2006; 355:51–6.
  19.  Mahé E, Beauchet A, de Maleissye MF, Salag P. Are sunscreens 
luxury products? Am Acad Dermatol 2011 Sep; 65(3):e73–9. (Pub-
lished online July 11, 2010; accessed April 2015.)

  20.  Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD. Sun-
screens—What’s important to know. J Eur Acad Dermatol Vene-
reol 2008; 22(9):1110–8.

  21.  Wang  SQ,  Balagula  Y,  Osterwalder  U.  Photoprotection: 
A review of the current and future technologies. Dermatol Ther 
2010; 23(1):31–47.

  22.  Beasley DG, Meyer TA: Characterisation of the UVA protection 
provided  by  avobenzone,  zinc  oxide  and  titanium  dioxide  in 
broad-spectrum  sunscreen  products.  Am  J  Clin  Dermatol  2010; 
11(6):413–21.

  39.  Gandini  S,  et  al.  Meta-analysis  of  risk  factors  for  cutaneous 
melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45–6.
  40.  Newton-Bishop  JA,  et  al.  Relationship  between  sun  exposure 
and  melanoma  risk  for  tumours  in  different  body  sites  in  a 
large  case-control  study  in  a  temperate  climate.  Eur  J  Cancer 
2010; 4(5):732–41.

  41.  Field  S,  Newton-Bishop  JA.  Melanoma  and  vitamin  D.  Mol 

Oncol 2011; 5(2):197–214.

  42.  Berwick M, et al. Sun exposure and mortality from melanoma. 

J Natl Cancer Inst 2005; 97:195–9.

  43.  Grant W. An estimate of premature cancer mortality in the U.S. 
due to inadequate doses of solar ultraviolet-B radiation. Cancer 
2002; 94:1867–75.

  44.  Burnett M, Wang S. Current sunscreen controversies: A critical 

  23.  Lautenschlager  S,  et  al.  Photoprotection.  Lancet  2007; 

review. Photodermatol Photoimmunol Photomed 2011; 27:58–67.

370(9586):528–37.

  24.  Roelandts R. Shedding light on sunscreens. Clin Exp Dermatol 

1998; 23:147–57.

  45.  Hanson  K.  Sunscreen  enhancement  of  UV-induced  reactive 
oxygen species in the skin. Free Radic Biol Med 2006; 41:1205–12.
  46.  Autier P, et al. Sunscreen use and increased duration of intentional 

  25.  Burnett M, Wang S. Current sunscreen controversies: A critical 

sun exposure: Still a burning issue. Int J Cancer 2007; 121(1):1–5.

review. Photodermatol Photoimmunol Photomed 2011; 27:58–67.

  47.  Autier  P.  Sunscreen  abuse  for  intentional  sun  exposure.  Br  J 

  26.  Werner M. Perspective: Protect the USA from UVA. Nature 2014; 

Dermatol 2009; 161(Supp. 3):40–5.

515(7527):S124–5.

  48.  Wang  SQ,  Dusza  SW.  Assessment  of  sunscreen  knowledge: 

  27.  Kamerow D. My New Year’s wish is for an effective sunscreen. 

A pilot survey. Br J Dermatol 2009; 161(Suppl 3):28–32.

BMJ 2014; 349:g7729.

  28.  Schalka S, dos Reis VM, Cucé LC. The influence of the amount 
of sunscreen applied and its sun protection factor (SPF): Evalua-
tion of two sunscreens including the same ingredients at differ-
ent concentrations. Photodermatol Photoimmunol Photomed 2009; 
25:175–80.

  29.  Reich  A,  Harupa  M,  Bury  M,  et  al.  Application  of  sunscreen 
preparation:  A  need  to  change  the  regulations.  Photodermatol 
Photoimmunol Photomed 2009; 25:242–4.

  30.  Gonzalez S, et al. The latest on skin photoprotection. Clin Der-

matol 2008; 26:614–26.

  31.  Jansen  R,  et  al,  Photoprotection:  Part  II.  Sunscreen:  Develop-
ment,  efficacy  and  controversies.  J  Am  Acad  Dermatol  2013; 
69(6):867e1–14.

  32.  Seite S, et al. A full-UV spectrum absorbing daily use cream pro-
tects human skin against biological changes occurring in photo-
aging. Photodermatol Photoimmunol Photomed 2000; 16:147–55.
  33.  Hughes M, et al. Sunscreen and prevention of skin aging. Ann 

Intern Med. 2013; 158:781–90.

  34.  Thompson S, et al. Reduction of solar keratoses by regular sun-

screen use. N Engl J Med 1993; 329:1147–51.

  35.  Green, AC et al. Daily sunscreen application and betacarotene 
supplementation in prevention of basal-cell and squamous-cell 
carcinomas of the skin: A randomised controlled trial. Lancet. 
1999; 354:723–29.

  36.  Dennis  L,  et  al.  Sunscreen  use  and  the  risk  for  melanoma: 
A quantitative review. Ann Intern Med 2003; 139:966–78.
  37.  Huncharek M, et al. Use of topical sunscreens and the risk of 
malignant melanoma: A meta-analysis of 9067 patients from 11 
case–control studies. Am J Public Health 2002; 92:1173–7.
  38.  Green  AC,  Williams  GM,  Logan  V,  et  al.  Reduced  melanoma 
after  sunscreen  use:  Randomised  trial  follow-up.  J  Clin  Oncol 
2011; 29:257–63.

  49.  Faurschou  A,  Wulf  HC.  The  relation  between  sun  protection 
factor  and  amount  of  suncreen  applied  in  vivo.  Br  J  Dermatol 
2007; 156(4):716–9.

  50.  Bränström R, et al. Predictors of sun protection behaviours and 
severe sunburn in an international on-line study. Cancer Epide-
miol Biomarkers Prev 2010; 1989:2199–210.

  51.  Ghiasvand R, et al. Sunscreen use and sunburn among Norwe-

gian women. Br J Dermatol 2015; 172:475–83.

  52.  Bandi  P,  et  al.  Sunburns,  sun  protection  and  indoor  tanning 
behaviours,  and  attitudes  regarding  sun  protection  benefits 
and tan appeal among parents of U.S. adolescents – 1998 com-
pared to 2004. Paediatr Dermatol 2010; 27(1):9–18.

  53.  Tuong W, et al. Participant satisfaction with appearance-based 
versus  health-based  educational  videos  promoting  sunscreen 
use: A randomized controlled trial. Dermatol Online J 2015 Feb 
16; 21(2):1.

  54.  Campbell  LB,  et  al.  Melanoma  trends  in  children  and  adoles-
cents: Decreasing trends in the United States. J Pediatr 2015 Apr 
9;  pii:S0022–3476(15)00221–8  [epub  ahead  of  print].  Accessed 
May 2015.

  55.  Erdmann F, et al. International trends in the incidence of malig-
nant melanoma 1953–2008—Are recent generations at higher or 
lower risk? Int J Cancer 2013; 132:385–400.

  56.  IARC.  IARC  Summary  recommendations  for  public  health 
action. In: IARC Handbooks of Cancer Prevention. International 
Agency  for  Research  on  Cancer.  World  Health  Organization, 
Lyon 2001a. Available at: http://www.who.int/uv/resources/rec-
ommendations/en/IARCSum.pdf (accessed May 2015).

  57.  Skin Cancer Foundation. Available at: http://www.skincancer.
org/prevention/sun-protection/prevention-guidelines/pre-
venting-skin-cancer (accessed May 2015).

  58.  Sunsmart.  Available  at:  http://www.sunsmart.com.au/tools/

interactive-tools (accessed May 2015).

 
24

Photodamage: Protection and Reversal 
with Topical Antioxidants

Karen E. Burke

INTRODUCTION
More than ever, our generation enjoys the luxury of travel and 
leisure time for outdoor sports, markedly increasing our expo-
sure to solar ultraviolet (UV) radiation. Exposure is increased 
at  high  altitudes  and  with  reflection  from  surfaces  covered 
with snow, sand, water, or concrete. Our skin suffers the great-
est  damage—both  acutely,  with  erythema  and  sunburn,  and 
chronically,  resulting  in  photoaging  with  mottled  pigmenta-
tion, wrinkling, dryness, and precancerous keratoses as  well 
as the severe consequence of skin cancer.

Certainly  sunscreens  are  essential  for  protection,  but 
they are not enough. The most significant inherent limitations 
are  inadequate  application  (too  little,  too  infrequently)  and 
incomplete spectral protection from both UVA and UVB radia-
tion. The skin naturally uses nutritional antioxidants to protect 
itself from photodamage, and when effective formulations are 
applied topically, sun protection is enhanced. Topical applica-
tion  of  these  antioxidants  can  give  far  higher  concentrations 
in the skin than even maximal oral intake. The challenge is to 
make  formulations  that  are  stable  and  give  effective  transcuta-
neous  absorption  to  deliver  effectively  high  concentrations  of  the 
active forms to the dermis as well as the epidermis.

This  chapter  describes  the  necessary  concentrations, 
molecular  forms,  and  requirements  for  stability  and  topical 
delivery  of  several  antioxidants  that  have  been  proven  effec-
tive: vitamin C, vitamin E, and selenium. New research on top-
ical application of genistein (a soy isoflavone) is also presented.

VITAMIN C
Vitamin C (L-ascorbic acid) is the body’s major aqueous-phase 
antioxidant  and  is  vital  for  life.  All  animals  make  their  own 
vitamin C except for humans and other primates, one species 
of  Indian  fruit-eating  bat,  and  the  guinea  pig—all  of  which 
lack the enzyme L-glocono-γ lactone oxidase. In fact, a 59 kg 
(130 lb) goat synthesizes 13 g of vitamin C per day, almost 200 
times  the  US  Food  and  Drug  Administration  (FDA)  require-
ment (1). Not only do other animals make hundreds of times 
the vitamin C we ingest but also, when under stress, they can 
make more than ten times their normal amount of vitamin C. 
Unfortunately, we humans do not have that capability (1).

Our  skin  is  the  organ  that  suffers  most  from  environ-
mental free-radical stress from exposure to sunlight, pollution, 
and smoking. This contact, furthermore, depletes the level of 
vitamin C in the skin. Even minimal UV exposure of 1.6 mini-
mal erythema dose (MED) decreases the level of vitamin C to 
70% of the normal level, and exposure to 10 MED decreases the 
vitamin C to only 54% (2). Exposure to 10 parts per million of 

ozone  in  city  pollution  decreases  the  level  of  epidermal  vita-
min C by 55% (3).

That was the bad news. The good news is that the most 
effective  way  to  increase  the  skin  level  of  vitamin  C  signifi-
cantly  is  by  topical  application.  To  optimize  percutaneous 
absorption and full activity of vitamin C, the precise formula-
tion  is  of  the  utmost  importance  (4).  Since  L-ascorbic  acid  is 
an excellent antioxidant, making it an inherently unstable mol-
ecule,  creation  of  an  effective  topical  delivery  system  is  cru-
cial. Many products contain stable esterified derivatives (such 
as  ascorbyl-6-palmitate  or  magnesium  ascorbyl  phosphate) 
which  are  not  metabolized  by  the  skin  to  the  active  ascorbic 
acid, so they have no activity (5). Furthermore, the ester mole-
cules are not absorbed percutaneously (5). Some of these esteri-
fied derivatives have been reported to give contact allergy (6,7). 
Other formulations do not result in measurable absorption of 
vitamin C because they are not at the correct pH. Delivery of 
L-ascorbic acid (pKa∆ = 4.2) depends upon removing the ionic 
charge—achieved optimally at a pH of 3.5 (5). New formula-
tions stabilizing the vitamin C in microcapsules (8), liposomes 
(9,10), and microemulsions (10) are being investigated for sta-
bility, absorption, and activity.

Topical absorption was proven to be effective by radio-
active labeling studies in pigs. After treatment with 10% vita-
min C cream, 8.2% was found in the dermis and 0.7% was in 
the blood (4). Formulations containing 5%, 10%, 15%, 20%, or 
25% vitamin C were tested. After 24 hours, 20% resulted in the 
highest skin levels, with maximized concentration in the skin 
after 3 days (5). In these experiments, levels of vitamin C after 
topical application of 15% serum were shown to be a factor of 
about 27 times that which could ever be attained by even very 
high  oral  intake.  If  topical  application  is  discontinued  after 
skin saturation is achieved, high levels remain in the skin for 
more than 3 days (5).

Topical  vitamin  C  protects  against  solar  damage  pri-
marily as an antioxidant that deactivates the UV-induced free 
radicals  (11).  Recent  experiments  with  human  epidermoid 
carcinoma  cells  demonstrate  that  vitamin  C  further  protects 
against  UV-induced  apoptosis  through  reactivating  silenced 
tumor  suppressor  genes  p21  and  p16  (12).  Vitamin  C  is  itself 
not  a  sunscreen,  although  applying  vitamin  C  decreases  the 
degree  of  redness  and  sunburn  suffered  even  when  applied 
after sun exposure. Protection can be confirmed by histologic 
examination. Treatment with topical 10% vitamin C decreases 
the number of abnormal “sunburn cells” by 40%–60% (5) and 
reduces the UV damage to DNA by 62% (4).

Topical  vitamin  C  is  also  directly  anti-inflammatory. 
More  aggressive  techniques  of  laser  resurfacing  used  in  the 

200 

 TEXTBOOK OF COSMETIC DERMATOLOGY

past  caused  redness  for  at  least  3–4  months.  With  vitamin  C 
applied before and after laser surgery, redness was decreased 
after  only  2  months  (13).  Topical  vitamin  C  can  also  be  used 
effectively to treat the inflammation of rosacea (14). This anti-
inflammatory action has been researched with human cells in 
vitamin  C-enriched  media  demonstrating  decreased  activa-
tion  of  the  transcription  factor  nuclear  factor  κβ  (NF-κβ),  the 
factor responsible for many pre-inflammatory cytokines such 
as tumor necrosis factor-α (TNF-α) and interleukins IL-1, IL-6, 
and IL 8 (15).

The main action of vitamin C on the skin is direct stim-
ulation  of  collagen  synthesis.  Vitamin  C  is  an  essential  cofac-
tor for the two enzymes required for collagen synthesis: prolyl 
hydroxylase  (which  makes  the  collagen  molecule  stable)  and 
lysyl hydroxylase (which cross-links the collagen to give struc-
tural  strength)  (16).  Recent  research  has  further  demonstrated 
that vitamin C acts directly on DNA to increase the transcription 
rate and to stabilize the procollagen messenger RNA, thus regu-
lating and maintaining the intercellular amount of collagen (17).
Exciting  experiments  have  demonstrated  that  vitamin 
C also has anti-aging effects. Studies compared newborn with 
elderly (80–95 year-old) fibroblasts (18). Elderly cells proliferate 
at  only  one-fifth  of  the  rate  of  newborn  cells.  However,  when 
vitamin  C  is  added  to  the  culture  medium,  the  elderly  cells 
proliferate  better  than  normal  newborn  fibroblasts.  Even  the 
newborn fibroblasts proliferate almost four times better when 
exposed to vitamin C (18). Not only do fibroblasts increase pro-
liferation in the presence of vitamin C, but they also synthesize 
more collagen. Newborn fibroblasts synthesize a larger percent-
age of collagen than elderly cells, but again, when elderly cells 
are exposed to vitamin C , they produce more collagen than the 
normal,  newborn  fibroblasts  (18).  Surprisingly,  even  the  new-
born cells double the amount of collagen synthesized (18).

Vitamin  C  further  reverses  the  adverse  appearance  of 
photoaging by inhibiting tyrosinase (19), thereby fading unat-
tractive solar lentigines. By directly decreasing inflammation, 
post-inflammatory  hyperpigmentation  can  also  be  reduced. 
Melasma and solar lentigines fade after only 2 months of daily 
application  of  topical  vitamin  C  (15%)  (personal  observation, 
KEB). Melasma treated by QS-Nd:Yag laser (20) or fluorescent 
pulsed  light  (2)  resolved  more  rapidly  and  effectively  with 
application of topical vitamin C.

Because  L-ascorbic  acid  may  inhibit  elastin  biosynthe-
sis  (22),  it  may  reduce  the  solar  elastosis  of  photoaged  skin. 
Also,  in  a  histologic  study  of  solar  elastosis  adjacent  to  skin 
cancers, patients with high oral vitamin C intake showed less 
solar elastosis (23). Topical vitamin C has also been shown to 
enhance collagen production in human skin. Postmenopausal 
women who applied 5% vitamin C to one arm and half of the 
neck  with  placebo  to  the  other  side  showed  an  increase  in 
mRNA  of  collagens  I  and  III  (24).  Tissue  levels  of  the  inhibi-
tor  of  metalloproteinase-I  (MMP-I)  were  also  increased,  thus 
decreasing UV-induced collagen breakdown. However, mRNA 
levels  of  elastin,  fibrillin,  and  tissue  inhibitor  of  MMP-2 
remained  unchanged.  Clinically,  a  significant  decrease  was 
observed in deep facial furrows and substantiated by silicone 
replicas.  Histology  showed  decreased  inflammation  as  well 
as deeper collagen and elastic tissue repair (24). Other studies 
demonstrated a decrease in the crepey laxity of forearm skin 
with restoration of a younger skinfold pattern after 6 months 
of once-daily treatment with 15% vitamin C.

This  remarkable  reversal  of  photoaging  can  be  appre-
ciated  clinically  in  Figure  24.1.  After  1  year  of  once-daily 
treatment  with  15%  topical  vitamin  C,  wrinkles  were  clearly 

reduced and mottled pigmentation resolved in both of the sub-
jects shown. The skin acquired a healthy, more youthful glow.
Another important action of vitamin C on the skin is that 
topical vitamin C increases the synthesis of several specific lipids 
of the skin surface (25). Not only does this mean that vitamin C 
helps the natural moisturization of the skin, but it also enhances 
the  protective  barrier  function  of  the  skin  (26).  Interestingly, 
topical  vitamin  C  significantly  enhances  the  deposition  of  the 
sunscreen nanoparticles of zinc oxide and titanium dioxide on 
the skin without increasing their permeation (27). Thus the sun-
screen efficacy is optimized without danger of absorption.

VITAMIN E
Natural  vitamin  E  is  the  most  important  lipid-soluble,  mem-
brane-bound antioxidant in the body. Vitamin E is especially 
abundant in the stratum corneum, delivered there by sebum 
(28,29).  Its  concentration  is  highest  at  the  lower  levels  of  the 
stratum corneum at the dermal depth of the sebaceous glands, 
with a decreasing gradient outward. As the outermost defense 
of the body, the stratum corneum is first to absorb the oxida-
tive stress of sunlight and pollution. Vitamin E is depleted in 
the process, so topical application can be particularly advanta-
geous,  especially  since  the  lipophilic  structure  makes  it  cos-
metically attractive for application and absorption.

Several  forms  of  vitamin  E  exist  in  natural  dietary 
sources.  The  form  that  is  found  in  mammalian  tissues  and 
which  has  by  far  the  greatest  biologic  activity  is  pure,  non-
esterified  RRR-α-tocopherol  (or  d-α-tocopherol)  (30,31),  which 
has three methyl groups on the 6-chromal ring (Figure 24.2). 
Humans  use  predominantly  α-tocopherol  because  a  specific 
α-tocopherol transfer protein selectively transfers α-tocopherol 
into  lipoproteins  (32).  The  other  natural  forms  are  β,  γ,  and  δ 
which contain only one or two methyl groups on the 6-chromal 
ring.  Relative  to  the  α  form,  the  β,  γ,  and  δ  RRR-tocopherols 
give  only  42%,  72%,  and  40%,  respectively,  of  the  protection 
against post-UV edema (33). The synthetic form is “dl” or “all-
rac,”  a  mixture  of  eight  stereoisomers.  The  synthetic  isomers 
are  esterified  (to  acetates  and  succinates)  for  use  in  commer-
cial vitamins and some topical formulations because the esters 
are far more stable. This ester must be hydrolyzed before there 
is any biologic activity, a reaction which readily occurs in the 
stomach after oral ingestion or in cell and organ culture, but is 
very slow after topical application.

The skin has only a limited capacity to cleave the esteri-
fied  forms  of  vitamin  E  to  the  active  free  tocopherol  form, 
so  the  antioxidant  potential  of  the  esters  is  minimal  (34,35). 
Furthermore, the all-rac form of vitamin E has been reported to 
cause allergic contact dermatitis (36) and erythema multiforme 
(37)  when  applied  topically.  No  such  adverse  reaction  has 
been  reported  with  d-α-tocopherol.  After  application  of  topi-
cal d-α-tocopherol, the concentration of vitamin E increases by 
a  factor  of  10.6  (38),  far  higher  than  can  be  achieved  by  oral 
supplementation.  To  enhance  stability  and  absorption,  sev-
eral formulations are being investigated, including liposomal 
encapsulation  (10,39),  microemulsions  (10),  and  nanostruc-
tured lipid carriers and emulsions (40).

Previous  studies  have  demonstrated  protection  from 
the  acute  (41–47)  UV-induced  damage  of  inflammation  (ery-
thema,  “sunburn”)  and  hyperpigmentation  (tanning)  as  well 
as  protection  from  the  chronic  UV-induced  damage  of  skin 
cancer (46–51) even by the various forms of vitamin E which 
are less metabolically potent when applied topically than the 
non-esterified  Eol.  Topical  d-α-tocopherol  was  shown  to  be 

 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  201

(a)

(b)

(c)

(d)

Figure 24.1  Correction of photoaging after 1 year of once-daily treatment with 15% vitamin C serum (SkinCeuticals). Notice the improve-
ment of periorbital wrinkles and lightening of solar lentigines. (Photographs courtesy of SkinCeuticals, Dallas, TX, USA).

HO

R2

R1

CH3

O

CH3

H

CH

CH

CH3

CH3

R1

CH3
CH3

H

H

α

β

γ

δ

R2

CH3
H

CH3
H

Figure 24.2  Molecular structures of tocopherols.

 
202 

 TEXTBOOK OF COSMETIC DERMATOLOGY

far more effective in protecting against all acute and chronic 
UV-induced damage than topical d-α-tocopheryl succinate in 
mice (38). In a model of chemically-induced skin cancer in mice, 
topical α-tocopherol was further shown to protect against skin 
cancer  and  against  lipid  peroxidation  with  enhancement  of 
several  protective  enzymes  such  as  glutathionine  peroxidase 
and  SOD  (52).  Studies  showed  decreased  chemically-induced 
cell  proliferation  and  decreased  activation  of  p38  and  NF-Κβ 
signalling in HaCaT cells (52). In other mouse studies, topical 
α-tocopheryl succinate and α-tocopheryl acetate not only failed 
to inhibit UVB-induced immunosuppression and carcinogen-
esis,  but  also  at  higher  concentrations  were  ineffective  (53) 
or  even  appeared  to  enhance  carcinogenesis  (53–55).  Topical 
α-tocopheryl  acetate  was  less  effective  than  α-  tocopherol  in 
protecting against UV-induced erythema in rabbits (54,56) and 
against UV-induced photoaging in mice (57).

Vitamin E has been demonstrated to reverse photoaging 
dramatically. A recent study showed that tocopherol enhanced 
collagen  synthesis  and  inhibited  collagen  degradation  by 
downregulating  MMP  gene  expression  in  human  fibroblasts 
stressed by exposure to hydrogen peroxide (58,59). This model 
further  demonstrated  that  γ-tocopherol  decreased  stress-
induced premature senescence and apoptosis by downregulat-
ing caspace-9 and caspace-3 (60). Also, vitamin E significantly 
stimulated  collagen  and  fibrinectin  synthesis  in  cultured 
human foreskin fibroblasts (61).

Figure  24.3  (62)  shows  the  dramatic  decrease  in  peri-
orbital  rhytides  in  a  48-year-old  woman  after  4  months  of 

(a)

(b)

Figure 24.3  Correction of periorbital wrinkles after 4 months of 
once-daily treatment with 0.05% d-α-tocopherol cream.

daily  application  of  d-α-  tocopherol  (5%).  This  correction  of 
UV-induced  damage  was  confirmed  by  histologic  examina-
tion.  Mice  were  exposed  to  UVB  for  six  weeks,  after  which 
epidermal  hypertrophy  with  thickened  stratum  corneum,  an 
increased  incidence  of  damaged  “sunburn  cells”  in  the  basal 
layer,  disruption  of  dermal  collagen  and  degradation  of  der-
mal elastin, and dermal inflammation were noted, as shown in 
Figure 24.4 (62). Each group was then treated for 8 weeks with 
either  vehicle  cream,  0.05%  retinoic  acid,  5%  d-α-tocopherol 
cream,  or  0.05%  L-selenomethionine  cream  (see  following 
section), after which multiple biopsies from each mouse were 
evaluated  (blind)  by  two  experienced  dermatopathologists. 
The  histologic  improvement  in  all  parameters  of  photoaging 
can be appreciated in Figure 24.4, with a marked decrease in 
hyperkeratosis and epidermal hypertrophy, repair of damaged 
dermal  collagen  and  elastin,  and  clearing  of  dermal  inflam-
mation  after  treatment  with  retinoic  acid  or  with  vitamin  E. 
Each of these parameters were graded on a scale of 0 (no dam-
age) to  4 (maximal damage) (62).  As  shown in Figure 24.5, in 
overall gradation, d-α-tocopherol cream was even more effec-
tive  at  reversing  UV-induced  damage  than  retinoic  acid,  the 
“gold-standard” of topical antiaging formulations. (KE Burke, 
L  Ricotti,  EG  Gross,  unpublished  observation).  Further  elec-
tron microscopic analysis confirmed correction of collagen and 
elastin fiber damage and demonstrated repair of UV-induced 
disruption of the basement membrane anchoring fibrils.

VITAMIN C WITH VITAMIN E
As  presented  above,  the  skin  uses  predominantly  vitamin  C 
to  protect  the  aqueous  environment  and  vitamin  E  to  pro-
tect  membranes  from  lipid  peroxidation.  Since  vitamin  C  is 
naturally  present  intracellularly  in  relatively  high  concentra-
tions, L-ascorbic acid not only acts directly as an antioxidant 
and  as  an  essential  cofactor  in  the  synthesis  of  collagen,  but 
also  regenerates  oxidized  membrane  vitamin  E,  so  that  the 
vitamin E need not be replaced (63). Oral vitamin C with E in 
high doses protects against UV-induced erythema in humans 
(64,65), whereas either vitamin alone is ineffective (65). Topical 
L-ascorbic  acid  (15%)  with  d-α-tocopherol  (1%)  gives  four-
fold  protection  against  UV-induced  erythema  and  thiamine 
dimer  formation  in  porcine  skin  (66).  This  protection  from 
UV-induced  erythema  (67)  and  tanning  (68)  by  vitamins  C 
and E combined with melatonin was further demonstrated in 
humans. Fortunately, mixing these hydrophilic and lipophilic 
antioxidants in a topical formulation stabilizes each (66) for a 
cosmetically attractive application.

VITAMIN C WITH VITAMIN E 
AND FERULIC ACID
Ferulic acid is found ubiquitously and at high concentrations 
in plants (69–71) where it cross-links polysaccharides and pro-
teins  during  lignin  cell  wall  synthesis  (72).  A  potent  antioxi-
dant, ferulic acid protects membranes from lipid peroxidation 
and neutralizes alkoxyl and peroxyl radicals. It has also been 
shown to have synergistic interactions with ascorbic acid (73). 
Furthermore, ferulic acid itself minimally blocks UVB to give 
some sunscreen protection (see Figure 24.6).

After testing the effectiveness of a series of low molecu-
lar  weight  antioxidants  that  are  available  in  chemically  pure 
form,  Zielinski  and  Pinnell  (74)  demonstrated  that  ferulic 
acid  provides  stability  of  more  than  90%  for  L-ascorbic  acid 
and 100% for α-tocopherol. Addition of ferulic acid (optimally 
0.5%) to the formulation of vitamin C (15%) + vitamin E (1%) 

 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  203

(a)

(c)

(b)

(d)

Figure 24.4  Histologic correction of photodamage by topical antioxidants. Four groups of 10 Skh:2 mice were exposed to UVB 3 days 
per week for 6 weeks to photodamage the skin. Then each group was treated 5 days/week for 8 weeks as follows: (i) vehicle, (ii) 0.05% 
retinoic acid, (iii) 5.0% d-α-tocopherol, (iv) 0.05% L-selenomethionine (discussed in following section). (a) Biopsies taken before UVB 
exposure show a thin, outer keratin layer, normal epidermis, normally aligned, fine fibrillar dermal collagen and elastin, and no dermal 
inflammation. (b) Biopsies after UV exposure show a markedly thickened keratin layer, epidermal hypertrophy, degradation of dermal 
collagen and elastin, and prominent dermal inflammation. After treatment for 6 weeks with (c) topical 0.05% retinoic acid or (d) topical 
5.0% d-α-tocopherol, there is reversal of hyperkeratosis and epidermal hypertrophy and repair of damaged dermal collagen and elastin 
with clearing of dermal inflammation (62). (The special stains that corroborate the degradation of collagen and elastin are not shown.)

doubles photoprotection to solar-simulated irradiation of skin 
from fourfold to approximately eightfold as measured by both 
erythema (as shown in Figure 24.6) and sunburn cell formation 
(75,76).  Enhanced  photoprotection  was  further  demonstrated 
immunohistochemically  by  inhibition  of  UV-induced  forma-
tion of thymine dimer mutations and of UV-induced p53 (76), 
both of which are associated with skin cancer (75–77). This for-
mulation of vitamin C + E + ferulic acid did in fact decrease the 
tumor  number  and  the  tumor  burden  in  mice  when  applied 
topically after UVB exposure but before the onset of the UVB-
induced  skin  cancers  (54)  and  when  applied  to  mice  before, 
during, and after UVB-exposure (10). However, other experi-
ments did not confirm this protection (78). Evaluation by real-
time  polymerase  chain  reaction  demonstrated  suppression 

of  UV-induced  cytokine  mRNA  formation  (for  inflammatory 
cytokines  interleukin  (IL)-1α,  IL-6,  IL-8,  and  tumor  necrosis 
factor (TNF)-α, as well as for the immunosuppressive cytokine 
IL-10) (76).

VITAMIN C WITH FERULIC ACID 
AND PHLORETIN
Phloretin  is  another  potent  plant-derived  phenolic  antioxi-
dant  (found  in  both  the  flesh  and  peel  of  apples)  which  can 
be  absorbed  by  the  skin.  When  combined  with  vitamin  C 
and ferulic acid, phloretin enhances photoprotection to UVA-
induced  erythema  and  pigmentation  (79).  Biopsies  from 
human  volunteers  after  UV  exposure  (89%  UVA  and  11% 

 
204 

 TEXTBOOK OF COSMETIC DERMATOLOGY

e
g
a
m
a
d
o
t
o
h
p
f
o
n
o
i
t
a
d
a
r
G

10

8

6

4

2

0

Veh

Veh

Veh

RA

SeMet

Vit E

– UV

+ UV
× 6 wk

+ UV × 6 wk
Treat × 8 wk

Figure 24.5  Gradation of histologic correction of photodamage 
by  topical  antioxidants.  Each  of  four  histological  parameters  for 
photodamage (hyperkeratosis, epidermal thickness, collagen dis-
ruption, and solar elastosis) were graded on a scale of 0 (no dam-
age)  to  4  (maximal  damage)  and  evaluated  before  exposure  to 
UVB, after exposure to UVB, and after treatment for 8 weeks with 
vehicle (veh), 0.05% retinoic acid (RA), 0.05% L-selenomethionine 
(SeMet), or 5.0% d-α-tocopherol (vit E). The average gradation of 
all parameters of damage is shown (62).

UVB)  and  treatment  with  a  formulation  containing  vitamin 
C  (10%),  ferulic  acid  (0.5%),  and  phloretin  (2.0%)  at  pH  =  2.5, 
demonstrated  significant  photoprotection  as  measured  by 
decreased thymine dimer formation, decreased matrix metal-
loproteinase-9 expression, and decreased p53 expression (79). 
This  topical  serum  also  protected  against  UV-induced  imu-
nosuppression.  There  was  no  UV-induced  decrease  in  CD1a-
expressing  Langerhans  cells  when  skin  was  pretreated  with 
vitamin C + ferulic acid + phloretin (79).7

SELENIUM
Selenium, an essential trace element in humans and animals, 
is  required  by  25  selenoproteins  and  selenium-dependent 
enzymes.  Most  important  to  skin  care  are  the  intracellular 
antioxidant enzymes glutathione peroxidase and thioredoxin 
reductase (80,81). Selenium has been shown to have other pro-
tective effects that may not directly involve selenium-dependent 
glutathione peroxidase activity (82), such as protecting (83) and 
repairing DNA (84,85), reducing the DNA binding of carcino-
gens  (86),  inhibiting  neoplastic  transformation  (87),  and  sup-
pressing gene mutations at the lysine and histidine loci (88).

For decades, selenium has been implicated in reducing 
carcinogenesis.  In  animal  tumor  models,  moderate  selenium 
supplementation  at  levels  above  the  dietary  requirements 

CON

VEH

FA

C+E

C+E+FA

2

4

6

X MEDS

8

10

Figure 24.6  Photoprotection by topical antioxidant formulations. Skin was (a) untreated or pretreated with (b) vehicle, (c) 0.5% feru-
lic acid, (d) 15% vitamin C + 1% vitamin E, or (e) 15% vitamin C + 1% vitamin E + 0.5% ferulic acid and irradiated with solar-simulated 
 radiation (2×–10× minimal erythema dose [MED]). Visual erythema 1 day later is shown. (From Murray JC, Burch JA, Streilein RD, et al., 
J Am Acad Dermatol 2008; 59:418–25. With permission.)

 
 
 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  205

decreases the number of tumors induced by several chemical 
carcinogens  (89)  and  viruses  (90),  and  reduces  the  incidence 
of  spontaneous  mammary  tumors  (91).  In  addition,  selenium 
supplements inhibit the growth of human tumor cell lines (92) 
as well as the growth of transplanted tumors in mice (93), and 
decrease the mutagenic activity of several known carcinogens 
(94–96).

Recent research has elucidated precise anticarcinogenic 
mechanisms, as excellently researched by Jackson and Combs 
(97). Selenium metabolites have been shown to impair angio-
genesis by tumors (98,99) and to promote cell cycle arrest and 
apoptosis of tumor cells (100), as well as inhibit local invasion 
and migration (99,101), even inhibiting pulmonary metastases 
of melanoma and melanoma migration (101,102) and metasta-
ses in mice, possibly by down-modulation of Il-18 expression 
(103).  That  Se  can  inhibit  malignant  spreading  was  demon-
strated  by  Yan  and  colleagues  for  several  oral  forms  of  the 
element:  methylseleninic  acid  (99),  selenite  (101),  and  high-Se 
soy protein (102). Their work showed that this effect involves 
reducing adhesion of cancer cells to extracellular matrix (104), 
inhibiting  the  urokinase  plasminogen  activator  (uPA)  system 
(99) and reducing angiogenesis (99). Also, two FDA-approved 
inhibiting histone deacetylase compounds with selenium pre-
vent  early  melanocylic  lesion  development  in  skin  by  induc-
ing apoptosis (105). These are currently being investigated as 
potential melanoma chemopreventative agents, as is selenium 
incorporated into the DNA alkylating agent temogolomide for 
treatment of melanoma and glioma (106). Selenium metabolites 
further enhance metabolism of foreign compounds including 
carcinogen-detoxifying enzymes (107).

Some,  but  not  all,  epidemiological  studies  have  found 
a  reduced  risk  for  several  kinds  of  cancer  associated  with  a 
higher blood concentration of selenium (108–110). A decreased 
selenium concentration and glutathionine peroxidase activity 
in  blood,  and  interestingly,  an  increase  of  these  parameters 
in  malignant  tissue  was  found  in  lung  cancer  patients  (110). 
Patients  with  malignant  melanoma  were  found  to  have  sig-
nificantly  lower  levels  of  serum  selenium,  and  patients  with 
more advanced disease (stage III disseminated melanoma) had 
the  lowest  levels  (111).  In  a  transgenic  mouse  model,  topical 
treatment  with  L-selenomethionine  resulted  in  a  significant 
delay in the time required for melanoma development (though 
established  tumors  grew  more  rapidly)  (112).  Patients  with 
cutaneous  lymphoma  (Sezary  syndrome  as  well  as  mycosis 
fungoides) were found to have decreased serum titers of sele-
nium, and stages III and IV had significantly lower levels than 
the earlier stages I and II (111). Also, the patients with Sezary 
syndrome  or  mycosis  fungoides  who  responded  less  well  to 
therapy were found to have lower levels of selenium (111).

A  study  of  240  non-melanoma  skin  cancer  patients  in 
good general health demonstrated a significantly lower mean 
plasma selenium concentration than control subjects without 
skin cancer (113). In fact, those patients whose blood concentra-
tions  were  in  the  lower  decile  had  4.4  times  the  incidence  of 
skin cancer as those in the highest decile (113).

This  interesting  correlation  led  to  a  10-year  prospec-
tive study of 1312 patients with a history of at least two basal 
cell  carcinomas  and/or  one  squamous  cell  carcinoma  of  the 
skin as well as at least one skin cancer within one year before 
entering the trial, selenium treatment did not initially protect 
against further development of such skin cancers; however, it 
did  reduce  total  cancer  incidence  and  the  incidence  of  lung, 
colorectal, and prostate cancer significantly (to 42%, 42%, and 
37%  incidence,  respectively)  as  well  as  total  cancer  mortality 

(to  50%)(114).  The  lack  of  protection  against  skin  cancer  dur-
ing  the  first  two  years  of  supplementation  may  suggest  that 
the degree of damage at the onset of the trial was sufficiently 
severe to preclude reversal of oncologic potential by selenium 
supplementation. This initial minimal increase in skin cancer 
(by  about  10%)  was  not  observed  for  skin  cancers  diagnosed 
after the first two years of treatment.

Topical  preparations  containing  selenium  sulfide  are 
frequently  used  for  the  treatment  of  tinea  versicolor  (115), 
seborrheic  dermatitis  (116),  and  dandruff  (117).  However,  the 
selenium from these preparations is not absorbed by the skin 
(117). Selenium can be absorbed transdermally in guinea pigs 
when applied as L-selenomethionine (118). After topical appli-
cation of 0.02% L-selenomethionine to mice, skin levels of sele-
nium increase by a factor of two to five over comparable oral 
doses (119), and after application of 0.05% L-selenomethionine 
by  a  factor  of  8.0  (62).  This  formulation  increased  the  MED 
in  humans  (120)  and  decreased  UV-induced  skin  damage,  as 
demonstrated by a decrease in post-UV tanning and skin can-
cer in Skh:2 mice (119).

With  topical  application  of  L-selenomethionine,  sele-
nium  levels  were  also  shown  to  increase  significantly  (×5) 
within tumor tissue. Thus, there was a possibility that the tim-
ing of L-selenomethionine application could affect the degree 
of  inhibition  of  UVB-tumorigenesis  (or  maybe  even  enhance 
tumorigenesis  at  some  stage).  Thus  an  investigation  was 
undertaken  applying  topical  L-selenomethionine  (a)  before, 
during, and after UVB exposure, (b) before UVB-exposure but 
discontining when tumors were first clinically detected, or (c) 
only after tumors were first detected and continuing thereaf-
ter  (121).  Optimal  inhibition  of  skin  cancer  was  achieved  by 
application of topical L-selenomethionine before, during, and 
after  exposure.  Unfortunately,  statistically  significant  protec-
tion  was  not  seen  with  L-selenomethionine  application  only 
prior to tumor detection. The good news is that significant pro-
tection was also attained with application only after the onset 
of  tumors.  Thus  even  beginning  L-selenomethionine  supple-
mentation late in the process of tumorigenesis can help protect 
from UV-induced photodamage and skin cancer (121).

Topical L-selenomethionine is highly effective not only in 
preventing but also in reversing photoaging (62). Because topi-
cal L-selenomethionine penetrates transdermally, both the epi-
dermis  and  dermis  are  protected,  so  previous  damage  can  be 
repaired. As a cofactor for the glutathione peroxidases, selenium 
quenches  ROS,  thus  decreasing  inflammation  and  preventing 
activation  of  mediators  which  induce  the  metalloproteinases 
(MMPs) that would otherwise degrade collagen and elastic tis-
sue. Also, selenomethionine decreased malondialdehyde (MDA, 
a measure of ROS) and protects normal human skin fibroblasts 
from  UVA-induced  metalloproteinases  MMP-1  and  MMP-3 
which break down collagen (122), directly causing wrinkles. As 
a cofactor for thioredoxin reductase, melanin synthesis is inhib-
ited and solar hyperpigmentation is corrected (123,124).

The  significant  decrease  in  periorbital  rhytides  in  a 
56-year-old  woman  after  4  months  of  daily  application  of 
L-selenomethionine  (0.05%)  can  be  seen  in  Figure  24.7.  This 
correction of UV-induced damage was similar to that of topi-
cal vitamin E as discussed previously and confirmed by his-
tologic examination as shown (for topical vitamin E) in Figure 
24.4. All histologic parameters of photodamage demonstrated 
reversal  after  treatment  with  topical  L-selenomethionine 
(62).  Transmission  electron  microscopy  further  confirmed 
repair  of  dermal  photoaging,  as  shown  in  Figure  24.8  (62). 
Normal,  non-UV-damaged  dermis  (Figure  24.8a)  consists  of 

 
206 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 24.7  Correction of periorbital wrinkles after 4 months of 
once-daily treatment with 0.05% L-selenomethionine lotion.

dense collagen with homogeneous bundles of uniformly dis-
persed fibers aligned parallel to the basal lamina above. The 
dermal-epidermal junction shows anchoring fibrils of dense 
collagen. After exposure to UV (Figure 24.8b), the dermal col-
lagen is sparse; bundles are not uniform and are irregularly 
dispersed; fibers are disoriented and fragmented. There is an 
increase in extracellular mucopolysaccharide matrix. The der-
mal-epidermal junction has sparse collagen with a decrease in 
anchoring fibrils. Treatment with topical L-selenomethionine 
did  indeed  reverse  this  UV-induced  damage  (Figure  24.8c): 
dermal  collagen  was  repaired,  fibers  became  oriented  and 
more  regular.  As  collagen  became  denser,  the  increase  in 
extracellular  mucopolysaccharide  matrix  resolved.  Collagen 
was  replaced  in  the  dermal-epidermal  junction  with  repair 
of the anchoring fibrils. Clearly topical L-selenomethionine is 
effective in reversing photodamage of the skin (62).

SELENIUM WITH VITAMIN E
In many biologic systems, vitamin E and selenium often act syn-
ergistically.  Borek  et  al.  (125)  demonstrated  that  selenium  and 
RRR-α-tocopheryl  succinate  (natural  vitamin  E  succinate)  act 
alone by different mechanisms to prevent radiogenic and chem-
ically induced transformation . They further showed that there 
was additive protection when both were used together (125).

In experiments in mice comparing and combining topi-
cal  L-selenomethionine  with  topical  d-α-tocopherol  (126),  the 

(a)

(b)

(c)

Figure  24.8  Reversal  of  photodamage  by  topical  antioxidants: 
transmission  electron  microscopy.  (a)  Before  UV  exposure,  (b) 
after  6  weeks  of  UVB  exposure,  (c)  after  treatment  for  8  weeks 
of UVB-exposed skin with topical 0.05% L-selenomethinoine (62).

 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  207

topical  combination  was  less  effective  than  topical  vitamin 
E alone—both in prolonging the onset and in decreasing the 
incidence of UV-induced skin cancers (126). However, topical 
L-selenomethionine  with  oral  vitamin  E  was  more  effective 
than either alone. Both forms of vitamin E alone were equally 
effective  and  more  effective  than  topical  L-selenomethionine 
alone  (126).  Topical  L-selenomethionine  (alone  or  in  com-
bination  with  each  form  of  vitamin  E)  was  most  effective  in 
preventing  the  UV-induced  inflammation  of  sunburn  (100% 
effective!) (126). In reducing UV-induced pigmentation, topical 
L-selenomethionine  with  topical  or  with  oral  vitamin  E  was 
more effective than either one of these antioxidants alone, par-
ticularly during the first 8 weeks of UV exposure.

GENISTEIN
Recent epidemiologic analysis comparing Asian diets high in 
soy (average daily intakes of 20–150 mg) (127) with American 
diets (average daily intake of only 1–3 mg) (127) indicate that 
soy confers major health benefits by decreasing the incidence 
of cancer (127–130) and reducing cardiovascular disease (128). 
Since genistein is the most plentiful isoflavone in soy, this mol-
ecule has been the most extensively studied component for its 
chemopreventive and anticancer effects.

Extensive  experimental  evidence  documents  the  direct 
anticarcinogenic  action  of  genistein.  Animal  studies  dem-
onstrate  protection  against  bladder,  breast,  colon,  liver,  lung, 
prostate, and skin cancer (127,131) with oral genistein. Growth 
of many cancer cell lines is inhibited by genistein (131). Dietary 
soy  inhibits  chemically  induced  skin  cancer  in  mice  (132). 
Exciting  research  demonstrates  that  genistein  arrests  the 
growth  and  induces  the  differentiation  of  malignant  mela-
noma  (133)  and  inhibits  pulmonary  metastases  of  melanoma 
(134,135).

The mechanism by which genistein inhibits carcinogen-
esis may be through its proven inhibition of tyrosine protein 
kinases (TPKs), the enzymes that phosphorylate proteins nec-
essary for regulation of cell division and transformation (136). 
Of particular importance is phosphorylation of TPK-dependent 
epidermal growth factor receptors (EGF-R) which are related 
to tumor promotion, including initiation of transcription fac-
tors,  release  of  inflammatory  mediators  (such  as  prostaglan-
dins), and stimulation of cell proliferation (137). Genistein was 
found to down-regulate both UVA- and UVB-induced EGF-R 
phosphorylation  in  human  epidermoid  carcinoma  cells  (138). 
By  similar  enzymic  inhibition,  genistein  retards  UV-induced 
apoptotic  changes  –  including  caspase-3  and  p21-activated 
kinase 2 activation of human epidermal carcinoma cells (139) 
and  phosphokinase  Cδ  in  human  keratinocytes  (140).  Recent 
experiments further show that genestein inhibits carcinogensis 
in pancreatic (141) and ovarian cancer cells (142) by down-reg-
ulation  of  oncogenic  microRNAs.  Hopefully  this  mechanism 
will be investigated in UV-exposed skin.

Genistein  is  also  a  potent  antioxidant.  Genistein  scav-
enges  peroxyl  free  radicals,  thereby  protecting  against  lipid 
peroxidation (143) and (144). The decreased incidence of cardio-
vascular disease with high soy diets may be due to genistein’s 
inhibiting the oxidation of low-density lipoprotein (LDL) cho-
lesterol in both aqueous and lipophilic environments. Of direct 
importance in protection of the skin from UV-induced damage, 
genistein  has  been  shown  to  inhibit  UV-induced  DNA  oxida-
tion (145) and cellular DNA oxidation induced by benzopyrene 
and UVA (146) and by phorbol ester stimulation (147), as well 
as  by  psoralen  plus  UVA  (PUVA)  therapy  (148).  The  fact  that 

genistein  also  reduces  erythema  and  histologic  inflammation 
induced  by  PUVA  in  mouse  skin  (149)  may  have  important 
implications for PUVA therapy, by reducing possible short- and 
long-term adverse reactions.

The  use  of  topical  genistein  to  prevent  and  reverse 
photoaging  has  recently  been  intensively  investigated,  with 
promising results. In animal studies, Wei et al. (138). demon-
strated  that  topical  genistein  (10  μmol/cm2)  protects  against 
acute  and  chronic  UV  damage  to  the  skin.  After  exposure 
of  Skh:1  hairless  mice  to  UVB,  topical  genistein  completely 
blocked  acute  skin  burns  and  inhibited  UVB-  induced  cuta-
neous  wrinkling  (as  seen  clinically  in  Figure  24.9)  (138).  This 
protection  from  UV-induced  erythema  with  topical  genes-
tein  (0.5%)  was  further  confirmed  in  pig  skin  by  an  increase 
in MED and a decrease in number of sunburn cells after pre-
treatment  with  topical  genestein  (150).  Histologic  analysis  in 
mice  showed  that  topical  genistein  substantially  blocked  the 
signs  of  chronic  photodamage:  epidermal  hyperplasia  and 
reactive  acanthosis  with  nuclear  atypia  (138).  At  a  molecular 
level,  UV-induced  damage  to  DNA  as  measured  by  the  bio-
marker  8-hydroxy-deoxyguanosine  was  markedly  reduced 
(151). Protection was also demonstrated by decreased expres-
sion of proliferating cell nuclear antigen (PCNA) (a marker of 
DNA repair which indirectly indicates degree of UV damage) 
as  well  as  by  decreased  cox-2  expression  and  by  increased 
catalase  concentration  in  mice  treated  with  topical  genestein 
(1-3mg/ml) prior to UVB exposure (152). Further recent experi-
ments in mice corroborated protection from UVB exposure by 
measuring inhibition of UVB-induced increased levels of nitric 
oxide (NO), which lead to nitrosative skin injury. Compared to 
the  UV-control  group,  the  group  treated  with  oral  genestein 
(10  mg/kg)  showed  tissue  protection,  decreased  lipid  perox-
ide  and  nitrotyrosine  formation,  low  CAT  activity  (153)  and 
DNA repair. Interestingly, higher doses of genestin (15 mg/kg) 
showed  more  histologic  damage  and  less  efficient  protection 
against lipid peroxide formation (153).

Inhibition  of  acute  UV-induced  erythema  with  topical 
genistein was also demonstrated in humans. Topical genistein 
(5 μmol/cm2) (applied 30 minutes before UVB radiation) inhib-
ited  by  one  MED  the  UVB-induced  erythema  (138).  Further 
immunohistologic studies on human reconstructed skin dem-
onstrated that pretreatment with genestein (10–50 μM) inhib-
its  UV-induced  DNA  damage,  as  measured  by  inhibition  of 
pyrimidine dimer formation and of expression of PCNA (154). 
The  degree  of  protection  is  dose  dependent,  increasing  with 
increasing  concentrations  of  genestein  (154).  Other  experi-
ments  using  UVB-irradiated  human  skin  cells  showed  34%–
35%  enhancement  of  DNA  damage  repair  four  hours  after 
treatment  with  the  soy  isoflavones  genestein:daidzein  (in  a 
ratio of 1:4 at a concentration of 10 µmole/L) (155).

Equally  impressive  is  the  fact  that  topical  genistein 
also  inhibits  the  most  serious  consequence  of  chronic  UVB 
damage:  skin  cancer.  Both  the  incidence  and  the  multiplic-
ity  of  UVB-induced  skin  tumors  in  Skh:2  hairless  mice  were 
reduced by about 90% after 25 weeks of UVB exposure (138). 
Furthermore,  after  induction  of  skin  tumors  in  mice  by 
7,12-  dimethyl  benzanthracene  (DMBA)  and  promotion  by 
12-O-tetradecanoylphorbol-13-acetate  (TPA),  topical  genistein 
(10 μM) inhibited tumor numbers by 60%–75% (151).

In  order  to  investigate  the  mechanism  of  inhibition  of 
UV-induced skin cancer, the effect of genistein on the expres-
sion  of  the  photo-oncogenes  c-fos  and  c-jun  on  mRNA  was 
investigated  in  mouse  skin  (156).  Expression  of  these  pro-
teins induces  matrix  melalloproteinases  that  degrade  dermal 

 
208 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(a) Effect of genistein on ultraviolet B (UVB)-induced acute skin burns. Once daily for 10 days, SKH-1 hairless mice were 
Figure 24.9 
treated with 5 µmol of genistein 60 minutes before UVB irradiation (1.8 kJ/m2). Photographs were taken 24 hours after final UVB irradia-
tion. (a) Negative (sham) control; (b) vehicle + UVB; (c) 5 µmol of genistein + UVB. (b) Effect of genistein on photodamage in mouse skin 
chronically exposed to UVB. Twice weekly for 20 weeks, SKH-1 hairless mice were treated topically with 5 µmol of genistein 60 minutes 
before or 5 minutes after UVB irradiation (0.3 kJ/m2). (d) Negative (sham) control; (e) vehicle + UVB; (f) UVB + genistein. (From Wei H, 
Spencer J, Gelfand J et al., Cosmet Dermatol 2001; 14:13–19. With permission.)

connective tissue, causing the wrinkles and laxity of photoag-
ing (157). Overexpression of these photo-oncogenes is related 
to promotion of cell proliferation in oncogenesis. At low-dose 
UVB,  genistein  (20μM)  substantially  inhibited  both;  at  high 
dose, genistein blocked c-fos but had little effect on c-jun (156). 
Treatment  of  mouse  skin  immediately  after  UVB  irradiation 
also inhibited the expression of both (156). In human skin, topi-
cal genestein (1%) did prevent UV-induced c-jun, thereby pre-
venting photoaging and oncogenesis (157).

Another possible dermatologic benefit of genistein is as 
a  phytoestrogen.  The  skin  has  both  α  and  β  nuclear  estrogen 
receptors (ER) (158), through which estrogen binding can regu-
late linked genes of proliferation and differentiation. Genistein 
has a 30-fold higher affinity for ERβ than ERα (159) but a greater 
ERα agonist activity than ERβ (160). Although estradiol has 700-
fold more ERα and 45-fold more ERβ activity than genistein, the 

possible biologic effect of genistein (even through dietary soy 
isoflavones) may be great. The modulation of estrogen receptors 
by genestein is being actively investigated in breast cancer in 
which ERβ expression indicates more benign tumors and ERα, 
more  malignant  tumors  (161).  Experiments  demonstrate  that 
genestein  has  antiproliferative  effects  on  some  breast  cancer 
cells (162,163), especially those with a low ERα/ERβ ratio (163). 
The potential benefits and risks of treatment with genestein are 
dependent on the ERα/ERβ ratio for each particular breast can-
cer and on genestein concentration (163,164).

Oral (165,166) and topical (167,168) estrogen increases the 
collagen  content  of  skin,  which  diminishes  with  aging,  and 
especially dramatically in women during and after menopause 
(169). Genistein may reduce the “crepey” appearance of aging 
skin by stimulating collagen synthesis. Indeed, genistein does 
increase collagen gene expression in fibroblasts (170).

 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  209

Table 24.1  Correction of Photoaging with Topical Estrogens

β-Estradiol 
(0.01%)

Genestein 
(4%)

75%

135%

20%

0%

↑ Epidermal thickness
↑ Number of dermal 

papillae
↑ Fibroblasts
↑ Blood vessels
Note: Biopsies of preauricular skin were taken before and after topical 
gel treatment once/day for 24 weeks and analyzed by image digitaliza-
tion (173).

123%
77%

0%
36%

In  other  studies  on  normal  human  fibroblasts  exposed 
to chemical oxidative stress, genestein prevented disturbances 
in the insulin-like growth factor-1 receptor-mediated collagen 
signalling  pathway  (171).  Also,  treatment  of  cultured  human 
dermal  fibroblasts  with  soy  extract  increased  synthesis  of 
collagen  and  hyaluronan  (172).  Topical  application  of  a  soy 
extract  emulsion  ameliorated  UV-induced  flattening  of  the 
dermo-epidermal  junction  and  enhanced  the  number  of  der-
mal papillae—thus demonstrating histologically rejuvenation 
of photoaged human skin (172). Armed with these auspicious 
and studies, a 6-month study of postmenopausal women com-
pared  topical  β-estradiol  (0.01%)  with  topical  genestein  (4%) 
(173).  Skin  biopsies  showed  that  topical  estrogens  gave  more 
correction of photodamage than did genestein, as summarized 
in Table 24.1.

Thus, topical genistein shows great promise not only in 
protection of the skin against extrinsic acute and chronic UV 
photodamage, but also in enhancing collagen synthesis, which 
is  diminished  with  normal  intrinsic  aging.  Because  genes-
tein has low water solubility, enhancement of topical delivery 
to  deeper  layers  of  the  skin  is  being  developed  by  formulat-
ing  with  hydrophilic  cyclodextrins  (174)  or  within  solid  lipid 
nanoparticles (175).

SUMMARY
There are two great advantages to applying an active formula-
tion of topical antioxidant(s) to the skin. First, the skin attains 
far higher levels of each antioxidant than can be achieved by 
only taking these supplements orally (5). For example, the level 
of vitamin C attained in the skin by topical application is 20–40 
times the level achievable with oral vitamin C (5); with topical 
application, the concentration of vitamin E increases by a factor 
of 11 (38), and selenium by a factor of 2–8 (62,119). Second, topi-
cal application arms the skin with a reservoir of antioxidant(s) 
that cannot be washed or rubbed off, a protection which stays 
in the skin for several days after application (5).

Because  topical  antioxidants  work  by  affecting  cellular 
mechanisms of photoprotection, they supplement sunscreens 
in  preventing  photoaging  and  skin  cancer.  Indeed,  scientific 
research  confirms  that  topical  application  of  antioxidant(s) 
offers  exciting  new  possibilities  not  only  in  protecting  the 
skin from UV damage (to reduce extrinsic photoaging and to 
retard intrinsic aging) but also in reversing previously incurred 
photodamage.

REFERENCES

1.  Pauling  L.  How  to  Live  Longer  and  Feel  Better.  New  York:  WH 

Freeman, 1987.

2.  Shindo Y, Wit E, Han D, Packer L. Dose response effects of acute 
ultraviolet irradiation on antioxidants and molecular markers 

of oxidation in murine epidermis and dermis. J Invest Dermatol 
1994; 23:470–5.

3.  Thiele JJ, Traber MG, Tsang KG, et al. In vivo exposure to ozone 
depletes  vitamins  C  and  E  and  induces  lipid  peroxidation 
in  epidermal  layers  of  murine  skin.  Free  Radic  Biol  Med  1997; 
23:85–91.

4.  Darr D, Combs S, Dunsten S, et al. Topical vitamin C protects 
porcine  skin  from  ultraviolet  radiation-induced  damage.  Br  J 
Dermatol 1992; 127:247–53.

5.  Pinnell  SR,  Yang  HS,  Omar  M,  et  al.  Topical  L-ascorbic  acid: 
Percutaneous absorption studies. Dermatol Surg 2001; 27:137–42.
6.  Assier H, Wolkenstein P, Grille C, Chosidow O. Contact derma-
titis caused by ascorbyl tetraisopalmitate in a cream used for the 
management of atopic dermatitis. Contact Dermatitis 2014; 71 60–1.
7.  Yagami A, Suzuki K, Morita Y, et al. Allergic contact dermatitis 
caused  by  3-o-ethyl-L-ascorbic  acid  (vitamin  C  ethyl).  Contact 
Dermatitis 2014; 70:376–7.

8.  Lem PL, Kok SH, Bian ZX, et al. Microencapsulation-protected 
l-ascorbic  acid  for  the  application  of  human  epithelial  HaCaT 
cell proliferation. J Microencapsul 2014; 31:754–8.

9.  Zhou  W,  Liu  W,  Zou  L,  et  al.  Storage  stability  and  skin  per-
meation  of  vitamin  C  liposomes  improved  by  pectin  coating. 
Colloids Surf B Biointerfaces 2014; 117:330–7.

  10.  Burke  KE,  Zhou  X,  Commisso  J,  et  al.  The  efficacy  of  various 
formulations of vitamins C+E in protecting against UV-induced 
skin cancer. In preparation, 2015.

  11.  Pinnell  SR,  Madey  DL.  The  benefits  of  topical  vitamin  C 
(L-ascorbic acid) for skin care and UV protection. Aesth Surg J 
1998; 18:126–34.

  12.  Lin JR, Qin HH, Wu WY, et al. Vitamin C protects against UV 
irradiation-induced  apoptosis  through  reactivating  silenced 
tumor  suppressor  genes  p21and  p26  in  a  Tet-dependent  DNA 
demethylation  manner  in  human  skin  cancer  cells.  Cancer 
Biother Radiopharm 2014; 29:257–64.

  13.  Alster  T,  West  TB.  Effect  of  vitamin  C  on  postoperative  CO2 
laser resurfacing erythema. Dermatol Surg 1998; 24:331–4.
  14.  Bergfeld W, Pinnell S. Topical vitamin C. Dialogues Dermatol Am 

Acad Derm 1996; 38:1.

  15.  Carcamo JM, Pedraza A, Borquez-Ojeda O, et al. Vitamin C sup-
presses TNF alpha-induced NF kappa B activation by inhibiting 
I Kappa B alpha phosphorylation. Biochem 2002; 41:12995–30002.
  16.  Kivirikko  KI,  Myllyla  R.  Post-translational  processing  of  pro-

collagens. Ann NY Acad Sci 1985; 460:187–201.

  17.  Tajima  S,  Pinnell  SR.  Ascorbic  acid  preferentially  enhances 
types I and III collagen gene transcription in human skin fibro-
blasts. J Dermatol Sci 1996; 11:250–3.

  18.  Phillips CL, Combs SB, Pinnell SR. Effects of ascorbic acid on 
proliferation and collagen synthesis in relation to donor age of 
human dermal fibroblasts. J Invest Dermatol 1994; 103:228–32.

  19.  Maeda K, Fukuda M. Arbutin. Mechanism of its depigmenting 
action in human melanocyte culture. J Pharmacol Exp Ther 1996; 
276:765–9.

  20.  Lee  MC,  Chang  CS,  Huang  YL,  et  al.  Treatment  of  melasma 
with mixed parameters of 1,064-nm Q-switched Nd:YAG laser 
toning and an enhanced effect of ultrasonic application of vita-
min C: A split-face study. Lasers Med Sci 2015; 30:159–63.
  21.  Shaikh ZI, Mashood AA. Treatment of refractory melasma with 
combination of topical 5% magnesium ascorbyl phosphate and 
fluorescent pulsed light in Asian patients.  Int J  Dermatol 2014; 
53:93–9.

  22.  Davidson JM, Luvalle PA, Zoia O, et al. Ascorbate differentially 
regulates elastin and collagen biosynthesis in vascular smooth 
muscle  cells  and  skin  fibroblasts  by  pretranslational  mecha-
nisms. J Biol Chem 1997; 272:345–52.

  23.  Husein-ElAhmed H, Aneiros-Fernandez J, Gutierrez-Salmeron 
MT,  et  al.  Relationship  between  food  intake  and  cutaneous 
solar  elastosis  adjacent  to  basal  cell  carcinoma.  J  Eur  Acad 
Dermatol Venereol 2013; 27:25–30.

  24.  Humbert  PG,  Haftek  M,  Creidi  P,  et  al.  Topical  ascorbic  acid 
in  photoaged  skin.  Clinical  topographical  and  ultrastructural 

 
 
 
 
 
 
 
 
 
 
210 

 TEXTBOOK OF COSMETIC DERMATOLOGY

evaluation: Double-blind study vs. placebo. Experiment Dermatol 
2003; 12:237–44.

  25.  Uchida Y, Behne M, Quiec D, et al. Vitamin C stimulates sphin-
golipid  production  and  markers  of  barrier  formation  in  sub-
merged  human  keratinocyte  cultures.  J  Invest  Dermatol  2001; 
117:1307–13.

  26.  Catiel-Higournenc Ferrais C, Guey C, Schmidt R, et al. Private 
communications:  L’Oréal  Advanced  Research  Laboratories, 
Clichy and Aulnay-sous-Bois, France.

  27.  Fathi-Azarbayjani A, Tan PL, Chan YY, et al. Ascorbic acid for the 
safe use of a sunscreen agent: Accumulation of nano zinc oxide 
and titanium dioxide on the skin. Sci Pharm 2013; 81 (4):1141–50.

  28.  Podda M, Weber C, Traber MG, Packer L. Simultaneous deter-
mination  of  tissue  tocopherols,  tocotrienols,  ubiquinols,  and 
ubiquinones. J Lipid Res 1996; 37:893–901.

  47.  Berton TR, Conti CJ, Mitchell DL, et al. The effect of vitamin E 
acetate on ultraviolet-induced mouse skin carcinogenesis. Mol 
Carcinog 1998; 23:175–84.

  48.  Black H, Lenger W, McCann V, Thornby J. Relation of UV dose 
to  antioxidant  modification  of  photocarcinogenesis.  J  Am  Coll 
Toxicol 1983; 2:201–7.

  49.  Bissett  D,  Chatterjee  R,  Hannon  D.  Protective  effect  of  a  topi-
cally  applied  antioxidant  plus  an  antiinflammatory  agent 
against  ultraviolet  radiation-induced  chronic  skin  damage  in 
the hairless mouse. J Soc Cosmet Chem 1992; 43:85–92.

  50.  Gensler  H,  Magdaleno  M.  Topical  vitamin  E  inhibition  of 
immunosuppression and tumorigenesis induced by ultraviolet 
irradiation. Nutr Cancer 1991; 15:97–106.

  51.  Gerrish  K,  Gensler  H.  Prevention  of  photocarcinogenesis  by 

dietary vitamin E. Nutr Cancer 1993; 19:125–33.

  29.  Thiele  JJ.  Oxidative  targets  in  the  stratum  corneum:  A  new 
basis  for  antioxidative  strategies.  Skin  Pharmacol  Appl  Skin 
Physiol 2001; 14:87–91.

  52.  Pal A, Alam S, Singhal J, et al. Protective effect of topical appli-
cation  of  α-tocopherol  and/or  N-acetyl  cysteine.  Nutr  Cancer 
2013; 65 Suppl:78–87.

  30.  Mayer P, Pittermann W, Wallat S. The effects of vitamin E on the 

skin. Cosmet Toiletries 1993; 108:99–109.

  31.  Burton  GW,  Traber  MG,  Acuff  RV,  et  al.  Human  plasma  and 
tissue α-tocopherol concentrations in response to supplementa-
tion with deuterated natural and synthetic vitamin E. Am J Clin 
Nutr 1998; 67:669–84.

  32.  Azzi A, Breyer I, Feher M, et al. Specific cellular responses to 

alpha-tocopherol. J Nutr 2000; 131(Suppl):369–75.

  33.  Potokar M, Holtmann W, Werner-Busse A. Effectiveness of vita-
min E protecting against UV light – comparative testing of the 
natural  tocopherols  on  the  skin  of  the  hairless  mouse.  Fat  Sci 
Technol 1990; 92:406–10.

  34.  Gensler HL, Aickin M, Peng YM, Xu M. Importance of the form 
of  topical  vitamin  E  for  prevention  of  photocarcinogenesis. 
Nutr Cancer 1996; 26:183–91.

  35.  Beijersbergen  van  Hanegouwne  GMJ,  Junginger  HE,  de  Vries 
H. Hydrolysis of RRR-alpha-tocopheryl acetate (vitamin E ace-
tate) in the skin and its UV protecting activity (an in vivo study 
with the rat). J Photochem Photobiol B Biol 1995; 29:45–51.
  36.  Hart M. Vitamin E: A contact sensitizer. Schoch Lett 1990; 40:48.
  37.  Saperstein H, Rapaport M, Rietschel RL. Topical vitamin E as 
a  cause  of  erythema  multiforme-like  eruption.  Arch  Dermatol 
1984; 120:906–8.

  38.  Burke KE, Clive J, Combs GF Jr, et al. The effects of topical and oral 
vitamin E on pigmentation and skin cancer induced by ultravio-
let irradiation in Skh:2 hairless mice. Nutr Cancer 2000; 38:87–97.

  39.  Tabandeh H, Mortazovi SA. An investigation into some effec-
tive  factors  on  encapsulation  efficiency  of  alph-tocopherol  in 
MLVs and the release profile from the corresponding liposomal 
gel. Iran J Pharm Res 2013; 12(Suppl):21–30.

  40.  Abla  MJ,  Banga  AK.  Formulation  of  tocopherol  nanocarriers 
and  in  vitro  delivery  into  human  skin.  Int  J  Cosmet  Sci  2014; 
36:239–46.

  41.  Möller  H,  Potokar  M,  Wallat  S.  Vitamin  E  also  Kosmetischer 

Wirkstoff. Parfüm Kosmet 1987; 68:688–708.

  42.  Potapenko A, Abijev G, Pistosov M, et al. PUVA-induced ery-
thema  and  changes  in  mechanoelectrical  properties  of  skin 
inhibition by tocopherols. Arch Dermatol Res 1984; 276:12–16.

  43.  Moeller H, Ansmann A, Wallat S. The effects of vitamin E on 
the skin in topical applications. Fett- Wissenschaft Technol 1989; 
8:295–315.

  44.  Trevithick  J,  Xiong  H,  Lee  S,  et  al.  Topical  tocopherol  acetate 
reduces  post-UVB,  sunburn-associated  erythema,  edema  and 
skin  sensitivity  in  hairless  mice.  Arch  Biochem  Biophys  1992; 
296:575–82.

  45.  Record  IR,  Dreosti  IE,  Konstantinopoulos  M,  Buckley  RA. 
The Influence of topical and systemic vitamin E on ultraviolet 
light-induced skin damage in hairless mice. Nutr Cancer 1991; 
16:219–25.

  53.  Burke KE, Zhou X, Comisso J, et al. The efficacy of varying con-
centrations of topical d-α-tocopherol on UV-induced skin can-
cer. In preparation, 2015.

  54.  Burns  EM,  Tober  Kl,  Riggenbach  JA,  et  al.  Differential  effects 
of topical vitamin E and C E Ferulic® treatments on ultraviolet 
light  B-induced  cutaneous  tumor  development  in  Skh-1  mice. 
PLoS One 2013; 8 (5):e63809. doi:10.1371/journal.pone.0063809.

  55.  Gensler HL, Aickin M, Peng YM, Xu M. Importance of the form 
of  topical  vitamin  E  for  prevention  of  photocarcinogenesis. 
Nutr Cancer 1996; 26:183–91.

  56.  Roshchupkin D, Pistsov MY, Potapenko AY. Inhibition of ultra-
violet  light-induced  erythema  by  antioxidants.  Arch  Dermatol 
Res 1979; 266:91–4.

  57.  Bissett  DL,  Chatterjee  R,  Hannon  DP.  Photoprotective  effect 
of  superoxide-scavenging  antioxidants  against  ultraviolet 
radiation-induced chronic skin damage in the hairless mouse. 
Photodermatol Photoimmunol Photomed 1990; 7:56–62.

  58.  Makpol  S,  Jam  FA,  Khor  SC,  et  al.  Comparative  effects 
of  biodynes,  tocotrienol-rich  fraction,  and  tocopherol  in 
enhancing  collagen  synthesis  and  inhibiting  collagen  deg-
radation  in  stress-induced  premature  senescence  model  of 
human  diploid  fibroblasts.  Oxid  Med  Cell  Longev  2013:298574. 
doi:10.1155/2013/298574.

  59.  Makpol S, Jam FA, Mohd Yusof YA, et al. Modulation of colla-
gen synthesis and its gene expression in human skin fibroblasts 
by tocotrienol-rich fraction. Arch Med Sci 2011; 7(5):889–95.
  60.  Makpol S, Rahim NA, Hui CK, et al. Inhibition of mitochondrial 
cytochrome c release and suppression of caspases by gamma-
tocotrienol prevent apoptosis and delay aging in stress-induced 
premature senescence of skin fibroblasts. Oxid Med Cell Longev 
2012:785743. doi:10.1155/2012/785743.

  61.  Hashim  P.  The  effects  of  Centella  asiatica,  vitamins,  glycolic 
acid  and  their  mixtures  preparations  in  stimulating  collagen 
and  fibronectin  synthesis  in  cultured  human  skin  fibroblast. 
Pak J Pharm Sci 2014; 27:233–7.

  62.  Burke KE. Method for the prevention and reversal of the extrin-
sic aging of the skin by transdermal application of selenamino 
acids and compositions therefore. US Patent no. 5,330,757. July 
19, 1994.

  63.  Chan AC. Partners in defense, vitamin E and vitamin C. Can J 

Physiol Pharmacol 1993; 71:725–31.

  64.  Eberlein-Konig  B,  Placzek  M,  Przybilla  B.  Protective  effect 
against  sunburn  of  combined  systemic  ascorbic  acid  (vitamin 
C)  and  d-α-tocopherol  (vitamin  E).  J  Am  Acad  Dermatol  1998; 
38:45–8.

  65.  Fuchs J, Kern H. Modulation of UV-light-induced skin inflam-
mation by d-α-tocopherol and L-ascorbic acid: A clinical study 
using  solar  simulated  radiation.  Free  Radic  Biol  Med  1998; 
25:1006–12.

  46.  Marenus K, Muizzuddin N, Kasman K, et al. The use of antioxi-
dants in providing protection from chronic suberythemal UV-B 
exposure. 16th IFSCC Conference, Oct 1990; 1:24–34.

  66.  Lin J, Selim A, Shea C, et al. UV photoprotection by combina-
tion topical antioxidants vitamin C and E. J Am Acad Dermatol 
2003; 48:866–74.

 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  211

  67.  Dreher F, Gabard B, Schwindt DA, Malbach HI. Topical melato-
nin in combination with vitamins E and C protects skin from 
ultraviolet-induced  erythema:  A  human  study  in  vivo.  Br  J 
Dermatol 1998; 139:332–9.

  68.  Quevedo  WC,  Holstein  TJ,  Dyckman  J,  McDonald  CI.  The 
responses  of  the  human  epidermal  melanocyte  system  to 
chronic  erythemal  doses  of  UVR  in  skin  protected  by  topical 
applications of a combination of vitamins C and E. Pigment Cell 
Res 2000; 13:190–2.

  69.  Graf E. Antioxidant potential of ferulic acid. Free Rad Biol Med 

1992; 13:435–48.

  70.  Rice-Evans  CA,  Miller  NJ,  Paganga  G.  Structure-antioxidant 
activity relationships of flavonoids and phenolic acids. Free Rad 
Biol Med 1996; 20:933–56.

  71.  Ou S, Kwok K-C. Ferulic acid: Pharmaceutical functions prepa-
ration and applications in foods. J Sci Food Agric 2004; 84:1261–9.
  72.  Mathew  S,  Abraham  TE.  Ferulic  acid:  An  antioxidant  found 
naturally  in  plant  cell  walls  and  feruloyl  esterases  involved 
in  its  release  and  their  applications.  Crit  Rev  Biotechnol  2004; 
24:59–83.

  73.  Trombino S, Serini S, Di Nicuolo F, et al. Antioxidant effect of 
ferulic acid in isolated membranes and intact cells: Synergistic 
interactions with alpha-tocopherol, beta-carotene, and ascorbic 
acid. J Agric Food Chem 2004; 52:2411–20.

  90.  Milner  JA.  Effects  of  selenium  on  virally  induced  and  trans-

plantable tumor models. Fed Proc 1985; 44:2568–72.

  91.  Schrauzer  GN,  McGinness  JE,  Kuehn  K.  Effects  of  temporary 
selenium supplementation on the genesis of spontaneous mam-
mary  tumors  in  inbred  female  C3H/St  mice.  Carcinogenesis 
1980; 1:199–201.

  92.  Redman C, Scott JA, Baines AT, et al. Inhibitory effect of seleno-
methionine on the growth of three selected human tumor cell 
lines. Cancer Lett 1998; 125:103–10.

  93.  Greeder GA, Miller JA. Factors influencing the inhibitory effect 
of selenium on mice inoculated with Erlich ascites tumor cells. 
Science 1980; 209:825–7.

  94.  Ip C. Prophylaxis of mammary neoplasia by selenium supple-
mentation in the initiation and promotion phases of chemical 
carcinogenesis. Cancer Res 1981; 41:4386–90.

  95.  Shamberger  RJ,  Beaman  KD,  Corlett  CL,  Kasten  BL.  Effect  of 
selenium and other antioxidants on the mutagenicity of malo-
naldehyde. Fed Proc 1978; 37:261(abstr).

  96.  Jacobs  MM,  Matney  TS,  Griffin  AC.  Inhibitory  effects  of  sele-
nium on the mutagenicity of 2 acetylaminofluorine (AAF) and 
AAF derivatives. Cancer Lett 1977; 2:319–22.

  97.  Jackson  MI,  Combs  GF  Jr.  Selenium  and  anticarcinogenesis: 
Underlying mechanisms. Curr Opin Clin Nutr Metab Care 2008; 
11:718–26.

  74.  Zielinski JE, Pinnell SR. Stabilized ascorbic acid compositions 

  98.  Chen YC, Prabhu KS, Mastro AM. Is selenium a potential treat-

and methods thereof. US Patent 34405.2. 2004.

ment for cancer metastases? Nutrients 2013; 5:1149–68.

  75.  Lin F-H, Lin J-Y, Gupta RD, et al. Ferulic acid stabilizes a solu-
tion  of  vitamins  C  and  E  and  doubles  its  photoprotection  of 
skin. J Invest Dermatol 2005; 125:826–32.

  76.  Murray JC, Burch JA, Streilein RD, et al. A topical antioxidant 
solution containing vitamins C and E stabilized by ferulic acid 
provides protection for human skin against damage caused by 
ultraviolet irradiation. J Am Acad Dermatol 2008; 59:418–25.
  77.  Wu  Y,  Zheng  X,  Xu  X-G,  et  al.  Protective  effects  of  a  topical 
antioxidant complex containing vitamins C and E and ferulic 
acid  against  ultraviolet  irradiation-induced  photodamage  in 
Chinese women. J Drugs Dermatol 2013; 12:464–8.

  78.  Burns EM, Tober KL, Riggenbach JA, et al. Extended UVB expo-
sures  alter  tumorigenesis  and  treatment  efficacy  in  a  murine 
model  of  cutaneous  squamous  cell  carcinoma.  J  Skin  Cancer 
2013; 2013:246848. doi 10.1155/2013/246848.

  79.  Oresajo C, Stephens T, Hino PD, et al. Protective effects of a top-
ical antioxidant mixture containing vitamin C, ferulic acid, and 
phloretin  against  ultraviolet-induced  photodamage  in  human 
skin. J Cos Dermatol 2008; 7:290–7.

  80.  Stadtman  TC.  Mammalian  selenoenzymes.  Ann  NY  Acad  Sci 

2000; 894:399–402.

  81.  Barceloux DG. Selenium. Clin Toxicol 1999; 37:145–72.
  82.  Ragman  MP.  The  importance  of  selenium  to  human  health. 

Lancet 2000; 356:233–41.

  83.  Roussyn I, Briviba K, Masumolo H, Sies H. Selenium-containing 
compounds protect DNA from single-strand breaks caused by 
peroxynitrite. Arch Biochem Biophys 1996; 330:218–20.

  84.  Lawson  T,  Birt  DF.  Enhancement  of  the  repair  of  carcinogen-
induced DNA damage in the hamster pancreas by dietary sele-
nium. Chem Biol Interact 1983; 45:95–104.

  85.  Russell GR, Nader CJ, Patrich EJ. Induction of DNA repair by 

some selenium compounds. Cancer Lett 1980; 10:75–80.

  86.  Chen  T,  Goelchius  MP,  Combs  GF,  Campbell  TC.  Effects  of 
dietary  selenium  and  vitamin  E  on  covalent  binding  of  afla-
toxin to chick liver cell macromolecules. J Nutr 1982; 112:350–5.
  87.  Chatterjee M, Banerjee MR. Influence of selenium (Se) and beta-
carotene on transformation of mammary cells in culture of the 
whole mammary organs of BALB:c mice. Proc Am Assoc Cancer 
Res 1983; 23:349(abstr).

  88.  Rosin MP. Effects of sodium selenite on the frequency of spon-
taneous mutation of yeast mutator strains. Proc Am Assoc Cancer 
Res 1981; 22:55(abstr).

  89.  Combs GF Jr. Selenium. In Micozzi MS, Moon TE, eds. Nutrition 
and Cancer Prevention. New York: Marcel Dekker, 1989: 389–420.

  99.  Yan  L,  Demars  LC.  Dietary  supplementation  with  methylsel-
eninic  acid,  but  not  selenomethionine,  reduces  spontaneous 
metastasis of Lewis lung carcinoma in mice. Int J Cancer 2012; 
131:1260–6.

  100.  Combs  GF  Jr,  Lu  J.  Selenium  as  a  cancer  preventive  agent. 
In:  Hatfield  DL,  ed.  Selenium:  Its  Molecular  Biology  and  Role  in 
Human Health. Dordrecht, The Netherlands: Kluwer Academic 
2001; pp. 205–218.

  101.  Yan L, Yee JA, McGuire MH, Graef GL. Effect of dietary supple-
mentation  of  selenite  on  pulmonary  metastasis  of  melanoma 
cells in mice. Nutr Cancer,1997; 28:165–9.

  102.  Li  D,  Graef  GL,  Yee  JA,  Yan  L.  Dietary  supplementation  with 
high-selenium  soy  protein  reduces  pulmonary  metastasis  of 
melanoma cells in mice. J Nutr 2004; 134:1536–40.

  103.  Song  H,  Kim  J,  Lee  SK,  et  al.  Selenium  inhibits  migration  of 
murine melanoma cells via down-modulation of IL-18 expres-
sion. Int Immunopharmacol 2011; 11:2208–13.

  104.  Yan  L,  Frenkel  GD.  Inhibition  of  cell  attachment  by  selenite. 

Cancer Research 1992; 52:5803–7.

  105.  Gowda  R,  Nadhunapantual  SV,  Denai  D,  et  al.  Selenium-
containing histone deacetylase inhibitors for melanoma man-
agement. Cancer Biol Ther 2012; 13:756–65.

  106.  Cheng Y, Sk UH, Zhang Y, Ren X, et al. Rational incorporation 
of selenium into temozolomide elicits superior antitumor activ-
ity  associated  with  both  apoptotic  and  autophagic  cell  death. 
PLOS One 2012; 4:e35104. doi:10.1371/journal.pone.0035104.
  107.  Whanger  PD.  Selenium  and  its  relationship  to  cancer:  An 

update. Br J Nutr 2004; 91:11–28.

  108.  Willett WC, Stampfer MJ. Selenium and cancer. Br Med J 1988; 

297:573–4.

  109.  Kabuto  M,  Imai  H,  Yonezawa  C,  et  al.  Prediagnostic  serum 
selenium  and  zinc  levels  and  subsequent  risk  of  lung  and 
stomach  cancer  in  Japan.  Cancer  Epidemiol  Biomarkers  Prev 
1994; 3:465–9.

  110.  Zachara  BA,  Marchaluk-Wisniewaka  E,  Maciag  A,  et  al. 
Decreased selenium concentration and glutathione peroxidase 
activity in blood and increase of these parameters in malignant 
tissue of lung cancer patients. Lung 1997; 175:321–32.

  111.  Reinhold  U,  Biltz  H,  Bayer  W,  Schmidt  KH.  Serum  selenium 
levels in patients with malignant melanoma. Acta Derm Venerol 
(Stockh) 1989; 69:132–6.

  112.  Cassidy PB, Fain HD, Cassidy Jr JP, Tran SM, Moos PJ, Boucher 
KM, et al. Selenium for the prevention of cutaneous melanoma. 
Nutrients 2013; 5:725–49.

 
212 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  113.  Clark  LC,  Graham  GF,  Crounse  RG,  et  al.  Plasma  selenium 
and  skin  neoplasms:  A  case–control  study.  Nutr  Cancer  1984; 
6:13–21.

  136.  Akiyama  T,  Ishida  J,  Nakagawa  S,  et  al.  Genistein,  a  specific 
inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 
262:5592–5.

  114.  Clark  LC,  Combs  GF,  Turnbull  BW,  et  al.  Effects  of  selenium 
supplementation  for  cancer  prevention  in  patients  with  carci-
noma of the skin. J Am Med Assoc 1996; 276:1957–63.

  115.  Faergemann  JU,  Fredriksson  T.  Tinea  versicolor:  Some  new 
aspects on etiology, pathogenesis and treatment. Int J Dermatol 
1982; 1:8–11.

  116.  Bereston  ES.  Use  of  selenium  sulfide  shampoo  in  seborrheic 

dermatitis. J Am Med Assoc 1954; 157:1246–7.

  137.  Hunter T, Cooper JA. Protein-tyrosine kinase. Annu Rev Biochem 

1985; 54:897–930.

  138.  Wei  H,  Spencer  J,  Gelfand  J  et  al.  The  isoflavone  genistein: 

A new agent in dermatology? Cosmet Dermatol 2001; 14:13–19.

  139.  Chan  WH,  Yu  JS.  Inhibition  of  UV  irradiation-induced  oxida-
tive  stress  and  apoptotic  biochemical  changes  in  human  epi-
dermal carcinoma A431 cells by genistein. J Cell Biochem 2000; 
78:73–84.

  117.  Cummins  LM,  Kimuka  ET.  Safety  evaluation  of  selenium 
sulfide  antidandruff  shampoos.  Toxicol  Appl  Pharmacol  1971; 
20:89–96.

  140.  Fukunaga M, Oka M, Ichihashi M, et al. UV-induced tyrosine 
phosphorylation of PKC delta and promotion of apoptosis in the 
HaCaT cell line. Biochem Biophys Res Commun 2001; 289:573–9.

  118.  Edwards  LI.  The  absorption  of  methionine  by  the  skin  of  the 

guinea pig. Biochemistry 1954; 57:542–7.

  119.  Burke  KE,  Combs  GF,  Gross  EG,  et  al.  The  effects  of  topical 
and oral L-selenomethionine on pigmentation and skin cancer 
induced by ultraviolet irradiation. Nutr Cancer 1992; 17:123–37.
  120.  Burke  KE,  Bedford  RG,  Combs  GF  Jr,  et  al.  The  effect  of  topi-
cal L-selenomethionine on minimal erythema dose of ultravio-
let  irradiation  in  humans.  Photodermatol  Photoimmun  Photomed 
1992; 9:52–7.

  121.  Burke  KE,  Zhou  X,  Wang  Y,  et  al.  The  effects  of  topical 
L-selenomethionone  on  protection  against  UVB-induced  skin 
cancer  when  given  before,  during,  and  after  UVB  exposure.  J 
Drugs Dermatol 2014; 19:611–20.

  122.  Hazene-Puch F, Champelovier P, Arnaud J, et al. Six-day sele-
nium  supplementation  led  to  either  UVA-photoprotection  or 
toxic  effects  in  human  fibroblasts  depending  on  the  chemical 
form and dose of Se. Metallomics 2014; 6:1683–92.

  123.  Schallreuter KU, Pittelkow MR, Wood JM. Free radical reduc-
tion by thioredoxin reductase at the surface of normal and viti-
liginous human keratinocytes. J Invest Dermatol 1986; 87:728–32.
  124.  Schallreuter  KU,  Hordinsky  MK,  Wood,  JM.  Thioredoxin 
reductase.  Role  in  the  radical  reduction  in  different  hypopig-
mentation disorders. Arch Dermatol 1987; 123:615–9.

  125.  Borek C, Ong A, Mason H, et al. Selenium and vitamin E inhibit 
radiogenic and chemically induced transformation in vitro via 
different mechanisms. Proc Natl Acad Sci 1986; 83:1490–4.
  126.  Burke  KE,  Clive  J,  Combs  GF,  Nakamura  RM.  The  effects  of 
topical L-selenomethionine with topical and oral vitamin E on 
pigmentation  and  skin  cancer  induced  by  ultraviolet  irradia-
tion in Skh:2 hairless mice. J Am Acad Dermatol 2003; 49:458–72.
  127.  Barnes S, Peterson TG, Coward L. Rationale for the use of genis-
tein-containing  soy  matrices  in  chemoprevention  trials  for 
breast and prostate cancer. J Cell Biochem Suppl 1995; 22:181–7.

  128.  Tham DM. Potential health benefits of dietary phytoestrogens: 
A review of the clinical, epidemiological and mechanistic evi-
dence. J Clin Endocrinol Metab 1998; 83:2223–35.

  129.  Messina M, Barnes S. The role of soy products in reducing risk 

of cancer. J Natl Cancer Inst 1991; 83:541.

  141.  Ma J, Cheng L, Liu H, et al. Genistein down-regulates miR-223 
expression  in  pancreatic  cancer  cells.  Curr  Drug  Targets  2013; 
14:1150–6.

  142.  Xu L, Xiang J, Shen J, et al. Oncogenci MicroRNA-27a is a tar-
get for genistein in ovarian cancer cells. Anticancer Agents Med 
Chem 2013; 13:1126–32.

  143.  Hwang J, Sevanian A, Hodis HN, Ursini F. Synergistic inhibi-
tion of LDL oxidation by phytoestrogens and ascorbic acid. Free 
Radic Biol Med 2000; 29:79–89.

  144.  Wiseman H, O’Reilly JD, Adlercreutz H, et al. Isoflavone phy-
toestrogens consumed in soy decrease F-2-isoprostane concen-
trations  and  increase  resistance  of  low-density  lipoprotein  to 
oxidation in humans. Am J Clin Nutr 2000; 72:395–400.

  145.  Wei H, Cal O, Rahn RO. Inhibition of UV light- and Fenton reac-
tion-induced oxidative DNA damage by the soybean isoflavone 
genistein. Carcinogenesis 1996; 17:73–7.

  146.  Liu ZS, Lu YH, Rosenstein B, et al. Benzo-[A]pyrene enhances 
the formation of 8-hydroxy-2[prime]- deoxyguanosine by ultra-
violet A radiation in calf thymus DNA and human epidermoid 
carcinoma cells. Biochemistry 1998; 37:10307–12.

  147.  Giles D, Wei HC. Effect of structurally related flavones/ isofla-
vones  on  hydrogen  peroxide  production  and  oxidative  DNA 
damage  in  phorbol  ester-stimulated  HI-60  cells.  Nutr  Cancer 
1997; 29:77–82.

  148.  Liu  ZS,  Lu  YH,  Lebwohl  M,  Wei  HC.  PUVA  (8-  methoxy-pso-
ralen  plus  ultraviolet  A)  induces  the  formation  of  8-hydroxy-
2'-deoxyguanosine  and  DNA  fragmentation  in  calf  thymus 
DNA  and  human  epidermoid  carcinoma  cells.  Free  Radic  Biol 
Med 1999; 27:127–33.

  149.  Shyong EQ, Lu YH, Lazinsky A, et al. Effects of the isoflavone 
(genistein)  on  psoralen  plus  ultraviolet  A  radiation  (PUVA)-
induced photodamage. Carcinogenesis 2002; 23:317–21.

  150.  Lin  J-Y,  Tournas  JA,  Burch  JA,  et  al.  Topical  isoflavones  pro-
vide effective photoprotection to skin. Photoderm, Photoimmun, 
Photomed 2008; 24:61–6.

  151.  Wei  H,  Bowen  R,  Zhang  X,  Lebwohl  M.  Isoflavone  genistein 
inhibits the initiation and promotion of two-stage skin carcino-
genesis in mice. Carcinogenesis 1998; 19:1509–14.

  130.  Messina M, Persky V, Setchell K, Barnes S. Soy intake and can-
cer risk: A review of the in vitro and in vivo data. Nutr Cancer 
1994; 21:113–31.

  152.  Chiu  T-M,  Huang  C-C,  Lin  T-J,  et  al.  In  vitro  and  in  vivo  anti-
photoaging effects of an isoflavone extract from soybean cake. 
J Ethnopharm 2009; 126:108–13.

  131.  Barnes  S.  Effect  of  genistein  on  in  vitro  and  in  vivo  models  of 

cancer. J Nutr 1995; 125(Suppl):S777–83.

  132.  Limtrakul  P,  Sutrajit  M,  Semura  R,  et  al.  Suppressive  effect  of 
soybean milk protein on experimentally induced skin tumors 
in mice. Life Sci 1993; 53:1591–6.

  133.  Kiguchi K, Constantinou AI, Huberman E. Genestein induced 
cell differentiation and protein-linked DNA strand breakage in 
human melanoma cells. Cancer Commun 1990; 2:271–8.

  134.  Menon  LG,  Kuttan  R,  Nair  MG,  et  al.  Effect  of  isoflavones 
genistein  and  daidzein  in  the  inhibition  of  lung  metastasis 
in mice induced by B16F-10 melanoma cells. Nutr Cancer 1998; 
30:74–7.

  135.  Li  D,  Yee  JA,  McGuire  MH,  et  al.  Soybean  isoflavones  reduce 
experimental metastasis in mice. J Nutr 1999; 29:1075–8.

  153.  Terra VA, Souza-Neta FP, Frade MA, et al. Genistein prevents 
ultraviolet B radiation-induced nitrosative skin injury and pro-
motes cell proliferation. Photochem Photobiol B 2015; 144:20–7.

  154.  Moore JO, Wang Y, Stebbins WG, et al. Photoprotective effect of 
isoflavone genistein on ultraviolet B induced pyrimidine dimer 
formation and PCNA expression in human reconstituted skin 
and its implications in dermatology and prevention of cutane-
ous carcinogenesis. Carcinogenesis 2006; 27:1627–35.

  155.  Iovine B, Garofalo M, Orefice M. Isoflavones in aglycone solu-
tion  enhance  ultraviolet  B-induced  DNA  damage  repair  effi-
ciency. Clin Exp Dermatol 2014; 39:391–4.

  156.  Wei  H,  Barnes  S,  Wang  Y.  Inhibitory  effect  of  genistein  on  a 
tumor  promoter-induced  c-fos  and  c-jun  expression  in  mouse 
skin. Oncol Rep 1996; 3:125–8.

 
PHOTODAMAGE: PROTECTION AND REVERSAL WITH TOPICAL ANTIOXIDANTS 

  213

  157.  Kang S, Chung J-H, Lee JH, et al. Topical N-acetyl cysteine and 
genistein prevent ultraviolet-light-induced signaling that leads 
to  photoaging  in  human  skin  in  vivo.  J  Invest  Dermatol  2003; 
120:835–41.

  158.  Brandenberger AW, Tee MK, Lee JY, et al. Tissue distribution of 
estrogen receptors alpha (er-alpha) and beta(er-beta) mRNA in 
the  midgestational  human  fetus.  J  Clin  Endocrinol  Metab  1997; 
82:3509–12.

  159.  Kuiper  GG,  Carlsson  B,  Grandien  K,  et  al.  Comparison  of 
the  ligand  binding  specificity  and  transcript  tissue  distri-
bution  of  estrogen  receptors  alpha  and  beta.  Endocrine  1997; 
138:863–70.

  160.  Barkhem T, Carlsson B, Nilsson S, et al. Differential response 
of  estrogen  receptor  alpha  and  estrogen  receptor  beta  to 
partial  estrogen  agonists/antagonists.  Mol  Pharmacol  1998; 
54:105–12.

  161.  Nadal-Serrano M, Pons DG, Sastre-Serra J. Genistein modulates 
oxidative stress in breast cancer cell lines according to ERα/ERβ 
ratio:  Effects  on  mitochondrial  functionality,  sirtuins,  uncou-
pling protein 2 and antioxidant enzymes. Int J Biochem Cell Biol 
2013; 45:2045–51.

  162.  Chen FP, Chien MH. Phytoestrogens induce differential effects 
on  both  normal  and  malignant  human  breast  cells  in  vitro. 
Climacteric 2014; 17:682–91.

  163.  Pons  DG,  Nadal-Serrano  M,  Blanquer-Rossello  MM,  et  al. 
Genistein modulates proliferation and mitochondrial function-
ality in breast cancer cells depending on ERalpha/ERbeta ratio. 
Cell Biochem 2014; 115:949–58.

  164.  Jiang Y, Gong P, Madak-Erdogan Z, et al. Mechanisms enforc-
ing  the  estrogen  receptor  β  selectivity  of  botanical  estrogens. 
FASEB J 2013; 27:4406–18.

  165.  Castelo-Branco  C,  Duran  M,  Gonzalez-Merlo  J.  Skin  collagen 
changes  related  to  age  and  hormone  replacement  therapy. 
Maturitas 1992; 15:113–19.

  166.  Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, 
placebo-controlled study on the effect of conjugated estrogens 
on skin thickness. Am J Obstet Gynecol 1994; 170:642–9.

  167.  Brincat  M,  Versi  E,  O’Dowd  T,  et  al.  Skin  collagen  changes  in 
post-menopausal  women  receiving  oestradiol  gel.  Maturitas 
1987; 9:1–5.

  168.  Varila E, Rantalia I, Oikarinen A, et al. The effect of topical oes-
tradiol on skin collagen of post-menopausal women. Br J Obstet 
Gynaecol 1995; 102:985–9.

  169.  Affinito  P,  Palomba  S,  Sorrentino  C,  et  al.  Effects  of  postmeno-
pausal  hypoestrogenism  on  skin  collagen.  Maturitas  1999; 
33:239–47.

  170.  Greenwel P, Hu W, Kohanski RA, Ramirez F. Tyrosine dephos-
phorylation  of  nuclear  proteins  mimics  transforming  growth 
factor beta-1 stimulation of alpha-2 (1) collagen gene expression. 
Mol Cell Biol 1995; 15:6813–19.

171.  Sienkiewicz P, Surazyriski A, Palka J, et al. Nutritional concentra-
tion of genistein protects human dermal fibroblasts from oxida-
tive stress-induced collagen biosynthesis inhibition through IGF-I 
receptor-mediated signaling. Acta Pol Pharm 2008; 65:203–11.
172. Sudel KM, Veneke K, Mielke H, et al. Novel aspects of intrin-
sic and extrinsic aging of human skin: Beneficial effects of soy 
extract. Photochem Photobiol 2005; B1; 581–7.

  173.  Moraes AB, Haidar MA, Suares Jr JM, et al. The effects of topi-
cal isoflavones on postmenopausal skin: Double-blind and ran-
domized clinical trial of efficacy. Eur J Ob Gyn Repro Bio 2009; 
146:188–92.

  174.  Danciu  C,  Soica  C,  Oltean  M,  et  al.  Genistein  in  1:1  inclusion 
complexes  with  ramified  cyclodextrins:  Theoretical,  physico-
chemical and biological evaluation. Int J Mol Sci 2014; 15:1962–82.
  175.  Andrade  LM,  de  Fatima  Reis  C,  Maione-Silva  L,  et  al.  Impact 
of lipid dynamic behavior on physical stability, in vitro release 
and  skin  permeation  of  genistein-loaded  lipid  nanoparticles. 
Eur J Pharm Biopharm 2014; 88:40–7.

 
25

Actinic Keratosis

Brigitte Dréno

Actinic  keratoses  (AK),  which  are  also  referred  to  as  solar 
keratoses, are atypical areas of keratinocyte proliferation and 
differentiation that occur on sun-damaged areas (Figure 25.1). 
In  places  such  as  northwest  England.  They  affect  15%  of 
40- year-old men and 34% of 70-year-old men (1). In women the 
prevalence is lower, with 6% of 40-year-old women and 18% of 
70-year-old  women  being  affected  (1).  In  the  southern  hemi-
sphere,  where  photoexposure  is  high,  40%  to  60%  of  elderly 
populations with a light skin phototype develop AK (1–5).

Risk factors for the development of AK include chronic 
sun  exposure,  light  skin  phototype  (I/II),  phototherapy,  age, 
exposure to skin carcinogens, history of cutaneous squamous 
cell  carcinoma  (SCC),  organ  transplantation,  and  long-term 
immunosuppressive treatments such as chemotherapy or bio-
therapy  (6,7).  Recently,  cutaneous  infection  by  betapapilloma 
virus has also been identified as a potential risk factor when 
combined  with  other  risk  factors  such  as  sun  exposure,  age, 
and light skin phototype (8,9).

DIAGNOSIS
AK are diagnosed based on their clinical appearance with no 
additional investigations being required. Lesions are keratotic, 
rough  on  palpation,  of  variable  thickness,  and  poorly  delim-
ited. They are characterized by a diameter of 1 cm or less and 
a  variable  degree  of  erythema.  In  some  cases,  they  can  be 
 pigmented or have a cutaneous horn shape. As AK rarely occur 
alone,  multiple  AK  are  often  found  in  surrounding  photo-
exposed areas.

AK  are  considered  to  be  a  risk  marker  for  cutaneous 
malignancies.  and  by  some  an  early  stage  of  SCC  (10).  As  a 
result,  each  lesion  needs  to  be  evaluated  individually.  If  the 
skin is thickened, the diameter is >1 cm. If infiltration, inflam-
mation, ulceration, bleeding, or pain on palpation are present, 
or if there is rapid expansion, the AK should be biopsied (11). 
In addition, a biopsy should be performed if the lesion recurs 
within 2–3 months, if it persists after standard treatment, or if 
it is located on a risk zone such as the lip, the back of the hand, 
or the ear.

PROGRESSION TO SQUAMOUS CELL 
CARCINOMA/SPINOCELLULAR CARCINOMA
Although no clinical, histological, or biological characteristics 
have  been  able  to  reliably  predict  the  progression  of  an  AK 
lesion (Figure 25.2) to invasive SCC, a clinicopathological con-
tinuum of transformation from AK to invasive SCC is believed 
to exist (10). The relationship between any given AK lesion and 
the development of SCC, however, is not necessarily linear. If 
left untreated, AK can either spontaneously disappear, persist 
without  progressing  to  invasive  SCC,  or  progress  to  invasive 

SCC  (12).  In  fact,  the  overall  rate  of  progression  from  AK  to 
SCC  is  low,  with  the  rate  of  transformation  to  SCC  over  the 
course of a year ranging from 0.01% to 0.24%, and over 10 to 25 
years from 5% to 20% (13–16). Spontaneous regression occurs 
at a rate of 15% to 25% (15). Fifteen percent of lesions that have 
regressed recur within a year (17).

THE FIELD OF CANCERIZATION
The  complicated  relationship  between  spontaneous  regres-
sion,  recurrence,  and  progression  is  likely  to  be  due  to  the 
existence  of  a  field  of  cancerization,  which  describes  the 
area of skin surrounding a group of AK and which has been 
shown to contain genetically altered cells that can provide a 
reservoir for clonal expansion (17). In any given field of can-
cerization (Figures 25.3 and 25.4), the ratio of subclinical foci 
to AK would be expected to be around 10:1 (17). As a result, 
it is hard to determine if an AK that spontaneously regresses 
but then recurs is an actual recurrence or the manifestation of 
another foci within the same field of cancerization.

In  most  cases  the  field  of  cancerization  contains  sub-
clinical changes in the periphery of the visible AK lesions that 
can  be  highlighted  using  noninvasive  reflectance  confocal 
microscopy or photodiagnosis with protoporhyrin IX-emitted 
fluorescence  (17).  More  invasive  analyses  that  require  tis-
sue samples such histology or molecular biology can also be 
used (18,19).

The  concept  of  field  cancerization  suggests  that  the 
apparently normal skin circling areas of AK sustains the base 
for the clonal expansion of genetically altered neoplastic cell. 
The  presence  of  a  great  number  of  mutated  cells  in  a  field  is 
considered  the  determinant  event  to  carcinogenesis  (17). 
Moreover, the association of multiple mutations of the kerati-
nocytes and a decrease in cutaneous innate immunity appear 
to be risk factors. These two factors worsen over time lead to 
the final formation of AK.

CHRONICITY AND SECONDARY PREVENTION
The  fact  that  lesions  that  have  spontaneously  regressed  can 
recur suggests that there is a chronic nature to the manage-
ment of AK (17). Whether these are the same lesions or a new 
lesion from another cell from the same field of cancerization 
is hard to determine. The clinical implications, however, are 
the  same:  at-risk  patients  should  be  monitored  at  least  once 
a year.

Viral infection may be associated with the chronicity of 
AK. In one study in which 37% of AK lesions were positive for 
human papilloma virus (HPV) (20), AK lesions recurred within 
45–60  days  of  removal  by  laser  in  all  HPV  positive  patients, 
whereas  they  did  not  recur  in  the  HPV  negative  patients. 

ACTINIC KERATOSIS 

 215

Figure 25.1 

Isolated actinic keratosis.

Figure 25.3  Field of cancerization. 

Figure 25.2  Hyperkeratotic actinic keratosis.

These data suggest that HPV infection may be an indicator for 
recurrence.

Organ transplant patients also have a particularly high 
rate of recurrence (21). Depending on the degree and duration 
of immunosuppression and the type of transplant, recurrence, 
as well as the development of new AK, resistance to treatment, 
and progression to SCC have all been shown to be increased 
(21,22).  These  patients  are  thus  high  risk  and  require  close 
monitoring.

TREATMENT ALGORITHM
There is no evidence that shows that all AK need to be treated 
systematically. Rather, the decision to treat should be based on 
the clinical characteristics of the AK lesion, the patient’s cuta-
neous history, the impact of the lesion on the patient’s quality 
of life, and the patient’s preference.

The  initial  choice  of  treatment  should  be  based  on  the 
number of lesions, their hyperkeratotic status, and their clinical 
appearance. The algorithm shown in Figure 25.5 was recently 
published by Dréno et al. (7).

Figure 25.4  Field of cancerization.

ISOLATED HYPERKERATOTIC AND 
NONHYPERKERATOTIC ACTINIC KERATOSIS 
For isolated hyperkeratotic and nonhyperkeratotic AK, cryo-
therapy  and  curettage  followed  by  electrocoagulation  are 
first-line therapies (23–29). Cryotherapy is a simple, rapid, and 
inexpensive technique. Rates of complete clearance after one 
and two applications are between 68% and 75% at 3 months 
and  between  82.5%  and  88%  at  24  weeks  after  two  applica-
tions.  Cryotherapy  is  very  much  dependent  on  the  proto-
col  used,  with  more  aggressive  protocols  resulting  in  fewer 
recurrences (30,31). Pain during and immediately after treat-
ment  is  the  most  frequently  reported  adverse  event  (25–29). 
Hyper- or hypopigmented scars can also occur. Surgery can 
be used as a second-line therapy if the isolated AK is resistant 
or if it recurs.

For isolated, suspicious AK with clinical signs evoking 

SCCs, a complete exeresis with histology is suitable.

 
216 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 25.5  Treatment algorithm for the management of actinic keratosis. The initial choice of treatment is based on the number of 
lesions, their hyperkeratotic status, their clinical appearance (suspicious or not). (From Dréno B et al., J Eur Acad Dermatol Venereol, 
28:1141–9, 2014.)

MULTIPLE, NON-HYPERKERATOTIC 
ACTINIC KERATOSES
First-line  treatments  for  multiple,  non-hyperkeratotic  AK 
include  topical  treatments  and  physical  treatments  such  as 
laser  or  photodynamic  therapy  (PDT).  Second-line  therapies 
include physical treatments combined with topical treatments 
or surgery. All treatments should encompass the entire field of 
cancerization in order to reduce the likelihood of recurrence of 
a treated lesion and/or the development of new lesions within 
the same field.

Topical Treatment Options
5-Fluorouracil 5%
5-fluorouracil is a cytotoxic antimetabolite that interferes with 
DNA synthesis and to a lesser extent inhibits RNA transcrip-
tion (32). After 3 to 4 weeks of treatment, the rate of complete 
clearance  varies  from  43%  to  96%  depending  on  the  study 
(25,33,34).  In  approximately  65%  of  patients,  lesions  recur 
within 12 months of treatment (25). The main adverse events 
are pain, pruritus, burning sensation, and hyperpigmentation 
at  the  site  of  application.  Application  on  healthy  skin  causes 
can cause an erythematous inflammatory  reaction (32).

Imiquimod 5%
Imiquimod,  which  is  an  imidazoquinoline-derivative,  medi-
ates cytokine synthesis and release, stimulates the innate cuta-
neous immunity, and has an indirect antineoplastic action. It 
can  be  used  to  treat  the  field  of  cancerization  as  well  as  the 
AK  lesions  (35).  In  studies  of  the  5%  cream,  rates  of  com-
plete  clearance  were  27%  and  55%  after  one  and  two  cycles, 
respectively (36–41). The recurrence rate 1 year after treatment 
ranges  from  17%  and  39%  depending  on  the  study  (25,37). 
Local  reactions  such  as  pruritus,  burning,  erythema,  pain, 

oedema,  dryness,  crusting,  erosions,  and  ulcerations  have 
been  reported.  Systemic  reactions,  such  as  myalgia,  fatigue, 
and  nausea  have  also  been  reported,  although  more  rarely. 
Few  reactions  have  been  shown  to  occur  during  the  second 
cycle  of  treatment.  In  the  special  population  of  immunosup-
pressed transplanted patients, imiquimod should be used with 
caution, as safety needs to be evaluated (30,31).

Diclofenac 3%, Hyaluronic Acid 2.5%
Diclofenac  3%  is  a  nonsteroidal  anti-inflammatory  drug  that 
inhibits  the  cyclooxygenase  pathway  and  decreases  prosta-
glandin  E2  synthesis.  The  rate  of  complete  clearance  is  31% 
after 2 months of treatment and 47% after 3 months of treat-
ment  (42,43).  After  1  year,  the  rate  of  recurrence  for  treated 
lesions  that  had  disappeared  is  21%.  Local  reactions  occur 
frequently. These include contact eczema, cutaneous dryness, 
edema,  pruritus,  scaly  rash,  ulcerations,  and   vesiculobullous 
rash  (42). Altogether, at a dosage of  two  applications per  day 
for 2–3 months, diclofenac gel appears to be well tolerated, but 
clinical data suggest that the efficacy profile may be less favor-
able compared to that of other topical treatments (30,31).

Ingenol Mebutate 150 µg/g and 500 µg/g 
Ingenol mebutate is a biological compound that has a  cytotoxic 
effect  that  causes  mitochondrial  edema  and  dissolution  of 
cytoplasmic membranes. It also has an immunomodulatory 
effect  that  causes  an  increased  production  of  inflammatory 
cytokines and the recruitment of neutrophils. In pooled anal-
yses, the rate of complete clearance observed after 2 months 
of  ingenol  mebutate  treatment  was  42%  for  AK  on  the  face 
and scalp and 34% for AK on the trunk and extremities (44). 
Twelve months after the end of treatment, the rate of recur-
rence  was  54%  on  the  face  and  scalp  and  56%  on  the  trunk 

 
and  extremities.  Local  cutaneous  reactions,  which  resolved 
within  2  to  4  weeks,  included  erythema,   scaling,  crusting, 
edema, vesicles/pustules, and erosions/ulcerations (45).

Physical Treatments
Ablative Ultrapulse Laser Therapy
Therapy  with  an  ablative  ultrapulse  laser  creates  a  thermal 
effect,  which  causes  nonselective  tissue  vaporization,  loss  of 
substance, and coagulation necrosis of the margins. Although 
this technique is included in recommendations, clearance rates 
have  not  been  evaluated  in  double-blind,  randomized,  con-
trolled clinical trials (24,31). The healing phase is often accom-
panied  by  erythema,  pain,  irritation,  pruritus,  oedema,  and 
sometimes by secondary infection.

Photodynamic Therapy
Photodynamic therapy selectively destroys tumor cells by tar-
geting them with light after topical application of a photosen-
sitizer (46). Photodynamic therapy can also be used to identify 
the limits of a field of cancerization (47). The rate of complete 
clearance  of  treated  lesions  after  two  PDT  sessions  ranges 
from  59%  to  91%  at  3  months  (26,27,48,49).  After  a  12-month 
follow-up period, the rate of recurrence of lesions was 17% (50). 
The best clearing results are obtained in studies that use two 
PDT  sessions  spaced  1  week  apart.  The  pain  associated  with 
application of the light to the photosensitized areas is a major 
limitation  of  this  technique.  In  addition,  the  rate  of  transient 
local reactions is high, with 60% to 80% of patients reporting 
burning  sensations,  cutaneous  pain,  crusting,  and  erythema. 
In many countries, such as France, the use of this technique is 
also limited by the fact that dermatologists in private practice 
rarely  own  red/blue  lamps.  European  guidelines  were  pub-
lished in 2013 (51).

Daylight-mediated  PDTs,  which  require  shorter  photo-
sensitizer application times and daylight-mediated PDT, have 
been developed and tested in three randomized controlled tri-
als (51,52). This treatment appears to be associated with good 
efficacy and lower levels of discomfort than conventional PDT.

MULTIPLE HYPERKERATOTIC 
ACTINIC KERATOSES
For  multiple  hyperkeratotic  AK,  first-line  treatments  should 
include  resurfacing  prior  to  the  use  of  the  topical  treatments 
and physical treatments described for non-hyperkeratotic AK. 
Resurfacing can be done manually or using topical keratolytics 
containing  urea  or  salicylic  acid.  Cleavage  of  the  corneodes-
mosomes  leads  to  exfoliation  of  the  superficial  layers  of  the 
epidermis.  Second-line  therapies  include  physical  treatments 
combined with topical treatments or surgery.

THERAPEUTIC PERSPECTIVES
Due  to  the  chronicity  of  AK,  long-term  strategies  need  to  be 
developed in order to reduce risk.

Comprehensive Approaches
A  multifaceted  approach  that  combines  yearly  checkups  and 
patient  education  is  likely  to  reduce  risk  further.  Educated 
patients  are  more  likely  to  use  protective  clothing  and  sun-
screen  and  to  adopt  protective  behavior.  They  are  also  best 
positioned to notice lesions that are changing rapidly or that 
have recurred after treatment.

ACTINIC KERATOSIS 

 217

Repeated Treatments
Repetition of treatment can be used to increase efficacy rates. 
With PDT, for example, the best clearing results are obtained 
in studies that use two sessions spaced 1 week apart (51). For 
imiquimod, the initial cycle of three applications per week for 
4 weeks can be repeated once in order to increase efficacy (35). 
Multiple cryotherapies have also been shown to be more effec-
tive than single cryotherapy as the rates of complete clearance 
at 3 months were 68% after one application and 78% after two 
applications (26,28).

Sequential Combination Treatments
The  sequential  combination  of  physical  and  topical  treat-
ments is also likely to increase efficacy. Cryotherapy alone, for 
example, is associated with high rates of recurrence (25). This 
is likely to be due to the fact that only the AK lesion is targeted 
and  the  field  of  cancerization  remains.  The  combination  of  a 
targeted  physical  approach  with  a  broader  topical  approach 
that encompasses the field of cancerization may thus be more 
effective.  After  treatment  with  a  combination  of  cryosurgery 
and  topical  ingenol  mebutate,  for  example,  the  rate  of  devel-
opment of new lesions 12 months after treatment was signifi-
cantly reduced compared to treatment with cryosurgery alone 
(52% vs 39%, respectively; p = 0.02) (53).

In  addition,  nonablative  fractional  lasers  (Er:Yag  and 
CO2), which are not particularly effective for AK in monother-
apy (54), can be used in combination strategies. As they  create 
microtunnels  in  the  dermis,  they  increase  the   penetration 
of  topical  treatments  and  chromophores.  In  clinical  trials, 
the  efficacy  of  PDT  in  combination  with  fractional  laser  was 
 significantly higher than the efficacy with PDT alone (88% vs 
59% for complete lesion resolution, respectively; p = 0.02) (55).

DNA Repair Enzymes
As UV is intrinsic in the development of AK, topical photoly-
ase  creams  may  become  an  integral  part  of  longterm  treat-
ment  plans.  These  creams  contain  photoreactive  DNA  repair 
enzymes  that  reverse  the  dimerization  of  pyrimidines  that 
occurs  from  UV  damage.  Once  the  cream  has  been  topically 
applied, the enzyme needs to be photoactivated by 300–500 nm 
light. Data have shown that use of this technique after expo-
sure  to  UVB  radiation  decreases  the  number  of  pyrimidine 
dimers  and  prevents  radiation-associated  immunosuppres-
sion and erythema formation (56).

CONCLUSIONS
As  Western  populations  age,  the  incidence  of  AK  in  derma-
tological  practices  is  likely  to  increase.  The  combination  of 
prompt management of suspicious AK, patient education, and 
long-term follow-up is likely to be the most effective approach 
to reducing the risk of SCC.

REFERENCES

1. Memon AA. et al. Prevalence of solar damage and actinic kera-
tosis in a Merseyside population. Br J Dermatol 2000; 142:1154–9.
2.  Frost  CA,  Green  AC.  Epidemiology  of  solar  keratoses. 

Br J Dermatol 1994; 131:455–64.

3.  Harvey  I,  et  al.  Non-melanoma  skin  cancer  and  solar  kerato-
ses II analytical results of the South Wales Skin Cancer Study. 
Br J Cancer 1996; 74:1308–12.

4.  Bickers DR, et al. The burden of skin diseases: 2004 a joint proj-
ect of the American Academy of Dermatology Association and 

 
 
 
 
218 

 TEXTBOOK OF COSMETIC DERMATOLOGY

the Society for Investigative Dermatology. J Am Acad Dermatol 
2006; 55:490–500.

5.  Green  A,  Battistutta  D.  Incidence  and  determinants  of  skin 
cancer in a high-risk Australian population. Intl J Cancer 1990; 
46:356–61.

6.  Salasche  SJ.  Epidemiology  of  actinic  keratoses  and  squamous 

cell carcinoma. J Am Acad Dermatol 2000; 42:4–7.

7.  Dreno  B,  et  al.  Management  of  actinic  keratosis:  A  practical 
report and treatment algorithm from AKTeam(TM) expert cli-
nicians. J Eur Acad Dermatol Venereol 2014; 28:1141–9.

8.  McBride  P,  et  al.  Sun-related  factors,  betapapillomavirus,  and 
actinic  keratoses:  A  prospective  study.  Arch  Dermatol  2007; 
143:862–8.

9.  Lebwohl  MG,  RosenT,  Stockfleth  E.  The  role  of  human  papil-
lomavirus in common skin conditions: Current viewpoints and 
therapeutic options. Cutis 2010; 86(suppl): –11; quiz (suppl):2.

  10.  Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous 

cell carcinoma. Br J Dermatol 2006; 155:9–22.

  11.  Quaedvlieg PJ, et al. Actinic keratosis: How to differentiate the 

good from the bad ones? Eur J Dermatol 2006; 16:335–9.

  12.  Frost C, Williams G, Green A. High incidence and regression 
rates  of  solar  keratoses  in  a  Queensland  community.  J  Invest 
Dermatol 2000; 115:273–7.

  13.  Dodson JM, et al. Malignant potential of actinic keratoses and 
the controversy over treatment. A patient-oriented perspective. 
Arch Dermatol 1991; 127:1029–31.

  14.  Feldman  SR,  Fleischer  AB  Jr.  Progression  of  actinic  keratosis 
to  squamous  cell  carcinoma  revisited:  Clinical  and  treatment 
implications. Cutis 2011; 87:201–7.

  15.  Marks  R,  et  al.  Spontaneous  remission  of  solar  keratoses: 
The  case  for  conservative  management.  Br  J  Dermatol  1986; 
115:649–55.

  16.  Marks  R,  Rennie  G,  Selwood  TS.  Malignant  transformation 
of  solar  keratoses  to  squamous  cell  carcinoma.  Lancet  1988; 
1:795–7.

  17.  Torezan  LA,  Festa-Neto  C.  Cutaneous  field  cancerization: 
Clinical,  histopathological  and  therapeutic  aspects.  Anais 
Brasileiros Dermatol 2013; 88:775–86.

  18.  Kanjilal S, et al. p53 mutations in nonmelanoma skin cancer of 
the head and neck: Molecular evidence for field cancerization. 
Cancer Res 1995; 55:3604–9.

  19.  Szeimies  RM,  et  al.  Clinical,  histopathological  and  immuno-
histochemical  assessment  of  human  skin  field  cancerization 
before  and  after  photodynamic  therapy.  Br  J  Dermatol  2012; 
167:150–9.

  20.  Dianzani C, et al. Cutaneous human papillomaviruses as recur-
rence  factor  in  actinic  keratoses.  Intl  J  Immunopath  Pharmacol 
2008; 21:145–52.

  21.  Zwald  FO,  Brown  M.  Skin  cancer  in  solid  organ  transplant 
recipients:  Advances  in  therapy  and  management:  Part  II. 
Management of skin cancer in solid organ transplant recipients. 
J Am Acad Dermatol 2011; 65:263–79.

  22.  Zwald  FO,  Brown  M.  Skin  cancer  in  solid  organ  transplant 
recipients:  Advances  in  therapy  and  management:  Part  I. 
Epidemiology  of  skin  cancer  in  solid  organ  transplant  recipi-
ents. J Am Acad Dermatol 2011; 65:253–61.

  23.  de  Berker  D,  et  al.  Guidelines  for  the  management  of  actinic 

keratoses. Br J Dermatol 2007; 156:222–30.

  24.  Rossi R, et al. Italian guidelines and therapeutic algorithm for 

  27.  Szeimies RM, et al. Photodynamic therapy using topical methyl 
5-aminolevulinate compared with cryotherapy for actinic ker-
atosis:  A  prospective,  randomized  study.  J  Am  Acad  Dermatol 
2002; 47:258–62.

  28.  Morton C, et al. Intraindividual, right-left comparison of topical 
methyl aminolaevulinate-photodynamic therapy and cryother-
apy in subjects with actinic keratoses: A multicentre, random-
ized controlled study. Br J Dermatol 2006; 155:1029–36.

  29.  Kaufmann  R,  et  al.  Multicentre  intraindividual  random-
ized  trial  of  topical  methyl  aminolaevulinate-photodynamic 
therapy  vs.  cryotherapy  for  multiple  actinic  keratoses  on  the 
extremities. Br J Dermatol 2008; 158:994–9.

  30.  Bonerandi JJ, et al. Guidelines for the diagnosis and treatment 
of cutaneous squamous cell carcinoma and precursor lesions. 
J Eur Acad Dermatol Venereol 2011; 25(Suppl 5):1–51.

  31.  French  Society  of  Dermatology,  [Guidelines  for  the  diagnosis 
and treatment of cutaneous squamous cell carcinoma and pre-
cursor lesions. Arguments - May 2009]. Ann Dermatol Venereol 
2009; 136(Suppl 5):S189–242.

  32.  Résumé des caractéristiques du produit, Efudix®. VIDAL 2012.
  33.  Tanghetti  E,  Werschler  P.  Comparison  of  5%  5- fluorouracil 
cream  and  5%  imiquimod  cream  in  the  management  of 
actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 
6:144–7.

  34.  Loven K, et al. Evaluation of the efficacy and tolerability of 0.5% 
fluorouracil cream and 5% fluorouracil cream applied to each 
side of the face in patients with actinic keratosis. Clin Ther 2002; 
24:990–1000.

  35.  Résumé des caractéristiques du produit, Aldara®. VIDAL 2012.
  36.  Jorizzo  JL,  et  al.  A  randomized,  double-blinded,  placebo- 
controlled,  multicenter,  efficacy  and  safety  study  of  3.75% 
imiquimod  cream  following  cryosurgery  for  the  treatment  of 
actinic keratoses. J Drugs Dermatol 2010; 9:1101–8.

  37.  Lebwohl  M,  et  al.  Imiquimod  5%  cream  for  the  treatment  of 
actinic  keratosis:  Results  from  two  phase  III,  randomized, 
 double-blind,  parallel  group,  vehicle-controlled  trials.  J  Am 
Acad Dermatol 2004; 50:714–21.

  38.  Szeimies RM, et al. Imiquimod 5% cream for the treatment of 
actinic keratosis: Results from a phase III, randomized, double-
blind, vehicle-controlled, clinical trial with histology. J Am Acad 
Dermatol 2004; 51:547–55.

  39.  Korman N, et al. Dosing with 5% imiquimod cream 3 times per 
week for the treatment of actinic keratosis: Results of two phase 3, 
randomized, double-blind, parallel-group, vehicle-controlled tri-
als. Arch Dermatol 2005; 141:467–73.

  40.  Jorizzo  J,  et  al.  Vehicle-controlled,  double-blind,  randomized 
study of imiquimod 5% cream applied 3 days per week in one 
or two courses of treatment for actinic keratoses on the head. 
J Am Acad Dermatol 2007; 57:265–8.

  41.  Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, 
double-blind  study  to  assess  safety  and  efficacy  of  imiqui-
mod  5%  cream  applied  once  daily  3  days  per  week  in  one 
or  two  courses  of  treatment  of  actinic  keratoses  on  the  head. 
Br J Dermatol 2007; 157:133–41.

  42.  Résumé  des  caractéristiques  du  produit,  Solaraze®.  VIDAL 

2012.

  43.  Wolf  JE  Jr,  et  al.  Topical  3.0%  diclofenac  in  2.5%  hyaluronan 
gel  in  the  treatment  of  actinic  keratoses.  Intl  J  Dermatol  2001; 
40:709–13.

actinic keratoses. G Ital Dermatolog Venereolog 2009; 144:713–23.

  44.  Lebwohl  M,  et  al.  Ingenol  mebutate  gel  for  actinic  keratosis. 

  25.  Krawtchenko  N,  et  al.  A  randomised  study  of  topical  5% 
imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immu-
nocompetent patients with actinic keratoses: A comparison of 
clinical and histological outcomes including 1-year follow-up. 
Br J Dermatol 2007; 157(Suppl 2):34–40.

  26.  Freeman  M,  et  al.  A  comparison  of  photodynamic  therapy 
using  topical  methyl  aminolevulinate  (Metvix)  with  single 
cycle cryotherapy in patients with actinic keratosis: A prospec-
tive, randomized study. J Dermatol Treat 2003; 14:99–106.

N Engl J Med 2012; 366:1010–9.

  45.  Résumé  des  caractéristiques  du  produit,  Picato®  extract  from 

EPAR 29. EMA 2012.

  46.  Résumé  des  caractéristiques  du  produit,  Metvixia®.  VIDAL 

2012.

  47.  Braathen LR, et al. Photodynamic therapy for skin field cancer-
ization:  An  international  consensus.  International  Society  for 
Photodynamic  Therapy  in  Dermatology.  J  Eur  Acad  Dermatol 
Venereol 2012; 26:1063–6.

 
 
 
 
 
 
ACTINIC KERATOSIS 

 219

  48.  Pariser  D,  et  al.  Topical  methyl-aminolevulinate  photo-
dynamic  therapy  using  red  light-emitting  diode  light  for 
treatment  of  multiple  actinic  keratoses:  A  randomized,  dou-
ble-blind,  placebo-controlled study. J Am Acad Dermatol 2008; 
59:569–76.

  49.  Pariser  DM,  et  al.  Photodynamic  therapy  with  topical  methyl 
aminolevulinate  for  actinic  keratosis:  Results  of  a  prospec-
tive  randomized  multicenter  trial.  J  Am  Acad  Dermatol  2003; 
48:227–32.

  50.  Braathen  LR,  et  al.  Short  incubation  with  methyl  aminolevu-
linate for photodynamic therapy of actinic keratoses. J Eur Acad 
Dermatol Venereol 2009; 23:550–5.

  51.  Morton  CA,  et  al.  European  guidelines  for  topical  photody-
namic  therapy  part  1:  Treatment  delivery  and  current  indica-
tions - actinic keratoses, Bowen’s disease, basal cell carcinoma. 
J Eur Acad Dermatol Venereol 2013; 27:536–44.

  52.  Wiegell  SR,  et  al.  Daylight  photodynamic  therapy  for  actinic 
keratosis: An international consensus: International Society for 
Photodynamic  Therapy  in  Dermatology.  J  Eur  Acad  Dermatol 
Venereol 2012; 26:673–9.

  53.  Berman B, et al. Efficacy and safety of ingenol mebutate 0.015% 
gel  after  cryosurgery  of  actinic  keratosis:  12-month  results. 
J Drugs Dermatol 2014; 13:741–7.

  54.  Katz  TM,  et  al.  Nonablative  fractional  photothermolysis  for 
facial actinic keratoses: 6-month follow-up with histologic eval-
uation. J Am Acad Dermatol 2011; 65:349–56.

  55.  Togsverd-Bo  K,  et  al.  Intensified  photodynamic  therapy  of 
actinic keratoses with fractional CO2 laser: A randomized clini-
cal trial. Br J Dermatol 2012; 166:1262–9.

  56.  Stege H. Effect of xenogenic repair enzymes on photoimmunol-
ogy  and  photocarcinogenesis.  J  Photochem  Photobiol  B,  Biology 
2001; 65:105–8.

 
26

Safety of UV Nail Lamps as used in Professional Nail Salons

Douglas Schoon

Questions  about  the  safety  of  UV  nail  lamps  were  raised  in 
2009  and  have  since  been  addressed  by  four  published  sci-
entific studies, which are outlined in this chapter. An under-
standing  of  how  these  lamps  are  designed  and  used  is  also 
important to understanding their safety.

UV NAIL LAMP DESIGN AND USE
Two styles of UV nail lamps are used in salons, utilizing either 
fluorescent bulbs or LEDs, as shown in Figure 26.1. Both types 
emit  UV  and  can  quickly  harden  UV-curable  artificial  nail 
coatings. A client’s hands are inserted into a covered chamber 
where UV exposure occurs. LED-style UV nail lamp exposure 
is  typically  30  seconds  per  hand,  while  fluorescent-style  UV 
nail lamp exposure times are typically 2 minutes or less. This 
is repeated three or four times per hand for a total exposure 
time  ranging  from  90  seconds  to  8  minutes  per  hand.  Salon 
services are typically semi-monthly exposures for those who 
keep to the recommended maintenance schedule.

The bulbs used in traditional UV nail lamps are fluo-
rescent  tubes,  while  the  equivalent  of  a  bulb  used  in  LED-
style UV nail lamps are light emitting diodes (LED). UV nail 
lamps  emit  UVA,  with  very  little  or  no  UVB  and  no  UVC. 
Artificial  nail  coatings  are  specially  formulated  to  cure 
(polymerize)  using  relatively  low  levels  of  near  UVA,  rely-
ing exclusively on wavelengths between 400–350 nm, while 
the UVA region extends to 315 nm, as shown in Figure 26.2. 
Fluorescent  tubes  have  peak  emissions  near  365  nm.  The 
most commonly used LEDs have peak emissions at 405 nm, 
which is in the visible range, however, wavelengths between 
400–380 nm are chiefly responsible for most polymerization. 
Therefore, it is incorrect to categorize these as visible curing 
nail coatings. Visible curing is not currently practical or com-
mercially feasible, due almost exclusively to the lack of suit-
able  photoinitiators  that  are  activated  by  visible  light.  It  is 
incorrect to refer to UV as “light.” Light is the visible portion 
of the electromagnetic spectrum. UV is not visible and there-
fore not considered light, but instead is correctly referred to 
as UV energy.

Different  UV-curable  nail  product  formulations  may 
require  differing  UV  wavelengths  for  curing.  The  required 
wavelengths are determined by the selection of the photosen-
sitive  polymerization  imitator(s)  chosen.  Photoinitators  (PI) 
are  activated  by  specific  UV  wavelengths,  and  the  intensity 
of these wavelengths is also important. The degree of polym-
erization of the nail coating is dependent on exposure to the 
proper wavelengths at the correct intensity for the necessary 
duration  of  time.  Therefore,  proper  polymerization  is  largely 
determined by the type of photoinitiator(s) used in the formu-
lations as well as its concentration. The chemical structure of a 

typical photoinitator, ethyl-2,4,6 trimethylbenzoylphenyl phos-
phinate, is shown in Figure 26.3.

The  UV  wavelength  and  intensity  (irradiance)  needed 
to  properly  cure  a  specific  UV  nail  coating  can  vary  widely, 
depending on the coating formulation. UV nail lamps that do 
not properly match the curing requirements of a particular UV 
nail product van lead to either over- or under-curing the nail 
coating. Proper curing requires exposing the UV-curable coat-
ing to the correct UV nail lamp for the required time.

ACHIEVING PROPER POLYMERIZATION
Nail professionals tend to oversimplify the UV curing process 
and may not fully appreciate the many factors that influence 
polymerization and mistakenly believe that wattage of the nail 
lamp is the critical factor. Wattage is the power consumption, 
while  the  far  more  important  property  is  irradiance  (watts/
cm/nm). The second mistake that some make is to focus on the 
range  of  wavelengths  emitted  by  their  UV  bulbs,  which  also 
ignores  the  importance  of  irradiance,  which  determines  the 
intensity of exposure over an area.

Proper curing of nail coatings is best achieved by con-
sistently applying a thin layer of UV gel, exposing the coat-
ing for the proper length of time, and using a UV nail lamp 
that  emits  the  correct  UV  wavelengths  at  the  proper  inten-
sity  for  the  formulation.  When  the  irradiance  is  excessive, 
the nail coating can exothermically release sufficient heat to 
cause oncholysis. When irradiance is insufficient, unreacted 
monomer can remain trapped in the nail coating with dust, 
which can contribute to overexposure and increased risk of 
adverse skin reactions. When properly cured, these risks are 
minimized.

Lamp  design  is  also  important  to  ensure  proper  cure. 
Physics inverse square law demonstrates that UV intensity is 
inversely proportional to the square of the distance from the 
source,  which  is  why  the  distance  between  the  coated  nail 
plates  and  the  UV  source  is  important,  as  are  the  electronic 
components  which  power  the  bulbs  or  diodes.  Different  UV 
nail lamps utilize different electrical components. These vari-
ous  factors  help  to  explain  why  the  identical  UV  bulbs  have 
differing irradiance when used in two different brands of UV 
nail lamp, and why it is important to use the UV nail lamp that 
was designed to cure a specific nail coating. Expired UV bulbs 
should be replaced with the same type and model of UV bulb, 
and fluorescent style bulbs should generally be changed two 
to four times per year, depending on how often the nail lamps 
are used. LED-style UV nail lamps claim to have usable lives 
of 10,000 hours, but in practical terms these lamps are expected 
to last 3–4 years before they must be replaced with a new unit, 
since the diodes are not replaceable.

SAFETY OF UV NAIL LAMPS AS USED IN PROFESSIONAL NAIL SALONS 

  221

O

P

O

O

Figure 26.3  2,4,6-trimethylbenzoyl diphenylphosphine oxide 
(MW 316), a typical photoinitiator for UV curable nail coatings.

UV NAIL LAMP SAFETY
Questions were raised in 2009 about the safety of lamps used 
in nail salons to photopolymerize artificial nail coatings. Texas 
dermatologists  MacFarlane  and  Alonso  claimed  to  have  had 
two  patients  who  they  suspected  had  developed  nonmela-
noma skin cancer (NMSC) as a result of using UV nail lamps 
during regular salon services (2).

MacFarlane  and  Alonso  made  no  UV  measurements—
instead, they performed several calculations in an attempt to 
compare  UV  nail  lamps  to  tanning  beds;  however,  these  cal-
culations were flawed and based on several incorrect assump-
tions.  For  instance,  they  erroneously  assumed  the  spectral 
output  of  tanning  bed  bulbs  were  the  same  as  those  used  in 
nail curing applications; however, the spectral outputs of these 
two sources are very different, which makes their NMSC risks 
quite different as well.

MacFarlane and Alonso stated that one of the only two 
patients  described  had,  “Fitzpatrick  skin  type  III,  several 
actinic keratoses on her face and arms” and was determined to 
have “moderate recreational UV exposure.” It was claimed this 
patient’s previous sole exposure to UV nail lamps was approxi-
mately eight times over the course of a single year. This indi-
cates  that  the  patient’s  exposure  was  64  minutes  or  less,  and 
this was her lifetime exposure to a UV nail lamp. These derma-
tologists discounted many years of recreational UV exposure 
of the face and arms to indicate their belief that this instance of 
NMSC on the hand’s dorsum was attributed to 64 minutes of 
low-intensity UVA exposure spread over eight nail salon visits 
during the course of a year. In light of studies that followed, 
this  claim  is  highly  implausible.  According  to  Dowdy  and 
Sayre in Photobiological Safety Evaluation of UV Nail Lamps, the 
most comprehensive paper published concerning the safety of 
UV nail lamps, MacFarland and Alonso’s patient would have 
had more than three times greater NMSC risks from natural 
sunlight if she walked for 8 minutes under mid-angle sunlight 
to and from the salon for her appointments, twice per month 
(3).  Dowdy  and  Sayre’s  study  is  the  only  study  that  utilized 
the  proper  international  standard  testing  methodology  and 
made risk calculations based on threshold limit values of the 
American  Conference  of  Government  Industrial  Hygienists 
(ACGIH). Other published papers have observations made by 
utilizing inadequate testing equipment, incorrect calculations, 
and/or  failing  to  adhere  to  the  internationally-recognized 
standard testing protocols.

UV energy sources are difficult to measure properly. To 
overcome these inherent difficulties the ANSI/IESNA RP-27 is 
the recommended standard for photobiological safety evalua-
tion of lamps and lamp systems. Part 2 of the Standard outlines 

Figure 26.1  Typical LED (top) and fluorescent-style (bottom) 
UV nail lamps used to polymerize (cure) artificial nail coatings 
designed to cure via exposure to relatively low levels of near 
region of the UV-A wavelengths.

)

m
n
/
2

m
c
/
W

(
e
c
n
a
d
a
r
r
I

i

0.0020

0.0015

0.0010

0.0005

0.0000

LED nail lamp
Fluorescent nail 
lamps

275 300 325

350 375 400 425 450

Wavelength (nm)

Figure 26.2  Linear plot of irradiance for LED-style UV nail 
lamps when compared to fluorescent-style UV nail lamps (1).

Nail  technicians  may  underestimate  the  importance  of 
using  the  correct  UV  nail  lamp  intended  for  curing  the  nail 
coating  product  of  their  choice,  and  mistakenly  believe  that 
“wattage” is the only important factor. UV nail coatings will 
harden when they are only 50% cured, but to reach the ideal 
coating durability and minimize the potential for adverse skin 
reactions, these crosslinked nail coatings should be more fully 
polymerized.  When  properly  cured,  the  potential  for  overex-
posure to partially cured dust and filings decreases the poten-
tial for adverse skin reactions.

 
 
222 

 TEXTBOOK OF COSMETIC DERMATOLOGY

ways in which significant errors are introduced when incorrect 
equipment and testing procedures are utilized:

continuous exposure on a daily basis. Actual usage is 8 min-
utes or less, twice per month.*

…  special  problems  related  to  photobiological  hazards  mea-
surements.  The  results  of  hazard  evaluations  will  be  influ-
enced  by  the  instruments’  characteristics.  The  bandwidth  of 
the  monochromator  will  change  the  weighted  results  of  any 
spectrum  with  varying  levels.  All  finite  bandwidths  instru-
ments report signal at the wrong wavelength, leading to errors 
in a weighted sum. (4, p. 3)

Relying  on  improper  testing  procedures  and/or  inade-
quate testing equipment will skew results up to 30%–50% and 
result in significantly increasing the weighting of the shorter 
UVA wavelengths. This results in significant overestimation of 
skin  exposure  for  these  lower  wavelengths  and  a  large  over-
estimation of the actual NMSC risks. Other than Dowdy and 
Sayre’s study, the spectrometers used in the published studies 
discussed  were  not  suitable  for  this  type  of  analysis  per  this 
International Standard.

Dowdy and Sayre measured five UV nail lamps—three 
fluorescent-style and two LED-style—using a dual monochro-
mator  spectroradiometer  and  integrating  sphere,  calibrated 
using a tungsten filament spectral irradiance standard trace-
able  to  the  National  Institute  of  Standards  and  Technology 
(NIST)  to  provide  an  uncertainty  of  measurement  of  <  5% 
allowing  for  source  positioning  uncertainty  estimated  to  be 
no greater than ~ 2.5%. Secondary calibration to a deuterium 
spectroradiometric  standard  lamp  was  conducted  to  extend 
the calibration spectral measurement range down to 200 nm.

Three other studies, Curtis et al., Markova and Weinstock, 
and Shipp and Wagner, each utilized nonstandardized testing 
by not following the published International Standard, ANSI/
IESNA RP-27, and therefore their results are likely to be overap-
proximations that do not correctly reflect the true NMSC risks 
(5–7). UV measurement devices used by these researchers were 
low-end  devices  that  are  especially  prone  to  the  errors  previ-
ously described and which caused a significant overestimation 
of NMSC risks. Part 3 of the International Standard states,

The performance of the necessary measurements is normally 
not  an  easy  task  without  sophisticated  instruments…  The 
purpose of this standard [RP-27.3] is to provide guidance for 
the  proper  categorization,  classification  and  informational 
requirements of lamps so that such sources may be properly 
applied… (8).

For their study, Dowdy and Sayre utilized a dual mono-
chromator spectroradiometer that meets the necessary require-
ment of the RP-27.2-00 internationally accepted standard to make 
proper measurements of UV nail lamps, and they then compared 
these results with the UV output of tanning bed lamps. Dowdy 
and  Sayre  performed  a  risk  analysis  based  upon  the  ACGIH 
threshold limit values for exposure to UV and stated,

The results indicate that a person could in their workplace, once 
every day, put their hand under a UV nail lamp for 25 minutes 
and remain within the permissible daily occupational exposure 
limits  for  workers,  according  to  the  applicable  international 
ANSI/IESNA RP-27.1-05 standard. (9,10, pers. comm.).

Dowdy  and  Sayre  concluded  that  the  UV  lamp  tested 
for  photobiological  safety  to  skin  properly  belonged  within 
the  Risk  Group  2-Moderate  Risk  (RG-2)  with  S  (λ)  weighted 
actinic  UV  ranging  1.2-1.7  μW/cm2  and  permissible  exposure 
times of 29.8–129.31 minutes. This indicates that these UV nail 
lamps are permissible for up to approximately 30 minutes of 

For all nail lamps tested, exposures were in the Exempt 
classification  for  both  skin  and  eyes  when  UV  was  measured 
at the specified distance and angle, 20 cm (7.8 inches) and a 45° 
angle from the nail lamp. Radiant output was below maximum 
levels allowed for Exempt classification for UV risk to skin and 
eyes. S(λ) weighted actinic UV ranged 0.009–0.078 μW/cm2 and 
unweighted near UV (320–400 nm) ranged 0.091–0.483 mW/cm2. 
The  retinal  photochemical  blue  light  hazard  was  also  within 
the Exempt range. Meter readings detected negligible Infrared 
(IR); consequently retinal thermal and cornea/lens IR were also 
Exempt. For one device, however, the aphakic eye hazard (indi-
viduals  implanted  with  non-UV  blocking  intraocular  lenses) 
slightly exceeded this limit, rising into Class 1 (low risk). These 
specific devices were all found to be classified into Risk Group 
Class 2 (moderate risk) for actinic UV to skin exposed inside the 
chamber with no other risks to normal individuals.

Although they did not adhere to the RP-27 standard as did 
Dowdy  and  Sayre,  Markova  and  Weinstock  reached  a  similar 
conclusion. They tested three commonly used UV nail lamps—
two fluorescent-style and one LED style—and used the SCUP-h 
action spectrum to determine a UV nail lamp session’s carcino-
genic-effective irradiance in terms of narrow band ultraviolet B 
(NBUVB)  phototherapy  courses,  assuming  10  minutes  per  UV 
nail lamp session for each device’s carcinogenic effective irradi-
ance. They then compared the measured UV dose with that of a 
single course of NBUVB, assuming a cumulative UV dose of 25 
J cm_2 was received per patient per NBUVB course. The carcino-
genic equivalence was calculated in terms of NBUVB courses to 
determine that depending on the UV lamp tested, 13,000–40,000+ 
sessions lasting for 10 minutes would be required to expose the 
nail plate and surrounding skin to equal the UV dose received 
during one NBUVB course. They concluded that given the tiny 
fractional exposure when compared to a single NBUVB course, 
the UV nail lamps tested and hence do not produce a clinically 
significant increased risk of developing skin cancer. They stated 
that “One would need over 250 years of weekly UV nail sessions 
to experience the same risk exposure.” These authors also com-
mented on the calculations made by MacFarlane and Alonso and 
stated, “… this case review is anecdotal and the spectral irradi-
ance cannot be calculated by using bulb wattage (bulb’s power 
requirements)  and  exposed  to  body  surface  area,  but  must  be 
measured spectroradiometrically…” (2, p. 2).

Curtis reported very small MED of 0.06–0.09 per nail ser-
vice and estimated that after 1 year of exposure, the MED could 
be 1.1–1.5, which is very low. Yet these authors refer to the nail 
lamps  as  “high-intensity”  devices  that  produced  “high-dose 
UVA irradiation,” which is in contradiction to their own mea-
sured results. Semi-monthly exposure of 0.06–0.09 MED which 
they  reported  and  no  justification  is  provided  to  support  the 
contention that these are “high-intensity lamps” (6, p. 1). This is 
in contrast to Dowdy and Sayre, who stated, “All of the various 
UV nail lamps submitted for evaluation were found to be sig-
nificantly less hazardous than might be anticipated based on 
the initial concerns raised by MacFarlane and Alonso” (3, p. 3).
Had Curtis utilized the proper test equipment and pro-
cedures  or  been  provided  with  Dowdy  and  Sayre’s  results 

* Exposure is approximately 2 minutes or less per applied layer of nail 
coating,  totaling  approximately  8  minutes  or  less.  The  exposure  is 
not a continuous 8 minutes since the lamps take only one hand at a 
time.  LED  lamp  exposure  is  even  less  since  each  coat  requires  only 
30 seconds.

 
SAFETY OF UV NAIL LAMPS AS USED IN PROFESSIONAL NAIL SALONS 

  223

prior to their publication, they would have seen that they erred 
in  their  cursory  evaluations  and  conclusions.  Curtis  made  a 
misleading  statement  by  claiming  these  lamps  produce  4.2 
times the energy of the sun between 355 and 385 nm, but failed 
to recognize this is the least risky portion of the spectrum and 
sunlight contains a much greater concentration of more harm-
ful  shorter  UVA  wavelengths  not  emitted  by  UV  nail  lamps. 
This  helps  explain  why  exposure  to  UV  nail  lamps  is  much 
safer than exposure to sunlight and not riskier as erroneously 
suggested  by  Curtis.  UV  nail  lamps  utilize  the  safest  region 
of the UVA spectrum. When the spectral risk weighting func-
tions are properly applied as required by the RP-27 Standard, 
it is clearly not correct to suggest UV nail lamps have greater 
NMSC risk than natural sunlight, when in fact UV nail lamps 
create less exposure to harmful wavelengths and instead pro-
duce safer, low intensity energy, emitting near-UVA and vis-
ible light wavelengths.

Since  both  lamps  tested  by  Curtis  were  also  properly 
tested by Dowdy and Sayre using the appropriate international 
standard for testing, it can only be concluded that Curtis erred 
in  the  measurement  techniques  utilized,  which  negatively 
affected the conclusion and led to an overestimation of risks.

Shipp and Wagner also failed to utilize the proper test 
equipment  and  did  not  cite  the  results  published  by  Dowdy 
and  Sayre.  Instead,  they  purchased  a  $170  UV  detector  and 
improper  test  methodology  which  produced 
developed 
 inconsistent  and  inaccurate  results  causing  the  authors  to 
significantly  overestimate  the  risks  of  NMCS  from  UV  nail 
lamps.  Their  testing  of  various  UV  nail  lamps  produced 
widely   varying  results  with  variances  so  significant  that 
proper  statistical analysis was impossible, “Using the Shapiro-
Wilks test however, the data failed normality testing because 
the local irradiance values of the 5 different positions were not 
homogeneous” (5, p. 1).

Rather  than  recognize  this  failure  as  a  result  of  inade-
quate measuring devices and poorly designed test methodol-
ogy, these authors ignored problems with the data to publish 
inaccurate conclusions about NMSC risks.

Dowdy  and  Sayre  also  compared  the  International 
Electrotechnical  Commission  (IEC)  indoor  tanning  annual 
NMSC exposure limits to sunlight and to the UV nail lamps 
studied.  Table  26.1  compares  fluorescent-style  UV  nail  lamps 
with  fluorescent-style  tanning  lamps  to  both  overhead  and 

Table 26.1 
Compared to UV Nail Lights and Natural Sunlight

IEC Indoor Tanning Annual NMSC Exposure Limits 

UV Source

IEC Annual 
Tanning Limit
(25 kJ NMSC)

FDA Maximum 
Timer for Tanning 
Session (Te)

UV Type 5 tanning 

8 hours

14.47 minutes

booth

Overhead sunlight
CIE AMIG T7/1
UV Type 4 body 
tanning lamp
UV Type 4 facial 
tanning lamp

Mid-angle sunlight
CIE AM1.5G 77/2
UV nail lamp F3*
UV nail lamp F4*
UV nail lamp F2*

*Not a tanning appliance.

10 hours

20.47 minutes

13 hours

15 hours

23.47 minutes

29.73 minutes

29 hours

62.68 minutes

96 hours
114 hours
154 hours

145 minutes
176 minutes
234 minutes

mid-angle sunlight by comparing their exposure times needed 
to  reach  the  25  kJ  m2  NMSC  effective  dose.  The  lower  the 
reported number, the greater the NMSC risk. The table dem-
onstrates  what  Dowdy  and  Sayre’s  paper  states,  i.e.  “Using 
spectral  weighting  relative  to  overhead  and  mid-angle  sun-
light the UV nail lamps were 11–46 times less NMSC effective-
irradiance than at overhead 1 atmosphere solar spectrum and 
3–12  times  less  than  mid  angle  1.5  atmosphere  sun”  (3,  p.  5) 
Also  shown  is  a  comparison  of  FDA  sunlamp  calculations 
for  determining  maximum  exposure  times  (Te)  for  tanning 
applied to UV nail lamps as an objective index of comparison 
(11).  This  table  demonstrates  that  UV  nail  lamps  would  not 
function well as miniature hand tanners, as erroneously sug-
gested by MacFarlane and Alonso.

Mid-angle sunlight is safer for skin exposure than over-
head sunlight because  of the association  between  UV inten-
sity  and  the  ratio  of  shadow  length  to  the  object’s  height; 
longer shadow lengths equal lower UV intensity of sunlight. 
Mid-angle  sun  produces  erythema  after  20–30  minutes;  ery-
thema  is  produced  after  only  several  minutes  when  the  sun 
is  overhead.  The  UVA  nail  lamps  measure  clearly  present 
many times lower risk than equal time exposure to mid-angle 
sunlight.

Table  26.1  shows  the  International  Electrotechnical 
Commission  (IEC)  indoor  tanning  annual  NMSC  exposure 
limits to sunlight compared to fluorescent-style tube UV nail 
lamps, tanning lamps which utilize use fluorescent tubes and 
to both overhead and mid-angle sunlight. The lower the effec-
tive dose; the greater the NMSC risk.

Manufacturers  provide  users  with  detailed  directions 
for proper use and warning labels which accompany UV nail 
lamps that help ensure that users know how to properly use 
the nail lamp.

Dowdy and Sayre state their discussion demonstrate that 
nail  lamps  are  “…  vastly  less  hazardous.  In  terms  of  NMSC-
weighted exposure, the most powerful UV nail lamp was more 
than an order of magnitude less than the most powerful sun-
lamp” (3, p. 3).

UV  curing  of  artificial  nail  enhancements  (artificial 
nails) and other types of UV-curable nail coatings have been 
widely  used  as  a  popular  nail  services  in  Europe,  Canada, 
Australia, Japan, and the United States for more than 25 years. 
UV nail lamps, when correctly tested under appropriate stan-
dards, are demonstrated to be acceptable according to the cited 
standards  and  therefore  should  be  considered  safe  as  used 
for  curing  of  artificial  nail  coatings.  Normal  exposure  to  UV 
nail lamps provides a low bioeffective skin dose from the least 
risky portion of the UVA spectrum for about 8 minutes or less, 
at 2–3 week intervals. Identically exposing skin to mid-angle 
sunlight  in  this  fashion  would  pose  an  insignificant  NMSC 
risk. UV nail lamps have at least three times lower NMSC risks 
when compared to mid-angle sunlight. Most people are likely 
to not be overly concerned with 8 minutes of exposure to mid-
angle  sunlight  twice  per  month  and  neither  should  they  be 
concerned  with  8  minutes  of  exposure  using  UV  nail  lamps, 
which have a significantly lower NMSC risk than natural mid-
angle sunlight.

CONCLUSION
It can be concluded that total exposure following typical salon 
exposure  times  and  exposure  steps  accumulate  to  only  a 
small fraction of the permissible daily exposure under ANSI/
IESNA RP-27. These risks are further mitigated in realistic use 

 
224 

 TEXTBOOK OF COSMETIC DERMATOLOGY

scenarios, since they is not a daily occurrence. Also, the natural 
nail plate is a very efficient blocker of UV, protecting the nail 
bed making the UV exposure risks to the nail bed comparable 
to that of skin protected by high SPF topical sunscreen, and the 
dorsum of the hand is four times more resistant to UV than the 
forehead  or  cheek  and  three-and-a-half  times  more  resistant 
than a person’s back, making the dorsum of the hand the most 
UV  acclimatized,  photo  adapted,  and  UV-resistant  body  site 
(12,13,14).

To  put  things  into  the  proper  perspective,  it  is  very 
unlikely for anyone to suffer from overexposure to UV through 
normal use of a UV nail lamp, and it is highly improbable that 
even the most dedicated nail salon client would approach an 
unsafe level of exposure.

REFERENCES

Illuminating Engineering Society of North America,  America 
National Standards Institute 2001; p. 1.

5.  Shipp L, Warner C, et al. Further investigation into the risk of 
skin  cancer  associated  with  the  use  of  nail  lamps.  J  Am  Acad 
Dermatol, published online April 30, 2014.

6.  Curtis J, Tanner P. Acrylic nail curing UV lamps: High-intensity 
exposures warrants further research of skin cancer risk. J Am 
Acad Dermatol 2013; 69(6):1069–70.

7.  Markova A, Weinstock M. Risk of skin cancer associated with 
the use of the UV nail lamp. J Inv Dermatol 2012; doi: 10, 1038/
jid.2012.440.

8.  IESNA RP-27.3-96. Recommended Practices for Photobiological Safety 
for Lamps and Lamp System- Risk Group Classifications & Labeling, 
Illuminating Engineering Society of North America; p. 1

9.  ANSI/IESNA RP-27.1-05 Recommended Practices for Photobiological 
Safety  for  Lamps  and  Lamp  System-  General  Requirements. 
Illuminating Engineering Society of North America, America 
National Standards Institute.

1.  Dowdy J, Sayre R. Photobiological safety evaluations of UV nail 

lamps, Photochem Photobiol 2013; 89:961–7.

2.  MacFarlane D, Alonso C. Occurrence of nonmelanoma skin can-
cers on the hands after UV nail light exposure. Arch Dermatol 
2009; 145(4):447–9.

  10.  Sayre R. Personal communication. February 22, 2014.
  11.  Dowdy  J,  Sayre  R.  Comparison  of  IEC  and  USFDA  sunlamp 
standards:  Critical  discrepancies  in  exposure  timers  and 
annual  exposure  limits.  Proc  CIE  Symposium  2004,  Light  and 
Health Non-Visual Effects.

3.  Dowdy J, Sayre R. Photobiological safety evaluations of UV nail 

  12.  Dowdy J, Sayre R. Photobiological safety evaluations of UV nail 

lamps, Photochem Photobiol 2013; 89:961–7.

lamps, Photochem Photobiol 2013; 89:961–7.

4.  ANSI/IESNA RP-27.3-96. Recommended Practices for Photobiologial 
Safety  for  Lamps  and  Lamp  Systems-  Measurement  Techniques. 

  13.  Dowdy J, Sayre R. Photobiological safety evaluations of UV nail 

lamps, Photochem Photobiol 2013; 89:961–7.

 
 
 
 
 
 
 
 
 
 
Section IV 

Specific Locations and Conditions

27

Hair Care

John Gray

INTRODUCTION
Hair  is  one  of  nature’s  survivors  and,  although  technically 
“dead,”  one  of  its  most  resilient  creations.  The  visible  hair 
shaft may appear very simple but the mechanism to create it, 
the hair follicle deep in the skin, is a highly complex biologi-
cal system.

Hair first arrived on the evolutionary scene some 310 mil-
lion years ago on reptilian-like animals. It preceded and sur-
vived the rise and extinction of the dinosaurs and emerged as 
the dominant skin appendage of mammals (1). As part of this 
class, modern humans have “inherited” skin which, although 
bearing several million hair follicles, has largely confined itself 
to growing hair in any profusion on the scalp in women and 
scalp and face in men.

The modern obsession for the complex grooming of hair 
is entirely consistent with mammalian habits which enhances 
appearance, and subconsciously imparts status, health, physi-
cal attractiveness, and perhaps less romantically, helps remove 
parasites. Hair care is an (almost) ubiquitous human habit in 
the 21st century and is driven by conscious as well as subcon-
scious social and evolutionary pressures.

The  varied  appearance  of  human  hair  types  can  be 
explained  to  some  extent  by  inherited  regional  phenotype 
based  on  founder  effects  and  partly  by  both  adaptive  con-
sequences  to  the  environment  and  sexual  selection  that 
occurred after the modern human diaspora out of its origins 
in  Africa  some  70–90,000  years  ago.  These  differences  now 
play an important role in determining grooming habits and 
the  type  of  hair  care  products  people  use  as  part  of  their 
grooming ritual.

HAIR
Some mammals such as Polar bears invest an estimated 30% 
of their dietary protein in the manufacture of hair (2). Despite 
their reputation as naked apes, humans still invest extraordi-
nary amounts of protein, particularly at a young age, in grow-
ing  scalp  hair  to  a  greater  length  than  any  other  mammal 
(Figure 27.1).

The length of an individual’s hair depends on the dura-
tion of continuous growth (anagen) from the follicle (3). Only 
the  merino  sheep  has  a  comparable  duration  of  hair  growth, 
although this is artificially induced by selective breeding

It is open to debate quite why homo sapiens are so blessed 
with  profuse  head  hair  when  young,  and  why  subsequently 
so many lose it. Human hair’s function may now primarily be 
that  of  a  critical  signaling  device,  conveying  age,  health,  and 
even social status to others of the species. In prime condition it 
can act as a powerful beacon of sexual attraction; in a damaged 
or dishevelled state, quite the reverse (5).

HUMAN HAIR AND THE FOLLICLE
This  chapter  focuses  primarily  on  the  hair  shaft.  The  origin 
of the visible hair and what influence the follicle has on hair 
health is also addressed.

The Hair Follicle
By  definition,  a  follicle  is  a  mammalian  skin  organ  that  pro-
duces hair. It contains many of the complex biological systems 
found throughout the body and is a reservoir of stem cells for 
regeneration of both hair and skin. These attributes infer the 
fundamental importance of such tiny organs to the body as a 
whole and reflect our mammalian heritage where fur and pelts 
are essential to survival.

Of  the  2–5  million  hair  follicles  on  the  human  body, 
those  on  the  scalp  are  the  most  fascinating  and  important. 
Possibly as a mark of its importance, the hair follicle has, like 
the eye, brain, and human reproductive organs, been granted 
“immune  privilege.”  It  is  postulated  that  the  demise  of  this 
privilege is an initiating phase of alopecia areata (3).

Types of Follicle
In infancy, hair follicles are generally small other than those 
on the scalp which produce significant hairs. After puberty 
and  under  androgenic  influence,  selected  follicles  enlarge 
and develop sebaceous glands and terminal hairs which are 
produced  on  other  body  areas  such  as  the  trunk,  although 
there  are  large  inter-  and  extra-regional  differences.  These 
large and heavily pigmented hairs are described as terminal 
hairs (3).

Of  the  100,000–150,000  follicles  on  the  scalp,  75%–90% 
produce  terminal  hairs.  The  associated  sebaceous  glands 
deliver sebum—a natural mixture of triglycierides, wax esters, 
and squalene which helps to maintain the integrity of the scalp 
and has both protective and thermoregulatory properties (3). 
The  remaining  10%–25%  of  scalp  follicles  are  small  and  pro-
duce fine vellus hairs

COSMETIC ASPECTS OF HAIR
The  result  of  this  hair  growth  activity  is  the  production  of  a 
terminal hair shaft. This may be described, like the carapace 
of a crustacean, as a filamentous biomaterial since it contains 
no  living  matter  and  possesses  no  biofeedback  mechanisms. 
From this point on, the fate of the hair shaft may be regarded as 
cosmetic, which includes beauty, aesthetics, or appearance. In 
reality, modern proteomic research has identified that behind 
these cosmetic changes are structural and measurable changes 
to the core of the hair.

228 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 27.2  Scanning electron microscope image of hair shaft.

grey hairs) the medulla. The main constituents of these struc-
tures  are  sulphur-rich  proteins,  lipids,  water,  melanin,  and 
trace elements.

The Cuticle
The cuticle is composed of specialized keratins and consists of 
six to eight layers of flattened overlapping cells with their free 
edges  directed  upward  to  the  tip  of  the  hair  shaft.  There  are 
several layers to each cell. The innermost endocuticle is covered 
by the exocuticle which lies closer to the external surface and is 
comprised of three parts: the b-layer, the a-layer, and the epicuti-
cle. The b-layer and the a-layer are largely protein. The epicuticle 
is a hydrophobic (water resistant) lipid layer of 18-methyleicosa-
noic acid attached by a covalent chemical bond to the surface of 
the fiber. This is commonly known as the f-layer. The f-layer is of 
critical importance to hair “health” since it affords considerable 
protection to the shaft (Figure 27.3).

The  cuticle’s  complex  structure  allows  it  to  slide  as  the 
hair  swells,  and  the  f-layer  imbues  a  considerable  degree  of 
water  resistance  (hydrophobicity).  It  is  critical  in  protecting 
the hair and rendering it resistant to the influx and outflow of 
moisture.

The  normal  cuticle  has  a  smooth  appearance,  allowing 
light  reflection  and  limiting  friction  between  the  hair  shafts. 
It is primarily responsible for the luster and texture of the hair 
(Figure  27.4).  The  cuticle  may  be  damaged  by  four  different 
“insult”  sources:  environmental,  mechanical,  chemical,  and 
heat.

Chemical  removal  of  the  f-layer  (Figure  27.5)—particu-
larly  by  oxidation  during  bleaching  or  perming—eliminates 
the first hydrophobic defense and leaves the hair more porous 
and vulnerable. If the cuticle is damaged there is little change 
in the tensile properties of hair; however, its protective func-
tion is diminished (3).

The Cortex
The cortex forms the main bulk of a fully formed (keratinized) 
hair shaft and contributes almost all the mechanical properties 
of the hair, particularly strength and elasticity.

The  cortex  consists  of  closely  packed  spindle-shaped 
cells  rich  in  keratin  filaments  comprising  400–500  amino 
acid  residues paired together  to  form protofilaments  which 

Figure 27.1  Female, age 7. Massive amounts of protein are used 
to manufacture a signaling device of youth and health.

The Terminal Hair Shaft
A single human hair is merely a bundle of compressed protein 
with  a  small  quantity  of  fats  and  traces  of  minerals  and  vita-
mins. It contains no living cells and receives no support other 
than mechanical from the follicle. The visible hair shaft has no 
active  metabolism,  yet  in  combination  with  its  neighbors  can 
exude an almost mystical vitality and strength (Figure 27.2).

There are three essential types of hair in humans which 
are age related and dependent to some extent on the size of the 
follicle.

•  Lanugo  hair  is  fine  and  non-medullated  hair  which 
appears on the fetus, and with rare exceptions is shed prior 
to or immediately after birth.

•  Vellus hair is fine (less than 40 microns in diameter), short, 
and non- or lightly pigmented and is the most numerous 
of  human  hairs.  It  can  be  seen  from  the  neonatal  period 
onward, covering all surfaces except the palms and soles 
of the feet. At puberty, some vellus hairs enlarge to become 
terminal hairs and develop sebaceous glands. Vellus hairs 
occur on the scalp but are far less numerous than terminal 
hairs.

•  Terminal  hair  is  thick  (50–150  microns),  long,  and  pig-
mented.  Terminal  hairs  are  the  dominant  hairs  on  the 
scalp, eyebrows, lashes, axillae, and genital areas. In men, 
terminal  hairs  are  variably  found  on  the  trunk  and  legs. 
There is great regional difference in terminal body hairs. 
Terminal body hair is relatively uncommon in Asians and 
more common in Indo-Europeans.

The cross section of the hair terminal shaft reveals three major 
components: the cuticle, the cortex, and (rarely, other than in 

 
HAIR CARE 

 229

Outer β-layer
(18-MEA)

d = 2.5 nm

Epicuticle

O

S

O
S

O

S

O

S

O

S

O
S

O

S

S

O

Figure 27.5  Preservation of the outer f-layer is of critical impor-
tance in maintaining “hair health” or homeostasis. Removal ren-
ders the hair shaft potentially vulnerable to further damage. See 
further  ref.  10.  (Courtesy  of  JR  Smith,  University  of  Portsmouth 
SPM Dept and P&G Beauty.)

Figure 27.3  Overlapping scales of the cuticle.

Keratin molecular

Protofibrils

Microfibril

Macrofibil

Cortical scale

Nuclear remnant

Paracortex

Orthocortex

Endocuticle

Exocuticle

Epicuticle

Cuticular scale

Cortex

Figure  27.4  Healthy  hair.  Reflection  from  the  intact  cuticles  of 
well aligned hair is largely responsible for hair shine.

Figure 27.6  The outer composition of the cortex.

make up a keratin chain. These are orientated parallel to the 
long axis of the hair shaft and embedded in an amorphous 
matrix  of  high  sulphur  proteins.  The  keratin  chains  have  a 
large  number  of  sulphur-containing  cystine  bonds  which 
create  a  strong  cross-link  between  adjacent  chains.  These 
so-called  disulphide  bonds  are  critical  in  conferring  shape, 
stability,  and  resilience  to  the  hair  shaft  and  can  only  be 
broken by external oxidative chemical agents such as occurs 
with perming or relaxing (Figure 27.6).

Weak hydrogen bonds and salt link the keratin polypep-
tide chains together. These weaker bonds are easily overcome 

by  water  rendering  curly  hair—temporarily—straight.  The 
powerful  disulphide  bonds  and  weaker  hydrogen  bonds  are 
crucial  to  hair  health.  The  cortex  contains  melanin  granules 
which  color  the  fiber  based  on  the  number,  distribution,  and 
types of melanin granules (Figures 27.7 and 27.8).

The Medulla
The medulla is a soft, proteinaceous core present in thicker and 
white hair. It has no known function in humans.

 
230 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Hair
cuticle

Microﬁbril (three
chains coiled
into one strand)

Coiled keratin
polypeptide
chain

Figure 27.7  Composition of the cortex: macrofibrils and microfibrils.

One hair cell

Keratin
macrofibril

Figure  27.8  Melanin  granules  in  the  cortex  with  overlapping 
scales of the cuticle.

(a)

(b)

Abnormal Hairs
Not all hairs are “normal.” Genetically inherited hair diseases 
may produce abnormal hairs which result in weakness and/or 
major  problems  in  grooming.  One  such  example  is  cheveaux 
incoiffable (uncombable hair syndrome; Figure 27.9).

Figure  27.9 
hair shafts.

(a)  Uncombable  hair  due  to  (b)  abnormality  of  the 

Hair texture is a less precise term but is usually classi-

Hair Diameter and Texture
The diameter of human hair varies from 17 to 180 micrometers 
(0.00067 to 0.0071 in). Hair less than 40 microns is regarded as 
vellus hair.

fied as follows:

•  Fine: less than 60 microns
•  Medium: 60–80 microns
•  Thick: 80–150 microns

 
Many  women,  on  questioning,  believe  their  hair  to  be 
finer  than  accurate  measuring  would  confirm.  This  misun-
derstanding may affect their less than ideal choice of hair care 
products.

Hair Types
Not  all  terminal  hairs  have  the  same  structural  phenotype. 
Terminal  hairs  have  traditionally  been  described  as  round, 
oval, or flat. Further, these shapes have been assigned geneti-
cally  redundant  racial  acronyms.  In  reality  there  is  a  broad 
spectrum of hair shapes and although individuals tend to bear 
essentially one type on their scalps, it has been observed that 
all three can be present.

While peoples from subequatorial Africa and their dis-
persed  descendants  have  hair  follicles  which  are  curved,  the 
final shape of the hair emerging from the follicle is more deter-
mined  by  the  activity  of  the  matrix  cells  deep  in  the  follicle 
and the manner in which the keratin proteins are laid down 
in the cortex.

The hypothesis that hair shaft shape is principally due to 
the shape of the follicle is further confounded by the ability of 
terminal hair follicles to produce different phenotypes under 
altered  circumstances.  Patients  after  chemotherapy  routinely 
report dramatic change in hair shaft phenotypes, presumably 
due to a change in arrangements of keratins in the cortex from 
a “reprogrammed” matrix.

The Concept of Aging of Hair
The  tissues  of  the  scalp  and  hair  follicle  inevitably  age  and 
their  activity  declines.  The  proliferative  tissues  in  the  hair 
matrix are subject to the intrinsic factors associated with con-
stant  metabolic  activity  and  natural  (chronological)  aging. 
External  (extrinsic)  factors  may  also  impact  on  the  quality  of 
hair  produced.  These  factors  inevitably  occur  in  conjunction 
and are cumulative over time.

Intrinsic factors are overwhelmingly inherited and result 
in, for instance, male pattern balding and premature greying. 
Extrinsic  factors  include  the  effects  of  ultraviolet  radiation 
(UVR), smoking, and possibly nutrition.

As  a  result  of  continuous  metabolic  activity,  highly 
reactive  oxygen  molecules  (ROS)  are  generated  in  the  cells, 
leading  to  oxidative  stress  which  is  now  believed  to  play 
a  major  role  in  the  aging  process.  The  damaging  effects  of 
these ROS are induced from the mitochondria in the matrix 
cells and melanocytes and externally from the environment. 
The follicle possesses enzymes and vitamins (E and C) which 
help to quench the ROS. Eventually, the ROS overwhelm the 
defenses  leading  to  damage  to  the  active  cells.  The  effects 
of this are seen as greying and an imperceptible but steady 
decrease  in  hair  production  both  in  terms  of  quantity  and 
quality.

Allied to this concept is that of hair shaft “aging.” Hair 
as it emerges from the follicular opening is in its most perfect 
state. As this growth progresses, the hair shaft quality deterio-
rates or “ages” due to external factors such as environmental, 
chemical, and physical insults. The process is known as weath-
ering and is the most common hair disorder encountered. The 
combined effect of the intrinsic and  extrinsic  factors at a  fol-
licular  level  and  extrinsic  aging  of  the  shaft  is  to  render  the 
hair thinner, weaker, and less “healthy.” This concept of hair 
aging has become important in the development of hair care 
products targeted to meet both intrinsic and extrinsic aging.

HAIR CARE 

 231

Hair Thinning: Reducing Hair Density, Diameter, and Hair Mass
A common complaint of women as they age is that of losing 
hair density, or in common parlance, thinning. This may be 
manifest as a tangible loss of bulk, a visible scalp, or reduc-
tion  in  the  volume  of  a  ponytail.  It  is  often  difficult  for  an 
observer,  stylist,  or  dermatologist  to  interpret  early  thin-
ning, particularly if there is no evidence of greater than nor-
mal  daily  hair  loss.  By  the  time  this  reduction  in  total  hair 
mass is apparent, some 50% loss of hair may have occurred 
(Figure 27.10) (5).

Hair Density
At all ages, there is a wide and normally distributed scatter of 
hairs over the scalp. Possibly as a result of the impact of ROS 
described  above,  density  in  women  gradually  declines  from 
293 cm-2± at age 35 to 211 cm-2± at age 70.

Hair Diameter
Mean hair diameter increases from age 22 to a peak in the mid-
30s but gradually declines with advancing age (Table 27.1). In 
addition, some follicles cease functioning altogether.

As  an  individual  ages,  the  keratin  production  slows 
and  the  hair  shaft  becomes  thinner  with  a  mean  diameter 
of  terminal  hairs.  Finally,  the  interval  between  cessation  of 
growth of one hair and the commencement of a new (keno-
gen) extends (4).

All these factors contribute to a gradual reduction in hair 
mass caused by reduced number of hairs, reduced diameters, 
and  extended  intervals  of  growth.  This  perception  or  reality 
of  reduced  hair  density  can  have  a  major  impact  on  the  self-
perception of healthy hair and self-esteem (3).

Figure 27.10  Visible scalp indicates up to 50% hair loss.

 
232 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 27.1  Mean Hair Diameter Increases from Age 22 to a 
Peak in The Mid-30s but Gradually Declines with Advancing 
Age (4)

Age
(Indo-European Women)

Average 
Hair Density
(hairs/cm2)

Delta (%) in 
Density
vs Age 30

30

40
50
60
70
80

290

270
263
235
211
185

–6.8
–9.3
–18.9
–27.2
–36.2

Phenotype and Hair Health
The shape of the shaft(s) has significant implications for long-
term hair health. Increased susceptibility of the cuticle to phys-
ical  damage  is  more  common  in  flatter  hair.  The  greater  the 
diameter of the cortex, the greater the the resistance of the hair 
shaft to environmental and self-inflicted damage.

HAIR DAMAGE: NATURAL AND 
ACCELERATED WEATHERING
For most adults, there is both a natural and progressive dete-
rioration in the internal and external condition of the hair shaft 
over time. This is the result of environmental and self-inflicted, 
repeated  damage.  This  process,  known  as  weathering,  can 
vary from minimal to extreme (Figure 27.11).

In young women who do not use chemical processes or 
excessive heat on their hair, this weathering process is almost 
impossible  to  detect  with  the  naked  eye.  In  women  with 
repeated chemical applications, the damage (Figure 27.12), par-
ticularly at the tip, is evident.

Modern  research  techniques  (P&G  data  on  file)  now 
allow  hair  scientists  and  researchers  to  examine  the  break-
down  of  the  structures  of  the  hair  at  a  nano  scale  (i.e.  the 
breakdown of chemical bonds). It is possible to extrapolate not 
only how these breakdowns result in changes in a single fiber 
marker (such as loss of tensile strength) but how these single 
fiber changes impact bulk properties, such as noticeable shine. 
The extent of the structural changes and their manifestations 
will vary depending on the morphology of hair—i.e. diameter 
and curl—and on the prevailing hair style (long vs short).

The Process of “Weathering”
Hair  is  an  exceptionally  resilient  structure  able  to  withstand 
many  differing  traumas—environmental,  mechanical,  physi-
cal, and chemical. In the 21st century, in spite of this resilience, 
badly  weathered  hair  is  epidemic,  particularly  in  the  devel-
oped world (Figure 27.13).

When hair first emerges from the scalp, the cuticle con-
sists of up to ten layers of long “scales.” However, the cuticular 
layers are only 3 or 4 µm thick and may have to last for 6 years 
or more.

Natural weathering involves a wearing away of the cuti-
cle of the hair shaft, primarily from physical acts of grooming.
Accelerated weathering occurs as a result of additional 
and excessive physical and most importantly, repeated chemi-
cal  injury.  This  accelerated  weathering,  which  is  generally 
regarded  as  “damage,”  involves  destruction  not  only  of  the 
f-layer  and  damage  to  the  cuticle  but  ultimate  exposure  and 

(a)

(b)

Figure 27.11 

(a) Minimal and (b) severe weathering.

degradation  of  the  proteins  in  the  cortex.  The  latter  becomes 
increasingly  unable  to  maintain  the  structural  and  homeo-
static integrity of the hair and at its most extreme, the hair pro-
teins may unravel, causing split ends or breakage in mid-shaft 
(Figure 27.14).

Sources of Damage
Major  damaging  sources  include  wetting,  friction,  sunlight, 
heat from drying and styling appliances, chemicals, and heavy 
metals in swimming pools and in the home. Most devastating 

 
HAIR CARE 

 233

Figure 27.12  Difference in integrity from root (a) to tip (b).

(a)

(b)

(a)

(b)

Figure 27.13 

In the 21st century, badly weathered hair is epidemic. (a) Copenhagen, (b) New York, (c) South Africa, (d) Singapore.

(c)

(d)

are  chemical  procedures,  notably  bleaching,  perming,  relax-
ing,  and  straightening.  Other  insults  are  due  to  poor  habits 
and practices and include physical damage from brushing and 
combing and the use of excessive heat from implements such 
as  blow  dryers  and  flat  irons.  It  is  now  recognized  that  poor 
brushing and combing are more detrimental than previously 
thought.

Causes of Hair Damage
Figure  27.15  shows  an  average  exposure  to  these  various 
insults over 1 year, which equates to approximately 12—15 cm 
of growth. In Figure 27.15 the types of damage have been color-
coded to four main processes—environmental, physical, heat, 
and chemical. These insults do not occur in isolation. The final 
damage to hair is due to a combination of all these factors, their 

 
 
  
 
  
 
  
234 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(c)

(d)

Figure 27.14  EMGs of progressive severe weathering to a hair shaft. (a) Root, (b) mid-shaft and (c) tips, and (d) trichorhexis nodosa 
from a woman with 15-cm length hair.

up to 6
coloring
treatments

>100 hrs
heat
implements

>1000 hrs
UV
exposure

Healthy
Hair

up to
10,000
brush
strokes

> 1200 L
water

Environmental processes

Physical processes

Heat processes

Chemical processes

up to 200
washes

Figure 27.15  Causes of hair damage. (Data courtesy of P&G.)

frequency and intensity. If a woman possesses hair of 40 or 50 
cm length, there may be 4 or 5 years of these cumulative insults 
on the hair ends.

Most of these insults impact at the nanostructural level 
by causing changes to protein and lipid structures. The insults 
themselves cannot be detected but can be measured by tech-
niques such as roteomics and lipidomics that identify the exact 
structural changes. As a result there are micro-structural and 
single-fiber  changes  that  will  eventually  manifest  as  mac-
rostructural  or  bulk  hair  changes.  As  an  increasing  number 
of  fibers  lose  cuticles,  the  cortex  will  eventually  be  exposed, 
which further reduces shine and will increase the propensity 
of hair to form split ends. As more protein damage occurs, the 
tensile  strength  of  hair  will  decrease  and  eventually  lead  to 
breakage,  which  women  will  then  notice  as  additional  hairs 
in the brush or as a lack of smoothness from the broken ends 
(Figure 27.16).

 
 
  
 
  
HAIR CARE 

 235

(a)

(b)

Figure  27.16  Disruption  of  the  normal  structure  and  physiology  of  the  hair  shafts  results  in  dry  (a),  weak  (b),  and  unmanageable 
(c) heads of hair lacking shine.

(c)

COSMETIC HAIR CARE PRODUCTS
Selection  of  the  correct  products  from  the  plethora  avail-
able  is  not  necessarily  intuitive.  The  desire  for  constant 
change, which is a hallmark of the age, leads to constantly 
changing  to  different  product  ranges.  Research  demon-
strates  that  this  offers  no  advantage  and  indeed  is  poten-
tially deleterious. A clear understanding of the state of the 
hair, selection of the correct regimen type to address this, 
and  the  regular  use  of  these  products  is  the  key  to  pro-
longed hair health.

To  restore  and  maintain  healthy  hair  an  appropri-
ate  regimen  is  necessary.  This  is  a  combination  of  prod-
ucts  selected  for  an  individual’s  hair  type,  desired  end 
benefit,  and  which  fits  with  their  lifestyle  and  economic 
circumstance.

Hair Care Regimens
A basic haircare regimen includes a shampoo, a range of con-
ditioning variants, and ancillary products such as serums, heat 
protectors, smoothing agents, and styling products.

HAIR CARE PRODUCTS FOR 
DIFFERENT HAIR NEEDS
The cosmetic industry takes certain factors into account when 
designing a regimen for different needs and which to a large 
measure are independent of regional stereotypes, although in 
areas such as the Americas and increasingly in Europe, all phe-
notypes are present in the marketplace.

Product ranges are now principally designed to manage, 
fine, thick, curly, and chemically damaged hair wherever they 
occur and whatever the hair phenotype.

SHAMPOOS
Early  products  were  relatively  inefficient  and  many  were 
harsh  to  the  cuticular  surface,  the  skin,  and  the  eyes.  Today 
such products are highly efficient, aesthetically pleasing, and 
mild to the surfaces they touch. In addition to removing sebum 
from the hair and the detritus it inevitably collects, many now 
contain  ingredients  designed  to  enhance  the  natural  prop-
erties  of  hair  and  mitigate  environmental  and  self-inflicted 
damage. Products carry ingredient labels in compliance with 
worldwide and company regulations (Figure 27.17). Hair-care 

 
 
  
236 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 27.17  Products carry ingredient labels in compliance with 
worldwide and company regulations.

products,  in  comparison  to  skin  care,  are  inexpensive  and 
widely distributed.

General Attributes of Shampoos
Shampoo  formulations  seek  to  maximize  the  following 
qualities:

•  Effective cleaning
•  Easy rinsing
•  Good finish after washing hair
•  Pleasant  in-use  aesthetics  (lather,  product  thickness,  per-

fume, etc.)

•  Minimal skin/eye irritation
•  No damage to hair
•  Outstanding safety profile
•  Good biodegradability

Modern Shampoo Formulations
Shampoos  are  invariably  an  aqueous  (water-based)  product 
and consist of three major components:

1.  Primary  surfactants  for  removing  dirt  and  foaming 

power

2.  Secondary surfactants to improve and condition the hair
3.  Additives which complete the formulation and add spe-
cial aesthetic effects and endow secondary benefits such 
as volume and shine

Surfactant  Mode  of  Action  Both  soaps  and  shampoos  contain 
surfactants—compounds  that 
lower  the  surface  tension 
between  a  liquid  and  a  solid.  They  may  act  as  detergents  (a 
mixture  of  surfactants  with  cleaning  properties  in  dilute 
solutions),  wetting  agents,  emulsifiers,  foaming  agents,  or 
dispersants.

Soaps can bind to oils with such affinity that they removes 
too much if used on hair. Shampoos use certain surfactants bal-
anced to provide the level of surface cleaning suited to hair fibers. 
These  surfactant  systems  are  called  syndets—synthetic/deter-
gents which are manufactured with a range of properties (6).

Mode  of  Action  Undamaged  hair  has  a  negatively-charged 
hydrophobic  (water-resistant)  surface  to  which  lipids  (fats) 
adhere but from which water is initially repelled. Sebum and 

detritus are not easily removed when the hair is rinsed with 
plain water. Shampoo applied to wet hair is absorbed into the 
oil/hair interfaces.

A  surfactant  inherently  moves  toward  “surfaces”  and 
cleans  hair  by  removing  dirt  and  oils  (sebum)  that  are  not 
water soluble. It also forms a lather, which is a signal desired 
by many that the shampoo is working.

A surfactant has a head group that is hydrophilic (water 
loving/oil hating) and a tail group that is hydrophobic (water 
hating/oil  loving).  Surfactants  will  either  migrate  to  the  air/
water  interface  or  to  an  oil  material,  with  their  hydrophilic 
head group toward the water and the hydrophobic tail group 
toward the oil or air. The surfactant will try to surround the oil 
droplet and in doing so will lift it off the surface, where it will 
be rinsed off down the drain (Figure 27.18).

The  three  types  of  surfactants  or  detergents  found  in 

shampoos are anionic, nonionic, and amphoteric.

(a)

(b)

(c)

Figure 27.18 (a) Surfactant molecules with hydrophilic heads act 
by (b) removing the dirt from the hair with a lipophilic (fat-loving) 
component and (c) transferring it to the rinse water with hydrophilic 
(water-loving) component.

 
 
 
 
•  Anionic: These have a negatively charged hydrophilic com-
ponent and are mainly used as primary surfactants. Laureth 
sulfates and lauryl sulfates are often used to gently cleanse. 
They are highly effective and possess the foaming properties 
desired by  the consumer. Products which do not  foam  are 
often regarded as “ineffective” and may reduce compliance.
•  Nonionic: These surfactants condition the hair and perform 
gentle cleansing. They can increase the quality of lather in a 
shampoo as well as its viscosity and solubility. They can be 
added to for mildness or improve the anti-static qualities of 
a shampoo, e.g., ethoxylated fatty alcohols.

•  Amphoteric: These surfactants contain a balance of posi-
tive  and  negative  charges.  They  are  very  mild  cleansers. 
They  condition  the  hair  but  are  generally  less  effective 
cleaners  than  anionic  surfactants.  They  are  also  non-irri-
tating to the eyes, which is why they are commonly used 
in baby shampoos.

Key Ingredients of Shampoos
The key ingredients of shampoos are described and the chemi-
cal names found on products are included in Table 27.2.

Specialized Shampoos
Anti-Dandruff 
In  addition  to  regular  shampoos,  the  most 
popular  scalp  products  sold  worldwide  are  targeted  at 
preventing  dandruff,  a  condition  which  affects  over  half  the 
adult  population  at  some  time  in  their  lives.  Actives  such  as 
zinc pyrithione, climbazole, and salicylic acid are used in both 
shampoos  and  conditioners  to  improve  scalp  health  by  the 
elimination  of  the  putative  fungus  malassezia  globosa  and 
reduce surface sebum levels. If used regularly they can prevent 
signs and symptoms of dandruff.

Conditioning (2-in-1) Shampoos  Combination, or 2-in-1, products 
were developed first by Procter and Gamble in the late 1980s and 
delivered for the first time cleansing and conditioning benefits 
from  a  single  product  source.  Since  this  innovation,  it  has 
become possible and commonplace to incorporate conditioning 
ingredients into shampoos—primarily to prevent tangling but 
also to facilitate styling.

The challenge was to deliver conditioning actives from 
a  product  that  has  to  both  clean  hair  and  deposit  condition-
ing ingredients onto the hair surface. The main mechanism of 
achieving this is via a coacervate formation wherein an anionic 
polymer is formulated with a surfactant and silicone to deposit 
the silicone on hair as the shampoo is diluted during rinsing.

There exists a range of polymers that can be used for this 
including  natural  polymers,  celluloses,  and  synthetic  poly-
mers. These play a role in creating the coacervate (a miniscule 

Table 27.2  Key Ingredients of Shampoos

HAIR CARE 

 237

spherical droplet of assorted molecules which is held together 
by hydrophobic forces from a surrounding liquid). This enables 
deposition of silicone on hair but in some cases can imbue wet 
feel benefits (Figure 27.19). Consequently, hair can feel smooth 
during shampooing and with decreased friction forces.

Shampoos for Children  Shampoo for infants is formulated so that 
it is the same pH level as the eye, making it less irritating if it were 
to get into the eyes. Most contain sodium laureth sulfate and/
or sodium lauryl sulfate. Alternatively, infant shampoos may be 
formulated using other classes of surfactants, most notably non-
ionics, which are much milder than any charged anionics used.

Moisturizing  Shampoos  Moisturizing  products  are  a  huge 
need  globally  and  across  all  hair  types.  Moisturization  is 
not  the  same  as  adding  moisture  to  hair  and  is  more  about 
delivering a soft and conditioned feel. It has been shown that 
hair with higher moisture actually feels drier than hair with 
low moisture levels. The benefit can be delivered at different 
levels  depending  on  the  product.  There  are  very  intense 
formulations for women with very damaged and dry hair and 
lightweight versions for women who want conditioned feel but 
are concerned about a tradeoff of weigh down.

Shampoos for Color-Treated Hair 
In recent years products have 
become more advanced in terms of efficiency of deposition of 
conditioning  actives  and  also  adjustment  to  different  needs. 
Of  particular  interest  have  been  shampoos  and  conditioners 
designed for women who color and chemically treat their hair. 
Not  only  will  these  women  potentially  have  more  physical 
damage  in  terms  of  split  ends,  etc.,  but  the  efficiency  of 
deposition  of  silicones  such  as  dimethicones  on  colored  hair 
is significantly lower than on non-colored hair. This is driven 
by  surface  energy  changes  that  occur  during  coloring  and 
specifically  the  increase  in  surface  hydrophilicity  caused  by 
loss of the surface bound f-layer lipid.

Polymers are also being used in shampoo formulations to 
enhance silicone deposition on previously colored hair. As an 
example, a high charge density polymer, poly(diallyldimethyl) 
ammonium  chloride,  on  dilution  forms  a  hydrophobic  layer 
on hair, enhancing silicone deposition from both the shampoo 
itself and from the subsequent conditioner.

CONDITIONERS
The  concept  of  conditioning  hair  is  not  new.  Essential  oils 
(tea  tree,  jojoba)  were  used  historically  and  continue  to 
this  day.  The  Victorians  were  keen  on  Macassar  oil  and 
invented  the  antimacassar  cover  for  chair  backs  to  prevent 
greasy  residue.  Brilliantine  is  largely  regarded  as  the  first  of 

Material class

Name to look for on products

Function

Surfactant

Silicone

Polymer

Additional ingredients

Sodium lauryl sulfate
Sodium laureth sulfate Cocamidopropyl betaine

Cleans sebum, dust, and dirt from hair as well as 
previously applied product (e.g. gels, hairsprays)

Dimethicone

Polyquaternium-76
Guar hydroxypropyltrimonium chloride
Polyquaternium-6
Hydroxypropyl methylcellulose
Panthenol
Vitamin E
Trisodium ethylenediamine disuccinate

Provides lather
Makes hair easier to comb, softer and smoother
Increases shine by increasing fiber-to-fiber alignment
Provides wet feel
Aids in depositing silicone conditioning materials on hair

Targeted benefits, e.g. moisturization, antioxidant, 

chelant for UV protection

 
238 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 27.19  Deposition of silicones onto negatively-charged surface of the damaged hair from a 2-in-1product.

(a)

(b)

modern  conditioners  but  was  largely  employed  for  softening 
moustaches.

The practice of regular conditioning after shampooing is 
relatively recent and still not part of a global culture. In light of 
worldwide coloring and bleaching in addition to daily weath-
ering, conditioning hair is critical to its sustained health as it 
inevitably weathersin an accelerated manner.

Early  “conditioners,”  which  were  equivalent  to  greasy 
pomades, offered protection against the harsher effects of relax-
ers, permanents, straighteners, and colorants. Modern intensive 
conditioners can be formulated in a range from light to heavy 
and  have  much  greater  aesthetic  properties.  If  used  regularly 
they can obviate the effects of chemical and physical processes.

Conditioners’ Mode of Action
A conditioning product deposits actives onto the surface of the 
hair shaft. It typically does this by creating a lamellar gel network 
structure composed of fatty alcohol and cationic surfactants with 
silicone suspended in the hydrophobic part of the gel network.

During product application the gel network spreads on 
hair, giving a very smooth feel, reducing knots and tangles. As 
the product then dries the silicone spreads evenly over the hair 
surface forming a thin layer and increasing surface hydropho-
bicity. This hydrophobic layer will change hair feel, especially 
when hair is dry, giving it a smooth, soft feel, and it will reduce 
hair  friction  and  combing  forces  (Figure  27.20).  Importantly, 
this  will  also  reduce  knot  and  tangle  formation  and  reduce 
combing breakage.

Early  silicone  products  were  limited  by  the  ability  of 
formulators  to  include  this  type  of  technology  into  aqueous 
solutions.  In  the  last  20  years  there  has  been  an  explosion  in 
silicone technology such that one recent innovation has been 
the  introduction  of  functionalized  silicones  such  as  terminal 
amino silicones (TAS) which add amine groups to the end of 
the  silicone  chains.  By  more  closely  matching  the  interfacial 
tension  of  the  silicone  to  the  surface  energy  of  hair,  the  TAS 
silicone materials will deposit significantly better onto colored 
and damaged hair than uncharged silicones like dimethicone. 

(a)

(b)

Figure 27.20  Deposition of conditioning actives by creation of a 
lamellar gel network.

 
 
  
These  materials  also  have  an  additional  benefit  of  improved 
ability to deposit on severely damaged hair tips than previous 
dimethicone silicones.

Different Conditioning Variants
The  level  of  conditioning  benefit  can  be  increased  by  vary-
ing  the  levels  and  types  of  silicones  and  cationic  surfactants 
used  (in  general  longer  chain  surfactants  deliver  higher 
conditioning).

•  “Intensive” conditioners are heavy and creamy in consis-
tency since they contain high proportions of fatty alcohols, 
and  are  well  suited  to  hair  that  is  significantly  damaged 
or  coarse.  Such  conditioners  can  be  left  in  the  hair  for  a 
long  time,  and  can  temporarily  hold  split  ends  together 
(Figure 27.21).

•  “Leave-in”  conditioners  tend  to  contain  lighter-weight 
conditioning materials, which add little weight to the hair 
(Figure 27.22).

Figure 27.21 
(see ingredient listing) designed for significantly damaged hair.

Intensive conditioner. High levels of fatty alcohols 

Figure 27.22  Rinse-out conditioner; part of the regimen for thin-
ning hair.

HAIR CARE 

 239

There  are  also  “hold”  conditioners,  which  are  combination 
products that provide the benefits of conditioning while also 
holding the hair in place like a mousse. This effect is achieved 
using cationic polymers.

Conditioning Products in Ethnic Usage
In  Africa  many  women  who  retain  their  natural  phenotype 
employ  light  conditioning  agents  as  their  primary  hair  care 
product. As the essential need is for moisturization rather than 
cleansing, this by experience is often their  preferred method 
of hair care.

Oil Inclusion in Conditioning Products
Oils have a long history of use in hair care and are invariably 
culturally  based.  This  history  has  driven  the  introduction  of 
natural oils into modern hair care products to deliver dry and 
wet feel benefits. In some cases these ingredients supplement 
silicones.  Examples  of  these  oils  include  argan  oil,  Moroccan 
oil, and coconut oil.

Other ingredients in modern conditioners and hair care 
preparations similarly work to smooth the outer layers of the 
cuticle. These may include protein extracts (collagen, and the 
amino  acids  obtained  from  silk)  and  panthenol  and  similar 
compounds,  which  are  related  to  vitamin  B5.  Some  of  these 
are known to penetrate into the cortex and to help to increase 
its moisture content. Keratin or hydrolyzed keratin is another 
common  ingredient  added  to  products.  Keratin  proteins  will 
typically  not  readily  penetrate  inside  hair  due  to  their  large 
size. Hydrolyzed keratins are more likely to penetrate but nei-
ther active will replace lost proteins.

Key Ingredients of Conditioners
The  key  ingredients  of  conditioners  are  described  and  the 
chemical names found on products are included in Table 27.3.

Silicones
Silicones  are  an  example  of  polymers  and  are  now  widely 
used as ingredients in hair conditioners, shampoos, and hair 
gel  products.  They  are  synthetic  and  chemically  inert.  Some 
silicones, notably the amine functionalized amodimethicones, 
are excellent conditioners, providing improved compatibility, 
feel,  and  softness,  and  lessening  frizz.  The  phenyltrimethi-
cones  is another silicone  family  and these  are used  in  reflec-
tion-enhancing and color-correcting hair products, where they 
increase shine and glossiness.

Ethnic and Cultural Differences 
in Conditioning Preferences
The level of conditioning required to achieve optimum desired 
performance will depend on the hair phenotype and morphol-
ogy (curl, diameter, etc.), hairstyle, and the level of hair dam-
age. In general women with European phenotype hair tend to 
prefer lower-conditioning products more suitable for their fine 
hair (Figure 27.23). Women African descent tend to prefer high- 
conditioning products that give high protection against knots 
and tangles (Figure 27.24). Indian and Asian women will also 
tend to prefer high-conditioning benefits to drive a high shine, 
smooth look (Figure 27.25).

Special Hair Needs
Dry, woolly hair generally requires heavier deposits of condi-
tioners than other hair types. The use of leave-in and “inten-
sive”  conditioners  is  growing.  The  use  of  moisture-retaining 

 
240 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 27.3  Key Ingredients of Conditioners

Material class

Silicone

Cationic surfactant

Fatty alcohol

Oil/emollient

Additional ingredients

Name to look for on products

Dimethicone
Amodimethicone
Bis-aminopropyldimethicone

Stearamidopropyldimethylamine
Behentrimonium methosulfate
Behentrimonium chloride
Dicetyldimonium Chloride

Cetyl alchol
Stearyl alcohol
Cetearyl alcohol (mix of cetyl and stearyl alcohol)

Hydrogenated coconut oil
Mineral oil
Argan oil
Moroccan oil
Panthenol
Vitamin E

Function

Makes hair easier to comb, softer and smoother
Increases shine by increasing fiber to fiber 

alignment

Positively charged molecules preferentially 

attracted to areas of damage

Makes hair easier to comb, softer and smoother 

and less static

Gives hair a smooth fee when dry and improves 

wet combing

Give products a thick, creamy appearance

Moisturizes hair to improve softness

Targeted benefits, e.g. moisturization, antioxidant

(a)

(b)

Figure  27.24  Women  of  African  heritage  tend  to  prefer  high-
conditioning products that give high protection against knots and 
tangles.

In general women with European phenotype hair 
Figure 27.23 
tend to prefer lower conditioning products more suitable for their 
fine hair.

ingredients (humectants) such as panthenol can be augmented 
by  cationic  ingredients  (e.g.,  polyquarternium  derivatives), 
which leave hair more manageable.

How to Select the Correct Hair Care Regimen
One of the major concerns women have for hair care prod-
ucts is choosing the correct one for their hair type and style. 
Too low a conditioning level will not deliver the feel, shine, 

 
HAIR CARE 

 241

(a)

(b)

(c)

Figure 27.25 

Indian and East Asian women tend to prefer high-conditioning benefits to give a high-shine, smooth look.

and  frizz  benefits  they  desire  but  too  high  a  conditioning 
level  may  create  weighed  down  hair  and  a  greasy,  sticky 
feel and look. These negatives can be an issue when a high-
conditioning  product  is  used  on  fine  and/or  straight  hair. 
To help women avoid these issues, version names are being 
chosen to indicate a desired benefit and the level of condi-
tioning is commensurate with this and the assumed state of 
the hair.

Products may be labeled as a collection (regimen) under 
the following main benefit categories (from lowest to highest 
moisture capability):

•  Volume
•  Clean
•  Defined curls
•  Smooth
•  Moisture
•  Strength/anti-breakage
•  Color
•  Damage repair

Within  these  broad  categories  will  be  a  range  of  shampoos 
(including  clarifying),  conditioners  of  varying  intensity,  and 
styling  products  including  mousses,  gels,  heat  defense,  hair-
sprays, and serums.

Volume
Women in this category tend to have finer, thinner hair texture 
or  shorter  length,  desire  more  cleaning,  and  wash  more  fre-
quently. They tend to use blow dryer, curling iron, and styling 
products to create and keep desired look.

Women state that they want to achieve healthy volume, 
but find their flat, lifeless hair is also prone to overstyling and 
overconditioning. These products tend to have low condition-
ing levels and contain polymers which add lift at the root. They 

are  suitable  for  women  with  fine  hair/low  volume/undam-
aged hair (Figure 27.26).

Technical  Solution:  The  technical  solution  for  women 
requiring volume is to increase cleaning and lather cushion for 
detangling  without  depositing  undue  levels  of  conditioning 
agents on the hair. Consequently, products incorporate:

1.  Higher surfactant levels, to increase cleaning
2.  Cationic  polymer,  to  improve  lather  cushion  and  detan-

gling but rinse clean to prevent deposition onto the hair
3.  Low  or  no  silicone,  to  minimize  deposition  on  the  hair 
shaft in order not to weigh down the hair mass and allow 
hair’s own natural conditioning to provide volume

Moisture or Smooth
Women seeking this benefit tend to have hair texture ranging 
from fine to coarse and would probably include hair which is 
dry  with  slight  damage  from  heat  and  coloring.  Such  hair  is 
susceptible to changes in humidity Women desire an improve-
ment in hair feel through balancing conditioning with clean-
ing. Shine is a requirement.

Products for these benefits are likely to have higher con-
ditioning levels and are suitable for women with a degree of 
damage and a tendency to develop frizz and flyaways. Women 
with  unruly  hair  prone  to  dryness  or  frizz  would  normally 
find a variant in this category (Figures 27.27 and 27.28).

Technical Solution:

1.  Higher  molecular  weight  cationic  polymer  to  provide 
more hair lubricity, detangling, and silicone deposition.
2.  Silicone,  which  provides  increased  wet  detangling  and 
excellent dry conditioning with less weight on the hair

3.  Oils are often added to minimize frizz and flyaway

 
 
  
 
  
242 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 27.26  Women with finer, thinner hair texture (a) and with shorter length (b) tend to wash more frequently.

(a)

(b)

Figure 27.28  Products for these benefits are likely to have higher 
conditioning  levels  and  are  suitable  for  women  with  a  degree  of 
damage and a tendency to develop frizz and fly-away.

Figure 27.27  Products for these benefits are likely to have higher 
conditioning  levels  and  are  suitable  for  women  with  a  degree  of 
damage  and  a  tendency  to  develop  frizz  and  fly-away.  Women 
with  moderately  unruly  hair  prone  to  dryness  or  frizz  would  nor-
mally find a variant in this category.

Damage Repair
Women in this category tend to have hair with high levels of 
damage  from  overprocessing  and  overstyling  (Figure  27.29). 
They  seek  high  conditioning  levels  from  products  but  also 
need sufficient cleaning, as they are likely to be using multiple 
steps. A technical challenge for this level of damaged hair is 
the strong negative charge it carries, so the deposition efficacy 

of  silicone  is  low.  These  products  will  have  the  highest  con-
ditioning  levels  and  are  almost  mandatory  for  women  with 
repeated bleaching where the hair is fragile, porous, and prone 
to tangling and breakage.

This category would include intense conditioners includ-
ing “masques,” heat defense serums, and potentially special-
ized products to manage severely damaged tips. The different 
conditioning  materials  in  Table  27.3  are  generally  specific  to 
the product used to deliver the benefit.

Technical Solution:

1.  Higher  level  of  cationic  polymers  to  protect  hair  during 

washing and wet combing (Figure 27.30)

2.  Silicones  to  give  high  levels  of  dry  conditioning  and  a 

moisturized, smooth feel.

 
 
  
HAIR CARE 

 243

Summary
Conditioning  materials  are  formulated  as  emulsions  and  are 
traditionally applied after shampooing to increase hair “qual-
ity”  before  grooming.  They  reduce  negative  charge,  prevent 
flyaways, increase manageability, and hence reduce tangling. 
Other ingredients are classed as humectants—essentially, they 
have  the  ability  to  increase  moisture  content  and  minimize 
moisture movement in and out of the hair.

Modern, high-quality conditioners increase the manage-
ability, shine, and moisture content of each hair shaft and are 
designed to provide one or more of the following functions:

Increase the ease of wet and dry combing

• 
•  Smooth, seal and realign damaged areas of the hair shaft; 

minimize porosity;
Impart sheen and a silken feel to hair

• 
•  Provide some protection against thermal and mechanical 

damage
•  Moisturize
•  Add volume and body
•  Eliminate static electricity

STYLING AND HAIR HEALTH
For most women, a “good” cut, utilizing the intrinsic nature of 
the hair and its patterns, is the first essential step for good style. 
Prior to this is the necessity for cleansing and regular condition-
ing, particularly if the hair is subjected to repeated insults.

Each  day,  millions  of  women  strive  to  achieve  their 
desired style for work and recreation. In order to do this they 
may  employ  nothing  other  than  natural  drying  or  alterna-
tively, a wide range of implements and products.

The application of physical forces on the hair (combing, 
brushing, teasing, backcombing) and the use of heat (natural 
or  forced  drying,  direct  heat)  have  potentially  serious  conse-
quences  for  the  hair  shaft,  especially  since  these  actions  will 
most likely be repeated thousands of times. The judicious use 
of  moisturizing  detanglers  and  heat  protection  sprays  can 
improve the quality and integrity of the hair shafts and help in 
the preservation of hair health.

The  technologies  behind  these  products  is  described 

here along with a practical guide to their use.

Styling Problems
Of all the various issues with hair styling, time and the intrin-
sic  nature  of  each  woman’s  hair  are  the  most  problematic. 
Hair  phenotype  dictates  what  is  easily  achieved.  Whatever 
the  issue,  modern  hair  care  products  applied  correctly  and 
regularly can contribute significantly to the improvement of 
these situations.

Certain  hair  phenotypes  have  inherent  problems—
Northern European hair is very fine and tends to lankness and 
lack of body. Very curly, dry hair suffers from physical groom-
ing  problems.  Indian  and  Asian  women  typically  desire  a 
smooth and sleek look but many have a considerable hair mass 
and  even  significant wave  which requires  excessive  amounts 
of time to manage. Wavy or very curly Caucasian hair suffers 
from frizz and flyaways and needs products to control it.

Volume Control
Control of “volume” is the most common driver for “styling.” 
Volume in the broadest sense implies either too little or too 

Figure 27.29  Women in this category tend to have hair with high 
levels of damage from overprocessing and overstyling.

Figure 27.30  Products contain polymers which help define even 
the most challenging of natural curls.

Other categories as listed below will have carefully bal-
anced cleansing and conditioning products aimed at address-
ing the prime concern of the woman.

Strength
These products are designed for the woman with a significant 
breakage problem.

Curls
Products contain polymers which help define natural curls.

 
244 

 TEXTBOOK OF COSMETIC DERMATOLOGY

much. It may be the desire to increase volume for those with 
fine  or  thinning  hair,  or  it  may  be  the  control  of  wayward 
curls.  The  desire  to  control  volume  and  keep  it  in  a  day-
long style is the ultimate end benefit for millions of women 
(Figure 27.31).

(a)

(b)

(c)

Figure  27.31  Three  volume  problems:  (a)  not  enough,  (b)  too 
much, and (c) managing curls.

Factors Influencing Hair Volume
The key factors affecting volume are:

•  Diameter
•  Density
•  Stiffness
•  Friction
•  Cohesion

For  women  with  fine  to  medium  hair  who  desire  to  increase 
or  control  volume  there  are  a  number  of  strategies  which  in 
combination  with  styling  and  heat  protection  products  can 
produce the desired end benefit.

Blowdrying
With  the  introduction  of  precision  cutting  techniques  in 
the  1970s,  blowdrying  became  universally  popular  in  the 
salon  and  at  home.  The  blowdryer  works  by  using  a  heated 
air flow (up to ~80ºC) to first rapidly remove water between 
hair  strands.  It  then  evaporates  water  from  inside  each  hair 
strand, at which point the hair can be shaped into the desired 
style, forming a “wet set.” The wet set is improved by evapo-
rating  as  much  water  as  possible,  and  inadequate  drying  is 
one  reason  style  does  not  hold.  How  long  the  wet  set  will 
keep its style during the day depends to some extent on the 
temperature and humidity. At high relative humidity, mois-
ture in the air will penetrate hair, break temporary hydrogen 
binds holding the style in place, and the hair will revert back 
to its natural shape.

Flat/Curling Irons
Flat irons or curling irons are also used to achieve the desired 
volume. These implements can reach temperatures up to 220ºC 
and are effective at removing water and creating a very effec-
tive  wet  set.  However,  these  implements  can  cause  signifi-
cant damage, especially if used at a high temperature setting 
or  used  for  an  excessive  amount  of  time  (Figure  27.32).  Care 
should be taken to keep the heat setting below 190ºC and limit 
the number of passes.

Heat  protection  products  can  help  reduce  damage  by 
smoothing  the  hair  surface,  making  it  easier  to  pass  the  flat 
iron through hair and reduce localized heating.

Temporarily Increasing Hair Friction for Volume
There are three ways of temporarily increasing friction, which 
also helps increase volume and fullness:

1.  Cleaning: Hair’s natural oils or sebum can build up over 
time, making hair more slippery and reduce friction and 
make  hair  limp.  Cleaning  these  oils  off  with  a  volume-
building shampoo will restore hair’s natural tendency to 
volume.

2.  Teasing or backcombing: Teasing or combing hair back-
ward from tip to root will roughen the cuticle, drastically 
increasing friction. This temporarily creates volume but is 
potentially very damaging over time. Teasing causes the 
cuticle layers to roll and peel up (Figure 27.33).

3.  Styling  products:  These  products  can  create  stiffness 
at the root to create volume. Spacer particles can also be 
added to provide volume by separating fibers.

Straightening
There  are  several  ways  to  straighten  hair  depending  on  the 
starting  level  of  curl  and  how  permanent  the  treatment  is. 

 
HAIR CARE 

 245

excessive heat (>190ºC) can be detrimental to hair health, as is 
excessive use of such implements.

A  recent  popular  straightening  treatment  is  keratin 
treatments  such  as  the  Brazilian  keratin  treatment.  These 
products  use  formaldehyde  to  crosslink  hair  into  a  straight 
shape. The active is applied and then crosslinking is activated 
by  heat  during  the  flat-ironing  final  step.  The  formaldehyde-
containing products have become less common in the last few 
years  as  regulations  have  restricted  its  use  globally  due  to 
safety concerns. Alternative products are emerging including 
those  containing  glyoxylic  acid  and  glyoxyloyl  carbocisteine, 
which work via a similar crosslinking mechanism. There have 
been  reports  of  these  products  causing  hair  breakage  which 
could either be due to the high flat iron temperatures used to 
create  the  original  style  or  repeated  treatments  where  mul-
tiple crosslinks eventually make hair very brittle and easy to 
break. Crosslink products are more effective for women with 
wavy hair versus very curly hair and typically last 2–3 months 
depending on wash frequency.

An alternative for women with curlier hair are Japanese 
straightening treatments. The products, which have been in the 
market  from  many  years,  employ  thiogycolate  technology  to 
straighten hair prone to frizz. Care must be taken when apply-
ing  the  thioglycolate  chemistry  as  it  can  irreversibly  damage 
hair by breaking down the disulphide bonds which give hair 
its strength if left too long on hair. Typically this chemistry is 
best applied in the salon by experts who can accurately judge 
processing  time  and  get  the  optimum  result.  These  products 
will work well on women with wavy and curly hair and will 
last  3–6  months.  However,  they  generally  will  not  be  able  to 
fully straighten high curly hair.

For  women  with  highly  curled  hair,  e.g.,  women  of 
African  descent,  straightening  is  achieved  with  relaxer  treat-
ments.  Most  relaxers  are  high-pH  products  in  the  form  of 
heavy  creams  consisting  of  very  high  oil-in-water  emulsions 
which are combed through the hair, where they slowly break 
down the structural bonds. The aggressiveness of the caustic 
is  controlled  by  the  incorporation  of  suitable  emollient  oils. 
The two most common types of relaxers are sodium hydrox-
ide (lye) and guanidine hydroxide (no-lye). Also on the market 
are potassium and lithium hydroxide relaxers and ammonium 
bisulfite relaxers. However, sodium hydroxide and guanidine 
hydroxide  have  proven  to  be  the  most  effective.  Guanidine 
hydroxide  relaxers  are  considered  less  irritating  to  the  scalp 
than  lye-based  relaxers;  therefore,  some  women  prefer  them. 
No-lye products, although considered less harsh, can still burn 
the scalp, eyes, and ears.

Relaxers  are  the  most  damaging  to  hair  structure  of  all 
the straightening products but they are also the most permanent 
and effective. Relaxed hair thus requires considerable aftercare 
(Figure 27.34). Modern hair care products have been developed 
for this market and the conditioners include fatty alcohols and 
light mineral oils to maintain the critical moisture content.

STYLING PRODUCTS
A range of styling products to create long-lasting styles have 
emerged to complement the new generation of cleansing and 
conditioning products. These can enhance or alter most com-
mon aesthetic styling problems. Foremost among these is the 
control  of  volume—either  too  little  or  too  much.  Managing 
frizzy  hair  is  also  important,  and  products  for  so-called 
“ethnic” hair are emerging.

Figure 27.32  The temperatures generated by some implements, 
hair  dryers,  and  hot  combs,  can  exceed  200°C  and  may  cause 
significant damage.

Figure 27.33  Teasing or combing hair backward from tip to root 
will roughen the cuticle, drastically increasing friction.

As  permanency  increases  there  are  also  tradeoffs  with  hair 
health, as these treatments involve reactive chemistry that can 
impact fiber integrity.

The least permanent method is blow drying and/or flat 
ironing, as discussed previously. This method uses heat to cre-
ate  a  wet  set  which  will  only  last  until  the  next  wash.  Using 

 
246 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(c)

Figure 27.34  Most relaxers are formulated in the form of heavy creams consisting of very high oil-in-water emulsions which are combed 
through the hair, where they slowly break down the structural bonds. Relaxed hair allows for easier grooming.

Styling products help keep long-lasting volume by creat-
ing reinforcing bonds between hair shafts at critical locations 
to the style. These bonds come in two types:

•  Seam  welds:  Bonds  created  that  hold  two  hair  shafts 

together in in side-by-side alignment.

•  Spot welds: Found where hairs cross each other to create 
a support structure. The styling polymer glues the shafts 
together at this critical structural point (Figure 27.35).

Hairspray
Hairspray  (also  called  hair  lacquer  or  spritz)  is  sprayed  onto 
dry hair to keep it stiff or in a certain style. The spray can be 
dispensed from a pump or aerosol spray nozzle. Modern hair-
sprays  were  developed  around  the  time  the  aerosol  can  was 
introduced in the 1940s.

Hairspray is the most common styler and is a solution 
of  polymer  in  a  mixture  of  solvents  and  propellants  that  is 
sprayed  on  the  hair  in  droplets.  The  droplets  are  formed 
when the liquid is forced through a pinhole in the nozzle of 
the can. In aerosol hairsprays, the force is supplied by pro-
pellant.  In  non-aerosols,  the  force  is  supplied  via  mechani-
cal  action  of  pumping  the  nozzle.  Typically,  non-aerosol’s 
propellants  provide  more  force  than  mechanical  pumping 
resulting in smaller droplet sizes. Smaller droplets dry faster 
giving  aerosol  hairspray  a  “drier”  feeling  than  non-aerosol 
hairspray.

Ingredients are a blend of polymers that provide struc-
tural support to hair and include copolymers of polyvinylpyr-
rolidone  (PVP)  and  polyvinyl  acetate  (PV).  This  copolymer 
mixture  is  usually  modified  to  achieve  the  desired  physical 
properties  (adhesive  strength,  foaming,  etc.).  As  the  product 
dries the polymer forms spot welds to hold the desired style 
in place

Figure 27.35  Spot welds are found where hairs cross each other 
to create a support structure. The styling polymer glues the shafts 
together at this critical structural point.

Mousse
Mousses are typically added to wet hair before styling. They 
use a propellant and a surfactant in addition to water-soluble 
styling  polymers  to  create  a  smooth,  creamy  foam  which  is 
easy  to  spread  through  hair.  The  hair  is  blow-dried  and  the 
polymers form spot and seam welds to hold style.

Hair Gels/Waxes/Pomades
These products are typically added to dry hair and are popular 
with  men  and  women  with  short  hair  styles.  They  can  hold 
hair in different shapes and create, for example a “wet look” or 
a “texturized” look. They contain polymers and high levels of 
waxes which hold the hair in place

 
 
  
 
  
HAIR CARE 

 247

REFERENCES

1.  Kardong  KV.  Vertebrates:  Comparative  Anatomy,  Function, 

Evolution. 3rd edition. New York: McGraw-Hill 2002.

2.  Perrin  WF,  Bernd  Würsig  JGM,  Thewissen  H.  Encyclopedia  of 
Marine Mammals 2nd edition. San Diego, CA: Academic Press 
2008; p. 1009. 

3.  Blume-Peytavi  U,  et  al.  Hair  Growth  and  Disorders.  Berlin 

Heidleberg: Springer-Verlag 2008.

4.  Messenger AG. Hair Through the female life cycle. Br J Dermatol 

2011 Dec; 165(Suppl 3):2–6.

5.  Gray  JE.  Assessment  Of  Hair  Quality  Using  Eye-Tracking 

Technology. ICSS 266. Royal Society of Medicine 2007.

6.  Robbins  C.  Chemical  and  Physical  Behavior  of  Human  Hair, 
4th  edition.  Berlin,  Heidelberg,  New  York:  Springer-Verlag 
2002; pp. 398–9,

7.  Berarddesca E, Leveque J-L, Maibach HI. Ethnic Skin and Hair. 

New York: Informa Healthcare USA 2007.

8.  Ogle RR, Fox MJ. Atlas of Human Hair; Microscopic Characteristics. 

Boca Raton, FL: CRC Press 1999.

9.  Franbourg A, et al, Current research on ethnic hair. J Am Acad 

Dermatol 2003; 48:S115–9.

  10.  Jones LN, Peet DJ, Danks DM, Negri AP, Rivett DE. Hairs from 
patients with maple syrup urine disease show a structural defect 
in the fiber cuticle. J Invest Dermatol 1996 Mar; 106(3):461–4.

 
 
 
 
 
 
 
 
 
 
28

Dandruff and Seborrheic Dermatitis

James R. Schwartz and Thomas L. Dawson, Jr.

INTRODUCTION
Modern society considers the formation of large, individually 
distinguishable flakes of scalp skin an abnormal condition (1). 
These flakes are dislodged by mechanical action and are visible 
either  within  the  hair  or  on  horizontal  surfaces  immediately 
below the hair such as shoulders and top of the back. This con-
dition is known by a number of equivalent names, each having 
slightly different connotations. The most common, yet not very 
descriptive,  is  “dandruff.”  “Seborrheic  dermatitis”  describes 
essentially  the  same  condition  with  an  emphasis  on  exces-
sive oiliness (seborrhea) and irritation/redness (dermatitis) (2). 
Names  reflecting  the  fungal  causality  (though  none  of  them 
correctly termed based on today’s knowledge; see below) are 
captured in “pityriasis simplex” and “pityriasis capitis” (refer-
ring to Pityrosporum) and “furfuracea” (referring to Malassezia 
furfur). As all of these terms are in common use today; the prac-
titioner  and  diagnostician  simply  needs  to  understand  they 
represent the same symptomology based on the same etiology, 
and prescribe treatments as summarized below (2).

CLINICAL FEATURES
Normal  scalp  has  few  flaking  areas  (Figure  28.1a)  and  healthy 
appearing,  smooth  skin.  Dandruff  is  characterized  by  patches 
of loosely adherent, oily flakes, often accompanied by pruritus. 
Dandruff has the clinical feature of small white or gray flakes that 
accumulate diffusely on the scalp surface or in localized patches 
(Figure 28.1b). Dandruff does not exhibit the overt inflammation 
seen in seborrheic dermatitis, and is confined to the scalp.

In  seborrheic  dermatitis  the  scales  are  greasy  and  yel-
lowish  in  color  (Figure  28.1c).  Seborrheic  dermatitis  flakes 
accumulate  in  adherent  mounds  on  the  scalp,  and  underlying 
inflammatory changes (seen as surface erythema) are evident. 
The  lesions  of  seborrheic  dermatitis  vary  in  appearance,  with 
the  characteristic  presentation  being  patches  of  red,  flaking, 
greasy  skin,  particularly  on  the  scalp,  nasolabial  folds,  ears, 
eyebrows, and chest. However, patients often vary with respect 
to  the  degree  of  erythema,  amount  of  flaking,  and  the  extent 
to which the affected areas have a greasy appearance. It is also 
important to note that, while patients with seborrheic dermatitis 
may have oily skin, this is not necessarily the cause (3–5). As the 
terms dandruff and seborrheic dermatitis are widely accepted 
to  refer  to  differing  severities  of  the  same  etiology,  herein  we 
will refer to them as dandruff/seborrheic dermatitis (D/SD).

Recently,  it  has  been  demonstrated  that  the  unhealthy 
skin state associated with D/SD has negative consequences to 
the quality of hair (6). Hair from D/SD scalp is thinner, has a 
more brittle surface, and is less shiny than hair from a normal 
scalp. These observations are very similar to those associated 
with scalp psoriasis.

PREVALENCE
Dandruff and seborrheic dermatitis are the most common scalp 
afflictions of adolescence and adult life and are rare and mild 
in  children  (1,2,4).  Historically,  it  was  thought  that  about  50% 
of the world’s population is afflicted to some degree with onset 
at puberty and peak incidence and severity reached at the age 
of about 20 years. Dandruff becomes less frequent after the age 
of 50 years (1,2). A broad, well-defined survey consisted of 1408 
Caucasians,  African  Americans,  and  Chinese  subjects  from 
Minnesota and Georgia, the United States and Beijing, Shanghai, 
and Guangzhou, China, and suggests that severity and preva-
lence of noticeable dandruff and seborrheic dermatitis is much 
higher in the adult population than first thought, at 81%–95% in 
African  Americans,  66%–82%  in  Caucasians,  and  30%–42%  in 
Chinese subjects (Table 28.1, Figure 28.2a) (5). Additionally, the 
prevalence of dandruff was as high in U.S. teens as their adult 
counterparts,  with  prevalence  at  75%–95%  in  Caucasian  and 
African-American teens (Table 28.1, Figure 28.2b) (7,8). Based on 
this survey, dandruff occurs in 60%–90% and seborrheic derma-
titis  in  3%–5%  of  immunocompetent  adults.  In  AIDS  patients, 
the prevalence of seborrheic dermatitis increases to 30%–33% (9).
Dandruff appears to have little variation due to climate, 
as incidence and severity are similar in north to south of United 
States  and  China  during  the  winter  (Figure  28.3)(7,8).  Higher 
shampooing frequency appears to result in lowered dandruff 
severity  in  all  populations  (Figure  28.4)  (8).  However,  when 
examining population statistics, the frequency of antidandruff 
product use needs careful consideration. Despite higher sham-
poo  frequencies  and  the  ready  availability  of  highly  effective 
over-the-counter  and  prescription  antidandruff  shampoos  in 
the  United  States,  the  most  recent  prevalence  study  in  both 
adults  and  teens  suggests  dandruff  is  occurring  at  a  much 
higher  rate  and  severity  than  initially  thought  in  the  United 
States  versus  China  (8).  The  higher  prevalence  of  dandruff  in 
the United States is most likely associated with the lower use of 
antidandruff shampoo in routine hair care regimens (10%–20%) 
versus  China  (40%–52%)  (Figure  28.5).  While  the  decreased 
incidence  and  lower  severity  of  dandruff  in  China  may  lead 
to the assumption that there is a different etiology in Chinese 
subjects,  recent  clinical  data  indicates  that  in  all  geographies 
treatment remains similar in effectiveness (9,10). Further, while 
current  DNA-based  microbial  identification  can  detect  subtle 
differences  distribution  of  genetic  subtypes  (11–13),  it  is  yet 
to  be  evidenced  that  these  differences  are  relevant  to  treat-
ment paradigms (14). In addition, the majority of clinical stud-
ies  demonstrated  that  scalp  itch,  a  key  symptom  of  dandruff 
and seborrheic dermatitis, was found to be correlated with the 
severity of dandruff flaking across all ethnic groups. Dandruff 
has recently received much attention as its presence can lead to 
loss of self-esteem and a negative social image (5,8,16).

DANDRUFF AND SEBORRHEIC DERMATITIS 

  249

e
r
o
c
s
F
S
A

30

25

20

15

10

5

0

AA
females

AA
males

Caucasian
females

Caucasian
males

Chinese
females

Chinese
males

(a)

Adults

Teens

100

80

60

40

20

0

i

g
n
k
a
l
f
e
b
i
s
i
v
h
t
i

l

w
s
t
c
e
b
u
s

j

f
o
%

Caucasian
females

Caucasian
males
(b)

AA
females

Figure 28.2  Dandruff incidence among ethnic groups and teens. 
(a)  Adherent  scalp  flaking  (ASF)  scores  in  African  Americans 
(AA), Caucasians, and Chinese. (b) Dandruff incidence as high 
in teens as in adults.

Minneapolis

Atlanta

Beijing

Guangzhou

s
e
r
o
c
s
F
S
A

35

30

25

20

15

10

5

0

(a)

(b)

(c)

Figure  28.1  Clinical  features  of  normal  (a),  dandruff  (b),  and 
seborrheic dermatitis (c) scalp.

Table 28.1  Adherent Scalp Flaking Severity Scores in Adult 
and Teens in the United States and China

Figure 28.3  Dandruff severity across climatic conditions. ASF, 
adherent scalp flaking; AA, African American.

Caucasian
males

Caucasian
females

AA
females

Chinese
males

Chinese
females

Adults

Teens

African-American females

African-American males

Caucasian females

Caucasian males

Chinese females

Chinese males

29.3

23.4

22.7

21.3

12.1

13.6

27.1

26

22.8

23.7

12.4

11.2

PATHOLOGY
The superficial flaking and redness that are the outward symp-
toms of dandruff and seborrheic dermatitis are manifestations 
of an abnormal epidermal structure and function (17). Flakes 
are generally believed to occur in “patches” on the scalp and 
these  eruptions  randomly  “move”  about  on  the  surface  over 
time. However, the underlying stratum corneum irregularities 

 
 
 
 
 
 
 
 
250 

 TEXTBOOK OF COSMETIC DERMATOLOGY

e
r
o
c
s
F
S
A

35

30

25

20

15

10

5

0

1

2–3

4–6

≥7

k
e
e
w

r
e
p
y
c
n
e
u
q
e
r
F

AA
females

Caucasian
females

Chinese
females

Caucasian
males

Chinese
males

Figure  28.4  Adherent  scalp 
flaking  (ASF)  score  (white 
bars)  versus  shampoo  frequency  (shaded  bars).  AA,  African 
American.

Cosmetic

Antidandruff

%

90
80
70
60
50
40
30
20
10
0

AA
females

Caucasian
females

Caucasian
males

Chinese
females

Chinese
males

Figure 28.5  Cosmetic versus antidandruff shampoo users. AA, 
African American.

occur  throughout  the  scalp  of  affected  individuals  (17),  sug-
gesting  the  actual  flakes  are  the  end  result  of  a  cycle  of  skin 
distress that may or may not be visible to the unaided eye.

The  stratum  corneum  of  affected  individuals  shows 
striking  features  consistent  with  a  hyperproliferative  state, 
as  is  indicated  by  functional  studies  that  measure   accelerated 
epidermal  maturation  times  (2).  The  physical  features  accom-
panying  this  state  are  dramatic  (4,5).  An  electron  microscopic 
study  of  stratum  corneum  using  new  fixation  methods  (17) 
reveals  that  dandruff  stratum  corneum  exhibits  parakeratotic 
nuclei, lipid droplets within corneocytes, a decreased number of 
desmosomes, irregular corneocyte envelope structure, intercel-
lular Malassezia yeasts, and massive quantities of unstructured 
intercellular lipid (Figure 28.6). All of these features are consistent 
with a state in which the feedback between epidermal synthesis 
and maturation rate is lost and uncontrolled growth leads to cor-
neocytes reaching the surface that are immature and not ready 
to be shed as individual cells.

The  intercellular  lipid  abnormalities  are  quite  striking 
in  their  size  as  well  as  lack  of  tightly  ordered  lamellae.  As 
expected, there is a lack of true intercellular lipids (ceramides) 
with most of the lipids being sebaceous in origin (18). Again, 
this  is  indicative  of  the  lack  of  an  ordered  temporal  chain  of 
events, resulting in low epidermal lipid secretion into the inter-
cellular space. Simply topically applying such lipids is unlikely 
to be meaningful as they cannot displace the sebaceous lipids 
present, and they not initiate the formation of missing features 
such as a tight lamellar structure or desmosomes and the other 
characteristics required for orderly desquamation.

Treatment of dandruff and seborrheic dermatitis are dis-
cussed below, but it is appropriate to mention here that as the 
outward symptom of flakes is improved, the underlying skin 
condition is also being restored (17). There is a direct correla-
tion  between  clinical  flaking  and  the  severity  of  the  stratum 
corneum  abnormalities,  suggestive  of  the  cause  and  effect 
relationship  between  the  superficial  (flaking)  and  subsurface 
(morphology) symptoms.

(a)

(c)

(b)

(d)

Figure 28.6  Stratum corneum features in dandruff. (a) Normal scalp. Note the closely apposed cells, flat, solid cell morphology, and 
close junctions between cells. (b–d) Dandruff scalp. Note the lipid droplets between cells (b), interdigitated cell membranes (c,d), para-
keratotic nuclei (d), and vast amount of extracellular lipid (d).

 
 
 
 
ETIOLOGY
The  relationship  between  dandruff  and  seborrheic  dermatitis 
has at times been controversial. While most investigators regard 
seborrheic  dermatitis  of  the  scalp  as  severe  dandruff,  others 
believe that dandruff should be used to describe any flaking of 
the scalp (19–22). The microbial origin of dandruff centers on the 
causal role of yeasts of the genus Malassezia (23,24). Originally 
named  Malassezia  by  Malassez  in  1898  (25,26),  this  genus  was 
renamed  and  referred  to  as  Pityrosporum  during  the  second 
half of the 20th century (27,28). In the mid 1990s, studies of the 
morphological,  ultrastructural,  physiological,  and  genomic 
differences  of  the  genus  Malassezia  led  to  the  identification  of 
the  following  seven  species:  M.  furfur  (Pityrosporum  ovale),  M. 
Pachydermatis, M. sympodialis, M. globosa (P. orbiculare), M. obtusa, 
M.  restricta,  and  M.  sloofiae  (29,30).  Recently,  there  have  been 
seven  additional  Malassezia  species  accepted:  M.  dermatis,  M. 
equi,  M.  nana,  M.  yamatoensis,  M.  japonica,  M.  cunicula,  and  M. 
capri (31–34). As detailed DNA-based identification techniques 
are  more  broadly  applied  to  the  Malassezia  genus,  there  will 
almost certainly be more species identified. Investigation of the 
etiologic  mechanism(s)  associated  with  Malassezia-associated 
disease has become of significantly increased interest due to the 
sequencing of multiple Malassezia genomes (35,36).

While  the  pathogenic  role  of  Malassezia  as  the  principal 
causative  agent  of  dandruff  and  its  association  with  disease 
severity  has  been  reported  (21,23,24,37,38,41),  it  was  a  novel 
molecular biological technique using terminal fragment length 
polymorphism (tFLP) analysis that identified M. globosa and M. 
restricta as the predominant fungal species present on both dan-
druff (flaking scores of >24) and normal (flaking scores of <10) 
scalps  (Figure  28.7)  (39–41).  M.  furfur  (P.  ovale)  was  absent  on 
human  scalps.  Though  M.  furfur  was  the  predominant  species 
previously  identified  using  culture  techniques  (41–43),  it  is  not 
the species present in vivo. This suggests that M. furfur is likely 
not the causal organism for dandruff, and perhaps is an artifact 
of isolation or culture techniques, or use of supplanted nomencla-
ture. In the 1950s to 1990s the entire Malassezia genus was referred 
to as M. furfur (27,28), and only in the 1990s was the species M. 
furfur split into the genus Malassezia with multiple unique species 

ASFS < 10

ASFS > 24

80

60

40

20

)

%

(
y
c
n
e
u
q
e
r
F

a
t
c
i
r
t
s
e
r

.

M

a
s
o
b
o
g

l

.

M

s
i
l

i

a
d
o
p
m
y
s
.

M

e
a
i
f
f
o
o
l
s
.

M

a
s
u
t
b
o

.

M

r
u
f
r
u
f

.

M

s
i
t
a
m
r
e
d
y
h
c
a
p

.

M

i

g
n
u
f
a
i
z
e
s
s
a
a
M
-
n
o
N

l

d
e
t
c
e
t
e
d

i

g
n
u
f
n
o
N

Figure  28.7  Malassezia  sp.  on  human  scalp.  ASFS,  adherent 
scalp flaking score.

DANDRUFF AND SEBORRHEIC DERMATITIS 

  251

(29,30). The species which retained the name M. furfur, while the 
most  robust  in  culture  and  likely  the  most  pathogenic,  is  very 
rarely isolated from normal human skin (39). More recent molec-
ular genotype analyses the Malassezia microflora on skin of atopic 
dermatitis and seborrheic dermatitis patients support the pres-
ence of M. globosa and its likely involvement in disease expression 
(25,44–46). The observation that the human eukaryotic microbi-
ome is far less complex that the prokaryotic microbiome, as well 
as  the  observation  at  M.  globosa  and  M.  restricta  are  the  domi-
nant members associated with the head, has been confirmed by 
modern techniques and the human microbiome project (47).

Increased  interest  in  the  role  of  Malassezia  yeasts  in  the 
development  of  dandruff  and  seborrheic  dermatitis  has  pro-
vided additional evidence that in most cases dandruff is indeed 
a mild form of seborrheic dermatitis. The vast majority of recent 
data supports a direct causal link between Malassezia fungi and 
dandruff.  First,  effective  treatment  of  the  condition  can  occur 
with  a  wide  range  of  material  types,  from  zinc  and  selenium 
salts to highly specific azoles, with the only known functional 
link  between  these  materials  being  antifungal  activity  (24). 
The second supporting factor is that improvement in dandruff 
correlates  exquisitely  with  reduction  in  scalp  Malassezia  level 
(40,48). While the absolute level of Malassezia correlates less well 
with the dandruff, its reduction among those individuals that 
express the symptoms strongly supports its role.

Identification of M. globosa as a lipophylic Malassezia spe-
cies which is both on the scalp and capable of digesting seba-
ceous triglycerides (40), thereby releasing free fatty acids (oleic 
acid), led to the hypothesis that these fatty acids penetrate the 
stratum  corneum  and  break  down  skin  barrier  function  (49). 
This barrier breakdown results in hyperproliferation as well as 
the secretion of more sebum, which then acts as food to sustain 
further Malassezia proliferation (40). Confirmation of the role of 
fatty acids in dandruff genesis is proven by the demonstration 
of  oleic  acid–induced  dandruff-like  flaking  when  applied  to 
scalps of dandruff-susceptible human subjects in the absence 
of Malassezia (40). The resurgence in interest in Malassezia biol-
ogy has also resulted in the sequencing of the M. globosa and 
M.  restricta  genomes  (50).  Key  findings  include  confirmation 
of many lipase genes and their expression on scalp, as well as 
proteomic identification of many other enzymes which would 
be detrimental to scalp and hair. For example, of 24 proteases 
identified,  more  than  half  were  shown  to  be  expressed  on 
human scalp. Also, multiple genes for generation of peroxides 
were identified, making it likely that Malassezia are involved in 
damage to the hair shaft as well as the scalp. This hypothesis 
is also supported by recent work indicating that hair sampled 
from  dandruff  sufferers  was  less  healthy  than  that  isolated 
from non-dandruff subjects (51).

Since both M. globosa and M. restricta are found in dandruff 
and normal scalps (39), the host immune system may have a role 
in manifestation of this scalp disorder. Why some individuals get 
dandruff and others with similar absolute levels of Malassezia do 
not will require further research into individual susceptibility.

Investigation  of  molecular  markers  and  precursors  of 
skin inflammatory, immunologic, and infectious processes in 
normal,  dandruff,  and  seborrheic  dermatitis  scalps  indicate 
that  skin  cellular  immunity  is  involved  in  this  scalp  disease 
process (52). Significantly higher levels of IL-1α/TP (total pro-
tein) levels ( p = 0.03) and IL-ra to IL-1α ratios were recovered 
from dandruff ( p = 0.07) and seborrheic dermatitis ( p = 0.002) 
scalps versus the scalps of normal subjects (Figure 28.7). The 
IL-ra  and  the  IL-ra  to  IL-1α  ratios  correlated  with  scalp  flak-
ing  severity  in  the  diseased  versus  the  nondiseased  scalps. 

 
 
 
 
 
 
 
 
 
 
 
 
252 

 TEXTBOOK OF COSMETIC DERMATOLOGY

The TNFα/TP levels recovered from dandruff scalps were sig-
nificantly higher ( p = 0.02) than levels recovered from the seb-
orrheic dermatitis and normal scalps. IL-2/TP was significantly 
increased ( p = 0.01) and IFN-γ and NO levels were significantly 
decreased  ( p  =  0.05)  in  seborrheic  dermatitis  versus  normal 
scalps  (34).  Recent  work  shows  that  pyrithione  zinc  has  the 
ability to abate surfactant-induced IL-1 expression (53).

ANTIDANDRUFF ACTIVES AND 
MODES OF ACTION OF ACTIVES
Multiple  topical  agents  identified  in  the  last  several  decades 
have  proven  to  be  successful  therapies  for  the  treatment  of 
dandruff and seborrheic dermatitis. These agents include pyri-
thione  zinc  (17,19,54–68),  selenium  sulfide  (19,54–59),  salicylic 
acid (54), sulfur (54), coal tar (54,69), hydrocortisone (54), and 
ketoconazole  (19,58,59,64,66,68,70–85)  in  the  United  States. 
In  addition,  piroctone  olamine  and  climbazole  are  accepted 
materials in other countries. A consistent therapeutic mode of 
action of all effective actives is their antifungal activity against 
Malassezia. In vitro fungistatic and fungicidal tests of ketocon-
azole (17,19,58,59,73,74), pyrithione zinc (17, 9,58,59,64), and sele-
nium  disulfide  (17,19,58,59,64)  have  demonstrated  extremely 
low  minimum  inhibitory  concentrations  of  growth  (MICs) 
against M. furfur as the marker organism (17). A recent investi-
gation (76) indicates the molecular basis for antifungal activity 
of ZPT involves transport of copper into cells which then inac-
tivates  iron–sulfur  active  centers  of  mitochondrial  enzymes. 
Coal tar (72) was also demonstrated to possess activity against 
54 Malassezia strains isolated from patients with dandruff, seb-
orrheic dermatitis, and pityriasis versicolor,  but with a  much 
lower potency. Other antimycotic agents such as itraconazole, 
terbinafine,  bifonazole,  climbazole,  fluconazole,  clotrimazole, 
dithranol, and liquor carbonis also have the ability to inhibit 
P.  ovale  (presumed  to  be  M.  furfur,  due  to  culture  conditions) 
(59,73).

Salicylic acid, sulfur, and liquor carbonis possess exfolia-
tive qualities expected to improve the appearance of scaling, 
while the antimitotic effect of topical corticosteroids and coal 
tars might also be involved in reducing the hyperproliferation 
associated with dandruff scaling.

Traditionally,  non-scalp  seborrheic  dermatitis  has  been 
treated  with  either  topical  or  oral  steroids  (48).  However,  the 
renewed interest in the role of Malassezia yeasts and the known 
side effects of topical steroids have made antifungal medications 
an increasingly popular choice. Tacrolimus has been shown to 
have potent antifungal activity against M. furfur in vitro (86). It 
has  been  suggested  that  topical  tacrolimus  and  pimecrolimus 
may  be  useful  alternatives  to  corticosteroids,  as  they  exhibit 
anti-inflammatory activity but do not have the side effects asso-
ciated with long-term corticosteroid use (87). Further, tacrolimus 
and  pimecrolimus  may  be  effective  as  they  possess  both  anti-
inflammatory and antifungal activity.

The  fungal  etiology  of  both  dandruff  and  seborrheic 
dermatitis  leads  to  a  refractory  condition.  Malassezia  yeasts 
are commensal microflora, so cessation of antifungal therapy 
will result in a return of the condition. When considering any 
topical  therapy  for  long-term  prophylaxis,  particularly  when 
concerning  hair,  it  must  be  cosmetically  acceptable  enough 
to assist in compliance. This highlights that for dandruff and 
scalp  seborrheic  dermatitis  the  use  of  cosmetic  antidandruff 
shampoos  should  be  the  first  choice,  with  less  cosmetically 
acceptable  shampoos,  lotions,  and  foams  reserved  for  use  in 
severe or refractory cases (88,89).

THERAPIES AND EFFICACY
The  objective  of  treatment  of  dandruff  and  seborrheic  der-
matitis is to control the scalp condition at the lowest possible 
cost  and  inconvenience  to  the  patient  (1,69,88,89).  Since  the 
1960s,  various  shampoos,  conditioners,  and  treatment  prod-
ucts  have  been  marketed  as  over-the-counter  or  prescrip-
tion products for the treatment of seborrheic dermatitis and 
dandruff.  Many  of  these  products  not  only  treat  the  scalp, 
but can also provide hair grooming needs for cleansing and 
conditioning hair (17). It is critical that the hair care products 
selected to treat D/SD have no cosmetic tradeoffs compared 
to purely cosmetic products, to increase the likelihood of long 
term compliance (17,70).

Therapies  considered  to  be  effective  include  pyrithi-
one  zinc  (17,19,54–68),  selenium  sulfide  (54–57,61,65,70,71,90), 
salicylic  acid  (4,5,54),  sulfur  (4,5,54),  coal  tar  (4,5,55),  hydro-
cortisone (48), and ketoconazole (19,58,59,64,68,70–85,91) in the 
United States. In addition, ciclopirox olamine (54,55), piroctone 
olamine (90), and climbazole (73) are approved for use in other 
countries. A consistent mode of action of most of the actives is 
their antifungal activity against Malassezia (19,24).

Pyrithione  zinc  (ZPT)  shampoo  and  conditioning 
rinse-off  products  have  been  marketed  since  the  1960s.  This 
category of antidandruff products has been approved for over-
the-counter use in the United States for the treatment of dan-
druff  and  seborrheic  dermatitis  at  levels  of  0.3%–2%  ZPT  in 
shampoo and rinse-off products (54–57), and 0.1%–0.25% ZPT 
in  conditioner  and  leave-on  products  (56,57).  The  efficacy  of 
these products has been demonstrated in many clinical trials 
(19,27,54–59,70).  While  pyrithione  zinc  possesses  high  intrin-
sic  microbial  inhibitory  activity  against  Malassezia  (27,54–59), 
its practical efficacy is dependent on a number of formulation 
parameters (93): mass of ZPT retained after rinsing, the spatial 
distribution of ZPT particles on the scalp surface and follicular 
infundibula, and the biomolecular activity of ZPT. The amount 
of ZPT retained on the scalp surface is controlled by delivery 
via  coacervate,  an  association  complex  that  phase-separates 
upon product dilution, trapping and depositing ZPT particles 
on  the  scalp.  The  details  of  this  technology  are  beyond  the 
scope of this review, but the exact nature of the coacervate can 
impact spatial distubution of ZPT particles, with large, highly 
aggregated coacervates impeding efficient spatial distribution.
Another  factor  that  can  impact  efficient  spatial  distri-
bution  is  the  size/shape  of  the  ZPT  particles  themselves.  For 
example, platelet ZPT at a particle size of 2.5 micron is optimal 
for  deposition  on  scalp  from  shampooing  and  provides  scalp 
surface coverage (Table 28.2, Figure 28.8) (17). The authors have 
compiled data from 14 separate clinical studies involving anti-
dandruff shampoos with 1% ZPT of different average particle 
size. To gauge the impact of particle size, the median effect size 
was evaluated relative to placebo as measured by the standard-
ized  mean  differences  of  the  reduction  in  scalp  flaking  after 
6 weeks of product use. (Since some ZPT shampoos appeared 
together  in  the  same  study,  the  effect  sizes  were  computed 
accounting  for  the  correlation  and  for  unequal  variances.) 
The  results  are  represented  graphically  in  Figure  28.9.  It  can 
be seen that particle size is a significant variable in ZPT-based 
product efficacy and that not all ZPT-based shampoos can be 
assumed to work equivalently. In practice, products containing 
2.5 micron platelet ZPT appear to be most effective (17, 94,95).

Finally, bioactivity of delivered ZPT can be affected by 
other formulation components. For example, a unique formu-
lation technology incorporates an additional source of zinc in 

 
DANDRUFF AND SEBORRHEIC DERMATITIS 

  253

Table 28.2  Optimization of Active Particle Size Increases Dandruff Efficacy of Marketed 1% Pyrithione Zinc Shampoos

1% Pyrithione Zinc Shampoo

Avg. Particle Size (μm)

Median Effect Size

Range of Effect Sizes

Shampoo A

Shampoo B

Shampoo C

Shampoo D

13

5

2.5

0.5

0.85

1.41

2.08

1.74

1 study only

[1.36, 2.93]

[0.55, 2.14]

1 study only

Note: Individual effect sizes are standardized mean differences between active and placebo shampoos of the reduction in scalp flaking after 6 
weeks of use. The results were taken from 14 separate studies. Since some pyrithione zinc shampoos appeared together in the same study, the 
effect sizes were computed accounting for the correlation and for unequal variances.

e
z
i
s

s
t
c
e
f
f
e
n
a
d
e
M

i

2.3

2.1

1.9

1.7

1.5

1.3

1.1

0.9

0.7

0.5

0

2

4

6

8

10

12

14

Average ZPT particle size (µm)

Figure  28.8  Effect  of  particle  size  is  a  significant  variable  in 
PTZbased product efficacy. Note that, in practice, products con-
taining 2.5 mm platelet PTZ appears to be most effective.

p = 0.002

p = 0.069

o
i
t
a
r

)
P
T
(

α
1
-
L
I
/
a
r
1
-
L
I

60

50

40

30

20

10

0

Normal scalp

Dandruff

Seborrheic
dermatitis

Figure 28.9  Ratio of interleukin (IL)-1ra/IL-1α normalized to total 
protein (TP) in normal scalps and scalps of dandruff and sebor-
rheic dermatitis sufferers. Values are mean +/- SE.

the  formula  to  maximize  the  activity  of  ZPT,  this  is  referred 
to  as  a  potentiated  ZPT  formula.  The  mechanism  apparently 
relies  on  the  additional  zinc  to  alter  an  equilibrium  between 
active  and  inactive  forms  of  ZPT,  enhancing  the  presence  of 
the former.

Selenium sulfide has been approved for over-the-coun-
ter use for the treatment of dandruff and seborrheic dermatitis 
at levels of 0.6% (micronized form) and 1% (54–57). Shampoos 
containing  selenium  sulfide  have  proven  efficacy  (21,37,38). 
Since selenium sulfide is a particulate, efficacy is dependent on 
the particle size to optimize coverage. Differences in efficacy 
may  be  related  to  the  particle  size  of  the  selenium  sulfide  in 
the shampoo. Further, selenium sulfide is a complex mixture of 
multiple isoforms and the relative constitution of formulations 
affect efficacy.

Ketoconazole,  an  imidazole  antimycotic  agent,  has  been 
used  orally  for  the  treatment  of  mycoses.  Several  large  anti-
dandruff  efficacy  studies  have  demonstrated  efficacy  against 
pityriasis  capitis  and  seborrheic  dermatitis  (21,24,37,38,54–57). 
Ketoconazole  has  been  approved  for  topical  over-the-counter 
use at 1% in shampoos and prescription use at 2%. Twice-weekly 
treatments  are  currently  recommended  for  ketoconazole-
containing shampoos. To achieve efficacy, these products are rec-
ommended to be left on the scalp for 5–10 minutes before rinsing, 
thereby requiring a change in shampooing habits and practices.
Coal  tar,  approved  for  over-the-counter  treatment  of 
dandruff,  seborrheic  dermatitis,  and  psoriasis  at  levels  of 
0.5%–5% (tar equivalent) (54–57) reduces the number and size 
of epidermal cells and decreases epidermal proliferation and 
dermal  infiltrates.  Coal  tar  has  also  been  reported  to  have 
slight antifungal activity, which could explain its limited anti-
dandruff efficacy (54–57,69). Coal tar–containing shampoo and 
treatment  products  have  been  marketed  for  decades,  mainly 
for psoriasis. This shampoo has been anecdotally reported to 
negatively impact hair color.

Salicylic acid, approved for over-the-counter treatment 
of  dandruff,  seborrheic  dermatitis,  and  psoriasis  at  concen-
trations  of  1.8%–3%  (54–57)  is  an  exfoliative  agent  that  loos-
ens  the  scales,  enabling  them  to  be  washed  away.  Sulfur  is 
approved for over-the-counter treatment of dandruff at levels 
of 2%–5%. Combinations of salicylic acid and sulfur have not 
been approved for over-the-counter use in the United States.

Climbazole,  an  antimycotic  agent  present  in  antidan-
druff shampoos in the European continent with high in vitro 
and  in  vivo  efficacy  against  Malassezia,  was  evaluated  for 
efficacy and safety (97). This shampoo is not marketed in the 
United States.

COMPARATIVE EFFICACY OF 
ANTIDANDRUFF THERAPIES
Potentiated ZPT Formulas versus 
Standard ZPT Formulas
A  recent  clinical  evaluation  (102)  compared  a  potentiated  1% 
ZPT  shampoo  to  a  standard  1%  ZPT  shampoo  (which  addi-
tionally contained 0.5% climbazole). Even with the secondary 

 
 
 
 
 
254 

 TEXTBOOK OF COSMETIC DERMATOLOGY

climbazole, the potentiated ZPT formula was found to be sig-
nificantly more effective at reducing the appearance of flakes. 
This conclusion was substantiated by quantitation of the objec-
tive biomarker histamine as well (103).

Ketoconazole versus ZPT
Comparison of optimized ZPT and ketoconazole products has 
demonstrated equivalent performance. As discussed above, it 
is important to consider the particle size of the ZPT contained 
in each product, as optimized ZPT particles have been shown 
to have increased performance. The relative antidandruff effi-
cacy of a 1% size-optimized ZPT particle–containing shampoo 
has been compared to 1%–2% ketoconazole shampoos (17,64,68). 
In  a  364  patient,  6-week,  randomized,  double  blind,  parallel 
group study (64), three groups of 112 patients were assigned a 
1% ZPT shampoo, or a 1% ZPT shampoo with a different use 
regimen, or a 2% ketoconazole shampoo; a fourth group of 28 
patients was assigned to a placebo shampoo. The antidandruff 
efficacy  of  the  two  1%  ZPT  shampoos,  regardless  of  the  use 
regimen, was found to be comparable to the 2% ketoconazole 
shampoo. All three active treatments were significantly more 
efficacious  than  the  placebo  shampoo.  In  a  small  60-patient, 
8-week,  randomized,  double  blind,  parallel  group  study  (65), 
a  1%  ketoconazole  shampoo  was  found  to  be  more  effica-
cious than a 1% non-optimized large particle ZPT–containing 
shampoo after 6 and 8 weeks of therapy in a subpopulation of 
patients with severe dandruff. The differences observed in this 
study are attributed to a shampoo with a larger non-optimum 
particle  size  ZPT  which  was  therefore  less  efficacious  than 
some of the currently marketed ZPT shampoos.

In  a  recent  clinical  study  (66),  the  efficacy  of  2%  keto-
conazole shampoo was compared to a 1% non-optimized ZPT 
shampoo  in  severe  dandruff  and  seborrheic  dermatitis  suf-
ferers. This randomized parallel group study in a total of 341 
sufferers consisted of a 2-week run period with a neutral non–
antidandruff shampoo followed by 4 weeks of active treatment 
with  either  2%  ketoconazole  twice  weekly  or  1%  ZPT  sham-
poo at least twice weekly, and a subsequent 4-week follow-up 
phase on non-active shampoo. While significant benefits were 
observed  for  both  shampoos  in  comparison  to  non-dandruff 
shampoos,  the  2%  ketoconazole  shampoo  achieved  a  73% 
improvement  in  total  dandruff  severity  scores  compared  to 
67%  improvement  for  1%  ZPT  shampoo  at  week  4  of  active 
treatment. These differences were significant at p = 0.02. Side 
effects  were  minimal.  Efficacy  differences  observed  in  this 
study were attributed to a shampoo with a larger particle size 
ZPT,  therefore  a  less  efficacious  product  than  currently  mar-
keted ZPT shampoos.

In  a  postmarketing  study  examining  the  efficacy  of  a 
combination  shampoo  containing  2%  ketoconazole  and  1% 
pyrithione  zinc(68),  greater  than  90%  reduction  in  dandruff 
severity was observed for all areas of the scalp in 236 moderate 
to severe dandruff sufferers in 4 weeks of treatment. In addi-
tion to the significant reduction in dandruff severity, improve-
ments in erythema and pruritis and minimal side effects were 
observed.  This  combination  shampoo,  while  offering  a  safe 
and  effective  option  for  the  treatment  of  dandruff  in  India 
and perhaps other geographies, is not approved for use in the 
United States.

Ketoconazole versus Selenium Sulfide
In a comparative efficacy study of a 1% selenium sulfide sham-
poo  versus  a  2%  ketoconazole  shampoo  (70),  a  1%  selenium 

sulfide shampoo was found to be more effective than the 2% 
ketoconazole  shampoo  after  4  weeks  of  therapy.  This  was  a 
large, 350-patient, 6-week, double-blinded, randomized paral-
lel group study where two groups of 150 patients with moder-
ate to severe dandruff or seborrheic dermatitis were randomly 
assigned  to  either  1%  selenium  sulfide  shampoo  or  2%  keto-
conazole shampoo, and one group of 50 patients was randomly 
assigned  to  placebo  shampoo.  Adherent  scalp  flaking  scores 
(ASFS) were assessed at baseline, and weeks 2, 4, and 6. Both 
the  1%  selenium  sulfide  shampoo  and  the  2%  ketoconazole 
shampoo were significantly more efficacious than the placebo 
shampoo  at  all  treatment  time  points.  While  the  efficacy  of 
these  shampoos  was  comparable  at  week  2,  the  1%  selenium 
sulfide shampoo was found to be significantly more effective at 
reducing adherent scalp flaking in comparison to the 2% keto-
conazole shampoo after 4 and 6 weeks of therapy. The supe-
rior efficacy associated with the 1% selenium sulfide shampoo 
may be a function of shampoo frequency. When the hair was 
shampooed  three  times  weekly,  patients  using  the  1%  sele-
nium  sulfide  shampoo  had  significantly  better  improvement 
than patients using the 2% ketoconazole shampoo. When the 
shampoo  frequency  was  comparable  at  two  times  per  week, 
the efficacy of the two active products was comparable.

In  a  4-week  study  (70),  246  patients  with  moderate  to 
severe  seborrheic  dermatitis  and  dandruff  used  either  a  2% 
ketoconazole  shampoo,  a  2.5%  selenium  sulfide  shampoo, 
or a placebo shampoo twice weekly for 4 weeks. Both active 
shampoos produced significant improvement in total adher-
ent dandruff scores relative to the placebo shampoo. The 2% 
ketoconazole  shampoo  was  found  to  be  significantly  better 
than the 2.5% selenium shampoo after 1 week, but not after 
2  and  4  weeks  of  therapy.  Assessments  of  the  reduction  in 
yeast  cell  counts  paralleled  the  adherent  flaking  results, 
with  the  ketoconazole  and  selenium  sulfide  shampoos  hav-
ing significantly reduced yeast cell counts relative to placebo 
treatment. Following the active treatment phase, 103 patients 
who  responded  to  treatment  entered  the  regression  phase, 
where they used a nonmedicated shampoo for an additional 
3 weeks. A progressive increase in adherent and loose dan-
druff  scores  and  an  increase  in  the  percentage  of  patients 
with yeast colonization were noted, indicating relapse on ces-
sation of therapy.

In  a  4-week,  double-blind  study  (75),  102  patients  with 
moderate  to  severe  dandruff  were  shampooed  at  the  test 
facility  with  either  a  2%  ketoconazole  shampoo,  a  2.5%  sele-
nium  sulfide  shampoo,  or  placebo  shampoo  twice  weekly 
for  4  weeks.  Adherent  scaling  and  yeast  organism  density 
were assessed at pre-, 2, and 4 weeks post-treatment. The 2% 
ketoconazole shampoo was comparable to the 2.5% selenium 
sulfide  shampoo  in  flaking  reduction  scores,  and  both  active 
shampoos  were  significantly  more  effective  than  the  placebo 
shampoo.  The  mean  yeast  count  reduction  scores  paralleled 
the  flake  reduction  efficacy  measures,  with  the  2%  ketocon-
azole  and  2.5%  selenium  sulfide  shampoos  producing  a  sig-
nificantly  higher  reduction  in  yeast  density  than  the  placebo 
shampoo.

Coal Tar, Selenium Sulfide, and ZPT
In  a  study  comparing  the  activity  of  a  1%  selenium  sulfide 
commercial  shampoo  with  two  commercial  shampoos  con-
taining  1%  ZPT  and  one  product  containing  coal  tar  (46,61), 
loose, adherent, and total dandruff flake scores were obtained. 
The  study  was  conducted  among  199  panelists  for  4  weeks. 

 
Most  clinical  evaluations  focus  on  the  adherent  scalp  flakes, 
thus this data is referred to here. The change versus baseline 
at 4 weeks was as follows: selenium sulfide, 7.1; ZPT prototype 
A, 7.0; ZPT prototype B, 5.7; and coal tar, 5.8. Coal tar does not 
appear  to  have  substantial  antidandruff  activity  and,  as  has 
been seen previously, ZPT-based products can vary consider-
ably in activity depending upon pharmacological delivery of 
the active.

Other Actives and Combinations
In a recent trial, the efficacy of a 1.5% ciclopirox olamine and 
3% salicylic acid shampoo was compared to 2% ketoconazole 
in a study with 224 (154 dandruff and 70 seborrheic dermatitis) 
subjects (78). The shampoos were used three times weekly for 
a  period  of  4  weeks  followed  by  a  2-week  follow-up  period. 
Clinical and self-assessments of efficacy were made. Both treat-
ments produced significant improvement, with lower clinical 
and  self-assessment  scores  observed  at  the  end  of  treatment 
and  follow-up  periods.  Only  subjects  treated  with  the  1.5% 
ciclopirox  olamine  and  3%  salicylic  acid  shampoo  showed  a 
significant reduction in scalp itching in the seborrheic derma-
titis subjects.

A  recent  randomized  double-blind  study  was  con-
ducted  in  two  groups  of  30  moderate  to  marked  dandruff 
sufferers  with  a  non-tar  (2%  salicylic  acid,  0.75%  piroctone 
olamine, and 0.5% elubiol) or 0.5% coal tar shampoo (98). The 
study consisted of a 3-week run-in washout period, followed 
by a 4-week treatment and a 4-week post-treatment regression 
phase. The non-tar shampoo was found to reduce Malassezia 
spp.  counts  and  squamometry  values  versus  the  0.5%  tar 
shampoo. However, the non-tar shampoo contained two anti-
fungal  agents,  namely  piroctone  olamine  and  elubiol,  and  a 
keratolytic agent (99).

The  effectiveness  of  2%  sulfur  and  2%  salicylic  acid 
either alone or in combination in a shampoo were assessed 
in a double-blind, parallel controlled study (100) using scal-
ing  and  corneocyte  counts  as  the  endpoints  for  efficacy. 
A total of 48 patients with moderate to severe dandruff were 
shampooed  twice  weekly  at  the  study  site  for  5  weeks.  At 
weekly intervals, scalp flaking and corneocyte counts were 
assessed. Significantly greater and earlier reductions in the 
degree  of  scaling  and  corneocyte  counts  were  observed  in 
patients treated with the formula containing 2% sulfur and 
2%  salicylic  acid  versus  the  individual  ingredients.  This 
combination active treatment is not approved for marketing 
in the United States.

In a small (eight patients on selenium sulfide and fifteen 
patients on miconazole nitrate treatment), parallel group study 
(64),  the  antidandruff  efficacy  of  a  2.5%  selenium  disulfide 
shampoo was compared to a 2% miconazole nitrate shampoo. 
Miconazole  nitrate  was  found  to  possess  antidandruff  activ-
ity equivalent to selenium disulfide. The endpoint for efficacy 
determination was clinical assessment of disease severity sup-
plemented by cytodiagnosis of exfoliated scalp epidermal cells 
by smear examination.

A  small,  4-week,  unblinded,  open  study  (67)  reported 
marked  decreases  in  scaling,  seborrhea,  erythema,  and  the 
burning  and  itching  of  the  scalp  of  seborrheic  dermatitis 
patients treated with either a 1% ZPT or a 1% econazole sham-
poo.  The  1%  econazole  shampoo  was  assessed  to  be  slightly 
better than the 1% ZPT shampoo. However, this 1% econazole 
shampoo is not marketed.

DANDRUFF AND SEBORRHEIC DERMATITIS 

  255

EFFICACY MEASURES (DERMATOLOGIC 
AND MICROBIOLOGIC)
The primary efficacy measure of antidandruff activity in clini-
cal trials is the severity of ASFS (15). This assessment is gener-
ally based on an 11-point flaking scale ranging from 0–1 (very 
light scaling) to 8–10 (severe scaling) (54, 65,66,68,75–81) or from 
0 (no scaling) to 10 (very heavy scaling) (54,60,62). The scalp is 
divided into six (54,65–68,75–80,83,84,91) or eight (54,60,62,64,70) 
anatomic sites, and the adherent flaking density is scored after 
parting  the  hair  at  each  anatomical  site  multiple  times.  The 
ASFS from each site is then summed across sites (total of 60 or 
80) for the primary efficacy measure. An alternative method, the 
colorimetric method (Chroma C*), called squamometry, is used 
to assess the amount of flakes obtained on D-squame tapes col-
lected from the most severely affected area at pretreatment and 
the same area post-treatment to assess flaking density changes 
resulting from treatment. Corneocyte counting is another alter-
native  method  for  assessing  flaking  changes.  These  two  latter 
methods are not used in the conduction of current clinical stud-
ies. In addition to the ASFS, assessment of loose dandruff, global 
involvement in the disease process, and subjective assessment 
of itch and dandruff severity serve as secondary efficacy mea-
sures.  Other  secondary  efficacy  endpoints  include  assessment 
of Malassezia density (71,75,82). Alternative approaches include 
molecular genetic techniques (39,40,44–46,101) in species identi-
fication and quantification.

DANDRUFF TREATMENT CONSIDERATIONS
While  intrinsic  antifungal  potency  of  antidandruff  products 
is important, these therapeutic results can only be achieved if 
antidandruff shampoos are incorporated into a patient’s rou-
tine  hair  care  regimen.  Despite  higher  shampoo  frequencies 
and the ready availability of highly effective over-the-counter 
and prescription antidandruff shampoos in the United States, 
the most recent prevalence study (17,54–57) in both adults and 
teens suggests dandruff is occurring at a much higher rate and 
severity than initially thought in the United States versus China 
(7). The higher prevalence of dandruff in the United States may 
be associated with the lower use of antidandruff shampoo in 
routine  hair  care  regimen  versus  China.  This  suggests  that 
shampooing more often with antidandruff shampoos that have 
excellent efficacy, aesthetics, and hair conditioning properties 
similar to cosmetic shampoo could lead to a lower prevalence 
and severity of dandruff. While most antidandruff shampoos 
have tradeoffs in usage regimen and hair end benefits such as 
negative odor attributes, unusual color or hair staining proper-
ties, or altered use regimen instructions such as a 5–10 minute 
residence  time  versus  30  seconds,  the  norm  for  shampoo-
ing  (80),  some  cosmetic  ZPT-containing  shampoos  have  been 
uniquely  formulated  to  have  no  significant  tradeoffs,  leaving 
the  hair  clean  and  conditioned.  Recommendations  for  more 
frequent use of antidandruff shampoos with superior cleans-
ing and conditioning properties as a patient’s regular hair care 
regimen may lead to more successful management of dandruff.
Once D/SD is brought under control, effective preventa-
tive treatment is required to decrease the high probability of 
reoccurrence (due to the commensal nature of Malassezia and 
hence  their  certain  repopulation  of  the  scalp).  This  requires 
long-term use of an effective antidandruff product that is cos-
metically desirable and affordable. ZPT-based shampoos have 
been shown (51) to be effective over long periods of time with-
out  the  risk  of  any  physiological  accommodation  (tachyphy-
laxis) that could gradually reduce the benefits.

 
256 

 TEXTBOOK OF COSMETIC DERMATOLOGY

REFERENCES

1.  Dawber  R.  Shampoos:  Scientific  Basis  and  Clinical  Aspects. 
International  Congress  and  Symposium  Series  216.The  Royal 
Society of Medicine Press, 1996.

2.  Dawber  R.  Isolated  dandruff.  In:  Maibach  HI,  ed.  Cosmetic 
Dermatology, 1st edition. London, UK: Martin Dunitz 1994.
3.  Broberg A. Pityrosporum ovale in healthy children, infantile seb-
orrhoeic  dermatitis  and  atopic  dermatitis.  Acta  Derm  Venereol 
Suppl (Stockh) 1995; 191:1–47.

4.  Ackerman AB, Kligman AM. Some observations on dandruff. 

J Soc Cosmet Chem 1969; 81–101.

5.  Orfanos CE, Happle R. Hair and Hair Diseases. 1st edition. Berlin: 

Springer-Verlag 1989; pp. 641–62.

6.  Sinclair RD, SJ, Rocchetta HL, Dawson Jr TL, Fisher BK, Meinert 
K,  Wilder  EA.  Dandruff  and  seborrheic  dermatitis  adversely 
affect hair quality. Eur J Dermatol 2009; 19(4):1–2.

7.  Hickman JG, WX, King B, Cardin CW. Dandruff among teens - 
incidence and fungal speciation characterization. In: American 
Academy of Dermatology Meeting 2003.

8.  Hickman JG, CC, Dawson TL, King BT. Dandruff, Part I: Scalp 
disease  prevalence  in  Caucasians,  African  Americans  and 
Chinese and the effects of shampoo frequency on scalp health. 
In: American Academy of Dermatology Meeting 2002.

9.  Bacon  RA,  et  al.  Assessing  therapeutic  effectiveness  of  scalp 
treatments  for  dandruff  and  seborrheic  dermatitis.  Part  1:  A 
reliable and relevant method based on the adherent scalp flak-
ing score (ASFS). J Dermatol Treat 2014; (25):232–6.

  10.  Bacon  RA,  et  al.  Assessing  therapeutic  effectiveness  of  scalp 
treatments for dandruff and seborrheic dermatitis. Part 2: The 
impact of gender and ethnicity on efficacy. J Dermatol Treat 2014; 
(25):237–40.

  11.  Clavaud C, et al. Dandruff is associated with disequilibrium in 
the  proportion  of  the  major  bacterial  and  fungal  populations 
colonizing the scalp. PLoS ONE 2013; 8:e58203.

  12.  Park  HK,  et  al.  Characterization  of  the  fungal  microbiota 
(mycobiome)  in  healthy  and  dandruff-afflicted  human  scalps. 
PLoS ONE 2012; 7(2):e32847.

  13.  Tanaka A. Molecular characterization of the skin fungal micro-
biota in patients with seborrheic dermatitis. J Clin Exp Dermatol 
Res 2014; 5:239.

  14.  Velegraki  A,  et  al.  Malassezia  infections  in  humans  and  ani-
mals:  Pathophysiology,  detection,  and  treatment.  PLoS  Pathog 
2015; 11(1):e1004523.

  15.  Farthing CF, SR, Rowland Payne CME. Skin disease in homo-
sexual  patients  with  Acquired  immune  deficiency  syndrome 
(AIDS)  and  lesser  forms  of  human  T  cell  leukaemia  virus 
(HTLV III) disease. Clin Exper Dermatol 1985; 10(1):3–12.
  16.  Hay  R,  Graham-Brown  R.  Dandruff  and  seborrhoeic  der-
matitis:  Causes  and  management.  Clin  Exp  Dermatol  1997; 
22(1):3–6.

  17.  Warner  R,  et  al.  Dandruff  has  an  altered  stratum  corneum 
ultrastructure that is improved with zinc pyrithione shampoo. 
J Am Acad Dermatol 2001; 45(6):897–903.

  18.  Harding  CR,  et  al.  Dandruff:  A  condition  characterized  by 
decreased  levels  of  intercellular  lipids  in  scalp  stratum  cor-
neum and impaired barrier function. Arch Dermatol Res 2002.

  19.  Bulmer A, Bulmer G. The antifungal action of dandruff sham-

poos. Mycopathologia 1999; 147(2):63–5.

  20.  Kligman AM. Perspectives and problems in cutaneous geron-

tology. J Invest Dermatol 1979; 73(1):9–46.

  21.  McGrath  J,  Murphy  GM.  The  control  of  seborrhoeic  derma-
titis  and  dandruff  by  antipityrosporal  drugs.  Drugs  1991; 
41(2):178–84.

  22.  Pierard Franchimont C, et al. From azioms to new insights into 

dandruff. Dermatology 2000; 200:93–98.

  23.  Saint-Leger D. The history of dandruff and dandruff in history. 
A homage to Raymond Sabouraud. Ann Dermatol Venereol 1990; 
117(1):23–7.

  24.  Shuster S. The aetiology of dandruff and the mode of action of 

therapeutic agents. Br J Dermatol 1984; 111(2):235–42.

  25.  Sei Y. Seborrheic dermatitis: Clinical diagnosis and therapeutic 
value of different drugs. Jpn J Med Mycol 2003; 44:77–80.
  26.  Malassez L. Note sur le champignon du pityriasis simple. Arch 

Physiologie 1874; 1:451.

  27.  Gordon MA. The lipophilic mycoflora of the skin. I. In vitro cul-
ture of Pityrosporum orbiculare n. sp. Mycologia 1951; 43:524–35.
  28.  Yarrow  D,  Ahearn  DG.  The  yeasts.  A  taxonomic  study  In: 
Kreger-Van Rij NJW, ed. Genus 7. Malassezia Baillon, Amsterdam: 
Elsevier 1984; pp. 882–5.

  29.  Gueho  E,  Midgley  G,  Guillot  J.  The  genus  Malassezia  with 
description of four new species. Antonie Van Leeuwenhoek 1996; 
69(4):337–55.

  30.  Guillot J, et al. Identification of Malassezia species. J Mycol Med 

1996; 6:103–10.

  31.  Sugita,T,  et  al.  New  yeast  species,  Malassezia  dermatis,  iso-
lated from patients with atopic dermatitis. J Clin Microbiol 2002; 
40(4):1363–7.

  32.  Nell  A,  et  al.  Identification  and  distribution  of  a  novel 
Malassezia species yeast on normal equine skin. Vet Rec 2002; 
150:395–8.

  33.  Sugita T, et al. A new yeast, Malassezia yamatoensis, isolated 
from  a  patient  with  seborrheic  dermatitis,  and  its  distribu-
tion  in  patients  and  healthy  subjects.  Microbiol  Immunol  2004; 
48(8):579–83.

  34.  Velegraki  A,  et  al.  Malassezia  infections  in  humans  and  ani-
mals:  Pathophysiology,  detection,  and  treatment.  PLoS  Pathog 
2015; 11(1):e1004523.

  35.  Gioti  A,  et  al.  Genomic  insights  into  the  atopic  eczema-
associated skin commensal yeast Malassezia sympodialis. mBio 
2013; 4(1):e00572–12.

  36.  Xu  J,  et  al.  Dandruff-associated  Malassezia  genomes  reveal 
convergent  and  divergent  virulence  traits  shared  with  plant 
and  human  fungal  pathogens.  Proc  Natl  Acad  Sci  U  S  A  2007; 
104(47):18731.

  37.  Leyden J, Kligman AM. Dandruff cause and treatment. Cosmet 

Toil 1979; 94:3.

  38.  Leyden JJ, McGinley KJ, Kligman AM. Role of microorganisms 

in dandruff. Arch Dermatol 1976; 112(3):333–8.

  39.  Gemmer C, et al. Fast, noninvasive method for molecular detec-
tion and differentiation of Malassezia yeast species on human 
skin and application fo the method to dandruff microbiology. 
J Clin Microbiol 2002; 40(9):3350–7.

  40.  DeAngelis YM, et al. Isolation and expression of a Malassezia 
globosa lipase gene, LIP1. J Invest Dermatol 2007; 127(9):2138–46.
  41.  Gupta  AD,  et  al.  Application  of  novel  molecular  methods 
to  delineate  the  role  of  specific  Malassezia  species  in  the  eti-
ology  of  dandruff.  In  American  Academy  of  Dermatology 
Meeting 2002.

  42.  Gupta AK, et al. Epidemiology of Malassezia yeasts associated 
with pityriasis versicolor in Ontario, Canada. Med Mycol 2001; 
39(2):199–206.

  43.  Nakabayashi  A,  Sei  Y,  Guillot  J.  Identification  of  Malassezia 
species  isolated  from  patients  with  seborrhoeic  dermatitis, 
atopic  dermatitis,  pityriasis  versicolor  and  normal  subjects. 
Med Mycol 2000; 38(5):337–41.

  44.  Sugita  T,  et  al.  Sequence  diversity  of  the  intergenic  spacer 
region of the rRNA gene of Malassezia globosa colonizing the 
skin of patients with atopic dermatitis and healthy individuals. 
J Clin Microbiol 2003; 41(7):3022–7.

  45.  Sugita T, Nishikawa A. Molecular and quantitative analysis of 
Malassezia microflora on the skin of atopic dermatitis patients 
and  genotyping  of  M.  globosa  DNA.  Jpn  J  Med  Mycol  2003; 
44:61–4.

  46.  Kawaguchi  H,  AK.  Malassezia  and  atopic  dermatitis.  Nippon 

Ishinkin Gakkai Zasshi,2003; 44(2):65–9.

  47.  Johnson  B,  Nunley  J.  Treatment  of  seborrheic  dermatitis.  Am 

Fam Physician 2000; 61(9):2703–10, 2713–4.

  48.  Ro BI, Thomas J, Dawson L. The role of sebaceous gland activ-
ity and scalp microfloral metabolism in the etiology of common 
scalp conditions. J Invest Dermatol. Symp Proc 2005; 10:194–197.

 
 
 
 
 
 
 
 
 
 
  49.  Xu  J,  et  al.  Dandruff-associated  Malassezia  genomes  reveal 
convergent  and  divergent  virulence 
traits  shared  with 
plant  and  human  fungal  pathogens.  Proc  Natl  Acad  Sci  2007; 
104(47):18730–5.

  50.  Schwartz  JR,  Rochetta  H,  Asawanonda  P,  Luo  F,  Thomas  JH. 
Does  tachyphylaxis  occur  in  long-term  management  of  scalp 
seborrheic  dermatitis  with  pyrithione  zinc-based  treatments? 
Intl J Dermatol 2009; 48(1):79–85.

  51.  Perkins  MA,  et  al.  A  noninvasive  tape  absorption  method  for 
recovery  of  inflammatory  mediators  to  differentiate  normal 
from  compromised  scalp  conditions.  Cosmet  Toiletries  2004; 
119(2):82.

  52.  Warren  R,  et  al.  Attenuation  of  surfactant-induced  interleu-
kin  1  expression  by  zinc  pyrithione.  Exogenous  Dermatol  2003; 
2(1):23–27.

  53.  Food  and  Drug  Administration.  Dandruff,  seborrheic  derma-
titis  and  psoriasis  drug  products  for  over-the-counter  human 
use. Federal Registrar 1982; 47(233):54664–6.

  54.  Food  and  Drug  Administration.  Dandruff,  seborrheic  derma-
titis  and  psoriasis  drug  products  for  over-the-counter  human 
use; final monograph. Fed Regist 1991; 56(19):63554–69.

  55.  Oh  J,  et  al.  Biogeography  and  individuality  shape  function  in 

the human skin metagenome. Nature 2014; 514:59–64.

  56.  Food  and  Drug  Administration.  Dandruff,  seborrheic  der-
matitis  and  psoriasis  drug  products  for  over-the-counter 
human  use;  amendment  to  the  monograph.  Fed  Regist  1994; 
59(19):4000–1.

  57.  Food  and  Drug  Administration.  Dandruff,  seborrheic  der-
matitis,  and  psoriasis  drug  products  containing  coal  tar  and 
menthol  for  over-the-counter  human  use;  amendment  to  the 
monograph. Final rule. Fed Regist 2007; 72(43):9849–52.

  58.  Van  Cutsem  J,  et  al.  The  in  vitro  antifungal  activity  of  keto-
conazole,  zinc  pyrithione,  and  selenium  sulfide  against 
Pityrosporum  and  their  efficacy  as  a  shampoo  in  the  treat-
ment of experimental pityrosporosis in guinea pigs. J Am Acad 
Dermatol 1990; 22(6 Pt 1):993–8.

  59.  Nenoff  P,  Haustein  UF.  Effect  of  anti-seborrhea  substances 
against Pityrosporum ovale in vitro. Hautarzt 1994; 45(7):464–7.
  60.  Marks R, Pearse AD, Walker AP. The effects of a shampoo con-
taining zinc pyrithione on the control of dandruff. Br J Dermatol 
1985; 112(4):415–22.

  61.  Rapaport  M.  A  randomized,  controlled  clinical  trial  of  four 
anti-dandruff shampoos. J Intl Med Res 1981; 9(2):152–6.
  62.  Cardin  CW,  AR,  Hanifin  JM.  The  antidandruff  efficacy  of 
Head  and  Shoulders  rinse-in  shampoo  (I%  zinc  pyrithione) 
and  Head  and  Shoulders  shampoo  (1%  zinc  pyrithione)  with 
Head and Shoulders conditioning rinse (0.3% zinc pyrithione) 
versus Merit shampoo with Merit Moisture Rinse. Nishininon J 
Dermatol 1990; 52:1208–16.

  63.  Rowlands CG, Danby FW. Histopathology of psoriasis treated 
with zinc pyrithione. Am J Dermatopathol 2000; 22(3):272–6.
  64.  Billheimer W, et al. Results of clinical trial comaring 1% pyrithi-
one zinc and 2% ketoconazole shampoos. Cosmet Dermatol 1996; 
9(5):34–9.

  65.  Cauwenbergh,  G.  International  experience  with  ketoconazole 
shampoo  in  the  treatment  of  seborrheic  dermatitis  and  dan-
druff.  In  Royal  Society  of  Medicine  Services  International 
Congress and Symposium 1988; The Royal Society of Medicine 
Services Limited.

  66.  Pierard  Franchimont  C,  et  al.  A  multicenter  randomized  trial 
of ketoconazole 2% and zinc pyrithione 1% shampoos in severe 
dandruff  and  seborrheic  dermatitis.  Skin  Pharmacol  Appl  Skin 
Physiol 2002; 15:434–41.

  67.  Rigoni C, et al. [1% Econazole hair-shampoo in the treatment of 
pityriasis capitis: A comparative study versus zinc-pyrithione 
shampoo]. G Ital Dermatol Venereol 1989; 124(11–12):LXVII–LXX.
  68.  Saple D, Ravichandran G, Desai A. Evaluation of safety and effi-
cacy  of  ketoconazole  2%  and  zinc  pyrithione  1%  shampoo  in 
patients  with  moderate  to  severe  dandruff—a  postmarketing 
study. J Indian Med Assoc 2000; 98(12):810–1.

DANDRUFF AND SEBORRHEIC DERMATITIS 

  257

  69.  Nenoff  P,  Haustein  UF,  Fiedler  A.  The  antifungal  activity  of 
a coal tar gel on Malassezia furfur in vitro.  Dermatology 1995; 
191(4):311–4.

  70.  Neumann  P,  Coffindaffer  T,  Cothran  P.  Clinical  investigation 
comparing  1%  selenium  sulfide  and  2%  ketoconazole  sham-
poos for dandruff control. Cosmet Dermatol 1996; 9:20–6.
  71.  Danby  FW,  et  al.  A  randomized,  double-blind,  placebo-
controlled trial of ketoconazole 2% shampoo versus selenium 
sulfide  2.5%  shampoo  in  the  treatment  of  moderate  to  severe 
dandruff. J Am Acad Dermatol 1993; 29(6):1008–12.

  72.  Faergemann J, Borgers M. The effect of ketoconazole and itra-
conazole on the filamentous form of Pityrosporum ovale. Acta 
Dermatol Venereol 1990; 70(2):172–6.

  73.  Schmidt A, Ruhl Horster B. In vitro susceptibility of Malassezia 

furfur against azole compounds. Mycoses 1996; 39(7–8):309–12.

  74.  Richardson  MD,  Shankland  GS.  Enhanced  phagocytosis  and 
intracellular killing of Pityrosporum ovale by human neutro-
phils after exposure to ketoconazole is correlated to changes of 
the yeast cell surface. Mycoses 1991; 34(1–2):9–33.

  75.  Hickman J. Nizoral (ketoconazole) shampoo therapy in sebor-

rheic dermatitis. J Int Postgrad Med 1990; 2(1):14–17.

  76.  Reeder N, et al. Zinc pyrithione inhibits yeast growth through 
copper influx and inactivation of iron-sulfur proteins. Antimic 
Agents Chemother 2011; 55:5753–60.

  77.  Ive FA. An overview of experience with ketoconazole shampoo. 

Br J Clin Pract 1991; 45(4):279–84.

  78.  Faergemann  J.  Treatment  of  seborrhoeic  dermatitis  of  the 
scalp with ketoconazole shampoo. A double-blind study. Acta 
Dermatol Venereol 1990; 70(2):171–2.

  79.  Peter RU, Richarz-Barthauer U. Successful treatment and pro-
phylaxis of scalp seborrhoeic dermatitis and dandruff with 2% 
ketoconazole shampoo: Results of a multicentre, double-blind, 
placebo-controlled trial. Br J Dermatol 1995; 132(3):441–5.
  80.  Berger  R,  Mills  O,  Jones  E.  Double-blind,  placebo-controlled 
trial of ketoconazole 2% shampoo in the treatment of moderate 
to severe dandruff. Adv Ther 1990; 7(5):247–56.

  81.  Go IH, Wientjens DP, Koster M. A double-blind trial of 1% keto-
conazole shampoo versus placebo in the treatment of dandruff. 
Mycoses 1992; 35(3–4):103–5.

  82.  Arrese J, et al. Effect of ketoconazole-medicated shampoos on 
squamometry and Malassezia ovalis load in pityriasis capitis. 
Cutis 1996; 58(3):235–7.

  83.  Pierard-Franchimont  C,  et  al.  Effect  of  ketoconazole  1%  and 
2%  shampoos  on  severe  dandruff  and  seborrhoeic  derma-
titis:  Clinical,  squamometric  and  mycological  assessments. 
Dermatology 2001; 202(2):171–6.

  84.  Squire  RA,  Goode  K.  A  randomised,  single-blind,  single-
centre  clinical  trial  to  evaluate  comparative  clinical  efficacy 
of  shampoos  containing  ciclopirox  olamine  (1.5%)  and  sali-
cylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment 
of  dandruff/seborrhoeic  dermatitis.  J  Dermatolog  Treat  2002; 
13(2):51–60.

  85.  Draelos Z. Shampoo, hair, and technology: Part two. Cosmetic 

Dermatology 2003; 16(2):71–76.

  86.  Nakagawa H, et al. Tacrolimus has antifungal activities against 
Malassezia  furfur  isolated  from  healthy  adults  and  patients 
with atopic dermatitis. Clin Drug Invest 1996; 12:245–50.
  87.  Ling MR. Topical tacrolimus and pimecrolimus: Future direc-

tions. Semin Cutan Med Surg 2001; 20(4):268–74.

  88.  Faergemann 

J. 

in 
Seborrheic  Dermatitis 
Cosmeceuticals:Drugs  vs.  Cosmetics.  In:  Elsner  HIM  P,  ed.  New 
York, NY: Marcel Dekker 2000; pp. 197–202.

(Dandruff), 

  89.  Caputo  R,  Barbareschi  M.  Itraconazole:  New  horizons.  G  Ital 

Dermatol Venereol 2002; 137:1–7.

  90.  Sheth  RA.  A  comparison  of  miconazole  nitrate  and  sele-
nium  disulfide  as  anti-dandruff  agents.  Intl  J  Dermatol  1983; 
22(2):123–5.

  91.  Zecevic  R,  Toskic-Radojicic  M,  Mijailovic  B.  [Therapy  of  dys-
seborrheic dermatitis with ketoconazole]. Vojnosanit Pregl 1993; 
50(1):61–3.

 
258 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  92.  Schwartz J. et al. Zinc pyrithione. Critical pharmacological fac-
tors  in  achieving  efficacious  dandruff  treatment  products.  In 
Barel A, Paye M, Maibach H, eds. Handbook of Cosmetic Science 
and Technology, 4th edition. Boca Raton, FL: CRC Press 2014; pp. 
627–33.

  93.  Bartalini P, Bilenchi R, Dina F. Anti-pityriasis of a line of prod-
ucts containing piroctone olamine. G Ital Dermatol Venerol 1987; 
122(3):XI–XIX.

  98.  Pierard-Franchimont  C,  et  al.  Comparative  anti-dandruff  effi-
cacy between a tar and a non-tar shampoo. Dermatology 2000; 
200(2):181–4.

  99.  Schwartz, J. [Letter to the Editor]. Eur J Dermatol 2002; 12:617.
  100.  Leyden JJ, et al. Effects of sulfur and salicylic acid in a sham-
poo  base  in  the  treatment  of  dandruff:  A  double-blind  study 
using  corneocyte  counts  and  clinical  grading.  Cutis  1987; 
39(6):557–61.

  94.  Gleser  L,  Olkin  I.  Stochastically  dependent  effect  sizes.  In 
IHCLVH, eds. The Handbook of Research Synthesis. 1994; pp. 339–55.
  95.  Wang M, Bushman BJ. Integrating Results through Meta-Analytic 

  101.  Sugita T, et al. Molecular analysis of malassezia microflora on 
the skin of atopic dermatitis patients and healthy subjects. J Clin 
Microbiol 2001; 39(10):3486–90.

Review Using SAS® Software. SAS Press 1999.

  96.  Schwartz  J.  Product  pharmacology  and  medical  actives  in 
achieving  therapeutic  benefits.  J  Invest  Dermatol  Symp  Proc 
2005; 10:198–200.

  97.  Wigger-Alberti  W,  Kluge  K,  Elsner  P.  [Clinical  effectiveness 
and  tolerance  of  climbazole  containing  dandruff  shampoo  in 
patients  with  seborrheic  scalp  eczema].  Schweiz  Rundsch  Med 
Prax 2001; 90(33):1346–9.

  102.  Schwartz  J,  et  al.  Therapeutic  efficacy  of  anti-dandruff  sham-
poos:  A  randomized  clinical  trial  comparing  products  based 
on potentiated zinc pyrithione and zinc pyrithione/climbazole. 
Intl J Cosm Sci 2013; 35:381–7.

  103.  Kerr  K,  et  al.  Scalp  stratum  corneum  histamine  levels:  Novel 
sampling method reveals association with itch resolution. Acta 
Derm Venereol 2011; 91(4):404–8.

 
29

The Periorbital Wrinkle

Martin R. Green

THE HUMAN PERIORBITAL WRINKLE
Wrinkles are the most obvious and perhaps the most disliked 
aspect of facial aging. Considering this, it is surprising that the 
biology of wrinkle formation remains unclear, as is the physi-
cal structure of wrinkles and why is it so hard to erase a wrin-
kle once it is formed.

Many  people,  scientists  and  laymen  alike,  have  con-
sidered  wrinkles  to  be  cosmetic  and  therefore  not  worthy  of 
research. There was a common belief that as the skin aged, col-
lagen stiffened, elastic networks collapsed, and the mechanical 
properties of the skin degraded. Wrinkles were just seen as the 
“points of weakness” where excess, lax skin formed creases.

Nothing has made a larger impact on this simplistic model 
than the success of botulinum toxin in reducing facial wrinkles. 
Botulinum toxin is injected into the muscles underneath the skin 
and causes a long-lasting paralysis and relaxation of those mus-
cles. The fact that this has such a dramatic effect on the appear-
ance of the wrinkle proves that deep wrinkles are not simply a 
phenomenon of changed properties of the skin but rather are an 
effect of the entire integumentary system including not only the 
dermis but also the subcutaneous fat and muscle layers.

Wrinkles  also  contribute  to  “perceived  age,”  the  aver-
age  facial  age  of  a  person  estimated  by  independent  assessors 
(1,2). Over the past 10 years perceived age has gained credence 
as a highly useful biomarker of aging and a method by which 
to study the facial attributes of attractiveness. Perceived age has 
been shown to be a robust indicator of health (3) and to be influ-
enced by facial wrinkles (2). In a 70+ age group, perceived age 
predicted human survival and correlated inversely with physi-
cal and cognitive functioning (1). As well as facial wrinkles, hair 
graying and lip height are also major contributors to perceived 
age. Twin studies have also shown that facial wrinkles are more 
or  less  equally  influenced  by  genetic  and  environmental  fac-
tors (2) while hair graying and lip height largely influenced by 
genetic factors (2). More recently factors such as serum glucose (4) 
and cortisol (5) have been shown to be correlated with perceived 
age, implying at least an indirect causal link to aging features.

This  chapter  briefly  reviews  what  is  known  about  the 
wrinkle  and  sets  out  studies  which  cast  new  light  on  how 
deep  periorbital  wrinkles  (“crow’s  feet”)  form  and  are  main-
tained,  pointing  to  new  therapeutic  approaches  to  treat  peri-
orbital wrinkles. It should be noted that the complex biological 
processes  leading  to  wrinkle  formation  are  certain  to  vary 
between wrinkle types (6) and that the conclusions drawn here 
relate only to periorbital wrinkles.

WRINKLES AS AN ASPECT OF AGED SKIN
There  is  a  considerable  literature  describing  the  differ-
ences  between  youthful  and  aged  skin.  In  many  cases,  no 
attempt  is  made  to  differentiate  between  the  area  of  the 

wrinkle  and  the  unwrinkled  skin  around  it.  In  large  part 
this  is  because  it  is  sometimes  difficult  to  locate  a  wrinkle 
in  a   histological  section–a  surprising  factor  to  which  I  will 
return later.

For  a  review  of  the  wrinkle  literature  the  reader  is 
guided to the articles by Kligman (7), Contet-Audonneau (8), 
Lavker (9), Tsuji (10), and Humbert (6). The key findings are 
as follows:

1. 

2. 

3. 

4. 

5. 

 The  epidermis  thins  with  age  and  the  properties  of  the 
stratum corneum change in a multitude of ways includ-
ing  reduced  barrier  repair  properties  and  decreased 
elasticity.  These  changes  are  particularly  important  in 
causing  “fine  lines”  and  are  the  changes  that  are  coun-
tered by the vast majority of effective topical moisturiz-
ing products.
 The  intricate,  interconnected,  elastic  fiber  network  in 
the  dermis  degrades  and  is  replaced  (especially  in  the 
case  of  sun  exposed  skin)  by  large  deposits  of  poorly 
organized  nonfunctional  elastin  deep  in  the  dermis. 
This  leads  directly  to  loss  of  resiliency–the  ability  of 
the  skin  to  quickly  return  to  its  original  shape  after 
 distortion. In extreme cases the large elastin deposits (so 
called   elastosis)  can  cause  the  skin  to  look  sallow  and 
yellowish  in  color.  Aspartic  acid  residues  in  elastin  are 
also  prone  to  racemization  and  the  protein  is  known 
to be turned over very slowly if at all (11). Accordingly, 
functional   elastin  networks  in  skin  appear  easy  to 
destroy  and   nonfunctional  elastotic   deposits  very  hard 
to remove.
less  well  organized  and 
 Collagen  fibers  become 
the 
changes 
chemical 
 including  crosslinking  that  reduce  its  mechanical  flex-
ibility.  Repeated  imperfect  collagen  repair  can  lead  to 
 “scar-like” patches of stiff, aligned collagen. The dermal 
thickness under major wrinkles decreases (12) and there 
may also be direct-dermal UV–mediated damage of pro-
teins (13).
 The  skin  glycosaminoglycan  composition  changes 
greatly.  In  sun-exposed  skin  with  chronic  (i.e.  years  of) 
photodamage there is a marked increase in types of sul-
phated  glycosaminoglycans  (versican)  at  the  expense  of 
others (decorin). Since these molecules can hold as much 
as  1000  times  their  own  weight  of  water  in  an  elastic 
gel these changes hugely affect the water content of the 
dermis.
 The  subcutaneous  fat 
in  women, 
decreases  markedly  in  thickness.  Major  wrinkles  also 
form  dermal  invaginations  into  the  subcutaneous  fat 
layer (12).

itself  undergoes 

layer,  especially 

 collagen 

260 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Skin which has undergone deleterious changes is obvi-
ously  prone  to  wrinkles.  However  photodamage  is  not  suffi-
cient on its own to cause some types of wrinkling to occur. The 
extra factor that seems to be necessary is repeated movement 
of  the  skin  causing  folding  of  the  skin.  Over  time,  and  com-
bined with the overall aging changes set out above, wrinkles 
form and progressively get worse. Thus wrinkling can be seen 
on the face where “expression lines” form but not in other sun-
exposed areas even though the histological degradation of the 
skin may be worse. The toxins introduced by cigarette smok-
ing  also  make  a  marked,  adverse  contribution  to  wrinkling 
(14), particularly around the mouth.

LOCAL DIFFERENCES IN THE WRINKLE 
COMPARED TO SUROUNDING SKIN
Considering  what  an  obvious  feature  a  wrinkle  represents, 
there are limited published data contrasting the wrinkle with 
the surrounding skin. Such studies that have been done sug-
gest  that  the  classic  features  of  solar  elastosis  are  less  in  the 
base of the wrinkle than in the surrounding skin (8,10).

One reason for the limited number of these studies is that 
it is difficult to identify wrinkles—even deep ones—in histologi-
cal  sections.  When  the  skin  is  excised,  the  wrinkle  opens  and 
partially disappears—obvious evidence that major wrinkles are 
under compression and in part maintained by the properties of 
the  surrounding  skin.  To  overcome  this  problem  a  novel  tech-
nique was used whereby a line of cyanoacrylate glue, visible in 
Figure 29.1, was introduced into the wrinkle and allowed to set 
prior to taking a biopsy of the wrinkle. With this precaution, the 
shape of the wrinkle was preserved, allowing a better correlation 
of histological changes to the architecture of the wrinkle.

Sections of these biopsies, which were taken from the peri-
orbital “crow’s feet” areas, were stained by a variety of techniques 
using  both  conventional  and  immunostaining   techniques.  We 
confirmed the finding (8,10) that the elastic fiber network was far 
less damaged at the base of a deep wrinkle than on the sides of 
the wrinkle or adjacent skin (Figure 29.1). This is thought to be 
a consequence of the base of the wrinkle being less exposed to 
ultraviolet (UV) light during and after formation than the sur-
rounding skin. It suggests that the damage to the elastic fiber net-
work in unlikely to be a primary cause of the wrinkle.

In contrast to the normal-appearing elastin at the wrinkle 
base, the “elastin” at the sides of the wrinkle is heavily disorga-
nized (elastotic), a phenomenon that is worse on the lower, more 

sun-exposed side, as viewed when a wrinkle would have been 
positioned  in  situ  on  the  face.  The  collagen  fiber  orientations 
were also quite abnormal. In stark contrast to the sides of the 
wrinkles, where the collagen fibers tended to run parallel to the 
long edge of the wrinkle and were in places relatively normal, 
at the wrinkle base there was a dense band of highly aligned 
collagen  fibers  running  perpendicular  to  and  underneath  the 
wrinkle (Figure 29.2, also clearly visible in Figure 29.1).

This band of highly aligned collagen was one of the few 
features  of  the  permanent  periorbital  wrinkle  that  correlated 
clearly with the wrinkle location and gave a clue to what dictated 
the shape of the wrinkle. Recently Pessa et al. have reported that 
lymphatic  vessels  with  perilymphatic  fat  lie  very  close  to  or 

(a)

(b)

Reduced elastosis

(0.5 mm)

Figure 29.1  Elastic fibers in the periorbital wrinkle (orcein stain).

Figure  29.2  Highly  aligned  collagen  at  the  base  of  the  wrin-
kle.  Red,  tropoelastin;  green,  fibroblasts;  blue,  mature  collagen 
(a).  Red,  nuclei;  green,  fibroblasts;  blue,  mature  collagen  (b). 
(Photographs courtesy of J. Wares).

 
directly underneath major facial wrinkles (15). Regretfully, lym-
phatic features were not evaluated in this study.

To  investigate  how  attached  collagen  fiber  alignment 
may occur, a computer model of the skin was developed (M. 
Eastwood  and  M.R.  Green,  unpublished  data)  incorporating 
the  structural  information  derived  from  the  histology  and 
building in physical material constants for the different parts 
of  the  skin.  Other  simulated  models  for  immediate  wrinkle 
formation  after  skin  compression  have  been  prepared  (16,17) 
but  these  do  not  take  account  of  the  effect  of  changing  ten-
sion  on  the  long-term  biological  responses  of  the  skin,  and 
local changes in wrinkle architecture. A novel method using 
digital  image  speckle  correlation  has  also  been  developed  to 
study the mechanical properties of skin, showing that lines of 
increased tension in skin coincide with the position of promi-
nent wrinkles (18). Using a new method, Yasui et al (19) have 
employed  polarization-resolved  second-harmonic–generation 
microscopy to study collagen fiber alignment in UV-irradiated 
mouse skin. The results show striking collagen fiber patterns 
developing around major wrinkles over 16 weeks of UV treat-
ment, with fiber alignments developing consistent with those 
reported here.

COMPUTER MODEL OF THE 
PERIORBITAL WRINKLE
Figure 29.3 shows the basic structure of the computer model. 
It incorporates four different layers: the epidermis, the papil-
lary dermis, the reticular dermis, and the highly aligned zone 
of collagen. Material properties of these zones were estimated 
from literature values, as shown in Table 29.1. The model was 
based  on  finite  element  analysis  using  Pro  Mechanica®  soft-
ware.  The  base  of  the  skin  in  the  model  was  anchored  to  an 
inflexible  substrate.  No  attempt  was  made  to  simulate  the 
effects of muscle or the attached subcutaneous fat layer.

THE PERIORBITAL WRINKLE 

  261

The first and critical finding in preparation of the model 
was that the simulated wrinkle could only maintain its shape 
with  compressive  forces  pushing  the  wrinkle  closed.  Three 
possible sources of this compressive force exist:

1. 

2. 

3. 

 Overall pressure from the surrounding skin. If older skin 
has  a  larger  natural  area  than  it  is  constrained  to  by  its 
attachment to the underlying tissue, then the whole area 
of skin will be under compression. This is probably a sig-
nificant factor where there has been significant loss of the 
subcutaneous fat layer leading to shrinkage of the attach-
ment area for the skin. Conventional “facelift” procedures 
act on this compression effect by reducing the natural area 
of  the  skin  so  that  wrinkle  compression  is  replaced  by  a 
tension.  Skin  is  usually  maintained  under  tension  as  is 
evident from its behavior when cut (it will gape) or from 
instrumental measurements (20–22).
 Action  of  subcutaneous  muscles.  The  integumentary 
system is extensively attached to muscle groups that can 
actively create tensions in the skin. This is particularly so 
on areas such as the forehead and around the mouth. Where 
muscle groups act to compress areas of skin, the compres-
sion can generate and sustain wrinkles. Botulinum toxin 
injections  act  on  these  muscle  groups  causing  them  to 
relax for as long as 6 months. The fact that in certain types 
of  wrinkle  such  injections  virtually  eliminate  the  visible 
wrinkle proves that for some types of wrinkles the muscle 
generated compressive forces are a primary cause.
 Tension  carried  within  the  aligned  collagen  at  the  wrin-
kle  base.  Figure  29.4  shows  the  computer  wrinkle  model 
when  the  wrinkle  has  been  allowed  to  open  up,  as  if  it 
were excised. The color scale shows the amount of stress 
in the different elements of the model. A major stress is 
found in a narrow zone at the base of the wrinkle, in the 
aligned collagen domain. This stress arises because of the 

Epidermis

Papillary dermis

Aligned collagen
running across
wrinkle base

Recticular dermis

Figure 29.3  Visualization of the wrinkle computer model. (Picture courtesy of M. Eastwood).

Table 29.1  Physical Constants Used in The Computer-Generated Wrinkle Model

Epidermis

Papillary dermis

Reticular dermis

Aligned collagen

Young’s modulus (MPa)
Poisson’s ratio

0.06

0.45

0.05

0.49

0.048

0.49

0.065

0.49

 
262 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Strain map

Excised human wrinkle

Figure 29.4  Strains calculated in the computer-wrinkle model of a “relaxed” wrinkle (left image) compared to the histology of an excised, 
“relaxed” human periorbital wrinkle where the cyanoacrylate glue failed to hold the wrinkle sides together (right image).

Increasing tension

removal  of  the  compressive  force  on  the  wrinkle  sides, 
and  gives  an  indication  of  what  might  happen  during 
day-to-day flexing of the wrinkle on the face. Put simply, 
the  aligned  collagen  band  is  stiff  but  under  little  stress 
when  the  wrinkle  is  closed.  As  the  wrinkle  opens,  the 
stiff collagen band deforms and resists the opening of the 
wrinkle. This strongly implies that the aligned collagen 
band  is  a  major  factor  in  maintaining  the  shape  of  the 
periorbital wrinkle.

ORIGIN OF THE ALIGNED COLLAGEN LAYER
Why does the wrinkle possess this deep zone of highly aligned 
“scar-like” collagen? While it is clearly important to the main-
tenance of the wrinkle once formed, it is unlikely to have a role 
in the initial formation of the wrinkle. Indeed if such a zone 
were present in an area of unwrinkled skin it might cause the 
wrinkle  to  form  nearby  rather  than  in  an  inflexible  zone.  To 
understand  how  the  zone  could  form  it  is  necessary  to  con-
sider the interplay of forces within the tissue and the biologi-
cal  behavior  of  fibroblasts  within  the  tissue  and  response  to 
mechanical force.

Fibroblasts are richly endowed with surface molecules, 
particularly integrins, that will bind to components of the con-
nective tissue—collagen, fibronectin, etc. When these surface 
molecules bind to the connective tissue matrix, they transduce 
mechanical forces (23,24) acting through the binding sites into 
biological changes in the cell. One outcome of this is that fibro-
blasts within a connective tissue matrix that is under tension 
increase  their  synthesis  of  collagen  and  deposit  it  preferen-
tially in the direction of the tension (25–27).

What  does  this  mean  for  the  skin?  In  unwrinkled  skin 
under uniform “360°” tension, individual collagen fibers have 
a  random  direction  of  alignment.  When  unwrinkled  skin  is 
flexed so as to form a temporary “expression” fold, the greatest 
tension is experienced by the tissue at the base of the fold and 
causes collagen fibers to align perpendicular to the furrow or 
fold  line.  In  response  to  that  tension,  fibroblasts  deposit  col-
lagen in the direction of the tension, perpendicular to the fold, 
adding to the aligned collagen. The next time the skin is flexed 
and the fold forms, the tissue at the base of the fold is just a little 

stiffer due to the deposited collagen. That makes the tension at 
the wrinkle base just a little higher and induces the deposition 
of still more aligned collagen. Over time this vicious circle con-
tinues until the aligned collagen comes to dominate the stress 
field in the skin to the point where it maintains a permanent 
wrinkle. Sunlight, particularly UVB radiation, exaggerates this 
effect by activation of proteases and the triggering of further 
collagen realignment (28) and loss of elastic fibers (29).

IMPLICATIONS FOR TREATMENT 
OF WRINKLES
It is clear from the discussion above that there are multiple dis-
tinct factors such as acute and chronic sun exposure, natural 
skin  tension,  skin  flexing,  intrinsic  aging  changes  including 
the thinning of the dermis and loss of subcutaneous fat, caus-
ing  and  sustaining  wrinkles.  In  all  body  and  facial  sites  it  is 
likely  that  all  the  factors  contribute  to  the  overall  wrinkling 
effect, but the relative contribution of the different factors will 
differ,  giving  rise  to  different  wrinkle  structures,  suggesting 
different  optimum  treatment  regimes  for  wrinkle  types  may 
be needed.

On  the  forehead,  the  dominant  factor  sustaining  wrin-
kles  appears  to  be  the  action  of  the  subcutaneous  muscles. 
Botulinum toxin injections are known to be highly effective.

On  the  cheeks  and  around  parts  of  the  mouth,  loss  of 
subcutaneous  fat  and  elastic  fibers  leads  to  a  general  loss  of 
tension of the skin. In these cases, botulinum toxin is less effec-
tive and surgical removal of flaps of skin or generalized con-
traction of the skin using laser treatment is necessary to have 
a substantial effect.

The crow’s feet area is characterized by wrinkles main-
tained  by  the  stiffened  aligned  collagen  zone  at  the  wrinkle 
base. Botulinum toxin has relatively little effect on these wrin-
kles and while surgical “facelift” procedures may have tempo-
rary  benefits,  the  analysis  above  suggests  that  stretching  the 
wrinkles out does not change the underlying histology, prob-
ably ensuring that the wrinkles will return.

The  analysis  above  suggests  that  a  promising  route  for 
treatment of such periorbital wrinkles would involve stimula-
tion  of  deep  dermal  collagen  remodeling,  to  put  into  reverse 

 
the  vicious  cycle  that  caused  the  aligned  collagen  zone  to 
form. If collagen turnover could be stimulated while the skin 
was exposed to tension parallel to the long edge of the wrin-
kle, then the existing perpendicular collagen fibers would be 
reduced  and  remodeled  while  new  fibers  remodeled  parallel 
to  the  wrinkle  would  no  longer  sustain  the  wrinkle  shape. 
Retinoic acid might be effective used in this way, as it has been 
shown both to increase collagenase expression in skin and to 
increase the deposition of newly synthesized collagen. To our 
knowledge, such a combined topical tension and topical treat-
ment experiment has yet to be attempted. Recently, promising 
clinical results for facial wrinkle reduction have been achieved 
after long-term consumption of a supplemented drink contain-
ing  isoflavones,  lycopene,  vitamin  C,  vitamin  E  and  fish  oils 
(30). Such a dietary approach may be better able to deliver ben-
efit agents to deep wrinkle sites which topical agents may not 
be able to affect.

ACKNOWLEDGMENTS
I  thank  Dr.  IR  Scott  for  co-authoring  the  first  edition  of  this 
book  chapter,  the  late  Dr.  WE  Parish,  Unilever  Research, 
Colworth Science Park, Sharnbrook, Bedford, UK; M Eastwood, 
University of Westminster, London; M Simon, Departments of 
Oral Biology and Dermatology, SUNY at Stony Brook, NY; and 
DM  Siegel,  Departments  of  Oral  Biology  and  Dermatology, 
SUNY at Stony Brook, NY, for access to results prior to publica-
tion, and Dr. S. Singleton, Unilever Research, Colworth Science 
Park, Sharnbrook, Bedford, UK, for critical comments.

REFERENCES

1.  Christensen K, Thinggaard M, McGue M et al. Perceived age is 
a clinically useful biomarker of ageing: Cohort study. Br Med J 
2009; 339:b5262.

2.  Gunn  DA,  Rexbye  H,  Griffiths  CEM,  et  al.  Why  some  women 

look young for their age. PLOS One 2009; 4:e8021.

3.  Gunn DA, de Craen AJ, Dick JL et al. Facial appearance reflects 
human  familial  longevity  and  cardiovascular  disease  risk  in 
healthy individuals. J Gerontol A Biol Sci Med Sci 2013; 68:145–62.
4.  Noordam R, Gunn DA, Tomlin CC, et al. High serum glucose 
levels  are  associated  with  a  higher  perceived  age.  Age  (Dordr) 
2013; 35:189–95.

5.  Noordam R, Gunn DA, Tomlin CC, et al. Cortisol serum levels 
in familial longevity and perceived age: The Leiden Longevity 
study. Psychoneuroendocrinology 2012; 37:1669–75.

6.  Humbert P, Vienet C, Legagneux K, et al. In the shadow of the 

wrinkle: Theories. J Cosmet Dermatol 2012; 11:72–8.

7.  Kligman AM. The classification and treatment of wrinkles. In: 
Kligman  AM,  Takase  Y,  eds.  Cutaneous  Ageing.  Tokyo,  Japan: 
University of Tokyo Press 1986; pp. 547–55.

8.  Contet-Audonneau  JL,  Jeanmarie  C,  Pauly  G.  A  histological 
study of human wrinkle structures: Comparison between sun-
exposed areas of the face, with or without wrinkles, and sun-
protected areas. Br J Dermatol 1999; 140:1038–47.

THE PERIORBITAL WRINKLE 

  263

  11.  Ritz-Timme S, Laumeier I, Collins MJ. Aspartic acid racemiza-
tion: Evidence for marked longevity of elastin in human skin. 
Br J Dermatol 2013; 149:951–9.

  12.  Tsukahara K, Tamatsu Y, Sugawara Y, Shimada K. The relation-
ship between wrinkle depth and dermal thickness in the fore-
head and lateral canthal region. Arch Dermatol 2011; 147:822–8.

  13.  Thurstan  SA,  Gibbs  NK,  Langton  AK,  et  al.  Chemical  conse-
quences of cutaneous photoageing. Chemistry Central J 2012; 6:34.

  14.  Morita  A.  Tobacco  smoke  causes  premature  skin  ageing. 

J Dermatol Sci 2007; 48:169–75.

  15.  Pessa  JE,  Nguyen  BA,  John  GB,  Scherer  PE.  The  anatomical 

basis for wrinkles. Aesthet Surg J 2014; 34:227–34.

  16.  Kuwazuru O, Saothong J, Yoshikawa, N. Mechanical approach 
to aging and wrinkling of human facial skin based on the mul-
tistage buckling theory. Med Eng Phys 2007; 30:516–22.

  17.  Flynn CO, McCormack BAO. A three-layer model of skin and 
its  application  in  simulating  wrinkling.  Comput  Meth  Biomech 
Biomed Engin 2009; 12:125–34.

  18.  Staloff IA, Guan E, Katz S, et al. An in vivo study of the mechan-
ical properties of facial skin and influence of aging using digital 
image speckle correlation. Skin Res Technol 2008; 14:127–34.
  19.  Yasui  T,  Takahashi  Y,  Fukushima  S  et  al.  Observation  of  der-
mal collagen fiber in wrinkled skin using polarization-resolved 
second-harmonic-generation  microscopy.  Opt  Express  2009; 
17:912–23.

  20.  Gibson  T,  Kenedi  RM.  The  significance  and  measurement 
of  skin  tension  in  man.  In  Transactions  of  the  3rd  International 
Congress on Plastic Surgery. Baltimore, MD: Williams & Wilkins 
1963; 387–95.

  21.  Alexander  A,  Cook  TH.  Accounting  for  natural  tension  in 
the  mechanical  testing  of  human  skin.  J  Invest  Dermatol  1977; 
69:310–4.

  22.  Diridollou S, Vabre V, Berson M, et al. Skin ageing: Changes of 
physical properties of human skin in vivo. Int J Cosmet Sci 2001; 
23:353–62.

  23.  Eckes B, Zweers MC, Zhang ZG, et al. Mechanical tension and 
integrin  alpha  2  beta  1  regulate  fibroblast  functions.  J  Invest 
Dermatol Symp Proc 2006; 11:66–72.

  24.  Leask A. Integrin ß1: A mechanosignaling sensor essential for 
connective  tissue  deposition  by  fibroblasts.  Adv  Wound  Care 
2013; 2:160–6.

  25.  Eastwood M, Mudera VC, McGrouther DA, Brown RA. Effect of 
precise mechanical loading on fibroblast populated collagen lat-
tices: Morphological changes. Cell Motil Cytoskel 1998; 40:13–21.

  26.  Wang JHC, Grood ES. The strain magnitude and contact guid-
ance determine orientation response of fibroblasts to cyclic sub-
strate strains. Connect Tiss Res 2000; 41:29–36.

  27.  Lindahl GE, Chambers RC, Papakrivopoulou J, et al. Activation 
of  fibroblast  procollagen  1α  transcription  by  mechanical 
strain is transforming growth factor β dependent and involves 
increased binding of CCAAT-binding factor (CBF/NF-Y) at the 
proximal promoter. J Biol Chem 2002; 277:6153–61.

  28.  Takema Y, Nishijima A, Ohsu H et al. Skin morphology at the 
time of UV irradiation is important for wrinkle formation. J Soc 
Cosmet Chem 1997; 48:297–306.

  29.  Lee JY, Kim YK, Seo JY, et al. Loss of elastic fibers causes skin 

9.  Lavker  RM.  Structural  alterations  in  exposed  and  unexposed 

wrinkles in sun damaged skin. J Dermatol Sci 2008; 50:99–107.

aged skin. J Invest Dermatol 1979; 73:59–66.

  10.  Tsuji  T,  Yorifuji  T,  Hayashi  Y,  Hamada  T.  Light  and  scanning 
electron microscopic studies on wrinkles in aged persons’ skin. 
Br J Dermatol 1986; 114:329–35.

  30.  Jenkins G, Wainwright LJ, Holland R, et al. Wrinkle reduction 
in  post-menopausal  women  consuming  a  novel  oral  supple-
ment: A double blind placebo controlled randomised study. Int 
J Cosmet Sci 2014; 36:22–31.

 
 
 
 
 
 
 
 
 
 
30

Cosmetology for Normal Nails

Robert Baran and Douglas Schoon

INTRODUCTION
Evolving from the primeval claw, the nail's working uses became 
less important, while over time their aesthetic value has grown 
in  importance.  The  application  of  cosmetics  to  the  nail  can  is 
done to enhance length, beautify or address specific needs. The 
nail is a convex, hard, horny plate covering the dorsal aspect of 
the  tips  of  the  fingers  and  toes  (Figure  30.1).  Its  appearance  is 
determined by the integrity of the terminal bony phalanx and 
the paronychium, and i.e. matrix, nail bed and hyponychium, 
and  nail  folds.  The  nail  plate,  produced  by  the  matrix,  grows 
from  a  pocket-like  invagination  of  the  epidermis  and  adheres 
firmly to the nail bed. Tissue from the undersurface of the proxi-
mal nail fold also tightly adheres to the surface of the nail and 
as  the  nail  grows,  emerges  from  underneath  the  eponychium 
to  create  the  cuticle.  This  cuticle  tissue  creates  a  resistant  gas-
ket-like seal which helps protect the nail pocket from infection, 
irritants,  etc.  The  most  distal  part  of  the  matrix,  the  whitish 
semicircular  lunula,  is  visible  wherever  it  extends  beyond  the 
proximal nail fold. Juxtaposed to the lunula, the pink nail bed 
epithelium  is  made  from  parallel  longitudinal  rete  ridges  and 
subepithelial capillaries running longitudinally at different lev-
els. Adjacent to the nail bed, the hyponychium, an extension of 
the epidermis under the nail plate, marks the point at which the 
nail  separates  from  the  underlying  bed  tissue.  There  is  small 
area between the nail and the distal bony phalanx that is occu-
pied by non-keratinizing nail epithelium, as well as highly vas-
cular mesenchyme containing glomus organs.

The Following Should Be Borne in Mind

• The  proximal  matrix  forms  the  surface  of  the  nail  plate, 
and the distal matrix forms its inferior part. It is therefore 
possible to locate initiating pathology by a thorough exam-
ination of the nail.

•  Fingernails  grow  at  a  rate  of  0.1  mm  a  day;  toenails  grow 
much more slowly. It can take 12–18 months to replace a large 
toenail as opposed to 5–6 months for the fingernail. The nail's 
functional  role  is  to  protect  the  nail  bed  and  help  prevent 
breakage or fracture of the bony tips at the end of each fin-
ger and toe. The underside provides counter pressure on the 
pulp;  essential  for  good  tactile  sensation  involving  the  fin-
gers. Nail beauty depends on several main factors: the shape 
and length of the nail, its color (or decoration), and its texture.

CARE AND ADORNMENT 
OF THE NORMAL NAIL
The Shape of the Nail
The  shape  of  the  nail  depends  on  proportion  and  con-
tour.  The  ratio  of  length  to  breadth  of  the  nail  is  critical  to 
its  aesthetic  appeal,  and  the  two  dimensions  should  be 

 approximately  equal  (1),  at  least  on  the  thumb.  When  the 
“magic” ratio  differs from the ideal, the nail is less attractive 
(Figure 30.2).

Until  the  early  1990s,  oval-shaped  nails  were  most 
popular,  but  the  current  trend  is  to  cut  the  tip  more  or  less 
squarely at the free edge (Figure 30.3) to create an illusion of 
thinner,  more  tapered  and  graceful  fingers.  When  too  long, 
however,  nails  may  not  only  become  unsightly,  the  length 
may  interfere  with  hand  performance  and  increase  the  risk 
of  injury.  A  long  nail  is  more  likely  to  become  caught  and, 
acting like a lever, can lead to catastrophic separation of the 
nail  plate–nail  bed  attachment,  a  condition  called  onychol-
ysis.  The  form  or  style  of  the  nail  can  vary  geographically. 
In  some  locales,  shorter  nail  lengths  are  preferred,  usually 
with  rounded  or  almond-shaped  free  edges  which  can  cre-
ate a very natural-looking nail, if skilfully applied, while in 
other areas the preference is for longer nails with higher apex 
arches. Artificial nails are often used to seal the surface of the 
nail to help prevent mild peeling or splitting at the free edge 
as  well  as  to  enhance  their  look  for  cosmetic  purposes,  i.e. 
reshape flat nails with more attractive natural looking arches 
or  to  create  more  dramatic  curvature  at  the  free  edge.  They 
can also be used to correct the coloration of the nail or under-
lying tissue bed or to create the illusion of a longer nail bed. 
It  is  a  misperception  that  artificial  nails  are  mostly  worn  to 
lengthen the nail plate.

Decoration of the Nail
For  nails  of  equal  length  and  corresponding  contour,  a  col-
ored  or  painted  nail  is  usually  considered  more  attractive 
(Figure  30.4).  Interest  continues  to  grow  for  the  many  types 
of sculptured artificial nails and the current trend is to deco-
rate  them  with  everything  from  a  painted  snowflake  to  a 
three-dimensional flower or flag to a portrait of a grandchild. 
Colorant powders or colored UV gels or glitters are used to 
create artificial nails with permanent designs that can be very 
intricate  and  beautiful.  In  some  places  this  is  considered  a 
new  art  form,  highly  sought  after  and  collected  by  nail  art 
enthusiasts. Diamonds or emeralds have even been fixed into 
the elongated nails, while some wear intricate jewelry attach-
ments to the free edge (Figure 30.5). Like jeweler, some prac-
titioners  utilize  preformed  nails  of  gold  or  goldplate,  some 
studded with jewels.

Modern  nail  art  was  invented  in  the  late  1960s  when 
American teens began to paint colorful designs on their nails. 
The  fad  evolved  during  the  1970s  when  Japanese  nail  tech-
nicians  began  mixing  colored  pigments  into  their  artificial 
nail  enhancement  products.  Airbrushing  with  paint  became 
popular for creating artistic designs on the nails and this ser-
vice is still performed in salons to a lesser degree. The newer 

H

NP

NB

PNF M

COSMETOLOGY FOR NORMAL NAILS 

 265

Figure 30.1  Anatomy of the nail apparatus. M, matrix; NB, nail 
bed; H, hyponychium; NP, nail plate; PNF, proximal nail fold. (After 
Dr E Haneke.)

Figure 30.4  Painted nails are more attractive than plain nails.

Figure 30.2  The racket nail of the middle finger is less attractive 
than the nail exhibiting the ideal ratio.

(a)

(b)

Figure 30.3  There is a tendency to cut the tips of the nails more 
squarely.

Figure  30.5 
extremity of the nail.

Intricate  jewelry  can  be  attached  to  the  free  top 

(c)

(d)

technique is to use decorated films (coated on one side with a 
heat-sensitive  adhesive  backing)  to  decorate  either  natural  or 
artificial  nails.  There  are  many  hundreds  of  colors  available 

for  UV  gels  and  acrylic  nail  powder  users  and  hundreds  of 
preprinted  designs  and  decorations  available  on  adhesive 
backed film. The newest technique involves UV gels designed 

 
   
266 

 TEXTBOOK OF COSMETIC DERMATOLOGY

to  closely  mimic  traditional  UV  gel  coatings,  but  formulated 
more like a nail varnish to be easily brushed on the nail and 
more easily removed (Figure 30.6).

Texture of the Nail
The appearance and condition of the nail can determine its 
aesthetic appeal. The nail may be exposed to external agents 
or  conditions  which  may  render  it  soft,  brittle,  or  peeling. 
The  brittle  nail  is  vulnerable  to  single  or  multiple  longitu-
dinal  splitting  and  horizontal  splitting  into  layers  (onycho-
schizia)  (Figure  30.7),  or  less  often  to  transverse  breaking 
(Figure 30.8).

Frail nails can benefit from external treatments with oils 
or waxes which may absorb to soften or may seal the surface of 
the nail to prevent excessive moisture loss or absorption. Such 
treatments  are  popular  and  may  provide  value,  especially 
when  used  in  conjunction  with  avoidance  of  “wet  work.”  In 
addition, the age-dependent decrease in cholesterol sulfate lev-
els might explain the previously observed higher incidence of 
brittle nails in women (2).

Items for Nail Care
The following are examples of tools used for nail care (3).

Nippers and Cutters
Nippers are used to chip away or loosen artificial nail placed 
over the lunula area in preparation for reapplication in the area 
where the nail has grown out or where product is losing adhe-
sion. This process is called “a fill” or “rebalance.” These tools 
are  often  used  to  nip  off  tags  of  dead  skin  in  the  areas  sur-
rounding the nail. Some are especially designed for toenails. 
Cutters  are  jaw-like  blades  operated  by  a  spring  mechanism 
and  used  to  sever  the  free  edge  of  the  nail  or  artificial  tips. 
They are available in many sizes.

Emery Boards
Flat,  disposable,  “paperboard”  wands,  coated  with  abrasives 
emery powder and used to shape, reduce the length, or smooth 
sharp or jagged edges on the nail's free edge. These types of 
abrasive  files  are  inexpensive  and  often  used  by  nail  salons 
offering low-cost services and are considered single-use, dis-
posable items.

Figure 30.6  Nail art. (Courtesy of Dr. A Batistini).

Figure 30.7  Onychoschizia (splitting into layers).

Figure 30.8  Complete transverse breaking.

Other Abrasive Nail Files
Other types of abrasive nail files are made by coating an elon-
gated  board  made  of  metal,  glass,  fiberglass,  hard  plastic,  or 
wood with abrasive particles ranging in size and hardness. The 
“grit” of abrasive nail files is measured by counting the number 
of abrasive particles per cubic centimeter. Low-grit boards (60–
120 grit) are use to quickly remove layers of the artificial nail 
and should not be used directly on a natural nail. Medium-grit 
boards (180–240) are for smoothing and shaping both artificial 
and natural nails, fingers and toes. High-grit boards (800–2400) 
are  used  for  buffing,  polishing,  and  finishing.  Grit  is  not  the 
only  determining  factor.  Nail  files  can  be  coated  with  either 
crystalline aluminium oxide or silicon carbide. Silicon carbide 
is 20% harder than aluminium oxide, making these materials 
significantly more aggressive. Fine particles of diamond dust 
are  electroplated  on  to  a  metalized  fiberglass  board,  giving 
these  abrasive  files  great  durability  and  longevity.  The  high 
cost and extreme hardness of diamonds (10% higher than sili-
con carbide) is the reason these files have limited value for this 
application.

Blocks
These are also abrasive nail files and they take the form of a 
larger,  rectangular  foam  block  that  fits  comfortably  into  the 
hand. Blocks are the most widely used primarily due to their 
improved comfort, ease of use and efficiency.

 
Nail Buffers
Specialty  nail  files  designed  to  create  very  smooth  and  high 
shine surfaces on natural or artificial nails. They are normally 
used as “three-way buffers,” having three different grit sizes 
used in succession from coarsest to finest particle size which 
remove scratches and create smooth, uniform surfaces.

Padded chamois buffers used in conjunction with mild 
pumice-type abrasive creams or waxes and oils will produce 
a very high shine on the nail surface. Such systems have been 
used  for  generations.  This  is  not  a  widely  used  mainstream 
technique, but is considered a more traditional technique used 
by more traditional practitioners

Pushers
These devices are used to gently push back the eponychium and 
expose more of the lunula. They can also be used to carefully 
loosen,  scrape,  and  remove  cuticle  tissue  from  the  nail  plate. 
Pushers can be polished, metallic probes with variously shaped 
rounded ends and relatively dull edges to minimize the poten-
tial for soft tissue injury. Another type is a pencil-shaped plastic 
or wooden implement used in the same fashion. The advantage 
of using wood is safety, since they are less likely to cause injury 
to the nail folds. Originally fabricated from orange wood, now 
they are primarily birch and are considered a single-use, dispos-
able item.

Cuticle Trimmers
The  small,  clipper-jawed  scissors  are  used  inappropriately 
for cutting frayed skin and living tissue (Figure 30.9). Devices 
that  are  curette-like,  using  a  V-shaped  blade  mounted  to  a 
plastic  handle,  are  used  to  shave  living  tissue.  Nail  techni-
cians  are  using  them  for  cutting  the  nail  fold,  which  they 
mistakenly believe it is the cuticle. Trimming this living skin 
creates hardened tissue. When nail technicians cut this tis-
sue away with any device, they often breach the skin barrier, 
increasing potential for infection, which is why government 
regulations  usually  forbid  service  providers  such  as  nail 
technicians  from  intentionally  cutting  living  skin  as  part 
of  their  professional  services.  Like  all  devices  designed  to 
shave  the  skin,  they  should  not  be  used  to  perform  salon 
services.

(a)

(b)

Figure 30.9 Cuticle trimmer.

COSMETOLOGY FOR NORMAL NAILS 

 267

Nail Whitener
This is a pencil-like device with a white clay (kaolin) core used 
to deposit color on the undersurface of the free edge of the nail. 
These should be avoided in professional salon settings because 
reuse can contribute to transmission of pathogenic organisms 
from client to client.

Disinfectant tContainer and Cover
A  disinfection  container  should  have  a  cover  and  be  large 
enough to contain disinfectant solution to completely cover all 
items intended for disinfection. Many have a tray for removing 
implements or provide tongs for reaching into the solution to 
withdraw  implements  and  to  help  prevent  skin  contact  with 
potentially irritating disinfectant solutions.

Pedicure Implements
Pedicures require specialized implements. Toenails are larger 
and thicker than fingernails, and hardened callus can be tough 
to handle without the proper tools. Heavy duty toenail cutters 
with a squeeze-grip action are used along with abrasive files 
to  smooth  and  shape  toenails.  Abrasive  grit  foot  buffers  are 
used on calluses. California has prohibited the use of metallic 
razors or abrasives on calluses in nail salons; the concern was 
that such tools were too aggressive and dangerous for use in 
nail salons.

Aggressive  tools  and  procedures,  i.e.  highly  acidic  or 
alkaline  callus  remover  that  completely  removes  the  callus, 
are  very  concentrated  and  therefore  have  a  higher  potential 
to  injure  the  underlying  tissue.  A  risky  practice  performed 
by  some  nail  technicians  is  to  use  razor-type  devices  to  cut 
calluses from the foot. Complete removal of the callus is con-
sidered a medical procedure and is not appropriate for salon 
services  and  should  be  discouraged.  Salon  services  should 
only smooth calluses, not remove them.

Toiletries and Cosmetics
Items discussed include evaporation coatings, including base 
coats, top coats, and nail varnish.

Nail Varnish Formulation
Whether referred to as nail varnish, polish, enamel, lacquer, 
varnish, or color, these products are identical in function and, 
for practical purposes, nearly the same in basic composition. 
These  different  terms  are  merely  marketing  terms  used  to 
establish  brand  identity.  The  varnish  may  be  clear,  opaque, 
or  shaded  with  color.  Varnishes  may  appear  to  be  nothing 
more than a paint-like coating for the nail, but the chemistry 
is much more complex. In its simplest form, a nail varnish is 
defined as a durable film coating created by evaporation of a 
volatile solvent component. However, the coating must with-
stand  severe  abuse  without  losing  color,  gloss,  or  adhesion. 
Luckily,  a  clever  formulator  has  a  wide  range  of  raw  mate-
rials  from  which  to  choose,  and  through  proper  ingredient 
selection these properties can be greatly enhanced. However, 
the  cosmetic  appearance  and  durability  of  the  final  product 
are  not  the  only  considerations  when  choosing  ingredients. 
Regulatory  agencies  and  consumer  perception  also  play 
important  roles.  For  these  and  other  reasons,  we  examine 
each  ingredient  type  to  provide  a  better  understanding  of 
these useful cosmetics.

 
268 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Nail Varnish Basics
A typical varnish formulation consists of seven basic types of 
ingredients:

1.  Film formers
2.  Film modifiers
3.  Plasticizers
4.  Solvents/diluents
5.  Viscosity modifiers
6.  Stabilizers
7.  Coloration additives

Each of these ingredients contributes to the quality of the final 
product.  If  proper  ingredient  selections  are  made  and  cor-
rectly balanced, the varnish will be easy to apply and remove, 
quick-drying,  waterproof,  glossy,  chip-  and  scratch-resistant, 
and flexible, and will adhere well to the nail. Ideally a prop-
erly applied coating should remain cosmetically attractive and 
intact for 5–7 days. The varnish coating also must have a low 
potential for toxicity and adverse skin reactions.

Film Formers
The  role  of  the  film  former  is  to  create  a  smooth,  continuous 
coating  over  the  nail  plate.  The  coating  material  of  choice  is 
an organic polymer called nitrocellulose (cellulose nitrate). The 
first  natural  polymer  to  be  successfully  modified  by  chemi-
cal  manipulation,  it  was  commercially  produced  in  1860  by 
treating  cellulose  with  a  mixture  of  nitric  and  sulfuric  acids. 
Originally used in high explosives, dry powdered nitrocellu-
lose is highly unstable and sensitive to light, UV energy, heat, 
atmospheric moisture, and oxygen, as well as an alkaline pH. 
It  is  so  chemically  reactive  that  it  must  be  transported  in  a 
polar organic solvent, usually ethanol or isopropanol, to pre-
vent  explosive  detonation.  Formulators  can  choose  from  sev-
eral viscosities and grades of material and use them alone or 
in synergistic blends. Non-nitrated cellulosic such as cellulose 
acetate and derivatives are also used with varying degrees of 
success. Polyurethanes, polyamides, and polyesters have also 
been utilized, but can’t match the surface gloss and hardness 
of  nitrocellulose.  Nitrocellulose  also  blends  superbly  with 
colored  pigments,  producing  bright  and  vibrant  colors.  Still, 
nitrocellulose's disadvantages drive formulators to constantly 
seek  alternative  materials,  since  the  coatings  it  produces  are 
brittle, adhere poorly, discolor quickly, and shrink excessively 
to  cause  poor  adhesion.  Some  newer  formulations  replace 
nitrocellulose  with  cellulose  acetate  butyrate  because  of  its 
superior  clarity,  durability,  and  color  stability.  Examples  of 
other film formers are meth(acrylate) polymers or copolymers.

acid/furmaric  acid/phthalic  acid/tricyclodecane  dimethanol. 
A multi-year independent study performed in salons at mul-
tiple  locations  in  northern  and  southern  California  in  both 
winter and spring, under the auspices of the California State 
Attorney General, was designed to address questions related 
to California Proposition 65. The study was commissioned by 
the Nail Manufacturers Council on Safety of the Professional 
Beauty Association. The study concluded that neither workers 
nor consumers in the salon had any risk from using  cosmetics 
nail containing formaldehyde and toluene (7). The  measured 
formaldehyde  concentrations  varied  between  0.0012  and 
0.0038  ppm,  which  is  what  would  be  normally  expected  in 
ambient air and far below the Occupational Safety and Health 
Administration  (OSHA)  8-hour  TWA  of  0.75  ppm,  and  the 
more conservate ACGIH maximum concentration is 0.3 ppm.

Plasticizers
Plasticizers  add  flexibility  to  polymer  films  and  offer  a  use-
ful way to improve the strength of nitrocellulose films. They 
reportedly  increase  separation  between  the  cellulose  chains 
and  act  as  in  internal  lubricant  (8).  Film  modifiers  counter-
balance  the  negative  aspects  of  nitrocellulose,  whereas  plas-
ticizers  alter  the  properties  of  the  entire  film  and  can  have 
profound,  positive  effects  on  flexibility  and  adhesion.  The 
plasticizer must be compatible and remain in solution without 
negatively affecting viscosity, consistency, flow, color, or shelf 
life.  It  must  not  readily  escape  from  the  film  through  migra-
tion or volatilization and must be dermatologically innocuous. 
Camphor  (b.p.  96°C)  is  the  most  common  example  of  a  low-
molecular-weight, high-boiling-point plasticizer. Other exam-
ples of plasticizers are acetyl tributyl citrate, castor oil, sucrose 
benzoate, glyceryl tribenzoate, PPG-2 dibenzoate, ethyl tosyl-
amide,   glycerol,  triacetin,  and  a  polymeric  plasticizer  called 
NEPLAST (a polyether–urethane) (9).

Dibutyl  phthalate  (DBT)  was  for  many  years  the  pre-
ferred plasticizer for nail varnish. In 2003, DBT was reviewed in 
the United States and declared “safe as used” by the Cosmetic 
Ingredient  Review  (CIR)  Expert  Panel.  However,  in  the  same 
year,  new  regulations  in  the  European  Union  (EU)  required 
that any ingredient listed as category 3 on the EU Dangerous 
Substance List or CMR (carcinogens, mutagens, and reproduc-
tive toxicants) list must prove to the EU's Scientific Committee 
on  Consumer  Products  that  they  are  safe  before  they  are 
allowed for use. DBT was listed as a category 3 (as an additive 
in  spray  paint),  so  rather  than  undergo  exhaustive  and  oner-
ous  toxicological  testing,  nail  varnish  manufacturers  around 
the world began to eliminate this ingredient since they did not 
wish to carry a separate inventory for the EU.

Film Modifiers
The purpose of a film modifier is to favorably offset some defi-
ciencies  of  the  primary  film  former.  Specifically,  film  modifi-
ers  are  used  to  improve  adhesion.  The  most  commonly  used 
modifier  used  to  be  toluenesulfonamide/formaldehyde  resin 
(TSFR)  or  tosylamide/formaldehyde  resin  (TF),  the  name 
listed  in  the  International  Nomenclature  of  Cosmetic  Ingredients 
(INCI) dictionary. Due to the public's erroneous and unfavor-
able  association  with  formaldehyde  gas  (see  “Formaldehyde 
controversy,”  below),  this  resin  has  fallen  out  of  favor  and  is 
being  replaced  by  other  resins,  i.e.  tosylamide/epoxy  resin 
(4),  polyvinyl  butyral,  ester  sucrose  benzoate,  polyesters  (5), 
acrylic ester oligomers, sucrose acetate isobutyrate (SAIB), and 
arylsulfonyl urethanes (6), and various copolymers, i.e. adipic 

Solvents and Diluents
Nail  varnish  solvents  give  these  products  their  characteristic 
odor  and  flammability,  but  solvents  are  vital  since  they  dis-
solve  solid  ingredients,  and  upon  evaporation,  deposit  them 
on  the  nail  plate.  The  most  commonly  used  are  alkyl  esters 
(ethyl, amyl, and n-butyl acetate) and glycol ethers (propylene 
glycol  monomethyl  ether).  Since  each  solvent  has  a  different 
boiling  point  and  evaporation  rate,  a  skilful  formulator  can 
balance  several  solvents  to  achieve  the  desired  drying  time. 
Good solvents are those that easily dissolve solid ingredients 
and reduce viscosity or improve brushability.

Even  though  they  are  not  solvents  for  nitrocellulose, 
ethanol, isopropanol, and butanol act as coupling agents and 
through hydrogen bonding act synergistically to increase the 

 
overall solubility and flow of the system. Diluents are usually 
non-polar compounds that are also non-solvents for nitrocel-
lulose,  but  help  to  regulate  evaporation  rates  and  stabilize 
viscosity  to  prevent  uneven  evaporation  that  may  affect  sur-
face gloss, color, and clarity, especially in humid conditions. A 
great advantage of diluents is that they may be added in con-
trolled amounts without reducing viscosity.

In the past, toluene was used without significant problems 
since the 1930s as a nail varnish diluent and often accounted for 
up to 25% of the formulation. Toluene was added to the list of 
chemicals for which California's Proposition 65 requires a warn-
ing label since is suspected of causing birth defects and cancer 
(10,11).  However,  study  by  the  Nail  Manufacturers’  Council 
(NMC)  performed  under  the  auspices  of  the  California  State 
Attorney General indicates that nail technicians’ salon exposure 
level was 769 times below U.S. federal safe limit set by OSHA (12).
Toluene exposures were well below the OSHA exposure limit of 
200 ppm TWA, and reported mean was 0.260 ppm TWA (7). Even 
so, in 2008 the California Air Resources Board identified toluene 
as  an  air  contaminant  that  contributes  ground  level  formation 
of  ozone,  and  therefore  most  manufacturers  have  voluntarily 
discontinued use of the solvent, replacing toluene generally by 
increasing the levels of ethyl and butyl acetate (13).

Viscosity Modifiers
Ideally,  a  nail  varnish  should  have  a  gel-like  consistency  to 
keep pigments suspended, but thinner, more brushable liquids 
produce better and more uniform films. Luckily, both consis-
tencies are possible in systems that display thixotropic behav-
ior. Thixotropic systems become thinner as they are mixed and 
brushed,  but  while  at  rest  they  will  reform  a  semi-gel  struc-
ture. Examples of substances used to create this effect are cat-
ionic  modified  montmorillonite  clays  that  are  approximated 
by the formula (Al,Mg)2(SiO2)(OH)2·nH2O. Treating these clays 
with  quaternary  ammonium  compounds  will  render  them 
organophilic.  Stearalkonium  hectorite  is  the  most  frequently 
used of these clays. The main disadvantage of clay additives is 
that they lower surface gloss. This can be offset by the addition 
of various polymers, e.g. acrylate copolymers and nylon. These 
additives improve gloss, as well as toughness and scratch resis-
tance. Amorphous (noncrystalline ) silica is also used as a vis-
cosity modifier, at very low levels.

Stabilizers
Color stability is a very important property in nail varnishes. 
Special  stabilizers  are  added  to  nail  varnishes  to  prevent  the 
colors from fading and shifting. Nitrocellulose is usually the 
culprit, since it is inherently unstable in ultraviolet (UV) energy, 
which is invisble (>400 nm) and therefore not considered to be 
“light” (<400 nm). Solutions of nitrocellulose will change from 
a clear to a yellow to a brown liquid with relatively little UV 
energy exposure. Pigments and dyes may also become unsta-
ble with longer periods of exposure. Lighter colored varnishes 
are less stable than darker colors. Sheerer varnishes with lower 
levels of colorant are more susceptible to UV energy than richer 
varnishes with higher levels of colorant. Generally varnishes 
with colors nearer to the blue end of the spectrum shift more 
readily  and  dramatically  than  colors  found  nearer  to  the  red 
side. To help prevent discoloration problems, nail varnish for-
mulations utilize UV energy–absorbing stabilizers that absorb 
UV energy and convert it into harmless visible light and infra-
red energy (heat). The most common of the stabilizers of this 
type are benzophenone-1 and etocrylene.

COSMETOLOGY FOR NORMAL NAILS 

 269

Coloration Additives
Unless  the  nail  varnish  is  clear  and  colorless,  additives  must 
be  used  to  alter  the  opacity  and  shade.  Color  additives  must 
have very low or no heavy metal content and must be certified 
by the U.S. Food and Drug Administration (FDA), and if sold 
internationally  must  also  use  be  allowed  in  the  EU,  Canada, 
and Japan. Occasionally, smaller manufacturers will risk using 
non-approved  colorants  (e.g.  “day-glo”  colors)  to  satisfy  the 
faddish demands of younger consumers, but for the most part 
these regulations are adhered to closely. Colorants must have 
relatively high light fastness and should not stain the nail plate. 
Colorants can be stabilized by creating precipitating a particu-
lar pigment with aluminium hydroxide to form a salt complex 
called a “pigment lake,” i.e. D&C Red No. 7 Calcium Lake and 
D&C Yellow No. 5 Zirconium Lake. Pastel shades are achieved 
by the addition of titanium dioxide (TiO2). Ferric ferrocyanide 
(Prussian blue) is used in small amounts to enhance blues and 
alter other shades. In order to achieve complete pigment dis-
persion and suspension, high energy ball or roll mills must be 
used to ensure uniform colors and to reduce the amount of col-
orant needed, i.e. 2% dry colorant or less. Pearlescent pigments 
continue  to  be  highly  desirable  commodities  in  modern  var-
nishes.  Bismuth  oxychloride  and  mica  coated  with  TiO2  and 
other colorants are used to create the many beautiful iridescent 
shades. More complete information on approved colorants can 
be obtained from the CTFA's (now known as the Personal Care 
Product Council [PCPC]) International Color Handbook (14).

Colorants  are  usually  indicated  on  the  label  by  their 
international  color  index  (CI)  number,  which  is  accepted  by 
most  regulatory  agencies  around  the  world;  however,  some-
times both the CI and INCI nomenclature is used, e.g. CI 77891 
(titanium dioxide), unless there is a lack of space on the label. 
The  U.S.  FDA  does  not  currently  accept  CI  numbers  when 
used alone and requires the use of Food, Drug and Cosmetics 
(FD&C, or D&C) names.

Other Additives
A variety of highly specialized additives are known to those 
skilled  in  the  art  of  nail  varnish  formulation.  Even  tiny 
amounts of many of these special additives can give dramatic 
differences in performance. Some examples are surfactants to 
improve  wetting  and  adhesion  and  organic  acids  to  stabilize 
colorants.  However,  some  additives  serve  no  function  other 
than  to  increase  consumer  appeal.  These  include  proteins, 
minerals, pearl, gem dusts, and vitamins.

Base and Top Coats
Base coats are applied to the nail plate before application of the 
nail  varnish.  They  are  usually  of  similar  composition  to  var-
nish, but contain more additives which improve adhesion and 
protect against staining of the nail. Top coats utilize higher lev-
els of ingredients that maximize surface gloss and hardness. 
Often, the top coat contains special UV-absorbing materials to 
prevent  discoloration.  Not  all  top  coats  are  evaporative  coat-
ings, since some are UV-cured urethane (meth)acrylate oligo-
mers and blends (15).

Film-Drying Accelerant
Silicone oil blends and silicone oil-in-water emulsions are often 
used to accelerate nail varnish dry times. Film-drying acceler-
ant is sprayed or brushed over freshly applied nail varnish to 
give rapid drying and increased protection from minor dents 
or surface scratches while remaining solvent evaporates from 

 
270 

 TEXTBOOK OF COSMETIC DERMATOLOGY

the coating allowing it to reach a hard set. Drying is acceler-
ated  because  the  thickener's  microstructure  collapses,  allow-
ing solvents to escape more quickly.

Formaldehyde Controversy
Formaldehyde is an anhydrous gas and cannot be utilized as 
a cosmetic ingredient for that reason. When formaldehyde is 
mixed with water, it does not simply dissolve, but undergoes 
a chemical reaction which converts it from the aldehyde into 
methylene  glycol  and  trace  levels  of  free  formaldehyde,  in 
equilibrium.  Unfortunately  all  around  the  world,  formalin  is 
incorrectly thought of as aqueous formaldehyde, even by med-
ical and scientific professionals. The so-called “formaldehyde-
releasing” preservatives do not release formaldehyde gas, but 
instead release methylene glycol. The INCI dictionary, which 
cosmetic product manufacturers are supposed to use to name 
their ingredients, used incorrectly to require that formalin be 
called  formaldehyde.  No  one  worried  about  the  misnaming 
until  advocacy  groups  began  saying  that  cosmetic  products 
contain cancer-causing formaldehyde as an ingredient, which 
is clearly incorrect. The NMC petitioned INCI to address this 
issue and as of December 2008, the INCI name for formalin is 
methylene glycol.

The  FDA  allows  the  use  of  up  to  5%  formalin  in  nail 
hardeners and requires warning labels on nail-care products, 
as  well  as  “nail  shields  which  restrict  application  …”  (16).EU 
regulations require “formaldehyde” warning labels when con-
centrations exceed 500 ppm formaldehyde gas. These levels of 
free formaldehyde gas are much greater than what is found in 
nail hardeners which typically contain less than 12 ppm, based 
on equilibrium calculations for these products, which typically 
contain 1.5% formalin or less (17).

It is suspected that formalin cross-links proteins (18) in 
the nail, resulting in increase in surface hardness and decreased 
flexibility, which the user misinterprets as improved strength 
and  durability.  After  months  of  continued  use,  nail  harden-
ers  may  eventually  increase  nail  plate  hardness  and  rigidity 
to  the  point  that  brittleness  becomes  obvious.  Users  remem-
ber the early success of the hardener, and usually respond to 
the brittleness by increasing the frequency of application. This 
leads to further cross-linking and nails may end up in worse 
condition  than  before.  Onycholysis  and  abnormal  growth  of 
the  hyponychium  may  results  of  prolonged  formalin  overex-
posure,  but  this  is  probably  uncommon  (19).  Typically,  these 
problems are a result of aggressive manicuring services (20).

Microbiological Contamination and Water-Based Varnish
Microbiological  studies  commissioned  in  2009  by  the  NMC 
show that traditional solvent-based nail polishes will quickly 
kill  common  pathogens  without  additional  preservation  and 
do not create the potential for transmitting pathogenic organ-
isms  (21).  Water-based  nail  varnishes  are  available,  but  they 
cannot compare to the performance of traditional nail polishes, 
and being prone to bacterial contamination must be preserved 
with, for example, quaternium (16).

New Developments
New  industry  trends  are  turning  toward  UVA-curable  top 
coats,  base  coats,  and  nail  color,  which  applies  like  tradi-
tional  nail  varnish  to  form  durable,  long-lasting  coating 
when  exposed  to  low  levels  of  UVA  energy  (400–450  nm). 
These  new  types  of  nail  coatings  are  referred  to  as  UV  gel 
polish or manicures, and are used to coat the nail plate with 
a longer-lasting colored coating capable of camouflaging nail 

defects such as nail bed bruises or splinter hemorrhages. UV 
gel  polish  is  removed  after  2–3  weeks  and  replaced  with  a 
fresh coating. Because these nail coatings are polymerized by 
UV energy, they produce superior scratch-resistant coatings 
with  enhanced  durability,  but  are  more  difficult  to  remove 
than traditional nail varnish.

One study has claimed UV gel polishes create nail weak-
ness,  brittleness,  and  thinning.  Ultrasound  measurements 
demonstrated  plate  thinning,  however  the  researchers  failed 
to  account  for  the  effects  of  filing  of  the  natural  nail  with  a 
coarse abrasive prior to application in order to improve adhe-
sion. Nail thinning was erroneously attributed to the UV coat-
ings, even though these formulations are not corrosive to the 
nail and have no ability to thin or weaken the plate (22). This 
type  of  thinning/weakening  of  the  nail  plate  is  commonly 
observed  after  aggressive  filing  and/or  improper  removal. 
When firmly bonded nail coatings are forcibly scraped or pried 
from  the  nail  plate,  surface  damage  becomes  more  likely.  To 
prevent  surface  damage  and  thinning,  more  time  should  be 
allowed for the solvent removers to loosen the bonds and allow 
nail coatings to be gently removed. Less aggressive filing tech-
niques using higher grit nail files will also reduce the potential 
for plate thinning.

Nail  varnishes  that  improve  nail  plate  health  are  cur-
rently  the  hottest  topics  of  interest  for  consumers.  There  is 
therefore  a  tremendous  economic  incentive  for  manufactur-
ers to discover ingredients that provide demonstrable benefits 
to the nail. Improved nail toughness and solutions for yellow, 
dry, brittle, and splitting nails would be enormously beneficial. 
When these technologies are developed, it may eventually lead 
to the Holy Grail of nail varnishes—one that truly prevents or 
helps treat common nail pathologies. A step in this direction 
was introduced in 2014 with the development of a UV-curable 
methacrylate formulation that penetrates only the uppermost 
layers  of  the  nail  plate  and  is  then  rapidly  polymerized  by 
UV energy. Because the nail plate has excellent barrier prop-
erties,  it  prevents  the  UV-curable  formulation  from  penetra-
tion  beyond  the  upper  10%–15%  of  the  nail  plate's  thickness. 
Upon  UV  exposure,  the  material  absorbed  into  the  surface 
layers  polymerizes  into  place  to  seal  the  upper  layers  of  the 
plate  and thus prevent  them from peeling  apart. The  surface 
is  thus  hardened  and  more  damage  resistant,  while  the  nail 
plate  is  rendered  tougher.  Once  polymerized  into  the  nail,  it 
also seals the nail against additional absorption and prevents 
staining. This differs significantly from methods of hardening 
that increase keratin cross-linking and may lead to embrittle-
ment with excessive use.

Nail Varnish Solvents (Nail Varnish Removers)
Acetone and/or butyl or ethyl acetate, methyl ethyl ketone, eth-
oxy ethanol, or similar compounds are used for rapid soften-
ing and solubilizing of nail polish as well as to remove oils and 
waxes to cleanse and prepare the nail for varnish application. 
Some varnish removers claim to minimize stripping of mois-
ture and oil from already brittle nails. The removers are based 
on solvents such lactones or dimethyl esters of adipic, glutaric, 
and succinic acids (dibasic esters).

Nail Creams and Lotions
Oil-in-water emulsion preparations aid in softening the keratin 
of the nail plate and contiguous skin. This is achieved initially 
by  the  addition  of  water  and  subsequently  by  the  reduction 
in evaporation of water from the nail. Cosmetic preparations 
are of two basic types: those designed to deliver water-soluble, 

 
hydrophilic substances into the nail plate, and those designed 
to  deliver  hydrophobic  substances,  such  as  natural  jojoba  or 
almond oil. Once absorbed, these ingredients have the poten-
tial  to  plasticize,  increasing  flexibility,  toughness,  and  dura-
bility, and are claimed to be especially useful for dry and/or 
brittle nails.

Cuticle Removers
These  are  lotions  or  gels  containing  approximately  2%–4% 
sodium or potassium hydroxide (pH 12–13.5). They are applied 
in the vicinity of the cuticular ridge to eliminate the remnants 
of cuticle that adhere to the nail plate as it grows outward. The 
lotion is left in place for approximately 1–2 minutes and then 
washed  off.  In  nail  salons,  the  process  is  hastened  by  using 
a  cuticle  pusher.  Creams  containing  low  levels  of  ɑ-hydroxy 
acids are also used as cuticle removers. These usually contain 
1%–5%  lactic  acid  (pH  2.5–3.5).  Besides  their  ability  to  soften 
and remove cuticle, daily use can eliminate hangnails.

ADVERSE REACTIONS TO NAIL 
COSMETIC PROCEDURES
Adverse  reactions  to  nail  cosmetic  procedures  (21)  may  be 
divided into two main categories: reactions to applied cosmet-
ics, and nail tool/implement damage.

Reactions to Applied Cosmetics
Cosmetics  may  produce  reactions  both  at  the  site  of  applica-
tion  to  the  nail  area  and  secondarily  elsewhere  on  the  body. 
The fingernails act as a reservoir for small amounts of cosmetic 
preparations transferred by the hand to other areas of skin, i.e. 
the face.

Nail Varnish Dermatitis
Nail  varnish  dermatitis  of  allergic  origin  can  appear  on  any 
part of the body accessible to the nails (Figure 30.10), but often 
with no signs in the nail apparatus. Exceptions, however, may 
exist—mainly  in  the  periungual  area  (24)  (Figure  30.11).  The 

COSMETOLOGY FOR NORMAL NAILS 

 271

eyelids  (Figure  30.12),  the  lower  half  of  the  face,  the  sides  of 
the neck, and the upper chest are the most commonly affected 
areas,  likely  from  scratching  the  skin  in  these  areas  with 
recently or freshly varnished nails (25,26). In addition to ecto-
pic  dermatitis,  allergic  airborne  contact  dermatitis  caused  by 
nail ingredients should be suspected when lesions on the face, 
neck,  and  ears  are  symmetrical  (27).The  allergen  in  nail  var-
nish is usually thermoplastic resin. Diagnostic skin patch test-
ing with nail varnish should be performed without occlusive 
covering, or with dry varnish films to avoid false-positive reac-
tions from the solvent.

The  thermoplastic  resin  used  to  promote  adhesion  is 
often  the  main  culprit  (28–31)  but  when  the  nail  varnish  is 
completely dry it is only a weak allergen (32). However, nail 
varnish that has completely dried on the fingernails contains 
water-soluble  components  that  may  reach  the  skin  during 
extensive,  transient  contact  (33).  To  make  “formaldehyde-
free” claims, cosmetic manufacturers have reformulated their 
nail varnish, replacing TF resin with other resins, i.e. tosyl-
amide/epoxy  resin  (trade  names  Lustrabrite®,  Nagellite®, 
a  condensation  product  of  bis-phenol  A  epoxy  resin34), 
phthallic  and  trimellitic  anhydride/glycol  copolymer  35, 
glycerophthalic polyester resin (PhaseTM), 4- methylbenzene 
sulfonamide-epoxy  resin  (CliniqueTM),  phthalic  polyester 

Figure 30.11  Rechallenge of nail varnish onto two fingers only, 
showing severe local dermatitis. (Courtesy of Dr. R Staughton.)

Figure 30.10  Distribution of nail varnish ectopic dermatitis. (After 
Bonu G, Zina G, Minerva Dermatol 1959; 33:507–9.)

Figure 30.12  Eyelid dermatitis.

 
272 

 TEXTBOOK OF COSMETIC DERMATOLOGY

resin (ShiseidoTM), or polyester saturated hydroxylated resin 
(DeborahTM) (36). Unfortunately, some of these and related 
“hypoallergenic”resins (37,38) have already produced distant 
contact dermatitis. Another potential exposure source is the 
(meth)acrylates used in some UVA-curable nail products.

Reactions may also occur when improper colorants are 
mixed  with  UV  gels  to  create  special  effects.  A  37  year-old 
housewife with no previous history of allergic contact derma-
titis purchased a glitter color from the Internet, mixed it with 
the  UV  gel  and  self-applied  the  mixture  to  her  nails.  After  7 
months,  she  developed  multiple  intensely  itchy,  eczematous 
periungual  and  palmar  lesions  on  both  hands.  Patch  testing 
resulted  in  a  strong  positive  for  cobalt  choride.  Cobalt  was 
listed  as  an  ingredient  in  the  glitter  and  was  responsible  for 
the adverse reaction, which resolved when the nail coating was 
removed (39).

The  following  substances  should  be  included  in  a  test 

battery:

•  Tosylamide/epoxy resin (10% petrolatum)
•  TSFR (10% petrolatum)
•  Glyceryl phthalate resin (polymer resin) 10% petrolatum
•  Formalin (1%–2% methylene glycol in aqua)
•  Phthalic and trimellitic anhydride (1% petrolatum)
•  Colophony (resin) 10% or 20% petrolatum (40)
•  Drometrizole (Tinuvin P) 1% to 5% petrolatum
•  Nickel  (0.5%  petrolatum)  and  1%  dimethylglyoxine  spot 

test for nickel from varnish mixing beads

•  Benzalkonium chloride (0.01 to 0.1% water)

Contact Urticaria
Recurrent urticaria involving the same area as contact derma-
titis  plus  the  distal  phalanx  of  the  fingers  has  been  reported 
with isomorphic response to nail varnish testing, immediately 
after simple contact (41).

Nail Plate Staining
Nail staining from the use of deeper shades of red and brown 
nail  varnish  is  most  commonly  yellow–orange  in  color  (42) 
(Figure 30.13). Typically, it begins near the cuticle area, extends 
to the top of the nail, and becomes progressively darker from 
base to tip. Colorants such as D&C Red no. 6, 7, 34 and FD&C 
Yellow no. 5 Lake can penetrate into the nail too deeply to be 
removed,  but  this  can  be  significantly  avoided  with  the  use 
of  a  base  coat  prior  to  nail  varnish  application.  Fingernail 

discoloration can be produced by chloroxine, an active ingre-
dient  in  a  shampoo  used  for  control  of  seborrheic  dermatitis 
which  is  highly  reactive  to  metals  such  as  iron  oxides  (com-
monly  used  as  pigments  in  nail  varnish)  and  it  is  likely  that 
discoloration may result from a reaction between the two (43). 
Patients  undergoing  therapy  with  minocycline  may  develop 
discoloration  of  the  nails  (44).  Analysis  of  the  nail  clippings 
from  minocycline-treated  women  showed  a  large  amount  of 
iron  concentrated  only  in  discolored  areas  of  the  nail,  which 
did not occur in women who did not varnish their nails or in 
men with nails free of a significant amount of iron. Nail discol-
oration may also result from the combined effect of nail var-
nish and dermatological treatment containing either resorcinol 
or resorcinol monoacetate (45).

Nail Keratin Granulation
Injury to the nail from nail varnish is rare. However, “granu-
lations”  of  nail  keratin  (Figure  30.14),  presenting  as  superfi-
cial friability (46), can sometimes be observed. In these cases 
individuals  continually  remove  old  nail  varnish  and  apply 
fresh coats for periods of weeks. Nail keratin granulation may 
be avoided by lessening the frequency of removal and reap-
plication of nail varnish, i.e. no more than once per week, to 
avoid damaging the surface of the nail. These products con-
tain acetone and/or butyl or ethyl acetate, methyl ethyl ketone 
or similar compounds which can dehydrate the nail plate and 
decrease  corneocyte  adhesion,  extract  lipids,  and  contribute 
to  brittleness  (47).  Some  polish  removers  contain  significant 
amounts of water (17%) and/or conditioners for skin, to reduce 
tissue  damage,  making  them  the  preferred  solvents  for  var-
nish removal. Oils are sometimes added to prevent excessive 
drying of the nail. Nail varnish removal may cause inflamma-
tion  of  the  paronychial  area  when  the  solvent  remover  solu-
tion is left in contact with the skin. Rarely, irritant and allergic 
contact  dermatitis,  blistering,  onycholysis,  and  brittleness 
may occur (48).

Cuticle Removers and Softeners
Removers (see above) are designed to destroy keratin by attack-
ing  the  disulfide  bonds  of  cystine.  After  the  nails  have  been 
soaked  in  soapy  water,  cuticle  removers  are  applied  and  left 
in place for approximately 2 minutes before being washed off. 
The loosened cuticle tissue is usually removed from the nail by 
being rubbed gently with a wooden stick covered with cotton. 
Removers should not be applied to the fibrous cuticular ridge, 

Figure  30.13  Yellow-orange  nail-plate  staining.  (Courtesy  of 
Prof. A Tosti.)

Figure 30.14 

“Granulation” of nail keratin.

 
and this tissue should not be removed with sharp implements 
such as nippers or V-shaped curettes.

Cuticle softeners are often misnamed since they are actu-
ally  designed  to  soften  and  moisturize  the  eponychium  and 
lateral folds and not designed to remove cuticle tissue from the 
nail  plate;  the  pH  of  these  products  is  typically  4.5–6.0.  Skin 
conditioners or softeners often contain substances such as qua-
ternary ammonium or urea or α-hydroxyacids at low concen-
trations and are used as emollient creams. Triethanolamine is 
used to adjust the product’s pH and may act as a sensitizing 
agent (5% in petrolatum for patch testing).

Stick-On Nail Dressings
“Stick-on  nail  dressings”  (decorative  coatings)  are  thin,  clear 
or colored synthetic films (Figure 30.15) with an adhesive that 
fixes  them  firmly  to  the  nail.  Decorative  adhesive  films  have 
undergone  a  resurgence  and  become  very  popular  again.  In 
some cases, pathologic changes(45) of traumatic origin are said 
to be produced in nails by the occlusive nature of the film. In 
fact, they can be attributed to a temporary overhydration of the 
nail plate. The same is true for any occlusive or semiocclusive 
coating on the natural nail. For example, when artificial nails 
are  removed,  the  nail  may  feel  weaker  and  thinner  because 
the higher moisture content increases flexibility. Surface dam-
age with the appearance of whitish patches can occur if these 
films are peeled from the nail plate without first warming to 
soften the adhesive bond using a hair dryer or under an infra-
red lamp designed for the purpose. Press-on nail extender tips 
are  also  used  for  temporary  extension  of  the  nail.  Generally, 
these  are  only  used  for  special  occasions,  i.e.  weddings,  and 
are removed within a day or two.

Potential for Injury/Infection
Traumatic  injuries  from  nail  files,  wooden  or  plastic  sticks, 
and metal or porcelain spatulas may cause not only infection, 
but also onycholysis (Figure 30.16) and Beau's lines (transverse 
white  streaks)  from  overzealous  manicuring,  pedicuring,  or 
filing the nail (49). It is therefore wise to use wooden sticks cov-
ered with cotton or instruments with blunt edges. Nail techni-
cians usually remove too much of the natural nail plate with 
coarse abrasives and powered electric files, which should only 
be used on artificial nails. Cutting the nail with dull or blunt 
tools may contribute to increased weakening, peeling, fractur-
ing,  or  splitting.  Tools  should  be  sharpened  regularly  or  the 
blades should be changed when they become dull. An alterna-
tive method is to shape the fingernail with an abrasive board, 

Figure 30.15  Stick-on nail dressing.

COSMETOLOGY FOR NORMAL NAILS 

 273

Figure 30.16  Onycholysis due to overzealous manicure.

filing from the sides of the nail toward the center. Peeling any 
type  of  nail  coating  or  tightly  adhering  film  from  the  plate 
can  cause  nail  cells  on  the  surface  to  peel  upward  and  cre-
ate  whitish-appearing patches that are often mistaken by nail 
technicians and clients for dry patches, when in fact they are 
surface  disruptions.  Such  damage  is  completely  avoidable  if 
these coatings or adhesive films are carefully removed.

Procedures  for  consistent  and  proper  hand  washing 
by all hospital personnel should be reinforced, as well as the 
maximum  3-mm  rule  for  end-of-finger  nail  lengths  (50).  The 
subungual space of the hand is heavily colonized with micro-
organisms,  and  contaminated  instruments  may  lead  to  acute 
bacterial  or  chronic  Candida  paronychia  and  onycholysis. 
Overfiling  of  the  nail  plate  with  coarse  abrasives  or  heavy-
handed filing techniques with even the mildest buffing block 
can disrupt the thin tissue seal that holds the plate to the bed 
and lead to onycholysis and possibly subsequently Candida or 
other  infections.  Acrylic  nail  extensions  are  also  implicated 
in  Candida  nail  bed  infection  (51),  but  much  more  commonly 
the  issue  is  increased  bacterial  carriage  versus  natural  nails 
(52),particularly Staphylococcus aureus and S. epidermidis, which 
are  not  uncommon  under  the  free  edge  and  are  more  diffi-
cult to remove out of this area despite surgical scrubs (53). In 
contrast to fresh nail polish worn on short, healthy nails (54), 
chipped nail varnish is a known potential reservoir for bacte-
rial growth on natural nails (53). In addition, bacterial carriage 
is  higher  in  subjects  with  artificial  nails  than  in  those  with 
natural  nails,  possibly  because  of  the  longer  length  of  artifi-
cial nails and more surface area for colonization (55). Serious 
eye infections have also been reported following Pseudomonas 
involvement in the nail apparatus (56), as has subacute bacte-
rial endocarditis after nail trauma (57).

Warts can affect mainly the periungual tissue and some-
times are found on the proximal nail fold as a result of nail biting 
or other insult (58) In the mid-1990s, a woman was awarded $3.1 
million after contracting herpes on all ten fingers at a salon (59).

Transmission of more serious diseases such as hepatitis 
B and AIDS (HIV) seems to be virtually impossible through 
nail  services.  The  approximately  200,000  nail  technicians  in 
the  United  States  perform  on  average  about  20–25  services 
per  week.  Since  1985,  very  conservative  estimates  are  that 
over  six  billion  nail  services  have  been  performed  without 
a  single  identified  or  suspected  case  of  HIV  or  hepatitis  B 

 
274 

 TEXTBOOK OF COSMETIC DERMATOLOGY

transmission.  If  this  type  of  transmission  were  possible,  it 
would be expected that a noticeable increase in unexplained 
infections  in  women  who  frequent  salons  would  have  been 
noticed, but no such link as ever been discovered. Of course, 
all  infectious  complications  can  be  avoided  with  effective 
sanitary  practices,  and  this  has  become  an  increasingly 
important focus in nail salons.

Sanitation and Disinfection Practices
Sanitation 
It  is  generally  not  understood  that  “to  sanitize” 
simply means low-level cleaning, in which potentially harmful 
micro- organisms  are  reduced  to  levels  considered  safe  by 
public  health  standards.  The  simple  act  of  wiping  an  object 
with  soap  and  water  is  a  method  of  sanitizing.  Sanitation  is 
often  confused  with  disinfection.  Sanitation/sanitizing  is  a 
primary  method  for  infection  control  and  must  be  properly 
performed or disinfection procedures will be less effective.

is 

Disinfection  Disinfection 
the  elimination  of  most 
potentially harmful microorganisms, except bacterial spores, 
on  a  surface.  U.S.  Environmental  Protection  Agency  (EPA)-
registered  disinfectants  are  authorized  for  use  only  on 
hard,  non-porous  surfaces,  since  this  is  how  their  efficacy 
is  verified.  Bleach  and  alcohol  are  examples  of  effective 
disinfectants that existed before the creation of the EPA and 
therefore  they  do  not  require  EPA  registration.  It  is  against 
U.S.  federal  law  to  use  an  EPA-registered  disinfectant  in  a 
manner contrary to its registration, therefore soft or porous 
surfaces can be disinfected with appropriate bleach or alcohol 
solutions and meet EPA requirements if properly performed. 
In  American  nail  salons,  most  state  board  of  cosmetology 
regulations  require  that  hard,  non-porous  implements  be 
thoroughly washed and then disinfected for 10 minutes in an 
EPA-registered disinfectant that is virucidal, fungicidal, and 
bactericidal.

Wooden  sticks,  cotton  balls,  emery  boards,  and  certain 
types of abrasive files are considered single-use items (i.e. they 
should be disposed of after one use). These items should not 
be stored or put aside for one specific client, since this can con-
tribute  to  spread  of  microorganisms  in  the  salon.  Salon  dis-
infection  regulations  nationwide  are  confusing  and  in  many 
cases antiquated or use incorrect terminology, i.e. interchang-
ing  “sanitize”  with  “disinfect.”  Each  licensed  nail  technician 
receives training in the best practices of sanitation and disin-
fection during the course of their education and must pass an 
examination,  but  sometimes  this  information  is  not  properly 
taught or fully understood.

Improper  cleaning  and  disinfection  probably  account 
for the vast majority of salon-related infections which would 
be prevented by adhering to the proper guidelines. A compre-
hensive set of recommendations for cleaning and disinfecting 
both  manicure  and  pedicure  equipment  in  salons  has  been 
developed  by  the  NMC  and  is  available  for  free-will  down-
load  in  several  languages  (60).  These  recommendations  have 
been accepted and endorsed by competent associations in the 
United States, the European Union, Australia, and Korea.

Some people prefer to keep their own clippers or other 
implements at their regular salon, but doing so means loss of 
all control over these devices. Patrons have been known to use 
them on other family members and even their pets. Nail pro-
fessionals must clean and disinfect all implements prior to use 
on a client. Due to time constraints, this is almost never done; 
therefore the practice of leaving one’s instruments at the salon 
should be discouraged.

Sterilization
Complete elimination of living organisms, including viruses, 
bacteria,  and  bacterial  spores,  from  a  surface  is  required  to 
achieve  sterilization.  Ethanol  90%  (effective  against  herpes) 
and  10%  sodium  hypochlorite  (bleach)  work  well  if  instru-
ments are fully submerged for 10 minutes. Some authorities are 
convinced  that  glutaraldehyde  should  not  be  recommended 
for salons, claiming that the risks of overexposure do not war-
rant  using  potentially  unsafe,  toxic,  and  highly  aggressive 
pesticides.

Autoclaves are growing in popularity, but some experts 
estimate that less than 3% of the salons in the United States 
use autoclaves. Those that do often do not properly maintain 
the units or verify their efficacy by spore testing, as required. 
Due to the negative press and positive PR value of using auto-
claves,  this  trend  is  expected  to  continue.  Use  of  autoclaves 
is  more  prevalent  in  Australia,  due  to  government  regula-
tions. An interesting development is that several companies 
have  set  up  services  that  sterilize  implements  for  salons. 
Sterilization  will  never  replace  disinfection  and  since  many 
items that come in contact with patrons are too large to fit in 
autoclaves they therefore must be properly cleaned and dis-
infected before reuse.

REFERENCES

1. Alkiewicz  J,  Pfister  R.  Atlas  der  Nagelkrankheiten.  Stuttgart: 

Schatthauer-Verlag, 1976.

2. Brosche  T,  Dressler  S,  Platt  D.  Age-associated  changes  in 
integral  cholesterol  and  cholesterol  sulfate  concentrations  in 
human scalp hair and finger nail clippings. Aging Clin Exp Res 
2001; 13:131–8.

3. Brauer E, Baran R. Cosmetics: The care and adornment of the 
nail. In Baran R, De Berker D, Haneke E, Tosti A, eds. Baran & 
Dawber's Diseases of the Nails and their Management, 3rd edition. 
Oxford: Blackwell Science 2001.

4. Mallavarapu L, U.S. Patent 4,996,284. 1991.
5. Schlossman ML, U.S. Patent 4,301,046 (to Tevco). 1981.
6. Lecaheur  M,  Mutterer  J,  Wimmer  E,  French  Patent  9202486. 

1992.

7. McNary, JE, Jackson, EM, Inhalation exposure to formaldehyde 
and toluene in the same occupational setting, Inhal Toxicol, 2007; 
19:573–6.

8. Schlossman ML. Nail cosmetics. Cosmet Toiletries 1986; 101:24.
9. Schlossman  ML.  Advances  in  nail  enamel  technology.  J  Soc 

Cosmet Chem 1992; 43:331–7.

10. California  Environmental  Protection  Agency.  Office  of 
Environmental  Health  Hazard  Assessment  Proposition  65. 
Implementation.  Sacramento,  CA:  California  Environmental 
Protection Agency, 1986.

11. Donald  JM,  Hooper  K,  Hopenhayen-Rich.  Reproductive  and 
development  toxicity  of  toluene:  A  review.  Environ  Health 
Perspect. 1991; 94:237–44.

12. Schoon D. The truth about toluene. Nails Magazine 1994; Nov:76.
13. Environmental  Protection  Agency.  Federal  Register,  40  CFR, 
part 51 and 59, National Volatile Organic Compound Admission 
Standards for Aerosol Coating-Final Rule, June 23, 2009

14. CTFA. International Color Handbook. Washington, DC: Cosmetics, 

Toiletries and Fragrance Association, 1992.

  15.  Schoon  D.  Nail  polish  chemistry,  Nail  Structure  and  Product 
Chemistry, Second Edition Albany, NY: Thomson/Delmar 2005; 
pp.122–7.

  16.  FDA. Cosmetic Handbook, June 1989.
  17.  Winkelman  JGM,  et  al.  Kinetics  and  chemical  equilibrium  of 
the hydration of formaldehyde. Chem Eng Sci 2002; 57:4067
  18.  Kiernan  J.A.  Formaldehyde,  formalin,  paraformaldehyde  and 
glutaraldehyde:  What  they  are  and  what  they  do.  Microscopy 
Today 2000; 1:8.

 
COSMETOLOGY FOR NORMAL NAILS 

 275

  19.  van Ginkel C. Onycholysis door nagelverharders: Ficte of realit-

  40.  Cronin E. Contact Dermatitis. Edinburgh: Churchill Livingstone 

eit? Letter, 2008.

1980; 150–7.

  20.  Baran R, Dawber R, de Berker D, Haneke E, Tosti A. Cosmetics: 
The Care and Adornment of the Nail, Disease of the Nails and their 
Management, 3rd edition. Blackwell Science 2001; p. 367
  21.  Nail  Manufacturers  Council  (NMC)  Investigation  of  the 
Potential  for  Microbial  Contamination  in  Nail  Polish.  2008. 
Available at: www.probeauty.org/NMC/

  22.  Chen AF, Chimento SM, Sanchez M, et al. Nail damage from gel 

polish manicure. J Cosmet Dermatol 2012; 11:27–9

  23.  Baran  R.  Nail  cosmetics.  Allergies  and  irritations.  Am  J  Clin 

Dermatol 2002; 3:547–55.

  24.  Liden  C,  Berg  M,  Färm  G,  Wrangsjö  K.  Nail  varnish  allergy 

with far-reaching consequences. Br J Dermatol 1993; 123:57–62.

  25.  Calnan CD, Sarkany J. Studies in contact dermatitis: Nail var-

nish. Trans St John's Hosp Dermatol Soc 1958; 40:1–11.
  26.  Schorr WF. Nail polish allergy. Dermatol Allergy 1981; 4:23.
  27.  Dooms-Goossens  E.  Contact  dermatitis  caused  by  airborne 

  41.  Bonu G, Zina G. Reazione da contatto morfologicamente incon-

sueta. Minerva Dermatol 1959; 33:507–9.

  42.  Calnan  CD.  Reactions  to  artificial  colouring  materials.  J  Soc 

Cosmet Chem 1987; 18:215–23.

  43.  Cortese  TA.  Capitrol  shampoo,  nail  discoloration.  The  Schoch 

Letter 1981; 31:item 154.

  44.  Gordon G, Sparano BM, Iatropulos MJ. Hyperpigmentation of 
the  skin  associated  with  minocycline  therapy.  Arch  Dermatol 
1985; 121:618–23.

  45.  Loveman  AB,  Fliegelman  MT.  Discoloration  of  the  nails. 
Concomitant  use  of  nail  lacquer  with  resorcinol  or  resorcinol 
acetate as a cause. Arch Dermatol 1955; 72:153–6.

  46.  Baran R. Pathology induced by the application of cosmetics to 
the nail. In Frost P, Horowitz SN, eds. Principles of Cosmetics for 
the Dermatologist. St Louis: Mosby, 1982; pp. 181–4.

  47.  Kechijian  P.  Nail  polish  removers.  Are  they  harmful?  Semin 

agents. J Am Acad Dermatol 1986; 15:1–18.

Dermatol 1991; 10:26–8.

  28.  Tosti A, Guerra L, Vincenzi C et al. Contact sensitization caused 
by  toluene  sulfonamide–formaldehyde  resin  in  women  who 
use nail cosmetics. Am J Contact Dermatitis 1993; 3:150–3.

  48.  Samman PD. Onychia due to synthetic coverings. Experimental 
studies. Trans St John’s Hosp Dermatol Soc 1961; 46:68–73.
  49.  Baran R. Nail beauty therapy: An attractive enhancement or a 

  29.  Hausen BM. Nagellack-Allergie. Z Hautkr 1994; 69:252–62.
  30.  Anonide  A,  Usiglio  D,  Pestarino  A,  Massone  L.  Frequency  of 
positivity  to  nail  varnish  allergens.  Study  of  eighty  women. 
G Ital Dermatol Venereol 1995; 130:13–6.

  31.  De Groot AC, Weyland JW, Nater JP. Unwanted Effects of Cosmetics 
and Drugs used in Dermatology, 3rd edition. Amsterdam: Elsevier 
1993; pp. 524–9.

  32.  Fisher AA. Contact dermatitis. Philadelphia: Lea & Febiger 1986.
  33.  Hausen BM, Milbrodt M, Koenig WA. The allergens of nail pol-

potential hazard? J Cosmet Dermatol 2002; 1:24–9.

  50.  Jackson EM. Some hospitals ban artificial nails. Cosmet Dermatol 

2001; 14:52–3.

  51.  Symonds J, O’Dell CA. Candida nail bed infection and cosmetic 
acrylic nail extension – a potential source of hospital infection? 
J Hosp Infect 1993; 23:243–7.

  52.  Pottinger J, Burns S, Manske C. Bacterial carriage by artificial 

versus natural nails. Am J Infect Control 1989; 17:340–4.

  53.  Wynd CA, Samstag DE, Lapp AM. Bacterial carriage on the fin-

ish. Contact Dermatitis 1995; 33:157–64.

gernails of OR nurses. AORN J 1994; 60:796–805.

  34.  Lee  HN,  Pokorny  CD,  Law  S,  et  al.  Cross-reactivity  among 
epoxy acrylates and bisphenol F epoxy resins in patients with 
bisphenol  A  epoxy  resin  sensitivity.  Am  J  Contact  Dermatitis 
2002; 13:108–15.

  35.  Moffitt  DL,  Sansom  JE.  Allergic  contact  dermatitis  from 
phthalic anhydride/trimellitic anhydride/glycols copolymer in 
nail varnish. Contact Dermatitis 2002; 46:236.

  36.  Giorgini S, Brusi C, Francalanci S, et al. Prevention of allergic 
contact dermatitis from nail varnishes and hardeners. Contact 
Dermatitis 1994; 31:325.

  54.  Baumgardner  CA,  Maragos  CS,  Walz  JA,  Larson  E.  Effects  of 
nail  polish  on  microbial  growth  of  fingernails.  AORN  J  1993; 
58:84–8.

  55.  Senay  H.  Acrylic  nails  and  transmission  of  infection.  Can  J 

Infect Control 1991; 6:52.

  56.  Parker  AV,  Cohen  EJ,  Arentsen  JJ.  Pseudomonas  corneal  ulcers 
after  artificial  fingernail  injuries.  Am  J  Ophthalmol  1989; 
107:548–9.

  57.  Aderka  D.  Bacterial  endocarditis  following  nail  trauma.  Arch 

Intern Med 1988; 148:752–4.

  37.  Shaw S. A case of contact dermatitis from hypoallergenic nail 

  58.  Schoon  D.  Nail  Structure  and  Product  Chemistry,  2nd  edition. 

varnish. Contact Dermatitis 1989; 20:385.

Albany, NY: Milady/Delmar, 2005; pp. 66–7

  38.  Kanerva  L,  Lauerma  A,  Jolanki  R,  Estlander  T.  Methyl  acry-
late:  A  new  sensitizer  in  nail  lacquer.  Contact  Dermatitis  1995; 
33:203–4.

  39.  Guarneri,  F,  Guarneri,  C,  Cannavo,  SP,  Nail-art  and  cobalt 

allergy. Contact Dermatitis 2010:62:320–1

  59.  ABC NEWS.com: Woman gets $3.1 M in herpes manicure case. 

[29 May, 1990]

  60.  Nail  Manufactures  Council  (NMC),  A  series  of  safety  related 
brochures for nail technicians, Professional Beauty Association, 
Scottsdale, Arizona. Available at: www.probeauty.org/NMC

 
31

Cosmetics for Abnormal and Pathological Nails

Douglas Schoon and Robert Baran

INTRODUCTION
Medical  or  surgical  nail  disorders  can  sometimes  be  camou-
flaged  by  cosmetic  nail  techniques.  This,  however,  covers  up 
the underlying process, and proper diagnosis and therapy are 
therefore essential to correct the underlying condition (1).

There are limits to the use of cosmetics, such as acrylic 
chemicals,  in  some  at-risk  patients:  those  who  have  had  a 
reaction to artificial nails in the past, for example, or individ-
uals with circulatory disorders, particularly with scarring or 
ulceration around the fingertip. Any bacterial or fungal infec-
tion should be treated before applying any type of artificial 
nail. Individuals whose hands are in water for long periods 
will have difficulty keeping on artificial nails. Psoriasis pro-
duces an isomorphic reaction (2), so artificial nails should be 
avoided in persons affected by this condition, since just nick-
ing  the  hyponychium  or  nail  folds  may  provoke  a  Koebner 
reaction.  Lichen  planus  and  lupus  erythematosus  may  also 
precipitate this type of reaction. If the condition is minor or 
temporary—that is, waiting for hangnails to heal—then arti-
ficial  nails  are  acceptable;  however,  for  potentially  chronic 
conditions such as onycholysis, it might be prudent to avoid 
artificial nails until the condition is resolved. This will avoid 
medicolegal problems (3). For the same reasons, an ultravio-
let (UV) energy-cured acrylic should never be used in people 
who  are  taking  photosensitizing  medications,  or  who  are 
affected by photodermatitis.

ARTIFICIAL NAILS
There  are  three  major  methods  for  applying  artificial  nails. 
Approximately 30% are sculptured on a form, 60% are molded 
on an acrylonitrile butadiene styrene (ABS) plastic tip, and 10% 
are applied as thin overlay on the natural nail. Each is popular 
for a variety of reasons.

•  All three methods can correct the coloration of nail plates 

or beds.

•  Each method can build a natural-looking curvature to flat 

natural nail.

•  All will increase the durability of the nail plate and may 

be decorated with colors, designs, ornaments, and jewels.

•  Each type can attractively replace a deteriorated nail plate, 
one  reduced  by  onychophagia,  affected  by  splitting  for 
example,  or  one  that  is  simply  broken—acrylics  can  even 
cosmetically correct “ski-jump” nails or unsightly “racket” 
nails.

•  Sculpting  and  plastic  tips  specifically  add  length  beyond 
the  free  edge  and  can  create  the  illusion  of  a  longer  nail 
bed.

•  Plastic  tips  require  less  technical  skill  to  create  a  natural 

looking nail.

•  Natural  nail  overlays  add  no  length  and  require  lower 
maintenance  while  providing  a  protective  coating. 
Artificial nail products are applied both in salons and in 
the home.

Since  the  sculpting  technique  requires  considerably  more 
skill, it is usually restricted to the salon setting.

There are three basic types of products used to perform 
these services. They share similar ingredients but feature dif-
ferent  chemistries.  All  three  are  discussed  in  this  chapter. 
They  are  “liquid/powder”  (methacrylate  based),  “UV  gels” 
([meth]acrylate based), and “wraps” (cyanoacrylate based). In 
this chapter the term (meth)acrylates will be used to indicate 
methacrylates and/or acrylates.

A 

typical  methacrylate 

liquid/powder  based  kit 

contains (4):

•  A metallized paperboard template, placed on the natural 

nail surface to frame the new nail for sculpting

•  A liquid methyl*, ethyl or isobutyl methacrylate monomer 
blend  containing  proprietary  blends  of  other  mono-,  di-, 
tri-, and tetrafunctional methacrylate monomers

•  A  powdered,  spherical  polymer  made  from  poly(methyl 
methacrylate) and/or poly(ethyl methacrylate) polymer (or a 
copolymer of both methacrylates) with benzoyl peroxide as 
an initiator and possibly titanium dioxide as a white colorant
•  A stabilizer such as resorcinol, eugenol, thymol, or (most 
commonly) hydroquinone (HQ) or methyl ethyl hydroqui-
none (MEHQ)

•  A  catalyst,  such  as  N-N-dimethyl-p-toluidine,  to  catalyze 
the  production  of  free  radicals  from  benzoyl  peroxide  in 
the polymer powder

•  Plasticizers such as tricresyl phosphate
•  Very low levels of solvents to act as clarifiers or solubilizers
•  Dyes

In salons, metalized nail forms (Figure 31.1) and mylar-coated 
nail forms predominate over reusable.

Teflon nail forms are shown in Figure 31.2a,b.
The nail is first thoroughly cleansed, by brushing with 

soap and water and often painted with antiseptic solutions.

The  dried  nail  is  sometimes  coated  with  a  adhesion-
promoting  primer.  In  the  past,  these  primers  were  based  on 
diluted methacrylic acid, but developed acid-free primers are 
designed to react covalently with the keratin and the acrylic, 
providing increased adhesion to both surfaces.

Primers are “adhesion promoters.” Nonmethacrylic acid 
primers are adhesion promoters in a solvent base, and are not 

*  Methyl  methacrylate  monomer  is  specifically  prohibited  for  use  to 
create artificial nails in most U.S. states and Australia

COSMETICS FOR ABNORMAL AND PATHOLOGICAL NAILS 

 277

temperature  in  less  than  3  minutes.  The  prosthetic  nail  is 
enlarged  by  repeated  applications.  The  sculpted  nail  can  be 
filed and manicured to shape, and as the nail grows out, fur-
ther  applications  of  the  acrylic  mixture  are  added  every  2–3 
weeks  to  fill  in  the  new  growth  of  nail  plate  at  the  lunula. 
These types of services can be performed by sculpting either 
on a form or over a tip.

Colored  polymer  powders  can  create  the  illusion  of  a 
beautiful  nail  by  using  a  combination  of  natural  pink  color 
over the nail bed and opaque white distally for the nail plate’s 
free ledge. This combination perfectly simulates a natural nail 
and nail varnish need not to be used. Various shades of pink 
powders  are  used  to  hide  visible  defects  in  the  nail  bed  and 
plate.

ALLERGIC REACTIONS
These may occur 2–4 months, and even as long as 16 months, 
after the first application (5). One of the first indications is an 
itch in the nail bed or redness of the soft tissue surrounding 
the  nail  plate.  Paronychia,  which  is  usually  present  in  aller-
gic reactions, can be associated with excruciating pain in the 
nail area, and sometimes with paresthesia. The nail bed is dry 
and  thickened  (Figure  31.3),  and  there  is  often  onycholysis 
(Figure 31.4). The natural nail plate may appear thinner, usu-
ally  due  to  overly  aggressive  filing  techniques  (Figure  31.5), 
split,  and  sometimes  discolored.  It  takes  several  months  for 
the nails to return to normal. Permanent nail loss (Figure 31.6) 
is  exceptional,  as  is  intractable  prolonged  paresthesia  (6–8). 
Distant allergic contact dermatitis may affect the face and the 
eyelids  (9), and is  probably caused by touching  the face with 
the  hands.  The  arms  and  wrists  of  nail  technicians  may  be 
affected  if  these  areas  are  repeatedly  exposed  to  filing  dust. 
Filings  may  contain small amounts of  monomer  that has  not 
yet reacted, since it takes 24–48 hours for the enhancement to 
cure fully.

Technicians  should  be  instructed  to  wash  their  hands 
before touching the face or eye area. The area involved is usu-
ally the chin, where some technicians tend to rest their heads 
in their hands. They should also be warned to avoid skin con-
tact with the dust of freshly applied product and to avoid using 
the product with too high a ratio of liquid to powder.

Figure  31.1  Metalized  paperboard  template  for  sculptured  arti-
ficial nails.

(a)

(b)

Figure 31.2 

(a,b) Teflon templates for sculptured artificial nails.

corrosive  and  therefore  not  likely  to  burn  the  soft  tissue  on 
contact, as is the case with methacrylic acid.

Newer artificial nail formulations no longer require pre-

treatment of the nail with a primer.

Using  a  paper  or  Teflon  nail  form,  the  natural  nail 
is  coated  with  a  fresh  acrylic  mixture  to  harden  at  room 

Figure  31.3  Nail  bed  and  hyponychium  thickening  from  sculp-
tured artificial nails.

 
278 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 31.4  Onycholysis due to sculptured artificial nails.

Figure 31.5  Thinning of the nail plate after use of sculptured arti-
ficial nails.

Figure 31.6  Permanent loss of the nails due to sculptured artifi-
cial nails. (Courtesy of A Fisher.)

A  medium  dry  consistency  of  the  slurry  is  considered 
ideal. The filings from UV gel nails (discussed below) are also 
responsible for skin sensitizations.

The  UV  bulbs  used  to  cure  this  type  of  artificial  nail 
system lose about half of their original peak UV output after 
about 4–6 months, depending on usage. Newer LED-style UV 
nail lamps have been designed for use with UV gels specially 
formulated to cure with these more intense UV lamps. Curing 
can  be  up  to  75%  faster  when  LED-style  UV  nail  lamps  are 
utilized.

Technicians  should  be  told  to  change  the  UV  bulbs  in 
their  nail  lamps  three  times  per  year,  even  though  they  will 
continue  to  emit  visible  blue  light  for  many  years.  LED-style 
nail  lamps  are  designed  to  continue  to  produce  necessary 
levels of UV energy for 2–3 years, but then must be replaced 
since  the  diodes  are  soldered  to  a  circuit  board  and  can’t  be 
changed. Applying multiple thinner coats of products, rather 
than fewer and thicker coats, is preferred. The thicker the coat-
ing, the more difficult it is to cure the UV gel. UV penetration 
is  low  and  the  number  of  photons  reaching  beyond  a  depth 
of  2  mm  is  greatly  reduced,  and  a  complete  cure  cannot  be 
assured if applied too thickly. Although sensitization to butyl-
hydroxytoluene  is  possible,  UV  gels  use  acrylated  oligomers 
and monomers. Acrylates are many times more likely to cause 
sensitization than methacrylates or stabilizers. These systems 
also  rely  on  photoinitiators,  such  as  benzyldimethyl  ketal  or 
camphorquinone, (1%–3%) or benzophenone, which can all be 
sensitizing.

Gluteraldehdye  and  acrylic  acid  are  also  sometimes 
used  in  low  levels  (<1%),  as  keratin  adhesion  promoters  and 
certainly  contribute  to  adverse  skin  reactions.  Since  UV  gels 
contain  oligomers  with  high  molecular  weights,  they  tend  to 
be very sticky and messy, which further increases the risks of 
overexposure.

Patch Testing to Identify Reactions 
to Sculptured Artificial Nails
Patients  who  are  allergic  react  strongly  to  the  (meth)acrylate 
liquid monomer (10) (1%–5% monomer in petrolatum or olive 
oil). In the series of 11 patients of Koppula et al. (10), 0.1% ethyl 
acrylate  in  petrolatum  detected  91%  of  the  (meth)acrylate- 
allergic  users  of  artificial  nail.  These  authors  proposed  the 
following  five  chemicals  be  used  as  screens:  ethyl  acrylate, 
2-hydroxy ethyl acrylate, ethylene glycol dimethacrylate, ethyl 
cyanoacrylate,  and  triethylene  glycol  diacrylate.  The  pattern 
of  (meth)acrylate  cross-reactivity  among  the  most  frequently 
positive (meth)acrylates suggests that a functional group that 
is a carboxyethyl side group may be requisite for allergic con-
tact dermatitis to (meth)acrylates. Kanerva et al (11) reported 
that 6 out of 23 patients who were (meth)acrylate sensitive were 
sensitive to ethyl methacrylate which is consequently a signifi-
cant allergen.

The  powder  contains  ethyl  methacrylate  homopoly-
mer  or  ethyl/methyl  methacrylate  copolymer,  but  also  may 
contain  small  amounts  of  monomeric  methyl  methacry-
late  monomer  and  ethyl  methacrylate  (<0.1%)  and  up  to  2% 
benzoyl  peroxide.  This  explains  why  the  powder  may  in 
some  cases  provoke  an  allergic  patch  test  reaction  (11–12). 
Benzophenone  and  other  UV  energy  absorbers  used  in  nail 
enhancement may produce eyelid dermatitis (13). UV absorb-
ers  are  often  used  at  low  levels  (<1%)  to  protect  the  coating 
from UV-related discoloration.

Since  there  are  no  real  monomer-free  (meth)acrylate 
resins, an adaptable nail prosthesis made of silicone rubber 

 
COSMETICS FOR ABNORMAL AND PATHOLOGICAL NAILS 

 279

is  sometimes  an  alternative.  This  “thimble-shaped”   finger 
cover  takes  nail  polish  well  (14,15)  (Figure  31.7).  A  fur-
ther  development  is  for  UV  gel  nail  systems  to  be  used  as 
prosthetic  devices  for  toes  (Dr  Robert  Spaulding,  personal 
communication).

NON ALLERGIC REACTIONS
With continued wear, the edges become loose. These must be 
filed  or  clipped  and  then  rebuilt  to  prevent  development  of 
an environment prone to bacterial and, beneath the nail plate, 
Candida infection. This is a result of improper application and 
maintenance.

Failure  to  undergo  filling  every  2–3  weeks  may  result 
in  creation  of  a  lever  arm  that  can  predispose  to  traumatic 
onycholysis or damage to the natural nail. Older clients’ nails 
grow much more slowly and require regular maintenance less 
frequently.

Onycholysis  (16)  is  more  common  with  nail  extensions 
that  are  too  long  (lever  effect).  It  has  also  been  said  that  the 
bond between the sculptured and the natural nail can be stron-
ger than the adhesion between the nail plate and the nail bed. 
There  is  no  evidence  that  occlusive  prosthetic  nail  interferes 
with  the  nail’s  normal  vapor  exchange.  Irritant  reactions  to 
monomers are possible (4). These are manifested as a thicken-
ing of the nail bed’s keratin layer, which can sometimes cause 
the  entire  nail  bed  to  thicken,  with  or  without  onycholysis. 
Still,  without  question,  the  overwhelming  majority  of  cases 
result from physical trauma or abuse.

Damage  to  the  natural  nail  is  not  unusual  after  2–4 
months  of  wear  of  a  sculptured  nail.  If  it  becomes  yellow  or 
crumbly, this means that the product was applied and main-
tained incorrectly.

Higher-quality  products  which  are  properly  prepared 
do  not  suffer  from  these  problems.  Therefore,  instead  of  rec-
ommending  wearing  prosthetic  nails  for  no  more  than  3 
consecutive  months  with  1-month  intervals  before  resuming 
application (17), the dermatologist should find a better-qualified 

Figure 31.7  Adaptable nail prosthesis made of silicone rubber.

nail technician. It is probably unrealistic to assume that clients 
will  remove  their  artificial  nails  for  any  period  of  time.  The 
problem  may  not  be  the  acrylic  nail  materials  but  rather  the 
thinning  of  the  nail  due  to  overfilling  with  heavy  abrasives. 
Acid-based primer (methacrylic acid) is a strong irritant, which 
may  produce  third-degree  burns,  so  it  is  fortunate  these  are 
rarely used any longer. Acid-based primer is hazardous if one 
floods the soft, living tissue, neglects to clean up spills imme-
diately, or ignores an individual complaining of burning. One 
must  rinse  the  area  immediately  with  water  when  the  client 
says it is burning. Acid primer can permeate the plate and soak 
the nail bed if the nails are too thin. Soap or baking soda used 
with water are excellent neutralizers. If acid primer gets in the 
eyes, the eyes should be flushed with water for at least 15 min-
utes, making sure all traces of the chemical have been rinsed, 
then a poison control center should be called and emergency 
medical treatment sought. There is a general tendency to disre-
gard manufacturers’ instructions and warnings, which causes 
the majority of disorders.

Contact Urticaria
Butylhydroxytoluene  has  been  reported  as  a  cause  of  non-
allergic contact urticaria (18).

Removing Sculptured Artificial 
Nails and Nail Polish
Acetone  is  the  primary  solvent  used  to  remove  artificial  nail 
coating  of  all  types.  Usually,  20  to  30  minutes  is  all  that  is 
required  for  methacrylate-based,  liquid/powder  systems. 
Most UV gels are extremely difficult to remove with solvent, so 
they are more frequently removed by filing with a course abra-
sive.  The  use  of  acetone-free  nail  polish  remover  on  painted 
nails  is  not  necessarily  desirable.  The  alternative  solvents, 
especially methyl ethyl ketone, have higher orders of toxicity 
and can damage the underlying polymer surface, requiring the 
nail coatings to be removed with greater frequency than would 
be typically performed. Acetone diluted with 10% water works 
well  for  removing  colored  polish  without  excessively  drying 
the  skin  or  damaging  the  underlying  artificial  nail  coating. 
Reports have been published of severe and even fatal cases fol-
lowing  ingestion  or  inhalation  of  acetonitrile-containing  nail 
polish  and  acrylic  nail  removers,  because  the  acetonitrile  is 
metabolized into cyanide (19–22). Nitroethane poisoning from 
artificial fingernail remover has led to cyanosis and 39% met-
hemoglobinemia (23). Due to toxicity concerns, acetonitrile and 
nitroethane  are  rarely  used  any  longer  for  removal,  if  at  all. 
Ethyl  methacrylate  monomer  and  polymer  nails  and  the  UV 
or  photobonded  variety  may  produce  severe  and  prolonged 
paresthesia, even without associated allergic dermatitis (3), but 
this  is  relatively  rare.  Unfortunately,  the  product  the  patient 
was  using  could  have  contained  methyl  methacrylate  mono-
mer, since this ingredient is used in gray market products but 
not by mainstream manufacturers; it is often not disclosed in 
the ingredient listing.

UV-Curing Gels (UV Gel Systems, 
Gel Nails, Light-Curing)
The word gel applies to the physical form of the product—not 
the  product  itself.  Gels  are  made  from  oligomers,  which  are 
naturally  thicker  than  monomers  due  to  their  much  higher 
molecular weight. UV gel systems require no premixing of a 
powder component and either acrylates or methacrylate base 
(approximately 30% of the market, worldwide).

 
280 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Cyanoacrylate-based or so-called “no-light” gels are actu-
ally monomers that contain a thickening agent. They comprise 1% 
or less of the market worldwide and do not cure via UV energy 
nor  do  they  undergo  any  photochemical  reactions  (11).  These 
products cure via moisture and can be accelerated with internal 
or external applied catalyst, typically a tertiary amine. They have 
very little odor, which makes them popular in full-service beauty 
salons  and  spas  seeking  to  create  a  relaxing  environment.  UV 
gels may also require the use of a nail primer. The thick UV gels 
are is brushed on the nail and cured with via either UV energy. 
Visible light systems are impractical since the visible light lamps 
produce large quantities of heat and the photoinitators produce 
an unattractive yellow discoloration of the nail coating.

UV energy–cured gels are what is used. If is not correct 
to  refer  to  UV  as  light.  “Light”  is  defined  as  electromagnetic 
radiation that is visible to the eye, e.g. wavelengths lower than 
400 nm. UV is a higher wavelength (>400 nm) that is not vis-
ible  to  the  eye;  therefore  UV  is  energy  and  not  light.  These 
UV gels often contain urethane (meth)acrylates and/or epoxy 
urethane (meth)acrylate oligomers and mono- and/or difunc-
tional (meth)acrylate monomers for cross-linking and viscosity 
reduction,  one  or  more  photoinitiators,  plasticizers,  adhesion 
promoters, stabilizers, anti-yellowing agents, colorants, and a 
UVA energy source/unit that is typically refered to as a “UV 
nail lamp.” Many of the same types of ingredients used in two-
part methacrylate systems are also found in UV gels, but oligo-
mers are not used in two-part methacrylate systems.

Despite the fact that some products are marketed as not 
being “acrylics,” all two-part liquid/powder systems and UV 
gel systems are based on acrylic chemistry and use ingredients 
from  the  acrylic  family  of  chemicals,  which  means  they  con-
tain acrylic functional groups.

The  UV  gel  remains  in  a  semiliquid  form  until  cured 
under a UV lamp. For traditional fluorescent-style UV lamps 
the cure time is 2–3 minutes per applied layer. For LED-style 
UV nail lamps, the cure time is 30–60 seconds. Due to signifi-
cant  difference  in  the  UV  wavelength  and  irradience  (inten-
sity) produced by these different styles of UV nail lamps, UV 
gels are specially formulated to work with these very different 
energy  sources.  The  molecular  weight  of  the  oligomeric  res-
ins as well as the ratio of monomers to oligomers helps deter-
mines the UV gel consistency. The chemical structure of each 
also  plays  an  important  role  in  determining  the  consistency. 
When the UV gel is exposed to energy of the appropriate wave-
length  (UVA)  and  the  irradience  is  sufficent,  polymerization 
occurs, resulting in hardening of the UV gel. However, hard-
ening  occurs  after  only  50%  of  the  oligomer  and  monomers 
polymerize, therefore hardening does not ensure the UV gels 
are properly cured. Proper cure occurs when polymerization 
exceeds 85%. Proper cure helps ensure the resultant polymers 
have sufficient durability to withstand the rigors that artificial 
nail  coating  must  endure  and  also  helps  minimize  exposure 
to  uncured  monomers  and  oligomers  contained  in  fresh  fil-
ings created when the nail coating is shapd with an abrasive 
file. UV gels do not require external catalysts and often do not 
require primers. Newer formulations also use very low levels 
of highly efficient photoinitiators and avoid reliance on meth-
acrylic acid or glutaraldehyde for adhesion promotion.

Marketers  may  claim  that  some  systems  are  visible 
light  cure,  but  the  photoinitator  used  absorb  and  are  chiefly 
activated  by  UV  energy.  Both  fluorescent  and  LED-style  nail 
lamps  produce  UV  energy  and  visible  light,  but  the  visible 
wavelengths are not used to cure the coatings so it is mislead-
ing to refer to such systems as visible light curing.

No-light  cyanoacrylate  gels  have  a  completely  separate 
type of chemistry, utilizing a spray or a brush-on or dropper-
applied activator, usually N,N-dimethyl-p-toludine, which cat-
alyzes a moisture-initiated cure. In curing these gels, a thermal 
initiator replaces the photoinitiator. UV nail lamps and primer 
are never used with cyanoacrylate gels.

Some  individuals  with  distal  fissure  or  men  who  bite 
their nails may want more attractive hands. This can be accom-
plished  by  liquid/powder  systems,  UV  cured  or  no-light  gel 
nailcoatings.  Each  can  produce  completely  natural  looking 
nails with a smooth hard finish that makes the nail more resis-
tant to chewing. Liqiud/powder systems are the preferred way 
to extend the length of the nail plate, but UV gels can also be 
used as tip overlays for individuals who want to extend their 
nail  plate  length.  However,  cyanoacrylate-based  gels  do  not 
have the necessary strength or durablity to extend beyond the 
tip  of  the  fingernail.  Some  companies  provide  a  thicker  gel 
designed for building and sculpting nail extensions. Some UV 
gels may also be used as a “sealer” that can be applied over nail 
polish, making it more impervious to chipping, wearing, and 
fading. However, the difficulty in removing the sealer is a con-
sideration when evaluating the usefulness of this technique.

Colored UV Gels
Liked  colored  methacrylate  powders,  colored  UV  gels  are 
sometimes recommended to persons who do not often change 
polish  color,  or  to  create  nail  art  designs.  They  are  noted  for 
easy  application,  high  shine,  and  durability.  However  if  nail 
infection  or  onycholysis  occurs,  the  permanently  colored  UV 
gel makes detection nearly impossible. Also, colored pigments 
and  dyes  usually  block  UV  penetration,  making  them  more 
difficult to cure completely.

UV Gel Polish/Manicure
Newer  types  of  nail  coatings,  often  called  UV  gel  polish  or 
manicures,  have  became  very  popular.  These  types  of  nail 
coatings  are  used  to  coat  the  nail  plate  with  a  longer-lasting 
colored  coating  capable  of  camouflaging  nail  defects  such  as 
nail  bed  bruises  or  splint  hemorrhages.  UV  gel  polishes  are 
unique in that they are designed to be removed and replaced 
after  2–3  weeks  and  then  followed  up  with  a  fresh  nail  coat-
ing. Although they duplicate the look of nail polish/lacquer/
enamel,  these  nail  coatings  are  polymerized  by  UV  energy 
(400–450  nm)  to  result  in  superior,  scratch-resistant  colored 
coatings  with  enhanced  durability.  However,  UV  curing 
makes  these  types  of  coatings  more  difficult  to  remove  than 
traditional nail polish formulations that form film by solvent 
evaporation.

Because  these  are  often  more  difficult  to  remove, 
improper  removal  can  cause  small,  roughly  round  and  sym-
metrical whitish spots, typically 2–5 mm, to appear on the nail 
plates surface after removal. When these are found on the sur-
face of the nail plate immediately following removal of these 
types of coatings, forceable removal of residues of remaining 
nail coating is the most likely reason. The acetone remover is 
wrongly blamed for dehydrating the nail plate, but these areas 
are not a result of dehydration. The whitish spots appear fol-
lowing incorrect removal of any type of firmly adhering nail 
coatings.  Although  these  areas  sometimes  resemble  white 
superficial  onychomycosis,  they  are  are  not  caused  by  any 
pathogenic  organisms,  but  as  result  of  surface  damage  cre-
ated by overly aggressive removal techniques or when wear-
ers  forceaby  remove  the  nail  coating  by  picking,  peeling,  or 

 
COSMETICS FOR ABNORMAL AND PATHOLOGICAL NAILS 

 281

chewing  them  from  their  own  nail  plates.  When  nail  plate 
thinning is observed, excessive filing of the plate either before 
or after application of nail coatings is the likely cause.

usually  be  removed  every  2–3  months.  Better  formulations 
are more stable and resistant to these types of continued UV 
exposure.

Figure  31.8  shows  several  examples  of  white  spots 
caused by improper removal. These scanning electron micros-
copy  images  show  nail  coating  residues  and  surface  damage 
magnified  186–3830  times.  Examining  the  modes  of  failure 
indicates the damage is caused by prying and/or scraping off 
firmly adhered residual coatings. Often residual pieces of nail 
coating remains because of insuffficent contact time with the 
solvent remover, which results in failure to sufficiently soften 
and loosen these firmly bonded areas. Typically 15–20 minutes 
is required for removal in acetone or other solvent removers. 
However, UV nail coating designed for removal every 2 weeks 
will become even more firmly bonded after 3 weeks or longer 
of wear. Longer wear times will require longer solvent soaking 
time,  up  to  25  minutes,  as  well  as  more  gentle  removal  tech-
niques to avoid nail surface damage.

Surface nail damage and the resulting visible white spots 
are  avoidable  when  sufficient  time  is  allowed  to  more  com-
pletely  soften  the  UV-cured  nail  coating  and  gentle  removal 
techniques are practiced. Damage becomes more likely because 
the nail plates are softer and temporarily more susceptible to 
injury from removal implements used after soaking in acetone 
or other remover solvent blends. When wearing nail coatings 
of this type, users should be warned not to self-remove their 
nail  coatings  and  to  not  allow  their  nails  to  be  filed  using 
overly aggressive techniques.

Removing UV Gel Nail Coatings
Many  gels  slowly  embrittle  and  degrade  with  continued  UV 
exposure  from  tanning  beds  or  excessive  natural  sunlight. 
Those  with  formulations  susceptible  to  degradation  must 

Figure  31.8 Scanning  electron  microscopy  images  show  nail 
coating residues and surface damage magnified 186–3830 times. 
Image 1 is clearly the result of upward prying forces. Images 2 and 
3 are due to scraping forces caused by a wooden implement known 
as a “pusher.” Image 4 is a lower magnification that shows the resid-
ual  coatings  still  firmly  adhered  to  the  nail  plate  after  the  solvent 
soaking removal procedure is completed.

One good way to remove UV gels is to carefully file off 
the upper 75% of the coating with an abrasive file and remove 
the  remainder  with  acetone  or  specially  blended  solvent 
removers.

Acetone  will  have  no  effect  on  some  UV  gels,  depend-
ing on their composition and degree of curing. These types of 
UV formulation suffer serious disadvantages when compared 
to  more  advanced  and  easily  removed  UV  gel  formulations. 
There is no basis to the claims that these types of artificial nails 
are  “safer”  or  healthier  for  the  nail.  In  fact,  they  are  no  bet-
ter for the nail than any other system. History has shown that 
nail technicians’ knowledge and skill are the primary determi-
nants for successful application and avoiding nail damage or 
other adverse reactions.

REMOVABLE UV GELS
The latest trend in UV-curable gels is to make products that can 
be removed easily. This is usually accomplished by either low-
ering the amount of cross-linking monomers, thereby lowering 
the cost link density of the artificial nail, or by using an insuffi-
cient amount of photoinitiator to lower the degree of curing and 
creating a partially cured artificial nail, or by softening the nail 
coating with an excess amount of plastizers or adding polymeric 
substances to make the nail coating more susceptible to solvents, 
or some combination of these. These types of UV gels generally 
require 30 minutes soaking in acetone to remove.

ADVERSE REACTIONS
Artificial nails shrink when they polymerized. UV gel enhance-
ments shrink up to 18%, which can result in adhesion loss and 
a tight feeling on the nail that causes throbbing, warmth below 
the nail plate. This may lead to tender, sore fingertips, but usu-
ally the condition resolves within a day or two. Adverse nail 
reactions,  even  with  nail  loss  (24)  and  paresthesia  with  UV 
gels, have been observed (25).

UV-cured (meth)acrylates sensitize some individuals in 
many applications including inks, lacquers, composite dental 
resins,  audiological  ear  molds,  and  nail  cosmetics  (26–30).  In 
patients wearing UV-cured (meth)acrylic nails who had peri-
onychial  and  subungual  eczema  with  fingertips  fissuring 
extending under the nails (31), Hemmer et al. (32) patch-tested 
“hypoallergenic”  commercial  products.  The  omission  of  irri-
tant methacrylic acid primers from use with UV curable gels 
does not reduce the sensitizing potential of acrylate systems, 
since  they  still  contain  several  other  potential  sensitizers.  In 
contrast  to  the  manufacturers’  declarations,  all  “hypoaller-
genic” products continue to include (meth)acrylate functional 
monomers  and  oligomers,  and  therefore  continue  to  cause 
allergic sensitization.

UV gels and two-part liquid/powder systems (commonly 
called  acrylic  nails)  share  many  similar  ingredients  but  are 
compositionally distinct enough that they will not necessarily 
cross-react (11,24). The resistance of disposable latex gloves to 
penetration by (meth)acrylates is low (33,34). Disposable nitrile 
or  vinyl  gloves  are  a  better  alternative,  as  their  resistance  to 
methacrylates is much higher than latex.

Preformed Artificial Nails
Plastic  press-on  nails  are  preformed  by  injection  molding 
with the thermoplastic resin ABS and temporarily glued with 

 
282 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 31.9  Preformed plastic “nail tips.”

Figure 31.10  Preformed nail in gold plate.

cyanoacrylate  to  the  nail  (Figure  31.9).  They  are  packaged  in 
several shapes and sizes to conform to normal nail plate con-
figurations. They come in two types:

  1.  Those that are adhered to the free edge of the nail plate 
to act as platform to support artificial nail coatings.
  2.  Those that are adhered over the entire nail plate as a 
temporary  application  for  special  occasions,  such  as 
weddings.

Decorative,  preformed  nails  in  gold  plate  (Figure  31.10)  may 
be  used  in  the  same  way  as  plastic  nails.  The  application  of 
preformed prosthetic nails is limited by the need for some nor-
mal nail to be present for attachment (Figure 31.11). When used 
alone  (item  2  above)  it  is  recommend  that  they  are  removed 
after 1–2 days as they are not very durable and can cause ony-
cholysis and nail surface damage when improperly removed. 
Since these tips are adhered by using cyanoacrylate, in some 
cases  they  can  produce  allergic  changes  indistinguishable 
from dermatitis caused by so-called formaldehyde nail hard-
eners. Ectopic allergic or irritant contact dermatitis may affect 
the face and eyelids (35) and large areas of the trunk (36) but 
disappears with removal of the cause.

Allergic  onychia  and  paronychia  due  to  cyanoacrylate 
nail preparations require some comment (9,37). After about 3 
months,  painful  paronychia,  onychia,  dystrophy,  and  discol-
oration of the nails may become apparent and last for several 
months (Figure 31.12).

Eyelid dermatitis disappears with removal of the aller-
gen. Shelley & Shelley (38) reported an isolated chronic aller-
gic contact dermatitis simulating a plaque of parapsoriasis due 
to  an  allergic  reaction  to  cyanoacrylate  adhesive  used  on  the 
fingernails.

Not surprisingly, patients react far more often on patch 
testing  to  the  adhesive  than  to  the  plastic  nails.  Suggested 
allergens for patch testing are:

•  p-t-butyl phenol resin (1% petrolatum) (39,40)
•  Tricresyl ethyl phthalate (5% petrolatum)
•  Cyanoacrylate adhesives (10% petrolatum)
•  5% methyl ethyl ketones
•  MEHQ or HQ and
•  The artificial nail itself

(a)

(b)

(c)

Figure 31.11 

(a–c) Different stages for shaping the tips of nails.

 
COSMETICS FOR ABNORMAL AND PATHOLOGICAL NAILS 

 283

Figure  31.12  Dystrophic  nails  with  subungual  hyperkeratosis 
due to preformed plastic nails. (Courtesy of P. Lazar.)

Figure 31.13 

(a,b) Nail mending.

(a)

(b)

Most cyanoacrylate adhesive formulations contain HQ  at  con-
centration up to 1000 ppm, but more typically 200 ppm. Since 
higher levels of HQ are need to prevent premature polymeriza-
tion of cyanoacrylate monomers used in artificial nail products, 
the  European  Union  has  been  petitioned  by  several  cosmetic 
associations  to  raise  the  allowable  limit  of  HQ  to  1000  ppm 
from a 200 ppm limit in artificial nail systems (after mixing if 
contained in a two-part system) (41). Therefore most investiga-
tors perform patch testing not only with cyanoacrylate glue or 
nail preparations, but also with HQ.

Nail Mending and Wrapping
The purpose of nail mending is to create a splint for a partially 
fractured  nail  plate  (Figure  31.13)  or  one  longitudinal  split 
extending the full length of the nail. The splint is first bonded 
with  cyanoacrylate  monomer.  Then  a  piece  of  wrap  fabric  is 
cut and shaped to fit over the nail surface. This is then embed-
ded within the cyanoacrylate monomer and several coats are 
applied;  or  the  fabric  is  applied  directly  over  the  crack  and 
subsequently sealed to the nail with cyanoacrylate monomer 
or  no-light  gel.  In  nail  wrapping,  or  “wraps,”  the  free  edge 
of  the  nail  should  be  long  enough  to  be  splinted  with  paper, 
silk,  linen,  or  fiberglass  and  fixed  to  the  plate  with  cyanoac-
rylate monomer (Figure 31.14). The activator for cyanoacrylate 
wraps is a catalyst and contains N,N-dimethyl-p-toluidine in 
a solvent carrier. Methemoglobinemia with resultant cyanosis 
may follow its ingestion (22). DMPT is typically 0.5% of the for-
mulation  and  HQ  up  to  1000  ppm.  The  ethyl  acetate  and  tri-
chloroethane in these products do not promote curing, but are 
instead solvents.

Paper is not very effective, but silk wraps are sheer, very 
thin, and work quite well. Linen is thicker and offers increased 
strength but inhibits cyanoacrylate penetration to the nail, thus 
lowering adhesion, and it does not have as natural an appear-
ance as other materials. Fiberglass combines many benefits of 
both silk and linen and is the most universally used.

Most wrap systems consist of a few basic elements (42):

•  Monometric cyanoacrylate, polymerizing from moisture in 
the air or in the natural nail’s surface, to form the hard nail 
coating that is both the base and top coats of the nail wrap. 
A mesh material, for example fiberglass or silk, is preferred.

(a)

(b)

Figure 31.14 

(a,b) Nail wrapping.

•  An  activator  or  catalyst  that  cuts  the  hardening  time  to 

seconds.

See above for patch testing patients sensitized to cyanoacrylate.

NAIL HARDENERS AND TREATMENTS
There are two main types of products which make nail hard-
ening claims. In one group the products are modified nail pol-
ish containing, among ingredients, nylon fibers, (meth)acrylate 
resin, and hydrolyzed proteins. They function either as a base 
coat for nail polish or as a standalone treatment. These prod-
ucts provide a protective coating, therefore the implied bene-
fits come from the added strength and durability of the coating 
itself  rather  than  altering  the  physical  properties  of  the  nail 
plate. These products may also consist of polyesters and poly-
amides. These nail hardeners are essentially a modification of 
clear nail polish and the addition of nonfunctional ingredients 
for marketing purposes, that is, nylon fibers and amino acids 
or hydrolyzed protein.

 
 
 
284 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Like nail varnish and base coats, they are applied to the 
clean nail plate. Some are designed with a dual purpose and 
also function as a varnish base coat (17).

The second type of hardener chemically alters the struc-
ture of the nail. The U.S. FDA allows these products to contain 
up  to  5%  formalin  (International  Nomenclature  of  Cosmetic 
Ingredients  [INCI]  name:  methylene  glycol)  and  kits  are 
required  to  contain  a  skin  shield  to  protect  the  eponychium 
and side walls from exposure (43).

The  INCI  dictionary  no  longer  requires  manufactur-
ers  to  call  formalin  by  the  incorrect  name  formaldehyde. 
Formaldehyde  is  an  anhydrous  gas  that  upon  mixing  with 
water  reacts  to  form  a  methylene  glycol  and  residual  traces 
of formaldehyde in equilibrium. Most products never exceed 
1.5% methylene glycol since at higher concentrations both the 
nail plate and the surrounding tissue can quickly show signs 
of  adverse  changes.  At  these  concentrations  used  products 
contain  less  than  12  ppm  (0.0012%)  free  formaldehyde  (44). 
Companies selling these products generally disregard require-
ments for skin shields, so accidental skin exposure can occur.

Most products never exceed 1.5% methylene glucol, since 
at higher concentration. Both the nail plate and the surround-
ing tissue can quickly show signs of adverse changes. At these 
concentrations  products  contain  less  than  12  ppm  (0.0012%) 
free formaldehyde (44).

Companies  selling  these  products  generally  disregard 
requirements for skin shields, so accidental skin exposure can 
occur. Using a concentration of less than 0.2% methylene glycol 
seems  to  have  little  or  to  no  positive  benefits  on  the  surface 
hardness of the nail plate.

Methylene  glycol  permanently  alters  the  structure 
of  the  nail  plate  by  cross-linking  the  keratin  (45),  which  can 
quickly  lead  to  embrittlement  since  the  cross-link  density 
rises  over  time  with  continued  regular  use.  Repeated  use 
also  allows  a  deeper  migration  into  the  plate,  further  affect-
ing the bulk properties of the natural nail. Greater cross-link 
density increases the surface hardness of the nail plate, but it 
also lowers the flexibility while increasing the strength, result-
ing in an imbalance called brittleness (46). The property that 
people  are  unknowingly  seeking  is  toughness.  This  occurs 
when  there  exists  a  favorable  balance  between  strength  and 
flexibility.  Since  the  general  public  doesn’t  understand  how 
or  why  these  products  work,  the  products  are  often  applied 
to nails which are already overly brittle or rigid and therefore 
not suitable for further hardening. Even on nails which could 
benefit,  these  products  are  frequently  misused.  The  prepara-
tions work so well on thin, weak nails that users see an almost 
instant  improvement,  which  encourages  repeated  and  fre-
quently excessive use. After several weeks of success, the nails 
can eventually become overly hard and rigid. Continued use 
can  cause  splitting,  cracking,  and  breaking  which  unaware 
users can misinterpret. This will often cause them to continue 
to use these products with even greater frequency, leading to 
the problems associated with overexposure to this ingredient.
Methylene  glycol  preparations  may  cause  nail  changes 
including  a  bluish  discoloration  (Figure  31.15)  ,  which  may 
turn red, with intense throbbing (47). Resolving hemorrhages 
produce  reddish-rust  or  yellow  discoloration  of  the  nail. 
Methyl  glycol  can  also  be  responsible  for  paronychia, 
onycholysis  (Figure  31.16),  subungual  hyperkeratosis,  and 
dryness  of  the  fingertips,  but  nail  shedding  is  uncommon. 
Pterygium  inversum  (48)  (Figure  31.17)  has  been  observed, 
sometimes accompanied by severe pain necessitating systemic 
corticosteroid (43).

Figure 31.15  Acute formaldehyde reaction. (Courtesy of P Lazar.)

Figure 31.16  Longstanding onycholysis due to formaldehyde.

Figure 31.17  Pterygium inversum due to formaldehyde.

 
COSMETICS FOR ABNORMAL AND PATHOLOGICAL NAILS 

 285

Isolated onycholysis and ectopic contact dermatitis, even 
associated with hemorrhages of the lips in nail biters (49), have 
been reported. Airborne contact dermatitis of the face may also 
be seen.

Formalin  (1%–2%  in  water)  should  be  used  for  patch 
testing, but caution is necessary in interpreting the reactions, 
because the agent also acts as an irritant.

A new nail hardening ingredient has now been introduced 
which overcomes the objections related to formalin. The ingre-
dient,  dimethyl  urea,  is  nonsensitizing  and  2%  concentrations 
in an basecoat preparation does not overcross-link the keratin. 
The higher molecule weight and relative increase in hydropho-
bicity  prevent  dimethyl  urea  from  penetrating  as  deeply  into 
the plate as methylene glycol. This effectively limits the cross-
linking action to the surface of the plate, thereby dramatically 
reducing the potential for overhardening and embrittlement. In 
addition, the greater the cross-linking on the surface, the more 
restricted the dimethyl urea penetration will become, essentially 
creating a self-limiting cross-linking reaction while having the 
additional benefit of being non-sensitizing (50).

Other  alternatives  to  formaldehyde  hardeners  are  alu-
minium  chloride  (5%  in  water)  tannin,  and  nail  creams  with 
a low water (30%) and high lipid content for minimizing nail 
fragility.

Overall Risk
One study showed 9 out of 819 patients manifested a contact 
allergy  to  nail  polish,  while  two  persons  reacted  to  artifi-
cial  nails  (51).  The  Cosmetic  Ingredient  Review  Expert  Panel 
reviewed  24  artificial  nail  enhancement  methacrylate  mono-
mers used to create the two-part systems and declared all to 
be “safe as used,” while recognizing that it was important to 
avoid direct skin contact with the monomers to minimize the 
potential for skin sensitization.

REFERENCES

1.  Barnett  JM,  Scher  RK.  Nail  cosmetics.  Int  J  Dermatol  1992; 

31:675–81.

2.  Fisher AA, Baran R. Occupational nail disorders with a refer-
ence  to  Koebner’s  Phenomenon.  Am  J  Contact  Dermatitis  1992; 
3:16–23.

3.  Baran R, Schibli H. Permanent paresthesia to sculptured nails. 

A distressing problem. Dermatol Clin 1990; 8:138–41.

4.  Engasser  P.  Cosmetics  and  Contact  Dermatitis.  Dermatol  Clin 

1991; 9:69–80.

5.  Marks JC, Bishop ME, Willis WF. Allergic contact dermatitis to 

sculptured nails. Arch Dermatol 1979; 115:100.

6.  Fisher AA. Permanent loss of fingernails from sensitization and 
reaction to acrylic in a preparation designed to make artificial 
nails. J Dermatol Surg Oncol 1980; 70–6.

7.  Fisher  AA,  Baran  R.  Adverse  reactions  to  acrylate  sculptured 
nails with particular reference to prolonged paresthesia. Am J 
Contact Derm 1991; 2:38–42.

8.  Freeman S, Lee MS, Gudmundsen K. Adverse contact reactions 
to  sculptured  acrylic  nails:  4  cases  -  reports  and  a  literature 
review. Contact Dermatitis 1995; 33:381–5.

9.  Fitzgerald  DA,  Enolish  JSC.  Widespread  contact  dermatitis 

from sculptured nails. Contact Dermatitis 1994; 30:118.

  10.  Koppula  SV,  Fellman  JH,  Storrs  FJ.  Screening  allergens  for 
acrylate dermatitis associated with artificial nails. Am J Contact 
Derm 1995; 6:78–85.

  11.  Kanerva  L,  Lauerma  A,  EstlandeerT  et  al.  Occupational  aller-
gic contact dermatitis caused by photobonded sculptured nails 
and a review on (Meth)acrylates in nail cosmetics. Am J Contact 
Derm 1996; 7:1–9.

  12.  Lane CW, Kost LB. Sensitivity to artificial nails. Arch Dermatol 

1956; 74:671–2.

  13.  Guin  JD.  Eyelid  dermatitis  from  benzophenone  used  in  nail 

enhancement. Contact Dermatitis 2000; 43:308–9.

  14.  Pillet J. The aesthetic hand prosthesis. Orthop Clin North Amer 

1981; 12:961–9.

  15.  Beasley RW, de Beze G. Prosthetic substitution for fingernails. 

Hand Clinics 1990; 6:105–12.

  16.  Goodwin  P.  Onycholysis  due  to  acrylic  nail  applications.  Clin 

Exp Dermatol 1976; 1:1991–2.

  17.  Draelos  ZK.  Cosmetics  in  Dermatology.  2nd  edition.  New  York, 

Edinburgh: Churchill Livingstone 1995.

  18.  Schubert HJ, Lindner K, Prater E. Kontaktallergie im nagelstu-

dio. Z Hautkr 1992; 1067–9.

  19.  Turchen SG, Monaguerra AS, Whitney C. Severe cyanide poi-
soning  from  the  ingestion  of  an  acetonitrile  containing  cos-
metic. Am J Emerg Med 1991; 9:264–7.

  20.  Caravati  EM,  Litovitz  TL.  Pediatric  cyanide  intoxication  and 
death  from  an  acetonitrile  containing  cosmetic.  JAMA  1988; 
260:3470–3.

  21.  Rainey  PM,  Roberts  WL.  Diagnosis  and  misdiagnosis  of  poi-
soning with cyanide precursor acetonitrile: Nail polish remover 
or nail glue remover? Am J Emerg Med 1993; 11:104–8.

  22.  Potter  JL  et  al.  Methemoglobinemia  due  to  ingestion  of  N,N-
dimetyl-p-toluidine,  a  componant  used  in  the  fabrication  of 
artificial finger nails. Ann Emerg Med 1988; 17:1098–100.
  23.  Hornfeldt CS, Rab WH. Nitroethane poisoning from an artifi-

cial remover. J Tox Clin Tox 1994; 32:321–4.

  24.  Halgmüller  T,  Hemmer  W,  Kusak  I  et  al.  Loss  of  fingernails 
due to persisting allergic contact dermatitis in an artificial nail 
designer. J Allergy Clin Immunol 1995; 95:250.

  25.  Fischer AA. Adverse nail reactions and paresthesia from photo-
bonded acrylate sculptured nails. Cutis 1990; 45:293–4.
  26.  Nethercott JR, Nosal R. Contact dermatitis in printing trades-

men. Contact Dermatitis 1986; 14:280–7.

  27.  Carmichael AJ, Foulds IS. Allergic contact dermatitis due to an 
amino-substituted  diacrylate  in  a  UV-cured  lacquer.  Contact 
Dermatitis 1993; 28:45–6.

  28.  Kanerva  L,  Estlander  T,  Jolanki  R.  Allergic  contact  dermatitis 
from dental composite resins due to aromatic epoxy acrylates 
and aliphatic acrylates. Contact Dermatitis 1989; 20:201–11.
  29.  Koefoed-Nielsen B, Pedersen B. Allergy caused by light-cured 

ear moulds. Scand Audiol 1993; 22:193–4.

  30.  Fisher AA. Adverse nail reactions and paraesthesia from “pho-
tobonded acrylate sculptured nails”. Cutis 1990; 45:293–4.
  31.  Brooke RCC, Beck MH. A new source of allergic contact derma-
titis from UV-cured (meth)acrylate adhesive. Contact Dermatitis 
2002; 47:179–80.

  32.  Hemmer W, Focke M, Wantke F et al. Allergic contact dermati-
tis to artificial fingernails prepared from UV light-cured acry-
lates. J Am Acad Dermatol 1996; 35:377–80.

  33.  Pegum JS, Medhurst FA. Contact dermatitis from penetration of 
rubber gloves by acrylic monomer. Br Med J 1971; 2:141–3.
  34.  Pegum  JS.  Penetration  of  protective  gloves  by  epoxy  resin. 

Contact Dermatitis 1979; 5:281–3.

  35.  Calnan  CD.  Cyanoacrylate  dermatitis.  Contact  dermatitis  1979; 

5:165–6.

  36.  Fitzgerald  DA,  Bhaggoe  R,  English  JSC.  Contact  sensitivity  to 
acyanoacrylate  nail  adhesive  with  dermatitis  at  remote  sites. 
Contact Dermatitis 1995; 32:175–6.

  37.  Shelley ED, Shelley WB. Nail dystrophy and periungual derma-
titis due to cyanoacrylate glue sensitivity. J Am Acad Dermatol 
1988; 19:574–5.

  38.  Shelley ED, Shelley WB. Chronic dermatitis simulating small-
plaque  parapsoriasis  due  to  cyanoacrylate  adhesive  used  on 
fingernails. JAMA 1984; 252:2455–6.

  39.  Burrows D, Rycroft RJG. Contact dermatitis from PTBP and tri-
creyl ethyl phthalate in a plastic resin. Contact Dermatitis 1981; 
7:336–7.

 
 
 
 
 
 
 
 
 
 
286 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  40.  Pigatto PD, Giacchetti A, Altomare GF. Unusual sensitization to 

cyanoacrylate ester. Contact Dermatitis 1986; 14:193

  41.  Opinion of the Scientific Committee on Cosmetic Products and 
Nonfood Products Intended for Consumers (SCNFP). The use 
of benzyol peroxide (BPO), hydroquinone (HQ), hydroquinone 
methylether (MeHQ) in artificial nail systems. SCCNFP/0486/
final June 2002.

  45.  Kieran  JA.  Formaldehyde,  formalin,  paraformaldehyde  and 
glu-taraldehyde: What are they and what do they do? Microsc 
Today 2000; 8:8–12.

  46.  Schoon D. Milady’s Nail Structure and Product Chemistry. 2nd edi-

tion. Albany: Thomson/Delmar 2005; pp. 205–6.

  47.  Lazar P. Reactions to nail hardeners. Arch Dermatol 1966; 94:446–8.
  48.  Daly  BM,  Johnson  M.  Pterygium  inversum  inguis  due  to  nail 

  42.  Hill  S.  The  fiberglass  option:  Natural  look,  supernatural 

fortifier. Contact Dermatitis 1986; 15:256–7.

strength. Nails 1990 Aug; 44–52.

  49.  Hüldin DH. Hemorrhages of the lips secondary to nail harden-

  43.  Norton  LA.  Common  and  uncommon  reactions  to  form-
aldehyde-containing  nail  hardeners.  Semin  Dermatol  1991; 
10:29–33.

  44.  Winkelman JGM, Voorwinde OK, Ottens M, et al. Kinetic and 
chemical equilibrium of the hydration of formaldehyde. Chem 
Engin Sci 2002; 57:4067.

ers. Cutis 1968; 4:708.

  50.  Caletto J, Patel A. Composition for application to keratinous sub-
strate  and  a  method  for  strengthening  such  substrates,  Revlon 
Consumer Products Corp., U.S. patent 5,993,833, Nov. 30, 1999

  51.  Kohl  L,  Blondeel  A,  Song  M.  Allergic  contact  dermatitis  from 

cosmetics. Dermatology 2002; 204:334–7.

 
32

Evaluating Hand and Body Lotions

F. Anthony Simion

INTRODUCTION: LOTIONS AND THE SKIN
Skin, the largest organ of the body, plays a critical role as the 
interface  between  the  human  body  and  the  environment. 
Originally it was thought mainly to have a passive role, being 
a physical barrier to environmental threats such as low humid-
ity,  biological  pathogens,  UV  radiation,  physical  trauma,  and 
environmental  pollutants.  It  has  always  been  recognized  as 
playing a vital role as a sensory organ alerting us to the pres-
ence  and  nature  of  objects  surrounding  us,  extremes  of  tem-
perature,  and  noxious  chemicals.  More  recently  its  active 
interactions with the environment have become better appre-
ciated. It is physiologically active: the immunological response 
involves  keratinocytes  and  Langerhans  cells  as  well  as  the  T 
and  B-lymphocytes.  Melanin  in  the  skin  protects  it  from  UV 
damage. Upon exposure to light, melanin can be redistributed 
to the keratinocytes protecting the cells of the lower epidermis. 
The skin has significant levels of enzymes such as cytochrome 
P450 that can metabolize xenobiotics. Unsurprisingly, it is most 
effective as a barrier if it is intact. Hand and body lotions play 
a vital role in helping to maintain the integrity and plasticity 
of  the  SC  in  the  face  of  many  outside  threats.  They  have  the 
ability to prevent or reduce dryness and the impact of many 
irritants (1,2) as well as improving the skin feel and consumers’ 
quality of life (QoL).

Dermatologists continue to see many patients suffering 
from dryness and itching often associated with visible scaling 
and  flaking  of  their  skin.  Many  more  consumers  treat  them-
selves  without  medical  intervention.  There  are  many  causes 
for the increasing prevalence of dry skin. Shifting demograph-
ics,  specifically  the  aging  population  in  combination  with 
increased usage of low-humidity central heating and air con-
ditioning systems has significantly contributed to the increase 
in  dry  skin  complaints.  The  prevalence  of  atopic  eczema  is 
increasing  in  children  although  the  reasons  are  not  clear. 
Additionally, skin is exposed to household detergents and per-
sonal  cleansers,  which  can  quickly  damage  the  SC  proteins, 
extract small hygroscopic molecules, and deplete or rearrange 
the bilayer structure of key intercellular lipids. This causes a 
dramatic decrease in the skin’s ability to act as a barrier. Deter-
gent-induced dryness and primary irritation has made derma-
titis  one  of  the  most  common  forms  of  occupational  disease 
in  developed  countries.  Health  care  workers,  hairdressers, 
nurses, and food handlers are especially at risk (3,4).

During  the  last  100  years  hand  and  body  moisturiz-
ers  have  been  used  to  provide  relief  to  dry  skin  sufferers  by 
increasing the skin’s softness and smoothness (plasticity) while 
eliminating  skin  scaling.  There  are  several  mechanisms  to 
achieve this. They include increasing the skin’s water content 
by forming an occlusive barrier, by binding more water more 
effectively  (humectancy),  and  by  supplementing  the  water 

with other plasticizing materials. Indeed individual moistur-
izing  ingredients  may  deliver  benefits  to  the  skin  by  several 
mechanisms.  For  instance  glycerin  works  as  a  humectant,  a 
fluidizer of the lipid bilayer, and an activator of SC enzymes. It 
also is a skin softening agent (emollient). Today’s moisturizers 
are far superior to those of the past. This is due to new materi-
als that are capable of mimicking the skin’s biological moisture 
holding mechanisms and the ability to deliver these materials 
effectively to the skin. Ingredients such as ceramide analogs, 
pro-vitamins, and essential fatty acids have been successfully 
incorporated into hand and body lotions. When moisturizers 
are used regularly, they help to mitigate dry skin. Furthermore, 
advances in formulating have produced aesthetically superior 
products that consumers enjoy using, yet maintain their effi-
cacy. The leading hand and body lotion brands in the United 
States are shown in Table 32.1.

A  second  role  for  hand  and  body  moisturizers  is  as 
a  vehicle  for  functional  and  imagery  ingredients  including 
over-the-counter  (OTC)  drug  actives  such  as  sunscreens  and 
anti-puretics  as  well  as  cosmetic  ingredients  such  as  dihy-
droxyacetone (DHA), alpha-hydroxy acids (AHAs), and a mul-
titude of botanical extracts. Sunscreens are a good example. As 
a result of increased awareness regarding the negative effects 
of the sun, recent marketplace trends show an increase in the 
number of hand (and facial) moisturizers that have the ability 
to block UVA and UVB exposure. Hand and body moisturizers 
serve  as  an  effective  and  convenient  vehicle  for  the  delivery 
and application of sunscreen ingredients. Optimization of the 
vehicle not only provides consumers with much preferred tac-
tile benefits such as a non-sticky, non-greasy, and non-oily skin 
feeling—attributes which encourage usage (i.e. compliance)—
but can impact the efficacy of the sunscreen molecule to absorb 
UV light (5).

Sunless  tanners  are  lotions  containing  DHA  and/
or  erythritol.  These  ingredients  react  with  amino  acids  and 
small peptides in the skin via the Milliard reaction to provide 
a  brown–yellow  color  reminiscent  of  a  suntan.  Nguyen  and 
Kochevar have shown that the water content of the skin greatly 
affects  the  rate  at  which  color  develops  (6),  and  the  balance 
between  DHA  and  erythritol  impacts  how  natural  the  color 
appears  to  the  consumer.  In  this  way,  consumers  can  appear 
to  have  tanned  skin,  which  is  aesthetically  desired  in  many 
 Western  counties,  but  without  sun  exposure  that  can  lead  to 
skin  damage  and  possibly  eventually  skin  cancer.  Addition-
ally, the reaction products are strong UV-A absorbers that can 
give the skin some protection.

The  efficacy  and  aesthetics  of  hand  and  body  lotions 
depend on several factors. Gross chemical composition is not 
the  only  factor  that  effects  both  efficacy  and  skin  feel.  Most 
lotions  are  emulsions,  heterogeneous  mixtures  of  oil-  and 

288 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 32.1  Leading Hand and Body Lotions in the United States

Brand*

Jergens

Vaseline Intensive Care

Aveeno

Eucerin

Curel

Gold Bond

Nivea

Jergens Natural Glow

Manufacturer

Kao USA
Cincinnati, OH
Cheseborough–Ponds
(Unilever)
Tumbrall, CT
Johnson&Johnson
Los Angeles, CA
Beiersdorf
Norwalk, CT

Kao USA
Cincinnati, OH
Chattem
Chattanooga, TN
Beiersdorf
Norwalk, CT

Kao USA
Cincinnati, OH

Emulsion Type

Oil in water

Oil in water

Oil in water

Water in oil

Oil in water

Oil in water

Oil in water

Oil in water

Cetaphil

Gelderma Laboratories
Fort Worth, TX

Oil in water

*Several brands have many variants—the “key ingredients” are a composite between variants.

Key Moisturizing Ingredients

Glycerin, cetearyl alcohol, 

petrolatum stearate

Glycerin, sunflower seed oil, 
C11-13 paraffin, petrolatum 
TEA stearate

Glycerin, cationic surfactants, 

petrolatum

Petrolatum, mineral oil, 

lanolin alcohol, hydrogenated 
castor oil

Glycerin, cationic surfactants, 

petrolatum

Glycerin, cationic surfactants, 

petrolatum

Mineral oil, glycerin, isopropyl 
palmitate, glyceryl stearate 
SE, cetearyl alcohol
Glycerin, zea mays (corn) 
starch, cetearyl alcohol, 
dihydroxyacetone, erythru-
lose, mineral oil, petrolatum

Glycerin, hydrogenated 

polyisobutene, cetearyl 
alcohol, ceteareth 20

water-soluble materials in aqueous solution. How ingredients 
are  distributed  between  the  oil  and  aqueous  phases  plays  a 
significant role in how they are delivered to and partition into 
the skin to have their moisturizing and possibly physiological 
effects,  as  well  as  their  impact  on  skin  feel  during  and  after 
application.

Although  many  skin  characteristics  are  genetically 
determined, the environment also has significant effects. Neg-
ative effects from both sources can be ameliorated by regular 
use of moisturizers. The regular use of moisturizers, a healthy 
diet, protection from the sun, and regular exercise will contrib-
ute to significantly healthier, younger looking skin.

INGREDIENTS FOR HAND AND BODY LOTIONS
As  anyone  who  has  looked  at  the  ingredient  statement  for  a 
typical hand and body lotion can attest, the number and vari-
ety  of  ingredients  used  in  these  products  can  be  somewhat 
intimidating. Consequently, it is clear that a full review of all 
of these ingredients is beyond the scope of this chapter. How-
ever,  this  chapter  covers  the  major  categories  of  ingredients, 
organized according to their putative function in the product.
Before we begin the review of specific ingredients, a few 
general comments about ingredient disclosure may be helpful. 
In many countries including the United States and those of the 
European Union (EU), manufacturers of cosmetic products are 
required  to  provide  a  full  disclosure  of  the  ingredients  used 
in  their  products.  This  requirement  was  established  to  allow 
consumers  to  monitor  ingredients  and  to  make  an  informed 
purchase. Package labeling guidelines require listing ingredi-
ents in descending order of weight percent. One exception is 
for ingredients used at levels of 1% or less. In the United States, 
such minor ingredients can be listed in any order. Since many 
of the ingredients used in hand and body lotions are complex 
or  ill-defined  chemical  entities,  a  standard  nomenclature  has 

been developed by the Personal Care Products Council, (PCPC; 
formerly the Cosmetics, Toiletries, and Fragrance Association). 
Under the PCPC guidelines, manufacturers are obliged to use 
the  assigned  International  Cosmetic  Ingredient  (INCI)  name 
for  all  ingredients  used  in  their  products.  Information  about 
these ingredients, manufacturers, and chemical structures are 
compiled in the PCPC INCI Dictionary, which is a highly rec-
ommended resource for cosmetic  formulators.  The  European 
Union follows a similar system, although there are a few dif-
ferences.  For  example,  there  are  some  fragrance  ingredients 
that must be listed if their concentration exceeds 10 parts per 
million (ppm) in a leave on-product (7). Additionally, the man-
ufacturer is only free to follow their preference for ingredient 
order on the Ingredient Statement below 1% concentration.

Ingredient Classes
Water
This ingredient can be found at the beginning of many ingre-
dient statements for hand and body lotions since it can make 
up 70% or more of the formula. Water has an important func-
tion  in  a  hand  and  body  lotion—it  is  the  vehicle  by  which 
many other ingredients are delivered to the skin. However it 
should not be viewed as an active ingredient, as any hydration 
it produces is short-lived, usually less than 15 minutes, before 
evaporating.  Although  the  PCPC  does  not  recognize  the  use 
of any particular type of water (such as “purified water”) for 
the purpose of ingredient labeling, most manufacturers do use 
treated  water.  They  use  water  that  is  softened,  or  deionized 
(demineralized)  in  their  products  to  avoid  any  interactions 
between calcium, magnesium, and iron ions with components 
in the formula. It is also customary in the industry to process 
the deionized water to remove problematic microorganisms.

Since the water concentration is transient after applica-
tion  and  quickly  evaporates,  water-soluble  materials  become 
more  concentrated.  As  a  result,  minor  components  of  the 

 
formula  may  penetrate  more  easily,  a  fact  that  is  sometimes 
forgotten  when  determining  the  benefits  and  risks  of  these 
ingredients.

Emollients
An emollient can be defined as an ingredient that softens the 
SC. Emollients used in hand and body lotions are frequently 
oily  materials  that  help  plasticize  dry  skin  either  by  direct 
interaction  with  the  SC  or  by  providing  an  occlusive  barrier 
that  traps  water  from  the  underlying  skin  strata.  However, 
glycerin and other polyols have a similar skin softening effect, 
although  they  do  not  fulfill  either  characteristic.  The  plasti-
cized SC is exhibits more flexibility and a surface that is more 
uniform which consumers perceive as smooth and soft. Also 
the skin surface may be less likely to crack, especially in body 
areas  that  are  constantly  flexed,  such  as  knuckles,  thereby 
reducing possible penetration of irritants and allergens.

Lanolin was one of the first commercial emollients used 
widely by the industry. It was a prominent ingredient in apoth-
ecaries  from  the  1920s  to  the  early  1960s,  where  pharmacists 
used  lanolin  as  a  base  for  compounding  ointments.  It  has 
the unique ability to adsorb up to 30% of its weight in water. 
Lanolin is a refined portion (deodorized and bleached) of raw 
wool wax—the fatty, waxy residue separated from the wash-
ings of sheep’s wool, yielding a complex mixture of semisolid 
oils, fats, and waxes. As an emollient, lanolin provides a strong 
occlusive  effect  when  applied  to  skin  and  may  also  directly 
plasticize the SC. Lanolin, its constituents and derivatives are 
still used in some hand and body lotions, but have largely been 
replaced by other emollients because of its reported sensitiza-
tion potential. These adverse reactions may be due to the pres-
ence of low levels of alkane-α, β-diols, and alkane-α,ω-diols (8). 
Pesticide residues are an additional potential issue for lanolin, 
and  the  United  States  Pharmacopoeia  monograph  specified 
limits for organic pesticides (9). This change in the monograph 
has forced manufacturers to commercialize a higher purity of 
an old emollient.

Two of most common emollients used today are mineral 
oil  and  petrolatum,  which  are  hydrocarbon-based  materials 
derived from petroleum. Petrolatum, in particular, resembles 
lanolin in its physical characteristics and its occlusive effect on 
the skin. In addition to forming an occlusive barrier, Ghadially 
et al. (10) showed that petrolatum penetrates into the intercel-
lular  lipids  of  the  SC.  Kligman  (11)  reported  that  petrolatum 
was  very  effective  at  reducing  observable  skin  dryness  and 
preventing its reappearance. Compositionally, the only differ-
ence between mineral oil and petrolatum is the number of car-
bons in the hydrocarbon chains, with mineral oil having fewer 
carbons. Mineral oil is less occlusive but has better spreading 
properties and is generally believed to have a less greasy feel 
on the skin compared with petrolatum.

Silicones are a class of synthetic polymers that are also 
widely used in hand and body lotions. Most silicones are used 
for their good spreading and de-tackifying properties as well 
as their emolliency. They also form good barriers to environ-
mental  agents  and  often  are  the  principal  active  ingredient 
in  skin  protection  OTC  drug  products.  Common  examples 
are  dimethicone  and  cyclopentasiloxane.  However  they  have 
recently come under additional scrutiny in the European Union 
for their human and environmental safety profiles (12,13).

Another  class  of  emollients  is  triglycerides,  which  are 
derived from animal fats or vegetable oils. These oils are usu-
ally named according to the original source, such as sunflower 
seed  oil.  Triglycerides  (oils)  contain  approximately  5%  free 

EVALUATING HAND AND BODY LOTIONS 

  289

fatty  acids.  Many  triglycerides  contain  essential  fatty  acids 
(EFAs).  EFAs  are  unsaturated  fatty  acids  that  cannot  be  syn-
thesized by the body yet are required for maintaining the SC 
barrier function. Experiments have shown that when EFAs are 
withheld from rats’ diets, their skin becomes scaly and water 
barrier  function  is  compromised  (14).  Healthy  skin  can  be 
restored by topical application of triglycerides that are rich in 
EFAs. Similar results were observed in human patients whose 
lipid intake had been reduced due to stomach surgery (15).

Processing of triglycerides is a major industry. Triglycer-
ides as neutral fats and oils are hydrolyzed to form fatty acids, 
fatty alcohols, and a predominant raw material in the manu-
facturing  of  soap.  The  hydrolysis  produces  monoglycerides 
and diglycerides, which are also used in emulsion products as 
a secondary agent for stabilizing the suspension.

The use of unsaturated triglycerides in a hand and body 
lotion  can  create  problems  due  to  the  susceptibility  of  these 
oils to oxidation, producing discoloration and off odors (ran-
cidity) over time. To prevent this oxidation, stabilizers such as 
antioxidants,  e.g.,  tocopherol  (vitamin  E),  BHA,  or  BHT,  and 
chelators, e.g., EDTA salts, are often added to the formula.

Triglycerides may be processed to provide a large vari-
ety of other emollient ingredients. Glycerides are used not only 
for emolliency, but also for their ability to stabilize the lotion 
by emulsification. Examples of glycerides are glyceryl stearate 
(monoglyceride), glyceryl dilaurate (diglyceride), and palm oil 
glyceride (mixed glycerides). Fatty acids are also processed to 
produce fatty esters. Numerous types of fatty esters are used 
in hand and body lotions. Some common examples are isopro-
pyl myristate, isopropyl palmitate, octyl hydroxystearate, and 
cetyl palmitate.

Humectants
Humectants  are  water-soluble  organic  compounds,  typically 
polyhydric alcohols, which have an affinity for water. The most 
common humectant is glycerin; others include sorbitol, propyl-
ene glycol, dipropylene glycol, and butylene glycol. Once it was 
believed that these ingredients helped to moisturize the skin 
simply by binding additional water in the SC, thus plasticizing 
the SC and reducing the rate of evaporation. However within 
the  last  20  years,  two  additional  mechanisms  by  which  glyc-
erin  may  moisturize  have  been  proposed.  Froebe,  Matti,  and 
their colleagues showed that glycerin at low humidity can pre-
vent the conversion of liquid crystals in the intercellular lipids 
to a solid, rigid crystal within the SC (16,17). The solid crystal is 
more readily removed by environmental factors, e.g., cleansing, 
and provides less resistance to water loss. This effect may be 
responsible for the improvement in barrier function observed 
when  glycerin  (and  possibly  other  humectants)  is  applied  to 
the skin. Additionally, Rawlings et al. showed that glycerin is 
able to promote normal desquamation by enhancing the activ-
ity of the proteases that degrade desmosomes (18). It is likely 
that all three mechanisms occur in the SC simultaneously.

Emulsifiers
Classically,  these  are  surface-active  ingredients,  which  are 
used  to  promote  temporary  mixing,  and  suspension  of  the 
discontinuous  phase  (often  oils)  into  the  continuous  phase 
(usually water). This will significantly slow the rate at which 
the  two  phases  separate  (Figure  32.1).  Conventional  emulsifi-
ers are often classified on the inherent charge associated with 
the surface-active ingredient. The classes are anionic (negative 
charge),  cationic  (positive  charge),  and  nonionic  (no  charge/
neutral).

 
290 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(a) Emulsifiers reduce the rate at which the oil and aqueous phases separate. The left-hand bottle contains an emulsifier 
Figure 32.1 
with the oil and aqueous phases and the right-hand bottle contains no emulsifier. After mixing, the system on the left separates more 
slowly. (b) Emulsions are opaque systems (left) compared with an unemulsified two-phase oil/water system (right).

The anionic emulsifiers were widely used for many com-
mercial moisturizers. Most early oil-in-water (o/w) emulsions 
utilized a soap (anionic) formed in situ by neutralization of a 
fatty acid with a metallic hydroxide, an amine, or basic amino 
acid. The common material used as a soap emulsifier is neu-
tralized  stearic  acid.  The  anionic  emulsifiers  especially  with 
chain lengths around C12 could be somewhat irritating so their 
level of use should be balanced to produce a stable product that 
is proven to be nonirritating to skin.

Nonionic  emulsifiers  are  probably  the  most  commonly 
form used today. They produce stable and non-irritating emul-
sions or suspensions. The cosmetic formulator again will use 
these materials judiciously to maintain the desired properties 
without  adding  excess  amounts  of  the  surface-active  agents. 
Since these emulsifiers are surfactants, they have the potential 
to  be  irritating  to  the  skin  and  any  excess  adds  more  cost  to 
the formula. Common nonionic emulsifiers are ethoxylated or 
propoxylated fatty alcohols, such as ceteareth-20 or steareth-2.
The  third  class,  cationic  emulsifiers,  has  become  more 
widely used for moisturizers that are more therapeutic or long-
lasting.  The  cationic  products  are  substantive  to  the  stratum 
corneum (SC) as it is negatively charged from the fatty acids 
and  acidic  amino  acid  residues.  Hence  a  positively  charged 
emulsion droplet is attracted to the skin, especially when it is 
damaged, and the pH increases from its usual 4.5 to 5.5. These 
types of emulsions resist wash-off with water and possess dif-
ferent  aesthetics.  Common  cationic  emulsifiers  are  the  long-
chain  fatty  alcohols  bonded  to  quaternary  nitrogen,  such  as 
distearyldimonium chloride or behentrimonium chloride.

Recent advances in polymer science have now created a 
quasi-fourth class of emulsifiers. The new emulsifier is based 
on a hydrophobically-modified polymer based on poly(2-acryl-
amido-2-methylpropanesulfonate)  (AMPS).  It  is  an  amphipa-
thic  and  when  a  nonionic  emulsifier  is  added  the  emulsion 
yields a stable o/w emulsion. Most suppliers of polymers for 
personal care products now have variations of the AMPS copo-
lymers within their product line (19).

Water-Soluble Polymers (Thickeners and Conditioners)
Common  additives  to  emulsion  products  are  water-soluble 
polymers. The polymers can be synthetic or natural. The most 

common  class  is  the  acrylates.  These  polymers  are  synthetic 
with an anionic charge. Some common examples are acrylates/
C10-30  alkyl  acrylates  cross-polymer  and  carbomers.  Acrylic 
acid polymers often require neutralization with a base in order 
to realize their benefit in emulsion products. The base neutral-
izes the pendant acid chains allowing them to “unfold,” cre-
ating spoke-like projections which form an intricate network. 
The  network  builds  viscosity  and  resists  separation  of  the 
emulsion phases.

Many  water-soluble  polymers  are  derivatives  of  cellu-
lose.  The  cellulosic  polymers  possess  an  anionic  or  nonionic 
charge and numerous grades with various properties are com-
mercially available. The commercial grades vary in molecular 
weight,  ether  linkages  and  electrolyte  tolerance.  Examples 
of  common  cellulosics  are  sodium  carboxmethyl  cellulose, 
hydroxypropyl methylcellulose, and hydroxyethylcellulose.

There  are  also  cationic  water-soluble  polymers  both 
synthetic and natural. They are derivatives of cellulose, poly-
saccharides,  and  modified  acrylic  acids.  These  polymers  are 
usually  restricted  to  cationic  and  nonionic  emulsions  due  to 
the inherent instability that arises when added to anionic sys-
tems. Polyquaternium-10, chitosan, and derivatized guar gum 
are  three  such  polymers  frequently  found  in  hand  and  body 
lotions.

The  water-soluble  polymers  enhance  emulsion  stabil-
ity  by  preventing  the  small,  suspended  droplets  from  fusing 
together. The polymer network stearically restricts the move-
ment of the dispersed phase and enhances the formula’s appar-
ent viscosity.

Minor Components
Preservatives and Fragrances
Although  they  make  up  a  very  small  percentage  of  the  total 
formula, these ingredients are of concern to dermatologists as 
they are the predominant cause of the few sensitization reac-
tions from  lotions that  require medical  attention  (20). Indeed 
the mixture of fragrances used in patch testing has one of the 
highest  incidence  rates  observed  for  cosmetic  ingredients. 
Consumers’ recognition of the association between fragrance 
and  adverse  reactions  has  prompted  many  manufacturers  to 
develop unscented products. Their increasing popularity has 

 
 
   
led some manufacturers to include various botanical extracts 
which  technically  are  not  fragrances,  yet  still  include  many 
of the same chemicals found in certain fragrances. The Euro-
pean  Union  requires  common  fragrance  ingredients  that  are 
believed to be allergens to be declared in the ingredient state-
ment  when  exceeding  minimum  thresholds  are   established. 
This  is  10  ppm  for  leave-on  and  100  ppm  for  wash-off  prod-
ucts. Additionally, three fragrance ingredients (HICC; Lyral®, 
atranol, or chloroatranol) may be banned from cosmetics in the 
European Union in the near future (21). Additionally, the level 
of almost 20 other ingredients and extracts may be restricted.

Preservatives  are  included  in  hand  and  body  lotions 
to  prevent  the  growth  of  microorganisms,  specifically  bacte-
ria, mold, and yeast. These are necessary for several reasons. 
First,  most  hand  and  body  lotions  contain  a  high  percentage 
of  water,  which  makes  them  a  good  growth  media  for  these 
microorganisms.  Inadvertent  contamination  by  consumers 
during  use  can  lead  to  rapid  bacterial  growth  and  spoilage 
of the product. Further, if the growth of opportunistic patho-
genic bacteria such as Pseudomonas is not prevented, infection 
or blindness could result when applied to compromised skin 
or near the eye, respectively.

Given the need to prevent growth of microorganisms in 
their products, manufacturers use a variety of biocide and bio-
static agents together in sufficient concentrations to provide a 
product that does not allow for active growth. In other words, 
the  preservative  system  is  designed  and  tested  to  withstand 
multiple  contaminations  by  consumers  so  that  any  microor-
ganisms introduced into the product are either killed or pre-
vented from actively multiplying. These agents are most often 
used in various combinations to provide effective preservation 
against a broad spectrum of bacteria and mold.

The  preservatives  are  also  an  ingredient  class  which 
receives a significant amount of consumer concern. In today’s 
environment, misinformation can often be represented as sci-
entific data. The majority of consumers do not have the train-
ing to scrutinize data and determine its scientific validity but 
they do understand fear and wish to avoid harm to themselves 
and their loved ones. This has been the situation with the com-
mon  biocides  in  personal  care  products,  especially  parabens. 
With consumer access to the internet, many materials can be 
erroneously classified as harmful. Our challenge as an indus-
try  is  to  counter  and  correct  consumer  misperceptions.  To 
help in this process the PCPC has launched a website (www. 
Cosmeticsinfo.org) that provides accurate information on the 
safety of cosmetic ingredients.

The following is a partial listing of some of the common 

biocides used in hand and body lotions.

Preservatives  that  work  by  releasing  formaldehyde 

(formaldehyde donors):

•  DMDM hydantoin
•  Diazolidinyl urea
• 
•  Quaternium-15 (soon to be banned in the European Union)

Imidazolidinyl urea

Preservatives  that  work  by  mechanisms  other  than 

releasing formaldehyde:

•  Parabens  (esters  of  p-hydroxybenzoic  acid)—only  the 
straight-chained  (not  the  iso-)  parabens  are  permitted  in 
the European Union.

•  Methyldibromo glutaronitrile (not permitted in the Euro-

pean Union).
•  Benzyl alcohol.

EVALUATING HAND AND BODY LOTIONS 

  291

•  Benzoic acid/sodium benzoate.
•  Methylchloroisothiazolinone/methylisothiazolinone 
(MCI/MI)  (Kathon™  CG;  not  permitted  in  the  European 
Union in leave-on cosmetics).

•  MI  (probably  will  not  be  permitted  in  European  Union 

leave-on skin care products in the near future).

•  Ethanol.
•  Phenoxyethanol.
• 

Iodopropynyl butylcarbamate (should be avoided in prod-
ucts that are readily inhaled).

•  Chlorphenesin.
•  Salicylic acid.

Skin Care Additives
Many  lotions  have  cosmetic  materials  added  at  low  levels 
for  marketing  purposes,  i.e.  to  persuade  consumers  of  addi-
tional  benefits  from  these  ingredients  and  to  buy  the  prod-
uct. In these cases the moisturization benefits that consumers 
require are delivered by the overall product. However in the 
last few years, additives have been identified that improve the 
appearance and feel of the skin over the vehicle alone. These 
include AHAs, retinol, and ceramide analogs (22,23). Imokawa 
et  al.  showed  that  ceramide  analogs  increase  the  water  hold-
ing capacity and barrier function, especially of damaged skin. 
Addition  of  3%  pseudoceramides  has  been  shown  to  reduce 
erythema in atopic dermatitis lesions (24). Stiller et al. showed 
that 8% lactic or glycolic acids reduce the signs of photodam-
age compared with a vehicle after 22 weeks of treatment. How-
ever these levels of AHAs have also been shown to increase the 
skin’s sensitivity to the sun (25).

ASSESSING MOISTURIZER EFFICACY
The primary use of hand and body moisturizers is to alleviate 
skin dryness and irritation and prevent their return. Measuring 
these effects both from a consumer and an objective perspec-
tive  are  primary  objectives  for  assessing  a  moisturizer’s  effi-
cacy. Clinical methods with controlled application have been 
developed that assess dry skin and irritation or their absence 
by visual scoring by a trained observer, using biophysical mea-
surements of the skin and by panelists’ self-assessments. How-
ever, clinical efficacy alone is not sufficient to make a product 
commercially  successful.  To  appeal  to  consumers,  the  lotion 
must be both efficacious and aesthetically pleasing, i.e. pleas-
antly scented (or unscented) and have acceptable tactile char-
acteristics during and immediately after application.

Clinical Evaluation of Moisturizer Efficacy
Alleviating Dry Skin
Clinical evaluation is an important component in the measure-
ment  of  moisturizer  efficacy.  The  visual  assessment  of  skin 
dryness is a direct link to the perceivable benefits of “moistur-
ization” that consumers readily recognize such as skin flaking 
and  scaling,  fine  dry  lines,  rough  texture,  ashiness,  and  skin 
cracking. Figure 32.2 shows the different levels of skin dryness 
observed  in  clinical  studies.  In  many  studies,  visual  assess-
ments are supplemented with instrumental measures of skin 
hydration, surface topography and/or elasticity. These instru-
mental  measurements  are  more  easily  standardized  than 
observer  assessments  and  each  provides  an  objective  assess-
ment of a particular cosmetic benefit.

There are a variety of methods used to assess the ability 
of moisturizers to alleviate dry skin. These include the single-
application test and the regression test developed by Kligman 

 
292 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(c)

(b)

(d)

Figure 32.2  Different levels of skin dryness observed in a moisturization study, utilizing a 0 to 4 scoring scale: (a) Grade 0; (b) Grade 
1; (c) Grade 2; (d) Grade 4.

(11)  and  later  modified  by  others  (see  below).   Typically  these 
studies  start  with  dry  skin,  frequently  on  the  legs,  and  then 
the skin is treated. In the single-application test, the condition 
of the skin can be reassessed as little as 2 hours after product 
application and at subsequent time points, some even beyond 
24 hours. It is important to include time points of 2 hours or 
greater  post-application,  as  many  lotions  contain  water  that 
rapidly evaporates. This is usually completed within 2 hours. 
In these studies, moisturization is frequently assessed by elec-
trical and imaging measurements as well as observer scoring.

The  regression  test  was  developed  by  Kligman  to 
assess the effects of both products and their constituents on 
dry  skin.  Test  material  (2  mg/cm2)  is  applied  to  the  lower 
legs  of  12  to  30  female  panelists  twice  daily  for  up  to  3 
weeks  (see  Figure  32.3).  Visual  dryness  was  assessed  prior 
to treatment (baseline) and at the end of each week. Panel-
ists started with dry skin and the improvement in dryness 
from baseline was the measure of moisturization efficacy, or 
the relief of dryness.

Using the regression test, Kligman showed that hydro-
phobic oils, such as mineral oil or olive oil, alone had little abil-
ity to alleviate dry skin. The efficacy of these oils was enhanced 
when  they  were  formulated  with  hydrophilic  materials  into 
cold creams. Kligman’s data suggested that the moisturizer’s 
composition could have a greater influence on its efficacy than 
the number of applications (dosage). He demonstrated a large 
range  in  the  ability  of  ingredients  to  alleviate  dryness,  but 
increasing  the  dosage  had  limited  effects,  especially  beyond 
four applications a day.

The Kligman regression protocol has been modified by 
several  groups  to  meet  different  assessment  needs.  Boisits  et 
al.  (1989)  (26)  applied  more  rigorous  conditions  to  reduce  the 
experimental variability and increase test sensitivity. The most 
notable modifications include:

1.  Conducting the test only if the temperature and humid-

ity were below 45°F and 40%, respectively.

2.  Throughout  the  study,  washing  test  sites  with  a  true 
(fatty  acid–based)  soap  prior  to  lotion  application  to 
increase the propensity of the skin to dry out.

3.  Requiring  leg  shaving  no  more  than  two  times  a  week 

and no later than 30 hours before an observation.

Biosits et al. claimed the refined methodology allows for 

better differentiation between products.

Other modifications can be grouped together as “mini-
regression methods.” Prall et al. (27) reported a regression study 
using a 4-day treatment followed by a 6-day regression phase. 
The protocol was similar to Kligman’s method as the applica-
tions were conducted twice daily with a dose of approximately 
2 mg/cm2. Product efficacy differences were determined dur-
ing  regression  in  the  following  descending  order  of  efficacy: 
5% lactic acid lotion >  o/w lotion >  placebo. Grove et al.  (28) 
utilized the same mini-regression time frame to examine the 
efficacy  of  marketed  moisturizers.  Clear  differences  between 
each of the two products and between the treated sites and the 
untreated site were observed. In this study skin conductance 
was used to confirm the observer scored dryness.

 
 
 
 
 
   
 
   
EVALUATING HAND AND BODY LOTIONS 

  293

3

2.5

2

1.5

1

0.5

s
s
e
n
y
r
D
d
e
r
o
c
S
r
e
v
r
e
s
b
O

Treatment

Regression

Patrolatum
Lanolin

0

0

7

14

21
Day

28

35

42

Figure  32.3  Relative  efficacies  of  petrolatum  and  lanolin  reducing  dry  skin  and  preventing  its  return  in  the  regression  test.  The 
 regression test shows that under similar conditions and dosage, petrolatum is more effective at alleviating dry skin and preventing 
its  return.  Test  material  was  applied  to  the  lower  leg  daily  for  3  weeks  (treatment  phase).  After  treatment  stopped,  the  legs  were 
observed  until  the  skin  condition  returned  to  its  original  level  of  dryness  (regression  phase).  (Adapted  from  Kligman  AM,  Cosmet 
Toilet; 93:27–35, 1978.)

In a similar study of moisturizers containing glycerin, 
Appa  et  al.  (29)  utilized  a  7-day  treatment  period  followed 
by  a  7-day  regression.  These  investigators  demonstrated 
that  the  moisturizer  efficacy  increased  with  the  concentra-
tion of glycerin. A plateau was reached with a 25% glycerin 
lotion  being  similar  in  efficacy  to  a  40%  glycerin  cream. 
These results could also relate to the ability of the products 
to deliver glycerin into the skin, or to the effect of ancillary 
ingredients.

A  third  adaptation  of  the  regression  test  utilizes  the 
lower arms, either the volar or dorsal aspect. Prall et al. (27) 
used a mini-regression design to compare the performance 
of  two  lotions  on  the  legs  using  a  controlled  lotion  dos-
age  to  performance  on  the  outer  aspect  of  the  arms  using 
ad- libitum  dosage.  They  concluded  that  either  method 
 accurately  predicted  the  directional  efficacy  of  the  lotions. 
Grove (20)  originally used the mini-regression methodology 
to   examine  lotion  efficacy  on  the  volar  forearm  using  the 
instrumental  method  of  skin  conductance  to  evaluate  per-
formance.

Preventing the Return of Dry Skin
Effective moisturizers are able to prevent the return of dry skin 
even after product applications have stopped. The residual effect 
is  important  to  consumers  who  wish  to  maintain  their  skin’s 
good condition until the next convenient application time, even 
though it is still exposed to the stresses that caused the dryness 
in the first place. Both the single application test and the regres-
sion test are able to measure this. When an effective product has 
moisturized the skin, the decay of the benefits can be measured 
after application ceases. A slow return to baseline is indicative of 
an efficacious product with lasting effects. Figure 32.3 shows the 
data obtained by Kligman for two cosmetic moisturizing ingre-
dients,  petrolatum  and  lanolin.  The  data  clearly  demonstrate 
product  efficacy  during  the  treatment  and  regression  phases. 
During the regression,  persistent moisturizing effects are dem-
onstrated 21 days after the last treatment with petrolatum but 
only 2 weeks for lanolin.

A  more  rapid  approach  to  measure  the  prevention  of 
dry skin was developed by Highley et al. (30). In the High-

ley  Hand  Wash  protocol,  the  analysis  begins  with  non-dry, 
healthy skin. The panelists wash their hands with bar soap 
for 1 minute five times a day over a 4-day period. One hand 
remains otherwise  untreated,  while  lotion  is  applied to the 
other  hand  after  the  first  four  washes  of  the  day.  The  con-
dition  of  the  skin  is  assessed  by  a  trained  observer  and  by 
instrumental measurements before the first wash of the study 
(baseline) and approximately 1 hour after the last (fifth) wash 
each day. Results show that ingredients such as petrolatum 
and  effective  commercial  lotions  can  prevent  the  induction 
of dry skin, which can be considerable on the untreated hand 
(see  Figure  32.4  and  Table  32.2).  Although  panels  as  small 
as five were used by Highley, it is more usual to use panels 
of 15 or more to enable the data to be statistically analyzed. 
Recently the test has been modified so only a defined area of 
each hand is treated with lotion. The surrounding area acts 
as that hand’s “no product” control. This enables more than 
one product or ingredient to be evaluated at a time, using a 
within-subject design. 

Reducing Primary Irritation
An  adverse  environment  or  working  conditions  may  drive 
the skin beyond dryness (xerosois) into the realm of primary 
irritation and dermatitis. In recent years many scientists and 
dermatologists have  realized that moisturizers may reduce the 
propensity of the skin to develop primary irritation and help 
accelerate it reduction should it occur. A review by Zhai and 
Maibach gives a good overview on this subject (1). The preven-
tion of irritation and its reduction when it does occur can be 
 modeled separately.

Hannuksela  and  Kinnunen  (1992)  (31)  performed 
a  study  using  1-minute  washes  with  dishwashing  liquid 
twice  a  day  on  the  arms  over  a  7-day  period.  The  authors 
evaluated  cleanser-induced  irritation  using   transepidermal 
water  loss  (TEWL)  as  a  measure  of  SC  integrity  and  laser-
Doppler  flowmetry to assess blood flow. They  demonstrated 
that  moisturizer  application  could  prevent  surfactant-
induced  skin  damage  and  accelerate  repair 
 compared 
 treatment,  but  were  unable  to  differentiate 
with  no 
between  products.

 
 
 
294 

 TEXTBOOK OF COSMETIC DERMATOLOGY

2.5

2.0

1.5

1.0

0.5

i

e
r
o
c
s
g
n
k
a
l
f
n
a
e
M

0

0

No Product

Petrolatum

5
Number of hand washes
(a)

2.5

2.0

1.5

1.0

e
r
o
c
s
g
n
k
a
l
f
n
a
e

i

0.5M

10

0

0

No Product

Test Lotion

5

10
Number of hand washes
(b)

15

20

Figure 32.4  Ability of petrolatum (a) and lotion (b) to prevent the induction of skin flaking by repeated washing with soap, petrolatum, and 
lotion, and no treatment. (From Simion FA, Babulak SW, Morrison BM et al. Experimental method soap induced dryness in the absence 
of erythema. Scientific Exhibit in the 50th American Academy of Dermatology Annual Meeting, Dallas, Texas, 1991.)

Table 32.2  Ability of Ingredients to Prevent Induction of Skin 
Dryness Due to Repeated Hand Washings with Soap

Ingredient

Ability to Prevent Dryness*

Petrolatum
Mineral oil
Glycerin (25% aqueous solution)
Sorbitol (25% aqueous solution)
Propylene glycol (25% aqueous 

solution)

54
49
34
14
−1

Source: Data from Highley DR et al., J Soc Cosmet Chem; 27:351–63, 
1976.
*The higher the score, the more effective the ingredient.

Another  approach  was  that  of  Loden  and  Andersen 
(32).  They  used  occlusive  patching  with  0.5%  sodium  laurel 
sulfate  (SLS)  to  generate  primary  irritation,  then  applied  dif-
ferent lipids to accelerate that rate at which the skin repaired 
itself. They utilized observer and instrument measures of ery-
thema to assess the skin’s response and hydrocortisone as the 
positive,  effective,  control.  They  found  that  soy  sterols  had  a 
beneficial effect. This model has been modified using 5% soap 
to  cause  the  irritation  and  evaporimetry  to  assess  SC  barrier 
function. In this case 1% hydrocortisone (an OTC drug in the 
United States), was highly effective at reducing erythema but 
the  results  on  barrier  function  appeared  to  be  dependent  on 
the  vehicle  rather  than  the  hydrocortisone  itself.  Some  high 
glycerin–containing  moisturizers  are  also  very  effective  at 
accelerating  erythema  reduction  and  restoring  barrier  integ-
rity (2). This is consistent with the observations of Fluhr and 
his colleagues on the restorative properties of glycerin.

Preventing Primary Irritation
The ability of moisturizers to prevent detergent-induced skin 
dryness has important public health implications. Dermatitis 
is a leading occupational disease and professions that involve 
frequent hand washings are at particular risk (3,4). Frequent, 
effective moisturization may provide a significant preventative 
benefit. However moisturization or using a barrier cream does 
not provide sufficient benefit alone. Their use must be part of a 

comprehensive education program to be able to provide a tan-
gible benefit in the workplace (33).

The two main models that assess the ability of a mois-
turizer  to  prevent  primary  irritation  are  the  occlusive  patch 
test  and  a  repeated  washing  test.  In  the  former,  test  lotions 
are applied to the skin and allowed to dry—about 30 minutes. 
Then  occlusive  patches  with  dilute  SLS  or  soap  solutions  are 
applied  for  24  hours  and  then  removed.  Twenty-four  hours 
later,  primary  irritation  is  assessed  by  a  trained  observer,  by 
colorimeter, and by evaporimetry. A no-product site is used as 
a control. High glycerin cationic emulsions were shown to be 
more  effective  at  preventing  the  induction  of  primary  irrita-
tion than hydrocarbon-based moisturizers that form occlusive 
barriers (2).

Similar methods have been utilized to assess the abil-
ity of barrier creams to reduce or even prevent the induction 
of  irritation  (34).  For  instance,  Schentz  et  al.  (35)  standard-
ized the repeated short-term occlusive irritation test (ROIT) 
to assess the ability of test barrier creams to reduced irrita-
tion  induced  by  toluene  or  0.5%  aqueous  solutions  of  SLS. 
Sites  on  the  volar  forearm  were  pretreated  with  the  test 
creams  at  25  mg/cm2.  Ten  minutes  later  the  irritants  were 
applied  under  occlusion  for  30  minutes.  This  was  repeated 
3.5 hours later, and the twice a day treatment was used for 2 
weeks  (excluding  the  weekend).  All  four  test  centers  found 
that the petrolatum-based creams were effective at reducing 
SLS induced irritation as measured by TEWL rates and ery-
thema  measurements  (both  trained  observer  and  colorim-
eter), but appeared to have a less consistent protective effect 
against  toluene,  possibly  due  to  the  hydrophobic  nature  of 
both  petrolatum  and  the  solvent.  Wigger-Alberti  et  al.  (36) 
used  a  similar  approach.  They  applied  petrolatum  to  sites 
on the ventral forearm of 20 volunteers. Thirty minutes later, 
test  irritants  such  as  aqueous  solutions  of  lauryl  sulfate, 
sodium  hydroxide,  and  lactic  acid  as  well  as  toluene  were 
applied for 30 minutes. This process was repeated daily for 
2  weeks.  Assessments  of  skin  condition  by  erythema  scor-
ing, chromameter, and TEWL demonstrated that petrolatum 
could  reduce  irritation  although  it  appeared  least  effective 
against lactic acid.

 
 
 
 
   
 
 
Instrumental Evaluations of Moisturizer Efficacy
Instrumental evaluation of skin condition is often used to sup-
plement visual assessments in clinical (controlled application) 
moisturization protocols. They provide an objective method to 
evaluate  a  specific  skin  parameter.  For  example,  TEWL  mea-
sures  SC  barrier  function  by  measuring  water  flux  from  the 
skin.  Conductance/capacitance  have  been  used  as  indirect 
measures of skin hydration. It must be emphasized that a sin-
gle instrumental parameter should not be used alone as a mea-
sure of moisturization. Instruments measure defined physical 
parameters, which may not always correlate with moisturiza-
tion  or  skin  condition.  For  instance,  hydrophobic  materials 
such as petrolatum, silicones, or mineral oil that can be effec-
tive moisturizers reduce skin conductance immediately upon 
application.  This  contradicts  the  usual  interpretation  of  this 
parameter that correlates increased conductance with moistur-
ization.  Instead  the  bioinstrumental  measurement  should  be 
used to support and expand on observer scoring and panelist 
self-assessment, and if possible multiple bioinstrumental mea-
sures should be used simultaneously.

Several bioinstrumental methods are briefly reviewed in 
this chapter. More thorough reviews of bioinstrumentation are 
available in the literature (37–41).

EVALUATING HAND AND BODY LOTIONS 

  295

The disk is pressed against the skin using uniform pressure. 
Scales  on  the  surface  of  the  SC  are  removed  along  with  the 
disk. These scales can be readily visualized when placed on 
a  black  background  and  scored  with  a  0–4  analog  scale  or 
image  analysis  (27,40).  Prall’s  quantization  utilized  reflected 
light  from  the  scales.  The  analysis  of  Schatz  et  al.  included 
both the area of scale coverage and the thickness of the scales 
to  yield  a  desquamation  index  (DI).  The  Corneofix®  (Cour-
age + Khazaka, Cologne, Germany) uses a similar approach 
in  a  commercially  available  instrument.  The  DI  is  techni-
cally  superior  to  observer  scoring,  as  skin  scales  are  read-
ily  obscured  from  the  trained  observer  by  high  humidity 
or  products  that  mat  the  scales  down  but  do  not  cause  des-
quamation.  However  as  they  are  still  present  on  the  skin’s 
surface,  they  still  can  be  harvested  by  the  sticky  tape  and 
quantified. An  ingredient or product that causes desquama-
tion  will  lower  the  measured  DI.  This  was  demonstrated  in 
a  regression  test  that  compared  lotions  C  and  E,  with  a  “no 
product”  control.  While  the  trained  observer  perceived  few 
differences, both D-Squames and conductance demonstrated 
that product C was significantly more effective than lotion E 
or the “no product” control (Figure 32.5).

Measuring Skin Dryness
Biophysical  methods  have  been  developed  as  alternatives 
to  assessments  by  a  trained  observer.  Chief  among  these 
is  assessing  skin  dryness  harvesting  skin  scaling  with 
D-Squame®  sticky  tape  strips,  then  quantification  by  com-
puterized image analysis (42). D-Squame tapes are clear plas-
tic  disks  with  a  homogenous  layer  of  adhesive  on  one  side. 

Assessing the Integrity of the Stratum Corneum’s Surface
Squamometry  has  been  developed  as  a  method  of  assessing 
the integrity of the corneocytes on the SC surface. D-Squame 
tape is used to harvest the surface corneocytes, which are then 
treated  with  a  hydrophilic  stain,  such  as  Polymultichrome 
stain  (PMS).  If  the  corneocytes  are  in  good  condition,  they 
do not take up stain and remain relatively clear, and in large 

i

s
s
e
n
y
r
d
n
k
s
e
b
a
v
r
e
s
b
O

l

l

)
e
a
c
s
4
–
0
(

4

3

2

1

0

Lotion E
Lotion C
No product

Treatment

Regression

Day 4
Day 7

x
e
d
n

i

n
o
i
t
a
m
a
u
q
s
e
D

25

20

15

10

5

0

Baseline

Day 1

Day 4

Day 7

Lotion E

Evaluation
(a)

e
c
n
a
t
c
u
d
n
o
c
n
k
S

i

120

100

80

60

40

20

0

Lotion E
Lotion C
No product

Treatment

Regression

Baseline

Day 1

Day 4

Day 7

Evaluation
(c)

Lotion C
Products
(b)

No product

Figure 32.5  Effect of lotions E and C on (a) observable dry skin in a miniregression test; (b) the skin’s desquamation index in a minire-
gression study; and (c) the skin’s hydration as measured by conductance.

 
 
 
 
 
 
296 

 TEXTBOOK OF COSMETIC DERMATOLOGY

sheets.  Damaged  corneocytes  appear  in  smaller  clumps,  and 
take up stain to give a purple color (Figure 32.6). This can be 
quantified by colorimetry.

Since it is measuring damage to the surface corneocytes, 
squamometry  is  a  very  sensitive  measure  of  damage  to  the 
skin’s surface. Previously Simion et al. showed that increased 
color uptake correlated to the sensory irritation produced by 
different cleansing bars before any clinical signs were observed 
(43). Similarly Pierard et al. showed that squamometry could 
demonstrate that fabric softeners could reduce damage on sen-
sitive skin (44).

Dry  skin  is  a  failure  of  the  normal  desquamation  pro-
cess,  resulting  in  damaged  corneocytes  remaining  on  the 
surface.  Hence  there  is  much  staining  of  the  harvested  cells. 
An effective moisturizer causes desquamation, removing the 
damaged  cells,  so  that  the  surface  corneocytes  are  in  good 
condition and staining is reduced. Under the microscope the 
corneocytes appear to have taken up less stain, indicating less 
damage (Figure 32.7).

Measuring  Skin  Surface  Topography  New  optical  methods 
have been developed to assess the changes that a lotion can 
produce  on  skin  topography  more  quickly  and  with  less 

damage  than  the  silicone  replicas  previously  used.  One 
example  is  the  Visioscan®  (Courage  +  Khazaka,  Cologne, 
Germany)  that  rapidly  measures  and  quantifies  skin  dry-
ness,  smoothness,  volume,  and  texture  utilizing  the  “Sur-
face  Evaluation  of  Living  Skin”  (SELS)  parameters  (45).  It 
uses UVA light sources to illuminate a small area (6 x 8 mm) 
uniformly and then the light reflected by the SC is captured 
by CCD camera with a high resolution black and white chip. 
When skin is hydrated using a moisturizer the flakes at the 
skin’s surface are no longer observed (Figure 32.7). Further-
more,  the  skin  can  appear  smoother  and  less  uneven  with 
repeated treatments.

Spectroscopic  Methods  for  Evaluating  Skin  Micro-structure  Dif-
ferent  components  of  the  skin  such  as  hemoglobin,  melanin, 
and collagen have the ability to absorb light at different wave-
lengths. By capturing and analyzing the reflected light for the 
different chromophores at different points across a large area, 
it is possible to build a map of the underlying surface structure 
down to a depth of about 2 mm. Using this method, Matts et al. 
showed that as the skin ages the distribution of both hemoglo-
bin and melanin in sun-exposed skin becomes more diffuse, 
less homogenous. This could be used to measure the effects of 
antiaging lotions on the skin (46).

(a)

(b)

(c)

(d)

Figure 32.6  Effect of lotion in preventing the reduction of surface corneocyte integrity. With lotion: (a) stained D-Squame disk (x20 
magnification) and (b) magnification of ×100. Without lotion: (c) stained D-Squame disk (x 20 magnification) and (d) magnification of ×100.

Figure 32.7  Effect of lotion on the appearance of the skin’s surface. (a) Before lotion application and (b) 8 hours after lotion application.

(a)

(b)

 
 
   
 
   
 
   
 
   
Measuring Water Content of the Skin
Direct  measurements  of  the  skin’s  water  content  have  been 
developed. Unfortunately the leading method, confocal Raman 
microscopy, is no longer commercially available.

Assessing  the  skin’s  electrical  properties  is  an  indirect 
measure  of  its  water  content.  Both  conductance  and  capaci-
tance can be measured. These parameters, while not identical, 
have been shown to strongly correlate to each other in moistur-
izer studies (r2 = 0.92) (Morrison and Scala [47]). Conductance 
measures the ability of a very small electrical current to pass 
through the skin, whereas capacitance measures the ability of 
the skin to hold a charge. However in practice the two param-
eters increase with hydration level produced by increasing the 
water  content  of  the  skin.  Conversely,  artificially  or  weather-
induced  dry  skin  holds  less  water  and  also  has  air  pockets 
between  the  scales,  the  latter  causing  a  white  appearance. 
These lower both conductivity and capacitance. Measurements 
are rapid, in the order of seconds, and reproducible. The four 
most common instruments for measuring electrical properties 
are the Skicon® and DermaLab which measure skin conduc-
tance, while the Corneometer and NovaTM Dermal Phase Meter 
measure skin capacitance.

The procedures for taking these electrical measurements 
must  be  carefully  controlled.  It  is  important  that  the  subject 
is  in  a  relaxed  state  in  a  climate-controlled  environment,  to 
remove  any  contributions  from  sweat  or  from  variable  envi-
ronmental conditions. Another source of error can result from 
product  residue  (48).  Measurements  taken  immediately  after 
lotion application will be especially high before the water from 
the vehicle has completely evaporated. In an opposite scenario, 
the presence of a hydrophobic product residue, such as petro-
latum  or  silicone,  will  lower  the  measured  value  even  if  the 
hydration level of the skin is increased.

Skin Elasticity
The  elasticity  of  skin  is  widely  recognized  to  decrease  with 
chronological  and  photodamage-induced  aging  and  has  been 
shown  experimentally  to  increase  with  hydration  level  (49). 
Though many devices have been used to measure elasticity in 
vivo, only a few are commercially available (50,51). The Dermal 

EVALUATING HAND AND BODY LOTIONS 

  297

Torque  MeterTM  was  designed  to  apply  a  torsional  force  (twist) 
in the plane of the skin and measure the deformation and relax-
ation of the affected skin. The Cutometer® and Dermaflex® both 
apply a vacuum suction perpendicular to the skin surface and 
measure the resultant displacement and relaxation of the skin, 
i.e. snap-back. Regardless of whether the force is applied perpen-
dicular or parallel to the plane of the skin, the data are described 
by the same standardized parameters (Figure 32.8). That differ-
ent  instruments  deform  the  skin  in  different  ways  but  use  the 
same parameter names has caused much confusion in the past.

There  is  a  rapid  initial  deformation  (Ue)  as  the  force  is 
applied followed by a slow viscous “creep” (Uv) if the applied 
force  remains  constant.  As  the  skin  is  moisturized  and 
becomes  more  plastic  and  flexible,  both  parameters  increase. 
The  final  (total)  deformation  is  termed  Uf.  When  the  force  is 
released,  the  skin  relaxes  rapidly  (Ur),  though  only  partially, 
toward the pre-force position. Over a longer period of time the 
skin  relaxes  back  to  its  original  state  by  viscous  flow.  All  of 
these  parameters  are  dependent  on  the  thickness  of  the  skin 
assessed. This in turn is dependent on the size and geometry 
of  the  probes  utilized  and  how  well  the  probe  isolates  the 
measurement site. Ideally for moisturizers the probes should 
assess the SC only. As this is difficult to accurately assess, the 
elasticity data are frequently presented as ratios. The ratio Ur/
Uf is called the biological elasticity.

Although  measurements  can  be  completed  within  sec-
onds, the techniques are not completely noninvasive. The skin 
may take up to an hour to completely return to its baseline val-
ues and in the case of the Dermal Torque Meter will undergo 
alterations from a tape-stripping effect of the adhesive used to 
attach the probe.

User Evaluation of Moisturizer Performance
Ultimately  whether  the  consumer  or  patient  experiences  the 
benefits  of  the  moisturizer  in  relieving  and  preventing  dry 
skin,  continued  usage,  i.e.  compliance,  is  a  critical  factor  in 
determining efficacy. Not only must the lotion be pleasant to 
use, but the benefits should be quickly apparent. Methods have 
been developed to assess the benefits of lotions, especially in 
dermatological patients. There are several ways of doing this. 

Skin response

e
u
q
r
o
t
d
e

i
l

p
p
A

n
o
i
t
a
m
r
o
f
e
d
r
a
u
g
n
A

l

Torque on

Torque off

Uv

Ue

Uf

Ur

Time

R

Time

Figure 32.8  Parameters used in assessing the viscoelastic properties of the skin. Abbreviations: Uf, total stretch; Ue, immediate defor-
mation; Ur, immediate relaxation; Uv, viscous stretch; Ur /Uf, skin elasticity ratio; R, residue.

 
 
 
298 

 TEXTBOOK OF COSMETIC DERMATOLOGY

For  immediate  effects,  panelists  can  assess  the  efficacy  of  a 
lotion  at  different  times  after  application,  using  a  question-
naire.  Equivalent  studies  using  cleansers  showed  that  self-
assessment  of  sensory  effects  was  a  more  sensitive  method 
at  detecting  product  differences  compared  with  observer-
assessed signs (52).

For  longer  term  effects  (days  to  weeks),  QoL  measures 
use questionnaires so patients can assess the signs and symp-
toms of their skin condition and also the impact on their lives 
both in their ability to function normally and their emotional 
well-being.  Some  of  the  questionnaires  can  be  very  general, 
being  able  to  compare  the  impact  of  diseases  of  different 
organs to each other (e.g., Short Form 36 and the Psychological 
General Well-Being Index) , while others are designed for skin 
in general (e.g., Skindex-29 and Skindex-16) (53–55). The Skin-
dex-16  assesses  how  much  the  consumer/patient  is  bothered 
by the sign or system rather than the magnitude of the effect. 
It consists of 16 questions divided into three domains: Symp-
toms, Emotions, and Functioning (see Table 32.3). Each ques-
tion is evaluated on a 7-point scale, where 0 is “never bothered” 
and 6 is “constantly bothered.”

Finally,  there  are  questionnaires  focusing  on  a  specific 
disease  or  condition  such  as  acne  or  atopic  dermatitis  (Acne 
Disability  Index  and  Eczema  Disability  Index,  respectively). 
Effective moisturizers have been shown to improve the QoL for 

Domains*

Symptoms

Emotions

Functioning

Table 32.3  Skindex-16 Questionnaire

During the past week, how often have you 
been bothered by:

   1.  Your skin condition itching
  2. Your skin condition burning or stinging
  3. Your skin condition hurting
  4. Your skin condition being irritated
  5. The persistence/recurrence of your skin 

condition

  6. Worry about your skin condition (e.g. 

that it will spread, get worse, scar, be 
unpredictable etc.)

  7. The appearance of your skin condition
  8. Frustration about your skin condition
  9. Embarrassment about your skin 

condition

10. Being annoyed about your skin condition
11. Feeling depressed about your skin 

condition

12. The effects of your skin condition on 
your interactions with others (e.g. 
interactions with family, friends, 
close relationships etc.)

13. The effects of your skin condition on 
your desire to be with people
14. Your skin condition making it hard to 

show affection

15. The effects of your skin condition on 

your daily activities

16. Your skin condition making it hard to 
work or do what you enjoy

Sources: Copyright MM Chren, August 1999; Chren MM et al., J Invest 
Dermatol;  107(5):707–13,  1996;  Chren  MM  et  al.,  Arch  Dermatol; 
133:1433–40,  1997;  Chren  MM,  et  al.,  J  Cutan  Med  Surg;  105–110, 
2001;  reproduced  with  permission  from  Mapi  Research  Trust,  Lyon, 
France (PROinformation@mapi-trust.org; www.proqolid.org).
*Response choices for all items are a continuous bipolar scale with 
seven boxes, anchored by “never bothered” and “constantly bothered”

patients  experiencing  atopic  dermatitis  and   non-pathological 
but  extremely  dry  skin  (56).  As  an  example  of  the  latter,  two 
small  groups  of  panelists  (<  20  panelists  each)  used  lotion 
in  parallel  for  12  weeks  during  the  Minnesota  (U.S.)  winter. 
Those  panelists  using  a  high-efficacy  test  lotion  containing 
synthetic ceramides and elevated levels of glycerin reported a 
significantly higher QoL compared with panelists using their 
usual lotion, even after the first week (Figure 32.9).

It is interesting to note that QoL is not always strongly 
correlated  to  the  clinical  observation  of  symptoms  and  their 
reduction  by  treatment.  This  suggests  that  these  skin  condi-
tions and the products used to alleviate them have effects that 
go well beyond what is observed by the clinician (57).

As companies develop new lotions, they want to ensure 
that  the  target  consumers  recognize  that  the  new  product 
delivers its intended benefits and has the appropriate aesthet-
ics such as fragrance and appearance as well as tactile proper-
ties  including  optimal  levels  of  greasiness  and  spreadability. 
Prior  to  launch  in  the  marketplace,  this  will  be  achieved  by 
consumer usage testing. These studies can vary greatly in size, 
ranging  from  small  exploratory  studies  to  those  that  utilize 
large panels of several hundred volunteers. Usually panelists 
use the test moisturizer(s) for a designated period according to 
their normal routine. Afterward, they are debriefed with ques-
tionnaires and/or with individual interviews in focus groups. 
Feedback on product attributes such as greasiness, stickiness, 
and after-feel enables the cosmetic formulator to optimize the 
products to the needs of the target consumers.

Product Evaluation by a Trained Expert Sensory Panel
Since  large  scale  consumer  testing  is  time-consuming  and 
expensive, the intensity of product attributes including sticki-
ness,  greasiness,  and  after-feel  can  be  rapidly  evaluated  by  a 
trained expert sensory panel. One such method is the Skin Feel 
Spectrum Descriptive Analysis (SDA) used by Meilgaard et al. 
(58).  This  method  outlines  the  product  attribute  descriptors 
and  scoring  scales  used  to  evaluate  moisturizers.  An  expert 
panel of 8–15 persons is required to complete many hours of 
training to ensure they can reproducibly quantify moisturizer 
and  skin  attributes  such  as  spreadability,  amount  of  residue, 
and absorbency, which are scored using a zero (0) to ten (10) 
scale (see Figure 32.10). Once the panel is calibrated, they can 
be used to evaluate competitors’ products and optimize new 
formulas. It should be noted that these panels measure attri-
bute intensity only, and do not assess the preferences of differ-
ent consumer groups (hedonics).

Advertising Claims Made for Moisturizers
Modern-day hand and body moisturizers have been developed 
to meet the varied needs of today’s consumers. These products 
span  the  range  from  lightweight  lotions  designed  to  provide 
a  pampered  feeling  for  normal  skin  to  heavy,  greasy  creams 
formulated to relieve severely dry skin. Communication of the 
benefits to consumers is known as advertising, which is made 
up of some or many claims, each elucidating an efficacy, sen-
sory, or other benefit. Some of the common descriptors found 
on  hand  and  body  lotion  packaging  are  listed  in  Table  32.4. 
Beyond package labels there are multiple other locations that 
claims may occur. These include TV, radio, and print advertis-
ing, as well as an increasing presence in the digital space.

In  almost  all  jurisdictions,  claims  made  must  be  sup-
ported  by  the  manufacturer.  For  North  America,  the  Euro-
pean  Union,  and  Australia  this  is  done  by  post-launch, 
in-market verification. In the United States if a label is found 

 
EVALUATING HAND AND BODY LOTIONS 

  299

Percent Improvement in Quality of Life After 12 weeks

t
n
e
m
e
v
o
r
p
m

I

%

100.0

80.0

60.0

40.0

20.0

0

Week 1

Week 2

Week 4

Week 8

Week 12

Test product

Panelist’s usual product

Figure 32.9  Results: Quality of life (QoL) assessment indicated significant improvement for panelists’ total QoL for the test product and 
the normal habits group. However, for those using the test product, the improvement was significantly greater (95% CL) starting at 1 week 
of usage. (Data from Adams L et al., Poster #86567 presented at: 72nd Annual AAD Meeting, 2014; Denver, CO.)

l

)
e
a
c
s
0
1
o
t
0
(
y
t
i
s
n
e
t
n

I

10

8

6

4

2

0

Product
stickiness

Product
greasines

Speed of
absorption

Amount of
residue

Skin shine
after
absorption

(a)

(b)

Figure 32.10  Expert panel testing of lotions. (a) Product application. (b) Prototypical results for the sensory profile of two lotions: lotion 
A and lotion B.

to be false, the product is considered to be misbranded under 
Section 601 of the Federal Food, Drug, and Cosmetic Act. A 
deceptive act or practice, i.e. a false claim, is also illegal under 
Section  5  of  the  Federal  Trade  Commission  Act.  However, 
the  U.S.  industry  is  largely  self-regulated  by  the  National 
Advertising Division (NAD) of the Council of Better Business 
Bureaus, through which competitors or outside agencies can 
challenge claims made in advertising. In deciding whether a 
claim  has  been  adequately  substantiated  the  NAD  assesses 
three types of support: rationale, subjective data, and objec-
tive data (59,60). The manufacturer will use a combination of 
test  methods  reviewed  earlier  in  this  section  to  provide  the 
necessary support.

In  the  European  Union,  Proof  of  Effects  is  an  inte-
gral  part  of  the  Product  Information  File  (PIF)  required 
for  all  cosmetic  products.  Expectations  and  requirements 
for  claims  made  in  different  EU  countries  may  vary  with 
national expectations and sensibilities. To address this varia-
tion the EU commission has published guidelines (Common 

Criteria) for what is expected from advertising (61). There are 
six principles:

1.  Legal compliance
2.  Truthfulness
3.  Evidential support
4.  Honesty
5.  Fairness
6.  Informed decision-making

The  EU  Commission  is  also  developed  guidelines  for 

“Free-of” and “Hypoallergenic” claims.

Requirements  to  substantiate  the  claim  are  dependent 
on both the country and the venue for the claim. For instance, 
claims made on TV in the UK must be pre-cleared with Com-
cast  before  transmission.  Comcast  has  a  reputation  for  being 
extremely  conservative  in  the  substantiation  standards  they 
apply.  Part  of  this  is  due  to  the  requirement  that  in  case  of 
a  challenge  both  they  and  the  company  must  answer  to  the 
Advertising Standards Authority (60).

 
 
 
 
 
 
300 

 TEXTBOOK OF COSMETIC DERMATOLOGY

15

10

5

0

s
n
o
i
t
c
a
e
r
e
v
i
t
i
s
o
P
%

1994–1996

1998–2000

2001–2002

2003–2004

2005–2006

2007–2008

2009–2010

2011–2012

Fragrance mixture I (8% pet)

Quaternium-15 (2% pet)
Formaldehyde (1% aq)

Methyldibromo-glutaronitrile/Phenoxyethanol
(2.5% aq)
Diazolidinyl urea (1% pet)

Cinnamic aldehyde (1% pet)

MCI/MI (100 ppm aq)

DMDM hydantoin (1% pet)
Lanolin alchohol (30% pet)

Paraben mix (12% pet)

Testing cycle (years)

Figure  32.11  The  rates  of  positive  dermal  allergic  reactions  in  patch  testing  run  by  the  North  American  Contact  Dermatitis  Group 
(NACDG) for multiple testing cycles. (Data derived from Zug KA et al., Dermatitis, 2009; 20:149–60; Farnsway AF et al., Dermatitis. 2013; 
24:10–21.; Warshaw EM et al., Dermatitis. 2013; 24:50–9; Warshaw EM et al., Dermatitis, 2015; 26:49–59; Marks JG et al., J Am Acad 
Dermatol, 1998; 38:911–18; Marks JG et al., Am J Contact Dermatitis, 2003; 14:59–62; Warshaw EM et al., Dermatitis, 2008; 19:129–36.)

Table 32.4  Common Descriptors of Moisturizer Performance Used in Advertising

Action of Moisturizer

Controls dry skin
Heals dry skin
Protects dry skin*
Relieves dry skin
Soothes dry skin
Ends dry skin
Nourishes skin
Younger-looking skin

Description of Skin

Severe dry skin
Extra dry skin
Over-dry skin
Rough, dry skin
Normal to dry skin
Itchy/tight skin

*May be an over-the-counter (OTC) drug claim in the United States.

Other Claims

Long-lasting relief
Fast relief
Penetrates skin
Repairs moisture barrier
Soft, smooth, healthy skin
Firming/reduces appearance of cellulite
Reveals its natural glow
Skin (color/appearance) evening
Lasts up to × hours
Dermatologist tested/recommended
Lightweight/non-greasy
Fragrance free

THE TOXICOLOGY OF HAND 
AND BODY LOTIONS
Although  cosmetic  hand  and  body  lotions  are  leave-on 
products,  they  have  a  low  rate  of  adverse  reactions  in  nor-
mal usage. Adams and Maibach (20) reported that cosmetics 
caused  5.4%  of  the  contact  dermatitis  cases  studied  by  the 
North  American  Contact  Dermatitis  Group  (NACDG)  from 
1979–1983.  Hand  and  body  lotions  were  probably  a  small 
group  within  this  total,  based  on  the  observation  that  rela-
tively  few  reactions  occurred  on  the  legs,  arms,  or  torso, 
with many more reactions occurring on the face and in the 
eye  area.  This  is  supported  by  more  recent  data  from  the 
U.S.  Food  and  Drug  Administration  (FDA).  They  reported 
that  for  the  years  1991–1994,  hand  and  body  lotions  caused 
approximately  three  “possible  allergic  or  other  severe  irri-
tation”  reactions  for  the  first  million  units  distributed.  In 
contrast, facial moisturizers caused six reactions for the first 
million  units  distributed,  while  bath  soaps  caused  45  (U.S. 
FDA’s Cosmetic Product Experience Report Summary). This 

indicates that the hand and body lotions developed and sold 
by leading U.S. manufacturers deliver their benefits with lit-
tle risk to consumers. However, even with minimal rates of 
adverse reactions, some consumers do experience reactions. 
This  section  reviews  the  types  of  adverse  reactions  experi-
enced by consumers, the materials that may cause the reac-
tions, and how lotion manufacturers test for them.

Most  adverse  reactions  to  hand  and  body  lotions 
experienced  by  consumers  are  forms  of  primary  dermal  or 
 sensory  irritation.  These  are  usually  dependent  on  three 
 factors:

•  The lotion’s composition
•  The condition of consumers’ skin
•  How the consumer uses use the product

Lotion Composition
The first point appears self-evident. If a product does not con-
tain any potential irritants, then it is unlikely to cause irrita-

 
 
 
tion. Lotion manufacturers strive to market products that are 
both non-irritating and non-sensitizing.

to contact the manufacturer or a poison control center in case 
of a question.

EVALUATING HAND AND BODY LOTIONS 

  301

However the addition of beneficial ingredients to lotions 
can  cause  adverse  reactions.  Such  ingredients  include  sun-
screens  and  AHAs  that  may  cause  sensory  irritation  such  as 
facial stinging or burning in about 15% of the population. Pre-
servatives can potentially cause very low rates of sensitization 
but  are  required  to  prevent  microbiological  contamination  of 
products. Such contamination, especially by Pseudomonas, could 
pose  a  greater  threat  to  a  larger  number  of  consumers.  Some, 
such as quaternium-15 and Kathon CG, do cause higher sensi-
tization rates than others and are not usually used in leave-on 
products. Indeed, Kathon CG is in the process of being banned 
for leave-on use in the European Union (regulation enforced for 
products on sale, July 2016). Novel delivery systems, skin pro-
tectants,  and  anti-irritants  have  been  used  to  reduce  adverse 
reactions by limiting release of, or penetration into the skin of, 
potential allergens or irritants. Responsible manufacturers seek 
to minimize these risks for lotions which consumers essentially 
regard  as  being  “risk-free,”  while  maximizing  the  benefits  to 
their consumers.

Role of Consumers’ Skin Condition
Most hand and body moisturizers are well tolerated by the gen-
eral  population  as  evidenced  by  the  low  adverse  reaction  rate 
reported  to  the  FDA.  However,  there  are  groups  of  consumers 
that respond adversely to a product or ingredient more readily 
than the general population. There are several different reasons 
for this phenomenon. People with a damaged SC barrier due from 
pre-existing  trauma  or  pathology  may  be  more  reactive,  espe-
cially  to  marginal  or  cumulative  irritants.  This  group  includes 
people with atopic dermatitis or chronic pre-existing irritation.

A  subset  of  the  population  experiences  sensory 
 irritation—stinging or burning—when they apply lactic acid 
or sunscreens to their facial skin. The mechanism by which 
this  sensory  irritation  is  induced  is  not  clear,  but  it  may 
involve  the  C-fiber  nerve  as  the  sensations  can  be  inhibited 
by  the  “-caine”  anesthetic/anti-pruritic  and  strontium  salts 
which  are  known  to  affect  this  nerve  type  (62–64).  Sensory 
irritation  is  distinct  from  detergent-induced  irritation,  as 
SLS, an irritating surfactant, does not cause stinging (65), and 
stingers to lactic acid demonstrate a wide range of irritation 
responses to lauryl sulfate (66).

Finally, people with a known allergy must avoid expo-
sure to that allergen. Listing the ingredients on the package/
label  in  all  cosmetics  sold  in  the  United  States,  Canada,  and 
the European Union as well as U.S. OTC drugs and Canadian 
Natural Health Products, provides consumers with this infor-
mation. If there are any questions, especially about a fragrance 
component,  the  lotion  manufacturer  should  be  contacted  via 
the toll free/free phone number shown on the package label. 
Additionally, U.S. dermatologists have access to the American 
Contact Dermatitis Society (ACDS) database that lists the com-
position of many personal care products (not just lotions), and 
can be searched to determine if a desired product contains the 
ingredient to which a patient has a sensitivity.

How Consumers Use the Product
Usually consumers do not misuse hand and body lotions in 
such a way that they are harmed. Most lotions are relatively 
mild  to  the  eyes  and  are  not  toxic  when  ingested.  However 
this may not be the case for all products, and it is advisable 

Predicting Adverse Skin Effects
Primary Dermal Irritation
Erythema  occurs  when  the  concentration  of  an  irritant  and 
the  time  and  conditions  of  skin  exposure  exceeds  a  critical 
threshold level: Malten’s theory of traumalative irritation (67). 
Redness usually is localized to the exposure site. It may occur 
rapidly after the first exposure to an acute irritant or after sev-
eral applications of a weaker or cumulative irritant. Diagnosti-
cally, irritation is  frequently  differentiated  from  sensitization 
reactions by factors such as:

If the response occurs after the first usage

•  Composition and dose of the product
• 
•  Rapid onset of irritation after usage
•  The type and spreading of the reaction
•  How long the erythema and/or swelling lasts

Lotion  manufacturers  routinely  probe  for  this  type 
of  information  when  consumers  complain  concerning  an 
adverse reaction and may utilize a dermatologist to  diagnose 
or  follow  up  as  appropriate.  This  process  often  called 
 cosmeto-vigilance,  is  now  a  requirement  of  the   Cosmetic 
Regulations  in  the  European  Union.  Ingredients  that  can 
cause  primary  irritation  in  lotions  are  frequently  anionic 
surfactants used as emulsifiers, or AHAs that are added for 
their antiaging benefits.

A sensitive method to assess and differentiate lotions 
based  on  their  primary  dermal  irritation  potential  is  the 
cumulative  irritation  test  (CIT)  (68).  Panelists  are  randomly 
selected  from  a  general  population,  and  the  product  is 
applied under an occlusive patch for 24 hours. The patch is 
then  removed  and  the  site  is  evaluated  for  irritation  using 
a  0  to  3  scale.  Traditionally  this  process  is  repeated  for  21 
consecutive days, with patches remaining in place over the 
weekend. However, Berger et al. modified this test to where 
applications are only made for 14 days (69) and showed that 
this  modification  gave  the  same  lineup  of  irritation  poten-
tials as the 21-day study, but with a reduced chance of tape 
reactions. The cumulative irritation score in a panel of 10 to 
25 subjects is a measure of primary irritation potential. The 
mean cumulative score per panelist for most lotions is low—
frequently less than 5 out of a possible 45 in the 21-day test. 
In contrast, a 0.1% SLS solution, which is used as a positive 
control, usually yields a mean cumulative score per panelist 
that exceeds 20.

An alternative method for assessing irritation potential 
utilizes  the  induction  phase  of  the  human  repeated  insult 
patch  (HRIPT).  Although  the  primary  purpose  of  this  test 
is  to  identify  sensitizing  ingredients  or  products,  it  begins 
with  an  induction  phase.  During  induction,  usually  100+ 
panelists  are  occlusively  patched  with  the  product  for  24  to 
48 hours over a 3-week period. In the Jordan-King and Mai-
bach-Marzulli variants of the HRIPT, the patches are applied 
for  48  hours  and  are  removed  shortly  before  scoring  and 
repatching. As in the 21-day CIT, the skin does not have time 
to  recover.  This  methodology  resembles  the  21-day  CIT  but 
on a larger scale, so it can be used to assess irritation poten-
tial, especially when an irritation benchmark such as SLS, is 
included. After the induction phase, the panel is rested. Two 
weeks later, sensitization potential is assessed when panelists 

 
302 

 TEXTBOOK OF COSMETIC DERMATOLOGY

are challenged by patching with the product at a naïve as well 
as the original site.

Damaged  skin  may  be  more  readily  irritated  than 
“ normal”  skin.  This  has  been  confirmed  epidemiologically 
for occupations that involve repeated hand washings such as 
nurses  and  kitchen  workers,  who  have  significantly  higher 
rates  of  hand  dermatitis  than  their  cohorts  who  do  not  do 
“wet”  work,  e.g.,  clerical  workers  (70).  Atopy  also  increases 
the risks of occupational dermatitis. Such effects can be mod-
eled.  For  instance,  Freeman  and  Maibach  showed  a  greater 
TEWL response on skin repatched with lauryl sulfate 2 weeks 
after the initial insult, even though the skin appeared normal 
(71).  This  suggested  that  there  was  a  level  of  subclinical  or 
“invisible dermatitis” still present at the cellular level. Indeed 
Kligman  reported  that  patching  with  0.5%  lauryl  sulfate 
can cause spongiosis even though the skin’s surface appears 
normal (72). Typically,  subclinical levels of skin damage  are 
caused  by  cold  winter  weather,  repeated  exposure  to  deter-
gent  solutions  (i.e.  “wet”  work),  or  physical  microtrauma. 
It  has  been  suggested  that  the  use  of  ancillary  cosmetic  or 
cleansing  products  can  cause  subthreshold  levels  of  irrita-
tion.  Subsequent  application  of  a  second  product,  such  as  a 
lotion, may elevate the irritation above the threshold, result-
ing in observable irritation (73).

To examine the role of the stratum corneum (SC) in pre-
venting  irritation,  Frosch  and  Kligman  developed  a  model 
(74).  The  SC  is  mechanically  damaged  by  scratching  with  a 
needle  and  then  is  occlusively  patched  for  three  consecutive 
days.  They  showed  that  damaging  the  hydrophobic  SC  bar-
rier  reduced  the  concentration  of  water-soluble  compounds 
required to cause irritation tenfold for SLS to 50-fold for nickel 
salts.  The  threshold  concentration  to  cause  irritation  by  lipo-
philic irritants such as triclosan or fatty acids was reduced less 
than sixfold by this method.

The final approach to assess the irritation potential of a 
product on a vulnerable group is to have individuals from that 
group, e.g., atopics or lactic acid stingers, use the product under 
exaggerated conditions.

Sensory Irritation
This type of irritation is more common than many people real-
ize. It may cover several different mechanisms, such as subclin-
ical irritation and low-level contact urticaria as well as effects 
such as facial stinging, e.g., to lactic acid. Over half the adverse 
reactions to cosmetics involve sensory irritation in the absence 
of any visible signs (75). Frosch and Kligman (1977) examined 
many ingredients for their potential to cause facial stinging and 
showed that 5% lactic acid, and sunscreens such as PABA had 
the potential to cause facial stinging in approximately 15% of 
the population (65). It is unclear what the rate of reaction would 
be on other parts of the body, although it is probably lower. More 
recently, Christensen and Kligman showed that damaging the 
skin by repeated facial washing with soap would enhance the 
stinging response (76). Low levels of cinnamic aldehyde (0.01%) 
have  been  used  to  cause  tingling  in  chewing  gum.  At  higher 
concentrations it can produce visible contact urticaria and with 
repeated exposure, sensitization.

Sensitization-Delayed (Type IV) Contact Hypersensitivity
Typically,  dermatologists  are  most  familiar  with  this  type  of 
adverse reaction. From 1979 to 1983 the NACDG reported that 
60% of adverse reactions to cosmetic products observed by the 
NACDG were allergic in nature (20). This differs from epide-
miological  data  that  indicate  that  most  adverse  reactions  are 

due  to  irritation  (75).  This  difference  may  reflect  the  greater 
intensity and duration of allergic reactions that would require 
medical  intervention.  The  leading  allergens  identified  by  the 
NACDG  that  are  found  in  cosmetics  include  fragrances  and 
preservatives such as fragrance mix,  quaternium-15, and form-
aldehyde. With the exception of the 2011–2012 testing cycle, the 
sensitization rates for many of the key allergens has fallen with 
time (see Table 32.5 and  Figure 32.11) (77–83). This includes fra-
grance mix 1, formaldehyde, and some formaldehyde-donning 
preservatives such as quaternium-15. The rates for other pre-
servatives  such  as  the  parabens  and  DMDM  hydantoin  have 
not  changed  much  with  time.  In  the  2011–2012  testing  cycle 
there  appears  to  be  a  generalized  increase  in  sensitization 
rates. The reason for this is unclear—does it reflect a change 
in methodology or is it a true epidemiological effect? An exam-
ple of the latter may be the increase in Kathon CG (MCI/MI) 
allergy due to increased sensitization/crossreaction to one of 
its components—MI. Analysis of the data from the next testing 
cycle (2013–2014) will help resolve this issue.

Sensitization to ingredients may occur more readily on 
damaged  or  irritated  skin.  Previously  parabens  had  devel-
oped  a  reputation  as  a  potential  sensitizer.  However,  this 
may be due to parabens being used to preserve mendicants 
for dermatitic skin. The parabens will penetrate the damaged 
SC more readily and be more available to induce sensitization 
reactions (84), as opposed to be hydrolyzed by full thickness 
skin.  Recent  epidemiological  data  has  shown  parabens  to 
have a relatively low sensitization rate compared with other 
preservatives (Table 32.5).

Preservatives:  Lotion  manufacturers  prefer  to  avoid 
potential allergens by excluding them from products. When this 
is not possible, such as in selecting effective preservatives, then 
the least sensitizing product that ensures microbiological integ-
rity should be utilized. The preservatives frequently used in U.S. 
products are listed in the “Ingredients” section this chapter.

Fragrances: The Research Institute for Fragrance Materi-
als (RIFM) is a fragrance industry organization that evaluates 
the safety of individual components. It recommends if a com-
ponent should be used or not be used, or if there is maximum 
safe  level.  Most  major  U.S.  manufacturers  follow  or  exceed 
these guidelines. In the last few years the RIFM has updated its 
guidelines, basing them more on quantitative risk assessment 
(QRA) and the class of product and type of exposure consum-
ers will experience (85).

Sensitization Testing
After  reviewing  the  proposed  ingredients  for  potential  aller-
gens,  lotion  manufacturers  utilize  the  HRIPT  to  experi-
mentally  confirm  that  the  product  or  its  components  do  not 
sensitize. This testing involves occlusively patching a panel of 
over  100  individuals  from  the  general  population  for  up  to  3 
weeks with a test material. After a 2-week rest period, the pan-
elists are challenged with a 24–48 hour patch and the response 
is evaluated (86). If the responses at challenge are greater than 
during the induction phase, are long-lasting—increasing in the 
48 hours after patch removal—or spread beyond the patch site, 
there is a possible sensitization that should be investigated fur-
ther. Pre-damaging the SC with SLS can enhance the sensitiv-
ity of the test (87). This method, known as the maximization 
test, is not often used as it causes many false positives.

Acnegenesis and Comedogenesis
These two terms are frequently used interchangeably, although 
they  likely  represent  different  biological  events.  Acnegenesis 

 
EVALUATING HAND AND BODY LOTIONS 

  303

Table 32.5  % Positive Patch Test Reactions to Ingredients Used in Hand and Body Lotions

Years Tested

Compound/
Mixture*

Fragrance 

mixture I  
(8% pet)
Quaternium  
15 (2% pet)
Formaldehyde 

(1% aq)

Methyldibromo-
glutaronitrile/
Phenoxyetha-
nol (2.5% pet)
Diazolidinyl urea 

(1% pet)
Cinnamic 

aldehyde  
(1% pet)
MCI/MI (100  
ppm aq)

DMDM Hydan-
toin (1% pet)
Lanolin alcohol 
(30% pet)‡
Paraben mix 
(12% pet)

2011–2012

2009–2010

2007–2008

2005–2006

2003–2004

2001–2002

1998–2000

1994–1996

12.1

6.4

6.6

3.7

2.1

3.9

5.0

1.6

4.6

1.4

8.5

5.8

5.8

3.8

2.2

2.3

2.5

1.0

2.5

0.8

9.4

8.6

7.7

5.5

3.1

2.4

3.6

2.7

2.1

1.1

11.5

10.3

9.0

5.8

3.7

3.1

2.8

2.6

1.8

1.2

9.1

8.9

8.7

6.1

3.5

2.4

2.2

2.3

2.2

1.1

10.4

10.9

14.0

9.3

8.4

5.8

3.1

NR†

2.3

2.8

2.3

0.6

9.2

9.2

6.0

3.0

3.7

2.7

2.0

2.4

1.0

9.2

9.2

NR†

3.9

2.4

3.0

2.3

3.3

1.7

Sources: Zug KA et al., Dermatitis; 20:149–60, 2009; Farnsway AF et al., Dermatitis; 24:10–21, 2013; Warshaw EM et al., Dermatitis; 24:50–9, 
2013; Warshaw EM et al., Dermatitis; 26:49–59, 2015; Warshaw EM et al., Dermatitis; 19:129–3, 2008; Marks JG et al., J Am Acad Dermatol; 
38:911–18, 1998; Marks JG et al., Am J Contact Dermatitis; 14:59–62, 2003.
*Concentration tested and vehicle. Pet = petrolatum as the vehicle.
†NR, not recorded
‡In the 2011–2012 cycle, the concentration of lanolin alcohol was increased to 50%.

is  the  occurrence  of  breakouts,  blackheads,  and  whiteheads, 
especially on the face but also on the back. Frequently there is 
a strong inflammatory component that is not observed in com-
edogensis. Inflammation is due to Propionibacterium acnes pro-
liferation  and  the  body’s  immune  response  to  them.  Lesions 
seem to appear rapidly, although formation of the initial hyper-
keratotic plug may occur subclinically over a longer period.

Comedogenesis  originally  was  the  term  given  to  the 
formation of large hyperkeratotic impactions due to exposure 
to  chlorinated  hydrocarbons.  Such  exposure  can  result  from 
industrial  accidents  such  as  in  Seveso,  Italy  (88).  These  com-
edones  do  not  have  an  inflammatory  component,  are  larger, 
and develop more slowly than facial acne.

The interchangeably of the terms arose from two factors. 
The first is mechanistic—both events involve the formation of 
hyperkeratotic plugs. Secondly, the original models for assess-
ing  comedone  formation—the  rabbit  ear  test  and  comedone 
formation on the human back—are more convenient than for 
acnegensis (89,90). This enables many products and ingredients 
to be readily assessed and claims can be made that a product 
is noncomedogenic. Comedogenic materials include branched 
and  unsaturated  fatty  acids  and  esters.  However,  combining 
these ingredients into products can greatly modify their com-
edogenic potential. Indeed the oil used to dissolve a fatty acid 
greatly modifies its comedogenic potential (Table 32.6). In con-
trast,  the  test  method  for  acnegenicity  requires  a  panel  of  at 
least  40  normal  and  acne  prone  subjects  to  use  a  product  on 
their faces for at least 6 weeks. A non-acnegenic product will 

not significantly increase the level of acne over this test period 
(91).  This  is  a  more  expensive  test  than  patching  especially 
since each panelist can test only one product at one time.

Contact Urticaria
Clinically defined contact urticaria is often characterized by the 
rapid formation of wheals or flares frequently within an hour 
of exposure to a causative agent. Either an immunological or a 
nonimmunological pathway can cause this. However, the exact 
molecular and cellular mechanisms are not well understood.

Potential urticants that may occur in cosmetic products 
include  the  preservative  benzoic  acid,  and  fragrance  compo-
nents—cinnamic  aldehyde  and  Balsam  of  Peru.  It  should  be 
stressed that  the  incidence of reaction  to  these ingredients is 
not  known,  so  their  epidemiological  importance  is  not  clear. 
At lower concentrations, many urticants can produce sensory 
irritation,  especially  itching  or  tingling,  without  observable 
clinical signs. von Krogh and Maibach proposed a cascade of 
increasing rigorous testing for contact urticarial (92). It must be 
stressed  that  this  testing,  especially  invasive  scratch  or  prick 
testing, should be carried out by an experienced physician who 
has resuscitation apparatus readily available.

Photoreactions
The  interaction  of  UV  radiation  with  certain  ingredients  can 
cause chemical changes that produce irritation or allergic reac-
tions. Usually products are tested only if they contain ingre-
dients  that  absorb  UV  light.  This  includes  sunscreens  and 

 
304 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 32.6  A. Comedogenicity and Irritation Potential of 
Cosmetic Ingredients in the Rabbit Ear Model

Material

Ingredient

Comedogenicity Irritation

Oils

Coca butter
Coconut butter
Evening primrose oil
Soyabean oil
Peanut oil
Castor oil
Sunflower oil
Mineral oil

4
4
3
3
2
1
0
0–2

Acetylated lanolin
Acetylated lanolin alcohol
Anhydrous lanolin
Lanolin alcohol
PEG-16 lanolin
PEG-75 lanolin

Lauric acid
Myristic acid
Palmatic acid
Stearic acid
Butyl stearate
Cetyl acetate
Cetyl ester NF
Isopropyl isostearate
Isopropyl lineolate
Isopropyl myristate

Lanolin and derivatives
0
4
0–1
0–2
4
0
Fatty acids and esters
4
3
2
2–3
3
4
1
5
4
5

Alcohol sugars and their derivatives

Isopropyl alcohol
Cetyl alcohol
Isocetyl alcohol
Oleyl alcohol
Stearyl alcohol
Sorbitol
Sorbitan laurate
Sorbitan oelate
Sorbitan stearate
Oleth-3
Oleth-5
Oleth-10
Oleth-20

0
2
4
4
2
0
1–2
3
0
5
3
2
1

0
0
2
0
0
0
0
0

0
2
0
0
3
0

1
0
0
0
0
2
1
0
2
3

0
2
4
2
2
0
1–2
0
0
2
2
1
0

B. Effect of Solvent on Comedogenicity Potential

Organic Solvent*
(Grade 0–5)

Sunflower Oil
(Grade 0–5)

0
3
0
0
1

3 (in mineral oil)

2
4
2
2
1
0 (in PEG 400)

Caproic acid
Lauric acid
Palmitic acid
Stearic acid
Behenic acid
D&C red #36

*Ethyl ether or acetone

C. Comparison of Human Back and Rabbit Ear Comedogenicity 
Scores

Material

Mean Comedogenicity Score

Rabbit*

Human

Acetylated lanolin alcohol
Cocoa butter
5% Crude coal tar†
Isopropyl myristate
Safflower oil

3
3
3
1
1

2
2
3
0.4
0

Mean Comedogenicity Score

Rabbit*

Human

5 or 8% sulfur†
2.5% sulfur†
Hydrophilic ointment

3
2
0

2
1.2
0

Sources:  Fulton  JE  Jr.,  J  Soc  Cosmet  Chem;  40:321–33,  1989;  Mills 
OH, Kligman AM, Arch Dermatol; 118:417–9, 1982.
*Comedogenicity scored on a 0–3 scale. n = 3 rabbits or 5 humans.
†These test materials were diluted with hydrophilic ointment. All other 
test materials used at full strength.

fragrances,  although  fragrance  ingredients  that  cause  photo-
allergy  and  phototoxicity  have  been  identified  by  RIFM  and 
are  not  used  by  most  lotion  manufacturers.  Predictive  test 
methods  involve  application  of  the  test  material  to  the  skin, 
then exposure to UV radiation. A parallel site has the product 
applied but is not exposed to UV light. This accounts for nor-
mal irritation or sensitization reactions.

Use of Testing to Assess Adverse Reactions
It  is  apparent  from  the  section  above  that  there  are  many 
causes  of  the  adverse  reactions  that  consumers  describe  as 
“irritation.”  In  normal  usage,  any  of  these  reactions  may 
occur, but with drastically different frequencies. The reaction 
rates depend not only the product’s composition and the con-
sumer’s  skin  condition  but  also  on  how  the  consumer  uses 
the product. This last factor can only be determined by when 
a target consumer uses or misuses the product under normal 
conditions. Frequently such tests are run on panels that exceed 
100, as the adverse reaction rate is low. To interpret the data 
properly, it is important to be able to benchmark the results, 
either from historical data for similar products or by includ-
ing a standard—preferably a commercially available product 
with  a  known  rate  of  adverse  reactions  in  the  marketplace. 
For  those  panelists  who  do  experience  an  adverse  reaction, 
follow-up  is  appropriate.  Besides  appropriate  medical  assis-
tance, this may include a questionnaire to better understand 
the symptoms and their cause, and in a few cases diagnostic 
testing.  Diagnostic  tests  include  exaggerated  usage  such  as 
the Repeated Open Application Test (ROAT) and the Provoca-
tive Usage Test (93,94). For contact urticaria, von Krogh and 
Maibach (92) suggested a cascade of open application on nor-
mal skin, then slightly affected skin, followed by open then 
occlusive  patching  on  slightly  or  previously  effected  skin. 
Whealing or erythema and edema indicate contact urticaria. 
If  indicated,  diagnostic  patch  testing  for  suspected  allergic 
reactions should be run. A dermatologist experienced in this 
issue should run all the diagnostic testing.

Eye Irritation
Accidental exposure of hand and body lotions to the eyes does 
occur, as a sizable minority of consumers uses these products 
on  their  faces.  As  with  skin  irritation,  pre-marketing  safety 
assessment has two major steps. First a review of the ingre-
dients’ toxicological profiles—is this ingredient a known eye 
irritant (hazard evaluation), and at what concentration/how 
will  the  ingredient  be  used  (risk  assessment)?  Second,  test-
ing. Traditionally the Draize test in rabbits was used to assess 
irritation  potential.  Recently  this  has  been  supplemented 
and in many cases superseded by predictive, in vitro meth-
ods.  These  include  the  Chorioallantoic  Membrane  Vascular 
Assay (CAMVA) in hen’s eggs, which models damage to the 

 
conjunctiva, and the Bovine Corneal Opacity and Permeabil-
ity  Test  (BCOP)  which  models  corneal  damage.  Cell  culture 
methods such as the STE and ICE are also used especially for 
assessment of ingredients (95,96). Human test methods such 
as  direct  eye  instillation  under  the  direction  of  an  ophthal-
mologist may be used, but these are more common for facial 
care products.

ACKNOWLEDGEMENTS
I wish to acknowledge Dr. Judith K. Woodford for her input on 
claims substantiation and Ward Billhimer, MS, for our discus-
sions on QoL measures.

REFERENCES

1.  Zhai H, Maibach HI. Moisturizers in preventing irritant contact 
dermatitis: An overview. Contact Dermatitis 1998; 38:241–4.
2.  Simion FA, Abrutyn ES, Draelos ZD. Ability of moisturizers to 
reduce dry skin and irritation and to prevent their return. J Cos-
met Sci 2005; 56:427–44.

3.  Wall  LM,  Gebauer  KA.  Occupational  skin  disease  in  Western 

Australia. Contact Dermatitis 1991; 24:101–5.

4.  Halkier-Sorensen  L.  Notified  occupational  skin  diseases  in 

Denmark. Contact Dermatitis 1996; 35(Suppl 1):1–35.

5.  Shaath NA. The chemistry of sunscreens. In Sunscreens Devel-
opment,  Evaluation  and  Regulatory  Aspects.  Cosmetic  Science  and 
Technology Series vol. 10. 1996; pp. 225–30.

6.  Nguyen BC, Kochevar IE. Factors influencing sunless tanning 

with dihydroxyacetone. Br J Dermatol 2003; 149:332–40.

7.  Perfume allergies. Available at: http://ec.europa.eu/health/sci-
entific_committees/opinions_layman/perfume-allergies/en/
links/index.htm#content (accessed August 13 2015).

8.  Takano S, Yamanaka M, Okamoto K, Saito F. Allergens of lano-

lin: Parts I and II. J Soc Cosmet Chem 1983; 34:99–125.

9.  USP XXVI Lanolin Monograph. 2003; 26:1056–8.

  10.  Ghadially  R,  Halkier-Sorensen  L,  Elias  PM.  Effects  of  petro-
latum on stratum corneum structure and function. J Am Acad 
Dermatol 1992; 26:387–96.

  11.  Kligman AM. Regression method for assessing the efficacy of 

moisturizers. Cosmet Toilet 1978; 93:27–35.

  12.  EU.  SCCS  Opinion  on  decametylcyclopentasiloxane  in  cos-
metic products. 2015. Available at: http://ec.europa.eu/health/
scientific_committees/consumer_safety/docs/sccs_o_174.pdf 
(accessed August 13 2015).

  13.  UK  Health  and  Safety  Executive.  Environmental  Risk 
Assessment  Report:  Decamethylcyclopentasiloxane.  Available 
at: www.gov.uk/government/uploads/system/uploads/attach-
ment_data/file/290561/scho0309bpqx-e-e.pdf  (accessed  Octo-
ber 26 2015).

  14.  Elias  PM,  Brown  BE,  Ziboh  VA.  The  permeability  barrier  in 
essential  fatty  acid  deficiency:  Evidence  for  a  direct  role  for 
linoelic acid in barrier function. J Invest Dermatol 1980; 74:230–3.
  15.  Prottey  C,  Hartop  PJ,  Press  M.  Correction  of  the  cutaneous 
manifestations  of  essential  acid  deficency  in  man  by  applica-
tion  of  sunflower  seed  oil  to  the  skin.  J  Invest  Dermatol  1975; 
64:228–34.

  16.  Froebe CL, Simion FA, Ohlmeyer H, Rhein LD, et al. Prevention 
of stratum corneum lipid phase transition in vitro by glycerol: 
An alternative mechanism for skin moisturization. J Soc Cosmet 
Chem 1990; 41:51–65.

  17.  Mattai J, Froebe CL, Rhein LD, Simion FA, et al. Prevention of 
model  stratum  corneum  lipid  phase  transitions  by  cosmetic 
additives:  Differential  scanning  calorimetry,  optical  micros-
copy  and  water  evaporation  studies.  J  Soc  Cosmet  Chem  1993; 
44:89–100.

  18.  Rawlings A, Harding C, Watkinson A, Banks J, et al. The effect 
of glycerol and humidity on desosome degradation in stratum 
corneum. Arch Dermatol Res 1995; 287:457–64.

EVALUATING HAND AND BODY LOTIONS 

  305

  19.  Braun O, Mallo P, Basset S. U.S. Patent 7,462,363 B2. 2008.
  20.  Adams  RM,  Maibach  HI,  et  al.  A  five  year  study  of  cosmetic 

reactions. J Am Acad Dermatol 1985; 13:1062–9.

  21.  EU  Commission  public  consultations  on  fragrance  allergens. 
Available  at:  www.ec.europa.eu/dgs/health_food-safety/dgs_
consultations/ca/consultation_cosmetic-products_fragrance-
allergens_201402_en.htm (accessed November 28 2015).
  22.  Stiller  MJ,  Bartolone  J,  Stern  R,  et  al.  Topical  8%  glycolic  acid 
and 8% L-lactic acid creams for the treatment of photodamaged 
skin. Arch Dermatol 1996; 132:631–6.

  23.  Imokawa  G,  Asasaki  S,  Kawamata  A,  et  al.  Water  retaining 
function in the stratum corneum and its recovery properties by 
synthetic pseudoceramides. J Soc Cosmet Sci 1989; 40:273–85.

  24.  Ishida  K,  Takahashi  A,  Bito  K,  et  al.  The  Ability  of  Ceramide 
Complex to Reduce Erythema and Enhance Barrier Function of 
Atopic Skin. Poster at the American Academy of Dermatology. 
2012.

  25.  Kornhauser A, Wei RR, Yamaguchi Y, Coelho SG, Kaidbey K, 
Barton C, et al. The effects of topically applied glycolic acid and 
salicylic  acid  on  ultraviolet-induced  erythema,  DNA  damage 
and sunburn cell formation in human skin. J Dermatol Sci 2009; 
55:10–17.

  26.  Boisitis  EK,  Nole  GE,  Cheney  MC.  The  refined  regression 

method. J Cutan Aging Cosmet Dermatol 1989; 1:155–63.

  27.  Prall JK, Theiler RF, Bowser PA, Walsh M. The effectiveness of 
cosmetic products in alleviating a range of skin dryness condi-
tions  as  determined  by  clinical  and  instrumental  techniques. 
Intl J Cosmet Sci 1986; 8:159–74.

  28.  Grove  GL.  Skin  surface  hydration  changes  during  a  mini-
regression test as measured in vivo by electrical conductivity. 
Curr Ther Res 1992; 52:556–61.

  29.  Appa Y, Hemingway L, Orth DS, Lazer W, Lockhart L. Poster 
Presentation  at  the  53rd  Annual  Meeting  of  the  American 
Academy of Dermatology. 1995.

  30.  Highley DR, Savoyka VO, O’Neill  JJ, Ward JB.  A stereomicro-
scopic method for the determination of moisturizing efficacy in 
humans. J Soc Cosmet Chem 1976; 27:351–63.

  31.  Hannuksela A, Kinnunen T. Moisturizers prevent irritant der-

matitis. Acta Dermatol Venereol (Stockh) 1992; 72:42–4.

  32.  Lodén M, Andersson A-C. Effect of topically applied lipids on 
surfactant-irritated skin. Br J Dermatol 1996; 134:215–20.
  33.  Agner T, Held E. Skin protection programmes. Contact Dermati-

tis 2002; 46:253–6.

  34.  Frosch PJ, Kurte A. Efficacy of barrier creams (IV): The repeti-
tive irritation test (RIT) with a set of 4 standard irritants. Contact 
Dermatitis 1994; 31:161–8.

  35.  Schentz  E,  Diepgen  TL,  Elsner  P,  et  al.  Multicentre  study  for 
the development of an in vivo model to evaluate the influence 
of  topical  formulations  on  irritation.  Contact  Dermatitis  2000; 
42:336–41.

  36.  Wigger-Alberti  W,  Caduff  L,  Burg  G,  et  al.  Experimentally 
induced  chronic  irritant  dermatitis  to  evaluate  the  efficacy  of 
protective creams in vivo. J Am Acad Dermatol 1999; 40:590–6.

  37.  Potts RO. Stratum corneum hydration: Experimental techniques 

and interpretation of results. J Soc Cosmet Chem 1986; 37:9–33.

  38.  Kajs  TM,  Gartstein  V.  Review  of  the  instrumental  assessment 
of skin: Effects of cleansing products. J Soc Cosmet Chem 1991; 
42:249–71.

  39.  Frosch PJ, Kligman, AM, eds. Non-Invasive Methods for the Quan-

tification of Skin Functions. New York: Springer-Verlag, 1993;
  40.  Serup  J,  Jemec  GBE,  Grove  GL,  eds.  Handbook  of  Non-Invasive 
Methods and the Skin 2nd edition. Boca Raton, FL: CRC Press 2006.
  41.  Berardesca E, Elsner P, Wilhelm K-P, Maibach HI, eds. Bioengi-
neering of the Skin: Methods and Instrumentation. Boca Raton, FL: 
CRC Press 1995.

  42.  Schatz  H,  Altmeyer  PJ,  Kligman  AM.  Dry  skin  and  scaling 
evaluated  by  D-squames  and  image  analysis.  In:  Handbook  of 
Non-Invasive  Methods  and  the  Skin.  Boca  Raton,  FL:  CRC  Press 
1995; pp.153–7.

 
 
 
 
 
 
 
 
 
 
306 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  43.  Simion FA, Witt PS, Rau AH, Thueneman PJ, Peters HE. Stra-
tum corneum cellular damage produced by surfactants during 
dry skin induction. Poster presentat at: American Academy of 
Dermatology, 1996.

  44.  Pierard GE, Arrese JE, Rodriguez C, Daskaleros PA. Effects of 
softened and unsoftened fabrics on sensitive skin. Contact Der-
matitis 1994; 30:286–91.

  45.  Tronnier H, Wiebusch M, Heinrich U, Stute R. Surface evalua-

tion of living skin. Adv Exp Med Biol 1999; 455:507–16.

  63.  Zhai  H,  Hannon  W,  Hahn  GS,  et  al.  Strontium  nitrate  sup-
presses chemically-induced sensory irritation in humans. Con-
tact Dermatitis. 2000; 42:98–100.

  64.  Zhai H, Hannon W, Hahn GS, et al. Strontium nitrate decreased 
histamine-induced  itch  magnitude  and  duration  in  man. 
Dermatology 2000; 200:244–6

  65.  Frosch  PJ,  Kligman  AM.  A  method  of  apprising  the  stinging 
capacity of topically applied substances. J Soc Cosmet Chem 1977; 
28:197–210.

  46.  Matts  PJ,  Fink  B,  Grammer  K,  Burquest  M.  Color  homogene-
ity  and  visual  perception  of  age,  health,  and  attractiveness  of 
female facial skin. J Am Acad Dermatol 2007; 57:977–84.

  66.  Basketter  DA,  Griffiths  HA.  A  study  of  the  relationship 
between susceptibility to skin stinging and skin irritation. Con-
tact Dermatitis 1993; 29:185–9.

  47.  Morrison BM, Scala DD. Comparison of instrumental methods 
of skin hydration. J Toxicol Cutan Occular Toxicol 1996; 15:305–14.
  48.  Loden M, Lindberg M. The influence of a single application of 
different moisturizers on the skin capacitance. Acta Derm Vene-
reol (Stock.) 1991; 71:79–82.

  67.  Malten  KE.  Thoughts  on  irritant  contact  dermatitis.  Contact 

Dermatitis. 1981; 7:238–47

  68.  Phillips L, Steinberg M, Maibach HI, Akers WA. A comparison 
of rabbit and human skin response to certain irritants. Toxicol 
and Applied Pharmacol 1972; 21:369–82.

  49.  Agache  PG.  Twistometry  measurement  of  skin  elasticity.  In: 
Serup J, Jemec GBE, eds. Handbook of Non-Invasive Methods and 
the Skin. Boca Raton, FL: CRC Press 1995; pp. 319–28.

  69.  Bowman JP, Berger RS, Mills OH, Kligman AM, Stoudemayer T. 
The 21-day human cumulative irritation test can be reduced to 
14 days without loss of sensitivity. J Cosmet Sci 2003; 54:443–9.

  50.  Barel AO, Courage W, Clarys P. Suction methods for measure-
ment of skin mechanical properties: The cutometer. In: Serup J, 
Jemec GBE, eds. Handbook of Non-Invasive Methods and the Skin. 
Boca Raton, FL: CRC Press 1995; pp. 335–40.

  51.  Elsner P. Skin elasticity. In: Berardesca E, Elsner P, Wilhelm K-P, 
Maibach HI, eds. Bioengineering and the Skin: Methods and Instru-
mentation. Boca Raton, FL: CRC Press, 1995; pp. 53–64.

  52.  Simion FA, Rhein LD, Morrison BM Jr, et al. Self-perceived sen-
sory  responses  to  soap  and  synthetic  detergent  bars  correlate 
with clinical signs of irritation. J Am Acad Dermatol 1995; 32:205–
11.

  53.  Ahmed  A,  Leon  A,  Butler  DC,  Reichenberg  J.  Quality-of-life 
effects  of  common  dermatological  diseases.  Semin  Cutan  Med 
Surg 2013; 32:101–9.

 53A.  Chren  MM,  Lasek  RJ,  Quinn  LM,  Mostow  EN,  Zyzanski  SJ. 
Skindex,  a  quality-of-life  measure  for  patients  with  skin  dis-
ease: Reliability, validity and responsiveness. J Invest Dermatol 
1996; 107(5):707–13.

  54.  Chren MM, Lasek R, Flocke S, Zyzanski S. Improved discrimi-
native  and  evaluative  capability  of  a  refined  version  of  Skin-
dex, a quality-of-life instrument for patients with skin diseases. 
Arch Dermatol 1997; 133:1433–40.

  55.  Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement prop-
erties of Skindex-16: A brief quality-of-life measure for patients 
with skin diseases. J Cutan Med Surg 2001; 105–110.

  56.  Adams  L,  Billhimer  W,  DiMuzio  A,  Waterhouse  S.  Effect  of 
pseudo-ceramide  moisturizer  on  barrier  integrity  and  treat-
ment of winter xerosis. Poster #86567 presented at: 72nd Annual 
AAD Meeting, 2014; Denver, CO.

  57.  Jones-Caballero M, Chren MM, Soler B, et al. Quality of life in 
mild  to  moderate  acne:  Relationship  to  clinical  severity  and 
factors influencing change with treatment. J Eur Acad Dermatol 
Venerol 2007; 21:219–26.

  58.  Meilgaard  M,  Civielle  GV,  Carr  BT.  Sensory  Evaluation  Tech-

niques. Boca Raton, FL: CRC Press 1987.

  59.  Smithies  RH.  Moisturization  claims  challenged  through  the 

NAD. J Toxicol Cutan Ocular Toxicol 1992; 11:205–11.

  60.  Woodford  JK.  Design  of  claims  support  for  moisturizers.  In 
Loden  M,  Maibach  HI,  eds.  Treatment  of  Dry  Skin  Syndrome. 
Berlin and Heidelberg: Springer-Verlag 2012.

  61.  Guidelines  to  Commission  Regulation  (EU)  No  655/2013  lay-
ing down common criteria for the justification of claims used in 
relation to cosmetic products. Available at: www.ec.europa.eu/
consumers/sectors/cosmetics/files/pdf/guide_reg_claims_
en.pdf (accessed October 24 2015).

  62.  Leopold  CS,  Maibach  HI.  Percutaneous  penetration  of  local 
anesthetic  bases:  Pharmacodynamic  measurements.  J  Invest 
Dermatol 1999; 113:304–7.

  70.  Nilsson E, Mikaelsson B, Andersson S. Atopy, occupation and 
domestic work as risk factors for hand eczema in hospital work-
ers. Contact Dermatitis 1985; 13:216–23.

  71.  Freeman  S,  Maibach  HI.  Study  of  irritant  contact  dermatitis 
produced by repeated patch testing with sodium lauryl sulfate 
and assessed by visual methods, transepidermal water loss and 
laser doppler velocimetry. J Am Acad Dermatol 1988; 19:496–501.
  72.  Kligman  AM.  The  invisible  dermatoses.  Arch  Dermatol  1991; 

127:1375–82.

  73.  Lee CH, Maibach HI. Study of cumulative contact irritant con-
tact  dermatitis  in  man  utilizing  open  application  on  subclini-
cally irritated skin. Contact Dermatitis 30:271–5.

  74.  Frosch PJ, Kligman AM. The chamber scarification test for irri-

tancy. Contact Dermatitis 1976; 2:314–24.

  75.  de Groot AC, Nater JP, van der Hende R, et al. Adverse effects 
of cosmetics and toiletries: A retrospective study in a general 
population. Int J Cosmet Sci 1988; 9:255–9.

  76.  Christensen  M,  Kligman  AM.  An  improved  procedure  for 
conducting lactic acid stinging tests on facial skin. J Cosmet Sci 
1996; 47:1–11.

  77.  Zug KA, Warshaw EM, Fowler JF, Maibach HI, et al. Patch-test 
results of the North American Contact Dermatitis Group 2005–
2006. Dermatitis 2009; 20:149–60.

  78.  Farnsway AF, Zug KA, Belsito DV, et al. North America Contact 
Dermatitis  Group  patch  test  results  for  2007–2008.  Dermatitis 
2013; 24:10–21.

  79.  Warshaw EM, Belsito DV, Taylor JS, et al. North America Con-
tact Dermatitis Group patch test results: 2009–2010. Dermatitis 
2013; 24:50–9.

  80.  Warshaw EM, Maibach HI, Taylor JS, et al. North America Con-
tact  Dermatitis  Group  patch  test  results:  2011–2012.  Dermatitis 
2015; 26:49–59.

  81.  Marks JG, Belsito DV, DeLeo VA, et al. North American Contact 
Dermatitis Group patch test results for the detection of delayed 
type hypersensitivity to topical allergens. J Am Acad Dermatol, 
1998; 38:911–18.

  82.  Marks  JG,  Belsito  DV,  DeLeo  VA,  et  al.  North  American  Con-
tact Dermatitis Group patch test results 1998–2000. Am J Contact 
Dermatitis, 2003; 14:59–62.

  83.  Warshaw  EM,  Belsito  DV,  DeLeo  VA,  et  al.  North  American 
Contact  Dermatitis  Group  patch  test  results,  2003–2004  study 
period. Dermatitis 2008; 19:129–36.

  84.  Jackson EM. Paraben paradoxes. Am J Contact Dermatitis 1993; 

4:69–70.

  85.  Api AM, Basketter DA, Cadby PA, Cano MF, Ellis G,  Gerberick 
GF,  et  al.  Dermal  sensitization  quantitative  risk  assessment 
(QRA) for fragrance ingredients.  Regul Toxicol Pharmacol 2008; 
52:3–23.

 
EVALUATING HAND AND BODY LOTIONS 

  307

  86.  Marzulli FN, Maibach HI. Contact allergy predictive testing in 
humans. In Marzulli FN, Maibach HI, eds. Dermatolotoxicology 
4th edition. New York, NY: Hemisphere 1991.

  87.  Kligman  AM,  Epstein  W.  Updating  the  maximization  test 
for  identifying  contact  allergens.  Contact  Dermatitis  1975; 
1:231–9.

  88.  Pesatori AC, Consonni D, Bachetti S, et al. Short- and long-term 
morbidity  and  mortality  in  the  population  exposed  to  dioxin 
after the “Seveso accident.” Ind Health 2003 Jul;41:127–38.
  89.  Morris WE, Kwan SC. Use of the rabbit ear model in evaluating 
the  comedogenic  potential  of  cosmetic  material.  J  Soc  Cosmet 
Chem 1983; 34:215.

  90.  Mills OH, Kligman AM. Human model for assessing comedo-

genic substances. Arch Dermatol 1982; 118:903.

  91.  Strauss  JS,  Jackson  EM.  American  Academy  of  Dermatology 
Invitational Symposium on Comedogenicity. J Am Acad Derma-
tol 1989; 20:272–7.

  92.  von  Krogh  C,  Maibach  HI.  The  contact  urticaria  syndrome. 

Semin Dermatol 1982; 1:59–66.

  93.  Zhai HB, Maibach HI. Use Tests: ROAT (repeated open applica-
tion test)/PUT (provocative use test): An overview. Contact Der-
matitis, 2000; 43:1–3.

  94.  Fischer LA, Voelund A, Andersen KE, Menne T, Johansen JD. 
The  dose  response  relationship  between  the  patch  test  and 
ROAT and the potential use for regular purposes. Contact Der-
matitis 2009; 61:201–8.

  95.  Hayashi K, Mori T, Abo T, et al. A tiered approach combining 
the short time exposure (STE) test and the bovine corneal opac-
ity and permeability (BCOP) assay for predicting eye irritation 
potential of chemicals. J Toxicol Sci 37:269–80.

  96.  Cazelle E, Eskes C, Hermann M, et al. Suitability of histopathol-
ogy as an additional endpoint to the Isolated Chicken Eye Test 
for  classification  of  non-extreme  pH  detergent  and  cleansing 
products. Toxicol In Vitro 2014; 28:657–66.

 
33

Anticellulite Products and Therapies

Enzo Berardesca

INTRODUCTION
The term cellulite, first used in the 1920s by Alquier and Paviot, 
defines a localized lipodystrophic disease which affects more 
women  than  men.  Nodular  liposclerosis,  edematofibroscle-
rotic panniculopathy, panniculosis, and gynoid lypodistrophy 
are  some  of  the  other  names  proposed  over  the  last  decades 
instead  of  cellulite.  The  pathophysiological  aspects  of  cellu-
lite  are  still  poorly  cleared.  Many  predisposing  factors  seem 
to  influence  cellulite  onset,  including  gender,  heredity,  race, 
body  weight,  and  age.  Hormones  and  impairment  of  both 
microvascular  and  lymphatic  circulation  are  considered  the 
most  important  etiological  factors.  Cellulite  usually  develops 
in particular anatomic sites such as lateral thighs and buttocks. 
The histopathological modifications that characterize cellulite 
involve the different “operational units” of the fatty tissue: the 
matricial-interstitial  unit,  the  microcirculatory  unit,  the  neu-
rovegeative  unit,  and  the  energy-fatty  unit.  These  alterations 
are accountable for the padded and orange peel appearance of 
the affected areas and induce irregular body profile. Cellulite 
represents a heartfelt aesthetic problem for millions of women 
around  the  world.  Various  systemic  and  topical  products  as 
well as numerous medical procedures have been developed to 
resolve cellulite, very often with poor results and little scien-
tific basis.

ETIOPATHOGENESIS
In 1922, Alquier and Paviot were the first to describe cellulite as 
a  nonphlogistic  dystrophy  of  the  mesenchymal  tissue,  which 
implied  accumulation  of  interstitial  liquids.  They  suggested 
that  the  disorder  was  a  reaction  to  stimuli  of  different  origin: 
infectious,  traumatic,  toxic,  etc.  Since  then,  many  contrasting 
theories  have  been  expressed  to  explain  the  etiopatogenesis  of 
cellulite,  which  is  currently  often  considered  a  physiological 
phenomenon, especially in Anglo Saxon countries. Among the 
different hypothesis, the theory proposed by Curri has gained 
approval  and  remains  one  of  the  most  popular  (1).  According 
to  Curri,  cellulite  begins  with  alterations  of  the  precapillary 
arteriolar  sphincter,  as  described  by  Merlen,  which  induce 
capillary  ectasia,  increased  capillovenular  permeability  with 
accumulation of interstitial liquid, and consequent intercellular 
edema. Edema provokes fibroblast activation and proliferation, 
which cause hyperpolimerization of glycosaminoglycans in the 
connective matrix of the subcutaneous tissue. This phenomenon 
increases  hydrophilicity  of  the  intercellular  matrix  as  well  as 
the interstitial osmotic pressure. These alterations induce tissue 
hypoxia, which results in collagen production and damaged adi-
pocytes.  Anisopoikilocytotic  adipocytes  are  hence  surrounded 
by thickened fibrosclerotic septae; groups of adipocytes gradually 
form  micronodules  and  subsequently  macronodules.  Around 
85% of postpubertal women suffer from cellulite, independently 

of their weight. This is due to the anatomy of the subcutaneous 
fat, which is constituted by two layers divided by a superficial 
fascia.  The  areolar  layer  is  located  just  underneath  the  dermis; 
in this layer adipocytes are large and arranged vertically. In the 
lamellar layer, which is the deeper one, adipocytes are small and 
arranged  horizontally.  If  weight  increases,  the  lamellar  layer 
enlarges. When cellulite occurs it is the superficial part of hypo-
dermis that tends to protrude into the dermis. The areolar layer 
is thicker in women than in men and is under the control of estro-
gen. Hormonal factors seem to play a significant role in cellulite 
onset as well as in its evolution. Cellulite affects predominantly 
women, appears after puberty, and worsens during pregnancy 
and contraceptive therapy; therefore cellulite is greatly influenced 
by  estrogen.  Estrogen  acts  on  adipocyte  increasing  lipogenesis 
and  hence  causing  adipocyte  hypertrophy  and  anysopoikilo-
cytosis;  it  promotes  fibroblast  proliferation  and  alterations  in 
glycosaminoglicans  and  collagen,  leading  to  fibrosclerosis. 
Insulin, prolactin, and thyroid hormones are also involved in the 
pathophysiology of cellulite. Furthermore, recent investigations 
on  the  adipose  organ  have  highlighted  that  adipocytes  release 
several substances which act in an endocrine or paracrine way 
as well as so-called adipokine (2). On the basis of the new knowl-
edge, it is clear that adipose tissue is not a passive organ but rather 
a dynamic organ able to interact with and regulate other cells, 
such as endothelial cells. Cellulite development also depends on 
predisposing  factors  such  as  genetic,  nutritional,  lifestyle,  and 
pharmacological  factors.  Gender  is  the  most  important  genetic 
predisposing  factor.  On  the  basis  of  histological  examinations, 
Nürnberger  and  Müller  noticed  that  a  female  subcutaneous 
tissue  presents  some  anatomical  peculiarities  such  as  fibrous 
bands  whose  course  is  perpendicular  to  the  skin’s  surface 
and  which  could  be  responsible  of  the  “hill”  profile  of  the 
dermohypodermic  border,  whereas  in  men  the  fibrous  septa 
present  a  different  disposition,  more  oblique  with  reference  to 
the  skin  (3).  Furthermore,  a  recent  study  performed  by  means 
of  magnetic  nuclear  resonance  imaging  (MRI)  has  confirmed 
that women with cellulite have constitutional characteristics of 
fibrous  interlobular  bands,  which  induce  bigger  and  radial  fat 
chambers  (4).  Caucasian  women  are  more  frequently  affected 
by cellulite than Asian or Black women. Genetic influences the 
number and the sensitivity of hormone receptors on adipocytes 
as well as the tendency to circulatory insufficiency. Nutritional 
factors  are  very  important.  As  hyperinsulinemia  stimulates 
lipogenesis, excessive intake of fats and carbohydrates contributes 
to cellulite onset and worsening. But although adiposity is linked 
to  cellulite,  MRI  has  demonstrated  that,  among  women  with 
body mass index over 30, there are women who do not manifest 
cellulite at all. Salt favors hydric retention and alcohol stimulates 
lipogenesis.  Sedentary  lifestyle  contributes  to  cellulite  as  it  is 
associated with ponderal increase and decreased activity of the 

muscular pumping in the lower limbs with consequent venous 
stasis. The muscular pumping activity is also influenced by the 
habit to wear tight clothes and high-heeled shoes. Among drugs, 
estrogens, antihistamines, and beta-blockers have shown to play 
a role in cellulite development.

CLASSIFICATION
On  the  basis  of  clinical  and  histological  modifications  that 
occur  in  the  subcutaneous  tissue,  four  stages  of  cellulite  are 
distinguishable (5).

Stage I
In  the  first  stage,  the  patient  may  be  asymptomatic  or  only 
manifest a pale and pasty skin. Histologically, we can observe 
a thicker areolar layer, increased capillary permeability, aniso-
poikilocytotic adipocytes, capillary ectasia, and lipoedema.

Stage II
Clinical alterations are not clearly evident at rest but only after 
skin pinching or muscular contraction we can observe an orange 
peel appearance, with decreased skin temperature and elastic-
ity. Histologically, the fibril network, which surrounds adipo-
cytes, appears hypertrophic; there is an important microvessel 
dilatation, and there are microhemorrhages.

Stage III
In this phase, clinical changes are appreciable at rest with the 
characteristic orange peel aspect. On palpation, we can notice 
small lumps, hypoelasticity, and decreased skin temperature. 
This  clinical  picture  histologically  corresponds  to  anisopoi-
kilocytotic  adipocytes  encapsulated  in  micronodules,  neofi-
brillogenesis, and dilation of small veins.

Stage IV
The  clinical  characteristics  of  stage  III  are  more  evident;  in 
particular  there  are  macronodules  due  to  the  agglomeration 
of  many  micronodules.  In  this  stage,  cellulite  may  be  pain-
ful because of the compression of the nerves by the nodules. 
According to skin consistency, we can distinguish four types 
of cellulite: hard, flaccid, edematous, and mixed (6). Hard cel-
lulite  is  characteristic  of  teenagers  and  young  women  who 
regularly practice sport; at rest skin appears firm and compact 
and orange peel becomes evident only after pinching. On the 
contrary, inactive subjects usually show flaccid cellulite, which 
is associated with muscular hypotonia. In the edematous form, 
lower limbs are globally enlarged and patients complain of a 
sense of heaviness, cramps, and swelling.

NONINVASIVE TECHNIQUES 
TO EVALUATE CELLULITE
The variety of anticellulite products and professional (surgical 
or not) approaches to treat cellulite is quite huge, ranging from 
topical products to oral regimens, from manual or mechanical 
massages, to garments. We can find many strategies to contrast 
the condition, a borderline one with pathology. In general, the 
efficacy  of  cellulite  treatments  is  often  debated  and  objective 
studies  are  needed  to  claim  support.  Furthermore,  it  is  very 
difficult to investigate cellulite by bioengineering methods.

Thigh Circumference Measurement
This traditional measure indicates the reduction of thigh circum-
ference, which can be due to both the reduction of edema and the 

ANTICELLULITE PRODUCTS AND THERAPIES 

  309

effect on the fatty layer. It is recorded on hips, ankles, and thighs 
as follows:

1. 

2. 

3. 

  Hip:  The  tape  measure  is  positioned  around  the  hips, 
putting it finally on the superanterior iliac crest.
  Thigh:  The  tape  measure  is  placed  around  the  thigh, 
marking the site of interest.
  Ankle:  The  tape  measure  is  placed  around  the  ankle, 
exactly above the malleolar bone (7).

Ultrasonography
Ultrasound is used to study  the  thickness  and  the quality of 
the connective tissue and the edematous component of cellu-
lite. Frequencies between 10 and 15 MHz should be chosen for 
skin  examination.  With  higher  frequencies  it  becomes  more 
difficult to view in depth (8).

Laser Doppler Flowmetry
Laser  Doppler  flowmetry  (LDF)  is  an  optical  technique  used 
to  evaluate  skin  microcirculation,  which  provides  informa-
tion  on  blood  flow  and  erythema.  The  method  consists  of  a 
Ne-He laser source of 632 nm wavelength applied to the skin 
via a small probe. The incident radiation enters the skin and is 
scattered and reflected by nonmoving tissue components and 
by  mobile  red  blood  cells  encountered  as  the  radiation  pen-
etrates to a depth of 1 to 1.5 mm. A portion of the scattered and 
reflected incident radiation exits the skin and is collected by a 
second optical fiber that carries the light back to a photodetec-
tor where it is converted to an electrical signal. Stationary skin 
tissue reflects and backscatters light with the same frequency 
as the incident source,  while moving erythrocytes reflect the 
frequency-shifted radiation. The shift increases with increas-
ing  erythrocytes  speed.  The  LDF  extracts  the  frequency-
shifted signal and derives an output proportional to the flux 
of erythrocytes of the blood flow. LDF is a reliable method for 
estimating cutaneous microcirculation (9).

Thermography
Anticellulite products are meant to increase local skin blood 
flow. By increasing the blood flow, they increase the local skin 
temperature.  Thermography  is  an  electrooptical  method  for 
the imaging of temperature. The current technology used is 
based on the detection of the infrared radiation emitted by the 
skin. A conventional color thermogram uses a spectral color 
range, where blue is cold and red/white is hot. Intermediary 
temperatures  are  shown  as  shades  of  green,  yellow,  orange, 
etc. (10).

Plicometry
The technique implies the use of the plicometer, a device that 
allows evaluation of the thickness of cutaneous plicae or folds 
to calculate the percentage of fat in human body. The measure-
ment  is  usually  performed  on  the  thigh,  on  a  defined  point 
which  can  be  determined  by  measuring  the  half  distance 
between the iliac crest and the center of the knee as reference 
points. During measurement, the leg is relaxed. All measure-
ments are performed in standard conditions, which guarantee 
reliability and suitability of collected data.

Magnetic Resonance Imaging
Among in vivo skin imaging methods, MRI (11) is the most 
recent  approach,  being  of  high  interest  not  only  for  its  abil-
ity to distinguish structures at a submillimeter scale, but also 

 
310 

 TEXTBOOK OF COSMETIC DERMATOLOGY

for its ability to describe the physiology of the different skin 
layers through the measurement of their intrinsic MR param-
eters.  High  spatial  resolution  MRI  allows  differentiation  of 
the  different  skin  departments—epidermis,  dermis,  and 
hypodermis—offering  new  and  interesting  opportunities 
for  the  evaluation  of  anticellulite  treatments.  Some  authors 
(4) found that changes in skin architecture with cellulite can 
be well visualized by that method, pointing out clearly in the 
images  the  skin  fat  layers  beneath  the  dermis  and  down  to 
the  level  of  muscles.  Also,  the  diffuse  pattern  of  extrusion 
of  underlying  adipose  tissue  into  dermis  is  clearly  imaged, 
and  was  found  to  correlate  with  cellulite  grading.  Other 
researchers (12) applying such a technique characterized the 
topography of the dermohypodermal junction and the three-
dimensional architecture of the subcutaneous fibrous septae, 
giving a more clear frame of skin condition in areas affected 
by cellulite.

Since methods and guidelines to evaluate clinically and 
objectively cellulite are lacking, a multidisciplinary group has 
been created in order to define a valuable and reliable method-
ology for this purpose (13)

THERAPIES
Pharmacological Agents
Several  proximate  principles  have  been  employed  topically, 
systemically, or transdermally, in attempt to contrast the differ-
ent  pathophysiological  aspects  of  cellulite.  Notwithstanding, 
only  a  few  scientific  studies  proving  their  real  efficacy  have 
been  published.  Methylxanthines  such  as  theobromine,  the-
ophylline, aminophylline, and caffeine, β-adrenergic agonists 
such as isoproterenol and adrenaline, and α-antagonists such 
as  yohimbine,  piperoxan,  and  phentolamine  represent  drugs 
with a lipolytic effect. Among these, topical aminophylline has 
been demonstrated to be the most effective, but the best results 
are obtained applying aminophylline together with yohimbine 
and isoproterenol (14). The use of coenzyme A and L-carnitine 
may contribute to improve the effects of the above-mentioned 
drugs, as they induce the discharge of free fatty acids. A 2.8-
mm decrease in subcutaneous fat thickness has been observed 
after a month of application of a product containing caffeine, 
horsechestnut,  ivy,  algae,  bladderwrack,  plankton,  butcher-
broom,  and  soy  (15).  Extracts  from  Centella  asiatica  are  active 
either  on  connective  tissue  or  microcirculation,  and  they  are 
commonly  used  orally  and  topically.  In  particular,  60  mg  of 
Centella  asiatica  once  a  day  for  90  days  induces  reduction  of 
adipocytes’ dimensions (16). Distante et al. have performed a 
prospective, longitudinal double-blind designed study aimed 
to  test  a  plant  complex  on  the  basis  of  seed  extracts  of  grape 
(Vitis  vinifera),  Ginkgo  biloba,  Centella  asiatica,  Melilotus 
(Melilotus officinalis), Fucus vesiculosus, fish oil, and borage oil. 
Data  obtained  from  these  trials  have  demonstrated  that  the 
oral intake of the mixture of plant extracts leads to significant 
improvement of cellulite (17). A 4-week oral intake of peroxi-
some  proliferator-activated  receptors  (PPAR)  agonists  have 
demonstrated reduction in subcutaneous fat thickness in mice 
(18). There is no FDA-approved dietary supplement for cellu-
lite treatment. The slimming effects of a cosmetic composition 
have been recently evaluated showing good efficacy and toler-
ability (19).

Massage Treatment
Bayrakci et al. (20) have investigated the effects of mechanical 
massage,  manual  lymphatic  drainage,  and  connective  tissue 

manipulation  techniques  on  cellulite.  They  have  reported 
improvement  in  all  groups  treated,  with  a  decrease  of  thigh 
circumference and fat thickness. This study confirms previous 
data obtained by Lucassen et al. (21) who have monitored the 
effectiveness  of  electromechanical  massage  device  by  ultra-
sound  imaging.  A  “smoothening”  of  the  dermis-hypodermis 
interface has been observed but the improvement was transi-
tory as the result regresses after treatments end.

Endermologie
LPG endermologie is an electromechanical handheld massage 
device designed by Louis Paul Guitay, a French engineer and 
approved by FDA for cellulite treatment. The machine consists 
of  two  rollers  and  a  vacuum  chamber.  The  rollers  rhythmi-
cally fold and unfold skin and subcutaneous tissue while the 
vacuum applies negative pressure. In the few published stud-
ies,  the  results  obtained  note  that  LPG  induces  fat  mobiliza-
tion and redefines body profile. In a recent trial performed on 
33 women with cellulite grades 1 to 3, treated with LPG twice 
weekly  for  15  sessions,  Gülec  (22)  observed  a  circumference 
reduction  in  all  patients  but  only  15%  of  the  subjects  had  a 
reduction of cellulite grade.

Optical Devices
Velasmooth  (Syneron  Medical  Ltd.,  Yokeneam,  Israel)  com-
bines  negative  tissue  massage,  radio  frequency  (RF)  and  a 
700-nm infrared light (IR). It has been approved by FDA for 
the treatment of cellulite. The mechanical massage improves 
microcirculation and facilitates lymphatic drainage while RF 
and  IR  heat  the  tissue,  thus  inducing  collagen  contraction 
and  neocollagenesis.  Improvement  is  usually  obtained  after 
eight or more treatments, delivered on a twice-weekly basis. 
Monthly  maintenance  treatment  is  recommended.  Results 
decline  within  6  months  post  treatment  (23).  TriActive 
(Cynosure,  Inc.,  Chelmsford,  Massachusetts)  combines  a 
810-nm  diode  laser,  contact  cooling,  suction,  and  massage. 
It represents another FDA-approved device to contrast cellu-
lite and has shown to be as effective as Velasmooth in a ran-
domized,  comparative,  prospective  clinical  study  in  which 
patients were treated twice a week for 6 weeks. Bruising was 
the only reported side effect, occurring globally in about 55% 
of the patients (24). Goldberg et al. have investigated the use 
of a unipolar RF device (Alma Lasers, Buffalo Grove, Illinois), 
which delivers a high-frequency electromagnetic radiation at 
40  MHz,  inducing  heating  of  the  tissue.  Good  results  have 
been  obtained  with  a  treatment  regimen  of  six  every-other-
week sessions and benefits were persistent for the following 
6 months (25). More recently, a new bipolar RF system emit-
ting  variable  frequencies,  called  automatic  multifrequency 
and low impedance (AMPLI) RF, has been experimented for 
cellulite in the buttocks in a multicenter study. Enrolled sub-
jects underwent one treatment per week for 12 sessions. An 
improvement  in  body  profile  was  observed.  With  reference 
to the other types of RF devices already used, the AMPLI RF 
technology  has  the  advantage  of  a  continuous  emission  of 
different  frequencies  with  consequent  progressive  heating, 
homogeneous  thermal  damage,  sparing  epidermidis  (26). 
Manuskiatti  et  al.  have  tested  a  Tripollar  RF  device  (Regen, 
Pollogen  Ltd.,  Tel  Aviv,  Israel)  for  cellulite  reduction.  This 
novel system employs a three-electrode technology to deliver 
the RF. Patients were treated once a week for eight sessions. 
Good results were reached in terms of reduction of circum-
ference and better appearance of cellulite (27).

 
Surgical Subcision
The surgeon tears the connective bands that tie the dermis to 
the  fascia  by  means  of  a  needle  (28).  This  mechanism  is  also 
exploited by liposculpture, which also reduces local adiposity.

Mesotherapy
This  method  that  delivers  drugs  directly  into  the  dermis  of 
the  affected  areas  by  means  of  several  injections,  was  con-
ceived  by  Pistor  in  1958  and  has  been  commonly  employed 
since  1964.  Despite  its  popularity,  mesotherapy  is  lacking  in 
scientific published supports. Several drugs are used such as 
aminophylline, enzymes, minerals, L-carnitine, and, recently, 
phosphatidycholine.

REFERENCES

1.  Curri  SB.  Adiposita  Localizzata  e  Pannicolopatia  Edematofibro-

Sclerotica. 1990 Sepem Ed., Milano.

2.  Havel PJ. Update on adipocyte hormones: Regulation of energy 
balance  and  carbohydrate/lipid  metabolism.  Diabetes  2004; 
53(suppl 1):S143–51.

3.  Nürnberger  F,  Müller  G.  So-called  cellulite:  An  invented  dis-

ease. J Dermatol Surg Oncol 1978; 4(3):221–9.

4.  Mirrashed F, Sharp JC, Krause V, et al. Pilot study of dermal and 
subcutaneous fat structures by MRI in individuals who differ 
in  gender,  BMI,  and  cellulite  grading.  Skin  Res  Technol  2004; 
10(3):161–8.

5.  Curri SB. Las panniculopatias de estasis venosa: Diagnostico clinic e 

instrumental. Hausmann, Barcelona, 1991.

6.  Rossi  AB,  Vergnanini  AL.  Cellulite:  A  review.  J  Eur  Acad 

Dermatol Venereol 2000; 14(4):251–62. Review.

7.  Smith  PW.  Cellulite  treatments:  Snake  oils  or  skin  science. 

Cosmet Toilet 1995; 110:61–70.

8.  Serup  J.  Skin  imaging  techniques.  In:  Berardesca  E,  Elsner  P, 
Wilhelm  K,  eds.  Bioengineering  and  the  Skin:  Methods  and 
Instrumentation. Boca Raton: CRC Press 1995; pp. 65–79.

9.  Bernardi L, Berardesca E. Measurements of skin blood flow by 
laser  Doppler  flowmetry.  In:  Berardesca  E,  Elsner  P,  Wilhelm 
K, eds. Bioengineering and the Skin: Methods and Instrumentation. 
Boca Raton: CRC Press 1995; pp. 13–28.

  10.  Sherman RA, Woerman AL, Arstetter KW. Comparative effec-
tiveness  of  videothermography,  contact  thermography,  and 
infrared  beam  thermography  for  scanning  relative  skin  tem-
perature. J Rehabil Res Dev 1966; 33:377–86.

  11.  Querleux B. Magnetic resonance imaging and spectroscopy of 

skin and subcutis. J Cosmet Dermatol 2004; 3:156–61.

  12.  Querleux B, Cornillon C, Jolivet O, et al. Anatomy and physiol-
ogy of subcutaneous adipose tissue by in vivo magnetic reso-
nance  imaging  and  spectroscopy:  Relationships  with  sex  and 
presence of cellulite. Skin Res Technol 2002; 8:118–24.

  13.  Seidenari, S., Bassoli, S., Flori, M. L., Rigano, L., Sparavigna, A., 
Vesnaver,  R.,  &  Berardesca,  E.  Methods  for  the  assessment  of 

ANTICELLULITE PRODUCTS AND THERAPIES 

  311

the efficacy of products and slimming treatments for cellulite 
according  to  the  Italian  Interdisciplinary  Group  for  the  stan-
dardization of efficacy tests on cosmetic products. It J Dermatol 
2013; 148(2), 217–23.

  14.  Greenway FL, Bray GA. Regional fat loss from the thigh in obese 

women after adrenergic modulation. Clin Ther 1987; 9(6):663–9.
  15.  Buscaglia DA, Conte ET. The treatment of cellulite with methyl-
xanthine and herbal extract based cream: An ultrasonographic 
analysis. Cosmet Dermatol 1996; 9:30–10.

  16.  Hachem  A,  Borgoin  JY.  Etude  anatomo-clinique  des  effets  de 
l’extrait titré de Centella asiatica dans la lipodystrophie local-
iseé. La Med Prat 1979; 12(suppl 2):17–21.

  17.  Distante F, Bacci PA, Carrera M. Efficacy of a multifunctional 
plant  complex  in  the  treatment  of  the  so-called  ‘cellulite’: 
Clinical  and  instrumental  evaluation.  Int  J  Cosmet  Sci  2006; 
28(3):191–206.

  18.  Tsuzuki T, Kawakami Y, Nakagawa K, et al. Conjugated doco-
sahexaenoic  acid  inhibits  lipid  accumulation  in  rats.  J  Nutr 
Biochem 2006; 17(8):518–24 [Epub October 25, 2005].

  19.  Berardesca E, Abril E, Rona C, Vesnaver R, Cenni A, Oliva M. 
An effective night slimming topical treatment. Int J Cosmet Sci 
2012 Jun;34(3):263-72.

  20.  Bayrakci Tunay V, Akbayrak T, Bakar Y, et al. Effects of mechan-
ical massage, manual lymphatic drainage and connective tissue 
manipulation techniques on fat mass in women with cellulite. 
J  Eur  Acad  Dermatol  Venereol  2010;  24(2):138–42  [Epub  July  13, 
2009].

  21.  Lucassen GW, van der Sluys WLN, van Herk JJ, et al. The effec-
tiveness  of  massage  treatment  on  cellulite  as  monitored  by 
ultrasound imaging. Skin Res Technol 1997; 3:154–60.

  22.  Gülec AT. Treatment of cellulite with LPG endermologie. Int J 

Dermatol 2009; 48(3):265–70.

  23.  Alster  TS,  Tehrani  M.  Treatment  of  cellulite  with  optical 
devices: An overview with practical considerations. Lasers Surg 
Med 2006; 38(8):727–30. Review.

  24.  Nootheti PK, Magpantay A, Yosowitz G, et al. A single center, 
randomized, comparative, prospective clinical study to deter-
mine the efficacy of the VelaSmooth system versus the Triactive 
system  for  the  treatment  of  cellulite.  Lasers  Surg  Med  2006; 
38(10):908–12.

  25.  Goldberg DJ, Fazeli A, Berlin AL. Clinical, laboratory, and MRI 
analysis of cellulite treatment with a unipolar radiofrequency 
device.  Dermatol  Surg  2008;  34(2):204–9;  discussion  209  [Epub 
December 17, 2007].

  26.  Van der Lugt C, Romero C, Ancona D, et al. A multicenter study 
of cellulite treatment with a variable emission radio frequency 
system. Dermatol Ther 2009; 22(1):74–84.

  27.  Manuskiatti  W,  Wachirakaphan  C,  Lektrakul  N,  et  al. 
Circumference  reduction  and  cellulite  treatment  with  a 
TriPollar  radiofrequency  device:  A  pilot  study.  J  Eur  Acad 
Dermatol Venereol 2009; 23(7):820–7 [Epub April 8, 2009].
  28.  Hexsel  DM,  Mazzuco  R.  Subcision:  A  treatment  for  cellulite. 

Int J Dermatol 2000; 39(7):539–44.

 
 
 
 
 
 
 
 
 
 
34

Therapy of Telangiectasia and Varicose 
Veins and Their Complications

Christian R. Halvorson, Robert A. Weiss, and Margaret A. Weiss

INTRODUCTION
One of the most commonly treated cosmetic disorders in der-
matology is telangiectatic webs, or spider veins. The methods 
of  treatment  most  commonly  employed  by  the  dermatologic 
surgeon include sclerotherapy and lasers. For larger varicose 
veins,  dermatologic  surgeons  employ  sclerotherapy  with  the 
newest  improvement  of  foamed  detergent  sclerosing  agents, 
ambulatory phlebectomy, and endovenous occlusion and abla-
tion by intravascular radiofrequency or laser energy.
Sclerotherapy,  which  consists  of  the 

intravascular 
introduction of a sclerosing substance, is the most frequently 
utilized process. Sclerotherapy is actually endovenous chemo-
ablation  with  subsequent  fibrosis  and  concomitant  vein  wall 
collagen  dissolution.  The  term  “sclerotherapy”  gained  accep-
tance during the nineteenth century and has never changed. In 
the United States, sclerotherapy gained wide acceptance in the 
early 1990s and is regarded as a highly effective treatment for 
telangiectasias as well as veins of all sizes (1,2). It also serves as 
an effective addition to surgical techniques such as ambulatory 
phlebectomy  for  saphenous  tributaries  (3,4)  and  endovenous 
obliteration  of  refluxing  saphenous  veins  (5,6).  Knowledge  of 
venous  anatomy  and  physiology,  principles  of  venous  insuf-
ficiency, methods of diagnosing venous malfunction, uses and 
actions of sclerosing solutions, and proper use of compression 
are essential elements of successful venous therapy.

EPIDEMIOLOGY
Bulging  varicose  veins  and  unsightly  “roadmap”  telangiec-
tatic webs affect millions of patients and the number affected 
is increasing every year as the population ages. Telangiectases 
comprise one of the most common cosmetic complaints, affect-
ing up to 50% of women, while larger varicose veins affect up 
to  40%  of  the  population  (7,8).  Varicose  veins  may  cause  sig-
nificant  morbidity  including  chronic  stasis  dermatitis,  ankle 
edema,  spontaneous  bleeding,  superficial  thrombophlebitis, 
recurrent  cellulitis,  lipodermatosclerosis,  and  skin  ulceration 
on the ankle and foot.

The  incidence  of  varicose  veins  increases  with  each 
decade of life. Increased incidence has led to increased demand 
for treatment of varicose and telangiectatic veins as the aver-
age age of the United States population grows. While 41%  of 
women  in  the  fifth  decade  have  varicose  veins,  this  number 
rises  to  72%  in  the  seventh  decade  (9).  Statistics  for  men  are 
similar, with 24% incidence in the fourth decade, increasing to 
43% by the seventh decade. Six million workdays per year may 
be lost due to complications of varicose veins including stasis 
dermatitis, cellulitis, and ulceration (10).

HISTORICAL ASPECTS
In  the  second  century  AD,  Galen  proposed  tearing  out  the 
veins with hooks, a precursor to the modern day technique of 
ambulatory  phlebectomy  originated  by  Swiss  dermatologist 
Robert Muller in the late 1960s. Primitive stripping and cauter-
ization, however, were practiced by Celsus, while ligation was 
mentioned by Antillus (30 AD).

In 1851, Pravaz attempted sclerotherapy with ferric chlo-
ride  using  his  new  invention,  the  hypodermic  syringe.  The 
foundation  of  modern  sclerotherapy  can  be  traced  to  World 
War I when Linser and Sicard both noticed the sclerosing effect 
of  intravenous  injections  used  to  treat  syphilis,  which  often 
resulted in vein sclerosis. Tournay greatly refined the sclero-
therapy technique in Europe and wrote the gold standard of 
textbooks. French physicians were leaders in the field of vein 
diagnosis and treatment, which evolved into the subspecialty 
of  phlebology.  It  was  not  until  1946,  when  a  safe  sclerosant, 
Sotradecol  (sodium  tetradecyl  sulfate)  had  been  tested  and 
described, that sclerotherapy began to be seriously studied in 
the United States (11).

Another key to success and acceptance of the treatment 
of varicose veins by sclerotherapy was the addition of com-
pression. The most significant contributions were European 
with  Sigg  and  Orbach  in  the  1950s  and  Fegan  in  the  1960s 
emphasizing the importance of combining external compres-
sion immediately following injections. Starting in the 1980s, 
Duffy  promoted  the  technique  in  the  United  States  among 
dermatologists  and  advocated  the  use  of  polidocanol  and 
hypertonic  saline  as  safe  and  effective  sclerosing  solutions 
(12).  The  first  endovenous  obliteration  technique   utilizing 
radiofrequency,  designed  as  a  substitute  for  ligation  and 
stripping of the greater saphenous vein, was researched and 
pioneered  by  dermatologic  surgeons  (6).  Subsequent  proce-
dures, including 1320 nm laser ablation, were also pioneered 
by  dermatologists,  and  these  ablative  procedures  have  now 
become  accepted  as  the  standard  for  treatment  of  saphe-
nous vein reflux (13). Utilization began in Europe in 1998 on 
saphenous vein incompetence, and the technique was made 
available in the United States in March 1999. Goldman’s first 
American  textbook  of  sclerotherapy  (now  in  its  5th   edition) 
(14) integrated the world’s phlebology literature, introduced 
new sclerosing solutions and validated dermatology’s claim 
to  expertise  in  vein  treatment  (15).  Several  additional  text-
books by dermatologic surgeons have now firmly established 
 phlebology,  which  includes  the  diagnosis  and  treatment 
of  spider  and  varicose  veins,  firmly  within  the  sphere  of 
 dermatology (16,17).

THERAPY OF TELANGIECTASIA AND VARICOSE VEINS AND THEIR COMPLICATIONS 

  313

VENOUS ANATOMY AND PHYSIOLOGY: THE 
KEY TO CHOOSING THE RIGHT TECHNIQUE
The superficial venous system consists of three primary ter-
ritories: the great saphenous vein, the small saphenous vein, 
and the subdermic lateral venous system. Due to gravitational 
hydrostatic  pressure,  sequential  retrograde  breakdown  of 
venous valve function often follows a leak at one point lead-
ing  to  propagation  of  a  varicosity  or  spider  vein.  All  veins 
regardless of their size contain valves (18). Increased diameter 
between valve leaflets with failure to oppose properly caused 
by  genetically  weak  venous  wall  or  venous  valve  structure 
may initiate these events (8). Calf muscle pump pressure plus 
gravitational  hydrostatic  forces  are  transmitted  directly  via 
the  incompetent  perforating  vein  or  communicating  veins 
to  the  surface  veins.  Venous  pressure  may  reach  as  high  as 
300  mmHg  in  the  cutaneous  venules  with  the  patient  erect. 
Transmission  of  pressure  may  result  in  venular  dilatation 
over  a  wide  area  of  skin  including  the  formation  of  telangi-
ectatic webs.

When  present  in  significant  quantity,  the  volume  of 
blood sequestered and stagnant in reticular veins and asso-
ciated telangiectatic webs (particularly of the lateral venous 
system) may cause enough distention to produce symptoms 
(19). Symptoms are relieved by the wearing of support hose 
or with rest and elevation of the legs. Prolonged standing or 
sitting  worsens  symptoms.  The  size  of  the  vessels  causing 
moderately severe symptoms may be as small as 1–2 mm in 
diameter.  Sclerotherapy  has  been  reported  to  yield  an  85% 
reduction  in  these  symptoms  as  well  as  superb  cosmetic 
results (19).

Contraindications to Treatment of Spider Veins
A high rate of recurrence for sclerotherapy is commonly seen 
when reflux originates at the major saphenous junctions. When 
reflux exists at the saphenofemoral junction, this must be dealt 
with  prior  to  treatment  of  distal  varicosities  or  telangiecta-
sias. Since the goal of sclerotherapy and other treatments is to 
eliminate reflux at its origin, the goal of noninvasive diagnos-
tic evaluation is to reveal the primary source of reverse flow. 
The  techniques  of  endovenous  occlusion  by  radiofrequency 
or  laser  have  been  developed  to  address  reflux  occurring  at 
the termination point of the saphenous veins. Over a decade 
of  experience  has  shown  that  radiofrequency  or  endovenous 
ablation  is  as  effective  as  the  surgical  techniques  of  ligation 
and stripping to eliminate saphenous and associated varicose 
veins (13,20).

Previous  urticaria  or  suspected  allergy  to  a  sclerosing 
agent should serve as a relative contraindication to use of that 
particular sclerosing agent. A history of deep venous throm-
bosis (DVT) or previous trauma to the leg (e.g. auto accident) 
should  preclude  sclerotherapy  until  adequately  evaluated  by 
Duplex  ultrasound.  Venous  treatment  is  contraindicated  in 
a  bedridden  patient  since  ambulation  is  important  for  mini-
mizing risks of thrombosis. Similarly, patients under general 
anesthesia  for  non-related  procedures  should  not  undergo 
simultaneous sclerotherapy. Severely restricted arterial flow to 
the legs necessitates postponement of vein treatment. During 
hot summer months, heat-induced vasodilatation and inability 
to comply with wearing of compression hose may also require 
postponement of treatment.

Pregnancy  is  no  longer  considered  a  contraindication 
to  sclerotherapy  and  extremely  painful  or  bleeding  varices 
may  be  treated  even  in  the  last  trimester  in  our  experience. 

Endovenous  techniques  may  be  employed  to  treat  refluxing 
saphenous veins in pregnancy. However, treatment is typically 
postponed  since  many  varicosities  and  telangiectasias  will 
spontaneously  clear  within  1–6  months  postpartum.  Obesity 
should  be  considered  a  relative  contraindication  since  main-
taining adequate external compression is difficult.

TREATMENT TECHNIQUES
Sclerotherapy or Endovenous 
Chemo-Ablation Techniques
General Principles
Progression  from  proximal  to  distal  regions  will  focus  ini-
tial  treatment  on  vessels  most  likely  to  be  proximal  pres-
sure  sources.  Thus  a  basic  principle  of  treatment  is  to  begin 
at  the  largest  (reflux  sources)  and  progress  to  the  smallest 
varicosities. Sclerotherapy of telangiectasias is approached by 
combined injection of visibly connected reticular veins, venu-
lectases, and telangiectatic webs or networks.

Reticular  veins  are  treated  only  after  all  sources  of 
reflux  from  major  varicosities  have  been  treated  by  sclero-
therapy and/or surgery. When no clear feeder vessel is seen or 
identified  by  duplex  ultrasound,  transillumination  (Veinlite, 
3Gen,  Dana  Point,  CA)  may  be  used.  Newer  handheld,  non-
contact devices that project infrared light can also be used to 
locate  and  map  feeding  reticular  veins  that  may  be  difficult 
to  see  with  the  naked  eye  (VeinViewer®,  Christie  Medical 
Holdings,  Inc.,  Memphis,  TN;  AV400  Vein  Viewing  System, 
AccuVein,  Inc.,  Huntington,  NY)  When  unable  to  locate  an 
associated reticular vein, then the point at which the telangi-
ectasias begin to branch out is the site at which to begin injec-
tion. Injection of telangiectasias is simultaneously performed 
with injection of reticular veins in the hopes of decreasing the 
number of treatments (21).

Technique of Sclerotherapy
Liquid Sclerotherapy 
The preferred method for treating telangiectasia to reduce side 
effects is to use a liquid, as opposed to foamed sclerosant (see 
below). The American dermatology technique of sclerotherapy 
has  been  described  in  detail  by  Duffy  and  Goldman  (12,22). 
The sclerotherapy tray is prepared with the necessary equip-
ment,  including  a  30-gauge  needle  bent  to  an  angle  of  10–30 
degrees with the bevel up, which is placed on the skin so that 
the needle is parallel to the skin surface. A 3-cc syringe filled 
with 0.5 cc of solution is held between the index and middle 
fingers  while  the  fourth  and  fifth  finger  support  the  syringe 
against the leg in a fixed position, facilitating accurate penetra-
tion of the vessel (Figure 34.1). The nondominant hand is used 
to stretch the skin around the needle and may offer additional 
support for the syringe. Magnifying lenses or operating loupes 
on the order of 1.5–3× are recommended to aid in cannulation 
of the smallest telangiectasias.

The initial treatment of telangiectatic webs begins with 
lowest possible concentration that will cause a telangiectasia 
to  sclerose  over  a  period  of  1–6  months  postinjection.  This 
typically  is  0.1%  sodium  tetradecyl  sulfate,  0.2%  polidocanol 
or compounded 72% glycerin diluted with 1% lidocaine with 
epinephrine  (1:100,000).  When  ineffective  sclerosis  occurs 
judged at a subsequent visit, the concentration but not the vol-
ume per site of sclerosing solution is increased. Post-treatment 
compression consists of graduated 20–30 mmHg support hose 
for 2 weeks for telangiectasia associated with reticular veins 
and  OTC  15  mmHg  compression  for  telangiectasias  only. 

 
314 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Treatment  intervals  vary  between  physicians,  but  allowing 
4–8  weeks  between  treatments  allows  time  for  resorption  of 
treated  telangiectasias  and  therefore  helps  to  minimize  the 
number  of  necessary  sessions.  Typical  results  are  shown  in 
Figure 34.2.

Sclerosing Solutions 
Sclerosing solutions have been classified into groups based on 
chemical  structure  and  effect:  hyperosmotic,  detergent,  and 
corrosive agents (chemical toxins – salts, alcohols, and acid or 
alkaline solutions). The distinct advantage of detergent agents 
is the ability to foam these solutions to use for larger varicosi-
ties. Table 34.1 summarizes the sclerosing agents.

Figure  34.1  Position  of  the  hands  for  sclerotherapy.  While  the 
dominant hand holds the syringe and creates a platform with the 
5th digit, the nondominant hand stretches the skin and acts as a 
support  for  the  needle  hub  so  that  fine  changes  in  position  are 
permitted.

Table 34.1  Comparison of Sclerosing Agents

(a)

(b)

Figure 34.2  Typical results following sclerotherapy of telangiec-
tasia. (a) Treatment with 0.1% STS. (b) Excellent clinical results at 
4-month follow-up.

Category

Advantages

Disadvantages

Vessels 
Treated

Sclerosing 
Solution

Sodium 

tetradecyl 
sulfate (STS)

Detergent

Polidocanol 
(POL)

Detergent

+ dextrose 
(HSD)
Sodium 

morrhuate

Glycerin (72% 
glycerin with 
1% lidocaine)

Polyiodinated 

iodine 
(Varigloban)

May be foamed
Low incidence of allergic 
reaction when used 
with Latex-free syringe

May cause skin 

All sizes

breakdown at higher 
concentrations

May be foamed
Forgiving with 

intradermal injection

May inadvertently be 

Small to 

injected into arteriole 
without pain

medium

Hypertonic saline 

Hyperosmolar

Not allergic

(HS)

Hypertonic saline 

Hyperosmolar

Less painful than HS

Ulcerogenic
Painful to inject

Relatively weak 
sclerosant

Small

Small

Detergent

None

Allergic reactions 

Small

highest

Treats matting
Low incidence of 
pigmentation

Chemical 
irritant

Chemical 
irritant

Powerful for largest veins

Avoid in iodine allergic 

Largest

patients

Very weak sclerosant

Smallest

Undiluted to ½ 

Concentrations (reduce 
concentrations for foamed 
solution by 50%)

0.1%–0.2% telangiectasias
0.2%–0.5% reticular
0.5%–1.0% varicose
1.0%–3.0% axial varicose

0.25%–0.5% telangiectasias
0.5%–1.0% reticular
1.0%–3.0% varicose

23.4%–11.7% telangiectasias
23.4% reticular

Undiluted–telangiectasias
Undiluted–reticular

Undiluted–telangiectasias
Undiluted–reticular

strength–telangiectasias

1%–2% for up to 5 mm veins
2%–6% for the largest veins

 
THERAPY OF TELANGIECTASIA AND VARICOSE VEINS AND THEIR COMPLICATIONS 

  315

Hypertonic Saline  Hypertonic saline (HS) is still a commonly 
employed  solution  (only  in  the  United  States)  in  spite  of  the 
extreme pain on injection and relatively low efficacy in vessels 
over 0.4 mm. We recommend against using this as a sclerosing 
solution.  Used  at  a  concentration  of  23.4%  (HS),  a  theoretical 
advantage of HS is its total lack of allergenicity when unadul-
terated. HS has been commonly used in various concentrations 
from 10%–30%, with occasional addition of heparin, procaine, 
or  lidocaine.  Additional  agents  typically  provide  no  benefit. 
Therefore, HS is used either unadulterated or diluted to 11.7% 
with sterile water for smaller telangiectasias (23,24).

With hypertonic solutions, damage of tissue adjacent to 
injection sites may easily occur. Skin necrosis may be produced 
by extravasation at the injection site, particularly when inject-
ing very close to the skin surface. HS is not one of our favorite 
solutions for this reason. Injection of hyaluronidase into sites 
of  extravasation  may  significantly  reduce  the  risks  of  skin 
necrosis with HS, although this has not been demonstrated in 
human clinical applications (24).

Hypertonic Saline and Dextrose  Hypertonic saline and dextrose 
(HSD)(Sclerodex®, Omega Laboratories Ltd., Montreal, Canada) 
is a viscous mixture of dextrose 250 mg/mL, sodium chloride 
100 mg/mL, propylene glycol 100 mg/mL, and phenethyl alco-
hol  8  mg/mL.  HSD  is  a  relatively  weak  sclerosant  for  local 
treatment  of  small  vessels,  with  a  total  volume  of  injection 
not to exceed 10 mL per visit, with 0.1 mL–1.0 mL per injection 
site.  HSD  is  marketed  predominately  in  Canada.  Although  a 
slight burning sensation occurs, pain is far less than with HS. 
Efficacy has been seen by us in over 5000 patients with excel-
lent  results  for  treatment  of  telangiectasias  and  small  associ-
ated reticular veins.

Polidocanol  Polidocanol  (POL)  (Asclera®,  Merz  Aesthetics, 
Frankfurt, Germany) is the first new sclerosing solution intro-
duced  in  the  United  States  since  1946.  It  was  FDA-cleared 
in  2010  in  concentrations  of  0.5%  and  1.0%,  and  prior  to  this 
was   available  in  the  United  States  only  through  compound-
ing   pharmacies.  The  detergent-based  POL,  a  urethane  com-
pound,  was  originally  developed  as  an  anesthetic  but  was 
found to have the property of sclerosing small diameter ves-
sels  after  intradermal  injection.  POL  contains  hydroxypolye-
thoxydodecane  dissolved  in  distilled  water  with  5%  ethanol 
as a stabilizer. First used as a sclerosing agent in the late 1960s 
in  Germany,  POL  is  popular  worldwide  for  smaller  vessels 
due  to  painless  injection  and  lowest  incidence  of  cutaneous 
necrosis  with  intradermal  injection.  Lower  concentrations 
of  POL  were  initially  suspected  to  have  a  lower  incidence  of 
 hyperpigmentation  than  HS  or  STS,  but  recent  clinical  trials 
indicate  a  significant  percentage  of  hyperpigmentation  also 
occurs (25). Australian comparison studies have preferred POL 
over STS with increased efficacy with fewer  complications (25).
POL is also available in a 1% foam that utilizes a proprie-
tary canister device to generate a consistent, low-nitrogen, sta-
ble small-bubble foam which is FDA-cleared for the treatment 
of great saphenous vein incompetence (Varithena®, Provensis 
Ltd., A BTG International group company, Conshohocken, PA) 
(26). Notably, compounded formulations of POL have recently 
been  found  to  have  largely  inconsistent  concentrations  and 
impurities,  and  such  non-branded  formulations  should  be 
avoided (27).

Sodium  Tetradecyl  Sulfate  Sodium  tetradecyl  sulfate  (STS) 
(Sotradecol®,  AngioDynamics,  Inc.,  Latham,  NY;  Fibrovein, 

STD  Pharmaceuticals,  UK;  Trombovar,  Omega  Labs, 
Montreal, Canada) is a long-chain fatty acid salt with strong 
detergent  properties  and  is  a  highly  effective  sclerosing 
agent used worldwide. Approved for use in the United States 
since 1946, it has been popular with vascular surgeons since 
the 1960s and first described for use in telangiectasias in the 
1970s.  A  relatively  high  incidence  of  postsclerosis  pigmen-
tation was reported at inappropriately high doses (1% STS). 
More  appropriate  concentrations  for  superficial  telangiecta-
sias  are  0.1%–0.3%.  Other  concentrations  are  0.2%–1.0%  in 
reticular veins or small varicosities (1–3 mm diameter), and 
0.5%–3% in larger varicosities related to major sites of valvu-
lar  reflux.  Recent  use  of  foamed  STS  indicates  that  half  the 
concentration  may  be  utilized  when  the  solution  is  frothed 
with air (see below).

Sodium Morrhuate  Sodium morrhuate (Scleromate®, Palisades 
Pharmaceuticals,  Inc.,  Tenafly,  NJ)  is  a  5%  solution  of  the 
salts  of saturated and  unsaturated  fatty acids  in cod liver  oil. 
Approximately  10%  of  its  fatty  acid  composition  is  unknown 
and use is limited by reports of fatalities secondary to anaphy-
laxis (15). Although sodium morrhuate is approved by the FDA 
for the sclerosis of varicose veins, use in treatment of telangi-
ectasias  is  not  common  and  cannot  be  recommended  due  to 
the caustic qualities with potential for cutaneous necrosis and 
higher risks of allergy. This agent is reserved primarily for scle-
rosis of esophageal varices.

Chemical  Irritants  The  chemical  irritants  include  polyiodin-
ated iodine (very caustic) and chromated glycerin (very weak) 
and are believed to have a direct toxic effect on the endothe-
lium. After injection of polyiodinated iodine salt, the endothe-
lium near the site of injection is destroyed within seconds. The 
corrosive action is limited due to rapid inactivation by blood 
proteins.  At  the  sites  of  endothelial  destruction  the  chemical 
can penetrate further and diffuse into deeper layers of the ves-
sel wall causing further destruction. These agents are not com-
mercially cleared by the U.S. FDA.

A preparation of 72% glycerin diluted 2:1 with 1% lido-
caine with epinephrine can be prepared by local compounding 
pharmacies. Glycerin without the chromate salt may work pri-
marily by osmotic injury. A commercial glycerin product has 
been reported to give a lower incidence of inflammation and 
subsequent pigmentation in smaller telangiectasias (28). In our 
experience in over 10,000 patients over the last 5 years, the 72% 
glycerin solution was the most effective at eliminating telangi-
ectatic matting and resistant telangiectasias. It is particularly 
effective  in  treating  smaller  residual  telangiectasias,  with  a 
greatly reduced incidence of matting and hyperpigmentation. 
Glycerin cannot be foamed.

Foam Sclerotherapy  Detergent agents such as POL and STS may 
be mixed with air to create a foamed sclerosing solution (29–33). 
Typically,  air  is  added  at  a  ratio  of  one  part  solution  to  3  to  4 
parts air. Agitation is performed by rapid transfer from syringe 
to  syringe  via  an  IV  stopcock  or  a  two-way  leur  lock  syringe 
connector. The advantages of foamed solutions for treatment of 
larger  vessels  include:  (1)  by  displacing  blood  in  the  vein,  the 
highest  concentration  of  sclerosant  is  always  contacting  ves-
sel  wall,  (2)  the  total  amount  of  sclerosant  injected  is  greatly 
reduced,  (3)  there  is  great   persistence  of  sclerosant  with  very 
slow washout, and (4) foamed  solutions can be used as a con-
trast  agent  under  Duplex  ultrasound,  making  Duplex-guided 
treatments easier and safer. An illustration of the persistence of 

 
316 

 TEXTBOOK OF COSMETIC DERMATOLOGY

foam is seen is Figure 34.3. Recently it was reported with POL 
that  the  foamed  version  is  far  more  potent  on  varicose  veins 
than the non-foamed of equal concentration (34).

Side Effects and Complications of Sclerotherapy
Postsclerotherapy Hyperpigmentation
Postsclerosis  pigmen-tation  is  defined  as  the  appearance  of 
increased  visible  pigmentation  along  the  course  of  a  treated 
vein of any size. Initially perivascular hemosiderin deposition 
and not increased melanin production causes this appearance 
(35). However, after several weeks to months the hemosiderin 
is replaced by melanin. The reason for persistence of pigmen-
tation  is  unknown.  The  incidence  of  pigmentation  is  related 
to dilution and type of sclerosing agent as well as diameter of 
treated  vessel  (36).  Pigmentation  incidence  ranges  from  11%–
30% using HS (18), 11%–30% with POL (12,37), and up to 30% 
with  STS.  The  incidence  of  pigmentation  may  be  reduced  in 
varicose veins by expressing the dark, viscous blood thought 
to be a liquefied coagulum or intravascular hematoma, which 
may accumulate 1–4 weeks following sclerotherapy. For those 
patients  highly  susceptible  to  pigmentation,  such  as  African-
American patients, the use of glycerin as a sclerosant agent is 
highly recommended.

Pigmentation  clears  in  70%  within  6  months  but  rarely 
persists for greater than a year (36,38). Attempts to hasten reso-
lution  of  pigmentation  have  been  mostly  unsuccessful  as  the 

(a)

(b)

Figure 34.3  Foam sclerotherapy. (a) Injection of foam. (b) Persistence 
of foamed sclerosant at 2 minutes post-injection.

pigment  is  dermal  hemosiderin  and  not  epidermal  melanin. 
Bleaching agents, exfoliants such as trichloroacetic acid or phe-
nol, cryotherapy, various lasers, and intense pulsed light have 
achieved  limited  success  (39,40).  The  Q-switched  ruby  laser 
has been found to be the most consistently effective for treat-
ment  of  postsclerosis  pigmentation  (41).  Our  experience  with 
multiple wavelengths of Q-switched lasers indicate that ruby, 
alexandrite, or Nd:YAG Q–switched lasers may be successfully 
applied to clear the pigmentation more rapidly. We have also 
noted improvement with a picosecond alexandrite device uti-
lizing a diffractive lens array handpiece.

Telangiectatic Matting
Telangiectatic matting is defined as the appearance of groups 
of  new,  fine  (<0.2  mm  diameter)  telangiectasias  surrounding 
or  replacing  a  previously  treated  area  in  a  blush-like  man-
ner. A retrospective analysis of over 2000 patients reports an 
incidence  of  16%  in  patients  treated  with  HS  and  POL  (42). 
Resolution usually occurs spontaneously within a 3–12 month 
period with 70%–80% spontaneous resolution within the first 
6 months (43).

Matting  may  also  occur  as  a  result  of  trauma  to  the  leg 
in association with pregnancy or hormonal therapy, or in scars 
around  previous  sites  of  surgical  stripping.  Predisposing  fac-
tors include predilection for certain areas of the leg, such as the 
medial  lower  thigh,  obesity,  hormonal  therapy  with  estrogen, 
family  history,  and  a  longer  history  of  telangiectasias  (42).  The 
relative  risk  factor  for  development  of  telangiectatic  matting  is 
3.17  times  greater  for  female  patients  taking  hormonal  supple-
ments  (44).  Successful  treatment  of  matting  with  a  pulsed-dye 
laser (PDL) is reportedly accompanied by temporary hyperpig-
mentation (45). The use of enhanced visualization with a cross-
polarized light source (Syris Scientific, LLC, Grey, MA) has been 
found to assist injection of sclerosing solution into telangiectatic 
matting.  Treatment  is  often  not  required  since  matting  will 
resolve spontaneously except when caused by a source of reflux 
superiorly.

Cutaneous Necrosis/Ulceration
Cutaneous ulceration may occur with all sclerosing solutions 
in  spite  of  the  most  skilled  technique.  Unavoidably,  a  tiny 
amount  of  sclerosing  solution  may  be  left  along  the  needle 
tract as the needle is withdrawn. Sclerosing solution may also 
leak out into the skin through the small puncture sites of ves-
sel  cannulation.  The  varicose  vein  may  have  a  fragile,  thin 
wall, with the injection causing rapid injury leading to sudden 
unexpected  rupture  with  perivascular  accumulation  of  scle-
rosant. Additionally, injection may inadvertently occur into a 
small arteriole associated with telangiectatic varicosities with 
resultant necrosis and ulceration.

When the dermatologic surgeon recognizes that extrava-
sation has occurred the risk for necrosis can be minimized by 
injecting normal saline in a ratio of 10:1 into the extravasation 
site. Extensive massage of small subcutaneous blebs to spread 
the trapped sclerosing agent as quickly as possible will mini-
mize prolonged blanching of the area. We have found that the 
application  of  topical  2%  nitroglycerine  paste  applied  imme-
diately to the suspected extravasation site greatly reduces the 
risks of necrosis but will not always prevent it.

Superficial Thrombophlebitis
This complication is most commonly mistaken for the normal 
nodular fibrosis (endosclerosis) that occurs with proper sclero-
therapy. After sclerotherapy, a nontender, nonpigmented, non-
erythematous fibrotic cord may normally be palpable along the 

 
THERAPY OF TELANGIECTASIA AND VARICOSE VEINS AND THEIR COMPLICATIONS 

  317

course of a treated 4–8 mm vein. This frequent finding is due 
to a liquefied intravascular hematoma with surrounding vein 
wall  sclerosis  and  is  not  a  thrombus.  In  contrast,  superficial 
thrombophlebitis is characterized clinically by a very tender, 
indurated, linear erythematous swelling. Incidence of superfi-
cial thrombophlebitis is quite variable, estimated at 0.01%–1% 
following  sclerotherapy  (46),  although  some  report  that  the 
incidence is higher than typically reported (47). Treatment con-
sists of leg elevation and/or compression and regular admin-
istration  of  aspirin  or  other  nonsteroidal  anti-inflammatory 
drugs. Extension of superficial thrombophlebitis into the deep 
system is extremely rare, so aggressive anticoagulation is not 
the usual course of therapy.

Pulmonary Embolism
Pulmonary emboli probably occur from extension of a super-
ficial  thrombus  into  the  deep  venous  system.  Evidence  of 
extension from superficial thrombus to deep thrombophlebitis 
should be treated promptly by anticoagulation. The incidence 
of pulmonary embolism has been associated with injection of 
large quantities of sclerosant at a single site. The incidence is 
extremely low with less than 1 in 40,000. We have not seen this 
complication in treatment of over 20,000 patients.

Arterial Injection
This  dreaded  medical  emergency  is  fortunately  extremely 
rare.  Classic  warning  signs  include  immediate  intense  pain 
far beyond the normal discomfort at the initiation of injection, 
although leakage of sclerosant into the arterial circulation may 
present  in  an  atypical  fashion.  Continuous  intense  burning 
pain  with  immediate  bone-white  cutaneous  blanching  over 
an area of several square centimeters is the usual initial sign. 
Progression to a sharply demarcated cyanosis within minutes 
is typical for arterial injection. Emergency treatment involves 
immediate  application  of  ice,  attempts  to  flush  the  inadver-
tently injected artery with normal saline and/or heparin, injec-
tion  of  3%  procaine  to  inactivate  STS,  and  vascular  surgery 
consultation for intravenous anticoagulation.

A  major  clinical  problem  is  that  arterial  injection  may 
rarely not be accompanied by any pain or cutaneous signs. The 
atypical cases are suspected to arise from arteriovenous mal-
formations  (AVMs),  which  allow  sclerosant  to  enter  the  arte-
rial system via the venous system (48). This is most commonly 
seen in the popliteal fossa. Arterial injection may lead to wide 
areas of skin necrosis and damage to subcutaneous tissue and 
muscle which take months to heal.

Neurologic Events
Neurologic  side  effects  are  a  rare  comp-lication  of  sclero-
therapy. In a recent review of 10,819 patients undergoing both 
liquid and foam sclerotherapy, 97 patients (0.90%) were found 
to experience neurologic events, including speech and visual 
disturbances,  migraines,  cerebrovascular  accidents  (CVAs) 
and transient ischemic attacks (TIAs) (49). In total, there were 
12 reported CVAs and 9 TIAs, occurring both with liquid and 
foamed sclerotherapy, with the majority of symptoms resolv-
ing  by  the  time  of  discharge.  These  events  are  hypothesized 
to  occur  secondary  to  sclerosant  particles  entering  the  cere-
bral  vasculature  via  a  patent  foramen  ovale  (PFO),  although 
not all affected patients have this malformation (49). In a sepa-
rate study of 3259 patients who underwent ultrasound-guided 
foam  sclerotherapy,  seven  (0.21%)  experienced  side  effects 
including  visual  disturbances,  migraines,  and  chest  discom-
fort, all of which resolved by 2 weeks (50). Notably, five of these 
patients  were  found  to  have  a  PFO.  Accordingly,  a  known 

symptomatic PFO is considered a contraindication to foamed 
sclerotherapy  by  the  2nd  European  Consensus  Meeting  on 
Foam Sclerotherapy (51). When a TIA or CVA is suspected dur-
ing  treatment, the patient  should be  placed  on oxygen  in  the 
office and transferred to a facility that administers hyperbaric 
oxygen (52–54).

Modern Minimally Invasive Surgical 
Approaches for Varicose Veins
Endovenous Occlusion Techniques
When  it  has  been  determined  by  ultrasound  that  the  origi-
nating  point  of  reverse  flow  or  reflux  is  the  great  saphenous 
vein  or  small  saphenous  vein,  endovenous  radiofrequency 
or  laser  techniques  are  the  treatment  of  choice.  The  efficacy 
for RF elimination of reflux is 90% at 2 years (55) and is now 
known to give similar results at 10 years follow-up (56). This 
method involves the placement of a catheter within the vari-
cose vein through a small puncture or incision. The catheter 
is threaded up to the saphenofemoral junction typically under 
duplex ultrasound guidance. Following placement of tumes-
cent local anesthesia between the vein and the skin and or in a 
perivenous location, energy is applied as the catheter is slowly 
withdrawn. This results in collagen shrinkage of the vein wall 
accompanied by complete occlusion (19). Midterm studies sug-
gest  a  very  favorable  comparison  to  traditional  ligation  and 
stripping with far less morbidity without the risks of general 
anesthesia (55).

The  other  endovenous  technique  involves  the  use  of 
laser  energy.  This  technique  is  termed  endovenous  laser 
treatment  (EVLT).  Very  similar  to  RF  occlusion,  this  tech-
nique involves the placement of a laser fiberoptic via a small 
puncture.  Wavelengths  presently  utilized  are  810  nm,  940 
nm,  and  980  nm.  The  newest  wavelength,  1320  nm,  which 
is absorbed only by water, has been shown to provide supe-
rior  results  (57).  The  primary  problem  with  wavelengths 
absorbed  by  hemoglobin  is  the  requirement  for  blood  for 
laser  absorption  (20).  This  leads  to  increased  risks  of  bruis-
ing, pain, and skin burns. A wavelength absorbed by water 
only  appears  to  eliminate  these  side  effects  by  contracting 
the vein with far less heat generation. Accordingly, endove-
nous laser ablation with a wavelength of 1320 nm (CTEVTM, 
CoolTouch Corporation, Roseville, CA) has become our pre-
ferred  modality  for  laser  ablation  and  recently  published 
long-term results have confirmed its superiority over alterna-
tive modalities (58).

A promising future treatment option for great saphenous 
insufficiency is a recently FDA-cleared injectable adhesive that 
works  to  seal  the  great  saphenous  vein  (VenaSealTM  Sapheon 
Closure  System,  Medtronic,  Inc.,  Dublin,  Ireland)  (59).  With 
this  system,  incompetent  great  saphenous  veins  are  treated 
with  an  endovenous  cyanoacrylate  adhesive,  injected  under 
ultrasound guidance without the need for tumescent anesthe-
sia  or  postoperative  compression  stockings.  Two-year  follow-
up data has been promising, with a 92% occlusion rate (59).

Surgical Ligation and Limited Stripping
For  larger  varicose  veins,  particularly  originating  from  an 
incompetent valve at the saphenofemoral junction, ligation of 
the greater saphenous vein with short stripping of its proxi-
mal  half  in  the  thigh  is  the  traditional  surgical  method  but 
has  been  replaced  by  endovenous  ablation  by  RF  or  laser. 
After  proximal  ligation  without  stripping  of  the  saphenous 
vein, varicography has shown persistent mid-thigh perforator 

 
318 

 TEXTBOOK OF COSMETIC DERMATOLOGY

incompetence in 34%, a patent portion of saphenous vein in 
54%, and residual or recurrent femoral–saphenous communi-
cation in 80% (60). High ligation combined with sclerotherapy 
or with varicosity excision was inferior to high ligation and 
stripping  of  the  saphenous  vein  (61).  The  technique  of  liga-
tion and stripping has virtually been replaced by endovenous 
techniques.

Ambulatory Phlebectomy
This  technique,  originally  described  by  Robert  Muller  and 
further  refined  by  another  Swiss  dermatologist,  Albert-
Adrien  Ramelet,  involves  the  use  of  tiny  incisions  through 
which the varicose vein is removed by a small hook (62,63). 
This  safe,  outpatient  local-anesthesia  technique  allows 
removal of almost any varicose vein except the saphenofem-
oral or saphenopopliteal junction. Ambulatory phlebectomy 
is  used  for  primary  or  secondary  branches  of  saphenous-
related  varicosities.  Areas  or  veins  that  are  resistant  to 
sclerotherapy  (axial)  are  particularly  indicated  for  ambula-
tory phlebectomy (Figure 34.4). Risks minimized compared 
with  sclerotherapy  are  DVT,  postsclerotherapy  pigmenta-
tion,  skin  necrosis,  and  superficial  phlebitis.  In  many  cases 
larger  varicose  veins  coexist  with  smaller  reticular  veins 
and  associated  telangiectatic  webs.  It  is  reasonable  to  treat 

(a)

(b)

Figure 34.4  Ambulatory phlebectomy of a large truncal varicose 
vein. (a) Before. (b) After AP and endovenous RF occlusion of the 
great  saphenous  vein.  It  is  important  to  eliminate  the  source  of 
reflux into this vein concomitant with the ambulatory phlebectomy 
of this primary branch arising from the great saphenous vein.

larger  varicose  veins  by  various  surgical  techniques  and 
follow  up  with  sclerotherapy  of  the  remaining  reticular 
networks.

Lasers and Light Sources
New trends for improved results with lasers and light sources 
for spider veins include longer wavelengths, larger spot sizes, 
and  cooling  to  protect  the  skin.  The  first  report  of  1064-nm 
Nd:YAG  laser  indicated  that  75%  improvement  was  possi-
ble  after  a  single  treatment  at  3  months  (64).  These  findings 
were confirmed and mechanism of action explained as heat-
induced  vessel  damage  and  subsequent  fibrosis  (65).  Recent 
reports also indicate the effectiveness of a 940-nm diode laser 
(66). Shorter wavelengths used in the past, like PDL, are use-
ful on fine leg telangiectasias, such as telangiectatic matting, 
especially with longer pulse durations up to 40 milliseconds. 
A broadband, noncoherent intense pulsed light (IPL) has been 
reported  to  improve  70%  of  patients  responding  with  up  to 
five treatments per region (67). In our practice, the vast major-
ity of laser treatments are performed using 1064-nm Nd:YAG 
in the millisecond domain on isolated telangiectasias, sclero-
therapy-resistant  telangiectasias,  ankle  telangiectasias,  and 
suspected  AVMs.  We  also  use  PDL  for  fine  telangiectasias, 
especially using an elliptical optical spot at 10 milliseconds or 
longer which can be oriented along the long axis of telangiec-
tasia of the leg (68).

SUMMARY
Phlebology is an integral part of dermatological surgery. The 
method of endovascular chemoablation or sclerotherapy is the 
gold standard for treatment of telangiectasias and small vari-
cosities. A supplemental technique for telangiectasias is laser. 
Larger  veins  that  originate  from  saphenous  reflux  require 
endovenous  RF  or  laser  techniques  for  effective  treatment. 
These  techniques  replace  traditional  stripping  and  ligation. 
Primary or secondary branches of saphenous varicosities can 
be  treated  by  ambulatory  phlebectomy  or  the  newest  tech-
nique of foam sclerotherapy.

REFERENCES

1. Weiss RA, Weiss MA, Goldman MP. Physicians’ negative per-
ception  of  sclerotherapy  for  venous  disorders:  Review  of  a 
7-year experience with modern sclerotherapy. South Med J 1992; 
85:1101–6.

2.  Weiss RA, Goldman MP. Advances  in sclerotherapy.  Dermatol 

Clin 1995; 13(2):431–45.

3.  Goldman  MP,  Weiss  RA,  Bergan  JJ.  Diagnosis  and  treatment 
of varicose veins - a review [review]. J Am Acad Dermatol 1994; 
31(3:Part 1):393–413.

4.  Weiss  RA,  Weiss  MA.  Ambulatory  phlebectomy  compared 
to  sclerotherapy  for  varicose  and  telangiectatic  veins: 
Indications  and  complications.  Adv  Dermatol  1996;  11:3–16; 
discussion 7.

5.  Weiss  RA.  Endovenous  techniques  for  elimination  of  saphe-
nous reflux: A valuable treatment modality. Dermatol Surg 2001; 
27(10):902–5.

6.  Goldman  MP.  Closure  of  the  greater  saphenous  vein  with 
endoluminal radiofrequency thermal heating of the vein wall 
in  combination  with  ambulatory  phlebectomy:  Preliminary 
6-month follow-up. Dermatol Surg 2000; 26(5):452–6.

7.  Biegeleisen  K.  Primary  lower  extremity  telangiectasias  rela-

tionship of size to color. Angiology 1987; 38:760–8.

8.  Golledge  J,  Quigley  FG.  Pathogenesis  of  varicose  veins.  Eur  J 

Vasc Endovasc Surg 2003; 25(4):319–24.

 
 
 
 
 
 
 
 
THERAPY OF TELANGIECTASIA AND VARICOSE VEINS AND THEIR COMPLICATIONS 

  319

9.  Engel  A,  Johnson  ML,  Haynes  SG.  Health  effects  of   sunlight 
exposure  in  the  United  States:  Results  from  the  first  national 
1971–1974. 
health 
Arch Dermatol 1988; 124:72–9.

and  nutrition 

examination 

survey, 

  10.  Lofgren  KA.  Varicose  veins:  Their  symptoms,  complications, 

and management. Postgrad Med 1979; 65(6):131–9.

  11.  Cooper WM. Clinical evaluation of sotradecol, a sodium alkyl 
sulfate solution, in the injection therapy of varicose veins. Surg 
Gynecol Obstet 1946; 83:647–52.

  12.  Duffy  DM.  Small  vessel  sclerotherapy:  An  overview. 

Adv Dermatol 1988; 3:221–42.

  13.  Ravi R, Trayler EA, Barrett DA, Diethrich EB. Endovenous ther-
mal  ablation  of  superficial  venous  insufficiency  of  the  lower 
extremity: Single-center experience with 3000 limbs treated in 
a 7-year period. J Endovascular Ther 2009; 16(4):500–5.

  14.  Goldman MP. Sclerotherapy: Treatment of Varicose and Telangiectic 

Leg Veins, 5th edn. Saunders, 2011.

  15.  van HE, Liasis N, van RB, Moll FL. The development of valvu-
lar incompetence after deep vein thrombosis: A 7 year follow-
up study with duplex scanning. Eur J Vasc Endovasc Surg 1996; 
12(3):295–9.

  16.  Weiss RA, Feied CF, Weiss MA. Vein Diagnosis and Treatment: A 
Comprehensive Approach. New York: McGraw-Hill, 2001.
  17.  Sadick  NS.  Manual  of  Sclerotherapy.  Philadelphia:  Lippincott 

Williams & Wilkins, 2000.

  18.  Scultetus AH, Villavicencio JL, Rich NM. Facts and fiction sur-
rounding the discovery of the venous valves. J Vasc Surg 2001; 
33(2):435–41.

  19.  Weiss RA, Weiss MA. Resolution of pain associated with vari-
cose and telangiectatic leg veins after compression sclerother-
apy. J Dermatol Surg Oncol 1990; 16(4):333–6.

  20.  Weiss  RA.  Comparison  of  endovenous  radiofrequency  versus 
810 nm diode laser occlusion of large veins in an animal model. 
Dermatol Surg 2002; 28(1):56–61.

  21.  Weiss  RA,  Weiss  MA.  Painful  telangiectasias:  Diagnosis  and 
treatment. In: Bergan JJ, Weiss RA, Godman MP, eds. Varicose 
Veins  and  Telangiectasias:  Diagnosis  and  Treatment,  2nd  edition. 
St. Louis: Quality Medical Publishing, 1999; pp. 389–406.
  22.  Goldman  MP,  Bennett  RG.  Treatment  of  telangiectasia:  A 

review. J Am Acad Dermatol 1987; 17:167–82.

  23.  Sadick NS. Sclerotherapy of varicose and telangiectatic leg veins. 
Minimal sclerosant concentration of hypertonic saline and its 
relationship to vessel diameter [see comments]. J Dermatol Surg 
Oncol 1991; 17(1):65–70.

  24.  Zimmet  SE.  The  prevention  of  cutaneous  necrosis  following 
extravasation of hypertonic saline and sodium tetradecyl sul-
fate. J Dermatol Surg Onc 1993; 19:641–6.

  25.  Conrad  P,  Malouf  GM,  Stacey  MC.  The  Australian  polidoca-
nol  (aethoxysklerol)  study.  Results  at  1  year.  Phlebology  1994; 
9(1):17–20.

  26.  Carugo  D,  Ankrett  DN,  Zhao  X,  Zhang  X,  Hill  M,  O’Byrne  V, 
et al. Benefits of polidocanol endovenous microfoam (Varithena®) 
compared  with  physician-compounded  foams.  Phlebology  2016; 
31(4):283–95.

  27.  Weiss RA, Voigts R, Howell DJ. Absence of concentration con-
gruity in six compounded polidocanol samples obtained for leg 
sclerotherapy. Dermatol Surg 2011; 37(6):812–5.

  28.  Georgiev  M.  Postsclerotherapy  hyperpigmentations.  Chro-
mated glycerin as a screen for patients at risk (a retrospective 
study). J Dermatol Surg Oncol 1993; 19(7):649–52.

  29.  Belcaro  G,  Cesarone  MR,  Di  Renzo  A,  Brandolini  R,  Coen  L, 
Acerbi G, et al. Foam-sclerotherapy, surgery, sclerotherapy, and 
combined treatment for varicose veins: A 10-year, prospective, 
randomized,  controlled,  trial  (VEDICO  trial).  Angiology  2003; 
54(3):307–15.

  30.  Frullini A, Cavezzi A. Sclerosing foam in the treatment of vari-
cose  veins  and  telangiectases:  History  and  analysis  of  safety 
and complications. Dermatol Surg 2002; 28(1):11–5.

  31.  Frullini  A.  New  technique  in  producing  sclerosing  foam  in  a 

disposable syringe. Dermatol Surg 2000; 26(7):705–6.

  32.  Sadoun S, Benigni JP. Bonnes pratiques cliniques et mousse de 
sclérosant: Propositions pour une étude randomisée contrôlée, 
prospective,  multicentrique,  comparative,  en  aveugle,  sur  le 
traitement  sclérosant  par  la  mousse  d’aetoxisclérol  à  0,20%. 
Phlebologie 1999; (3):291–8.

  33.  Tessari L, Cavezzi A, Frullini A. Preliminary experience with 
a  new  sclerosing  foam  in  the  treatment  of  varicose  veins. 
Dermatol Surg 2001; 27(1):58–60.

  34.  Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of 
great saphenous vein sclerotherapy using standardised polido-
canol foam (ESAF): A randomised controlled multicentre clini-
cal trial. Eur J Vas Endovasc Surg 2008; 35(2):238–45.

  35.  Goldman MP, Kaplan RP, Duffy DM. Postsclerotherapy hyper-
pigmentation:  A  histologic  evaluation.  J  Dermatol  Surg  Oncol 
1987; 13:547–50.

  36.  Weiss RA, Weiss MA. Incidence of side effects in the treatment 
of  telangiectasias  by  compression  sclerotherapy:  Hypertonic 
saline vs. polidocanol. J Dermatol Surg Oncol 1990;16(9):800–4.

  37.  Goldman  PM.  Sclerotherapy  for  superficial  venules  and  tel-
angiectasias  of  the  lower  extremities.  Dermatol  Clin  1987; 
5:369–79.

  38.  Georgiev  M.  Postsclerotherapy  hyperpigmentations:  A  one-
year follow-up. J Dermatol Surg Oncol 1990; 16(7):608–10.
  39.  Thibault  P,  Wlodarczyk  J.  Postsclerotherapy  hyperpigmenta-
tion. The role of serum ferritin levels and the effectiveness of 
treatment  with  the  copper  vapor  laser.  J  Dermatol  Surg  Oncol 
1992; 18:47–52.

  40.  Goldman MP. Postsclerotherapy hyperpigmentation. Treatment 
with a flashlamp-excited pulsed dye laser. J Dermatol Surg Oncol 
1992; 18(5):417-22.

  41.  Tafazzoli  A,  Rostan  EF,  Goldman  MP.  Q-switched  ruby  laser 
treatment  for  postsclerotherapy  hyperpigmentation.  Dermatol 
Surg 2000; 26(7):653–6.

  42.  Davis LT, Duffy DM. Determination of incidence and risk fac-
tors  for  postsclerotherapy  telangiectatic  matting  of  the  lower 
extremity: A retrospective analysis. J Dermatol Surg Oncol 1990; 
16:327–30.

  43.  Goldman  MP,  Sadick  NS,  Weiss  RA.  Cutaneous  necrosis,  tel-
angiectatic matting, and hyperpigmentation following sclero-
therapy. Etiology, prevention, and treatment. [review]. Dermatol 
Surg 1995; 21(1):19–29.

  44.  Weiss MA, Weiss RA. Efficacy and side effects of 0.1% sodium 
tetradecyl  sulfate  in  compression  scleortherapy  of  telangiec-
tasias:  Comparison  to  1%  polidocanol  and  hypertonic  saline. 
J Dermatol Surg Oncol 1991; 17:90–1.

  45.  Goldman MP, Fitzpatrick RE. Pulsed-dye laser treatment of leg 
telangiectasia:  With  and  without  simultaneous  sclerotherapy. 
J Dermatol Surg Oncol 1990; 16:338–44.

  46.  Goldman MP. Sclerotherapy treatment for varicose and telangi-
ectatic leg veins. In: Coleman WP, Hanke CW, Alt TH, Asken S, 
eds. Cosmetic Surgery of the Skin. Philadelphia: Decker; 1991; pp. 
197–211.

  47.  Feied CF. Deep vein thrombosis: The risks of sclerotherapy in 
hypercoagulable states. Semin Dermatol 1993; 12:135–49.
  48.  Bergan  JJ,  Weiss  RA,  Goldman  MP.  Extensive  tissue  necrosis 
following high-concentration sclerotherapy for varicose veins. 
Dermatol Surg 2000; 26(6):535–41.

  49.  Sarvananthan  T,  Shepherd  AC,  Willenberg  T,  Davies  AH. 
Neurological complications of sclerotherapy for varicose veins. 
J Vasc Surg 2012; 55(1):243–51.

  50.  Raymond-Martimbeau  P.  Transient  adverse  events  positively 
associated with patent foramen ovale after ultrasound-guided 
foam sclerotherapy. Phlebology 2009; 24(3):114–9.

  51.  Breu  FX,  Guggenbichler  S,  Wollmann  JC.  2nd  European 
Consensus  Meeting  on  Foam  Sclerotherapy  2006,  Tegernsee, 
Germany.  VASA  Zeitschrift  Gefasskrankheiten  2008;  37(Suppl 
71):1–29.

  52.  Bush  RG,  Derrick  M,  Manjoney  D.  Major  neurological  events 
following foam sclerotherapy. Phlebology 2008; 23(4):189–92.

 
 
320 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  53.  Regan JD, Gibson KD, Rush JE, Shortell CK, Hirsch SA, Wright 
DD. Clinical significance of cerebrovascular gas emboli  during 
polidocanol  endovenous  ultra-low  nitrogen  microfoam  abla-
tion  and  correlation  with  magnetic  resonance  imaging  in 
patients with right-to-left shunt. J Vasc Surg 2011; 53(1):131–7.

  54.  Dexter  F,  Hindman  BJ.  Recommendations  for  hyperbaric 
 oxygen therapy of cerebral air embolism based on a mathemati-
cal model of bubble absorption. Anesth Analg 1997; 84(6):1203–7.
  55.  Weiss RA, Weiss MA. Controlled radiofrequency endovenous 
occlusion using a unique radiofrequency catheter under duplex 
guidance to eliminate saphenous varicose vein reflux: A 2-year 
follow-up. Dermatol Surg 2002; 28(1):38–42.

  56.  Nijsten  T,  van  den  Bos  RR,  Goldman  MP,  Kockaert  MA, 
Proebstle TM, Rabe E, et al. Minimally invasive techniques in 
the treatment of saphenous varicose veins. J Am Acad Dermatol 
2009; 60(1):110–9.

  57.  Goldman MP, Mauricio M, Rao J. Intravascular 1320-nm laser 
closure of the great saphenous vein: A 6- to 12-month follow-up 
study. Dermatol Surg 2004; 30(11):1380–5.

  58.  Weiss RA, Weiss MA, Eimpunth S, Wheeler S, Udompunturak S, 
Beasley  KL.  Comparative  outcomes  of  different  endove-
nous  thermal  ablation  systems  on  great  and  small  saphenous 
vein  insufficiency:  Long-term  results.  Lasers  Surg  Med  2015; 
47(2):156–60.

  59.  Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle 
TM.  Two-year  follow-up  of  first  human  use  of  cyanoacry-
late  adhesive  for  treatment  of  saphenous  vein  incompetence. 
Phlebology 2014.

  60.  Corbett CR, Runcie JJ, Lea Thomas M, Jamieson CW. Reasons to 
strip the long saphenous vein. Phlebology 1988;41:766–9.
  61.  Neglen  P.  Treatment  of  varicosities  of  saphenous  origin: 
Comparison  of  ligation,  selective  excision,  and  sclerotherapy. 
In: Bergan JJ, Goldman MP, eds. Varicose Veins & Telangiectasias: 
Diagnosis and Management. St. Louis: Quality Medical, 1993; pp. 
148–65.

  62.  Ramelet  AA.  Muller  phlebectomy.  A  new  phlebectomy  hook. 

J Dermatol Surg Oncol 1991; 17:814–6.

  63.  Ramelet AA. Le Traitement des telangiectasies: Indications de 
la phlebectomie selon Muller. Phlebology 1995; 47(4):377–81.
  64.  Weiss  RA,  Weiss  MA.  Early  clinical  results  with  a  multiple 
synchronized pulse 1064 NM laser for leg telangiectasias and 
reticular veins. Dermatol Surg 1999; 25(5):399–402.

  65.  Sadick  NS,  Prieto  VG,  Shea  CR,  Nicholson  J,  McCaffrey  T. 
Clinical  and  pathophysiologic  correlates  of  1064-nm  Nd:Yag 
laser  treatment  of  reticular  veins  and  venulectasias.  Arch 
Dermatol 2001; 137(5):613–7.

  66.  Kaudewitz  P,  Klovekorn  W,  Rother  W.  Effective  treatment  of 
leg vein telangiectasia with a new 940 nm diode laser. Dermatol 
Surg 2001; 27(2):101–6.

  67.  Goldman MP, Eckhouse S. Photothermal sclerosis of leg veins. 
ESC Medical Systems, LTD Photoderm VL Cooperative Study 
Group. Dermatol Surg 1996; 22(4):323–30.

  68.  Galeckas  KJ.  Update  on  lasers  and  light  devices  for  the 
treatment  of  vascular  lesions.  Semin  Cutan  Med  Surg  2008; 
27(4):276–84.

 
35

Management of Hirsutism and Hypertrichosis

Ralph M. Trüeb and Daisy Kopera

INTRODUCTION
The queen [of Sheba] was brought before him, and when she 
saw the king [Solomon] sitting in his glass house, she thought 
within  herself  that  the  king  sat  on  water,  and  so  proceeded 
to draw up the hem of her dress so that she could pass over 
without  getting  wet.  The  king  then  saw  her  legs  that  they 
were  full  of  hair,  and  when  the  queen  had  sat  down  beside 
him,  he  said  unto  her,  “Thy  beauty  is  the  beauty  befitting 
women, but thy hairs are the hairs befitting men. Hair on a 
man’s body is comely, but uncomely on a woman’s.” Now the 
king greatly desired her beauty, but was taken aback by the 
hair on her legs, and so it was that he devised a method by 
which unwanted hairs may be removed, that is, by taking an 
admixture  of  lime  and  water  and  orpiment  [arsenic  trisul-
fide], which the king himself discovered and made known its 
usage abroad, calling it neskasir. When the queen had bathed 
herself that night in its solution, the hair on her legs fell off, 
and she found favor in the eyes of the king (from the Midrash 
Book of Proverbs).

Throughout  the  history  of  civilized  mankind,  over-
growth of hair has been of significant concern, the object of 
superstition and mystery, as well as of cosmetic and medical 
interest. Excessive hair may cause cosmetic embarrassment, 
resulting  in  a  significant  emotional  burden,  particularly  if 
extensive. Sometimes the complaint of excess hair may pose 
a  vexing  problem  for  nonspecialized  physicians,  who  tend 
to  trivialize  the  complaint,  though  an  individual’s  percep-
tion of abnormality is important in determining whether or 
not medical care is sought. Besides significant racial and eth-
nic  differences  in  normal  hair  growth  patterns,  the  role  of 
society  is  to  set  the  threshold  level  for  “normality,”  which 
is  much  determined  by  advertisement  for  cosmetic  treat-
ments.  With  the  advent  of  effective  laser  epilation  devices 
this increasingly also applies to the perception of excess hair 
by men.

No single method of hair removal is appropriate for all 
body  locations  or  patients,  therefore  patients  should  be  ade-
quately advised of the available treatment modalities for tem-
porary  or  permanent  hair  removal.  The  method  adopted  for 
removal of unwanted hair will depend on the cause, the char-
acter, area, and amount of excessive hair growth, as well as on 
the age of the patient, and personal preference (1–3).

CAUSES OF EXCESSIVE HAIR
Hirsutism
Hirsutism  is  characterized  by  androgen-dependent,  exces-
sive  growth  of  terminal  hairs  in  women  in  a  pattern  more 
characteristic of adult men. Such androgen-dependent areas 
include  the  chin,  upper  lip,  chest,  breasts,  abdomen,  back, 
and  anterior  thighs  (Figure  35.1).  Objective  assessment  of 

hirsutism can be obtained by evaluation and grading of hair 
growth and distribution according to the Ferriman-Gallwey 
(F-G) scale (Figure 35.2). The F-G score quantifies the extent 
of  hair  growth  in  nine  key  anatomic  sites,  which  is  graded 
using  a  scale  from  0  (no  terminal  hair)  to  4  (complete  and 
heavy  cover),  for  a  maximum  score  of  36  (4).  Hirsutism  is 
defined  by  a  score  of  8  or  more.  Approximately  5%  to  10% 
of women of reproductive age in the general population are 
hirsute,  assessed  as  having  a  F-G  score  of  8  or  more  (5).  A 
1993  market  survey  of  25,000  women  in  the  United  States 
concluded  that  41%  of  women  remove  unwanted  hair  and 
22%  remove  facial  hair  on  a  weekly  basis  (6).  But  far  from 
being  only  a  cosmetic  problem,  hirsutism  may  be  a  marker 
for  an  underlying  hormonal  disorder,  and  identification  of 
the  underlying  etiology  helps  to  detect  patients  at  risk  for 
infertility,  diabetes  mellitus,  cardiovascular  disease,  and 
endometrial carcinoma (6).

Hirsutism  results  from  either  an  exogenous  or  endog-
enous  increase  in  circulating  androgens  or  from  individu-
ally  increased  sensitivity  (metabolism)  of  the  hair  follicle  to 
normal  serum  androgen  levels.  Exogenous  sources  include 
androgenic  medications,  such  as  oral  contraceptives  with 
androgenic  progestins  (norgestrel,  levonorgestrel,  norethin-
drone), anabolic steroids (danazol), high-dose glucocorticoids, 
androgen  therapy  (testosterone),  and  valproic  acid  (raises 
plasma testosterone). Endogenous androgens in women arise 
from the ovary or adrenal glands, and peripherally from the 
skin and fat. There is thought to be considerable heterogeneity 
of responses among androgen-dependent follicles in different 
individuals  (7).  Therefore,  the  clinical  severity  of  hirsutism 
does not always correlate well with expected levels of circu-
lating androgens.

Seventy  to  eighty  percent  of  patients  with  androgen 
excess demonstrate hirsutism (8), with the most common cause 
being polycystic ovary syndrome (PCOS). Up to 6% of women 
overall  are  affected  by  PCOS  in  whom  hirsutism  is  the  most 
common  symptom.  PCOS  represents  a  syndrome  of  hyper-
androgenic  anovulation  that  is  due  to  an  intrinsic  ovarian 
dysfunction,  which  is  often  aggravated  by  insulin-resistant 
hyperinsulinemia with its risks of diabetes mellitus, metabolic 
syndrome,  and  their  complications  (9).  Other,  less  frequent 
causes  of  androgen  excess  are  late  onset  congenital  adrenal 
hyperplasia,  Cushing  syndrome,  and  hyperandrogenism, 
insulin  resistance,  and  acanthosis  nigricans  (HAIR-AN)  syn-
drome (Figure 35.3). Pituitary, ovarian, and adrenal tumors are 
important but rare causes of hirsutism.

Hirsutism  is  deemed  idiopathic  where  it  develops  in 
the absence of detectable androgen excess and in conjunction 
with  regular  ovulation.  It  accounts  for  less  than  20%  of  hir-
sute women (5). The definition of idiopathic hirsutism has been 

322 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(c)

(e)

(b)

(d)

Figure 35.1  Hirsutism: excessive growth of terminal hairs in androgen-dependent areas: (a) chin, (b) chest, (c) abdomen, (d) thighs, and 
(e) lower back. (From Trüeb RM, Haare Praxis der Trichologie, Darmstadt, Germany: Steinkopff, 2003.)

an evolving concept, since normal androgen levels have been 
defined  by  conventional  laboratory  tests,  while  more  sophis-
ticated  testing  methods  may  uncover  occult  ovarian  or  adre-
nal functional hyperandrogenism in quite a number of these 
patients (10).

Hypertrichosis
Hypertrichosis  is  the  term  used  for  excess  growth  of  hair 
 compared  to  the  “normal”  amount  of  hair  in  persons  of  the 
same age,  ethnicity,  and  sex,  in  any  part  of  the  body,  exclud-
ing androgen-induced hair growth (11). It may involve lanugo 
(hypertrichosis  lanuginosa),  vellus,  or  terminal  hairs,  and 
is  classified  on  the  basis  of  the  age  of  onset  (congenital  or 

acquired),  the  extent  of  distribution  (generalized  or  circum-
scribed),  and the  site  involved (12). In both its generalized and 
circumscribed forms, hypertrichosis may be an isolated finding, 
or be associated with other abnormalities. For instance, lumbosa-
cral hypertrichosis (Figure 35.4) frequently indicates occult spinal 
defects, and it is essential that this possibility should be excluded 
as early as possible, if neurologic sequels are to be prevented.

Universal  congenital  hypertrichosis  (Figure  35.5)  is  a 
rare  and  particularly  dramatic  familial  disorder.  In  former 
times  such  individuals  were  sought  after  by  sovereigns  to 
adorn their courts, or exhibited by showmen to satisfy the curi-
osity of the public. Since the first well-documented observation 
concerns  a  man  named  Petrus  Gonsalvus,  born  in  1556,  and 

 
MANAGEMENT OF HIRSUTISM AND HYPERTRICHOSIS 

 323

Figure  35.3  HAIR-AN:  woman  with  hirsutism  and  acanthosis 
nigricans of the lateral neck area. (From Trüeb RM, Haare Praxis 
der Trichologie, Darmstadt, Germany: Steinkopff, 2003.)

the 
Figure  35.4  Lumbosacral  hypertrichosis  should  draw 
attention  to  the  possibility  of  underlying  spinal  dysraphism  with 
potential neurologic sequels. (From Trüeb RM, Haare Praxis der 
Trichologie, Darmstadt, Germany: Steinkopff, 2003.)

Figure  35.5  Universal  congenital  hypertrichosis  or  Ambras  syn-
drome: congenital generalized vellus-type hair hypertrichosis.

1

2

3

4

Figure 35.2  Ferriman-Gallwey score: hair growth is rated from 
0  (no  growth  of  terminal  hair)  to  4  (complete  and  heavy  cover) 
in  nine  locations,  giving  a  maximum  score  of  36.  (Adapted  from 
Trüeb  RM,  Haare  Praxis  der  Trichologie,  Darmstadt,  Germany: 
Steinkopff,  2003;  Ferriman  D,  Gallwey  JD,  J  Clin  Endocrinol 
Metab; 21:1440–7, 1961.)

his family, whose portraits are shown in the castle of Ambras 
near Innsbruck, Austria, the term Ambras syndrome has been 
coined for this disorder (13). The whole body is covered with 
a  remarkable  amount  of  long,  vellus-type  hair,  sparing  only 
areas  in  which  ordinarily  no  hair  grows,  including  palms, 
soles,  and  mucosae.  The  forehead,  eyelids,  nose,  cheeks  and 
preauricular region are uniformly covered with hair, reaching 
a  length  of  several  centimeters.  The  hair  is  light-colored  and 
silky;  only  the  scalp  hair,  eyebrows,  eyelashes  and  the  axil-
lary hair are darker. No decrease of hairiness during later life 
occurred in any of the well-documented cases.

Prepubertal  hypertrichosis  (Figure  35.6)  is  a  general-
ized  terminal  hair  hypertrichosis  affecting  healthy  children 
(14). There is hair growth on the temples spreading across the 
forehead, bushy eyebrows, and marked growth of hair on the 
upper back and proximal limbs. The condition is usually noted 

 
324 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 35.7  Acquired generalized terminal hair hypertrichosis in 
POEMS syndrome. (From Trüeb RM, Haare Praxis der Trichologie, 
Darmstadt, Germany: Steinkopff, 2003.)

endocrine  dysfunction,  monoclonal  gammopathy,  and  skin 
changes)  syndrome  (Figure  35.7)  (17).  This  particular  type  of 
hypertrichosis  producing  terminal  hair  is  most  common  on 
the extensor surfaces, malar areas, and forehead.

Finally,  several  drugs  are  well  known  to  cause  signifi-
cant  generalized  hypertrichosis,  the  most  frequent  currently 
being  corticosteroids,  phenytoin  sodium,  cyclosporin  A,  and 
minoxidil  (Figure  35.8)  (11).  Discontinuation  of  the  offending 
drug leads to resolution of drug-induced hypertrichosis within 
several months to 1 year, depending on the hair cycling charac-
teristics of the affected site (face, 3 months; arms, 1 year).

MANAGEMENT OF EXCESSIVE HAIR
Accurate  classification  of  excess  hair  must  precede  treatment 
and  includes  characterization  of  the  type  of  hair  involved 
(lanugo,  vellus,  terminal),  characterization  of  the  pattern  of 
hair  growth  (generalized  or  circumscribed  hypertrichosis, 
hirsutism),  age  at  initial  manifestation  (congenital,  acquired), 
patient  history  with  regard  to  systemic  disorders  or  drug 
intake, physical examination for associated abnormalities, and 
family  history,  including  ethnic  and  racial  background  (11). 
It  must  always  be  kept  in  mind  that  hair  overgrowth,  either 
hirsutism or hypertrichosis, may be a manifestation of a more 
general medical problem that needs to be investigated. Testing 
of androgen levels is recommended in women with moderate 
to  severe  hirsutism  (F-G  score  of  15  or  more),  and  in  women 
with any degree of hirsutism when it is sudden in onset, rap-
idly progressive, or when it is associated with any of the fol-
lowing:  menstrual  irregularity,  central  obesity,  acanthosis 
nigricans, or clitoromegaly (18).

The  current  available  treatment  methods  for  removal 
of unwanted hair include cosmetic procedures, medical treat-
ment, and hair removal using lasers and light sources. These 
treatments may be combined (11,19).

Cosmetic Procedures for Removal of  
Excessive Hair
Unwanted  hair  may  be  masked  by  bleaching  or  removed  by 
a  variety  of  physical  methods  such  as  trimming  of  the  hair, 
shaving, plucking or tweezing, and waxing, or chemical proce-
dures (depilatories), and electrosurgical epilation (20).

Figure 35.6  Prepubertal hypertrichosis: congenital generalized 
terminal  hair  hypertrichosis.  (From  Trüeb  RM,  Haare  Praxis  der 
Trichologie, Darmstadt, Germany: Steinkopff, 2003.)

at  birth,  increases  in  severity  during  early  childhood,  and  is 
not  as  rare.  It  probably  often  has  been  confused  with  “racial 
hirsutism,” though it is neither limited to a specific ethnicity 
nor androgen mediated.

Congenital generalized  hypertrichosis  has  been  associ-
ated with a number of abnormalities, such as gingival fibroma-
tosis, osteochondrodysplasia, or congential amaurosis, or may 
be a symptom of a more complex syndromatic disorder, such 
as  Cornelia  de  Lange  syndrome,  the  mucopolysaccharidoses, 
and porphyrias (11). In these cases, excessive body and facial 
hairs is either present at birth or develops during early infancy 
or puberty, and frequently involves terminal hairs.

A variety of underlying pathologic states may give rise 
to  acquired  generalized  hypertrichosis.  These  include  head 
injuries  and  other  cerebral  disturbances,  malnutrition  and 
anorexia nervosa, juvenile hypothyroidism, and juvenile der-
matomyositis (11). Besides acquired trichomegaly (overgrowth 
of  eyelashes),  a  more  generalized  form  of  hypertrichosis  has 
also been observed in patients with AIDS (15).

Acquired  hypertrichosis  lanuginosa  describes  the  sud-
den onset and rapid growth of long, fine, lanugo-type, white-
yellow downy hairs over a large area of the body in association 
with  an  underlying  malignancy.  The  growth  of  lanugo  (so-
called “malignant down”), particularly on the face of patients 
with  malignant  disease,  is  not  uncommon  (16).  The  lanugo 
may develop a few weeks or up to 2 years before an underlying 
malignancy is diagnosed.

Yet  another  form  of  paraneoplastic  hypertrichosis  may 
be found in the POEMS (peripheral neuropathy, organomegaly, 

 
MANAGEMENT OF HIRSUTISM AND HYPERTRICHOSIS 

 325

Shaving
While unacceptable for removing facial hair to many women, 
the majority accepts to shave excess body hair. It is perceived 
as  being  fast,  effective,  easy,  and  cheap.  Contrary  to  popular 
belief, shaving does not affect the width or rate of regrowth of 
individual hairs (22), though the perception of the stubble as it 
grows out, without the finer tapered end of unshaven hair, may 
give this impression. As a consequence, daily shaving must be 
undertaken or the cosmetic result is worsened. The disadvan-
tages of shaving are the need to shave daily, and skin irritation. 
Although dry or electrical shaves are not as close as wet shaves, 
a dry electric razor has been effectively used to treat general-
ized hypertrichosis during the neonatal period (23).

Plucking
Plucking  is  an  effective  temporary  hair  removal  method, 
but  it  is  slow,  tedious,  and  painful.  It  is  only  appropriate  for 
individual,  small  groups  or  scattered  coarse  hair  and  is  per-
formed with tweezers (tweezing). Adverse reactions to pluck-
ing include hyperpigmentation, folliculitis, scarring, ingrown 
hairs, and distorted follicles. A variation of plucking for treat-
ment of more diffuse hypertrichosis acts as mechanized twee-
zers  using  a  rotating,  fine,  coiled  spring  that  grasps  the  hair 
shaft and pulls it out. The device is handheld and moved over 
the skin like a shaver. A drawback of this method is that it is 
painful.

Waxing
Waxing is performed with cold, warm, or hot wax. The wax is 
applied to hair-bearing areas and then stripped off, epilating 
the embedded hairs. Waxing methods are an efficient way of 
plucking vellus hairs in all areas of the body, and inexpensive 
when  performed  at  home.  The  major  disadvantages  are  dis-
comfort, poor removal of short hair, and skin irritation or fol-
liculitis. This method is too painful for use on children with 
hypertrichosis. As with hair plucking, the regrowth period is 
longer than that for shaving, and it needs to be repeated only 
every 2 to 6 weeks.

The  Asian  techniques  of  sugaring  (24)  and  threading 
(25)  remove  hair  in  the  same  manner.  Instead  of  using  wax, 
the hairs are plucked out by a caramelized sugar mass or the 
scissoring action of a twisted thread, respectively.

Chemical Depilatories
Chemical  depilatories  function  by  damaging  the  hair  to  the 
point  where  it  breaks  at  the  skin  surface.  Substituted  thiols 
form  the  basis  of  practically  all  contemporary  preparations. 
Depilatories contain detergents to remove the protective sebum 
from the hair, adhesives that aid the depilatory in sticking to the 
hair shaft, swelling agents for better penetration of the bond-
breaking  agent,  pH  adjusters,  and  disulfide  bond-breaking 
agents (thioglycolic acid, calcium thioglycolate). Thioglycolates 
are used in a concentration of 2% to 4%, and act within 5 to 15 
minutes. Since thioglycolates attack keratin, and the hair shaft 
and skin are similar in their keratin composition, most chemi-
cal  depilatories  hold  a  high  irritancy  potential  and  may  have 
adverse  effects  on  the  skin  if  the  manufacturers’  recommen-
dations  are  not  carefully  followed.  Additional  adverse  effects 
from the use of thioglycolates include allergic contact derma-
titis,  and  with  inadvertent  eye  contact,  corneal  alkali  burns 
(26,27). Their application is messy, and they have an unpleasant 
odor and are relatively expensive, especially if treating larger 
areas.  Chemical  depilatories  are  most  appropriate  for  weekly 
hair  removal  from  small  areas.  In  children  with  extensive 

(a)

(b)

Figure  35.8  Drug-induced  hypertrichosis:  (a)  cyclosporin  A 
induced in a child and (b) topical minoxidil induced in a woman. 
(From  Trüeb  RM,  Haare  Praxis  der  Trichologie,  Darmstadt, 
Germany: Steinkopff, 2003.)

Bleaching
Bleaching  is  a  quick,  easy,  and  painless  process  that  can 
make  unwanted  hair  less  apparent  through  the  partial  or 
total  removal  of  natural  hair  pigment,  lightening  the  hair 
to a yellowish hue. A home bleach is made by mixing 40 mL 
hydrogen peroxide with 7 mL 20% ammonia. This is left in 
contact with the hair until the color is removed, usually 5 to 
10 minutes. Bleaching can last up to 4 weeks. This method 
is  best  for  treatment  of  localized  excess  pigmented  hair  on 
the  face  or  arms  of  fair-skinned  patients,  because  yellow-
bleached hair may emphasize the hair when viewed against 
the  skin  of  more  darkly  pigmented  patients.  Occasionally, 
bleaching  results  in  skin  irritation.  The  addition  of  a  per-
sulfate to boost the peroxide bleach in commercial products 
may  occasionally  result  in  anaphylaxis  in  the  sensitized 
individual (21).

Trimming
Trimming  of  the  hair  is  a  recommended  option  for  young 
children  with  either  localized  or  generalized  hypertrichosis, 
making  the  hair  of  involved  areas  less  noticeable,  while  not 
resulting in acceleration of hair regrowth.

 
326 

 TEXTBOOK OF COSMETIC DERMATOLOGY

hypertrichosis, treatment with chemical depilatories should be 
limited to localized sites because of a theoretical risk of addi-
tional toxicity from systemic thioglycolate absorption (28).

Electrosurgical Epilation
In  contrast  to  other  cosmetic  procedures  for  hair  removal, 
electrosurgical epilation represents a permanent mode of hair 
removal. Treatment involves the insertion of a disposable fine 
wire  needle  into  the  hair  follicle.  Through  this  instrument  a 
regulated and controlled electric current is transmitted from a 
sophisticated apparatus known as an epilator. The procedure 
has to be performed by a highly trained professional in order 
to  be  effective,  as  the  hair  bulb  should  not  be  missed  by  the 
fine needle. Three techniques are available: galvanic electroly-
sis, thermolysis, and the blend method (29,30).

Galvanic electrolysis uses galvanic current to destroy the 
hair growing cells of the hair follicle. This involves a direct cur-
rent producing electrochemical sodium hydroxide formation, 
congealing the hair follicle. Thermolysis uses high-frequency 
electrocoagulation  that  cauterizes  the  hair  follicle.  Galvanic 
electrolysis is slower, but destroys more follicles in one treat-
ment, while thermolysis is quicker, but more regrowth is seen 
with this method. The blend method combines both galvanic 
and high-frequency current from a single machine, and is con-
sidered by most users to be the most effective method of elec-
trosurgical epilation.

Disadvantages of electrosurgical epilation are the length 
and number of treatments required for permanent removal of 
hair from a particular body site and discomfort during treat-
ment, which is why the method is poorly tolerated in children. 
Generally,  operators  can  only  deal  with  25  to  100  hairs  per 
session,  and  individual  treatments  last  from  15  minutes  to  1 
hour.  Problems  that  may  occur  are  perifollicular  inflamma-
tion, postinflammatory hyper- or hypopigmentation, and less 
frequently, punctate scarring. The method is most suitable for 
treatment of localized, coarse hair.

Medical Treatment
Since abnormal hair growth in hirsutism is either stimulated 
by excess androgens or is related to hair follicle sensitivity to 
androgens, hormonal treatment of hirsutism is based on sup-
pressing  androgen  production  or  counteracting  the  biologic 
activity of androgens.

Today,  for  the  majority  of  women  with  hirsutism,  a 
monotherapy  with  oral  contraceptive  pills  (OCPs)  that  have 
antiandrogenic  activity  is  recommended  as  first-line  treat-
ment.  Antiandrogens  may  be  the  first-line  therapy  for  post-
menopausal  women,  or  may  be  indicated  in  conjunction 
with  OCPs  in  premenopausal  women  if  clinical  improve-
ment  is  insufficient  after  6  or  more  months  of  monotherapy. 
The  choice  between  the  different  antiandrogens  depends 
on  patient  preferences  regarding  efficacy,  side  effects,  and 
costs (31). Antiandrogens including spironolactone, cyproter-
one acetate, and flutamide, or the 5α-reductase inhibitors such 
as finasteride, should not be used in women of childbearing 
age  unless  they  are  strictly  combined  with  a  safe  contracep-
tion  method  due  to  their  potential  feminizing  effect  on  the 
male fetus (18, 32).

In women with hirsutism, hyperandrogenism, and insu-
lin resistance, insulin sensitizers such as metformin and rosi-
glitazone  are  effective  for  the  treatment  of  hirsutism  as  well 
as  hyperinsulinemia,  hyperandrogenism,  and  infertility,  but 
there is no convincing evidence that they are effective for hir-
sutism itself (33,34).

Topical  eflornithine  cream  is  a  medical  treatment  for 
slowing  excessive  hair  growth  but  not  removing  excess 
hair (35). The compound is a specific and irreversible inhibi-
tor of the enzyme ornithine decarboxylase that is important 
for hair growth and present in hair follicles. In clinical stud-
ies in women with facial hirsutism, twice daily application of 
eflornithine hydrochloride monohydrate 15% cream (Vaniqa1, 
Bristol-Myers  Squibb,  New  York,  NY  )  was  superior  to  pla-
cebo  in  reducing  hair  growth,  as  demonstrated  by  objective 
and  subjective  methods,  after  2-  to  8-week  treatment.  After 
24-week  treatment,  58%  of  eflornithine  and  34%  of  placebo 
recipients  had  at  least  some  improvement,  and  32%  versus 
8% of patients were judged to be successfully treated (at least 
marked improvement) (36). Hair growth returned to pretreat-
ment  rates  within  8  weeks  of  stopping  treatment.  Local  irri-
tation,  characterized  by  burning,  stinging,  and/or  tingling, 
occurred  more  frequently  in  eflornithine-treated  patients. 
Use  of  eflornithine  cream  in  combination  with  other  thera-
pies, including laser epilation, can be effective and results in a 
more rapid, visible hair reduction compared with laser mono-
therapy (37,38). The safety and efficacy of topical eflornithine 
treatment for widespread hypertrichosis and children has not 
been established.

Topical application of finasteride 0.5% solution combined 
with intense pulsed light (IPL) treatment has also been tested 
(39). Various herbal oils have been shown to have some value in 
reducing hair in young women (40).

Hair Removal Using Lasers and Light Sources
The  need  for  a  rapid,  noninvasive  method  for  hair  removal 
has led to the development of various laser and light sources 
for this purpose. An array of devices is now available. All are 
based  on  the  principle  of  selective  photothermolysis:  mela-
nin pigment in the hair follicle provides the chromophore for 
selective targeting of hair follicles, while the surrounding der-
mis is spared. Therefore, at deeply penetrating wavelengths in 
the 600- to 1100-nm range, melanin absorption may be used for 
selective photothermolysis of hair follicles (41).

Several  hair  removal  systems  have  been  shown  to  be 
effective  in  this  setting:  long-pulsed  ruby  lasers  (wavelength 
694  nm;  pulse  duration  1–3  msec),  long-pulsed  alexandrite 
lasers (755 nm; 2–20 msec), diode lasers (810 nm; 5–400 msec), 
long-pulsed neodynium:yttrium-aluminium-garnet (Nd:YAG) 
lasers  (1064  nm;  5–250  msec),  and  IPL  sources  (590–1400  nm; 
2.5–5  msec)  (42–-45).  The  physical  parameters  (wavelength, 
pulse duration, fluence, spot size, repetition rate) and cooling 
systems used with each system vary considerably. Regardless 
of the type of laser or light source used, all systems have been 
shown  to  temporarily  reduce  hair  growth.  Long-term,  con-
trolled  hair  counts  have  shown  an  average  of  20%  hair  loss 
with  each  treatment,  indicating  the  need  for  multiple  treat-
ments  to  achieve  satisfactory  results.  Research  indicates  that 
in  80%  of  patients  significant  hair  reduction  can  be  achieved 
(Figure  35.9),  while  20%  will  fail  (42).  Effectiveness  for  long-
lasting  hair  reduction  is  strongly  correlated  with  hair  color. 
Blond-,  red-,  or  white-haired  patients  are  unlikely  to  experi-
ence a permanent reduction. In contrast, the patient with dark 
hair and fair skin may experience long-term hair removal after 
a single treatment (43). Regrowing hairs are often thinner and 
lighter in color, contributing to the improvement in the overall 
appearance.

Although  there  is  no  obvious  advantage  of  one  laser 
system  over  another  in  terms  of  treatment  outcome,  laser 
parameters may be important for choosing the ideal laser for 

 
MANAGEMENT OF HIRSUTISM AND HYPERTRICHOSIS 

 327

One rare and peculiar unwanted effect of laser-assisted 
hair  removal  is  the  stimulation  of  new  hair  growth  within 
previously treated areas or in close proximity. This “paradox-
ical  effect”  has  occasionally  been  seen  following  treatment 
with each of the laser and light hair removal systems, and its 
development  has  been  attributed  to  activation  of  previously 
dormant hair follicles by either the application of subthresh-
old  fluences  or  the  conduction  of  heat  to  surrounding  areas 
(49,50).

As  with  traditional  electrosurgical  epilation,  laser  epi-
lation is painful, which limits its usefulness in children with 
widespread hypertrichosis (6).

Since removing hair with in-office laser- or light-based 
treatments  is  expensive  and  requires  multiple  treatments 
sessions, a novel, low-energy, pulsed-light device for home-
use hair removal (Silk’n1, Home Skinovations Ltd., Yokneam, 
Israel) (Figure 35.10) has been developed to overcome these 
disadvantages. The device is composed of two flashlamps in 
a  handheld  applicator  (optical  filter  475–1200  nm;  fluences 
up to 5 J/cm2). A study was performed with 20 women with 
Fitzpatrick  skin  phototypes  I  to  IV  and  dark  terminal  hair 
in  nonfacial  sites  (axilla,  forearms,  inguinal  region,  legs) 
who self-administered three treatments at 2-week intervals 
using  the  device.  Matched  untreated  skin  sites  were  com-
pared. Hair counts and clinical photographs were obtained 
pretreatment,  and  at  1,  3,  and  6  months  after  the  third 
treatment,  side  effects  and  patient  satisfaction  scores  were 
recorded.  All  patients  showed  a  positive  clinical  response 
to  treatment,  with  reduction  of  unwanted  hair,  while  no 
hair reduction was noted in untreated matched areas. Hair 
counts  were  reduced  37.8%  to  53.6%  six  months  after  the 
three  treatments.  Lower  legs  exhibited  greater  hair  reduc-
tion than arms, inguinal, and axillary areas. Mild erythema 
was experienced in 25% of patients, but no other unwanted 
effects  were  encountered.  Patient  satisfaction  scores  were 
high, with all patients stating that they would purchase the 
device for future home use (51, 52).

Figure  35.10  Silk’n1:  handheld  intense  pulse  light  device  for 
home-based hair removal.

(a)

(b)

Figure 35.9  Terminal hair growth of the back in a male patient 
(a) before and (b) 6 months after fifth in-office intense pulsed-light 
treatment (delivered at 2-month intervals).

a patient (44). A major drawback to using shorter wavelengths, 
for example, 694 nm ruby, is that a more deeply pigmented epi-
dermis impedes laser radiation penetration of the dermis. The 
amount of light that reaches the hair bulb is therefore reduced 
with  decreased  efficacy.  At  the  same  time,  unwanted  epider-
mal injury may occur. Patients with darker skin tones should 
therefore  receive  laser  treatment  with  either  lower  fluences 
of alexandrite and diode laser or with a long-pulsed Nd:YAG 
laser.

Adverse  effects  commonly  include  erythema  and  peri-
follicular edema, while crusting and vesiculation of treatment 
site,  hypopigmentation,  and  hyperpigmentation  are  less  fre-
quent, depending on skin color and other factors (45,46). Most 
complications are usually temporary, and their incidence can 
be reduced by lightening of the skin and UV light avoidance 
prior  to  laser  treatment,  effective  cooling  of  the  skin  during 
treatment, and sun avoidance and protection following treat-
ment (44). Shaving the hair-bearing site is performed preopera-
tively to prevent conduction of thermal energy to the adjacent 
epidermis from overlying hairs. In a study conducted on 242 
hirsute patients the mean hair plucking interval was extended 
4.11 times, from a median of 3.69 days before treatment to an 
average  of  15.19  days  after  diode  laser  epilation,  inducing  a 
well accepted increase in quality of life and selfconciousness 
(47), as similarly in other studies (48).

 
328 

 TEXTBOOK OF COSMETIC DERMATOLOGY

CONCLUSIONS
Removal of unwanted hair is the most popular skin treatment 
worldwide.  Excessive  hair  may  cause  cosmetic  embarrass-
ment,  resulting  in  significant  emotional  burden.  Sometimes 
the  complaint  of  excess  hair  may  pose  a  vexing  problem  for 
nonspecialized  physicians,  who  tend  to  trivialize  the  com-
plaint,  though  an  individual’s  perception  of  abnormality 
is  important  in  determining  whether  or  not  medical  care  is 
sought.  Moreover,  it  must  always  be  kept  in  mind  that  hair 
overgrowth, either hirsutism or hypertrichosis, may be a man-
ifestation of a more general medical problem requiring inves-
tigation. The dermatologist seeing a patient with hirsutism or 
hypertrichosis must be prepared to look for physical clues and 
perform  the  workup  that  will  help  both  define  the  extent  of 
excess hair and suggest the presence of associated disorders. 
There is no single method of hair removal appropriate for all 
patients or body locations. The method adopted will depend 
on the cause, the character, the area, and the amount of exces-
sive hair growth, as well as on the age of the patient, and per-
sonal  preference.  The  best  treatment  of  hirsutism  is  often  a 
combination of medical therapy and the physical removal of 
unwanted hair. Over the recent past, hair removal using vari-
ous efficacious lasers and light sources have been advocated 
for use in an office setting, although most people continue to 
remove unwanted hair with a variety of temporary physical 
methods in a home setting, presumably due to cost and con-
venience factors.

REFERENCES

1.  Trüeb  RM.  Haare  Praxis  der  Trichologie.  Darmstadt,  Germany: 

Steinkopff, 2003.

2.  Blume-Peytavi  U.  An  overview  of  unwanted  female  hair. 

Br J Dermatol 2011; 165 Suppl 3:19–23. Review.

3.  Somani N, Turvy D. Hirsutism: An evidence-based treatment 

update. Am J Clinical Dermatol 2014 Jul; 15(3):247–66.

4.  Ferriman  D,  Gallwey  JD.  Clinical  assessment  of  body  hair 

growth in women. J Clin Endocrinol Metab 1961; 21:1440–7.

5.  Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr 

Rev 2000; 21:347–62.

6.  Somani N, Harrison S, Bergfeld WF. The clinical evaluation of 

hirsutism. Dermatol Ther 2008; 21:376–91.

  17.  Perniciario C. POEMS syndrome. Semin Dermatol 1995; 14:162–5.
  18.  Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treat-
ment  of  hirsutism  in  premenopausal  women:  An  Endocrine 
Society clinical practice guideline. J Clin Endocrinol Metab 2008; 
93:1105–20.

  19.  Liew  SH.  Unwanted  body  hair  and  its  removal:  A  review. 

Dermatol Surg 1999; 25:431–9.

  20.  Draelos  ZK.  Cosmetics  in  Dermatology.  New  York:  Churchill 

Livingstone, 1990; p. 99.

  21.  Wagner  RF.  Physical  methods  for  the  management  of  hirsut-

ism. Cutis 1990; 45:19–26.

  22.  Lynfield YL, MacWilliams P. Shaving and hair growth. J Invest 

Dermatol 1970; 55:170–172.

  23.  Partridge JW. Congenital hypertrichosis lanuginosa: Neonatal 

shaving. Arch Dis Child 1987; 62:623–5.

  24.  Tannir  D,  Leshin  B.  Sugaring:  An  ancient  method  of  hair 

removal. Dermatol Surg 2001; 27:309–11.

  25.  Scott MJ, Scott MJ III, Scott HM. Epilation. Cutis 1990; 46:216–7.
  26.  Yamasaki  R,  Dekio  S,  Jidio  J.  Allergic  contact  dermatitis  to 
ammonium thioglycolate. Contact Dermatitis 1984; 11:255.
  27.  Smith RS, Shear G. Corneal alkali burns arising from acciden-
tal  instillation  of  a  hair  straightener.  Am  J  Ophthalmol  1975; 
79:602–5.

  28.  Freeman MV, Draize JH, Smith PK. Some aspects of the absorp-
tion, distribution and excretion of sodium thioglycolate. J Pharm 
Exp Ther 1956; 118:296–303.

  29.  Hobbs ER, Ratz JL, James B. Electrosurgical epilation. Dermatol 

Clin 1985; 5:437–44.

  30.  Richards  RN,  Meharg  GE.  Electrolysis:  Observation  from  13 
years and 140,000 hours of experience. J Am Acad Dermatol 1995; 
33:662–6.

  31.  Swiglo BA, Cosma M, Flynn DN, et al. Antiandrogens for the 
treatment of hirsutism: A systematic review and metaanalyses 
of  randomized  controlled  trials.  J  Clin  Endocrinol  Metab  2008; 
93:1153–60.

  32.  Tartagni  MV,  Damiani  GR,  Montagnani  M,  De  Salvia  MA, 
De  Pergola  G,  Tartagni  M,  Loverro  G.  Intermittent  low-dose 
finasteride  administration  is  effective  for  treatment  of  hirsut-
ism in adolescent girls: A pilot study. J Pediatr Adolesc Gynecol 
2014; 27:161–5.

  33.  Cosma M, Swiglo BA, Flynn DN, et al. Insulin sensitizers for the 
treatment of hirsutism: A systematic review and metaanalyses 
of  randomized  controlled  trials.  J  Clin  Endocrinol  Metab  2008; 
93:1135–42.

7.  Rosenfield RL. Hirsutism and the variable response of the pilo-
sebaceous unit to androgen. J Investig Dermatol Symp Proc 2005; 
10:205–8.

  34.  Pasquali  R,  Gambineri  A.  Therapy  in  endocrine  disease: 
Treatment of hirsutism in the polycystic ovary syndrome. Eur J 
Endocrinol 2013; 170:R75–90.

8.  Azziz R. The evaluation and management of hirsutism. Obstet 

  35.  Barman  Balfour  JA,  McCellan  K.  Topical  eflornithine.  Am  J 

Gynecol 2003; 101:995–1007.

Clinical Dermatol 2001; 2:197–201.

9.  Rosenfield RL. What every physician should know about poly-

cystic ovary syndrome. Dermatol Ther 2008; 21:354–61.

  10.  Rossi  R,  Tauchmanova  L,  Luciano  A,  et  al.  Functional  hyper-
androgenism  detected  by  corticotropin  and  GnRH-analogue 
stimulation  tests  in  women  affected  by  apparently  idiopathic 
hirsutism. J Endocrinol Invest 2001; 24:491–8.

  11.  Trüeb  RM.  Causes  and  management  of  hypertrichosis.  Am  J 

Clinical Dermatol 2002; 3:617–27.

  12.  Vashi  RA,  Mancini  AJ,  Paller  AS.  Primary  generalized  and 
localized  hypertrichosis  in  children.  Arch  Dermatol  2001; 
137:877–84.

  13.  Baumeister FAM, Egger J, Schildhauer MT, et al. Ambras syn-
drome: Delineation of a unique hypertrichosis universalis con-
genital and association with a balanced pericentric inversion (8) 
(p11.2;q22). Clin Genet 1993; 44:121–8.

  14.  Barth JH, Wilkinson JD, Dawber RPR. Prepubertal hypertricho-
sis: Normal or abnormal? Arch Dis Child 1988; 63:666–8.
  15.  Prose NS, Abson KG, Scher RK. Disorders of the nails and hair 
associated with human immunodeficiency virus infection. Int J 
Dermatol 1992; 31:453–7.

  16.  Fretzin DF. Malignant down. Arch Dermatol 1967; 95:294–7.

  36.  Wolf JE Jr, Shander D, Huber F, et al. Randomized, double-blind 
clinical evaluation of the efficacy and safety of topical eflorni-
thine HCl 13.9% cream in the treatment of women with facial 
hair. Int J Dermatol 2007; 46:94–8.

  37.  Smith SR, Piacquadio DJ, Beger B, et al. Eflornithine cream com-
bined with laser therapy in the management of unwanted facial 
hair growth in women: A randomized trial. Dermatol Surg 2006; 
32:1237–43.

  38.  Vissing AC, Taudorf EH, Haak CS, Philipsen PA, Haedersdal M. 
Adjuvant eflornithine to maintain IPL-induced hair reduction 
in women with facial hirsutism: A randomized controlled trial. 
J Eur Acad Dermatol Venereol 2015 Oct 27. [Epub ahead of print]

  39.  Farshi S, Mansouri P, Rafie F. A randomized double blind, vehi-
cle  controlled  bilateral  comparison  study  of  the  efficacy  and 
safety of finasteride 0.5% solution in combination with intense 
pulsed light in the treatment of facial hirsutism. J Cosmet Laser 
Ther 2012;14:193–9.

  40.  Tirabassi G, Giovannini L, Paggi F, Panin G, Panin F, Papa R, 
et al. Possible efficacy of Lavender and Tea tree oils in the treat-
ment  of  young  women  affected  by  mild  idiopathic  hirsutism. 
J Endocrinol Invest 2013; 36:50–4.

 
 
 
 
 
 
 
 
 
 
MANAGEMENT OF HIRSUTISM AND HYPERTRICHOSIS 

 329

  41.  Ross EV, Ladin Z, Kreindel M, et al. Theoretical considerations 

  47.  Kopera D. Hair reduction: 48 months of experience with 800nm 

in laser hair removal. Dermatol Clin 1999; 17:333–55.

diode laser. J Cosmet Laser Ther 2003; 5: 146–9.

  42.  Dierickx  C,  Alora  MB,  Dover  JS.  A  clinical  overview  of  hair 
removal  using  lasers  and  light  sources.  Dermatol  Clin  1999; 
17:357–66.

  48.  Roche  A,  Sedgwick  PM,  Harland  CC.  Laser  treatment  for 
female facial hirsutism: Are quality-of-life benefits sustainable? 
Clin Exp Dermato; 2015 Dec 1. [Epub ahead of print]

  43.  Olsen EA. Methods of hair removal. J Am Acad Dermatol 1999; 

  49.  Alajlan A, Shapiro J, Rivers JK, et al. Paradoxical hypertrichosis 

40:143–55.

after laser epilation. J Am Acad Dermatol 2005; 53:85–8.

  44.  Liew SH. Laser hair removal. Guidelines for management. Am J 

  50.  Lolis MS, Marmur ES. Paradoxical effects of hair removal sys-

Clinical Dermatol 2002; 3:107–15.

  45.  Wanitphakdeedecha  R,  Alster  TS.  Physical  means  of  treating 

unwanted hair. Dermatol Ther 2008; 21:392–401.

  46.  Mohanan  S,  Basheerahmed  P,  Priyavathani  R,  Nellainayagam 
G. New intense pulse light device with square pulse technol-
ogy  for  hirsutism  in  Indian  patients:  A  pilot  study.  J  Cosmet 
Laser Ther 2012; 14:14–7.

tems: A review. J Cosmet Dermatol 2006; 5:274–6.

  51.  Alster  TS,  Tanzi  EL.  Effect  of  a  novel  low-energy  pulsed-
light  device  for  home-use  hair  removal.  Dermatol  Surg  2009; 
35:483–9.

  52.  Haedersdal M, Beerwerth F, Nash JF. Laser and intense pulsed 
light hair removal technologies: From professional to home use. 
Br J Dermatol 2011; 165 Suppl 3:31–6.

 
36

Pigmentation: Dyschromia

Thierry Passeron and Jean-Paul Ortonne

Variations of skin pigmentation are mostly due to quantitative 
or  qualitative  defects  of  melanin  pigments  (eumelanin  and 
pheomelanin). However, dyschromia can also result from an 
abnormal increase or decrease of other endogenous pigments 
(hemoglobin, bilirubin …) or from the deposit of exogenous 
pigments  (heavy  metals,  cosmetic  tattoos  …).  This  leads  to 
a  heterogeneous  group  with  numerous  causes.  Although 
most of the patients will consult for the cosmetic disturbance 
due  to  the  dyschromia,  it  is  essential  to  determine  the  ori-
gin  of  the  pigmentary  trouble  in  order  to  propose  the  more 
adapted treatment and if necessary to ask for complementary 
investigations.

PATHOPHYSIOLOGY OF DYSCHROMIA
The color of the skin results from the presence of pigments in 
the  epidermis  and  in  the  dermis.  The  melanins  (eumelanin, 
dark  brown,  mostly  produced  by  dark  skin  types,  and  phe-
omelanin, red-fair brown, mostly observed in fair skin types) 
are  the  most  important  pigments  in  human  skin.  However, 
other endogenous pigments such as hemoglobin and bilirubin 
also play a role in the color of the teguments. Dyschromia can 
result from a darkening, a lightning, and the occurrence of an 
unusual skin color (1). Quantitative or qualitative defects in the 
production or in the deposition of melanin explains most of the 
pigmentary disorders but abnormal variations of other endog-
enous pigments and deposit of exogenous pigments also lead 
to dyschromic lesions.

An  increased  amount  of  melanin  in  the  skin  is  called 
hypermelanosis or melanoderma. A brown hypermelanosis is 
caused by excessive amounts of melanin within the epidermis 
whereas  ceruloderma  (or  blue  hypermelanosis)  results  from 
large amounts of melanin in the dermis. Mixed hypermelano-
sis is characterised by an excess of melanins in both epidermis 
and  dermis  may  also  occur.  Epidermal  hypermelanosis  may 
result from increased melanin production by a quantitatively 
normal melanocyte density in the epidermis (melanotic hyper-
melanosis)  or  by  an  increased  number  of  epidermal  melano-
cytes  (melanocytic  hypermelanosis).  Dermal  hypermelanosis 
can  be  due  to  the  production  of  melanin  by  ectopic  dermal 
melanocytes (dermal melanocytosis) or to an abnormal trans-
fer of melanin from epidermal cells to the dermis (pigmentary 
incontinence).  In  this  situation,  melanin  granules  accumu-
late within melanophages or may be free in the extracellular 
matrix of the dermis.

Skin lightening or whitening (leukoderma, hypopigmen-
tation) is most commonly the result of decreased melanin con-
tent in the skin (hypomelanosis). Epidermal hypomelanosis may 
be the result of at least two different pathogenic mechanisms: 
partial or total absence of epidermal melanocytes (melanocyto-
penic hypomelanosis) or even melanin synthesis, melanosome 

biogenesis,  transport  and  transfer  and  melanosome  transfer 
despite  a  normal  number  of  epidermal  melanocytes  (melano-
penic hypomelanosis). Increase of epidermal turn over can also 
induce  hypomelanosis.  Hypo-  and  hyperpigmentation  disor-
ders can be inherited or acquired (2,3).

Dyschromia that results from variation of the hemoglo-
bin  content  within  the  skin  (diffuse  such  as  in  anemia  or  in 
polycythemia, or localized such as in Bier spots) can be easily 
distinguished from other pigmentary disorders as the change 
in color disappears with pressure (Figure 36.1). Xanthoderma 
describes a yellow to orange macular discoloration of the skin. 
Jaundice and carotenoderma are the two main causes of xan-
thoderma.  Although  patients  may  consult  for  the  cosmetic 
disturbance, drug and excessive dietary intake of carotenoids 
and  search  for  underlying  disease  have  to  be  performed  (4). 
The  treatment  is  etiological.  Heavy  metals  (e.g.,  iron,  silver, 
copper  …)  and  traumatic,  medical,  or  esthetical  tattoos  are 
other sources of skin discoloration. An increased thickness of 
the  epidermis  can  lead  to  diffuse,  patchy  or  reticulated  light 
to  dark  brown  hyperpigmentation.  The  chronic  avoidance 
of  washing  can  also  induce  hyperpigmented  and  sometimes 
keratotic patches. Finally, the discoloration of the skin cannot 
only be due to pigment abnormality within the skin, but also 
to an abnormal coloration of the sweat (called chromhidrosis 
or pseudochromhidrosis).

DEPIGMENTING AGENTS
Phenolic Compounds
Hydroquinone
Hydroquinone  (HQ)  is  the  most  popular  depigmenting 
agent  (5).  Several  studies  have  established  the  therapeutic 
effect  of  HQ  in  the  treatment  of  hypermelanosis  (6).  HQ  is 
still  the  “gold  standard”  of  depigmenting  agents.  The  effec-
tiveness  of  HQ  is  related  directly  to  the  concentration  of  the 
preparations,  the  vehicle  used  and  the  chemical  composition 
of the final product. Two percent HQ was reported to improve 
hypermelanosis  in  14%–70%  of  the  patients.  However,  HQ  is 
most commonly used at a 4% concentration by dermatologists. 
At  this  concentration,  HQ  is  very  effective,  but  it  can  have  a 
significant  irritant  effect.  Concentrations  as  high  as  6%–10% 
are prescribed extemporaneously for resistant cases, but may 
be a strong irritant effect. Because of the hazard of long-term 
treatments,  the  use  of  HQ  in  cosmetics  has  been  banned  by 
the European Committee (24th Dir. 2000/6/EC). Formulations 
are  available  only  by  prescription  of  physicians  and  derma-
tologists. A number of different vehicles can be used for HQ, 
but the most suitable for the formulation is a hydro-alcoholic 
solution (equal parts of propylene glycol and absolute ethanol). 
A nitro-oxidant such as ascorbic acid or sodium bisulphate is 
regularly used to preserve the stability of the formulation.

PIGMENTATION: DYSCHROMIA 

 331

concentration  for  the  treatment  of  various  acquired  hyper-
melanoses including melasma and post-inflammatory hyper-
melanoses.  Side  effects  include  irritant  and  allergic  contact 
dermatitis,  post-inflammatory  hypermelanosis  and  leuko-
derma en confetti at treated sites. Hypomelanosis at sites dis-
tant from the application areas have been reported.

Others
4-n-Butylresorcinol (Rucinol®)
4-n-butylresorcinol  has  an  inhibitory  effect  on  tyrosinase 
and  tyrosinase-related  protein  (TRP-1).  A  lotion  containing 
0.3%  4-n-butylresorcinol  has  been  demonstrated  to  improve 
melasma.  This  product  also  decreases  post-inflammatory 
hyperpigmentation following laser therapy (9).

4-isopropylcatechol (4-4PC)
This compound is considered as more potent and more consis-
tent in his depigmenting effect than hydroquinone. A clinical 
trial involving  68  patients treated with  1% and 3%  4-IPC has 
demonstrated that this product is a potent depigmenting agent 
and is of use for the topical therapy of hypermelanosis (10).

Phenolic-Thioether
N-acetyl-4-S-cystalminylphenol  has  been  evaluated  in  a  small 
number  of  patients  with  melasma  (11).  Marked  improvement 
or  complete  clearing  with  minimal  side  effects  were  obtained 
in 75% of patients. These compounds are not widely used and 
large clinical trials to evaluate their safety and efficacy are not 
available.

Azelaic Acid
Azelaic  acid  (AA)  is  a  naturally  occurring  9-carbon-dicarbox-
ylic  acid  isolated  from  cultures  of  Pityrosporum  ovale.  AA  is 
thought to play a key-role in the pathogenesis of hypomelanotic 
tinea versicolor. AA has been used at concentrations of 15%–20% 
for the treatment of melasma and post-inflammatory hypomela-
noses. The best results demonstrated that AA is more effective 
than 2% HQ and equivalent in efficacy with 4% HQ for the treat-
ment  of  melasma  in  dark-skinned  women  (12).  Similar  good 
results  have  never  been  obtained  in  European  patients.  AA  is 
well  tolerated.  Adverse  effects  such  as  pruritus,  transient  ery-
thema,  scaling,  and  irritation  are  usually  mild  and  disappear 
within a few weeks. Phototoxic and allergic reactions are rare.

AA  may  halt  the  progression  of  lentigo  maligna  and 
even  induce  its  disappearance  suggesting  that  AA  exert  an 
antiproliferative  and  cytotoxic  effect  mainly  on  hyperactive 
and abnormal melanocytes.

Soy and Soy-Based Products
Soy  and  soy-based  products  may  affect  skin  pigmentation. 
Several  studies  have  demonstrated  that  soy-derived  serine 
protease  inhibiting  PAR-2  mediated  phagocytosis  of  mélano-
somes  by  keratinocytes.  Thus  soy-based  products  containing 
these  serine  protease  inhibitors  represent  safe  and  effective 
products to treat hyperpigmentation (13).

Kojic Acid
Kojic acid (KA) a fungal metabolic product is used at 1%–4% 
concentrations. In monotherapy, KA shows a modest effective-
ness.  Thus,  it  is  mainly  used  in  combinations.  It  is  a  potent 
tyrosinase inhibitor and functions by chelating copper at the 
active  site  of  the  enzyme.  Long-term  side  effects  of  KA  are 
not  known.  A  high  frequency  of  contact  sensitivity  has  been 
reported (14). The use of KA in cosmetics has been banned in 
Japan.

Figure 36.1  Bier spots on the arm of a young adult.

The acute side effects of HQ include irritant and allergic 
contact  dermatitis,  nail  discoloration,  and  post-inflammatory 
hypermelanosis  (7).  These  adverse  events  are  temporary  and 
resolve after HQ discontinuation. Higher concentrations (≥5%) 
may induce persistent hypo or amelanosis (leukoderma en con-
fetti). Exogenous ochronosis is a very rare complication occur-
ring  in  dark-skinned  or  black  individuals  after  chronic  use. 
This irreversible disorder presents in the form of reticulated, 
ripple-like, sooty pigmentation affecting common sites of HQ 
applications  (cheeks,  forehead,  periorbital  areas).  The  lesions 
are  typically  localized  on  photo-exposed  areas.  Histological 
examination  of  these  lesions  shows  banana-shaped  yellow-
brown  pigment  granules  in  and  around  collagen  bundles  in 
conjunction  with  giant-cell  and  melanophage-containing 
granulomas in the upper dermis.

The pathogenesis of HQ-induced ochronosis is unknown 
and no effective treatment is available. The mode of action of 
HQ is not fully understood. HQ seems to exert its effect mainly 
in melanocyte with active tyrosinase activity. Guidelines and 
radical oxygen species arising from the oxidation of HQ induce 
an oxidative damage of membrane lipids and proteins includ-
ing tyrosinase and depletion of glutathione contributes to the 
lightening action (8). Other depigmenting pathways attributed 
to  HQ  include  inhibition  of  tyrosinase  through  the  covalent 
binding  to  histidine  or  interactions  with  copper  at  the  active 
site of tyrosinase, inhibition of DNA and RNA synthesis, and 
alteration of melanosome formation and melanization extent.

Hydroquinone Derivatives
Monobenzylether d’Hydroquinone
The clinical use of monobenzylether d’hydroquinone (MBEH) 
is  restricted  for  generalized  depigmentation  in  patients  with 
extensive  vitiligo.  MBEH  should  never  be  used  for  the  treat-
ment  of  melasma  or  post-inflammatory  hypermelanosis. 
Indeed  MBEH  cause  permanent  depigmentation  of  the  skin 
even  at  sites  distant,  for  those  of  application.  MBEH  induced 
vitiligo  depigmentation  has  been  described  in  dark-skinned 
individuals.  MBEH  is  metabolized  to  reactive  free  radicals 
inside the cells resulting in melanocyte destruction.

Monomethyl of Hydroquinone
Monomethyl  of  hydroquinone  (MMEH)  is  also  called 
4-hydroxyanisole  (para-hydroxy-methoxy-benzene).  This 
compound  is  oxidized  by  tyrosinase  and  exhibits  strong 
melano-cytotoxicity.  MMEH  is  used  in  France  at  8%  or  10% 

 
332 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Ascorbic Acid
A stable ester of ascorbic acid (ASA) (magnesium L-ascorbyl-2 
phosphate) in a 10% cream base produced a significant light-
ening effect in patients with melasma after 3 months of twice 
daily application (15). ASA interferes with the different steps of 
melanogenesis by interacting with copper ions at the tyrosinase 
active site and reducing dopaquinone and by blocking DHICA 
oxidation.  A  randomized  double-blind  placebo-controlled 
trial of vitamin C iontophoresis in melasma has demonstrated 
that  this  strategy  may  be  an  effective  treatment  for  melasma 
(16). A double-blind left/right randomized comparative study 
in  melasma  patients  showed  that  93%  of  good  and  excellent 
subjective  results  are  observed  on  the  4%  hydroquinone  side 
compared with 62.5% on the 5% ascorbic acid side. However, 
colorimetric  measures  showed  no  statistical  differences.  Side 
effects  were  more  common  with  hydroquinone  (68.7%)  than 
with ascorbic acid (6.2%) (17).

Tranexamic Acid
Tranexamic  acid  is  known  as  an  oral  medicine  for  treating 
melasma.  The  antiplasma  activity  of  tramexamic  acid  has 
been proposed for treating melasma by targeting the vascular 
component  of  this  disorder  (18–20).  Although  proposed  also 
topically,  best  results  seems  to  be  achieved  with  oral  admin-
istration. A prospective randomized study is still required to 
determine the usefulness of this approach.

Arbutin
Arbutin  is  a  naturally  occurring  beta-D-glucopyranoside 
derivative  of  hydroquinone.  It  inhibits  tyrosinase  activity.  In 
a  clinical  trial,  an  arbutin-containing  formulation  (3%)  was 
shown to be effective for treating hyperpigmentary disorders 
(21,19).

Ellagic Acid
Ellagic  acid  inhibits  tyrosinase  activity  by  chelating  copper 
atoms  in  its  active  site.  In  a  clinical  trial,  a  0.5%  ellagic-
containing  cream  was  shown  to  be  effective  for  treating 
UVB-induced hyperpigmentation of the skin (22,19).

Chamomilla Extract
Chamomilla extracts have been shown to act as an antagonist 
for  endothelin  receptor  binding  which  mediates  cell-to-cell 
signaling  between  keratinocytes  and  melanocytes  and  leads 
to  the  inhibition  of  melanin  synthesis  in  melanocytes.  In  a 
clinical trial, a 0.5% chamomilla extract–containing cream was 
shown to be effective for treating UVB-induced hyperpigmen-
tation of the skin (23,24,19).

Adenoside Monophosphate Disodium Salt
Adenosine  monophosphate  disodium  salt  accelerates  ele-
vated intracellular energy metabolism that leads to the excre-
tion of melanin from the skin, preventing the accumulation 
of  melanin  in  the  skin.  In  a  clinical  trial,  a  3%  adenosine 
monophosphate  disodium  salt-containing  salt  formulation 
was shown to be effective for treating hyperpigmentary dis-
orders (19).

5,5’-Dipropyl-biphenyl-2,2-diol (Magnolignan)
Magnolignan inhibits the maturation due to the glycosylation 
of  tyrosinase  and  thus  induces  decreased  melanin  synthesis. 
0.5%  Magnolignan-containing  formulation  was  shown  to  be 
effective for treating UVB hyperpigmentation of the skin (25) 
and also is effective in treating hyperpigmentation disorders 
such as melasma and while lentigo (26,19).

4-(4-Hydroxyphenyl)-2-butanol (4-HPB)
4-HPB, a phenol compound, inhibits melanin synthesis due to 
its competitive inhibition of tyrosinase activity (19).

Tranexamic Acid Cetyl Ester Hydrochloride
The effect of tranexamic acid cetyl ester hydrochloride to treat 
hyperpigmentary  disorders  is  due  to  the  inhibition  of  UVB-
induced  inflammation  that  leads  to  the  quiescence  of  active 
melanocytes (19).

4-Methoxy Potassium Salicylate (4-MSK)
4-MSK inhibits melanin synthesis through competitive mela-
nin of tyrosinase activity (19).

Cystamine and Cysteamine
Cystamine and derivatives have been shown to inhibit tyrosi-
nase activity as well as the level of tyrosinase protein (27,28). 
However,  as  it  reduces  eumelanin  it  increases  pheomelanin 
synthesis.  A  recent  prospective  randomized  study  showed  a 
moderate  but  statistically  significant  superiority  compared 
to  placebo  for  treating  melasma  (29).  However,  as  it  reduces 
eumelanin  it  increases  pheomelanin  synthesis  (28).  At  the 
contrary  to  eumelanin,  pheomelanin  has  no  photoprotective 
properties.  When  pheomelanin  is  exposed  to  UV  radiation 
it  produces  radical  species  (30,31).  More  recently  it  has  been 
shown that pheomelanins without UVR may promote melano-
magenesis by the radical species they produce (32). Thus, great 
caution should be taken with such products and in light of the 
current  knowledge  it  is  very  difficult  to  advise  their  use  for 
treating pigmentary disorders.

Retinoid Monotherapy
Tretinoin
Tretinoin  (all  trans  retinoic  acid—ATRA)  has  been  used  in 
concentrations  from  0.025%–0.1%  to  treat  a  variety  of  pig-
mentary  disorders  such  as  pigmented  spots  of  photoaged 
skin,  melisma,  and  postinflammatory  hyperpigmentation 
in  dark-skinned  individuals  (33–36).  Erythema  and  peel-
ing  in  the  area  of  application  are  adverse  events  of  ATRA 
0.05%–0.1%. Post-inflammatory hyperpigmentation may also 
occur.  Topical  ATRA  appears  to  exert  its  action  by  enhanc-
ing   keratinocyte  proliferation  and  increasing  epidermal 
cell turnover. However ATRA, acting on retinoid-activating 
transcription  factors,  interferes  with  melanogenesis.  ATRA 
does  not  inhibit  melanogenesis  in  skin  equivalent  or 
monolayer  cultures  of  melanocytes,  however  it  enhances 
the   pigmentation  of  low-melanized  melanoma  cells  and 
decreases  that  of  highly  pigmented  normal  melanocytes 
after UV irradiation (37).

Tazarotene
This acetylenic topical retinoid improves the irregular hyper-
pigmentation  associated  with  photoaging  and  lightening 
the  pigmented  spots.  Tazarotene  0.1%  gel  is  associated  with 
reduced  mottling  on  the  dorsal  aspects  of  forearms.  The 
Fontana  stain  showed  a  moderate  to  marked  depigmenting 
effect with decreased pigmentation on the tazarotene-treated 
side.  Melanin  granules  were  sparser  and  less  heavily  pig-
mented, probably explaining the bleaching of hyperpigmented 
spots (38).

Adapalene
Adapalene  gel  0.1%  and  0.3%,  a  synthetic  retinoid,  improves 
solar lentigines as well as other features of photodamaged skin 
and is well tolerated (39).

 
Liquorice Extracts
Liquiritin, a flavonoid glycoside of liquorice, has been found 
to  induce  a  significant  improvement  of  hypermelanosis  in 
patients with bilateral epidermal melasma (40). The mecha-
nism  proposed  involved  melanin  dispersion  and  increased 
epidermal  turnover.  Glabridin,  the  main  component  of 
the  hydrophobic  fraction  of  liquorice,  extracts  decreased 
tyrosinase  activity  in  melanoma  cells.  Furthermore,  this 
compound  inhibits  UVB-induced  skin  pigmentation  (41). 
Although  no  clinical  trials  have  evaluated  its  efficacy  as  a 
depigmenting  agent,  one  available  glabridin  may  be  found 
in some cosmetics.

Thioctic Acid (α-Lipoic Acid)
This compound i  s  a  disulfide  derivative  of  octanoic  acid.  It 
acts  as  Ros  scavenger  and  Redox  regulator  but  also  inhibits 
tyrosinase activity, probably by chelating the cooper ions, and 
prevents UV-induced photoactive damage (42). This product is 
commercially available.

Unsaturated Fatty Acids
Oleic  acid  (C18:1),  linoleic  acid  (C18:2),  and  α-linolenic  acid 
(C18:3)  suppress  pigmentation  in  vitro.  Some  of  these  com-
pounds have in vivo a lightening effect in UVB-induced pig-
mentation without toxic effects on melanocytes (43). Fatty acids 
have recently been shown to regulate pigmentation via proteo-
somal degradation (44). Linoleic acid accelerates the degrada-
tion of tyrosinase, thus inhibiting melanogenesis. In contrast, 
palmitic acid, a saturated fatty acid, retards the proteolysis of 
and thus accelerates melanogenesis.

Inhibitory Oligopeptides
A  short  sequence  oligopeptides  (10  aminoacids)  (Lumixyl) 
with  inhibitory  activity  against  mushroom  and  human 
 tyrosinase  (Elixir  Institute  of  Regenerative  Medicine,  San 
Jose,  CA,  U.S.).  This  oligopeptide  showed  no  cytotoxic-
ity  to  human  melanocytes.  Only  a  split-face  double-blind, 
 randomized  and  placebo-controlled  evaluation  including 
five  female   participants  with  moderate  melasma  has  been 
performed.  The  results  of  this  clinical  trial  were  positive. 
However,  this  oligopeptide  warrants  further  evaluation 
(45,46).

Combination Therapies
Combination  therapies  are  widely  used  for  the  treatment  of 
hypermelanoses. The purpose of these strategies is to augment 
efficacy by associating active ingredients with different modes 
of  action  in  order  to  obtain  a  synergic  effect,  to  shorten  the 
duration of therapy, and to reduce the risk of adverse effects.

Kligman’s Formula
The  most  popular  combination  treatment  for  depigmenting 
skin is Kligman’s formula. This polytherapy includes 5% HQ, 
0.1% tretinoin, and 0.1% dexamethasone in a hydrophilic oint-
ment.  Tretinoin  functions  as  an  enhancer  of  HQ  penetration 
in  the  epidermis.  Furthermore,  tretinoin  increases  epidermal 
turnover,  thus  facilitating  melanin  dispersion  within  kerati-
nocytes and also melanin removal from corneocyte shedding. 
Dexamethasone  decreases  the  irritation  and  inflammation 
caused  by  HQ  and/or  tretinoin  and  melanin  synthesis  by 
inhibiting  metabolic  activity.  This  formula  demonstrated 
efficacy  in  the  treatment  of  melasma,  ephelides,  and  post-
inflammatory  hypermelanosis.  Depigmentation  occurs  rap-
idly,  beginning  within  3  weeks  after  twice-daily  application. 

PIGMENTATION: DYSCHROMIA 

 333

Unfortunately,  the  efficacy  of  this  formula  depends  upon  its 
stability.  Extemporaneous  formulation  is  useful  but  bears  a 
strong  risk  of  instability.  Recently,  a  stabilized  formulation 
containing  4%  HQ,  0.05%  tretinoine,  and  0.01%  fluocinolone 
acetonide  has  been  launched.  Two  multicenter,  randomized 
double-blind  controlled  trials  demonstrated  the  safety  and 
efficacy of this combination treatment in patients with moder-
ate to severe melisma (47). After 8 weeks of treatment, a 75% 
reduction  of  melasma  was  found  in  more  than  70%  of  the 
patients.  Furthermore,  superiority  of  the  formulation  over 
its  three  components  (HQ,  tretinoine,  fluocinolone  aceton-
ide)  was  demonstrated.  There  are  already  many  variants  of 
the  extemporaneous  Kligman’s  formula.  The  suggestion  that 
topical  steroids  are  not  necessary  for  achieving  depigmenta-
tion led to a modification of this formula by removing topical 
steroids. Clinical trials demonstrated that 2% HQ combined to 
0.05%–1% tretinoin cream and lotions are also effective.

4-Hydroxyanisole + Tretinoin (Mequinol®)
A solution containing monomethyl ether of hydroquinone (2%) 
and tretinoin 0.01% has been launched in North America for 
the  treatment  of  actinic  lentigo.  This  combination  treatment 
has been shown to improve the appearance of these lesions in 
several controlled and non-controlled studies (48,49).

Azelaic Acid + Tretinoin
A combination regimen of 20% AA with topical tretinoin 0.05% 
produces an earlier and more pronounced lightening pigmen-
tation  during  the  early  phase  of  the  treatment.  However,  an 
equivalent efficacy of the combination 20% AA-topical tretinoin 
0.05% versus AA monotherapy was obtained after 6 months of 
treatment (50). 20% AA has also been associated with 15%–20% 
glycolic acid lotion. This combination regimen was as effective 
as 4% HQ cream for the treatment of facial hyperpigmentation 
in dark-skinned individuals (51).

HQ + Kojic Acid
Kojic  acid  has  also  been  included  in  combination  regimens. 
2% Kojic acid in a gel containing 10% glycolic acid and 2% HQ 
improves epidermal melasma after 12 weeks of treatment, 1–4 
kojic acid combined with tretinoin, HQ, and/or corticosteroid 
or glycolic acid appears to act synergically (52).

Westerhof Formula
The  combination  of  4.7%  N-acetycystein  (NAC),  2%  HQ,  and 
0.1%  triamcinolone  acetonide  has  been  demonstrated  to  be 
effective in the treatment of melasma. The mechanism of action 
of  NAC  is  not  fully  characterized.  NAC  exerts  an  inhibitory 
effect on tyrosinase. However, it is likely the NAC stimulates 
pheomelanogenesis  rather  than  eumelanogenesis,  clinically 
producing  lighter  color.  Thus  caution  again  has  to  be  taken 
with such a drug stimulating pheomelanogenesis.

Hydroquinone-Salicylic Acid Conjugates
Recently,  new  conjugates  were  obtained  by  joining  HQ  and 
salicylic  acid:  monoester  (4-hydroxyphenyl  2-hydroxybenzo-
ate,  HPH)  and  diester  (1,4-phenylene  bis(2-hydroxybenzoate), 
PBH) (53). These conjugate compounds inhibit tyrosinase and 
have efficient skin absorption. Clinical studies on pigmentary 
disorders  are  now  required  to  evaluate  their  tolerance  and 
efficiency.

Cosmetic use of Bleaching Products
This  is  a  common  practice  in  dark-skinned  women  from 
sub-Saharan  Africa  and  a  few  other  parts  of  the  world.  The 

 
334 

 TEXTBOOK OF COSMETIC DERMATOLOGY

products  used  include  HQ,  potent  or  super-potent  topical 
glucocorticoids,  mercury,  salts,  and  caustic  agents  such  as 
liquid  soaps,  hydrogen  peroxide,  and  salicylic  preparations. 
Most  users  (>90%)  apply  the  products  once  or  twice  daily  to 
the  whole  body,  for  months  or  years.  Side  effects,  often  very 
severe,  include  skin  atrophy,  delayed  cicatrisation,  infectious 
dermatoses  (Bacteriae,  mycoses,  parasites),  acne,  dyschromia 
with  a  typical  pattern,  irritant  and  allergic  contact  dermati-
tis,  prominent  striae,  ochronosis,  poikiloderma  of  the  neck, 
and  perioricular  hyperchromia  (Figure  36.2).  Nephrotic  syn-
drome can be observed after the use of mercurial derivatives. 
The daily use of potent topical steroids over years can lead to 
Cushing syndrome. This practice is a real health problem, not 
only in Africa, but in Northern countries receiving large immi-
grant  communities.  A  careful  dermatological  examination  of 
patients is helpful to detect the skin symptoms resulting from 
this practice (54).

Chemical Peels
Chemabrasion  and  peels  using  various  chemicals  is  another 
treatment modality for removal of  freckles,  actinic  lentigines 
and  other  pigmented  spots,  melisma,  and  post-inflammatory 
hypermelanosis.  Deep  peels  are  avoided  in  patients  with 
hypermelanosis because of the high risk of post-inflammatory 
hyper-  or  hypomelanosis,  scarring,  and  keloid  formation. 
Mainly  superficial  and  medium-depth  chemical  peels  have 
been used for the treatment of hypermelanosis, mainly in fair-
skinned individuals.

Glycolic acid is an alpha-hydroxy acid that has an epider-
mal discohesive effect at low concentrations. Removal of cor-
neocytes and epidermal upper layer keratinocytes by chemical 
peeling reduces the epidermal melanin content and improves 
hypermelanoses. Glycolic acid peels (50%–70%) are becoming 
increasingly popular in the treatment of melasma. They can be 
safely used in dark-skinned patients due to a quite low risk of 
hyperpigmentation (55).

A few studies have demonstrated the efficacy of chemi-
cal  peels  with  other  depigmenting  agents  in  patients  with 
hypermelanosis.  Complete  bleaching  of  diffuse  melasma 
was observed in patients (30%) treated with glycolic acid 50% 
plus  kojic  acid  10%  and  partial  blanching  in  60%  of  patients 
Serial glycolic acid peels (30%–40%) combined with a modified 

Figure  36.2  Exogenous  ochronosis  due  to  chronic  application 
of hydroquinone.

Kligman  formula  (2%  hydroquinone  +  0.05%  tretinoin  +  1% 
hydrocortisone) provided an additional effect to the standard 
topical  treatment  in  dark-skinned  patients  with  melasma. 
Another study suggested that daily application of 10% glycolic 
acid lotion and 2% hydroquinone combined with 70% glycolic 
acid  peels  every  3  weeks  showed  some  improvement  of  pig-
mented spots of photoaging in Asian women (56). In contrast, 
a  split-face  prospective  study  in  21  Hispanic  women  within 
melasma showed no differences in the bleaching effect of 4% 
hydroquinone + glycolic peels 20%–30% versus hydroquinone 
4% alone.

Five  peelings  with  salicylic  acid  20%–30%  at  20-week 
intervals in dark-skinned patients (phototypes V to VI), after 
initial treatment with hydroquinone 5% for 2 weeks, gave good 
results for melasma and other types of pigmentation (57).

The  use  of  trichloracetic  20%–35%  followed  by  hydro-
quinone hydro-alcoholic 4% solution or tretinoine 0.05% plus 
hydrocortisone  acetate  1%  cream  has  produced  excellent 
results for hypermelanosis in white patients with higher com-
plexions (55).

Resorcinol is used as Jessner’s solution (14 g resorcinol, 
14 g salicylic acid, 14 g lactic acid 85%, and enough ethanol to 
make up 10 mL) or in Unna’s paste (up to 10% resorcinol plus 
zinc  oxide  and  ceisatile)  have  also  been  demonstrated  to  be 
effective in hypermelanosis with an acceptable rate of adverse 
effects.

Peels  that  combine  kojic  acid,  salicylic  acid,  and  alpha-
hydroxy preparations with or without hydroquinone or resor-
cinol  are  commercially  available  (55).  Applied  every  3  weeks 
they do not require neutralization.

Dermabrasion
Dermabrasion using rotary diamond fraises has been used for 
the  treatment  of  melasma.  Patients  were  followed  for  about 
5  years  (58).  According  to  the  authors,  most  patients  (97%) 
obtained persistent clearance of melasma and only 12 out of 410 
have a partial recurrence. Only two patients developed hyper-
trophic scars and one patient had permanent hypomelanosis.
Dermabrasion-induced  post-inflammatory  hyperpig-
mentation  (PIH),  common  in  Asian  and  dark-skinned  indi-
viduals,  limits  considerably  the  use  of  this  strategy  in  these 
groups of patients. Even the more superficial microdermabra-
sion using a device emitting aluminium oxide crystals bears an 
important risk of post-inflammatory dyspigmentation. Due to 
the important risk of PIH along with the risk of relapse, derm-
abrasion  is  no  longer  recommended  for  treating  melasma.  It 
has  to  be  used  with  great  care  for  treating  other  pigmentary 
disorders.

Liquid Nitrogen Cryotherapy
Melanocytes  are  particularly  susceptible  to  freezing,  and 
hence they should be avoided in dark-skinned people because 
of  the  risk  of  permanent  depigmentation.  The  freezing  agent 
must  be  applied  gently  to  avoid  blistering  and  skin  necrosis. 
Cryotherapy with liquid nitrogen is commonly used success-
fully to treat individual pigmented lesions. Although satisfac-
tory  results  are  common,  cryotherapy  for  benign  epidermal 
lesions  is  problematic  because  of  hypopigmentation,  hyper-
pigmentation, atrophy, scarring, and/or frequent recurrence.

Liquid  nitrogen  cryotherapy  has  also  been  proposed 
for  the  treatment  of  nevus  of  Ota,  delayed  nevus  spilus,  and 
blue nevus. Nowadays laser approaches provide clearly better 
results and cryotherapy should no longer be used for removing 
these  hypermelanocytoses.  Liquid  nitrogen  can  be  proposed 

 
for the treatment of hypermelanoses (actinic lentigos and other 
pigmented  spots  of  photodamaged  skin)  and  hypomelanosis 
(idiopathic guttate hypomelanosis).

LASERS AND PHOTOTHERAPY
The  treatment  of  pigmentary  disorders  by  lasers  is  based 
on  selective  photothermolysis  (59).  In  order  to  have  selective 
action,  the  length  of  the  laser  impulsion  has  to  be  at  least  10 
times shorter than the relaxation time of the target. This relax-
ation  time  is  proportional  to  the  size  of  the  target  (but  also 
depends  on  the  shape  and  the  diffusivity  of  the  target).  For 
pigmentary disorders due to melanin defects the target is the 
melanosome. It is a lysosome-related organelle specific to the 
melanocytes within which the melanin is produced. With their 
maturation, the melanosomes will be progressively filled with 
melanin and be transferred to the surrounding keratinocytes 
(60). The size of a melanosome is about 1 μm. Its relaxation time 
varies from 1 to 10 μs. Thus, the impulsion time of the laser has 
to be inferior to 100 ns. The lasers used for pigmentary disor-
ders are Q-switched and their impulsion length is from 10 to 
100 ns, allowing them to target the melanosomes and most of 
the exogenous pigments.

The location of the pigment in the dermis or the epider-
mis guides in part the choice of wavelength. Thus, dermal pig-
mentation will be better treated with 1064 nm Nd:YAG lasers 
which wavelength could penetrate deeper in the skin tissue. 
Those  lasers  are  also  preferred  for  dark-skinned  people  as 
they interact less with the melanin of the superficial layers of 
the skin.

The type of pigment has also to be taken into consider-
ation. Pheomelanin is a good target for 532 nm Nd:YAG lasers 
when  it  is  a  less  interesting  chromophore  for  694,  755,  and 
1064 nm lasers (61). The choice of the laser wavelength is even 
more important for the treatment of tattoos.

All lasers can induce side effects and patients have to be 
clearly informed about the potential risks. If scars are excep-
tional and are due to excessive fluencies, PIH is the most com-
mon  side  effect.  PIH  is  mostly  observed  in  dark  skin  types. 
Photoprotection is required before and after the laser sessions 
to decrease this risk. PIH usually regresses in a couple of weeks 
or  months.  Topical  steroid  eventually  combined  with  hydro-
quinone  could  be  helpful  in  the  early  stages.  Leukodermas 
are  less  frequently  observed.  They  are  usually  transient,  but 
permanent  leukodermas  have  been  reported  mainly  with 
694 nm ruby lasers. The treatment of tattoos leads to more side 
effects. Cicatricial scars and leukoderma are more frequently 
observed. Patients and physicians have to be aware of the risk 
of paradoxical darkening of tattoos after a first session. Finally, 
allergic  or  granulomatous  reactions,  koebner  phenomenon, 
and pseudolymphomas have been also reported.

Ultraviolet  (UV)  A  and  B  phototherapies  are  both 
widely  used  in  dermatology.  UVA  radiation  includes  elec-
tromagnetic  waves  with  wavelengths  between  320  and  400 
nm. UVB wavelengths are between 290 and 320 nm. It is used 
with systemic or topical psoralens, which selectively absorbs 
the  radiation  (PUVA  therapy).  The  main  action  of  PUVA  on 
biological  systems  is  the  inhibition  of  DNA  synthesis  due 
to  photo-adducts  formed  between  psoralen  and  pyrimidine 
bases in the nucleic acid. PUVA was for a long time considered 
to be the phototherapy of choice, including for hypochromic 
disorders  such  as  vitiligo.  Because  of  potential  side  effects, 
including cutaneous cancers, many authors now recommend 
the  use  of  UVB  therapy  instead  (62–65).  Prospective  studies 
and  meta-analysis  have  now  showed  that  narrowband  UVB 

PIGMENTATION: DYSCHROMIA 

 335

(NB-UVB)  therapy  (around  311  nm)  is  superior  to  PUVA  for 
treating vitiligo (66,67).

The  308  nm  excimer  lasers  have  been  used  in  derma-
tology  since  1997  (68).  The  development  of  308  nm  excimer 
lamps  is  more  recent.  At  the  difference  of  the  lasers,  the 
wavelength  is  not  strictly  monochromatic  and  the  beam  of 
light is not coherent but those systems are much less expen-
sive than lasers. Those devices emit a wavelength in the UVB 
spectrum. The wavelength at 308 nm provides photobiologi-
cal  effects  theoretically  superior  for  those  devices  as  com-
pared  to  NB-UVB,  especially  for  their  immunologic  effects. 
Indeed,  308  nm  is  the  most  effective  wavelength  to  induce 
lesions  to  the  lymphocyte  DNA,  and  the  dose  required  to 
induce the apoptosis of lymphocytes is clearly lower with 308 
nm  as  compared  with  NB-UVB  (69,70).  However,  in  vitiligo 
and more clearly for the other hypopigmentary disorders, the 
stimulation  of  the  migration  and  the  proliferation  of  mela-
nocytes  appear  to  have  a  key  role,  but  fundamental  data  to 
compare the respective photobiological propigmenting prop-
erties  of  the  308  nm  and  NB-UVB  wavelengths  are  still  not 
available. The use of the 308 nm excimer laser and lamps is 
approved  by  the  FDA  (Food  and  Drug  Administration)  for 
the treatment of vitiligo.

The 632.8 nm  helium  neon laser  is the first device that 
does  not  use  the  UV  spectrum  to  repigment  hypochromic 
lesions,  especially  vitiligo.  Indeed,  this  laser,  which  emits 
a  wavelength  in  the  red  visible  light,  has  been  proven  to 
enhance  the  proliferation  and  the  differentiation  of  melano-
blasts  to  mature  melanocytes  in  vitro  (71).  It  has  also  been 
demonstrated that this laser acts on mitochondria to increase 
the  proliferation  rate  of  the  cells  (72).  These  photobiological 
effects  could  explain,  at  least  in  part,  the  action  of  the  632.8 
nm helium neon laser in repigmenting vitiligo. However, clini-
cal data remain poor concerning the efficacy of this device in 
hypochromic disorders (73).

SURGICAL APPROACHES
Surgical  approaches  (74)  aim  to  reconstitute  the  epidermal 
(and perhaps follicular) compartment of the melanocyte pop-
ulation  of  the  skin  by  bringing  to  the  hypochromic  lesion, 
after dermabrasion, a new pigmented skin or a suspension of 
melanocytes, isolated or associated with other epidermal cells 
such  as  keratinocytes.  For  vitiligo  such  methods  are  usually 
considered for stable and localized lesions after medical treat-
ment has failed. However, for piebaldism or to a lesser extent 
for nevus depigmentosus, they are almost the only treatment 
available.

Several  methods  are  available  including  punch  grafts, 
blister grafts, split-thickness grafts, and autologous transplan-
tation  of  melanocyte  suspensions,  cultured  melanocytes,  or 
cultured epidermal grafts including melanocytes. Grafting of 
follicular  melanocytes  to  repigment  vitiligo  leukotrichia  has 
also been performed successfully (75).

Punch grafting (1.2–3 mm punch biopsies) is the simplest 
technique, and grafts are implanted into perforations prepared 
at  the  recipient  sites  by  different  techniques  (punch  biopsy, 
ablative  lasers).  Minigrafting  using  small  grafts  (1.2  mm)  is 
the  best  technique.  The  potential  side  effects  include  spotted 
pigmentation, polka dot appearance, color mismatch, a cobble-
stone effect, sinking pits, and scarring. Furthermore, this tech-
nique is time consuming.

Split-thickness grafting is obtained by a standard or an 
electrical dermatome. The main advantage of this treatment is 
to  allow  treatment  of  large  areas.  Esthetical  results  are  often 

 
336 

 TEXTBOOK OF COSMETIC DERMATOLOGY

satisfactory with a homogenous repigmentation. However, this 
approach  may  be  associated  with  esthetically  unacceptable 
results at the donor site (dyspigmentation, scarring). Adverse 
events include miliae-like cyst formation at the recipient site, 
partial loss of the grafts, hematoma formation, and thickening 
of the graft margins.

In  flip-top  transplantation,  the  epidermis  at  the  recipi-
ent  site  is  used  to  form  multiple  hinged  flaps,  each  covering 
an ultra-thin 1.2 mm graft harvested from the donor site by a 
razor blade (76).

Autologous  blisters  can  be  induced  in  different  ways, 
i.e.,  vacuum,  liquid  nitrogen.  The  mechanical  split  occurs  at 
the dermo–epidermal junction. The recipient site is prepared 
by  dermabrasion,  laser  ablation  (erbium:YAG  or  carbon  diox-
ide  laser),  liquid  nitrogen,  or  PUVA-induced  blisters,  derma-
tome. The graft (top of the blister) is applied and secured on 
the  recipient  site.  The  only  adverse  event  is  transient  hyper-
pigmentation at both the donor and recipient sites. The advan-
tages  of  this  technique  are  the  absence  of  scarring  and  the 
possibility  of  reusing  the  donor  site.  Split-thickness  grafting 
and blister grafts have a better success rate than punch graft-
ing (77). These techniques are not expensive and can be done 
in private practice.

The use of epidermal suspension (melanocytes alone or 
combined  with  keratinocytes)  is  more  recent.  Non-cultured 
keratinocyte/melanocyte  suspensions  can  be  obtained  after 
trypsinization  of  a  shave  biopsy  of  the  buttock  or  full  thick-
ness biopsy of the scalp. Melanocytes obtained from the hair 
follicles and interfollicular epidermis as well as keratinocytes, 
are  put  into  a  suspension  with  the  patient’s  serum  for  direct 
application  to  the  recipient  site  without  expansion  in  culture 
(78). The recipient site is prepared with dermabrasion using a 
dermatome or an ablative CO2 or Erbium laser. This technique 
allows  treating  large  lesional  surfaces  with  a  small  piece  of 
skin, as a ratio of 1:5 to 1:10 is commonly used. A prospective 
randomized  double-blind  study  has  demonstrated  that  epi-
dermal  suspension  followed  by  UV  (PUVA  or  Nb-UVB)  was 
more effective than UV combined with only dermabrasion and 
serum (79). This technique used to require a specialized labo-
ratory but the development of ready-to-use kits now allow it to 
be used by any trained physician.

The  number  of  melanocytes  (combined  or  not  with 
keratinocytes)  can  be  expended  in  culture  before  grafting. 
Applied  on  vitiligo  lesions,  it  gives  satisfactory  results  in 
30%–44%  of  patients.  Improvement  of  melanocyte  culture 
conditions and grafting devices have made possible the trans-
plantation of autologous cultured melanocytes on large areas 
(up  to  500  cm²  during  one  session)  of  vitiligo  involved  skin 
(80,81).  A  95%  repigmentation  is  obtained  in  approximately 
40% of the treated areas. However, while the results are usu-
ally excellent for stable vitiligos, active forms lead to failure 
of  the  procedure,  and  careful  selection  of  patients  remains 
crucial (82). All the techniques involving melanocyte culture 
and epidermal reconstruction require specialized laboratory 
expertise and are very expensive. For these reasons, they are 
not widely used.

CAMOUFLAGING
Camouflaging  has  been  shown  to  increase  the  quality  of  life 
(DLQI) of people using it (83,84) The use of medical makeup 
has become progressively more popular and is now integrated 
in  many  dermatological  centers.  Cosmetic  products  with 
high  concentration  in  pigments  allow  very  interesting  and 
esthetical results but require training of the technique (85,86). 

A  siliconated  spray  could  be  used  to  cover  the  makeup  and 
increase its waterproofing properties, allowing the practice of 
water activities (87).

Dihydroxyacetone  (DHA)  can  also  be  very  useful  to 
decrease the contrast of hypopigmented lesions with the sur-
rounding skin. The brown color is due to the chemical com-
bination of the DHA with the amino acids of the skin leading 
to  the  formation  of  polymeric  pigments  called  melanoidins. 
Those pigments remain in the startum corneum until desqua-
mation of the corneocytes. The coloration appears a few hours 
after the application of the DHA and progressively fades after 
5–7  days  (88–90).  The  main  advantages  of  this  are  to  resist 
to water and to not stain the dressings. It is used mainly for 
the  hands  and  the  feet.  Concentrations  between  2.5%–10% 
can be used depending on the intensity of the desired color. 
As DHA combines with the amino acids of the stratum cor-
neum, the intensity of the reaction depends on the thickness 
of  this  skin  layer.  Thus  patients  should  be  advised  to  apply 
less  quantity  on  locations  with  thick  stratum  corneum  such 
as palms, soles, knees, or ankles. The patient would also have 
to be informed that the pigmentation produced is not photo-
protective against UV.

Micropigmentation could also be helpful, especially for 

areas such as lips or nipples in dark skin phototypes (91,92).

TREATMENT OF PIGMENTARY LESIONS
Melasma
The gold standard treatment for melasma is topical bleaching 
agents  (Figure  36.3).  Kligman’s  formula  is  the  most  effective 
treatment,  especially  in  its  stabilized  form  (47,93–96).  Peeling 
and  dermabrasion  can  be  also  proposed  but  their  efficacy  is 
inconsistant and these strategies frequently induce PIH (60,97).
Ablative  and  non-ablative  fractional  lasers  have  been 
reported  to  improve  melasma  (98,99).  However,  the  risk  of 
relapse  is  important  and  up  to  10%  worsening  has  been 
reported  with  such  approaches  (100).  Moreover,  non-ablative 
fractional laser has been shown to not be superior to Kligman’s 
trio (101). Interesting results have been reported with the 1927 
nm thulium laser (102,103). However some PIH were reported 
along  with  relatively  frequent  relapses.  Prospective  random-
ized comparative trials are still required to determine the use-
fulness of this new device for treating melasma.

Pigmentary lasers such as Q-switched ruby, alexandrite, 
or  Nd:YAG  lasers  induce  almost  constant  PIH  and  relapses. 
More  recently,  Q-switched  laser  used  with  low  fluencies  and 
repetitive sessions has been reported to be effective for treat-
ing  melasma.  However,  when  long-term  follow-up  is  per-
formed a constant relapse is observed along with up to 20% of 
worsening  of  the  hyperpigmentation  due  to  PIH  (104).  Thus, 
such approaches can’t be recommended for treating melasma.
Intense  pulsed  light  (IPL)  has  shown  some  efficacy  in 
the  treatment  of  melasma  (105–108).  The  risk  of  PIH  remains 
important but appears to be lower than the one observed with 
Q-switched lasers. Topical bleaching preparations, frequently 
containing hydroquinone, have been used with IPL in order to 
prevent  PIH  (109,110).  Although  potentially  useful,  this  asso-
ciation approach has never been compared to bleaching cream 
used in monotherapy.

Increasing data shows that in addition to the increase in 
pigmentation,  melasma  lesions  have  more  elastosis  and  vas-
cularization compared to the perilesionnal skin (111–113). The 
association  of  a  fixed  triple  combination  cream  and  a  pulsed 
dye  laser  (PDL)  with  vascular  and  pigmentary  parameters 

 
PIGMENTATION: DYSCHROMIA 

 337

(a)

(b)

(c)

(d)

Figure 36.3  Melasma before treatment in direct light (a) and UV light (b), and after 3 months of Kligman’s preparation in direct light (c) 
and UV light (d).

showed significantly better decrease of the hyperpigmentation 
of melasma and reduced the relapses observed after the sum-
mer (114,115). Following the same aim of targeting the vascu-
lar component of melasma tranexamic acid, an antifibrinolytic 
used to prevent and to treat some hemorrhagic events was also 
proposed for treating melasma. The combined use of this agent 
topically and orally for 8 weeks led to a decrease of the hyper-
pigmentation  in  melasma  lesions.  Histological  examinations 
showed a decrease in melanin content and in vascularization 
(116,20). Those pilot studies clearly need to be confirmed, but 
they underline the potential interest of targeting the vascular 
component for treating melasma.

To  conclude,  Kligman’s  trio  remains  the  gold  standard 
for treating melasma and should be used as the first treatment 
option. Other options can be proposed if the trio fails to depig-
ment  the  melasma.  In  all  cases,  patients  have  to  be  advised 
about  the  limitations  and  potential  side  effect  of  the  treat-
ments. However, all the therapeutic approaches do not prevent 
relapses of melasma. After the initial treatment (in most cases 
3–4 months of Kligman’s trio), a maintenance treatment has to 
be prescribed. Cosmetic depigmenting agents are very useful 
for maintenance due to their good safety profile in most cases. 
Last  but  not  least,  preventing  triggering  factors  is  crucial. 
Discontinuation  of  estroprogestative  medications  should  be 
discussed but not proposed in all cases, as the impact of their 
discontinuation on the evolution of melasma has been shown 
to be weak (117). Repetitive friction should be avoided. More 
importantly, strict photoprotection with clothing, sunglasses, 
sun avoidance, and sunscreens with very good UVB and UVA 
protection are mandatory. Recent data showed that the shorter 
wavelengths of visible light plays can trigger hyperpigmenta-
tion of the skin and that protection against these wavelengths 
in addition to strong UVA and UVB protection is effective for 
preventing melasma relapses (118,119).

Vitiligo
Many medical or surgical treatments are available for vitiligo, 
but only a few have clearly demonstrated their efficacy in treat-
ing vitiligo.

Phototherapy  (PUVA  or  Nb-UVB)  is  the  gold  standard 
for  generalized  forms  (67,120,121).  If  available,  Nb-UVB  is 

preferable  to  PUVA,  as  has  greater  efficacy  with  lesser  side 
effects and better tolerance (66).

Once-daily applications of topical steroids or twice-daily 
application of 0.1% tacrolimus or 1% pimecrolimus should be 
used first for localized forms of vitiligo (67,120,121).

Targeted phototherapy with 308 nm excimer lamps and 
lasers is also effective for localized forms, but are more expen-
sive  (Figure  36.4)  (122–127).  However,  bony  prominences  and 
extremities remains extremely difficult to treat (127).

The  data  concerning  the  other  therapeutic  approaches 
including antioxidants or topical vitamin D are more contro-
versial (128–138).

Combination  approaches  associating  tacrolimus  oint-
ment  or  pimecrolimus  cream  with  phototherapy  (308  nm 
excimer  light  or  Nb-UVB)  have  shown  their  superiority  to 
monotherapy  (139–144).  Such  a  synergic  effect  has  been  also 
reported  with  the  association  of  topical  steroids  and  excimer 
laser (145). Those associations should proposed for difficult to 
treat areas such as bony prominences.

Surgical treatment is a good option for localized or seg-
mental forms that have been stable for at least 3 years (Figure 
36.5) (67,120,121).

When  treatments  have  failed  corrective  cosmetics,  use 
of  DHA  (dihydroxyacetone  1,3-dihydroxydimethylcetone)  or 
dermopigmentation (especially for nipples and mucosal areas) 
can be useful (146,60). Finally, depigmentation that we would 
like  as  permanent  can  be  proposed  usually  for  people  more 
than  40  years  old,  after  detailed  information  is  given  to  the 
patient.  Psychological  evaluation  is  also  useful.  The  mono-
benzylether  of  hydroquinone  (MBEH)  causes  a  permanent 
depigmentation  of  the  skin  that  has  been  used  for  general-
ized vitiligo. However, the side effects that include irritant and 
allergic  contact  dermatitis,  post-inflammatory  hypermelano-
sis, leukoderma en confetti at treated sites, and hypomelano-
sis at sites distant from the application areas strongly limit the 
use of this compound and have prompted clinicians to explore 
therapeutic alternatives. Q-switched lasers are as effective as 
MBEH  with  fewer  side  effects,  and  should  now  be  preferred 
(Figure  36.6)  (147–150).  Better  results  seem  to  be  obtained  if 
the vitiligo is active (151). Depigmentation therapies should be 
reserved for limited surfaces and they should not be proposed 

 
338 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(c)

Figure 36.4  Vitiligo of the face (a). Clinical aspect after 40 ses-
sions of 308 nm excimer laser (b) and 18 months after the end of 
the treatment (c).

if depigmentation involves less than 50% of the affected area. 
In all cases, patients must be clearly informed of the potential 
risk of later repigmentation, and photoprotection of the treated 
areas should be systematically prescribed.

Halo Nevus
Halo  nevi  usually  do  not  require  any  treatment.  However, 
some  patients  seek  treatment.  Some  successes  have  been 
reported with the 308 nm excimer laser (152).

(a)

(b)

Figure  36.5  Localized  and  stable  vitiligo  lesion  (a).  Clinical 
aspect  2  months  after  epidermal  cell  suspension  graft  (b). 
(Courtesy of Dr. P. Bahadoran).

Piebaldism
Piebaldism  is  a  rare  autosomal  dominant  disorder  with  con-
genital  hypomelanosis.  Most  patients  have  a  mutation  in  the 
KIT gene (153). The pigmentary disorder is limited to hair and 
skin without neurological, ocular, or hearing defects. The topo-
graphical distribution of the lesions spreading to the anterior 
part of the trunk, abdomen, extremities, and the frontal part of 
the  scalp  is  characteristic  of  the  disease  (154,155).  Unlike  vit-
iligo, these patches are congenital, stable with time, and do not 
repigment. Nice results can be obtained with surgical grafting 
procedures (156–159).

Nevus Depigmentosus
Nevus depigmentosus can be effectively treated with grafting 
(160,161). Late recurrences are possible and the patient should 
be informed about this potential risk (162). The 308 nm excimer 
laser has been proposed but data are still limited (163).

Solar Lentigines
Solar  lentigines  are  effectively  treated  with  topical  blanch-
ing  cream,  liquid  nitrogen,  Q-switched  lasers,  and  IPL 

 
PIGMENTATION: DYSCHROMIA 

 339

(a)

(a)

(b)

(b)

Figure 36.6  Extensive vitiligo of the face that did not respond to 
repigmenting therapies (a). Depigmentation of the remaining pig-
mented areas 2 months after one session of 755 nm alexandrite 
Q-switched laser (b).

Figure  36.7  Actinic  lentigos  of  the  face  (a).  Clinical  aspect  1 
month after one session of 755 nm alexandrite Q-switched laser 
(b).

(Figure  36.7).  Treatment  with  Q-switched  laser  has  proved 
to  be  the  most  effective  approach,  especially  if  the  lesions 
are  numerous,  but  it  remains  more  expensive  (164).  One  or 
two laser sessions are sufficient (165). While 694 and 755 nm 
are  usually  preferred  is  most  cases,  light  lentigos  are  bet-
ter  treated  with  532  nm  Q-switched  lasers  (166).  The  use 
of  sunscreens  and  cosmetic  depigmenting  cream  will  be 
advised in all patients to decrease recurrences. If the lesion 

is  atypical,  a  skin  biopsy  has  to  be  performed  to  detect  a 
lentigo maligna.

Pigmented Seborrheic Keratosis
Thin  pigmented  seborrheic  dermatosis  can  be  treated  with 
Q-switched  lasers  and  IPL,  but  shaving,  liquid  nitrogen,  or 
ablative lasers are the most frequently used treatments.

 
340 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Congenital and Acquired Dermal 
Hypermelanocytosis
Ota  nevi  are  dermal  hypermelanocytosis  of  the  periorbital 
region.  Such  dermal  hypermelanocytosis  can  also  affect  the 
shoulder (Ito nevus) or rarely other parts of the body. Acquired 
dermal  hypermelanocytosis  has  also  been  reported  (Figure 
36.8).  Although  more  frequently  observed  in  Asian  people,  it 
affects  all  races.  Ruby,  alexandrite,  and  Nd:YAG  Q-switched 
lasers have shown their efficacy. The depth of the target pig-
ment  leads  to  the  use  of  longer  wavelength.  The  1064  nm 
Q-switched Nd:YAG has shown its superiority over the 755 nm 
alexandrite  (167).  Early  treatment  at  a  young  age  and  brown 
rather than blue lesions are good predictive factors of response 
to  treatment  (168,169).  Relapses  can  be  observed  and  patients 
should be made aware of this (170).

Although the literature is poor, Ito nevus and acquired 
dermal  hypermelanocytosis  can  also  be  effectively  treated 
with the above lasers.

Poikiloderma of Civatte
Laser and IPL approaches are the best treatments for the poi-
kiloderma of Civatte. Both PDL and IPL have shown their effi-
cacy  (171–174).  However,  persistent  depigmentation  has  been 
reported as a late adverse event, and high fluencies should be 
avoided in this fragile location (175). Some authors have sug-
gested the use of fractional photothermolysis with interesting 
results, but the data remain limited (176,177).

Café-au-Lait Macules
Café-au-lait  macules  can  be  treated  with  lasers  and  IPL.  The 
response  is  variable  and  recurrences  are  very  frequent.  No 
clinical or histological markers have been determined to pre-
dict the response to treatment (178). Thus, the patient should 
be clearly informed of those risks. For large lesions, we advise 
a test session on a small area and seeing the patient after one 
summer to evaluate the response and the stability after treat-
ment before treating the entire lesion.

Nevus Spilus
Q-switched lasers, including ruby and alexandrite, have dem-
onstrated  their  efficacy  to  treat  nevus  spilus  (179,180).  As  for 
café-au-lait  macules,  relapses  have  been  observed.  Moreover, 
the risk of melanoma, though rare, is real, and laser treatment 
should be proposed with caution and a biopsy must done if the 
lesion is atypical.

Lentigines and Freckles
Q-switched lasers are effective for treating lentigines, includ-
ing  those  associated  with  a  genetic  disorder  such  as  Peutz-
Jeghers-Touraine syndrome (181).

Freckles can also be treated with laser. As they contain 
mainly pheomelanin, the optimal wavelength will be the 532 
nm (182,61). However, due to the constant relapses we do not 
recommend the treatment of ephelides.

Becker Nevus
The  hair  component  of  Becker  nevus  responds  well  to  laser 
hair  removal  (Figure  36.9).  The  hyperpigmentation  can  also 
be  treated  with  Q-switched  lasers  but  the  response  is  more 
inconstant  and  recurrences  are  observed.  A  test  session  is 
required  before  treating  large  lesions.  Most  of  the  authors 
advise  to  first  treat  the  hair  component,  but  the  sequence 
of treatment does not change the final result and the choice 
mainly depends on the type of lesions and the preference of 
the patient.

Pigmentary Mosaicism (Linear 
and Whorled Hypermelanosis)
There is almost no data concerning the treatment of pigmen-
tary mosaicism. Blanching products are ineffective, and only 
Q-switched  lasers  have  provided  some  interesting  results 
(183) (Figure 36.10). However, pigmentary mosaicism is a het-
erogeneous group and response to treatment is highly vari-
able.  A  test  session  using  several  wavelengths  is  required 
to  determinate  the  optimal  laser  approach  and  the  risk  of 
recurrences.

Dark Rings
Dark  rings  under  the  eyes  are  a  heterogeneous  group  with 
multifactorial  etiologies.  Superficial  location  of  vasculature 
and  constitutional  hyperpigmentation  are  the  most  frequent 
causes.  However,  dark  rings  may  have  other  origins  such  as 
periorbital  edema,  PIH,  shadowing,  loss  of  subcutaneous  fat, 
xerosis, and skin laxity (184). A vascular origin is noted mainly 
in  fair-skinned  individuals,  while  constitutional  hyperpig-
mentation  occurs  most  frequently  in  dark-skinned  patients. 
Dark  rings  due  to  constitutional  hyperpigmentation  can  be 
treated  topically  with  tretinoin  cream,  peeling,  CO2  laser,  or 

Figure 36.8  Acquired Ota nevus (Hori nevus).

Figure 36.9  Becker nevus.

 
PIGMENTATION: DYSCHROMIA 

 341

Postinflammatory Pigmentation
Postinflammatory  pigmentation  is  frequent  and  can  be 
observed after a surgical or cosmetical procedure. Laser treat-
ments  are  not  a  good  option  for  such  hyperpigmentation  as 
they can worsen the lesions. Photoprotection and treatment of 
the  underlying  dermatosis,  if  there  is  one,  is  mandatory  and 
could be effective by themselves. If needed, class 3 topical ste-
roids  alone  or  combined  with  4%–10%  hydroquinone  can  be 
added.

Idiopathic Guttate Hypomelanosis
Idiopathic  guttate  hypomelanosis  is  associated  with  chronic 
sun exposure (Figure 36.11). Any phototherapy, even focused 
treatment  with  the  308  nm  excimer  laser  or  lamp,  should  be 
avoided.  Some  isolated  successes  have  been  reported  with 
topical  tretinoin,  liquid  nitrogen,  or  localized  superficial 
dermabrasion treatments (197–199). In our practice, superficial 
Erbium-assisted dermabrasion provides good results. Recently, 
interesting results have been reported using ablative and non-
ablative fractional lasers (200,201).

Hypopigmented Striae and 
Iatrogenic Leukoderma
Although quite frequent, those two conditions have no effec-
tive treatment. Isolated cases have reported some success with 
the 308 nm excimer laser (202–204). The absence of a group of 
control, the weaknesses in the evaluation of the results, and 
the  need  for  maintenance  sessions  should  moderate  those 
results.

Progressive Macular Hypomelanosis
Progressive macular hypomelanosis (PMH) is a common skin 
disorder that is often misdiagnosed (mostly for pityriasis ver-
sicolor) (Figures 36.12 and 36.13). PMH is characterized by ill-
defined  nummular,  non-scaly  hypopigmented  spots  on  the 
trunk, often confluent in and around the midline, and rarely 
extending to the proximal extremities and neck/head region. 
There is no itch, pain, or preceding inflammation. Westerhof et 
al. suggested the causative role of Propionibacterium acnes bac-
teria  and  thus  proposed  as  a  treatment  the  application  of  1% 
clindamycin  lotion  during  the  day,  5%  benzoyl  peroxide  gel 
at  night,  and  UVA  light  irradiation  three  times  a  week  for  a 
period of 12 weeks (205). However, phototherapy alone (PUVA 
or Nb-UVB) appears also to be effective (206).

Ochronosis
Alcaptonuria is a rare genetic disorder which leads to endoge-
nous ochronosis. Exogenous ochronosis is much more frequent 
and  is  due  to  the  chronic  application  of  hydroquinone.  Most 
cases are seen in dark-skinned people who seek to blanch their 
skin.  Discontinuing  hydroquinone  application  is  of  course 
required. Little data are available for the treatment; dermabra-
sion, CO2 laser, and more recently Q-switched laser have been 
proposed (207–209).

Dyskeratosis
Dyskeratosis,  including  ictyosis,  seborrheic  keratosis,  derma-
tosis papulosa nigra, and confluent and reticulated papilloma-
tosus of Gougerot et Carteau can lead to hyperpigmentation.

Ictyosis  is  effectively  treated  by  the  daily  use  of  emol-
lients. The  treatment of  dermatosis  papulosa  nigra treatment 
is  similar  to  seborrheic  keratosis  (cf.  upper),  curettage,  elec-
trodessication,  Q-switched  lasers,  fractional  or  continuous 

(a)

(b)

Figure 36.10  Pigmentary mosaicism of the thigh. A part of the 
lesion was chosen for the test session with 532, 755, and 1064 nm 
Q-switched lasers (a). Two months after the test session only the 
area treated with the 755 nm laser showed a nice improvement, 
in this case emphasizing the importance of testing several wave-
lengths in such pigmentary disorders.

surgical  treatment  (185–188).  However,  best  results  are  usu-
ally  obtained  with  Q-switched  lasers  and  IPL  (189,190).  Only 
cosmetic approaches with makeup can be proposed when the 
origin  is  vascular.  Skin  laxity  can  be  treated  surgically  and 
autologous fat injection can be proposed if the cause is loss of 
subcutaneous fat.

Pigmentation due to Hemosiderosis 
and Siderosis
One of the most common manifestations of this is stasis der-
matitis, but other causes can trigger such hyperpigmentation 
(vascular  or  thrombopenic  purpura,  post-Kaposi  sequelae, 
iron  extravasation  …).  Although  the  data  are  still  limited, 
treatment with Q-switched lasers and IPL appear to be effec-
tive (191–193).

Drug-Induced Pigmentation
Pigmentation  induced  by  drugs  (such  as  cyclines  or  amioda-
rone)  can  be  removed  with  Q-switched  lasers  (194–196).  The 
pigmentation is usually in the dermis, so 694, 755, and 1064 nm 
wavelength should be preferred to Nd:YAG 532 nm.

 
342 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 36.11 

Idiopathic guttate hypomelanosis.

Figure 36.12  Progressive macular hypomelanosis.

ablative  lasers  have  been  reported  (210–212).  The  confluent 
and reticulated papillomatosis of Gougerot et Carteau can be 
treated with topical agents such as tretinoin or vitamin D but 
most authors agree on the use of minocycline (213–216).

Chromhidrosis and Pseudochromhidrosis
Chromhidrosis  and  pseudochromhidrosis  are  rare  skin  dis-
orders. Chromhidrosis refers to the excretion by the apocrine 
glands  of  sweat  containing  lipofuscin  pigments,  while  the 
terms  pseudochromhidrosis  or  extrinsic  chromhidrosis  are 
used  when  the  eccrine  sweat  is  colored  on  the  surface  of  the 
skin  as  a  result  of  the  deposit  of  extrinsic  dyes  or  paints,  or 
by  transformation  by  chromogenic  bacteria.  Only  few  fungi 
and  bacteria  are  known  to  induce  pseudochromhidrosis. 
Corynebacteria  are  responsible  for  red  pseudochromhidrosis 
and Malassezia furfur and Bacillus sp. are the agents involved in 

Figure 36.13  Achromic tinea versicolor.

blue  pseudochromhidrosis  (217).  Treatment  of  pseudochrom-
hidrosis consists of removing clothes or tissues responsible for 
the  deposit  of  the  extrinsic  dyes  or  treating  the  chromogenic 
bacteria or fungi proliferation.

TATTOOS
Tattoos are inclusions of pigments in the dermis or the hypo-
dermis.  Their  cause  can  be  traumatic,  esthetic,  or  medical 
(marks  for  radiotherapy).  The  variety  of  the  color  sometimes 
leads to the necessity of using several wavelengths. Black pig-
ments can be easily removed by almost all kinds of Q-switched 
lasers. Blue and green tattoos will be treated with 755 nm alex-
andrite  lasers  and  red  color  will  be  better  targeted  with  532 
nm Nd:YAG lasers. The quantity, quality, and depth of the pig-
ments in the skin and the individual responses of the patients 
account  for  the  variability  of  results  and  the  potential  side 
effects sometimes observed.

Many  Q-switched  have  demonstrated  their  efficacy  to 
remove tattoos (218). Due to their side effects, the non-fractional 
ablative lasers are no longer used. The choice of the laser will 
be guided by the color of the tattoos. Amateur tattoos, perma-
nent makeup, blue-black color, and monochromatic tattoos are 
good predictive factors of response to treatment (Figure 36.14) 
(219). For traumatic tattoos, metal and asphalt origin and large-
size pigments appear to be more resistant to laser treatment. A 
2-month delay between each session is usually recommended 
to allow elimination of the fragmented pigments and decrease 
the risk of cicatricial scars. Gunpowder tattoos should not be 
treated  with  Q-switched  lasers  as  the  high  energy  pulses  of 
laser on the powder particles creates microexplosions of these 
fragments, resulting in cavitation and provoking transepider-
mal  holes  and  subsequent  scars  (220).  Recently,  picosecond 
lasers  have  been  commercialized  for  removing  tattoos.  For 
now  they  are  still  relatively  close  to  the  nanosecond  as  their 
pulse duration time is 500–800 picosec. They aim to induced 
better  fragmentation  of  the  pigments  and  thus  allow  better 
elimination  compared  to  Q-switched  lasers.  Published  data 
provide encouraging results but prospective comparative ran-
domized intra-individual studies are still missing, preventing 
us to draw a definitive conclusion about the real contribution 
of this technique (221,222).

 
PIGMENTATION: DYSCHROMIA 

 343

wavelength,  usually  allows  removing  the  remaining  pig-
ments.  However,  ablative  lasers  or  fractional  non-ablative 
can also be proposed (223).

REFERENCES

1. Nordlund JJ, Boissy RE, et al. The Pigmentary System: Physiology 
and Pathophysiology. New York: Oxford University Press, 1998.
2. Passeron T, Mantoux F, et al. Genetic disorders of pigmentation. 

Clin Dermatol 2005; 23(1):56–67.

3. Nordlund JJ, Boissy RE, et al. The Pigmentary System: Physiology 

and Pathophysiology. Edinburgh: Blackwell Science, 2006.

4. Haught JM, Patel S, et al. Xanthoderma: A clinical review. J Am 

Acad Dermatol 2007; 57(6):1051–18.

5.  Stratigos  AJ,  Katsambas  AD.  Optimal  management  of  recalci-
trant disorders of hyperpigmentation in dark-skinned patients. 
Am J Clin Dermatol 2004; 5(3):161–8.

6.  Jimbow  K,  Obata  H,  et  al.  Mechanism  of  depigmentation  by 

hydroquinone. J Invest Dermatol 1974; 62:436–49.

7.  Katsambas  AD,  Stratigos  AJ.  Depigmenting  and  bleaching 
agents:  Coping  with  hyperpigmentation.  Clin  Dermatol  2001; 
19(4):483–8.

8. Briganti  S,  Camera  E,  et  al.  Chemical  and  instrumental 
approaches  to  treat  hyperpigmentation.  Pigment  Cell  Research 
2003; 16(2):101–10.

9.  Khemis A, Kaiafa A, et al. Evaluation of efficacy and safety of 
rucinol  serum  in  patients  with  melasma:  A  randomized  con-
trolled trial. Br J Dermatol 2007; 156(5):997–1004.

  10.  Bleehen SS. The treatment of hypermelanosis with 4-isopropyl-

catechol. Br J Dermatol 1976; 94(6):687–94.

  11.  Jimbow  K.  N-acetyl-4-S-cysteaminylphenol  as  a  new  type 
of  depigmenting  agent  for  the  melanoderma  of  patients  with 
melasma. Arch Dermatol 1991; 127(10):1528–34.

  12.  Verallo-Rowell VM, Verallo V, et al. Double-blind comparison 
of azelaic acid and hydroquinone in the treatment of melasma. 
Acta Derm Venereol Suppl (Stockh) 1989; 143:58–61.

  13.  Paine C, Sharlow E, et al. An alternative approach to depigmen-
tation by soybean extracts via inhibition of the PAR-2 pathway. 
J Invest Dermatol 2001; 116(4):587–95.

  14.  Nakagawa  M,  Kawai  K,  et  al.  Contact  allergy  to  kojic  acid  in 

skin care products. Contact Dermatitis 1995; 32(1):9–13.

  15.  Kameyama  K,  Sakai  C,  et  al.  Inhibitory  effect  of  magnesium 
L-ascorbyl-2-phosphate  (VC-PMG)  on  melanogenesis  in  vitro 
and in vivo. J Am Acad Dermatol 1996; 34:29–33.

  16.  Huh  CH,  Seo  KI,  et  al.  A  randomized,  double-blind,  placebo-
controlled  trial  of  vitamin  C  iontophoresis  in  melasma. 
Dermatology 2003; 206(4):316–20.

  17.  Espinal-Perez L., Moncada B, et al. A double-blind randomized 
trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J 
Dermatol 2004; 43(8):604–7.

  18.  Chung WC, Shi GY, et al. Human plasmin induces a receptor-
mediated  arachidonate  release  coupled  with  G  proteins  in 
endothelial cells. Am J Physiol 1993; 264:C271–81.

  19.  Ando H, Matsui MS, et al. Quasi-drugs developed in Japan for 
the prevention or treatment of hyperpigmentary disorders. Int 
J Mol Sci 2009; Jun 18;11(6):2566–75.

  20.  Li Y, Sun Q, et al. Treatment of melasma with oral administra-
tion of compound tranexamic acid: A preliminary clinical trial. 
J Eur Acad Dermatol Venereol 2014; 28(3):393–4.

  21.  Sugai  T.  Clinical  effects  of  arbutin  in  patients  with  chloasma. 

Skin Research (Hifu) 1992; 34:522–9.

  22.  Kamide  R,  Arase  S,  et  al.  Clinical  effects  of  XSC-29  formula-
tion  on  UV-induced  pigmentation.  Nishinihon  J  Dermatol  1995; 
57:136–42.

  23.  Ichihashi M, Kobayashi A, et al. Effect of chamomilla extracts 
application  on  UV-induced  pigmentation.  Skin  Research  (Hifu) 
1999; 41:475–80.

  24.  Kawashima M, Okuda M, et al. Inhibitory effect of chamomilla 
extracts  on  UV-induced  pigmentation.  Nishinihon  J  Dermatol 
1999; 61:682–5.

(a)

(b)

Figure 36.14  Blue ritual tattoos of the face (a) almost completely 
removed after only 2 sessions of Q-switched 755 nm alexandrite 
Q-switched laser (b).

Some  tattoos  (especially  cosmetic  and  yellow  tattoos) 
can  darken  or  change  color  after  a  first  session.  A  test  ses-
sion on a limited area is recommended. If the tattoo changes 
color,  an  additional  treatment  eventually,  changing  the 

 
 
 
 
 
344 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  25.  Takeda  K,  Yokota  M,  et  al.  Inhibitory  effect  of  a  formulation 
containing 0.5% Magnolignan (5,5’-dipropyl-biphenyl-2,2’-diol) 
on UV-induced skin pigmentation. Nishinihon J Dermatol 2006; 
68:288–92.

  26.  Takeda  K,  Arase  S,  et  al.  Clinical  evaluation  of  the  topical 
application  of  Magnolignan  (5,5’-dipropyl-biphenyl-2,2’diol) 
for hyperpigmentation on the face. Nishinihon J Dermatol 2006; 
68:293–8.

  47.  Taylor  SC,  Torok  H,  et  al.  Efficacy  and  safety  of  a  new  triple-
combination  agent  for  the  treatment  of  facial  melasma.  Cutis 
2003; 72(1):67–72.

  48.  Fleischer  AB,  Schwartzel  EH,  et  al.  The  combination  of  2% 
4-hydroxyanisole  (Mequinol)  and  0.01%  tretinoin  is  effective 
in  improving  the  appearance  of  solar  lentigines  and  related 
hyperpigmented lesions in two double-blind multicenter clini-
cal studies. J Am Acad Dermatol 2000; 42:459–67.

  27.  Qiu  L,  Zhang  M,  et  al.  Inhibition  of  melanin  synthesis  by 
cystamine  in  human  melanoma  cells.  J  Invest  Dermatol  2000; 
114(1):21–7.

  49.  Ortonne JP, Camacho F, et al. Safety and efficacy of combined 
use  of  4-hydroxyanisole  (mequinol)  2%/tretinoin  0.01%  solu-
tion and sunscreen in solar lentigines. Cutis 2004; 74(4):261–4.

  28.  Hwang  JS,  Choi  H,  et  al.  Pigment-lightening  effect  of  N,N’-
dilinoleylcystamine  on  human  melanoma  cells.  Br  J  Dermatol 
2004; 150(1):39–46.

  29.  Farshi S, Mansouri P, et al. Evaluation of efficacy of cysteamine 
cream  in  the  treatment  of  epidermal  melasma:  A  random-
ized double blind placebo controlled study. Br J Dermatol 2014; 
Jul;173(1):209–17.

  30.  Rouzaud F, Hearing VJ. Regulatory elements of the melanocor-

tin 1 receptor. Peptides 2005; 26(10):1858–70.

  31.  Napolitano  A,  Panzella  L,  et  al.  Pheomelanin-induced  oxi-
dative  stress:  Bright  and  dark  chemistry  bridging  red  hair 
phenotype  and  melanoma.  Pigment  Cell  Melanoma  Res  2014; 
27(5):721–33.

  32.  Mitra  D,  Luo  X,  et  al.  An  ultraviolet-radiation-independent 
pathway to melanoma carcinogenesis in the red hair/fair skin 
background. Nature 2012; 491(7424):449–53.

  33.  Rafal  ES,  Griffiths  CE,  et  al.  Topical  tretinoin  (retinoic  acid) 
treatment for liver spots associated with photodamage. N Engl J 
Med 1992; 326(6):368–74.

  34.  Griffiths  CE,  Finkel  LJ,  et  al.  Topical  tretinoin  (retinoic  acid) 
improves  melasma.  A  vehicle-controlled,  clinical  trial.  Br  J 
Dermatol 1993; 129(4):415–21.

  35.  Kimbrough-Green CK, Griffiths CE, et al. Topical retinoic acid 
(tretinoin) for melasma in black patients. A vehicle-controlled 
clinical trial. Arch Dermatol 1994; 130(6):727–33.

  36.  Bulengo-Ransby  SM,  Griffiths  CE,  et  al.  Topical  tretinoin 
(retinoic  acid)  therapy  for  hyperpigmented  lesions  caused  by 
inflammation of the skin in black patients. N Engl J Med 1993; 
328(20):1438–43.

  37.  Romero C, Aberdam E, et al. Retinoic acid as modulator of UVB-
induced  melanocyte  differentiation.  Involvement  of  the  mela-
nogenic enzymes expression. J Cell Sci 1994; 107(Pt 4):1095–103.
  38.  Sefton J, Kligman AM, et al. Photodamage pilot study: A double-
blind, vehicle-controlled study to assess the efficacy and safety 
of tazarotene 0.1% gel. J Am Acad Dermatol 2000; 43(4):656–63.

  39.  Kang  S,  Goldfarb  MT,  et  al.  Assessment  of  adapalene  gel  for 
the treatment of actinic keratoses and lentigines: A randomized 
trial. J Am Acad Dermatol 2003; 49(1):83–90.

  40.  Amer M, Metwalli M. Topical liquiritin improves melasma. Int 

J Dermatol 2000; 39(4):299–301.

  41.  Yokota T, Nishio H, et al. The inhibitory effect of glabridin from 
licorice extracts on melanogenesis and inflammation. Pigment 
Cell Research 1998; 11(6):355–61.

  42.  Saliou C, Kitazawa M, et al. Antioxidants modulate acute solar 
ultraviolet radiation-induced NF-kappa-B activation in a human 
keratinocyte cell line. Free Radic Biol Med 1999; 26(1–2):174–83.

  43.  Ando  H,  Ryu  A,  et  al.  Linoleic  acid  and  alpha-linolenic  acid 
lightens  ultraviolet-induced  hyperpigmentation  of  the  skin. 
Arch Dermatol Res 1998; 290(7):375–81.

  44.  Ando  H,  Watabe  H,  et  al.  Fatty  acids  regulate  pigmentation 
via  proteasomal  degradation  of  tyrosinase:  A  new  aspect  of 
ubiquitin-proteasome function. J Biol Chem 2004; 279(15):15427–33.
  45.  Hantash BM, Jimenez F. A split-face, double-blind, randomized 
and  placebo-controlled  pilot  evaluation  of  a  novel  oligopep-
tide for the treatment of recalcitrant melasma. J Drugs Dermatol 
2009; 8(8):732–5.

  50.  Graupe  K,  Cunliffe  WJ,  et  al.  Efficacy  and  safety  of  topical 
azelaic  acid  (20  percent  cream):  An  overview  of  results  from 
European  clinical  trials  and  experimental  reports.  Cutis  1996; 
57(1 Suppl):20–35.

  51.  Kakita  LS,  Lowe  NJ.  Azelaic  acid  and  glycolic  acid  combina-
tion  therapy  for  facial  hyperpigmentation  in  darker-skinned 
patients:  A  clinical  comparison  with  hydroquinone.  Clin  Ther 
1998; 20(5):960–70.

  52.  Lim  JT.  Treatment  of  melasma  using  kojic  acid  in  a  gel  con-
taining  hydroquinone  and  glycolic  acid.  Dermatol  Surg  1999; 
25(4):282–4.

  53.  Hsieh  PW,  Aljuffali  IA,  et  al.  Hydroquinone-salicylic  acid 
conjugates  as  novel  anti-melasma  actives  show  superior  skin 
targeting  compared  to  the  parent  drugs.  J  Dermatol  Sci  2014; 
76(2):120–31.

  54.  Mahe A, Ly F, et al. Skin diseases associated with the cosmetic 
use of bleaching products in women from Dakar, Senegal. Br J 
Dermatol 2003; 148(3):493–500.

  55.  Perez-Bernal A, Munoz-Perez MA, et al. Management of facial 
hyperpigmentation. Am J Clin Dermatol 2000; 1(5):261–8.
  56.  Lim  JT,  Tham  SN.  Glycolic  acid  peels  in  the  treatment  of 
melasma among Asian women. Dermatol Surg 1997; 23(3):177–9.
  57.  Grimes  PE.  The  safety  and  efficacy  of  salicylic  acid  chemi-
cal  peels  in  darker  racial-ethnic  groups.  Dermatol  Surg  1999; 
25(1):18–22.

  58.  Kunachak S, Leelaudomlipi P, et al. Dermabrasion: A curative 

treatment for melasma. Aesthetic Plast Surg 2001; 25(2):114–17.

  59.  Anderson, RR, Parrish JA. Selective photothermolysis: Precise 
microsurgery  by  selective  absorption  of  pulsed  radiation. 
Science 1983; 220(4596):524–7.

  60.  Ortonne  JP,  Passeron  T.  Melanin  pigmentary  disorders: 

Treatment update. Dermatol Clin 2005; 23(2):209–26.

  61.  Ye T, Pawlak A, et al. Different molecular constituents in phe-
omelanin  are  responsible  for  emission,  transient  absorption 
and  oxygen  photoconsumption.  Photochem  Photobiol  2008; 
84(2):437–43.

  62.  Stern  RS,  Nichols  KT,  et  al.  Malignant  melanoma  in  patients 
treated for psoriasis with methoxsalen (psoralen) and ultravio-
let A radiation (PUVA). New Engl J Med 1997; 336:1041–5.
  63.  Lindelof  B,  Sigurgeirsson  B,  et  al.  PUVA  and  cancer  risk:  The 
Swedish follow-up study. Br J Dermatol 1999; 141(1):108–12.
  64.  Stern RS. The risk of melanoma in association with long-term 
exposure to PUVA. J Am Acad Dermatol 2001; 44(5):755–61.
  65.  Garland CF, Garland FC, et al. Epidemiologic evidence for dif-
ferent roles of ultraviolet A and B radiation in melanoma mor-
tality rates. Ann Epidemiol 2003; 13(6):395–404.

  66.  Yones SS, Palmer RA, et al. Randomized double-blind trial of 
treatment of vitiligo: Efficacy of psoralen-UV-A therapy vs nar-
row band-UV-B therapy. Arch Dermatol 2007; 143(5):578–84.
  67.  Gawkrodger DJ, Ormerod AD, et al. Guideline for the diagnosis 

and management of vitiligo. Br J Dermatol 2008; 159(5):1051–76.
  68.  Bonis B, Kemeny L, et al. 308 nm UVB excimer laser for psoria-

sis. Lancet 1997; 350(9090):1522.

  69.  Chilbert  MA,  Peak  MJ,  et  al.  Effects  of  intensity  and  fluence 
upon DNA single-strand breaks induced by excimer laser radi-
ation. Photochem Photobiol 1988; 47:523–5.

  46.  Ubeid  AA,  Zhao  L,  et  al.  Short-sequence  oligopeptides  with 
inhibitory  activity  against  mushroom  and  human  tyrosinase. 
J Invest Dermatol. 2009; 129:2242–9.

  70.  de  With  A,  Greulich  KO.  Wavelength  dependence  of  laser-
induced DNA damage in lymphocytes observed by single-cell 
gel electrophoresis. J Photochem Photobiol B 1995; 30(1):71–6.

 
  71.  Lan CC, Wu CS, et al. Low-energy helium-neon laser induces 
locomotion  of  the  immature  melanoblasts  and  promotes 
the  more  differentiated  melanoblasts: 
melanogenesis  of 
Recapitulation  of  vitiligo  repigmentation  in  vitro.  J  Invest 
Dermatol 2006; 126(9):2119–26.

  72.  Hu WP, Wang JJ, et al. Helium-neon laser irradiation stimulates 
cell  proliferation  through  photostimulatory  effects  in  mito-
chondria. J Invest Dermatol 2007; 127(8):2048–57.

  73.  Lan CC, Wu CS, et al. Low-energy helium-neon laser induces 
melanocyte proliferation via interaction with type IV collagen: 
Visible  light  as  a  therapeutic  option  for  vitiligo.  Br  J  Dermatol 
2009; 161(2):273–80.

  74.  Gupta  S,  Olson  M,  Kanwar  AJ,  Ortonne  JP,  eds.  Surgical 

Management of Vitiligo. Blackwell, 2007.

  75.  Na GY, Seo SK, et al. Single hair grafting for the treatment of 

vitiligo. J Am Acad Dermatol 1998; 38(4):580–4.

  76.  McGovern TW, Bolognia J, et al. Flip-top pigment transplanta-
tion:  A  novel  transplantation  procedure  for  the  treatment  of 
depigmentation. Arch Dermatol 1999; 135(11):1305–7.

  77.  Njoo  MD,  Westerhof  W,  et  al.  A  systematic  review  of  autolo-
gous  transplantation  methods  in  vitiligo.  Arch  Dermatol  1998; 
134(12):1543–9.

  78.  Gauthier Y, Surleve-Bazeille JE. Autologous grafting with non-
cultured  melanocytes:  A  simplified  method  for  treatment  of 
depigmented lesions. J Am Acad Dermatol 1992; 26(2 Pt 1):191–4.
  79.  van Geel N, Ongenae K, et al. Double-blind placebo-controlled 
study  of  autologous  transplanted  epidermal  cell  suspensions 
for repigmenting vitiligo. Arch Dermatol 2004;140(10):1203–8.

  80.  Olsson  MJ,  Juhlin  L.  Melanocyte  transplantation  in  vitiligo. 

Lancet 1992; 340(8825):981.

  81.  Olsson MJ, Juhlin L. Transplantation of melanocytes in vitiligo. 

Brit J Dermatol 1995; 132:587–91.

  82.  Chen YF, Yang PY, et al. Treatment of vitiligo by transplantation 
of cultured pure melanocyte suspension: Analysis of 120 cases. 
J Am Acad Dermatol 2004; 51:68–74.

  83.  Ongenae K, Dierckxsens L, et al. Quality of life and stigmatiza-
tion profile in a cohort of vitiligo patients and effect of the use 
of camouflage. Dermatology 2005; 210(4):279–85.

  84.  Tanioka M, Yamamoto Y, et al. Camouflage for patients with vit-
iligo vulgaris improved their quality of life. J Cosmet Dermatol 
2010; 9(1):72–5.

  85.  Deshayes P. [Cosmetic camouflage for a better quality of life]. 

Ann Dermatol Venereol 2008; 135(Suppl 3):S208–10.

PIGMENTATION: DYSCHROMIA 

 345

  96.  Chan  R,  Park  KC,  et  al.  A  randomized  controlled  trial  of  the 
efficacy  and  safety  of  a  fixed  triple  combination  (fluocinolone 
acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared 
with hydroquinone 4% cream in Asian patients with moderate 
to severe melasma. Br J Dermatol 2008; 159(3):697–703.

  97.  Gupta  AK,  Gover  MD,  et  al.  The  treatment  of  melasma:  A 
review of clinical trials. J Am Acad Dermatol 2006; 55(6):1048–65.
  98.  Rokhsar  CK,  Fitzpatrick  RE.  The  treatment  of  melasma  with 
fractional photothermolysis: A pilot study. Dermatol Surg 2005; 
31(12):1645–50.

  99.  Tannous  ZS,  Astner  S.  Utilizing  fractional  resurfacing  in  the 
treatment  of  therapy-resistant  melasma.  J  Cosmet  Laser  Ther 
2005; 7(1):39–43.

  100.  Lee  HS,  Won  CH,  et  al.  Treatment  of  melasma  in  Asian  skin 
using  a  fractional  1,550-nm  laser:  An  open  clinical  study. 
Dermatol Surg 2009; 35(10):1499–1504.

  101.  Kroon  MW,  Wind  BS,  et  al.  Nonablative  1550-nm  fractional 
laser  therapy  versus  triple  topical  therapy  for  the  treatment 
of  melasma:  A  randomized  controlled  pilot  study.  J  Am  Acad 
Dermatol 2011; 64(3):516–23.

  102.  Lee HM, Haw S, et al. Split-face study using a 1,927-nm thulium 
fiber fractional laser to treat photoaging and melasma in Asian 
skin. Dermatol Surg 2013; 39(6):879–88.

  103.  Niwa  Massaki  AB,  Eimpunth  S,  et  al.  Treatment  of  melasma 
with  the  1,927-nm  fractional  thulium  fiber  laser:  A  retrospec-
tive analysis of 20 cases with long-term follow-up. Lasers Surg 
Med 2013; 45(2):95–101.

  104.  Wattanakrai  P,  Mornchan  R,  et  al.  Low-fluence  Q-switched 
 neodymium-doped yttrium aluminum garnet (1,064 nm) laser 
for  the  treatment  of  facial  melasma  in  Asians.  Dermatol  Surg 
2010; 36(1):76–87.

  105.  Chan  H.  The  use  of  lasers  and  intense  pulsed  light  sources 
for  the  treatment  of  acquired  pigmentary  lesions  in  Asians. 
J Cosmet Laser Ther 2003; 5(3–4):198–200.

  106.  Chan  H,  Kono  T.  The  use  of  lasers  and  intense  pulsed  light 
sources for the treatment of pigmentary lesions. Skin Therap Lett 
2004; 9(8):5–7.

  107.  Konishi  N,  Kawada  A,  et  al.  Clinical  effectiveness  of  a  novel 
intense pulsed light source on facial pigmentary lesions. Arch 
Dermatol Res 2008; 300(Suppl 1):S65–7.

  108.  Li YH, Chen JZ, et al. Efficacy and safety of intense pulsed light 
in  treatment  of  melasma  in  Chinese  patients.  Dermatol  Surg 
2008; 34(5):693–700; discussion 700–691.

  86.  Tanioka  M,  Miyachi  Y.  Camouflage  for  vitiligo.  Dermatol  Ther 

  109.  Moreno Arias GA, Ferrando J. Intense pulsed light for melano-

2009; 22(1):90–3.

cytic lesions. Dermatol Surg 2001; 27(4):397–400.

  87.  Tanioka M, Miyachi Y. Waterproof camouflage age for vitiligo 
of  the  face  using  Cavilon  3M  as  a  spray.  Eur  J  Dermatol  2008; 
18(1):93–4.

  110.  Wang CC, Hui CY, et al. Intense pulsed light for the treatment 
of  refractory  melasma  in  Asian  persons.  Dermatol  Surg  2004; 
30(9):1196–1200.

  88.  Suga Y, Ikejima A, et al. DHA application for camouflaging seg-
mental  vitiligo  and  piebald  lesions.  J  Am  Acad  Dermatol  2002; 
47:436–8.

  111.  Kang WH, Yoon KH, et al. Melasma: Histopathological charac-
teristics in 56 Korean patients. Br J Dermatol 2002; 146(2):228–37.
  112.  Kim EH, Kim YC, et al. The vascular characteristics of melasma. 

  89.  Hsu S. Camouflaging vitiligo with dihydroxyacetone. Dermatol 

J Dermatol Sci 2007; 46(2):111–6.

Online J 2008; 14(8):23.

  90.  Rajatanavin N, Suwanachote S, et al. Dihydroxyacetone: A safe 
camouflaging option in vitiligo. Int J Dermatol 2008; 47(4):402–6.
  91.  Halder RM, Pham HN, et al. Micropigmentation for the treat-
ment of vitiligo. J Dermatol Surg Oncol 1989; 15(10):1092–8.
  92.  Garg G, Thami GP. Micropigmentation: Tattooing for medical 

  113.  Hernandez-Barrera  R,  Torres-Alvarez  B,  et  al.  Solar  elastosis 
and presence of mast cells as key features in the pathogenesis 
of melasma. Clin Exp Dermatol 2008; 33(3):305–8.

  114.  Passeron T, Fontas E, et al. Melasma treatment with pulsed-dye 
laser and triple combination cream: A prospective, randomized, 
single-blind, split-face study. Arch Dermatol 2011; 147(9):1106–8.

purposes. Dermatol Surg 2005; 31(8 Pt 1):928–31; discussion 931.

  115.  Passeron T. Long-lasting effect of vascular targeted therapy of 

  93.  Torok H, Taylor S, et al. A large 12-month extension study of an 
8-week trial to evaluate the safety and efficacy of triple combi-
nation (TC) cream in melasma patients previously treated with 
TC cream or one of its dyads. J Drugs Dermatol 2005; 4(5):592–7.

melasma. J Am Acad Dermatol 2013; 69(3):e141–2.

  116.  Na JI, Choi SY, et al. Effect of tranexamic acid on melasma: A 
clinical  trial  with  histological  evaluation.  J  Eur  Acad  Dermatol 
Venereol 2013; 27(8):1035–9.

  94.  Torok  HM,  Jones  T,  et  al.  Hydroquinone  4%,  tretinoin  0.05%, 
fluocinolone acetonide 0.01%: A safe and efficacious 12-month 
treatment for melasma. Cutis 2005; 75(1):57–62.

  117.  Ortonne JP, Arellano I, et al. A global survey of the role of ultra-
violet radiation and hormonal influences in the development of 
melasma. J Eur Acad Dermatol Venereol 2009; 23(11):1254–62.

  95.  Ferreira Cestari T, Hassun K, et al. A comparison of triple com-
bination cream and hydroquinone 4% cream for the treatment 
of  moderate  to  severe  facial  melasma.  J  Cosmet  Dermatol  2007; 
6(1):36–9.

  118.  Duteil  L,  Cardot-Leccia  N,  et  al.  Differences  in  visible  light-
induced pigmentation according to wavelengths: A clinical and 
histological study in comparison with UVB exposure. Pigment 
Cell Melanoma Res 2014; 27(5):822–6.

 
346 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  119.  Boukari  F,  Jourdan  E,  et  al.  Prevention  of  melasma  relapses 
with  sunscreen  combining  protection  against  UV  and  short 
wavelengths  of  visible  light:  A  prospective  randomized  com-
parative trial. J Am Acad Dermatol. 2015; Jan;72(1):189–90.
  120.  Whitton ME, Ashcroft DM, et al. Therapeutic interventions for 

vitiligo. J Am Acad Dermatol 2008; 59(4):713–7.

  121.  Taieb  A,  Alomar  A,  et  al.  Guidelines  for  the  management  of 
vitiligo:  The  European  Dermatology  Forum  consensus.  Br  J 
Dermatol 2013; 168(1):5–19.

  122.  Baltas  E,  Csoma  Z,  et  al.  Treatment  of  vitiligo  with  the 
308-nm  xenon  chloride  excimer  laser.  Arch  Dermatol  2002; 
138(12):1619–20.

  123.  Spencer  JM,  Nossa  R,  et  al.  Treatment  of  vitiligo  with  the 
308-nm excimer laser: A pilot study. J Am Acad Dermatol 2002; 
46(5):727–31.

  124.  Leone G, Iacovelli P, et al. Monochromatic excimer light 308 nm 
in the treatment of vitiligo: A pilot study. J Eur Acad Dermatol 
Venereol 2003; 17(5):531–7.

tacrolimus  ointment  with  narrowband  UV-B  plus  placebo 
in  the  treatment  of  generalized  vitiligo.  Arch  Dermatol  2006; 
142(7):927–9.

  143.  Fai D, Cassano N, et al. Narrow-band UVB phototherapy com-
bined  with  tacrolimus  ointment  in  vitiligo:  A  review  of  110 
patients. J Eur Acad Dermatol Venereol 2007; 21(7):916–20.
  144.  Hui-Lan Y, Xiao-Yan H, et al. Combination of 308-nm excimer 
laser with topical pimecrolimus for the treatment of childhood 
vitiligo. Pediatr Dermatol 2009; 26(3):354–6.

  145.  Sassi F, Cazzaniga S, et al. Randomized controlled trial compar-
ing the effectiveness of 308-nm excimer laser alone or in com-
bination with topical hydrocortisone 17-butyrate cream in the 
treatment  of  vitiligo  of  the  face  and  neck.  Br  J  Dermatol  2008; 
159(5):1186–91.

  146.  Levy SB. Tanning preparations. Dermatol Clin 2000; 18(4):591–6.
  147.  Njoo MD, Vodegel RM, et al. Depigmentation therapy in vitiligo 
universalis with topical 4-methoxyphenol and the Q-switched 
ruby laser. J Am Acad Dermatol 2000; 42(5 Pt 1):760–9.

  125.  Taneja  A,  Trehan  M,  et  al.  308-nm  excimer  laser  for  the  treat-
ment of localized vitiligo. Int J Dermatol 2003; 42(8):658–62.
  126.  Esposito M, Soda R, et al. Treatment of vitiligo with the 308 nm 

  148.  Kim  YJ,  Chung  BS,  et  al.  Depigmentation  therapy  with 
Q-switched  ruby  laser  after  tanning  in  vitiligo  universalis. 
Dermatol Surg 2001; 27(11):969–70.

excimer laser. Clin Exp Dermatol 2004; 29(2):133–7.

  127.  Ostovari N, Passeron T, et al. Treatment of vitiligo by 308-nm 
excimer  laser:  An  evaluation  of  variables  affecting  treatment 
response. Lasers Surg Med 2004; 35(2):152–6.

  128.  Schallreuter  KU,  Wood  JM,  et  al.  Treatment  of  vitiligo  with  a 
topical application of pseudocatalase and calcium in combina-
tion with short-term UVB exposure: A case study on 33 patients. 
Dermatology 1995; 190(3):223–9.

  129.  Chiaverini C, Passeron T, et al. Treatment of vitiligo by topical 
calcipotriol. J Eur Acad Dermatol Venereol 2002; 16(2):137–8.
  130.  Kose O, Riza Gur A, et al. Calcipotriol ointment versus clobeta-
sol ointment in localized vitiligo: An open, comparative clinical 
trial. Int J Dermatol 2002; 41(9):616–8.

  131.  Patel DC, Evans AV, et al. Topical pseudocatalase mousse and 
narrowband UVB phototherapy is not effective for vitiligo: An 
open, single-centre study. Clin Exp Dermatol 2002; 27(8):641–4.

  132.  Baysal  V,  Yildirim  M,  et  al.  Is  the  combination  of  calcipotriol 
and  PUVA  effective  in  vitiligo?  J  Eur  Acad  Dermatol  Venereol 
2003; 17(3):299–302.

  133.  Anke  Hartmann  CL,  Henning  Hamm  E-B,  Bröcker  U, 
Hofmann  B.  Narrow-band  UVB311  nm  vs.  broad-band  UVB 
therapy in combination with topical calcipotriol vs. placebo in 
vitiligo. Int J Dermatol 2004; published online.

  134.  Ada  S,  Sahin  S,  et  al.  No  additional  effect  of  topical  calcipot-
riol  on  narrow-band  UVB  phototherapy  in  patients  with  gen-
eralized  vitiligo  Photodermatol  Photoimmunol  Photomed  2005; 
21(2):79–83.

  149.  Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite 
laser to treat recalcitrant pigment after depigmentation therapy 
for vitiligo. Dermatol Surg 2004; 30(7):1043–5.

  150.  Boukari  F,  Lacour  JP,  et  al.  Laser-assisted  depigmentation  for 
resistant  vitiligo:  A  retrospective  case  series  with  long-term 
follow-up. J Eur Acad Dermatol Venereol. 2012; Mar;28(3):374–7.

  151.  Komen  L,  Zwertbroek  L,  et  al.  Q-switched  laser  depigmenta-
tion  in  vitiligo,  most  effective  in  active  disease.  Br  J  Dermatol 
2013; 169(6):1246–51.

  152.  Mulekar  SV,  Issa  AA,  et  al.  Treatment  of  halo  nevus  with  a 
308-nm  excimer  laser:  A  pilot  study.  J  Cosmet  Laser  Ther  2007; 
9(4):245–8.

  153.  Grabbe  J,  Welker  P,  et  al.  Stem  cell  factor,  a  novel  cutaneous 
growth factor for mast cells and melanocytes. Arch Dermatol Res 
1994; 287(1):78–84.

  154.  Mosher  DB,  Fitzpatrick  TB.  Piebaldism.  Arch  Dermatol  1988; 

124(3):364–5.

  155.  Spritz  RA.  Piebaldism,  Waardenburg  syndrome,  and  related 
disorders  of  melanocyte  development.  Semin  Cutan  Med  Surg 
1997; 16(1):15–23.

  156.  Guerra L, Primavera G, et al. Permanent repigmentation of pie-
baldism by erbium:YAG laser and autologous cultured epider-
mis. Br J Dermatol 2004; 150(4):715–21.

  157.  Bondanza  S,  Bellini  M,  et  al.  Piebald  trait:  Implication  of  kit 
mutation  on  in  vitro  melanocyte  survival  and  on  the  clinical 
application of cultured epidermal autografts. J Invest Dermatol 
2007; 127(3):676–86.

  135.  Hartmann A, Lurz C, et al. Narrow-band UVB311 nm vs. broad-
band UVB therapy in combination with topical calcipotriol vs. 
placebo in vitiligo. Int J Dermatol 2005; 44(9):736–42.

  158.  Goh BK, Chua XM, et al. Simplified cellular grafting for treat-
ment  of  vitiligo  and  piebaldism:  The  6-well  plate  technique. 
Dermatol Surg 2009; Feb;36(2):203–7.

  136.  Arca E, Tastan HB, et al. Narrow-band ultraviolet B as mono-
therapy  and  in  combination  with  topical  calcipotriol  in  the 
treatment of vitiligo. J Dermatol 2006; 33(5):338–43.

  137.  Goktas  EO,  Aydin  F,  et  al.  Combination  of  narrow  band  UVB 
and topical calcipotriol for the treatment of vitiligo. J Eur Acad 
Dermatol Venereol 2006; 20(5):553–7.

  159.  van Geel N, Wallaeys E, et al. Long-term results of noncultured 
epidermal  cellular  grafting  in  vitiligo,  halo  naevi,  piebaldism 
and naevus depigmentosus. Brit J Dermatol 2010; 163(6):1186–93.
  160.  Gupta  S,  Goel  A.  Letter  to  the  editor:  Nevus  depigmentosus 
needs  transplant  of  epidermal  sheets.  Dermatol  Surg  2005; 
31(12):1746–7.

  138.  Goldinger SM, Dummer R, et al. Combination of 308-nm xenon 
chloride excimer laser and topical calcipotriol in vitiligo. J Eur 
Acad Dermatol Venereol 2007; 21(4):504–8.

  161.  Raskovic  D,  Bondanza  S,  et  al.  Autologous  in  vitro  reconsti-
tuted epidermis in the treatment of a large nevus depigmento-
sus. J Am Acad Dermatol 2006; 54(5 Suppl):S238–40.

  139.  Tanghetti  EA,  Gillis  PR.  Clinical  evaluation  of  B  Clear  and 
Protopic treatment for vitiligo. Lasers Surg Med 2003; 32(S15):37.
  140.  Kawalek  AZ,  Spencer  JM,  et  al.  Combined  excimer  laser  and 
topical  tacrolimus  for  the  treatment  of  vitiligo:  A  pilot  study. 
Dermatol Surg 2004; 30(2 Pt 1):130–5.

  141.  Passeron T, Ostovari N, et al. Topical tacrolimus and the 308-nm 
excimer  laser:  A  synergistic  combination  for  the  treatment  of 
vitiligo. Arch Dermatol 2004; 140(9):1065–9.

  142.  Mehrabi  D,  Pandya  AG.  A  randomized,  placebo-controlled, 
double-blind  trial  comparing  narrowband  UV-B  Plus  0.1% 

  162.  Kim do Y, Park YK, et al. Recurrence of nevus depigmentosus 
after an autologous epidermal graft. J Am Acad Dermatol 2008; 
58(3):527–9.

  163.  Kim  do  Y,  Lee  KY,  et  al.  Use  of  the  308-nm  excimer  laser  for 
nevus depigmentosus: A promising treatment for either nevus 
depigmentosus or vitiligo. J Dermatol 2007; 34(3):217–8.

  164.  Todd  MM,  Rallis  TM,  et  al.  A  comparison  of  3  lasers  and 
liquid  nitrogen  in  the  treatment  of  solar  lentigines:  A  ran-
domized,  controlled,  comparative  trial.  Arch  Dermatol  2000; 
136(7):841–6.

 
  165.  Tanzi EL, Lupton JR, et al. Lasers in dermatology: Four decades 
of progress. J Am Acad Dermatol 2003; 49(1):1–31; quiz 31–4.
  166.  Passeron  T.  Lasers.  Ann  Dermatol  Venereol  2012;  139(Suppl  4): 

S159–65.

  167.  Chan HH, Ying SY, et al. An in vivo trial comparing the clinical 
efficacy  and  complications  of  Q-switched  755  nm  alexandrite 
and  Q-switched  1064  nm  Nd:YAG  lasers  in  the  treatment  of 
nevus of Ota. Dermatol Surg 2000; 26(10):919–22.

  168.  Ueda S, Isoda M, et al. Response of naevus of Ota to Q-switched 
ruby  laser  treatment  according  to  lesion  colour.  Br  J  Dermatol 
2000; 142(1):77–83.

  169.  Kono  T,  Chan  HH,  et  al.  Use  of  Q-switched  ruby  laser  in  the 
treatment  of  nevus  of  ota  in  different  age  groups.  Lasers  Surg 
Med 2003; 32(5):391–5.

  170.  Chan HH, Leung RS, et al. Recurrence of nevus of Ota after suc-
cessful treatment with Q-switched lasers. Arch Dermatol 2000; 
136(9):1175–6.

  171.  Batta K, Hindson C, et al. Treatment of poikiloderma of Civatte 
with the potassium titanyl phosphate (KTP) laser. Br J Dermatol 
1999; 140(6):1191–2.

  172.  Langeland  J.  Treatment  of  poikiloderma  of  Civatte  with  the 
pulsed dye laser: A series of seven cases. J Cutan Laser Ther 1999; 
1(2):127.

  173.  Weiss  RA,  Goldman  MP,  et  al.  Treatment  of  poikiloderma  of 
Civatte with an intense pulsed light source. Dermatol Surg 2000; 
26(9):823–7; discussion 828.

  174.  Rusciani  A,  Motta  A,  et  al.  Treatment  of  poikiloderma  of 
Civatte using intense pulsed light source: 7 years of experience. 
Dermatol Surg 2008; 34(3):314–9; discussion 319.

  175.  Meijs  MM,  Blok  FA,  et  al.  Treatment  of  poikiloderma  of 
Civatte  with  the  pulsed  dye  laser:  A  series  of  patients  with 
severe  depigmentation.  J  Eur  Acad  Dermatol  Venereol  2006; 
20(10):1248–51.

  176.  Behroozan  DS,  Goldberg  LH,  et  al.  Fractional  photothermoly-
sis for treatment of poikiloderma of civatte. Dermatol Surg 2006; 
32(2):298–301.

  177.  Tierney  EP,  Hanke  CW.  Treatment  of  Poikiloderma  of  Civatte 
with ablative fractional laser resurfacing: Prospective study and 
review of the literature. J Drugs Dermatol 2009; 8(6):527–34.
  178.  Grossman  MC,  Anderson  RR,  et  al.  Treatment  of  cafe  au  lait 
macules  with  lasers.  A  clinicopathologic  correlation.  Arch 
Dermatol 1995; 131(12):1416–20.

  179.  Grevelink JM, Gonzalez S, et al. Treatment of nevus spilus with 
the  Q-switched  ruby  laser.  Dermatol  Surg  1997;  23(5):365–369; 
discussion 369–70.

  180.  Moreno-Arias GA, Bulla F, et al. Treatment of widespread seg-
mental nevus spilus by Q-switched alexandrite laser (755 nm, 
100 nsec). Dermatol Surg 2001; 27(9):841–3.

  181.  Kato S, Takeyama J, et al. Ruby laser therapy for labial lentigi-
nes in Peutz-Jeghers syndrome. Eur J Pediatr 1998; 157(8):622–4.
  182.  Kollias N, Baqer AH. Absorption mechanisms of human mela-
nin in the visible, 400–720 nm. J Invest Dermatol 1987; 89:384–8.

  183.  Catherine S, Lacour JP, et al. Treatment of linear and whorled 
hypermelanosis  with  Q-switched  laser.  Dermatol  Surg  2014; 
40(9):1044–6.

PIGMENTATION: DYSCHROMIA 

 347

  189.  Cymbalista NC, Prado de Oliveira ZN. Treatment of idiopathic 
cutaneous  hyperchromia  of  the  orbital  region  (ICHOR)  with 
intense  pulsed  light.  Dermatol  Surg  2006;  32(6):773–83;  discus-
sion 783–774.

  190.  Watanabe  S,  Nakai  K,  et  al.  Condition  known  as  dark  rings 
under the eyes in the Japanese population is a kind of dermal 
melanocytosis which can be successfully treated by Q-switched 
ruby laser. Dermatol Surg 2006; 32(6):785–9; discussion 789.
  191.  Pimentel  CL,  Rodriguez-Salido  MJ.  Pigmentation  due  to  sta-
sis dermatitis treated successfully with a noncoherent intense 
pulsed light source. Dermatol Surg 2008; 34(7):950–1.

  192.  Hughes  R,  Lacour  JP,  et  al.  Pigmentary  sequelae  of  AIDS-
related  cutaneous  Kaposi  sarcoma:  Successful  treatment  by 
Q-switched  755-nm  alexandrite  and  532-nm  Nd:YAG  lasers. 
Arch Dermatol 2011; 147(7):779–81.

  193.  Hammami  Ghorbel  H,  Lacour  JP,  et  al.  Successful  treatment 
with 532-nm Q-switched Nd:YAG laser of cutaneous siderosis 
following  intravenous  iron  extravasation.  J  Eur  Acad  Dermatol 
Venereol 2015; Apr;29(4):818–9.

  194.  Collins  P,  Cotterill  JA.  Minocycline-induced  pigmentation 
resolves  after  treatment  with  the  Q-switched  ruby  laser.  Br  J 
Dermatol 1996; 135(2):317–9.

  195.  Karrer S, Hohenleutner U, et al. Amiodarone-induced pigmen-
tation resolves after treatment with the Q-switched ruby laser. 
Arch Dermatol 1999; 135(3):251–3.

  196.  Alster TS, Gupta SN. Minocycline-induced hyperpigmentation 
treated  with  a  755-nm  Q-switched  alexandrite  laser.  Dermatol 
Surg 2004; 30(9):1201–4.

  197.  Ploysangam  T,  Dee-Ananlap  S,  et  al.  Treatment  of  idiopathic 
guttate hypomelanosis with liquid nitrogen: Light and electron 
microscopic studies. J Am Acad Dermatol 1990; 23(4 Pt 1):681–4.
  198.  Hexsel  DM.  Treatment  of  idiopathic  guttate  hypomelanosis 
by  localized  superficial  dermabrasion.  Dermatol  Surg  1999; 
25(11):917–8.

  199.  Pagnoni  A,  Kligman  AM,  et  al.  Hypopigmented  macules  of 
photodamaged skin and their treatment with topical tretinoin. 
Acta Derm Venereol 1999; 79(4):305–10.

  200.  Goldust  M,  Mohebbipour  A,  et  al.  Treatment  of  idiopathic 
guttate  hypomelanosis  with  fractional  carbon  dioxide  lasers. 
J Cosmet Laser Ther 2013; May 8. [Epub ahead of print].

  201.  Rerknimitr P, Chitvanich S, et al. Non-ablative fractional pho-
tothermolysis  in  treatment  of  idiopathic  guttate  hypomelano-
sis. J Eur Acad Dermatol Venereol 2014; Jun;55(6):549–52.

  202.  Friedman PM, Geronemus RG. Use of the 308-nm excimer laser 
for postresurfacing leukoderma. Arch Dermatol 2001; 137(6):824–5.
  203.  Goldberg  DJ,  Sarradet  D,  et  al.  308-nm  Excimer  laser  treat-
ment  of  mature  hypopigmented  striae.  Dermatol  Surg  2003; 
29(6):596–8; discussion 598–9.

  204.  Gundogan  C,  Greve  B,  et  al.  [Repigmentation  of  persistent 
laser-induced hypopigmentation with an excimer laser follow-
ing tattoo removal]. Hautarzt 2004.

  205.  Relyveld  GN.  Kingswijk  MM,  et  al.  Benzoyl  peroxide/
clindamycin/UVA  is  more  effective  than  fluticasone/UVA 
in  progressive  macular  hypomelanosis:  A  randomized 
study. J Am Acad Dermatol 2006; 55(5):836–43.

  184.  Ranu H, Thng S, et al. Periorbital hyperpigmentation in Asians: 
An epidemiologic study and a proposed classification. Dermatol 
Surg 2011; 37(9):1297–1303.

  206.  Chung YL, Goo B, et al. A case of progressive macular hypomel-
anosis  treated  with  narrow-band  UVB.  J  Eur  Acad  Dermatol 
Venereol 2007; 21(7):1007–9.

  185.  Ditre  CM, Griffin TD, et al. Effects of alpha-hydroxy acids on 
photoaged skin: A pilot clinical, histologic, and ultrastructural 
study. J Am Acad Dermatol 1996; 34(2 Pt 1):187–95.

  207.  Lang  PG  Jr.  Probable  coexisting  exogenous  ochronosis  and 
mercurial pigmentation managed by dermabrasion. J Am Acad 
Dermatol 1988; 19(5 Pt 2):942–6.

  186.  Olsen EA, Katz HI, et al. Tretinoin emollient cream for photo-
damaged  skin:  Results  of  48-week,  multicenter,  double-blind 
studies. J Am Acad Dermatol 1997; 37(2 Pt 1):217–26.

  208.  Diven  DG,  Smith  EB,  et  al.  Hydroquinone-induced  localized 
exogenous  ochronosis  treated  with  dermabrasion  and  CO2 
laser. J Dermatol Surg Oncol 1990; 16(11):1018–22.

  187.  West TB, Alster TS. Improvement of infraorbital hyperpigmen-
tation following carbon dioxide laser resurfacing. Dermatol Surg 
1998; 24(6):615–6.

  209.  Bellew SG, Alster TS. Treatment of exogenous ochronosis with 
a  Q-switched  alexandrite  (755  nm)  laser.  Dermatol  Surg  2004; 
30(4 Pt 1):555–558.

  188.  Zarem  HA,  Resnick  JI.  Expanded  applications  for  transcon-
junctival  lower  lid  blepharoplasty.  Plast  Reconstr  Surg  1999; 
103(3):1041–1043; discussion 1044–5.

  210.  Schweiger ES, Kwasniak L, et al. Treatment of dermatosis papu-
losa nigra with a 1064 nm Nd:YAG laser: Report of two cases. 
J Cosmet Laser Ther 2008; 10(2):120–122.

 
348 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  211.  Katz TM, Goldberg LH, et al. Dermatosis papulosa nigra treat-
ment  with  fractional  photothermolysis.  Dermatol  Surg  2009; 
35(11):1840–3.

  217.  Castela  E,  Thomas  P,  et  al.  Blue  pseudochromhidrosis  sec-
ondary  to  topiramate  treatment.  Acta  Derm  Venereol  2009; 
89(5):538–9.

  212.  Kundu RV, Joshi SS, et al. Comparison of electrodesiccation and 
potassium-titanyl-phosphate laser for treatment of dermatosis 
papulosa nigra. Dermatol Surg 2009; 35(7):1079–83.

  213.  Schwartzberg JB, Schwartzberg HA. Response of confluent and 
reticulate papillomatosis of Gougerot and Carteaud to topical 
tretinoin. Cutis 2000; 66(4):291–3.

  214.  Ginarte M, Fabeiro JM, et al. Confluent and reticulated papil-
lomatosis (Gougerot-Carteaud) successfully treated with tacal-
citol. J Dermatolog Treat 2002; 13(1):27–30.

  215.  Bowman  PH,  Davis  LS.  Confluent  and  reticulated  papilloma-
tosis:  Response  to  tazarotene.  J  Am  Acad  Dermatol  2003;  48(5 
Suppl):S80–1.

  216.  Davis MD, Weenig RH, et al. Confluent and reticulate papilloma-
tosis  (Gougerot-Carteaud  syndrome):  A  minocycline-respon-
sive dermatosis without evidence for yeast in pathogenesis. A 
study of 39 patients and a proposal of diagnostic criteria. Br J 
Dermatol 2006; 154(2):287–93.

  218.  Burris K, Kim K. Tattoo removal. Clin Dermatol 2007; 25(4):388–92.
  219.  Prinz BM, Vavricka SR, et al. Efficacy of laser treatment of tat-
toos using lasers emitting wavelengths of 532 nm, 755 nm and 
1064 nm. Br J Dermatol 2004; 150(2):245–51.

  220.  Fusade  T,  Toubel  G,  et  al.  Treatment  of  gunpowder  traumatic 
tattoo by Q-switched Nd:YAG laser: An unusual adverse effect. 
Dermatol Surg 2000; 26(11):1057–9.

  221.  Brauer JA, Reddy KK, et al. Successful and rapid treatment of 
blue  and  green  tattoo  pigment  with  a  novel  picosecond  laser. 
Arch Dermatol 2012; 148(7):820–3.

  222.  Saedi N, Metelitsa A, et al. Treatment of tattoos with a picosec-
ond alexandrite laser: A prospective trial. Arch Dermatol 2012; 
148(12):1360–3.

  223.  Wang CC, Huang CL, et al. Treatment of cosmetic tattoos with 
nonablative fractional laser in an animal model: A novel method 
with histopathologic evidence. Lasers Surg Med 2013; 45(2):116–22.

 
37

Treatment of Keloids

Joshua E. Lane

INTRODUCTION
Keloids  and  hypertrophic  scars  represent  abnormal  wound 
responses. These occur most commonly in predisposed indi-
viduals.  Keloids  are  benign  tumors  that  arise  from  scar  tis-
sue and grow beyond the borders of the original scar (Figure 
37.1). The formation of keloids and hypertrophic scars typically 
occurs following some form of trauma, whether intentional or 
not.  This  may  include  surgery,  burns,  trauma,  inflammation, 
and/or infection. However, some keloids may form spontane-
ously, without any apparent predisposing trauma. Keloids are 
characterized by scar tissue that extends beyond the original 
dimensions  of  a  wound,  while  hypertrophic  scars  maintain 
size within predictable dimensions of the original wound.

Keloids  can  thus  be  differentiated  from  normal  scars 
and hypertrophic scars, the latter being confined to the origi-
nal  dimensions  of  a  wound.  A  normal  scar  heals  within  the 
confines of the inciting injury. Hypertrophic scars increase in 
size as an outward growth while keloids are capable of both 
inward and outward extension.

Both  keloids  and  hypertrophic  scars  present  a  clinical 
challenge  in  prevention  and  treatment.  Multiple  methods  of 
treatment have been reported; however, no single modality is 
optimal.

HYPERTROPHIC SCARS VERSUS KELOIDS
Keloids and hypertrophic scars can occur in individuals of all 
ages and races; however, they are more common with darker-
pigmented skin types. They represent examples of exuberant 
scarring. The incidence of keloids has been reported to be as 
high as 16% in African-American individuals. Keloids tend to 
be less prevalent in the young and the elderly. The highest inci-
dence  was  reported  to  range  from  ages  10–30.  Other  reports 
suggest the average age of patients with keloids at the time of 
initial treatment to be about 26.

Recommendations  for  ear  piercing  to  avoid  keloid  for-
mation have been made based on these trends. In one study, 
individuals  formed  fewer  keloids  following  ear  piercing  if 
performed before the age of 11. In fact, women with multiple 
ear piercings often demonstrate keloid  formation from  pierc-
ing  during  puberty  or  within  teenage  years,  while  piercings 
performed as an infant did not keloid. Genetic inheritance pat-
terns have also been reported.

Keloids tend to demonstrate a predilection for certain 
anatomic regions, including the presternal area, chest, back, 
shoulder,  anterior  and  posterior  neck,  and  earlobes.  Many 
summarize  this  predilection  as  the  “cape  area.”  Areas  of 
greater skin tension such as the back and chest are common 
areas  for  keloid  formation.  In  addition,  keloids  continue  to 
evolve  while  hypertrophic  scars  typically  subside.  Just  as 

there are clinical differences between keloids and hypertro-
phic  scars,  so  too  are  there  characteristic  histologic  differ-
ences which separate the two entities.

ETIOLOGY
A genetic predisposition combined with some form of external 
injury may lead to the formation of keloids and/or hypertro-
phic  scarring  in  certain  individuals.  An  abnormal  response 
of the connective tissue following skin trauma occurs. Injury 
to  the  skin  may  occur  in  a  variety  of  intentional  or  uninten-
tional  means.  Spontaneous  keloids  develop  without  a  clear-
cut   history  of  trauma  and  often  favor  the  chest,  upper  back, 
 shoulders, and arms (Figures 37.1 and 37.2).

Another  important  aspect  of  keloid  and  hypertrophic 
scar formation is that of wound tension, which has been impli-
cated as an instigating factor. Surgical incisions should be per-
formed to minimize these forces of tension whenever possible. 
Additionally,  the  use  of  dermal  sutures  placed  appropriately 
can assist in the reduction of wound tension and in this way 
help minimize the chance of keloid formation.

A combination of factors including the nature of injury, 
severity,  depth,  anatomic  location,  tensional  stress,  infection, 
environmental factors, and genetic predisposition all contrib-
ute  to  the  potential  for  and  severity  of  hypertrophic  scar 
and/or  keloid  formation.  Evidence  of  a  genetic  predisposi-
tion  for  keloid  formation  is  demonstrated  by  its  increased 
frequency in different ethnic populations, a family history of 
keloid  formation, and its occurrence in twins.

CLINICAL ASPECTS
An  understanding  of  both  hypertrophic  scars  and  keloids  is 
essential  for  accurate  diagnosis  of  keloids.  Clinical  examina-
tion  can  typically  differentiate  between  these  two  entities. 
Hypertrophic  scars  are  confined  to  the  traumatized  region 
while  keloids  extend  beyond  the  initial  confines  of  trauma 
(Figure  37.2).  This  is  the  primary  visual  means  of  differenti-
ating hypertrophic scars and keloids. In areas where stretch-
back scarring can be predicted, hypertrophic scar formation is 
often mistaken for keloid formation because of the increased 
width of the scar. Occasionally, removal of a keloid results in 
a  hypertrophic  scar  which,  again,  is  often  confused  with  a 
recurrence of the keloid. In reality, the  distinction may not be 
as important, as treatment methods are similar.

Hypertrophic  scars  typically  develop  quickly  after  an 
inciting  surgery  and  subside  gradually  over  time.  In  con-
trast,  keloids  often  develop  more  slowly  and  do  not  resolve 
(Figure 37.3). Hypertrophic scars may be treated with surgical 
revision while this may result in additional keloid formation 
and/or worsening of the treated keloid.

350 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure  37.1  Keloids  on  the  chest  with  restriction  of  movement 
due to extensive involvement. These are spontaneous keloids and 
occurred without any known trauma.

Figure 37.2  Spontaneous keloids on the chest wall. No known 
surgical or trauma occurred to form these keloids.

The size of a hypertrophic scar is usually reflective of the 
inciting injury; however, even a small injury can yield a large 
keloid (Figures 37.4–37.8). Keloids in areas such as the neck and 
chest can grow to massive size and cause restriction of move-
ment (Figure 37.1). Treatment of keloids of this size and body 
restriction prove especially difficult. Keloids may form second-
ary  to  hair  cut  short  with  resultant  inflammation  of  the  skin 
from  the  hair  with  keloid  formation  (acne  keloidalis  nuchae, 
Figure 37.9). Hidradenitis suppurativa can include keloid for-
mation,  most  commonly  involving  the  axillae  and  inguinal 
region of the groin (Figure 37.10). Keloids can form after severe 
acne  as  well  (Figure  37.11).  It  is  important  to  remember  that 
intentional therapeutic measures such as re-excision, injection, 
or laser treatments can themselves cause keloid formation.

(a)

(b)

Figure 37.3  Hypertrophic scar (a) following a surgical procedure 
and keloid (b) resulting from trauma to the left arm.

HISTOLOGY
Histologic examination of a keloid (and hypertrophic scars) dem-
onstrates a random array of thick, hyalinized, eosinophilic col-
lagen bundle deposition (Figure 37.12). This is in contrast to that 
of normal skin, in which the collagen bundles are seen in par-
allel  to  the  skin  surface.  Differentiation  between  hypertrophic 

scars and keloids is also possible. The collagen bundles seen in 
hypertrophic scars are flatter and less demarcated than those in 
normal skin. Collagen fibers are seen in a wavy pattern. These 
features are more pronounced in keloids. Occlusion of microves-
sels is reported to occur in both hypertrophic scars and keloids. 
Differentiation is typically possible via clinical examination.

 
TREATMENT OF KELOIDS 

 351

Figure 37.4  Keloid formation secondary to piercing of the ear in 
an adolescent. Piercing was performed at the age of 13.

Figure 37.6  Keloid on the right earlobe secondary to piercing of 
the ear in adolescence.

Figure  37.5  Keloid  on  the  posterior  ear  secondary  to  piercing 
of the ear.

Figure  37.7  Large  pedunculated  keloid  on  the  right  earlobe. 
Patient had piercing performed in adolescence.

 
352 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(c)

Figure  37.8 
transmural excision (dumbbell technique).

(a,  b,  c)  Excision  of  keloid  on  right  earlobe  with 

Figure  37.9  Acne  keloidalis  nuchae  in  the  scalp  secondary  to 
short haircut.

Figure 37.10  Keloid formation in the setting of axillary hidradeni-
tis suppurativa. Treatment is typically difficult and may consist of 
topical and oral antibiotics. The use of CO2 laser as well as some 
biologics may offer some benefit.

PATHOGENESIS
The  pathogenesis  of  keloid  formation  still  remains  largely 
unknown. Recent advances have implicated the role of trans-
forming growth factor-β (TGF-β) and platelet-derived growth 
factor  (PDGF).  These  play  a  role  in  modulating  contractile 
forces in skin fibroblasts. A brief overview of wound healing 
assists in the discussion of pathogenesis.

There  are  three  primary  phases  of  normal  wound 
 healing: inflammatory, proliferative/fibroblastic, and matura-
tion/remodeling. The inflammatory phase consists of an imme-
diate influx of inflammatory mediators into the site involved. 
A  fibrin  clot  is  initiated  during  this  phase.  This  occurs  by 

 
capillary dilation and subsequent delivery of these mediators. 
The fibroblastic phase consists of fibroblast advancement into 
the  fibrin  clot  with  production  of  new  collagen.  The  matura-
tion phase occurs as the wound matures via collagen synthe-
sis and degradation. A variety of signaling molecules (TGF-β, 

Figure 37.11  Keloid formation secondary to severe acne on the 
back.

TREATMENT OF KELOIDS 

 353

PDGF, matrix metalloproteinases [MMPs], tissue inhibitors of 
metalloproteinases [TIMPs]) regulate this process.

With this basic template of the wound healing process 
in place, the faults by which keloids and hypertrophic scars 
occur  can  be  demonstrated.  Early  forms  of  fibroblasts  have 
been shown to persist longer in keloids than in normal skin. 
This persistence of early fibroblasts likely results in increased 
collagen  production.  This  collagen  synthesis  is  20  times 
greater in keloids than in normal skin. While the dominant 
type  of  collagen  in  normal  skin  is  type  I,  keloids  have  both 
types I and III.

Growth  factors  have  shown  the  most  promise  in  the 
quest  for  keloid  pathogenesis.  TGF-β  promotes  fibroblasts 
to  localize  to  sites  of  inflammation  to  begin  extracellular 
matrix  protein  synthesis.  While  this  activity  is  normally 
turned  off  when  repair  is  complete,  dysregulation  of 
TGF-β  activity  is  likely  a  key  factor  in  keloid  production. 
Decreased  synthesis  of  molecules  that  promote  collagen 
matrix  breakdown  (MMPs)  has  also  been  shown  to  be  a 
factor  in  keloid  pathogenesis.  Other  studies  have  shown 
that  infrared  light  can  inhibit  fibroblast  proliferation  and 
activity.  How  this  happens  is  unknown,  but  it  may  be  why 
some  success  has  been  reported  with  CO2  laser  excision  of 
keloids.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

Figure 37.12  Histopathology of normal skin (a–c), hypertrophic scars (d–f), and keloids (g–i). These are shown at 4× magnification (top 
row), 10× magnification (middle row), and 20× magnification (bottom row). Normal skin has distinct collagen bundles that are predomi-
nantly arranged parallel to the epidermal surface. Evaluation of hypertrophic scars demonstrates less order of the collagen bundles, and 
keloids are marked by haphazard arrangement of collagen fibers with random orientation.

 
354 

 TEXTBOOK OF COSMETIC DERMATOLOGY

TREATMENT
Treatment of keloids and hypertrophic scars presents a  clinical 
challenge  (Table  37.1).  As  the  two  entities  are  similar,  treat-
ments  are  also  similar.  The  fact  that  traumatic  injury  is  the 
typical cause highlights the difficulty of any type of surgical 
 treatment. Treatment options include a multitude of possibili-
ties ranging from noninvasive to invasive. The choice of treat-
ment  depends  on  a  variety  of  factors,  including  the  patient 
(age, health), location, size, depth, and previous treatments.

A number of topical treatment modalities have been suc-
cessfully used to treat keloids and hypertrophic scars. A com-
mon  technique  used  at  the  initial  time  of  diagnosis  is  gentle 
massage of the site. Instructions to the patient include a gentle 
rocking massage for several minutes to be performed several 
times per day. This can be useful for smaller scars and espe-
cially in sites where web formation is a possibility. The use of 
topical “keloid medications” has not been shown to be better 
than just massage alone.

The  use  of  mechanical  pressure  is  used  as  both  treat-
ment and prophylaxis. This is commonly seen with pressure 
earrings used to both treat and prevent keloids secondary to 
ear  piercing.  Treatment  with  mechanical  pressure  takes  time 
and may require as long as 6 to 12 months or longer for accept-
able  results.  Additionally,  pressure  garments  should  be  used 
23 to 24 hours/day. Success in treatment is largely dependent 
on patient compliance.

Silicon  gel  sheeting  is  believed  to  act  by  scar  hydration, 
resulting in decreased capillary flow with subsequent reduction 
in collagen deposition from a decrease in circulating proinflam-
matory  cytokines.  Some  authors  have  demonstrated  excellent 
success rates with silicon gel sheeting, while others attribute its 
success to the occlusive wound effects. Silicone sheeting should 
be worn for a minimum of 12 hours per day and for a minimum 
of 2 months. The true “gel” types of sheeting have been shown 
to give more consistent results than the dry “card-like” sheeting.
The use of cryosurgery in the treatment of keloids and 
hypertrophic  scars  is  much  like  that  in  treatment  of  other 
dermatologic  conditions.  Cryosurgery  utilizes  a  cryogenic 
agent  (liquid  nitrogen)  to  induce  direct  cellular  and  micro-
circulatory  damage.  This  leads  to  tissue  necrosis  and  hope-
ful flattening of the lesion. The primary risk of this method is 

Table 37.1  Treatment of Keloids and Hypertrophic Scars

Topical

 Massage
 Pressure
 Silicon gel
 Cryotherapy
 Tacrolimus
 Retinoids

Intralesional injection

 Corticosteroid (Triamcinolone acetonide)
 Interferon-α-2b
 5-fluorouracil
 Mitomycin C
 Verapamil

Laser

 Pulsed dye
 Argon laser
 Nd:YAG laser
 CO2 laser

Oral
Surgical
Radiation therapy
Other

hypopigmentation of the treatment site. Success rates as high 
as 74% have been claimed with the use of cryosurgery to treat 
keloids.  It  has  also  been  noted  that  younger  keloids  tend  to 
respond better to cryosurgery than older keloids. It can also be 
used as an adjunct to initial corticosteroid intralesional injec-
tion.  The  edema  which  results  from  cryosurgery  loosens  the 
scar-like fibers and facilitates easier injection.

Topical corticosteroids remain a common first-line treat-
ment  of  both  keloids  and  hypertrophic  scars.  The  known 
side effect of skin atrophy is harnessed and used to the clini-
cian’s advantage. Similar medications such as tacrolimus and 
pimecrolimus demonstrate some potential; however, these are 
weaker  than  most  corticosteroids  utilized  and  thus  may  be 
most efficacious in anatomic locales where stronger corticoste-
roids are not possible.

Intralesional  injection  remains  a  mainstay  of  treatment 
of keloids and hypertrophic scars. The most common and per-
haps  most  useful  medication  used  is  triamcinolone  acetonide. 
Triamcinolone acetonide as injected is available in multiple con-
centrations. Stock concentrations of 10 mg /mL and 40 mg/mL 
are most often used, while alternate dilutions can be prepared 
easily by diluting these stock concentrations. A common diluent 
is lidocaine, which offers the added benefit of local anesthesia 
at the injection site. The dose and concentration varies based on 
the size and location of keloid; however, this may range from 5 to 
40 mg/mL. Injecting a medication into a keloid often represents 
a physical challenge due to the density and firmness of a keloid. 
A  basic  understanding  of  Poiseuille’s  law  is  important  in  the 
delivery of medication. This law defines the volume flow-rate by 
the pressure difference divided by the viscous resistance. More 
succinctly,  it  determines  the  resistance  to  flow.  The  important 
point for the clinician is that a smaller diameter syringe allows 
a  greater  mechanical  advantage  for  injection.  A  1-cc  tubercu-
lin syringe with a lure lock tip and 27-gauge or larger needle is 
recommended. Lack of a lure lock system frequently results in 
propulsion of the needle from the syringe. The N-tralig injector 
utilizes a ratchet-type mechanism to allow injection of medica-
tion into keloids and hypertrophic scars (Figures 37.13 and 37.14). 
Use of this device proves especially helpful for firm keloids and 
initial treatments, where the mechanical force needed to inject 
is great. Another technique with keloid injection is the derma-
jet  (Figure  37.15).  This  specialized  syringe  allows  one  to  inject 
medication without using a needle.

In  all  cases,  it  is  important  to  avoid  injecting  into  the 
subcutaneous  fat,  as  the  atrophy  that  follows  is  difficult  to 

Figure 37.13 N-tralig mechanical injector.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT OF KELOIDS 

 355

(a)

(b)

(a)  Treatment  of  keloids  with  CO2  laser.  Multiple 
Figure  37.16 
treatment sessions were required with (b) resultant  improvement 
and decreased thickness. Of note, the resultant scars represent 
hypertrophic scars, an improvement over the previous keloids.

(a)

Figure 37.17 
pre- and postauricular cheek. (Continued)

(a, b) Use of CO2 laser to ablate large keloid on the 

Figure 37.14 
the N-tralig mechanical injector.

Intralesional treatment of a hypertrophic scar with 

Figure 37.15  Dermajet injector.

correct. Injection around or near the eye should also be carried 
out with caution, as particles from the suspension have been 
shown to cause amaurosis through embolization.

The  use  of  retinoids  for  the  treatment  of  keloids  and 
hypertrophic  scars  has  been  suggested  topically;  however, 
they have also been cited as a potential causative agent when 
taken orally. Decrease in size of keloids treated with tretinoin 
0.05%  topically  for  12  weeks  has  been  described.  The  risk  of 
scarring is well documented following recent treatment with 
isotretinoin  and  acitretin.  Typical  recommendations  suggest 
waiting 6 months after cessation of accutane prior to elective 
surgery when keloid formation may be of concern.

The use of imiquimod 5% cream has been met with mixed 
reviews in the prevention and treatment of keloids. Imiquimod is 
a topical immune response modifier that stimulates interferon-α 
(INF-α). This is a proinflammatory cytokine that increases col-
lagen breakdown. Although there are conflicting results in the 
literature, most of these studies consist of small study groups. 
Given  the  favorable  results  in  many  studies  and  the  overall 
safety profile of imiquimod, it is a simple and potentially useful 
adjunctive therapy for treatment of keloids.

Reports of using calcium antagonists to retard extracel-
lular  matrix  production  in  connective  tissue  equivalents  and 
intralesional verapamil to treat keloids have also appeared in 
the literature.

The  use  of  lasers  to  treat  keloids  and  hypertrophic 
scars  has  been  met  with  some  success  (Figures  37.13–37.19). 

 
356 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(b)

Figure 37.17 (Continued) 
keloid on the pre- and postauricular cheek.

(a, b) Use of CO2 laser to ablate large 

(c)

Figure  37.18  (Continued)  Postoperative  result  after  CO2  abla-
tion of keloid (from Figure 37.17) at 2.5 months (a) and 4.5 months 
(b  and  c).  The  resultant   surgical  scar  represents  a  hypertrophic 
scar but an improvement over the previous keloid

(a)

(b)

Figure 37.19  Large keloid on right cheek of a young man (a) and 
after CO2 resurfacing (b).

(b)

Figure  37.18  Postoperative  result  after  CO2  ablation  of  keloid 
(from  Figure  37.17)  at  2.5  months  (a)  and  4.5  months  (b  and  c). 
The resultant  surgical scar represents a hypertrophic scar but an 
improvement over the previous keloid. (Continued)

 
TREATMENT OF KELOIDS 

 357

Figure 37.22  Use of CO2 ablation to treat a keloid secondary to 
ear piercing.

A  number  of  different  lasers  have  been  tried  but  the  main 
two that remain in use are the pulsed dye laser and the car-
bon dioxide (CO2) laser. The pulsed dye laser is a 585 or 595 
nm  system.  Frequency-doubled  Nd:YAG  systems  have  also 
demonstrated benefit in the treatment of keloids and hyper-
trophic scars. Pulsed dye lasers have the benefit of reduction 
in size and redness of keloids and hypertrophic scars as well 
as normalizing the surface texture of keloids. The CO2 laser 
is an ablative laser that vaporizes tissue and can be used to 
excise  keloids  (Figures  37.13–37.23).  It  is  thought  to  have  an 
inhibitory effect on fibroblasts.

Surgery  is  commonly  used  to  treat  keloids  and  hyper-
trophic  scars;  however,  it  must  be  used  with  caution  as  this 
may  result  in  keloid  formation  itself,  sometimes  worse  than 
the initial lesion. The risk of anticipated keloid formation from 
surgical intervention often warrants adjuvant therapy such as 
postoperative  corticosteroid  injections.  Recurrence  of  keloids 
following surgical intervention varies from 50% to 80%.

Radiation  therapy  may  be  utilized  for  reduction  of 
keloid size on account of its ability to destroy fibroblasts and 

Figure 37.20  Surgical excision of large keloid.

(a)

(b)

Figure  37.21  Surgical  excision  and  CO2  resurfacing  of  large 
keloid on cheek.

Figure 37.23  Use of CO2 ablation to remove and recontour keloid 
on right cheek. The initial keloid (a) was first surgically excised (b) 
in an effort to debulk the lesion. Despite the use of intralesional 
corticosteroids, silicon sheeting, and topical imiquimod, the keloid 
recurred. (Continued)

 
358 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(c)

(d)

Figure  37.23  (Continued)  Use  of  CO2  ablation  to  remove  and 
recontour keloid on right cheek. The initial keloid (a) was first sur-
gically  excised  (b)  in  an  effort  to  debulk  the  lesion.  Despite  the 
use  of  intralesional  corticosteroids,  silicon  sheeting,  and  topical 
imiquimod, the keloid recurred.

neovascular buds via ionizing radiation. Radiation is  typically 
used in conjunction with surgery. The risks of ionizing radia-
tion must certainly be weighed against the  possible benefits.

A number of less common but reported treatments include 
the use of onion extract, cultured epithelial autografts, pentoxy-
fylline, colchicine, calcium antagonists, tranilast, and vitamin E.
The  use  of  combination  therapy  to  treat  keloids  is  not 
new but has become a focus in more recent literature. This has 
classically included excision with either immediate or subse-
quent injection of intralesional corticosteroids. More recently, 
reports of combinations including excision, mitomycin C, and 
radiotherapy  have  demonstrated  some  success.  The  use  of 
additional  lasers  such  as  the  1064  nm  Nd:YAG  has  also  been 
reported to have some benefit.

BIBLIOGRAPHY
Akaishi  S,  Akimoto  M,  Ogawa  R,  Hyakusoku  H.  The  relationship 
between  keloid  growth  pattern  and  stretching  tension:  Visual 
analysis  using  the  finite  element  method.  Ann  Plast  Surg  2008; 
60:445–51.

Berman  B,  Harrison-Balestra  C,  Perez  OA,  Viera  M,  Villa  A,  Zell  D, 
Ramirez  C.  Treatment  of  keloid  scars  post-shave  excision  with 
imiquimod  5%  cream:  A  prospective,  double-blind,  placebo-
controlled pilot study. J Drugs Dermatol 2009; 8:455–8.

Bran  GM,  Goessler  UR,  Hormann  K,  Riedel  F,  Sadick  H.  Keloids: 
Current concepts of pathogenesis. Int J Mol Med 2009; 24:283–93.

Border WA, Noble NA. TGF-β. Sci Am Sci Med 1995; 2:68–77.
Bouzari N, Davis SC, Nouri K. Laser treatment of keloids and hypertro-

phic scars. Int J Dermatol 2007; 46:80–8.

Brissett  AE,  Sherris  DA.  Scar  contractures,  hypertrophic  scars,  and 

keloids. Facial Plast Surg 2001; 17:23–272.

Brown  JJ,  Bayat  A.  Genetic  susceptibility  to  raised  dermal  scarring. 

Br J Dermatol 2009; 11:8–18.

Burk  CJ,  Aber  C,  Connelly  EA.  Ehlers-Danlos  syndrome  type  IV: 
Keloidal  plaques  of  the  lower  extremities,  amniotic  band  limb 
deformity,  and  a  new  mutation.  J  Am  Acad  Dermatol  2007; 
56:S53–4.

Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to 
prevent recurrence of surgically excised trunk keloids. Dermatol 
Surg 2009; 35:629–33.

Chrapil  M,  Peacock  E,  Carlon  ES,  Blau  S,  Steinbronn  N,  Morton  D. 
Colchicine and wound healing. J Surg Res 1980; 28:49–56.
Copcu  E,  Sivrioglu  N,  Oztan  Y.  Combination  of  surgery  and  intrale-
sional verapamil injection in the treatment of the keloid. J Burn 
Care Rehabil 2004; 25:1–7.

Cosman B, Crikelair GF, Ju MC, Gaulin JC, Lattes R. The surgical treat-

ment of keloids. Plast Reconstr Surg 1961; 27:335–45.

D’Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of 
keloids with intralesional verapamil. Dermatology 2002; 204:60–2.
Darzi  MA,  Chowdi  NA,  Kaul  SK.  Evaluation  of  various  methods  of 
treating  keloids  and  hypertrophic  scars:  A  10-year  follow-up 
study. Br J Plastic Surg 1992; 45:374.

Dockery  GL,  Nilson  RZ.  Treatment  of  hypertrophic  and  keloid  scars 
with Silastic gel sheeting. J Foot Ankle Surg 1994; 33:110–9.
Edgerton MT, Hahrahan EM, Davis WB. Use of vitamin E in the treat-

ment of keloids. Plast Reconstr Surg 1951; 8:224–33.

English  RS,  Shenefelt  PD.  Keloids  and  hypertrophic  scars.  Dermatol 

Surg 1999; 25:631–8.

Engrav  LH,  Gottlieb  JR,  Millard  SP,  et  al. A  comparison  of  intramar-
ginal  and  extramarginal  excision  of  hypertrophic  burn  scars. 
Plast Reconstr Surg 1988; 81:40–5.

Goeminne L. A new probably X-linked inherited syndrome: Congenital 
muscular torticollis, multiple keloids, cryptorchidism and renal 
dysplasia. Acta Genet Med Gemellol (Roma) 1968; 17:439–67.
Goodfellow A, Emmerson RW, Calvert HT. Rubinstein-Taybi syndrome 
and spontaneous keloids. Clin Exp Dermatol 1980; 5:369–70.
Haas AF, Reilly DA. Cultured epithelial autografts in the treatment of 

extensive recalcitrant keloids. Arch Dermatol 1998; 134:549–52.

Hendrix JD Jr, Greer K. Rubinstein-Taybi syndrome with multiple flam-

boyant keloids. Cutis 1996; 57:346–8.

Hintz  BL.  Radiotherapy  for  keloid  treatment.  J  Natl  Med  Assoc  1973; 

5:71–5.

Kaminer  MS,  Arndt  KA,  Dover  JS,  Rohrer  TE,  Zachary  CB.  Atlas  of 

Cosmetic Surgery, 2nd edition. China: Saunders 2009.
Katz BE. Silicone gel sheeting in scar therapy. Cutis 1995; 56:65–7.
Kim  WJH,  Levinson  H,  Gittes  GK,  Longaker,  MT.  Molecular  mecha-
nisms in keloid biology. In: Garg HG, Longaker MT eds. Scarless 
Wound Healing. New York: Marcel Dekker, 2000; pp. 161–71.
Kischer  CW,  Shetlar  MR,  Shetlar  CL,  Chrapil  M.  Immunoglobulins  in 
hypertrophic scars and keloids. Plast Reconstr Surg 1983; 71:821–5.
Kleinerman R, Kilmer SL, Chotzen VA. Mitomycin C in the treatment 

of keloids: A case and review. J Drugs Dermatol 2013; 12:701–3.

Koc E, Arca E, Surucu B, Kurumlu Z. An open, randomized, controlled, 
comparative study of the combined effect of intralesional triam-
cinolone acetonide and onion extract gel and intralesional triam-
cinolone acetonide alone in the treatment of hypertrophic scars 
and keloids. Dermatol Surg 2008; 34:1507–14.

Kurwa AR, Rubinstein-Taybi syndrome and spontaneous keloids. Clin 

Exp Dermatol 1979; 4:251–4.

Lane JE, Waller JL, Davis LS. Relationship between age of ear piercing 

and keloid formation. Pediatrics 2005; 115:1312–4.

Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant 
intralesional  verapamil  and  pressure  earrings.  Ann  Plast  Surg 
1996; 37:167–9.

 
TREATMENT OF KELOIDS 

 359

Ledon  JA,  Savas  J,  Franca  K,  Chacon A,  Nouri  K.  Intralesional  treat-
ment for keloids and hypertrophic scars: A review. Dermatol Surg 
2013; 39:1745–57.

Lee R, Ping J. Calcium antagonists retard extracellular matrix  production 
in connective tissue equivalent. J Surg Res 1990; 49:463–6.
Lee RC, Doong H, Jellem AF. The response of burn scars to intralesional 
verapamil. Report of 5 cases. Arch Surg 1994; 129:107–11.
Mandal A, Imran D, Rao GS. Spontaneous keloids in siblings. Ir Med J 

2004; 97:250–1.

Marneros AG, Norris JEC, Olsen BR, Reichenberger E. Clinical genetics 

of familial keloids. Arch Dermatol 2001; 137:1429–34.

Menezes  N,  Moreira  A,  Furtado  A,  Bacelar  E,  et  al.  Eruptive  keloids: 
Spontaneous reactivation after 60 years. Dermatol Online J 2009; 15.

Murray JC. Scars and keloids. Dermatol Clin 1993; 11:697–707.
Murray  JC,  Pinnell  SR.  Keloids  and  excessive  dermal  scarring.  In: 
Kelman  Cohen  I,  Diegelmann  RF,  Lindblad  WJ,  eds.  Wound 
Healing;  Biochemical  and  Clinical  Aspects.  Philadelphia,  PA:  WB 
Saunders Company., 1992; pp. 500–9.

Nemeth AJ. Keloids and hypertrophic scars. J Dermatol Surg Oncol 1993; 

19:738–46.

Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hyper-
trophic  scars  and  keloids:  A  review.  Plast  Reconstr  Surg  1999; 
104:1435–58.

Panabiere-Castaings  MH.  Retinoic  acid  in  the  treatment  of  keloids. 

J Dermatol Surg Oncol 1988; 14:1275–6.

Partington MW. Rubinstein-Taybi syndrome: A follow-up study. Am J 

Med Genet Suppl 1990; 6:65–8.

Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars. 

A comprehensive review. Plast Reconstr Surg 1989; 84:827–37.

Rossi A, Lu R, Frey MK, Kubota T, Smith LA, Perez M. The use of the 
300  microsecond  1064  nm  Nd-YAG  laser  in  the  treatment  of 
keloids. J Drugs Dermatol 2013; 12:1256–62.

Rudolph  R.  Wide  spread  scars,  hypertrophic  scars  and  keloids.  Clin 

Plast Surg 1987; 14:253–60.

Rusciani  L,  Rossi  G,  Bono  R.  Use  of  cryotherapy  in  the  treatment  of 

keloids. J Dermatol Surg Oncol 1993; 19:529–34.

Selmanowitz  VJ,  Stiller  MJ.  Rubinstein-Taybi  syndrome.  Cutaneous 
manifestations  and  colossal  keloids.  Arch  Dermatol  1981; 
117:504–6.

Stegman  SJ,  Tromovitch  TA,  Glogan  RG.  Treatment  of  keloids.  In: 
Stegman  SJ,  ed.  Cosmetic  Dermatologic  Surgery,  2nd  edition. 
Chicago: Year Book Medical, 1990; pp. 201–6.

Suzawa H, Kibuchi S, Arai N, Koda A. The mechanism involved in the 
inhibitory action of tranilast on collagen biosynthesis of keloid 
fibroblasts. Jpn J Pharmacol 1992; 60:91–6.

Ulrich D, Ulrich F, Unglaub F, Piatkowski A, Pallua N. Matrix metal-
loproteinases  and  tissue  inhibitors  of  metalloproteinases  in 
patients with different types of scars and keloids. J Plast Reconstr 
Aesthet Surg 2009; 1–7.

Waki EY, Crumley RL, Jaowatz JG. Effects of pharmacologic agents on 
human keloids implanted in thymic mice. Otolaryngol Head Neck 
Surg 1991; 117:1177–81.

Wolfram  D,  Tzankov  A,  Pulzl  P,  Piza-Katzer  P.  Hypertrophic 
scars  and  keloids  –  A  review  of  their  pathophysiology,  risk 
factors,  and  therapeutic  management.  Dermatol  Surg  2009; 
35:171–81.

Younai S, Ventors G, Vu S, Nichter L, Nimni M, Taun T. Role of growth 
factors in scar contraction: An in vitro analysis. Ann Plast Surg 
1996; 36:495–501.

Zouboulis  CC,  Blume  U,  Buttner  P,  Orfanos  CE.  Outcomes  of  cryo-
surgery in keloids and hypertrophic scars. Arch Dermatol 1993; 
129:1146–51.

Zurada  JM,  Kriegel  D,  Davis  IC.  Topical  treatments  for  hypertrophic 

scars. J Am Acad Dermatol 2006; 55:1024–31.

 
38

Keratolytic Treatment of Acne

Brigitte Dréno

INTRODUCTION
Topical  keratolytics  are  agents  that  dissolve  or  break  down 
the  outer  layer  of  skin.  They  loosen  and  assist  exfoliation 
of the skin cells. In acne, their target is the comedo and the 
most powerful keratolytics are used topically. These topical 
keratolytic  agents  have  long  been  employed  for  acne  treat-
ment  and  have  always  played  a  central  role  in  the  treat-
ment of retentional lesions. Shalita et al. state that “the first 
histologically  visible  change  in  acne  is  a  disruption  in  the 
normal  pattern  of  keratinization,  resulting  in  dense,  coher-
ent squamae of keratinous material that accumulate to form 
a  plug  in  the  orifice  of  the  follicle,  leading  to  formation  of 
the  microcomedo.”  Microcomedo  is  the  precursor  of  acne 
lesion, histologically but not clinically visible. Furthermore, 
these  aberrancies  in  proliferation,  adhesion,  and  differen-
tiation  of  the  keratinocytes  obstruct  the  infundibulum  and 
the  sebaceous  duct,  paving  the  way  for  excessive  sebum 
secretion,  bacterial  overgrowth  (Propionibacterium  acnes), 
and  inflammatory  response  due  to  activation  of  cutaneous 
innate immunity. Under light microscopy, microcomedones 
are visualized as layers of horny cells surrounding a sebum 
and bacteria core (1). Keratolytic agents are thought to func-
tion  by  relaxing  the  cohesiveness  of  the  stratum  corneum 
(SC) layer, which serves as a crucial, life-sustaining barrier, 
keeping  hydration  “in”  and  harmful  foreign  agents  “out.” 
The  mechanism  of  action  does  not  involve  keratin  lysis  as 
the  name  implies,  but  rather  disintegration  of  desmosomes 
and corneodesmosomes that link keratinocytes of the follicle 
and bind them to the extracellular matrix, respectively (2). In 
this manner, these agents can secondly modulate and correct 
abnormal follicular keratinization.

Currently many classes of keratolytics exist (Table 38.1). 
Available in varying concentrations and vehicles, they may 
be  specifically  indicated  depending  on  the  type,  duration, 
and severity of acne and the sensitivity of the skin and the 
part of the body (face or trunk). Their targets are the micro-
comedo  and  the  comedo.  This  chapter  covers  widely  avail-
able topical and oral keratolytics, controlled trials comparing 
keratolytic  agents,  and  in  vivo  keratolytic  protein  assays. 
Uncontrolled trials and older acne treatments are discussed 
briefly.

This  overview  was  based  on  PubMed,  Embase,  and 
Science  Citation  Index  utilizing  the  following  words:  kera-
tolytics,  benzoyl  peroxide,  azelaic  acid,  retinoids,  sulfur, 
resorcinol,  glycolic  acid,  salicylic  acid,  combined  therapy, 
peeling,  acne  vulgaris.  For  clinical  trials,  we  firstly  consid-
ered  double-blind  controlled  trials  and  if  not,  randomized 
controlled trials with more than 80 included patients. Only 
studies that assessed subjects with acne vulgaris on the face 
were included.

BENZOYL PEROXIDE
Benzoyl peroxide (BPO), a mainstay treatment of mild to mod-
erate acne for decades, has mainly antimicrobial, anti-inflam-
matory  effect  and  only  mild  anticomedogenic  effects.  Acting 
through oxidation and formation of free radicals, its bacterio-
static activity is superior even to that of topical antibiotics (3). 
It decreases inflammation by killing polymorphonuclear leu-
kocytes (PMNs), preventing the release of reactive oxygen spe-
cies (4). The mild keratolytic activity is probably linked to the 
destruction of P. acnes. Indeed recently it has been shown that 
P. acnes is able to increase the proliferation and modulate the 
differentiation of keratinocytes, thus playing a role in the for-
mation of the comedo (5). Unfortunately, oxidative destruction 
of the SC may deplete cutaneous vitamin E, resulting in oxida-
tion of surface lipids and proteins; this may predispose to skin 
dryness  and  desquamation  (6).  BPO  is  absorbed  effectively 
into  the  epidermis,  particularly  by  pilosebaceous  units,  and 
converted to benzoic acid, with approximately 2% entering the 
systemic circulation (7,8). Its lipophilicity allows it to enter and 
accumulate in the lipid-rich pilosebaceous units and subcuta-
neous fat (4). It is an FDA Pregnancy Category C agent, with 
little  known  about  potential  fetal  harm  or  breast  milk  excre-
tion, and positive in the rodent photocarcinogenicity assay. In 
Europe, it can be prescribed to pregnant women. It is widely 
available both over the counter (OTC) and by prescription, and 
comes  in  different  concentrations  ranging  from  2.5%  to  10%. 
Adverse  effects  include  dryness,  peeling,  burning,  and  red-
ness of skin, with contact allergy only in 1% to 2% of patients 
(3). To that end, patients should avoid excessive UV radiation, 
which can exacerbate irritation. Additionally, the water-based 
formulations may exert less drying, scaling, burning, and ery-
thema than the alcohol-based formulations (3,9). Of note, BPO, 
an oxidizing agent, can bleach hair, clothing, and colored fab-
rics. It may also inactivate tretinoin if both are applied concur-
rently (10); in contrast, adapalene and tazarotene remain stable 
in the presence of BPO (7).

The 2.5% formulation may be as effective as the 5% and 
10%  formulations  in  reducing  retentional  and  inflammatory 
lesions,  while  causing  fewer  adverse  reactions  than  the  10% 
solution (11).

Benzoyl  peroxide  has  been  combined  with  other 
molecules  to  increase  its  keratolytic  efficacy.  In  a  split-
face,  double-blind  trial,  a  combination  of  BPO  5%  and  urea 
8%  lotion  was  not  more  efficacious  in  diminishing  acne 
than  BPO  5%  lotion  alone;  the  combination  took  longer  to 
dry  and  was  stickier,  according  to  subjects  (12).  Combina-
tion  therapy  with  topical  antibiotics  and  BPO  may  be  more 
effective  than  BPO  alone.  Both  the  clindamycin/BPO  and 
the  erythromycin/BPO  formulations  have  shown  superior 
efficacy  when  compared  with  either  the  antibiotic  or  BPO 

KERATOLYTIC TREATMENT OF ACNE 

 361

Table 38.1  Keratolytics Currently Used in the United States and Europe in Acne

Name

Class

First Introduced

Usual Concentration(s) (%)

Vehicle(s)

Salicylic acid
Glycolic acid
Benzoyl peroxide
Tretinoin
Isotretinoin
Tazarotene
Adapalene
Azelaic acid
Sulfur
Urea
Resorcinol
Clindamycin/benzoyl peroxide
Erythromycin/benzoyl peroxide
Adapalene/benzoyl peroxide
Tretinoin/clindamycin

β-Hydroxy acid
α-Hydroxy acid
Organic peroxde
Retinoid
Retinoid
Retinoid
Retinoid-like
Dicarboxylic acid
Sulfur
Urea
Phenol
Antibiotic combination
Antibiotic combination
Retinoid-like/BPO
Retinoid/Antibiotic

1887
1900 
1920s
1962
1979
1997
1996
2002
1998
1828
1866
2009
2006
2009
2010

No more than 2.0
<10%
2.5, 5.0, 10
0.025, 0.05, 0.1
0.05
0.1, 0.05, 0.5
0.1
15.0, 20.0
10.0
<10%
–
1.0/5.0
3.0/5.0
0.1/2.5
0.025/1.2%

Bar, foam, cream
Superficial peeling
Gel, bar
Cream, gel
Gel
Gel, cream
Gel, cream
Cream, gel
Bar
Cream
Peeling
Gel
Gel
Gel
Gel

alone  (13).  Three  well-designed,  randomized,  double-blind, 
vehicle-controlled,  multicenter  clinical  trials  comparing 
the  clindamycin/BPO  gel  with  each  individual  agent  and 
vehicle demonstrated significantly superior efficacy both in 
retentional and inflammatory lesion reduction after 10 to 16 
weeks.  Furthermore,  the  side  effect  profile  (dry  skin,  peel-
ing, and erythema) of combination therapy is comparable to 
that  of  BPO  alone  (4).  Two  other  multicenter,  double-blind 
randomized  studies  of  2813  acne  patients  with  moderate  to 
severe acne compared the efficacy and safety of a fixed com-
bination  clindamycin  phosphate  1.2%  and  BPO  2.5%  with 
each  drug  alone  and  a  vehicle  arm,  in  moderate  or  severe 
acne subpopulations. Clindamycin-BP 2.5% gel significantly 
reduced  inflammatory  and  non-inflammatory  lesions  com-
pared with each active ingredient and vehicle only in mod-
erate acne at week 12. Rates of adverse events were low and 
similar  between  treatment  groups  and  baseline  acne  sever-
ity.  This  study  confirms  that  the  target  of  this  combined 
therapy is moderate and not severe acne (14).

Concerning  the  combination  BPO/erythromycin,  no 
double-blind  study  has  been  performed.  Leyden  et  al.  com-
pared  clindamycin/BPO  and  erythromycin/BPO  demon-
strating  statistically  equivalent  lesion  reduction  and  global 
improvement, with similar tolerability (15).

In vivo data suggest that the increased efficacy of a BPO/ 
antibiotic  combination  may  have  an  immunological  basis  as 
demonstrated  by  decreased  antioxidant  enzyme  activities  in 
leukocytes after month-long combination treatment (16). Addi-
tionally, this combinatory approach may prevent the evolution 
of resistant P. acnes strains (17).

RETINOIDS: TRETINOIN, 
TAZAROTENE, ADAPALENE
Topical retinoids encompass a group of powerful comedolytic, 
anticomedogenic,  and  anti-inflammatory  agents.  They  are 
powerful keratolytics, targeting both primary and secondary 
prevention  of  comedones.  There  are  two  generations  of  topi-
cal  retinoids—first-generation,  represented  by  the  tretinoin, 
and  second-generation,  represented  by  adapalene  and  taz-
arotene—that  are  specific  of  retinoic  acid  receptors  (RARs). 
Retinoids exert their effects through nuclear receptor families 
RARs and RXRs (retinoic X receptors), subsequently inducing 
retinoic acid–responsive target gene expression (18),(19). Both 

receptor  families  are  ligand-dependent  transcription  factors 
and consist of three receptor subtypes (a, b, and ϒ), encoded by 
three separate genes (20).

Although  RAR-a  is  ubiquitous  in  embryonic  skin, 
RAR-ϒ  is  the  most  abundant  RAR  in  human  epidermis,  cul-
tured  keratinocytes,  and  dermal  fibroblasts  (20,21).  Retinoids 
also  inhibit  expression  of  certain  genes  by  down  regulating 
other  transcription  factors,  notably  activator  protein  1  (AP-1) 
and nuclear factor-interleukin 6 (NF-IL6) (18). This inhibitory 
action may be partly responsible for the antiproliferative and 
anti-inflammatory actions of retinoids (20).

Prior to binding with nuclear RARs, retinoids must first 
bind  to  intracellular  proteins.  Cellular  retinoic  acid  proteins 
(CRABP I and II) are present in the skin. Intracellular retinoid 
concentrations are dependent on CRABP, primarily type II (18). 
However, CRABP II is not essential for biological retinoid activ-
ity as adapalene does not bind to it; interestingly, it may play 
a  role  in  retinoid-induced  epidermal  irritation  (20).  Through 
this genetic regulation, retinoids are thought to affect cellular 
differentiation  and  proliferation  (22).  Experimental  studies, 
some using primary neonatal mouse epidermal keratinocyte 
cultures,  have  confirmed  this  concordant  decrease  in  kerati-
nocyte  differentiation  and  proliferation  (23).  Retinoids  also 
regulate activity of keratinocyte adhesion and cohesion mol-
ecules  (integrins),  resulting  in  breakdown  and  obliteration 
of  the  horny  plug  (21).  Mechanisms  of  action  are  numerous 
and include an anti-inflammatory activity with an inhibition 
of  neutrophil  chemotaxis,  expression  of  toll-like  receptors 
involved  in  innate  immunity,  inhibition  of  prostaglandins, 
leukotrienes,  and  interferon-ϒ  release.  They  also  inhibit  the 
release  of  proinflammatory  cytokines  (interleukins  12  and  8 
and tumor necrosis factor) via down regulation of monocyte 
TLRs (24,25). Interestingly, P. acnes acts through TLR-2 to stim-
ulate  proinflammatory  cytokine  production  (26).  The  major 
drawback to topical retinoids is local skin irritation and acne 
exacerbation,  also  termed  “retinoid  flare,”  which  may  occur 
during  the  first  month  of  treatment  and  last  several  weeks 
(7).  This  flareup  may  be  secondary  to  release  of  follicular 
inflammatory  factors  after  topical  retinoid  treatment  (27,28). 
Another limiting factor of topical retinoids is the contraindi-
cation to their use during pregnancy. Limb-reduction defects 
and ear malformations have been reported with maternal use 
of topical retinoids in two papers (29,30). However, Jick et al., 

 
362 

 TEXTBOOK OF COSMETIC DERMATOLOGY

in a retrospective study, did not substantiate this suggestion, 
and the clinical issue remains to be confirmed (31).

Tretinoin
Tretinoin,  the  first  topical  retinoid  to  be  studied,  binds 
with high activity to all three RAR subtypes and to CRABP, 
and with low activity to RXRs. It is both a comedolytic and 
anticomedogenic,  preventing  formation  of  microcomedo-
nes  (20).  Employing  the  technique  of  skin  surface  biopsy, 
microscopic examination of comedones showed progressive 
loss  of  cohesiveness  and  significant  alterations  in  epithe-
lial  structure;  thick  keratinous  plugs  infested  with  bacteria 
were  transformed  into  a  few  wispy  layers  of  keratin  with 
few  bacteria.  Using  transmission  electron  microscopy,  it 
was possible to track microcomedones with compact, adher-
ent  SC  morphing  into  spongy,  loosely  adherent  layers  of 
corneocytes  (1).  Mills  and  Kligman,  using  a  cyanoacry-
late  follicular  biopsy  technique,  demonstrated  a  profound 
microcomedone  reduction  in  8  and  12  weeks  (32).  From  an 
immunological  perspective,  in  vitro  studies  have  demon-
strated that tretinoin down regulates and decreases surface 
expression of TLR-2 and CD14 mRNA, preventing secretion 
of  tumor  necrosis  factor  and  IFN-ϒ,  as  well  as  production 
of free radicals (21,23). Tretinoin cream 0.025% significantly 
reduced  inflammatory  but  mainly  non-inflammatory  acne 
lesions compared with vehicle by 12 weeks. Numerous trials 
have  also  demonstrated  the  efficacy  of  0.05%  and  0.1%  gel 
tretinoin in mild to moderate acne with a decrease of reten-
tional lesions between 30 and 50% according the studies (1). 
Additionally, tretinoin may bring out the postinflammatory 
darkening  that  occurs  in  healing  acne  of  darker-skinned 
patients (27). Surprisingly, topical tretinoin has poor percu-
taneous absorption and does not alter systemic retinoid lev-
els,  which  stay  constant  despite  application  (7).  Side  effects 
include  peeling,  erythema,  dryness,  burning,  exfoliation, 
and  itching  (7,21,33).  Side  effects  included  erythema,  dry 
skin, and exfoliation. Despite some evidence to the contrary, 
topical tretinoin is not advised during pregnancy and lacta-
tion. Potential for systemic exposure and excretion in breast 
milk have not been adequately studied.

Addition of some chemical substances or medical devices has 
been  proposed  to  increase  efficacy  and  decrease  irritation. 
Thus,  addition  of  polyolprepolymer-2  (PP-2),  localizes  drug 
molecules  in  upper  skin  layers,  preventing  deep  penetration 
(33). PP-2 forms a liquid reservoir of polymer and solubilized 
drug  on  the  skin  surface,  slowing  percutaneous  absorption 
and  transcellular  cutaneous  diffusion,  potentially  targeting 
folliculo-infundibular  delivery  in  the  process.  Clinical  tri-
als  have  demonstrated  reduced  irritation  as  less  drug  pen-
etrates the skin (34). The Microsponge Delivery System found 
in  0.1%  microsphere  gel  also  helps  reduce  drug  release  rate 
and increase drug retention in the SC, inhibiting deeper pen-
etration  (7).  Tretinoin  is  trapped  within  porous  copolymer 
microspheres which selectively localize to the follicle, releas-
ing tretinoin over time and producing less irritation (than the 
standard  0.025%  cream)  due  to  reduced  concentration  on  the 
skin (21,35).

A  recent  study  compared  the  efficacy  and  safety  pro-
file  of  tretinoin  0.05%  with  adapalene  0.1  and  0.3%  and  pla-
cebo in Mexican subjects with acne vulgaris. Tretinoin 0.05% 
and adapalene 0.3% were more effective than adapalene 0.1% 
and placebo in the reduction of both inflammatory and non-
inflammatory lesions, but the adverse events (topical irritation) 
were also more important (36).

Two other studies have compared micronized tretinoin 
gel 0.05% versus tretinoin gel microsphere 0.1%, with similar 
efficacy in both. Concerning tolerance, the results were contra-
dictory  between  the  two  studies,  not  permitting  any  conclu-
sions (37).

Combination:  The  alteration  in  SC  integrity  incurred 
during tretinoin treatment may enhance penetration of other 
agents  such  as  topical  antibiotics  (38).  Topical  retinoid  ther-
apy, by weakening the horny layer barrier, may increase skin 
permeability,  enhancing  penetration  of  antimicrobial  agents. 
Increased cell turnover of follicular epithelium enables greater 
access of antibiotic into the canal that houses P. acnes. A hydro-
gel containing 1% clindamycin and 0.025% tretinoin was found 
to be more efficacious in treating both inflammatory and non-
inflammatory  acne  lesions  than  either  agent  alone  or  vehicle 
(39). Three other double-blind randomized studies have been 
performed confirming that the combination clindamycin phos-
phate 1.2% and tretinoin 0.025% decreased significantly more 
both retentional and inflammatory lesions in mild to moderate 
acne compared with each of the drug used alone (40–42). The 
inflammatory flareup of the first days of treatments was also 
less important.

Finally,  a  BPO  6%  cleanser–tretinoin  0.1%  microsphere 
gel  demonstrated  significantly  greater  inflammatory  lesion 
reduction than tretinoin alone (43). However, tretinoin should 
not be used with BPO (an oxidizing agent), which can result in 
degradation and deactivation.

Topical Isotretinoin
One  multicentric  double-blind  randomized  study  (44)  has 
compared isotretinoin 0.05% gel with its vehicle. Patients were 
treated twice daily for up to 14 weeks. Efficacy of Isotretinoin 
was  significantly  better  than  vehicle  both  for  inflammatory 
and  retentional  lesions  with  low  irritation.  But  in  a  general 
manner  topical  Isotretinoin  is  considered  as  less  efficacious 
than other topical retinoids with a low keratolytic effect. The 
efficacy cannot be compared with systemic Isotretinoin.

Tazarotene
Tazarotene, a second generation of topical retinoids, is a topi-
cal  acetylenic  retinoid  indicated  in  both  psoriasis  and  acne 
vulgaris. Currently, only the 0.1% formulation of tazarotene is 
approved by the FDA for acne and tazarotene is not approved 
in Europe for acne. It is primarily used in cases of acne refrac-
tory to tretinoin and adapalene treatment (7).

Tazarotene  is  hydrolyzed  by  keratinocyte  esterases  to 
tazarotenic  acid,  its  active  metabolite  (18).  It  binds  all  three 
RARs  but  not  RXR,  activates  gene  expression  only  in  RAR-ϒ 
and  ϒ.  It  down  regulates  AP-1  (18,20,45).  As  tretinoin,  it  nor-
malizes  the  keratinization  pattern  and  decreases  coherence 
of follicular keratinocytes, manifesting both comedolytic and 
anticomedogenic  properties  (22).  Tazarotene  also  has  anti-
inflammatory properties (22). In the systemic circulation, taz-
arotenic  acid  is  rapidly  converted  to  inactive  sulfur-oxidized 
forms, resulting in limited exposure (45). Nonetheless, animal 
studies  have  demonstrated  that  tazarotene  has  low  systemic 
absorption  with  no  toxic  effects  even  at  high  topical  doses 
(45). Additionally, after 12 weeks of normal tazarotene appli-
cation, serum samples from 22 subjects demonstrated limited 
systemic  exposure  with  most  below  the  quantifiable  limit 
(<0.05  ng/mL)  (22).  Despite  little  evidence  of  fetal  malforma-
tions  or  spontaneous  abortions,  topical  tazarotene  is  an  FDA 

 
Pregnancy Category X drug; little is known about its excretion 
in breast milk. Of all topical retinoids in acne treatment, it is 
the  only  one  requiring  sufficient  contraception  in  women  of 
childbearing age (21).

At the clinical level, a randomized, double-blind, vehicle-
controlled study demonstrated that 0.05% and 0.1% tazarotene 
gels  significantly  decrease  retentional  acne  lesions  and  pro-
duce a higher success rate than vehicle at 12 weeks (22). More-
over,  0.1%  gel  was  significantly  more  efficacious  than  0.05% 
gel,  mainly  on  inflammatory  acne  (22).  Two  randomized  tri-
als comparing tazarotene 0.1% cream to adapalene 0.1% cream 
demonstrated tazarotene to be significantly and rapidly more 
effective  in  reducing  comedone  and  inflammatory  lesions 
with no significant difference in side effects at 12 weeks in one 
study (22,46). But another more recent study showed that daily 
therapy with adapalene 0.1% gel was not inferior to tazarotene 
0.1%  cream  in  total  acne  lesion  reductions  and  during  initial 
stages of treatment and demonstrated better tolerability with 
respect  to  erythema  and  scaling.  Finally,  one  trial  compared 
once-daily  tazarotene  0.1%  cream  and  adapalene  0.3%  gel  in 
patients with moderate to severe acne (47).

Tazarotene  0.1%  cream  appeared  to  be  more  effective 
and nearly as well tolerated as adapalene 0.3% gel in reducing 
acne lesions and was more effective than adapalene 0.3% gel 
in  reducing  PIH.  Furthermore,  a  large  clinical  trial  suggests 
that even short-contact application (<5 minutes), once daily for 
12 weeks, produces significant reduction in both inflammatory 
and noninflammatory acne lesions (48). A multicenter, double-
blind,  randomized  trial  found  a  daily  5%  BPO/1%  clindamy-
cin  gel–tazarotene  0.1%  cream  regimen  to  be  more  effective 
than daily tazarotene monotherapy in reducing comedo count 
and inflammatory lesion count, with a similar, if not slightly 
improved,  tolerability  profile  (49).  Recently,  two  randomized 
study  determined  the  efficacy  of  tazarotene  foam,  0.1%  once 
daily compared to vehicle for 12 weeks (50). The weakness of 
this study is the evaluation of adverse events, not very clearly 
explained.

Local  side  effects  include  itching,  burning,  irritation, 
and  erythema  (7,22).  In  fact,  tazarotene  is  thought  to  be  the 
most  irritating  of  the  topical  retinoids.  In  the  Bershad  study 
cited  above,  half  of  the  patients  applying  tazarotene  for  only 
2 to 10 minutes daily reported local skin irritation. These side 
effects are most common during the first 2 weeks of therapy; 
cream formulations, alternate-day application, and short-con-
tact therapy can curtail side effects (21).

Adapalene
Adapalene  0.1%  or  0.3%,  as  tazarotene,  is  a  second  genera-
tion of topical retinoids. It is a derivative of retinoic acid that 
binds selectively to RAR-β and -ϒ in vitro but can activate gene 
expression through all three RARs; it does not bind CRABP II  
but  increases  CRABP  II  mRNA  (18,20).  It  has  comedolytic, 
antiproliferative,  and  anti-inflammatory  properties  which 
are  more  important  that  the  first  generation  of  topical  reti-
noids (20). Its anti-inflammatory action stems from inhibitory 
effects on PMN chemotactic response, free radical production, 
and  toll-like  R2  receptors  expressed  by  perifollicular  mono-
cytes (21). It also inhibits production of leukotrienes by 5- and 
15-lipoxygenase  pathways  (20,21).  Furthermore,  adapalene 
may  have  a  dose-dependent  response,  with  0.3%  statistically 
superior  to  0.1%  in  several  different  measures,  while  demon-
strating equivalent tolerability (51).

Adapalene’s  particle  size  (diameter  between  3  and  10 
mm)  and  its  lipophilic  properties  result  in  optimal  follicular 

KERATOLYTIC TREATMENT OF ACNE 

 363

duct penetration (20); furthermore, after 5 minutes of exposure, 
14-C labeled adapalene applied to human skin in vitro demon-
strates radio sensitivity in the pilosebaceous units, with sparse 
activity  in  the  SC  and  epidermis.  Adapalene  demonstrates 
higher stability than tretinoin in the presence of light, in the 
dark,  and  with  BPO  (10).  In  a  study  comparing  the  chemical 
stability of 0.1% adapalene gel/10% BPO and 0025% tretinoin 
gel/10% BPO after 24 hours of light exposure, approximately 
100%  of  adapalene  remained  intact  versus  only  20%  of  treti-
noin (52).

At  the  clinical  level,  a  meta-analysis  of  five  large  ran-
domized  trials  (900  patients)  demonstrated  equivalent  acne 
reduction, quicker onset of action (significant at 1 week), and 
fewer side effects in 0.1% adapalene gel compared with that in 
0.025% tretinoin  gel (53). Recently  it has been confirmed  that 
adapalene 0.1% is more keratolytic than benzoyl peroxide.

Maintenance  therapy:  Cyanoacrylate  strip  data  suggests 
that application of adapalene 0.1% gel every other day may be 
effective  maintenance  therapy  in  microcomedone  reduction, 
resulting in decreased exposure (62).

Side  effect  profile  was  significantly  better  in  regard  to 
scaling,  erythema,  dryness,  immediate  and  persistent  burn-
ing, and immediate pruritus (53). With its three aromatic rings, 
in  a  study  examining  two  21-day–long  trials,  adapalene  0.1% 
gel  demonstrated  greater  tolerability  and  significantly  less 
irritation  than  tretinoin  0.1%  cream,  tretinoin  0.05%  cream, 
tretinoin  0.025%  cream,  tretinoin  0.01%  gel,  tretinoin  0.025% 
gel,  and  tretinoin  0.1%  gel  microsphere  (54).  Furthermore,  in 
both  studies,  adapalene  0.1%  gel  was  no  more  irritating  than 
the petrolatum control (54). Favorable tolerability to adapalene 
may be explained by its receptor specificity, neutral molecular 
structure, and lack of breakdown products.

Combination:  A  study  testing  0.1%  adapalene/2.5%  BPO 
combination  gel  against  vehicle  and  individual  monothera-
pies  demonstrated  combination  therapy  to  have  faster  onset 
of  action,  significantly  greater  reductions  in  all  lesion  types, 
and no increase in adverse effects compared with monother-
apy  (26).  This  efficacy  has  been  confirmed  in  a  double-blind 
randomized trial in 1670 patients (55). Focusing on subgroups 
of  patients,  0.1%  adapalene/2.5%  BPO  is  also  well  tolerated 
in  the  black  subjects  with  similar  results  to  Caucasians.  No 
cases  of  treatment-related  PIH  were  observed  (56)  in  young 
preadolescent patients with moderate acne (57). The combina-
tion associated with systemic cyclines (doxycycline 100 mg/D, 
lymecycline  300  mg/D)  can  be  efficient  in  severe  acne  and 
thus can be an alternative to a contraindication to isotretinoin 
(58,59).  In  addition  of  0.1%  adapalene,  the  combination  0.1% 
adapalene/2.5%  BPO  is  also  able  to  prevent  the  occurrence 
of relapse among patients with severe acne, and reduces acne 
lesions during 6 months (58).

AZELAIC ACID
Azelaic acid, a naturally occurring, saturated C9-dicarboxylic 
acid,  modifies  epidermal  keratinization  (cytostatic),  combats 
both  aerobic  and  anaerobic  bacteria  (reducing  P.  acnes  pro-
liferation),  and  exhibits  anti-inflammatory  activity  (18,60). 
This anti-inflammatory activity may potentially be mediated 
through  inhibition  of  hydroxyl  and  superoxide  radical  pro-
duction by neutrophils (61). Contributing to its anti-inflamma-
tory properties, in vitro, azelaic acid is an oxygen free radical 
scavenger,  inhibiting  hydroxylation  of  aromatic  compounds 
and arachidonic acid peroxidation (60,62). In their review arti-
cle,  Fitton  and  Goa  describe  that  azelaic  acid  in  vivo  affects 

 
364 

 TEXTBOOK OF COSMETIC DERMATOLOGY

differentiation of human keratinocytes by decreasing synthe-
sis of filaggrin (keratin filament aggregating protein) (62). This 
results  in  alterations  of  epidermal  keratinization,  including 
reductions in the number and size of keratohyaline granules 
and  tonofilament  bundles  in  the  SC,  abnormal  tonofilament 
arrangements,  intercellular  edema,  swollen  mitochondria, 
enlargement  of  rough  endoplasmic  reticulum  (RER),  and 
reductions in the thickness of the horny layer in infundibular 
areas. Azelaic acid functions in a cytostatic, antiproliferative 
manner  on  keratinocytes,  affecting  both  early  and  terminal 
phases of keratinocyte differentiation, with primary effects on 
mitochondria and RER (63).

After application of azelaic acid, 3% to 5% remains on the 
SC, up to 10% penetrates into the epidermis and dermis, and 
4% is absorbed systemically (although this can double with gel 
formulations).  Nevertheless,  baseline  serum  and  urine  levels 
are not altered by topical usage and are primarily dependent 
on dietary intake of whole grain cereals and animal products 
(7). It is an FDA Pregnancy Category B drug, as animal studies 
have shown favorable results; meaningful human studies are 
lacking.

In  2  weeks  of  topical  treatment,  200  mL  of  20%  azelaic 
acid attenuated tetradecane-induced comedo formation in the 
rabbit  ear,  a  model  of  follicular  epithelial  hyperplasia  (62,64). 
These  microscopic  and  experimental  findings  indicate  kera-
tolytic  and  anticomedogenic  properties  for  azelaic  acid  via 
normalization  of  disordered  keratinization  of  the  follicular 
infundibulum. Cyanoacrylate skin surface biopsies have dem-
onstrated significant reductions (>50%) in comedo count after 
4 months of twice-daily 20% azelaic acid treatment when com-
pared  with  vehicle  (65).  Azelaic  acid  has  demonstrated  sig-
nificant  inflammatory  and  non-inflammatory  acne  reduction 
in  numerous  studies  (60,61).  Comparing  20%  azelaic  acid  to 
0.05%  tretinoin  over  6  months,  one  group  found  statistically 
equivalent  comedone  and  total  lesion  reduction  and  similar 
overall improvement. However, tretinoin use led to increased 
erythema, scaling, and irritation-induced discontinuation over 
azelaic  acid  (66).  Another  trial  comparing  20%  azelaic  acid 
with 5.0% BPO demonstrated a more rapid initial effect with 
BPO but similar results for global response, and inflammatory 
lesion reduction by 4 months. Keeping with the theme, azelaic 
acid demonstrated milder, more transient adverse events than 
BPO (67). Transient side effects lasting 2 to 4 weeks have been 
described. These include burning, erythema, dryness, scaling, 
pruritus, and hypopigmentation (60).

Despite  efficacy  as  a  monotherapy,  a  large  randomized 
trial demonstrated that azelaic acid functions better in combi-
nation with one of the following drugs: 4% BPO gel twice daily, 
1%  clindamycin  gel  twice  daily,  0.025%  tretinoin  cream  once 
daily, or 3% erythromycin/5% BPO gel twice daily (61).

Azelaic acid 15% is indicated in rosacea but has no label-

ing in acne.

SALICYLIC ACID
A core component in many OTC acne treatments, salicylic acid 
(SA) is a widely available topical keratolytic agent. It may have 
a profound structural effect on the SC, resulting in disruption 
of  intercorneocyte  cohesion  and  subsequent  desquamation 
(68). Dissolution of intercellular cement is further supported by 
scanning electron microscopy, which has demonstrated marked 
squamous cell separation in SA-treated human skin (69). Mills 
and  Kligman,  using  cyanoacrylate  follicular  biopsy,  demon-
strated significant decreases in microcomedone count. Although 

various  concentrations  exist  (0.5%–10%),  2%  is  the  maximum 
strength allowed by the FDA and European Medicines Agency 
(EMA) in OTC products. In five human subjects, microcomedo 
formation  was  induced  via  10%  coal  tar  distillate  ointment  at 
four sites on the back; formation was confirmed by cyanoacry-
late biopsy. At each site, subjects were treated with one of three 
different concentrations of SA (0.5%, 1%, and 2%), twice daily for 
2 weeks, and one site was left untreated (70). Ultimately, lesions 
were  rebiopsied  and  examined  microscopically;  all  three  con-
centrations  displayed  tremendous  comedolytic  activity,  with 
the 2% preparation superior to the lower concentrations (73).

SA  is  well  absorbed  as  evidenced  by  numerous  stud-
ies;  its  bioavailability  in  topical  application  varies  according 
to  duration  of  contact  (71,72).  One  study  estimated  bioavail-
abilities for topically applied SA at 57.6% and 44.0% for hydro-
alcoholic  and  cream  delivery  vehicles,  respectively  (73).  The 
same  study  also  demonstrated  the  hydro-alcohol  vehicle  to 
have superior peak plasma SA concentrations and earlier time 
to peak when compared with a cream vehicle.

In a related study, absorption was enhanced significantly 
in a mineral oil/petrolatum ointment compared with an oint-
ment containing polyethylene glycol, glycerol, petrolatum, 10% 
urea (Kerasal) (74).

Two  12-week  studies  comparing  0.5%  and  2%  SA  pads 
to placebo pads demonstrated significant efficacy in reducing 
inflammatory acne, non-inflammatory acne, and total lesions, 
while  producing  significantly  higher  proportions  of  good-
to-excellent  overall  treatment  assessments  (70).  In  both  stud-
ies, side effects were minimal and well tolerated (with 73). In 
a  study  comparing  medicated  pads  0.5%  SA  in  an  alcoholic 
detergent (Stridex) to placebo (pads soaked in buffered water), 
the  treatment  group  experienced  a  54%  reduction  in  inflam-
matory acne compared with 29% in the placebo group. Reduc-
tions of open comedones and total lesions were also significant 
compared with placebo.

A  4-week  crossover  study  comparing  a  2%  SA  acne 
cleanser to a 10% BPO wash demonstrated that only patients 
treated  with  the  SA  cleanser  had  a  significant  decrease  in 
comedonal lesions (75). A small study comparing a 2% SA/1% 
clindamycin combination with placebo demonstrated a signifi-
cant reduction in inflammatory and non-inflammatory lesions, 
with  71%  of  subjects  reporting  improvement  after  8  weeks 
(compared with 11% of placebo group) (76).

Although local skin irritation (e.g., peeling) at concentra-
tions greater than 2% is common, systemic toxicity is rare (7). 
However,  if  applied  to  large  areas  of  the  body  for  prolonged 
periods of time, salicylate toxicity, toxic inner ear damage, and 
hypersensitivity reactions are plausible (7). To that end, these 
manifestations  are  uncommon  in  appropriate  acne  therapy. 
Like several other keratolytic agents, SA is an FDA Pregnancy 
Category C agent, with unknown effects on breast-feeding.

As  a  member  of  this  family,  the  SA  derivative  known 
in the literature as 2-hydroxy-5-octanoyl benzoic acid or beta-
lipohydroxy acid has also been proposed as an exfoliant and 
as a treatment of acne. The lipophilic nature of C8-LHA and its 
relatively slow penetration in the skin afford it an exfoliating 
effect that is efficient at low concentrations. It appears to have 
antimicrobial, anti-inflammatory, and anticomedogenic prop-
erties. It targets more specifically the coneodesmosome (77).

New chemical peels using 30% SA in polyethylene glycol 
vehicle  have  demonstrated  efficacy  and  safety,  with  marked 
reductions in comedones and papules (78). Polyethylene glycol 
may be a more tolerable vehicle than the commonly used ethyl 
alcohol in SA chemical peels.

 
SULFUR
Sulfur,  a  yellow  nonmetallic  element,  is  an  old  ingredient 
that has many dermatological indications, including but not 
limited to acne vulgaris, rosacea, seborrheic dermatitis, and 
dandruff (79). Once a very common ingredient in acne treat-
ments, sulfur has fallen out of favor, partly due to its pungent 
odor (80). In the acne area, sulfur is thought to be keratolytic 
and  bacteriostatic.  After  application  to  skin,  sulfur  reacts 
with cysteine in the SC, resulting in reduction to hydrogen 
sulfide.  Hydrogen  sulfide  is  thought  to  break  down  keratin 
and inhibit growth of P. acnes (79). Sulfur penetrates skin; it 
is detectable in the epidermis at 2 hours, throughout the skin 
in 8 hours, and completely undetectable by 24 hours. There 
is  no  evidence  of  systemic  absorption  in  intact  skin  (79). 
Appearing  in  a  variety  of  vehicles  (lotions,  creams,  soaps, 
ointments),  it  appears  to  be  more  efficacious  when  used  in 
combination with other drugs, namely BPO and sodium sul-
facetamide (7). Clinical trials have demonstrated that lotions 
containing  sulfur  5%  with  sodium  sulfacetamide  10%  have 
resulted  in  reduction  of  inflammatory  lesions,  comedones, 
and seborrhea (79).

Rare, transient side effects include dryness, itching, and 
malodorous skin. Nonetheless, given a lack of knowledge, it is 
an FDA Pregnancy Class C drug with nothing known regard-
ing breast milk excretion.

GLYCOLIC ACID AND SUPERFICIAL PEELINGS
Glycolic acid, a naturally hydrophilic organic acid (hydroxy 
acid), has keratolytic properties targeting SC and is present in 
many peel formulations due to its desquamating efficacy. In 
the context of acne, research has been conducted examining 
glycolic  acid  chemical  peels.  Various  chemical  preparations 
have been employed, all of which result in a partial thickness 
skin injury, or peel (81); The exact mechanism of action may be 
due to inhibition of ionic bond–forming enzymes involved in 
creating sulfated and phosphorylated mucopolysaccharides, 
glycoproteins,  sterols,  and  lipid  phosphatides.  This  results 
in  fewer  electronegative  groups  on  the  outer  walls  of  kera-
tinocytes and corneocytes, effectively diminishing cohesion 
forces  (82).  This  diminished  cohesion  loosens  keratinocytes 
in the follicular epithelium, resulting in breakdown of com-
edones, inhibition of comedone formation, and unroofing of 
pustules (83). Comedones are removed after only two or three 
peels, and the procedure may be repeated every 2 or 3 weeks. 
Between  peels,  low  concentrations  of  glycolic  acid  may  be 
used as a daily cleanser to prevent occlusion of follicles (83). 
A randomized split-face prospective clinical trial comparing 
glycolic  acid  to  Jessner’s  solution  (salicylic  acid,  lactic  acid, 
and  resorcinol)  demonstrated  significant  acne  improvement 
in both after three treatment sessions. Furthermore, glycolic 
acid  was  associated  with  significantly  less  exfoliation  than 
Jessner’s  solution,  resulting  in  more  facile  makeup  applica-
tion and suggesting a more favorable side effect profile (84). 
In a similar study comparing glycolic acid and SA peels, both 
were equally effective by the second treatment; however, SA 
demonstrated  greater  sustained  effectiveness  and  a  more 
favorable side effect profile (81). A study examining 35% and 
50%  glycolic  acid  peels  on  Asian  patients  found  significant 
resolution of comedones, papules, and pustules; decrease in 
follicular  pore  size;  improvement  in  acne  scarring;  and  few 
side  effects  (85).  One  recent  article  examines  the  evidence 
base  that  supports  the  widespread  use  of  superficial  peels 
in  acne.  The  conclusions  were  that  search  of  the  literature 

KERATOLYTIC TREATMENT OF ACNE 

 365

revealed very few clinical trials of peels in acne. A majority 
of these trials included small numbers of patients, were not 
controlled, and were open label. Notably, no studies of chemi-
cal peels have used an acne drug as a comparator (86).

RESORCINOL
We  have  very  limited  and  old  information  about  resorcinol 
and  keratolytic  activity  in  acne;  all  are  extracted  from  a 
review article by Karam in 1993 (87). No longer significantly 
used in the United States and Europe, resorcinol, an isomer 
of hydroquinone and a relative of phenol, is soluble in water, 
ether,  and  alcohol.  It  is  a  reducing  agent  with  antibacterial 
and keratolytic properties. Even at low concentrations, it can 
disrupt hydrogen bonds of keratin. A 50% resorcinol paste is 
used in some countries for chemical peels. It is used to treat 
the  post  inflammatory  hyperpigmentation,  erythema,  and 
shallow  scars  resulting  from  facial,  chest,  upper  back,  and 
buttocks acne. One facial peel, typically 30 minutes in dura-
tion, may be sufficient for treatment. Additional peels can be 
done  a  few  hours  to  2  days  later.  Patients  typically  receive 
pretreatment  with  0.05%  retinoic  acid  cream  for  a  period  of 
2  weeks  to  3  months  before  the  facial  peel.  This  pretreat-
ment  may  help  assist  in  resorcinol  absorption,  resulting  in 
a  deeper  peel.  In  addition  to  acne,  resorcinol  peels  can  be 
used  to  treat  melasma,  sun-damaged  skin,  and  freckling. 
Contraindications  include  pregnancy  and  skin  type  VI,  due 
to  inadequate  data  regarding  complications.  Acne  surgery 
prior  to  the  peel  is  recommended  to  prevent  aggravation  of 
deep comedones and subsequent pustular development. Side 
effects include burning sensation and paresthesia, which can 
be felt anywhere from 2 to 30 minutes after application. Diz-
ziness  immediately  after  the  peel  may  last  10  to  15  minutes 
and  is  probably  secondary  to  flushing  related  to  resorcinol 
application.  Burning  intensity  increases  initially,  stopping 
after  1  hour;  despite  discomfort,  pain  is  usually  tolerable. 
Subsequent resorcinol applications cause more intense burn-
ing sensation, prompting shorter exposure. Corticoid creams 
and cold compresses may provide some relief. Histologically, 
shortly  after  resorcinol  application,  splitting  occurs  at  the 
granular cell layer along with vasodilatation. One week later, 
prominent  basal  cell  layer  mitosis,  fibroblast  proliferation, 
vasodilatation, and formation of a thickened dermal band are 
visible. Although the vasodilation resolves, the other changes 
are present even 4 months later. Recently, the FDA give rules 
of new warnings of labeling for OTC topical acne drug prod-
ucts  containing  resorcinol,  resorcinol  monoacetate,  salicylic 
acid, and/or sulfur (88).

CONCLUSION
Taken together, a century of clinical trials and clinical use sup-
port the efficacy of topical keratolytics in acne. But we also cru-
elly lack new keratolytic—no new original molecule has been 
found for more than 30 years. In addition, taking into account 
the mechanism of action of a keratolytic—that is, it dissolves 
or  breaks  down  the  outer  layer  of  skin—they  are  all  topical. 
We strongly hope that the near future will provide more rapid 
advances, based on the power and ease of interpretation of the 
newly devised in vivo human keratolytic assay.

ACKNOWLEDGMENT
This chapter is an update of the chapter from the previous edi-
tion by Ali Alikhan and Howard I. Maibach.

 
366 

 TEXTBOOK OF COSMETIC DERMATOLOGY

REFERENCES

1.  Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of 
the  effects  of  topical  tretinoin  on  microcomedones.  Clin  Ther 
1992 Dec; 14(6):773–80.

2.  Hatakeyama S, Hayashi S, Yoshida Y, Otsubo A, Yoshimoto K, 
Oikawa  Y,  et  al.  Retinoic  acid  disintegrated  desmosomes  and 
hemidesmosomes in stratified oral keratinocytes. J Oral Pathol 
Med 2004 Nov; 33(10):622–8.

3.  Russell JJ. Topical therapy for acne. Am Fam Physician 2000 Jan 

15; 61(2):357–66.

4.  Warner GT, Plosker GL. Clindamycin/benzoyl peroxide gel: A 
review of its use in the management of acne. Am J Clin Dermatol 
2002; 3(5):349–60.

5.  Isard O, Knol AC, Ariès MF, Nguyen JM, Khammari A, Castex-
Rizzi  N,  et  al.  Propionibacterium  acnes  activates  the  IGF-1/
IGF-1R system in the epidermis and induces keratinocyte pro-
liferation. J Invest Dermatol 2011 Jan; 131(1):59–66.

6.  Worret W-I, Fluhr JW. [Acne therapy with topical benzoyl per-
oxide, antibiotics and azelaic acid]. J Ger Soc Dermatol 2006 Apr; 
4(4):293–300.

7.  Akhavan A, Bershad S. Topical acne drugs: Review of clinical 
properties,  systemic  exposure,  and  safety.  Am  J  Clin  Dermatol 
2003; 4(7):473–92.

8.  Degitz K, Ochsendorf F. Pharmacotherapy of acne. Expert Opin 

Pharmacother 2008 Apr; 9(6):955–71.

9.  Fyrand O, Jakobsen HB. Water-based versus alcohol-based ben-
zoyl  peroxide  preparations  in  the  treatment  of  acne  vulgaris. 
Dermatologica 1986; 172(5):263–7.

  10.  Shroot B. Pharmacodynamics and pharmacokinetics of topical 
adapalene. J Am Acad Dermatol 1998 Aug; 39(2 Pt 3):S17–24.
  11.  Mills OH, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 
5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. 
Int J Dermatol 1986 Dec; 25(10):664–7.

  12.  Prince RA, Harris JM, Maroc JA. Comparative trial of benzoyl 
peroxide  versus  benzoyl  peroxide  with  urea  in  inflammatory 
acne. Cutis 1982 Jun; 29(6):638–40, 644–5.

  13.  Lookingbill  DP,  Chalker  DK,  Lindholm  JS,  Katz  HI,  Kempers 
SE,  Huerter  CJ,  et  al.  Treatment  of  acne  with  a  combination 
clindamycin/benzoyl  peroxide  gel  compared  with  clindamy-
cin gel, benzoyl peroxide gel and vehicle gel: Combined results 
of  two  double-blind  investigations.  J  Am  Acad  Dermatol  1997 
Oct; 37(4):590–5.

  14.  Webster  G,  Rich  P,  Gold  MH,  Mraz  S,  Calvarese  B,  Chen  D. 
Efficacy  and  tolerability  of  a  fixed  combination  of  clindamy-
cin  phosphate  (1.2%)  and  low  concentration  benzoyl  peroxide 
(2.5%) aqueous gel in moderate or severe acne subpopulations. 
J Drugs Dermatol 2009 Aug; 8(8):736–43.

  15.  Leyden  JJ,  Hickman  JG,  Jarrat  MT.  The  efficacy  and  safety  of 
a combination benzoyl peroxide/clindamycin topical gel com-
pared  with  benzoyl  peroxide  alone  and  a  benzoyl  peroxide/ 
erythromycin  combination  product.  J  Cutan  Med  Surg  2001; 
5(1):37–42.

  16.  Basak PY, Gultekin F, Kilinc I, Delibas N. The effect of benzoyl 
peroxide and benzoyl peroxide/erythromycin combination on 
the antioxidative defence system in papulopustular acne. Eur J 
Dermatol 2002 Feb;12(1):53–7.

  17.  Leyden JJ. A review of the use of combination therapies for the 
treatment of acne vulgaris. J Am Acad Dermatol 2003 Sep; 49(3 
Suppl):S200–10.

  18.  Krautheim A, Gollnick HPM. Acne: Topical treatment. Clin Der-

matol 2004 Oct; 22(5):398–407.

  19.  Kang S. The mechanism of action of topical retinoids. Cutis 2005 

Feb; 75(2 Suppl):10–13; discussion 13.

  20.  Bikowski  JB.  Mechanisms  of  the  comedolytic  and  anti-
inflammatory properties of topical retinoids. J Drugs Dermatol 
2005 Feb; 4(1):41–7.

  21.  Chivot M. Retinoid therapy for acne. A comparative review. Am 

J Clin Dermatol 2005; 6(1):13–9.

  22.  Shalita  AR,  Chalker  DK,  Griffith  RF,  Herbert  AA,  Hickman 
JG,  Maloney  JM,  et  al.  Tazarotene  gel  is  safe  and  effective  in 
the  treatment  of  acne  vulgaris:  A  multicenter,  double-blind, 
vehicle-controlled study. Cutis 1999 Jun; 63(6):349–54.

  23.  Marcelo CL, Madison KC. Regulation of the expression of epi-
dermal  keratinocyte  proliferation  and  differentiation  by  vita-
min A analogs. Arch Dermatol Res 1984; 276(6):381–9.

  24.  Leyden  JJ,  Shalita  A,  Thiboutot  D,  Washenik  K,  Webster  G. 
Topical  retinoids  in  inflammatory  acne:  A  retrospective, 
investigator-blinded,  vehicle-controlled,  photographic  assess-
ment. Clin Ther 2005 Feb; 27(2):216–24.

  25.  Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, 
et al. A double-blinded, randomized, vehicle-controlled, multi-
center, parallel-group study to assess the safety and efficacy of 
tretinoin  gel  microsphere  0.04%  in  the  treatment  of  acne  vul-
garis in adults. Cutis 2007 Aug; 80(2):152–7.

  26.  Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark 
S, et al. Adapalene-benzoyl peroxide, a fixed-dose combination 
for the treatment of acne vulgaris: Results of a multicenter, ran-
domized  double-blind,  controlled  study.  J  Am  Acad  Dermatol 
2007 Nov; 57(5):791–9.

  27.  Spellman  MC,  Pincus  SH.  Efficacy  and  safety  of  azelaic  acid 
and glycolic acid combination therapy compared with tretinoin 
therapy for acne. Clin Ther 1998 Aug; 20(4):711–21.

  28.  Lammer EJ, Flannery DB, Barr M. Does isotretinoin cause limb 

reduction defects? Lancet 1985 Aug 10; 2(8450):328.

  29.  Lipson AH, Collins F, Webster WS. Multiple congenital defects 
associated  with  maternal  use  of  topical  tretinoin.  Lancet  1993 
May 22; 341(8856):1352–3.

  30.  Camera  G,  Pregliasco  P.  Ear  malformation  in  baby  born  to 
mother using tretinoin cream. Lancet 1992 Mar 14; 339(8794):687.
  31.  Jick  SS,  Terris  BZ,  Jick  H.  First  trimester  topical  tretinoin  and 
congenital disorders. Lancet 1993 May 8; 341(8854):1181–2.
  32.  Mills OH, Kligman AM. Assay of comedolytic activity in acne 

patients. Acta Derm Venereol 1983; 63(1):68–71.

  33.  Lucky  AW,  Cullen  SI,  Jarratt  MT,  Quigley  JW.  Comparative 
efficacy  and  safety  of  two  0.025%  tretinoin  gels:  Results  from 
a multicenter double-blind, parallel study. J Am Acad Dermatol 
1998 Apr; 38(4):S17–23.

  34.  Skov  MJ,  Quigley  JW,  Bucks  DA.  Topical  delivery  system  for 
tretinoin: Research and clinical implications. J Pharm Sci 1997 
Oct; 86(10):1138–43.

  35.  Nyirady J, Nighland M, Payonk G, Pote J, Phillips S, Grossman R. 
A comparative evaluation of tretinoin gel microsphere, 0.1%, ver-
sus tretinoin cream, 0.025%, in reducing facial shine. Cutis 2000 
Aug; 66(2):153–6.

  36.  Tirado-Sánchez A, Espíndola YS, Ponce-Olivera RM, Bonifaz A. 
Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin 
gel  0.05%  for  acne  vulgaris:  Results  of  a  single-center,  random-
ized, double-blinded, placebo-controlled clinical trial on Mexican 
patients (skin type III-IV). J Cosmet Dermatol 2013 Jun; 12(2):103–7.
  37.  Lucky  AW,  Sugarman  J.  Comparison  of  micronized  tretinoin 
gel 0.05% and tretinoin gel microsphere 0.1% in young adoles-
cents with acne: A post hoc analysis of efficacy and tolerability 
data. Cutis 2011 Jun; 87(6):305–10.

  38.  Nighland M, Grossman R. Tretinoin microsphere gel in facial 
acne vulgaris: A meta-analysis. J Drugs Dermatol 2008 Aug; 7(8 
Suppl):s2–8.

  39.  Leyden  JJ,  Krochmal  L,  Yaroshinsky  A.  Two  randomized, 
double-blind, controlled trials of 2219 subjects to compare the 
combination  clindamycin/tretinoin  hydrogel  with  each  agent 
alone and vehicle for the treatment of acne vulgaris. J Am Acad 
Dermatol 2006 Jan; 54(1):73–81.

  40.  Leyden JJ, Wortzman M. A novel gel formulation of clindamy-
cin  phosphate-tretinoin  is  not  associated  with  acne  flaring. 
Cutis 2008 Aug; 82(2):151–6.

  41.  Jarrat MT, Brundage T. Efficacy and safety of clindamycin-treti-
noin gel versus clindamycin or tretinoin alone in acne vulgaris: 

 
 
 
 
 
 
 
 
 
 
KERATOLYTIC TREATMENT OF ACNE 

 367

A randomized, double-blind, vehicle-controlled study. J Drugs 
Dermatol 2012; 11(3):318–26. 

adapalene-benzoyl  peroxides.  J  Drugs  Dermatol  2013  Jun  1; 
12(6):611–8.

  42.  Chang ALS, Alora-Palli M, Lima XT, Chang TC, Cheng C, Chung 
CM,  et  al.  A  randomized,  double-blind,  placebo-controlled, 
pilot study to assess the efficacy and safety of clindamycin 1.2% 
and tretinoin 0.025% combination gel for the treatment of acne 
rosacea over 12 weeks. J Drugs Dermatol 2012 Mar; 11(3):333–9.

  43.  Shalita  AR,  Rafal  ES,  Anderson  DN,  Yavel  R,  Landow  S,  Lee 
W-LS.  Compared  efficacy  and  safety  of  tretinoin  0.1%  micro-
sphere  gel  alone  and  in  combination  with  benzoyl  peroxide 
6% cleanser for the treatment of acne vulgaris. Cutis 2003 Aug; 
72(2):167–72.

  44.  Chalker DK, Lesher JL, Smith JG, Klauda HC, Pochi PE, Jacoby 
WS, et al. Efficacy of topical isotretinoin 0.05% gel in acne vul-
garis: Results of a multicenter, double-blind investigation. J Am 
Acad Dermatol 1987 Aug; 17(2 Pt 1):251–4.

  45.  Chandraratna RA. Tazarotene: The first receptor-selective topi-
cal retinoid for the treatment of psoriasis. J Am Acad Dermatol 
1997 Aug; 37(2 Pt 3):S12–17.

  46.  Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. 
Tazarotene cream versus adapalene cream in the treatment of 
facial acne vulgaris: A multicenter, double-blind, randomized, 
parallel-group study. J Drugs Dermatol 2005 Apr; 4(2):153–8.
  47.  Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, 
et al. Randomized comparison of the safety and efficacy of taz-
arotene 0.1% cream and adapalene 0.3% gel in the treatment of 
patients with at least moderate facial acne vulgaris. J Drugs Der-
matol 2010 May; 9(5):549–58.

  48.  Bershad S, Kranjac Singer G, Parente JE, Tan M-H, Sherer DW, 
Persaud AN, et al. Successful treatment of acne vulgaris using 
a new method: Results of a randomized vehicle-controlled trial 
of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 
2002 Apr; 138(4):481–9.

  49.  Tanghetti  E,  Abramovits  W,  Solomon  B,  Loven  K,  Shalita  A. 
Tazarotene  versus  tazarotene  plus  clindamycin/benzoyl  per-
oxide in the treatment of acne vulgaris: A multicenter, double-
blind,  randomized  parallel-group  trial.  J  Drugs  Dermatol  2006 
Mar; 5(3):256–61.

  50.  Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolera-
bility of tazarotene foam, 0.1%, in the treatment of acne vulgaris 
in 2 multicenter, randomized, vehicle-controlled, double-blind 
studies. J Drugs Dermatol 2013 Apr; 12(4):438–46.

  51.  Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH, Kanof 
NB, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: 
A multicenter, randomized, double-blind, controlled, phase III 
trial. J Am Acad Dermatol 2006 Feb; 54(2):242–50.

  52.  Martin B, Meunier C, Montels D, Watts O. Chemical stability of 
adapalene  and  tretinoin  when  combined  with  benzoyl  perox-
ide  in  presence  and  in  absence  of  visible  light  and  ultraviolet 
radiation. Br J Dermatol 1998 Oct; 139 Suppl 52:8–11.

  53.  Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A compari-
son of the efficacy and tolerability of adapalene 0.1% gel versus 
tretinoin  0.025%  gel  in  patients  with  acne  vulgaris:  A  meta-
analysis of five randomized trials. Br J Dermatol 1998 Oct; 139 
Suppl 52:48–56.

  54.  Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Compara-
tive tolerance of adapalene 0.1% gel and six different tretinoin 
formulations. Br J Dermatol 1998 Oct; 139 Suppl 52:34–40.
  55.  Gollnick  HPM,  Draelos  Z,  Glenn  MJ,  Rosoph  LA,  Kaszuba  A, 
Cornelison  R,  et  al.  Adapalene-benzoyl  peroxide,  a  unique 
fixed-dose  combination  topical  gel  for  the  treatment  of  acne 
vulgaris: A transatlantic, randomized, double-blind, controlled 
study in 1670 patients. Br J Dermatol 2009 Nov; 161(5):1180–9.

  56.  Alexis  AF,  Johnson  LA,  Kerrouche  N,  Callender  VD.  A  sub-
group analysis to evaluate the efficacy and safety of adapalene-
benzoyl  peroxide  topical  gel  in  black  subjects  with  moderate 
acne. J Drugs Dermatol 2014 Feb; 13(2):170–4.

  57.  Eichenfield  LF,  Draelos  Z,  Lucky  AW,  Hebert  AA,  Sugar-
man  J,  Stein  Gold  L,  et  al.  Preadolescent  moderate  acne  vul-
garis: A randomized trial of the efficacy and safety of topical 

  58.  Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarratt M, Kempers S, 
et al. A 6-month maintenance therapy with adapalene-benzoyl 
peroxide gel prevents relapse and continuously improves effi-
cacy among patients with severe acne vulgaris: Results of a ran-
domized controlled trial. Br J Dermatol 2011 Jun; 164(6):1376–82.
  59.  Dréno B, Kaufmann R, Talarico S, Torres Lozada V, Rodríguez-
Castellanos MA, Gómez-Flores M, et al. Combination therapy 
with adapalene-benzoyl peroxide and oral lymecycline in the 
treatment of moderate to severe acne vulgaris: A multicentre, 
randomized, double-blind controlled study. Br J Dermatol 2011 
Aug; 165(2):383–90.

  60.  Mackrides PS, Shaughnessy AF. Azelaic acid therapy for acne. 

Am Fam Physician 1996 Dec; 54(8):2457–9.

  61.  Webster G. Combination azelaic acid therapy for acne vulgaris. 

J Am Acad Dermatol 2000 Aug; 43(2 Pt 3):S47–50.

  62.  Fitton A, Goa KL. Azelaic acid. A review of its pharmacological 
properties and therapeutic efficacy in acne and hyperpigmen-
tary skin disorders. Drugs 1991 May; 41(5):780–98.

  63.  Mayer-da-Silva A, Gollnick H, Detmar M, Gassmüller J, Parry A, 
Müller R, et al. Effects of azelaic acid on sebaceous gland, sebum 
excretion rate and keratinization pattern in human skin. An in 
vivo and in vitro study. Acta Derm Venereol Suppl (Stockh) 1989; 
143:20–30.

  64.  Töpert M, Rach P, Siegmund F. Pharmacology and toxicology of 

azelaic acid. Acta Derm Venereol Suppl (Stockh) 1989; 143:14–9.

  65.  Barbareshi M, Hendricks I, Angius A. The anticomedonic activ-
ity of azelaic acid investigated by means of scanning electron 
microscopy on horny layer biopsy. J Dermatol Treat 1991; 2:55–7.
  66.  Katsambas  A,  Graupe  K,  Stratigos  J.  Clinical  studies  of  20% 
azelaic acid cream in the treatment of acne vulgaris. Compari-
son with vehicle and topical tretinoin. Acta Derm Venereol Suppl 
(Stockh) 1989; 143:35–9.

  67.  Cavicchini  S,  Caputo  R.  Long-term  treatment  of  acne  with 
20% azelaic acid cream. Acta Derm Venereol Suppl (Stockh) 1989; 
143:40–4.

  68.  Bashir SJ, Dreher F, Chew AL, Zhai H, Levin C, Stern R, et al. 
Cutaneous bioassay of salicylic acid as a keratolytic. Int J Pharm. 
2005 Mar 23; 292(1–2):187–94.

  69.  Davies  M,  Marks  R.  Studies  on  the  effect  of  salicylic  acid  on 

normal skin. Br J Dermatol 1976 Aug; 95(2):187–92.

  70.  Zander E, Weisman S. Treatment of acne vulgaris with salicylic 

acid pads. Clin Ther 1992 Apr; 14(2):247–53.

  71.  Feldmann  RJ,  Maibach  HI.  Absorption  of  some  organic  com-
pounds  through  the  skin  in  man.  J  Invest  Dermatol  1970  May; 
54(5):399–404.

  72.  Rougier A, Dupuis D, Lotte C, Roguet R. The measurement of 
the stratum corneum reservoir. A predictive method for in vivo 
percutaneous absorption studies: Influence of application time. 
J Invest Dermatol 1985 Jan; 84(1):66–8.

  73.  Davis DA, Kraus AL, Thompson GA, Olerich M, Odio MR. Per-
cutaneous absorption of salicylic acid after repeated (14-day) in 
vivo administration to normal, acnegenic or aged human skin. 
J Pharm Sci 1997 Aug; 86(8):896–9.

  74.  Schwarb FP, Gabard B, Rufli T, Surber C. Percutaneous absorp-
tion of salicylic acid in man after topical administration of three 
different formulations. Dermatol Basel Switz 1999; 198(1):44–51.

  75.  Shalita AR. Comparison of a salicylic acid cleanser and a ben-
zoyl peroxide wash in the treatment of acne vulgaris. Clin Ther 
1989 Apr; 11(2):264–7.

  76.  Touitou E, Godin B, Shumilov M, Bishouty N, Ainbinder D, Shou-
val  R,  et  al.  Efficacy  and  tolerability  of  clindamycin  phosphate 
and salicylic acid gel in the treatment of mild to moderate acne 
vulgaris. J Eur Acad Dermatol Venereol 2008 May; 22(5):629–31.

  77.  Saint-Léger D, Lévêque J-L, Verschoore M. The use of hydroxy 
acids on the skin: Characteristics of C8-lipohydroxy acid. J Cos-
met Dermatol 2007 Mar; 6(1):59–65.

  78.  Dainichi  T,  Ueda  S,  Imayama  S,  Furue  M.  Excellent  clinical 
results  with  a  new  preparation  for  chemical  peeling  in  acne: 

 
368 

 TEXTBOOK OF COSMETIC DERMATOLOGY

30% salicylic acid in polyethylene glycol vehicle. Dermatol Surg 
2008 Jul; 34(7):891–899; discussion 899.

domized prospective clinical trial of split-face model therapy. 
Dermatol Surg 1999 Apr; 25(4):270–3.

  79.  Gupta AK, Nikol K. The use of sulfur in dermatology. J Drugs 

Dermatol 2004; 3(4):427–31.

  80.  Kaminsky  A.  Less  common  methods  to  treat  acne.  Dermatol 

Basel Switz 2003; 206(1):68–73.

  81.  Kessler E, Flanagan K, Chia C, Rogers C, Glaser DA. Compari-
son of alpha- and beta-hydroxy acid chemical peels in the treat-
ment of mild to moderately severe facial acne vulgaris. Dermatol 
Surg 2008 Jan; 34(1):45–50; discussion 51.

  82.  Van Scott EJ, Yu RJ. Hyperkeratinization, corneocyte cohesion, and 
alpha hydroxy acids. J Am Acad Dermatol 1984 Nov; 11(5 Pt 1): 867–79.
  83.  Kneedler JA, Sky SS, Sexton LR. Understanding alpha-hydroxy 
acids.  Dermatol  Nurse  1998  Aug;  10(4):247–254,  259–262;  quiz 
265–266.

  84.  Kim SW, Moon SE, Kim JA, Eun HC. Glycolic acid versus Jess-
ner’s  solution:  Which  is  better  for  facial  acne  patients?  A  ran-

  85.  Wang CM, Huang CL, Hu CT, Chan HL. The effect of glycolic 
acid on the treatment of acne in Asian skin. Dermatol Surg 1997 
Jan; 23(1):23–9.

  86.  Dréno B, Fischer TC, Perosino E, Poli F, Viera MS, Rendon MI, 
et  al.  Expert  opinion:  Efficacy  of  superficial  chemical  peels  in 
active  acne  management—What  can  we  learn  from  the  litera-
ture today? Evidence-based recommendations. J Eur Acad Der-
matol Venereol 2011 Jun; 25(6):695–704.

  87.  Karam  PG.  50%  resorcinol  peel.  Int  J  Dermatol  1993  Aug; 

32(8):569–74.

  88.  Food  and  Drug  Administration,  HHS.  Classification  of  ben-
zoyl  peroxide  as  safe  and  effective  and  revision  of  labeling 
to  drug  facts  format;  topical  acne  drug  products  for  over-
the-counter  human  use;  final  rule.  Fed  Regist  2010  Mar  4; 
75(42):9767–77.

 
39

Hidradenitis Suppurativa

Emil Knudsen List and Gregor B.E. Jemec

Hidradenitis  suppurativa  (HS)  is  a  chronic  inflammatory 
skin  disease  which  characteristically  presents  with  recurrent 
inflamed  and  scarring  lesions  restricted  to  axillae,  submam-
mary or perigenital areas (1) (Figures 39.1 and 39.2). The preva-
lence  of  the  disease  has  not  been  accurately  described,  but 
population surveys in Europe indicate a prevalence of 1%–2%, 
whereas a much lower figure is suggested by studies relying 
on  the  general  patient  records  and  predominantly  published 
from U.S. centers (2–5). The discrepancies have not been fully 
elucidated  but  reviews  of  patients’  records  show  an  appar-
ently rapidly increasing incidence, indicating the possibility of 
reporting or diagnosing bias (2,6).

Underreporting is in good agreement with the cumula-
tive  life  course  of  these  patients,  which  is  often  described  as 
a  disheartening  experience.  Because  of  the  seemingly  banal 
symptomatology, most patients are treated as simple infections 
by  physicians  using  antistaphylococcal  antibiotics  combined 
with incision and drainage (7). These treatments are rarely if 
ever effective, and therefore patients who are ultimately diag-
nosed at specialist centers often experience a significant delay 
in  both  diagnosis  and  effective  treatment.  For  some  patients 
physician  contact  stops  after  a  few  unsuccessful  attempts  at 
therapy and they are consequently not diagnosed correctly.

AGE AND SEX DISTRIBUTION
HS typically appears when the patient is past puberty, although 
cases in prepubertal and pubertal children are well described. 
The age at onset clearly differentiates HS form acne vulgaris.

Numerous studies have noticed the sex difference seen 
in  HS.  Typically  the  F/M  ratio  is  described  as  approximately 
3/1, implying that either female factors or the absence of male 
factors play a role in the pathogenesis of HS (8). In prepuber-
tal children HS appears associated with adrenarche or hyper-
androgenism,  which  has  led  researchers  to  look  for  signs  of 
cutaneous virilization in the many women suffering from HS 
(9–12).  Hitherto  the  search  has  been  unrewarding,  although 
some women are prescribed oral antiandrogens in an effort to 
control the disease, with good effect (13).

The real-life prognosis is described in a long-term follow-
up  study  (14).  Although  the  data  was  based  on  self-reported 
presence of HS, the authors speculated that when dealing with 
a  painful  suppurating  recurrent  chronic  disease,  the  valid-
ity of self-reported disease activity will be high. In a 22 year 
 follow-up of 212 patients in the Netherlands and Denmark, a 
self-reported remission rate was 39.4%, indicating that the clin-
ical  impression  that  the  disease  becomes  progressively  more 
rare as the patients age may be true.

IMPACT
HS is a high-impact disease. It causes acute symptoms such as 
smell,  scars,  itching,  and  painduring  active  phases,  and  scar-

ring and soreness during more quiet periods (8). It furthermore 
affects private intimate areas of the skin, including the genitalia 
and perigenital skin, linking it directly to personal relationships 
with significant others. Finally, the sociocultural aspects of the 
symptomatology  should  not  be  underestimated.  The  plight  of 
Job  describes  the  prototypical  psychosocial  understanding  of 
recurrent abscesses in many cultures and is widely maintained 
today in spite of the secularization of many societies (15).

It is therefore easily understood that HS has a significant 
emotional  impact  on  patients.  Smell,  appearance,  and  a  strong 
feeling of lack of control affect interpersonal contacts, leading to 
significant psychological reactions (16). These affect many aspects 
of patients’ lives negatively. In addition to obvious consequences 
such  as  negatively  affecting  patients’  sex  lives,  the  emotions 
include  irritation  with  the  unpredictable  course  of  the  disease, 
frequent  itching,  and  significant  (17–19)  pain  (8,16,20).  Several 
studies  have  described  an  increased  prevalence  of  depressive 
thoughts as well as clinically diagnosed depression in patients 
suffering from HS (21–26). These reactions have a significant cor-
relation with disease severity, underlining the importance of the 
individual  patient’s  coping  abilities.  Similarly,  several  studies 
have described the negative impact of HS on the patients’ qual-
ity of life (QoL) (15,18,27–30). Using different general and specific 
questionnaires to describe HS patients’ QoL, the negative effects 
of the disease have consistently been described as very signifi-
cant across the studies, e.g. as reflected by DLQI scores from 8.4 
to  12.7.  It  is  speculated  that  the  strength  of  the  symptoms,  the 
chronic  recurrent  nature  of  the  disease,  as  well  as  the  location 
and the psychosocial connotations of the disease all contribute to 
this high negative impact on QoL.

TREATMENT
A limited number of randomized controlled trials (RCTs) has 
been published on the treatment of HS, and guidelines for the 
treatment of HS have recently been published (1). These sug-
gest  that  all  patients  should  be  approached  in  a  multimodal 
way, i.e. using adjuvant, medical, and surgical treatments com-
bined, tailored to the severity of the disease.

Adjuvant  treatment  includes  the  judicious  use  of  anal-
gesics  to  ameliorate  the  pain,  treatment  of  superinfections 
following  identification  of  pathogens  and  their  susceptibility 
to antibiotics, and support aimed at weight reduction and ces-
sation of tobacco smoking. Although these adjuvant measures 
are not supported by high-grade RCTs, there is a high degree 
of consensus that they are necessary to reduce both the short-
term morbidity as well as improve the overall prognosis (1).

Medical treatment is based on RCTs as well as substan-
tial  observational  studies,  and  should  be  appropriate  to  dis-
ease severity. For milder cases the use of topical clindamycin 
0.1% b.i.d. applied to inflamed lesions for up to for 10 weeks is 
supported by an RCT (31), as is the use of systemic tetracycline 

370 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 39.1  An example of a hidradenitis lesion. Inflammation 
of the right axillary with multiple nodules. Scarring and sinus tract 
formation from earlier activity is evident.

500 mg b.i.d. for up to 12 weeks (32), the former being more suit-
able for individual lesions, the latter for more scattered lesions.
For  more  advanced  disease,  observational  studies  sup-
port  the  use  of  a  combination  of  clindamycin  300  mg  b.i.d. 
and  rifampicin  300  mg  b.i.d.  for  10  weeks,  but  the  treatment 
is untested in an RCT (33–37). In yet more advanced cases, the 
use of TNFα antibodies is based on RCTs. Infliximab (5 mg/kg) 
has been tested and found effective, although only in a post-
hoc analysis (38). The beneficial effect is, however, supported 
by  numerous  reported  case  series.  In  contrast,  adalimumab 
has  been  tested  in  three  RCTs  and  found  effective  based  on 
an  intention-to-treat  analysis  of  each  of  the  trials  (39,40).  The 
dosage of adalimumab is identical to that used to treat Crohn 
disease (baseline: 160 mg, week 2: 80 mg, and then 40 mg every 
week).

Surgical  treatment  is  similarly  graded,  ranging  from 
minor  surgery  to  major  excisions  of  all  diseased  skin  (1). 
The  traditional  surgical  experience  of  most  patients  is  that 
of  repeated  but  generally  unsuccessful  attempts  at  incision 
and  drainage.  It  is  usually  unsuccessful  if  inflamed  nodules 
are  incised,  carries  100%  recurrence  rate,  and  may  only  add 
scarring to an already scarring disease. Incision and drainage 
should  only  be  used  if  soft,  fluctuating,  large  abscesses  are 
present.

The formation of sinus tracts predisposes to recurrences. 
Sinus  tracts  can  be  surgically  treated  with  simple  excisions 
if few and small, but are generally better managed using so-
called  “deroofing.”  In  this  simple  office  procedure  the  “roof” 

Figure 39.2  Areas most often affected by hidradenitis (circles): axillary, submammary, groin and perianal area.

 
of the sinus is removed after the tracts have been probed using 
a blunt narrow steel probe. By only removing the “roof” and 
leaving  the  already  epithelialized  floor  of  the  sinus  in  place, 
healing is usually rapid and recurrences few (41).

Larger lesions can be excised or evaporated using a CO2
laser with a scanner head, and the wounds left to heal by sec-
ondary  intention  (42–46).  Even  larger  wounds  generally  heal 
within  8–12  weeks,  and  although  secondary  intention  heal-
ing of larger wounds is in contradiction with the general sur-
gical  paradigms,  patients  mostly  take  well  to  the  procedure, 
which  has  a  low  recurrence  rate.  Primary  closure  appears  to 
have  a  higher  recurrence  rate,  possibly  because  the  excisions 
are  subconsciously  made  more  conservative  to  ease  closure 
(47).  A  trial  comparing  split-skin  grafting  with  foam  dress-
ings of postsurgical wounds indicated that patients preferred 
foam dressings over skin grafting (48). Advanced disease may 
require major excisions usually carried out in cooperation with 
surgeons and sometimes requiring the creation of a temporary 
ostomy  to  ensure  optimal  healing.  If  the  resources  are  avail-
able  even  very  large  wounds  have  been  left  successfully  for 
secondary intention healing.

Randomized  trials  have  been  used  to  document  the 
effect of depilatory treatment of HS lesions and HS-prone skin, 
using  either  a  Nd:YAG  laser  or  an  IPL  device  (49–52).  Using 
repeated monthly treatment of HS lesions with a Nd:YAG laser, 
the investigators achieved a clinically significant reduction of 
the disease severity compared to contralateral lesions treated 
with topical clindamycin. Similar results were achieved inde-
pendently using IPL. These trials are in agreement with cur-
rent understanding of HS as a disease of the hair follicle, and 
although the exact mechanism of action on the pathogenesis of 
HS is not fully understood, the use of these methods provides 
a stepping stone between the purely medical aspects of the dis-
ease and the cosmetic.

COSMETICS OF HS
Like any skin disease, HS has a cosmetic aspect, although the 
disease is primarily a medical condition causing scarring and 
pain of the affected regions. One important factor appears to 
be that while the lesions are also easily hidden to others, they 
are clearly visible to the patient and thereby affects their sense 
of self-worth and QoL negatively.

Very little attention has been paid to the cosmetic aspects 
of HS, although the affected regions are often a focus of other 
cosmetic  products  and  procedures  such  as  depilatories, 
deodorants, or mammoplasties.

SMELL
Smell  is  a  particularly  unpleasant  adverse  consequence  of 
active  HS.  Patients  are  disturbed  by  it  as  it  may  appear  sud-
denly  and  unexpectedly,  and  is  noticeable  even  though  the 
lesion that causes it remains hidden (16). Smell was addressed 
in  the  trial  of  infliximab,  but  is  generally  not  included  as  an 
outcome variable in studies (38). Foul smell may derive from 
bacterial  decomposition  of  necrotic  tissue,  indicating  that  in 
addition  to  overall  disease  control,  reduction  of  the  surface 
bacteria  population  may  be  a  useful  approach  (53).  Topical 
disinfectants are often recommended for this, although no for-
mal evidence of their efficacy exists. If a disinfectant is chosen, 
the sensitizing potential must be considered as it is applied to 
naturally occluded and diseased areas of the skin, which may 
aid  sensitization.  Topical  clindamycin  may  achieve  a  similar 

HIDRADENITIS SUPPURATIVA 

 371

effect,  but  the  published  RCT  contains  no  description  of  any 
effect on odor.

If  better  control  of  the  disease  and  the  surface  bacte-
ria cannot achieve the desired control for the patient, it is an 
option to seal  the area with  an occlusive  absorptive bandage 
that can also absorb suppuration (54).

SUPPURATION
Episodes  of  increased  suppuration  and  pain  characterize 
superinfections  but  can  also  be  seen  in  flares  of  the  disease 
not  associated  with  superinfection.  If  recognized  pathogens 
such  as  Staphylococcus  aureus  are  identified  in  the  suppurat-
ing lesions, it may be possible to reduce the suppuration with 
targeted  antibiotic  therapy,  whereas  flares  of  HS  itself  may 
require  a  more  immunosuppressive  approach.  In  either  case 
suppuration  can  be  treated  with  some  effect.  Many  patients 
however find the effects of treatment unsatisfactory, and have 
to resort to adjuvant therapies such as bandages. The bandages 
preferred by patients cover a wide range, from simple rags or 
sanitary  pads  for  simple  absorption  to  state-of-the-art  occlu-
sive bandages that are capable of absorbing drainage and con-
taining  odor.  Most  modern  bandages  are  however  designed 
to  be  applied  to  convex  surfaces,  and  therefore  require  some 
experience in application. Modifying modern bandages breaks 
the  seals  that  prevent  leakage  of  pus  and  odor  and  is  there-
fore generally not recommended. Most patients find square to 
oblong bandages with a maximum width of 4–7 cm most use-
ful.  In  addition  to  good  sealing  and  absorptive  qualities,  the 
bandages  should  be  soft  and  the  adhesive  not  too  strong,  to 
avoid peeling of the skin when changing the bandage. There 
have been no specific investigations to guide the choice of ban-
dage, and the collaboration of a nurse trained in wound man-
agement  and  bandaging  is  therefore  often  very  useful  in  the 
management of HS patients.

SCARS
Considerable efforts are made toward creating less noticeable 
scars following surgery, or improving the cosmesis of existing 
scars (55). The areas are affected by HS are generally invisible 
during normal social intercourse. The axilla may even be used 
as a place to hide scars in cosmetic surgery. Nevertheless, the 
appearance  of  such  private  areas  is  of  considerable  cosmetic 
relevance, as reflected by e.g. the apparently growing demand 
for genital cosmetic surgery (56). The perception of the human 
body  may  therefore  be  affected  by  scars  irrespective  of  their 
location,  and  scars  are  generally  perceived  as  unsightly  by 
most patients. In addition, contractures due to disease activity 
or surgical intervention may have functional consequences for 
HS patients by restricting the movement of e.g. an arm, adding 
to  the  morbidity  caused  by  the  disease.  Scarring  of  the  inti-
mate areas of skin involved in HS is therefore of importance to 
patients on many levels.

Disease-associated  scarring  is  best  dealt  with  through 
improved  disease  control.  The  judicious  use  of  excisional  sur-
gery  and  intralesional  corticosteroid  injections  in  combination 
with  medical  treatment  can  often  reduce  disease  activity  suf-
ficiently to make the ensuing scarring acceptable to the patient 
both  functionally  and  cosmetically.  Atrophic  scarring  rarely 
appears to be a problem, while hypertrophic scarring or frank 
keloid formation may occasionally pose therapeutic challenges. 
The treatment of hypertrophic scars or keloids follows the gen-
eral guidelines for management of these complications (57).

 
372 

 TEXTBOOK OF COSMETIC DERMATOLOGY

CONCLUSION
HS is a disease that may alter the life course of patients. There 
are no pathognomonic tests for HS, but a clear clinical defini-
tion based on characteristic constellations of lesions, affected 
regions  of  the  skin,  and  a  chronic  recurrent  pattern  of  easily 
recognizable flares. It appears to be more common than hith-
erto  reflected  in  hospital  records,  possibly  due  to  underdiag-
nosing and underreporting of cases. International guidelines 
for the management of cases have been published and provide 
a simple approach to treatment, which should include adjuvant 
therapies and surgical and medical elements.

The  impairment  caused  by  HS  generally  overshad-
ows  the  cosmetic  consequences  of  the  disease;  nevertheless, 
improved  cosmesis  can  be  seen  as  a  natural  part  of  the  nec-
essary  adjuvant  therapy.  In  particular,  management  of  smell, 
suppuration, and scars have a cosmetic aspect which is of the 
utmost importance to patients.

REFERENCES

1.  Zouboulis  CC,  et  al.  European  S1  guideline  for  the  treatment 
of  hidradenitis  suppurativa/acne  inversa.  J  Eur  Acad  Dermatol 
Venereol 2015; 29(4):619–44.

2.  Shahi  V,  et  al.  Prevalence  of  hidradenitis  suppurativa: 
A  population-based study in Olmsted County, Minnesota. Der-
matology 2014; 229(2):154–8.

3.  Vinding GR, et al. The prevalence of inverse recurrent suppura-
tion: A population-based study of possible hidradenitis suppu-
rativa. Br J Dermatol 2014; 170(4):884–9.

4.  Revuz JE, et al. Prevalence and factors associated with hidrad-
enitis suppurativa: Results from two case-control studies. J Am 
Acad Dermatol 2008; 59(4):596–601.

5.  Jemec  GB,  Heidenheim  M,  Nielsen  NH.  The  prevalence  of 
hidradenitis  suppurativa  and  its  potential  precursor  lesions. 
J Am Acad Dermatol 1996; 35(2 Pt 1):191–4.

6.  Sung S, Kimball AB. Counterpoint: Analysis of patient claims 
data to determine the prevalence of hidradenitis suppurativa in 
the United States. J Am Acad Dermatol 2013; 69(5):818–9.

7.  von  der  Werth  JM,  Williams  HC.  The  natural  history  of 
 hidradenitis  suppurativa.  J  Eur  Acad  Dermatol  Venereol  2000; 
14(5):389–92.

8.  Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J 

Med 2012; 366(2):158–64.

9.  Mikkelsen PR, Jemec GB. Hidradenitis suppurativa in children 
and adolescents: A review of treatment options. Paediatr Drugs 
2014; 16(6):483–9.

  10.  Farrell  AM,  Dawber  RP.  Endocrine  factors  in  pre-  and  post-
menopausal women with hidradenitis suppurativa. Br J Derma-
tol 1997; 136(5):802–3.

  11.  Mortimer  PS,  et  al.  Mediation  of  hidradenitis  suppurativa  by 
androgens. Br Med J (Clin Res Ed), 1986; 292(6515):245–8.
  12.  Harrison  BJ,  et  al.  Hidradenitis  suppurativa:  Evidence  for  an 

endocrine abnormality. Br J Surg 1985; 72(12):1002–4.

  13.  Kraft  JN,  Searles  GE.  Hidradenitis  suppurativa  in  64  female 
patients:  Rretrospective  study  comparing  oral  antibiotics  and 
antiandrogen therapy. J Cutan Med Surg 2007; 11(4):125–31.
  14.  Kromann CB, et al. Risk factors, clinical course and long-term 
prognosis in hidradenitis suppurativa: A cross-sectional study. 
Br J Dermatol 2014; 171(4):819–24.
  15.  Book of Job 2:3–10, in The Holy Bible.
  16.  Esmann  S,  Jemec  GB.  Psychosocial  impact  of  hidradenitis 
 suppurativa:  A  qualitative  study.  Acta  Derm  Venereol  2011; 
91(3):328–32.

  17.  Zarchi  K,  et  al.  Pain  and  inflammation  in  hidradenitis  sup-
purativa  correspond  to  morphological  changes  identified  by 
high-frequency ultrasound.  J Eur Acad Dermatol Venereol 2015; 
29(3):527–32.

  18.  Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: 
A common and burdensome, yet under-recognised, inflamma-
tory skin disease. Postgrad Med J 2014; 90(1062):216–21; quiz 220.
  19.  Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppura-

tiva. Clin J Pain 2010; 26(5):435–44.

  20.  Kurek  A,  et  al.  Profound  disturbances  of  sexual  health  in 
patients with acne inversa. J Am Acad Dermatol 2012; 67(3):422–8, 
428 e1.

  21.  Shavit E, et al. Psychiatric comorbidities in 3207 patients with 
hidradenitis  suppurativa.  J  Eur  Acad  Dermatol  Venereol  2015; 
29(2):371–6.

  22.  Scheinfeld  N.  Diseases  associated  with  hidranitis  suppura-
tiva: Part 2 of a series on hidradenitis. Dermatol Online J 2013; 
19(6):18558.

  23.  Kurek A, et al. Depression is a frequent co-morbidity in patients 
with acne inversa. J Dtsch Dermatol Ges 2013; 11(8):743–9, 743–50.
  24.  Vazquez  BG,  et  al.  Incidence  of  hidradenitis  suppurativa  and 
associated  factors:  A  population-based  study  of  Olmsted 
County, Minnesota. J Invest Dermatol 2013; 133(1):97–103.
  25.  Onderdijk  AJ,  et  al.  Depression  in  patients  with  hidradenitis 
suppurativa. J Eur Acad Dermatol Venereol 2013; 27(4):473–8.
  26.  Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects 
of hidradenitis suppurativa. Acta Derm Venereol 2010; 90(3):264–8.
  27.  Alavi  A,  et  al.  Quality-of-life  impairment  in  patients  with 
hidradenitis suppurativa: A Canadian study. Am J Clin Dermatol 
2015; 16(1):61–5.

  28.  Vinding  GR,  et  al.  Self-reported  skin  morbidities  and  health-
related quality of life: A population-based nested case-control 
study. Dermatology 2014; 228(3):261–8.

  29.  Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppura-
tiva markedly decreases quality of life and professional activ-
ity. J Am Acad Dermatol 2010; 62(4):706–8, 708 e1.

  30.  von der Werth JM, Jemec GB. Morbidity in patients with hidrad-

enitis suppurativa. Br J Dermatol 2001; 144(4):809–13.

  31.  Clemmensen OJ, Topical treatment of hidradenitis suppurativa 

with clindamycin. Int J Dermatol 1983; 22(5):325–8.

  32.  Jemec  GB,  Wendelboe  P.  Topical  clindamycin  versus  systemic 
tetracycline in the treatment of hidradenitis suppurativa. J Am 
Acad Dermatol 1998; 39(6):971–4.

  33.  Bettoli  V,  et  al.  Oral  clindamycin  and  rifampicin  in  the  treat-
ment  of  hidradenitis  suppurativa-acne  inversa:  A  prospec-
tive  study  on  23  patients.  J  Eur  Acad  Dermatol  Venereol  2014; 
28(1):125–6.

  34.  Wall D, Kirby B. Rifampicin and clindamycin for hidradenitis. 

J Am Acad Dermatol 2011; 64(4):790.

  35.  van der Zee HH, et al. The effect of combined treatment with 
oral clindamycin and oral rifampicin in patients with hidrad-
enitis suppurativa. Dermatology 2009; 219(2):143–7.

  36.  Gener  G,  et  al.  Combination  therapy  with  clindamycin  and 
rifampicin  for  hidradenitis  suppurativa:  A  series  of  116  con-
secutive patients. Dermatology 2009; 219(2):148–54.

  37.  Mendonca CO, Griffiths CE. Clindamycin and rifampicin com-
bination  therapy  for  hidradenitis  suppurativa.  Br  J  Dermatol 
2006; 154(5):977–8.

  38.  Grant A, et al. Infliximab therapy for patients with moderate to 
severe hidradenitis suppurativa: A randomized, double-blind, 
placebo-controlled  crossover  trial.  J  Am  Acad  Dermatol  2010; 
62(2):205–17.

  39.  Kimball AB, et al. Adalimumab for the treatment of moderate to 
severe Hidradenitis suppurativa: A parallel randomized trial. 
Ann Intern Med 2012; 157(12):846–55.

  40.  Miller  I,  et  al.  A  double-blind  placebo-controlled  randomized 
trial of adalimumab in the treatment of hidradenitis suppura-
tiva. Br J Dermatol 2011; 165(2):391–8.

  41.  van  der  Zee  HH,  Prens  EP,  Boer  J.  Deroofing:  A  tissue-sav-
ing  surgical  technique  for  the  treatment  of  mild  to  moderate 
hidradenitis  suppurativa  lesions.  J  Am  Acad  Dermatol  2010; 
63(3):475–80.

 
 
 
 
 
 
 
 
 
 
HIDRADENITIS SUPPURATIVA 

 373

  42.  Mikkelsen  PR,  et  al.  Recurrence  rate  and  patient  satisfaction 
of  CO2  laser  evaporation  of  lesions  in  patients  with  hidrad-
enitis  suppurativa:  A  retrospective  study.  Dermatol  Surg  2015; 
41(2):255–60.

  43.  Hazen  PG,  Hazen  BP.  Hidradenitis  suppurativa:  Successful 
treatment  using  carbon  dioxide  laser  excision  and  marsupial-
ization. Dermatol Surg 2010; 36(2):208–13.

  44.  Madan  V,  et  al.  Outcomes  of  treatment  of  nine  cases  of  recal-
citrant  severe  hidradenitis  suppurativa  with  carbon  dioxide 
laser. Br J Dermatol 2008; 159(6):1309–14.

  45.  Lapins  J,  Marcusson  JA,  Emtestam  L.  Surgical  treatment 
of  chronic  hidradenitis  suppurativa:  CO2  laser  stripping- 
secondary intention technique. Br J Dermatol 1994; 131(4):551–6.
  46.  Sherman AI, Reid R. CO2 laser for suppurative hidradenitis of 

  50.  Highton  L,  et  al.  Treatment  of  hidradenitis  suppurativa  with 
intense  pulsed  light:  A  prospective  study.  Plast  Reconstr  Surg 
2011; 128(2):459–65.

  51.  Mahmoud  BH,  et  al.  Prospective  controlled  clinical  and  his-
topathologic  study  of  hidradenitis  suppurativa  treated  with 
the  long-pulsed  neodymium:yttrium-aluminium-garnet  laser. 
J Am Acad Dermatol 2010; 62(4):637–45.

  52.  Tierney E, et al. Randomized control trial for the treatment of 
hidradenitis  suppurativa  with  a  neodymium-doped  yttrium 
aluminium garnet laser. Dermatol Surg 2009; 35(8):1188–98.
  53.  Hampton  S,  Malodorous  fungating  wounds:  How  dressings 
alleviate symptoms. Br J Community Nurs 2008; 13(6):S31–2, S34, 
S36 passim.

  54.  Patel B, Cox-Hayley D. Managing wound odor #218. J Palliat Med 

the vulva. J Reprod Med 1991; 36(2):113–7.

2010; 13(10):1286–7.

  47.  Ritz JP, et al. Extent of surgery and recurrence rate of hidradeni-

tis suppurativa. Int J Colorectal Dis 1998; 13(4):164–8.

  48.  Morgan  WP,  Harding  KG,  Hughes  LE.  A  comparison  of  skin 
grafting  and  healing  by  granulation,  following  axillary  exci-
sion  for  hidradenitis  suppurativa.  Ann  R  Coll  Surg  Engl  1983; 
65(4):235–6.

  55.  Durani  P,  McGrouther  DA,  Ferguson  MW.  Current  scales  for 
assessing  human  scarring:  A  review.  J  Plast  Reconstr  Aesthet 
Surg 2009; 62(6):713–20.

  56.  McDougall LJ, Towards a clean slit: How medicine and notions 
of normality are shaping female genital aesthetics. Cult Health 
Sex 2013; 15(7):774–87.

  49.  Jain V, Jain A. Use of lasers for the management of refractory 
cases of hidradenitis suppurativa and pilonidal sinus. J Cutan 
Aesthet Surg 2012; 5(3):190–2.

  57.  Monstrey  S,  et  al.  Updated  scar  management  practical  guide-
lines: Non-invasive and invasive measures. J Plast Reconstr Aes-
thet Surg 2014; 67(8):1017–25.

 
Section V

Specific Groups

40

Age-Related Changes in Male Skin

Stefanie Lübberding and Nils Krüger

BACKGROUND
At  first  glance,  the  physiological  properties  of  the  human’s 
largest  organ  seem  equal  in  both  genders.  However,  with 
the  beginning  of  hormonal  production  in  puberty,  skin 
 differences  become  conceivable.  Moreover,  it  is  known  that 
the  susceptibility  to  several  skin  diseases,  such  as  acne, 
 rosacea,  and  seborrhoic  eczema,  vary  between  the  sexes, 
and that therapeutic needs of male and female skin are often 
diverse (1,2).

As in modern society attractiveness and beauty play an 
important  role,  the  market  for  cosmetic  and  aesthetic  treat-
ments is also booming (3). However, men and women likewise 
try to enhance their personal imperfections, but the use of the 
men’s  cosmetics  and  aesthetic  procedures  has  been  widely 
ignored  in  the  past  (4).  As  women  have  been  the  marketing 
target over many years, dermatological research and cosmetic 
science have mainly been focused on female skin. Men were 
the  forgotten  customers  when  it  came  to  cosmetics  and  skin 
care, but as modern men have recently changed their beauty 
and  grooming  habits  there  is  an  increasing  demand  for  cos-
metic  products  for  men  (5).  This  burgeoning  trend  is  also 
attracting the attention of the traditional cosmetics manufac-
turers,  who  launch  and  implement  cosmetics  series  for  male 
skin. As a response to the demands of men, this development 
is  extremely  gratifying,  however  very  little  information  is 
known  about  the  dermatological  needs  and  physical  proper-
ties  of  male  skin.  Most  published  data  including  male  skin 
deal with gender differences (6,7) or evaluate skin care prod-
ucts  related  to  shaving  procedures  (8)  and  androgenetic  alo-
pecia (1).

Due  to  the  fact  that  male  skin  is  still  an  uninvesti-
gated  area,  a  unique  research  project  was  conducted  with 
the  objective  to  carry  out  the  first  systematic  assessment  of 
the skin physiology in men. A large cohort of 150 Caucasian 
subjects,  evenly  distributed  among  five  age  groups,  was 
included  following  very  strict  inclusion  and  exclusion 

criteria.  Well-accepted  biophysical  measuring  methods  and 
clinical scores were used for the assessment of skin barrier 
parameters (9), including sebum excretion (SE), stratum cor-
neum (SC) hydration, transepidermal water loss (TEWL) and 
skin  surface  pH,  as  well  as  wrinkle  severity  (10).  The  aim 
of the project was to get a better understanding of the skin 
physiological properties in males and how they change with 
aging.

MATERIAL AND METHODS
A carefully selected cohort of 150 healthy Caucasian men aged 
20 to 70 years was included in the large clinical trial following 
very strict inclusion and exclusion criteria, involving age, sun 
behavior, smoking habits or minimally-invasive treatments. To 
guarantee a balanced age structure the subjects were distrib-
uted evenly into five age groups (group I: 20–29 years, group II: 
30–39  years,  group  III:  40–49  years,  group  IV:  50–59  years, 
group V: 60–70 years) (Table 40.1).

The  male  subjects  were  invited  to  the  study  site  for  a 
one-time  skin  examination.  Worldwide-accepted  biophysi-
cal measuring methods and clinical scores were used in the 
assessment of the skin physiological properties, including the 
skin barrier parameters SE (Sebumeter® SM 815, Courage & 
Khazaka), SC hydration (Corneometer® CM 825, Courage & 
Khazaka), TEWL (Tewameter® TM 300, Courage & Khazaka) 
and  skin  surface  pH  (Skin-pH-Meter®  PH  905,  Courage  & 
Khazaka).  Wrinkle  severity  was  assessed  with  3D  fringe 
projection  method  (PRIMOSpremium,  GFMesstechnik)  and 
5-point  photonumeric  rating  scale  validated  assessment 
scales (VAS). To consider physiological cutaneous variations, 
the  measurements  were  performed  at  the  forehead,  cheek, 
neck, volar forearm, and dorsum of the hand. Measurements 
were  done  under  standardized  room  conditions  (20°C  and 
50%  relative  humidity),  after  an  acclimatization  period  of 
30 minutes.

Table 40.1  Group Assignment According to Subject’s Age

Age Group

Group I

Group II

Group III

Group IV

Group V

Range

20 to 29 years

30 to 39 years

40 to 49 years

50 to 59 years
60 to 74 years

Age ± SD

25.70 ± 2.48

33.23 ± 2.90

44.23 ± 3.09

54.20 ± 3.13
66.63 ± 2.61

n

30

30

30

30
30

378 

 TEXTBOOK OF COSMETIC DERMATOLOGY

SKIN BARRIER FUNCTION
Cutaneous  health  and  functionality  is  best  represented  by 
assessment  of  the  skin  barrier  which  is  primarily  formed  by 
the  epidermis  (11).  This  physiological  barrier  is  a  selectively 
permeable  squamous  epithelium  protecting  against  desicca-
tion and preventing the penetration of foreign molecules into 
the body (12). This two-way protection is based on the physical 
barrier, formed by the unique structure of intercellular lipids 
and  corneocytes  in  the  SC  (11),  and  a  chemical/biochemical 
barrier, built by the hydro-lipid film of the skin surface (13,14). 
Although the skin barrier cannot be directly measured, TEWL, 
SC hydration, SE, and pH value are considered to be the stan-
dard surrogate markers for the assessment of the skin barrier 
function and permit an objective evaluation of the skin physi-
ological properties in vivo (15–17).

TRANSEPIDERMAL WATER LOSS
TEWL is regarded as one of the most important parameters for 
assessment of skin physiology, as it shows the quantity of water 
that  passes  through  the  skin’s  protective  barrier.  Therefore, 
the ability of the SC to retard evaporative water loss is a sur-
rogate marker for the functionality of the skin barrier in vivo. 
Data analysis indicates that TEWL in men varies by localiza-
tion (Figure 40.1). Average values for the forehead, cheek, and 
hand range from 9 to 11 g/h/m2, while TEWL is lower at neck 
and forearm with mean values between 5.5 and 7 g/h/m2. The 
higher  water  evaporation  in  the  face  and  the  dorsum  of  the 
hand is probably caused by the higher number of sweat glands 
at  these  localizations,  as  it  is  known  that  the  TEWL  is  par-
ticularly  influenced  by  water  evaporation  from  eccrine  acro-
syringium  (18,19).  Data  analysis  also  indicates  that  TEWL  is 
not subjected to greater fluctuations over a lifetime. However, 
TEWL  at  the  neck  significantly  increases  with  age,  which  is 
contrary  to  other  studies  that  showed  a  decreasing  TEWL  in 
non-facial  areas  with  aging  (17,20–22).  Further,  men  between 
the  ages  of  50  through  60  years  show  significantly  higher 
water  loss  (with  the  exception  of  the  hand)  in  comparison  to 
the data of other age groups. It can be assumed that the higher 
water evaporation is due to hot flushes caused by progressive 
hypoandrogenism (23–25). It was previously assumed that hot 

flushes commonly occur in castrated men and cancer patients 
(26,27),  but  current  studies  indicate  that  even  “normal”  aged 
men suffer from flushes. Therefore, the prevalence seems to be 
highest in men’s mid-50s (23), which can be an explanation for 
the sudden increase in TEWL in the age group IV.

STRATUM CORNEUM HYDRATION
While TEWL is an indicator for the ability of the epidermis to 
hold water, it is closely related to the hydration of the SC which 
keeps the skin surface smooth and prevents the penetration of 
hydrophobic  substances  (28).  Whereas  TEWL  generally  does 
not seem to be affected by the subject’s age, man’s skin partly 
loses its ability to maintain water in the SC (Figure 40.2). At the 
forehead, cheek, and neck, SC hydration significantly decreases 
with aging. Therefore, the greatest decrease in hydration was 
assessed at the forehead with a decline of about 25% from the 
youngest  to  the  oldest  subjects.  Also,  Man  et  al.  (6)  demon-
strated a decrease in epidermal hydration level at the forehead 
with  age,  which  confirms  the  generally  accepted  assumption 
that skin gets drier in elderly people (29,30). Several factors may 
contribute  to  the  lower  SC  hydration  mainly  influenced  by  a 
progressive reduction of natural moisturizers in the SC, such 
as epidermal lipids and lactate (31,32). Whereas the age related 
decrease is significant at the face and neck, SC hydration at the 
forearm  and  hand  remains  unchanged.  These  localization-
dependent  differences  are  probably  influenced  by  the  higher 
sun exposure of the face and neck. This presumption was con-
firmed by Liu et al. (33) who showed that cumulative sun expo-
sure does reduce SC hydration, probably due to a UVB-induced 
down-regulation of epidermal ceramides, fillagrins, and aqua-
porins (34–37).

PH VALUE
The  pH  value  on  the  skin  surface  is  of  great  importance  for 
cutaneous  antimicrobial  defense  and  regulates  epidermal 
enzyme activity and expression (13). The pH also influences the 
buffering capacity of the skin, with respect to both acidifying 
and alkalinizing effects from internal and external influences 
(38). The skin surface pH in men was in physiological range 

2

m
/
h
/
g

25

20

15

10

5

0

*
*

*
*

**

**
*

*

2
8
8

.

4
5
8

.

2
8
8

.

1
5
1
1

.

7
9
8

.

7
7
0
1

.

7
0
1
1

.

4
4
1
1

.

7
3
9

.

1
4
9

.

8
6
5

.

8
4
5

.

.

6
4
4 9
3
6

.

*

*

8
1
9

.

4
9
1
1

.

4
2
1
1

.

5
6
1
1

.

4
8
0
1

.

3
8
7

.

3
4
5

.

3
2
5

.

5
5
5

.

9
3
6

.

*

3
0
5

.

Forehead

Cheek

20–29 years

30–39 years

Neck
40–49 years

Forearm

Hand

50–59 years

60–70 years

Figure 40.1  Mean values (SE) of transepidermal water loss arranged by age group and location.

 
AGE-RELATED CHANGES IN MALE SKIN 

 379

85

75

65

s
t
i
n
u
-
M
C

55

45

35

25

15

***

*
*

***

*

***

*

.

9
9
5

5
5
4
5

.

.

5
8
4

1
1
6
4

.

2
5
5
4

.

5
8
4
6

.

1
1
1
6

.

7
3
3
5

.

9
9
5
5

.

6
9
2
5

.

6
6
4
6

.

7
3
3
6

.

3
7
0
6

.

5
4
5
5

.

8
3
3
5

.

3
3
5
4

.

.

9
3
4

.

8
1
4

3
1
1
4

.

.

3
3
4

*

*

1
7
3
3

.

7
4
4
3

.

8
9
3
3

.

1
1
1
3

.

8
1
9
2

.

Forehead

Cheek

20–29 years

30–39 years

Neck
40–49 years

Forearm

Hand

50–59 years

60–70 years

Figure 40.2  Mean values (SE) of stratum corneum hydration arranged by age group and location.

e
u
l
a
v
-
H
p

5.80

5.30

4.80

4.30

3.80

**

**

7
7
4

.

4
7
4

.

2
8
4

.

8
6
4

.

3
9
4

.

2
7
4

.

3
6
4

.

2
6
4

.

6
7
4

.

3
7
4

.

7
4
4

.

5
4

.

6
5
4

.

7
5
4

.

1
3
4

.

9
4
4

.

5
4

.

3
5
4

.

2
6
4

.

8
5
4

.

1
4
4

.

8
3
4

.

3
3
4

.

5
5
4

.

6
4
4

.

Forehead

Cheek

20–29 years

30–39 years

Neck
40–49 years

Forearm

Hand

50–59 years

60–70 years

Figure 40.3  Mean values (SE) of pH value arranged by age group and location.

for all age groups. Overall, lowest pH value was  measured at 
the  hand  and  highest  at  the  cheek  (Figure  40.3).  The  results 
of  the  present  study  indicate  that  skin  surface  pH  increases 
at  all  assessed  localizations,  but  significantly  at  the  fore-
head and cheek. This result is in agreement with other stud-
ies (6,39) which found an increase in skin  surface pH in  age 
compared with younger men. Man et al. (6) assume that the 
elevated skin surface pH with aging is linked to the simulta-
neous decrease in epidermal expression of sodium-hydrogen 
 antiporter  (Na+/H+),  as  Na+/H+  is  known  as  one  of  the  key 
factors regulating skin surface pH (40). Further, the increased 
SC  pH  negatively  influences  cutaneous  permeability  barrier 
homeostasis  and  lipid  processing  which  may  have  a  nega-
tive  influence  on  water  holding  capacity  of  the  SC  resulting 
in lower hydration levels (39,40). This connection is probable 

as  age-related  changes  occur  simultaneously  in  the  present 
study.

SEBUM EXCRETION
The  influence  of  androgens,  such  as  testosterone  and  dehy-
droepiandrosterone,  on  the  sebum  production  has  been 
shown in several studies (41–43): the higher the level of sex-
ual steroids, the higher is the SE rate (43). As with increasing 
age  men  experience  a  gradual  decrease  of  circulating  bio-
available androgens (17,25,44), it can be assumed that sebum 
production  decreases  accordingly,  resulting  in  drier  skin. 
While this hypothesis was confirmed by prior studies (6,45), 
the results of this large study show no age-related decrease 
in  SE  in  males  (Figure  40.4).  A  possible  explanation  for  this 

 
380 

 TEXTBOOK OF COSMETIC DERMATOLOGY

260

210

2

m
c
/
g
µ

160

110

60

10

.

7
7
0
2
1

.

3
5
7
2
1

.

3
4
5
2
1

.

3
9
5
2
1

.

1
9
3
1

7
2
1
8

.

6
7
9
8

.

3
8
0
9

.

3
9
7
7

.

7
0
1
8

.

Forehead

Cheek

20–29 years

30–39 years

40–49 years

50–59 years

60–70 years

Figure 40.4  Mean values (SE) of sebum production arranged by age group and location.

result  can  be  the  wide  distribution  of  measured   values 
found in all age groups, indicating that inter-individual dif-
ferences  in  SE  are  huge  and  probably  overlay  the  relatively 
small  influence  of  aging.  Therefore,  a  larger  cohort  or  an 
assessment  of  individual  subjects  over  a  longer  timeframe 
would  be  necessary  to  confirm  the  decrease  of  sebum  pro-
duction with age. However, it should be noted that previous 
 studies,  which  found  a  distinct  influence  of  aging  onto  SE, 
had  a   preponderance  of  young  men  in  their  cohorts,  which 
may  result  in  a  right-skewed   distribution  and  a  potential 
 statistical bias. (6,45).

WRINKLES AND MECHANICAL PROPERTIES
The most obvious and probably the most unloved sign of the 
aging  process  is  the  development  of  facial  wrinkles  and  the 
loss of skin firmness and elasticity. Despite the different clini-
cal  manifestations,  skin  laxity  and  wrinkles  share  the  same 
underlying mechanisms and are most likely due to complex 
structural  and  molecular  alterations  in  the  dermal  connec-
tive  tissue  (46).  Therefore,  the  progressive  breakdown  of  the 
collagen  and  elastin  fiber  network  throughout  the  lifetime 
results in less tensile strength and a decreased elastic ability 
of  the  skin  to  recover  after  stretching  (47–49).  These  altera-
tions,  especially  the  loss  of  elasticity,  significantly  correlate 
with  the  clinical  visibility  of  facial  wrinkles  (50,51).  Even 
though the reasons for wrinkle formation with aging are not 
yet  fully  understood,  it  can  be  assumed  that  lines  and  fur-
rows  are  the  visible  results  of  deep  dermal  creasing,  caused 
by repeated facial muscle contraction, combined with dermal 
elastosis  (52);  since  the  elastic  fibers  are  altered  with  aging 
they  do  not  permit  the  skin  to  snap  back  to  its  initial  shape 
after deformation, resulting in the development of permanent 
facial  wrinkles (53).

WRINKLE DEVELOPMENT
According to expectation, clinical rating and 3D  measuring 
indicate  that  wrinkle  severity  in  male  skin  increases  with 
aging at all assessed localizations. This age-related increase 
of skin wrinkling is largely linear. Therefore, facial  wrinkles 
manifest  clinically  first  at  the  forehead  and  latest  at  the 

glabella  area.  Whereas  wrinkles  at  crow’s  feet  constantly 
increase  about  0.5  grades  of  the  VAS  every  10  years,  wrin-
kle  severity  at  glabella  lines  increase  very  slowly  until  the 
age  of  40  but  sharply  increase  in  the  fifth  decade  of  life 
(Figure 40.5).

The  study  results  show  that  the  visibility  of  wrinkles 
in clinical rating also vary by location. While forehead lines 
in  men  can  be  recognized  as  very  fine  wrinkles  already  by 
an average wrinkle depth of 60 µm and periorbital lines by 
a  depth  of  70  µm,  glabella  frown  lines  are  first  recognized 
at  180  µm.  It  can  be  assumed  that  the  surrounding  macro-
structure of the craniofacial bones, including Orbita and Os 
nasale, and the eyebrows probably deflect from the very fine 
lines  of  the  glabella.  Furthermore,  the  relatively  small  area 
of only 2–3 cm2 makes it even more challenging to recognize 
early wrinkles.

The  results  also  indicate  that  wrinkles  do  not  develop 
simultaneously  on  all  areas  of  the  face,  but  vary  by  location. 
Facial rhytides in male skin manifest clinically first at the fore-
head,  then  at  the  crow’s  feet,  and  latest  at  the  glabella  area. 
Therefore,  forehead  lines  and  crow’s  feet  are  pronounced  in 
males in their end-20s/mid-30s, whereas glabella frown lines 
develop  in  subject’s  mid-40s.  The  wrinkle  severity  further 
increases at all locations every 10 years of age by one level of 
the  VAS.  Thus  exemplary,  at  crows’  feet  the  average  age  for 
no wrinkles is ≤28 years, 37 years for very fine wrinkles, 49 years 
for fine wrinkles, 59 years for moderate wrinkles, and 66 years for 
severe wrinkles (Figure 40.6).

The  same  progressive  increase  with  each  level  of  the 
VAS  can  be  seen  for  the  parameters  of  the  3D  fringe  projec-
tion method. As a broad rule of thumb, the increase of wrinkle 
depth (Wd) per VAS level is about 100 µm at glabella and fore-
head lines and about 50 µm at crow’s feet. Wrinkle volume (Wv) 
is relatively low at VAS level no wrinkles and very fine wrinkles, 
but doubles with every additional VAS level (Figure 40.7). The 
explanation for this effect is probably the strong influence of 
the number of wrinkles on the wrinkle volume (Wv) parameter, 
while  the  wrinkle  depth  (Wd)  is  independent  from  the  num-
ber of wrinkles: the more wrinkles in the area of interest, the 
higher  the  total  wrinkle  volume.  Thereby,  it  can  be  assumed 
that wrinkles not only become more and deeper over the years, 
but also wider, resulting in an additional increase in wrinkle 
volume (54).

 
AGE-RELATED CHANGES IN MALE SKIN 

 381

500

450

400

350

300

m
250µ

200

150

100

50

0

.

0
0
6
0
2

.

0
5
3
6
1

.

3
3
7
1
1

5
9
3
5

.

7
1
3
7

.

.

8
1
6
7
1

3
7
5
6

.

.

0
0
8
7
4

.

7
6
8
3
3

.

2
9
5
6
2

.

7
6
2
6
3

.

3
2
3
7
1

.

2
0
6
1
1

0
0
1
4

.

2
0
2
6

.

Crow’s feet

Glabella lines

Forehead lines

no wrinkles

very fine wrinkles 

fine wrinkles  moderate wrinkles 

severe wrinkles 

Figure 40.5  Matching of VAS with 3D imaging arranged by the parameter overall average wrinkle depth in men.

Figure 40.6  Matching of VAS with 3D fringe projection method (a: VAS = 0, no wrinkles; b: VAS = 1, very fine wrinkles; c: VAS = 2, 
fine wrinkles; d: VAS = 3, moderate wrinkles; e: VAS = 4, severe wrinkles).

60

50

40

3

m
m

30

20

10

0

8
4
0

.

0
0
6
2

.

6
9
0

.

.

4
1
6
0 1
2
7

.

8
8
3
4

.

4
2
6
3

.

6
3
1
2

.

3
5
0

.

0
8
1

.

.

6
3
8
0 1
2
9

.

Glabella lines

Forehead lines

3
7
2
1

.

1
5
1

.

.

2
4
6
Crow’s feet

Figure 40.7  Matching of VAS with 3D imaging arranged by the parameter total wrinkle volume (Wv) in men.

no wrinkles

very fine wrinkles 

fine wrinkles  moderate wrinkles 

severe wrinkles 

 
382 

 TEXTBOOK OF COSMETIC DERMATOLOGY

CONCLUSION
Based on the statistical analysis of the data of 150 male  subjects, 
this  study  assigns  systematic  reference  values  for  standard-
ized  biophysical  measuring  methods  reflecting  men’s  skin 
physiology  in  relationship  to  age  for  the  very  first  time.  The 
results show that the physiology of male skin partly changes 
with  aging.  Therefore,  the  ability  of  the  SC  to  retard  evapo-
rative  water  loss  does  not  decline  with  aging  in  general,  but 
TEWL  is  significantly  higher  in  men’s  50s.  This  temporary 
increase is probably due to hot flushes caused by progressive 
hypoandrogenism.  An  expected  negative  impact  of  hypoan-
drogenism  onto  sebum  production  cannot  be  confirmed  in 
this cohort.

The present study further shows age-related changes in 
the lifetime development of skin wrinkles in men. The increase 
in wrinkle formation is largely linear in men’s lifetime, how-
ever,  varies  strongly  by  localization.  Therefore,  the  first  pro-
nounced  wrinkles  in  men,  the  forehead  lines,  are  already 
marked in their 20s, while periorbital and glabella lines mani-
fest in their fourth and fifth decade of life.

The results of the present study are a first step toward a 
systematic understanding of male skin and the lifetime devel-
opment  of  skin  physical  properties,  including  skin  barrier 
parameters, wrinkle severity, and mechanical properties. This 
new  knowledge  is  an  important  step  toward  a  better  under-
standing  of  age-  and  gender-related  influences  in  male  skin 
and can be used as a base to develop gender-specific skin care 
solutions  as  well  as  age-appropriate  treatment  concepts  for 
skin rejuvenation. This is of particular importance to address 
the increasing demand for skin care and antiaging approaches 
in our constantly aging society.

REFERENCES

1.  Dao H Jr, Kazin RA. Gender differences in skin: A review of the 

literature. Gend Med 2007; 4(4):308–28.

2.  Giacomoni PU, Mammone T, Teri M. Gender-linked differences 

in human skin. J Dermatol Sci 2009; 55(3):144–9.

3.  Most  SP,  Alsarraf  R,  Larrabee  WF  Jr.  Outcomes  of  facial  cos-

metic procedures. Facial Plast Surg FPS 2002; 18(2):119–24.

4.  Elsner P. Overview and trends in male grooming. Br J Dermatol 

2012; 166 Suppl 12–5.

5.  Schlessinger  J.  Skin  care  for  men  and  its  marketing.  Dermatol 

Ther 2007; 20(6):452–6.

6.  Man  MQ,  Xin  SJ,  Song  SP,  Cho  SY,  Zhang  XJ,  Tu  CX,  et  al. 
Variation of skin surface pH, sebum content and stratum cor-
neum hydration with age and gender in a large Chinese popu-
lation. Skin Pharmacol Physiol 2009; 22(4):190–9.

7.  Kim M-K, Patel RA, Shinn AH, Choi S-Y, Byun H-J, Huh C-H, 
et  al.  Evaluation  of  gender  difference  in  skin  type  and  pH. 
J Dermatol Sci 2006; 41(2):153–6.

8.  Draelos Z. Male skin and ingredients relevant to male skin care. 

Br J Dermatol 2012; 16613–16.

9.  Luebberding  S,  Krueger  N,  Kerscher  M.  Age-related  changes 
in male skin: Quantitative evaluation of one hundred and fifty 
male subjects. Skin Pharmacol Physiol 2014; 27(1):9–17.

  10.  Luebberding  S,  Krueger  N,  Kerscher  M.  Comparison  of 
Validated  Assessment  Scales  and  3D  digital  fringe  projection 
method to assess lifetime development of wrinkles in men. Skin 
Res Technol 2014 Feb;20(1):30–6.

  11.  Proksch E, Brandner JM, Jensen J-M. The skin: An indispens-

able barrier. Exp Dermatol 2008; 17(12):1063–72.

  12.  Rawlings  AV,  Harding  CR.  Moisturization  and  skin  barrier 

function. Dermatol Ther 2004; 1743–48.

  13.  Schmid-Wendtner M-H, Korting HC. The pH of the skin surface 
and  its  impact  on  the  barrier  function.  Skin  Pharmacol  Physiol 
2006; 19(6):296–302.

  14.  Lambers  H,  Piessens  S,  Bloem  A,  Pronk  H,  Finkel  P.  Natural 
skin surface pH is on average below 5, which is beneficial for its 
resident flora. Int J Cosmet Sci 2006; 28(5):359–70.

  15.  Stefaniak AB, Plessis J du, John SM, Eloff F, Agner T, Chou T-C, 
et al. International guidelines for the in vivo assessment of skin 
properties in non-clinical settings: Part 1. pH. Skin Res Technol 
2013; 19(2):59–68.

  16.  Plessis  J  du,  Stefaniak  A,  Eloff  F,  John  S,  Agner  T,  Chou  T-C, 
et al. International guidelines for the in vivo assessment of skin 
properties in non-clinical settings: Part 2. Transepidermal water 
loss and skin hydration. Skin Res Technol 2013 Aug;19(3):265–78.
  17.  Piérard GE, Piérard-Franchimont C, Marks R, Paye M, Rogiers 
V. EEMCO guidance for the in vivo assessment of skin greasi-
ness. The EEMCO Group. Skin Pharmacol Appl Skin Physiol 2000; 
13(6):372–89.

  18.  Pinnagoda J, Tupker RA, Agner T, Serup J. Guidelines for tran-
sepidermal  water  loss  (TEWL)  measurement.  A  report  from 
the Standardization Group of the European Society of Contact 
Dermatitis. Contact Dermatitis 1990; 22(3):164–78.

  19.  Rogiers V. EEMCO guidance for the assessment of transepider-
mal  water  loss  in  cosmetic  sciences.  Skin  Pharmacol  Appl  Skin 
Physiol 2001; 14(2):117–28.

  20.  Roskos  KV,  Guy  RH.  Assessment  of  skin  barrier  function 
using transepidermal water loss: Effect of age. Pharm Res 1989; 
6(11):949–53.

  21.  Wilhelm KP, Cua AB, Maibach HI. Skin aging. Effect on tran-
sepidermal  water  loss,  stratum  corneum  hydration,  skin 
surface  pH,  and  casual  sebum  content.  Arch  Dermatol  1991; 
127(12):1806–9.

  22.  Cua  AB,  Wilhelm  KP,  Maibach  HI.  Frictional  properties  of 
human  skin:  Relation  to  age,  sex  and  anatomical  region, 
stratum  corneum  hydration  and  transepidermal  water  loss. 
Br J Dermatol 1990; 123(4):473–9.

  23.  Spetz  A-CE,  Fredriksson  MG,  Hammar  ML.  Hot  flushes  in  a 
male  population  aged  55,  65,  and  75  years,  living  in  the  com-
munity of Linköping, Sweden. Menopause 2003; 10(1):81–7.
  24.  Spetz  A-CE,  Palmefors  L,  Skobe  RSP,  Strömstedt  MT, 
Fredriksson  MG,  Theodorsson  E,  Hammar  ML.  Testosterone 
correlated to symptoms of partial androgen deficiency in aging 
men  (PADAM)  in  an  elderly  Swedish  population.  Menopause 
2007; 14(6):999–1005.

  25.  Schreiber  G,  Ziemer  M.  The  aging  male-diagnosis  and  ther-
apy  of  late-onset  hypogonadism.  J  Dtsch  Dermatol  Ges  2008; 
6(4):273–9.

  26.  Yousaf  O,  Stefanopoulou  E,  Grunfeld  EA,  Hunter  MS.  A  ran-
domised  controlled  trial  of  a  cognitive  behavioural  interven-
tion  for  men  who  have  hot  flushes  following  prostate  cancer 
treatment (MANCAN): Trial protocol. BMC Cancer 2012; 12230.
  27.  Grunfeld  EA,  Halliday  A,  Martin  P,  Drudge-Coates 
L. Andropause syndrome in men treated for metastatic prostate 
cancer: A qualitative study of the impact of symptoms. Cancer 
Nurs 2012; 35(1):63–9.

  28.  Rawlings  AV.  Trends  in  stratum  corneum  research  and  the 
management  of  dry  skin  conditions.  Int  J  Cosmet  Sci  2003; 
25(1-2):63–95.

  29.  Engelke M, Jensen JM, Ekanayake-Mudiyanselage S, Proksch E. 
Effects  of  xerosis  and  ageing  on  epidermal  proliferation  and 
differentiation. Br J Dermatol 1997; 137(2):219–25.

  30.  Manuskiatti  W,  Schwindt  DA,  Maibach  HI.  Influence  of 
age,  anatomic  site  and  race  on  skin  roughness  and  scaliness. 
Dermatol Basel Switz 1998; 196(4):401–7.

  31.  Ghadially  R,  Brown  BE,  Sequeira-Martin  SM,  Feingold  KR, 
Elias PM. The aged epidermal permeability barrier. Structural, 
functional, and lipid biochemical abnormalities in humans and 
a senescent murine model. J Clin Invest 1995; 95(5):2281–90.

 
 
 
 
 
 
 
 
 
 
  32.  Egawa M, Tagami H. Comparison of the depth profiles of water 
and  water-binding  substances  in  the  stratum  corneum  deter-
mined in vivo by Raman spectroscopy between the cheek and 
volar forearm skin: Effects of age, seasonal changes and artifi-
cial forced hydration. Br J Dermatol 2008; 158(2):251–60.

  33.  Liu Z, Song S, Luo W, Elias PM, Man M-Q. Sun-induced changes 
of stratum corneum hydration vary with age and gender in a 
normal Chinese population. Skin Res Technol 2012; 18(1):22–8.

  34.  Takagi  Y,  Nakagawa  H,  Kondo  H,  Takema  Y,  Imokawa  G. 
Decreased levels of covalently bound ceramide are associated 
with  ultraviolet  B-induced  perturbation  of  the  skin  barrier. 
J Invest Dermatol 2004; 123(6):1102–9.

  35.  Mildner  M,  Jin  J,  Eckhart  L,  Kezic  S,  Gruber  F,  Barresi  C, 
Stremnitzer C, Buchberger M, Mlitz V, Ballaun C, Sterniczky B, 
Födinger  D,  Tschachler  E.  Knockdown  of  filaggrin  impairs 
diffusion  barrier  function  and  increases  UV  sensitivity  in  a 
human skin model. J Invest Dermatol 2010; 130(9):2286–94.
  36.  Meguro  S,  Arai  Y,  Masukawa  K,  Uie  K,  Tokimitsu  I.  Stratum 
corneum lipid abnormalities in UVB-irradiated skin. Photochem 
Photobiol 1999; 69(3):317–21.

  37.  Jiang Q, Cao C, Lu S, Kivlin R, Wallin B, Chu W, et al. MEK/
ERK  pathway  mediates  UVB-induced  AQP1  downregulation 
and water permeability impairment in human retinal pigment 
epithelial cells. Int J Mol Med 2009; 23(6):771–7.

  38.  Parra  JL,  Paye  M.  EEMCO  guidance  for  the  in  vivo  assess-
ment of skin surface pH. Skin Pharmacol Appl Skin Physiol 2003; 
16(3):188–202.

  39.  Choi  E-H,  Man  M-Q,  Xu  P,  Xin  S,  Liu  Z,  Crumrine  DA,  et  al. 
Stratum corneum acidification is impaired in moderately aged 
human and murine skin. J Invest Dermatol 2007; 127(12):2847–56.
  40.  Behne  MJ,  Meyer  JW,  Hanson  KM,  Barry  NP,  Murata  S, 
Crumrine D, et al. NHE1 regulates the stratum corneum per-
meability barrier homeostasis. Microenvironment acidification 
assessed with fluorescence lifetime imaging. J Biol Chem 2002; 
277(49):47399–406.

  41.  Giltay  EJ,  Gooren  LJ.  Effects  of  sex  steroid  deprivation/
administration on hair growth and skin sebum production in 
transsexual  males  and  females.  J  Clin  Endocrinol  Metab  2000; 
85(8):2913–21.

AGE-RELATED CHANGES IN MALE SKIN 

 383

  42.  Stewart  ME,  Downing  DT,  Cook  JS,  Hansen  JR,  Strauss  JS. 
Sebaceous  gland  activity  and  serum  dehydroepiandros-
terone  sulfate  levels  in  boys  and  girls.  Arch  Dermatol  1992; 
128(10):1345–8.

  43.  Zouboulis  CC,  Chen  W-C,  Thornton  MJ,  Qin  K,  Rosenfield  R. 
Sexual hormones in human skin. Métabolisme 2007; 39(2):85–95.
  44.  Zouboulis  CC.  Intrinsische  Hautalterung.  Hautarzt  2003; 

54(9):825–32.

  45.  Jacobsen  E,  Billings  JK,  Frantz  RA,  Kinney  CK,  Stewart  ME, 
Downing  DT.  Age-related  changes  in  sebaceous  wax  ester 
secretion  rates  in  men  and  women.  J  Invest  Dermatol  1985; 
85(5):483–5.

  46.  Tzaphlidou M. The role of collagen and elastin in aged skin: An 

image processing approach. Micron 2004; 35(3):173–7.

  47.  Oxlund  H,  Manschot  J,  Viidik  A.  The  role  of  elastin  in  the 
mechanical properties of skin. J Biomech 1988; 21(3):213–8.
  48.  Frances C, Branchet MC, Boisnic S, Lesty CL, Robert L. Elastic 
fibers in normal human skin. Variations with age: A morpho-
metric analysis. Arch Gerontol Geriatr 1990; 10(1):57–67.

  49.  Krueger N, Luebberding S, Oltmer M, Streker M, Kerscher M. 
Age-related changes in skin mechanical properties: A quanti-
tative  evaluation  of  120  female  subjects.  Skin  Res  Technol  2011; 
17(2):141–8.

  50.  Fujimura T, Haketa K, Hotta M, Kitahara T. Loss of skin elastic-
ity precedes to rapid increase of wrinkle levels. J Dermatol Sci 
2007; 47(3):233–9.

  51.  Tsuji  N,  Moriwaki  S,  Suzuki  Y,  Takema  Y,  Imokawa  G.  The 
role  of  elastases  secreted  by  fibroblasts  in  wrinkle  formation: 
Implication  through  selective  inhibition  of  elastase  activity. 
Photochem Photobiol 2001; 74(2):283–90.

  52.  Lemperle G, Holmes RE, Cohen SR, Lemperle SM. A classifica-
tion of facial wrinkles. Plast Reconstr Surg 2001; 108(6):1735–52.
  53.  Kligman  AM,  Zheng  P,  Lavker  RM.  The  anatomy  and  patho-

genesis of wrinkles. Br J Dermatol 1985; 113(1):37–42.

  54.  Luebberding S, Krueger N, Kerscher M. Life-time development 
of facial wrinkles of men and women: Using three-dimensional 
fringe  projection  method  and  Validated  Assessment  Scales. 
Dermatol Surg 2014 Jan;40(1):22–32.

 
41

Ethnic Cosmetics

Enzo Berardesca

INTRODUCTION
Ethnic  differences 
in  skin  physiology  and  reaction  to 
 environmental  stimuli  are  more  and  more  described  (1),  but 
notwithstanding  the  increasing  number  of  studies,  data  are 
often conflicting. In fact, it is difficult to define and interpret 
the cutaneous pathophysiologic phenomena that are not only 
anatomical and functional characteristics of ethnic groups but 
also the result of socioeconomic, hygienic, and nutritional fac-
tors.  Furthermore,  skin  status  may  be  influenced  by  climate, 
circadian  rhythms,  and  changes  in  circulating  sex  hormones 
or stress hormones. Indeed, even though it is well established 
that all humans belong to the same species, many physical dif-
ferences exist among human population. This chapter reviews 
the more consistent differences reported between racial groups 
and their implications in determining different responses after 
use of topical products and in treating skin aging.

SKIN COLOR
According  to  the  classification  of  Fitzpatrick,  Caucasians  are 
generally included in phototypes I to III, having fair complex-
ion, red to light brown hair, tendency to sunburn, and tanning 
difficultly, whereas colored skin belongs to skin type IV, V, or 
VI, rarely burning, tanning easily. Phenotypically ethnic skin 
ranges from brown to black-brown. Clearly, differences in skin 
color  are  the  most  striking  characteristic  in  ethnic  skin.  The 
color of the skin is due to the combination of four cromophores: 
hemoglobin,  oxygenated  hemoglobin,  exogenously  produced 
carotenoids,  and  melanin.  Melanin  is  the  most  important 
pigment  for  the  determination  of  skin  color.  The  increased 
quantity of melanin correlates with the activity of tyrosinase 
and  probably  with  the  level  of  protease-activated  receptor-2 
(PAR-2) that is involved in melanosome transfer from melano-
cyte to keratinocyte (2–4). No interracial variation concerning 
the number of melanocytes has been reported.

STRATUM CORNEUM STRUCTURE, 
WATER CONTENT, AND pH
Stratum corneum is equally thick in black and white skin (5,6). 
However, the number of cell layers and resistance to stripping 
and other physicochemical insults is still debated (7–18).TEWL, 
skin  conductance, and skin mechanical properties have  been 
measured  under  basal  conditions  in  whites,  Hispanics,  and 
blacks  to  assess  whether  skin  color  (melanin  content)  could 
induce changes in skin biophysical properties (19). Differences 
appear in skin conductance are more marked in biomechanical 
features  such  as  skin  extensibility,  skin  elastic  modulus,  and 
skin recovery. They differ in dorsal and ventral sites according 
to race and highlight the influence of solar irradiation on skin 

and  the  role  of  melanin  in  maintaining  it  unaltered.  Wilson 
et al. (15) demonstrated higher in vitro TEWL values in black 
compared to white skin taken from cadavers. They also found 
differences  in  black  and  white  skin  physiology:  the  TEWL 
of  both  races  increased  with  skin  temperature.  In  their  own 
study,  they  concluded  that  black  skin  would  have  a  greater 
rise  to  achieve  the  same  temperature  and  therefore  a  higher 
TEWL. Since TEWL depends on passive water loss that is theo-
retically directly related to the ambient relative humidity and 
temperature (20), then the increased TEWL in black skin could 
be associated with an increase in temperature because it is well 
established that a difference in black and Caucasian tempera-
ture  exists.  Most  studies  using  the  forearm,  back,  and  inner 
thigh  (13,16,21–23)  show  a  greater  TEWL  in  blacks  compared 
to whites; however, other studies don’t confirm these findings 
(11,12). Skin lipids may play a role in modulating the relation 
between stratum corneum water content and TEWL resulting 
in higher conductance values in blacks and Hispanics. Ethnic 
differences  in  skin  conductance  are  difficult  to  interpret  in 
terms of stratum corneum water content because other physi-
cal factors, such as the skin surface or the presence of hair, can 
modify  the  quality  of  the  skin-electrode  contact.  In  all  races, 
significant differences exist between the volar and dorsal fore-
arms  (19).  These  results  are  in  apparent  contrast  with  TEWL 
recordings. Indeed, increased stratum corneum water content 
correlates with a higher TEWL (24). The data may be explained 
on the basis of the different intercellular cohesion or lipid com-
position.  A  greater  cell  cohesion  with  a  normal  TEWL  could 
result in increased skin water content. The acidity of the skin 
mostly derives from the fatty free acid content of the skin sur-
face and the buffer capacity of the skin is due to several mech-
anisms—one  of  the  most  important  is  the  lactic-acid-lactate 
system. According to Berardesca et al. (22), pH values in skin 
surface,  measured  on  the  volar  forearm,  are  similar  in  black 
and in Caucasian women, but it decreases after tape stripping 
only  in  black  subjects.  Warrier  et  al.  (11),  who  measured  the 
pH  on  the  cheek,  reported  a  significantly  lower  pH  in  black 
women than in the Caucasian ones. The results of Fotoh et al. 
(12) are quite the reverse: a significantly higher cutaneous pH 
in black women compared to the other groups.

CUTANEOUS APPENDAGES
Although  the  amount  of  sweat  is  variable  between  racial 
groups, with more sweat secretion found in black subjects, the 
phenomenon does not derive from differences in gland number 
but more likely from differences in density of actively sweat-
ing glands (25). Concerning apocrine glands, studies highlight 
that,  compared  to  Caucasians  and  Chinese,  blacks  present 
apocrine  glands  greater  in  number  and  size  (25).  Evaluating 

the  sebum  quantity  present  on  skin  surface,  measured  on 
the  forehead using Sebumeter1, Fotoh et al. (12) showed sim-
ilar  results  in  all  groups  in  contrast  to  previous  studies  that 
reported significantly higher level of sebum secretion in black 
people in comparison with white subjects.

SKIN DISEASE AND COSMETIC PROBLEMS
Irritation and Stinging
Dark skin is generally believed to be more resistant to  irritation 
(26–28).  These  differences  seem  to  be  modulated  by  stratum 
corneum,  since  its  removal  by  stripping  induces  similar 
responses  in  different  ethnic  groups.  Stinging  may  occur  in 
the nasolabial folds and on cheeks after an irritant (i.e. lactic 
acid)  is  applied.  Frosch  and  Kligman  reported  that  the  most 
“stingers”  were  light-complexioned  persons  of  Celtic  ances-
try who sunburned easily and tanned poorly (29). Later, how-
ever,  Grove  et  al.  found  no  skin  type  propensity  to  stinging; 
they applied 10% lactic acid to the nasolabial folds and cheek 
of  volunteers  and  noted  that  increased  stinging  was  related 
mainly to the person’s history of sensitivity to soaps,  cosmetics, 
and  drugs  (30).  Jourdain  et  al.  (31)  have  performed  an  epide-
miological  survey  aimed  to  assess  ethnic  variations  in  self-
perceived  sensitive  skin.  They  included  four  ethnic  groups: 
Afro-Americans,  Euro-Americans,  Hispanics,  and  Asians. 
Fifty-two  percent  of  the  women  declared  to  have  sensitive 
facial  skin  but  the  prevalence  of  self-reported  sensitive  skin 
was alike in all ethnicities. Among the sensitive skin subpop-
ulation,  some  slight  differences  between  ethnic  groups  have 
been noted concerning the cause of irritation or sensitization. 
Euro-Americans  showed  higher  reactivity  to  environmental 
stimuli such as cold and wind, and less reactivity to cosmet-
ics,  whereas  Afro-Americans  reacted  less  to  environmental 
factors  and  Asians  tended  to  react  to  wind,  spices,  and  alco-
hol. Kaidbey and Kligman studied race-dependent cutaneous 
reactivity  to  topical  coal  (32).  There  was  a  strikingly  differ-
ent  response  in  the  two  groups:  in  whites,  the  response  was 
primarily  inflammatory,  with  development  of  papules  and 
papulopustules  in  about  2  or  3  weeks,  whereas  in  blacks  the 
inflammatory  response  was  largely  absent  and,  after  about 
14 days, an eruption of small open comedones appeared. The 
follicles  of  white  subjects  responded  early,  with  rupture  of 
the  wall  and  outpouring  of  follicular  contents  in  the  dermis, 
whereas  in  blacks,  the  first  response  was  proliferative  with 
production and retention of horny cells. That is, in blacks, the 
skin reacts to a comedogenic compound with hyperkeratoses 
rather than with disintegration of follicles, suggesting a greater 
resistance to irritants. Conflicting findings have been reported 
on  the  incidence  of  allergic  contact  dermatitis  in  blacks. 
Kenney  reported  a  decreased  rate  (5%  in  black  patients)  (33). 
Marshall  and  Heyl  reported  that  the  incidence  of  industrial 
contact dermatitis in South Africa is less in darkly pigmented 
blacks (34). Dogliotti showed a 7.4% prevalence among Bantus 
(35).  Scott  noted  that  contact  dermatitis  was  less  frequent  in 
Bantus  handling  detergents,  waxes,  and  fuels  (36).  Despite  a 
previous  report  describing  an  increased  sensitization  rate  in 
whites, Kligman and Epstein found no significant difference in 
the two races after testing many topical materials (37). Fisher 
reported an approximately equal incidence of contact derma-
titis in blacks and whites (38). Paraphenylenediamine, nickel, 
and potassium dichromate appeared to be the most common 
allergens. In Nigeria, nickel was the most frequent sensitizer, 
with an incidence of 12.3% (39) compared with 11% in North 
America. In Lagos, the female-male ratio is 1:1, whereas Fregert 

ETHNIC COSMETICS 

 385

et al. recorded a ratio of 6:1 (40). In North America, the ratio is 
3:1 and in Stockholm it is 7:3. Clinically, acute contact dermati-
tis with exudation, vesiculation, or bullae is more common in 
whites, whereas blacks more commonly develop disorders of 
pigmentation and lichenification. Hypopigmentation has been 
described  from  contact  with  phenolic  detergents  (41),  alkyl 
phenols, and monobenzylether of hydroquinone (42).

Acne
Acne  vulgaris  is  believed  to  be  one  of  the  most  frequent 
dermatologic disorders in ethnic patients. Although the acne 
pathophysiology  is  the  same  in  all  ethnicities,  the  most  dra-
matic  difference  between  black  and  white  skin  is  the  higher 
incidence  of  post-inflammatory  hyperpigmentation  (PIH) 
and  keloidal  scarring  as  a  result  of  inflammatory  reaction. 
Hyperpigmentation  occurs  as  darkly  pigmented  spots  or 
macules  that  may  persist  for  months  or  years  after  the  reso-
lution  of  acne  lesions  (43).  Therefore,  because  of  the  elevated 
risk  of  important  acne  sequelae  that  influence  quality  of  life, 
clinicians may have recourse to more aggressive therapies to 
treat acne in ethnic skin and thereby limit its negative conse-
quences. The high rate of PIH has been confirmed in a recent 
study including black, Hispanic, and Asian patients (44). PIH 
can derive from both acne lesions such as inflammatory papule 
or pustules or comedones and skin irritation due to topical or 
systemic therapy. Keloidal scarring is also considered more fre-
quent in ethnic skin than in white patients, with an incidence 
that can be between 5 and 16 times higher (45). Furthermore, in 
treating acne in ethic skin, dermatologists must always assess 
the cosmetic habits and the use of some over-the-counter (OTC) 
products. In particular, almost half of acne African American 
patients regularly apply greasy hair moisturizers. This custom 
leads  to  a  special  form  of  acne,  the  so-called  “pomade-acne” 
(46).  This  eruption,  consisting  mainly  of  comedones  on  the 
forehead and temporal area, seems to be a peculiar response 
of  black  skin  to  topical  agents,  because  this  reaction  can  be 
detected in black children from 1 to 12 years of age (47). Plewig 
et  al.  examined  735  blacks  and  found  that  70%  of  long-term 
users of pomades had a form of acne (48). The more elaborate 
formulations induced pomade acne more frequently and more 
intensively than simpler preparations such as mineral oil and 
petroleum  jelly.  The  distribution  of  the  lesions  corresponded 
to the area of contact. Comparable data for whites are lacking. 
According to the previously outlined problems, acne treatment 
in  dark  skin  requires  a  delicate  balance  between  aggressive 
and nonirritating therapy. Topical retinoids are considered the 
first choice therapy as they act either on the acne itself or on 
PIH (49,50). To reduce their irritating side effect, it is advisable 
to start with a low concentration or with alternate-day dosing 
and choose a cream rather than a gel formulation. Among reti-
noids, adapalene 1% cream or gel has been reported to be effec-
tive  and  well tolerated even  in patients  with dry or sensitive 
skin (51). Once-daily tazarotene 0.1% cream has also shown to 
improve acne and PIH in blacks (52). Concerning nonretinoid 
acne topical, azelaic acid is often prescribed because of its low 
potential of irritation and bleaching effect (53,54). Severe forms 
of acne require early employing of systemic isotretinoin (55). 
Skin dryness is the most common side effect of the treatment 
and  may  itself  result  in  PIH  but  can  easily  be  corrected  by 
 regular application of emollients.

Post-Inflammatory Hyperpigmentation
When  acne  is  under  control,  therapy  can  be  focused  on  PIH. 
Hydroquinone remains the gold standard for PIH treatment. 

 
386 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Its effectiveness is related to its concentration and the stability 
of  the  preparation  (56).  The  OTC  products  available,  usually 
already used by ethnic patients at time of presentation, contain 
1%  to  2%  hydroquinone  but  are  often  inefficacious.  In  clini-
cians’  prescriptions,  the  concentration  varies  from  3%  to  5%, 
compounded  in  cold  cream  or  hydroalcoholic  base.  It  is  nor-
mally applied once daily and results are appreciable after 4 to 
8 weeks of therapy, and optimal effects are observed after 6 to 
10 weeks of therapy. Hydroquinone is usually combined with 
other  proximate  principles,  exploiting  the  synergistic  action 
of each compound. Hydroquinone 5% with tretinoin 0.1% and 
dexamethasone  0.1%,  known  as  the  Kligman  formulation, 
represents  the  most  famous  association.  As  long-term  use  of 
this  preparation  may  determine  skin  atrophy,  telangiectasia, 
erythema, rosacea-like acneiform eruptions, increased growth 
of  vellus  hair,  and  perioral  dermatitis,  FDA  has  approved  a 
modified  combination  of  the  Kligman  formulation,  contain-
ing  hydroquinone  4%,  tretinoin  0.05%,  and  fluocinolone  ace-
tonide 0.01%. This association has proved its efficacy without 
significant  side  effects  in  a  multicentric  safety  study  (57). 
Irritation is the most common acute complication, but hydro-
quinone  may  also  induce  infrequent  allergic  reactions,  PIHs, 
and  transient  hypochromia.  Chronic  adverse  events  consist 
of leukomelanoderma en confetti, exogenous ochronosis, and 
nail discoloration; these are usually related to prolonged use of 
formulations containing high concentrations of hydroquinone 
(56). Beside OTC bleaching products, ethnic people still employ 
traditional  drugs,  transferred  from  generation  to  generation. 
An interesting recent screening of some of these compounds, 
used  by  Nepalese  people  to  treat  acquired  pigmentation  dis-
orders, has been performed by Adhikari et al. (58). They have 
found 53 crude drugs—52 were plant extract, and one derived 
from  a  shell  called  Cypraea  moneta.  All  the  products  tested 
for  the  tyrosinase  inhibitory  activity  showed  some  efficacy. 
Extracts of roots of Glycyrrhiza glabra, leaves of Morus alba, 
flowering  bud  of  Syzygium  aromaticum,  fresh  peel  of  Citrus 
aurantifolia,  shell  of  C.  moneta,  seed  of  Punica  granatum, 
and  fresh  peel  of  Citrus  aurantium  demonstrated  the  higher 
 activity, some with more than 50% inhibition.

Exogenous Ochronosis
Exogenous  ochronosis  is  a  bluish-black  pigmentation  of 
 connective tissue in the area treated with hydroquinone. The 
pathogenesis  is  unknown,  but  it  has  been  supposed  that  it 
derives  from  the  accumulation  and  polymerization  of  homo-
gentisic acid (HGA) resulting from the inhibition of its oxidase 
by hydroquinone. In particular, pigmentation may be induced 
by the binding of HGA to fibrillar collagen. Exogenous ochro-
nosis can occur in pigmented skin as a consequence of the use 
of  some  topical  compounds  such  as  pycric  acid,  phenol,  res-
orcinol, and hydroquinone. Usually, when induced by hydro-
quinone (which is a phenolic compound similar to HGA), the 
discoloration appears within few months of application (59). In 
the U.S. population, the condition has been described to appear 
in pigmented skin (blacks and Hispanics) after use of topical 
hydroquinone at concentrations of 2% or higher for months or 
years and who have failed to observe sun protection. In these 
subjects, hydroquinone was applied continuously as a bleach-
ing agent to treat dark pigmentation or dark skin discoloration 
such  as  melasma  or  post-inflammatory  pigmentation  (60). 
Nevertheless,  exogenous  ochronosis  is  not  so  frequent  in  the 
United  States  as  in  some  African  populations  and  countries. 
This  appears  to  be  due  to  the  high  concentrations  of  hydro-
quinone available in skin-lightening products prior to 1984 in 

South Africa (average 6% to 8%) (61). Other compounds capable 
of  inducing  irreversible  depigmentation,  such  as  tert-butyl 
alcohol  and  mercury,  were  included  in  skin  care  products  in 
South  Africa  up  to  1986.  Resorcinol,  used  in  some  African 
countries in cosmetic products for acne, has been also related 
to the onset of exogenous ochronosis. Hydroquinone and res-
orcinol  are  also  used  simultaneously  to  achieve  faster  depig-
mentation (61). Furthermore, alcoholic lotions and vehicle used 
in lightening and acne products can increase the percutaneous 
absortpion of hydroquinone (62). From a clinical point of view 
exogenous ochronosis can classified in three stages (63):

•  Stage  I  involves  erythema  and  mild  pigmentation  of  the 

face and the neck.

•  Stage  II  is  characterized  by  appearance  of  papules  and 

mottled pigmentation.

•  Stage III includes papulo-nodules and inflammation.

While low concentrations of hydroquinone inhibit tyrosinase, 
higher ones can increase melanin synthesis apparently as con-
sequence  of  tyrosinase  stimulation  (64).  Melanocytes  can  be 
involved in the process of ochronosis since it does not appear 
in  areas  affected  by  vitiligo.  The  role  of  sun  exposure  is  still 
debated as well (65). Indeed, the condition is often limited to 
sun-exposed  areas.  The  treatment  of  exogenous  ochronosis 
is difficult. Generally, it tends to resolve slowly after stopping 
the  drug.  Avoidance  of  exposure  to  the  causative  agent  may 
improve the condition; chemical peels, cryotherapy, and reti-
noic acid have been used with poor results.

SUN PROTECTION
As  mentioned  previously,  different  skin  colors  are  due  to 
the  adaptation  to  different  intensities  of  sun  irradiation  that 
changes with latitude. In the late 1970s, Kaidbey et al. (66) dem-
onstrated that 5.7% of UVB are transmitted into the dermis in 
blacks  as  opposed  to  the  29.4%  in  whites.  In  blacks,  17.5%  of 
UVA reaches the upper dermis whereas in whites 55.5% pen-
etrates. Antoniou et al. (67) have investigated the optical trans-
mission properties of different skin types, demonstrating that, 
as expected, skin of color is naturally better protected against 
damage caused by UVA and also against visible and red range 
of the spectra. They conclude that, because of the different rela-
tion between UVA and UVB protection among skin types, spe-
cific sunscreens should be developed.

CHEMICAL PEELING
As  underlined  by  Roberts  (68),  chemical  peeling  was  first 
employed  precisely  by  people  of  color.  Cleopatra's  habit 
to  bathe  in  sour  milk  can  be  correctly  considered  an  early 
employment of α-hydroxy acids as an exfoliating agent. In eth-
nic patients, chemical peeling is useful especially for the man-
agement of pigmentary disorders such as PIH, solar lentigines, 
mottled  dyschromia,  and  melasma.  Acne  vulgaris,  scarring, 
and pseudofolliculitis barbae represent other significant indi-
cations (68).

Acne
Among  α-hydroxy  acids,  glycolic  acid  is  the  one  most 
frequently  used.  Its  application  on  the  skin  induces  epider-
molysis in a few minutes. Concentration and vehicle are both 
important to modulate peeling intensity as well as the amount 
of acid delivered and the method of application. To reduce side 
effects,  partially  buffered  glycolic  acid  is  recommended  (69). 

 
Concentration  varies  from  30%  to  70%.  It  has  shown  to  be 
effective and safe for the treatment of acne in ethnic skin (70). 
Chemical peeling with a 20% to 30% liquid salicylic acid solu-
tion improves acne with a good safety profile (71).

PIH
PIH may benefit from glycolic or salicylic acid peeling. Trichloro 
acetic acid (TCA) 25% and Jessner’s solution have been used suc-
cessfully.  A  full  face  peeling  or  alternatively  a  “spot  peel”  can 
be  performed.  Spot  peel  is  recommended  using  TCA  25%  and 
Jessner’s solution. Improvement is perceptible after three to six 
peeling  sessions.  Patients  should  always  have  been  pretreated 
with topical skin-lightening agents prior to peeling, and topical 
therapy should be continued for about 4 to 8 weeks (68).

Melasma
Melasma is a common complaint of patients with skin of color, 
especially  Asians,  fair-complected  African  Americans,  and 
Hispanic  women.  Once  possible  causative  factors  have  been 
screened,  sunscreens,  topical  hydroquinone,  and  chemical 
peels remain the treatments of choice. Among available chemi-
cal  peels,  glycolic  acid  and  salicylic  acid  represent  a  good 
tool  to  reduce  epidermal  pigmentation  in  melasma  in  ethnic 
skin. Asians and Asian Americans respond better to glycolic 
peels (72) than to salicylic ones whereas the opposite occurs in 
blacks. Pre- and posttreatment with topical bleaching agents is 
advisable as well as daily UV protection.

Acne Scarring
Nonhypertrophic acne scarring may be improved with a series 
of  combined  peels  with  70%  glycolic  acid  gel  and  25%  TCA. 
Seventy  percent  glycolic  gel  is  first  applied  followed  by  25% 
TCA; at the beginning of the frosting, the peel is neutralized 
with a sodium bicarbonate solution (68).

Pseudofolliculitis Barbae
Excellent  results  are  obtained  treating  pesudofolliculitis  bar-
bae with series of glycolic or salicylic peels (68).

Solar Lentigines and Mottled Pigmentation
As in fair complexions, solar lentigines and mottled pigmenta-
tion are a manifestation of aging. Spot peel with a 25% TCA, 
applied until a white frost is achieved, represents a good ther-
apeutic  option  for  solar  lentigines  in  ethnic  skin.  Mottling  is 
improved by series of 50% to 70% glycolic acid peels or by 20% 
to 30% salicylic acid peels (68).

SKIN AGING AND REJUVENATION
Skin Aging
Thanks  to  progress  in  in  vivo  imaging  modalities  such  as 
ultrasound  (US)  and  optical  coherence  tomography  (OCT), 
differences  between  ethnicities  concerning  skin  structure 
have  been  recently  better  investigated.  With  a  25  MHz  US 
imaging  system,  it  is  possible  to  measure  skin  thickness 
and  the  subepidermal  nonechogenic  band  (SENEB)  that 
depends  on  skin  aging.  On  the  other  side,  OCT  imaging 
supplies  a  description  of  epidermis  morphology.  Querleux 
et  al.  (73)  have  reported  interesting  data.  On  the  basis  of 
OCT measurements, their study has demonstrated that epi-
dermis  thickness,  taken  at  the  top  of  the  papillae,  does  not 
change  with  age  in  all  ethnic  groups,  whereas  dermo  epi-
dermal junction (DEJ) is influenced by the aging process and 

ETHNIC COSMETICS 

 387

flattens. This phenomenon concerning the DEJ is accentuated 
in  Caucasians  compared  to  blacks.  It  is  therefore  deducible 
that blacks show signs of aging later than whites. This data 
is confirmed by the measurement of SENEB by means of US 
imaging at 25 MHz; SENEB is  thinner in African Americans 
than  in  Caucasians.  In  blacks,  photoaging  appears  unusu-
ally  before  the  sixth  decade.  Mottled  pigmentation,  fine 
wrinkling,  laxity,  and  dermatosis  papulosa  nigra  represent 
the  most  common  manifestations  of  photoaging  in  African 
Americans (74). In Asians, due to their geographic position, 
photoaging is frequent, especially in East Asians whose skin 
color is quite light. Features of photoaging in East Asians are 
mainly seborrheic keratosis and wrinkling (74).

Nonablative Photorejuvenation
As  ablative  resurfacing  implies  high  risk  of  serious  and  pro-
longed side effects in ethnic skin, such as PIH, scarring, and 
postinflammatory  hypopigmentation,  the  choice  of  nonabla-
tive devices is advisable (75). Wherever using visible and near-
infrared lasers or light devices, efficient cooling is fundamental 
to avoid thermal injury. 532 nm has been used for rejuvenation 
in ethnic skin with improvement of erythema, texture, pigmen-
tation, and wrinkling (76,77). Low incidences of hyperpigmen-
tation  and  hypopigmentation  have  been  reported.  Successful 
rejuvenation, without side effects, has been obtained by Trelles 
et  al.  (78)  using  a  combination  of  595  and  1450  nm  lasers. 
Different authors have described the use of IPL in ethnic skin. 
Excellent results have been achieved employing a 550 nm cut-
off filter (79,80) or a 640 nm cutoff filter. Recently, perioral and 
periocular rhytids as well as neck and forehead rhytids have 
been treated with a 1540 nm erbium:glass laser in patients with 
type IV skin. Clinical improvement was also confirmed by US 
imaging  and  digital  profilometry;  the  procedure  has  demon-
strated  an  excellent  safety  profile  (81).  Light-emitting  diodes 
(LEDs),  fractional  photothermolysis,  and  radiofrequency  rep-
resent  new  nonablative  devices  for  rejuvenation.  LED  light 
therapy  has  been  approved  by  FDA.  It  has  been  established 
that  specific  wavelengths  of  visible  red  and  infrared  light 
emitted by LEDs stimulate fibroblastic activity and the release 
of  adenosine  triphosphate  (ATP),  boost  collagen  production, 
diminish hyperpigmentation, induce formation of new capil-
laries, and increase lymphatic system activity. In skin type IV, 
clinical results have been excellent, and there were no reported 
adverse effects (82,83). Fractional phothermolysis is delivered 
by a nonablative erbium:glass laser (1500 nm) and consists in 
microscopic  columns  of  thermal  damage  (84).  It  is  an  FDA-
approved  device  for  treating  pigmented  lesions,  periorbital 
rhytides,  skin  resurfacing,  and  melasma.  As  epidermidis  is 
protected from injury and melanin is not a target of this type 
of  laser,  fractional  photothermolysis  possesses  suitable  fea-
tures  to  be  used  in  skin  of  color.  Indeed,  the  procedure  has 
been  described  as  safe  and  effective  for  treating  photoaging 
as well as acne scarring in ethnic patients (85). Together with 
photoaging, skin laxity is an important sign of advanced age 
and is common in all skin types. The demand for an effective 
treatment  for  skin  laxity  is  increasing.  Patients  with  skin  of 
color seek nonsurgical procedures because of their proneness 
of scarring. Radio frequency (RF) is electromagnetic radiation 
in the frequency range of 3 kHz to 300 GHz. It works by selec-
tively delivering heat energy to the dermis, thus inducing col-
lagen remodeling and contraction. In their study performed on 
Asian patients, Kushikata et al. (86) concluded that RF repre-
sents  an  effective  and  safe  tool  to  achieve  skin  tightening  in 
skin of color.

 
388 

 TEXTBOOK OF COSMETIC DERMATOLOGY

REFERENCES

1.  Berardesca E, Maibach H. Racial differences in skin pathophys-

iology. J Am Acad Dermatol 1996; 34:667–72.

2.  Parvez S, Kang M, Chung HS, et al. Survey and mechanism of 
skin  depigmenting  and  lightening  agents  (review).  Phytother 
Res 2006; 20(11):921–34.

3.  Antoniou C, Lademan J, Richter H, et al. Analysis of the mela-
nin  distribution  in  different  ethnic  groups  by  in  vivo  laser 
scanning microscopy. Laser Phys Lett 2009; 6(5):393–8.

4.  Rawlings AV. Ethnic skin types: Are there differences in skin 

structure and function? Int J Cosmet Sci 2006; 28(2):79–93.

5.  Freeman  RG,  Cockerell  EG,  Armstrong  J,  et  al.  Sunlight  as  a 
factor influencing the thickness of epidermis. J Invest Dermatol 
1962; 39:295–7.

6.  Thomson  ML.  Relative  efficiency  of  pigment  and  horny  layer 
thickness  in  protecting  the  skin  of  European  and  Africans 
against solar ultraviolet radiation. J Physiol (Lond) 1955; 127:236.
7.  Weigand DA, Haygood C, Gaylor JR. Cell layers and density of 
Negro and Caucasians stratum corneum. J Invest Dermatol 1974; 
62:563–5.

8.  Rienertson RP, Wheatley VR. Studies on the chemical composi-
tion of human epidermal lipids. J Invest Dermatol 1959; 32:49–51.
9.  Johnson  LC,  Corah  NL.  Racial  differences  in  skin  resistance. 

Science 1963; 139:766–9.

  10.  Corcuff P, Lotte C, Rougier A, et al. Racial differences in corneo-
cytes.  A  comparison  between  black,  white  and  oriental  skin. 
Acta Derm Venereol 1991; 71:146–8.

  11.  Warrier AG, Kligman AM, Harper RA, et al. A comparison of 
black and white skin using non invasive methods. J Soc Cosmet 
Chem 1996; 47:229–40.

  12.  Fotoh C, Elkhyat A, Mac S, et al. Cutaneous differences between 
Black, African or Caribbean Mixed-race and Caucasian women: 
Biometrological  approach  of  the  hydrolipidic  film.  Skin  Res 
Technol 2008; 14(3):327–35.

  13.  Sugino K, Imokawa G, Maibach H. Ethnic difference of stratum 
corneum lipid in relation to stratum corneum function. J Invest 
Dermatol 1993; 100:597.

  14.  Kompaore  F,  Marty  JP,  Dupont  Ch.  In  vivo  evaluation  of  the 
stratum  corneum  barrier  function  in  Blacks,  Caucasians  and 
Asians  with  two  noninvasive  methods.  Skin  Pharmacol  1993; 
6:200–7.

  15.  Wilson  D,  Berardesca  E,  Maibach  HI.  In  vitro  transepidermal 
water loss: Differences between Black and white human skin. 
Br J Dermatol 1988; 199:647–52.

  16.  Berardesca E, Maibach HI. Racial differences in sodium lauryl 
sulphate induced cutaneous irritation: Black and white. Contact 
Dermatitis 1988; 18:136–40.

  17.  Yosipovitch  G,  Theng  CTS.  Asian  skin:  Its  architecture,  func-
tion, and differences from caucasian skin. Cosmet Toiletr 2002; 
117(9):57–62.

  18.  Reed  JT,  Ghadially  R,  Elias  PM.  Effect  of  race,  gender  and 
skin type on epidermal permeability barrier function. J Invest 
Dermatol 1994; 102:537.

  19.  Berardesca  E,  de  Rigal  J,  Leveque  JL,  et  al.  In  vivo  biophysi-
cal  characterization  of  skin  physiological  differences  in  races. 
Dermatologica 1991; 182:89–93.

  20.  Baker  H.  The  skin  as  a  barrier.  In:  Rook  A,  ed.  Textbook  of 

Dermatology. Oxford: Blackwell Scientific, 1986; p. 355.

  21.  Reed  JT,  Ghadially  R,  Elias  PM.  Skin  type,  but  neither  race 
nor  gender,  influence  epidermal  permeability  function.  Arch 
Dermatol 1995; 131(10):1134–8.

  22.  Berardesca  E,  Pirot  F,  Singh  M,  et  al.  Differences  in  stratum 
 corneum  pH  gradient  when  comparing  white  Caucasian  and 
Black African-American skin. Br J Dermatol 1998; 139:855–7.
  23.  Berardesca  E,  Maibach  HI.  Sodium  lauryl  sulphate  induced 
cutaneous  irritation.  Comparison  of  white  and  Hispanic 
 subjects. Contact Dermatitis 1988; 19:136–40.

  24.  Rietschel RL. A method to evaluate skin moisturizers in vivo. 

J Invest Dermatol 1978; 70:152–5.

  25.  Quinton  PM,  Elder  HY,  Jenkinson  DME,  et  al.  Structure  and 
function of human sweat glands In: Laden K, ed. Antiperspirants 
and Deodorants. New York: Marcel Dekker, 1999; pp. 17–58.
  26.  Marshall  EK,  Lynch  V,  Smith  HV.  Variation  in  susceptibility 
of  the  skin  to  dichloroethylsulfide.  J  Pharmacol  Exp  Ther  1919; 
12:291–301.

  27.  Weigand  DA,  Mershon  GE.  The  cutaneous  irritant  reaction  to 
agent O-chlorobenzylidene malonitrile (CS). Quantitation and 
racial  influence  in  human  subjects.  February  1970  Edgewood 
Arsenal Technical Report 4332.

  28.  Weigand  DA,  Gaylor  JR.  Irritant  reaction  in  Negro  and 

Caucasian skin. South Med J 1974; 67:548–51.

  29.  Frosh  P,  Kligman  AM.  A  method  for  appraising  the  stinging 
capacity of topically applied substances. J Soc Cosmet Chem 1981; 
28:197.

  30.  Grove GL, Soschin DM, Kligman AM. Adverse subjective reac-
tions  to  topical  agents.  In:  Drill  VA,  Lazar  P,  eds.  Cutaneous 
Toxicology. New York: Raven Press, 1984.

  31.  Jourdain  R,  de  Lacharrière  O,  Bastien  P,  et  al.  Ethnic  varia-
tions  in  self-perceived  sensitive  skin:  Epidemiological  survey. 
Contact Dermatitis 2002; 46(3):162–9.

  32.  Kaidbey KH, Kligman AM. A human model for coal tar acne. 

Arch Dermatol 1974; 109:212–5.

  33.  Kenney J. Dermatoses seen in American Negroes. Int J Dermatol 

1970; 9:110–3.

  34.  Marshall J, Heyl T. Skin diseases in the Western Cape Province. 

S Afr Med J 1963; 37:1308.

  35.  Dogliotti M. Skin disorders in the Bantu: A survey of 2000 cases 

from Baragwanath Hospital. S Afr Med J 1970; 44:670.

  36.  Scott F. Skin diseases in the South African Bantu. In: Marshall 
J,  ed.  Essays  on  Tropical  Dermatology.  Amsterdam:  Excerpta 
Medica, 1972.

  37.  Kligman  AM,  Epstein  W.  Updating  the  maximization  test  for 
identifying contact allergens. Contact Dermatitis 1975; 1:231.
  38.  Fisher  AA.  Contact  Dermatitis  in  black  patients.  Cutis  1977; 

20:303–20.

  39.  Olumide YM. Contact dermatitis in Nigeria. Contact Dermatitis 

1985; 12:241–6.

  40.  Fregert S, Hjorth N, Magnusson B, et al. Epidemiology of con-

tact dermatitis. Trans St John’s Hosp Dermatol Soc 1969; 55:17.
  41.  Fisher AA. Vitiligo due to contactants. Cutis 1976; 17:431–7.
  42.  Kahn G. Depigmentation caused by phenolic detergent germi-

cides. Arch Dermatol 1970; 102:177–87.

  43.  Taylor  S.  Cosmetic  problems  in  skin  of  color.  Skin  Pharmacol 

Appl Skin Physiol 1999; 12:139–43.

  44.  Taylor  SC,  Cook-Bolden  F,  Rahman  Z,  et  al.  Acne  vulgaris  in 
skin  of  color  (review).  J  Am  Acad  Dermatol  2002;  46(2  suppl 
understanding):S98–106.

  45.  Kelly AP. Keloids: Pathogenesis and treatment. Cosmet Dermatol 

2003; 16:28–32.

  46.  Kligman  AM,  Mills  OH.  Acne  cosmetic.  Arch  Dermatol 

1972:106:843–50.

  47.  Verhagen  AR.  Pomade  acne  in  black  patients.  Arch  Dermatol 

1974; 110:465.

  48.  Plewig G, Fulton JE, Kligman AM. Pomade acne. Arch Dermatol 

1970; 101:580.

  49.  Halder  RM.  The  role  of  retinoids  in  the  management  of  cuta-
neous  conditions  in  blacks  (review).  J  Am  Acad  Dermatol  1998; 
39(2 pt 3):S98–103.

  50.  Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe 
and effective in the treatment of acne vulgaris: A multicenter, 
double-blind, vehicle-controlled study. Cutis 1999; 63(6):349–54.
  51.  Czernielewski  J,  Poncet  M,  Mizzi  F.  Efficacy  and  cutaneous 
safety of adapalene in black patients versus white patients with 
acne vulgaris. Cutis 2002; 70(4):243–8.

 
 
 
 
 
 
 
 
 
 
ETHNIC COSMETICS 

 389

  52.  Grimes  PE,  Callender  VD.  Tazarotene  cream  0,1%  in  the 
treatment  of  facial  post-inflammatory  hyperpigmentation 
associated with acne vulgaris: A two-center, double-blind, ran-
domized, vehicle controlled study. Poster presented at the 61st 
Annual Meeting of the American Academy Dermatology, San 
Francisco, CA, March 2003; 21–6.

  53.  Perez A, Sanchez JL. Treatment of acne vulgaris in skin of color. 

Cosmet Dermatol 2003; 16:23–8.

  54.  Nguyen  QH,  Bui  TP.  Azelaic  acid:  Pharmacokinetic  and 
 pharmacodynamic  properties  and  its  therapeutic  role  in 
 hyperpigmentary  disorders  and  acne  (review).  Int  J  Dermatol 
1995; 34(2):75–84.

  55.  Kelly AP, Sampson DD. Recalcitrant nodulocystic acne in black 
Americans: Treatment with isotretinoin. J Natl Med Assoc 1987; 
79(12):1266–70.

  56.  Picardo  M,  Carrera  M.  New  and  experimental  treatments  of 
cloasma  and  other  hypermelanoses  (review).  Dermatol  Clin 
2007; 25(3):353–62, ix.

  57.  Torok H, Taylor S, Baumann L, et al. A large 12-month extension 
study of an 8-week trial to evaluate the safety and efficacy of 
triple combination (TC) cream in melasma patients previously 
treated  with  TC  cream  or  one  of  its  dyads.  J  Drugs  Dermatol 
2005; 4(5):592–7.

  58.  Adhikari A, Devkota HP, Takano A, et al. Screening of Nepalese 
crude drugs traditionally used to treat hyperpigmentation: In 
vitro tyrosinase inhibition. Int J Cosmet Sci 2008; 30(5):353–60.

  70.  Wang CM, Huang CL, Hu CT, et al. The effect of glycolic acid 
on  the  treatment  of  acne  in  Asian  skin.  Dermatol  Surg  1997; 
23(1):23–9.

  71.  Grimes  PE.  The  safety  and  efficacy  of  salicylic  acid   chemical 
peels  in  darker  racial-ethnic  groups.  Dermatol  Surg  1999; 
25(1):18–22.

  72.  Javaheri  SM,  Handa  S,  Kaur  I,  et  al.  Safety  and  efficacy  of 
 glycolic acid facial peel in Indian women  with melasma.  Int J 
Dermatol 2001; 40(5):354–7.

  73.  Querleux B, Baldeweck T, Diridollou S, et al. Skin from various 
ethnic origins and aging: An in vivo cross-sectional multimo-
dality imaging study. Skin Res Technol 2009; 15(3):306–13.
  74.  Munavalli GS, Weiss RA, Halder RM. Photoaging and nonab-
lative  photorejuvenation  in  ethnic  skin.  Dermatol  Surg  2005; 
31(9 pt 2):1250–60; discussion 1261.

  75.  Cho  SI,  Kim  YC.  Treatment  of  atrophic  facial  scars  with  com-
bined use of high-energy pulsed CO2 laser and Er:YAG laser: 
A practical guide of the laser techniques for the Er:YAG laser. 
Dermatol Surg 1999; 25(12):959–64.

  76.  Lee  MW.  Combination  532-nm  and  1064-nm 

lasers  for 
 noninvasive skin rejuvenation and toning. Arch Dermatol 2003; 
139(10):1265–76. Erratum in: Arch Dermatol 2004; 140(5):625.
  77.  Rashid T, Hussain I, Haider M, et al. Laser therapy of  freckles 
and  lentigines  with  quasi-continuous,  frequency-doubled, 
Nd:YAG (532 nm) laser in Fitzpatrick skin type IV: A 24-month 
follow-up. J Cosmet Laser Ther 2002; 4(3–4):81–5.

  59.  Levin  CY,  Maibach  H.  Exogenous  ochronosis.  An  update 
on  clinical  features,  causative  agents  and  treatment  options 
(review). Am J Clin Dermatol 2001; 2(4):213–7.

  78.  Trelles  MA,  Allones  I,  Levy  JL,  et  al.  Combined  nonablative 
skin  rejuvenation  with  the  595-  and  1450-nm  lasers.  Dermatol 
Surg 2004; 30(10):1292–8.

  60.  Touart  D,  Sau  P.  Cutaneous  deposition  diseases.  Part  II.  J  Am 

Acad Dermatol 1998; 39:527–44.

  61.  Burke  P,  Maibach  H.  Exogenous  ochronosis:  An  overview. 

J Dermatol Treat 1997; 8:21–6.

  62.  Bucks D, McMaster J, Guy R, et al. Percutaneous absorption of 
hydroquinone  in  humans:  Effect  of  1-dodecylazacycloheptan-
2one  (azone)  and  the  2-ethylhexylester  of  4-( dimethylamino)
benzoic  acid  (Escalol  507).  J  Toxicol  Environ  Health  1988; 
24:279–89.

  63.  Dogliotti  M,  Leibowitz  M.  Granulomatous  ochronosis: 
A  cosmeticinduced  skin  disorder  in  blacks.  S  Afr  Med  J  1979; 
56:757–60.

  64.  Chen  Y,  Chavin  W.  Hydroquinone  activation  and   inhibition 
of  skin  tyrosinase.  In:  Riley  V,  ed.  Proceedings  of  the  9th 
International Pigment Cell Conference. New York: Karger, 1976; 
pp. 105–12.

  65.  O’Donoghue  M,  Lynfield  Y,  Derbes  V.  Ochronosis  due  to 

 hydroquinone. J Am Acad Dermatol 1983; 8:123–5.

  66.  Kaidbey  KH,  Agin  PP,  Sayre  RM,  et  al.  Photoprotection  by 
 melanin—A  comparison  of  black  and  Caucasian  skin.  J  Am 
Acad Dermatol 1979; 1(3):249–60.

  67.  Antoniou C, Lademann J, Schanzer S, et al. Do different  ethnic 
groups  need  different  sun  protection?  Skin  Res  Technol  2009; 
15(3):323–9.

  68.  Roberts  WE.  Chemical  peeling  in  ethnic/dark  skin  (review). 

Dermatol Ther 2004; 17(2):196–205.

  79.  Negishi  K,  Tezuka  Y,  Kushikata  N,  et  al.  Photorejuvenation 
for  Asian  skin  by  intense  pulsed  light.  Dermatol  Surg  2001; 
27(7):627–31; discussion 632.

  80.  Negishi  K,  Wakamatsu  S,  Kushikata  N,  et  al.  Full-face 
 photorejuvenation  of  photodamaged  skin  by  intense  pulsed 
light  with  integrated  contact  cooling:  Initial  experiences  in 
Asian patients. Lasers Surg Med 2002; 30(4):298–305.

  81.  Fournier N, Dahan S, Barneon G, et al. Nonablative  remodeling: 
A  14-month  clinical  ultrasound  imaging  and  profilometric 
evaluation  of  a  1540  nm  Er:Glass  laser.  Dermatol  Surg  2002; 
28(10):926–31.

  82.  Weiss  RA,  Weiss  MA,  Geronemus  RG,  et  al.  A  novel  non- 
thermal  non-ablative  full  panel  LED  photomodulation  device 
for  reversal  of  photoaging:  Digital  microscopic  and  clinical 
results in various skin types. J Drugs Dermatol 2004; 3(6):605–10.
  83.  Weiss  RA,  McDaniel  DH,  Geronemus  RG,  et  al.  Clinical  trial 
of  a  novel  non-thermal  LED  array  for  reversal  of  photoaging: 
Clinical,  histologic,  and  surface  profilometric  results.  Lasers 
Surg Med 2005; 36(2):85–91.

  84.  Manstein  D,  Herron  GS,  Sink  RK,  et  al.  Fractional  photother-
molysis:  A  new  concept  for  cutaneous  remodeling  using 
microscopic  patterns  of  thermal  injury.  Lasers  Surg  Med  2004; 
34(5):426–38.

  85.  Hu  S,  Chen  MC,  Lee  MC,  et  al.  Fractional  resurfacing  for  the 
treatment of atrophic facial acne scars in Asian skin. Dermatol 
Surg 2009; 35(5):826–32 [Epub April 6, 2009].

  69.  Becker  FF,  Langford  FP,  Rubin  MG,  et  al.  A  histological  com-
parison of 50% and 70% glycolic acid peels using solutions with 
various pHs. Dermatol Surg 1996; 22(5):463–5.

  86.  Kushikata  N,  Negishi  K,  Tezuka  Y,  et  al.  Non-ablative  skin 
tightening with radiofrequency in Asian skin. Lasers Surg Med 
2005; 36(2):92–7.

 
42

Ethnic Variation in Hair

Nina Otberg

INTRODUCTION
The diversity of human skin types and its appendages is a result 
of  various  stages  of  evolution,  climate  changes,  and  migra-
tion.  Studying  the  complexity  of  ethnic  variations  in  human 
hair and skin is not only interesting from an anthropological 
point of view but certainly of interest for the  dermatologist as 
well as for the cosmetic and pharmaceutical industry.

Classifying  different  ethnic  groups  is  particularly 
 difficult  because  ancient  or  more  recent  migration  processes 
and  mixes  between  ethnic  groups  or  subgroups  are  usually 
not  taken  into  account.  Many  studies  have  broadly  distin-
guished  three  ethnic  human  subgroups:  African,  Asian,  and 
Caucasian. Such a broad classification cannot account for the 
great complexity of human biological diversity, resulting from 
multiple past or recent mixed origins.

The  term  African  refers  to  people  who  live  in  Africa 
or  people  who  trace  their  ancestry  to  indigenous  inhabit-
ants  of  Africa.  This  includes  people  who  were  displaced  in 
the  African  diaspora  resulting  from  the  Atlantic  Slave  Trade 
such  as  African-Americans,  African-Canadians,  Afro-Latin 
Americans, Afro-Caribbeans, and Black British. The term black 
people is often used as a synonym for people of African  ancestry 
(in  particular  sub-Saharan  Africa).  The  term  Asian  refers 
most  commonly  to  people  of  predominantly  East  Asian  and 
Southeast Asian ancestry. The term Caucasian has been used 
to characterize the general physical type of some or all of the 
indigenous populations of Europe, North Africa and western, 
south and middle Asia (1). The concept of a Caucasian, Asian, 
or African race is highly controversial today. It is rejected by 
many academics and political activists who view any system 
of  categorizing  humanity  based  on  physical  type  as  obsolete 
(1,2). Responses to drugs and cosmetics can vary dramatically 
based on ethnicity. There is a great debate as to whether ethnic 
categorizations as broad as Caucasian, Asian, and African are 
medically valid (3,4).

Nevertheless, since most studies on ethnic hair  diversity 
use this broad and unsatisfactory characterization, this  chapter 
retains the terms Caucasian, Asian, and African.

SCALP HAIR
Scalp hair is probably one of our most distinctive features. It 
represents  health,  beauty,  sexual  attraction,  and  moreover 
it  reflects  our  personality  and  individuality.  Depending  on 
its  structure  and  physical  properties,  scalp  hair  is  subject  to 
limitations that will only permit certain styles without major 
 damage to the hair shaft.

Several  features  of  the  scalp  hair,  such  as  form,  color, 
thickness,  density,  maximal  length,  and  tensile  strength  are 
genetically  determined  and  show  great  variation  between 

different ethnic groups and subgroups. The understanding of 
the diversity of scalp hair and its different response to physical 
and chemical treatments is the prerequisite for a proper devel-
opment and application of hair care and is likewise important 
for  the  dermatologist,  cosmetic  scientist,  product  formulator, 
and hair stylist.

Ethnic Diversity of Human Scalp Hair
Hair Shape and Thickness
The  term  Caucasian  or  Indo-European  comprised  a  vast 
diversity  of  different  ethnic  subgroups  originating  from 
Europe,  North  Africa,  and  western  (as  well  as  south  and 
middle) Asia. Therefore this group shows a tremendous vari-
ability in hair shaft shape and caliber. Luther et al. found that 
Caucasians  had  significantly  larger  terminal  hair  follicles 
than  Asians  and  Africans  (5).  In  general,  Caucasian  hair  has 
a slightly flattened or oval cross-section with a diameter rang-
ing  from  50–90  µm  (6,7).  In  Europeans,  hair  shaft  diameters 
can  range  from  approximately  50–120  µm  (Otberg,  unpub-
lished  data).  Very  fine  hair  with  diameters  less  than  50  µm 
is  most  frequently  seen  in  the  Scandinavian  population  and 
northwestern Europe (6). Straight Caucasian hair is relatively 
untwisted along the shaft, whereas wavy or curly hair shows 
a  higher  degree  of  twisting  proportional  to  the  degree  of 
curling (6,8–11).

Hair  of  people  originating  from  East  Asia  (China, 
Korea,  and  Japan)  is  usually  referred  to  as  Oriental  or  Asian 
hair.  It  generally  shows  the  greatest  diameter,  ranging  from 
100–130  µm  (6)  (Otberg,  unpublished  data).  Asian  hair  shafts 
are straight with no or very few twists along the shaft and with 
a round cross section (8–10).

Hair  from  people  of  sub-Saharan  Africa  is  highly 
 characteristic in shape. African hair is considerably flattened, 
grooved,  and  frequently  varies  in  diameter  along  one  single 
shaft.  It  tends  to  be  highly  twisted,  with  random  reversal  in 
twist direction. Lindelof et al. showed that the hair follicle in 
African  hair  is  spiral  in  shape.  They  found  that  the  shape  of 
the hair shaft conformed to the shape of the follicle in all three 
major  ethnic  hair  types  (Caucasian,  Asian,  and  African)  (12). 
African hair  can  be quite sharply kinked at  the edges and is 
especially  vulnerable  to  damage  at  such  points.  The  hair  of 
people from different African countries shows great variabil-
ity in the degree of curling, with eastern African hair  showing 
the  least  degree  of  curling  (6,13,14).  African  hair  tends  to  be 
more  easily  harmed  by  cosmetic  procedures  than  cylindrical 
hair  and  grooming  usually  requires  more  force,  especially 
when the hair is dry (6,13,15).

Since  the  conventional  classification  of  three  ethnic 
subgroups hardly accounts for the great diversity of human hair 
characteristics, De la Mettrie et al. developed a new approach 

to  classify  hair  based  on  physical  features.  Hair  types  were 
defined according to three different hair shape criteria (curve 
diameter, curl index, and number of waves) without referring 
to  human  ethnicity.  This  method  leads  to  a   classification  of 
hair in eight well-defined categories and may be more appro-
priate and more reliable than conventional  standards in both 
cosmetic sciences and anthropology (16).

Hair Density
The  appearance  of  thick  full  hair  depends  not  only  on  the 
number  of  hairs  but  certainly  on  the  thickness  of  the  hair 
shaft,  on  its  shape  and  color,  and  its  contrast  to  the  skin.  In 
general,  there  is  a  relationship  between  the  number  of  hairs 
(density) and size of the hair shafts (thickness), so that ethnic 
groups with the thickest caliber hair have the lowest density 
(i.e., Asians) and those with fine hair have the highest density 
(i.e., Scandinavians) (17). An average Caucasian brown-haired 
man is believed to have approximately 100,000 hair follicles on 
the scalp, while blondes tend to have 20% more and redheads 
around 20% less hair (18,19).

Surprisingly  few  studies  are  published  on  normal 
scalp hair density. Whiting, Aslani et al., Sperling, Templeton 
et al., and Lee et al. utilized horizontal sections of scalp biop-
sies to determine terminal and vellus hair density as well as 
anagen:telogen  ratio  in  Caucasian,  African-American,  and 
Asian  patients.  Lee  et  al.  showed  the  lowest  hair  counts  in 
Asian  patients  (35  Korean  patients)  with  1.2  terminal  hairs/
mm2 (120/cm2) on average (20). Higher counts, showing 1.5 ter-
minal hairs/mm2 (150/cm2) were found in 22 African-American 
patients (21). Highest hair counts were found in scalp biopsies 
of 22 Caucasian men by Whiting 3.1 hairs/mm2 (310/cm2)(22). 
Aslani  et  al.  counted  2.8  hairs/mm2  (280/cm2,  n = 21)  in  scalp 
biopsies  of  male  volunteers  and  slightly  lower  numbers  in 
women  (2.5  hairs/mm2 = 250/cm2,  n = 9)  (23),  Templeton  et  al. 
found  2.7  terminal  hairs/mm2  (270/cm2)  (24),  and  Sperling 
found  2.5  terminal  hairs/mm2  (250/cm2)  (21)  on  average  in 
Caucasian patients. Whiting and Aslani et al. obtained speci-
mens from control subjects with no evidence of alopecia (22,23), 
whereas Sperling, Templeton et al. and Lee et al. evaluated hair 
density in specimens from clinically normal occipital scalp of 
patients with androgenetic alopecia (20,21,24).

Surprisingly,  great  variations  were  found 

in  the 
terminal:vellus hair ratio (T:V ratio) among the different stud-
ies. Whiting found a T:V ratio of 1.7:1 (22), whereas Sperling, Lee 
et al. and Aslani et al. found much higher values (Caucasian: 
6.0:1  [21],  17.6:1  [23],  Asian:  13.5:1  [20],  African:  6.1:1  [21]). 
Different levels of the horizontal section of the punch biopsy 
may explain these differences. Vellus hair follicles on the scalp 
seem to be much smaller compared to vellus hair follicles on 
the rest of the body. Their infundibulum is located in the very 
upper part of the dermis; therefore vellus hairs can easily be 
missed if the horizontal section is evaluated at a deeper level 
(unpublished data, Otberg).

Noninvasive techniques have also been utilized to deter-
mine scalp hair density. One of the earliest methods of measur-
ing hair density was devised by Bouhanna, who used camera 
attachments to create a “phototrichogram,” an ultra close-up 
photograph of hair exiting the scalp (25). van Neste combined 
the  phototrichogram  with  computer-assisted  image  analy-
sis (26). A further development is the TrichoScan® technique 
introduced  by  Hoffmann,  which  combines  epiluminescence 
microscopy with digital image analysis for the measurement 
of hair density and hair growth parameters (27). Loussouarn 
et  al.  confirmed  the  results  for  African  and  Caucasian  hair 

ETHNIC VARIATION IN HAIR 

 391

density by using the phototrichogram technique. They found 
162  terminal  hairs/cm2  in  the  occipital  area  of  106  male  vol-
unteers of African descent. Hair density was highly variable 
(from 90 to 396 hairs/cm2 and significantly higher on the ver-
tex  than  on  occipital  and  temporal  areas.  Women  showed 
a  slightly  higher  hair  density  in  the  occipital  region  than 
men  (167/cm2  on  average,  n = 110).  Vertex  and  temporal  area 
showed  no  statistically  significant  difference  between  male 
and  female  volunteers;  the  vertex  area  showed  the  highest 
count  (M:188/cm2,  F:199/cm2);  the  temporal  area  showed  the 
lowest  values  (M:128/cm2,  F:121/cm2).  Male  Caucasian  vol-
unteers  (n = 56)  showed  an  average  terminal  hair  density  of 
217 hairs/cm2 in the occipital area, 264/cm2 in the vertex area, 
and  151/cm2  in  the  temporal  area.  Female  Caucasian  volun-
teers  showed  significantly  higher  values  (occipital:  250/cm2, 
vertex: 308/cm2, and temporal: 169/cm2) (28). Much higher val-
ues  compared  to  Lee  et  al.  were  found  in  the  Asian  group. 
Loussouran et al. measured hair densities in 188 Chinese vol-
unteers.  Male  Chinese  volunteers  (n = 92)  showed  179/cm2  in 
the occipital area, 217/cm2 in the vertex area, and 122/cm2 in 
the temporal area, female Chinese volunteers (n = 96) showed 
significantly  higher  values  in  the  occipital  and  vertex  area 
(occipital:  185/cm2,  vertex:  231/cm2)  and  lower  values  in  the 
temporal area: 169/cm2) (28). The finding of Loussourian et al. 
and  Lee  et  al.  indicate  the  diversity  of  hair  characteristics 
among  different  Asian  subgroups.  Furthermore,  the  results 
indicate that sexual difference might have different patterns 
according to the ethnic background (28).

Jiménez  and  Poblet  used  phototrichgrams  to  measure 
follicular  unit  (FU)  density  in  the  occipital  area  in  patients 
undergoing  hair  transplantation.  Follicular  unit  density 
ranged  from  60–100  FU/cm2  with  an  average  hair  density  of 
260  terminal  hairs/cm2.  The  authors  note  that  FU  density  is 
significantly  lower  in  Asian  and  African  patients.  Follicular 
units tend to maintain a certain distance between each other. 
This distance correlates with the FU density according to a for-
mula described by Jiménez and Ruiferandez L = 10/√n, where 
L  represents  the  average  distance  between  FUs  expressed  in 
millimeters and n the number of FUs/cm2 (29,30).

Rassman et al. used a small handheld magnifier called 
a desitometer to determine hair density and follicular group-
ings in patients seeking hair restoration surgery. They found 
that  the  average  hair  density  and  the  average  follicular  unit 
density  vary  significantly  among  different  ethnic  groups. 
African-American  patients  showed  and  average  hair  density 
of  1.6  terminal  hairs/mm2  (160/cm2)  in  contrast  to  Caucasian 
patients,  showing  2.0  hairs/mm2  (200/cm2).  In  patients  of 
African  descent  FU  groupings  were  predominantly  found  to 
be in 3s, in Caucasian in 2s and 3s, opposed to Asian patients 
showing FUs with only 1–2 hairs (17).

A more modern noninvasive technique to measure scalp 
hair  density  is  videodermoscopy  (31–33).  Videodermoscopy 
allows  evaluating  the  scalp  in  20-  to  100-fold  magnification. 
Hair  and  scalp  disorders  can  be  easily  diagnosed,  and  when 
combined with digital image analysis it allows measurement 
of hair density and thickness of the hair shaft without shaving, 
clipping, or dyeing.

Hair Growth
Whiting, Aslani et al. and Sperling and Lee et al. found a very 
similar  percentage  of  terminal  anagen  and  telogen  hairs  of 
approximately 94:6 in all three major ethnic groups (Caucasian, 
Asian, African) (20–23). Lee et al. state that this ratio could be 
uniformly  applied  as  a  normal  value  in  interpreting  scalp 

 
392 

 TEXTBOOK OF COSMETIC DERMATOLOGY

biopsy specimens regardless of the ethnic background of the 
patients  (20–23).  Loussouran  used  the  phototrichogram  tech-
nique  to  measure  hair  growth  parameters  in  Caucasian  and 
African men and women (28). Increased telogen counts com-
pared  to  the  data  obtained  from  scalp  biopsies  were  found 
in both the African and Caucasian groups. The percentage of 
telogen hair in the vertex area was found to be 17% in African 
volunteers  and  16%  in  Caucasian  group;  the  occipital  area 
showed 19% of telogen hairs (African) versus 11% (Caucasian). 
Growth  rates  were  highly  variable  in  both  groups,  with  a 
higher  variability and overall lower growth rates in the African 
group. On average, growth rates of 260 µm/day (African) ver-
sus 397 µm/day (Caucasian) were found for the vertex area and 
252  µm/day  (African)  versus  402  µm/day  (Caucasian)  for  the 
occipital area (28).

Hair Color
Hair  color  is  determined  mainly  by  melanin  pigmentation 
within  keratinocytes  of  the  hair  fiber.  Melanin  is  a  complex 
quinone/indole-quinone–derived  mixture  of  biopolymers 
produced  in  melanocytes  from  tyrosine  (34).  Melanocytes 
are   dendritic  neural  crest-derived  cells  that  migrate  into  the 
 epidermis in the first trimester. Hair and epidermal pigmen-
tation  are,  insofar  as  melanocytes  are  concerned,  similar 
 processes:  in  interfollicular  skin,  melanin,  packed  in  mela-
nosomes,  is  passed  from  the  melanocytes  to  the  adjacent 
keratinocytes;  in  hair  a  similar  process  exists,  with  pigment 
being added to the growing keratinocytes (35). Hair melanin 
is  formed  by  melanocytes  situated  in  the  hair  bulb  epithe-
lium around the upper half of the dermal papilla among cells 
destined  to  form  the  hair  cortex.  The  pigment  is  donated  to 
cells undergoing early differentiation to form the hair cortex. 
Melanosomes are also found in the hair medulla, whereas it is 
unusual to find melanin in the cuticle of human hair shafts (35). 
Two different types of melanin can be distinguished: eumela-
nin, which is brown or black, and pheomelanin, which results 
from  the  incorporation  of  cysteine,  is  yellow  or  red  (36–39). 
Eumelaninogenic  and  phaeomelanogenic  melanosomes  can 
coexist in the same melanocyte but are produced in different 
pathways (40–42). The absence or relative absence of both mel-
anin  types is associated with white hair; a preponderance of 
eumelanin with brown or black hair; and a preponderance of 
phaeomelanin with red or blond hair.

Since the term Caucasian comprises such a large number 
of ethnic subgroups, the entire range of hair colors can be found 
within this group. People of Celtic descent seem have predomi-
nantly phaeomelanin and therefore reddish-brown or -blonde 
hair (6), whereas in people originating from southern Europe, 
North Africa, or western, south, or middle Asia, eumelanin is 
the predominant chomophore and therefore leads to all shades 
of brown to deep black hair. Asian and African hair is usually 
densely pigmented with eumelanin and is therefore  black or 
dark brown.

Differences  in  pigmentation  between  people  are  not  a 
result of the number of melanocytes but are largely the result 
of differences in the amount and types of melanin produced 
and the macromolecular structure and packaging of melanin. 
Blonde  hair  appears  light  because  melanosomes  are  poorly 
melanized (40). Melanosomes are secreted in different shapes 
and sizes; such differences change the way of light scattering 
and thereby the hair color (36).

Furthermore,  hair  color  may  vary  both  in  time  and 
site. For example, scalp hair may be blonde in childhood and 
become brown or black in adolescence, before becoming white 

again  in  middle  or  old  age;  beard  or  pubic  hair  may  be  red 
and the scalp hair black or dark brown in the same individual 
(36,40,43).

Hair Biochemistry
Despite the obvious differences in phenotype, hair of different 
ethnic origin shows relatively little biochemical difference (44). 
Keratin fiber analysis showed no significant differences in the 
amino acid composition in Caucasian, Asian, and African hair 
(10,45). The distribution of cystine-rich proteins in the hair of 
volunteers  of  African  descent,  Caucasians,  and  Asian  volun-
teers  was  found  to  be  similar  (46).  No  ethnic  difference  was 
found  in  the  composition  of  low-sulfur  S-carboxymethylated 
fibrous proteins (10,47,48). However, a difference in the ratio of 
fibrous protein and matrix protein, with African hair  showing 
a  lower  ratio  of  low-sulfur  fibrous  proteins  to  high-sulfur 
matrix  proteins  compared  to  Asian  and  Caucasian  hair  was 
found (48).

Hair Characteristics
A  cross-section  of  fully  mature  and  keratinized  human 
 terminal hair reveals three major structures. The central layer 
is  the  medulla,  the  intermediate  layer  is  the  cortex,  and  out-
ermost  layer  is  the  cuticle.  The  medulla  consists  of  a  vacu-
olated, trabecular mass formed from aggregated trichohyalin 
granules. It contains melanosomes and citrulline-red granules 
(49).  The  cortex  gives  the  hair  shaft  its  elasticity  and  tensile 
strength. It consists of elongated cells containing tonofilaments 
and interfilamentous matrix material, which is rich in cysteine. 
Cortex keratin is different from epithelial keratin, primarily in 
the increased number of disulfide bonds in the hair shaft. The 
cuticle forms the protective shield of the hair shaft. It consists 
of flattened highly keratinized cells arranged like shingles. The 
scale-like cells overlap tightly in a proximal-to-distal direction 
along the hair shaft. The cuticle mainly protects the hair shaft 
from an excessive penetration of water and swelling of the cor-
tex. When the cuticle is intact, the scales are flat and smooth, 
reflect light, and provide a shiny, healthy look to the hair (6,49).
Function and appearance of scalp hair depends on three 

major characteristics: Porosity, elasticity, and texture.

Porosity  of  the  hair  measures  the  ability  to  allow 
 moisture  to  pass  through  the  cuticle  into  the  cortex.  In  a 
healthy  undamaged  hair,  only  minimal  amounts  of  water  or 
other  substances  can  penetrate  the  cuticle.  In  order  to  allow 
chemicals to penetrate the hair for permanent waving or hair 
coloring, which takes place in the hair cortex, the cuticle has 
to be altered. A higher permeability is achieved by increased 
temperature  or/and  by  changing  the  pH  of  the  environment 
along  the  shaft.  When  the  processing  of  the  hair  is  finished, 
the cuticular scales gradually close again. If processing is too 
harsh or applied too many times, the cuticle cells cannot return 
to their original tightness, which results in an imperfect bar-
rier  and  increased  porosity.  Increased  porosity  can  also  be  a 
result of UV radiation, overheating from flat or curling irons. 
and close, hot blowdrying as well as from excessive combing 
and  teasing  (6,49).  Highly  porous  hair  tends  to  be  dry  and 
 fragile, appears dull, and often contains split ends.

Asian hair is more resistant to chemicals that open the 
cuticle.  Therefore  stronger  chemicals  are  needed  if  cosmetic 
alterations  are  desired  such  as  coloring  and  permanent  wav-
ing.  African  hair  in  general  is  more  fragile  and  sensitive  to 
chemical  alterations.  It  tends  to  be  drier  and  since  grooming 
requires  more  force,  especially  in  longer  African  hair,  the 
 cuticle is more likely to be damaged (6).

 
Elasticity  is  a  measure  of  how  far  the  hair  can  be 
stretched without losing the ability to spring back to its orig-
inal  length.  Healthy  hair  can  stretch  approximately  1  1/3  of 
its original length when wet and return to its regular length 
when dry (49). The tensile strength of the hair shaft is related 
to its  elasticity and is assessing the weight it can support. One 
healthy  hair  shaft  can  support  approximately  100  g  weight 
without  breaking.  Elasticity  and  tensile  strength  depend  on 
the hair cortex. Thick, curly hair shows the highest elasticity 
and  tensile  strength,  whereas  thin,  straight  Caucasian  hair 
shows the least resistance to stretching and the lowest tensile 
strength.

The  third  major  characteristic  is  the  hair  texture. 
It  depends  on  the  diameter  and  shape  of  the  hair  shaft.  As 
 discussed earlier, Asian hair shows the thickest diameter and 
a  round,  cylindrical  shape.  Healthy  Asian  hair  is  very  well 
suited for long hairstyles; it may become spiky if worn short 
(Figure 42.1). African hair is highly twisted with high variabil-
ity  in  diameter  along  the  shaft  and  a  flat  oval  cross-section. 
Therefore  light  reflects  in  different  directions,  which  may 
result in  a dull appearance. African hair  is particularly  diffi-
cult  to  manage  and  to  remain  healthy  when  worn  in  longer 
hairstyles. A tremendous variety in hair texture can be found 
in Caucasian hair, ranging from very thin cylindrical hair to 
thick curly hair shafts.

Hair Care and Styling
Hair care and styling depends on the cultural background and 
on  current  trends.  As  discussed  earlier,  African  hair  is  very 
different from Asian and Caucasian hair. African hair tends to 
be very dry; considerable force is needed to comb the hair and 
although the hair is susceptible to mechanical damage, African 
hair can be more easily combed when wet. Too-frequent sham-
pooing will result in excessive dryness and brittleness. It was 
found  that  50%  of  African-American  women  shampoo  once 
weekly and another third only once every other week (10,50). 
This is considerably less compared to people of Caucasian or 

ETHNIC VARIATION IN HAIR 

 393

Asian  descent.  African  hair  is  usually  easy  to  care  for  when 
worn  short.  Oils  and  pomades  are  often  used  to  assist  in 
grooming or to treat dry, scaly scalp skin. Braiding is a popular 
way to manage longer African hair. Artificial braids are often 
attached to natural braids; classical “cornrow” braids are more 
frequently  seen  in  children.  Tight  braids  or  ponytails  may 
result in prolonged tension on the hair follicle; this may result 
in  traction  alopecia  and  ultimately  in  permanent  hair  loss 
(Figure 42.2). Today only very few African-American women 
are wearing a natural hairstyle. Many women have their hair 
regularly  straightened.  African  hair  with  its  tight  curls  can 
only be straightened properly by using hot comb procedures 
or chemical relaxers. Hot combing involves the application of 
oil to the hair shaft, combing the hair straight with a hot comb 
(150–250  °C)  until  there  are  no  more  curls  and  then  option-
ally  reshaping  the  hair  with  large  rollers.  Chemical  relaxers 
contain either sodium hydroxide or guanidine hydroxide and 
lithium hydroxide (lye-free straighteners). Chemically relaxed 
hair can also be gently re-permed to induce light curls (6,10,49). 
The  use  of  hot  combs  and  straighteners  has  been  associated 
with central centrifugal cicatricial alopecia (CCCA), an inflam-
matory hair loss condition that leads to permanent progressive 
hair loss, especially on the central parietal scalp (51–53).

Very  fine  straight  Caucasian  hair  is  difficult  to  style, 
 especially  if  left  to  grow  much  beyond  shoulder  length. 
A   layered  haircut  as  well  as  styling  products  such  as  volu-
mizing  shampoo,  mousse,  and  hair  spray  can  help  to   create 
the  impression  of  more  volume.  Setting  straight  hair  can 
give waves or curls by temporarily changing the position of 
the weak hydrogen bonds in the hair shaft by wetting, rear-
ranging, and holding with hair spray. Fine Caucasian hair is 
especially  vulnerable  to  mechanical  damage  when  wet  and 
therefore  excessive  combing  of  wet  hair  should  be  avoided; 
less  damage  is  done  to  the  cuticle  when  the  hair  is  dry. 
Teasing  or  backcombing  involves  combing  or  brushing  the 
hair toward the root to create small tangles that will hold the 
hair  in  place.  This  procedure  was  very  popular  in  the  1950s 

Figure 42.1  Spiky appearance of hair in a Chinese man with 
short haircut. (Courtesy of Dr. Jerry Shapiro.)

Figure  42.2  34-year  old  African-Brazilian  patient  with 
cicatricial  traction  alopecia  in  her  frontotemporal  hairline 
caused by tight hair styles.

 
394 

 TEXTBOOK OF COSMETIC DERMATOLOGY

and  1960s  to  create  voluminous  hairstyles  and  the  popular 
beehive  style.  However,  backcombing  leads  to  severe  dam-
age  of  the  cuticle  and  will  result  in  increased  porosity  and 
hair breakage. A permanent wave chemically alters the strong 
disulfide bonds in the hair cortex. Since the hair cortex holds 
the perm, very fine Caucasian hair may be difficult to perm, 
because the hair cortex forms a lower proportion of the hair 
fiber. Thick, straight Asian hair is generally difficult to set or 
perm  because  it  doesn’t  flex  readily  in  any  preferred  direc-
tion. Higher concentrations of perming solutions are usually 
required for Asian hair (6).

The  cold  wave  or  base  permanent  was  invented  in  the 
1930s.  It  involves  the  application  of  a  solution  of  ammonium 
thioglycolate to break the disulfide bonds; after that the hair is 
neutralized and hardens into a new shape by applying hydro-
gen peroxide, perborate, or sodium or potassium bromate (49). 
In  the  1970s  a  more  gentle  acid-based  glycerol  monothiogly-
colate (GMTG) permanent wave was introduced. GMTG sepa-
rates  the  cuticular  scales  to  a  lesser  degree  with  a  lower  pH 
and therefore the cuticle is more likely to return to the original 
stage after treatment. The acid-based permanent requires heat 
to be activated. This kind of wave is usually not strong enough 
to perm very coarse Asian or African hair. A high incidence of 
contact dermatitis caused by GMTG has been described (49,54).
Changing the color of hair that is heavily pigmented with 
eumelanin, such as Asian, African, or East-Indian hair is partic-
ularly difficult, especially if a much lighter hair color is desired. 
Bleaching destroys eumelanin and tends to produce red-tinged 
hair as well as leading to increased weathering and porosity.

Ethnic Differences in Hair and Scalp Disorders
Ethnic variations in the incidence of androgenetic alopecia have 
been  reported.  In  1951,  Hamilton  found  that  most  Chinese 
retained  the  frontal  hairline  after  puberty  and  that  baldness 
was less common, less extensive, and started later in life com-
pared to Caucasians (55). In 1981, Takashima et al. found that 
Japanese  men  develop  male  pattern  hair  loss  approximately 
10  years  later  in  life  and  have  a  1.4  times  lower  incidence  in 
each decade compared to Caucasians (56). Tang et al. investi-
gated  the  scalp  hair  of  254  men  in  Singapore.  They  found  a 
prevalence of 87% in the East Indian population and 61% in the 
Chinese  population  (57).  Paik  et  al.  investigated  5531  Korean 

men. An increase of prevalence with age occurs with an overall 
prevalence of 14.1% (58). A study carried out on 1124 Chinese 
and  Thai  men  aged  between  18  and  90  years  in  Bangkok 
showed a prevalence of 38.5% of male pattern hair loss type III 
or higher (59). Setty reported that androgenetic alopecia is four 
times less frequent in men of African origin (60) (Figure 42.3).

Certain inflammatory hair disorders are more frequently 
seen  in  people  of  African  ancestry.  Pseudofolliculitis  barbae  is 
found  in  45%–83%  of  African-American  men  who  regularly 
shave (10). Pseudofolliculits barbae is characterized by perifol-
licular and follicular papules and pustules as well as scarring 
in the shaved area. Very kinky hair tends to grow back into the 
skin  surface  or  pierces  the  follicular  epithelium,  followed  by 
inflammation when the hair is cut extremely short.

Dissecting  folliculitis  (DF)  is  also  known  as  perifollicu-
litis  capitis  abscedens  et  suffodiens  (of  Hoffman),  dissecting 
cellulitis, dissecting perifolliculitis, and perifolliculitis capitis. 
DF is a primary neutrophilic cicatricial alopecia. It manifests 
with  perifollicular  pustules,  nodules,  abscesses,  and  sinuses 
leading  to  scarring  alopecia.  The  etiology  of  dissecting  cel-
lulitis  is  unclear.  There  are  three  implicated  factors:  infec-
tion, follicular occlusion, and immune cell–mediated chronic 
inflammation (61). DF occurs predominantly in black men aged 
18 to 40 years (52). It can also occur in men of other ethnicities; 
women  and  children  are  rarely  affected  (62,63).  Chronic  and 
relapsing courses result in cicatricial alopecia which can pres-
ent as hypertrophic or keloidal scars (64,65).

Acne  keloidalis,  also  named  acne  keloidalis  nuchae,  der-
matitis papillaris capillitii, or folliculitis keloidalis, is a chronic 
idiopathic, inflammatory process leading to hair loss and hyper-
trophic scarring in papules and plaques (65). The exact etiology 
of  acne  keloidalis  is  unknown.  Probable  participating  factors 
include  constant  irritation  from  shirt  collars,  excoriation  and 
seborrhea, localized infection, shaving of the neck, coarse hair, 
and  autoimmunity  (52,66).  Acne  keloidalis  occurs  predomi-
nantly  in  black  men  between  14  and  25  years  of  age  (21).  The 
initial  lesions  are  dome-shaped,  firm,  skin-colored  follicular 
papules and pustules, which are located mostly on the occipital 
scalp and the nape of the neck, although they may also be found 
on the vertex and parietal area (21,67). As the disease progresses, 
papules and pustules may enlarge and coalesce into keloid-like 
plaques, associated with variable hair loss (Figure 42.4).

Figure  42.3  Young  African  American  women  with  early 
female pattern hair loss, (Courtesy of Dr. Jerry Shapiro.)

Figure  42.4  African  American  men  with  acne  keloidalis 
nuchae displaying keloid-like plaques and pustules. (Courtesy 
of Dr. Jerry Shapiro.)

 
Folliculitis decalvans (FD) is a common form of  primary 
cicatricial  alopecia  comprising  10.7%–11.2%  of  all  cases 
with  cicatricial  alopecia  (68,69).  The  etiology  of  FD  remains 
unclear. It may be a complex combination of a bacterial infec-
tion,  particularly  Staphylococcus  aureus,  a   hypersensitivity 
reaction  to  “superantigens,”  and  a  defect  in  host  cell– 
mediated immunity regulation (68,70,71). FD predominantly 
occurs in young and middle-aged adults with a slight prefer-
ence of the male gender. FD seems to occur more frequently 
in  African-Americans  compared  to  Caucasians  (68,69).  The 
primary lesions are painful or pruritic follicular pustules or 
papules  (70).  With  progression,  more  pustules  and  papules, 
as well as crusting and nodules, can be seen. Associated with 
the  inflammatory  activity,  one  or  more  round  to  irregular 
patches  of  scarring  alopecia  develop.  The  patches  look  like 
ivory pseudopelade skin centrally with surrounding follicu-
lar pustules and crusts at the margins of active lesions (51,72) 
(Figure 42.5).

CCCA is a lymphocytic primary cicatricial alopecia that 
primarily  affects  African-American  Women.  It  can  rarely  be 
seen in Caucasians (sometimes called “central elliptical pseu-
dopelade”)  and  African-American  men.  CCCA  presents  with 
a patch of scarring alopecia similar to Pseudopelade of Brocq 
on  the  central  scalp,  which  slowly  progresses  centrifugally. 
It  remains  unclear  if  chemical  processing,  heat,  traction,  or 
other traumas contribute to the development of this condition 
(21,51,53)  (Figure  42.6).  The  etiology  of  cicatricial  alopecias  is 
poorly  understood.  Inflammatory  cicatricial  alopecias  seem 
to  be  less  frequent  in  people  of  Asian  ancestry,  suggesting 
that the shape of the follicle and hair shaft plays a role it the 
pathogenesis.

Figure  42.5  Caucasian 
 folliculitis decalvans. (Courtesy of Dr. Jerry Shapiro.)

female  patient  with  extensive 

ETHNIC VARIATION IN HAIR 

 395

Figure 42.6  African American women with central centrifugal 
cicatricial alopecia (CCCA). (Courtesy of Dr. Jerry Shapiro)

BODY HAIR
Very little data is available on ethnic differences in body hair. 
The density in chest hair in men has been reported to be high-
est in Caucasians, especially in those with a darker skin color. 
Blonde  Italian  man  showed  denser  chest  hair  compared  to 
Scandinavian  men.  In  general,  growth  of  terminal  body  hair 
seems to be more prominent in men of Mediterranean descent 
compared  to  Nordic  descent  (73).  Men  of  African  and  Asian 
ancestry were found to have considerably low body hair com-
pared Caucasian men (73). Axillary hair growth in Caucasians 
was found to be much denser than in Japanese of both sexes 
(18). Dense terminal hair growth of the external ear or pinna 
(hypertrichosis  pinnae  auris)  is  very  commonly  seen  in  men 
of  East  Indian  descent.  Eighty-five  percent  of  Caucasian  men 
also show some degree of terminal hair growth in this area as 
opposed to 55% of men of African ancestry. The mode of inher-
itance of this form of hypertrichosis seems to be Y-linked (74).

Growth  of  terminal  body  hair  is  of  concern  for  most 
women.  However  it  is  very  difficult  to  decide  whether  the 
hair growth is excessive and should be classified as Hirsutism 
or  within  the  range  of  normal  variation.  Hirsutism  is  highly 
unusual in Asian women, despite the fact that levels of andro-
gens may even be higher (18).

Eyelashes
Na et al. performed a study to determine differences in  eyelash 
shape  and  growth  rate  in  Asian  and  Caucasian  volunteers. 
Lateral  digital  photographs  of  upper  eyelashes  were  taken 
and  curl-up  and  lift-up  angles  of  the  upper  eyelashes  were 
measured  from  lateral  views.  Additionally,  the  phototricho-
gram technique was used to determine total number, length, 
and  thickness  of  upper  eyelashes.  The  central  portion  of  the 
eyelashes  or  whole  eyelashes  was  clipped  and  images  were 
taken immediately and 7 days later to obtain the growth rate 
and anagen ratio. The number and thickness of the cuticular 
 layers were measured by electron microscopy. Asian eyelashes 
revealed lower lift-up and curl-up angles, fewer numbers, and 
a  thicker  transverse  diameter  compared  to  Caucasian  lashes. 

 
396 

 TEXTBOOK OF COSMETIC DERMATOLOGY

No statistical difference was found in length or growth rate. The 
duration of the anagen phase was estimated at about 2 months. 
The  eyelash  anagen  rate  obtained  was  approximately  17.8%. 
The number of cuticular layers was greater in Asians (8.0) than 
in Caucasians (6.5), but no statistical difference was found in 
the thickness of a single cuticle layer between the two groups 
(75).  No  data  is  available  for  African  eyelashes.  Eyelashes  of 
people of African descent seem to be curlier  compared to those 
of Asians or Caucasians.

Villus Hair
Very  little  is  published  on  the  size  and  distribution  of  vellus 
hair.  Hwang  and  Baik  obtained  skin  samples  from  different 
body sites of Korean adults to determine the density and dis-
tribution  of  hair  follicles  and  sweat  glands.  The  average  hair 
density was found to be 36/cm2 on the back, 33/cm2 on the tho-
rax, 40/cm2 on the upper arm, 18/cm2 on the forearm, 28/cm2
on the thigh, and 11/cm2 on the calf (76). Cyanoacrylate surface 
biopsies have been utilized to study vellus hair parameters in 
seven  different  body  sites  in  Caucasian,  Asian,  and  African-
American volunteers with comparable height and body mass 
index (77,78). Hair density, hair shaft diameter, size, and sur-
face area of the follicular orifices and the volume of vellus hair 
follicles  have  been  measured  and  calculated  on  microscopic 
images in combination with digital image analysis. The high-
est hair density was found on the forehead; significantly lower 
densities have been determined on the other body areas (upper 
arm > back > chest > thigh > forearm > calf). This overall trend 
was seen in all three ethnic skin types. Significant differences in 
vellus hair density were found on the forehead with Caucasians 
showing  the  highest  average  density  (292/cm2)  followed  by 
African-American  (189/cm2)  and  Asians  (138/cm2).  These  dif-
ferences  correlate  well  with  the  ethnic  differences  found  for 
scalp hair density. No significant differences have been found 
in vellus hair density were found in the other six skin areas. 
The diameter of the follicular orifice showed the greatest inter-
site variation on the forehead of Caucasian  volunteers, whereas 
Asian hair follicles on the forehead seemed to be more uniform 
in size. The percentage of the surface area taken by the follicu-
lar orifice was calculated by multiplying the average circle area 
of the orifice with the hair density per cm2. Caucasians showed 
the highest values in general with the forehead (1.28%) repre-
senting the highest percentage of follicular orifices. Hair shaft 
diameters were found to be the highest on the calf in all three 
skin types. However, significant differences among the groups 
were  seen,  with  Caucasian  showing  the  thickest  hair  shaft 
diameter on average (42 µm), followed by African-Americans 
(22 µm) and Asians (17 µm). Hair shaft diameters on the fore-
head, back, chest, upper arm, and  forearm were below 20 µm 
with no significant differences among the ethnic groups. The 
thigh showed a trend similar to the area on the calf. The dif-
ferences in follicle size and hair shaft diameter indicate higher 
androgen  sensitivity  in  Caucasians.  This  hypothesis  corre-
sponds well with the higher incidence of androgenetic alope-
cia in the Caucasian population.

CONCLUDING REMARKS
Hair  of  people  of  different  ethnic  ancestries  shows  great 
 differences  in  size,  shape,  and  color.  The  broad  distinction 
between Caucasian, Asian, and African hair can hardly accom-
plish  the  great  variety  and  different  needs  of  human  hair. 
A  more  elaborate  distinction,  as  suggested  by  De  la  Mettrie 

et al., seems to be more useful, especially for the development 
of  hair  care  and  styling  products  (16).  Ethnic  differences  in 
hair are found not only in scalp hair but also in body hair and 
vellus hair. The shape and size of hair follicles seems to be a 
pathogenetic factor for the susceptibility to certain scalp and 
skin  disorders.  Further  research  is  needed  to  provide  more 
insight into the chemical and structural differences in human 
hair and the related clinical problems.

REFERENCES

1.

Jackson  JP  Jr.  “In  Ways  Unacademical”:  The  reception  of 
Carleton  S.  Coon’s  The  Origin  of  Races  J  History  Biol  2001; 
34:247–85.

2. Cavalli-Sforza  LL,  Menozzi  P,  Piazza  A.  The  History  and 
Geography  of  Human  Genes.  Vol.  1.  Princeton  University  Press, 
1994.

3. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans 
in  biomedical  research:  Genes,  race  and  disease.  Genome  Biol 
2002; 3:2007.

4.  Jorde  LB,  Wooding  SP.  Genetic  variation,  classification  and 

’race’. Nature Genet 2004; 36:S28–33.

5.  Luther N, Darvin ME, Sterry W, Lademann J, Patzelt A. Ethnic 
differences in skin physiology, hair follicle morphology and fol-
licular penetration. Skin Pharmacol Physiol 2021; 25:182–91.

6.  Gray J. Human Hair Diversity. 1st edn, Vol. 1. Blackwell Science, 

2000.

7.  Hutchinson  PE,  Thompson  JR.  The  cross-sectional  size  and 
shape  of  human  terminal  scalp  hair.  Br  J  Dermatol  1997; 
136:159–165.

8.  Steggerda M, Seiber HC. Size and shape of head hairs from six 

racial groups. J Hered 1942; 32:315–8.

9.  Hrdy  D.  Quantitative  hair  form  variation  in  several  popula-

tions. Am J Phys Anthropol 1973; 39:7–8.

  10.  Wilborn WS. in Disorders of Hair Growth - Diagnosis and Treatment. 
Vol. 1. In: Olsen EA, ed. McGraw Hill, 2003; pp. 497–517.
  11.  Bernard BA. Hair shape of curly hair. J Am Acad Dermatol 2003; 

48:S120–6. Review.

  12.  Lindelöf  B,  Forslind  B,  Hedblad  MA,  Kaveus  U.  Human  hair 
form.  Morphology  revealed  by  light  and  scanning  electron 
microscopy  and  computer  aided  three-dimensional  recon-
struction. Arch Dermatol 1988; 124:1359–63.

  13.  Porter CE, et al. The behavior of hair from different countries. 

J Cosmet Sci 2009; 60:97–109.

  14.  Loussouarn  G,  et  al.  Worldwide  diversity  of  hair  curliness:  A 

new method of assessment. Int J Dermatol 2007; 46:2–6.

  15.  Porter CE, Diridollou S, Holloway, Barbosa V. The influence of 
African-American hair’s curl pattern on its mechanical proper-
ties. Int J Dermatol 2005; 44:4–5.

  16.  De  la  Mettrie  R,  Saint-Léger  D,  Loussouarn  G,  Garcel  APC, 
Langaney A. Shape variability and classification of human hair: 
A worldwide approach. Hum Biol 2007; 79:265–81.

  17.  Rassman WR, Pomerantz, M. The art and science of minigraft-

ing. Int J Aesthet Rest Surg 1993; 1:27–36.

  18.  Tobin DJ, ed. Hair in Toxicology - An Important Bio-Monitor Vol. 1. 

RSC Publishing, 2005.

  19.  Szabo  G.  In:  Montagna  W,  Ellis  RA,  eds.  The  Biology  of  Hair 

Growth. Vol. 1. Academic Press, 1958; pp. 33–8.

  20.  Lee  HJ,  et  al.  Hair  counts  from  scalp  biopsy  specimens  in 

Asians. J Am Acad Dermatol 2002; 46:218–21.

  21.  Sperling LC. Hair density in African Americans. Arch Dermatol 

1999; 135:656–8.

  22.  Whiting  DA.  Diagnostic  and  predictive  value  of  horizontal 
 sections  of  scalp  biopsy  specimens  in  male  pattern  androge-
netic alopecia. J Am Acad Dermatol 1993; 28:755–63.

  23.  Aslani  FS,  Dastgheib  L,  Banihashemi  BM.  Hair  counts  in 
scalp biopsy of males and females with androgenetic alopecia 
 compared with normal subjects. J Cutan Pathol 2009; 36:734–9.

 
 
 
 
 
 
 
ETHNIC VARIATION IN HAIR 

 397

  24.  Templeton SF, Santa Cruz DJ, Solomon AR. Alopecia: Histologic 
diagnosis  by  transverse  sections.  Semin  Diagn  Pathol  1996; 
13:2–18.

  51.  Olsen EA, et al. Update on cicatricial alopecia. J Investig Dermatol 

Symp Proc 2003; 8:18–9.

  52.  Ross EK, Tan E, Shapiro J. Update on primary cicatricial alope-

  25.  Bouhanna  P.  In:  Montagna  W,  et  al.,  eds.  Hair  and  Aesthetic 

cias. J Am Acad Dermatol 2005; 53:1–37.

Medicine. Vol. 1. Salus Ed, 1983; pp. 277–80.

  26.  Van  Neste  D,  Dumortier  M,  De  Coster  W.  In:  Lachapelle  JM 
Van Neste D, Antoine JL, eds. Trends in Human Hair Growth and 
Alopecia Research. Kluwer Academic, 1989; pp. 155–65.

  27.  Hoffmann R. TrichoScan: Combining epiluminescence micros-
copy with digital image analysis for the measurement of hair 
growth in vivo. Eur J Dermatol 2001; 11:362–8.

  28.  Loussouarn G. African hair growth parameters. Br J Dermatol 

2001; 145:294–7.

  29.  Jiménez  F,  Poblet  E.  In:  Haber  RS,  Stough  DB,  eds.  Hair 

Transplantation. Vol. 1. Elsevier, 2006; pp. 35–42.

  30.  Jiménez  F,  Ruifernández  JM.  Distribution  of  hair  in  follicular 

units. Dermatol Surg 1999; 25:294–8.

  53.  Otberg  N,  Wu  WY,  McElwee  KJ,  Shapiro  J.  Diagnosis  and 
 management  of  primary  cicatricial  alopecia:  Part  I.  Skinmed 
2008; 7:19–26.

  54.  Adams  RM,  Maibach  HI.  A  five-year  study  of  cosmetic 

 reactions. J Am Acad Dermatol 1985; 13:1062–9.

  55.  Hamilton JB. Patterned loss of hair in man: Types and  incidence. 

P Ann NY Acad Sci 1951; 53:708–28.

  56.  Takashima  I,  Iju  M,  Sudo  M.  In:  Orfanos  CE,  Montagna  W, 
Stuttgen G, eds. Hair Research Status and Future Aspects. Vol. 1. 
Springer-Verlag, 1981; pp. 287–93.

  57.  Tang PH, Chia HP, Cheong LL, Koh D. A community study of 
male androgenetic alopecia in Bishan, Singapore. Singapore Med 
J 2000; 41:202–5.

  31.  Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evalu-
ation  of  hair  and  scalp  disorders.  J  Am  Acad  Dermatol  2006; 
55:799–806.

  58.  Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and 
types of androgenetic alopecia in Korean men and women. Br J 
Dermatol 2001; 145:95–9.

  32.  Rudnicka L, Olszewska M, Rakowska A, Kowalska-Oledzka E, 
Slowinska M. Trichoscopy: A new method for diagnosing hair 
loss. J Drugs Dermatol 2008; 7:651–4.

  59.  Pathomvanich  D,  Thienthaworn  P,  Manoshai  S.  A  Random 
study  of  Asian  male  androgenetic  alopecia  in  Bangkok, 
Thailand. Dermatol Surg 2002; 28:804–7.

  33.  Iorizzo  M,  Pazzaglia  M,  Starace  M,  Militello  G,  Tosti  A. 
Videodermoscopy: A useful tool for diagnosing congenital tri-
angular alopecia. Pediatr Dermatol 2008; 25:652–4.

  34.  Ito  S,  Ozeki  H,  Wakamatsu  K.  In:  Hori  K,  Hearing  VJ, 
Nakayama  J,  eds.  Melanogenesis  and  Malignant  Melanoma: 
Biochemistry,  Cell  Biology,  Molecular  Biology,  Pathophysiology, 
Diagnosis  and  Treatment.  Vol.  1.  Oxford  University  Press,  2000; 
pp. 63–72.

  60.  Setty LR. Hair pattern of the scalp of white and negro males. 

Am J Phys Anthropol 1970; 33:49–55.

  61.  Salim A, David J, Holder J. Dissecting cellulitis of the scalp with 
associated spondylarthropathy: Case report and review. J Eur 
Acad Dermatol Venereol 2003; 17:689–91.

  62.  Stites  PC,  B.  A.  Dissecting  cellulitis  in  a  white  male:  A  case 
report and review of the literature. 2001; Cutis 67:37–40.
  63.  Ramesh  V.  Dissecting  cellulitis  of  the  scalp  in  2  girls. 

  35.  Messenger  AG.  In:  Olsen  EA,  ed.  Disorders  of  Hair  Growth  - 

Dermatologica 1990; 180:48–50.

Diagnosis and Treatment. Vol. 1 McGraw Hill, 2003; pp. 49–74.

  64.  Scheinfeld NS. A case of dissecting cellulitis and a review of the 

  36.  Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003; 

literature. Dermatol Online J 2003; 9:8.

37:67–90. Review.

  37.  Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, eds. 
The  Pigmentary  System:  Physiology  and  Pathophysiology.  Oxford 
University Press, 1998.

  65.  Wu WY, Otberg N, McElwee KJ, Shapiro J. Diagnosis and man-
agement  of  primary  cicatricial  alopecia:  Part  II.  Skinmed  2008; 
7:78–83.

  66.  Kelly AP. Pseudofolliculitis barbae and acne keloidalis nuchae. 

  38.  Wakamatsu K, Ito S. Advanced chemical methods in melanin 

Dermatol Clin 2003; 21:645–53.

determination. Pigment Cell Res 2002; 15:174–83.

  67.  Goette  DK,  B.  T.  Acne  keloidalis  nuchae.  A  trans-epithelial 

  39.  Wakamatsu  K,  Ito  S,  Rees  JL.  Usefulness  of  4-amino-3- 
hydroxyphenylalanine  as  a  specific  marker  of  pheomelanin. 
Pigment Cell Res 2002; 15:225–32.

  40.  Tobin  DJ.  In:  Tobin  DJ,  ed.  Hair  in  Toxicology  -  An  Important 

 Bio-Monitor. Vol. 1. RSC Publishing, 2005.

  41.  Oyehaug L, Plahte E, Vage DI, Omholt SW. The regulatory basis 
of melanogenic switching. J Theor Biol 2002; 215:449–68.
  42.  Inazu  M,  Mishima  Y.  Detection  of  eumelanogenic  and  phe-
omelanogenic  melanosomes  in  the  same  normal  human 
 melanocyte. J Invest Dermatol 1993; 100:172S–5S.

  43.  Tobin  DJ,  Hordinsky  M,  Bernard  BA.  Hair  pigmentation:  A 

research update. J Investig Dermatol Symp Proc 2005; 10:275–9.

elimination disorder. Int J Dermatol 1987; 26:442–4.

  68.  Whiting DA. Cicatricial alopecia: Clinico-pathological findings 

and treatment. Clin Dermatol 2001; 19:211–5.

  69.  Tan  E  MM,  Ball  N,  Shapiro  J.  Primary  cicatricial  alopecias: 
Clinicopathology  of  112  cases.  J  Am  Acad  Dermatol  2004; 
50:25–32.

  70.  Powell JJ, D. R., Gatter K. Folliculitis decalvans including tufted 
folliculitis: Clinical, histological and therapeutic findings. Br J 
Dermatol 1999; 140:328–33.

  71.  Powell J, Dawber RP. Successful treatment regime for  folliculitis 
decalvans  despite  uncertainty  of  all  aetiological  factors.  Br  J 
Dermatol 2001; 144:428–9.

  44.  Wolfram LJ. Human hair: A unique physicochemical compos-

  72.  Sullivan  JR,  Kossard  S.  Acquired  scalp  alopecia.  Part  2:  A 

ite. J Am Acad Dermatol 2003; 48:S106–14. Review.

review. Australas J Dermatol 1999; 40:61–70.

  45.  Baum JD, Hughes EA, Harris DA. Neonatal hair as a record of 

  73.  Danforth CH, Trotter M. The distribution of body hair in white 

intra-uterine nutrition. Biol Neonate 1974; 25:208–18.

subjects. Amer J Phys Anthropol 1922; 5:259.

  46.  Khumalo  NP,  Dawber  RP,  Ferguson  DJ.  Apparent  fragility  of 
African  hair  is  unrelated  to  the  cystine-rich  protein  distribu-
tion: A cytochemical electron microscopic study. Exp Dermatol 
2005; 14:311–4.

  47.  Dekio  S,  Jidoi  J.  Amino  acid  compositions  of  human  hair 
fibrous  protein  components  purified  with  two-dimensional 
 electrophoresis. J Dermatol 1989; 16:453–7.

  48.  Dekio  S,  Jidoi  J.  Amounts  of  fibrous  proteins  and  matrix 

  74.  Dronameraju  KR.  Hypertrichosis  of  the  pinna  of  the  human 

ear, Y-linked pedigrees J Genet 1960; 57:230–43.

  75.  Na JI, et al. Ethnic characteristics of eyelashes: A comparative 
analysis  in  Asian  and  Caucasian  females.  Br  J  Dermatol  2006; 
155:1170–6.

  76.  Hwang K, Baik SH. Distribution of hairs and sweat glands on 
the bodies of Korean adults: A morphometric study. Acta Anat 
1997; 158:112–20.

 substances in hairs of different races. J Dermatol 1990; 17:62–4.

  77.  Otberg N, et al. Variations of hair follicle size and distribution 

  49.  O’Donoghue MN. In: Olsen EA, ed.  Disorders of Hair Growth - 

in different body sites. J Invest Dermatol 2004; 122:14–9.

Diagnosis and Treatment. Vol. 1. McGraw Hill, 2003; pp. 481–96.

  50.  Grimes  PE.  Skin  and  hair  cosmetic  issues  in  women  of  color. 

  78.  Mangelsdorf S, et al. Ethnic variation in vellus hair follicle size 
and distribution. Skin Pharmacol Physiol 2006; 19:159–67.

Dermatol Clin 2000; 18:659–65.

 
43

Ethnic Differences in Skin Properties

Rishu Gupta and Howard Maibach

INTRODUCTION
Differences  in  ethnic  skin  properties  have  been  minimally 
investigated  and  the  available  literature  investigating  these 
parameters  is  sparse.  Variations  in  skin  structure  may  con-
tribute to differences observed in cutaneous diseases between 
ethnic groups. The current human skin model is largely based 
on  physical  and  functional  properties  from  Caucasian  skin. 
However,  physiological  parameters  in  skin  of  different  races 
and  color  can  alter  a  disease  process  and  if  the  fundamental 
disease  process  is  not  understood,  appropriate  treatments  of 
diseases  may  not  be  considered.  As  patients  are  increasingly 
presenting  with  cutaneous  concerns  stemming  from  their 
unique  skin  physiology,  clinicians  and  scientists  are  analyz-
ing the skin proprieties that are fundamental to understand-
ing  these  disease  processes.  However,  the  available  data  can 
be difficult to interpret, especially when comparing one study 
against another.

In  this  review  article,  we  consolidate  the  data  in  an 
attempt  to  clarify  the  published  studies  and  to  help  provide 
insight  into  the  differences  in  skin  structure  and  function 
between ethnic groups or skin types. The objective skin prop-
erties  we  present  include  transepidermal  water  loss  (TEWL), 
water content (WC), blood vessel reactivity (BVR), corneocyte 
variability,  elastic  recovery/extensibility,  pH  gradient,  lipid 
content, antioxidant status, pore size/architecture, and epider-
mal innervation.

METHODS
A literature search was performed through EMBASE, PubMed, 
Science Citations Index Expanded, and the Melvyl Catalogue 
(CDL-Hosted  Database  of  University  of  California,  San 
Francisco,  California)  from  1967–2012.  Keywords  in  searches 
included  words  pertaining  to  race  (race,  ethnicity,  black, 
African, white, Caucasian, Asian, Hispanic, Chinese, Japanese) 
and  dermatology  (skin  physiology,  skin  function,  epidermal 
barrier  function).  A  manual  review  of  the  reference  list  from 
the acquired articles was performed. Studies examining skin 
color and hair were excluded to maintain focus of the article 
on skin structure and function.

TRANSEPIDERMAL WATER LOSS
The  skin  provides  a  critical  barrier  between  the  body’s  own 
internal environment and the external environment. One of the 
functions of the barrier is to regulate water loss, which is pri-
marily performed by the stratum corneum, a layer within the 
epidermis.  TEWL  (transepidermal  water  loss)  is  an   objective 

measure  that  is  defined  as  the  total  amount  of  water  loss 
through the skin excluding loss due to sweat. In the presence 
of an insult such as trauma or irritants, the skin also triggers 
repair mechanisms involving lipid synthesis and secretion to 
minimize TEWL. TEWL is the most studied parameter when 
comparing differences in biophysical properties between eth-
nic skins.

In  1988,  Wilson  et  al.  observed  higher  in  vitro  TEWL 
 values  in  black  skin  compared  to  white  skin  by  taking 
samples  from  22  cadavers  matched  for  age  and  gender  (1). 
Furthermore, Kompaore et al. and Sugino et al. found a signifi-
cantly higher TEWL in Blacks and Asians compared to whites 
(2,3).  In  contrast,  Berardesca  and  Maibach  found  no  signifi-
cant differences in baseline TEWL between Hispanics, blacks, 
and whites in two separate studies (4,5). Recently Fotoh et al. 
came to a similar conclusion as their study did not observe a 
significant  difference  in  baseline  TEWL  between  Caribbean 
blacks,  Caribbean  mixed  races,  and  Caucasians  (6).  Luther 
et al. also found no significant differences in baseline TEWL 
between  Caucasians,  Africans,  and  Asians  (7).  However,  in 
one of the largest number of subjects studied, Muizzuddin et 
al. reported the following significant differences in baseline 
TEWL values: Caucasians > African Americans > East Asians 
(8).  The  investigators  also  reported  that  African  Americans 
exhibited  superior  skin  barrier  strength,  since  African 
Americans  required  the  most  number  of  tape  strippings  to 
raise the baseline TEWL past a threshold value (8). Similarly, 
Chu et al. also found that Caucasian females had significantly 
higher TEWL at baseline than African American females in a 
total of 151 patients matched by age (9). Comparing Japanese 
subjects  to  French  Caucasians,  Yamashita  et  al.  observed 
statistically  significant  lower  baseline  TEWL  values  in  the 
Japanese subjects (10).

In  addition  to  baseline  TEWL,  several  authors  have 
investigated  TEWL  differences  between  races  in  response 
to  skin  irritation.  Berardesca  and  Maibach  found  that  blacks 
had 2.7 times higher TEWL than whites after topical applica-
tion of an irritant, 0.5% and 2.0% sodium laurel sulfate (SLS) 
to  untreated  and  preoccluded  skin  (5).  This  finding  suggests 
that  blacks  are  more  susceptible  to  irritation,  which  contra-
dicts previous reports that blacks are less reactive to irritable 
substances  than  whites  based  on  observable  erythema  (5,11). 
Berardesca  and  Maibach  investigated  the  TEWL  values  in 
Hispanics and whites and did not find a significant difference 
between  the  ethnic  groups.  They  did  however  report  higher 
values  of  TEWL,  though  not  significant,  in  Hispanics  com-
pared  to  whites  after  exposure  to  SLS-induced  irritation  (12). 
In contrast, Berardesca et al. were unable to reproduce earlier 

results, as the investigators did not find significant differences 
in baseline TEWL values between race (blacks, Hispanics, and 
whites) or anatomical site (4). Aramaki et al. also observed no 
significant differences in TEWL and barrier function pre and 
post exposure to SLS irritation between German and Japanese 
women  (13).  Additional  studies  by  Astner  et  al.,  Tagami, 
Pershing  et  al.,  and  Hicks  et  al.  report  differences  in  TEWL 
and  skin  irritancy  between  Caucasian  and  non-Caucausian 
skin (14–17).

Reid  et  al.  compared  TEWL  between  skin  pigmenta-
tion types instead of ethnicity and found that skin types V/
VI  required  a  greater  number  of  tape  strippings  than  skin 
types II/III to achieve the same TEWL (18). The results sig-
nified that skin types V/VI exhibited increased skin barrier 
strength. Furthermore, in the same study, TEWL was found 
to recover more quickly for skin types V/VI. Gunathilake et 
al.  agreed  with  this  study  by  similarly  observing  that  skin 
types  IV/V  required  an  increased  numbers  of  tape  strip-
pings, compared to skin types I/II, to achieve a TEWL value 
three  times  of  the  baseline  TEWL  value.  The  investigators 
also  found  that  skin  types  IV/V  exhibited  quicker  barrier 
repair  kinetics  compared  to  skin  types  I/II  as  measured 
by  the  recovery  of  TEWL  24–48  hours  after  the  tape  strip-
pings  (19).  In  contrast,  Berardesca  et  al.  found  that  African 
Americans  had  higher  TEWL  values  at  baseline  and  after 
each  tape  stripping   compared  to  Caucasian  skin,  although 
Caucasian skin similarly increased in TEWL values after the 
tape strippings (20).

The data regarding differences in TEWL in ethnic skin 
is  conflicting  (Table  43.1).  Initially,  the  literature  suggested 
that  African  Americans  had  an  increased  TEWL  at  baseline. 

ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  399

However, recent studies with larger sample sizes have reported 
conflicting  results  and  have  shown  that  Caucasians  have  a 
higher  baseline  TEWL  compared  to  African  Americans  and 
even  Asian  subjects.  There  is  also  increasing  literature  avail-
able citing studies reproducing differences in TEWL and skin 
irritancy.

The  evidence  does  not  entirely  validate  the  notion  that 
water  barrier  function  is  dependent  on  the  degree  of  pig-
mentation  since  there  have  not  been  any  studies  of  acquired 
hyper- or hypopigmentation and its affect on barrier integrity. 
However,  studies  by  Reed  et  al.  and  Gunathilake  et  al.,  that 
measure differences in skin type instead of by ethnic groups, 
have  observed  a  superior  water  barrier  function  and  its  abil-
ity  to  recovery  quickly  in  darkly  pigmented  subjects.  If  the 
integrity of the barrier function is dependent on the degree of 
pigmentation, then there are clinical implications on the abil-
ity  of  people  with  different  skin  types  to  recover  quickly  to 
environmental insults or to absorb topical therapeutic agents. 
Furthermore,  TEWL  may  also  be  a  factor  of  physiological  or 
disease states and the health of participating subjects should 
be documented in future studies.

WATER CONTENT
Water  content  is  an  indication  of  skin  hydration  and  can  be 
measured  by  multiple  methods  including  skin  conductance, 
resistance,  capacitance,  and  impedance.  Skin  conductance 
is  dependent  on  the  changes  in  electrical  properties  of  the 
stratum  corneum  based  on  skin  hydration.  For  example,  dry 
stratum  corneum  has  a  weaker  electrical  conduction,  while 
hydrated  stratum  corneum  is  more  sensitive  to  the  electrical 

Table 43.1  TEWL

Study

Technique

No. of subjects

Site

Results

Wilson et al. 1988

In vitro

Blacks 10 (mean age 

Inner thigh

Berardesca and 
Maibach 1988

In vivo – topical 
application of 
SLS (irritant)

38.6y)

Caucasians 12  

(mean age 41.1y)

Black men 10  

(age 29.9 ± 7.2y)

White men 9  

(age 30.6 ± 8.8y)

Back

No significant difference in TEWL between 

TEWL Blacks 1.1× > Caucasians (mean 
corrected log TEWL 2.79 and 2.61 µg/
cm2/h, respectively) [ p < 0.01 for both 
values]

blacks and whites at baseline

After SLS stress:
TEWL blacks (untreated, pre-occluded, 
and pre-delipidized) > whites but only 
statistically significant (2.7× greater) for 
0.5% SLS applied in the pre-occluded 
area ( p < 0.04)

No significant differences in TEWL 
between Hispanics and whites at 
baseline

After SLS stress:
TEWL Hispanics (untreated, pre-occluded, 
and pre-delipidized) > whites, but not 
statistically significant

No significant difference in TEWL between 

site or race at baseline

(continued)

Berardesca and 
Maibach 1988

In vivo – topical 
application of 
SLS (irritant)

Hispanic men 7  

(age 27.8 ± 4.5y)

White men 9  

(age 30.6 ± 8.8y)

Upper back

Berardesca et al. 

In vivo

1991

Blacks 15 (mean age 

46.7 ± 2.4y)

Whites 12 (mean age 

49.8 ± 2y)

Hispanics 12 (mean age 

48.8 ± 2y)

Volar and 
dorsal 
forearm

 
400 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 43.1  TEWL (continued)

Study

Technique

No. of subjects

Site

Results

Kompaore et al. 

1993

In vivo – topical 
application of 
MN – vasodilator

Blacks 7
Caucasians 8
Asians 6
(ages 23–32y, all)

Volar forearm

Sugino et al. 1993

In vivo

Blacks, Caucasians, 

Not 

Hispanics, Asians (no. of 
subjects, ages not 
specified)

documented

MN given before tape stripping:
TEWL blacks & Asians 1.3× > Caucasians 

( p < 0.01); no difference between 
blacks & Asians

After eight and 12 tape strips:
TEWL Asians > blacks > Caucasians  

( p < 0.05)

[Asians 1.7× > Caucasians]
Baseline TEWL:
Blacks > Caucasians ≥ Hispanics ≥ 

Asians

Reed et al. 1995

In vivo

Warrier et al. 1996

In vivo

Skin type V/VI:
African American 4
Filipino 2
Hispanic 1
Skin type II/III:
Asian 6
Caucasian 8
(ages 22–38y, all)

Black women 30
White women 30
(ages 18–45y, all)

Berardesca et al. 

In vivo

1998

Aramaki et al. 2002

In vivo – topical 
application of 
SLS (irritant)

Tagami 2002

In vivo

Hicks et al. 2003

In vivo

Black women 8
Caucasian women 10
(mean age 42.3 ± 5y, both)

Japanese women 22 
(mean age 25.84y)

German women 22 (mean 

age 26.94y)

Japanese women 120
French women 322
(ages 20–70y, all)

White 8
Blacks 6
(ages 18–40y, all)

Grimes et al. 2004

In vivo – topical 
application of 
5% SLS (irritant)

African American 18
White 19
(ages 35–65y, women, all)

Pershing et al. 2006

Astner et al. 2006

In vivo – topical 
application of 
capsaicinoid 
analogs

In vivo – topical 
application of 
ivory soap 
(irritant)

Caucasians:
Male 3
Female 3
Asians:
Male 3
Female 3
(ages 19–63y, all)

Volar forearm

Skin type V/VI required more tape 

strippings (66.7 ± 6.9) compared with 
skin type II/III (29.6 ± 2.4) to achieve the 
same TEWL, i.e. skin type V/VI had 
increased water barrier strength 
(integrity)

Barrier function in skin type V/VI recovered 

more quickly

TEWL blacks < whites on cheeks (20% 
less) and legs (17% less) at baseline  
( p < 0.05); also lower on forearm but not 
statistically significant

After tape stripping:
TEWL blacks 1.2× > Caucasians after 3 
(p < 0.05) and 6 tape strips ( p < 0.03)

Left and right 
medial 
cheeks, 
mid-volar 
forearms, 
lateral 
mid-lower 
legs

Mid-volar 
forearm

Forearm

No significant difference at baseline or 

after SLS stress

Cheeks and 
mid-flexor 
forearm

Volar forearm

Inner Forearm

TEWL Japanese < Whites but not 

statistically significant

TEWL whites > blacks but not statistically 

significant

Baseline: No significant difference
After SLS stress: immediate increase in 

TEWL of white subjects, but increase no 
longer evident after 24 hr and found to 
be similar to African Americans (not 
statistically significant)

Volar Forearm

Increasing concentrations of total 

capsaicinoid not associated with 
proportional change in TEWL, in all 
subjects

Capsaicinoid concentration of 16mg/mL 
produced increased mean TEWL in 
Caucasians, decreased mean TEWL in 
Asians ( p < 0.05)

Caucasians 15 (skin type 

Anterior 

Postitive dose-dependent correlation 

II/III)

forearm

African Americans 15 (skin 

type V/VI)

(ages 18–49y, all)

between TEWL and irritant 
concentration:

Mean TEWL Caucasians > African 

Americans (P < 0.005)

Relative increment of increase in TEWL 

after irritant:

Caucasians > African Americans (P < 0.005)
(continued)

 
Table 43.1  TEWL (continued)

Study

Technique

No. of subjects

Site

Results

ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  401

Fotoh et al. 2008

In vivo

Gunathilake et al. 

In vivo

2009

Muizzuddin et al. 

In vivo

2010

Forehead and 
volar forearm

No significant differences in baseline 
TEWL between races at each site 
Baseline forehead TEWL significantly 
higher than volar forearm for each race 
( p < 0.001)

Volar forearm

Barrier recovery kinetics, measured by 
TEWL at 24 and 48 hours after tape 
stripping, was significantly higher in skin 
type IV–V than skin type I–IIs

Left facial 
cheek

Baseline TEWL: African Americans < East 

Asians < Caucasians ( p < 0.001)

Sub-Saharan Africans or 

Carribbean black women 
25 (mean age 24 ± 4y)

African or Caribbean 

mixed-race women 25 
(mean age 24 ± 7y)
European Caucasian 

women 25 (mean age 
12 ± 4y)

Skin type I–II:
Germany 20
Skin type IV–V:
Sri Lanka 20

African American women 
Skin type IV–VI 73  
(35.1 ± 7.5y)

Caucasian women skin 

type II–III 119  
(36.0 ± 6.0y)

East Asian women skin 

type III–IV 149  
(30.2 ± 5.8y)

Chu et al. 2011

In vivo

Caucasian females 84
African American females 

Dorsal forearm
Upper inner 

Caucasian had a significantly higher 
TEWL matched by age ( p < 0.05)

Luther et al. 2012

In vivo

Yamashita et al. 

In vivo

2012

67

Age range 15–75y

Caucasian males 6 – skin 
type II–III (28.1 ± 4.3y)
African males 6 – skin type 

V–VI (27.3 ± 3.2y)

Asian males 6 – skin type 

IV (23.5 ± 1.6y)
Japanese Asian 43  

(41.1 ± 12.8y)

French Caucasian 104 

(40.4 ± 14.4y)

arm

Volar forearm

No statistically significant differences in 

TEWL between the three ethnic groups

Cheek
Dorsal hand
Upper arm

Japanese subjects had a lower baseline 
TEWL compared to French Caucasians

field. Resistance is the reciprocal of conductance. Capacitance 
values are indicative of water content as they are dependent on 
the  high  dielectric  constant  of  water  compared  to  other  sub-
stances.  Generally,  capacitance  and  conductance  values  have 
similar  trends  with  regard  to  observed  values  of  WC  for  the 
skin,  while  resistance  and  impedance  exhibit  the  opposite 
behavior. There are also several sources of potential error when 
measuring WC such as the electrolyte content of the stratum 
corneum, sweat production, filling of the sweat gland, number 
of hair follicles, and artifacts from applied topical agents.

Historically, in 1962, Johnson and Corah reported higher 
skin  resistance  levels  in  blacks  compared  to  whites  in  both 
children and adults. Though the study did not provide a link 
between  resistance  levels  and  hydration,  an  inferred  conclu-
sion  of  the  study  can  be  that  blacks  had  lower  WC  based  on 
skin resistance values (21).

Berardesca  and  Maibach,  in  addition  to  measuring 
TEWL, investigated WC by capacitance pre and post exposure 
to topical SLS in blacks and whites. The authors did not find 
any  significant  differences  in  WC  before  or  after  SLS  stress 
between the two ethnic groups (5). In a similar study involv-
ing  Hispanics  and  whites,  there  were  no  overall  statistically 
significant differences in WC values observed between the two 
groups (12).

Berardesca et al. studied WC by conductance in blacks, 
whites,  and  Hispanics  on  two  different  sites,  the  dorsal  and 
the  volar  forearm.  Regarding  the  dorsal  forearm,  blacks  and 
Hispanics  had  a  statistically  significant  increased  WC  than 
Caucasians.  Sugino  et  al.  measured  WC  with  an  imped-
ance  meter  and  found  a  higher  WC  in  Asians  compared  to 
Caucasians,  blacks,  and  Hispanics.  Though  the  exact  study 
parameters  were  not  documented,  the  authors  did  correlate 
the  high  WC  with  higher  ceramide  and  lower  TEWL  values 
that  were  also  investigated  in  the  same  study  (3).  Warrier  et 
al. reported a significantly higher WC on the cheeks of black 
women compared to whites. The authors did not observe dif-
ferences  between  the  ethnic  groups  on  the  forearms  and  the 
legs (22).

Additional studies by Manuskiatti et al., Sivamani, and 
Grimes  et  al.  did  not  find  differences  in  WC  between  ethnic 
groups that included Caucasian, African American, Hispanic, 
and  Asian  participants  (23–25).  Recently,  Fotoh  et  al.  and 
Luther et al. conducted studies that also did not observe statis-
tically significant differences in skin hydration between ethnic 
groups (6,7).

Recent studies have reported differences in WC between 
ethnic  groups  with  respect  to  sun-exposed  sites.  Diridollou 
et  al.  measured  WC  in  311  women  with  capacitance  tests 

 
402 

 TEXTBOOK OF COSMETIC DERMATOLOGY

and found that lighter skin tone groups such as Chinese and 
Caucasians had a higher dryness skin index on sun-exposed 
sites compared to African Americans and Mexicans (26). Chu 
et al. corroborated these results when comparing WC through 
conductance  on  the  dorsal  forearm  and  the  upper  inner  arm 
between  84  Caucasian  females  and  67  African  American 
females.  In  the  study,  African  American  females  exhibited  a 
statistically  significant  higher  WC  compared  to  Caucasian 
females at the sun-exposed dorsal forearm (9). Yamashita also 
found lowered water content in French Caucasians compared 
to Japanese Asians (10).

The results from the published studies regarding WC in 
different  ethnic  groups  remain  conflicting  and  inconclusive 

(Table 43.2). Multiple studies were unable to find a significant 
difference  in  WC.  There  is  evidence  suggesting  a  possible 
racial variance in WC at sun-exposed sites, but this conclusion 
has  yet  to  be  validated.  Based  on  the  available  literature,  no 
conclusions  with  respect  to  ethnicity  and  WC  can  be  made. 
Comparing  WC  measurements  between  studies  is  difficult 
because of possible confounding factors. Physical factors, such 
as sweat production and hair presence, can affect the measure-
ments by modifying the quality of the skin electrode contact. 
Therefore,  there  may  be  variables  other  than  race  that  deter-
mine  the  WC  of  a  person’s  skin.  Future  studies  with  larger 
sample  sizes  and  multiple  methods  for  measuring  WC  can 
help assess the true relationship between race and WC.

Table 43.2  Water Content

Study

Technique

No. of subjects

Site

Results

Johnson and Corah 1962

In vivo

St Louis:
Black boys 22; black 

First and third fingers 

of right hand

girls 32

White boys 65; white 

girls 55

(age 83–92mo, all)
San Diego:
Black men 16; black 

women 5

White men 16; white 

women 5
(age 23y, all)

Berardesca and Maibach 

In vivo – topical 

Black men 10 (age 

Back

1988

application of SLS 
(irritant) 
– capacitance

29.9 ± 7.2y)

White men 9 (age 
30.6 ± 8.8y)

Berardesca and Maibach 

In vivo – topical 

Hispanic men 7 (age 

Upper back

1988

application of SLS 
(irritant)

27.8 ± 4.5y)

White men 9 (age 
30.6 ± 8.8y)

Berardesca et al. 1991

In vivo

Blacks 15 (mean age 

Volar and dorsal 

forearm

46.7 ± 2.4y)

Whites 12 (mean age 

49.8 ± 2y)

Hispanics 12 (mean age 

48.8 ± 2y)

Sugino et al. 1993

In vivo – impedance

Blacks, Caucasians, 

Not documented

Hispanics, Asians (no. 
of subjects, ages not 
specified)

Skin resistance blacks > 
whites at baseline  
( p < 0.01); i.e. blacks 
have lower water 
content

No significant difference 
in WC between blacks 
and whites at baseline 
before or after SLS 
stress

No significant differences 
between Hispanics and 
whites at baseline

After SLS stress:
Hispanics > whites when 
negative visual score 
was given for irritation 
( p < 0.01) [large 
standard deviations]

Blacks (13% less) volar < 

dorsal forearm ( p < 0.02)
Whites (22% les) dorsal < 
volar forearm (P < 0.001)

Hispanics (11% less) 

dorsal < volar forearm 
( p < 0.05)

Black and Hispanics > 

whites on dorsal forearm 
at baseline

Hispanics > blacks and 

whites on volar forearm 
at baseline

Asians > Caucasians, 
blacks, and Hispanics

(continued)

 
Table 43.2  Water Content (continued)

Study

Technique

No. of subjects

Site

Results

ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  403

Warrier et al. 1996

In vivo – capacitance

Black women 30
White women 30
(ages 18–45y, all)

Left and right medial 

cheeks

Mid-volar forearms
Lateral mid-lower legs

Manuskiatti et al. 1998

In vivo – capacitance

Sivamani et al. 2003

In vivo – impedance, 

topical application of 
petrolatumand 
glycerin

Grimes et al. 2004

In vivo – capacitance

Diridollou et al. 2007

In vivo – capacitance

Fotoh et al. 2008

In vivo – capacitance

Black women 7
White women 5
(mean age 25.8 ± 4.2y, 

both)

Black women 5
White women 5
(mean age 64.7 ± 3.8y, 

both)

White 22
African American 14
Hispanic 14
Asian 9
(ages 18–60y, all)

African American 18
White 19
(ages 35–65y, women, 

all)

311 American women 
from four ethnic 
groups: African 
American, Chinese, 
Caucasian, Mexican

Divided into two age 

groups
Age 18–50y:
African Americans 56; 

Chinese 44; 
Caucasian 41; 
Mexican 30

Age > 51y:
African American 58; 

Chinese 45; 
Caucasian 22; 
Mexican 15

Sub-Saharan Africans 
or Carribbean black 
women 25 (mean age 
24 ± 4y)

African or Caribbean 

mixed-race women 25 
(mean age 24 ± 7y)
European Caucasian 

women 25 (mean age 
12 ± 4y)

Chu et al. 2011

In vivo – conductance

Caucasian females 84
African American 

Dorsal forearm
Upper inner arm

females 67

age range 15–75y

Blacks > whites on 

cheeks at baseline  
(P < 0.05)

No significant difference 
between races on 
forearms and legs

No significant differences 
between blacks and 
whites at baseline

Preauricle, posterior 
neck, dorsal upper 
arm, dorsal forearm, 
volar forearm, lower 
back, abdomen, 
thigh, lower leg

Volar forearm

Baseline: No significant 

differences in electrical 
impedance between 
age, gender, or 
ethnicity; impedance of 
proximal < distal forearm 
(P < 0.001)

Inner forearm

Baseline: African 

Ventral forearm
Dorsal forearm

Americans < Whites, but 
not statistically 
significant

Dryness Skin Index is 
higher in lighter skin 
tone groups on sun-
exposed sites (Chinese 
and Caucasian women) 
than the other ethnic 
groups

Forehead and volar 

forearm

No statistically significant 
differences in hydration 
between the three 
groups

Black women had a 

reduced cutaneous 
hydrophilicity compared 
to the mixed-race group 
and Caucasian group

African Americans > 

Caucasians with respect 
to the dorsal forearm  
( p < 0.05)

No significant differences 

in conductance 
between the ethnicities 
at the upper inner 
arm site

(continued)

 
404 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 43.2  Water Content (continued)

Study

Luther et al. 2012

Technique

In vivo – not 

documented

Yamashita et al. 2012

In vivo – conductance 

for Japanese; 
capacitance for 
French

No. of subjects

Site

Results

Caucasian males 

Volar forearm

No statistically significant 

6 – skin type II–III 
(28.1 ± 4.3y)

African males 6 – skin 

type V–VI 
(27.3 ± 3.2y)

Asian males 6– skin 

type IV (23.5 ± 1.6y)

Japanese Asian 43 
(41.1 ± 12.8y)

French Caucasian 104 

(40.4 ± 14.4y)

differences in skin 
hydration between the 
three ethnic groups

Cheek
Dorsal hand
Upper arm

Japanese subjects had 
higher water content 
compared to French 
Caucasians

CORNEOCYTE VARIABILITY
Keratinocytes  produce  corneocytes  that  differ  in  size  and 
shape from the keratinocytes. Corneocytes are shaped in the 
form of a disk that allows them to have a larger surface area 
in  the  horizontal  position.  In  Caucasians,  it  has  been  shown 
that  the  surface  area  of  corneocytes  differs  by  body  site  and 
that the surface area has an important role in determining the 
permeability of the skin to water as well as the percutaneous 
absorption of topical substances (27–29).

Corcuff  et  al.  studied  the  corneocyte  surface  area  and 
spontaneous  desquamation  between  African  Americans, 
Caucasians,  and  Asian  Americans.  The  investigators  did  not 
observe a difference in the surface area between the groups but 
found  that  spontaneous  desquamation,  indicated  by  corneo-
cyte count, was increased in African Americans by a factor of 
2.5 compared to the other ethnic groups (30). The investigators 
concluded  that  the  enhanced  desquamation  could  partially 
explain  the  “ashing”  phenomenon  clinically  seen  in  African 
Americans.  Warrier  et  al.  compared  the  desquamation  index 
in  30  blacks  and  30  white  subjects,  matched  for  age,  on  their 
cheeks, foreheads, and lower legs. Warrier et al. did report a sig-
nificantly lower desquamation index in African Americans on 
the cheeks and forehead compared to Caucasians. This result 
contradicts the clinical finding of dry skin commonly seen in 
African Americans. No significant difference was found on the 
legs. The authors suggested that the differences found on the 
face may be due to the differences of the moisturizing proper-
ties of sebum between the ethnic groups (22). Manuskiatti et 
al. studied the desquamation index in a smaller population of 
African Americans and Caucasians. The authors found no sig-
nificant differences in desquamation indices between African 
Americans and Caucasians at the posterior neck, dorsal upper 
arm,  dorsal  volar  forearm,  lower  back,  abdomen,  thigh,  and 
lower leg. Though they did find a significant difference at the 
preauricular  area,  the  authors  said  that  the  difference  might 
not be valid due to the small sample size.

Fotoh  et  al.  measured  the  thickness  of  the  corneocytes 
from  spontaneous  desquamation  at  the  dorsal  and  volar 
forearm  in  three  different  ethnic  groups  comprised  of  only 
females: 25 Caribbean Africans, 25 Caribbean mixed-race, and 
25  European  Caucasians.  No  significant  differences  between 
the groups were observed (6).

Gunathilake  et  al.  observed  an  increase  in  retention  of 
corneodesosmoes  in  the  upper  layer  of  the  stratum  corneum 

for  darker  skin  types,  potentially  resulting  in  enhanced  SC 
barrier  function  (19).  Recently,  Muizuddin  et  al.  compared 
the degree of cross-linking in corneocytes (maturation index) 
between  African  Americans,  Caucasians,  and  East  Asians 
on  the  left  facial  cheek.  The  authors  found  that  the  matura-
tion  index  value,  indicative  of  the  degree  of  terminal  differ-
entiation, was the highest in African Americans compared to 
Asians.  The  investigators  suggested  that  higher  value  could 
be  positively  associated  with  enhanced  barrier  integrity  in 
African  Americans  (8).  Furthermore,  Yamashita  et  al.  found 
a  statistically  significant  increased  size  of  corneocytes  in 
Japanese Asians compared to French Caucasians. The authors 
concluded that the finding might validate the enhanced barrier 
function observed by the measurements of other values in the 
same study (10).

Instead 

between 

of  differentiating 

ethnicities, 
Gunathilake  et  al.  compared  the  cornified  envelope  thick-
nesses  between  pigment  skin  types  of  I/II  and  IV/V.  The 
authors reported that the darker pigment skin types exhibited 
thicker  cornified  envelopes.  The  authors  suggested  that  the 
thicker cornified envelopes in skin types IV/V could help the 
permeability barrier function of the epidermis (19).

The evidence regarding corneocyte variability between 
ethnic groups remains inconclusive (Table 43.3). Multiple ear-
lier  studies  either  found  contradictory  results  with  regard  to 
degree  of  corneocyte  desquamation  or  desquamation  index 
between  ethnic  groups,  or  did  not  find  statistically  signifi-
cant  differences  (6,22,23,30).  However,  recent  studies  suggest 
that  parameters  measuring  different  elements  of  corneocyte 
desquamation can play an important factor in enhanced bar-
rier  function  for  African  Americans,  Japanese  Asians,  and 
skin types IV/V compared to Caucasians and skin types I/II 
(10,19,23). Further controlled studies are required to adequately 
measure corneocyte desquamation and provide insight into its 
clinical implications in skin disorders including xerosis.

BLOOD VESSEL REACTIVITY
Blood flow in the skin has been investigated to evaluate skin 
physiology,  irritation,  cutaneous  pathology,  dermatologic 
treatments, drug delivery, and wound healing. Early on, cuta-
neous  blood  flow  was  evaluated  by  visual  assessment  of  the 
degree of erythema or pallor. However, newer techniques have 
been implemented to measure cutaneous microcirculation by 

 
Table 43.3  Corneocyte Variability

Study

Technique

No. of Subjects

Site

Results

ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  405

Corcuff et al. 1991

In vivo

Warrier et al. 1996

In vivo

Manuskiatti et al. 1998

In vivo

Fotoh et al. 2008

In vivo

Gunathilake et al. 2009

In vivo

Black (mean age 
33.5 ± 7.5y)

Caucasian (mean age 

31 ± 7y)

Asian (mean age  

26.5 ± 7.5y)

(18–25 subjects per 

group)

Black women 30
White women 30
(ages 18–45y, all)

Black women 7
White women 5
(mean age 25.8 ± 4.2y, 

both)

Black women 5
White women 5
(mean age 64.7 ± 3.8y, 

both)

Sub-Saharan Africans 
or Carribbean black 
women 25 (mean age 
24 ± 4y)

African or Caribbean 

mixed-race women 25 
(mean age 24 ± 7y)
European Caucasian 

women 25 (mean age 
12 ± 4y)

Skin Type I–II:
Germany 110
San Francisco 14
Skin type IV–V:
Sri Lanka 129
San Francisco 10

Upper outer arm

Left and right medial 

cheeks

Mid-volar forearms
Lateral mid-lower legs

Preauricle, posterior 
neck, dorsal upper 
arm, dorsal forearm, 
volar forearm, lower 
back, abdomen, thigh, 
lower leg

No difference in corneocyte 
surface area spontaneous 
desquamation 
(corneocyte count) blacks 
2.5× > Caucasians & 
Asians ( p < 0.001)

Desquamation index blacks 
< whites on cheeks (18% 
less) and forearms 
(20% less)

[ p < 0.05]; but no 

significant differences 
on the legs

No difference in 

desquamation index 
between blacks and 
whites except at 
preauricular area  
( p = 0.02) [which 
race greater not  
specified]

Forehead and volar 

No significant differences in 

forearm

Volar forearm
Dorsal hand

Muizzuddin et al. 2010

In vivo

African American 

Left facial cheek

Yamashita et al. 2012

In vivo

women skin type 
IV–VI 73 (35.1 ± 7.5y)
Caucasian women skin 

type II–III 119  
(36.0 ± 6.0y)

East Asian women skin 

type III–IV 149  
(30.2 ± 5.8y)

Japanese Asian 43 
(41.1 ± 12.8y)

French Caucasian 104 

(40.4 ± 14.4y)

Cheek
Dorsal hand
Upper arm

the thickness of 
spontaneous 
desquamation of the 
corneocytes, 
desquamation index, 
between the ethnic 
groups

Skin type IV–V exhibited 
significantly thicker 
cornified envelopes 
and retention of 
corneodesmosomes 
in upper layer of SC 
compared to skin 
types I–II  
( p < 0.0006)

African Americans had the 
highest maturation index 
value, indicative of 
terminal 
differentiation, compared 
to the other groups  
( p < 0.001) followed by 
Caucasians, then  
Asians

Japanese subjects had a 
statistically significant 
increased size of 
corneocytes on the 
cheek only compared to 
French Caucasians  
( p < 0.01)

 
406 

 TEXTBOOK OF COSMETIC DERMATOLOGY

objective  metrics.  The  techniques  utilized  by  the  presented 
studies  include  laser  Doppler  velocimetry  (LDV)  and  photo-
plethysmography (PPG).

LDV is noninvasive and measures the flow of red blood 
cells  based  on  the  Doppler  frequency  shift  in  the  laser  light 
reflected  from  the  blood  cells  in  motion.  The  shift  outputs  a 
flow  measurement  that  is  related  to  the  number  of  erythro-
cytes multiplied by their velocity in the skin microvasculature. 
PPG is another noninvasive method that measures blood flow 
in  the  cutaneous  microcirculation.  PPG  utilizes  a  transducer 
to  emit  infrared  light  that  is  absorbed  by  the  hemoglobin  in 
the  skin  blood  vessels.  A  photodetector  detects  and  records 
the  backscattered  radiation  that  is  dependent  on  the  amount 
of  hemoglobin  in  the  skin.  LDV  and  PPG  have  been  utilized 
for studies on skin physiology, dermatological disorders, and 
systemic diseases.

Guy et al. investigated the response of cutaneous blood 
vessels  to  a  topical  vasodilator,  methyl  nicotinate,  with  LDV 
and PPG in six black and six white subjects. The investigators 
found  no  significant  differences  between  the  ethnic  groups 
with respect to multiple measurements including area under 
the response–time curve and time to 75% delay of maximum 
response. Though the authors did note lowered PPG maximal 
responses in blacks, their overall conclusion was that the blood 
vessel reactivity between ethnic groups was similar (31).

Berardesca  and  Maibach  compared  the  differences  in 
blood vessel reactivity pre and post exposure to topical 0.5% 
and 2.0% SLS between ethnic groups in two different studies: 
one study between blacks and whites and the other between 
Hispanics and whites. Both studies did not reveal a significant 
difference  in  blood  vessel  response  between  either  groups 
before and after application of SLS (5,12). However, Berardesca 
and  Maibach  utilized  LDV  to  examine  differences  in  blood 
vessel reactivity between blacks and whites to topical cortico-
steroid, a vasoconstrictor, instead of to topical SLS. The authors 
found that black subjects showed a 40% decreased area under 
the  curve  response,  50%  decreased  peak  response,  and  a 

Table 43.4  Blood Vessel Reactivity

decreased slope of decay after maximum blood flow compared 
to  whites.  The  authors  concluded  that  black  subjects  exhib-
ited  a  decreased  blood  vessel  reactivity  compared  to  whites 
in response to topical corticosteroids (32). Gean et al. observed 
conflicting results in their study as they studied blood vessel 
reactivity by LDV in response to a vasodilator (methyl nicotin-
ate) between blacks, Caucasians, and Asians. The investigators 
found a statistically significant increased area under the curve 
response in blacks and Asians compared to Caucasians (33).

Kompaore et al. evaluated lag time to vasodilation with 
LDV  before  and  after  tape  strippings  to  remove  the  stratum 
corneum  in  black  and  Caucasian  subjects.  The  investigators 
found an increase in lag time in vasodilation in blacks before 
tape  stripping  but  in  response  to  methyl  nictotinate.  After 
8 and 12 tape strips, the lag time to vasodilation decreased in 
all three ethnic groups but a statistically significant decrease in 
lag time was specifically observed in Asians. The authors were 
unable to explain the reason behind the ethnic differences in 
lag time to vasodilation (2).

Aramaki  et  al.  did  not  observe  blood  vessel  reactiv-
ity  measured  by  LDV  in  response  to  SLS-induced  irrita-
tion  between  Japanese  and  German  women  (13).  Hicks  et  al. 
also  did  not  find  statistically  significant  differences  in  LDV-
measured  blood  vessel  response  to  1%  and  4%  SLS  between 
black and white skin (17).

Overall,  the  evidence  regarding  blood  vessel  reactivity 
and its differences in ethnic groups is limited and contradic-
tory  (Table  43.4).  Studies  have  reported  both  increased  and 
decreased  statistically  significant  differences  in  blood  ves-
sel  response  between  ethnic  groups.  Many  studies  also  did 
not  observe  blood  vessel  reactivity  differences  among  ethnic 
groups. One limitation in the comparison of the studies is the 
differences  in  the  topical  substance  used  in  each  study  (SLS 
vs.  corticosteroid  vs.  methyl  nicotinate).  Further  studies  are 
needed to clearly elucidate the differences, as the results could 
explain  disparities  seen  in  irritation  and  dermatotoxicology/
pharmacology among ethnic groups.

Study

Guy et al. 1985

Technique

No. of Subjects

Site

Results

Topically administered 

MN (vasodilator); LDV 
and PPG

Blacks 6 (age 20–30y)
Whites 6 (age 20–30y)
Whites 6 (age 63–80y)

Volar forearm

Berardesca and Maibach 

In vivo – topical 

Black men 10 (age 

Back

1988

application of SLS 
(irritant); LDV

29.9 ± 7.2y)

White men 9 (age 
30.6 ± 8.8y)

Berardesca and Maibach 

In vivo – topical 

Hispanic men 7 (age 

Upper back

1988

application of SLS 
(irritant); LDV

27.8 ± 4.5y)

White men 9 (age 
30.6 ± 8.8y)

MN given:
No significant difference in time 
to peak response, area under 
response-time curve, or time 
for response to decay to 75% 
of its max value PPG max 
response young black (40% 
less) < young White ( p < 0.05)

SLS stress:
No significant difference 

between blacks and whites
Blood vessel reactivity minimal 
in blacks from baseline to 
application of 0.5% SLS on 
untreated skin

SLS stress:
Similar LDV response in 
Hispanics and whites

(continued)

 
ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  407

Table 43.4  Blood Vessel Reactivity (continued)

Study

Berardesca and  
Maibach 1989

Technique

No. of Subjects

Topically administered 

corticoid 
(vasoconstrictor); LDV

Black men 6
Caucasian men 8
(mean age 27 ± 3y, 

both)

Site

Forearm

Results

After vasoconstrictor given:
40% decreased area under the 

curve response blacks 
compared with whites  
( p < 0.04)

50% decreased peak response 

in blacks compared with 
whites ( p < 0.01)

Decreased decay slope after 
peak blood flow in blacks 
compared with Caucasians
Less blood vessel reactivity 

noted in blacks

Gean et al. 1989

Topically administered 

MN (vasodilator); LDV

Blacks 5
Caucasians 5
Asians 5
(age 20–35y, all)

Upper 1/3 volar 

forearm

MN given:
Area under the curve for LDV 

Kompaore et al. 1993

In vivo – topical 

application of MN 
– vasodilator; LDV

Blacks 7
Caucasians 8
Asians 6
(age 23–32y, all)

Volar forearm

response versus time blacks > 
Caucasians for all MN 
concentrations ( p < 0.05)
Area under the curve for LDV 

response versus time Asians 
> Caucasians for higher dose 
levels of MN ( p < 0.05)

MN given:
Before tape stripping: no 

difference between the groups 
in basal perfusion flow, but lag 
time before vasodilatation was 
blacks > Caucasians > Asians 
( p < 0.05)

After 8 and 12 tape strips: lag 
time before vasodilatation 
decreased in all three groups, 
but significantly decreased in 
Asians > Caucasians > blacks 
( p < 0.05)

No significant difference at 

baseline or after SLS stress

Aramaki et al. 2002

In vivo – topical 

Hicks et al. 2003

application of SLS 
(irritant); LDV

Topically administered 
SLS (irritant); LDV

Japanese women 22 
(mean age 25.84y)

German women 22 

(mean age 26.94y)

White 8
Blacks 6
(all subjects in the age 

range 18–40y)

Forearm

Volar forearm

SLS stress:
No significant differences in LDV 

response between groups

ELASTIC RECOVERY/EXTENSIBILITY
Berardesca  et  al.  investigated  elastic  recovery  and  skin 
 extensibility on the dorsal and volar forearm in blacks, whites, 
and Hispanics. The authors measured the biomechanical prop-
erties by applying torque parallel to the skin and subsequently 
measuring the ability of the skin to stretch (skin extensibility) 
and  the  time  necessary  for  the  skin  to  recover  to  its  original 
state  after  releasing  the  torque  (elastic  recovery).  They  found 
that blacks had a 26% decrease in elastic recovery compared to 
whites on the volar forearm, but an increase in elastic recov-
ery  in  blacks,  though  not  significant,  on  the  dorsal  forearm. 
Furthermore,  there  were  no  differences  observed  in  elastic 
recovery  between  whites  and  Hispanics  on  either  site.  The 
authors suggested that the superior recovery time on the dor-
sal forearm was related to the greater sun damage to the skin 
experienced by white skin and that black skin exhibited greater 
photoprotection with the presence of increased melanin (4).

The same study reported significant differences in skin 
extensibility between anatomical sites (dorsal < volar forearm) 
in Hispanics and whites, but not in blacks. With regard to race, 
blacks  did  exhibit  greater  extensibility  than  whites  on  the 
dorsal forearm but less extensibility than whites on the volar 
forearm. The authors concluded that the differences between 
anatomic sites for Hispanics and whites, but not blacks, corre-
lated to the fact that blacks had superior photoprotection sec-
ondary to melanin and thus were less susceptible to changes 
in skin elasticity due to sun exposure. This reasoning also was 
applied  to  the  finding  of  greater  extensibility  of  blacks  com-
pared  to  whites  on  the  dorsal  forearm.  However,  this  theory 
could  not  explain  the  increased  extensibility  of  whites  com-
pared to blacks on the volar forearm (4).

Warrier et al. solely looked at elastic recovery in a larger 
sample of patients (30 in each group) between black and white 
women. They found that blacks had a statistically significant 

 
408 

 TEXTBOOK OF COSMETIC DERMATOLOGY

greater increase in elastic recovery compared to whites on the 
cheeks. The investigators did not find a significant difference 
in elastic recovery between the groups on the legs (22).

The  reported  studies  examining  the  biomechanical 
properties, such as elastic recovery and extensibility, between 
ethnic groups are contradictory (Table 43.5). These properties 
are  dependent  on  the  anatomic  site  and  confound  the  data 
attempting  to  observe  differences  in  ethnic  group.  Age  may 
also play a factor in conflicting results, as Warrier et al. had a 
larger age range (18–45 years) while Berardesca enrolled sub-
jects within a small age range (mean age was 46.7–49.8 years) 
(4,22).  Therefore,  based  on  the  available  studies,  the  data  on 
effect  of  ethnic  skin  on  elastic  recovery  or  skin  extensibility 
remains inconclusive.

pH GRADIENT
Differences  in  pH  between  races  and  skin  pigmentation  are 
a  continuing  subject  of  investigation.  Earlier,  Berardesca  et 
al.  did  not  find  differences  in  baseline  cutaneous  pH  values 
between black and Caucasian women. However, the investiga-
tors  did  report  that  the  pH  significantly  decreased  in  blacks 
after  three  tape  strips  (but  not  after  9,  12,  and  15  tape  strips 
indicative of the deeper layers) compared to Caucasians. The 
authors  found  the  results  difficult  to  interpret  but  suggested 
that  the  greater  increase  in  TEWL  observed  in  blacks  after 
three tape strips could allow for an increase in hydrogen ion 
concentration.

Warrier  et  al.  examined  pH  at  baseline  between  black 
and white females but without the use of tape stripping. Blacks 
had a significantly lower pH than whites on the cheeks (22). 
The authors reported a difference on the legs as well between 
the  groups,  but  the  difference  was  not  statistically  signifi-
cant. The authors believed the decreased pH observed on the 
cheeks for blacks to be related to sebum production and the 
potential  notion  that  blacks  have  a  higher  amount  of  sweat 
glands (22). Luther et al. found no statistically significant dif-
ferences of cutaneous pH on the volar forearm of Caucasians, 
Africans, and Asians. The study involved a smaller number 
of  patients  as  the  authors  included  six  patients  per  ethnic 
group (7).

Recently, Gunathilake et al. investigated pH at the skin 
surface  and  melanocytes  with  respect  to  skin  pigment  type 
instead  of  race  alone  in  a  large  number  of  patients.  The  sub-
jects were divided into two skin type groups, skin types I/II 
(n = 124) and IV/V (n = 139), and by three geographical locations: 
Germany,  Sri  Lanka,  and  the  United  States  (San  Francisco). 
The  investigators  found  that  skin  types  IV/V  had  signifi-
cantly  lower  pH  values  on  the  skin  surface  than  skin  types  
I/II.  Furthermore,  skin  types  IV/V  exhibited  lower  pH  val-
ues of the cell bodies and dendrities of melanocytes than skin 
types I/II. The authors concluded that pH played a significant 
role  in  pigment  type  differences  in  epidermal  structure  and 
function. Specifically, they attributed the enhanced epidermal 
barrier function and recovery in skin types IV/V, also reported 
in  the  same  study,  to  the  lower  pH  values.  Furthermore,  the 
investigators  found  that  the  topical  application  of  two  poly-
hyroxyl acids, to lower the pH of skin type I/II to that of the 
darker pigment skin types, resulted in accelerated epidermal 
barrier recovery and kinetics in the lighter skin types (19).

Earlier  studies  found  limited  differences  in  pH  levels 
between ethnic groups (Table 43.6). However, the studies were 
smaller compared to the larger trial conducted by Gunathilake 
et  al.  The  differences  in  pH  between  ethnic  groups  or  skin 
types  should  be  further  investigated  because  of  its  possible 
affect  on  the  epidermal  barrier  function  and  recovery.  These 
differences  could  explain  a  person’s  propensity  to  develop 
cutaneous infections or eczematous dermatoses.

LIPID CONTENT
Racial differences in lipid content in the skin have been increas-
ingly studied. Initially, Reinerston and Wheatley utilized skin 
from black and white cadavers and found an increase in epi-
dermal lipid and sterol content in blacks compared to whites. 
In contrast, Sugino et al. investigated ceramide levels between 
blacks, whites, Hispanics, and Asians. They found that blacks 
had 50% lower ceramides, which was statistically significant, 
compared  to  whites  and  Hispanics  (34).  Harding  et  al.  stud-
ied stratum corneum lipid content of the scalp in UK and Thai 
subjects who had dandruff. The investigators reported similar 
levels of scalp lipids in both groups (35).

Table 43.5  Elastic Recovery/Extensibility

Study

Technique

No. of subjects

Site

Results

Berardesca et al. 1991

In vivo

Blacks 15 (mean age 

Volar and dorsal 

forearm

46.7 ± 2.4y)

Whites 12 (mean age 

49.8 ± 2y)

Hispanics 12 (mean age 

48.8 ± 2y)

Warrier et al. 1996

In vivo

Black women 30
White women 30
(ages 18–45y, all)

Left and right medial 

cheeks

Mid-volar forearms
Lateral mid-lower legs

No significant difference 
between races on 
dorsal forearm

Significant dorsal < volar 
extensibility within 
whites and Hispanics  
( p < 0.0001 and  
p < 0.0002, 
respectively) black > 
white extensibility dorsal 
forearm ( p < 0.01) black 
< white extensibility 
volar forearm ( p < 0.01)
No significant difference 
between races on the 
legs

Elastic recovery blacks 
1.5× > whites on 
cheeks ( p < 0.05)

 
Table 43.6  pH Gradient

Study

Warrier et al. 1996

Technique

In vivo

Berardesca et al. 1998

In vivo

Grimes et al. 2004

In vivo

Gunathilake et al. 2009

In vivo

Luther et al. 2012

In vivo

ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  409

No. of subjects

Site

Results

Black women 30
White women 30
(ages 18–45y, all)

Black women 8
Caucasian women 10
(mean age 42.3 ± 5y, 

both)

African American 18
White 19
(ages 35–65 yr, women, 

all)

Skin Type I–II:
Germany 110
San Francisco 14
Skin type IV–V:
Sri Lanka 129
San Francisco 10

Left and right medial 

pH blacks (pH = 5.15)  

cheeks

Mid-volar forearms
Lateral mid-lower legs

< whites (pH = 5.52) on 
cheeks at baseline  
( p < 0.05)

No significant difference 
in pH on the legs at 
baseline

Mid-volar forearm

No significant difference 

in pH at baseline

After tape stripping: pH 

significantly decreased 
in blacks after three 
tape strips, i.e. 
superficial SC layers
No differences between 
races after 9, 12, and 
15 tape strips, i.e. 
deeper SC layers

Inner forearm

Baseline: African 

Volar forearm
Dorsal hand

Americans < whites, 
but not statistically 
significant

Skin type IV–V had 
significantly lower/
acidic surface pH 
values compared to 
skin type I–II  
( p < 0.0001)

Skin types IV–V had a 
lower pH value of the 
cell bodies and 
dendrities of 
melanocytes than skin 
type I–II ( p < 0.05)

No statistically significant 

differences in 
cutaneous pH between 
the three ethnic groups

Volar forearm

Caucasian males 6 
– skin type II–III  
(28.1 ± 4.3y)

African males 6 – skin 

type V–VI  
(27.3 ± 3.2y)

Asian males 6– skin 

type IV (23.5 ± 1.6y)

Fotoh  et  al.  studied  sebum  quantity  and  measured 
the  lipidic  index  in  Caribbean,  Caribbean  mixed-race,  and 
European Caucasian women (6). The authors did not see a sig-
nificant difference in these metrics between the three groups. 
Luther et al. also did not reveal any ethnic differences of sebum 
content between Caucasian, African, and Asian males, though 
their sample size was fairly small (total n = 18) (7).

However, recently, studies have pointed to a difference 
in ceramide and lipid composition of the epidermis between 
racial groups. Gunathilake et al. found that darker skin pig-
ment types IV/V exhibited increased density of lamellar bod-
ies  in  the  stratum  corneum  and  increased  epidermal  lipid 
content  compared  to  skin  types  I/II.  The  authors  attributed 
these results to the explanation of the superior barrier func-
tion  and  recovery  the  authors  also  discovered  in  the  same 
study  (19).  Muizzuddin  et  al.  found  that  African  Americans 
had  significantly  fewer  lipid  ceramides,  specifically  C18 
phytosphingosine–based  ceramides,  than  Caucasians  and 

Asians.  The  authors  only  quantified  C19  phytosphingosine 
bases  but  suggested  that  these  levels  were  representative  of 
the total amount of ceramides in the epidermis. The investiga-
tors concluded that the lower ceramide levels could be charac-
teristic of dry and scaly skin representing possible impaired 
water retention (8). Jungersted et al. specifically measured the 
ceramide/cholesterol ratio in African, Asian, and Danish sub-
jects. They found that Africans had a statistically decreased 
ceramide:cholesterol  ratio  and  the  findings  correlated  with 
the  global  incidence  of  atopic  dermatitis  found  in  these 
groups (36).

The  data  regarding  lipid  content  in  the  skin  remains 
inconclusive  as  studies  arrived  at  different  conclusions 
(Table  43.7).  However,  larger  recent  studies  have  indicated 
possible  differences  in  lipid  content  that  can  reveal  informa-
tion about the development of pathological disorders between 
ethnicities.  Further  studies  are  needed  to  validate  these 
conclusions.

 
Site

Results

Cadavers: Abdomen
Living: Back and thigh

Lipid and sterol content in 
total epidermis blacks > 
whites

410 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 43.7  Lipid Content

Study

Technique

Reinertson and Wheatley 

In vivo

1959

Sugino et al. 1993

In vivo

Harding et al. 2002

In vivo

Fotoh et al. 2008

In vivo

Gunathilake et al. 2009

In vivo

No. of subjects

Cadavers:
Black man 1
White man 3
Living:
Black man 1
White man 1
(age 49–68, all)

Blacks, Caucasians, 
Hispanics, Asians
(no. of subjects, ages 

not specified)

UK 41
Thai (dry season) 31
Thai (humid season) 31
(age 20–40y, all)

Sub-Saharan Africans 
or Carribbean black 
women 25 (mean age 
24 ± 4y)

African or Caribbean 

mixed-race women 25 
(mean age 24 ± 7y)
European Caucasian 

women 25 (mean age 
12 ± 4y)

Skin Type I–II:
San Francisco 14
Skin type IV–V:
San Francisco 10

Not documented

Scalp

Forehead and volar 

forearm

Volar forearm
Dorsal hand

Muizzuddin et al. 2010

In vivo

African American 

Left facial cheek

Jungersted et al. 2010

In vivo

Luther et al. 2012

In vivo

women skin type 
IV–VI 73 (35.1 ± 7.5y)
Caucasian women skin 

type II–III 119  
(36.0 ± 6.0y)

East Asian women skin 

type III–IV 149  
(30.2 ± 5.8y)

African 18 (median age 
27y, range 22–34y)
Asians 25 (median age 
24y, range 20–39y)
Danish 28 (median age 
25y, range 20–38y)

Caucasian males 6 
– skin type II–III  
(28.1 ± 4.3y)

African males 6 – skin 

type V–VI  
(27.3 ± 3.2y)

Asian males 6– skin 

type IV (23.5 ± 1.6y)

Volar forearm

Volar forearm

Ceramide levels blacks 
(50% less) < whites 
and Hispanics  
( p < 0.05)

UK and Thai subjects 

demonstrated similar 
levels of total lipids

No significant differences 
in the lipidic index and 
sebum quantity 
between the ethnic 
groups

Skin type IV–V exhibited 
increased density of 
lamellar bodies in the 
stratum granulosum 
and increased 
epidermal lipid content 
compared to skin types 
I–II

African Americans had 
significantly fewer 
ceramides (C18 
phytosphingosine 
based ceramides) than 
Caucasians and Asians 
( p < 0.001)

African subjects had the 
statistically significant 
lowest ceramide/
cholesterol ratio 
compared to both Asian 
and Danish subjects ( p 
< 0.001). Asian subjects 
had the highest ratio
No statistically significant 
differences in sebum 
content between the 
three ethnic groups

 
ANTIOXIDANT STATUS
The antioxidant system in the skin is important in  neutralizing 
free radicals generated by oxidative stress that can be a result 
of  UV  radiation  or  other  stressors.  The  free  radicals  can  be 
cytotoxic  and  have  many  consequences,  including  impaired 
barrier function or development of cutaneous carcinoma (37). 
The presence of the photoprotective melanin has always been 
thought to be the main reason for the lowered incidence of skin 
cancers in ethnic skin compared to Caucasian skin. However, 
differences in antioxidant levels may also play a critical role.

Recent  studies  have  investigated  the  potential  ethnic 
differences in antioxidant activity within the skin. Yamashita 
et  al.  measured  the  levels  of  the  antioxidant  catalase  in  43 
Japanese Americans and 104 French Caucasians. Japanese sub-
jects had statistically significant higher catalase  activity  than 
French subjects. The authors correlated the increased catalase 
activity  with  the  superior  hydration  and  barrier  function  in 
Japanese  skin  also  reported  in  the  same  study  (10).  Luther  et 
al. were unable to find a statistically significant difference in 
cutaneous levels of antioxidants such as β-carotene and lyco-
pene  between  Caucasians,  Africans,  and  Asians.  The  sample 
size in this study was limited, as 18 subjects were enrolled in 
the study.

Antioxidant  activity  between  ethnic  groups  has  only 
recently been investigated and reported, but the clinical impli-
cations can be great (Table 43.8). The detailed classification of 
differences  in  antioxidant  capacity  between  ethnic  skins  can 
reveal  information  about  ethnic  variations  in  dermatological 
disorders  as  well  as  incidences  of  cutaneous  carcinoma  and 
should be further investigated.

FACIAL PORE SIZE
Sugiyama  et  al.  investigated  the  differences  in  pore  sizes 
between Caucasian, African, and Hispanic females (Table 43.9). 
The investigators found that Asians had the smallest pore areas 
on the cheek compared to the other groups. African Americans 
had  the  most  severe  impairment  of  architecture  around 
the  facial  pores.  The  authors  suggested  that  impairment  of 

ETHNIC DIFFERENCES IN SKIN PROPERTIES 

  411

surrounding epidermal architecture affected pore size in each 
ethnic group and ultimately affected the visual appearance of 
facial pores (38).

EPIDERMAL INNERVATION
Reilly et al. analyzed the racial differences of skin innervation 
and  nociceptor  activity  in  response  to  irritancy.  The  investi-
gators  did  not  find  any  significant  differences  in  epidermal 
innervation  between  Caucasian,  Japanese,  and  Chinese  sub-
jects in response to capsaicin (39).

CONCLUSION
Ethnic  variations  in  skin  properties  have  currently  not  been 
adequately  defined.  Different  studies  analyzing  properties 
in similar ethnic groups often report conflicting results from 
the previous literature. Also, only a limited number of studies 
have been conducted with an appropriate sample size and con-
trols for confounding factors to adequately elicit valid conclu-
sions. A significant proportion of the studies only look at black 
and white skin and do not incorporate other racial groups such 
as  Asian,  Hispanic,  Indian,  Mediterranean.  One  obstacle  in 
analyzing the studies is the classification of race or ethnicity. 
Anthropologists  segregate  racial  groups  based  on  the  notion 
that  racial  variations  underwent  a  natural  selection  process 
resulting in changes in genetics to help each group to adapt to 
their  particular  environments.  Race  can  also  be  defined  sub-
jectively  based  on  one’s  own  perception  of  oneself  and  their 
presumed  ancestry.  The  ambiguity  of  these  subjective  labels 
can obscure the interpretation of these studies in defining true 
variations  inherent  in  skin  structure  and  physiology.  Future 
studies into genetics would assist in providing insight on the 
published data and help draw conclusions. Among many fac-
tors, future research studies should involve larger numbers of 
subjects, investigate the differences by Fitzpatrick skin types, 
control  for  geography/climate,  incorporate  skin  disease  sta-
tus,  and  document  skin  care  use  of  the  subject.  Currently, 
there is enough data to suggest that there are inherent ethnic 

Table 43.8  Antioxidant Status

Study

No. of subjects

Site

Results

Luther et al. 2012

Caucasian males 6 – skin type 

Volar forearm

II–III (28.1 ± 4.3y)

African males 6 – skin type 

V–VI (27.3 ± 3.2y)

Asian males 6 – skin type IV 

(23.5 ± 1.6y)

Yamashita et al. 2012

Japanese Asian 43  

(41.1 ± 12.8y)

French Caucasian 104  

(40.4 ± 14.4y)

Cheek
Dorsal hand
Upper arm

No statistically significant differences in skin levels of 
antioxidants, β-carotene and lycopene, between 
the three ethnic groups

Japanese subjects had a statistically significant 
higher catalase activity than French subjects  
( p < 0.01)

Japanese subjects had significantly lower values of 
protein carbonylation of the stratum corneum than 
French subjects ( p < 0.05)

Table 43.9  Facial Pore Size

Sugiyama-Nakagiri et al. 

In vivo

2009

Caucasian females 20
African females 20
Asian females 20
Hispanic females 20
All subjects in the age range (20–39y)

Cheek

Asians had smallest pore areas 

than other ethnic groups

African Americans had the most 

severe impairment of 
architecture around facial pores

 
412 

 TEXTBOOK OF COSMETIC DERMATOLOGY

differences in critical skin properties that affect the function of 
the skin. Describing and detailing these differences will lead 
to a better understanding of dermatological diseases in ethnic 
groups and ultimately to more effective treatment options.

REFERENCES

1.  Wilson  D,  Berardesca  E,  Maibach  HI.  In  vitro  transepidermal 
water loss: Differences between black and white human skin. 
Br J Dermatol Nov 1988; 119(5):647–52.

2.  Kompaore F, Marty JP, Dupont C. In vivo evaluation of the stra-
tum corneum barrier function in blacks, Caucasians and Asians 
with two noninvasive methods. Skin Pharmacol 1993; 6(3):200–7.
3.  Sugino  K,  Imokawa  G,  Maibach  HI.  Ethnic  difference  of  stra-
tum-corneum lipid in relation to stratum-corneum function. J 
Invest. Dermatol Apr 1993; 100(4):587.

4.  Berardesca E, de Rigal J, Leveque JL, Maibach HI. In vivo bio-
physical  characterization  of  skin  physiological  differences  in 
races. Dermatologica 1991; 182(2):89–93.

5.  Berardesca E, Maibach HI. Racial differences in sodium lauryl 
sulphate induced cutaneous irritation: Black and white. Contact 
Dermatitis Feb 1988; 18(2):65–70.

6.  Fotoh  C,  Elkhyat  A,  Mac  S,  Sainthillier  JM,  Humbert 
P. Cutaneous differences between Black, African or Caribbean 
Mixed-race  and  Caucasian  women:  Biometrological  approach 
of the hydrolipidic film. Skin Res Technol Aug 2008; 14(3):327–35.
7.  Luther N, Darvin ME, Sterry W, Lademann J, Patzelt A. Ethnic 
differences in skin physiology, hair follicle morphology and fol-
licular penetration. Skin Pharmacol Physiol 2012; 25(4):182–91.
8.  Muizzuddin  N,  Hellemans  L,  Van  Overloop  L,  Corstjens  H, 
Declercq  L,  Maes  D.  Structural  and  functional  differences  in 
barrier  properties  of  African  American,  Caucasian  and  East 
Asian skin. J Dermatol Sci Aug 2010; 59(2):123–8.

9.  Chu  M,  Kollias  N.  Documentation  of  normal  stratum  cor-
neum scaling in an average population: Features of differences 
among  age,  ethnicity  and  body  site.  Br  J  Dermatol  Mar  2011; 
164(3):497–507.

  10.  Yamashita Y, Okano Y, Ngo T, et al. Differences in susceptibility 
to oxidative stress in the skin of Japanese and French subjects 
and  physiological  characteristics  of  their  skin.  Skin  Pharmacol 
Physiol 2012; 25(2):78–85.

  11.  Basketter DA, Griffiths HA, Wang XM, Wilhelm KP, McFadden 
J. Individual, ethnic and seasonal variability in irritant suscep-
tibility of skin: The implications for a predictive human patch 
test. Contact Dermatitis Oct 1996; 35(4):208–13.

  12.  Berardesca  E,  Maibach  HI.  Sodium-lauryl-sulphate-induced 
cutaneous  irritation.  Comparison  of  white  and  Hispanic  sub-
jects. Contact Dermatitis Aug 1988; 19(2):136–40.

  13.  Aramaki J, Kawana S, Effendy I, Happle R, Loffler H. Differences 
of skin irritation between Japanese and European women. Br J 
Dermatol Jun 2002; 146(6):1052–6.

  14.  Astner  S,  Burnett  N,  Rius-Diaz  F,  Doukas  AG,  Gonzalez  S, 
Gonzalez E. Irritant contact dermatitis induced by a common 
household irritant: A noninvasive evaluation of ethnic variabil-
ity in skin response. J Am Acad Dermatol Mar 2006; 54(3):458–65.
  15.  Pershing  LK, Reilly CA, Corlett JL, Crouch DJ. Assessment of 
pepper spray product potency in Asian and Caucasian forearm 
skin  using  transepidermal  water  loss,  skin  temperature  and 
reflectance colorimetry. J Appl Toxicol Jan-Feb 2006; 26(1):88–97.

  16.  Tagami H. Racial differences on skin barrier function. Cutis Dec 

2002; 70(6 Suppl):6–7; discussion 21–3.

  17.  Hicks  SP,  Swindells  KJ,  Middelkamp-Hup  MA,  Sifakis  MA, 
Gonzalez  E,  Gonzalez  S.  Confocal  histopathology  of  irritant 
contact dermatitis in vivo and the impact of skin color (black vs 
white). J Am Acad Dermatol May 2003; 48(5):727–34.

  18.  Reed JT, Ghadially R, Elias PM. Skin type, but neither race nor 
gender,  influence  epidermal  permeability  barrier  function. 
Arch Dermatol Oct 1995; 131(10):1134–8.

  19.  Gunathilake R, Schurer NY, Shoo BA, et al. pH-regulated mech-
anisms account for pigment-type differences in epidermal bar-
rier function. J Invest Dermatol Jul 2009; 129(7):1719–29.

  20.  Berardesca E, Pirot F, Singh M, Maibach H. Differences in stra-
tum  corneum  pH  gradient  when  comparing  white  Caucasian 
and  black  African-American  skin.  Br  J  Dermatol  Nov  1998; 
139(5):855–7.

  21.  Johnson LC, Corah NL. Racial Differences in Skin Resistance. 

Science Feb 22 1963; 139(3556):766–7.

  22.  Warrier A, Kligman A, Harper R. A comparison of black and 

white skin using. J Soc Cosmet Chem 1996; 47:229–40.

  23.  Manuskiatti  W,  Schwindt  DA,  Maibach  HI.  Influence  of 
age,  anatomic  site  and  race  on  skin  roughness  and  scaliness. 
Dermatology 1998; 196(4):401–7.

  24.  Sivamani RK, Wu GC, Gitis NV, Maibach HI. Tribological test-
ing  of  skin  products:  gender,  age,  and  ethnicity  on  the  volar 
forearm. Skin Res Technol Nov 2003; 9(4):299–305.

  25.  Grimes P, Edison BL, Green BA, Wildnauer RH. Evaluation of 
inherent differences between African American and white skin 
surface  properties  using  subjective  and  objective  measures. 
Cutis Jun 2004; 73(6):392–6.

  26.  Diridollou S, de Rigal J, Querleux B, Leroy F, Holloway Barbosa 
V. Comparative study of the hydration of the stratum corneum 
between four ethnic groups: Influence of age. Intl J Dermatol Oct 
2007; 46 Suppl 1:11–4.

  27.  Rougier  A,  Lotte  C,  Corcuff  P,  Maibach  HI.  Relationship 
between  skin  permeability  and  corneocyte  size  according  to 
anatomic  site,  age,  and  sex  in  man.  J  Soc  Cosmet  Chem  1988; 
39(1):15–26.

  28.  Leveque JL, Corcuff P, de Rigal J, Agache P. In vivo studies of 
the evolution of physical properties of the human skin with age. 
Intl J Dermatol Jun 1984; 23(5):322–9.

  29.  Plewig G, Marples RR. Regional differences of cell sizes in the 
human stratum corneum. I. J Invest Dermatol Jan 1970; 54(1):13–8.
  30.  Corcuff P, Lotte C, Rougier A, Maibach HI. Racial differences in 
corneocytes. A comparison between black, white and oriental 
skin. Acta Derm Venereol 1991; 71(2):146–8.

  31.  Guy RH, Tur E, Bjerke S, Maibach HI. Are there age and racial 
differences  to  methyl  nicotinate-induced  vasodilatation  in 
human skin? J Am Acad Dermatol Jun 1985; 12(6):1001–6.
  32.  Berardesca  E,  Maibach  H.  Cutaneous  reactive  hyperae-
mia:  Racial  differences  induced  by  corticoid  application.  Br  J 
Dermatol Jun 1989; 120(6):787–94.

  33.  Gean CJ, Tur E, Maibach HI, Guy RH. Cutaneous responses to 
topical methyl nicotinate in black, oriental, and caucasian sub-
jects. Arch Dermatol Res 1989; 281(2):95–8.

  34.  Reinertson RP, Wheatley VR. Studies on the chemical compo-
sition  of  human  epidermal  lipids.  J  Invest  Dermatol  Jan  1959; 
32(1):49–59.

  35.  Harding  CR,  Moore  AE,  Rogers  JS,  Meldrum  H,  Scott  AE, 
McGlone FP. Dandruff: A condition characterized by decreased 
levels  of 
in  scalp  stratum  corneum 
and  impaired  barrier  function.  Arch  Dermatol  Res  Jul  2002; 
294(5):221–30.

intercellular 

lipids 

  36.  Jungersted  JM,  Hogh  JK,  Hellgren  LI,  Jemec  GB,  Agner  T. 
Ethnicity  and  stratum  corneum  ceramides.  Br  J  Dermatol  Dec 
2010; 163(6):1169–73.

  37.  Fuchs  J,  Packer  L.  Oxidative  Stress  in  Dermatology.  Vol  8.  Boca 

Raton, FL: CRC Press, 1993.

  38.  Sugiyama-Nakagiri Y, Sugata K, Hachiya A, Osanai O, Ohuchi 
A, Kitahara T. Ethnic differences in the structural properties of 
facial skin. J Dermatol Sci Feb 2009; 53(2):135–9.

  39.  Reilly DM, Ferdinando D, Johnston C, Shaw C, Buchanan KD, 
Green MR. The epidermal nerve fibre network: Characterization 
of  nerve  fibres  in  human  skin  by  confocal  microscopy  and 
assessment  of  racial  variations.  Br  J  Dermatol  Aug  1997; 
137(2):163–70.

 
 
 
 
 
 
 
 
 
 
44

Changes in Female Hair with Aging: New 
Understanding and Measures

Paradi Mirmirani, R. Scott Youngquist, and Thomas L. Dawson Jr

INTRODUCTION
Hair is among the most defining aspects of human appearance 
and  often  a  major  initial  driver  of  perceptions  of  youth  and 
beauty.  Ubiquitous  hair-related  changes  in  women  associated 
with aging are often distressing and met with feelings of anxiety 
or depression which can progress to a lost sense of identity (1–5). 
Women with alopecia not only face the loss of their hair, but often 
feel isolated, embarrassed to seek care, and may be frustrated by 
misinformation, misdiagnosis, or poor treatment options.

In both men and women there is an increasing incidence 
of hair loss with advancing age (6–12). Women may uniquely 
encounter  various  hormonal  and  physiologic  changes  that 
can  lead  to  alterations  in  the  appearance,  quality,  and  quan-
tity  of  the  hair  fiber  and  hair  follicle  or  pilo-sebaceous  unit. 
Androgens,  menopausal-related  hormonal  changes,  and  age-
related  senescent  signals  are  all  biological  changes  that  can 
lead to significant alterations in the female pilo-sebaceous unit. 
Although  these  changes  are  complex,  our  ability  to  measure 
changes in hair parameters has improved dramatically. With 
these  improved  measures  and  a  better  understanding  of  the 
complex  molecular  signals  governing  hair  biology,  there  is  a 
greater  opportunity  to  develop  pharmacologic  and/or  cos-
metic treatments that may specifically benefit women.

CLINICAL MANIFESTATIONS
Female Pattern Hair Loss
Female pattern hair loss (FPHL) is considered the equivalent of 
male  pattern  baldness  or  androgenetic  alopecia  (Figure  44.1A) 
(13).  There  is  a  reported  prevalence  of  approximately  50%  in 
Caucasians  (14),  and  a  much  lower  prevalence  in  Asians  (15), 
Native  Americans,  and  African-Americans  (16).  In  both  men 
and  women,  thinning  typically  begins  in  the  teens,  twenties, 
and thirties as a result of androgen-mediated follicular minia-
turization (14,17), although the linkage to androgens is less clear 
in  females  than  males  (18).  However,  there  is  increased  recog-
nition that there may be non-androgen causes of hair thinning 
in women that have no counterpart in men (19). Thus, the term 
female  pattern  hair  loss  has  been  favored  to  encompass  the 
clinical phenotype of hair loss in the central and temporal scalp 
region that may occur in genetically predisposed women result-
ing from androgens as well as hormonal changes due to meno-
pause and potentially other metabolic or extrinsic factors (20,21). 
Women  with  FPHL  usually  first  notice  a  gradual  thinning 
of  their  hair,  mostly  on  the  top  of  their  heads,  and  their  scalp 
becomes more visible (11). Over time, the hair on the sides may 
also become thinner. The patient may notice that her “ponytail” 
is smaller or that her longer hair looks “skimpy” at the ends. This 

thinning of scalp hair can vary in extent but it is extremely rare 
for a woman to become bare on top. With more extensive thin-
ning there may be a “Christmas tree” pattern of thinning on top 
of the scalp with hair loss most notable behind the frontal hair-
line (Figure 44.1B) (22). Miniaturized hairs are characteristic (23).

Senescent or Chronogenetic Alopecia
Senescent alopecia (SA) is defined as hair thinning that does not 
become apparent until after approximately 50 years of age and in 
a person with no family history of androgenetic alopecia (8,24,25). 
Alternate  terms  include  “chronogenetic,”  “late  onset,”  or  “age-
related” hair thinning. Such hair thinning is often identified as 
a marker of  systemic  senescence. In support of this concept, it 
is  observed  that  patients  with  progeria,  who  have  genetically 
programmed premature senescence, show a phenotype of hair 
loss (26). In reality, senescent alopecia likely frequently coexists 
with  androgenetic  alopecia  or  FPHL.  Clinically,  the  hair  thin-
ning  in  senescent  alopecia  is  described  as  being  diffuse  when 
seen in its “pure” form but having both a diffuse and patterned 
thinning when seen in combination with androgenetic alopecia 
(25,27). Clinically and histologically, there is follicular downsiz-
ing or miniaturization and subsequently the hair shaft becomes 
narrower  (28).  Changes  in  hair  density  have  also  been  associ-
ated with aging in women with and without perceived hair loss 
(29). Interestingly, imaging data supports that women who self-
report having thin or thinning hair have significantly less hair 
and a faster rate of hair loss with age (29).

Telogen Effluvium/Chronic Telogen Effluvium
Normally, the majority of scalp hair is in the anagen or growth 
phase, with a small percentage of hairs in the resting or telogen 
phase,  normally  being  shed  at  a  low  daily  rate  (100–200  hairs 
shed daily) (30). Under certain circumstances a higher percent-
age  of  hairs  cycle  into  the  resting  phase,  and  a  sudden  onset 
shedding, or telogen effluvium (TE), may be noted. Postpartum 
TE is a commonly observed clinical phenomenon that highlights 
the  impact  hormonal  changes  can  have  on  the  hair  cycle  (31). 
With age, both the number of hairs in anagen and the duration 
of anagen may be decreased, thus leading to an alteration and 
increase in the number of hairs shed daily (29).

Chronic  TE  is  another  condition  that  results  in  diffuse 
scalp hair loss and is typically seen in women in their fourth 
to  sixth  decades  of  life  (32).  It  often  presents  with  an  abrupt 
hair  shedding  that  can  have  a  fluctuating  course  lasting  at 
least 6 months and may continue for 6–7 years (32). Although 
chronic TE is usually self-limiting, the volume of hair typically 
does not return to premorbid volume and may be a comorbid 
manifestation of FPHL or SA.

414 

 TEXTBOOK OF COSMETIC DERMATOLOGYS

(a)

(b)

Figure 44.1  Female pattern hair loss. (a) Savin patterns of hair loss (13). (b) Clinical perspective showing diffuse hair loss with 
preserved frontal hairline. (From Olsen EA, J Am Acad Dermatol; 40(1):106–9, 1999.)

Hair Shaft Changes
The hair shaft is made primarily of keratin bundles that are com-
pacted  together  and  surrounded  with  an  outer  cuticular  layer 
to  form  a  rope-like  structure  that  is  flexible  yet  strong.  Sulfur 
crosslinks within and between the keratin fibrils provide for the 
longitudinal  strength  of  the  hair.  The  outer  cuticle  resembles 
overlapping shingles on a roof and forms the “armor” that pro-
tects the underlying hair shaft and provides “torsional” strength 
and resistance to bending (33). The quality and caliber of the hair 
shaft decreases with age and can significantly affect how the hair 
is perceived (34). Studies suggest that with age there is increased 
damage to the fragile substructure (endocuticle) of the hair shaft 
cuticle leading to increased fragility of the hair. As many hair 
care  products  interact  negatively  with  the  hair  surface  cuticle, 
various hair care practices that include chemicals and heat can 
also diminish the integrity of the hair shaft (35). Damage or loss 

of the outer cuticle or “weathering” can lead to alterations in the 
optical properties of the hair (loss of luster) (36), decreased man-
ageability (“flyaway hairs” and hair tangling), or hair breakage 
(37). If breakage occurs, it can happen anywhere along the length 
of the hair, causing a “shaggy” or “skimpy” appearance and vis-
ible and tactilely perceptible blunt (broken) hair tips.

Ultraviolet light can lead to oxidative changes of the hair 
shaft, resulting in damage to the hair color (photobleaching) as 
well as weathering of the hair structure through changes includ-
ing lipid oxidation, disulfide bond cleavage, tryptophan degrada-
tion, protein degradation, and cysteic acid formation (38–40). The 
result is an increase in fiber porosity, increase in surface rough-
ness, and decreased mechanical strength. With age and greying, 
the absence of the natural protective pigments in the hair leads 
to  increased  ultraviolet  damage  including  loss  of  mechanical 
strength and an increase in surface roughness (34,38).

 
CHANGES IN FEMALE HAIR WITH AGING: NEW UNDERSTANDING AND MEASURES 

 415

Hair Greying
Hair greying is one of the most characteristic changes of aging. 
It is often quoted that, as a rule of thumb, 50% of people are 
50% grey by the age of 50 (28). However, recent epidemiologic 
studies  of  men  and  women  of  various  races  suggests  a  far 
lower number—only 6%–23% of people have 50% grey hair at 
age 50 (34). Compared to people of Caucasian descent, those of 
Asian and African descent showed less grey hair (34). The age 
of onset of hair greying is thought to be influenced by genetics. 
Grey hairs have been noted to have different size (shaft diam-
eter) and mechanical properties and are often perceived as dry 
and less manageable (41).

MECHANISMS
Androgens
Pathophysiologically,  androgens  mediate  and  drive  the  fol-
licular transformation in androgenic alopecia. There is a sub-
stantial  increase  in  the  local,  or  follicular,  transformation  of 
testosterone  to  dihydrotestosterone  by  the  enzyme  5-alpha 
reductase  (12).  Dihydrotestosterone,  which  has  a  five  times 
higher affinity for the androgen receptor compared to testos-
terone,  triggers  specific  genes  that  then  lead  to  the  gradual 
miniaturization of genetically programmed hair follicles (13).

The effects of androgens on the follicle have, for the most 
part, been studied in men under the age of 50. Hence, further 
work will be required to define the role of androgens in female 
hair  loss.  It  has  been  suggested  that  the  various  clinical  pat-
terns of androgenetic alopecia in men and women may reflect 
quantitative  differences  in  levels  of  androgen  receptor  and 
steroid-converting enzymes in specific scalp regions at differ-
ent ages (42).

There is increased recognition that androgen excess can 
occur  in  patients  with  various  conditions  such  as  metabolic 
syndrome, polycystic ovary, and obesity and that these changes 
can lead to alterations in the hair follicle (43). Androgen excess 
may be a result of changes in sex binding hormones or due to 
an increase in peripheral conversion.

Menopause/Estrogens
Menopause  is  defined  as  either  the  permanent  cessation  of 
menses or the lack of menses for 12 consecutive months (44), 
with  the  major  hormonal  changes  during  menopause  being 
the  near  cessation  of  ovarian  estrogen  production.  The  defi-
nition and appreciation of perimenopause remains controver-
sial,  but  recent  reviews  (45)  suggest  that  hormonal  changes 
begin  much  earlier  than  previously  understood,  resulting  in 
symptoms such as night sweats, mid-sleep waking, and other 
physiological  changes.  Perimenopause,  or  the  transition  to 
menopause, spans a variable period of time when estrogen lev-
els can be erratic before they decrease to the low, stable levels 
of menopause (45). This transitional phase occurs on average 
5 years prior to the onset of actual menopause but can start as 
early as 10 years prior (46). While it has been recognized that 
estrogen is an important modulator of hair growth, the details 
of the molecular regulatory pathways have not been well char-
acterized. Hair changes, including thinning of the hair shaft, 
temporally  equate  with  the  earlier  onset  “perimenopausal” 
period (29) which usually falls in the early 40s but may begin 
as early as 35 years of age. The mean age women undergo com-
plete menopause is 51; thus women spend about one-third of 
their  life  in  the  postmenopausal  period  (44).  However,  if  one 
includes perimenopause, where many of the reported negative 
symptoms  begin  to  be  reported,  the  period  where  a  woman 

lives with the symptoms of menopause may be as much as half 
of her life.

Estrogen is synthesized in the ovary as well as in a num-
ber of peripheral tissues and acts via estrogen receptors which 
belong  to  a  superfamily  of  nuclear  receptors.  There  are  two 
estrogen receptors, alpha (ER alpha) and beta (ER beta). The rel-
atively recent discovery of ER beta has broadened the range of 
potential estrogenic target tissues and has also redefined prior 
concepts of estrogen activity and signaling. In the human hair 
follicle, immunohistochemical studies have shown ER beta to 
be the predominant receptor (47,48). Similar to other estrogenic 
target tissues, the biologic activity of estrogen in the hair fol-
licle likely depends on a complex interplay of signals that may 
differ  depending  on  the  relative  distribution  and  location  of 
the two ERs, as well as the activity of the peripheral converting 
enzyme, aromatase (49–51). Several studies have demonstrated 
the influence of estrogen on the murine and other mammalian 
hair cycle, however it is clear that the distribution, expression, 
and  biologic  activity  of  estrogen  receptors  in  murine  models 
may be quite different than in humans (51–57). In vitro studies 
have  shown  that  organ  culture  of  human  scalp  hair  follicles 
exposed  to  estradiol  results  in  decreased  growth,  whereas 
cells of the dermal papilla responded with proliferation (58,59). 
Estradiol has also been noted to induce aromatase activity in 
human  scalp  follicles,  one  possible  mechanism  by  which  it 
may exert biologic activity (60). Since hair growth is influenced 
by numerous hormones, growth factors, transcription factors, 
and cytokines, many of which are known to be modulated by 
estrogens, it is plausible that an intricate orchestration of these 
pathways occurs in response to estrogen. Further clarification 
and study of estrogen effects in different tissues, species and 
genders is ongoing (49,50,61).

Senescent Signals
Although androgenetic alopecia and senescent alopecia share 
many  clinical  and  histologic  features,  the  mechanisms  by 
which  follicular  downsizing  and  miniaturization  occur  have 
recently been shown to be distinct (62). Microarray comparison 
of age-matched subjects with androgenetic alopecia, senescent 
alopecia, and normal controls without hair loss has shown that 
androgenetic alopecia is associated with altered expression of 
genes  known  to  be  required  for  hair  follicle  cycling.  In  con-
trast,  the  transcriptional  profile  of  senescent  alopecia  reveals 
changes  in  the  complex  phenomenon  of  alternative  splicing, 
oxidative stress response, and apoptosis, which are character-
istic  of  aging  tissues  (62).  This  difference  in  mechanism  has 
significant implications in terms of treatment of hair loss at dif-
ferent  ages.  Further  characterization  of  these  senescent  path-
ways may lead to attractive therapeutic targets for treatment of 
senescent alopecia, but may also prove to be useful markers of 
other systemic senescent processes.

Pigmentation
Much  like  the  skin,  the  pigment  of  the  hair  shaft  is  derived 
from melanocytes, which transfer melanin via melanosomes. 
However, unlike the skin, in which there is continual produc-
tion of pigment, the activity of the melanocytes surrounding 
the hair follicle is intermittent and is tightly linked to follicu-
lar cycling. Hair pigmentation occurs only during the growth, 
or  anagen,  phase,  which  typically  lasts  3–5  years.  With  each 
hair cycle, various factors may impact the fidelity of hair pig-
mentation,  and  these  changes  become  most  notable  after  the 
first 10 cycles or so (63). Hairs with absent pigment are seen as 
white, whereas those with a dilution, or a mixture of pigment 

 
416 

 TEXTBOOK OF COSMETIC DERMATOLOGYS

and white hair, are seen as grey. Interestingly, white hairs may 
have  increased  thickness  and  greater  hair  growth  rate  than 
pigmented  hairs  (64).  Studies  have  shown  that  grey  hair  is 
associated with a decrease in follicular melanocyte population 
and a decrease in melanin content (65). A buildup of reactive 
oxygen species along with a decreased ability to handle oxida-
tive damage has also been implicated in the process of greying 
(63,66,67).

EFFICACY MEASURES OF HAIR 
REGROWTH IN HUMANS
Density
Overview
A  key  weakness  in  hair  research  remains  to  reliably  and 
predicatively measure the effect of aging, hormone changes, 
or  treatment  on  hair  quantity  and  quality.  Most  methods 
require sampling from a small (1–5 cm2) site then extrapolat-
ing  to  the  entire  scalp.  This  can  lead  to  significant  error,  as 
hairs  are  under  differential  control  across  the  scalp  (29,42). 
A  further  complication  is  the  non-random,  highly  irregular 
pattern of scalp hairs, making repositioning crucially impor-
tant and mandating a permanent relocation mark (tattoo) for 
consistent  analyses  (68).  There  are  methods  utilizing  global 
photography, but they suffer from variability resulting from 
styling, color, and humidity, among others. Here we review 
common  methods  to  measure  changes  in  hair  density  and 
diameter, focusing on detecting subject perceptible changes 
in hair amount from any cause.

Direct Manual Hair Count
Early  hair  growth  studies  began  in  the  1980s  and  used  the 
direct  hair  count  method  (69–78).  Changes  were  determined 
by  counting  all  vellus,  intermediate,  and  terminal  hairs  in 
a  1-inch  diameter  (5.1  cm2)  midvertex  area.  This  was  labor 
intensive  and  prone  to  systematic  bias  by  missing  small  or 
minimally  pigmented  hairs.  The  primary  benefit  was  that 
the hairs most noticeable by subjects were ones most reliably 
quantified.

Macrophotographic Manual Hair Count
In the 1990s, manual hair counting was updated by counting 
dot maps representing hairs present in enlarged color macro 
photographs (79–92,93). This involved clipping all hairs in a 
1-inch diameter area (5.1  cm2) to 1 mm at the anterior  edge 
of  the  thinning  vertex,  with  a  dot  tattoo  to  maximize  relo-
cation. Photographs must be taken with a dedicated, preset 
camera system to maintain reproducibility. The photographs 
are  enlarged  to  color  transparencies  and  converted  to  dot 
maps  of  visible  hairs.  This  revealed  more  small  or  nonpig-
mented hairs, and was a step forward in precision. However, 
it  is  reliant  on  labor-intensive  human  counting  and  subject 
to bias from the individual counter. Also, exact repositioning 
remained  difficult,  increasing  the  signal-to-noise  ratio  and 
adding variability.

Automated or Semi-Automated 
Phototrichograms
Overview
Macro  photographs  improved  hair  count  methodology  but 
manual  analysis  remained  cumbersome  and  labor  intensive. 
Hence,  digital  image  acquisition  and  computational  analysis 
enabled  more  sensitive,  precise,  and  time-saving  methods 
using fully or semi-automated systems (68,94–96).

At  baseline,  imaging  sites  are  tattooed  and  the  hair 
clipped. A water drop is used to minimize light scattering due 
to  scalp  flakes  or  texture.  This  is  essential  to  enable  semi  or 
fully automated counting of hairs via identification of straight 
edges. Water has a similar refractive index to hair and so mini-
mizes  the  appearance  of  nonpigmented  hairs.  This  has  the 
disadvantage of underestimating miniaturized, vellus, or grey 
hairs, but the advantage of biasing to the pigmented, terminal 
hairs  which  are  most  likely  to  be  subject  noticeable.  A  base-
line image is acquired as a reference, and at each subsequent 
visit  the  probe  is  repositioned  to  achieve  alignment  with  the 
partially transparent baseline image (Figure 44.2). Anagen hair 
counts can  be  determined by  counting hairs  that  lengthened 
in images taken 24 hours later. Image analysis algorithms can 
also be employed to measure hair diameter.

TrichoScan®
TrichoScan  is  an  automated  digital  phototrichogram  tool  to 
analyze  macro  scalp  images  (97–99).  It  is  reported  to  analyze 
multiple  hair  parameters  including  density  (hairs/cm2),  diam-
eter  (pixels  converted  to  microns),  growth  rate  (mm/day),  and 
anagen:telogen  ratio.  TrichoScan  combines  epiluminescence 
microscopy  (ELM)  with  automatic  image  analysis.  Briefly,  the 
site is identified, tattooed, and clipped as above. The clipped hair 
is  dyed  black  to  increase  the  hair–scalp  contrast,  complicating 
the analysis by counting grey hairs the same as pigmented hairs. 
For density and diameter determinations, the hairs are colored 
immediately after clipping. For growth rate and anagen:telogen 
ratio, the hairs are colored 3 days after clipping.

Automated  algorithms  select  color  components,  reject 
artifacts  (bubbles  and  reflections),  determine  the  threshold, 
define the hairs, eliminate the tattoo, and analyze the hair from 
each region. This method is routinely used in clinical studies 
for assessing growth-promoting substances as well as to study 
diffuse hair loss in various hair-related disorders (97,99–101).

TrichoScan has been used extensively and has improved 
the speed of analysis, enabling use of more subjects and assist-
ing  in  stronger,  more  powerful  clinical  designs.  However,  as 
with  any  new  method,  the  precision  and  accuracy  remain 
controversial.  van  Neste  and  Trueb  compared  TrichoScan  to 
manual  counting  and  found  significant  differences  between 
the  “gold  standard”  of  manual  counting  and  the  computer-
assisted analyses (102). Further work will be necessary to fully 
understand  the  positive  and  negative  aspects  of  automated 
analysis. As technology improves, so will automated methods.

Canfield EpiLume®
Canfield EpiLume is a macro digital image capture system fre-
quently paired with the Canfield Hair Metrix image analysis 
system  or  TrichoScan  image  analysis  to  measure  changes  in 
hair growth properties, including treatment effects (103). The 
photographic system leverages a fixed focal camera for imag-
ing  scalp  sites  prepared  as  above  and  then  images  are  pro-
cessed using a validated image analysis system (104)

Hair Diameter
The perception of hair mass or volume (hair amount) is a func-
tion of both density and diameter (105), but careful consider-
ation reveals that changes in hair diameter could be as or more 
influential than changes in hair density. For example, an 80-μm 
hair has almost twice the mass or volume of a 60-μm hair of 
the same length because it has approximately double the cross-
sectional area. Therefore in two samples with the same num-
ber  of  hairs,  the  one  with  80-μm  shafts  has  almost  twice  the 

 
CHANGES IN FEMALE HAIR WITH AGING: NEW UNDERSTANDING AND MEASURES 

 417

Hair clipping
1 mm in length

Image acquisition
Blend live baseline image

Identify and
enumerate all hairs

0 hours

Baseline

24 hours

0 hours

Week 1

24 hours

Document emergence of new hairs

Track hair length and growth

Document loss of hairs

Figure 44.2  Macro-photographic image analysis. Optional imaging parameters available in manual or semi-automated systems.

hair amount as the one with 60-μm shafts. To put this in context, 
a 10% drop in density will result in a 10% change in amount, 
while a 10% change in diameter will result in a 20% change in 
amount—twice the effect of the same change in density.

Hair  diameter  can  be  obtained  from  multiple  methods, 
including linear density (106) phototrichogram (94,95), laser fiber 
analysis (Diastron®), and optical fiber diameter analysis (OFDA) 
(Figure 44.3) (107). As human hair is variable in diameter even 
across a single fiber, methods have been developed that assess 
either single points along the fiber or averages for the entire fiber. 
Further,  the  shape,  or  cross-sectional  area,  can  be  highly  vari-
able and account for multiple hair “feel” parameters. All of these 
factors must be considered when choosing an optimal method.

Linear Density
The linear density diameter is a calculation based on the num-
ber of fibers in a sample, the length of the sampled fibers, and 
an average density for human hair (106). This method provides 
an  accurate  average  diameter  but  does  not  take  into  account 
variations in diameter along fibers or variations in fiber shape.

Phototrichogram
Current high resolution phototrichograms can be used to mea-
sure  diameter  (68).  This  method  enumerates  the  fibers  and 
counts the total hair area, then calculates the average diameter 
of  each  hair.  This  method  is  limited  to  average  diameters  as 
the resolution of current camera technology limits the size of a 
pixel in an image to approximately 1–4 μm. This means many 
hairs  must  be  averaged  for  accurate  and  meaningful  results. 
This method also measures hair approximately 1 mm from the 
scalp and so is useful for measuring the effect of treatments, as 
newly grown hair is all that is contained in that short fragment.

Diastron
The  most  common  method  is  the  laser  method  using  the 
Diastron device. Description of the full utility of his method is 
beyond the scope of this review, but ample information can be 
found on the Diastron company website. Briefly, single 4-inch 
hair  fibers  are  mounted  in  a  holder  and  rotated  while  in  the 
beam  of  a  laser.  This  is  highly  precise  and  provides  detailed 
information on single fibers. In addition to average diameter, 
it provides fiber shape (ellipticity) and can be applied to mul-
tiple sites along the fiber. The limitation is the low throughput 
relative  to  the  diversity  of  human  scalp  hair.  It  also  requires 
4  inches  of  hair,  so  about  8  months  growth,  necessitating 
extended  clinical  trials  to  measure  hair  changed  during  the 
study.

Optical Fiber Diameter Assessment
OFDA allows measurement of many hundreds to thousands of 
fibers per sample (107–109). Briefly, 2-mm snippets are cut from 
each sample, washed, equilibrated, and cast onto glass slides. 
The slides are read by an optical laser which finds the 2-mm 
axis and measures the perpendicular. As this technique allows 
for measurement of many fibers per sample, it is valuable for 
understanding effects of treatment across larger sites and the 
effect on the diameter distributions. As it measures short seg-
ments, it can be used to evaluate the effect of treatment of less 
than 1 month. Recently OFDA was used to measure differences 
in hair diameter in pre- and postmenopausal women, demon-
strating its utility in human clinical studies (Figure 44.4) (29). 
The  limitation  is  that  variability  is  not  determined  along  the 
fiber and no information is gleaned about fiber shape or ellip-
ticity. The primary advantages are throughput and breadth of 
analysis (29).

 
418 

 TEXTBOOK OF COSMETIC DERMATOLOGYS

(a)

(b)

4.00

s
n
o
i
t
a
v
r
e
s
b
o
f
o
t
n
e
c
r
e
P

3.00

2.00

1.00

0.00

8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168 176 184 192 200

Fiber diameter-microns

Figure  44.3  Optical  fiber  diameter  analysis  showing  diversity  of  human  hair  shapes.  (a)  Bundle  of  hair  fibers  from  Caucasian 
female embedded and cross-sectioned. (b) Same bundle of hair fibers examined by OFDA. Arrows represent different populations 
of hair diameters (108). (With kind permission from Springer Science and Business Media: Hair growth parameters in pre- and post-
menopausal women. In M. R. Trüeb, MR and Tobin, JD, eds., Aging Hair, 2010, pp. 49–60, Mirmirani, P, Luo, F, Youngquist, SR, 
Fisher, BK, Li, J, Oblong, J, Dawson, TL.)

Premenopausal
Postmenopausal

0.020

0.015

0.010

0.005

s
r
i
a
h
f
o
n
o
i
t
r
o
p
o
r
P

1

25

50

100

150

Hair diameter (mm)

Figure 44.4  Optical fiber diameter analysis of pre- and postmenopausal female scalp hair. Scalp hair collected from 1 cm2 area of 
frontal or occipital scalp (108). (With kind permission from Springer Science and Business Media: Hair growth parameters in pre- and 
postmenopausal women. In M. R. Trüeb, MR and Tobin, JD, eds., Aging Hair, 2010, pp. 49–60, Mirmirani, P, Luo, F, Youngquist, SR, 
Fisher, BK, Li, J, Oblong, J, Dawson, TL.)

 
 
 
 
 
CHANGES IN FEMALE HAIR WITH AGING: NEW UNDERSTANDING AND MEASURES 

 419

Combination Measures
As  hair  quantity  is  determined  by  the  hair’s  density  (#/cm2) 
and diameter (μm), hair loss and growth result from changes in 
either or both. Therefore an ideal hair-measuring technology 
would combine these two measures into a single more descrip-
tive and sensitive “hair amount” metric (29,105)

Cross-Section Trichometer
A new device has recently been developed, the cross-sectional 
trichometer.  This  measure  captures  hairs  from  a  predeter-
mined area and compresses them into a precise caliper. Care 
must be taken for accurate sample selection, as small changes 
in  the  number  of  fibers  have  a  strong  influence.  Control  of 
the site is accomplished with a 2 × 2-cm dye marker. All hairs 
inside the demarked 4-cm2 area are captured, providing highly 
reproducible results. Future work could provide a noninvasive, 
fast, and accurate measure of hair “mass” or “volume,” which 
would  be  predicted  to  be  highly  relevant  to  the  perceived 
 efficacy in hair loss treatment (105).

Hair Weight
Hair  weight  and  hair  number  have  been  demonstrated  to  be 
valid parameters for assessing efficacy of both minoxidil (17,72) 
and finasteride. Briefly, a representative site is selected on the 
thinning frontal/parietal scalp and all hairs clipped to 1 mm. 
In  subsequent  visits,  the  procedure  is  repeated.  All  the  hairs 
from each collection are manually counted, with pointed ver-
sus blunt tipped hairs separated, then each sample is weighed. 
In addition to hair weight and hair count, hair width and length 
may  be  assessed  by  projection  microscopy.  While  extremely 
precise, this methodology remains highly labor intensive.

Global Assessment
Global Macro Photos
While precise technical measures of hair growth are important 
for evaluation of pharmacologic intervention, it is also impor-
tant  to  understand  whether  technically  measurable  changes 
lead to changes perceptible by the subject and/or investigator 
(110–112).  These  evaluations  are  based  on  global,  or  whole-
head,  macro  photography  and  rating  using  perceptual  scales 
by the subjects and investigators. While it is crucial to measure 
perceptible changes, it is extremely difficult due to numerous 
and  aforementioned  complicating  factors.  The  investigator 
must  tightly  control  humidity,  hair  style,  hair  color,  back-
ground  and  clothing  colors,  lighting,  camera  type  and  mag-
nification, among others. It is also vital to observe and control 
these features in presentations of hair benefit claims and data, 
as  manipulation  of  any  of  these  facets  can  lead  to  inaccurate 
interpretation.

Subject Self Perception
Patient  assessment  is  measured  by  administration  of  a  vali-
dated questionnaire based on seven parameters: four on effi-
cacy and three on appearance. These parameters include visible 
scalp, hair appearance, hair growth, slowing of hair loss, and 
satisfaction  with  the  hair  appearance  and  the  frontline  (93). 
Patients may also evaluate changes by reviewing randomized 
pre-  and  post-treatment  photographs  (68).  It  is  common  for 
self-perception  to  lag  far  behind  technical  assessment,  likely 
due to the amount of time required for new hairs to grow to 
a length appreciated by the subject and that the affected area 
may not be easily visible to the subject. For instance, technical 
effects of minoxidil can be measured in 8–12 weeks, but self-
perception requires 9–12 months.

Expert Assessment
Investigators assess subjects using a standardized seven-point 
rating scale (–3 to +3) after referring to a baseline photograph 
as a reference (93). Generally, investigator assessment time to 
noticeability falls between technical and self assessment.

Changes  can  also  be  evaluated  by  an  expert  panel.  In 
this method, standardized color photographs were taken with 
the head in a stereotactic positioning device and then visually 
graded  by  trained,  calibrated  experts  (111).  Paired  baseline-
to-post-treatment  slides  are  then  independently  and  blindly 
reviewed  by  an  expert  panel  using  vertex  and  frontal  views 
(68,93). Expert graders have much higher sensitivity than sub-
ject assessments and usually are able to identify effects sooner. 
However,  the  perception  of  the  individual  under  treatment 
must remain the ideal, and be the focus of development of new 
therapies.

DISCUSSION
Complex biologic mechanisms regulate hair growth and char-
acteristics over the course of a woman’s life. With age, there is a 
waning of many of these functions with an associated increase 
in self-perceived thinning (29). Our current understanding is 
that hormonal controls (including androgens and estrogens) as 
well as age-related physiological changes influence scalp hair 
including alterations in hair diameter and density. Prior stud-
ies have shown that hair fiber diameter increases to 40 years of 
age, reaches a plateau, then decreases with advancing age (29). 
Further, hair diameters for Caucasian women are significantly 
higher pre- versus postmenopausal for frontal but not occipi-
tal  scalp.  This  suggests  that  menopausal  status  and  estrogen 
alteration affect  scalp  hair  diameter. In contrast,  hair  density 
in  women  decreases  throughout  teen  and  adult  life,  with  no 
abrupt change near the perimenopausal period. This suggests 
senescent  as  opposed  to  hormonal  signals  lead  to  follicular 
dropout and decreased hair density.

Using the combined measure of hair density and diam-
eter, hair amount, to more accurately quantify the perception 
of hair loss shows that hair amount in Caucasian women peaks 
at 35 years of age. The values are similar at ages 25 and 45, only 
6%  and  5%  less  than  the  maximum.  However,  at  age  50  hair 
amount is 11% less. As the amount of hair changes little from 
age 25 to 45, normal loss is less likely to be noticed until after 
the diameter begins to decline in the mid 40s, consistent with 
the increased self-perception of hair loss in midlife women.

In addition to density and diameter, other factors affect 
the self-perceived appearance and amount of a woman’s hair 
with advancing age. While several of these reported changes 
are  subjective,  a  variety  of  quantifiable  factors  contribute. 
Nonbiologically  regulated  factors  include  length,  style,  color 
(from dying and bleaching), curvature (chemical waving), and 
damage  (through  breakage  and  volume)  (11,113).  Biologically 
regulated  facets  include  density  and  diameter,  color  (due  to 
pigmentation), and curvature. Hair density is a function of fac-
tors including anagen:telogen ratio and growth rate. The rela-
tive  importance  of  each  of  these  factors  on  the  perception  of 
hair loss is not fully understood.

While  the  methods  described  in  this  review  are  all 
appropriate for assessing changes in hair growth in humans, 
no  single  method  addresses  all  questions  relating  to  hair 
growth  properties  or  the  efficacy  and  mode  of  action  of  hair 
loss  treatments.  Therefore  one  must  always  consider  the  pri-
mary objective and utilize an appropriate array of techniques 
to address the question posed.

 
420 

 TEXTBOOK OF COSMETIC DERMATOLOGYS

The  continual  rapid  advancements 

in  optics  and 
 computers  will  continue  to  improve  the  study  of  basic  hair 
biology and treatments, increasing both sensitivity and speed. 
Hair  count  techniques  have  progressed  from  manual  counts 
to macrophotography. Recent developments using automated 
methods have increased the capability and sensitivity to moni-
tor hair loss and treatment responses, including measures of 
density,  diameter,  growth  rate,  and  anagen:telogen  ratio  (99). 
Software and algorithms have increased accuracy and speed, 
giving  these  methods  the  capacity  necessary  for  analysis  of 
data from large clinical trials.

While new quantitative techniques facilitate field execu-
tion and decrease the time, effort, and costs required in mate-
rial screening trials, the conduct of large pivotal phase III trials 
to establish the efficacy and safety of hair regrowth active sub-
stances for FDA submission still requires a duration long enough 
for subjects to self-perceive a benefit. Furthermore, these tech-
niques  do  not  replace  exploratory  methods  targeted  at  under-
standing  the  mechanism  of  new  interventions.  Methods  such 
as  biopsies  combined  with  imaging  or  molecular  DNA/RNA 
or biochemical marker techniques are still needed to derive an 
understanding of how and why these treatments work.

For  clinical  design,  the  use  of  both  active  and  placebo 
controls  and  having  adequate  subject  numbers  and  diversity 
are  critical  for  properly  evaluating  any  changes  in  hair  biol-
ogy,  including  therapies.  For  example,  considerations  in  sub-
ject  enrollment  include  ensuring  that  the  population  covers 
a  range  of  hair  loss  progression  (Norwood/Hamilton  scale 
scores for men, Ludwig scale scores for women) and accounting 
for critical variables such as age, ethnicity, medical conditions, 
and medications that can affect hair biology. The selection of 
the scalp site is also critical for study outcome. For example, in 
women the effect of FPHL is more pronounced on the frontal 
than on the occipital scalp so studies with measurements from 
the frontal region will likely be more sensitive (109).

Since  the  above  objective  measurements  do  not  neces-
sarily  translate  immediately  into  patient-perceived  benefits, 
subjective perception measures by both patients and investiga-
tors are necessary in treatment evaluation, especially in pivotal 
long-term  trials,  to  insure  that  clinically  meaningful  benefits 
have been produced. A self-perceived benefit is the key to suc-
cessful hair regrowth products.

This chapter has focused on describing the fundamental 
changes associated with hair loss in normal women with age 
and the methods used to objectively quantify those changes. We 
have addressed methods for tracking hair density and diam-
eter, as they are the variables most likely to be noticed by sub-
jects seeking treatment. Historically, treatment regimens have 
focused on scalp hair number density as this was perceived to 
be the parameter most influencing hair loss. However, recent 
research is indicating that characteristics beyond density play 
a crucial role in subjects’ satisfaction with their hair. For exam-
ple, hair diameter has been found to play a critical and highly 
influential role in both the perception of hair loss and in the 
efficacy of treatment (6,10,105,109). In another study, grey hair 
was found to be a more significant contributor to apparent age 
than hair thinning, and therefore addressing greying may be 
an  important  intervention  for  improving  patient  satisfaction 
(5).  Given  the  importance  of  these  hair  characteristics,  in  the 
next  few  years  new  methods  must  be  developed  to  measure 
these  endpoints.  A  final  consideration  for  addressing  patient 
hair concerns is the strong linkage between scalp health and 

hair quality, and it is likely that measures of scalp health will 
begin to be used to link skin and hair biology (114).

REFERENCES

1. van  der  Donk  J,  Passchier  J,  Knegt-Junk  C,  van  der 
Wegen-Keijser  MH,  Nieboer  C,  Stolz  E,  et  al.  Psychological 
characteristics  of  women  with  androgenetic  alopecia:  A  con-
trolled study. Br J Dermatol 1991; 125(3):248–52.

2.  Cash  TF,  Price  VH,  Savin  RC.  Psychological  effects  of  andro-
genetic  alopecia  on  women:  Comparisons  with  balding  men 
and  with  female  control  subjects.  J  Am  Acad  Dermatol  1993; 
29(4):568–75.

3.  Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: 
Stress and the underestimated psychosocial impact of telogen 
effluvium  and  androgenetic  alopecia.  J  Invest  Dermatol  2004; 
123(3):455–7.

4.  Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. 
Patient-perceived  importance  of  negative  effects  of  androge-
netic alopecia in women. J Women Health Gender Based Med 1999; 
8(8):1091–5.

5.  Gunn  DA,  Rexbye  H,  Griffiths  CE,  Murray  PG,  Fereday  A, 
Catt SD, et al. Why some women look young for their age. PloS 
one 2009; 4(12):e8021.

6.  Birch  MP,  Messenger  JF,  Messenger  AG.  Hair  density,  hair 
diameter  and  the  prevalence  of  female  pattern  hair  loss. 
Br J Dermatol 2001; 144(2):297–304.

7.  Courtois  M,  Loussouarn  G,  Hourseau  C,  Grollier  JF.  Ageing 

and hair cycles. Br J Dermatol 1995; 132(1):86–93.

8.  Kligman  AM.  The  comparative  histopathology  of  male- 
pattern  baldness  and  senescent  baldness.  Clin  Dermatol  1988; 
 6(4):108–18.

9.  Loussouarn G, El Rawadi C, Genain G. Diversity of hair growth 

profiles. Int J Dermatol 2005; 44 Suppl 1:6–9.

  10.  Tajima M, Hamada C, Arai T, Miyazawa M, Shibata R, Ishino A. 
Characteristic  features  of  Japanese  women’s  hair  with  aging 
and with progressing hair loss. J Dermatol Sci 2007; 45(2):93–103.
  11.  Mirmirani P. Managing hair loss in midlife women. Maturitas 

2013; 74(2):119–22.

  12.  Mirmirani  P.  Age-related  hair  changes  in  men:  Mechanisms 
and  management  of  alopecia  and  graying.  Maturitas  2015; 
80(1):58–62.

  13.  Olsen  EA.  The  midline  part:  An  important  physical  clue  to 
the  clinical  diagnosis  of  androgenetic  alopecia  in  women. 
J Am Acad Dermatol 1999; 40(1):106–9.

  14.  Hamilton  JB.  Patterned  loss  of  hair  in  man;  types  and  inci-

dence. Ann NY Acad Sci 1951; 53(3):708–28.

  15.  Paik  JH,  Yoon  JB,  Sim  WY,  Kim  BS,  Kim  NI.  The  prevalence 
and types of androgenetic alopecia in Korean men and women. 
Br J Dermatol 2001; 145(1):95–9.

  16.  Hoffmann  R,  Happle  R.  Current  understanding  of  androge-
netic  alopecia.  Part  I:  Etiopathogenesis.  Eur  J  Dermatol  2000; 
10(4):319–27.

17. Norwood  OT.  Incidence  of  female  androgenetic  alopecia 

(female pattern alopecia). Dermatol Surg 2001; 27(1):53–4.

18. Birch MP, Lashen H, Agarwal S, Messenger AG. Female  pattern 
hair  loss,  sebum  excretion  and  the  end-organ  response  to 
androgens. Br J Dermatol 2006; 154(1):85–9.

19. Mirmirani  P.  Hormonal  changes  in  menopause:  Do  they 
contribute to a ’midlife hair crisis’ in women? Br J Dermatol 2011; 
165 Suppl 3:7–11.

20. Olsen  EA.  Female  pattern  hair  loss.  J  Am  Acad  Dermatol  2001; 

45(3 Suppl):S70–80.

21. Olsen  EA,  Hordinsky  M,  Roberts  JL,  Whiting  DA.  Female 

pattern hair loss. J Am Acad Dermatol 2002; 47(5):795.

22. Olsen EA. Current and novel methods for assessing efficacy of 
hair growth promoters in pattern hair loss. J Am Acad Dermatol 
2003; 48(2):253–62.

 
 
 
 
 
 
 
 
 
CHANGES IN FEMALE HAIR WITH AGING: NEW UNDERSTANDING AND MEASURES 

 421

  23.  Messenger AG, Sinclair R. Follicular miniaturization in female 
pattern hair loss: Clinicopathological correlations. Br J Dermatol 
2006; 155(5):926–30.

  24.  Hordinsky M, Sawaya M, Roberts JL. Hair loss and hirsutism in 

the elderly. Clin Geriatr Med 2002; 18(1):121–33, vii.
  25.  Sperling L. Senescent Balding. New York: Parthenon, 2003.
  26.  Korf B. Hutchinson-Gilford progeria syndrome, aging, and the 

nuclear lamina. N Engl J Med 2008; 358(6):552–5.

  27.  Sperling  LC,  Lupton  GP.  Histopathology  of  non-scarring 

 alopecia. J Cutan Pathol 1995; 22(2):97–114.

  28.  Price VH SM, Headington JT: Histology and hormonal activity 
in senescent thinning in males. Presented at the Annual Meeting 
of the Society for Investigative Dermatology, Washington DC, 
May 2001.

  29.  Robbins  C,  Mirmirani  P,  Messenger  AG,  Birch  MP, 
Youngquist  RS,  Tamura  M,  et  al.  What  women  want  -  quan-
tifying  the  perception  of  hair  amount:  An  analysis  of  hair 
diameter  and  density  changes  with  age  in  caucasian  women. 
Br J Dermatol 2012; 167(2):324–32.

  30.  Headington  JT.  Telogen  effluvium.  New  concepts  and  review. 

Arch Dermatol 1993; 129(3):356–63.

  47.  Thornton  MJ,  Taylor  AH,  Mulligan  K,  Al-Azzawi  F,  Lyon  CC, 
O’Driscoll J, et al. The distribution of estrogen receptor beta is 
distinct  to  that  of  estrogen  receptor  alpha  and  the  androgen 
receptor  in  human  skin  and  the  pilosebaceous  unit.  J  Investig 
Dermatol Symp Proc 2003; 8(1):100–3.

  48.  Thornton  MJ,  Taylor  AH,  Mulligan  K,  Al-Azzawi  F,  Lyon  CC, 
O’Driscoll J, et al. Oestrogen receptor beta is the predominant 
oestrogen  receptor  in  human  scalp  skin.  Exp  Dermatol  2003; 
12(2):181–90.

  49.  Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R. The 
hair follicle as an estrogen target and source. Endocr Rev 2006; 
27(6):677–706.

  50.  Conrad  F,  Paus  R.  Estrogens  and  the  hair  follicle.  J  Dtsch 

Dermatol Ges 2004; 2(6):412–23.

  51.  Ohnemus U, Uenalan M, Conrad F, Handjiski B, Mecklenburg L, 
Nakamura  M,  et  al.  Hair  cycle  control  by  estrogens:  Catagen 
induction  via  estrogen  receptor  (ER)-alpha  is  checked  by  ER 
beta signaling. Endocrinology 2005; 146(3):1214–25.

  52.  Stenn KS, Paus R, Filippi M. Failure of topical estrogen receptor 
agonists  and  antagonists  to  alter  murine  hair  follicle  cycling. 
J Invest Dermatol 1998; 110(1):95.

  31.  Gizlenti  S,  Ekmekci  TR.  The  changes  in  the  hair  cycle  during 
gestation  and  the  post-partum  period.  J  Eur  Acad  Dermatol 
Venereol 2014; 28(7):878–81.

  53.  Smart  RC,  Oh  HS.  On  the  effect  of  estrogen  receptor  ago-
nists and antagonists on the mouse hair follicle cycle.  J Invest 
Dermatol 1998; 111(1):175.

  32.  Whiting  DA.  Chronic  telogen  effluvium:  Increased  scalp  hair 
shedding  in  middle-aged  women.  J  Am  Acad  Dermatol  1996; 
35(6):899–906.

  33.  Wolfram LJ. Human hair: A unique physicochemical compos-

ite. J Am Acad Dermatol 2003; 48(6 Suppl):S106–14.

  34.  Trueb RM. Aging of hair. J Cosmet Dermatol 2005; 4(2):60–72.
  35.  Takahashi  T,  Mamada  A,  Breakspear  S,  Itou  T,  Tanji  N. 
 Age-dependent changes in damage processes of hair cuticle. J 
Cosmet Dermatol 2015; 14(1):2–8.

  36.  Kim  SN,  Lee  SY,  Choi  MH,  Joo  KM,  Kim  SH,  Koh  JS,  et  al. 
Characteristic features of ageing in Korean women’s hair and 
scalp. Br J Dermatol 2013; 168(6):1215–23.

  37.  Draelos  ZD.  The  biology  of  hair  care.  Dermatol  Clin  2000; 

18(4):651–8.

  38.  Lee  WS.  Photoaggravation  of  hair  aging.  Int  J  Trichol  2009; 

1(2):94–9.

  39.  Lu Z, Fischer TW, Hasse S, Sugawara K, Kamenisch Y, Krengel S, 
et al. Profiling the response of human hair follicles to ultravio-
let radiation. J Invest Dermatol 2009; 129(7):1790–804.

  40.  Marsh  JM,  Davis  MG,  Flagler  MJ,  Sun  Y,  Chaudhary  T, 
Mamak M, et al. Advanced hair damage model from ultra-vio-
let radiation in the presence of copper. Int J Cosmet Sci 2015.
  41.  Kaplan PD, Polefka T, Grove G, Daly S, Jumbelic L, Harper D, 
et  al.  Grey  hair:  Clinical  investigation  into  changes  in  hair 
fibres  with  loss  of  pigmentation  in  a  photoprotected  popula-
tion. Int J Cosmet Sci 2011; 33(2):171–82.

  42.  Sawaya ME, Price VH. Different levels of 5alpha-reductase type 
I and II, aromatase, and androgen receptor in hair follicles of 
women and men with androgenetic alopecia. J Invest Dermatol 
1997; 109(3):296–300.

  43.  Yi SM, Son SW, Lee KG, Kim SH, Lee SK, Cho ER, et al. Gender-
specific  association  of  androgenetic  alopecia  with  metabolic 
syndrome  in a middle-aged Korean population.  Br J Dermatol 
2012; 167(2):306–13.

  44.  Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. 
Executive  summary  of  the  Stages  of  Reproductive  Aging 
Workshop + 10: Addressing the unfinished agenda of staging 
reproductive aging. Menopause 2012; 19(4):387–95.

  45.  Prior  JC.  Perimenopause:  The  complex  endocrinology  of  the 

menopausal transition. Endocr Rev 1998; 19(4):397–428.

  46.  Burger  H,  Woods  NF,  Dennerstein  L,  Alexander  JL,  Kotz  K, 
Richardson  G.  Nomenclature  and  endocrinology  of  meno-
pause  and  perimenopause.  Exp  Rev  Neurotherapeut  2007;  7(11 
Suppl):S35–43.

  54.  Ohnemus U, Unalan M, Handjiski B, Paus R. Topical estrogen 
accelerates hair regrowth in mice after chemotherapy-induced 
alopecia by favoring the dystrophic catagen response pathway 
to damage. J Invest Dermatol 2004; 122(1):7–13.

  55.  Oh  HS,  Smart  RC.  An  estrogen  receptor  pathway  regulates 
the  telogen-anagen  hair  follicle  transition  and  influences 
epidermal  cell  proliferation.  Proc  Natl  Acad  Sci  U  S  A  1996; 
93(22):12525–30.

  56.  Chanda S, Robinette CL, Couse JF, Smart RC. 17beta-estradiol 
and ICI-182780 regulate the hair follicle cycle in mice through 
an estrogen receptor-alpha pathway. Am J Physiol Endocr Metab 
2000; 278(2):E202–10.

  57.  Moverare  S,  Lindberg  MK,  Faergemann  J,  Gustafsson  JA, 
Ohlsson C. Estrogen receptor alpha, but not estrogen receptor 
beta,  is  involved  in  the  regulation  of  the  hair  follicle  cycling 
as  well  as  the  thickness  of  epidermis  in  male  mice.  J  Invest 
Dermatol 2002; 119(5):1053–8.

  58.  Kondo S, Hozumi Y, Aso K. Organ culture of human scalp hair 
follicles:  Effect  of  testosterone  and  oestrogen  on  hair  growth. 
Arch Dermatol Res 1990; 282(7):442–5.

  59.  Conrad F, Ohnemus U, Bodo E, Biro T, Tychsen B, Gerstmayer B, 
et  al.  Substantial  sex-dependent  differences  in  the  response 
of  human  scalp  hair  follicles  to  estrogen  stimulation  in  vitro 
advocate  gender-tailored  management  of  female  versus  male 
pattern balding. J Investig Dermatol Symp Proc 2005; 10(3):243–6.
  60.  Hoffmann R, Niiyama S, Huth A, Kissling S, Happle R. 17alpha-
estradiol  induces  aromatase  activity  in  intact  human  anagen 
hair follicles ex vivo. Exp Dermatol 2002; 11(4):376–80.

  61.  Thornton  MJ.  Oestrogen  functions  in  skin  and  skin  append-

ages. Expert Opin Ther Targets 2005; 9(3):617–29.

  62.  Karnik P, Shah S, Dvorkin-Wininger Y, Oshtory S, Mirmirani P. 
Microarray  analysis  of  androgenetic  and  senescent  alopecia: 
Comparison  of  gene  expression  shows  two  distinct  profiles. 
J Dermatol Sci 2013; 72(2):183–6.

  63.  Tobin  DJ.  Aging  of  the  hair  follicle  pigmentation  system. 

Int J Trichol. 2009; 1(2):83–93.

  64.  Van Neste D. Thickness, medullation and growth rate of female 
scalp hair are subject to significant variation according to pig-
mentation  and  scalp  location  during  ageing.  Eur  J  Dermatol 
2004; 14(1):28–32.

  65.  Commo  S,  Gaillard  O,  Bernard  BA.  Human  hair  greying  is 
linked to a specific depletion of hair follicle melanocytes affect-
ing both the bulb and the outer root sheath. Br J Dermatol 2004; 
150(3):435–43.

 
422 

 TEXTBOOK OF COSMETIC DERMATOLOGYS

  66.  Wood  JM,  Decker  H,  Hartmann  H,  Chavan  B,  Rokos  H, 
Spencer JD, et al. Senile hair graying: H2O2-mediated oxidative 
stress affects human hair color by blunting methionine sulfox-
ide repair. FASEB J 2009; 23(7):2065–75.

  67.  Shi Y, Luo LF, Liu XM, Zhou Q, Xu SZ, Lei TC. Premature gray-
ing  as  a  consequence  of  compromised  antioxidant  activity 
in  hair  bulb  melanocytes  and  their  precursors.  PloS  one  2014; 
9(4):e93589.

  68.  Berger  RS,  Fu  JL,  Smiles  KA,  Turner  CB,  Schnell  BM, 
Werchowski KM, et al. The effects of minoxidil, 1% pyrithione 
zinc and a combination of both on hair density: A randomized 
controlled trial. Br J Dermatol 2003; 149(2):354–62.

a type 2 5alpha-reductase inhibitor, in men with male pattern 
hair loss. J Am Acad Dermatol 1999; 41(4):555–63.

  87.  Rushton  DH,  Unger  WP,  Cotterill  PC,  Kingsley  P,  James  KC. 
Quantitative  assessment  of  2%  topical  minoxidil  in  the  treat-
ment  of  male  pattern  baldness.  Clin  Exper  Dermatol  1989; 
14(1):40–6.

  88.  Shapiro  J,  Kaufman  KD.  Use  of  finasteride  in  the  treatment 
of  men  with  androgenetic  alopecia  (male  pattern  hair  loss). 
J Investig Dermatol Sym Proc 2003; 8(1):20–3.

  89.  Stough  DB,  Rao  NA,  Kaufman  KD,  Mitchell  C.  Finasteride 
improves male pattern hair loss in a randomized study in iden-
tical twins. Eur J Dermatol 2002; 12(1):32–7.

  69.  Civatte J, Laux B, Simpson NB, Vickers CF. 2% topical minoxi-
dil  solution  in  male-pattern  baldness:  Preliminary  European 
results. Dermatologica 1987; 175 Suppl 2:42–9.

  90.  Tang PH, Chia HP, Cheong LL, Koh D. A community study of 
male androgenetic alopecia in Bishan, Singapore. Singapore Med 
J 2000; 41(5):202–5.

  70.  Piepkorn MW, Weidner M. Comparable efficacy of 2% minoxi-
dil gel and solution formulations in the treatment of male pat-
tern alopecia. J Am Acad Dermatol 1988; 18(5 Pt 1):1059–62.
  71.  Price VH, Menefee E. Quantitative estimation of hair growth. 
I. androgenetic alopecia in women: Effect of minoxidil. J Invest 
Dermatol 1990; 95(6):683–7.

  72.  Price VH, Menefee E, Strauss PC. Changes in hair weight and 
hair count in men with androgenetic alopecia, after application 
of 5% and 2% topical minoxidil, placebo, or no treatment. J Am 
Acad Dermatol 1999; 41(5 Pt 1):717–21.

  73.  Rietschel  RL,  Duncan  SH.  Safety  and  efficacy  of  topical  min-
oxidil in the management of androgenetic alopecia. J Am Acad 
Dermatol 1987; 16(3 Pt 2):677–85.

  74.  Savin RC. Use of topical minoxidil in the treatment of male pat-
tern baldness. J Am Acad Dermatol 1987; 16(3 Pt 2):696–704.
  75.  Shupack JL, Kassimir JJ, Thirumoorthy T, Reed ML, Jondreau L. 
Dose-response study of topical minoxidil in male pattern alo-
pecia. J Am Acad Dermatol 1987; 16(3 Pt 2):673–6.

  76.  Vanderveen  EE,  Ellis  CN,  Kang  S,  Case  P,  Headington  JT, 
Voorhees  JJ,  et  al.  Topical  minoxidil  for  hair  regrowth.  J  Am 
Acad Dermatol 1984; 11(3):416–21.

  77.  Katz  HI,  Hien  NT,  Prawer  SE,  Goldman  SJ.  Long-term  effi-
cacy of topical minoxidil in male pattern baldness. J Am Acad 
Dermatol 1987; 16(3 Pt 2):711–8.

  78.  Olsen  EA,  DeLong  ER,  Weiner  MS.  Dose-response  study  of 
topical minoxidil in male pattern baldness. J Am Acad Dermatol 
1986; 15(1):30–7.

  79.  Connors TJ, Cooke DE, De Launey WE, Downie M, Knudsen RG, 
Shumack S, et al. Australian trial of topical minoxidil and pla-
cebo in early male pattern baldness. Australas J Dermatol 1990; 
31(1):17–25.

  80.  Dallob  AL,  Sadick  NS,  Unger  W,  Lipert  S,  Geissler  LA, 
Gregoire SL, et al. The effect of finasteride, a 5 alpha-reductase 
inhibitor,  on  scalp  skin  testosterone  and  dihydrotestosterone 
concentrations  in  patients  with  male  pattern  baldness.  J  Clin 
Endocrinol Metab 1994; 79(3):703–6.

  81.  Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, 
et al. Finasteride in the treatment of men with frontal male pat-
tern hair loss. J Am Acad Dermatol 1999; 40(6 Pt 1):930–7.
  82.  Lin  JH,  Chen  WC.  Finasteride  in  the  treatment  of  Taiwanese 
men with androgenetic alopecia: A 12-month open-label study. 
Kaohsiung J Med Sci 2002; 18(8):379–85.

  83.  McClellan KJ, Markham A. Finasteride: A review of its use in 

male pattern hair loss. Drugs 1999; 57(1):111–26.

  84.  Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, 
Tschen EH, et al. A randomized clinical trial of 5% topical min-
oxidil versus 2% topical minoxidil and placebo in the treatment 
of  androgenetic  alopecia  in  men.  J  Am  Acad  Dermatol  2002; 
47(3):377–85.

  85.  Price  VH,  Roberts  JL,  Hordinsky  M,  Olsen  EA,  Savin  R, 
Bergfeld  W,  et  al.  Lack  of  efficacy  of  finasteride  in  postmeno-
pausal women with androgenetic alopecia. J Am Acad Dermatol 
2000; 43(5 Pt 1):768–76.

  86.  Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, 
Shupack J, et al. Clinical dose ranging studies with finasteride, 

  91.  Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, 
Whiting D, et al. Finasteride increases anagen hair in men with 
androgenetic alopecia. Br J Dermatol 2000; 143(4):804–10.
  92.  Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, 
et al. Efficacy and tolerability of finasteride 1 mg in men aged 
41 to 60 years with male pattern hair loss. Eur J Dermatol 2003; 
13(2):150–60.

  93.  Kaufman  KD,  Olsen  EA,  Whiting  D,  Savin  R,  DeVillez  R, 
Bergfeld  W,  et  al.  Finasteride  in  the  treatment  of  men  with 
androgenetic  alopecia.  Finasteride  Male  Pattern  Hair  Loss 
Study Group. J Am Acad Dermatol 1998; 39(4 Pt 1):578–89.
  94.  Barman JM, Pecoraro V, Astore I. Method, technique and com-
putations in the study of the trophic state of the human scalp 
hair. J Invest Dermatol 1964; 42:421–5.

  95.  Barth  JH.  Measurement  of  hair  growth.  Clin  Exper  Dermatol 

1986; 11(2):127–38.

  96.  Hayashi S, Miyamoto I, Takeda K. Measurement of human hair 
growth by optical microscopy and image analysis. Br J Dermatol 
1991; 125(2):123–9.

  97.  Gassmueller  J,  Hoffmann  R,  Webster  A.  Topical  fulvestrant 
solution  has  no  effect  on  male  and  postmenopausal  female 
androgenetic alopecia: Results from two randomized, proof-of-
concept studies. Br J Dermatol 2008; 158(1):109–15.

  98.  Gassmueller  J,  Rowold  E,  Frase  T,  Hughes-Formella  B. 
Validation of TrichoScan technology as a fully-automated tool 
for evaluation of hair growth parameters. Eur J Dermatol 2009; 
19(3):224–31.

  99.  Hoffmann R. TrichoScan, a GCP-validated tool to measure hair 
growth.  J  Eur  Acad  Dermatol  Venereol  2008;  22(1):132–4;  author 
reply 4–5.

  100.  Blume-Peytavi  U,  Kunte  C,  Krisp  A,  Garcia  Bartels  N, 
Ellwanger  U,  Hoffmann  R.  Comparison  of  the  efficacy  and 
safety of topical minoxidil and topical alfatradiol in the treat-
ment of androgenetic alopecia in women. J German Soc Dermatol 
2007; 5(5):391–5.

  101.  Lopez V, Martin JM, Sanchez R, Ortega C, Ricart JM. Usefulness 
of  TrichoScan  professional  in  the  evaluation  of  hair  loss  in 
females. Report of 180 cases. J Eur Acad Dermatol Venereol 2011; 
25(9):1068–72.

  102.  Van Neste D, Trueb RM. Critical study of hair growth analysis 
with computer-assisted methods. J Eur Acad Dermatol Venereol 
2006; 20(5):578–83.

  103.  Blume-Peytavi  U,  Hillmann  K,  Dietz  E,  Canfield  D,  Garcia 
Bartels  N.  A  randomized,  single-blind  trial  of  5%  minoxidil 
foam  once  daily  versus  2%  minoxidil  solution  twice  daily  in 
the  treatment  of  androgenetic  alopecia  in  women.  J  Am  Acad 
Dermatol 2011; 65(6):1126–34 e2.

  104.  Jimenez  JJ,  Wikramanayake  TC,  Bergfeld  W,  Hordinsky  M, 
Hickman JG, Hamblin MR, et al. Efficacy and safety of a low-
level laser device in the treatment of male and female pattern 
hair loss: A multicenter, randomized, sham device-controlled, 
double-blind study. Am J Clin Dermatol 2014; 15(2):115–27.
  105.  Cohen B. The cross-section trichometer: A new device for mea-
suring hair quantity, hair loss, and hair growth. Dermatol Surg 
2008; 34(7):900–10; discussion 10–1.

 
CHANGES IN FEMALE HAIR WITH AGING: NEW UNDERSTANDING AND MEASURES 

 423

  106.  Robbins  CR.  Chemical  and  Physical  Behavior  of  Human  Hair. 

New York: Springer; 2002.

  107.  Lupton  CJ,  Pfeiffer  FA.  Measurement  of  medullation  in  wool 
and mohair using an optical fibre diameter analyser. J Animal 
Sci 1998; 76(5):1261–6.

  108.  Wortmann  FJ,  Schwan-Jonczyk  A,  In  cooperation  with  the 
working group Hair Care Products of the DGK. Investigating 
hair properties relevant for hair ‘handle’. Part I: Hair  diameter, 
bending  and  frictional  properties.  Int  J  Cosmet  Sci  2006; 
28(1):61–8.

  110.  Blume-Peytavi  U,  Blumeyer  A,  Tosti  A,  Finner  A,  Marmol  V, 
Trakatelli  M,  et  al.  S1  guideline  for  diagnostic  evaluation 
in  androgenetic  alopecia  in  men,  women  and  adolescents. 
Br J Dermatol 2011; 164(1):5–15.

  111.  Canfield  D.  Photographic  documentation  of  hair  growth  in 

androgenetic alopecia. Dermatol Clin 1996; 14(4):713–21.

  112.  Dhurat  R,  Saraogi  P.  Hair  evaluation  methods:  Merits  and 

demerits. Int J Trichol. 2009; 1(2):108–19.

  113.  Draelos  ZD.  Shampoos,  conditioners,  and  camouflage  tech-

niques. Dermatol Clin 2013; 31(1):173–8.

  109.  Mirmirani P, Fangyi L, Youngquist RS, Fischer BK, Li J, Oblong J, 
et al. In: Tobin DJ, Trueb RM, eds. Hair Growth Parameters in Pre-
and Post-Menopausal Women. New York: Springer, 2010.

  114.  Sinclair  RD,  Schwartz  JR,  Rocchetta  HL,  Dawson  TL  Jr, 
Fisher BK, Meinert K, et al. Dandruff and seborrheic dermatitis 
adversely affect hair quality. Eur J Dermatol 2009; 19(4):410–1.

 
45

Menopause, Skin, and Cosmetology

Michel Faure and Evelyne Drapier-Faure

INTRODUCTION
The  hormonal  disorders  of  menopause  affect  the  whole 
 organism,  including  skin  and  skin  appendages.  Women 
can  avoid  or  limit  some  side  effects  of  menopause  with 
 hormonal replacement therapy (HRT), and an appropriate cos-
metology may complement the favorable effects of HRT on the 
skin (1,2).

Skin  changes  at  menopause,  in  perimenopause,  and  in 
postmenopausal women include changes that can be related to 
the complex process of aging and others, among them signs of 
cutaneous  hyperandrogenism.  These  changes  affect  not  only 
skin,  but  also  mucous  membranes,  hair,  and  other  append-
ages. As far as skin and skin aging are concerned, HRT may 
be used with some success. However, HRT only very partially 
prevents  or  corrects  what  happens  in  terms  of  skin,  mucous 
 membranes,  and  appendages  with  menopause,  that  is,  the 
 so-called  hormonal aging of the skin (1–4).

MENOPAUSE AND HRT
Menopause  is  a  natural  biologic  process,  not  an  estrogen 
 deficiency  disease.  Menopause  represents  the  permanent 
 cessation  of  menses  resulting  from  loss  of  ovarian  follicular 
function (5). Menopause can occur spontaneously or be induced 
through  a  medical  intervention,  i.e.  surgery,   chemotherapy, 
radiation  therapy.  Aging  of  the  female  reproductive  system 
begins  at  birth  and  proceeds  as  a  continuum.  It  consists  of  a 
steady  loss  of  oocytes  from  atresia  or  ovulation,  which  does 
not occur at a constant rate, as evidenced by the relatively wide 
range  (42–58  years)  for  spontaneous  menopause.  Menopause 
is  defined  as  the  anchor  point  after  12  months  of  amenor-
rhea  following  the  final  menstrual  period,  which  reflects  a 
near- complete  but  natural  diminution  of  ovarian  hormone 
 secretion. In the Western world, menopause occurs at an aver-
age age of 51.4 years. Although there has been an increase in 
life expectancy over the last century, the age of menopause has 
not changed, unaffected by improving nutrition and reduction 
of disease.

The  term  premenopause  only  refers  to  the  whole  of  the 
(reproductive?) period prior to the menopause (since birth?) and 
therefore should be abandoned. Perimenopause (or menopause 
transition)  begins  with  variation  in  menstrual  cycle  length 
and  ends  with  the  final  menstrual  period.  For  most  women, 
the  transition  lasts  approximately  4  years.  Postmenopause  is 
the span of life dating from the final menstrual period and is 
defined as stage 1 (early: the 5 years following final menstrual 
period)  and  stage  2  (late,  with  a  duration  variable  since  end-
ing with the woman’s death). Climateric syndrome defines the 
symptomatology  associated  with  the  reproductive  transition 

of  perimenopause/menopause.  This  (and  some  changes 
in   postmenopausal  women  such  as  osteoporosis)  may  be 
 prevented with HRT (5).

Estrogen-based  therapies  for  postmenopausal  women 
may  be  divided  into  two  categories:  estrogen  replace-
ment  therapy  (ERT)  and  HRT,  a  combination  of  estrogen 
(for  instance,  estradiol  [E2])  and  of  progestin.  Progestins 
reduce  the  risk  of  endometrial  adenocarcinoma,  which  is 
 significantly  increased  in  women  with  a  uterus  who  use 
unopposed  estrogen.  However,  in  some  women,  these  pro-
gestins  may  favor  the  development  of  cutaneous  signs  of 
hyperandrogenism,  such  as  seborrhea,  acne,  alopecia,  and 
facial  hirsutism (1,2,5).

Porphyrias  and  lupus  erythematosus  (LE)  are  the 
only  dermatologic  conditions  in  which  HRT  should  not  be 
used  (1,2,6,7).  Although  a  few  studies  suggested  that  estro-
gen  replacement  does  not  increase  the  risk  for  lupus  flares 
in  postmenopausal  women  with  LE  (8–10),  HRT  and  ERT 
may  be  responsible  for  clinical  and  biologic  accentuations  in 
women with lupus, and for a first manifestation of the disease 
in  women  with  no  past  history.  Melasma  was  evidenced  in 
women under HRT (11).

The  initiation  of  hormone  therapy  may  be  proposed 
around  the  menopause  to  treat  menopause-related  symp-
toms  or  to  reduce  the  risk  of  osteoporosis  or  fractures  in 
select postmenopausal women, or both. The benefit-risk ratio 
for  HRT  is  favorable  close  to  menopause  but  decreases  with 
aging and with time since menopause in previously untreated 
women (12).

SKIN AGING AND MENOPAUSE
Skin  aging  is  a  progressive  and  complex  process,  which 
corresponds  to  at  least  two  major  components.  Intrinsic  or 
chronobiologic  aging,  on  one  hand,  affects  all  tissues,  while 
photoaging,  that  is,  helioderma,  only  affects  skin  in  sun-
exposed  areas.  Helioderma  is  not  influenced  by  hormonal 
status.

SO-CALLED HORMONAL SKIN AGING
Around  menopause,  during  premenopause  and  early 
postmenopause, the skin usually becomes thinner and rougher 
(Figures 45.1 and 45.2). So-called “dry skin” is only rough skin, 
which is due to chemophysical alterations of the stratum cor-
neum  at  the  skin  surface  level,  not  to  changes  in  dermal  or 
epidermal hydratation. Menopausal skin in non–sun-exposed 
areas is characterized by a diminution in skin thickness that 
affects  both  the  epidermis  and  the  dermis  (Figure  45.3),  and 

MENOPAUSE, SKIN, AND COSMETOLOGY 

 425

by  a  decrease  in  some  constituents  of  the  dermal  extracellu-
lar  matrix  such  as  collagens  and  glycoaminoglycans  (13–15). 
Some 30% of skin collagen is lost during the first 5 years after 
 menopause,  that  is,  early  postmenopause.  This  decrease  in 
dermal  collagen  also  parallels  bone  loss  in  postmenopausal 
women (16,17).

What  is  also  generally  observed  is  an  increase  in 
 percutaneous water loss correlated to alterations in the hydra-
tion and the lipid constitution of the stratum corneum, which 
becomes  more  compact  (1,3,4).  Taken  together,  this  leads  to 
alterations  in  skin  extensibility  (increased)  and  elasticity 
(decreased) (18).

The correction of some skin changes in postmenopausal 
women  with  HRT  supports  the  existence  of  what  has  been 
called hormonal skin aging.

HORMONE REPLACEMENT THERAPY 
AND SKIN AGING
The  observation  of  cutaneous  change  correction 
in 
postmenopausal  women  under  ERT  suggests  that  some  skin 
alterations noted with aging are due to the decrease in estro-
gens.  Studies  in  postmenopausal  women  indicated  that  the 
skinfold  thickness  is  maintained  with  long-term  hormone 
therapy (19). In some initial studies it was suggested that oral 
estrogen  therapy  can  prevent  epidermal  thinning  for  at  least 
3 years after castration (20).

More recent studies (ultrasonography and skin  biopsies) 
indicated  that  skin  atrophy  and  dermal  atrophy  in  sun- 
unexposed  areas  are  corrected  with  HRT  (21,22).  No  effect 
on  the  epidermis  could  be  evidenced  (21,22).  HRT  corrects 
or  prevents  the  decrease  in  dermal  thickness  and  in  dermal 
collagen  content  (15,16,23).  These  effects  of  HRT  are  systemic 
and  do  not  depend  on  the  way,  oral  or  percutaneous,  estro-
gens are  administered. However, the previous observations of 
the  correction  of  the  epidermal  atrophy  following  castration 
with  estrogen  substitution  (20)  were  not  confirmed  (21,22). 
Estrogens  may  also  affect  skin  surface  lipids,  epidermal 
 hydratation, sebum excretion, wrinkling. and skin elasticity in 
 postmenopausal women (24–27).

SKIN AGING AND OTHER HORMONE 
REGIMENS
DHEA
No  effect  of  DHEA  could  be  found  in  terms  of  correction  or 
prevention of skin aging in pre- or postmenopausal women (28).

Estrogens in Topical Treatments
When topically applied to the skin, estrogens have been shown 
to  induce  a  partial  correction  of  some  skin  aging  changes 
without evidence of systemic effect (29). Estriol and Estradiol 
ointments  improved  elasticity  and  reduced  the  wrinkle 
depth, but no control is available in this open 6-month study 
(30).  However,  the  effects  of  conjugated  estrogen  (Premarin1 
cream)  were  studied  in  a  randomized,  double-blind,  parallel 
group study: 54 women applied 1 g of either Premarin cream 
or placebo cream to the face daily for 24 weeks (31). Skin thick-
ness was measured by B-scan ultrasonic echography and skin 
microrelief  by  profilometry.  Skin  thickness  (dermal  plus  epi-
dermal) increased in the treated group. Premarin was also sig-
nificantly more effective than placebo in improving facial fine 
wrinkles. There was no effect on other parameters (skin rough-
ness, laxity, and hyperpigmentation) (31). Topical estradiol was 

Figure 45.1  Menopausal skin thinning.

Figure 45.2  Menopausal “dry skin.”

Figure 45.3  Epidermal thinning and compact stratum 
corneum.

 
426 

 TEXTBOOK OF COSMETIC DERMATOLOGY

also shown to increase the amount of dermal collagen (32,33) 
and stimulate collagen synthesis (33).

Phytoestrogens, Isoflavones
Genistein has been shown to be an inhibitor of UVR-induced 
skin  carcinogenesis  (34).  The  effects  of  isoflavones  and  other 
phytoestrogens  on  skin  atrophy,  dermal  collagen  are  under 
investigation  to  determine  their  possible  use  in  the  preven-
tion of skin aging in postmenopausal women. Animal studies 
showed an increased collagen metabolism in animals treated 
with a preparation of genistein and daizein (35).

OTHER SKIN CARE AND MENOPAUSE
Taken  together,  these  data  indicate  that  HRT,  alone  or  in 
 combination with preparations with estrogens or isoflavones, 
may be used to minimize skin changes due to estrogen defi-
ciency. However, because of the possible adverse effects, such 
as the increased risk of breast cancer and cardiovascular dis-
ease, HRT cannot be recommended today to treat skin aging. 
On the other hand, cosmeceutical care has an important role to 
play for the menopausal woman (36). Tretinoin, glycolic acid, 
and  ascorbic  acid–containing  products  have  been  shown  to 
change age and/or sun-related skin damage (37–41). They may 
therefore be considered as medicines, which may complement 
the action of HRT. Collagen injections, botulic toxin, peelings, 
and resurfacing lasers are designed for photoinduced  wrinkles 
and  solar  keratosis,  conditions  where  HRT  has  no  action. 
Surgery is necessary for cutaneous ptosis of the face and neck.

OTHER SYMPTOMS
Genital Discomfort
Vulvar atrophy (Figure 45.4), vaginal atrophy, and genital dry-
ness  may  be  observed  in  postmenopausal  women.  Vaginal 

dryness  may  respond  well  to  HRT.  However,  HRT  is  not 
 effective  on  vulvar  atrophy,  and  topical  estrogens  have  to  be 
used (1,40).

Hirsutism or Hypertrichosis
True  hirsutism,  if  absent  before  menopause,  is  uncommon 
after, but facial hirsutism, or hypertrichosis is not uncommon 
(41). Facial hirsutism (Figure 45.5), either in perimenopause or 
after menopause, may be related to an idiopathic skin hyper-
androgenism,  even  in  the  absence  of  biologic  evidence  of 
 hyperandrogeny (2,40). Together with alopecia, excess in sebor-
rhea, and to a lesser degree acne, this hypertrichosis may also 
be related to progestin intake (either in women under HRT, or 
progestin therapy in premenopausal women), to DHEA, or to 
tibolone (42). When true hirsutism develops, whether alone or 
with other patterns of hyperandrogenism, it may correspond 
to an ovarian or adrenal tumor (43).

True  hirsutism,  but  not  facial  hypertrichosis,  responds 
well to antiandrogens (cyproterone acetate or spironolactone) 
(44). HRT has no or little effect. Facial hirsutism needs  epilation 
(by  laser  or  any  other  method).  Eflornithine  (45),  a  potent 
inhibitor of polyamine metabolism, may also be used (Vanica1 
cream). The 5a-reductase inhibitor finasteride was also shown 
to  improve  cases  of  facial  hirsutism  when  topically  applied, 
with decreased hair growth and thickness (46).

Alopecia
Hair  loss  may  only  occur  in  postmenopause  alone  or  in 
association  with  facial  hirsutism,  but  is  not  infrequent  in 
premenopausal  women  after  40.  When  mild  and  with  a  pro-
gressive installation, this so-called androgenogenetic alopecia 
(AAG), or female-pattern hair loss (Figure 45.6), has to be distin-
guished from other causes of progressive hair loss in women: 
hypothyroidism,  iron  deficiency  (47),  lichen   planus  (48),  or 
more commonly, senile alopecia (2).

Neither  ERT  nor  HRT  can  prevent  hair  loss,  and 
 antiandrogens,  such  as  cyproterone  acetate  or  spironolac-
tone,  should  be  recommended  in  association  with  ERT  and 
topically  applied  minoxidil  (44,49).  Finasteride,  which  blocks 
the  reduction  of  testosterone  into  active  diOH  testosterone, 
does  not  prevent  progression  of  hair  loss  in  postmenopausal 
women with female-pattern hair loss (50). However, the recent 
report  of  the  possibility  of  an  improvement  of  some  AAG  in 
postmenopausal women with hyperandrogenism supports the 
hypothesis that not all types of female hair loss have the same 

Figure 45.4 Postmenopausal vulval atrophy.

Figure 45.5  Postmenopausal facial hirsutism.

 
MENOPAUSE, SKIN, AND COSMETOLOGY 

 427

5.  NAMS,  Menopause  Core  Curriculum  Study  Guide.  2nd  edition. 

The North American Menopause Society, 2002.

6.  Meier CR, Sturkenboom MC, Cohen A, et al. Postmenopausal 
estrogen  replacement  therapy  and  the  risk  of  developing 
 systemic  lupus  erythematosus  or  discoid  lupus.  J  Rheumatol 
1998; 25:1515–9.
7.  Sanchez-Guerrero 

J,  Liang  MH,  Karlson  EW,  et  al. 
Postmenopausal estrogen therapy and the risk for developing 
systemic lupus erythematosus. Ann Intern Med 1995; 122:430–3.
8.  Arden  NK,  Llyod  M,  Spector  TD,  et  al.  Safety  of  hormone 
replacement  therapy  (HRT)  in  systemic  lupus  erythematosus 
(SLE). Lupus 1994; 3:11–3.

9.  Kreidstein S, Urowitz MB, Gladman DD, et al. Hormone replace-
ment  therapy  in  systemic  lupus  erythematosus.  J  Rheumatol 
1997; 24:2149–52.

  10.  Mok  CC,  Lau  CS,  Ho  CTK,  et  al.  Safety  of  hormonal  replace-
ment therapy in postmenopausal patients with systemic lupus 
erythematosus. Scand J Rheumatol 1998; 27:342–6.

  11.  Johnston  GA,  Sviland  L,  McLelland  J.  Melasma  of  the  arms 
associated  with  hormone  replacement  therapy  Br  J  Dermatol 
1998; 139:932.

  12.  North  American  Menopause  Society.  Position  statement. 
Estrogen and progestogen use in postmenopausal women: July 
2008  position  statement  of  the  North  American  Menopause 
Society. Menopause 2008; 15:584–603.

  13.  Brincat M, Moniz CF, Kabalan SE, et al. Decline in skin  collagen 
content  and  metacarpal  index  after  the  menopause  and  its 
 prevention with sex hormone replacement. Br J Obstet Gynecol 
1987; 94:126–9.

  14.  Brincat M, Moniz CF, Studd JWW, et al. Sex hormones and skin 
collagen  content  in  post  menopausal  women.  Br  Med  J  1983; 
287:1337–8.

  15.  Brincat  M,  Versi  E,  Moniz  CF,  et  al.  Skin  collagen  changes 
in  postmenopausal  women  receiving  different  regimens  of 
 estrogen therapy. Obstet Gynecol 1987; 70:123–7.

  16.  Castelo-Branco  C,  Duran  M,  Gonzalez-Merlo  J.  Skin  collagen 
changes  related  to  age  and  hormone  replacement  therapy. 
Maturitas 1992; 15:113–9.

  17.  Castelo-Branco C, Pons F, Gratacos E, et al. Relationship between 
skin collagen and bone changes during aging. Maturitas 1994; 
18:199–206.

  18.  Sumino  H,  Ichikawa  S,  Abe  M,  et  al.  Effects  of  aging  and 
 postmenopausal hypoestrogenism on skin elasticity and bone 
mineral density in Japanese women. Endocrine J 2004; 51:159–64.
  19.  Punnonen  R,  Vilska  S,  Rauramo  L.  Skinfold  thickness  and 
long-term  post-menopausal  hormone  therapy.  Maturitas  1984; 
5:259–62.

  20.  Punnonen  R,  Rauramo  L  The  effect  of  long-term  oral  oestriol 
succinate  therapy  on  the  skin  of  castrated  women.  Ann  Chir 
Gynaecol 1977; 66:214–5.

  21.  Callens  A,  Vaillant  L,  Lecomte  P,  et  al.  Does  hormonal  skin 
aging  exist?  A  study  of  the  influence  of  different  hormone 
therapy  regimens  on  the  skin  of  postmenopausal  women 
using noninvasive measurement techniques. Dermatology 1996; 
193:289–94.

  22.  Maheux R, Naud F, Rioux M, et al. A randomized double-blind 
placebo-controlled study on the effect of conjugated estrogens 
on skin thickness. Am J Obstet Gynecol 1994; 170:642–9.

  23.  Savvas M, Bishop J, Laurent G, et al. Type III collagen content 
in the skin of postmenopausal women receiving oestradiol and 
testosterone implants. Br J Obstet Gynaecol 1993; 100:154–6.
  24.  Guinot C, Malvy D, Ambroisine L, et al. Effets de traitements 
hormonaux de substitution sur des propriétés biophysiques de 
la peau de femmes menopausées. Ann Dermatol Venereol 2002; 
129:1129–33.

  25.  Pierard  GE,  Letawe  C,  Dowlati  A,  et  al.  Effect  of  hormone 
replacement  therapy  for  menopause  on  the  mechanical 
 properties of skin. J Am Geriatr Soc 1995; 43:662–5.

  26.  Pierard-Franchimont  C,  Cornil  F,  Dehavay  J,  et  al.  Climateric 
skin aging of the face—A prospective longitudinal  comparative 

Figure 45.6  Postmenopausal alopecia.

Figure 45.7  Climateric hyperkeratosis of the palms.

pathophysiology (51). Psychotherapy is often necessary, and in 
some cases hair transplantation and scalp surgery.

OTHER TREATMENTS
Topically applied androgens, not estrogens, can be considered 
in  cases  of  genital  hair  loss.  HRT  has  no  effect  on  genital  or 
axillary depilation. Neither HRT nor other hormonal regimens 
have any proved effect on postmenopausal nail changes.

Climateric  keratodermas  (Figure  45.7)  are  very  poorly 
understood and no data are available concerning the effect of 
hormone replacement (52).

REFERENCES

1.  Faure  M,  Drapier-Faure  E.  Menopause,  HRT  and  the  skin.  In: 
Rozenbaum  H,  ed.  First  Congress  of  the  Federation  of  National 
European Menopause Societies. EKSA, Paris, 2001; pp. 31–35.
2.  Faure  M,  Drapier-Faure  E.  Peau,  phanères  et  stéroïdes  sex-
uels.  Encycl  Med  Chir  (Elsevier,  Paris)  Dermatologie  1988; 
12(960A)10:1–8.

3.  Bolognia  JL,  Braverman  IM,  Rousseau  ME.  Skin  changes  in 

menopause. Maturitas 1989; 11:295–304.

4.  Dunn LB, Damesyn M, Moore AA, et al. Does estrogen prevent 

skin aging? Arch Dermatol 1997; 133:339–342.

 
 
 
 
 
 
 
 
 
 
428 

 TEXTBOOK OF COSMETIC DERMATOLOGY

trial  on  the  effect  of  oral  hormone  replacement  therapy. 
Maturitas 1999; 32:87–93.

  27.  Sator PG, Sator O, Schmidt JB, et al. A prospective,  randomized, 
double-blind,  placebo-controlled  study  on  the  influence  of  a 
hormone  replacement  therapy  on  skin  aging  in  postmeno-
pausal women. Climateric 2007; 10:320–34.

  28.  Beaulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone 
(DHEA),  DHEA  sulfate,  and  aging:  Contribution  of  the  DHE 
age  study  to  a  sociobiomedical  issue.  Proc  Natl  Acad  Sci  2000; 
97:4279–84.

  29.  Kainz C, Gitsch G, Stami J, et al. When applied to facial skin, 
does  estrogen  ointment  have  systemic  effects?  Arch  Gynecol 
Obstet 1993; 253:71–4.

  30.  Schmidt  JB,  Binder  M,  Demschik  G,  et  al.  Treatment  of  skin 
aging with topical estrogen. Int J Dermatol 1996; 35:669–74.
  31.  Creidi P, Faivre B, Agache P, et al. Effect of a conjugated oestro-
gen  (Premarin  R)  cream  on  ageing  facial  skin.  A  comparative 
study with a placebo cream. Maturitas 1994; 19:211–3.

  32.  Patriarca  MT,  Goldman  KZ,  dos  Santos  JM,  et  al.  Effects  of 
topical estradiol on the facial skin collagen of postmenopausal 
women under oral hormone therapy: A pilot study. Eur J Obstet 
Gynecol Reproduct Biol 2007; 130:202–5.

  33.  Varila  E,  Rantala  I,  Oikarinen  A,  et  al.  The  effect  of  topi-
cal   oestradiol  on  skin  collagen  of  postmenopausal  women. 
Br J Obstet Gynaecol 1995; 102:985–9.

  34.  Wei H. Photoprotective action of isoflavone genistein: Models, 
mechanisms and relevance to clinical dermatology. Am J Acad 
Dermatol 1998; 39:271–2.

  35.  Simeon A, Macquart FX, Cohen-Letessier A. Effet d’une prépa-
ration à usage topique contenant de l’extrait titré de Soja à 5%, 
de  l’extrait  titré  de  Centella  asiatica  à  1%  et  l’association  des 
deux dans le vieillissement cutané chez l’animal. Nouv Dermatol 
2000; 19:636–40.

  36.  Gilchrest BA. A review of skin ageing and its medical therapy. 

Br J Dermatol 1996; 135:867–75.

  37.  Kligman AM, Grove GL, Hirosse R, et al. Topical tretinoin for 

photoaged skin. Am J Acad Dermatol 1986; 15:836–59.

  38.  Creidi  P,  Humbert  P.  Clinical  use  of  topical  retinaldehyde  on 

photoaged skin. Dermatology 1999; 199(S1):49–52.

  39.  Nusgens  BV,  Humbert  P,  Rougier  A,  et  al.  Topically  applied 
vitamin  C  enhances  the  mRNA  level  of  collagens  I  and  III, 

their  processing  enzymes  and  tissue  inhibitor  of  matrix 
 metalloproteinase  1  in  the  human  dermis.  J  Invest  Dermatol 
2001; 116:853–9.

  40.  Faure  M,  Drapier-Faure  E.  Effets  benéfiques  des  traitements 
hormonaux  en  cosmetologie.  Encycl  Med  Chir  (Editions 
Scientifiques  et  Medicales  Elsevier  SAS,  Paris),  Cosmetol 
Dermatol Esthet, 2001; 50(240-B)10:5.

  41.  Moses  RG,  Theile  H,  Colagiuri  S.  Postmenopausal  idiopathic 

hirsutism. Menopause 1994; 1:205–9.

  42.  Modelska  K,  Cummings  S.  Tibolone  for  postmenopausal 
women:  Systematic  review  of  randomized  trials.  J  Clin 
Endocrinol Metab 2002; 87:16–23.

  43.  Conn JJ, Conway GS. Severe virilization in a postmenopausal 

woman. Curr Opin Obstet Gynecol 1996; 8:385–9.

  44.  Faure M, Drapier-Faure E. La prise en charge des hyperandro-

génies. Ann Dermatol Venereol 1998; 125:533–40.

  45.  Hamzavi  I,  Tan  E,  Shapiro  J,  et  al.  A  randomized  bilateral 
 vehicle controlled study of eflornithine cream combined with 
laser treatment versus laser treatment alone for facial hirsutism 
in women. Am J Acad Dermatol 2007; 57:54–9.

  46.  Lucas  KJ.  Finasteride  cream  in  hirsutisme.  Endocr  Pract  2001; 

7:5–10.

  47.  Ruschton  DH,  Ramsay  ID.  The  importance  of  adequate 
serum  ferritine  levels  during  oral  cyproterone  acetate  and 
 ethinylestradiol  treatment  of  diffuse  androgen  dependent 
 alopecia in women. Clin Endocrinol 1992; 36:421–7.

  48.  Kossard  S,  Lee  MS,  Wilkinson  B.  Post-menopausal  frontal 
fibrosing alopecia: A frontal variant of lichen planopilaris. Am J 
Acad Dermatol 1997; 36:59–66.

  49.  Vexiau  P,  Chaspoux  C,  Boudou  P,  et  al.  Effects  of  minoxidil 
2%  vs.  cyproterone  acetate  treatment  on  female  androgenetic 
 alopecia: A controlled, 12-month randomized trial. Br J Dermatol 
2002; 146:992–9.

  50.  Price  VH,  Roberts  JL,  Hordinsky  M,  et  al.  Lack  of  efficacy  of 
finasteride  in  postmenopausal  women  with  androgenetic 
 alopecia. Am J Acad Dermatol 2000; 43:768–76.

  51.  Shum  KW,  Cullen  DR,  Messenger  AG.  Hair  loss  in  women 
with hyperandrogenism: Four cases responding to finasteride. 
Am J Acad Dermatol 2002; 47:737–9.

  52.  Hawthausen H. Keratoderma climatericum. Br J Dermatol 1934; 

46:161–7.

 
Section VI

Cosmetological Treatments

46

Mesotherapy

Maria Pia De Padova, Gabriella Fabbrocini, Sara Cacciapuoti, and Antonella Tosti

INTRODUCTION
Mesotherapy was first developed in 1952 by Dr. Michel Pistor, 
a French physician, for the management of pain and vascular 
disorders (1), who coined the term mesotherapy. He defined it as 
treatment of the mesoderm (the primary germ layer that devel-
ops into connective tissue, muscle, and circulatory system). In 
1976, he described mesotherapy as “… little volume, few times 
and in the right place” (2).

Pistor  founded  the  French  Society  of  Mesotherapy  in 
1964 and The French National Academy of Medicine officially 
acknowledged mesotherapy as a medical specialty in 1987. In 
the meantime, mesotherapy became popular in most parts of 
Europe and South America, and more recently in the United 
States and Asian countries.

TERMINOLOGY
Mesotherapy,  broadly  defined,  represents  a  variety  of  mini-
mally invasive techniques that consists of the intra- or subcu-
taneous injection of variable mixtures of natural plant extracts, 
homeopathic  agents,  pharmaceuticals,  vitamins,  and  other 
bioactive substances in small quantities through dermal multi 
punctures.  The  term  mesotherapy  is  derived  from  the  Greek 
words  mesos  (meaning  “middle”  or  “mean”)  and  therapeia 
(meaning  “to  treat  medically,”  i.e.  injecting  into  the  middle 
layer of skin or intradermotherapy). Therapeutic effects of chem-
ical  products  used  for  mesotherapy  are  prevalently  used  for 
skin rejuvenation and local fat deposits.

INDICATIONS
Mesotherapy  is  reported  to  have  a  wide  array  of  applica-
tions,  especially  in  the  field  of  cosmetic  dermatology.  Skin-
rejuvenation/glow, lift, and fat reduction are the most common.

Mesotherapy can be performed for:

•  Chronoaging: mild–moderate (Glogau I/II)
•  Photoaging: mild–moderate (Glogau I/II)
•  Prevention of aging
•  Preparation for sun exposure
•  Smokers

Many  products  are  available  on  the  market  to  perform 
 mesotherapy  for  skin  rejuvenation.  Some  contain  only 
one  active  ingredient  and  others  are  mixture  of  different 
 compounds (Table 46.1). Some authors believe that injection of 
a  single  ingredient  can  provide  better  results  than  a   cocktail 
injection:  the  side  effects  resulting  from  the  interactions 
among  different  ingredients  can  be  reduced  and  the  active 
 ingredients, injected alone, can be more effective (3).

Mesotherapy is also proposed for reduction of local fat 

deposits or cellulite and for body contouring.

MESOTHERAPY FOR FAT DEPOSITS
Cellulite  is  an  abnormal  accumulation  of  fat  above  the  fas-
cia  resulting  in  dimpling  appearance  of  skin  resembling  an 
orange peel (4). It is most commonly seen in the buttocks and 
thighs of females. It is seen in both normal and obese persons. 
It is believed to occur due to abnormality in the venous lym-
phatic  system.  According  to  literature,  the  treatment  of  local 
fat  deposits  and  cellulite  is  based  on  the  agents  reported  in 
Table 46.2 (5).

The  two  different  types  of  mesotherapy  used  for  cos-
metic fat reduction are lipolytic stimulation and ablative meso-
therapy. Lipolytic stimulation is based on activation of lipolysis 
in  fat  cells.  There  are  at  least  three  general  mechanisms  by 
which lipolysis can be increased: (1) inhibition of phosphodies-
terase or the adenosine receptor (6–7); (2) activation of the beta-
adrenergic receptor, and (3) inhibition of the alpha-2 receptor. 
Aminophylline, isoproterenal or forskolin, and yohimbine are 
thought to act on all the three different lipolytic signalling path-
ways (8). Isoproterenol, aminophylline, and yohimbine should 
have additive effects as they act at different points in the same 
physiological pathway. Ablative mesotherapy is based on the 
destruction of fat cells using a detergent. Injectable phosphati-
dylcholine and deoxycholate are the major components used in 
ablative mesotherapy. Phosphotidylcholine is able to:

Table 46.1  Products Used for Mesotherapy

Hyaluronic acid alone (1.35%–3%)
Hyaluronic acid 0.2%, 1%, or 3% plus other active ingredients
Polynucleotide macromolecules
Organic silicium
Autologous cultured fibroblasts
Growth factors
Homeopathic products

Table 46.2  Agents Contained in Solution for  
Treatment of Cellulite

Lipolytic

Venostatic

Anesthetic

L-carnitine, caffeine, isoproterenol

Rutin, aminophylline, pentoxiphylline

Procaine (also improves circulation)

Connective tissue 

Collagenase, hyaluronidase

breakdown

Drainage

Artichoke, gingko biloba

432 

 TEXTBOOK OF COSMETIC DERMATOLOGY

1.  Penetrate  the  adipocytes  and  break  down  fat,  which  is 
then carried to the blood stream and excreted via the kid-
neys and bowel (9). Since phosphotidylcholine is viscous, 
an emulsifying agent, deoxycholate, is added to facilitate 
its  injection.  This  chemical  has  been  shown  to  indepen-
dently cause lysis of the adipocytes (10).

2.  Promote lipolysis by stimulating β receptors and inhibit-
ing α2 receptors present on the adipocyte membrane (11).

3.  Cause  inflammatory  cytokine-mediated  necrosis  and 
reabsorption  of  adipocytes.  Once  the 
inflammation 
 subsides, new collagen is formed, leading to retraction of 
the loosened tissue (12).

Phosphotidylcholine  induces  lipolysis  via  the  activation  of 
cyclic-monophosphate  and  the  activation  of  beta  adrener-
gic receptors. Gluteofemoral adipocytes have a significantly 
lower  number  of  beta  adrenergic  receptors  as  compared  to 
other  localized  adiposities.  Deoxycholate  alone  is  recom-
mended for use in small localized fat deposits, with a phos-
phatidylcholine  and  deoxycholate  combination  reserved 
for  larger  treatment  areas  (13).  The  observation  that  post-
injection resolution of inflammation is faster with the phos-
phatidylcholine  and  deoxycholate  mixture  compared  to 
deoxycholate  alone  supports  these  recommendations  (14). 
Depth of injection varies from 6 mm to 12 mm at a dose of 
250  mg  (15).  Although  the  therapeutic  effects  of  this  pro-
cedure  are  linked  to  the  properties  of  the  molecules  listed 
above, an essential part in the treatment of this condition is 
a low glycemic diet and regular, preferably aerobic, physical 
exercise.

MESOTHERAPY FOR SKIN RENJUVENATION
Areas of Application
•  Face (cheeks, chin, forehead)
•  Neck
•  Low neckline
•  Back of hands
•  Abdomen
•  Arms and legs (inner surface)

Although  mesotherapy 
is  an 
 easy- to-perform  technique,  contraindications  and  disadvan-
tages are always to be considered (Table 46.3).

rejuvenation 

skin 

for 

Technique
Classical Mesotherapy
For the procedure, common disposable syringes are used with 
a 4 mm × 0.4 mm (27G) needle (Leble needle) that permits cor-
rect intradermal injection in any cutaneous surface. With this 
needle, it is easy to avoid telangiectasia and skin lesions. The 
13 mm × 0.3 mm (30G) needle, however, is more appropriate for 
skin biostimulation.

The  injections  can  be  performed  using  three  different 
techniques,  always  keeping  the  needle  with  an  inclination 
of 45°:

•  Picotage.  One  drop  of  the  product  is  injected  into  the 
superficial dermis. The injections are spaced at 2 mm, and 
the  needle  penetrates  2  to  2.5  mm.  The  physician  main-
tains a constant pressure on the plunger.
•  Cross-linking.  Consists  of  vertical 

injections,  with 
 complete  penetration  of  needle,  followed  by  horizon-
tal  injections  (1-cm  distance  between  lines).  The  product 
is  injected  during  the  extraction  of  the  needle  from  the 
dermis.  This  technique  is  particularly  useful  for  cheeks 
and  low  neckline  in  patients  with  advanced  stage  of 
chronoaging.

•  Linear  threading.  Either  vertical  or  horizontal  injections 
are  performed  (Figure  46.1).  Vertical  injections  are  use-
ful to prepare the nasolabial and glabellar wrinkles 10 to 
15  days  before  injecting  dermal  fillers  and  botulinum 
toxin.  Horizontal  injections  are  useful  in  treating  neck 
wrinkles. To reduce the burning sensation, the physician 
can apply EMLA cream or use mesotherapy products con-
taining lidocaine chlorhydrate 1 hour before treatment.

Microtherapy and Electroporation
Microtherapy  and  electroporation  are  new  methodolo-
gies  that  offer  some  advantages  over  classical  mesotherapy. 
Microtherapy  is  a  procedure  that  facilitates  the  intradermal 
injection  of  drugs.  The  use  of  extra-fine  needles  permits  the 

Table 46.3  Mesotherapy for Skin Rejuvenation: Contraindications and Disadvantages

Contraindications

Allergy to ingredients of the cocktail

History of hypertrophic scars

Disadvantages

Only for mild–moderate aging

Mild erythema, slight itching/burning sensation 5 min after 

Bleeding abnormalities and/or anticoagulant therapy

Pregnancy/ breastfeeding

Autoimmune disorders

Epilepsy

Diabetes

Herpes simplex virus type 1 (HSV-1) infection in active phase

Bacterial infections

Inflammatory skin disorders (acute phase)

injections

Small hematomas

Possibility of allergic reactions

Lack of controlled clinical trials

Lack of guidelines according to the evidence-based medicine

 
MESOTHERAPY 

 433

limiting  factor  in  the  optimal  penetration  of  topical  agents. 
The horny layer represents the main block to the  penetration 
of  hydrophilic  molecules  and/or  of  molecules  having  a  high 
molecular weight (16,17). The method is based on the applica-
tion of an electric impulse to the epithelial surface. The electric 
impulse is able to generate a transmembrane potential differ-
ence of 0.5–1.5 V, giving rise to the phenomenon of poration of 
cell membranes. At the same time, it causes an electrochemi-
cal perturbation of the horny layer, with a consequent increase 
in its permeability. It is well known that a specific molecular 
weight and lipophilic properties can be passively diffused in 
the  horny  layer  and  reach  the  dermal  region  (18).  The  proce-
dure is absolutely painless and safe for the patient. The system 
is characterized by a 100-V condenser that generates a typical 
reversible exponential wave and by a metallic activation cham-
ber in which is placed a conductive gel containing the active 
molecules. The electropores allow cell penetration of molecules 
that usually do not penetrate because of their high molecular 
weight. The aqueous channel is rather large (1–2 μm), permit-
ting  the  passage  of  molecules  such  as  medium-molecular–
weight  polysaccharides  (hyaluronic  acid),  peptides  (soluble 
collagen), and glucosides. The first step of the treatment is to 
remove the horny layer with crystal microdermoabrasion, fol-
lowed  by  superficial  peeling.  The  second  step  consists  of  the 
introduction  of  the  revitalizing  substances  (hyaluronic  acid, 
vitamins,  peptides,  etc.)  in  the  conductive  gel,  which  is  then 
ionized in the ionization chamber and applied to the area to 
be treated by a light massage (19). The treatment lasts about 30 
minutes, including the pre-peeling  (cavitation) stage, and can 
be repeated every 1–2 weeks for a cycle of 10  sessions at most.

Results
Mesotherapy is believed to improve the global appearance of 
the skin and it can be an excellent complement to all other reju-
venating procedures. Two or three treatments are necessary to 
see  results:  in  general  the  skin  appears  firmer,  brighter,  and 
better moisturized. (Figures 46.2–46. 5)

Figure 46.1  Linear threading, horizontal injections.

drugs to reach the papillary level of the dermis, thus  avoiding 
damage  to  the  skin's  superficial  nerves  and  vessels.  This 
reduces risks of undesired side effects. Some of the advantages 
of this procedure are the following:

•  Painless injections, because the needle does not reach the 

nerves

•  Reduced hematomas, since only capillaries and not venules 

are touched

•  Slow absorption of the drug because it does not reach the 
venules of the deep dermis and thus barely enters the cir-
culation, remaining locally active for a long time

•  No  scars  in  the  deep  dermis  that  might  cause  undesired 

sequelae

Dermo-electroporation is a very interesting methodology with 
manifold  applications  in  dermatology  and  cosmetology.  This 
innovative  procedure  diffuses  pharmacologically  active  sub-
stances  through  the  horny  layer,  which  represents  the  most 

Figure 46.2  A patient (a) before and (b) 2 weeks after mesotherapy.

(a)

(b)

 
434 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 46.3  A patient (a) before and (b) after mesotherapy and filler injection.

(a)

(b)

Figure 46.4  A patient (a) before and (b) 3 weeks after mesotherapy.

(a)

(b)

Figure 46.5  A patient (a) before and (b) 3 weeks after mesotherapy

(a)

(b)

 
MESOTHERAPY 

 435

CONCLUSION
In recent years, mesotherapy has gained popularity due to its 
noninvasive,  painless  nature,  but  to  date,  the  mode  of  action 
of  many  products  used  in  mesotherapy  is  either  doubtful  or 
unknown and there are no clear-cut guidelines on the dosage 
and efficacy of the products. Safety of molecules that are injected 
is not established for all compounds and  phosphatidylcholine, 
for instance, is not approved for mesotherapy in most areas of 
the  world.  Thus,  continued  research  and  well-designed  con-
trolled scientific studies are required to enhance the claims of 
effectiveness of these new products and techniques. It can be 
hopeful  to  have  guidelines  and   recommendations  regarding 
their use for aesthetic applications.

REFERENCES

1.  Pistor M. What is mesotherapy? Chir Dent Fr 1976; 46:59–60.
2.  Herreros FO, Moraes AM, Velho PE. Mesotherapy: A  bibliographic 

review. An Bras Dermatol 2011; 86:96–101.

3.  Konda  D,  Thappa  DM.  Mesotherapy:  What  is  new?  Indian  J 

Dermatol Venereol Leprol 2013 Jan–Feb; 79(1):127–34.

9.  Raghvendra,  Tyagi  S,  Yadav  P,  Saxena  S,  Dodia  RA,  Patel  TD. 
Mesotherapy:  A  non  surgical  cosmetic  medicine  treatment: 
A review. Int J Pharm Sci Rev Res 2010; 4:45–7.

  10.  Rotunda  AM,  Suzuki  H,  Moy  RL,  Kolodney  MS.  Detergent 
effects of sodium deoxycholate are a major feature of an inject-
able  phosphatidylcholine  formulation  used  for  localized  fat 
dissolution. Dermatol Surg 2004; 30:1001–8.

  11.  Matarasso  A,  Pfeifer  TM.  Mesotherapy  for  body  contouring. 

Plast Reconstr Surg 2005; 115:1420–4.

  12.  Rose  PT,  Morgan  M.  Histological  changes  associated  with 
mesotherapy  for  fat  dissolution.  J  Cosmet  Laser  Ther  2005; 
7:17–9.

  13.  Duncan D, Rotunda AM. Injectable therapies for  localized fat 

loss: State of the art. Clin Plast Surg 2011; 38:489–501.

  14.  Salti  G,  Ghersetich  I,  Tantussi  F,  Bovani  B,  Lotti  T. 
Phosphatidylcholine and sodium deoxycholate in the treatment 
of  localized  fat:  A  double-blind,  randomized  study.  Dermatol 
Surg 2008; 34:60–6; discussion 66.

  15.  Gillette,  Bill.  Mesotherapy:  Valuable,  versatile  treatment 
option.  Dermatol  Times  2006  Jan;  Sect.  Cosmetic  Dermatology, 
54–61.

  16.  Walters  KA.  Dermatological  and  Transdermal  Formulations. 

4.  Sarkar R, Garg VK, Mysore V. Position paper on mesotherapy. 

New York: Marcel Dekker, 2002.

Indian J Dermatol Venereol Leprol 2011; 77:232–7.

5.  Vedamurthy M. Mesotherapy. Indian J Dermatol Venereol Leprol 

2007;7 3:60–2.

6.  Greenway FL, Bray GA, Heber D. Topical fat reduction. Obes Res 

1995; 3(Suppl. 4):561S–8S.

7.  Caruso  MK,  Pekarovic  S,  Raum  WJ,  Greenway  F.  Topical  fat 
reduction from the waist. Diabetes Obes Metab 2007; 9:300–3.
8.  Mersmann HJ. Effect of anesthetic or analgesic drugs on lipo-
genic  and  lipolytic  adipose  tissue  activities.  Proc  Soc  Exp  Biol 
Med 1983; 172:375–8.

  17.  Sharma A, Kara M, Smith FR, Krishnan TR. Transdermal drug 
delivery  using  electroporation.  I.  Factors  influencing  in  vitro 
delivery of terazosin hydrochloride in hairless rats. J Pharm Sci 
2000; 89:528–35.

  18.  P.  Santoianni.  Intradermal  delivery  of  active  principles.  G  Ital 

Dermatol Venereol 2005; 140:549–55.

  19.  Forgione  P,  De  Natale  F,  Sammarco  E,  Chianese  N,  Vitiello  P. 
The effectiveness of an innovative biorevitalizing mixture car-
ried  by  the  transermal  electrodelivery.  J  Appl  Cosmetol  2006; 
24:1–6.

 
 
 
 
 
 
 
 
 
 
47

Microneedles and Cosmetics

Raja K. Sivamani and Howard I. Maibach

The field of transdermal drug delivery has significantly advanced 
over the past decade (1). Traditionally, drugs are delivered either 
orally  or  through  the  use  of  a  hypodermic  needles,  but  both 
have significant drawbacks. Oral drug delivery is affected by the 
acidity of the stomach, poor intestinal absorption, and first pass 
hepatic  metabolism,  which  contribute  to  lower  bioavailability. 
Hypodermic needles are painful and lead to patient discomfort 
and anxiety. Transdermal drug delivery is an alternative deliv-
ery method that introduces drugs by bypassing the skin barrier 
to allow for either systemic or local drug delivery. Transdermal 
drug  delivery  approaches  do  not  mechanically  penetrate  as 
deeply as hypodermic needles.

A  major  barrier  in  transdermal  drug  delivery  is  the 
stratum corneum. It is the outermost layer of skin that is com-
posed  of  keratinized  dead  cells.  Transdermal  drug  delivery 
systems aim to bypass the stratum corneum since it is usually 
the rate-limiting barrier in transdermal delivery. The stratum 
corneum is lipophilic in nature and is resistant to the passage 
of hydrophilic substances or the passage of molecules that are 
larger than a few hundred Daltons. In general, multiple differ-
ent  approaches  are  taken  to  bypass  the  stratum  corneum  (1). 
Microneedles enhance transdermal drug delivery by creation 
of physical conduits or channels through the stratum corneum.

MICRONEEDLE FABRICATION
Microneedles are miniature needles that are created using lith-
ographic techniques. Most are designed to penetrate the stra-
tum  corneum  and  enter  into  the  epidermis  without  entering 
the underlying dermis. By dong so, they avoid nerve endings 
in the dermis, rendering insertion painless (2–6). However, in 
the case of cosmetic uses where dermal remodeling is desired, 
deeper microneedles are used such that they enter the dermis 
and are painful with application.

Microneedles  have  been  developed  in  several  different 
designs,  including  out-of-plane  and  in-plane  (7).   Out-of-plane 
needles are designed such that the microneedle is perpendicular 
to the surface (Figure 47.1). In-plane microneedles are parallel to 
the  surface  but  are  more  difficult  to  place  into  arrays.  Because 
cosmetic applications have focused on the out-of-plane micronee-
dle, this chapter reviews their use in cosmetics. In-depth discus-
sions of in-plane microneedles can be found elsewhere (8). One 
exception  is  where  in-plane  microneedles  are  used  to  develop 
out-of-plane microneedle sheets, which are then converted into 
a microneedle roller (9). Microneedle rollers have been used for 
cosmetic  applications  and  this  will  be  discussed  later.  Out-of-
plane microneedles are further subdivided into solid and hollow 
microneedles. Solid microneedles do not have an internal con-
duit for infusion of drugs and are used to either create physical 
holes  in  the  stratum  corneum  or  to  coat  the  microneedle  such 

that  the drug is delivered from  the surface of the microneedle 
upon insertion. Hollow microneedles have a conduit (Figure 47.1) 
that  allows  for  either  bolus  or  continuous  infusion  after  the 
microneedle is inserted (Figure 47.2). Microneedles are made out 
a variety of materials including metal (10), titanium (11,12), glass 
(13–15), polymers (9,14,16–19), and even sugars (3,16,20).

(a)

(b)

silicon  hollow  microneedles. 
Figure 47.1  Out-of-plane 
(a)  Symmetric  hollow  microneedles  are  designed  so  that 
the  opening  is  right  at  the  point  of  insertion.  (b)  Asymmetric 
microneedles  are  designed  with  the  opening  offset  from  the 
point of insertion. 

Microneedle

Skin surface

Stratum coreum
(Lipophilic)

Epidermis
(Hydrophilic)

k1

k3

k2

Figure  47.2  Schematic  of  hollow  out-of-plane  microneedle 
injection. The ability of a substance to move from the skin sur-
face into the stratum corneum is determined by k1. The rate of 
movement  from  the  lipophilic  stratum  corneum  into  the  more 
hydrophilic   epidermis  is  determined  by  the  ratio  k3/k2.  Drug 
solutions injected by microneedle bypass the transitions indi-
cated by k1 and k2. In the case of lipophilic drugs, some of the 
drug may partition back into the stratum corneum due to the 
“effective partition  coefficient” k3/k2. (From Sivamani RK et al., 
J Dermatolog Treat; 20(3):156–9, 2009.) 

MICRONEEDLE STRATEGIES 
FOR DRUG DELIVERY
The  strategy  for  drug  delivery  depends  on  the  design  of  the 
microneedle. Because solid microneedles do not have an inter-
nal  conduit,  they  cannot  be  used  to  infuse  drug  through  the 
needle. Instead, solid microneedles are used in three different 
strategies. The first strategy is to create micropores in the stra-
tum through insertion and removal of the microneedle array, 
and  it  has  been  shown  that  these  pores  remain  open  for  up 
to  24  hours  before  they  close  (6).  Drug  solutions  can  then  be 
applied topically such that they can traverse these transiently 
open channels to bypass the stratum corneum, and some stud-
ies have utilized iontophoresis to accelerate movement through 
these  transiently  open  channels  (21–23).  A  second  strategy  is 
to coat microneedles with a drug prior to insertion. The third 
strategy is to create dissolving microneedles that dissolve upon 
insertion to deliver a drug payload. Both the strategy of coating 
microneedles or encapsulating a drug payload into a dissolv-
ing microneedle is limited to drugs that are stable to undergo 
the coating or encapsulation process (24). Hollow microneedles 
have  an  internal  conduit  and  can  be  used  to  infuse  drugs  as 
a bolus (25,26) or as a continuous infusion (27) after insertion.

Utilizing  these  various  strategies,  microneedles  have 
been employed to deliver vaccines (28–30) or drugs in animals 
including  insulin  (10,14,16,27,31),  erythropoietin  (16),  desmo-
pressin  (11),  and  methotrexate  (32).  Microneedles  have  also 
been testing in humans with in vivo studies that have shown 
the  ability  to  inject  nicotinic  acid  derivatives  through  hollow 
silicon out-of-plane microneedles (25,26) and insulin through a 
hollow glass micropipette tip (33).

COSMETIC USES
Solid Microneedles
The  length  of  the  microneedle  greatly  influences  it   potential 
applications.  Short  microneedles  are  defined  as  those  that  do 
no penetrate past the epidermis and their role is for enhance-
ment of penetration past the stratum corneum. Because short 
microneedles  will  not  penetrate  into  the   dermis,  there  is 
 typically no bleeding and minimal pain. On the other hand, long 
microneedles  are  able  to  penetrate  past  the   stratum   corneum 
into  the  superficial  dermis.  This  subset  of   microneedles  typi-
cally causes pain and bleeding.

Several  studies  have  investigated  the  use  of  solid 
microneedles  (Table  47.1)  for  use  in  cosmetics  and  several 
microneedle-based devices are available commercially, includ-
ing both short and long microneedles. Their applications have 
included  topical  anesthesia,  increased  penetration  of  topical 
hair growth products, photodynamic therapy, and revision of 
scars. An example of a microneedle roller with short micronee-
dles is shown in Figure 47.3.

Previous  studies  have  shown  that  pretreatment  with 
solid microneedles allows for topical anesthesia to be quicker 
in onset (34,35). Both of these studies indicated that anesthesia 
was accelerated within 30 minutes. One showed that in more 
pain-sensitive  subjects,  the  anesthesia  acceleration  was  noted 
by 10 minutes (35).

Several studies have investigated the use of microneedles 
for enhancement of hair growth. One study evaluated the use 
of  a  polymer-based  microneedle  roller  to  enhance  the  topical 
delivery of l-ascorbic acid for hair growth in mice. In this study, 
the  strategy  employed  was  to  create  microchannels  and  then 
topically apply l-ascorbic acid. Microneedle roller pretreatment 

MICRONEEDLES AND COSMETICS 

 437

Figure 47.3  Microneedle roller. Stainless steel microneedles 
are placed in a cylindrical arrangement. This photo depicts roll-
ers that are too shallow to penetrate to the dermis but can cre-
ate holes in the stratum corneum.

enhanced cutaneous permeation by approximately 10-fold and 
showed that this enhanced hair growth in mice (36). A human 
study  in  eleven  women  with  female  pattern  hair  loss  was 
conducted  as  a  split-scalp  study  where  a  growth  factor  mix 
that  consisted  of  basic  fibroblast  growth  factor  (2.5  μg/mL), 
insulin-like  growth  factor-1  (1  μg/mL),  vascular  endothelial 
growth factor (2.5 μg/mL), stem cell factor (2.5 μg/mL), kera-
tinocyte growth factor-2 (2.5 μg/mL), superoxide dismutase-1  
(5  μg/mL)  and  Noggin  (2.5  μg/mL)  was  compared  against  a 
saline  placebo  control  treatment  (37).  The  subjects  received 
weekly treatments for 5 weeks with a motorized microneedle 
that was set to a penetration depth of 0.5 mm. The mean hair 
shaft size (p < 0.05) and the hair counts (p < 0.001) both increased 
by 15% after 5 weeks.

Photodynamic  therapy  (PDT)  frequently  requires  the 
local  application  of  a  photosensitive  drug  in  conjunction 
with  incident  light  to  selectively  destroy  cells,  presumably 
through  locally  generated  singlet  oxygen  (38).  In  an  attempt 
to more efficiently deliver topical photosensitive drugs, silicon 
microneedle patches were used to create transient microchan-
nels in nude mice and deliver either 5-ALA (39) or Meso-tetra 
(N-methyl-4-pyridyl)  porphine  tetra  tosylate,  a  preformed 
photosensitizer (40). Both of these studies delivered the photo-
sensitizing drug by placing a transdermal patch over the area 
that had been transiently perforated with a microneedle patch. 
Both studies found that the photosensitizing drug was deliv-
ered in greater quantities, to a greater depth, and in a shorter 
time in comparison to sites that were not perforated with the 
microneedle patch. The greater depth of penetration is likely 
the result of faster penetration past the stratum corneum, and 
future studies should assess the kinetics of the penetration. As 
such,  one  potential  advantage  of  microneedle  based  therapy 
would  be  to  reduce  incubation  times  for  PDT.  One  clinical 
study  evaluated  the  role  of  short  microneedles  with  PDT  for 
photorejuvenation  and  noted  clinical  improvement  of  photo-
damage (41). However, there was no control group where the 
subjects did not receive microneedle pretreatment and there-
fore  it  is  not  clear  how  much  extra  benefit  the  microneedles 
may have provided.

A  commercially  available  microneedle  device  is  the 
Dermaroller®  (Dermaroller  S.A.R.L.)  (42),  which  is  a  hand-
held  roller  with  rows  of  stainless  steel  solid  out-of-plane 
microneedles. Two claims regarding the Dermaroller are that 
it can be used to enhance transdermal drug delivery and it can 
be used to reorganize underlying collagen in the dermis (42). 
The  first  claim  for  enhancing  transdermal  drug  delivery 
works on the strategy of creating transient microchannels in 
the stratum corneum to allow for topical delivery of various 
drugs, sera, or vitamins necessary for the particular cosmetic 

 
Device

Microneedle 
roller (35)

Microneedle 
array (34)

Microneedle 
array (52)

Microneedle 
roller (40)

Microneedle 
roller (46)

Microneedle 
roller (44)

Microneedle 
roller (47)

Microneedle 
roller (48)

438 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 47.1  Clinical Studies of Microneedles Used for Cosmetic Treatments

Material

Study design

Use

Results/Notes

Stainless steel

Split-body controlled 

study

Not indicated

Controlled study with 
sham microneedles

Glass

Controlled study 
comparing 
microneedle vs 
hypodermic needle

Stainless steel

Uncontrolled clinical 

study

MN pretreatment to 
facilitate topical 
anesthesia 
(lidocaine 4%)

MN treatment has faster onset of 

anesthesia at 30 min

In pain-sensitive subgroup, MN 

accelerated anesthesia by 10 min

MN treatment after 

MN treatment had faster onset of 

topical application of 
dyclonine 1%

anesthesia

MN-based injection of 

MN-based injection was similar to 

2% lidocaine

hypodermic needle–based injection

Motorized 

microneedles (37)

Steel

Split-body controlled 

study

Microneedle 
roller (45)

Titanium

Uncontrolled clinical 

study

MN pretreatment and 
5-ALA–based PDT 
led to even 
application of 5-ALA

Topical application of 
growth factor mix 
(bFGF, IGF-1, VEGF, 
SCF, KGF-2, SOD, 
Noggin)

MN treatment of 
hypertrophic 
burn scars

Note improvement in facial scars and 

hyperpigmentation

No control group

15% improvement in hair shaft size and 

hair counts after 5 weeks on 
MN-treated side

Scars pretreated with topical vitamin A 

and vitamin C for 4 weeks

Hisology showed increased collagen 

and elastin production

Scars improved in clinical appearance
No control group

Improvement in rolling scars
No hyperpigmentation.
No control group

MN superior to 100% TCA CROSS for 
rolling scars; no difference for boxcar 
scars; worse for icepick scars

Transient postinflammatory 

hyperpigmentation noted in six 
patients

Stainless steel

Uncontrolled clinical 

MN treatment for acne 

study

scarring

Stainless steel

Randomized, 

controlled, unblinded 
study

MN vs 100% TCA 
CROSS peel 
treatment of acne 
scarring on the face

Stainless steel

Uncontrolled clinical 

MN treatment for the 

Noted improvement in rolling and boxcar 

study

atrophic scars 
in acne

Stainless steel

Uncontrolled clinical 

MN treatment of acne 

study

scars (n = 4), 
posttraumatic scars 
on lower extremity 
and trunk (n = 6), and 
striae on upper 
leg (n = 1)

scars. Authors note 81% had 
“excellent” improvement

No MN-induced hyperpigmentation
No control group

Scars improved in clinical appearance
Histology showed elastin increasing in 

most, but three subjects had 
decreased elastin

No control group

Microneedle 
roller (49)

Stainless steel

Split-face controlled 

MN treatment of 

MN-treated side had greater 

study

atrophic acne scars

improvement in acne scarring at 
6 months

Abbreviations: MN, microneedle; TEWL, transepidermal water loss; TMP, meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate; ALA,  aminolevulonic 
acid; PDT, photodynamic therapy; TCA CROSS, trichloroacetic CROSS peel

treament.  This  is  supported  by  a  study  that  evaluated  the 
use  of  the  Dermaroller  in  human  skin  ex  vivo  to  show  that 
the  use  of  the  Dermaroller  significantly  enhanced  transder-
mal  drug  penetration  (43).  Increased  penetration  was  noted 
with  an  increase  in  the  microneedle  size.  In  support  of  the 
second claim, one study that compared a microneedle roller 
composed of 1.5-millimeter needles to tichloracetic acid cross 

showed that the microneedles increased collagen  production 
(44).  Interestingly,  the  Dermaroller  is  claimed  to  be  pain-
less.  However,  a  claim  that  the  microneedles  could  cause 
microinjuries  to  the  dermis  to  stimulate  reorganization  of 
the  collagen  would  require  penetration  into  the  dermis  and 
would stimulate the pain fibers in the dermis. Clinically, the 
Dermaroller leads to bleeding at the insertion and treatment 

 
sites. This indicates that the microneedles penetrate into the 
dermis since the epidermis does not contain blood vessels. It 
is likely that the Dermaroller penetrates into the dermis and 
causes pain, necessitating the use of anesthetics prior to use. 
Further clinical studies will better clarify the pain that results 
from use.

is 

Another 

commercially 

available  device 

the 
 MTS-Roller™ (Clinical Resolution Laboratories, Inc.), which is 
another  roller  composed  of  an  array  of  microneedles  similar 
to the Dermaroller. The MTS-Roller is used to create transient 
microchannels in the stratum corneum to deliver two propri-
etary  formulas  for  wrinkles  and  for  hair  loss.  However,  no 
clinical studies are publicly reported regarding the use of the 
MTS-Roller for these indications. The company lists two stud-
ies of MTS-Roller for the stimulation of collagen reformation in 
the dermis and for comparative investigation against intense 
pulsed light (IPL) as a stimulus for collagen synthesis. Similar 
to  the  Dermaroller,  the  MTS-Roller  is  claimed  to  induce  col-
lagen  reformation  through  injury  to  the  dermis.  Autologous 
platelet rich plasma is obtained from the patient and then this 
is delivered to the treatment side to induce more collagen syn-
thesis,  but  there  are  no  published  clinical  studies  to  support 
or refute this claim. The MTS-Roller is claimed to be painless; 
however,  the  MTS-Roller  likely  reaches  the  dermis.  Because 
the  dermis  contains  nerve  endings,  a  formal  clinical  study 
would better elucidate the mechanisms involved in the use of 
the MTS-Roller.

Multiple  studies  have  evaluated  the  use  of  long 
 microneedles in the treatment of scarring (44–49). Microneedle-
based scar revision in acne scars appears to be more effective 
for rolling and boxcar scars rather than icepick scars (44,46,47). 
In  a  comparative  study  in  the  treatment  of  acne  scarring, 
microneedle-based  scar  revision  was  found  to  have  similar 
results to 100% tichloroacetic acid chemical reconstruction of 
skin  scars  (CROSS)  peeling  (44).  Microneedle-treated  areas 
were assessed by histology, with increased collagen and elas-
tin production (45,48) with normalization of the papillary der-
mis in hypertrophic burn scars (45).

One  study  has  evaluated  the  role  of  coated  micronee-
dles that dissolved after insertion to deliver ascorbic acid and 
the retinoid retinyl retinoate (50). The study was designed as 
a split-body design where the wrinkles at the lateral canthus 
(crow’s  feet)  were  treated  with  a  loaded  microneedle  while 
the  other  side  was  left  untreated  as  a  control.  The  authors 
showed that both ascorbic acid- and retinyl retinoate–coated 
microneedle-based  delivery  lead  to  an  improvement  of  the 
wrinkles  of  the  lateral  canthus  in  comparison  to  the  control 
treatment.

Hollow Microneedles
Only a few animal (27,51) and clinical (25,26,33) studies of hol-
low microneedles have been performed. Currently, there are no 
commercial cosmetic devices that utilize hollow microneedles. 
One study showed that injection of anesthesia through hollow 
microneedles  was  comparable  to  a  hypodermic  needle  (52). 
However,  microinjection  through  microneedles  offers  many 
exciting  opportunities  including  the  injection  of  botulinum 
toxin,  photodynamic  therapy,  localized  stimulation  of  hair 
growth  or  hair  loss,  and  localized  melanin  injection.  Future 
research  will  determine  the  hollow  microneedle's  impact  in 
cosmetic therapy. In particular, superficial and painless injec-
tions of botulinum toxin may be possible in light of the devel-
opment of topical botulinum toxin delivery (53).

MICRONEEDLES AND COSMETICS 

 439

SAFETY OF MICRONEEDLES
One  of  the  initial  concerns  with  microneedles  was  the 
biocompatibility  of  silicon  or  glass,  since  there  are  reports  of 
silicon- and glass-related granulomas (54,55). Most micronee-
dles are developed to only penetrate into the epidermis and not 
into  the  dermis.  Therefore,  any  broken  pieces  of  a  micronee-
dles will likely be discarded within 2 weeks, as this is the nor-
mal turnover time for the epidermis. In addition, microneedle 
fabrication  has  moved  toward  polymer-  and  sugar-based 
synthesis  since  silicon  is  expensive  when  considering  mass 
production  for  commercialization.  The  polymers  and  sugars 
are  biocompatible  and  many  are  designed  to  biodegrade.  As 
microneedle technology continues to move toward biocompat-
ibility, microneedle material-related toxicity will likely become 
less of a concern.

The  stratum  corneum  is  also  a  formidable  barrier 
against infection. Microneedles physically breach this barrier, 
raising the possibility for cutaneous infections. Channels cre-
ated by solid microneedles are open transiently for 24 hours 
or  less  (6),  and  microneedles  create  a  lower  bacterial  bur-
den  than  injection  with  traditional  hypodermic  needles 
(56).  Transient  insertions  of  solid  microneedles  likely  pres-
ent  decreased  infectious  risk  as  compared  to  the  traditional 
hypodermic  needle.  However,  the  use  of  hollow  micronee-
dles for extended infusions may theoretically elevate the risk 
for  infection.  There  are  no  studies  of  the  infectious  risk  of 
long-term  infusions  with  hollow  microneedles,  and  the  risk 
of  cutaneous  infections  will  need  to  be  addressed  in  future 
studies.

In one case, a “tram-track” like scar appeared after the 
application  of  microneedle  treatment  (57)  and  this  may  be 
result of aggressive microneedling over convex surfaces where 
there  may  be  bony  prominences  (48).  In  another  case  report, 
a subject had a severe reaction to the cosmetic agent that was 
applied  with  the  microneedle  device.  Therefore,  topical  sub-
stances should be tested prior to use with a microneedle device. 
Additionally, some advise the use of light pressure around the 
eyes  to  lessen  the   possibility  of  a  hematoma  or  bruising  (48). 
Postinflammatory hyperpigmentation is rare (46) and appears 
to be transient and respond to topical hydroquinone when it is 
present (44).

CONCLUSION
The  future  of  microneedle  use  in  cosmetics  is  bright.  With 
microneedles, it is now possible to transdermally deliver large 
peptides and molecules that would not have been possible pre-
viously. Because the short microneedles are typically painless 
upon insertion, this can greatly increase patient comfort and 
acceptance. Currently cosmetics research has focused on long 
solid  microneedles.  This  may  broaden  to  the  use  of  hollow 
microneedles with continued research in this area. Continued 
collaboration  between  bioengineers  and  dermatologists 
will  be  critical  to  the  continued  evolution  and  growth  of  the 
 microneedle's applications within cosmetics.

REFERENCES

1. Prausnitz  MR,  Langer  R.  Transdermal  drug  delivery.  Nat 

Biotech 2008; 26(11):1261–8.

2. Sivamani RK, Stoeber B, Wu GC, Zhai H, Liepmann D, Maibach 
H. Clinical microneedle injection of methyl nicotinate: Stratum 
corneum penetration. Skin Res Technol 2005; 11(2):152–6.

 
440 

 TEXTBOOK OF COSMETIC DERMATOLOGY

3.  Miyano T, Tobinaga Y, Kanno T, Matsuzaki Y, Takeda H, Wakui 
M, et al. Sugar micro needles as transdermic drug delivery sys-
tem. Biomed Microdevices 2005; 7(3):185–8.

4.  Kaushik  S,  Hord  AH,  Denson  DD,  McAllister  DV,  Smitra  S, 
Allen MG, et al. Lack of pain associated with microfabricated 
microneedles. Anesth Analges 2001; 92(2):502–4.

5.  Bal SM, Caussin J, Pavel S, Bouwstra JA. In vivo assessment of 
safety of microneedle arrays in human skin. Eur J Pharmaceut 
Sci 2008; 35(3):193–202.

6.  Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, 
et  al.  Clinical  administration  of  microneedles:  Skin  puncture, 
pain and sensation. Biomed Microdevices 2009; 11(1):35–47.

7.  Sivamani  RK,  Liepmann  D,  Maibach  HI.  Microneedles  and 
transdermal applications. Expert Opin Drug Deliv 2007; 4(1):19–25.
8.  Reed ML, Lye WK. Microsystems for drug and gene delivery. 

Proc IEEE 2004; 92(1):56–75.

9.  Han M, Hyun D-H, Park H-H, Lee SS, Kim C-H, Kim C. A novel 
fabrication process for out-of-plane microneedle sheets of bio-
compatible polymer. J Micromechan Microeng 2007; 17(6):1184–91.
  10.  Davis SP, Martanto W, Allen MG, Prausnitz MR. Hollow metal 
microneedles  for  insulin  delivery  to  diabetic  rats.  IEEE  Trans 
Biomed Eng 2005; 52(5):909–15.

  11.  Cormier  M,  Johnson  B,  Ameri  M,  Nyam  K,  Libiran  L,  Zhang 
DD,  et  al.  Transdermal  delivery  of  desmopressin  using  a 
coated microneedle array patch system. J Control Release 2004; 
97(3):503–11.

  12.  Tsuchiya K, Nakanishi N, Uetsuji Y, Nakamachi E. Development 
of blood extraction system for health monitoring system. Biomed 
Microdevices 2005; 7(4):347–53.

  13.  Lee S, Jeong W, Beebe DJ. Microfluidic valve with cored glass 
microneedle for microinjection. Lab Chip 2003; 3(3):164–7.
  14.  McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen 
MG, et al. Microfabricated needles for transdermal delivery of 
macromolecules  and  nanoparticles:  Fabrication  methods  and 
transport studies. Proc Natl Acad Sci U S A 2003; 100(24):13755–60.
  15.  Wang  PM,  Cornwell  M,  Prausnitz  MR.  Minimally  invasive 
extraction  of  dermal  interstitial  fluid  for  glucose  monitoring 
using microneedles. Diabetes Technol Ther 2005; 7(1):131–41.
  16.  Ito  Y,  Yoshimitsu  J,  Shiroyama  K,  Sugioka  N,  Takada  K.  Self-
dissolving  microneedles  for  the  percutaneous  absorption  of 
EPO in mice. J Drug Target 2006; 14(5):255–61.

  17.  Matsuda T, Mizutani M. Liquid acrylate-endcapped biodegrad-
able  poly(epsilon-caprolactone-co-trimethylene  carbonate).  II. 
Computer-aided stereolithographic microarchitectural surface 
photoconstructs. J Biomed Mat Res 2002; 62(3):395–403.

  18.  Park  JH,  Allen  MG,  Prausnitz  MR.  Biodegradable  polymer 
microneedles:  Fabrication,  mechanics  and  transdermal  drug 
delivery. J Control Release 2005; 104(1):51–66.

  19.  Park  JH,  Allen  MG,  Prausnitz  MR.  Polymer  microneedles  for 
controlled-release drug delivery. Pharm Res 2006; 23(5):1008–19.
  20.  Kolli  CS,  Banga  AK.  Characterization  of  solid  maltose 
microneedles and their use for transdermal delivery. Pharm Res 
2008; 25(1):104–13.

  21.  Chen  H,  Zhu  H,  Zheng  J,  Mou  D,  Wan  J,  Zhang  J,  et  al. 
Iontophoresis-driven  penetration  of  nanovesicles  through 
microneedle-induced skin microchannels for enhancing trans-
dermal delivery of insulin. J Control Release 2009; 139(1):63–72.

  22.  Katikaneni S, Badkar A, Nema S, Banga AK. Molecular charge 
mediated  transport  of  a  13  kD  protein  across  microporated 
skin. Int J Pharm 2009; 378(1–2):93–100.

  23.  Wu  XM,  Todo  H,  Sugibayashi  K.  Enhancement  of  skin  per-
meation  of  high  molecular  compounds  by  a  combination  of 
microneedle  pretreatment  and  iontophoresis.  J  Control  Release 
2007; 118(2):189–95.

  24.  Gill HS, Prausnitz MR. Coating formulations for microneedles. 

Pharm Res 2007; 24(7):1369–80.

  25.  Sivamani RK, Stoeber B, Liepmann D, Maibach HI. Microneedle 
penetration and injection past the stratum corneum in humans. 
J Dermatolog Treat 2009; 20(3):156–9.

  26.  Sivamani  RK,  Stoeber  B,  Wu  GC,  Zhai  HB,  Liepmann  D, 
Maibach H. Clinical microneedle injection of methyl nicotinate: 
Stratum corneum penetration. Skin Res Technol 2005; 11(2):152–6.
  27.  Roxhed N, Samel B, Nordquist L, Griss P, Stemme G. Painless 
drug  delivery 
transdermal 
patches featuring active infusion. IEEE Trans Biomed Eng 2008; 
55(3):1063–71.

through  microneedle-based 

  28.  Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz 
MR. Improved influenza vaccination in the skin using vaccine 
coated microneedles. Vaccine 2009.

  29.  Zhu  Q,  Zarnitsyn  VG,  Ye  L,  Wen  Z,  Gao  Y,  Pan  L,  et  al. 
Immunization  by  vaccine-coated  microneedle  arrays  protects 
against lethal influenza virus challenge. Proc Natl Acad Sci U S 
A 2009; 106(19):7968–73.

  30.  Ding Z, Verbaan FJ, Bivas-Benita M, Bungener L, Huckriede A, 
van den Berg DJ, et al. Microneedle arrays for the transcutane-
ous immunization of diphtheria and influenza in BALB/c mice. 
J Control Release 2009; 136(1):71–8.

  31.  Gardeniers H, Luttge R, Berenschot EJW, de Boer MJ, Yeshurun 
SY,  Hefetz  M,  et  al.  Silicon  micromachined  hollow  micronee-
dles for transdermal liquid transport. J Microelectromechan Sys 
2003; 12(6):855–62.

  32.  Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect 
of  iontophoresis  and  soluble  microneedles  for  transdermal 
delivery of methotrexate. J Pharm Pharmacol 2008; 60(1):27–33.

  33.  Gupta  J,  Felner  EI,  Prausnitz  MR.  Minimally  invasive  insu-
lin  delivery  in  subjects  with  type  1  diabetes  using  hollow 
microneedles. Diabetes Technol Ther 2009; 11(6):329–37.

  34.  Li X, Zhao R, Qin Z, Zhang J, Zhai S, Qiu Y, et al. Microneedle 
pretreatment improves efficacy of cutaneous topical anesthesia. 
Am J Emerg Med. 2010;28(2):130–4.

  35.  Ornelas  J,  Foolad  N,  Shi  V,  Burney  W,  Sivamani  RK.  Effect 
of  Microneedle  Pretreatment  on  Topical  Anesthesia: 
A Randomized Clinical Trial. JAMA Dermatol 2016:1–2.
  36.  You SK, Noh YW, Park HH, Han M, Lee SS, Shin SC, et al. Effect 
of  applying  modes  of  the  polymer  microneedle-roller  on  the 
permeation of l-ascorbic acid in rats. J Drug Target 2009.
  37.  Lee  YB,  Eun  YS,  Lee  JH,  Cheon  MS,  Park  YG,  Cho  BK,  et  al. 
Effects  of  topical  application  of  growth  factors  followed  by 
microneedle therapy in women with female pattern hair loss: 
A pilot study. J Dermatol. 2013; 40(1):81–3.

  38.  Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with 
endogenous  protoporphyrin  IX:  Basic  principles  and  present 
clinical experience. J Photochem Photobiol B 1990; 6(1–2):143–8.

  39.  Donnelly  RF,  Morrow  DI,  McCarron  PA,  Woolfson  AD, 
Morrissey  A,  Juzenas  P,  et  al.  Microneedle-mediated  intra-
dermal  delivery  of  5-aminolevulinic  acid:  Potential  for 
enhanced topical photodynamic therapy. J Control Release 2008; 
129(3):154–62.

  40.  Donnelly  RF,  Morrow  DI,  McCarron  PA,  David  Woolfson 
A,  Morrissey  A,  Juzenas  P,  et  al.  Microneedle  arrays  permit 
enhanced intradermal delivery of a preformed photosensitizer. 
Photochem Photobiol 2009; 85(1):195–204.

  41.  Clementoni MT, M BR, Munavalli GS. Photodynamic photore-
juvenation  of  the  face  with  a  combination  of  microneedling, 
red  light,  and  broadband  pulsed  light.  Lasers  Surg  Med.  2010; 
42(2):150–9.

  42.  [cited 2009 October 14]. Available at: http://www.dermaroller.

de/us/welcome-to-dermaroller.html.

  43.  Badran MM, Kuntsche J, Fahr A. Skin penetration enhancement 
by a microneedle device (DermarollerÆ) in vitro: Dependency 
on  needle  size  and  applied  formulation.  Eur  J  Pharmaceut  Sci 
2009; 36(4–5):511–23.

  44.  Leheta T, El Tawdy A, Abdel Hay R, Farid S. Percutaneous colla-
gen induction versus full-concentration trichloroacetic acid in the 
treatment of atrophic acne scars. Dermatol Surg 2011; 37(2):207–16.
  45.  Aust MC, Knobloch K, Reimers K, Redeker J, Ipaktchi R, Altintas 
MA, et al. Percutaneous collagen induction therapy: An alterna-
tive treatment for burn scars. Burns 2010; 36(6):836–43.

 
 
 
 
 
 
 
 
MICRONEEDLES AND COSMETICS 

 441

  46.  Fabbrocini  G,  Fardella  N,  Monfrecola  A,  Proietti  I,  Innocenzi 
D.  Acne  scarring  treatment  using  skin  needling.  Clin  Exper 
Dermatol 2009;34(8):874–9.

  52.  Gupta  J,  Denson  DD,  Felner  EI,  Prausnitz  MR.  Rapid  local 
 anesthesia in humans using minimally invasive microneedles. 
Clin J Pain 2012; 28(2):129–35.

  47.  Majid  I.  Microneedling  therapy  in  atrophic  facial  scars:  An 
objective assessment. J Cutan Aesth Surg 2009; 2(1):26–30.
  48.  Schwarz  M,  Laaff  H.  A  prospective  controlled  assessment  of 
microneedling with the Dermaroller device. Plastic Reconstruct 
Surg 2011;127(6):146e–8e.

  49.  Alam M, Han S, Pongprutthipan M, et al. Efficacy of a needling 
device  for  the  treatment  of  acne  scars:  A  randomized  clinical 
trial. JAMA Dermatology 2014; 150(8):844–9.

  50.  Kim  M,  Yang  H,  Kim  H,  Jung  H,  Jung  H.  Novel  cosmetic 
patches for wrinkle improvement: Retinyl retinoate- and ascor-
bic acid-loaded dissolving microneedles. Int J Cosmet Sci 2014; 
36(3):207–12.

  53.  Glogau RG. Topically applied botulinum toxin type A for the 
treatment of primary axillary hyperhidrosis: Results of a ran-
domized, blinded, vehicle-controlled study. Dermatol Surg 2007; 
33(1 Spec No.):S76–80.

  54.  Millard DR, Jr., Maisels DO. Silicon granuloma of the skin and 

subcutaneous tissues. Am J Surg 1966; 112(1):119–23.

  55.  Finley  J,  Knabb  J.  Cutaneous  silica  granuloma.  Plast  Reconstr 

Surg 1982; 69(2):340–3.

  56.  Donnelly  R,  Singh  T,  Tunney  M,  Morrow  D,  McCarron 
P,  O’Mahony  C,  et  al.  Microneedle  arrays  allow  lower 
microbial  penetration  than  hypodermic  needles  in  vitro. 
Pharmaceut Res.

  51.  Hafeli UO, Mokhtari A, Liepmann D, Stoeber B. In vivo evalua-
tion of a microneedle-based miniature syringe for intradermal 
drug delivery. Biomed Microdevices 2009.

  57.  Pahwa M, Pahwa P, Zaheer A. “Tram track effect” after treat-
ment of acne scars using a microneedling device. Dermatol Surg 
2012; 38(7 Pt 1):1107–8.

 
48

Photodynamic Therapy in Dermatology

Jacques Savary

Photodynamic  therapy  (PDT)  is  a  therapeutic  that  has  been 
used since the beginning of the 20th century to destroy tumor-
ous skin lesions.

• 

•  1903: von Tappeiner describes the first PDT with eosin and 

sun exposure to treat a carcinoma of inferior lip.

•  1913:  Friedrich  Metz-Beyer  administers  porphyrin  to 

 himself and becomes photosensitive.

•  1950: The absorption of porphyrin by cancerous cells that 

become photosensitive is highlighted.

•  1980: The interest for PDT increases but patient's photosen-

sitivity is an obstacle.
•  1993:  Publication  of 

the  first  clinical  essay  on 

 a-aminolevulinic acid (ALA) in PDT.

•  1995: Registration of the first ALA-modified patent.

This  therapeutic  was  developed  in  Northern  Europe  essen-
tially  for  the  treatment  of  nonmelanocytic  skin  cancers. 
PDT  then  expanded  to  other  European  countries  and  North 
America  for  other  indications  than  those  dealing  with  skin 
carcinologic.

PRINCIPLE
The  basic  principle  in  cancer  research  lies  in  the  selective 
destruction  of  abnormal  cells  of  target  tissue  by  a  chemical 
reaction  activated  by  specific  light,  while  preserving  nor-
mal  skin  structures.  This  reaction  results  from  the  fixation 
of  a   photosensitizing  agent  on  tumorous  cells  followed  by 
its  activation  by  a  floodlight  of  a  light  visible  at  appropriate 
wavelength. This activation is followed by a phototoxic effect 
created by an irreversible oxidation mechanism that destroys 
tumorous cells.

The mechanism of this photochemical reaction is based 
on  light  effects  on  the  photosensitizing  molecule  (1).  To  each 
kind  of  molecule  matches  a  type  of  wavelength  likely  to  be 
absorbed.  In  the  basal  state,  this  photosensitizing  molecule 
presents an energy ground state (S8); under the effects of pho-
tons  produced  by  the  light,  this  molecule  reaches  a  superior 
and unstable level of excitation. At this unstable level, the mol-
ecule holds an excess of energy that it quickly looses in three 
ways:  heat  liberation,  fluorescence  emission,  and  transition 
to a triplet intermediate stage. Turning back from this triplet 
stage to the basal stage is slow. It is during the triplet stage that 
the  photosensitizing  molecule  interacts  with  cells’  organelles 
by  two  mechanisms  requiring  the  presence  of  oxygen  in  the 
 targeted tissues:

•  Direct mechanism: Production of toxic-free radical. In that 

case, the photosensitizing is damaged.

Indirect  mechanism:  Transfer  of  energy  to  the  oxygen. 
This fosters its transition to a singlet state able to oxidize 
amino  acids,  nucleic  acids,  and  membranes’  cell  lipids. 
This  mechanism  prevails;  in  that  case,  the  photosensitiz-
ing returns to it basal state likely to be excited by the light 
anew.

Effects on Tissues
Cellular  damage  caused  by  this  oxidative  stress  essentially 
affects  cellular  membranes  and  organelles  of  cell  (mitochon-
dria,  endoplasmic  reticulum,  plasma  membrane).  These 
deteriorations  lead  to  cellular  necrosis  (2).  Histological  signs 
of  necrosis  (eosinophilic  cytoplasm,  hyperchromatic  nuclei) 
appear within an hour after the lighting.

This  cellular  necrosis  is  associated  with  apoptosis 
(3) phenomenon (cellular suicide). Apoptosis signs occur more 
lately; they can be seen 24 hours after the PDT.

Three “actors” are necessary for PDT:

•  A photosensitizing molecule
•  A light source
•  Oxygen

Photosensitizing
Several photosensitizing agents have been used at the begin-
ning of the PDT, part of them were systemic sensitizing. These 
had  no  specificity  and  would  lead  to  residual  phototoxic-
ity  phenomena  of  the  whole  tegument  imposing  on  patients 
extended ousting from visible light. Thus, to be easily used in 
 dermatology, photosensitizing requires specificities:

•  To focus on tumorous cell
•  Can be activated by a light penetrating into the skin
•  To  produce  a  significant  amount  of  cytotoxic  substances 

(free radicals and singlet oxygen)

•  Can quickly be eliminated from the skin

The use of topical photosensitizing agents has been favored in 
 dermatology. Most of them are five ALA drifts. In reality, ALA 
is not the photosensitizing. It is the precursor of an endogenous 
 photosensitizing that physiologically exists in the skin and nota-
bly in keratinocytes: protoporphyrin 9 (Pp9). This porphyrin is 
an  intermediate stage in the heme synthesis chain (Figure 48.1).

Physiologically, some mechanisms can autoregulate this 
heme  synthesis  by  enzymatic  systems,  especially  ferrochela-
tase, which transforms Pp9 in heme. During an ALA or methyl 
aminolevulinate  (MAL)  excess  supply  these  autoregulation 
mechanisms  are  overwhelmed  and  a  cellular  accumulation 
occurs.

ALA

Porphobilinogen

MAL

Intermediates

Porphobilinogen
deaminase

Ferrochetalase

Heme

PAP

Figure 48.1  Mechanism of action of ALA/MALA.

The accumulation increases in epidermic dysplasia (4,5). 
The real mechanism of this specific accumulation is not clearly 
solved. Several mechanisms are suspected:

• 

Intense  penetration  of  the  ALA  in  the  epidermic  dys-
plasic  cells  due  to  membranous  modified  transportation 
phenomena
Increase of porphobilinogen desaminase activity

• 
•  Decrease of ferrochelatase activity

Nowadays, two kinds of Pp9 precursors are used in skin PDT: 
amino levulinic acid ALA (Levulan1, Kerastick1) and its pre-
cursor methyl aminolevulinic acid (Metvix1, Metvixia1).

These  two  drifts  have  different  properties;  the  MAL  is 
more lipophilic than the ALA, which gives it better penetration 
in the skin. This indication will have an impact on the occlusion 
time necessary for the product to penetrate: 12 to 18 hours recom-
mended for the ALA (Levulan) and 3 hours for the MAL (Metvix, 
Metvixia).  Moreover,  the  specificity  to  the  P9   accumulation  in 
keratinocytes  in  differentiation  is  more  important  for  the  MAL 
than for the ALA, whereas for healthy skin, the Pp9 production 
is much more important after the ALA  application than after the 
MAL one (6). The systemic diffusion of MAL is less important than 
the one of ALA for the mouse (7). Photoactive porphyrin synthe-
sis detected by  fluorescence for the mouse decreases faster after 
the MAL application than after the ALA one (8). After 24 hours, 
the fluorescence induced by the MAL has nearly disappeared.

As for the human healthy skin, the fluorescence decreases 
to 93.4% +/- 6.1% 30 hours after the cream removal to 20% MAL 
(9). The depth of MAL penetration measured by the fluorescence 
intensity is estimated to 2 mm after 3 hours of occlusion (10).

Light Source
It requires two characteristics: activate the Pp9 and penetrate 
sufficiently  into  the  skin  to  allow  the  destruction  of  the  tar-
geted lesions.

The  Pp9  activation  spectrum  consists  of  several  stripes 
of color (Figure 48.2). The maximal absorption stripe for which 
the Pp9 becomes more energetic lies in the blue at 410 nm, it is 
the Soret band. Other absorption peaks are of 510, 530, 580, and 
630 nm, but they are less energizing (5).

The  light  penetration  in  the  skin  depends  on  the 
 wavelength  of  the  light.  The  longer  the  wavelength  is,  the 
deeper the penetration in the skin is. Thus, the blue penetrates 
the stratum corneum, whereas the red penetrates until 2 mm 
in the skin reaching the dermis hypodermis limits.

Red  is  preferred  for  the  treatment  of  cancerous  and 
 precancerous lesions because of its better penetration into the 
skin. The merest absorption by Pp9 being countered by the use 
of a more important light energy.

Several sources can be used.

PHOTODYNAMIC THERAPY IN DERMATOLOGY 

 443

IV

III

II

I

400

λ (nm)

600

Figure 48.2  Pp 9 activation spectrum.

•  Sources of high energy

•  Lasers  are  attractive  as  they  are  monochromatic  and 
very  energetic.  Although  the  lightening  scope  size  is 
narrow, the exposure time is very short. As the pulse 
dye  laser  emits  at  695  nm,  it  can  be  used  to  activate 
the Pp9.
Intense  pulsed 
lights  (IPLs)  are  very  energetic 
 polychromatic  light  sources.  The  light  emission  spec-
trum  depends  on  the  filters  used,  which  allows  to 
choose the inferior limit of the spectrum 550, 560, 580, 
and 590 nm.

• 

•  For lasers, the exposure time to light is very short (on the 
order of millisecond kind), but the lightening scope size is 
broader.

•  Sources of low energy

•  Slide  projectors  that  emit  between  570  and  1100  nm 

have been used by PDT pioneers.

•  Xenon  halogens  (630  nm)  and  fluorescent  lights  emit 
narrow spectrum and have a good energetic capacity.
•  Light-emitting  diodes  (LEDs)  are  the  most  frequently 
used.  Their  specificity  is  to  emit  on  a  very  precise 
wavelength (variation between 5 to 10 nm). Those small 
diameter light bulbs are braced to one another to create 
lamps of which the surface is significant and the form 
adaptable  to  the  targeted  skin  area.  Their  life  span  is 
long (10,000 hours) without any energy loss. They are 
even more attractive in that they do not emit infrared 
and so have no thermal impact.

Should  a  high-  or  low-energy  source  be  chosen?  A  short 
 lightening with a very strong energy will sharply activate the 
porphyrins, which will lead to an intense release of free radi-
cals and of singlet oxygen responsible for the selective destruc-
tion  of  the  targeted  tissues.  Nevertheless,  Pp9  synthesis  by 
keratinocytes recurs itself. Some authors advocate for the use 
of  low-energy  light  sources  that  allow  a  long  lightening  and 
a continuous activation of porphyrin, which ensure the emis-
sion of less brutal and better distributed cytotoxic substances 
during the lightening (9). Some teams use low-energy sources 
made of LED (11).

One  study  (12)  compared  MAL  PT  with  LED  (530  nm, 
37  J/cm2)  versus  MAL  PDT  with  IPL  (610–950  nm  80  J/cm2) 
for  the  treatment  of  actinic  keratosis,  the  patient  being  his 

 
444 

 TEXTBOOK OF COSMETIC DERMATOLOGY

own witness. Neither the complete remission rate at 3 months 
nor  the  cosmetic  outcomes  show  a  significant  difference. 
On  the  other  hand,  the  pain  is  less  important  with  IPL  as 
the   lightening  time  is  very  short.  There  is  no  comparative 
study  dealing  with  basal  cell  carcinoma  (BCC)  and  Bowen 
disease.

What Kind of Energy Can Activate Pp9 and 
Lead to Cell Destruction?
The amount of necessary energy depends on the Pp9 ALA or 
MAL  precursor,  its  concentration,  and  the  lightening  spec-
trum. The necessary energy had been evaluated for different 
topical  (ALA,  MAL)  depending  on  the  intensity  of  the  fluo-
rescence  visible  in  a  Wood  lamp.  Thus,  the  maximal  fluence 
had been determined to obtain the maximal fluorescence. The 
latter  will  depend  on  the  emission  spectrum:  the  larger  the 
spectrum (so outside Pp9 absorption peaks), the more impor-
tant the fluence will have to be. For instance, for the MAL, the 
necessary energy is:

•  37 J/cm2 for a narrow spectrum of 630 nm
•  75 J/cm2 for a spectrum from 570 to 670 nm
•  85 J/cm2 for a spectrum of 600 to 750 nmFor LED,  halogens, 
and  fluorescent  lamps,  several  indications  will  have  an 
influence  on  this  fluence  (J/cm2):  the  power  of  the  lamp 
(mW/cm2),  the  distance  between  the  lamp  and  the  skin, 
and the lightening time.

Using Daylight to Activate Pp9:Daylight PDT (DL-PDT)
Common adverse events are stinging and burning associated 
with  pain.  Pain  is  a  real  problem  for  the  treatment  of  actinic 
keratoses (AK) on the face and scalp. The pain intensity is pro-
portional to the area of the lesions, especially on face and scalp. 
The sudden activation of Pp9 accumulated during the 3 hours 
is  responsible  for  the  pain.  Conventional  PDT  requires  dedi-
cated equipment and long time incubation (3 hours) between 
the  photosensitizer  application  and  the  illumination.  These 
elements  can  limit  the  availability  for  patients  and  increase 
costs.

Daylight  PDT  uses  the  visible  light  from  the  sun  as  a 
light source for photo activation of Pp9. The spectrum of day-
light extends from 380 nm to 780 nm.

The Protoporphyrin IX absorption peaks are: in the blue 
light at 410 nm (Soret band), with others absorption peaks at 
505 nm (green), 540 nm (yelow), 580 nm (orange) and 635 nm 
(red).  All  PplX  absorption  peaks  are  within  the  visual  spec-
trum of daylight.

The principle of this method is a continuous production 
and  progressive  activation  of  Pp9  avoids  a  sudden  release  of 
active oxygen in the skin. This photoactivation with low light 
intensity requires prolonged sun exposure. The patient has to 
be exposed less than 30 mn after the photosensitizer applica-
tion and stay 2 hours exposed to the daylight. Studies on day-
light  PDT  focus  only  on  the  treatment  of  actinic  keratosis  of 
face and scalp (13–16).

The protocol for daylight PDT with MAL in patients with 
actinic keratoses (AK) of the face or scalp (Table 48.1) is differ-
ent than conventional PDT (cPDT).

Oxygen
Oxygen  is  circulated  by  the  blood.  Therefore,  the  elements 
fostering lack of oxygen in the soft tissue will decrease the effi-
ciency of the technique - cold, vasoconstrictors, sclerosis.

PDT INDICATIONS IN DERMATOLOGY
Validated Indications
They  are  at  the  center  of  studies  allowing  the  registration  of 
products.  Today,  only  the  MAL  is  registered  in  Europe  since 
2002 with the following indications:

•  Actinic keratosis
•  Nodular and superficial BCC when surgery is impossible
•  Bowen disease

Actinic Keratosis
Those  precancerous  lesions  are  common  on  photo-exposed 
field of scalp, face, hands, and forearms (Figure 48.3). As they 
are often many on these areas, they create real fields of possible 
cancer development (Figure 48.4). The annual rate of transfor-
mation  of  AK  in  squamous  cell  carcinoma  can  change  from 
one  extreme  to  another.  According  to  authors,  it  ranks  from 
0.25% to 16% (17). All the studies had been done with the MAL, 
which is the only available product on the market.

Table 48.1  Protocol for daylight PDT

Pathology

Grades I and II actinic keratosis on the face and/or scalp.
Fields of actinic damage including AK and subclinical lesions.

Period of the year when the treatment is possible

This period is a different function of the latitude. In northern Europe between 

Weather condition

Treatment modality

After the treatment

March and October, in southern Europe and Australia all year long.

All weather conditions except rain, very cloudy weather, and if the temperature is 

suitable for the patient to stay comfortably outdoors for 2 h.

•  Preparation of skin: thickness lesion reduction by keratolytic preparation (urea 

or salicylic acid) application the week before treatment.

•  Apply chemical (no mineral containing titanium dioxide, zinc oxide, which 

blocks visible light) sunscreen to the treatment area and to all sun-exposed 
areas of the skin.

•  Smooth curettage to remove scales and scabs.
•  Apply a thin layer of MAL to treatment areas, without occlusion.
•  Begin daylight exposure within a maximum of 30 mn afterMAL application.
•  The patient stays 2 continuous hours outside.
•  After 2 hours the patient removes the residual cream, washes the skin, and 

protects the treated area with hat, cap, etc. for the rest of the day.

•  Use moisturizer cream for 1 week after the treatment.
•  Evaluation of the treated lesions after 3 months.

 
PHOTODYNAMIC THERAPY IN DERMATOLOGY 

 445

•  The MAL PDT cosmetic outcomes are considered superior 

• 

as the cryotherapy ones.
In  majority,  the  MAL  PDT  treatment  is  considered  very 
satisfactory by patients who had already been treated, and 
is preferred to former treatments.

•  MAL  PDT  using  red  light  is  an  appropriate  alternative 
treatment  for  multiple  actinic  keratosis  on  a  large  skin 
surface (Figure 48.4).

In its conclusion (17), the International Society for Photodynamic 
Therapy (IPDT) considers that PDT can be considered as a first 
intention treatment in the treatment of AK.

Treatment of AK by daylight DL-PDT is in development; 
DL-PDT  with  MAL  cream  has  labeling  for  this  indication  in 
some countries.

The first phase II studies were performed in Scandinavia 
and showed that DL-PDT with MAL is as effective as conven-
tional PDT(C-PDT) in treating grade I and II AK on the face and 
scalp associated with a lower frequency of skin reactions and 
almost painless. Two phase II studies performed in Australia 
and Europa demonstrated a non-inferiority of DL-PDT versus 
C-PDT.  The  multicenter  trial  in  Australia  DL-PDT  reported 
complete lesion response rate of 89% of mild AK on the face/
scalp, and 93% for C-PDT. The similar protocol study in Europe 
demonstrated  efficacy  on  mild  and  moderate  AK  (70%  of 
lesions  cleared  after  one  session  of  DLPDT,  versus  a  compa-
rable rate 74% for C-PDT). In these two studies DL-PDT is sig-
nificantly almost painless.

Superficial BCC
BCCs are the most frequent tumors occurring in human. The 
superficial  forms  are  the  less  aggressive  and  are  considered 
low-risk  lesions  outside  the  face  H  zone.  Most  of  the  time, 
these lesions are of large area or multiple with a risk of having 
significant of numerous scars after the surgical cure. PDT is a 
noninvasive treatment and the quality of its healing result has 
to  be  taken  into  account  in  the  therapeutic  decision-making 
process.

A  European  multicenter  study  carried  out  in  seven 
countries compared the MAL PDT one session to cryotherapy 
(freezing of at least 20 seconds) in two groups of patients car-
rying  BCC  (21,22).  The  rate  of  complete  answers  at  3  months 
and  at  30  months  and  5  years  per  patient  and  per  lesion  did 
not show significant differences between the two groups. The 
healing quality assessed by investigators and patients is supe-
rior  in  the  MAL  PDT  group.  More  patients  had  an  excellent 
cosmetic  outcome  with  PDT  than  with  cryotherapy.  Those 
recurrence rates are higher compared to surgery. That is why 
it  is  better  avoiding  risky  face  areas,  but  PDT  offers  a  better 
cosmetic outcome than simple excision surgery (23).

PDT is a therapeutic alternative for the treatment of BCCs 
as surgery would be hard to perform because of the localiza-
tion,  the  size,  the  number  of  lesions  (Figure  48.5),  the  patho-
logic state of the patient, or because the healing risk would be 
disproportionate  for  a  low-risk  lesion.  The  other  advantage 
compared to other nonsurgical techniques such as cryotherapy 
and electro curettage is that it does not leave any scar, which 
is satisfying to the patient (Figure 48.6). Moreover, in the case 
of recurrence, PDT can be repeated and surgery remains pos-
sible, as there is no skin modification.

In superficial CBC treatment:

Figure 48.3  Actinic keratosis.

Figure 48.4  Fields of possible cancer development.

The  studies  done  versus  placebo  (18)  showed  a  slightly 
superior  efficiency  on  complete  cure  rate  (the  lesion  having 
completely disappeared).

Comparative  studies  were  made  versus  cryotherapy 
(19,20), which is the reference treatment. Cryotherapy was per-
formed using nitrogen spray and a double-freeze-thaw cycle; 
the  MAL  PDT  was  done  regarding  two  protocols,  either  one 
session or two sessions with a week of interval. There was no 
significant difference in the complete response rate at 3 months 
and 5 years between cryotherapy and MAL PDT one session.

The difference between these two techniques lies in the 
healing result. In studies (19,20), cosmetic outcomes are seen as 
excellent and good according to more than 90% of the investi-
gators.  In  comparison  to  cryotherapy,  cosmetic  outcomes  are 
seen as superior for the MAL PDT.

•  MAL  PDT  efficiency  is  significantly  superior  to  the 
 placebo:  the  complete  answer  rate  per  patient  and  per 
lesion increases under MAL PDT.

•  MAL  PDT  is  as  efficient  as  cryotherapy,  reference  treat-

ment of KA.

•  A single session of MAL PDT is efficient on AK lesions and 

•  The clinical efficiency of the MAL PDT is equivalent to the 

can be renewed if necessary.

one of cryotherapy.

 
446 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure  48.5  Multiple  superficial  basal  cell  carcinoma  on  a 
patient treated by X-ray therapy for Hodgkin disease.

Figure 48.7  Bowen disease before treatment.

Figure 48.6  Cryotherapy scars for basal cell carcinoma.

•  This  efficiency  is  maintained  in  an  equal  way  after  five 

years of follow-up for both treatments.

•  The  PDT  cosmetic  outcome  is  better  than  the  one  of 

cryotherapy.

In its conclusions, the IPDT (17) considers the PDT as an effec-
tive and reliable treatment option for BCCs that offers excellent 
or  good  cosmetic  outcomes.  PDT  offers  an  advantage  in  the 
treatment of large, extensive, and multiple lesions.

Photodynamic  diagnosis  (PDD)  fluorescence  diagnosis 
serves  as  a  valuable  noninvasive  diagnostic  and  treatment 
tool.  Following  topical  application  of  the  photosensitizer,  a 
large amount of Pp9 selectively accumulates in the neoplastic 
cells.  When  the  skin  is  illuminated  with  a  UVA  light  source 
(370–405 nm), the tumoral area shows a distinctive pink to red 
fluorescence on a background of blue light. This PDD is useful 
to detect tumors but is not sufficient to evaluate their margins. 
Margin evaluation with PDD is better than clinical evaluation 
but  does  not  correspond  with  the  real  margins  found  with 
Mohs surgery (24).

Figure 48.8  Bowen disease after two sessions.

Nodular Basal Cell Carcinoma
The  difficulty  in  the  treatment  of  these  lesions  lies  in  the 
 penetration  of  both  the  light  and  the  photosensitizer  in  the 
superior lesions at 2 mm of thickness. For this kind of tumor, 
debulking  is  performed  preliminary  to  the  photosensitiz-
ing application. Several studies (25) show 3 months complete 
answers  rate  between  73%  and  94%  with  the  MAL  PDT.  At 
5 years, recurrence rates reach 14%.

A  comparative  study  between  MAL  PDT  and  surgery 
showed that the 3 months complete answers rate was not infe-
rior for the PDT (91% versus 98% for surgery). At 60 months, 
the recurrence rate was 14% versus 4% for surgery (26).

According to patients, the cosmetic outcome is superior 

to surgery.

In its conclusions, the IPDT believes PDT is an effective 
and reliable treatment for thin lesions, with the advantage of 
good cosmetic outcome.

Bowen Disease
This  squamous  cell  carcinoma  in  situ  is  frequent  in  elderly 
patients.  It  appears  anywhere  on  the  skin  but  mainly  on  the 
lower legs. Approximately 3% transforms into invasive carci-
noma. There are often healing problems on leg localization for 
elderly patients regarding circulatory insufficiency. The treat-
ment  of  reference  is  surgery  when  possible  or  5-FU  topically 
(Figures 48.7 and 48.8).

 
A European multicenter comparative random study (27) 
assessed  the  MAL  PADT  in  Bowen  disease  treatment.  The 
assessed  therapeutics  were  MAL  PDT  or  PDT  placebo,  5-FU, 
and cryotherapy.

In Bowen disease treatment:

•  MAL PDT efficiency is significantly superior to placebo.
•  The answer rate per patient or per lesion is similar when 
the patient is treated by MAL PDT, cryotherapy, or 5-FU.
•  Those  results  are  maintained  24  months  after  the  treat-
ment;  the  lesion  recurrence  rate  under  MAL  PDT  is  the 
same as under cryotherapy or 5-FU.

•  The great majority of investigators believe that the  cosmetic 
outcomes are excellent or good after the treatment by MAL 
PDT.  These  results  are  superior  to  those  obtained  after 
cryotherapy.

In  its  conclusions,  the  IPDT  considers  PDT  to  be  an   effective 
treatment  for  Bowen  disease.  This  therapeutic  can  be 
 considered  as  a  first-line  treatment  for  Bowen  disease.  After 
repeated treatments, nonresponders should be considered for 
surgery.

Out-of-Label Indications
PDT had been used in multiple indications in studies started 
with varying protocols. These several studies had been taken 
up  again  in  a  consensual  conference  by  North  American 
authors (28).

Acne
The mechanism of action is not clearly elucidated. There is a 
clear  diminution  of  Propionibacterium  acnes,  but  the  target  of 
free  radicals  and  singlet  oxygen  is  essentially  the  sebaceous 
gland (29).

Atrophy or even destruction is demonstrated in biopsy 
after  one  PDT  treatment.  Comparison  can  be  made  with 
isotretinoin that induces a cellular apoptosis of sebocytes and 
reduces the sebum excretion rate. This glandular atrophy is not 
permanent and seems to be restored with time, but there is a 
lack of long-term histological data on sebaceous gland atrophy 
after PDT.

PDT  is  especially  useful  for  inflammatory  acne  but 
side effects are sometimes serious. Observations report vary-
ing  degrees  of  pain,  erythema,  edema,  blistering,  and  acute 
flareup. This last side effect can be compared to isotretinoin. 
Optimization of efficacy-tolerance ratio is necessary.

Concentration  of  photosensitizer,  time  of  application, 
occlusion or not, and fluence parameters are certainly different 
from  those  used  to  treat  nonmelanoma  skin  cancer.  Mavilia 
et al. report a significant improvement of inflammatory acne. 
It appears that the nature of photosensitizer has an impact on 
efficacy.

The  acne  indication  had  benefit  from  many  studies, 
 especially  with  the  ALA  PDT  and  several  light  sources.  The 
consensual conference conclusions are as follows:

1.  The best indications are inflammatory and cystic acne.
2.   The improvement is limited in comedonal acne, except in a 

study with pulseddye laser (PDL).

3.   Acneiform flares appear after each treatment. They seem to 
depend on the photosensitizing concentration, the applica-
tion  time,  and  the  light  source.  Nevertheless,  these  thera-
peutic protocols are not clearly defined yet.

PHOTODYNAMIC THERAPY IN DERMATOLOGY 

 447

Photoaging
This  indication  has  also  been  submitted  to  several  works  in 
Canada and in the United States. Pp9 is prone to store in kera-
tinocytes  in  multiplication.  Therefore,  PDT  is  particularly 
recommended in severe photodamage: severe elastosis associ-
ated with AK, early skin cancer, pigmentary changes, vascular 
changes (erythema, telangiectasia), and rhytides (30).

Photorejuvenation action of PDT was found after AK treat-
ment and the skin on the treatment area appears younger, with-
out rhytides, smooth with a best trophicity. This improvement 
of the appearance of skin corresponds to significant molecular 
changes in the photodamaged skin. Type I and type III procol-
lagen mRNA significantly increased after treatment with ALA, 
PDT, and PDL versus PDL alone. Historically, increased prolifer-
ation and changes in epidermis thickness were observed. High-
resolution echography shows an increase in skin thickness and a 
reduction of subepidermal low echogenic band thickness.

Clinically,  there  is  an  improvement  of  signs  of  photo-
damage:  mottled  pigmentation,  fine  lines,  roughness,  and 
sallowness of the skin. There is no change in deep wrinkles, 
telangiectasia, and sebaceous gland hypertrophy.

The majority of North American studies deal with PDT 
with ALA and IPL with various protocols regarding photosen-
sitizing  concentration,  time  of  application,  and  light  energy. 
There is no doubt that the decrease of the concentration and of 
the application time diminishes side effects but it also implies a 
very weak synthesis of Pp9, which can damage the technique's 
efficiency. The use of IPL PDT versus IPL only would reduce 
the number of IPL sessions to obtain the same result on photo-
aging signs. European studies with MAL PDT also confirm the 
efficiency on photoaging (31).

PDT and Onychomycosis
Some case reports suggest that PDT may represent an alterna-
tive treatment in therapeutic strategy for onychomycosis. The 
nail  plate  and  the  hyperkeratosis  nail  bed  are  first  removed, 
and  the  treatment  is  repeated  between  three  and  six  times 
according to the studies. The MAL PDT protocol is the same as 
that in oncologic indications: MAL 20% 3 hours with occlusion, 
uncoherent red light (630 nm), 37 J/cm2. Patients do not report 
pain during or after irradiation or after.

Other out-of-label indications include:

•  Warts
•  Dyskeratosis: Hailey-Hailey; Darier
•  Healing
•  Extramammary Paget
•  Psoriasis
•  Hair removal
•  Cutaneous leishmaniasis
•  Cutaneous T cell lymphoma
•  Molluscum contagiosum

PDT IN PRACTICE
PDT  a  simple  technique;  non-operator-dependent,  that  can 
easily be performed at a medical office. The PDT session takes 
place in three stages:

•  Lesion  preparation:  soft  cleaning  with  the  curette  to 
remove loose scales and crusts, application of the MAL as 
a cream covering the lesion with a 1-cm margin at the edge. 
Cover with an occlusive dressing and then with a totally 
opaque dressing, especially on exposed areas.

 
448 

 TEXTBOOK OF COSMETIC DERMATOLOGY

•  Keep the cream and the dressing on for 3 hours.
•  Remove  the  dressings,  wash  the  remaining  cream  with 
a  compress  and  saline  solution,  and  start  the  lighten-
ing.  Parameters  of  LED  lamps  are  generally  already  set. 
Depending  on  the  lamps,  it  usually  lasts  between  8  and 
10 minutes (Figure 48.9)

Post-treatment care is simple: the treated zone needs to be pro-
tected from light for at least 24 hours, then a dry dressing and 
application of emollient can be done daily.

Right  after  the  procedure,  the  reactions  are  pain,  ery-

thema, and edema. Later, the following reactions may occur:

•  Squamae
•  Crusts
•  Suppuration
•  Blisters
•  Skin ulceration
•  Skin pigmentation after sun exposure

PDT and Pain
•  All  patients  report  an  unpleasant  burning,  stinging,  or 

prickling feeling.

•  Around 20% of patients report pain ranking between 7 and 
10 (on a pain analogical scale) requiring specific care (32).
•  Pain  appears  at  the  beginning  of  the  lightening  and 
increases after the first few minutes, reaches a plateau, and 
decreases slowly once the lightening is stopped (33).

•  The  pain  origin  seems  to  be  neurological  as  less  GABA 

receptors intervene (34).
•  This pain depends on (35):

•  Localization: more intense at the scalp and face than on 

the rest of the body (36)

•  Kind  of  tumor:  more  important  for  AK  than  for  BCC 

and Bowen disease

•  Lesion size: the pain increases with the size
•  Fluence  rate:  pain  is  reduced  with  lower  fluence  rate 

but time exposure is increased.

•  The physician has to take the pain into account during the 

lightening
•  Vocal anesthesia: do not leave the patient alone, talk to 
reduce his anxiety, modify the pain, and suggest a solu-
tion to reduce it.

Figure 48.9  Lesion illumination.

•  Physical means aimed at cooling down the pain are the 
most efficient: fan, water spray, liquid nitrogen spray. If 
the pain is too severe, the procedure can be interrupted 
for a few minutes to cool down the skin before restart-
ing the lightening (24).

•  Nerve block and local anesthesia without vasoconstric-

tive agent may be useful.

PDT should be considered as a new therapeutic resource that 
especially  fits  numerous  AK  on  large  area  treatment.  Future 
studies  will  have  to  confirm  the  PDT  preventive  aim  in  field 
cancerization. Regarding Bowen disease and CBCs, PDT rep-
resents a solution for broad and multiple lesions when surgery 
is  hard  to  perform  or  risky.  We  can  only  wish  that  in  a  few 
years indications out of nonmelanoma skin cancer will benefit 
from studies able to define precise protocols.

REFERENCES

1. Mordon  S.  La  thérapie  photodynamique  vasculaire:  Une 
nouvelle thérapeutique pour le treatment des angiomes plans. 
Ann Dermatol Venereol 2007; 134:281–6.

2. Noodt  BB,  Berg  K,  Stokke  T,  et  al.  Apoptosis  and  necrosis 
induced with light and 5-aminolaevulinic acid derived proto-
porphyrin IX. Br J Cancer 1996; 74:22–9.

3.  Nakaseko H, Kobayashi M, Akita Y, et al. Histological changes 
and involvement of apoptosis after photodynamic therapy for 
actinic keraoses. Br J Dermatol 2003; 148:122–7.

4.  Angell-Petersen  E,  Serensen  R,  Warloe  T,  et  al.  Porphyrin 
 formation  in  actinic  keratosis  and  basal  cell  carcinoma  after 
topical  application  of  methyl  5  aminolevulinate.  J  Invest 
Dermatol 2006; 126:265–71.

5.  Chamberlain  AJ,  Kurwa  HA.  Photodynamic  therapy:  Is  it 
a  valuable  treatment  option  for  actinic  keratose?  Am  J  Clin 
Dermatol 2003; 4:149–55.

6.  Fritsch  C,  Homey  B,  Stzhl  W,  et  al.  Preferential  relative 
 porphyrin  enrichment  in  solar  keratoses  upon  topical  appli-
cation  of  delta  aminolevulinic  acid  methyl  ester.  Photochem 
Photobiol 1998; 68:218–21.

7.  Sorensen R, Juzenas P, Iani V, et al. Formation of protoporphyrin 
IX in mouse skin after topical application of 5– aminolevulinic 
acid and its methyl ester. SPIE 1998; 3563:77–81.

8.  Peng  Q,  Moan  J,  Warloe  T,  et  al.  Build-up  of  esterified 
 aminolevulinic-acid-derivative-induced  porphyrin  fluores-
cence in  normal mouse skin. J Photochem Photobiol B Biol 1996; 
34:95–6.

9.  Angell-Petersen E, Christensen C, Müller CR, et al. Phototoxic 
reaction  and  porphyrin  fluorescene  in  skin  after  topical 
 application  of  methyl  aminolevulinate.  Br  J  Dermatol  2007; 
156:301–7.

  10.  Juzeniene  A,  Juzenas  P,  Ma  L-W,  et  al.  Topical  application  of 
5-aminolaevulinic  acid,  methyl  5-aminolevulinate  on  normal 
human skin. Br J Dermatol 2006; 155:791–9.

  11.  Moseley H. Update on PDT light sources 7th Euro-PDT Annual 

Congress Paris, 2007.

  12.  Babilas P, Knobler R, Hummel S, et al. Variable pulsed light is 
less  painful  than  light-emitting  diodes  for  topical  photody-
namic therapy of actinic keratosis: A prospective randomized 
controlled trial. Br J Dermatol 2007; 157:111–7.

  13.  Wiegell  SR,  Haedersdal  M,  Philipsen  PA,  Eriksen  P,  Enk  CD, 
Wulf  HC.  Continuous  activation  of  PpIX  by  daylight  is  as 
effective as and less painful than conventional photodynamic 
therapy for actinic keratoses: A randomized, controlled, single-
blinded study. Br J Dermatol 2008; 158:740–6.
 Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic 
therapy of actinic keratoses with 8% and 16% methyl aminolae-
vulinate and home-based daylight exposure: A double-blinded 
randomized clinical trial. Br J Dermatol 2009; 160:1308–14.

  14. 

 
 
 
 
 
 
 
 
  15.  Wiegell  SR,  Fabricius  S,  Stender  IM  et  al.  A  randomized, 
 multicentre  study  of  directed  daylight  exposure  times  of 
1(1/2)  vs.  2(1/2)  h  in  daylight-mediated  photodynamic  ther-
apy  with  methyl  aminolaevulinate  in  patients  with  multiple 
thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 
164:1083–90.

  16.  Rubel  DM,  Spelman  L,  Murrell  DF  et  al.  Daylight  PDT  with 
methyl  aminolevulinate  cream  as  a  convenient,  similarly 
effective,  nearly  painless  alternative  to  conventional  PDT  in 
actinic  keratosis  treatment:  A  randomised  controlled  trial. 
Br J Dermatol 2014; 171:1164–71.

  17.  Braathen  LR,  Szeimies  RM,  Basset-Seguin  N,  et  al.  and  all 
Guidelines on the use of PDT for nonmelenoma skin cancer: An 
international consensus. J Am Acad Dermatol 2007; 56:125–43.

  18.  Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic  therapy 
with  topical  methyl  aminolevulinate  for  actinic  keratosis: 
Results  of  a  prospective  randomized  multicenter  trial.  J  Am 
Acad Dermatol 2003; 48:227–32.

  19.  Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic 
therapy  using  topical  methyl  5-aminolevulinate  compared 
with cryotherapy for actinic keratosis: A prospective, random-
ized study. J Am Acad Dermatol 2002; 47:258–62.

  20.  Freeman  M,  Vinciullo  C,  Francis  D,  et  al.  A  comparison  of 
photodynamic  therapy  using  topical  methyl  aminolevulinate 
(Metvix1) with single cycle cryotherapy in patients with actinic 
keratosis:  A  prospective,  randomized  study.  J  Dermatol  Treat 
2003; 14:99–106.

  21.  Basset-Seguin N, Ibbotson S, Emtestam L, et al. Topical methyl 
aminolevulinate photodynamic therapy versus cryotherapy for 
superficial  basalcell  carcinoma:  A  five  year  randomized  trial. 
J Eur Acad Dermatol Venereol 2008; 18(5):547–53.

PHOTODYNAMIC THERAPY IN DERMATOLOGY 

 449

  24.  Alkalay  R,  Alkalay  J,  Maly  A,  et  al.  Fluorescence  imaging  for 
the demarcation of basal cell carcinoma tumor borders. J Drugs 
Dermatol 2008; 7:1033–7.

  25.  Tope WD, Menter A, EI-Azhary RA, et al. Comparison of topical 
methyl aminolevulinate photodynamic therapy versus placebo 
photodynamic  therapy  in  nodular  BCC.  J  Eur  Acad  Dermatol 
Venereol 2004; 18(suppl 2):413–4.

  26.  Rhodes  LE,  de  Rie  M,  Leifsdottir  R,  et  al.  Five  year  follow-
up  of  a  randomized,  prospective  trial  of  topical  methyl 
 aminolevulinate  vs  surgery  for  nodular  basal  cell  carcinoma. 
Arch Dermatol 2007; 143(9):1131–6.

  27.  Morton  CA,  Horn  M,  Leman  J,  et  al.  A  randomized,   placebo 
controlled,  European  study  comparing  MAL-PDT  with 
 cryotherapy  and  5-fluoracil  in  subjects  with  Bowen's  disease. 
J Eur Acad Dermatol Venereol 2004; 18(suppl 2):41S.

  28.  Nestor  MS,  Gold  MH,  Kauvar  AN,  et  al.  The  use  of  PDT  in 
 dermatology:  Results  of  a  consensus  conference.  J  Drugs 
Dermatol 2006; 5:140–54.

  29.  Taylor MN, Gonzalez ML. The practicalities of photodynamic 
therapy in acne vulgaris. Br J Dermatol 2009; 160:1140–8.
  30.  Nestor MS, Goldbert DJ, Goldman MP, et al. New perspectives 

on photorejuvenation. Skin Aging 2003; 11:68–74.

  31.  Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic 

photorejuvenation. Dermatol Surg 2002; 28:742–4.

  32.  Langan  SM.  Randomised  double  blind  study,  placebo  con-
trolled prospective study of topical anesthesia for topical ALA 
PDT  for  extensive  scalp  actinic  keratoses.  Br  J  Dermatol  2006; 
154:146–9.

  33.  Wiegell SR. Pain associated with PDT using ALA  or  MAL on 
tape stripped normal skin. Arch Dermatol 2003; 139:1173–7.
  34.  Grapengiesser S. Pain caused by PDT of skin cancer. Clin Exp 

  22.  Basset-Seguin N. MAL PDT for superficiel basal cell carcinoma. 

Dermatol 2002; 27:493–7.

7th Euro-PDT Annual congress Paris, 2007. 

  23.  Szeimies  RM,  Ibbotson  S,  Murrel  DF,  et  al.  A  clinical  study 
 comparing  methyl  aminolevulinate  photodynamic  therapy  in 
small  superficial  cell  carcinoma  (8–20  mm),  with  a  12  month 
 follow up. J Eur Acad Dermatol Venereol 2008; 22(11):1302–11.

  35.  De  Haas  E.  Fractionated  illumination  significantly  improves 
response of superficial BCC to ALA PDT. J Invest Dermatol 2006; 
126:2679–86.

  36.  Sandberg C. Important factors for pain during PDT for actinic 

keratosis. Acta Derm Venereol 2006; 86:404–8.

 
49

Cosmetic Cryotherapy

Eshini Perera, Poorna Weerasinghe, and Rodney Sinclair

INTRODUCTION
Most  dermatologists  and  dermatologic  surgeons 
limit 
 themselves  to  warts  and  keratoses.  Some  also  treat  skin 
 cancers. Many are unaware of the diverse range of  conditions, 
pathologic  and  cosmetic,  amenable  to  treatment  with   liquid 
nitrogen.  Cryosurgical  treatments,  when  applied  correctly  to 
appropriately  selected  patients,  produce  excellent   cosmetic 
results,  which  justifies  a  description  of  these  techniques  in 
a  cosmetic  dermatology  text.  As  liquid  nitrogen  is  freely 
 available and cheap, and can be used without local  anesthetic, 
it is often thought of as “low-tech” and unable to compete with 
the   newest  lasers.  On  the  contrary,  cryosurgery  is  the  equal 
of high-tech alternatives for therapeutic efficacy and aesthetic 
 outcome for a wide range of conditions. Despite these advan-
tages,   cryosurgery  tends  to  be  underutilized.  Cryosurgery 
developed  as  a  dermatological  treatment   modality  about 
a  century  ago,  with  the  first  cryogens  being  liquid  air  and 
 compressed carbon dioxide snow (1). The following is a descrip-
tion of the specific cryosurgical techniques for treatment of an 
array of lesions seen by the cosmetic and  dermatologic surgeon 
and describes the steps to be taken to achieve good cosmetic 
results.

TECHNIQUE AND TERMINOLOGY
Various methods have been devised in the use of cryotherapy 
of lesions.

1.  Open spray freeze technique
2.  Applicator technique
3.  Cryoprobe method
4.  Thermocoupler method

Timed Spot Freeze Technique
The spot freeze technique involves the use of a liquid nitrogen 
spray gun (Brymill Cryac Gun, Owen Galderma, Fort Worth, 
Texas, U.S.) that, through an appropriate nozzle, emits an open 
spray of liquid nitrogen (Figure 49.1). In general, the nozzle size 
is chosen according to the size of the lesion; however a “D” noz-
zle will be suitable for most benign lesions. The flask should be 
two-thirds full to ensure an even flow of cryogen. Overfilling 
the flask can lead to the valve icing over. The nozzle is held 1 cm 
from the skin surface at a 90° angle and the center of the lesion 
is sprayed until an ice ball forms that encompasses the lesion 
and the desired margin. The “designated ice field” may need 
to be marked out with a suitable pen, as freezing blurs lesion 
margins. Once the ice field reaches the desired size, freezing is 
stopped temporarily to allow palpation of the ice ball to ensure 
that the lesion is entirely frozen. Once satisfied of adequate ice 

formation, the spray of liquid nitrogen may recommence and 
continue for the appropriate treatment time. During this time, 
the ice field size should remain constant, with the spray of liq-
uid nitrogen adjusted with the trigger on the spray gun appro-
priately.  If  more  than  one  freeze-thaw  cycle  (FTC)  is  needed, 
then complete thawing should occur before the next cycle. This 
usually takes longer than 60 seconds. This can be assessed by 
palpation  between  the  finger  and  thumb  again  for  the  pres-
ence  of  an  ice  ball  as  well  as  waiting  for  the  disappearance 
of  the  frozen-white  surface  appearance.  Lesions  greater  than 
2 cm in diameter are generally best divided into overlapping 
treatment fields to ensure that the timed spot freeze technique 
adequately treats all parts of a large lesion (Figure 49.2). Using 
only  one  treatment  field  may  not  adequately  freeze  the  deep 
margins at the periphery of a large lesion. The open spray tech-
nique  is  extremely  versatile  and  can  be  used  for  most  easily 
accessible lesions. Variations do exist: the paintbrush method 
involves  spraying  starting  from  one  side  of  the  lesion  and 

Figure  49.1  Liquid  nitrogen  cryosurgery  equipment.  Two 
standard machines together with pedestal containing a variety 
of sprays, spray needles, and probes.

COSMETIC CRYOTHERAPY 

 451

that will eventually block the nozzle and lead to uneven flow 
of cryogen.

Cryoprobe
Various types of cryoprobes are available; the choice of probe 
depends on the type and site of the lesion (4). Cryoprobes may 
be attached to the liquid nitrogen spray guns and are cooled 
by the stream of nitrogen. The probe is applied directly to the 
lesion. A thin layer of Vaseline or similar gel may be used on 
the  tip  of  the  probe  to  facilitate  contact  with  the  lesion  and 
release  of  the  probe  on  thawing.  As  cooling  occurs  through 
conduction  of  heat  from  the  skin,  comparatively  longer  peri-
ods  of  freezing  are  required  with  this  technique.  Once  the 
ice  forms,  the  probe  and  lesion  is  gently  retracted  to  prevent 
further injury to the surrounding tissues. Direct pressure on a 
vascular lesion can also be used to empty the lesion and pro-
duce a greater fall in temperature, but the amount of pressure 
will influence the depth of freeze and lateral spread.

Thermocouple Device
To  treat  malignant  lesions,  a  temperature  probe  coupled  to  a 
digital thermometer that can read 10 to 75°C can be used. Local 
anaesthetic is injected in to the lesion, and a temperature probe 
is  inserted  into  the  estimated  depth  of  the  lesion.  Usually  a 
metal  or  styrene  cone  is  used  to  concentrate  the  freeze.  The 
liquid nitrogen is sprayed into the cone until the desired tem-
perature is reached, usually –50 to –60°C. The process can be 
repeated until the desired destruction is achieved.

MECHANISM OF ACTION
The mechanism of lesion destruction is similar for all cryogens 
and can be divided into four phases:

1.  Heat transfer
2.  Cell injury
3.  Vascular stasis and occlusion
4. 

Inflammation

HEAT TRANSFER
The rapid freezing of skin lesions depends on a quick transfer 
of heat from the skin to a heat sink, for example, liquid nitro-
gen. The rate of heat transfer is dependent on the temperature 
difference between the two, in this case 36 to –196°C.

TISSUE INJURY
On application of the cryogen, the initial event is extracellular 
ice formation. This commences at –10 to 15°C. The transforma-
tion  of  water  into  ice  leads  to  loss  of  water  from  the  extracel-
lular compartment. This concentrates the extracellular solutes 
and sets up an osmotic gradient across the cellular membranes. 
The  movement  of  water  across  membranes  is  exacerbated  by 
mechanical  compression  from  extracellular  ice  crystals  that 
damages the cell membrane. The movement of water out of the 
cell leads to an intracellular concentration of solutes. This dam-
age is mostly reversible. Irreversible damage is due to intracel-
lular ice formation and is dependent on the rate of cooling and 
the minimum temperature achieved. The faster the cooling and 
the lower the temperature, the greater the intracellular ice for-
mation. Ice crystals do not form until temperature –5 to –10°C. 
The  ice  damages  organelles  (mitochondria  and  endoplasmic 
reticulum)  and  further  concentrates  electrolytes  intracellular. 

Figure  49.2  Bowen  disease:  showing  method  of  freezing 
successive  2-cm  overlapping  circles  to  ensure  uniformity  of 
treatment of the whole lesion.

moving up and down across the lesion, and the spiral method, 
where  treatment  starts  in  the  center  of  the  lesion  and  moves 
outward  in  ever-increasing  circles  (2).  These  two  techniques 
are  particularly  useful  for  larger  lesions  and  when  a  light, 
superficial freeze is desired. Hyperpigmentation may compli-
cate the treatment of some lesions. Hyperpigmentation is par-
ticularly  common  in  people  with  Fitzpatrick  type  III  and  IV 
skin. Although usually temporary, it may take 3 to 4 months 
to  resolve.  In  general  before  embarking  on  this  treatment  in 
people  with  darker  complexions,  a  small  test  should  be  per-
formed first.

Hypopigmentation  is  generally  only  seen  after  large 
doses of liquid nitrogen are applied to the skin, for example, 
in the treatment of skin cancer. In very fair people, this may go 
unnoticed. For patients with an olive complexion, to prevent a 
sharp  demarcation  between  the  hypopigmented  treated  area 
and  surrounding  normal  pigmentation,  “feathering”  may  be 
performed. This involves spraying the border of the ice field to 
ice formation to produce mild hypopigmentation that reduces 
the  contrast  with  untreated  skin.  A  better  cosmetic  outcome 
may  be  achieved  when  treating  lesions  within  a  single  cos-
metic unit by light spraying the entire cosmetic unit. Because 
any depigmentation so produced will be permanent, it is better 
to proceed cautiously when deliberately lightening the skin.

Cotton-Tipped Dipstick
The  dipstick  technique  involves  dipping  a  cotton  wool  bud 
into a cup containing liquid nitrogen and firmly applying the 
bud to the lesion until a narrow halo of ice forms around the 
bud. This method is most effective with a cotton bud slightly 
smaller than the lesion to be treated and the cotton bud is home-
made using loosely wrapped cotton wool around the wooden 
orange  (or  satay)  stick.  This  holds  more  liquid  nitrogen  than 
prefabricated cotton buds. Pressure applied to the skin facili-
tates  lower  temperatures  as  a  wider  area  comes  into  contact. 
The pressure can also be used to empty vascular lesions lead-
ing to a greater fall in temperature. As adenovirus is capable of 
survival within liquid nitrogen and other viruses may poten-
tially survive and cross-contaminate one's store of nitrogen (3), 
redipping  is  therefore  not  recommended.  Decanting  a  small 
amount of liquid nitrogen into a separate new disposable con-
tainer for each patient treatment is preferred. Dipping a cotton 
bud  into  the  flask  of  a  spray  unit  leaves  behind  cotton  fibers 

 
452 

 TEXTBOOK OF COSMETIC DERMATOLOGY

The rate of thawing also influences the degree of damage, with 
long thaw times being associated with greater damage due to 
the  accumulation  of  intracellular  electrolytes.  Rapid  freezing 
and slow thaw maximize tissue damage to epithelial cells and 
is most suitable for the treatment for malignancies. In addition, 
repeat  FTCs  produce  more  tissue  injury  than  a  single  freeze 
and thaw. The minimum temperature needed for destruction is 
cell-specific. Cryosurgery causes selective destruction of differ-
ent cell or tissue types, depending on the temperature reached. 
The collagen-containing connective tissue types are more resis-
tant  to  cryodamage  than  the  epidermal  cell  types,  especially 
melanocytes  and  deeper  epidermal  cell  layers.  Mild  freezing 
causes  dermoepidermal  separation.  Keratinocyte  destruction 
requires a minimum temperature of at least –30 to –40°C, while 
melanocytes are much more sensitive, dying at –4 to –7°C. This 
fact is the reason for the resulting hypopigmentation following 
cryotherapy on darker skin individuals. Repigmentation often 
occurs with migration of melanocytes from the edge of the fro-
zen zone or from undamaged melanocytes within hair follicles. 
Fibroblasts produce less collagen after a rapid thaw. Therefore, 
a rapid thaw may be more suitable for the treatment of keloids 
or benign lesions in areas prone to scarring.

VASCULAR STASIS AND OCCLUSION
Cold  temperatures  lead  to  vasoconstriction  and  endothelial 
damage. At –15°C, endothelium is damaged and platelet aggre-
gation, along with microthrombus formation, leads to ischemic 
necrosis  of  the  treated  tissue  in  succeeding  hours.  A  reflex 
hyperemia lasting minutes to hours also occurs, appearing as a 
purplish discoloration at the edge of the defrosting lesion.

INFLAMMATION
Over  the  next  24  hours,  inflammation  develops  in  response 
to cell death and further contributes to the destruction of the 
lesion. Significant edema may occur, especially where the skin 
is  loosely  attached  to  underlying  tissues,  for  example,  the 
dorsum  of  hand  and  around  the  orbital  region.  Histological 
changes  first  become  apparent  30  minutes  after  cryotherapy. 
Eosinophilia and vacuolation of the cytoplasm appear initially, 
and the entire cytoplasm becomes homogenized over the next 
few hours. This is accompanied by nuclear pyknosis. There is 
separation  at  the  dermoepidermal  junction,  resulting  in  blis-
ter formation. At 2 hours, edema, focal capillary damage, and 
isolated  microthrombi  are  seen;  at  5  to  8  hours,  there  is  seg-
mental necrosis of blood vessels. There is initially a wet exuda-
tive wound, nature's own biologic dressing, followed by a dry 
eschar  and,  usually  within  a  month,  a  well-healed  hypopig-
mented scar.

LESION SELECTION
Accurate  diagnosis  is  essential  to  determine  duration  of  the 
freeze required. An appropriate biopsy of the lesion should be 
performed  if  there  is  any  diagnostic  uncertainty.  If  a  punch 
biopsy specimen is taken from the center of the lesion, informa-
tion regarding the thickness of the tumor will also be gained. 
Vast experience in the treatment of numerous and varied skin 
lesions  by  cryosurgery  has  been  accumulated  over  the  past 
30 years since this treatment was popularized by Zacarian for 
skin neoplasms (5,6). Much of this experience is summarized 
in Tables 49.1 to 49.4, while that pertaining to skin cancer can 
be found elsewhere (7).

Table 49.1  Suggested treatment regime for disturbances of pigmentation and melanocytic lesions

Lesion

Melasma

Idiopathic guttate 
hypomelanosis

Tattoos

Freckles

Technique

Time, number of FTCs

Margin

Sessions and interval

Response

OS

OS

OS

P

Uniform ice formation × 1

Feathering

4–6 weekly according to response Moderate

5 sec, × 1

30 sec, × 2

1 mm

1 mm

4–6 weekly according to response Moderate to good

4–6 weekly according to response

54% improved

Uniform ice formation, × 1

Feathering

Usually only single treatment 

Variable

required

Lentigo simplex

OS or P

Light, × 1

Feathering

Usually only single treatment 

Good

required

Solar lentigo

OS or P

5–10 sec, × 1

Feathering

Usually only single treatment 

Good

required

Abbreviations: OS, open spray technique; P, cryoprobe technique; FTS, freeze-thaw cycle.

Table 49.2  Suggested treatment regime for vascular lesions and nevi

Lesion

Technique

Time, number of FTCs Margin

Sessions and intervals

AIDS- related Kaposi 

OS

10–30 sec, × 2

3 mm

3 at 3 weekly intervals

Response

80% improved

sarcoma
Venous lake

Cherry angiomas

P

P

Angiokeratoma of Mibell OS or P
Angiokeratoma of the 

OS or P

scrotum
Spider nevus

P

Capillary hemangioma

P
Cavernous hemangioma P
P
Pyogenic granuloma

10 sec, × 1

10 sec, × 1

10 sec, × 1

5–10 sec, × 1

10 sec, × 1

5–30 sec, × 2

5–30 sec, × 2
15 sec, × 1

1 mm

1 mm

1 mm

1 mm

1 mm

1 mm

1 mm
1 mm

Usually only single treatment

Excellent

Usually only single treatment

3 at 2 monthly intervals

3 at 2 monthly intervals

3 at 6 weekly intervals

2–4 at 8 weekly intervals

2–4 at 8 weekly intervals
1–2 at 4 weekly intervals

Good

Good

Good

Good

Excellent

Excellent
Excellent

 
Table 49.3  Suggested treatment regime for cysts, tumors, and nevi

COSMETIC CRYOTHERAPY 

 453

Technique

Time, number of 
FTCs

Margin

Sessions and intervals

Response

OS or D PB to 

5–15 sec, × 1

–

2–3 at monthly intervals

Good to excellent

Lesion

Acne cyst

Milia

Myxoid cyst

Syringoma

Trichoepithelioma

peeling

P

P or OS

P

P

Trichilemmal cyst

OS
Steatocystoma multiplex OS
Skin tag

OS or forceps

Hidrocystoma

OS or P

Dermatofibroma

OS or P

30 sec × 1

Seborrheic keratosis

OS or D or P

Ice formation × 1

Sebaceous hyperplasia

Chondrodermatitis 
nodularis helices

Verrucous nevus

OS or P

OS or P

OS

Ice formation × 1

30 sec × 2

Ice formation × 1

Ice formation × 1

Ice formation × 1

Ice formation × 1

5–10 sec, × 1

Ice formation × 1

5–15 sec × 1

15 sec × 1

1 mm

1 mm

1 mm

1 mm

1 mm

1 mm

1 mm

1 mm

2 mm

1 mm

1 mm

2 mm

Usually only single treatment

Good

1–3 at 8 weekly intervals

86% improved

2–3 at 1–2 monthly intervals

2–3 at 1–2 monthly intervals

Good

Good

2–3 at 1–2 monthly intervals

A minority respond

2–3 at 1–2 monthly intervals

A minority respond

Usually only single treatment

Excellent

2–3 at 1–2 monthly intervals

Small: good
Large: poor

1–3 at 1–2 monthly intervals

90% improved

Usually only single treatment

Excellent

Usually only single treatment

Good

2–3 at 1–2 monthly intervals

15–20% improved

5 sec × 1

1 mm

Up to 5 at 1–2 monthly 

Excellent

intervals

Hyperkeratosis nevoid of 

OS

20 sec × 1

1 mm

Up to 5 at 1–2 monthly 

Excellent

the nipple

Acrokeratosis 
verruciformis

OS

5 sec × 1

1 mm

Several at 6–8 weekly intervals Excellent

intervals

Dermatosis papulosa 

OS or P

Ice formation × 1

Nil

Several at 6–8 weekly intervals Excellent, but may 

nigra

Benign lichenoid 

keratosis

Adenoma sebaceum

OS

OS

5 sec × 1

1 mm

2–3 at 6–8 weekly intervals

Good

5–20 sec × 1

1 mm

3–6 at 3 weekly intervals

Satisfactory

depigment

Abbreviations: OS, Open spray technique; P, Cryoprobe technique; FTS, freeze-thaw cycle; D, freeze-thaw cycle

Table 49.4  Suggested treatment regime for various other conditions

Lesion

Keloid

Acne scar

Rhinophyma

Xanthelasma

Alopecia areata

Porokeratosis plantaris 

discreta

Elastosis perforans 

serpiginosa

Technique

OS or P

OS

OS

OS

D

OS

OS

Time, number of 
FTCs

15–30 sec, × 1

Face 5 sec, × 1
Back 5–15 sec, × 1

Margin

1 mm

1 mm

Sessions and 
intervals

5–10 at 4–8 

weekly intervals

Response

Variable

1–3 at 4–8 weekly 

Good to excellent

intervals

30 sec, × 2

Entire nose

4–6 at 8 weekly 

Satisfactory

intervals

5 sec, × 1

1 mm

2–3 at 4–8 weekly 

Satisfactory

2–5 sec, × 1

Nil

Ice formation × 1

2 mm

10 sec, X 1

1–2 mm

intervals

4 at weekly 
intervals

2 at 2 weekly 
intervals
2 at weekly 
intervals

Satisfactory

90.5% improved

Excellent

Abbreviations: OS, open spray technique; P, cryoprobe technique; FTS, freeze-thaw cycle; D, freeze-thaw cycle.

VASCULAR LESIONS
Spider  nevi  require  only  a  light  freeze.  A  5-second  single 
FTC  is  usually  ample.  Cryosurgery  is  a  good  alternative  to 
fine  wire  diathermy  for  people  with  pale  complexions,  espe-
cially  for  diffuse  lesions  with  more  than  one  feeding  vessel. 

Diffuse  telangiectasia,  such  as  that  associated  with  rosacea, 
can  also  be  treated  with  good  results  and  is  a  substantially 
cheaper alternative to the use of a pulsed dye laser. Pyogenic 
granulomas  also  respond  well  (Figure  49.3).  Cryosurgery  is 
also  useful  for  palliation  of  HIV-associated  Kaposi  sarcoma. 

 
454 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 49.3  Pyogenic granuloma (a) before and (b) after cryospray.

Small individual lesions (and a 3-mm margin) can be treated 
with  a  15-  to  30-second  single  FTC,  with  an  80%  complete 
response. Cryoprobes are useful when treating venous lakes, 
since they allow the operator to empty the lesion during treat-
ment,  which  leads  to  lower  tissue  temperatures  and  higher 
cure rates. A single 10-second FTC is usually sufficient.

There is a great variation in the size and depth of  cav-
ernous  and  capillary  hemangioma,  and  this  is  paralleled  by 
the variation in freeze times required. For small thin lesions, 
a  single   5-second  freeze  may  suffice,  while  for  larger  lesions 
a   30-second  double  FTC  will  be  required.  Experience  in  the 
treatment of these lesions allows the operator to better judge 
the length of treatment required.

ACNE
The  first  treatment  to  be  advocated  for  acne  was  a  solid  car-
bon dioxide slush that acted as a peeling agent to reduce the 
oiliness of the skin and hastened the resolution of comedones 
and papules as well as improving depressed pitted scars. This 
was superseded by cotton-tipped applicators dipped in liquid 
nitrogen, which has also been used for larger acne cysts. Better 
results and better control can be achieved with the open spray 
techniques  (8).  Small  inflammatory  papules  require  a  2-  to 
5-second single FTC, while the large cystic lesions of acne con-
globata may require a 15- to 20-second single FTC, depending 
on their size. Open spray liquid nitrogen has also been used as 
an  alternative  to  dermabrasion  and  laser  resurfacing  for  dif-
fuse scarring (9). The skin surface is divided into squares, each 
about  4  cm  on  a  side.  Using  the  paintbrush  technique,  each 
segment  is  frozen  for  between  5  and  15  seconds,  depending 
on the depth of the desired peel. Areas of hypertrophic scar-
ring  may  require  longer  freezes  because  of  the  relative  cold 
insensitivity  of  collagen,  while  areas  around  the  eyes,  where 
the skin is thin, only requires 5- to 10-second single FTCs. If 
more than one treatment is planned, 1 month is the suggested 
interval  between  sessions.  Of  the  patients  so  treated,  95% 
were  reported  to  have  had  good  or  excellent  results,  which 
were  similar  to  those  achieved  by  superficial  dermabrasion, 
with the advantage of their use in the presence of active acne. 
Pigmentary changes are often seen in ethnic patients and care 
should be taken when using this technique on darker skin (10).

SUN DAMAGED SKIN AND FACIAL PEELING
Solar  keratoses,  solar  lentigines,  solar  elastosis,  sebaceous 
hyperplasia,  colloid  milium,  and  the  fine  wrinkles  of  solar 
aging  are  all  within  the  realms  of  unsightly  sun-induced 
lesions amenable to cryosurgery. These lesions occur on highly 
visible sites, such as the face and hands, and may cause patients 
distress. Cryosurgery is an excellent option for limited disease. 
Many clinicians ignore sebaceous hyperplasia; however, a sin-
gle 5-second FTC will often make these lesions disappear. The 
same  applies  to  solar  elastosis,  solar  lentigo,  and  many  solar 
keratoses. For widespread changes, full-face cryopeels can be 
used  for  effective  depth-controlled  removal  of  actinic  kera-
toses,  pigmented  lesions,  and  seborrheic  keratoses.  Healing 
begins  immediately  and  is  usually  complete  within  10  days. 
The skin is left smoother, pinker, and tighter, and the results 
are  equivalent  to  those  of  a  chemical  peel;  however,  there  is 
greater control of the depth of the ice field, so it can be adjusted 
to accommodate localized lesions (9).

VIRAL WARTS
These are due to the human papillomavirus. On different body 
sites, warts often show different morphologic types. The cryo-
surgical treatment scheduled will vary with the site and type: 
Common warts are mainly seen on hands, fingers, and knees. 
For flat lesions, a single FTC using the open spray for 10 seconds 
is generally sufficient for an initial treatment. For hyperkera-
totic wart, it is often best to pare the keratosis prior to freezing. 
Periungual  warts  often  require  multiple  freezes  with  gradu-
ally increasing dose. The spray should be directed laterally to 
avoid overfreezing the nail matrix and to prevent pterygium. 
Plane warts are smooth, small, flat-topped papules most com-
monly seen on the back of the hands and around the mouth. 
They are often multiple and can Koebnerize. Each wart should 
be frozen individually using the open spray with an E tip for 
3- to 5-second single freeze. Plantar warts (verrucas) typically 
occur  on  weight-bearing  areas  of  the  sole.  Prior  to  cryosur-
gery,  they  should  be  pared  to  remove  excess  hyperkeratosis, 
then frozen with the open spray and a B or C nozzle for 10 to  
20  seconds  depending  on  size  and  thickness.  Repeat  treat-
ments at three to four weekly intervals are generally required. 
For recalcitrant lesions a double freeze thaw should be used. 

 
 
COSMETIC CRYOTHERAPY 

 455

(a)

(b)

Figure 49.4  Filiform wart of upper lip (a) before and (b) after fine “needle” cryospray.

(a)

(b)

Figure 49.5  Large seborrheic keratosis of right cheek (a) before and (b) after cryospray.

Filiform or digital warts are finger- or frond-like warts and are 
most common on the face, neck, and scalp (Figure 49.4). Each 
lesion should be sprayed with a fine “needle” to ice formation 
plus  10   seconds  of  continued  spray.  Treatment  may  need  to 
be  repeated  after  2  to  4  weeks.  The  likelihood  of  recurrence 
is dependent on the number of lesions, the user, and the tech-
nique used. With a gentle technique cure rates are estimated 
around 64.4% and this is increased with more aggressive treat-
ment  (11).  Aggressive  treatments  are  more  likely  to  lead  to 
increased  side  effects.  A  less  aggressive  approach  should  be 
used where skin and subcutaneous tissue are thin (12).

SEBORRHEIC KERATOSIS
Flat  lesions  can  be  effectively  treated  with  a  5-second  single 
FTC (Figure 49.5), but as keratin insulates the underlying epi-
dermis  from  the  cold,  large  hyperkeratotic  lesions  may  still 
survive 30-second double FTCs. A recent pilot study examin-
ing 25 patients with SK treated with cryotherapy versus curet-
tage  found  that  60%  of  patients  preferred  cryotherapy  and 
rated  their  cosmetic  outcome  as  better  with  cryotherapy  (13). 
The main pitfalls of treatment are the induction of permanent 

alopecia,  if  hair-bearing  areas  are  treated,  and  the  induction 
of transient hyperpigmentation. It is for that reason that der-
matosis  papulosa  nigra  occurring  on  pigmented  skin  is  best 
treated cautiously, and preferably with a test patch of a single 
lesion.

RHINOPHYMA
Cryosurgery  has  been  to  used  to  treat  rhinophyma  (14). 
However, in our hands, it has proved to be less effective than 
dermabrasion  or  serial  shaving.  However,  there  have  been  a 
number of case reports detailing successful methods for treat-
ing rhinophyma. In one case report a patient was treated with 
two or three FTC over a number of sessions using the paint-
brush method. Sessions were spaced fortnightly and combined 
with the use of spironolactone to reduce sebum excretion and 
pore  size  (15).  Thirty-second  double  FTCs  are  recommended 
and can often be performed without anesthesia, or solely with 
EMLA  cream.  Multiple  treatments  are  required,  but  are  well 
tolerated. For  mild cases, cryosurgery can  still  be  considered 
as an inexpensive option with low risk and low morbidity that 
has shown some success.

 
 
 
456 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 49.6  Tattoos (a) before and (b) 4 months after liquid nitrogen spray.

TATTOOS
Good results have been seen after cryosurgery of tattoos in up 
to  50%  of  cases  (Figure  49.6)  (16).  However,  newer  technolo-
gies  including  q-switched  lasers  are  the  preferred  option  for 
tattoo  removal  since  cryotherapy  can  leave  the  patient  with 
skin  discoloration  and  ink  retention  (17).  Cryotherapy  pro-
vides complete, rapid, and cheap tattoo removal and for some 
patients  desperate  for  the  treatment  there  is  no  affordable 
alternative (18).

KELOIDS
Many  cryosurgeons  disappointed  by  the  apparent  poor 
response of keloids to liquid nitrogen abandoned this form of 
treatment. Various techniques had been tried, including pro-
phylactic  and  intralesional  cryotherapy,  with  some  success. 
Results varied between 20 and 75% scar reduction (19–23). The 
incidence of hypopigmentation in intralesional cryotherapy is 
lower than in contact cryotherapy (24). A prospective clinical 
trial published in 2010 examined surgical excision with post-
operative  radiotherapy  versus  cryotherapy  with  intralesional 
steroids.  The  study  revealed  that  while  surgery  with  cryo-
therapy and intralesional steroids had more side effects and a 
higher recurrence rate, it was still a good choice for new, small 
keloids  (25).  Currently  randomized  trials  examining  intrale-
sional cryotherapy versus excision with corticosteroids or exci-
sion with brachytherapy are underway [NTR4151] (26).

COMPLICATIONS
Inflammatory morbidity, inevitable side effects, and complica-
tions are difficult to separate with this modality of treatment 
(27). Table 49.5 shows some of the well-known complications of 
cryosurgery. Some degree of pain is universal, but its intensity 
is extremely variable. Syncope can occur if the pain is severe, 
and  many  prefer  to  treat  patients  (particularly  young  men) 
lying down. During the freeze time, pain is felt as burning, and 
during  the  thaw  phase,  when  pain  is  commonly  worse  than 
during the freeze, it is felt as throbbing. The periungual region 
and the temples are the most persistent. Headache is an occa-
sional sequela after treatment of sites close to bone, such as the 
forehead, temple, or scalp. Immediate hemorrhage, if occurs, is 
often  prolonged,  but  can  usually  ultimately  be  stopped  with 
pressure alone. This can follow by performing biopsies imme-
diately prior to treatment, but can also occur if a pedunculated 

lesion  is  manipulated  while  frozen,  and  cracks.  Edema  is  the 
product  of  acute  inflammation.  Pronounced  idiosyncratic 
edema  may  occasionally  occur  after  short  freezes.  Edema  is 
often  more  severe  around  the  eyelids  and  lips  (Figure  49.7). 
The  edema  can  be  partly  inhibited  by  a  single  application  of 
a potent topical steroid immediately following treatment (28), 
and  if  severe  edema  is  anticipated  then  systemic  corticoste-
roids can be used. Temporary hyperpigmentation is common 
in people with an olive complexion and may last 2 to 3 months. 
Careful  sun  protection  following  treatment  may  reduce  this 
risk.  For  patients  with  Fitzpatrick  types  III  and  IV  skin,  even 
temporary hyperpigmentation may be unacceptable and treat-
ment of a small test area is recommended. Hypopigmentation 
is  virtually  universal  following  tumor  doses  of  cryosurgery, 
owing to the exquisite sensitivity of melanocytes to cold, and 
can occur unpredictably following lower doses. In pigmented 
skin, this will lead to an unacceptable cosmetic result; however, 
in fair-skinned people this is usually not a problem and can be 
dealt  with  by  feathering.  Any  loss  of  pigmentation  is  perma-
nent, but because the texture of the underlying skin is normal, it 
can be effectively disguised by cosmetics. Feathering is a tech-
nique described to minimize the contrast between normal and 
hypopigment  skin.  It  involves  a  light  spray  around  the  outer 
margin  of  the  ice  field  after  the  treatment.  Alopecia  will  fol-
low large doses of liquid nitrogen, and occasionally occurs at 
lower doses in an unpredictable fashion. Like pigment loss, any 
hair loss is usually permanent, and so cryosurgical treatment 
of lesions in the scalp and beard areas is generally only consid-
ered for small lesions. Scarring and wound contraction do not 
occur if the duration of the freeze after ice formation does not 
exceed 30 seconds, but can occur with higher doses (29). This is 
due to the relative resistance of fibroblasts and collagen fibers 
to cold, which leads to the preservation of the fibrous tissue net-
work,  which  then  acts  as  a  scaffold  on  which  wound  healing 
occurs. Cartilage is similarly cryoresistant, allowing lesions on 
the  ears  and  nose  to  receive  full  30-second  double  freezes  of 
liquid nitrogen without distortion of normal tissue contour (30). 
Sensory impairment following cryosurgery has been described 
in both the patient and the operator (31). Touch, pain, and cold 
sensations are all reduced and may take as long as 18 months to 
recover. The extent of sensory impairment is more pronounced 
with  longer  freeze  times.  Although  this  may  be  of  advan-
tage  for  repeat  treatment  of  lesions  or  if  analgesia  is  desired, 
patients must be warned of this complication if sensitive areas 
such as the fingertips are being treated. Neuropathy has been 

 
 
Table 49.5  Side effects of cryosurgery

Table 49.6  Contraindications to cryosurgery

COSMETIC CRYOTHERAPY 

 457

Immediate
Pain
Headache
Hemorrhage
Edema and blister formation
Syncope
Delayed
Infection
Hemorrhage
Excessive formation of granulation tissue
Prolonged but usually temporary
Hyperpigmentation
Milia
Hypertrophic scars
Alteration of sensation
Prolonged and usually permanent
Hypopigmentation
Alopecia
Atrophy
Ectropion
Notching of the eyelids, ear, or vermillion border.

Figure 49.7  Left upper facial and periorbital edema 24 hours 
after two 30-second freeze-thaw cycles to left temple basal cell 
carcinoma of 2.4 cm in diameter.

described when treating tumors on the side of the neck, near 
elbow or knee, and on the side of the finger. This is temporary, 
persisting usually for 3 to 6 months. Contraindications to cryo-
surgery generally relate to intercurrent illnesses such as those 
listed in Table 49.6. Relative contraindications arise with certain 
lesions where the cosmetic result would be more favorable with 
different treatments, such as the beard areas or in patients with 
pigmented skin, or in sites where wound healing may be slow, 
such as the pretibial region. Cryosurgery can still be used on 
all these lesions as long as the operator acknowledges that the 
cosmetic outcomes will be diminished.

CONCLUSION
As  can  be  seen  from  the  broad  range  of  conditions  listed  in 
the tables, distinguishing between the use of cryosurgery or 
cosmetic usage for treatment of disease is sometimes difficult. 
Many pathologies cause little functional impairment but cause 
psychological  morbidity  through  their  perceived  unpleasant 
appearance. To dismiss these disorders as trivial or unworthy 

Agammaglobulinemia
Blood dyscrasias of unknown origin
Cold intolerance
Raynaud disease
Cold urticaria
Cryoglobulinemia
Pyoderma gangrenosum
Collagen and autoimmune disease

and  merely  of  cosmetic  significance  is  to  deprive  the  patient 
of a balanced informed opinion. For many of these conditions 
there  are  few  published  data  that  specifically  address  how 
to perform the actual treatment. This is because experienced 
cryosurgeons will be able to judge the treatment required on 
the basis of the pathology of the lesion, its thickness, and its 
site.  For  instance,  a  lesion  on  the  lower  leg  of  a  person  with 
venous  insufficiency  is  likely  to  respond  to  shorter  freeze 
times,  and  may  have  prolonged  healing  times.  Even  if  all 
these treatments had been prospectively audited, more exact 
treatment protocols would be difficult to produce, since they 
would  not  allow  for  the  many  factors  clinicians  take  into 
account when performing cryosurgery. One reason clinicians 
may obtain unsatisfactory outcomes is the use of inadequate 
treatment  schedules.  It  is  hoped  that  this  description  of  the 
correct technique will ensure that others achieve results simi-
lar  to  those  presented  here.  Cryosurgery  is  easy  and  can  be 
learned quickly—but that is not the same as saying no training 
is  required.  As  Zacarian,  the  father  of  modern-day  cryosur-
gery, said,

A level of knowledge permitting an adequate understanding of 
the diagnosis and the pathophysiology of the condition to be 
treated must be a prerequisite. This is to be combined with a 
degree in skill in dermatocryosurgical procedures to allow the 
selection of those methods necessary to carry out the treatment 
plan. These skills must be acquired. There are no shortcuts (6).

REFERENCES

1. White AC. Liquid air: Its application in medicine and surgery. 

Med Rec 1898; 56:109–12.

2. Pusey W. The use of carbon dioxide in the treatment of nevi and 

other lesions of the skin. JAMA 1907; 49:1354–6.

3. Colver  GB,  Dawber  RPR.  Malignant  spots:  Spot  freezes.  In: 
Robins  P,  ed.  Surgical  Gems  in  Dermatology.  Vol  2.  New  York/
Tokyo: Igaku-Shoin, 1991; pp. 14–7.

4. Graham  GF.  Cryosurgery:  A  useful  tool  in  the  treatment  of 

selected infectious diseases. Int J Dermatol 1994; 33:107–8.

5. Dawber  RPR,  Colver  G,  Jackson  A.  Cutaneous  Cryosurgery. 
Principles and Practice. London: Martin Dunitz, 1997; p. 139.
6. Zacarian  SA,  ed.  Cryosurgery  for  Skin  Cancer  and  Cutaneous 

Disorders. St Louis: Mosby Press, 1985.

7. Korpan  NN.  In:  Korpan  NN,  ed.  Basics  of  Cryosurgery: 
Cryosurgery of Cancers. New York: Springer, 2001; pp. 58–108.
8. Graham  G.  Cryosurgery  for  acne.  In:  Zacarian  SA,  ed. 
Cryosurgery  for  Skin  Cancer  and  Cutaneous  Disorders.  St  Louis: 
Mosby Press, 1985:59–76.

9. Chicarello  SE.  Full-face-cry  (liquid  nitrogen)  peel.  J  Dermatol 

Surg Oncol 1992; 18:329–332.

10. Khunger N, IADVL Task force. Standard guidelines of care for 
acne surgery. Indian J Dermatol Venereol Lerol 2008;74:S28–36.
11. Khaled  A,  Romdhane  B,  Kharfi  M,  Zeglaoui  F,  Kamoun  M. 
Assessment of cryotherapy by liquid nitrogen in the treatment 
of hand and feet warts. Tunis Med 2009; 87(10):690–2.

12. Kandamany N, Ahmad M. Cool it! The judicious use of liquid 
nitrogen  for  viral  warts  is  important.  J  Plast  Reconstr  Aesthet 
Surg 2010; 63(2):e204. 

 
458 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  13.  Wood  LD,  Stucki  JK,  Hollenbeak  CS.  Effectiveness  of  cryo-
surgery  vs  curettage  in  the  treatment  of  seborrheic  keratoses. 
JAMA Dermatol 2013; 149(1):108–9.

  23.  Ledon JA, Avas J, Franca K, Chacon A, Nouri K. Intralesional 
treatment  for  keloids  and  hypertrophic  scars:  A  review.  2013; 
39(12):1745–57.

  14.  Sonnex  T,  Dawber  RPR.  Rhinophyma:  Treatment  by  liquid 
nitrogen cryosurgery. Br J Dermatol 1983; 109(suppl 24):18.
  15.  Kempiak SJ, Lee PW, Pelle MT. Rhinophyma treated with cryo-

surgery. Dermatol Surg 2009; 35(5):543–5.

  16.  Colver GB, Dawber RPR. Tattoo removal using a liquid nitrogen 

cryospray. Clin Exp Dermatol 1984; 9:364–6.

  17.  Kirby W, Chen CL, Desai A , Desai T. Causes and reccomenda-
tions for unanticipated ink retention following tattoo removal 
treatment. J Clin Aesthet Dermatol 2013; 6(7):27–31.

  18.  Takushima  A,  Okazaki  M,  Harii  K.  Tattoo  removal  by  graft-
ing  enzymatically  separated  epidermis.  Ann  Plast  Surg  2001; 
47(4):398–403.
  Zouboulis  CC,  Rosenberger  AD,  Forster  T,  Beller  G,  et  al. 
Modification  of  a  device  and  its  application  for  intralesional 
cryosurgery  of  old  recalcitrant  keloids.  Arch  Dermatol  2004; 
140(10):1293–4. 

  19. 

  20.  Har-Shai  Y,  Amar  M,  Sabo  E.  Intralesional  cryotherapy  for 
enhancing  the  involution  of  hypertrophic  scars  and  keloids. 
Plast Reconstr Surg 2003; 111(6):1841–52. 

  21.  Har-Shai  Y,  Sabo  E,  Rohde  E,  Hyams  M,  et  al.  Intralesional 
cryosurgery  enhances  the  involution  of  recalcitrant  auricular 
keloids:  A  new  clinical  approach  supported  by  experimental 
studies. Wound Repair Regen 2006; 14(1):18–27. 

  24.  Har-Shai Y, Dujovny E, Rohde E, Zouboulis CC. Effect of skin 
surface  temperature  on  skin  pigmentation  during  contact 
and  intralesional  cryosurgery  of  keloids.  J  Eur  Acad  Dermatol 
Venereol 2007; 21(2):191–8.

  25.  Emad  M,  Omidvari  S  Dastgheib  L,  Mortazavi  A,  Ghaem  H. 
Surgical  excision  and  immediate  postoperative  radiotherapy 
versus  cryotherapy  and  intralesional  steorids  in  the  manage-
ment of keloids: A prospective clinical trial. Med Princ Pact 2010; 
19(5):402–5.

  26.  Bijlard  E,  Timman  R,  Verduijn,  Niesen  F,  van  Neck  J  et  al. 
Intraleional cryotherapy versus excision and corticosteroids or 
brachytherapy  for  keloid  treatment:  Study  protocol  for  a  ran-
domised controlled trial. Trials 2013; 14:439.

  27.  Dawber  RPR.  Cryosurgery:  Complications  and  contraindica-

tions. Clin Dermatol 1990; 8:96–100.

  28.  Hindson TC, Spiro J, Scott LV. Clobetasol propionate ointment 
reduces  inflammation  after  cryosurgery.  Br  J  Dermatol  1985; 
112:599–602.

  29.  Shepard  JP,  Dawber  RPR.  Wound  healing  and  scarring  after 

cryosurgery. Cryobiology 1984; 21:157–69.

  30.  Burge SM, Shepard JP, Dawber RPR. Effect of freezing the helix 
and rim or edge of the human and pig ear. J Dermatol Surg Oncol 
1984; 10:816–9.

  22.  Gupta  S,  Kumar  B.  Intralesional  cryosurgery  using  lumbar 
puncture and/or hypodermic needles for large, bulky, recalci-
trant keloids. Int J Dermatol 2001; 40(5):349–53.

  31.  Sonnex  TS,  Jones  RL,  Wedell  AG,  et  al.  Long  term  effects 
of  cryosurgery  on  cutaneous  sensation.  Br  Med  J  1985; 
290:188–90.

 
50

Botulinum Toxins

Doris Hexsel

INTRODUCTION
The  cosmetic  use  of  botulinum  neurotoxin  type  A  (BoNT-A) 
on  the  upper  face  was  first  reported  by  Carruthers  and 
Carruthers  in  the  late  1980s  (1).  The  first  studies  of  the  cos-
metic  use  of  BoNT-A  were  published  in  the  early  1990s  and 
approximately 10 years later it was approved by the Food and 
Drug Administration (FDA) in the United States, and similar 
authorities in other countries. This represents one of the most 
important  contributions  to  the  approach  of  the  aging  face  in 
recent years.

Easily applied by experienced physicians, BoNT-A injec-
tions are now perhaps the most frequently used cosmetic pro-
cedure. In the United States, BoNT-A injections were the most 
frequently  performed  cosmetic  procedure  from  1995  to  2010, 
and  the  one  that  increased  at  the  greatest  rate  over  time  (2). 
Their  popularity  and  success  among  physicians  and  patients 
can be related to their consistent positive results and safety (3,4), 
besides being a fast, minimally invasive (5), and low-risk proce-
dure. Botulinum neurotoxin type A is now a recognized treat-
ment for a wide spectrum of conditions characterized by relative 
over activity of one or a few muscles (m.). BoNT-A injections are 
effective in the treatment of localized hyperhidrosis, and recent 
publications  report  their  effectiveness  in  other  dermatological 
conditions. The relative simplicity of the procedure and the low 
rates of side effects or significant complications make this proce-
dure increasingly attractive for cosmetic use.

Although  botulinum  neurotoxin  type  B  may  be  cos-
metically used and although there are varied botulinum toxin 
brands, this chapter discusses only the BoNT-A main prepara-
tions, such as Botox®, Xeomin®, and Dysport®.

PHARMACOLOGY AND 
MECHANISM OF ACTION
Clostridium botulinum produces an exotoxin that is considered 
the most poisonous of all poisons (6). It is an anaerobic, gram-
positive bacillus that forms spores and its strains are grouped 
into one of the eight serotypes: A, B, C, D, E, F, G, and H (7).

The  currently  available  serotypes  A  and  B  result  from 
modification of the protein structure and have been used for 
a  variety  of  medical  and  cosmetic  indications.  Botulinum 
neurotoxin  causes  a  temporary  chemical  denervation  of  the 
motor  neuron  in  the  treated  muscle,  resulting  in  therapeutic 
and cosmetic actions. It selectively inactivates these nerve ter-
minals  by  blocking  the  release  of  acetylcholine,  producing  a 
temporary  and  ultimately  reversible  blockade  of  cholinergic 
transmission (8). In the neuromuscular junction, the blockade 
of the release of acetylcholine promotes a different spectrum 
of action (9) varying from muscle relaxation to muscular palsy, 
depending on the subtypes and doses used.

Different  formulations  of  BoNT-A  are  available  world-
wide,  which  are  neither  identical  nor  interchangeable.  Botox 
(Allergan,  Inc.,  Irvine,  California)  is  the  trade  name  for  ona-
botulinumtoxinA (ONA) (10). ONA is also known as Vistabel® 
in  Europe  and  Vistabex®.  Dysport  (Ipsen  Pharma,  Boulogne-
Billancourt,  France)  is  the  trade  name  for  abobotulinumtox-
inA (ABO), which is also known as Azzalure®. Xeomin (Merz 
Pharmaceuticals,  Frankfurt,  Germany)  is  the  trade  name  for 
incobotulinumtoxinA (INCO), also known as Bocoture®. Table 
50.1  shows  the  principal  characteristics  of  the  main  commer-
cial preparations of BoNT-As.

RECONSTITUTION, HANDLING, 
DILUTION AND DOSE EQUIVALENCE
Available BoNT-A preparations are usually stored in a refrig-
erator  and  reconstituted  with  isotonic  sodium  chloride  (0.9% 
saline solution) with or without preservative (5) prior to their 
use, except incobotulinum toxin.

The  manufacturers  of  the  commercial  preparations  of 
BoNT-A recommend their use within the first 4 or 8 hours after 
reconstitution,  depending  on  the  product,  to  ensure  that  the 
potency of the drug is maintained and to prevent the possibil-
ity  of  contamination  of  the  vials.  Manufacturers  recommend 
storing  BoNT-A  in  the  refrigerator  no  longer  than  4  hours 
after  reconstitution.  However,  studies  support  the  safety 
and efficacy of BoNT-A when the product is reconstituted up 
to  15  days  (11)  and  6  weeks  before  the  injections  (12,13).  No 
signs  of  microbiological  contamination  were  verified  (11,13). 
Reconstitution  of  BoNT-A  in  smaller  rather  than  larger  vol-
umes  of  saline  solution  is  preferable.  For  cosmetic  purposes, 
a  higher  concentration  allows  a  low  injection  volume,  which 
permits more precise placement of the neurotoxin. Tables 50.2 
and 50.3 show the most common regular dilutions of Botox/
Vistabel, Xeomin/Bocoture, and the recommended equivalent 
doses for Dysport/Azzalure.

A  dose-equivalence  of  up  to  1:2.5U  between  Botox  or 
Xeomin and Dysport is adopted by the most experienced phy-
sicians in the use of both products, and is supported by recent 
studies (14,15). This dose equivalence is also inferred by com-
paring controlled studies that aimed to establish the optimal 
dose  for  glabellar  area  (16–18).  Such  studies  demonstrated 
comparable  results  and  optimal  effects  in  treating  glabellar 
wrinkles using doses of 20U of Botox (16) and 50U of Dysport 
(17,18). Hexsel and cols showed that injections of Dysport and 
Botox at the dosing ratios 2.0:1.0 U demonstrated similar field 
effects in both muscles and sweat glands. However, injections 
at  an  equivalence  ratio  of  2.5:1  U  (Dysport:Botox)  showed 
minimal differences but greater efficacy measured by diam-
eter and area of the field of anhidrotic effect for Dysport when 

460 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 50.1  Comparison of Different Commercial Preparations of BT Available in the Majority of Countries

Active substance

Botox®
100U

BT-A 

complex

(925 kD)

Suggested 

NA

Vistabel®
50U

BT-A 

complex

(925 kD)

NA

Dysport®
500 s.U

BT-A 

Dysport
300 s.U

BT-A 

Azzalure®
125 s.U

Prosigne®
100U

BT-A 

BT-A 

Xeomin®
100U

BT-A 

complex

complex

complex

complex

neurotoxin

Between 1:2 
and 1:2.5U

Between 1:2 
and 1:2.5U

Between 1:2 
and 1:2.5U

1:1

(150 kD)

1:1

equivalence for 
cosmetic uses 
(relative to 
Botox)

Mode of action: 
target protein
Pharmaceutical 

form

Reconstitution

SNAP 25

SNAP 25

SNAP 25

SNAP 25

SNAP 25

SNAP 25

SNAP 25

Lyophilized 
powder 

0.9 % NaCl 
solution

Lyophilized 
powder 

0.9 % NaCl 
solution

Lyophilized 
powder 

0.9 % NaCl 
solution

Lyophilized 
powder 

0.9 % NaCl 
solution

Lyophilized 
powder

0.9 % NaCl 
solution

Lyophilized 
powder 

0.9 % NaCl 
solution

Lyophilized 
powder 

0.9 % NaCl 
solution

Storage before 

2–8°C or 

2–8°C

2–8°C

2–8°C

2–8°C

2–8°C

25 °C

dilution
Storage after 
dilution
Shelf life 

(unopened)

Shelf life 

reconstituted

Auxiliary 

substances

24h/2–8°C

24h/2–8°C

4h/2–8°C

4h/2–8°C

4h/2–8°C

4h/2–8°C

24h/2–8°C

36 months

36 months

24 months

24 months

24 months

36 months

36 months

Up to 24h 

Up to 24h 

4–8h

4–8h

4h

4h

depending 
on country 
approval

depending 
on country 
approval

albumin 0.5 
mg /vial
NaCl 0.9 mg

albumin 0.5 
mg /vial
NaCl 0.9 mg

albumin 

albumin 

albumin 

0.125 mg 
lactose 
2.5 mg

0.125 mg 
lactose 
2.5 mg

0.125 mg 
lactose 
2.5 mg

gelatin 5 mg, 
dextran 
25 mg, and 
sucrose 
25 mg

Up to 24h 

depending 
on country 
approval

albumin 1 mg 
sucrose 
4.7 mg

pH-Wert

5–7

5–7

5–7

5–7

5–7

5–7

5–7

Toxin protein load 

5 ng/100 U

2.5 ng/50 U

5 ng/500 U

5 ng/300 U

5 ng/125 U

4–5 ng/100 U

0.6 ng/100 U

in dose-
equivalence 
range

Table 50.2  Regular Dilutions of 1, 2, and 2.5 mL for Botox®, Vistabel®/Bocoture®, and Xeomin® and equivalent dilutions to achieve a 
1:2.5U equivalence for Dysport®/Azzalure®

To achieve equivalence 
between Botox/Vistabel 
or Xeomin/Bocoture and 
Dysport/Azzalure of

If the vial of 100U 
(Botox or Xeomin) 
is usually diluted 
in

If the vial of 50U 
(Vistabel or 
Bocoture) is 
usually diluted in

The vial of 500U 
of Dysport should 
be diluted in

The vial of 300U 
of Dysport should 
be diluted in

The vial of 125U 
of Azzalure should 
be diluted in

1:2.5 U
1:2.5 U
1:2.5 U

1 mL
2 mL
2.5 mL

0.5 mL
1 mL
1.25 mL

2 mL
4 mL
5 mL

1.2 mL
2.4 mL
3 mL

0.5 mL
1 mL
1.25 mL

Table 50.3  Regular dilutions of 1, 2, and 2.5 mL for Botox®, Vistabel®/Bocoture®, and Xeomin® and equivalent dilutions to achieve a 
1:2U equivalence for Dysport®/Azzalure®

To achieve the 
equivalence between 
Botox/Vistabel or Xeomin/
Bocoture and Dysport/
Azzalure of

If the vial of 100U 
(Botox or Xeomin) 
is usually diluted 
in

If the vial of 50U 
(Vistabel or 
Bocoture) is 
usually diluted in

The vial of 500U 
of Dysport should 
be diluted in

The vial of 300U 
of Dysport should 
be diluted in

The vial of 125U 
of Azzalure should 
be diluted in

1:2 U
1:2 U
1:2 U

1 mL
2 mL
2.5 mL

0.5 mL
1 mL
1.25 mL

2.5 mL
5 mL
6.25 mL

1.5 mL
3 mL
3.75 mL

0.62 mL
1.25 mL
1.56 mL

 
compared to Botox (15). Another study from Hexsel and cols 
tested also the 1:1 dose-equivalence and showed greater diffu-
sion for Botox compared to Dysport. These studies confirmed 
that,  regarding  the  toxins,  diffusion  is  a  dose- dependent 
effect  rather  than  related  to  intrinsic  characteristics  of  each 
product (19).

Recently, an expert panel of French aesthetic physicians 
and biologists established a consensus on the clinical equiva-
lence  in  efficacy  and  safety  of  Botox  and  Xeomin.  They  con-
cluded both neurotoxins are clinically equivalent in terms of 
efficacy  and  safety,  and  that  1:1  conversion  ratio  can  be  used 
between them (20).

A recent study (21) presented similar results for the fields 
of  muscular  effect  (WSS  and  ECMAP)  between  Dysport  and 
Xeomin over time and larger FAE for Dysport compared with 
Xeomin at the 2.5:1 equivalence. The authors suggested that a 
lower dose equivalence between Dysport and Xeomin could be 
established, such as 2:1.

CONTRAINDICATIONS, PRECAUTIONS, 
AND RECOMMENDATIONS
Contraindications and/or limitations for BoNT-A are listed in 
Table 50.4. Pressure at the site before and after treatment, appli-
cation  of  cold,  and  the  use  of  small  syringes  and  fine-gauge 
needles can reduce pain and bruising at the injected sites (22). 
Hexsel and cols (23) presented a safe, economical, and effective 

Table 50.4  Contraindications for BoNT-A Injections

BOTULINUM TOXINS 

 461

tool to cool the skin for analgesic purposes. It is a single-use 
disposable  balloon  filled  with  a  frozen  solution  of  10%–20% 
isopropyl  alcohol  in  water  that  is  effective  in  reducing  pain, 
ecchymoses, and hematomas in common dermatologic proce-
dures. It is safer and more cost-effective than other tools (23).

Injections should be symmetrical regarding doses, mus-
cles, and areas. This is important for the natural balance of the 
facial structures and to avoid asymmetries. Exception includes 
evident asymmetries, such as those caused by facial palsy.

Since  the  results  are  expected  for  4  to  6  months,  treat-
ments  are  usually  repeated  twice  a  year,  for  maintenance  of 
the results. A period of 15 to 30 days for touch-ups should be 
respected.  It  is  important  to  avoid  more  than  one  touch-up 
and  respect  the  minimal  interval  of  3  to  4  months  between 
treatment sessions, due the risk of inducing the formation of 
antibodies.  However,  there  is  evidence  of  little  resistance  to 
BoNT-A  in  the  cosmetic  use  (24).  When  BoNT-A  is  injected 
adjunctively  to  some  surgical  procedures,  such  as  a  facelift, 
blepharoplasty, and laser resurfacing, some physicians prefer 
to inject in the postoperative period (25).

The  dose  to  be  injected  depends  on  the  target  muscle 
and  can  vary  from  patient  to  patient,  and  from  one  applica-
tion to another, according to patient's needs, muscle mass and 
activity  of  the  target  muscles,  gender,  and  number  of  previ-
ous treatments. The suggested doses by the consensus groups 
for Dysport (26,27)  and Botox  (28) are informed in Table  50.5 
according to the area to be treated.

Pregnancy and breastfeeding
Active infection in the proposed area
Neuromuscular transmission disorders (myasthenia gravis, Eaton-Lambert syndrome, Rooke syndrome)
Hypersensitivity to components of the BT-A injection solution (BT-A, human albumin)
Medication that influences neuromuscular transmission such as quinine, calcium channel blockers, penicillamine, aminoglycoside 

antibiotics, pancuronium, galamine, tubucurarin succinylcholine

Medication that interferes with coagulation (e.g. acetylsalicylic acid, anticoagulants, vitamin E) and coagulopathies
Candidates with unrealistic expectations, unrealistic fears of the toxin, psychiatric disorder such as psychosis, mania, body dysmorphic 

disorder, and eating disorders.

Source: Wollina U, Konrad H, Am J Clin Dermatol, 2005; 6(3):141–50.

Table 50.5  Suggested total doses of Botox or Xeomin® and Dysport® in Different Cosmetic Treatments

Botox or Xeomin

Dysport

Average Total Dose (U)

Average Total Dose (s.U)

Facial Indications

Glabellar lines

Forehead lines

Crow’s feet

Infraorbital rhytides

Bunny lines

Drooping nasal tip

Repeated nasal flare

Perioral area

Mentalis/dimpled chin

Depressor angulis oris

Gingival smile

Masseteric hypertrophy

Platysmal bands

Décolleté wrinkles

12–40

8–25

12–30

1–4

4–8

2–6

1–4

1–5

4–10

4–8

1–4

15–40

60

50–100*

*Doses suggested by the present author. Not defined by the consensus.

30–70

20–60

30–60

2–5

10–20

5–10

10–20*

4–12

10–20

10–20

5–10(48)

60 for Caucasians and 120 for Asians

Maximum dose 50 per side

75–120

 
462 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Patients  should  read  and  sign  an  informed  consent 
form  before  application,  and  photographs  should  be  taken 
before all cosmetic procedures, in order to evaluate the results. 
Photographs  must  be  taken  at  rest  and  also  with  contracted 
muscles.  Makeup  should  be  removed  and  the  skin  cleansed 
before application.

UPPER FACE
Cosmetic indications for the upper face include the treatment 
of glabellar lines, forehead lines, brow lifting, and crow's feet 
lines (26,28,29). The main cause of these wrinkles is the mus-
cular action (28); they are thus considered “expression lines.”

The direction of facial wrinkles and lines is usually per-
pendicular to the direction of the muscle fibers. The muscles of 
the upper face are intricately intertwined. In this area, location, 
muscle anatomy and muscle mass, as well as the way patients 
use  their  muscles  vary  greatly  between  individuals  (30). 
A recent study (21) showed thicker and thinner muscles pre-
sented  similar  wrinkle  severity  scores  at  baseline.  However, 
thicker muscles presented more severe wrinkles than thinner 
muscles  28  days  after  the  injections.  Authors  suggest  thicker 
muscles  may  need  higher  BoNT-A  doses  to  achieve  similar 
results of thinner muscles (21).

The frontalis m. have quite a variable anatomy and func-
tioning, being responsible for raising the eyebrows, thus caus-
ing the horizontal forehead lines. Besides being important in 
the  facial  expression,  aged  people  also  use  these  muscles  to 
amplify the visual field. Muscles controlling the frown include 
the  corrugators  m.  and  the  orbicularis  oculi  m.,  which  move 
the  brow  medially,  while  the  procerus  m.  and  the  depressor 
supercilli m. pull the brow inferiorly. The orbicularis oculi m. 
is divided into three parts, the orbital, the preseptal, and the 
pretarsal portions.

Glabellar Lines
Glabellar lines (Figure 50.1) are interpreted as presenting nega-
tive feelings, such as sadness, anger, and frustration (16,31).

A  variety  of  different  injection  techniques  and  doses 
have been reported over the years. One or two injection sites 
may  be  used  on  the  belly  of  the  procerus  m.  This  muscle 
can be treated with a single injection in the midpoint of an 

imaginary “X” formed by lines joining the inner brows and 
the contralateral inner canthus (26). If the frontalis m. is not 
treated, the middle to lateral portion of the eyebrows will be 
slightly  raised  by  the  opposing  levator  action  of  the  fronta-
lis m. (26) The conventional injection technique involves the 
observation  of  the  medial  aspect  of  the  eyebrow,  while  the 
patient  frowns.  BoNT-A  is  slowly  injected  into  the  belly  of 
each corrugator m., taking care to maintain the needle 0.5 cm 
from the upper orbital rim and internal to the midpupilary 
lines (26) (see Figure 50.2). The needle should be positioned 
perpendicularly  and  advanced  slightly  within  the  muscle 
fibers in a vertical direction toward the hairline (32).

The  total  doses  of  Botox  (28)  for  glabellar  lines  range 
from  12  to  40  U,  and  from  30  to  70  s.U  of  Dysport  (26).  The 
doses  should  be  adjusted  based  on  wrinkle  severity  and  on 
patient preference (26). Repeated injections of BoNT-A for gla-
bellar lines were shown to be safe and efficacious, and no loss 
of effectiveness or cumulative adverse effects is reported (33).

The eyebrow is a mobile structure elevated by frontalis 
m.  and  depressed  by  brow  depressors  (orbicularis  oculi  m., 
corrugator  supercilli  m.  and  procerus  m.).  Botulinum  neu-
rotoxin  type  A  treatment  for  glabellar  lines  causes  an  eleva-
tion of the medial and lateral brows (34) (Figures 50.3a and b), 
leading to a desirable arched shape and elevation of the brows 
(29) It was observed that the ideal brow shape in women is the 
lateral and medial elevation, instead of medial elevation only 
(29), whereas the rectilinear brow pattern is preferable for men. 
However, excessive elevation of the tail of the brows is undesir-
able by the majority of the patients.

Forehead Lines
The  frontal  region  should  always  be  treated  in  association 
with  the  glabellar  area  to  avoid  increased  compensatory  use 
of glabellar m., which are mainly depressors (34,35). It is also 
important  to  preserve  at  least  some  frontal  muscles  move-
ment,  responsible  for  facial  expression  and  lift  of  the  eyelids 
and brows. Since the frontalis m. are also responsible for facial 
expressiveness,  multiple  injections  of  small  doses  of  BoNT-A 
are used in  this area to create  only a  weakening  of  the mus-
cle  instead  of  a  total  paralysis,  preventing  brow  ptosis  and 
allowing  the  patient  to  maintain  some  movement  (32,36,37), 
especially  in  the  upper  part  of  these  muscles.  Besides,  injec-
tion  points  should  be  high  on  the  forehead  and  small  doses 
are  recommended  for  the  first  treatment  (32).  The  total  dose 

Figure  50.1 Glabellar  lines.  Muscles  involved:  corrugators 
and procerus.

Figure 50.2  The five-point technique for glabellar lines.

 
BOTULINUM TOXINS 

 463

(a)

(b)

(a)

(b)

(a)  Original  position  of  eyebrows,  before  treat-
Figure  50.3 
ment. (b) The same patient, showing changes in brow position 
and shape, after treatment.

(a)  Crow's  feet  wrinkles  before  treatment. 
Figure  50.4 
(b)  The  same  patient  after  treatment  with  botulinum  toxin, 
showing residual wrinkles, which may be treated with adjunc-
tive treatments.

varies from 8 to 25 of Botox (28) or Xeomin and 20 to 60 s.U of 
Dysport (26).

Periorbital or Crow's Feet Lines
The wrinkles radiate from the lateral canthus outwardly and 
laterally, and are perpendicular to the direction of the muscle 
fibers of the orbicularis oculi m. (32) (Figure 50.4a).

The total doses used to treat crow's feet lines range from  
6 to 15 U/side (28) of Botox or Xeomin and 15 to 30 s.U/side of 
Dysport (26) (Figure 50.4b). These doses are generally distrib-
uted over two or three injection sites (34), although sometimes 
four  to  five  sites  are  needed  (Figure  50.5).  A  study  showed 
no difference in safety and efficacy when the same dose was 
injected in one or three points in periocular area (38). All the 
injections must be performed at least 1 cm lateral to the lateral 
orbital rim.

Infraorbital  rhytides  (Figure  50.6)  can  be  treated  with 
intradermal injections of 0.5 to 2 U/side of Botox (28) or Xeomin 
and 1 to 2.5 s.U/side of Dysport (27), 3–4 mm below the eyelid. 
It increases the palpebral aperture and thus widens the eyes. 
It is not recommended for patients having dry eyes, prominent 
eye bags, scleral show, or morning eyelid edema (27).

Figure 50.5  Superficial injections of botulinum toxin type A 
for the treatment of crow's feet wrinkles.

 
464 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure  50.6 
rhytides and bunny lines.

Injection  sites  for  the  treatment  of  infraorbital 

MIDDLE FACE
Whereas the duration of the effects of BoNT-A injections in the 
upper face is about 3 to 4 months or longer, sometimes 6 to 8 
months (3) the duration in the middle and lower face is about 
2  to  3  months.  Technique  and  doses,  individual  differences, 
and previous treatment with BoNT-A may lead to a decreased 
duration (28).

Bunny Lines
This  is  the  most  common  indication  of  the  middle  face.  The 
levator labii superioris m. and nasal m., as well the medial por-
tion of the orbicularis oculi (39) are involved in these wrinkles. 
Nasal wrinkles, called “bunny lines” (Figure 50.6), are treated 
with low doses of BoNT-A (40). These lines may become more 
pronounced after BoNT-A injections for the treatment of gla-
bellar and periorbital wrinkles. The injection must be applied 
in the high lateral nasal wall, below the angular vein, avoid-
ing  injections  near  the  nasofacial  groove  in  order  to  prevent 
relaxation of the levator labii superioris m. which may lead to 
upper lip ptosis (40,41). The recommended dose is 1 to 4 U of 
Botox (28) or Xeomin and 5 U to 10 s.U of Dysport (27) injected 
intradermally  in  just  one  point  1  cm  above  the  upper  lateral 
part of nostril on each side. The treatment may be less effective 
in patients who recruit these muscles excessively or have had 
prior rhinoplasty (40).

Nasal Tip Droop
The  depressor  septi  nasi  m.  is  a  small  muscle  located  in  the 
external inferior base of the nasal septum, which contributes 
to the nasal tip lowering, aggravating the nasal tip ptosis that 
usually occurs with aging. Injections are done at the base of the 
columella (40). Injection of 2 to 6 U of Botox (28) or Xeomin and  
5 to 10 s.U of Dysport (27) perpendicular and deep in a single 
site at the junction of the columella and the upper lip can result 
in partial, very discrete lifting of the tip of the nose.

Repeated Nasal Flare
Some  people  present  dilate  or  rhythmic  contractions  of  the 
nostrils  on  certain  occasions,  which  may  cause  embarrass-
ment.  Injections  of  BoNT-A  are  indicated  on  each  side  in  the 
lower nasal fibers above the lateral nasal ala (40).

LOWER FACE
Lower doses of BoNT-A than those usually used in the upper 
face  are  recommended  for  the  lower  face.  Such  doses  permit 
muscle relaxation instead of paralysis of target muscles, which 
is desirable for this area (43). A recent study showed the safety 
and efficacy of full-face injections of BoNT-A also for the lower 
face indications (3).

Due to the low doses used to treat the lower face, it is rec-
ommended to inject lower face together with upper face. Care 
should be taken not to inject all areas in the lower face because 
of the increased risk of the accumulated effects and doses in 
this area, increasing the risks of side effects.

Most  of  the  muscles  of  the  lower  face  are  functionally 
related to the mouth and lips (43). In the lower face, BoNT-A is 
useful to treat a series of conditions, including perioral wrinkles, 
masseteric  hypertrophy,  “peau-d’orange”  chin  ( mentalis  m.), 
marionette lines (depressor angulis oris m.), as well as gingival 
and asymmetric smile.

Perioral Area
Photodamage, heredity, cigarette smoking, loss of deep struc-
tures and volume, sleep positions, orthodontic deformities, and 
dynamic  components  like  playing  a  musical  instrument  that 
requires embouchure, or even whistling have been thought to 
cause this aesthetic problem (40,44). Fine vertical lip rhytids are 
also caused by repetitive action of the orbicularis oris m. Tiny 
doses  of  BoNT-A  produce  localized  microparesis  of  the  orbi-
cularis  oris  m.  reducing  dramatically  perioral  lines  and  also 
giving a pleasant pseudoeversion of the lip, with enhancement 
of the vermilion contour (40).

To  define  the  injection  points,  the  patient  is  asked  to 
pucker  and  the  adjacent  areas  of  muscle  contractions  are 
marked.  It  is  recommended  to  inject  low  doses  and  superfi-
cially, above the vermilion ridge in the area of muscle contrac-
tion adjacent to the creases, away from the oral commissures 
and Cupid's bow. Injections of 1 to 5 U of Botox (28) or Xeomin 
and 4 to12 s.U of Dysport (27) divided among 4 to 6 injection 
sites  are  recommended.  Side  effects  for  this  area  are  dose-
dependent (45), and higher doses are associated to higher fre-
quency of side effects when treating this area (3).

Mentalis and Depressor Angulis Oris
Mentalis  m.  cause  wrinkles  giving  the  chin  a  dimpled  or 
“ cellulitic” aspect (Figure 50.7a). These muscles can be treated 
with one injection in the midline or two injections in each side 
of the insertion of these muscles at the point of the proeminence 
of the chin (Figure 50.7b), with good results (Figure 50.7c) (42). 
Consensus  recommendations  for  Dysport  suggest  superficial 
injections be performed to obtain satisfactory results (27). Total 
doses of 4 to 10U of Botox (28) or Xeomin and 10 to 20 s.U of 
Dysport (27) are recommended.

The  depressor  angulis  oris  m.  is  responsible  for  low-
ering  the  corner  of  the  mouth;  this  worsens  the  nasolabial 
fold, producing the called “marionette” lines and thus giving 
a negative expression to the patient (Figures 50.7b and 50.7c). 
These  muscles  can  be  treated  with  injections  of  BoNT-A  at 
the  border  of  the  jaw  bone,  at  a  point  on  an  imaginary  line 
descending  from  the  nasolabial  fold.  The  total  dose  ranges 
from 2 to 4 U/side of Botox (28,46) or Xeomin and from 5 to 
10  s.U/side  of  Dysport  (27).  Lower  lip  dysfunction  can  be 
caused when the injection is too medial and high, reaching 
the depressor labi m. (22).

 
BOTULINUM TOXINS 

 465

 zygomaticus  minor,  levator  anguli  oris,  orbicular  oris,  and 
risorius  muscles  are  also  involved.  A  classification  based  on 
area  of  gingival   exposure—anterior,  posterior,  mixed  and 
asymmetric— permits a better therapeutic approach (48).

BoNT-A injected into the levator labii superioris m. causes 
a slight to moderate drop of the upper lip, reducing the anterior 
gummy  exposure.  Doses  should  be  adjusted  according  to  the 
degree  of  gum  exposure  (48).  The  total  dose  suggested  by  the 
consensus for Botox use is 1 to 4U, but doses as high as 8U may 
be appropriate for some patients (28). A study reported the effi-
cacy of 4 to 6 U of Botox to treat gummy smile (49). The consen-
sus for the use of Dysport does not state doses for this indication 
(26).  The  total  doses  of  5  to  10  s.U  of  Dysport  to  treat  anterior 
gummy smile and maximum dose of 2.5 s.U of Dysport on each 
side to treat posterior gummy smile are suggested (48). Duration 
of effects were reported to last from 3 to 5 months (48). Results are 
less satisfactory in middle-aged and older patients, as this causes 
slight vertical elongation of the upper lip (46).

Masseteric Hypertrophy
The hypertrophy of masseter m. is a rare, asymptomatic prob-
lem of unknown cause. It can be uni- or bilateral and may also 
be  related  to  bruxism.  Usually  it  begins  during  infancy  and 
may determine a more square shape of the face.

BoNT-A can safely be considered as a noninvasive drug 
treatment for patients with masseteric m. hypertrophy (50). Its 
effectiveness is noticed as early as 2 weeks after injections and 
reached  a  peak  effect  in  3  months.  Injections  are  performed 
1 cm below and above a reference line drawn from the tragus of 
the ear to the corner of the mouth. About 44% of patients would 
complain of reduction of mastication strength (51). Although a 
previous study (52) showed that 6 months after the injections 
the  facial  contour  gradually  returned  to  the  original  shape 
and volume, Lee and cols reported that masseters treated with 
BoNT-A  maintained  significant  volume  reduction  24  weeks 
after treatment (53). The patients can be treated again every 3 to 
4 months, if needed. However, there are reports of retreatment 
each month until there is no palpable movement of the muscle 
on clenching the teeth (54). Doses can vary from 15 to 40U of 
Botox (28) or Xeomin, and up to 60 s.U of Dysport (27). Usually, 
higher doses are used in Asians (27,28).

FACIAL ASYMMETRY
Facial asymmetry is a frequent complaint and can result from 
many  different  causes,  which  determine  whether  it  will  be 
a  temporary  or  a  permanent  condition  (55,56).  Asymmetry 
occurs  when  one  of  the  bilateral  muscles  is  comparatively 
stronger  or  weaker  than  other.  Three  basic  types  of  facial 
asymmetries  have  been  described  and  result  from  different 
causes. The acquired facial asymmetry is the result of a medi-
cal or physical episode, for instance, a cerebral vascular acci-
dent.  Facial  asymmetries  can  also  be  the  result  of  iatrogenic 
causes  as  in  the  case  of  certain  types  of  surgery  on  the  face 
or accidents. A third type of facial asymmetry can be idiosyn-
cratic or familial, in which a muscle on one side of the face can 
be  comparatively  stronger  or  weaker  than  its  partner  muscle 
on the contralateral side of the face (55).

BoNT-A  can  also  be  used  to  treat  lesions  or  muscle 
hypertrophy resulting from surgical procedures or trauma, in 
order to achieve better cosmetic and functional results. Usually 
BoNT-A injections are performed on the unaffected side of hemi 
paresis, treating the hyperkinetic muscles (25). Application of 

(a)

(b)

(c)

(a) “Cellulitic” chin before treatment. (b) Treatment 
Figure 50.7 
of mentalis m. with 3 U of BoNT-A on each side. (c) Same patient 
after treatment of the mentalis m.

Gingival Smile
Gingival display is defined as the difference between the lower 
margin of the upper lip and the superior margin of the central 
incisors (47). Excessive upper gum exposure occurs when more 
than 3 mm of gingival is exposed when someone smiles and is 
called “gingival smile.”

Most  of  authors  consider  the  gingival  smile  a  conse-
quence of excessive retraction of levator labii superioris alae-
que  nasi  m.,  but  levator  labii  superioris,  zygomaticus  major, 

 
466 

 TEXTBOOK OF COSMETIC DERMATOLOGY

BoNT-A  in  the  healthy  side  of  the  face  can  improve  its  sym-
metry at rest and during facial motion, especially when smil-
ing, speaking, or exposing the teeth (57). BoNT-A can provide 
a  simple,  noninvasive  and  safe  way  of  correcting  obtrusively 
distracting asymmetry (55).

Asymmetric Smile
The  most  common  cause  of  asymmetric  smile  is  related  to 
depressor  labii  inferioris  m.  hyperkinesis  or  weakness.  The 
total doses are variable according to the patients and muscles 
to be treated. The toxin is injected into the belly of the hyper-
kinetic muscle. The results become evident in less than 5 days 
and the effects last 4 to 5 months after the first treatment. In 
subsequent treatments, it is recommended to reduce the doses 
and the results are usually longer (55).

PLATYSMAL BANDS AND 
DÉCOLLETÉ WRINKLES
Platysmas  m.  are  a  pair  of  flat  muscles  that  originate  in  the 
subcutaneous of the upper thorax, ascend laterally to the lower 
face, cross the neck, pass behind the mandible angle, and insert 
into the cutaneous muscles around the mouth (58). Platysmal 
bands are the result of the repeated and strong contractions of 
these muscles.

Platysmal bands are better visualized when the patient 
shows the lower teeth. In this indication, BoNT-A should be 
injected at various points along the length of the bands, at dis-
tances of 1–2 cm. The maximum suggested dose of Botox (28) 
or Xeomin for platysmal bands is 60 U and the consensus for 
Dysport  establishes  the  maximum  of  100  s.U  (27).  However, 
the  risk  of  complications  with  high  doses  can  exceed  the 
potential  benefits.  Goldman  and  Wollina  reported  the  injec-
tion of three to four sites with 5 U of Botox or Xeomin or 15 s.U 
of Dysport on both sides of the medial portion of the platysma 
m.  for  the  attenuation  of  the  platysmal  bands  and  elevation 
and redefinition of the angle of the mouth (59).

The  main  platysmal  bands  are  chosen  to  be  treated  in 
each  session  (usually  two  to  four  bands)  (40).  This  results  in 
improvement  of  the  appearance  of  the  bands  and  fine  wrin-
kles. In older people, it can reduce wrinkles and bands in cases 
where  surgical  lifting  is  contraindicated  or  when  there  are 
postsurgical residual wrinkles (39). Greater benefits are seen in 
patients with apparent bands, good elasticity of the skin, and 
minimal fat deposition in this area (60).

Cutaneous wrinkles in the décolleté area can be classified 
as  dynamic wrinkles,  static  wrinkles, and  combined  wrinkles. 
They  result  from  several  factors,  such  as  photoaging  (main 
cause),  intrinsic  aging,  contraction  of  the  pectoralis  major  m. 
and lower part of the platysmal bands as well as sleep position. 
Botulinum  toxin  relaxes  the  underlying  muscles,  improving 
these wrinkles (58). Doses of 2–5 U of Botox or Xeomin and 7.5–10 
s.U of Dysport can be used at each injection site in a V-shaped 
technique, being 4 to 6 sites per side. The total dose of 50–100 U of 
Botox or Xeomin and 75–120 s.U of Dysport (27) is used, improv-
ing décolleté wrinkles in selected patients in about 2 weeks (61).

ADJUNCTIVE TREATMENTS
Facial wrinkles are the result of a combination of many causes. 
Different therapeutic applications have been used throughout 
the years to give the face a youthful appearance. The combined 
use  of  BoNT-A  with  different  cosmetic  procedures  such  as 
fillers,  lasers,  light  sources  and  Subcision®  may  improve  the 

results and their duration, when compared to the same tech-
niques  used  alone,  producing  a  more  polished  and  refined 
result (62) (Figures 50.8a and b).

The aesthetic improvement in moderate to severe glabel-
lar  and  forehead  lines  can  be  effectively  achieved  with  neu-
rotoxin  alone.  However,  the  result  is  better  when  combining 
BoNT-A  with  hyaluronic  acid  fillers  (63,64).  Botulinum  toxin 
minimizes muscle contraction, allowing the filler to remain in 
place longer than when injected alone. Both frontal and glabel-
lar areas are considered dangerous areas for fillers injection.

In the perioral area, dermal fillers can be combined to 
BoNT-A to treat volume losses, a key component of perioral 
aging.  Resurfacing  techniques  can  also  be  used  in  combi-
nation  with  BoNT-A  in  this  area  (65).  The  adjunctive  use  of 
fillers  into  lip  margin  can  be  also  useful  in  gingival  smile 
treatment (40). Fractional therapies are also useful.

For  décolleté  wrinkles,  BoNT-A  can  be  combined  with 
other  techniques,  such  as  peels,  lasers,  and  surgical  lift  (58). 
A  study  showed  that  patients  may  be  treated  with  several 
nonablative lasers immediately after BoNT-A injection without 
loss of efficacy or other apparent untoward effect (66).

Although BoNT-A can be used in combination to surgi-
cal procedures, it has been shown that the combination of non-
surgical therapeutic modalities provides improvement of facial 

(a)

(b)

(a)  before  and  (b)  after  lip  augmentation  with 
Figure  50.8 
hyaluronic acid filler and botulinum toxin in the peri-oral area, 
including the orbicularis oris m. and depressor anguli oris m.

 
skin  texture,  pigmentation,  tone,  and  wrinkles,  as  well  as  an 
improvement in facial contour (67), and significantly increases 
patient satisfaction (68,69).

HYPERHIDROSIS
Hyperhidrosis  (HH)  is  a  condition  characterized  by  intense 
sweating in one or more areas of the body (70), mainly affect-
ing axilla, palms, soles, face, thigh, and inguinal area (70–72). 
HH  may  cause  significant  physical,  emotional  and/or  social 
discomfort for patients, having a considerable impact in their 
quality of life (73).

HH  occurs  due  to  the  exacerbated  perspiration  of  the 
eccrine  sweat  glands,  which  are  distributed  over  almost  the 
entire  body  surface.  There  is  a  high  density  of  these  glands  in 
some  areas  such  as  the  soles  of  the  feet  and  the  forehead,  fol-
lowed  by  the  palms  and  cheeks  (74).  The  function  of  apocrine 
and apoeccrine glands in HH is unknown, but they are believed 
to play only a minor role in the pathophysiology of the condition 
(72). Sweating is controlled by nerve fibers that, anatomically, are 
distributed through the sympathetic nervous system (75).

HH  can  be  primary,  which  is  idiopathic,  or  secondary 
to various causes. The main causes of secondary HH are high 
temperatures,  physical  exercise,  fever,  anxiety,  fear,  other 
 psychological  symptoms,  thyrotoxicosis,  lymphoma,  can-
cer,  hypoglycemia,  nausea,  neurological  lesions,  and  some 
drugs,  such  as  neuroleptics,  antidepressant  agents,  and  anx-
iolytic agents. In both cases, HH can be focal or generalized. 
Primary HH is a relatively common disorder, and it is usually 
localized and symmetrical (70).

The diagnosis is clinical and the criteria for focal forms 
of  HH  are  (71):  bilateral  and  relatively  symmetric;  impairs 
daily activities; frequency of at least one episode per week; 
age of onset less than 25 years; positive family history; ces-
sation  of  focal  sweating  during  sleep.  Some  tests  are  used 
to  visualize  (starch–iodine  or  Minor's  test),  and  quantify 
(gravimetric  test)  the  sweating.  These  tests  are  the  most 
widely  used  for  the  visualization  of  the  active  sweat  areas 
(76).  Hexsel  and  cols.  provided  suggestions  to  perform  the 
Minor's  test  and  presented  a  new  scale  (Sweating  Intensity 
Visual  Scale)  to  better  evaluate  and  interpret  Minor's  test 
results (76). Besides these methods, the Hyperhidrosis Area 
and Severity Index (HASI) has been developed to assess the 
HH  taking  into  account  not  only  the  amount  of  secretion, 

BOTULINUM TOXINS 

 467

but  also  the  size  of  the  secreting  area  (77).  Transepidermal 
water  loss  measurement  has  also  been  referred  as  a  rapid, 
practical, and reliable technique for quantifying palmoplan-
tar  sweating (78).

Several  treatments  are  used  for  HH  and  most  of  them 
cause significant adverse effects (64) or have limited efficacy in 
severe cases (75). Available treatments for HH include topical, 
medical, and surgical treatments. The Canadian Hyperhidrosis 
Committee developed guidelines that provide a recommended 
course of therapy for patients with different focal hyperhidro-
sis based on the severity of disease, which is evaluated through 
the Hyperhidrosis Disease Severity Scale (HDSS) (75).

Botulinum  neurotoxin  type  A  is  an  irreversible  inhibi-
tor  of  acetylcholine  release  from  the  presynaptic  membranes 
of  neuromuscular  junctions,  preventing  the  release  of  this 
neurotransmitter  on  the  postganglionic  sympathetic  fibers 
that act on the sweat glands (71). Since apocrine, eccrine, and 
apoeccrine glands respond to cholinergic stimuli, subcutane-
ous  injections  of  BoNT-A  into  the  sweating  regions  result  in 
complete  cessation  of  sweating  from  all  gland  types  (79).  So 
far, no anatomical differences in sweat glands have been dem-
onstrated between hyperhidrotic patients and control groups. 
But  after  BoNT-A  treatment  morphological  alterations  in  the 
glands ducts have been noticed (80).

Botulinum neurotoxin type A in the treatment of focal 
hyperhidrosis  is  considered  fast,  safe,  and  efficacious,  and 
rarely produces significant side effects (81). The application is 
usually intradermal because it targets the sweat glands, which 
are  located  2.5  mm  below  the  skin  (72).  A  recent  study  (82) 
showed that the field of anhidrotic effects (FAE) does not vary 
significantly  when  the  same  doses  in  different  dilutions  and 
depths are injected on the back of patients suffering from com-
pensatory hyperhidrosis. This study also showed that areas of 
more  intense  sweating,  like  the  midline  of  the  back,  needed 
twice the doses to achieve similar size of the FAE (82). These 
results supported the previous findings of the present author, 
who  stated  that  brand,  usual  dilutions,  and  depths  are  less 
important in the size of the FAE or “diffusion” than dose and 
amount of sweating of the treated areas (83).

Ideal  doses  have  been  focus  of  discussion,  aiming  to 
obtain  more  efficacious  and  lasting  results.  Table  50.6  lists 
some of the published articles with the proposed doses for the 
treatment  of  axillary,  inguinal,  and  palmar  HH.  The  average 
duration of effects is also reported.

Table 50.6  Proposed Doses for the Treatment of Axillary, Inguinal, and Palmar HH

Authors

Heckmann (71) 

(2001)

HH Area

Axillary

Study Design

Patients

Treatment

R, DB, PC, 

multicenter

145

200U (ABO) 

unilaterally vs. 
placebo

Placebo-treated 
side received 
100 U after 
2 weeks

Duration

26 weeks for 
both groups

Results

Similar 

reduction in 
sweating with 
200U and 
100U doses.

Naumann and Lowe 

Axillary

R, DB, PC, 

320

50 U (ONA) vs. 

Response at 

16 weeks

(84) (2001)

parallel group

placebo

week 4: 94% 
(active group) 
vs. 36% 
(placebo)
At week 16: 

82% (active) 
vs. 21% 
(placebo)

(Continued)

 
468 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 50.6  Proposed Doses for the Treatment of Axillary, Inguinal, and Palmar HH (Continued)

Authors

HH Area

Study Design

Patients

Galadari (85) (2003)

Axillary

Case series

15

Treatment

125U (ABO)

Hexsel (72) (2004)

Inguinal

Case series

26

100 U (ONA)
60 and 80U can 

be used to treat 
less severe 
cases

Duration

1–6 months

6–8 months

Results

93% of the 
patients 
showed 
anidrosis 
after 1 week

Improvement 
showed for 
inguinal HH 
for first time

Lowe (86) (2007)

Axillary

R, DB, PC, 

322

50 or 75 U (ONA) 

75% of the 

multicenter, 
parallel-group

Talarico-Filho (87) 

Axillary

DB, R, 

10

(2007)

prospective

or placebo
Retreatment if 

HDSS score of 
3 or 4 and at 
least 50 mg of 
spontaneous 
resting axillary 
sweat over 5 
minutes in each 
axilla

50 U (ONA) on 
one side and 
150U (ABO) on 
the other

subjects with 
at least 
2-point 
improvement 
in HDSS 
score at 
week 4
vs. 25% from 
placebo

6–7 months for 
the active 
group

Sweat rate 

260 days for 

decreased 
97.7% (ONA) 
and 99.4% 
(ABO)

ONA and 290 
days for ABO

Gregorious (88) 

(2010)

Palmar and 
plantar

Open label

36

100U (ONA) per 

Significant 

6.2 months

Frasson (89) (2011)

Axillary

R, SB, bilateral 

10

paired

Dressler and Adib 

Axillary

DB, intra-

51

Saberi (90) (2013)

individual 
comparison

improvement 
(assessed by 
gravimetry)

Plantar HH: 
marginal 
improvement  
in 12 patients 
and 
worsening in 
24

Both treatments 

6 months

were 
effective: 
reduction in 
sweat weight.

BoNT-B more 

effective than 
ONA

Both doses had 
similar effects

3–4 months

palm

50 U (ONA) vs. 
2500 U of 
BoNT-B 
(contralaterally)

First: 100U (ONA) 

bilaterally
Then: Direct 

comparison 
100U 
unilaterally vs. 
50U 
contralaterally; 
50U bilaterally 
(extension 
period)

Abbreviations: R, randomized; DB, double blind; SB, single blind; PC, placebo-controlled.

Although some reports refer multiples treatments do not interfere in the duration of effects (91), Lecouflet and cols suggest an 
increase in the duration of efficacy of botulinum injections with the repetition of injections (92). Glogau have described the use of 
topical applications of BoNT-A in treatment of axillary hyperhidrosis. This technique appeared to be safe and showed statistically 
significant quantitative reduction of sweat production (93).

 
COMPLICATIONS AND SIDE EFFECTS
The complications and adverse effects of the use BoNT-A are 
usually  transitory  and,  in  most  cases,  technique-dependent 
(35). There are isolated few reports of systemic adverse effects 
after BoNT-A injections with the use of doses larger than those 
usually recommended for cosmetic purposes (94).

The most common injection-related side effects are pain, 
transitory  edema,  erythema,  hematomas,  and  ecchymoses 
(35,94).  Common  technique-dependent  complications  include 
eyelid ptose, asymmetries, and excessive brow elevation.

In  the  lower  face,  the  most  common  complications  are 
related  to  high  doses  or  erroneous  application  of  BoNT-A. 
These  can  cause  undesirable  paralysis  of  the  musculature, 
resulting in asymmetric smiling and complications due to the 
incompetence of the sphincter function of the mouth (94). Some 
symptoms appear as a consequence of lip movement difficul-
ties, as in swallowing, speaking, smoking, whistling or play-
ing  wind  instruments,  involuntary  biting  of  the  tongue,  lip 
parenthesis,  filter  disappearance,  and  difficulties  in  specific 
lip  movements,  such  as  spreading  lipstick  with  the  lips  and 
involuntary  dribbling  during  speaking  (35).  Thus,  caution  is 
required  for  musicians  who  play  wind  instruments,  profes-
sional singers, speakers or actors, because of the chance to have 
difficulties with lip proprioception after treatment.

The most common complications in the treatment of the 
neck  are  dysphagia  and  difficulties  in  flexing  the  neck  and 
nodding (95).

In  some  focal  forms  of  hyperhidrosis,  some  transitory 
compromising  of  the  adjacent  musculature  can  occur  (96). 
Patients  who  perform  minutely  detailed  activities  with  the 
hands,  such  as  artisans,  pianists,  and  others,  deserve  special 
attention  (96).  Residual  areas  of  hyperhidrosis  and  asymme-
tries are also reported with the use of BoNT-A.

OTHER RECENT INDICATIONS
Recent studies showed effects of BoNT-A in other conditions 
or diseases, such as depression (97–100), rosacea (101–105), oily 
skin  and  associated  conditions  (106,107),  Raynaud’s  phenom-
enon (108–110), and inverse psoriasis (111–112). Further studies 
are needed to establish effective doses and safety.

CONCLUSION
Botulinum  neurotoxin  type  A  injections  are  safe  and  effec-
tive for a variety of therapeutic and cosmetic conditions. Facial 
wrinkles, especially those located in the upper face, and some 
asymmetries are mainly caused or worsened by the repeated 
contraction of facial muscles.

Knowledge of the anatomy of the facial muscles as well as 
the use of proper technique are mandatory to reach predictable 
results and avoid complications. Differences between products 
and patients must be considered in all BoNT-A treatments.

BoNT-A 

treatments  have  greatly  developed  and 
increased  in  the  last  few  years  with  new  potential  uses.  It  is 
nowadays one of the most performed minimally invasive pro-
cedures for skin rejuvenation.

REFERENCES

1.  Carruthers  JDA,  Carruthers  JA.  Treatment  of  glabellar  frown 
lines with C botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 
18:17–21.

2.  Ahn  CS,  Davis  SA,  Dabade  TS,  Williford  PM,  Feldman  SR. 
Cosmetic procedures performed in the United States: A 16-year 
analysis. Dermatol Surg 2013; 39(9):1351–9.

BOTULINUM TOXINS 

 469

3.  Hexsel  D,  Brum  C,  Porto  MD,  Soirefmann  M,  Siega  C, 
 Schilling-Souza  J,  et  al.  Full-face  injections  of  variable  total 
doses  of  abobotulinum  toxin  type  A:  A  randomized,  phase 
IV  clinical  trial  of  safety  and  efficacy.  J  Drugs  Dermatol  2013; 
12(12):1356–62.

4.  Cavallini M, Cirillo P, Fundarò SP, Quartucci S, Sciuto C, Sito 
G,  et  al.  Safety  of  botulinum  toxin  A  in  aesthetic  treatments: 
A  systematic  review  of  clinical  studies.  Dermatol  Surg  2014; 
40(5):525–36.

5.  Garcia  A,  Fulton  JE  Jr.  Cosmetic  denervation  of  the  muscles 
of  facial  expression  with  botulinum  toxin:  A  dose–response 
study. Dermatol Surg 1996; 22:39–43.

6.  Lamanna  C.  The  most  poisonous  poison.  Science  1959; 

130:763–72.

7.  Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular char-
acterization  of  a  novel  botulinum  neurotoxin  type  H  gene. 
J Infect Dis 2014; 209:192–202.

8.  Lebeda  FJ,  Hack  DC,  Gentry  MK.  Theoretical  analyses  of  the 
functional regions of the heavy chain of botulinum neurotoxin. 
In:  Jankovic  J,  Hallet  M,  eds.  Therapy  with  Botulinum  Toxin. 
New York: Marcel Dekker, 1994; pp. 51–61.

9.  Hexsel D, Hexsel CL, Bohn J. Long, mid, and short term effects 
of botulinum toxin on the musculature. In Hexsel D, Almeida 
AT,  eds.  Cosmetic  Use  of  Botulinum  Toxin.  Porto  Alegre:  AGE, 
2002; pp. 99–103.

  10.  Carruthers J, Carruthers A. The evolution of botulinum neuro-
toxin type A for cosmetic applications. J Cosmet Laser Ther 2007; 
9(3):186–92.

  11.  Hexsel  D,  Rutowitsch  MS,  de  Castro  LC,  do  Prado  DZ,  Lima 
MM. Blind multicenter study of the efficacy and safety of injec-
tions  of  a  commercial  preparation  of  botulinum  toxin  type  A 
reconstituted up to fifteen weeks prior injection. Dermatol Surg 
2009; 35(6):933–9.

  12.  Hexsel DM, Almeida AT, Rutowitsch M, de Castro IA, Silveira 
VL,  Gobatto  DO,  et  al.  Multicenter,  double-blind  study  of 
the  efficacy  of  injections  with  BTX-A  reconstituted  up  to  six 
consecutive  weeks  before  application.  Dermatol  Surg  2003; 
29:523–9.

  13.  Hexsel  D,  Castro  IA,  Zechmeister  D,  Almeida  do  Amaral  A. 
Multicenter,  double-blind  study  of  the  efficacy  of  injections 
with  botulinum  toxin  A  reconstituted  up  to  six  consecutive 
weeks before application. Dermatol Surg 2004; 30(5):823.
  14.  Karsai  S,  Raulin  C.  Current  evidence  on  the  unit  equivalence 
of different botulinum neurotoxin A formulations and recom-
mendations for clinical practice in dermatology. Dermatol Surg 
2009; 35:1–8.

  15.  Hexsel  D,  Brum  B,  Do  Prado  DZ,  Soirefmann  M,  Rotta  FT, 
Dal’Forno T, et al. Field effect of two commercial preparations 
of  botulinum  toxin  type  A:  A  prospective,  double-blind,  ran-
domized clinical trial. J Am Acad Dermatol 2012; 67(2):226–32.

  16.  Carruthers  JA,  Lowe  NJ,  Menter  MA,  Gibson  J,  Nordquist  M, 
Mordaunt  J,  et  al.  A  multicenter,  double-blind,  randomized, 
placebo-controlled  study  of  the  efficacy  and  safety  of  botuli-
num toxin type A in the treatment of glabellar lines. J Am Acad 
Dermatol 2002; 46(6):840–9.

  17.  Ascher  B,  Zakine  B,  Kestemont  P,  Baspeyras  M,  Bougara  A, 
Santini  J.  A  multicenter,  randomized,  double-blind,  placebo-
controlled study of efficacy and safety of 3 doses of botulinum 
toxin A in the treatment of glabellar lines. J Am Acad Dermatol 
2004; 51(2):223–33.

  18.  Monheit  G,  Carruthers  A,  Brandt  F,  Rand  R.  A  randomized, 
double-blind,  placebo-controlled  study  of  botulinum  toxin 
type  A  for  the  treatment  of  glabellar  lines:  Determination  of 
optimal dose. Dermatol Surg 2007; 33(1 Spec No.):S51–9.

  19.  Hexsel D, Hexsel C, Siega C, Souza JS, Rotta FT, Rodrigues TC. 
Fields  of  effects  of  2  commercial  preparations  of  botulinum 
toxin type A at equal labeled unit doses: A double-blind ran-
domized trial. JAMA Dermatol 2013; 149(12):1386–91.

  20.  Poulain B, Trevidic P, Clave M, Aharoni C, Baspeyras M, Bui P, 
et al. Clinical equivalence of conventional OnabotulinumtoxinA 
(900  KDa)  and  IncobotulinumtoxinA  (neurotoxin  free  from 

 
 
 
 
 
 
 
 
 
 
470 

 TEXTBOOK OF COSMETIC DERMATOLOGY

complexing proteins - 150 KDa): 2012 multidisciplinary French 
consensus in aesthetics. J Drugs Dermatol 2013; 12(12):1434–46.

  21.  Hexsel D, Soirefmann M, Porto MD, Siega C, Schilling-Souza J, 
Rodrigues TC. Fields of muscular and anhidrotic effects of two 
botulinum  toxin-a  commercial  preparations:  A  prospective, 
double-blind,  randomized,  multicenter  study.  Dermatol  Surg 
2015; 41(Suppl 1):S110–8.

  22.  Pena MA, Alam M, Yoo SS. Complications with the use of botu-
linum toxin type A for cosmetic applications and hyperhidro-
sis. Semin Cutan Med Surg 2007; 26(1):29–33.

  23.  Hexsel D, Dal'Forno T, Soirefmann M. Effective, low-cost, sim-
ple, disposable cooling tool for patient comfort in common der-
matologic procedures. Dermatol Surg 2013; 39(9):1402–4.
  24.  Naumann  M,  Boo  LM,  Ackerman  AH,  Gallagher  CJ. 
Immunogenicity  of  botulinum  toxins.  J  Neural  Transm  2013; 
120(2):275–90.

  25.  Goldman  A.  Combining  procedures  with  botulinum  toxin  in 
plastic surgery. In: Hexsel D, Almeida AT, eds. Cosmetic use of 
Botulinum Toxin. Porto Alegre: AGE, 2002; pp. 216–20.

  26.  Ascher B, Talarico S, Cassuto D, Escobar S, Hexsel D, Jaén P, et al. 
International consensus recommendations on the aesthetic usage 
of botulinum toxin type A (Speywood Unit)—Part I: Upper facial 
wrinkles. J Eur Acad Dermatol Venereol 2010; 24(11):1278–84.
  27.  Ascher  B,  Talarico  S,  Cassuto  D,  Escobar  S,  Hexsel  D,  Jaén  P, 
et  al.  International  consensus  recommendations  on  the  aes-
thetic usage of botulinum toxin type A (Speywood Unit)—Part 
II: Wrinkles on the middle and lower face, neck and chest. J Eur 
Acad Dermatol Venereol 2010; 24(11):1285–95.

  28.  Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, Wu 
Y, Vieira Braz  A,  et al. Global aesthetics  consensus: Botulinum 
toxin  type  A-evidence-based  review,  emerging  concepts,  and 
consensus recommendations for aesthetic use, including updates 
on complications. Plast Reconstr Surg 2016; Mar; 137(3):518e–529e.
  29.  Hexsel  D,  Dal’Forno  T.  Type  A  Botulinum  toxin  in  the  upper 

aspect of the face. Clin Dermatol 2003; 21:488–9.

  41.  Carruthers J, Carruthers A. The adjunctive usage of Botulinum 

toxin. Dermatol Surg 1998; 24:1244–71.

  42.  Carruthers  J,  Fagien  S,  Matarasso  SL.  Botox  Consensus 
Group.  Consensus  recommendations  on  the  use  of  botuli-
num toxin type A in facial aesthetics. Plast Reconstr Surg 2004; 
114(Suppl 6):1S–22S.

  43.  Mazzuco R. Perioral wrinkles. In: Hexsel D, Almeida AT, eds. 
Cosmetic  Use  of  Botulinum  Toxin.  Porto  Alegre:  AGE,  2002;  pp. 
158–63.

  44.  Kadunc  BV,  de  Almeida  ART,  Vanti  AA,  di  Chiacchio  N. 
Botulinum  toxin  A  adjunctive  use  in  manual  chemabrasion: 
Controlled long-term study for treatment of upper perioral ver-
tical wrinkles. Dermatol Surg 2007; 33:1066–72.

  45.  Cohen  JL,  Dayan  SH,  Cox  SE,  Yalamanchili  R,  Tardie  G. 
OnabotulinumtoxinA  dose-ranging  study  for  hyperdynamic 
perioral lines. Dermatol Surg 2012; 38:1497–505.

  46.  Carruthers  J,  Fournier  N,  Kerscher  M,  Ruiz-Avila  J,  Trindade 
de Almeida AR, Kaeuper G. The convergence of medicine and 
neurotoxins: A focus on botulinum toxin type A and its appli-
cation in aesthetic medicine: A global, evidence-based botuli-
num toxin consensus education initiative: Part II: Incorporating 
botulinum toxin into aesthetic clinical practice. Dermatol Surg 
2013; 39(3 Pt 2):510–25.

  47.  Polo  M.  Botulinum  toxin  type  A  (Botox)  for  the  neuromuscu-
lar correction of excessive gingival display on smiling (gummy 
smile). Am J Orthod Dentofacial Orthop 2008; 133(2):195–203.
  48.  Mazzuco R, Hexsel D. Gummy smile and botulin toxin: A new 
approach  based  on  the  gingival  exposure  area.  J  Am  Acad 
Dermatol 2010; 63(6):1042–51.

  49.  Suber JS, Dinh TP, Prince MD, Smith PD. OnabotulinumtoxinA 
for  the  treatment  of  a  “gummy  smile.”  Aesthetic  Surg  J  2014; 
34(3)2014–34(3)432–7.

  50.  Tartaro G, Rauso R, Santagata M, Santillo V, Itro A. Lower facial 
contouring with botulinum toxin type A. Craniofac Surg 2008; 
19(6):1613–7.

  30.  de Almeida AR, da Costa Marques ER, Banegas R, Kadunc BV. 
Glabellar  contraction  patterns:  A  tool  to  optimize  botulinum 
toxin treatment. Dermatol Surg 2012; 38(9):1506–15.

  51.  Wollina  U,  Konrad  H.  Managing  adverse  events  associated 
with botulinum toxin type A: A focus on cosmetic procedures. 
Am J Clin Dermatol 2005; 6(3):141–50.

  31.  Wieder JM, Moy RL. Understanding botulinum toxin. Surgical 
anatomy of the frown, forehead and periocular region. Dermatol 
Surg 1998; 24:1172–4.

  52.  Yu CC, Chen PK, Chen YR. Botulinum toxin a for lower facial 
contouring:  A  prospective  study.  Aesthetic  Plast  Surg  2007; 
31(5):445–51.

  32.  Benedetto AV. The cosmetic uses of botulinum toxin type A. Int 

J Dermatol 1999; 38:641–55.

  33.  Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Caird D. 
German-Austrian Retrospective Study Group. Repeated botu-
linum toxin A injections for the treatment of lines in the upper 
face: A retrospective study of 4,103 treatments in 945 patients. 
Dermatol Surg 2007; 33(1 Spec No.):S18–25.

  34.  Carruthers  A.  Botulinum  toxin  type  A:  History  and  current 
cosmetic use in the upper face. Dis Mon 2002; 48:299–322.
  35.  Hexsel D, Mazzuco R, Zechmeister M, Hexsel CL. Complications 
and  adverse  effects:  Diagnosis  and  treatment.  In:  Hexsel  D, 
Almeida AT, eds. Cosmetic use of Botulinum Toxin. Porto Alegre: 
AGE, 2002; pp. 233–9.

  36.  Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use 

in clinical dermatology. J Am Acad Dermatol 1996; 34:788–97.

  37.  Lorenc  ZP,  Smith  S,  Nestor  M,  Nelson  D,  Moradi  A. 
Understanding the functional anatomy of the frontalis and gla-
bellar  complex  for  optimal  aesthetic  botulinum  toxin  type  A 
therapy. Aesthetic Plast Surg 2013; 37(5):975–83.

  38.  Fabi  SG,  Sundaram  H,  Guiha  I,  Goldman  MP.  A  two-center, 
open-label,  randomized,  split-face  study  to  assess  the  efficacy 
and  safety  of  one  versus  three  intradermal  injection  sites  of 
abobotulinumtoxinA  in  the  treatment  of  lateral  periocular 
rhytides. J Drugs Dermatol 2013; 12(8):932–7.

  53.  Lee  DH,  Jin  SP,  Cho  S,  Feneran  A,  Youn  CS,  Won  CH,  et  al. 
Rimabotulinumtoxin  B  versus  OnabotulinumtoxinA  in  the 
treatment of masseter hypertrophy: A 24-week double-blind 
randomized split-face study. Dermatology 2013; 226(3):227–32.
  54.  Wu  WT.  Botox  facial  slimming/facial  sculpting:  The  role  of 
botulinum toxin-A in the treatment of hypertrophic masseteric 
muscle  and  parotid  enlargement  to  narrow  the  lower  facial 
width. Facial Plast Surg Clin North Am 2010; 18(1):133–40.
  55.  Benedetto  AV.  Asymmetrical  smiles  corrected  by  botulinum 
toxin serotype A. Dermatol Surg 2007; 33(1 Spec No.):S32–6.
  56.  Finn  JC.  Botulinum  toxin  type  A:  Fine-tuning  treatment  of 

facial nerve injury. J Drugs Dermatol 2004; 3(2):133–7.

  57.  Maio  M,  Bento  RF.  Botulinum  toxin  in  facial  palsy:  An  effec-
tive treatment for contralateral hyperkinesis. Plast Reconstr Surg 
2007; 120:917–27.

  58.  Hexsel  D,  Dal’Forno  T.  The  upper  trunk:  Décolleté  wrinkles 
and breast lift. In: Ascher B, Landau M, Rossi B, eds. Injection 
Treatments  in  Cosmetic  Surgery.  Informa  Healthcare:  London, 
2009; pp. 153–7.

  59.  Goldman  A,  Wollina  U.  Elevation  of  the  corner  of  the  mouth 
using  botulinum  toxin  type  A.  J  Cutan  Aesthet  Surg  2010; 
3(3):145–50.

  60.  Carruthers J, Carruthers A. Botox use in the mid and lower face 

and neck. Semin Cutan Med Surg 2001; 20:85–92.

  39.  Hexsel D, Mazzuco R, Dal’Forno T, Hexsel CL. Aplicações não-
clássicas. In: Kede MP, Sabatovich O, eds. Dermatologia Estética. 
Rio de Janeiro: Atheneu, 2003; pp. 573–81.

  61.  Becker-Wegerich  P,  Rauch  L,  Ruzicka  T.  Botulinum  toxin  A 
in  the  therapy  of  mimic  facial  lines.  Clin  Exp  Dermatol  2001; 
26(7):619–30.

  40.  Carruthers  J,  Carruthers  A.  Aesthetic  botulinum  A  toxin 
in  the  mid  and  lower  face  and  neck.  Dermatol  Surg  2003; 
29(5):468–76.

  62.  Coleman KR, Carruthers J. Combination therapy with BOTOX 
and fillers: The new rejuvenation paradigm. Dermatol Ther 2006; 
19:177–88.

 
  63.  Carruthers  J,  Carruthers  A.  A  prospective,  randomized,  par-
allel  group  study  analyzing  the  effect  of  BTX-A  (Botox)  and 
nonanimal  sourced  hyaluronic  acid  (NASHA,  Restylane)  in 
combination  compared  with  NASHA  (Restylane)  alone  in 
severe  glabellar  rhytides  in  adult  female  subjects:  Treatment 
of  severe  glabellar  rhytides  with  a  hyaluronic  acid  derivative 
compared with the derivative and BTX-A. Dermatol Surg 2003; 
29(8):802–9.

  64.  Dubina M, Tung R, Bolotin D, Mahoney AM, Tayebi B, Sato M, 
et  al.  Treatment  of  forehead/glabellar  rhytide  complex  with 
combination  botulinum  toxin  a  and  hyaluronic  acid  versus 
botulinum  toxin  A  injection  alone:  A  split-face,  rater-blinded, 
randomized control trial. J Cosmet Dermatol 2013; 12(4):261–6.

  65.  Suryadevara  AC.  Update  on  perioral  cosmetic  enhancement. 
Curr Opin Otolaryngol Head Neck Surg 2008; 16(4):347–51.
  66.  Semchyshyn  NL,  Kilmer  SL.  Does  laser  inactivate  botulinum 

toxin? Dermatol Surg 2005; 31(4):399–404.

  67.  Bosniak  S.  Combination  therapies:  A  nonsurgical  approach 
to  oculofacial  rejuvenation.  Ophthalmol  Clin  North  Am  2005; 
18(2):215–25.

  68.  Landau M. Combination of chemical peelings with botulinum 
toxin  injections  and  dermal  fillers.  J  Cosmet  Dermatol  2006; 
5(2):121–6.

  69.  Braccini  F,  Dohan  Ehrenfest  DM.  Advantages  of  combined 
therapies in cosmetic medicine for the treatment of face aging: 
Botulinum  toxin,  fillers  and  mesotherapy.  Rev  Laryngol  Otol 
Rhinol (Bord) 2010; 131(2):89–95.

  70.  Lear  W,  Kessler  E,  Solish  N,  Glaser  DA.  An  epidemiologi-
cal  study  of  hyperhidrosis.  Dermatol  Surg  2007;  33(1  Spec 
No.):S69–75.

  71.  Heckmann M, Ceballos Baumann AO, Plewig G. Hyperhidrosis 
Study  Group.  Botulinum  toxin  A  for  axillary  hyperhidrosis 
(excessive sweating). N Engl J Med 2001; 344(7):488–93.

  72.  Hexsel  DM,  Dal'Forno  T,  Hexsel  CL.  Inguinal,  or  Hexsel's 

hyperhidrosis. Clin Dermatol 2004; 22(1):53–9.

  73.  Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P, Rzany 
B.  Psychosocial  aspects  of  patients  with  focal  hyperhidrosis. 
Marked reduction of social phobia, anxiety and depression and 
increased quality of life after treatment with botulinum toxin 
A. Br J Dermatol 2005; 152(2):342–5.

  74.  Haider A, Solish N. Focal Hyperhidrosis: Diagnosis and man-

agement. Can Med Assoc J 2005; 172(1):69–75.

  75.  Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin 
M, et al. Canadian Hyperhidrosis Advisory Committee. A com-
prehensive approach to the recognition, diagnosis, and sever-
ity-based treatment of focal hyperhidrosis: Recommendations 
of the Canadian Hyperhidrosis Advisory Committee. Dermatol 
Surg 2007; 33(8):908–23.

  76.  Hexsel D, Rodrigues TC, Soirefmann M, Zechmeister-Prado D. 
Recommendations  for  performing  and  evaluating  the  results 
of Minor's Test according to a Sweating Intensity Visual Scale. 
Dermatol Surg 2010; 36(1):120–2.

  77.  Bahmer  FA,  Sachse  MM.  Hyperhidrosis  area  and  severity 

index. Dermatol Surg 2008; 34(12):1744–5.

  78.  Sakiyama  BY,  Monteiro  TV,  Ishy  A,  Campos  JR,  Kauffman  P, 
Wolosker N. Quantitative assessment of the intensity of palmar 
and  plantar  sweating  in  patients  with  primary  palmoplantar 
hyperhidrosis. J Bras Pneumol 2012; 38(5):573–8.

  79.  Lonsdale-Eccles A, Leonard N, Lawrence C. Axillary hyperhi-
drosis: Eccrine or apocrine? Clin Exp Dermatol 2003; 28:2–7.
  80.  Swartling C, Naver H, Pihl-Lundin I, Hagforsen E, Vahlquist A. 
Sweat gland morphology and periglandular innervation in essen-
tial palmar hyperhidrosis before and after treatment with intra-
dermal botulinum toxin. J Am Acad Dermatol 2004; 51(5):739–45.

  81.  Lowe  N,  Campanati  A,  Bodokh  I,  Cliff  S,  Jaen  P,  Kreyden  O, 
et al. The place of botulinum toxin type A in the treatment of 
focal hyperhidrosis. Br J Dermatol 2004; 151(6):1115–22.

  82.  Hexsel D, Soirefmann M, Porto MD, Schilling-Souza J, Siega C. 
Fields of anhidrotic effects of abobotulinumtoxinA in patients 
with compensatory hyperhidrosis. Dermatol Surg 2015; 41(Suppl 
1):S93–100.

BOTULINUM TOXINS 

 471

  83.  Hexsel  DM,  Soirefmann  M,  Rodrigues  TC,  do  Prado  DZ. 
Increasing the field effects of similar doses of Clostridium botu-
linum type A toxin–hemagglutinin complex in the treatment of 
compensatory hyperhidrosis. Arch Dermatol 2009; 145(7):837–40.
  84.  Naumann M, Lowe NJ. Botulinum toxin type A in treatment of 
bilateral  primary  axillary  hyperhidrosis:  Randomised,  paral-
lel group, double blind, placebo controlled trial. Br Med J 2001; 
323(7313):596–9.

  85.  Galadari I, Alkaabi J. Botulinum toxin in the treatment of axil-

lary hyperhidrosis. Skinmed 2003; 2(4):209–11.

  86.  Lowe NJ, Glaser DA, Eadie N, Dagget S, Kowalski JW, Lai PY. 
North  American  Botox  in  Primary  Axillary  Hyperhidrosis 
Clinical Study Group. Botulinum toxin type A in the treatment 
of primary axillary hyperhidrosis: A 52-week multicenter dou-
ble-blind, randomized, placebo-controlled study of efficacy and 
safety. J Am Acad Dermatol 2007; 56(4):604–11.

  87.  Talarico-Filho  S,  Mendonça  do  Nascimento  M,  Sperandeo  de 
Macedo  F,  de  Sanctis  Pecora  C.  A  double-blind,  randomized, 
comparative study of two type A botulinum toxins in the treat-
ment  of  primary  axillary  hyperhidrosis.  Dermatol  Surg  2007; 
33(1 Spec No.):S44–50.

  88.  Gregoriou S, Rigopoulos D, Makris M, Liakou A, Agiosofitou E, 
Stefanaki C, et al. Effects of botulinum toxin-A therapy for pal-
mar hyperhidrosis in plantar sweat production. Dermatol Surg 
2010; 36(4):496–8.

  89.  Frasson E, Brigo F, Acler M, Didonè G, Vicentini S, Bertolasi L. 
Botulinum toxin type A vs type B for axillary hyperhidrosis in 
a case series of patients observed for 6 months. Arch Dermatol 
2011; 147(1):122–3.

  90.  Dressler D, Adib Saberi F. Towards a dose optimisation of botu-
linum toxin therapy for axillary hyperhidrosis: Comparison of 
different Botox® doses. J Neural Transm 2013; 120(11):1565–7.

  91.  Doft  MA,  Kasten  JL,  Ascherman  JA.  Treatment  of  axillary 
hyperhidrosis with botulinum toxin: A single surgeon's expe-
rience  with  53  consecutive  patients.  Aesthetic  Plast  Surg  2011; 
35(6):1079–86.

  92.  Lecouflet M, Leux C, Fenot M, Célerier P, Maillard H. Duration 
of  efficacy  increases  with  the  repetition  of  botulinum  toxin 
A injections in primary axillary hyperhidrosis: A study in 83 
patients. J Am Acad Dermatol 2013; 69(6):960–4.

  93.  Glogau RG. Topically applied botulinum toxin type A for the 
treatment of primary axillary hyperhidrosis: Results of a ran-
domized, blinded, vehicle-controlled study. Dermatol Surg 2007; 
33(1 Spec No.):S76–80.

  94.  Klein  AW.  Complications  with  the  use  of  botulinum  toxin. 

Dermatol Clin 2004; 22(2):197–205.

  95.  Matarasso  SL.  Complications  of  botulinum  A  exotoxin  or 

hyperfunctional lines. Dermatol Surg 1998; 24:249–54.

  96.  Hexsel D, Hexsel CL, Dal Forno T. Complications in the use of 
botulinum toxin. In: Almeida AT, Hexsel DM, eds. Hyperhidrosis 
and Botulinum Toxin. São Paulo: Know-how Editorial Ltd. 2003; 
pp. 227–36.

  97.  Wollmer MA, de Boer C, Kalak N,  Beck J, Götz T, Schmidt T, 
et al. Facing depression with botulinum toxin: A randomized 
controlled trial. J Psychiatr Res 2012; 46(5):574–81. 

  98.  Hexsel  D,  Brum  C,  Siega  C,  Schilling-Souza  J,  Dal’Forno  T, 
Heckmann M, et al. Evaluation of self-esteem and depression 
symptoms  in  depressed  and  nondepressed  subjects  treated 
with  onabotulinumtoxinA  for  glabellar  lines.  Dermatol  Surg 
2013; 39(7):1088–96. 

  99.  Finzi E, Rosenthal NE. Treatment of depression with onabotu-
linumtoxinA: A randomized, double-blind, placebo controlled 
trial. J Psychiatr Res 2014; 52:1–6. 

  100.  Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette 
AK,  Kruger  TH,  et  al.  Treatment  of  major  depressive  disor-
der  using  botulinum  toxin  A:  A  24-week  randomized,  dou-
ble-blind,  placebo-controlled  study.  J  Clin  Psychiatry  2014; 
75(8):837–44. 

  101.  Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of 
intradermal  abobotulinumtoxinA  on  facial  erythema  of  rosa-
cea. Dermatol Surg 2015; 41 Suppl 1:S9–16. 

 
472 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  102.  Dayan  SH,  Pritzker  RN,  Arkins  JP.  A  new  treatment  regimen 
for  rosacea:  OnabotulinumtoxinA.  J  Drugs  Dermatol  2012; 
11(12):e76–9.

  103.  Park,  Hyun  MY,  Jeong  SY,  Kim  BJ,  Kim  MN,  Hong  CK. 
Botulinum toxin for the treatment of refractory erythema and 
flushing of rosacea. Dermatology 2015; 230:299–301. 

  104.  Sterodimas A, Nicolaou M, Paes TR. Successful use of botuli-
num toxin-A for the treatment of neck and anterior chest wall 
flushing. Clin Exp Dermatol 2003; 28(6):592–4. 

  105.  Yuraitis M, Jacob CI. Botulinum toxin for the treatment of facial 

flushing. Dermatol Surg 2004; 30(1):102–4.

  106.  Min  P,  Xi  W,  Grassetti  L,  Trisliana  Perdanasari  A,  Torresetti 
M, Feng S, et al. Sebum production alteration after botulinum 
toxin type A injections for the treatment of forehead rhytides: A 
prospective randomized double-blind dose-comparative clini-
cal investigation. Aesthet Surg J 2015; 35(5):600–10. 

  107.  Rose AE, Goldberg DJ. Safety and efficacy of intradermal injec-
tion of botulinum toxin for the treatment of oily skin. Dermatol 
Surg 2013; 39(3 Pt 1):443–8. 

  108.  Neumeister  MW.  Botulinum  toxin  type  A  in  the  treatment  of 

Raynaud’s phenomenon. J Hand Surg Am 2010; 35(12):2085-92. 

  109.  Zhang X, Hu Y, Nie Z, Song Y, Pan Y, Liu Y, Jin L. Treatment of 
Raynaud’s  phenomenon  with  botulinum  toxin  type  A.  Neurol 
Sci 2015; 36(7):1225–31. 

  110.  Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: A 
treatment option for digital ischemia in patients with Raynaud’s 
phenomenon. J Hand Surg Am 2009; 34(3):446–52.

  111.  Saber  M,  Brassard  D,  Benohanian  A.  Inverse  psoriasis  and 
hyperhidrosis  of  the  axillae  responding  to  botulinum  toxin 
type A. Arch Dermatol 2011; 147(5):629–30.

  112.  Zanchi  M,  Favot  F,  Bizzarini  M,  Piai  M,  Donini  M,  Sedona  P. 
Botulinum toxin type-A for the treatment of inverse psoriasis. 
J Eur Acad Dermatol Venereol 2008; 22(4):431–6.

 
51

Soft Tissue Augmentation

Kathleen Sikora Viscusi and C. William Hanke

INTRODUCTION
Throughout  the  past  several  decades,  we  have  seen  major 
changes and advancements in the injectable preparations used 
for  soft  tissue  augmentation.  Fillers  have  been  used  success-
fully for many years to improve the skin's contour and reduce 
depressions  in  the  skin  due  to  scars,  injury,  or  facial  aging. 
Examples of features that have been treated include static and 
dynamic lines of facial expression (e.g., glabellar lines, “smok-
er's”  lines,  “marionette”  lines,  forehead  lines,  “bunny”  lines, 
“crow's feet,” and nasolabial folds [NLFs]), cheek depressions, 
and  acne  scars.  However,  more  recently,  we  have  seen  the 
transition from the two-dimensional to the three-dimensional 
approach for the correction of facial aging. What was started 
by  Dr.  Arnold  Klein  in  the  1980s  with  lip  augmentation  and 
collagen has progressed to the broader concept of volumizing 
the face and the use of an arsenal of new filler materials and 
continuously evolving techniques to correct the subcutaneous 
atrophy and fat loss that are hallmarks of the aging face.

EVOLUTION OF FILLERS AND SOFT 
TISSUE AUGMENTATION
Soft-tissue augmentation can be traced back to 1893, when Neuber 
described autologous fat transfer from the arms for facial depres-
sions. In 1899, Gersuny first injected petrolatum into the scrotum 
for testicular prosthesis, and later Eckstein injected paraffin for 
fistulas, hernias, and cosmetic enhancement. With the discovery 
of the syringe, Bruning injected free fat in 1911. The use of liquid 
silicone for cosmetic purposes began in Germany, Switzerland, 
and Japan in the 1940s, and in the 1960s, the DOW Corporation 
developed  a  more  purified  medical  grade  silicone  that  gained 
popularity in the United States. However, despite initial success 
and reports of its safety in soft tissue augmentation by qualified 
medical professionals, illegal use of non–medical-grade silicone 
and  improper  injection  volumes  and  technique  continued  to 
produce  severe  adverse  reactions.  In  the  1990s  the  FDA  made 
its position on injectable silicone for aesthetic purposes clear—
injectable silicone is an unapproved medical device.

Following extensive clinical trials in the late 1970s, bovine 
collagen was first approved by the FDA in 1981. The approval of 
bovine collagen marked the beginning of a new era of soft-tissue 
augmentation. Over the past 10 years, the number of approved 
facial  fillers  in  the  United  States  and  Europe  has  grown  rap-
idly,  and  there  is  a  constantly  evolving  and  expanding  assort-
ment of filler materials and devices for soft tissue augmentation. 
Throughout  the  literature,  these  have  been  subdivided  based 
on injection level (superficial dermis, mid-dermis, deep dermis, 
and  subdermal),  derivation  (autologous,  biologic,  synthetic), 
and duration of effect, to name a few. For the purposes of this 
 chapter,  the  soft  tissue  fillers  are  categorized  as  temporary  

(~3–12  months),  long-lasting/ semipermanent  (~12  months–5 
years), and  permanent (>5 years).

TEMPORARY FILLERS
The most well established temporary fillers include bovine col-
lagen,  human  collagen,  porcine  collagen  and  hyaluronic  acid 
(HA) fillers. We only briefly overview the former three, as they 
are  either  no  longer  commercially  available  or  archaic.  The 
bulk of this section rightfully focuses on HA acid fillers.

Bovine  collagen  fillers,  Zyderm  I®,  Zyderm  II®,  and 
Zyplast® (Allergan/Inamed, Irvine, CA), were FDA approved 
in 1981 and have traditionally been considered the “gold stan-
dard”  for  fillers.  Bovine  collagen  is  composed  of  95%  type  I 
collagen and 5% type III collagen suspended in buffered saline 
and 0.3% lidocaine. Because 2%–3% of treated patients devel-
oped  localized  allergic  reactions  associated  with  injections, 
pretreatment skin testing was recommended.

The risk of hypersensitivity to bovine collagen led to the 
development of human collagen as a dermal filler, which elim-
inated  the  allergic  reactions  seen  with  the  bovine  products. 
Human  collagen,  Cosmoderm  1®  and  2®  and  Cosmoplast® 
(Allergan/Inamed, Irvine, CA), is bioengineered human colla-
gen grown from noncadaveric human tissue culture lines and 
have the same concentrations and consistency as their bovine 
counterparts.  However,  human-derived  collagen  exhibited 
a  limited  duration  of  effect  (~3–4  months)  and  different  flow 
characteristics. Their place in the market was short-lived with 
the  introduction  of  HA  fillers  only  9  months  later.  However, 
from 1981 to 2003, collagen was the only commercially avail-
able FDA-approved product in the U.S. market.

Porcine collagen, Evolence® (Colbar, Herzliya Israel), was 
approved by the FDA in 2008. It is composed of type I collagen 
derived from porcine tendons with ribose as a cross-linker. In 
contrast  to  bovine  collagen,  hypersensitivity  reactions  were 
rare  (skin  testing  was  not  required)  and  initial  findings  sug-
gested a longer duration of effect of up to 1 year. However, the 
manufacturer (Johnson and Johnson) discontinued production 
and marketing in 2009.

Hyaluronic Acid
HA is a member of the glycosaminoglycan family and a natu-
ral component of human connective tissue. The HA molecule 
is identical across all species and lacks a protein component, 
thus  it  has  little  to  no  potential  for  immunologic  reaction  in 
humans.  It  is  composed  of  repeating  disaccharide  units  sta-
bilized with cross-linked hydroxyl groups that bind water to 
create volume and plump the skin. With age and sun exposure, 
the  amount  of  HA  in  the  skin  decreases,  reducing  the  skin's 
water-binding capacity and turgor, ultimately leading to skin 

474 

 TEXTBOOK OF COSMETIC DERMATOLOGY

wrinkling  and  sagging.  HA  can  absorb  up  to  1000  times  its 
molecular  weight  in  water,  and  HA  fillers  volumize  the  face 
by  replacing  HA  and  restoring  hydration.  HA  gels  come  in 
 prepackaged syringes and do not require refrigeration

Initial  studies  establishing  the  biologic  compatibility 
and stability of HA as a filler material were pioneered in both 
a  guinea  pig  model  and  in  a  multicenter  clinical  study.  By 
varying the type of cross-linking material and its amount, the 
characteristics  of  the  gel  can  vary  in  the  degree  of  hardness, 
amount of lift, duration of effect, and resistance to degradation 
by  heat  or  enzymes.  Two  types  of  HA  filler  substances  have 
been  FDA  approved:  streptococcal-derived  fillers  or  NASHA 
(non–animal-sourced HA) gel and rooster comb–derived fillers 
(Hylaform®  and  Hylaform  Plus®  [Allergan/Inamed,  Irvine, 
CA]), with the latter being withdrawn from the market shortly 
after introduction in 2004. The first NASHA filler, Restylane® 
(Medicis, Scottsdale AZ), was approved by the FDA in 2003. The 
new NASHA formulation, produced from bacterial fermenta-
tion, was safe and effective and could be reversed with hyal-
uronidase injections if necessary. The following NASHA fillers 
are  currently  FDA-approved:  Juvederm®  Ultra,  Ultra  Plus, 
and Voluma® (Allergan Inc, Irvine, CA), Restylane/Perlane® 
(Medicis, Scottsdale, AZ), Prevelle® Silk (Mentor, Irving, TX), 
Hydrelle®  (formerly  Elevess®;  Anika  Therapeutics,  Woburn, 
MA), and Belotero® (Merz, San Mateo, CA).

Indications
HA  fillers  are  FDA  approved  for  correction  of  “moderate  to 
severe facial wrinkles and folds such as the nasolabial folds” 
(NLFs). However, they have been widely and successfully used 
for off-label volume enhancement of the vermilion lip, perioral 
area, suprabrow region, earlobes, back of hands,  prejowl sul-
cus, and tear troughs. Most recently in 2013, Juvederm Voluma 
became  the  first  HA  filler  FDA-approved  to  temporarily  cor-
rect  age-related  volume  loss  in  the  mid-face  in  adults  over 
the age of 21. Dermatologists Alam et al, Goldman et al, and 
Carruthers  et  al  have  also  explored  the  safety  and  synergis-
tic effects of combining HAs with other treatment modalities 
such as radiofrequency, intense pulsed light, and BoNT.

Application and Technique
As listed above, there are a plethora of HA fillers currently on the 
market from which to choose. The main difference among the 
various HA fillers is viscosity of the product and concentration 
of (cross-linked) HA. (Not all of the HA in a given filler is cross-
linked,  and  this  varies  among  the  products.  Non–cross-linked 
HA lubricates flow through the needle but does not contribute 
to the final correction.) In general, higher concentrations of HA 
and  larger  particle  sizes  are  associated  with  stiffer  products, 

greater capacity to lift, and longer duration of effect. However, 
multiple  variables  affect  the  performance  of   individual  fillers 
and ultimately, clinical efficacy is most  important. For instance, 
Juvederm  Voluma  consists  of  lower  molecular  weight  HA,  but 
this allows for more effective cross-linking, thus resulting in a 
more viscous product and greater lift capacity than all other HA 
fillers available currently (Table 51.1).

It  is  also  important  to  keep  in  mind  that  the  relative 
hydration  of  each  prepackaged  product  varies.  For  instance, 
Juvederm and Restylane are not fully saturated, while Prevelle 
Silk  is  maximally  saturated  with  water  in  the  syringe.  Due 
to  the  hydrophilic  nature  of  HA,  more  concentrated  and  less 
saturated products will absorb more water initially, resulting 
in  more  swelling  after  injection,  and  maintain  more  hydra-
tion after an equilibrium is reached with surrounding tissue, 
resulting in more sustained fullness in the treated area. Thus, 
overcorrection  is  not  recommended  or  necessary  with  HA 
fillers.

Combining HA fillers with lidocaine has helped improve 
tolerability. However, patient comfort is often optimized with 
local  anesthesia  or  nerve  blocks  with  injections.  Injection 
through a blunt tipped cannula also can increase tolerability 
and minimize pain, bruising, and edema. Numerous injection 
techniques  have  been  described  when  using  HA  fillers,  such 
as threading, fanning, serial puncture, cross-hatching, depot, 
layering, and the tower technique, to name a few. Further, the 
injection vehicle (cannulas and needle gauges), depth of injec-
tion, and particular brand of HA filler that is selected, as well 
as the personal preference of the physician, determine the area 
of the face to be treated.

Most commonly, HA fillers are injected into the subcu-
taneous plane. However, two newly approved NASHA fillers, 
Belotero and Juvederm Voluma, deserve special mention given 
their unique injection depths, intradermal and supraperiosteal, 
respectively.  Advocates  of  Belotero  argue  that  it  distributes 
more evenly within the dermis and optimally treats fine lines 
without  producing  the  Tyndall  effect.  And  as  noted  above, 
Juvederm Voluma is an FDA approved injectable HA filler indi-
cated for deep (subcutaneous and/or  supraperiosteal) injection 
for midface volumizing. Figures 51.1 and 51.2   illustrate some 
key injection strategies for HA fillers.

Safety and Efficacy
The safety and efficacy of currently FDA-approved HA fillers 
have  been  well  reported  in  the  literature  and  are  very  good. 
Notably, a pivotal randomized double-blind multicenter split-
face study in 138 patients first demonstrated superior efficacy 
and comparable safety of NASHA (Restylane) compared with 
collagen (Zyplast®) over 6 months. HA fillers have also shown 

Table 51.1  Total HA Concentrations and Notable Gel Properties/Particle Sizes for the Most Commonly Used, Commercially Available 
NASHA Fillers

NASHA Filler

Prevelle® Silk

Restylane®

Belotero®

Juvederm® Ultra and Ultra Plus

Juvederm® Voluma®

Perlane®

Hydrelle®

HA Concentration

5.5 mg/mL

20 mg/mL

22 mg/mL

24 mg/mL

20 mg/mL

20 mg/mL
28 mg/mL

Gel Property/Particle Size

~250 μm, maximally saturated

~260 μm

Continuous gel

Homogenized gel (variably sized particles, 

highly cohesive)

Lower molecular weight and smaller chain 

HA, highly cross-linked

~1000 μm
Contraindicated if sulfite allergy

 
SOFT TISSUE AUGMENTATION 

 475

(a)

(b)

(a,b).  Hyaluronic  acid  (HA),  tower  technique. 
Figure  51.1 
Possible  treatment  areas  (marionette  and  nasolabial)  for  HA 
fillers are outlined in red. Blue X's indicate injection sites. HA 
filler  is  injected  in  the  subcutaneous  plane  using  the  tower 
technique in this example.

(a)

(b)

a  longer  duration  than  collagen,  often  lasting  6–12  months. 
Further studies have shown that correction persists even longer 
than the expected 6–12 months when retreatment is performed 
before  dissolution  of  the  initial  treatment  product.  (Initial 
studies  of  the  newest  HA  filler,  Juvederm  Voluma,  have  sug-
gested an even longer persistence of 1 to 3 years.) Additionally, 
Dover et al compared a large-particle NASHA-based filler with 
a small-particle NASHA filler and found similar efficacy, dura-
bility, and safety profiles. Finally, Taylor et al and Grimes et al 
have established safety and efficacy of HA filler injections in 
over 300 patients with skin of color in two prospective random-
ized clinical trials.

As  reviewed  above,  HA  fillers  avidly  bind  water,  and 
adverse events are most commonly limited to redness, swell-
ing, and bruising in the days following treatment, which can 
be  mitigated  by  immediate  pressure  following  injection  and 
periodic post-op icing. To alleviate tenderness associated with 
swelling  in  the  days  that  follow  treatment,  acetaminophen  is 
preferred over NSAIDS. Arnica forte has also been reported to 

(a,b).  Hyaluronic  acid  (HA),  supraperiosteal. 
Figure  51.2 
Potential  treatment  areas  for  supraperiosteal  placement  of 
HA  (Juvederm®,  Voluma®,  or  Perlane®)  are  outlined  in  red. 
Supraperiosteal injection entry points are  indicated by the blue 
X's and blue arrow tips. The blue arrows  illustrate the recom-
mended direction of injection.

prevent bruising anecdotally, but no definitive evidence exists 
to support its efficacy.

While  HA  is  a  clear  substance,  blue  discoloration,  also 
known as the Tyndall effect, as well as lumps and nodules are 
possible if the product is placed too superficially. This may be 
corrected by dissolving the product with hyaluronidase injec-
tion.  In  addition,  an  acute  angioedema-type  hypersensitivity 
reaction  has  been  reported  with  Restylane  injection  into  the 
lip;  however,  the  incidence  of  hypersensitivity  reactions  has 
declined  dramatically  over  the  years  due  to  availability  of 
more  purified  product.  Intra-arterial  injection  is  perhaps  the 

 
476 

  TEXTBOOK OF COSMETIC DERMATOLOGY

most feared and serious complication of HA fillers; however, 
occurrences are rare. Extra care should be taken when inject-
ing  in  the  glabella  and  periorbitally,  as  risk  of  intra-arterial 
injection  is  higher  and  carries  greater  morbidity.  Moreover, 
Glogau  and  Kane  demonstrated  a  direct  correlation  between 
injector techniques such as rapid injection and higher volumes 
with the rate of local adverse events in a prospective, blinded, 
controlled study of 283 patients undergoing HA injection.

LONG-LASTING/SEMIPERMANENT 
FILLERS: 12 MONTHS TO 5 YEARS
Poly-L-Lactic Acid (Sculptra®)
Injectable poly-L-lactic acid (PLLA) has been used worldwide 
for more than a decade to treat soft-tissue lipoatrophy related 
to  aging  and  HIV-related  lipoatrophy.  Injectable  PLLA  is 
composed  of  microparticles  of  poly-L-lactic  acid  (polyglac-
tin 910), the same substance used for absorbable sutures (e.g., 
Vicryl®). PLLA was first approved in 1999 in Europe (New-
Fill®, Biotech Industry SA, Luxembourg) for soft tissue aug-
mentation of scars and wrinkles. In August 2004, injectable 
PLLA  was  approved  in  the  United  States  (Sculptra,  Dermik 
Laboratories,  Bridgewater,  NJ)  for  the  treatment  of  HIV-
associated lipoatrophy. It has been described in the literature 
as  an  “injectable  implant”  and  is  effective  in  replacing  dif-
fuse  volume  loss.  Injectable  PLLA  is  biocompatible,  biode-
gradable, and immunologically inert, thus no skin testing is 
required.

Indications
Sculptra is currently approved in the United States for correct-
ing HIV-associated facial lipoatrophy (2004) and for aesthetic 
treatment  of  lines  and  contour  deficiencies  (2009).  Injectable 
PLLA differs from other facial fillers such as HA in that it does 
not  directly  fill  in  lines  or  depressions.  It  creates  the  appear-
ance of immediate volumization due to the mechanical effects 
of  the  injected  suspension,  but  this  disappears  within  a  few 
days  as  the  suspension  fluid  is  absorbed.  The  long-lasting 
effects of injectable PLLA are seen in the months that follow as 
the PLLA microparticles degrade, inducing a fibroblastic host 
response and de novo collagen synthesis, resulting in gradual 
correction of the volume-depleted areas caused by lipoatrophy 
or age-related changes.

Application and Technique
To safely and effectively use injectable PLLA, it is imperative to 
understand facial anatomy, including location of major nerves, 
vessels, and fat pads, as well as to understand the changes that 
occur  with  aging.  Moreover,  awareness  of  the  varying  char-
acteristics  of  facial  skin  and  soft  tissue  in  different  cosmetic 
units is necessary for proper injection. Previous literature on 
this topic has highlighted the superficial and deep fat compart-
ments and associated retaining ligaments that serve as bound-
aries. Atrophy due to the loss of fat compartments contributes 
to  the  exaggerated  appearance  of  folds  and  lines  as  well  as 
contour changes in the aging face. Volumization of these com-
partments  restores  facial  contour  and  creates  a  fuller,  more-
youthful appearance.

Currently, the commercially available form of PLLA con-
sists  of  microparticles  measuring  40–63  µm  in  diameter.  The 
practical  reconstitution  recommendations  for  Sculptra  differ 
from  the  reconstitution  instructions  outlined  in  the  Sculptra 
Aesthetic  and  Sculptra  for  HIV  lipoatrophy  package  inserts. 
Reconstitution with sterile water +/– lidocaine with  epinephrine 

should be done at least 2 hours prior to injection and ideally 
24  hours  prior  to  injection  at  a  dilution  of  no  less  than  5  mL 
and  preferably  9  mL  per  vial  of  injectable  PLLA.  If  lidocaine 
with epinephrine is included in the reconstitution, we recom-
mend adding 6 mL of sterile saline at least 24 hours in advance 
and 3 mL of lidocaine with epinephrine prior to injection. (In 
our  practice,  we  have  found  that  lidocaine  with  epinephrine 
leads to less post-injection bruising and minimizes discomfort 
during injection.) After thorough hydration by reconstitution, 
the  injectable  PLLA  solution  may  be   vigorously  mixed  using 
a laboratory vortex to more evenly distribute the product and 
create a uniform suspension, decreasing the chance of nodule 
formation. With the more-dilute suspension, vigorous mixing 
using a laboratory vortex may be less important, but this has 
not  been  studied.  Just  before  injection,  the  mixed  product  is 
drawn  into  3-mL  syringes  using  an  18-G  needle,  and  a  25-G 
or 26-G needle (of length varying with personal preference) or 
25-G blunt tip cannula are often used for all injection locations 
and planes. As smaller-bore needles tend to clog easily, a mini-
mum 25-G bore size is recommend to allow adequate flow of 
product while optimizing patient comfort.

Early work by Vleggaar and Lowe helped establish the 
injection  techniques  and  demonstrated  efficacy  of  PLLA  for 
sculpting and rejuvenating the aging face. Notably, one should 
avoid intramuscular or intradermal injection, and we recom-
mend the fanning technique for deep subcutaneous injection 
(cheeks,  preauricular  areas)  and  fanning,  depot,  or  retro-
grade linear threading technique for supraperiosteal injection 
(medial maxillary area, zygomatic area, temples, prejowl sul-
cus,  chin).  After  injection,  manual  massage  is  performed  for 
5 minutes to further ensure even distribution of the product. 
Figure 51.3 (a, b) illustrates common areas of volume loss and 
associated site-specific injection techniques recommended by 
the authors when treating with injectable PLLA. 

It  is  important  to  counsel  patients  that  the  immedi-
ately  observed  effects  will  fade  over  the  following  days  as 
the injection fluid is absorbed. Moreover, overcorrection must 
be  avoided,  because  as  outlined  above,  injectable  PLLA  is  a 
progressive  collagen-stimulating  product  that  will  gradually 
volumize over the following weeks to months. Injectable PLLA 
requires multiple treatment sessions (generally 3–4) with 1–2 
vials at 4–6 week intervals to restore volume.

Safety and Efficacy
Akin to all soft tissue fillers, adverse events, such as bruising, 
edema, and erythema, may be seen. Recent retrospective and 
prospective studies have further examined the safety and effi-
cacy  of  injectable  PLLA,  including  an  extensive  cohort  study 
published by Hanke, Redbord, and Levy which explored the 
safety and efficacy of injectable PLLA for treating HIV lipoatro-
phy. Importantly, given that injectable PLLA relies on neocolla-
genesis to produce a clinical effect, results are less predictable. 
However, once effects are realized, they are long lasting, most 
often 12–24 months. Some reports suggest that PLLA may have 
a duration period of 3 years or more.

One  of  the  frequent  side  effects  of  injectable  PLLA  has 
been  product  clumping  and  formation  of  subcutaneous  nod-
ules.  Refinements  in  technique  have  led  to  greater  safety 
and  efficacy,  primarily  by  avoiding  intradermal  injections, 
by  paying  careful  attention  to  correct  injection  depth  and 
technique  according  to  anatomic  location,  particularly  peri-
orbitally and periorally, by thoroughly mixing the PLLA sus-
pension before injection, and by injecting only highly diluted 

 
SOFT TISSUE AUGMENTATION 

  477

insufficiency,  oral/maxillofacial  defects,  and  radiographic 
 tissue marking. It is a non-allergenic bioceramic that is iden-
tical  to  the  primary  mineral  constituents  found  in  bone  and 
teeth.  CaHA  has  several  properties  that  make  it  an  impor-
tant  tool  in  facial  recontouring,  including  lack  of  allergenic-
ity, long-lasting effects, and high elasticity. Radiesse contains 
microspheres of CaHA, 25 to 45 µm in diameter, in a soluble 
carboxymethylcellulose gel carrier.

After the CaHA is injected, the gel carrier is phagocytized, 
and  the  CaHA  microspheres  act  as  a  scaffold  for  autologous 
collagen synthesis. As time passes, the CaHA microspheres are 
gradually  broken  down  via  normal  metabolic  processes  into 
calcium and phosphate ions and are removed by the renal sys-
tem. New tissue deposition and collagen proliferation in com-
bination with the slow breakdown of the CaHA are responsible 
for the prolonged effects of Radiesse, often 12–18 months.

Indications
Radiesse  is  FDA-approved  for  subdermal  implantation  to 
 correct moderate to severe folds/wrinkles (e.g., NLFs) and for 
HIV  facial  lipoatrophy.  Currently,  it  is  also  widely  used  for 
volumization of facial soft tissue, including hand  rejuvenation, 
correction  of  dorsal  nasal  deformities,  chin  and  cheek 
 augmentation, jaw  recontouring, and for  volumization  of  the 
prejowl  sulcus,  among  other  uses.  It  is  not  advisable  to  use 
CaHA in the lips. Skin testing is not required prior to injection.

Application and Technique
In  2002,  Dr.  Mariano  Busso  became  the  first  dermatologist 
in the United States to explore the use of CaHA for aesthetic 
enhancement. Busso described a unique 3-dimensional vector-
ing technique to be used for filler injections. Moreover, Busso 
developed  a  series  of  safe  and  cosmetically  effective  CaHA 
injection  techniques  for  the  malar,  zygomatic,  temporal,  and 
supraciliary areas, as well as the lower face and hands. Notably, 
Busso's  hand  injection  technique  using  CaHA  represents  the 
first clinical trial to evaluate the efficacy of a soft tissue filler 
for hand rejuvenation.

Commercially  available  CaHA,  Radiesse,  is  sold  as  a 
white, sterile, semisolid gel in a 1.3-mL disposable syringe and 
can  be  stored  at  room  temperature  for  up  to  2  years.  CaHA 
premixed with lidocaine is not available. In the past, pain dur-
ing injection of CaHA was a significant limitation. However, a 
study by Busso and Voigts in 2008 showed that lidocaine can be 
added to CaHA safely without harmful changes in its physical 
properties or significant effects on the product longevity and 
clinical benefits. In 2009, a novel technique for mixing the prod-
uct  received  FDA  approval.  The  technique  involves  drawing 
up 0.2 mL of 2% plain lidocaine into a 3-mL syringe and then 
mixing this with the commercially available 1.3-mL syringe of 
Radiesse via a Luer-lock connector at least 10 times to create a 
homogeneous mixture. Further, as discussed in later commen-
tary by Busso, the addition of lidocaine to CaHA by definition 
alters the rheological properties of the filler (i.e. decreased vis-
cosity,  elasticity,  and  extrusion  force).  This  creates  more  pos-
sibilities  for  injectors  to  tailor  treatments,  as  the  rheological 
properties of the filler can be matched to the area being treated 
by adding varying amounts of a diluent such as lidocaine.

As a general rule for soft tissue fillers, the depth of the 
defect guides the depth of injection, and deeper defects are bet-
ter filled with more viscous fillers. Radiesse should be injected 
slowly in either an anterograde or retrograde  fashion into the 
deep  subcutaneous  or  supraperiosteal  planes  using  a  25-  to 
27-gauge  needle  or  cannula.  Importantly,  injectors  should  be 

(a)

(b)

(a,b). Poly-L-lactic acid (PLLA). Recommended 
Figure 51.3 
treatment areas for supraperiosteal (chin, jaw, and temple) and 
deep subcutaneous (submalar cheek and pre-auricular) place-
ment of PLLA are outlined in red. Blue X's and blue arrow tips 
indicate  needle  or  cannula  injection  points,  and  blue  arrows 
indicate direction of injection.

PLLA  suspensions.  Potential  treatments  reported  to  expedite 
nodule  resolution  in  some  cases  include  intralesional  triam-
cinolone (~40 mg/mL) and/or intralesional 5-FU (50 mg/mL). 
Fortunately, if encountered, most nodules or product clumping 
resolve spontaneously with time.

Calcium Hydroxylapatite (Radiesse®)
Injectable  calcium  hydroxylapatite  (CaHA),  also  known  as 
Radiesse  (BioForm  Medical  Inc.,  San  Mateo,  CA)  was  first 
used in 2002 and initially approved by the FDA for vocal fold 

 
478 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(a,b). Calcium hydroxylapatite (CaHA). Possible 
Figure 51.4 
treatment areas for supraperiosteal (chin, jaw, and temple) and 
deep  subcutaneous  (malar  cheek)   placement  of  CaHA  are 
outlined in red. Blue X's and blue arrow tips illustrate needle 
or cannula injection entry sites. The blue arrows indicate the 
direction of injection.

cognizant of danger zones and use extreme caution, particu-
larly if injecting the glabella (supratrochlear artery) and supe-
rior NLFs (angular artery and its branches/anastomoses), given 
the increased risk of embolization in these areas. As with other 
soft tissue fillers, a plethora of techniques have been described 
including linear retrograde, tunneling, threading, serial punc-
ture,  fanning,  and  cross-hatching,  and  often  the  technique 
utilized  is  guided  by  personal  preference  and  location  being 
treated. Overcorrection is not recommended. Areas of volume 
loss well suited for treatment with Radiesse and their associ-
ated injection techniques are shown in Figures 51.4 and 51.5

Figure 51.5  Calcium hydroxylapatite (CaHA), hand rejuvena-
tion. Treatment areas for hand volume loss are  outlined in red. 
Blue X’s indicate entry points for  cannula or needle, and blue 
arrows indicate recommended  direction of injection in subcu-
taneous plane.

Safety and Efficacy
In general, complications after treatment with injectable CaHA 
are mild and often related to technique. As CaHA requires a 
fibrotic  reaction  in  order  to  be  effective  (collagen  synthesis), 
granulomatous  reactions  and  nodules  can  be  seen.  Nodules 
are most frequently observed after lip augmentation, and thus 
CaHA is generally discouraged for correcting hypolabium. If 
encountered,  nodules  may  be  treated  with  massage,  needle 
disruption, or excision. Many also discourage the use of CaHA 
near  the  infraorbital  rim,  as  injuries  to  the  infraorbital  nerve 
may cause prolonged anesthesia and paresthesia.

The pivotal trial evaluating safety and efficacy by Smith, 
Busso,  McClaren,  and  Bass  compared  CaHA  with  human-
based  collagen  for  correction  of  NLFs.  The  randomized  con-
trolled  prospective  study  included  117  subjects  who  were 
treated with CaHA on one side and with collagen on the oppo-
site side. In this initial study, the subjects were followed up to 
6  months:  79%  had  superior  improvement  on  the  CaHA  side 
(P < 0.0001) using the Global Aesthetic Improvement Scale and 
significantly less volume was needed for optimal correction in 
the fold treated with CaHA. The adverse events were limited 
to  erythema,  edema,  and  bruising  and  comparable  between 
human-based  collagen  and  CaHA;  however,  bruising  and 
edema were more documented on the side treated with CaHA. 
One nongranulomatous nodule was observed after treatment 
with CaHA compared with three nodules seen after treatment 
with  human-based  collagen.  Subsequent  results  from  this 
same trial, including data from 99 of the original 117 subjects, 
were reported after more than 3 years, and at 30 months, 40% of 
the CaHA-treated folds were rated as “improved” or better. No 
long-term or delayed-onset adverse events were observed. Two 
additional blinded, split-face, randomized controlled trials by 
Moers-Carpi  and  colleagues  in  Europe  found  longer-lasting 
results and increased satisfaction with CaHA compared with 
HA fillers in the treatment of NLFs.

Busso  et.  al.  published  a  multicenter,  blinded,  random-
ized  clinical  trial  in  which  patients  were  treated  with  either 
CaHA  or  placebo  for  hand  rejuvenation.  They  found  statisti-
cally  significant  improvement  in  the  treatment  group,  and 
no adverse effects on hand function were noted in the study. 
Finally,  as  CaHA  is  a  normal  constituent  of  bone,  there  have 
been concerns that it may interfere with radiological imaging. 

 
Reassuringly, a study by Carruthers and co-workers found that 
while CaHA is usually visible (on CT scans more consistently 
than  on  x-rays),  it  does  not  obscure  underlying  structures, 
appears  distinct  from  surrounding  bone,  and  does  not  inter-
fere with normal analysis. In addition, the study did not find 
any  evidence  supporting  migration  of  injected  CaHA  or  evi-
dence of osteogenesis associated with deep dermal and subcu-
taneous injection.

PERMANENT FILLERS: >5 YEARS
The  comprehensive  list  of  commercially  available  injectable 
fillers,  including  those  available  outside  of  the  United  States, 
is not only too vast for the confines of this chapter, it is also a 
continuously moving target. Further, as the demand for facial 
volumization  and  rejuvenation  continues  to  grow,  the  search 
for  a  permanent,  safe,  effective,  and  cost-friendly  soft  tissue 
filler is particularly acute. An array of new classes of perma-
nent  fillers  such  as  polyacrylamide  gels,  carboxymethylcel-
lulose,  and  acrylic  acid-derived  fillers—to  name  a  few—are 
being  explored  throughout  other  parts  of  the  world,  but  are 
not FDA approved for use in the United States at this time. For 
completeness, two permanent soft tissue fillers with particular 
significance in the United States deserve brief mention: inject-
able silicone and polymethylmethacrylate (PMMA). However, 
in the opinion of the authors, in-depth knowledge of the tem-
porary and long-lasting/semipermanent soft tissue fillers dis-
cussed above is most clinically relevant and necessary for safe 
and effective facial volumization currently.

PMMA  (Artefill®;  Artes  Medical,  San  Diego,  CA),  is  a 
suspension containing 20% PMMA suspended in 80% bovine 
collagen.  It  was  FDA  approved  in  the  United  States  for  the 
correction  of  NLFs  in  October  2006,  following  earlier  use  in 
Europe and other parts of the world as Arteplast® and later 
Artecoll® in the 1990s. The carrier, bovine collagen, provides 
initial correction and is degraded over several months, leav-
ing behind the PMMA microspheres. Given the bovine com-
ponent, pretreatment skin testing is necessary. Sensitivity to 
bovine  collagen  and  animal  derivation  as  well  as  granulo-
matous reactions remain issues with injectable PMMA; how-
ever,  the  latter  has  declined  with  newer  generation  product, 
Artefill.

Injectable  silicone  is  a  synthetic,  viscous  compound 
composed of long polymers of dimethylsiloxanes with termi-
nal  trimethylsiloxane  ends.  As  reviewed  previously  in  this 
chapter, injectable silicone has been used in the United States 
since  the  1960s  but  was  never  FDA-approved  for  soft  tissue 
augmentation due to problems with product purity, misusage, 
and  tainted  public  perception  (at  least  partially  attributable 
to  controversy  surrounding  silicone  breast  implants  in  the 
1990s). Silikon-1000® (Alcon, Fort Worth, TX) is a highly puri-
fied 1000 centistoke liquid silicone oil FDA approved in 1994 
for  treatment  of  retinal  detachment.  Under  the  FDA's  mod-
ernization  act  of  1997,  injectable  silicon  such  as  Silikon-1000 
can legally be used “off-label,” including usage for soft tissue 
augmentation  and  other  aesthetic  purposes.  Some  derma-
tologists use Silikon-1000 for the treatment of HIV-associated 
facial lipoatrophy, acne scars, and to correct age-related sub-
cutaneous  atrophy  and  fat  loss.  The  safety  and  efficacy  of 
highly  purified  injectable  silicone,  such  as  Silikon-1000,  is  a 
point  of  controversy  between  its  critics  and  advocates  and 
remains  highly  debated.  More  objective  data  and  long-term 
studies  are  needed  to  elucidate  the  proper  space  injectable 
silicone should occupy in the expanding world of soft tissue 
fillers.

SOFT TISSUE AUGMENTATION 

  479

REFERENCES AND FURTHER READING

1. Alam  M,  Gladstone  H,  Kramer  EM,  Murphy  JP,  Nouri  K, 
Neuhaus  IM,  et  al.  ASDS  guidelines  of  care:  Injectable  fillers. 
Dermatol Surg 2008; 34:S115–48.

2. Alam  M,  Levy  R,  Pajvani  U,  Ramierez  JA,  Guitart  J,  Veen  H, 
et al. Safety of radiofrequency treatment over human skin pre-
viously  injected  with  medium-term  injectable  soft-tissue  aug-
mentation  materials:  A  controlled  pilot  trial.  Lasers  Surg  Med 
2006; 38:205–10.

3.  Bartus C, Hanke CM, Daro-Kaftan E. A decade  of  experience 
with  injectable  poly-l-lactic  acid:  A  focus  on  safety.  Dermatol 
Surg 2013; 39;698–705.

4.  Bass  LS,  Smith  S,  Busso  M,  McClaren  M.  Calcium  hydroxyl-
apatite (Radiesse) for treatment of nasolabial folds: Long-term 
safety and efficacy results. Aesthetic Surg J 2010; 30:235–8.

5.  Brody  HJ.  Use  of  hyaluronidase  in  the  treatment  of  granulo-
matous hyaluronic acid reactions or unwanted hyaluronic acid 
misplacement. Dermatol Surg 2005; 31:893–7.

6.  Busso M. Additional commentary on “addition of lidocaine to 

fillers.” Dermatol Surg 2010; 36:1795–6.

7.  Busso  M,  Karlsberg  P.  Cheek  augmentation  and  rejuvenation 
using  injectable  calcium  hydroxylapatite  (Radiesse).  Cosmet 
Dermatol 2006; 19:583–8.

8.  Busso  M,  Moers-Carpi  M,  Storck  R,  Ogilvie  P,  Ogilvie  A. 
Multicenter,  randomized  trial  assessing  the  effectiveness 
and  safety  of  calcium  hydroxylapatite  for  hand  rejuvenation. 
Dermatol Surg 2010; 36:790–7.

9.  Busso  M.  Vectoring  approach  to  facial  recontouring  using 
calcium  hydroxylapatite  (Radiesse)  and  hyaluronic  acid 
(Restylane). Cosmet Dermatol 2009; 22:522–8.

  10.  Busso  M,  Voigts  R.  An  investigation  of  changes  in  physical 
properties of injectable calcium hydroxylapatite in a carrier gel 
when  mixed  with  lidocaine  and  with  lidocaine/epinephrine. 
Dermatol Surg 2008; 34(suppl 1):S16–23; discussion S4.

  11.  Carruthers  A,  Carruthers  J,  Monheit  GD,  Davis  PG,  Tardie  G. 
Multicenter,  randomized,  parallel-group  study  of  the  safety 
and effectiveness of onabotulinumtoxinA and hyaluronic acid 
dermal  fillers  (24-mg/mL  smooth  cohesive  gel)  alone  and  in 
combination for lower facial rejuvenation. Dermatol Surg 2010; 
36(Suppl):2121–34.

  12.  Carruthers  J,  Carruthers  A.  A  prospective,  randomized,  par-
allel  group  study  analyzing  the  effect  of  BTX-A(Botox)  and 
nonanimal  sourced  hyaluronic  acid  (NASHA,  Restylane)  in 
combination compared with NASHA (Restylane) alone in severe 
glabellar rhytides in adult female subjects: Treatment of severe 
glabellar  rhytides  with  a  hyaluronic  acid  derivative  compared 
with the derivative and BTX-A. Dermatol Surg 2003; 29:802–9.

  13.  Carruthers J, Carruthers A. Soft Tissue Augmentation: Procedures 

in Cosmetic Dermatology Series. Elsevier Health Sciences, 2012.
14. Carruthers J, Klein AW, Carruthers A, Glogau RG, Canfield D. 
Safety and efficacy of nonanimal stabilized hyaluronic acid for 
improvement of mouth corners. Dermatol Surg 2005; 31:276–80.

15. Carruthers A, Liebeskind M, Carruthers J, et al. Radiographic 
and computed tomographic studies of calcium hydroxylapatite 
for treatment of HIV-associated facial lipoatrophy and correc-
tion of nasolabial folds. Dermatol Surg 2008; 34(suppl 1):S78–84
16. Carruthers J, Rzany B, Sattler G, Carruthers A. Anatomic guide-
lines  for  augmentation  of  the  cheek  and  infraorbital  hollow. 
Dermatol Surg 2012; 38:1223–33.

  17.  Dover JS, Carruthers A, Carruthers J, Alam M. Clinical use of 

Restylane. Skin Therapy Lett 2005; 10:5–7.

  18.  Dover JS, Rubin MG, Bhatia AC. Review of the  efficacy, dura-
bility, and safety data of two nonanimal stabilized hyaluronic 
acid  fillers  from  a  prospective,  randomized,  comparative, 
 multicenter study. Dermatol Surg 2009; 35(Suppl):322–31.

19. Duffy  DM.  Complications  of  fillers:  Overview.  Dermatol  Surg 

2005; 31:1626–33.

  20.  Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety 
data of injectable nonanimal stabilized hyaluronic acid gel for 
soft tissue augmentation. Dermatol Surg 2002; 28:491–4.

 
 
 
 
 
 
 
 
480 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  21.  Glogau  RG,  Kane  MA.  Effect  of  injection  techniques  on  the 
rate  of  local  adverse  events  in  patients  implanted  with  non-
animal  hyaluronic  acid  gel  dermal  fillers.  Dermatol  Surg  2008; 
34(Suppl):S105–9.

  22.  Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK. 
Tissue  response  and  in  vivo  degradation  of  selected  polyhy-
droxyacids: Polylactides (PLA), poly(3-hydroxybutyrate) (PHB),  
and   poly(3-hydroxybutyrate-co-3-hydroxyvalerate)  (PHB/VA). 
J Biomed Mater Res 1993; 27:1135–48

  23.  Goldman MP, Alster TS, Weiss R. A randomized trial to deter-
mine the influence of laser therapy, monopolar radiofrequency 
 treatment,  and  intense  pulsed  light  therapy  administered 
immediately  after  hyaluronic  acid  gel  implantation.  Dermatol 
Surg 2007; 33:535–42.

  24.  Grimes PE, Thomas JA, Murphy DK. Safety and effectiveness of 
hyaluronic acid fillers in skin of color. J Cosmet Dermatol 2009; 
8:162–8.

  25.  Hanke CW. Evolution of filler materials in dermatology. J Am 

Acad Dermatol 2013; 68:858–9.

  26.  Hanke CM, Moy RL, et al. Current status of surgery in derma-

tology. J Am Acad Dermatol 2013; 69(6):972–1001.

  27.  Hanke  CW,  Redbord  KP.  Safety  and  efficacy  of  poly-L-lactic 
acid  in  HIV  lipoatrophy  and  lipoatrophy  of  aging.  J  Drugs 
Dermatol 2007; 6:123–8.

  28.  Hanke  CW,  Rohrich  RJ,  Busso  M,  Carruthers  A,  Carruthers  J, 
Fagien S, et al. Facial soft-tissue fillers conference: Assessing the 
state of the science. J Am Acad Dermatol 2011; 64(Suppl):S66–85, 
S85e1–136.

  29.  Hexsel D, Soirefmann M, Porto MD, Siega C, Schilling-Souza J, 
Brum C. Double-blind, randomized, controlled clinical trial to 
compare safety and efficacy of a metallic cannula with that of a 
standard needle for soft tissue augmentation of the nasolabial 
folds. Dermatol Surg 2012; 38:207–14.

  30.  Jones D. Volumizing the face with soft tissue fillers. Clin Plastic 

Surg 2011; 38:379–90.

  31.  Levy  RM,  Redbord  KP,  Hanke  CW.  Treatment  of  HIV  lipoat-
rophy  and  lipoatrophy  of  aging  with  poly-L-lactic  acid:  A 
prospective  3-year  follow-up  study.  J  Am  Acad  Dermatol  2008; 
59:923–33.

  32.  Lowe NJ. Dispelling the myth: Appropriate use of poly-l-lactic 
acid  and  clinical  considerations.  J  Eur  Acad  Dermatol  Venereol 
2006; 20:2–6.

  33.  Moers-Carpi  MM,  Tufet  JO.  Calcium  hydroxylapatite  versus 
nonanimal  stabilized  hyaluronic  acid  for  the  correction  of 

nasolabial folds: A 12-month, multicenter, prospective, random-
ized, controlled, split-face trial. Dermatol Surg 2008; 34:210–5.

  34.  Moers-Carpi  M,  Vogt  S,  Santos  BM,  et  al.  A  multicenter,  ran-
domized trial comparing calcium hydroxylapatite to two hyal-
uronic  acids  for  treatment  of  nasolabial  folds.  Dermatol  Surg 
2007; 33(suppl 2):S144–51.

  35.  Narins RS, Brandt FS, Dayan SH, Hornfeldt CS. Persistence of 
nasolabial fold correction with a hyaluronic acid dermal filler 
with  retreatment:  Results  of  an  18-month  extension  study. 
Dermatol Surg 2011; 37:644–50

  36.  Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A 
randomized, double-blind, multicenter comparison of the effi-
cacy and tolerability of Restylane versus Zyplast for the correc-
tion of nasolabial folds. Dermatol Surg 2003; 29:588–95.

  37.  Narins RS, Dayan SH, Brandt FS, Baldwin EK. Persistence and 
improvement of nasolabial fold correction with nonanimal-sta-
bilized  hyaluronic  acid  100,000  gel  particles/mL  filler  on  two 
retreatment schedules: Results up to 18 months on two retreat-
ment schedules. Dermatol Surg 2008; 34(Suppl):S2–8.

  38.  Piacquadio  D.  Crosslinked  hyaluronic  acid  (hylan  gel)  as  a 
soft  tissue  augmentation  material:  A  preliminary  assessment. 
In:  Elson  ML,  ed.  Evaluation  and  Treatment  of  the  Aging  Face. 
New York:  Springer-Verlag, 1995; pp. 304–8.

  39.  Piacquadio D, Jarcho M, Goltz R. Evaluation of hylan b gel as a 
soft tissue augmentation implant material. J Am Acad Dermatol 
1997; 36:544–9.

  40.  Rohrich RJ, Pessa JE. The fat compartments of the face: Anatomy 
and  clinical  implications  for  cosmetic  surgery.  Plast  Reconstr 
Surg 2007; 119:2219–27.

  41.  Smith S, Busso M, McClaren M, Bass LS. A randomized, bilat-
eral,  prospective  and  multi-center  comparison  of  calcium 
hydroxylapatite microspheres in gel versus human-based  col-
lagen for the correction of nasolabial folds. Dermatol Surg 2007; 
33(Suppl):S112–21.

  42.  Taylor  SC,  Burgess  CM,  Callender  VD.  Safety  of  nonanimal 
stabilized  hyaluronic  acid  dermal  fillers  in  patients  with  skin 
of  color:  A  randomized,  evaluator-blinded  comparative  trial. 
Dermatol Surg 2009; 35(Suppl):1653–60.

  43.  Vleggaar  D.  Facial  volumetric  correction  with  injectable 

 poly-L-lactic acid. Dermatol Surg 2005; 31:1511–8.

  44.  Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy 
DK. A multi-center, double-blind, randomized controlled study 
of the safety and effectiveness of Juvederm injectable gel with 
and without lidocaine. J Cosmet Dermatol 2009; 8:205–10.

 
52

Bioelectricity and Its Application in Cosmetic Dermatology

Ying Sun and Jue-Chen Liu

INTRODUCTION
The interest in using electricity to treat ailment has a very long 
history.  The  electric  torpedo  fish  was  used  to  shock  people 
to  treat  headache  and  gout  over  two  centuries  ago  (1).  The 
 importance of the electrical control of cell physiology became 
apparent  from  the  famous  experiments  of  Galvani.  His  epic 
work  on  frog  nerve–muscle  preparations  included  the  use  of 
lightning rods connected to nerves via wires resulting in leg 
muscles  twitching  during  a  lightning  storm.  Similarly,  static 
electricity  generators  creating  sparks  that  activated  nerve 
 conduction  also  caused  muscle  to  twitch.  Equally  important 
was  his  observation  during  a  public  experiment  in  Bologna 
in  1794  that  the  cut  end  of  a  frog  sciatic  nerve  from  one  leg 
 stimulated  contractions  when  it  touched  the  muscles  of  the 
opposite leg.

Collectively,  these  experiments  provided  definitive 
 evidence  for  “animal  electricity”  or  bioelectricity,  i.e.,  the 
 electricity  generated  by  biological  systems.  In  addition,  with 
this last experiment, Galvani had demonstrated the  existence 
of  the  injury  potential.  An  injury  potential  is  a  steady,  long-
lasting  direct  current  voltage  gradient  induced  within  the 
 extracellular  and  intracellular  spaces  by  current  flowing 
into  and  around  an  injured  nerve.  This  discovery  predated 
the   finding  of  the  better  known  action  potential,  which  is  a 
rapid,   self-regenerating  voltage  change  localized  across  the 
cell  membrane (2). In parallel with Galvani's work, Volta was 
 developing these ideas to create the first battery.   Recognizing 
the  parallel  with  animal  electricity,  Volta  used  batteries 
 therapeutically  to  treat   deafness.  Others,  however,  were  less 
rigorous  scientifically  in  the  promotion  of  electrical-based 
therapies.

For  more  than  a  century  there  was  widespread  and 
 irrational  use  of  galvanism  and  static  electricity.  Static 
 electricity generators were in common use and were  promoted 
and sold because they created an allegedly beneficial “electric 
air bath” or a “negative breeze.” The electric air bath involved 
charging the patient and using a grounded electrode to draw 
sparks  from  a  chosen  part  of  the  body.  The  negative  breeze 
allegedly  was  helpful  in  treating  insomnia,  migraine,  and 
baldness.  With  the  electrode  polarity  reversed,  a  “positive 
breeze” was used to treat kidney disease (2).
Naturally  occurring  electric  currents  at  human  skin  wounds 
were measured by the German physiologist Emil Du Bois-Rey-
mond over 160 years ago. As a founder of  modern electrophysi-
ology, he documented in detail the electric  activities associated 
with nerve excitation, muscle contraction, and wounds. While 
electric activities in the nervous system and muscles are pre-
vailing concepts in science, however, the wound electric fields 
have  remained  very  poorly  understood  and  largely  ignored 
until  recently.  Modern  technologies,  such  as  vibrating  probe, 

glass and platinum microelectrodes have been used to confirm 
and  provide  significant  understanding  of  the  wound  electric 
fields.

less  well 

 understood 

Therapeutic  applications  of  electrotherapy  may  be 
 generally  grouped  into  two  areas:  electric  neurostimulation 
and biomimetic electric stimulation. Electric  neurostimulation 
applications  are  well  known  and  relatively  well  studied. 
 Electric  neurostimulation  devices  can  either  be  implanted 
inside the body such as pacemaker, or be applied to the skin 
 surface  such  as  transcutaneous  electric  nerve   stimulation 
(TENS) devices. While better mechanistic  understanding has 
been  achieved  with  electric  neurostimulation   applications, 
is  the  biomimetic  electric 
much 
 stimulation  that  utilizes  very  low  electric  potential  and 
 current  intensity  for  tissue   healing  and  regeneration.  In 
 contrast  to  electric   neurostimulation,  the  micro-amperage  of 
electricity used in biomimetic electric stimulation is  typically 
below  the  threshold  of  human  sensory  detection,  which  is 
in  the  similar  magnitude  of  body's  own  bioelectricity,  hence 
the  terminology  biomimetic  electric 
 stimulation.  While 
 electric   neurostimulation  offers  a  surprisingly  wide  range 
of   therapeutic  applications  and   possibilities,  the  potential 
of  electric  biomimetic   stimulation  is  equally  promising  due 
to  its   tissue  regenerative  ability.   Historically,  there  has  been 
periodic  interest  in  the   bioelectricity  and  use  of   biomimetic 
 electricity  for  therapeutic  applications.  However,  due  to  the 
separate  research  paths  between   biophysics  and  modern 
 cellular  biology and molecular biology, a knowledge gap exists 
between the biophysical and biochemical research.

It  is  well  known  that  the  levels  of  electric  current 
 intensities  affects  induced  biological  responses  (3).  There  are 
some general thresholds (as approximate reference points) cor-
responding to different tissue responses to  electrical  current. 
The  passage  of  a  high  electrical  current  (>  100  mA–200  mA) 
through the human body may result in serious injury or  tissue 
damage  such  as  cardiac  excitation,   fibrillation,  or  electri-
cal  burns.  If  greater  than  1000  mA,  the  electric   current  may 
cause  defibrillation  or  even  fatality.  Low  to  moderate  electri-
cal  currents (1–20 mA) are generally considered safe and have 
been  applied  to  patients  for  neuron  stimulation  for  a  wide 
variety of therapeutic applications (Figure 52.1) (3– 5). When an 
ultra-low electrical current (10–1000 µA) is applied to a patient, 
the electrical stimulation of the skin tissue  cannot be perceived 
by the patient because it is below the sensory detection thresh-
old  of  the  skin.  Nevertheless,  the  biological  responses  of  the 
tissue under the treatment are as profound as, if not more than, 
the neurostimulation by  commonly known electrotherapeutic 
modalities. Therefore, the focus of this chapter is on less com-
monly known ultra-low  microampere electrical stimulation of 
tissues and its potential applications to cosmetic dermatology.

482 

 TEXTBOOK OF COSMETIC DERMATOLOGY

10–1000 µA

1–10 mA

10–20 mA

100–200 mA

> 1000 mA

Low
Perception
  -Increase blood
   circulation
  -Enhance drug
   penetration

Moderate
Strong nerve
stimulation to
pain
  - TENS

High
Cardiac
excitation to
fibrillation

High

Very High
Defibrillation

Low

Ultra-Low
Below perception
  -Enhance
   metabolism &
   tissue repair
  -Enhance drug
   penetration
  -Enhance
    collagen
    production

Figure  52.1  Different  electrical  current  intensities  produce  different  biological  responses.  Ultralow  electric  current  intensity 
in  the  range  of  10  to  500  mA  is  known  to  have  regenerative  activity,  whereas  higher  current  intensities  in  1  to  20  mA  have  
neuron-stimulation  activity.  Above  certain  thresholds  of  electric  current  intensities,  adverse  effects  such  as  cardiac  excitation, 
fibrillation, or defibrillation may occur. (Note: these electric current intensities only serve as approximate reference points rather 
than precise threshold values.)

It should be noted that bioelectricity is low-level  electric 
potential  or  current  generated  by  the  biological  systems, 
whereas biomimetic electricity is a similar magnitude of  current 
generated  externally  to  mimic  the  levels  of   bioelectricity. 
 Scientists  have  devoted  significant  effort  to  investigating  the 
role of bioelectricity in healing, regeneration, and other effects 
as  well  as  to  develop  devices/delivery  systems  to  generate 
 biomimetic electricity for biological applications.

TRANSCUTANEOUS  ELECTROTHERAPY 
AND DELIVERY ENHANCEMENT 
Transcutaneous  electrotherapy  is  one  of  the  fundamental 
 elements of physiotherapy practice and sports medicine with 
widespread  applications  including  TENS,  and   interferential 
current, as well as microcurrent therapy for pain control and 
wound healing. Electrical devices and battery-powered patches 
are  used  for  topical  or  transdermal  drug   administration  via 
iontophoresis,  and  electrical  stimulation  in  various  medical 
practices  such  as  pain  and  chronic  wound  management  (6,7) 
and dermatology (8,9).

Ultra-Low Intensity Electricity Therapy
It  has  been  reported  that  direct  electric  currents  ranging 
from 10 μA to 1000 μA increase ATP concentrations in the tis-
sue and stimulate amino acid incorporation into the proteins 
of  rat  skin.  Minimum  current  intensities  of   approximately  
50  μA  are  necessary  to  obtain  a  maximal  stimulatory  effect 
on  protein   synthesis.  When  higher  currents  at  a  range  above 
1000 μA are applied, the current failed to increase ATP  levels 
 significantly.  These  stimulatory  effects  are  maintained  to  a 
level of approximately 1000 μA (10). The application of  specific 
low  intensity   currents  for  the  metabolic  effects  imply  a  new 
area for  exploration. The amino acid transport through the cell 
membrane, followed by the α-aminoisobutyric acid uptake, is 
 stimulated between 100 μA and 750 μA. The stimulatory effects 
on  ATP   production  and  on  amino  acid  transport,   apparently 
 mediated  by   different  mechanisms,  contribute  to  the  final 
increased   protein  synthesizing  activity,  DNA   metabolism 
 followed  by  thymidine  incorporation  remains  unaffected 
during  the  course  of  current  application.  The  effects  on  ATP 
 production can be explained by proton movements on the basis 

of  the   chemiosmotic  theory  of  Mitchell,  while  the   transport 
 functions  are  controlled  by  modifications  in  the  electrical 
 gradients across the membranes.

Microcurrent treatment was reported to be more  effective 
than  conventional  therapy  for  chronic  Achilles   tendinopathy 
in a randomized comparative trial (11). The healing processes 
of tendon tissue remain to be explored.

BIOELECTRICITY
Biological  systems  including  human  body  has  its  own 
innate  electrical  system.  For  example,  the  innate  electrical 
system in the human body regulates the body's functions via 
communication among organs through the well-known neural 
system, and some less understood cellular activities such as the 
bioelectricity  associated  with  tissue  regeneration  (12).  When 
injured, the body generates a low level wounding electricity to 
facilitate the healing process, e.g., human skin generates up to 
10 µA/cm2 of outward bioelectric current during healing, and 
common signaling pathways are able to steer cell movement in 
both electrical and chemical gradients (13,14).

Most  recently  developed  microneedle  arrays  are  able 
to  measure  the  transdermal  skin  potentials  at  multiple  sites 
simultaneously.  Bio-Electric  Imager®  detects  and  visualize 
electric  potential  at  skin  surface  without  direct  skin  contact, 
which will be discussed in detail in a later section.

The measurable bioelectricity during the wound  healing 
process has been described as the endogenous “skin battery” 
that pumps sodium ions from the exterior the epithelium to the 
interior using the Na/K-ATPase located on the basal  surface of 
epidermal  cells  together  with  Na+  channels  on  the  pical  sur-
face with an outward electric current of about 10–100 μA/cm 
and an electric potential gradient about 60 mV/mm around the 
wound  (1).  The  bioelectric  field  and  current  can  be  detected 
within about 0.5–1 mm from the edge of the wound and last 
until  the  wound  is  re-epithelialized  (2).  For  an  intact  epithe-
lium (or skin), because of the Na+ transported inwards is not 
completed  balanced  out  by  anion  movement,  an  excess  of 
positive charge accumulated results in positive potential of the 
epithelium  membrane,  i.e,  transepithelial  potential  as  shown 
in  Figure  52.2.  However,  if  the  epithelium  is  perforated  by 
a  wound,  as  shown  in  Figure  52.2,  the  potential  drives  the 

 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 483

V
m
0
7
+

d
n
u
o
W

Electric
field
(EF)

Stratum corneum

Epidermis

Dermis

Ion  transport  (predominantly  inward  transport 
Figure  52.2 
of  Na)  properties  of  mammalian  skin  result  in  a  substantial 
transepithelial  electric  potential  (TEP)  of  about  70mV,  which 
establishes an injury current (curved arrows) upon wounding 
and an electric field within the subepithelial tissues (horizontal 
arrow).  In  this  case,  the  return  path  for  the  current  is  in  the 
layer  between  the  dead,  cornified  stratum  corneum  and  the 
living epidermis. (Modified from McCaig CD et al., Physiol Rev; 
85:943–78, 2005.)

 current  flow  through  the  newly  formed  low  resistance  path, 
generating an electric filed with the negative pole at the wound 
and the positive under the unbroken epithelium or skin sur-
rounding the wound which behaves just like a  battery. Hence 
the term “skin battery” which is sometimes used to describe 
the  bioelectricity  phenomena  influencing  healing  of  a  skin 
wound.

As  mentioned  earlier,  endogenous  DC  electric  fields 
occurring naturally during skin injury was first demonstrated 
in wounds by Emil DuBois-Reymond over 150 years ago. He 
measured electric currents flowing out of a cut he made in his 
own finger. In recent studies with various modern techniques 
such as micro-glass electrodes and vibrating probes,  scientists 
confirmed  a  similar  electric  current  flow  in  wounds  in  both 
the skin and cornea of several species, including human skin 
(14). In cornea and skin, a laterally oriented, wound-induced 
 electric field is generated instantaneously when the  epithelium 
is damaged, and it persists until  re-epithelialization restores 
the  electrical  resistance  barrier  function  of  the  epithelium. 
These electric fields are estimated to be at least 40–50 mV mm–1 
at cornea wounds and 100–150 mV mm–1 at skin wounds (2). 
Growing  experimental  evidence  suggests  an  important  role 
for such electric signals in directing cell migration in wound 
healing.

Endogenous  DC  electric  fields  have  also  been  mea-
sured during development and regeneration and after dam-
age  to  non-epithelial  tissues.  These  EFs  arise  because  of 
spatial  and  temporal  variations  in  epithelial  transport  of 
charged ions such as Na+, K+, and Cl–, and spatial variations 
in  the  electrical  resistance  of  epithelial  sheets.  Disruption 
of  the  endogenous  electrical  gradients  during  development 
induces  skeletal  and  neural  abnormalities.  For  example, 
it  has  been  reported  that  the  spinal  cord  responds  to  dam-
age  by  generating  large  and  persistent  electrical  signals. 
Consequently,  externally  applied  electric  stimulation  of 
 physiological   magnitude  can  promote  spinal  cord  repair  in 
human and other mammals (21,23).

It is now generally accepted that there are endogenous 
electric fields, and disruption of these electric fields disrupts 
wound  healing.  Research  has  been  conducted  into  cellular 
response  to  electric  fields  for  several  decades.  Among  the 
 various  signals  hypothesized  to  guide  cell  migration  and 

 division  in  development  and  wound  healing,  electric   signals 
have  not  been  well  studied.  The  biological  and   medical 
research community generally is not familiar with the  possible 
roles  of  electric  fields  as  a  directional  signal  in  guiding  cell 
migration  to  heal  a  wound.  The  lack  of  rational  explanation 
for the mechanism of bioelectricity on tissue regeneration has 
led to skepticism, especially when modern molecular biology 
and  electrophysiology  has  taken  different  approaches  to  the 
phenomenon, and few researchers are really at home in both 
fields (1).

It  has  been  repeatedly  demonstrated  by  in  vitro 
 experiments  that  electric  fields  of  strength  similar  to  those 
measured  in  vivo  dictate  important  cell  behaviors  such  as 
directional  cell  migration  and  cell  division  orientation.  Zhao 
et  al.  (13)  provides  further  experimental  evidence  that  the 
electric  signal  as  a  directional  cue  probably  plays  a  far  more 
important  role  in  directing  cell  migration  in  wound  healing 
of   epithelium  than  previously  believed,  and  two  genes  are 
important  for   electric  field-induced  cellular  response.  It  was 
shown  that   polarized  phosphatidylinositol  3-kinase  (PI3K) 
 signaling steers the migration of human cells across a  gradient 
of  electric  potential,  a  process  called  electrotaxis.  The  lipid 
 phosphatidylinositol 3,4,5-triphosphate (PIP3) appears to be a 
pivotal molecule. It is concentrated at the leading edge of the 
cell,  where  signaling  components  bind  to  it.  These   signaling 
components,  in  turn,  lead  to  the  localized   polymerization  of 
actin  and  the  formation  of  a  protrusion  in  the  direction  of 
 migration (14). Figure 52.3 shows a promyelocytic cell with its 
leading edge labeled with a probe that detects PIP3  production. 
The narrow arrows at the top left show the gradient of electric 
potential  in  which  the  cells  are  migrating.  The  wide  arrows 
show  the  direction  of  cellular  movement.   Reversal  of  the 
polarity of the electric field is followed by a change in locale 
of PIP3 to a region that becomes the new leading edge, shown 
as arrowheads.

RECENT SCIENTIFIC ADVANCES IN 
APPLICATIONS OF  BIOELECTRICITY/ 
BIOMIMETIC ELECTRICITY
The application of biomimetic electrical stimulation  similar to 
the body's own bioelectricity has been used to achieve  clinical 
efficacy,  particularly  in  healing  enhancement  of  chronic 
wounds (15–17), as well as to perform various in vitro and in 
vivo  investigation on cellular activities in order to result in the 
effects  of  physiological  level  of  electricity  on  tissues   (18–26) 
or  to  utilize  its  powder  for  tissue  engineering  (27).  It  was 
reported  that  the  biomimetic  electric  field  appeared  to  play 
an   important  role  in  controlling  human  fibroblast  activity  by 
either   significantly  increasing  or  decreasing  gene  expression 
of  over  400  transcripts  investigated,  including  activity  within 
specific  cellular signaling pathways such as TGF-β, G-proteins, 
and inhibition of apoptosis.

BIOELECTRICITY OF THE SKIN WOUNDS 
AND ITS CONNECTION TO SKIN AGING
The  epidermis  generates  a  transepithelial  potential  (TEP)  of 
20–50 mV across itself, inside positive. Any wound or break in 
the epidermis creates a low resistance pathway and the TEP at 
the wound site is 0 mV. However the TEP of the intact  epidermis 
around the wound is still present, resulting in a  lateral  voltage 
gradient or electric field along the skin surrounding the wound. 
There  is  evidence  that  this  lateral  electric  field   stimulates 

 
484 

 TEXTBOOK OF COSMETIC DERMATOLOGY

–

+

0s

+

–

440s

Cell moving
toward
negative pole

–

+

Polarity
reversed

+

–

105s

170s

+

–

460s

New leading
edge formed

+

–

490s

New leading
edge forming after
pole reversal

Cell moving
toward
negative pole

Figure  52.3  The  effect  of  electric  signal  in  directing  the  migration  of  human  keratinocyte  cell  in  wound  healing.  It  shows  a 
 promyelocytic cell with its leading edge labeled with a probe that detects PIP3 production. The narrow arrows at the top left show 
the gradient of electric potential in which the cells are migrating. The wide red arrows show the direction of cellular movement. 
Reversal of the polarity of the electric field is followed by a change in locale of PIP3 to a region that becomes the new leading edge 
shown by blue arrowheads. (Modified from Huttenlocher A, Horwitz AR, N Engl J Med; 356:303 –4, 2007.)

 keratinocytes in the area to migrate toward the wound, with 
the optimal response occurring at field strength of 100 mV/mm.  
To determine the actual fields strength at the edge of human 
wounds,  Nuccitelli  et  al.  (27,28)  developed  a  new  instrument 
that  vibrates  a  small  sensor  perpendicular  to  the  skin  about 
100  micrometers  above  the  surface  and  uses  the  oscillating 
capacitance  signal  to  determine  the  surface  potential  of  the 
epidermis  just  beneath  the  stratum  corneum.  By  measuring 
this  surface  potential  in  many  positions  around  the  wound, 
a  spatial  map  of  the  surrounding  electric  field  was  gener-
ated. Based on an ultrasensitive vibrating probe technique for 
measuring extracellular currents (27), a sensitive noninvasive 
bioelectric  field  imager  developed  by  Nuccitelli  et  al.  (28)  as 
shown in (Figure 52.4), and was use to measure the bioelectric 
wound  current  in  vivo  in  mice.  A  more  detailed  description 
of  the  vibrating  probe  equipment  setup  and  technique  was 
given  by  Reid  et  al.  (29).  A  noninvasive  instrument  based  on 
the principle of vibrating probe (bioelectric field imager [BFI]) 
was  used  for  mapping  the  electric  field  between  the  epider-
mis and the stratum corneum near wounds in both mouse and 
human  skin  (28).  Rather  than  touching  the  skin,  the  vibrat-
ing  probe  vibrates  a  small  metal  probe  with  a  displacement 
of 180 micrometers in air above the skin to detect the surface 
potential of the epidermis through capacitative coupling. The 
application of the vibrating probe device was demonstrated by 
measuring the electric field between the stratum corneum and 
epidermis at the margin of skin wounds in mice (Figure 52.5). 
An electric field of 177 +/– 14 mV/mm was measured immedi-
ately  upon  wounding  and  the  field  lines  pointed  away  from 
the wound in all directions around it. Because the wound cur-
rent flows immediately upon wounding, this is the first signal 
 indicating skin damage. This electric field is generated at the 

outer surface of the epidermis by the outward flow of the cur-
rent of injury. An equal and opposite current must flow within 
the  multilayered  epidermis  to  generate  an  intra-epidermal 
field with the negative pole at the wound site. Because the cur-
rent flowing within the multilayered epidermis is spread over 
a larger area, the current density and subsequent E field gener-
ated in that region is expected to be smaller than that measured 
by the BFI beneath the stratum corneum. The field beneath the 
stratum  corneum  typically  remained  in  the  150–200  mV/mm  
range  for  3  days  and  then  began  to  decline  over  the  next 
few  days,  falling  to  zero  once  wound  healing  was  complete. 
 Figure  52.6  shows  the  bioelectric  field  imager  scans  of  the 
mouse skin wounds over time. It can be seen that wounding 
resulted in the development of wound electric potential, which 
persisted until the wound closed at day 3. Nuccitelli et al. (30) 
also  demonstrated  that  the  wounding  electric  field  can  be 
modified  by  topically  applied  pharmacological  agents.  The 
mean wound field strength decreased by 64 +/– 7% following 
the  application  of  the  sodium  channel  blocker,  amiloride,  to 
the skin near the wound and increased by 82 +/– 21% following 
the application of the Cl– channel activator, prostaglandin E2. 
This  experimental  evidence  suggests  that  both  sodium  ion 
influx and chloride ion efflux are maintaining the TEP of the 
skin and are carrying the wound current.

Recently, a similar bioelectric field imager, a commercially 
available DermaCorderTM (BioElectroMed, Berlingame, CA) was 
used to measure human skin's wound current in two test sub-
ject groups to investigate the role of endogenous  electric fields 
in wound healing of young and old human subjects (30). The 
lateral surface wound field was measured between the stratum 
corneum and epidermis near a lancet wound on the arm and 
leg in 40 adults by DermaCorder as shown in Figure 52.7. Ten 

 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 4 85

Scanning direction

Wound

EF

–40
–20
0mV
20
40

–400

0
400
Y distance (µm)

20

0

–20

20

0

–20

–40

20

0

–20

–40

0

–20

)
V
m

(

l

a
i
t
n
e
t
o
p
e
c
a
f
r
u
S

Before wounding

1 mm
Time 0

1 mm
2 days

1 mm
3 days

Figure  52.6  Bioelectric  field  imager  (BFI)  scans  of  skin 
wounds over time. Mouse skin wound scanned before and at 
the indicated times after wounding. The precise region that was 
scanned  is  indicated  by  the  dotted  lines  on  the  micrographs. 
Pink bar on the BFI scan indicates the location of the wound. 
(Modified from Nuccitelli R et al., Wound Rep Reg; 14:432–41, 
2008.)

Connector

BEI Kimco
Linear Voice
Coil

Holding Springs

Sensor

(a)

(b)

Figure  52.4  Bioelectric  field  imager  (BFI)  vibrator  and 
 motorized  manipulator.  (a)  Diagram  of  the  vibrator  using  a 
voice  coil  (BEI  Kimco  LA  16-27-000A,  Vista,  California).  The 
vibrator assembly incorporates two springs to hold the probe 
in  place  when  the  voice  coil  is  not  powered.  (b)  Photograph 
of motorized manipulator used to position BFI above a wound 
in  mouse  skin.  An  adjustable  mouse  platform  maintained  at 
378C is shown on the lower left and the cylinder above it is the 
vibrator.  (Modified  from  Nuccitelli  R  et  al.,  Wound  Rep  Reg; 
14:432–41, 2008.)

d
n
u
o
W

EF

–40
–20
0
20
40

0

–40

)
V
m

(

l

a
i
t
n
e
t
o
P
e
c
a
f
r
u
S

–80

0

X distance

4

with  wound  healing  among  elderly.  On  the  other  hand,  it  is 
 conceivable that if an external electric potential of physiological 
magnitude of electric would to apply on the wounds of these 
elderly to bring it to the level of the wound electric potentials 
among the younger subjects, the wound healing rates of these 
elderly might be enhanced.

1

2
Y distance (mm)

3

SCANNING DIRECTION

Figure  52.5  Common  field  profile  for  wounds  with  a  signifi-
cant break in the epidermis. (Modified from  Nuccitelli R et al., 
Wound Rep Reg; 14:432–41, 2008.)

women and ten men in the 18–29-year-old age group exhibited 
a mean electric field of 16359 mV/mm. Ten women and ten men 
in the 65–80 age range exhibited a mean field of 7815 mV/mm.  
Therefore  the  mean  electric  field  of  individuals  in  the  older 
age group is only half that of the younger group (Figure 52.8). 
Since  the  wound  electric  potential  is  linked  with  the  healing, 
the  reduced  wound  electric  potential  may  be  a  contributing 
 factor  to  the  well-known  decreased  healing  rate  associated 

CELLULAR EFFECTS OF  ELECTRICITY 
OF PHYSIOLOGICAL MAGNITUDE
In  a  well-cited  study,  Cheng  et  al.  (10)  reported  an  in  vitro 
study  to  examine  the  cellar  effects  of  low  intensity  direct 
electric  current  on  freshly  excised  rat  skin.  Direct  electric 
currents  ranging  from  10  µA  to  1000  µA  increased  ATP  con-
centrations  about  500%  in  the  tissue  and  stimulated  amino 
acid incorporation into the proteins of skin tissues. Minimum 
current  intensities  of  approximately  50  µA  were  necessary 
to  obtain  a  maximal  stimulatory  effect  on  protein  synthesis. 
The  amino  acid  transport  through  the  cell  membrane,  fol-
lowed  by  the  α-aminoisobutyric  acid  uptake,  was  stimulated 
between  100  µA  and  750  µA.  The   stimulatory  effects  on  ATP 
 production and on amino acid  transport, apparently mediated 

 
 
 
 
 
486 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 52.7  The DermaCorder™, a commercially available vibrating probe device, was used to measure wound electric potential 
by Nuccitelli et al. to investigate the effect of age on wound electric potentials in human subjects. (From Nuccitelli R et al., 18th 
Annual Meeting of the Wound Healing Society, San Diego, CA, April 24– 27, 2008. With permission.)

)

m
m
/
V
m

l

(
d
e
i
f
c
i
r
t
c
e
e
d
n
u
o
W

l

20 males and females 18–29 years old
20 males and females 65–80 years old

250

200

150

100

50

0

Arm control

Leg control

Arm wound

Leg wound

Figure 52.8  Ten women and ten men in the young group (18–29 years) exhibited a mean electric field of 16359 mV/mm, which 
is twice as much as the mean field of 7815 mV/mm exhibited by the 10 women and 10 men in the old group (65–80 years). (From 
Nuccitelli R et al., 18th Annual Meeting of the Wound Healing Society, San Diego, CA, April 24– 27, 2008. With permission.)

by   different  mechanisms,  contributed  to  the  final  increased 
protein  synthesizing  activity,  DNA   metabolism  followed  by 
thymidine  incorporation  remained  unaffected  during  the 
course  of  current  application.  The  highest  stimulatory  effects 

were obtained with 50 µA to 1000 µA, with glycine incorpora-
tion  increased  by  as  much  as  75%  compared  with  nontreated 
controls. Higher  current  intensities, exceeding 1000 µA, inhib-
ited the protein  synthesis by as much as 50% with currents of 

 
      
 
 
 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 487

15,000 µA.  Constant  currents from 100 µA to 500 µA increased 
the  transported  amino  acid  analog  by  30%–40%  above  con-
trol  levels.  Stimulation  with  higher  intensities  reduced  the 
α-aminoisobutyric  acid  uptake.  The  effects  on  ATP  produc-
tion can be explained by proton movements on the basis of the 
chemi-osmotic  theory  of  Mitchell,  while  the  transport  func-
tions are controlled by modifications in the electrical gradients 
across  the  membranes.  During  the  course  of  normal  wound 
healing, fibroblasts at the wound edge are exposed to electric 
fields ranging from 40 to 200 mV/mm. Various forms of electric 
fields influence fibroblast migration, proliferation, and protein 
synthesis.  Thus,  electric  fields  may  contribute  to  fibroblast 
activation during wound repair. To elucidate the role of elec-
tric fields during the normal progression of healing, Jennings 
et  al.  (20)  compared  gene  expression  in  normal  adult  dermal 
fibroblasts  exposed  to  a  100  mV/mm  electric  field  for  1  hour 
to non-stimulated controls. Significantly increased expression 
of 162 transcripts and decreased expression of 302 transcripts 
was detected using microarrays, with 126 transcripts above the 
level  of  1.4-fold  increases  or  decreases  compared  to  the  con-
trols.  Above  the  level  of  twofold,  only  11  genes  were  signifi-
cantly increased or decreased compared to controls. Many of 
these significantly regulated genes are associated with wound 
repair through the processes of matrix production, cellular sig-
naling, and growth. Activity within specific cellular signaling 
pathways is noted, including TGF-β, G-proteins, and inhibition 
of apoptosis. In addition, RT-PCR analysis of the expression of 
KLF6, FN1, RGS2, and JMJD1C over continued stimulation and 
at different field strengths suggests that there are specific win-
dows of field characteristics for maximum induction of these 
genes. EFs thus appear to have an important role in controlling 
fibroblast activity in the process of wound healing.

Endogenous  electric  fields  are  generated  lateral  to  skin 
wounds, with the cathodal pole of the field residing in the center 
of the wound. These fields are thought to be an important mech-
anism in guiding the migration of keratinocytes and other cells 
into wounds to effect healing. Sillman et al. (25) studied human 
dermal  fibroblasts  exposed  to  direct  current  electric  fields  of 
physiological strength, and quantified their migrational behav-
ior. It was observed that human dermal fibroblasts only moved 
randomly, not directionally, in direct-current electric fields under 
conditions that support the directional migration of human epi-
dermal keratinocytes. Additionally, neither the presence of the 
serum nor the serum plus additional Mg++ in the experimental 
medium supported the directional migration. Migratory rates of 
fibroblasts varied depending on the experimental medium used: 
in  serum-containing  medium  the  average  velocity  was  as  low 
as 0.23 µm/min, while in serum-free keratinocyte medium the 
average velocity was as high as 0.36 µm/min. These studies sug-
gest that dermal fibroblasts do not respond to the endogenous 
electric field of a wound, and use other migratory cues to direct 
their movement into the wound bed.

Directional cellular locomotion is thought to involve local-
ized  intracellular  calcium  changes  and  the  lateral  transport  of 
cell  surface  molecules.  Brown  et  al.  (26)  examined  the  roles  of 
both calcium and cell surface glycoprotein redistribution in the 
directional migration of two murine fibroblastic cell lines, in con-
trast to human dermal fibroblast result reported by Sillman et al. 
(25) and directional migration of NIH 3T3 and SV101. These cell 
types exhibit persistent, cathode-directed motility when exposed 
to  direct  current  electric  fields.  Using  time  lapse  phase  con-
trast microscopy and image analysis, we have determined that 
electric field-directed locomotion in each cell type is a calcium 

independent  process.  Both  exhibit  cathode-directed  motility  in 
the  absence  of  extracellular  calcium,  and  electric  fields  cause 
no  detectable  elevations  or  gradients  of  cytosolic  free  calcium. 
Based on the evidence, the authors suggested that galvanotaxis 
in these cells involves the lateral redistribution of plasma mem-
brane glycolproteins. Electric fields cause the lateral migration of 
plasma membrane concanavalin A receptors toward the cathode 
in both NIH 3T3 and SV101 fibroblasts. Exposure of direction-
ally migrating cells to Con A inhibits the normal change of cell 
direction following a reversal of electric field polarity. Addition-
ally, when cells are plated on Con A-coated substrata so that Con 
A receptors mediate cell-substratum adhesion, cathode-directed 
locomotion and a cathodal accumulation of Con A receptors are 
observed. Immunofluorescent labeling of the fibronectin recep-
tor in NIH 3T3 fibroblasts suggests the recruitment of integrins 
from large clusters to form a more diffuse distribution toward 
the cathode in field-treated cells. It was concluded that the mech-
anism of electric field directed locomotion in NIH 3T3 and SV101 
fibroblasts  involves  the  lateral  redistribution  of  plasma  mem-
brane glycol-proteins involved in cell substratum adhesion.

Sun  el  al.  (31)  reported  keratocyte  fragments  and  cells 
utilizes  competing  pathways  to  move  in  opposite  directions 
in  an  electric  field.  Sensing  of  an  electric  field  by  cells— 
galvanotaxis—is  important  in  wound  healing,  development, 
cell  division,  nerve  growth,  and  angiogenesis.  Different  cell 
types migrate in opposite directions in electric fields, and the 
same  cell  can  switch  the  directionality  depending  on  condi-
tions.  A  tug-of-war  mechanism  between  multiple  signaling 
pathways  can  direct  Dictyostelium  cells  to  either  cathode  or 
anode.  Mechanics  of  motility  is  simplest  in  fish  keratocytes. 
Keratocyte fragments are the simplest motile units. Cell frag-
ments  from  leukocytes  are  able  to  respond  to  chemotactic 
signals,  but  whether  cell  fragments  are  galvanotactic  was 
unknown.  It  was  found  that  keratocyte  fragments  are  the 
smallest motile electric field- sensing unit: they migrate to the 
anode, in the opposite direction of whole cells. Myosin II was 
essential  for  the  direction  sensing  of  fragments  but  not  for 
parental cells, while PI3 kinase was essential for the direction 
sensing of whole cells but not for fragments. Thus, two signal 
transduction  pathways,  one  depending  on  PI3K,  another  on 
myosin, compete to orient motile cells in the electric field. Gal-
vanotaxis is not due to electric field force and does not depend 
on  cell  or  fragment  size.  It  was  proposed  that  a  “compass” 
model according to which protrusive and contractile actomyo-
sin  networks  self-polarize  to  the  front  and  rear  of  the  motile 
cell, respectively, and the electric signal orients both networks 
toward cathode with different strengths.

Allen  et  al.  (32)  reported  the  electrophoresis  of  cellu-
lar  membrane  components  creates  the  directional  cue  guid-
ing  keratocyte  galvanotaxis.  The  key  findings  of  their  study 
include: (a) no evidence of asymmetric ion flow into the cell as 
the galvanotactic sensor, (b) cells move in the direction of fluid 
flow, but this is not required in galvanotaxis, (c) the charge and 
mobility of membrane components are critical to galvanotaxis, 
and (d) a PI3K-dependent pathway exists that transduces this 
polarization to the cytoskeleton.

BONE REGENRATION  INFLUENCED 
BY ELECTRIC FIELDS
Sundelacruz et al. (33) investigated bioelectric modulation of 
wound healing in a three-dimensional (3D) in vitro model of 
tissue-engineered bone. Long-standing interest in bioelectric 

 
488 

 TEXTBOOK OF COSMETIC DERMATOLOGY

regulation of bone fracture healing has primarily focused on 
exogenous stimulation of bone using applied electromagnetic 
fields. Endogenous electric signals, such as spatial  gradients 
of  resting  potential  among  non-excitable  cells  in  vivo,  have 
also  been  shown  to  be  important  in  cell  proliferation,  dif-
ferentiation,  migration,  and  tissue  regeneration,  and  may 
therefore  have  as  yet  unexplored  therapeutic  potential  for 
regulating wound healing in bone tissue. To study this form 
of bioelectric regulation, there is a need for 3D in vitro wound 
tissue models that can overcome limitations of current in vivo 
models. We present a 3D wound healing model in engineered 
bone tissue that serves as a preclinical experimental platform 
for  studying  electrophysiological  regulation  of  wound  heal-
ing.  Using  this  system,  we  identified  two  electrophysiology-
modulating  compounds,  glibenclamide  and  monensin,  that 
augmented  osteoblast  mineralization.  Of  particular  interest, 
these compounds displayed differential effects in the wound 
area compared to the surrounding tissue. Several hypotheses 
are proposed to account for these observations, including the 
existence of heterogeneous subpopulations of osteoblasts that 
respond  differently  to  bioelectric  signals,  or  the  capacity  of 
the  wound-specific  biochemical  and  biomechanical  environ-
ment to alter cell responses to electrophysiological treatments. 
These data indicate that a comprehensive characterization of 
the  cellular,  biochemical,  biomechanical,  and  bioelectrical 
components  of  in  vitro  wound  models  is  needed  to  develop 
bioelectric  strategies  to  control  cell  functions  for  improved 
bone regeneration.

OTHER TISSUES/ORGANS AFFECTED 
BY ELECTRIC FIELDS
Cao  et  al.  (34)  studied  polarizing  intestinal  epithelial  cell 
 electrically  through  the  tyrosine  protein  kinase  transmem-
brane  receptor  Cor2,  and  found  that  the  endogenous  electric 
field created by the transepithelial potential difference might 
act  as  an  essential  coordinating  signal  for  apical  membrane 
formation  at  a  tissue  level,  through  activation  of  the  serine/
threonine  kinase  LKB1  (also  known  as  STK11)  mediated  by 
Ror2-ERK  signaling.

Microorganisms  also  response  to  electric  fields.  Rudell 
et  al.  (35)  reported  migration  of  Acanthamoeba,  a  parasite,  in 
an electric field. Acanthamoeba keratitis is a serious and debili-
tating,  sight-threatening  infection  of  the  cornea.  Acantham-
oeba  organisms  have  been  found  widely  in  our  environment, 
including contaminated contact lens solutions, bottled water, 
public water supplies, freshwater lakes, and air, and the preva-
lence of Acanthamoeba infections has risen rapidly in the past 
few decades. The authors found that Acanthamoeba trophozo-
ites  move  directionally  in  response  to  an  EF  in  a  2D  and  3D 
culture  system.  Acanthamoeba  trophozoite  migration  is  also 
voltage-dependent, with increased directionality with increas-
ing  voltage.  This  may  provide  new  treatment  modalities  for 
Acanthamoeba keratitis.

BIOELECTRICITY AND SKIN PIGMENTATION 
Wounding  skin  generates  endogenous  electric  fields  of  
100–200 mV/mm in the immediate vicinity of the wound. When 
keratinocytes are exposed to direct current electric fields of this 
magnitude,  they  exhibit  galvanotaxis,  or  directional  migration 
toward  the  cathode,  suggesting  that  wound-generated  electric 
fields provide migrational cues that contribute to wound healing. 
Because melanocytes must also migrate into the healing wound 

to repigment it, their motility in response to electric fields of phys-
iologic magnitude of was examined. Human skin-derived mela-
nocytes, either exposed to 100 mV/mm direction current electric 
fields or non-exposed controls, both exhibited motility rates of 9 
µm/hour, significantly (three- to five-fold) lower than the motil-
ity  rates  of  keratinocytes  under  identical  conditions.  However, 
Grahn et al. (36) reported that in sharp contrast to keratinocytes, 
melanocytes  exhibited  no  directional  migration  in  the  electric 
field. Additionally, neither the number of primary dendrites per 
cell, nor the orientation of the dendrites with respect to the field 
vector, nor the average length of the dendrites was significantly 
different in melanocytes exposed to the electric field as compared 
to non-exposed controls. Thus, in marked contrast to keratino-
cytes, human skin-derived melanocytes do not respond to direct 
current electric fields of physiologic magnitude with either direc-
tional migration or reorientation of dendrites. This may account 
for the delay in repigmentation that often accompanies wound  
re-epithelialization.

BIOELECTRICITY RANGES AND 
CELL PROLIFERATION
Yi-lo Lin et al. (37) used tissue cultures of tendon fibroblasts or 
tenocytes taken from 20 horses. Cells from these cultures were 
used  for  microcurrent  stimulation  (METS)  experiments.  The 
METS device delivered waveform consisting of a brief mono-
phasic square pulse, duration 0.8 milliseconds. The pulse fre-
quency was 150 Hz. Electrical current consisted of 0, 0.05, 0.1, 
0.5, and 1.5 mA. To assess the effects of METS on tenocyte pro-
liferation, viable cells were quantified by use of a non-radioac-
tive, colorimetric cell proliferation kit (Cell Proliferation Kit II 
XTT,  Roche  Molecular  Biochemicals,  Basel,  Switzerland).  The 
spectrophotometric  absorbency  measured  with  the  Kit  was 
proportional to the cell proliferation. The investigators found 
that application of microcurrent had a stimulatory effect on cell 
proliferation which was significantly increased with repeated 
microcurrent applications (Figure 52.9). The same results were 
observed for DNA content, except that a single application of 
microcurrent did not lead to a significant DNA content increase 
in  comparison  with  the  control  sample.  However,  repeated 
microcurrent application significantly increased DNA content 
(Figure 52.10). Protein content significantly increased after one 
application of 0.5 and 1mA, and after two applications of 0.1, 
0,5, and 1 mA of microcurrent. However, application of micro-
current  three  times  significantly  decreased  protein  content. 
Apoptosis  rate  did  not  alter  after  the  first  application.  How-
ever after the third microcurrent application apoptosis rate sig-
nificantly increased with increasing current intensity, so that 
the  highest  rate  of  apoptosis  occurred  at  1.5  mA.  The  results 
of this study provide some evidence for the positive effects of 
microcurrent on cell proliferation, DNA, and protein content, 
however,  it  raises  questions  as  to  the  specifications  and  spe-
cific  ranges  of  microcurrent  necessary  to  produce  optimum 
cell  proliferation,  DNA,  and  protein  content,  while  minimiz-
ing apoptosis. Cheng et al. (10) who studied the effects of mil-
liampere  (mA)  and  microcurrent  on  ATP  generation  protein 
synthesis and membrane transport, showed that although low 
microcurrent stimulated physiologic activity of damaged cells 
and increased ATP up to 500%, ATP progressively decreased at 
mA ranges and dived down to 0 around 1.5 mA. Therefore, the 
cell apoptosis observed in Yi-lo Lin et al. study (37) cited above, 
that  appeared  to  be  maximum  with  repeated  applications  of 
1.5 mA, may well be the result of mA ranges depleting ATP.

 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 489

WOUND HEALING ENHANCEMENT
Application  of  electrical  stimulation  for  wound  healing 
enhancement is the subject of recent review papers (15,34–36). 
As  mentioned  above,  that  low-intensity  electrical  stimulation 
electricity  has  a  positive  impact  on  wound  healing  including 
increased  both  DNA  and  collagen  synthesis,  directed  epithe-
lial, fibroblast, and endothelial cell migration into wound sites, 
inhibited  growth  of  certain  wound  pathogens,  and  increased 
tensile  strength  of  wound  scar.  Clinical  reports  are  heavily 
dominated  by  case  studies  and  case  series.  A  number  of  ran-
domized  controlled  trials  have  demonstrated  efficacy  of  elec-
trical  stimulation  for  enhancing  chronic  wounds,  with  the 
strongest  evidence  on  treating  pressure  ulcers,  but  inconsis-
tencies  in  the  protocols  by  different  investigators  make  it  dif-
ficult to choose one regimen or electrical stimulation modality 
over  another.  Among  the  electrical  stimulation  modalities  or 

 electricity  waveforms  reported  in  the  literature  (Figure  52.11), 
both electrical stimulation from direct current (DC, monopolar, 
or monophasic) or alternating current (AC, bipolar, or biphasic) 
have  shown  efficacy  for  wound  healing  enhancement,  reflect-
ing  the  complex  nature  of  the  wound  healing  process  that 
requires the collaborative efforts of many different tissues and 
cell lineages and different electrical waveforms may affect dif-
ferent cellular pathways or cell responses (15).

Mehmandoust et. al. (38) investigated the effects of anodal 
and  cathodal  electrical  stimulation  on  wound  healing.  The 
results  indicated  that  both  cathodal  and  anodal  stimulations 
increased  the  rate  of  wound  closure.  Beginning  with  day  12, 
a significant difference was observed in the percentage of the 
decrease in wound surface between  all treatment and  control 
groups (p < 0.05). Ultimate tensile strength and stress increased 
in the anodal compared with the cathodal and control groups. 

n
o
i
t
a
r
e
f
i
l

o
r
p

l
l

e
c
o
t

l

a
n
o
i
t
r
o
p
o
r
p
e
c
n
a
b
r
o
s
b
A

)
d
e
t
a
u
m

l

i
t
s
-
n
o
n
o
t
e
v
i
t
a
e
r
(

l

0.4

0.3

0.2

0.1

0

0

1 time

2 times

3 times

l
l

e
w
/
g
µ

,

A
N
D

)
d
e
t
a
u
m

l

i
t
s
-
n
o
n
e
v
i
t
a
e
r
(

l

150

100

50

0

0

1 time

2 times

3 times

0.5

1

1.5

Stimulatory microcurrent (mA)

0.5

1

1.5

Stimulatory microcurrent (mA)

Figure 52.9  Effect of METS on cell proliferation of tenocytes 
in  culture.  Repeated  application  of  microcurrent  resulted  in 
 significantly  increased  cell  proliferation.  (Modified  from  Allen 
GM et al., Curr Biol; 23(7):560– 8, 2013.)

Figure  52.10  Effect  of  METS  on  DNA  content  of   tenocytes 
in  culture.  Repeated  application  of  microcurrent  resulted 
in   significantly  increased  DNA  content,  whereas  a   single 
 application  of  METS  did  not  cause 
in 
 comparison to the control. (Modified from Allen GM et al., Curr 
Biol; 23(7):560– 8, 2013.)

increased  DNA 

Direct current (DC)

Pulsed current (PC)

Alternating current (AC)

t
n
e
r
r
u
C

0

Time

t
n
e
r
r
u
C

t
n
e
r
r
u
C

0

0

Time

Time

+

t
n
e
r
r
u
C

0

–

+

0

–

t
n
e
r
r
u
C

Time

Time

Figure 52.11  Electric stimulation modalities (electricity waveforms) for wound healing. There are reported evidences that both 
DC and AC electric stimulation enhance wound healing.

 
 
 
 
 
 
 
 
 
490 

 TEXTBOOK OF COSMETIC DERMATOLOGY

The authors concluded that electrical stimulation, regardless of 
polarity regimen, benefits wound healing, but anodal stimula-
tion  the  first  3  days  and  cathodal  stimulation  the  remaining 
days can lead to stronger repaired tissue.

Lee  et  al.  (16)  conducted  a  study  to  investigate  the  effi-
cacy of ultra-low microcurrent delivered by the Electro Pres-
sure Regeneration Therapy (EPRT) device for the management 
of chronic wounds. In this study, 23 patients with chronic skin 
ulcers  and  two  with  abdominal  dehiscence  that  was  present 
for an average of 16.5 months, who were not responsive to stan-
dard conservative treatment in a hospital setting, were treated 
with the EPRT device. Wounds were treated with direct cur-
rent  (maximum  of  3  mA)  of  1  polarity  for  11.5  min  and  then 
with  a  current  of  the  opposite  polarity  for  another  11.5  min. 
Treatment  was  applied  through  ultra-low  microcurrents  (in 
the mA to nA range) conducted through special wraps applied 
above and below the wound. The results revealed that 34.8% 
of cases achieved complete wound healing after an average of 
45.6 h of treatment, and 39.1% achieved ≥50% healing after an 
average of 39.7 h of treatment. Several patients achieved signifi-
cant results after 1 to 2 treatments. The EPRT device not only 
accelerated healing but also appeared to negate the effect of a 
person's age on wound healing.

Driban  (39)  conducted  a  clinical  study  to  measure  the 
transient electric changes in skin and muscle tissue immedi-
ately  after  trauma,  with  11  participants  (8  females,  3  males) 
with  a  mean  age  of  65.18  ±  11.36  years  undergoing  total  hip 
arthroplasty.

An incision approximately 10 cm distal to the posterior 
superior iliac spine extended distally over the greater trochan-
ter and along the lateral limb. The incision was completed in 
2  cuts:  (1)  skin  and  subcutaneous  fat  and  (2)  muscle  tissue. 
Three  measurement  sessions  were  performed  with  an  elec-
trometer  before  and  after  a  skin  incision  and  after  a  muscle 
incision. Potential differences and current intensity were mea-
sured immediately after acute trauma to determine the tran-
sient  electric  changes  associated  with  soft  tissue  injury.  The 
electric  potentials  were  significantly  more  negative  after  the 
skin incision and skin plus muscle incision. Current intensity 
changed  significantly  after  the  skin  plus  muscle  incision.  It 
was concluded that soft tissue trauma generated negative tran-
sient electric changes.

TISSUE ENGINEERING
Low intensity biomimetic electricity has been shown to improve 
tissue  regeneration.  In  a  recent  review  on  regenerative  medi-
cine, Levin (40) pointed out that endogenous ion flows serve as 
key epigenetic regulators of cell behavior. Bioelectric signaling 
involves  feedback  loops,  long-range  communication,  polar-
ity,  and  information  transfer  over  multiple  size  scales.  Under-
standing the roles of endogenous voltage gradients, ion flows, 
and electric fields will contribute to the basic understanding of 
numerous  morphogenetic  processes  and  the  means  by  which 
they  can  robustly  restore  pattern  after  perturbation.  Many 
researchers have investigated the use of low level electricity to 
mimic bioelectricity to regenerate human tissues for tissue engi-
neering applications (41–44). Tandon et al. (45) reported an exper-
imental  methodology  for  tissue  engineering  of  synchronously 
contractile  cardiac  constructs  by  culturing  cardiac  cells  with 
the  application  of  pulsatile  electrical  fields  designed  to  mimic 
those present in the native heart. Tissue culture is conducted in 
a customized chamber built to allow for cultivation of (i) engi-
neered 3D cardiac tissue constructs, (ii) cell monolayers on flat 

 substrates,  or  (iii)  cells  on  patterned  substrates.  This  approach 
also allowed for analysis of the individual and interactive effects 
of pulsatile electrical field stimulation and substrate topography 
on  cell  differentiation  and  assembly.  The  experimental  proto-
col was designed to allow for delivery of predictable electrical 
field stimuli to cells, monitoring environmental parameters, and 
assessment of cell and tissue responses. Engineered constructs 
that were electrically stimulated during culture demonstrate a 
remarkable level of ultra-structural differentiation, comparable 
in several respects with that of native myocardium.

Collagen  synthesis  in  heart  tissue  was  reported  to 
increase  with  50  micro  A,  but  not  with  100  micro  A  electric 
current.  Mueller  et  al.  (50)  investigated  the  improvement  of 
cardiac  function  by  unloading  with  a  cardiac  assist  device, 
and  found  it  mainly  depends  on  the  duration  of  heart  fail-
ure. Patients with a short history of heart failure (~< 5 years) 
show  improvement  due  to  reverse  remodeling  of  the  cardio-
myocytes, and in particular of the collagen composition of the 
extracellular matrix. One reason why patients with long-term 
heart failure (~> 5 years) do not show significant cardiac func-
tion improvement is that the collagen composition of the extra-
cellular matrix is then insensitive to mechanical unloading.

It is successful clinical practice to apply microcurrent in 
patients with bone fractures and wound healing disturbances 
to improve the healing process by modulation of the collagen 
synthesis.

To examine whether microcurrent can also influence the 
collagen synthesis in the myocardium, the effect of microcur-
rent application on collagen synthesis of adult cardiomyocytes 
was  investigated  (46).  The  results  suggest  that  microcurrent 
is  able  to  modulate  the  synthesis  of  collagen.  In  dependency 
of  the  current  magnitude  collagen  I  can  be  up-  or  down- 
regulated.  Collagen  I  is  responsible  for  the  stiffness  and  the 
degree of dilatation of the heart.

MICROCURRENT THERAPY FOR 
PAIN AND OTHER TREATMENTS
Microcurrent  electrical  therapy  represents  a  significant 
improvement in rapid pain control and acceleration of healing 
(47,48).  It  uses  current  in  the  microampere  range,  1000  times 
less  than  that  of  TENS  and  below  sensation  threshold.  The 
pulse width, or length of time that the current is delivered with 
a microcurrent device is much longer than previous technolo-
gies. A typical microcurrent pulse is about 0.5 seconds, which 
is  2500  times  longer  than  the  pulse  in  a  typical  TENS  unit 
and  a  good  microcurrent  unit  has  approximately  ten  times 
the electronic circuitry of a TENS unit. Unlike TENS, MET is 
usually  administered  through  hand-held  probes  positioned 
so that current flows between them, through the painful area, 
for  ten  seconds.  Pain  control  following  painful  orthopedic 
procedures such as total knee arthroplasty is an ongoing chal-
lenge, as  current pain management techniques often result in 
 undermedication and/or complications.

Microampere current provides physiologic current flow 
and has been used in the treatment of some pain syndromes. 
McMakin (49) reported an uncontrolled retrospective analysis 
of patients receiving microcurrent treatment for fibromyalgia 
following cervical spine trauma, subjective pain scores are uti-
lized as a primary outcomes measure. Accompanying changes 
in inflammatory cytokines are examined in a subgroup of the 
same patient population to test the hypothesis that microcur-
rent treatment produces substantial measurable objective and 
subjective outcomes supporting the efficacy of this treatment.

 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 491

In this retrospective study based on analysis of  subjective 
VAS pain scores for 54 patients, symptoms of fibromyalgia fol-
lowing  cervical  spine  trauma  were  successfully  treated  with 
microamperage  current.  In  a  subgroup  of  the  same  patients, 
subjective pain improvement scores were accompanied by sub-
stantial  reduction  in  serum  levels  of  the  inflammatory  cyto-
kines  IL-1,  IL-6,  and  TNF-α,  and  the  neuropeptide  substance 
P. Beta-endorphin release and increases in serum cortisol were 
also  observed  in  these  patients  during  the  same  treatment 
period.  The  subjective  outcomes  scores  in  conjunction  with 
biological  markers  for  pain  and  pro-inflammatory  cytokines 
observed in response to this treatment protocol are important 
preliminary  findings.  Based  on  the  observations  reported  in 
this analysis, controlled prospective clinical studies to evalu-
ate the clinical efficacy of microcurrent treatment of FMS asso-
ciated with cervical spine trauma are warranted.

El-Husseini  et  al.  (50)  reported  a  study  designed  to 
test  the  effect  of  the  microcurrent  skin  patch  on  pain  relief 
in  patients  following  total  knee  arthroplasty.  Wound  heal-
ing  was  better  with  the  application  of  the  microcurrent  skin 
patch:  grade  1  wounds  were  observed  in  50%  of  the  patients 
of the microcurrent skin patch group as compared to 8.3% in 
control group. The total drain volume was lower in patients of 
the microcurrent skin patch group compared to the controls. 
None of the patients indicated that they wished to discontinue 
microcurrent skin patch therapy. This pilot study shows that 
microcurrent skin patch therapy led to better pain control with 
a markedly lower need for tramadol as compared to the control 
group.  This  better  pain  control  was  accompanied  by  a  better 
healing of the wound and a lower drain volume.

Cranial electrotherapy stimulation (CES), a noninvasive 
technique that delivers a microcurrent to the brain via ear clip 
electrodes, has been shown to effectively treat several neuro-
logical and psychiatric disorders. Tan et al. (51) reported a clini-
cal study using cranial electrotherapy stimulation to treat pain 
associated with spinal cord injury. Treatments for chronic pain 
in  persons  with  spinal  cord  injury  (SCI)  have  been  less  than 
effective. This study examined the effects of daily 1-hour active 
CES or sham CES treatment (randomly assigned) for 21 days 
on pain intensity and interference with activities in 38 males 
with  SCI.  The  active  CES  group  (adjustable  electric  current: 
100– 500 micro A) reported significantly decreased daily pain 
intensity  compared  with  the  sham  CES  group.  Additionally, 
the  active  CES  group  reported  significantly  decreased  pain 
interference in contrast to the non-significant decrease in the 
sham CES group. These results suggest that CES can  effectively 
treat chronic pain in persons with SCI.

Chronic low back pain associated with myofascial  trigger 
point activity has been historically refractory to conventional 
treatment. McMakin (52) reported a case review on microcur-
rent therapy for 22 patients with chronic low back myofascial 
pain,  of  8.8  years  average  duration,  is  presented.  Following 
treatment with frequency-specific microcurrent, a statistically 
significant  3.8-fold  reduction  in  pain  intensity  was  observed 
using a visual analog scale. This outcome was achieved over 
an average treatment period of 5.6 weeks and a visit frequency 
of  one  treatment  per  week.  When  pain  chronicity  exceeded 
5 years, there was a trend toward increasing frequency of treat-
ment  required  to  achieve  the  same  magnitude  of  pain  relief. 
In  90%  of  these  patients,  other  treatment  modalities  includ-
ing drug therapy, chiropractic manipulation, physical therapy, 
naturopathic  treatment,  and  acupuncture  had  failed  to  pro-
duce equivalent benefits. The microcurrent treatment was the 

single  factor  contributing  the  most   consistent  difference  in 
patient-reported pain relief.

ANTIMICROBIAL ACTIVITY
Low  intensity  electricity  was  known  to  have  inhibitive  or 
killing  activity  on  microorganisms,  and  was  also  known  to 
prevent attachment of bacterial biofilm to medical implants or 
to cause detachment of bacterial biofilm.

The  bioelectric  effect,  in  which  electric  fields  are  used 
to  enhance  the  efficacy  of  biocides  and  antibiotics  in  killing 
biofilm  bacteria,  has  been  shown  to  reduce  significantly  the 
amount of antibacterial agents needed to kill biofilm bacteria 
to levels very close to that needed to kill planktonic (free float-
ing) bacteria of the same species. Costerton et al. (53) reported 
that biofilm  bacteria  are readily killed by an antibiotic  on all 
areas of the active electrodes and on the surfaces of conductive 
elements that lie within the electric field but do not themselves 
function  as  electrodes.  Considerations  of  electrode  geometry 
indicate  that  very  low  (< 100  microA/cm2)  current  densities 
may  be  effective  in  this  electrical  enhancement  of  antibiotic 
efficacy against biofilm bacteria, and flow experiments indicate 
that this bioelectric effect does not appear to depend entirely 
on  the  possible  local  electrochemical  generation  of  antibacte-
rial  molecules  or  ions.  These  data  are  expected  to  facilitate 
the  use  of  the  bioelectric  effect  in  the  prevention  and  treat-
ment of device-related bacterial infections that are caused by 
bacteria that grow in biofilms and thereby frustrate antibiotic 
 chemotherapy.

Del  Pozo  (54)  recently  reviewed  the  bioelectric  effect 
and  bacterial  biofilms.  Bacteria  growing  in  biofilms  cause  a 
wide range of human infections. Biofilm bacteria are resistant 
to antimicrobics at levels 500 to 5000 times higher than those 
needed to kill non-biofilm bacteria. In vitro experiments have 
shown  that  electric  current  can  enhance  the  activity  of  some 
antimicrobial  agents  against  certain  bacteria  in  biofilms;  this 
has been termed the ''bioelectric effect.'' Direct electrical cur-
rent has already been safely used in humans for fracture heal-
ing.  Application  of  direct  electric  current  with  antimicrobial 
chemotherapy  in  humans  could  theoretically  abrogate  the 
need to remove the device in device-related infections, a pro-
cedure associated with substantial morbidity and cost. In this 
article,  we  review  what  has  been  described  in  the  literature 
with regard to the bioelectric effect.

Bacterial  biofilms  are  believed  to  be  a  major  factor  in 
problems of ineffective sterilization often encountered in clin-
ics, hospitals, and industrial processes. There have been indi-
cations  that  the  addition  of  a  relatively  low  intensity  direct 
current electric field with the sterilant used to combat the bio-
film greatly increases the efficacy of the sterilization process. 
The results of the experiments reported (53) support the con-
cept  of  the  bioelectric  effect  as  reported  by  Costerton's  work 
(53).  With  a  current  of  1  mA  flowing  through  the  chamber 
containing  bacterial  biofilm,  an  increase  in  the  killing  of  the 
bacteria of about 8 log orders was observed at the end of 24 h 
(compared with the control with the same amount of antibacte-
rial agent but no current). It was also confirmed that the cur-
rent alone does not affect the biofilm and that there appear to 
be optimum levels of both the current and the sterilant that are 
needed to obtain the maximum effect.

Kalinowski  et  al.  (55)  described  the  use  of  low   voltage 
direct  current  as  a  fungicidal  agent  for  treating  onycho-
mycosis.  Onychomycosis,  most  commonly  caused  by  two 
species  of   dermatophyte  fungi—Trichophyton  rubrum  and 

 
492 

 TEXTBOOK OF COSMETIC DERMATOLOGY

T   mentagrophytes—is  primarily  treated  with  regimens  of 
topical  and  systemic  antifungal  medications.  This  study  was 
undertaken  to  evaluate  in  vitro  the  efficacy  of  low-voltage 
direct current as an antifungal agent for treating onychomyco-
sis. Agar plate cultures of T rubrum and T mentagrophytes were 
subjected to low-voltage direct current electrostimulation, and 
antifungal effects were observed as zones in the agar around 
the  electrodes  lacking  fungal  growth.  Zones  devoid  of  fun-
gal growth were observed for T rubrum and T mentagrophytes 
around anodes and cathodes in a dose-dependent manner in 
the current range of 500 µA to 3 mA. Low-voltage direct cur-
rent electrostimulation has great clinical potential for the treat-
ment of onychomycosis and perhaps other superficial maladies 
of fungal etiology.

Bolton et at (56) reported that positive carbon-containing 
electrodes conveying 5 or more μA of constant direct current 
per  cm2  showed  bactericidal  activity  on  intact  back  skin  of 
13 human subjects. This effect increased with the duration of 
stimulation  up  to  a  total  surface  bacterial  kill  at  20  h.  When 
total  current  and  current  density  were  varied  independently 
on 16 sites on the backs of eight subjects, the effect was depen-
dent on current density, not on total current. Electrodes driven 
by  similar  voltages  but  which  removed  the  electrochemical 
reaction  from  inoculated  sites  on  the  backs  of  three  subjects 
failed to reduce the numbers of colony-forming units as com-
pared  with  those  sampled  from  control  sites.  This  showed 
the  bactericidal  effect  to  be  electrochemical  in  origin,  prob-
ably mediated by local acidity generated at the surface of the 
positive carbon-containing electrodes. With an adhesive tape 
stripping technique on three sites on each of six subjects, it was 
determined that the effect extended into the epidermis of the 
human back. No effect was observed beneath negative or con-
trol electrodes under the same conditions.

BIOMIMETIC ELECTRICITY FOR 
 DERMATOLOGICAL APPLICATIONS
Electrical stimulation of the body used in electrotherapy, and 
iontophoretic drug delivery are typically achieved  by  the  use 
of battery-powered electronic medical devices, which are often 
complicated and cumbersome to use. Other means of  applying 
biomimetic electricity to the body conveniently and effectively 
are therefore highly desirable. Physiological level of  biomimetic 
electricity  may  be  derived  from  the   electrochemical  reactions 
of a galvanic couple, a pair of dissimilar metals  electrically con-
nected together in contact with a conductive electrolyte medium. 
Galvanic current is the electron flow that runs between the two 
dissimilar metals of a galvanic couple and the surrounding elec-
trolyte solution. The theory of  galvanic couple's electrochemical 
reactions is well known, and is the underlying principle for bat-
teries/electrochemical cells. Galvanic electrochemical reactions 
have  been  used  as  the   electrical  power  source  in  commercial 
medical devices based on a zinc-silver/silver chloride galvanic 
couple  for  transdermal  iontophoretic  drug  delivery  (57,58). 
Electrochemical reactions on the electrode surfaces of the gal-
vanic couple concurrently generate zinc ions on zinc anode via 
oxidation of metallic zinc, and hydrogen gas on the cathode via 
reduction of hydrogen ions in the water (59). We are reporting 
here a new method of delivering biomimetic electricity for anti-
inflammatory effects by using fine particles of zinc-copper gal-
vanic couple made of pure metallic zinc metal partially coated 
with  metallic  copper  with  a  coplanar  electrode  configuration 
for the zinc anode and copper cathode similar to that reported 
by Doig and Flewitt (60).

Biomimetic-Electricity Delivery  Systems 
Containing Biomineral Complex
Based upon the insights of bioelectricity for wound  healing, a 
micro electricity delivery system was reported using a unique 
combination of elemental zinc and copper to generate biologi-
cal levels of electricity when in contact with conducted media 
such  as  physiological  fluid,  moisturizer,  etc.  The  titration 
results  demonstrated  that  the  intensity  and  duration  of  the 
electricity can be adjusted through bi-mineral complex combi-
nation, ratio, and particle size.

Tandan et al. (61) described characterization and model-
ing of the zinc-copper galvanic microparticles, and the obser-
vation  that  the  galvanic  microparticles  increased  migration 
of  human  dermal  fibroblasts  in  a  wound-healing  model  via 
reactive  oxygen  species.  One  method  to  generate  electrical 
signals  similar  to  those  naturally  occurring  in  wounds  is  by 
supplementation of galvanic particles dispersed in a cream or 
gel.  We  constructed  a  three-layered  model  of  skin  consisting 
of human dermal fibroblasts in hydrogel (mimic of dermis), a 
hydrogel barrier layer (mimic of epidermis), and galvanic mic-
roparticles in hydrogel (mimic of a cream containing galvanic 
particles  applied  to  skin).  Using  this  model,  we  investigated 
the  effects  of  the  properties  and  amounts  of  Cu/Zn  galvanic 
particles  on  adult  human  dermal  fibroblasts  in  terms  of  the 
speed  of  wound  closing  and  gene  expression.  The  collected 
data suggest that the effects on wound closing are due to the 
ROS-mediated enhancement of fibroblast migration, which is 
in turn mediated by the BMP/SMAD signaling pathway. These 
results imply that topical low-grade electric currents via mic-
roparticles could enhance wound healing.

In Vitro Biological Responses 
of Biomineral Complex
Anti-Inflammatory Activity 
In  several  in  vitro  cytokine  studies,  treatment  with  the 
bi- mineral  complex  significantly  reduced  release  of  pro- 
inflammatory  cytokines  from  activated  human  T-cells  and 
inhibited release of cytokines from keratinocytes and macro-
phages  exposed  to  bacteria  (62).  Furthermore,  topical  appli-
cation  of  a  lotion  containing  the  bi-mineral  complex  reduced 
the  UV-induced  damage  to  human  skin  equivalents.  Taken 
together these results demonstrate that biomimetic electricity 
reduces  inflammatory  responses  and  therefore  may  protect 
skin  from  the  numerous  external  aggressions  encountered 
daily by skin.

Kaur et al. (63) reported that galvanic zinc-copper mic-
roparticles  produce  electric  stimulation  that  reduces  the 
inflammatory and immune responses in skin. A galvanic cou-
ple comprised of elemental zinc and copper was used to deter-
mine  the  effects  of  low-level  electrical  stimulation  on  intact 
skin physiology using a Dermacorder device. Zn-Cu induced 
the electrical potential recorded on intact skin, enhanced H(2)
O(2)  production  and  activated  p38  MAPK  and  Hsp27  in  pri-
mary keratinocytes. Treatment with Zn-Cu was also found to 
reduce  pro-inflammatory  cytokines  such  as  IL-1α,  IL-2,  NO 
and TNF-α in multiple cell types after stimulation with PHA 
or Propionibacterium acnes bacteria. The Zn-Cu complex led to 
a  dose-dependent  inhibition  of  TNF-α-induced  NF-κB  levels 
in  keratinocytes  as  measured  by  a  dual-luciferase  promoter 
assay and prevented p65 translocation to the nucleus observed 
via 
immunofluorescence.  Suppression  of  NF-κB  activity 
via  crosstalk  with  p38  MAPK  might  be  one  of  the  potential 
pathways  by  which  Zn-Cu  exerted  its  inflammatory  effects. 

 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 493

 Topical   application  of  Zn-Cu  successfully  mitigated  TPA-
induced   dermatitis  and  oxazolone-induced  hypersensitiv-
ity  in  mice  models  of  ear  edema.  Anti-inflammatory  activity 
induced by the Zn-Cu galvanic couple appears to be mediated, 
at least in part, by production of a low level of hydrogen per-
oxide since this activity is reversed by the addition of catalase 
enzyme.  Collectively,  these  results  show  that  a  galvanic  cou-
ple containing Zn-Cu strongly reduces the inflammatory and 
immune  responses  in  intact  skin,  providing  evidence  for  the 
role of electric stimulation in non-wounded skin.

Dermal Extracellular Matrix Production
The  elemental  bi-mineral  complex,  which  produces  physi-
ological  levels  of  electricity,  was  also  evaluated  for  its  possi-
ble  effects  on  dermal  extracellular  matrix  (64).  Fresh  human 
abdominal  skin  samples  were  obtained  from  surgical  proce-
dures and tested as human skin explants maintained in a cul-
ture medium. Human skin explants were topically treated with 
this  bi-mineral  complex  once  daily  for  7  days,  and  the  effect 
on elastin and collagen was evaluated. LUNA elastin staining 
showed that treatment with the bi-mineral complex increased 
the  elastin  fiber  network,  as  compared  to  untreated  controls. 
QPCR  analysis  documented  an  increase  in  elastin  and  colla-
gen expression in the bi-mineral complex–treated skin samples 
(Figure 52.12). The results suggest that this bi-mineral complex 
may be effective in restoring the integrity and functionality of 
dermal extracellular matrix, and in particular of elastic fibers, 
suggesting its cosmetic use in the aged skin.

Melanogenesis Inhibition
To  examine  the  effect  of  electric  field  modulation  on 
 melanogenesis,  pigmented  epidermal  equivalents  were  topi-
cally treated with a proprietary elemental bi-mineral complex 
that  produces  biomimetic  electricity,  once  daily  for  7  days 
(65).  F&M  staining  showed  a  significant  decrease  in  melanin 

0

0.5

1
(a)

1.5

2

2.5

Untreated

ePowder

Untreated

TGF–β

ePowder

0

2

4

5
(b)

8

10

12

Figure 52.12  Effect of bimineral complex on upregulation of 
collagen and elastin expressions.

deposition in epidermal equivalents treated with the bi-min-
eral complex, compared to untreated control. This  reduction 
in   melanin  deposition  was  also  observed  in   epidermal 
 equivalents  treated  with  a  cosmetic  formula   containing 
the  bi-mineral  complex.  Exploring  the  mechanism  of  this 
 biomimetic  electricity-induced depigmentation, it was shown 
that there was no direct inhibitory activity against phagocytic 
activity of keratinocytes. Interestingly, the bi-mineral complex 
inhibited tyrosinase and tyrosinase related protein 1 (TRP-1) 
expression using mouse melanoma B 16 cells, as analyzed by 
TYR  and  TRP-1  promoter-luciferase  reporter  assays.  Using 
cultured human skin explants, it was confirmed that melanin 
content and TYR mRNA are reduced by the exposure to the 
bi-mineral complex. These data support the potential of using 
biomimetic  electricity  generated  by  an  elemental  bi-mineral 
complex for skin lightening applications.

Won  et  al.  (66)  reported  that  galvanic   zinc-copper 
 microparticles inhibit melanogenesis via multiple  pigmentary 
pathways.  The  findings  showed  that  galvanic  zinc-copper 
 microparticles inhibited melanogenesis in a human  melanoma 
cell  line  (MNT-1),  human  keratinocytes  and  melanoma 
cell  co-cultures,  and  in  pigmented   epidermal  equivalents. 
Treatment  of  galvanic  zinc-copper   microparticles  inhibited 
 melanogenesis  by  reducing  the  promoter   transactivation  of 
TYR  and  TRP-1  in  human  melanoma  cells.  In  a   co-culture 
 Transwell  system  of  keratinocytes  and   melanoma  cells, 
galvanic  zinc-copper  microparticles 
reduced  melanin 
 production  via  downregulation  of   endothelin-1  secretion 
from  keratinocytes  and  reduced  tyrosinase  gene   expression 
in  melanoma  cells.  In  addition,  exposure  of   pigmented 
 epidermal equivalents to galvanic zinc-copper microparticles 
resulted  in  reduced   melanin  deposition.  In  conclusion,  our 
data demonstrated for the first time that  galvanic zinc-copper 
microparticles reduced melanogenesis in melanoma cells and 
melanin  deposition  in  pigmented  epidermal  equivalents  by 
affecting multiple pigmentary pathways.

Clinical Safety and  Tolerability 
of Biomineral Complex
Several clinical and preclinical safety studies were conducted 
(67).  Clinical  safety  was  assessed  through  human  repeat 
insult  patch  tests  (RIPT).  Five  RIPT  studies  were  performed 
on topical compositions containing various  concentrations of 
the bi-mineral complex. Four RIPT studies were  conducted in 
a  predominately  Caucasian  population  in  the  United  States, 
and  one  study  was  conducted  in  an  Asian  population  in 
Thailand.  Combined, over 800 healthy subjects completed the 
clinical  safety  studies.  Results  show  that  none  of  the  topical 
compositions induced dermal sensitization.

In  addition,  a  topical  composition  containing  the 
bi-mineral  complex  was  evaluated  versus  placebo  for 
its   potential  to  induce  dermal  and  ocular  irritation  in  a 
human  skin  model  (EpiDermTM)  and  human  corneal  model 
 (EpiOcularTM). Results show that the bi-mineral complex has 
low potential for skin and eye irritation.

Topical 

containing 

compositions 

the  bi-mineral 
 complex have been evaluated for their tolerability and  efficacy 
in   reducing  the  signs  of  facial  and  periorbital  photo-aging 
in  over  eight  clinical  studies  spanning  populations  in  three 
countries—the  United  States,  France,  and  Singapore.  The 
bi-mineral  compositions  were  shown  to  be  mild  and  well 
 tolerated in all populations studied.

 
494 

 TEXTBOOK OF COSMETIC DERMATOLOGY

2%

0%

–2%

–4%

–6%

–8%

–10%

–12%

–14%

–16%

0%

–2%

–4%

–6%

–8%

–10%

–12%

–14%

–16%

e
n

i
l

e
s
a
b
m
o
r
f
e
g
n
a
h
C
%

e
n

i
l

e
s
a
b
m
o
r
f
e
g
n
a
h
C
%

0

2

4

6

8

10

12

weeks

*

*

*

*

1

0

12

*

*

*

*

(a)

68
weeks

0

2

4

*

*

*

*

*

(b)

Placebo

Bimineral
complex
formulation 1

Bimineral
complex
formulation 2

Placebo

Bimineral
complex
formulation 1

Bimineral
complex
formulation 2

Figure  52.13  Twelve-week  randomized  placebo-controlled  clinical  results  of  eye  conditions  after  topical  administration  of 
 bimineral complex.

Clinical Efficacy for Skin  Anti-Aging 
of Biomineral Complex
Twelve-Week Placebo-Controlled Anti-Aging Study
The clinical signs of photo-aging are a persistent concern for 
many  patients.  Intrinsic  factors  and  cumulative  exposure  to 
extrinsic  factors  such  as  UV  lead  to  the  development  of  skin 
laxity, fine lines, wrinkles, hyperpigmentation, and sallowness. 
A 12-week, double-blind, placebo-controlled clinical study was 
performed to evaluate the efficacy and tolerability of a topical 
composition  containing  the  bi-mineral  complex  in  reducing 
the clinical signs of facial photo-aging, including the delicate 
the periorbital area (68). The study consisted of three treatment 
groups: 1) placebo moisturizer, 2) bi-mineral complex moistur-
izer, and 3) bi-mineral complex moisturizer with activator. The 
study population consisted of 94 healthy women, ages 40– 65, 
with Fitzpatrick skin type II–IV and mild to moderate photo-
aging. Subjects applied the bi-mineral complex twice daily, in 
the morning and evening. Evaluations included clinical grad-
ing  of  safety  and  efficacy  parameters,  high-resolution  digital 
imaging,  and  subject  self-assessments.  All  measures  were 
taken at baseline and weeks 2, 4, 8, and 12.

Both  treatment  groups  using  the  bi-mineral  complex 
showed statistically significant (p < 0.05) clinical improvement 
versus  placebo  and  versus  baseline  starting  as  early  as  week 
2 in several parameters and continued to improve versus pla-
cebo  through  week  12.  The  bi-mineral  complex  performed 
significantly (p < 0.05) better than placebo and baseline in over-
all  appearance,  drooping  eyelids,  under-eye  bags,  under-eye 

wrinkles,  cheek  wrinkles,  pigmentation,  radiance,  fine  lines, 
and  global  lifting/firming.  Figure  52.13  shows  significant 
improvement  of  12-week  clinical  grades  for  under-eye  bag 
and  drooping  eyelids.  Figure  52.14  shows  a  pair  of  sample 
clinical images after 2 weeks of topical treatment of a formu-
lation containing bi-mineral complex. There were no adverse 
events related to the treatments in this clinical study, and the 
bi- mineral  complex  and  placebo  were  all  shown  to  be  well 
 tolerated throughout the 12-week study.

Four-Week Anti-Aging Study Combining 
 Bi-Mineral Complex with Natural Extracts
Natural  ingredients  are  increasingly  being  recognized  for 
their  skincare  benefits  as  they  continue  to  be  shown  to  have 
various  in  vitro  and  in  vivo  activities.  Preclinical  and  initial 
clinical data have shown the potential of a bi-mineral complex 
consisting of a proprietary blend of elemental zinc and copper 
that generates biomimetic signals for improving photo-aging, 
and in vitro data has also suggested the anti-aging benefits of 
a  combination  of  dill  and  blackberry  leaf  extract.  A  clinical 
study  was  performed  using  a  regimen  of  a  bi- mineral  com-
plex gel and a dill-blackberry leaf extract lotion with SPF 30 to 
evaluate its ability to rapidly improve multiple signs of facial 
photo-aging, while being mild to the skin (69). Thirty healthy 
female  subjects,  between  the  ages  of  30–55,  with  moderate 
facial  photo-aging,  exhibiting  mottled  hyperpigmentation, 
skin  roughness,  laxity,  and  fine  wrinkling  completed  this 
4-week  study.  Patients  applied  the  two-product  system  once 

 
 
 
 
 
 
 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 495

lines and wrinkles, dark circles and bags under the eye, and 
puffiness and laxity in both the upper and lower eyelids. Three 
clinical studies were conducted to evaluate efficacy and toler-
ability in reducing signs of photo-aging in the periorbital area 
for immediate and continuous benefits.

The  first  study  focused  on  immediate  benefits  after  a 
single application of the bi-mineral complex (71). Twenty-two 
females  ages  25–45  completed  this  double-blind,  benchmark 
controlled study. To enroll at baseline, subjects must experience 
at  least  one  of  the  following  conditions  of  mild  to  moderate 
severity  based  on  expert  grading:  under-eye  bags,  puffiness, 
dark circles, lines, and wrinkles. Clinical imaging and subject 
self-assessments  were  taken  at  baseline,  20–30  minutes  post-
product  application,  and  3  hours  post-product  application. 
Study results show that the bi-mineral complex demonstrated 
visible,  measureable  improvement  (p < 0.05)  at  20–30  minutes 
post application and continued to show improvement (p < 0.05) 
at 3 hours in parameters such as under-eye puffiness, bags, and 
fine lines.

The  second  clinical  study  was  a  placebo-controlled, 
double-blind study to evaluate the immediate and continuous 
effects  of  the  bi-mineral  complex  over  an  8-week  period  (71). 
120 women, ages 40–65, with mild to moderate photo-aging at 
baseline completed this study. Clinical grading, clinical imag-
ing, and subject self-assessments were performed at baseline, 
immediately  after  product  application,  and  after  1,  2,  4,  and 
8 weeks of product use. Clinical grading immediately after the 
first product application shows that the treatments containing 
the  bi-mineral  complex  have  significant  (p < 0.05)  improve-
ment versus placebo in under-eye dark circles, under-eye bags, 
skin radiance, and overall photodamage. In both studies, the 
 bi-mineral  complex  showed  immediate  and  lasting  improve-
ment versus baseline, and all compositions were well tolerated.
A  third  study  was  performed  on  34  healthy  Caucasian 
women  volunteers  aged  between  35  and  60  years  old  with 
wrinkles and/or fine lines at the eye contour area, dark circles, 
and puffiness (72). All volunteers signed an informed consent 
form. Product was applied for 8 weeks, once a day, in the morn-
ing. Clinical grading of the signs of ageing was done at base-
line, immediately after the first application, then after 1 week, 
4 weeks, and 8 weeks of application. Wrinkles, tone, and sag-
ging were assessed by an expert grader around the eyes using 
visual analog scales. A paired student t-test was performed ver-
sus baseline and the confidence level considered was p < 0.05.

Immediately after the first application, all the  parameters 
assessed were significantly improved versus baseline (p < 0.05). 
The  product  improved  bags  and  dark  circles  (respectively 
+32% and +21%) as well as wrinkles (crow's feet: +24%, under 
eye: +22%), sagging (sloping eyelids: +20.29%, folds on the eye-
lids:  17%),  and  skin  complexion  (radiance:  +17%,  yellowish 
complexion: +52%). Some of the changes were still increasing 
after 1 week of application. The tested product containing the 
new  biomimetic  signaling  technology  was  demonstrated  to 
be efficacious from the first week of use and delivered instant 
benefits to the eye area.

Nollent et al. (73) reported clinical evaluation of zinc- and 
copper-based eye area anti-aging complex. A zinc and copper 
complex  generating  biomimetic  electricity  on  a  physiologi-
cal  level  has  shown  to  improve  signs  of  photo-aging  in  clini-
cal  studies.  This  zinc-copper  complex  was  applied  to  the  eye 
area to confirm its efficacy as antiaging treatment option with 
good skin tolerance. The study was a non-interventional, open-
labeled  baseline-controlled  clinical  study,  including  a  30-day 
washout period and 8-week treatment period. The results of this 

(a)

(b)

Figure 52.14  Sample images of clinical results (a) before and 
(b) after 2 weeks of twice-daily topical treatment of a bimineral 
complex topical formulation.

per day in the morning. Clinical evaluations, self-assessments, 
and  instrumental  analysis  demonstrated  this  two-product 
regimen's  multiple  skin  benefits  throughout  the  study.  Clini-
cal  evaluations  indicated  significant  improvements  (p < 0.05) 
in  facial  skin  clarity,  smoothness,  and  overall  photo-aging 
after 2 weeks of use. Significant improvements (p < 0.05) in the 
appearance of mottled hyperpigmentation, firmness, and fine 
wrinkling  were  observed  by  the  4-week  time  point.  Patients 
also perceived significant (p < 0.05) improvements in skin tone, 
brightness, and textural parameters as early as after 2 weeks 
of  use.  Digital  photographs  also  confirmed  improvements  in 
various  overall  photo-aging  parameters.  In  conclusion,  this 
clinical  study  demonstrated  that  a  regimen  of  a  bi-mineral 
complex gel and a dill-blackberry leaf extract lotion with SPF 
30 was effective in improving the overall signs of facial photo-
damage  including  improvements  in  fine  lines  and  wrinkles, 
tone, pigmentation, and texture, while being mild and gentle 
to the skin.

Four-Week Laxity Clinical Study
We  have  evaluated  the  clinical  efficacy  of  a  facial  treatment 
regimen  consisting  of  this  bi-mineral  complex  plus  a  facial 
moisturizer in a 4-week double-blinded controlled study (70). 
Thirty subjects with mild to moderate signs of photodamage 
and  moderate  skin  laxity  completed  the  study.  The  patients 
applied  the  regimen  once  per  day  in  the  morning.  Clinical 
evaluations, self-assessments, and instrumental analysis dem-
onstrated  this  two-product  regimen's  multiple  skin  benefits 
throughout  the  study.  The  facial  treatment  was  particularly 
effective in improving skin firmness and laxity (p < 0.05) while 
also providing significant improvements in overall photodam-
age. Patients also perceived significant (p < 0.05) improvements 
in overall signs of photodamage and lifting. The regimen was 
well tolerated.

Anti-Aging Focusing on Eye Areas
The  first  signs  of  skin  aging  often  occur  in  the  delicate  skin 
of  the  periorbital  area.  Characteristic  signs  associated  with 
chronological  and  photo-aging  in  the  eye  area  include  fine 

 
496 

 TEXTBOOK OF COSMETIC DERMATOLOGY

study  showed  that  both  subjective  and   objective   assessments 
demonstrated significant decreases in facial phtodamage signs 
during  the  8-week  treatment  with  the  zinc- copper  complex. 
Clinical  grading  and  self-assessments  indicated  statistically 
significant  improvements  in  crow's  feet,  fine  lines  and  wrin-
kles, under-eye fine lines and bags, eyelid puffiness and dark 
circles, and skin texture (i.e., skin radiance and tone). Objective 
measurement  methods  showed  a  reduction  in  total  wrinkle 
surface and mean length in skin replicas. In this sensitive and 
fragile skin area, the treatment was also well tolerated through-
out the study period, with no adverse events.

SUMMARY
Bioelectricity is an emerging science presenting a new oppor-
tunity  for  medical  therapies.  Basic  research  suggests  that 
ultra  low  electrical  fields  can  enhance  tissue  healing,  ATP 
production,  antimicrobial  activities,  inflammation  reduc-
tion,  pain  relief,  and  improving  dermatological  conditions. 
However, specific mechanisms of action remain unclear. The 
application  of  a  specific  low  intensity  electricity  or  biomi-
metic electricity for the medical applications warrants a new 
area for exploration.

AKNOWLEDGMENT
The  authors  thank  many  colleagues  at  Johnson  and  Johnson 
Consumer  Products  for  their  contribution  and  support  to 
this work.

REFERENCES

1.  Slack JMW. The Spark of Life: Electricity and Regeneration. Sci 

STKE 2007; 405:pe54.

2.  McCaig  CD,  Rajnicek  AM,  Son  B,  Zhao  M.  Controlling  cell 
behavior  electrically:  Current  views  and  future  potential. 
Physiol Rev 2005; 85:943–78.

3.  Reily  JP.  Applied  Bioelectricity  –  From  Electrical  Stimulation  To 

Electrotherapy, Springer, 1998; pp 5–6

4.  Watson  T.  The  role  of  electrotherapy  in  contemporary  phyio-

therapy practice. Manual Ther 2000; 5:132–41.

5.  Robertson V, Ward A, Low J, Reed A. Electrotherapy Explained – 
Principles  and  Practice.  4th  edition.  Butterworth  Heinemann 
Elsevier, 2006.

6.  Subramony  JA,  Sharma  A,  Phipps,  JB.  Microprocessor  con-
trolled transdermal drug delivery. Intern J Pharm 2006; 317:1–6.
7.  Johnson  MI.  Transcutaneous  electrical  nerve  stimulation 
(TENS)  and  TENS-like  devices:  Do  they  provide  pain  relief? 
Pain Rev 2001; 8:121–58.

8.  Rai  R,  Srinivas  CR.  Iontophoresis  in  dermatology.  Indian  J 

 Dermotol Venereol Leoprol 2005; 71:236–41.

9.  Chen  CJ,  Yu  HS.  Acupuncture,  electrostimulation,  and  reflex 

therapy in dermatology. Dermatol Ther 2003; 16:87–92.

  10.  Cheng N, et al. The effects of electric currents on ATP genera-
tion,  protein  synthesis,  and  membrane  transport  in  rat  skin. 
Clin Orthop Relat Res 1982; 171:264–72.

  11.  Chapman-Jones  D,  Hill  D.  Novel  microcurrent  treatment  is 
more  effective  than  conventional  therapy  for  chronic  Achil-
les  tendinopathy  randomised  comparative  trial.  Physiotherapy 
2002; 88:8; 471–80.

  12.  Marx JL. Electric current may guide development. Science 1981; 

211:1147–9.

  13.  Zhao  M,  Song  B,  Pu  J,  Wada  T,  Reid  B,  Tai  G,  et  al.  Electrical 
signals  control  wound  healing  through  phosphatidylinositol-
3-OH kinase-γ and PTEN. Nature 2006; 442:457–60.

  14.  Huttenlocher  A,  Horwitz  AR.  Wound  healing  with  electric 

potential. N Engl J Med 2007; 356:303–4.

  16.  Lee BY, Wendell K, Butler G, Ultra-low microcurrent therapy: 
A  novel  approach  for  treatment  of  chronic  resistant  wounds. 
Adv Ther 2007; 24:1202–9.

  17.  Driban JB, Swanik CB, Huxel KC, Balsubramanian E. Transient 
electric  changes  immediately  after  surgical  trauma.  J  Athlet 
Train 2007; 42:524–9.

  18.  Hodges  SD,  Jason  C,  Humphreys  SC.  Use  of  electrical  bone 
stimulation  in  spinal  fusion.  J  Am  Acad  Orthop  Surg  2003;  
11:81–8.

  19.  McCaig CD, Zhao M. Physiological electrical fields modify cell 

behaviour. BioEssays 1997; 19:819–26.

  20.  Jennings  J,  Chen  D,  Feldman  D.  Transcriptional  response  of 
dermal  fibroblasts  in  direct  current  electric  fields.  Bioelectro-
magnetics 2008; 29:394–405.

  21.  Oishi M, Onesti ST. Electrical bone graft stimulation for spinal 

fusion: A review. Neurosurgery 2000; 47:1041–56.

  22.  Song B, Zhao M, Forrester J, McCaig C. Nerve regeneration and 
wound healing are stimulated and directed by an endogenous 
electrical field in vivo. J Cell Sci 2004; 117:4681–90.

  23.  Brighton  CT,  Wang  W,  Seldes  R,  Zhang  G,  Pollack  SR.  Signal 
transduction  in  electrically  stimulated  bone  cells.  J  Bone  Joint 
Surg 2001; 83:1514–23.

  24.  Pullar CE, Isseroff RR. Cyclic AMP mediates keratinocyte direc-
tional migration in an electric field. J Cell Sci 2005; 118:2023–34.
  25.  Sillman,  AL,  Guang  DM,  Barboud  B,  Fang  KS,  Nuccitelli  R, 
Isseroff  RR.  Human  dermal  fibroblasts  do  not  exhibit  direc-
tional migration on collagen I in direct-current electric fields of 
physiological strength. Exper Biol 2003; 12(4):396–402.

  26.  Brown MJ, Electric field-directed fibroblast locomotion involves 
cell surface molecular reorganization and is calcium indepen-
dent. J Cell Biol 1994; 127:117–28.

  27.  Jaffe LF, Nuccitelli R. An ultrasensitive vibrating probe for mea-
suring extracellular currents. J Cell Biol 1974; 63:614–28.

  28.  Nuccitelli  R,  Nuccitelli  P,  Ramlatchan  S,  Sanger  R,  Smith  PJS, 
Imaging  the  electric  field  associated  with  mouse  and  human 
skin wounds. Wound Rep Reg 2008; 14:432–41.

  29.  Reid B, Nuccitelli R and Zhao M. Non-invasive measurement of 
bioelectric current with a vibrating probe. Nature Protocol 2007; 
2(3):661–9.

  30.  Nuccitelli  R,  Nuccitelli  P,  Li  C,  Narsing  S,  Vendt  D,  Pariser  D, 
Hood  A.  The  electric  field  at  human  skin  wounds  declines 
sharply with age. 18th Annual Meeting of the Wound Healing 
Society, San Diego, CA, April 24–27, 2008.

  31.  Sun  Y,  Do  H,  Goa  J,  Zhao  R,  Zhao  M  and  Mogilner  A.  Kera-
tocyte  fragments  and  cells  utilize  competing  pathways  to 
move in opposite directions in an electric field. Curr Biol 2013; 
23(7):569–74.

  32.  Allen GM, Mogilner A, Therlot JA. Electrophoresis of cellular 
membrane  components  creates  the  directional  cue  guiding 
keratocyte galvanotaxis. Curr Biol 2013; 23(7):560–8.

  33.  Sundelacruz S, Li C, Choi YJ, Levin M. Bioelectric modulation 
of wound healing in a 3d in vitro model of tissue-engineered 
bone. Biomaterial 2013; 34:6695–705.

  34.  Cao L, McCaig CD, Scott RH, Zhao S, Milne G, Clevers H, et al. 
Polarizing intestinal epithelial cells electrically through Ror2. 
J Cell Sci 2014; 127:3233–9.

  35.  Rudell JC, Gao J, Sun Y, Sun Y, Chodosh J, Schwab I, Zhao M. 
Acanthamoeba migrationin an electric field. Investig Ophthalm 
Visual Sci 2013; 54(6):4225–33.

  36.  Grahn JC, Reilly DA, Nutccitelli RL,  Isseroff RR. Melanocytes 
do not migrate directionally in physiological DC electric fields. 
Wound Rep Reg 2003; 11:64–70.

  37.  Lin Y-L , Moolenaar H, van Weeren PR, van de Lest CHA. Effect 
of microcurrent electrical tissue stimulation on tenocyte in cul-
ture. Am J Vet Res 2006; 67:271–6.

  38.  Mehmandoust  FG,  Torkaman  G,  Froozabadi  M  and  Talebi  J. 
Anodal  and  cathodal  pulsed  electrical  stimulation  on  skin 
wound healing in guinea pigs. J Rehab R&D 2007; 44(4):611–8.

  15.  Ojingwa JC, Isseroff RR. Electric stimulation of wound healing. 

  39.  Driban JB, Transient electric changes immediately after surgi-

J Invest Derm 2003; 121:1–12.

cal trauma. J Athl Train 2007 Oct–Dec; 42(4):524–9.

 
 
 
 
 
 
 
 
 
 
BIOELECTRICITY AND ITS APPLICATION IN COSMETIC DERMATOLOGY 

 497

  40.  Levin  M,  Bioelectric  mechanisms  in  regeneration:  Unique 
aspects and future perspectives. Semin Cell Devel Biol 2009; 20(5) 
543–56.

  41.  Radisic M, Park H, Gerecht S, Cannizzaro C, Langer R, Vunjak-
Novakovic G. Biomimetic approach to cardiac tissue engineer-
ing. Phil Trans R Soc B 2007; 362:1357–68.

  42.  Pedrotty DM, Koh J, Davis BH, Taylor DA, Wolf P, Niklason LE. 
Engineering  skeletal  myoblasts:  Roles  of  three-dimensional 
culture and electrical stimulation. Am J Physiol Heart Circ Physiol 
2005; 288:1620–6.

  43.  Ghasemi-Mobarakeh  EL,  Molamma  P,  Prabhakaran  MP, 
 Morshed  M,  Nasr-Esfahani  MH,  Ramakrishna  S.  Electrical 
stimulation  of  nerve  cells  using  conductive  nanofibrous  scaf-
folds  for  nerve  tissue  engineering.  Tissue  Eng:  Part  A  2009; 
15(11):3605–19.

  44.  Ting  Y,  Ya  L,  Hai-Tao  W,  Wei-Wei  C,  Yu  W,  Xia-Bin,  et  al. 
Influence  of  pulse  electrical  stimulation  on  osteoblast  prolif-
eration and osteogenic activity on the surface of modified nano-
hydroxyapatite/poly(lactide-co-glycolide) composite material. J 
Clin Rehab Tissue Engineering Res 2009; 13(16):3065–9.

  45.  Tandon  N,  Cannizzaro  C,  Chao  PG,  Maidhof  R,  Marsano  A, 
Au HTH, et al. Electrical stimulation systems for cardiac tissue 
engineering. Natural Protocols 2009; 4(1)155–73.

  46.  Mueller J, Kapeller B, Macfelda K. Recovery of heart failure by 
normalization  of  the  cardiac  extracellular  matrix  after  micro-
current application. J Heart Lung Transplantation 2006; 24(2) Sup-
plement 1,133:S91.

  47.  Mercola  JM,  Kirsch  DL.  The  basis  for  microcurrent  electri-
cal  therapy  in  conventional  medical  practice.  J  Adv  Med  1995; 
8(2)107–20.

  48.  Kirsch  DL.  Microcurrent  electrical  therapy  (MET):  A  tutorial. 

Practical Pain Management 2006; 6(7):59–64.

  49.  McMakin CR. Cytokine changes with microcurrent treatment 
of fibromyalgia associated with cervical spine trauma. J Body-
work Move Therap 2005; 9:169–76.

  50.  El-Husseini  T,  El-Kawy  S,  Shalaby  H,  El-Sebai  M.  Microcur-
rent  skin  patches  for  postoperative  pain  control  in  total  knee 
 arthroplasty: A pilot study. Intl Orthopaed 2007; 31(2):229–33.

  51.  Tan  G,  Rintala  DH,  Thornby  JI,  Yang  J,  Wade  W,  Vasilev  C. 
Using  cranial  electrotherapy  stimulation  to  treat  pain  associ-
ated with spinal cord injury. J Rehab R&D 2006; 43(4):461–74.

  52.  McMakin CR. Using cranial electrotherapy stimulation to treat 
pain associated with spinal cord injury. J Bodywork Move Therap 
2004; 8:143–53.

  53.  Costerton  JW,  Ellis  B,  Lam  K,  Johnson  F.  Mechanism  of  elec-
trical  enhancement  of  efficacy  of  antibiotics  in  killing  biofilm 
bacteria. Antimicrob Agents  Chemother 1994; 38(12):2803–289.

  54.  Del  Pozo  JL,  Rouse  MS,  Patel  R,  Bioelectric  effect  and  bacte-
rial biofilms: A systematic review. Int J Artif Organs 2008; 31(9): 
786–95.

  55.  Kalinowski  DP,  Low-voltage  direct  current  as  a  fungicidal 
agent for treating onychomycosis. J Am Podiatr Med Assoc 2004; 
94(6):565–72.

  56.  Bolton L, et al. Direct-current bactericidal effect on intact skin. 

Antimicrob Agents Chemother 1980; 18(1):p137–41.

  57.  Chaturvedula  A, 

Joshi  DP,  Anderson  C,  Morris  RL, 
 Sembrowich  WL,  Banga  AK.  In  vivo  iontophoretic  delivery 
and pharmacokinetics and salmon calcitonin. Intl J Pharm 2005; 
297:190–6.

  58.  Vranken JH, Dijkgraaf MGW, Kruis MR, van Dasselaar, NT, van 
der  Vegt,  MH.  Iontophoretic  administration  of  S(+)–ketamine 

in patients with intractable central pain: A placebo-controlled 
trial. Pain 2005; 118:224–31.

  59.  Zhang  X.  Corrosion  and  Electrochemistry  of  Zinc.  New  York: 

 Plenum Press, 1996; pp. 32, 51.

  60.  Doig  P,  Flewitt  PEJ.  A  finite  difference  numerical  analysis  of 
galvanic corrosion for semi-infinite linear coplaner electrodes. 
J Electrochem Soc 1979; 126(12):2057–63.

  61.  Tandon  N,  Cimetta  E,  Villasante  A,  Kupferstein  N,  Southall 
MD, Fassih A, et al. Glavanic microparticles increase migration 
of  human  dermal  fibroblasts  in  a  wound-healing  model  via 
reactive oxygen species pathway. Exp Cell Res 2014; 320:79–91.

  62.  Sur  PR,  Lyte  P,  Garay  M,  Liebel  F,  Sun  Y,  Chantalat  J,  et  al. 
Biomimetic  Electricity  Generated  by  an  Elemental  Bi-Mineral 
Complex Produces Anti-Inflammatory Activity, Poster No.1618, 
Proc Am Acad Derm, 2010.

  63.  Kaur  S,  Lyte  P,  Garay  M,  Liebel  F,  Sun  Y,  Li  JC,  Southall  MD. 
Galvanic zinc-copper microparticles produce electrical stimu-
lation that reduces the inflammatory and immune responses in 
skin. Ar Dermatol Res 2011; 303:551–62.

  64.  Chen N, Hu Y, Rossetti D, Chantalat J, Bruning E, Sun Y, et al. 
Biomimetic  Electricity  Generated  by  an  Elemental  Bi-mineral 
Complex Increases Extracellular Matrix Production in Human 
Skin Explants, Poster No.1619, Proc Am Acad Derm, 2010.
  65.  Chen N, Loy CJ, Hu Y, Won YK, Chantalat J, Bruning E, et al. 
Biomimetic  Electricity  Generated  by  an  Elemental  Bi-Mineral 
Complex  Inhibits  Melanogenesis  via  Suppressing  Tyrosinase 
Expression, Poster No. 1621, Proc Am Acad Derm, 2010.

  66.  Won  YK,  Lin  CB,  Seiberg  M,  Chen  N,  Hu  Y,  Rossetti  D,  et  al. 
Galvanic  zinc-copper  microparticles  inhibit  melanogenesis 
via  multiple  pigmentary  pathways.  Arch  Dermatol  Res  2014;  
306:27–35.

  67.  Chantalat  J,  Loy  CJ,  McCarthy  T,  Southall  MD,  Walczak  V, 
Sun  Y,  Liu  JC.  Safety  and  Tolerability  of  a  Topical  Bi-Mineral 
Complex that Generates Biomimetic Signals. P1622 Poster, Proc 
Am Acad Derm, 2010.

  68.  Chantalat J, Bruning E, Sun Y, Liu JC. (Discussion Session), Bio-
mimetic Signaling Technology Generated by a Bi-Mineral Com-
plex Demonstrates Efficacy in Reducing Clinical Photo-Aging 
in a 12-Week Placebo-Controlled Study. Poster No. 304, Proc Am 
Acad Derm, 2010.

  69.  Miller  PD,  Wallo  W,  Appa  Y.  Clinical  Improvements  in  Facial 
Photo-Aging with Topical Application of a Biomimetic Mineral 
Complex  and  Naturals  Extract  Formulation.  Poster  No.  1638, 
Proceed Am Acad Derm, 2010.

  70.  Hornby SB, Miller D, Stephens T, Sigler, M, Herndon J, Appa Y. 
Facial  Moisturizer  Featuring  Biomimetic  Signaling  Technol-
ogy  From  A  Bi-Mineral  Complex  Reduces  Skin  Laxity.  Poster 
No.  625, Proc Am Acad Derm, 2010.

  71.  Chantalat  J,  Bruning  E,  Sun  Y,  Liu  JC.  Biomimetic  Signaling 
Technology Generated by a Bi-mineral Complex Reduces Signs 
of Photo-Aging in the Eye Area. Poster No. 1624, Proc Am Acad 
Derm, 2010.

  72.  Lanctin M, Roure R, Nkengne A, Bertin C, A Cosmetic  Product 
Containing  Biomimetic  Signaling  Technology  to  Improve  the 
Aging  Signs  in  the  Eye  Area.  Poster  No.1623,  Proc  Am  Acad 
Derm, 2010.

  73.  Nollent V, Lanctin M, Nkengne A, Bertin C. Clinical evaluation 
of a zinc- copper-based eye area anti-aging complex. Cosmetics 
and Toiletries, 2012; 127(10):718–25.

 
53

Chemical Peels

Philippe Deprez

INTRODUCTION
Various  peeling  formulas  are  currently  available,  many  of 
them  resulting  of  a  more  or  less  adequate  combination  of 
chemicals whose aim is usually to peel the skin and induce 
a  skin  rebuilding,  an  architectural  restructuration.  Some 
peels  consist  of  strongly  destructive  solutions,  able  to  dis-
solve  the  full  skin  thickness;  others  are  simply  stimulating 
solutions with little destructive power; their application can 
induce a nearly invisible skin desquamation. The difficulties 
of  peels  procedure,  the  results,  the  inconveniences,  and  the 
side effects are often directly linked to the depth reached by 
the acids.

Not much will be said about pre-peel skin conditioning 
in this chapter, breaking a quasi-dogma. Indeed, there is a pos-
sible way to do peels that makes this pre-peel strict condition-
ing not often necessary. I just use peeling formulas that usually 
penetrate evenly and that dramatically slow down the imme-
diate  post-peel  inflammatory  reaction,  mainly  responsible 
for  postinflammatory  hyperpigmentation  (PIH).  The  rest  is  a 
question of good indication (don’t go too deep if not necessary) 
and the practitioner’s ability or experience.

Pre-peel  conditioning  is  principally  used  when  a  quite 
deep chemical peel has to be done on a phototype IV to VI: in 
this case, molecules are used to equalize the acid penetration 
(glycolic  acid,  tretinoin),  to  speed  up  epidermal  regeneration 
(pre-peel Tretinoin does that but immediate post-peel tretinoin 
has a contrary effect; vitamins). Pre-peel conditioning is also 
necessary to induce melanocyte sedation and lower the risk of 
post-inflammatory hyperpigmentation. Many other molecules 
can be used during pre- and post-peel periods.

to  the  inhibition  of  enzymes  involved  in  the  formation 
of  ionic  links.  For  example,  AHAs  could  compete  with 
sulfates and phosphates at the level of sulfotransferases, 
phosphotransferases, or kinases, involved in the forma-
tion of sulfated or phosphorylated mucopolysaccharides, 
glycoproteins,  sterols,  and  lipids.  This  could  produce  a 
lower  quantity  of  electrically  negative  groups  on  the 
surface of keratinocytes and corneocytes and lower the 
adhesion  forces  with  amines  or  basic  aminated  acids 
(electrically positive).

Basically,  AHAs  penetrate  between  cells,  unsticking 
the proteins responsible for corneo-desmosome adhesiv-
ity  (it  is  a  non-covalent,  electric  link)  and  allowing  the 
cells  to  separate  from  each  other,  inducing  desquama-
tion.  Since  there  is  no  strict  chemical  reaction  during 
this process, AHAs are not much consumed and have to 
be neutralized. Rinsing with a basic solution stops their 
action.

Clinical signs: Irritative erythema is usually the only vis-
ible sign.

Desquamation:  Roughly,  no  desquamation  is  clinically 
seen

Risks  and  Problems:  Globally,  this  is  not  a  risky  depth. 
Main  risks are a  higher  sensitivity to  sun  during some 
days and a higher risk of skin infections. Neutralization 
is the main problem: if too early, it gives no result; if too 
late, it could induce more side effects. We will see later 
that this problem can be avoided by using specific slow-
release and self-neutralizing AHA mixtures.*

DEPTHS OF PEELS
I usually consider seven depths of peels, as seen in Figure 53.1.

Depth 1—Exfoliation: VHS
The most superficial peel consists of simple exfoliation of stra-
tum corneum dead cells: it gives a good skin cleansing, a touch 
of  better  hydration.  This  “hydration  touch”  results  in  reality 
of skin damage: the peel has removed the protective stratum 
corneum layer and the fingers are now directly in contact with 
superficial  keratinocytes.  Keratinocytes  are  living  cells  (only 
the most superficial layers are near to death), containing more 
water than stratum corneum cells.

Main types of peels: Alpha hydroxy acid peels are mostly 
used for this exfoliation purpose.

Depth 2—Intraepidermic Peel: VHS
The  peel  solution  penetrates  deeply  into  the  epidermis,  
removing more cells; nevertheless, it does not touch any part of 
dermis or the basal layer. The final touch of the skin is still more 
hydrated than in the case of simple exfoliation (depth 1). After 
the peel, living keratinocytes are suddenly directly exposed to 
air, sun, pollution, and dryness. They react, synthetizing more 
TNFa  (inducing  a  faster  transformation  of  keratinocytes  into 
corneocytes) and sending a message to the basal layer in order 
to stimulate  basal  layer  turnover and substitute  the removed 
cells with new ones. At the same time another message reaches 
the fibroblasts, responding by stronger synthesis of all the der-
mal intercellular matrix.

Intraepidermic  peels  (depth  2)  give  better  results  than 
depth 1 peels and can be used for treating superficial epider-
mal melasma and many keratinization problems.

Action  mode:  The  activity  of  AHA  on  the  corneocytes 
seems  to  be  secondary  to  an  action  on  ionic  charges, 

* Easy Phytic Solution.

Stratum disjunctum

Stratum compactum

Keratinocytes K

Basal layer

Lower limit of papillary dermis

K

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

GZ

CHEMICAL PEELS 

  499

Exfoliation
Very high security

Basal layer peel
Grenz zone peel

Intraepidermal peel
High security

Papillar dermis peel
Still secure zone

Superficial reticular
dermis peel
Quite secure zone

Deep reticular dermis peel
Difficult, dangerous

Overpeel
Unsecure

Hypodermis

Figure 53.1  Graph showing the various possible depths of peel.

tridimentional  structures  in  a  way  that  does  not  allow 
their normal function. All membrane proteins are there-
fore damaged, making the keratinocytes unable to sur-
vive.  In  the  same  time,  intercellular  proteins  are  also 
coagulated.

Clinical signs: More clearly visible erythema can be seen, 
but no white pinpoints appear yet (Figure 53.2).

Desquamation: Can look like very thin dandruff.

Risks  and  problems:  Intra-epidermic  peels  are  usually 
not  dangerous.  Nevertheless,  cases  of  post  inflamma-
tory  hyperpigmentation  (PIH)  have  been  seen,  making 
prevention of this side effect necessary when the skin is 
known to be sensitive. Neutralization of AHAs remains 
the main problem since it must be done following strict 
rules (neutralization has to be done when an erythema 
appears—it  is  always  irregular  erythema—and  in  any 
case, before any sign of protein coagulation that would 
appear  as  skin  frosting  points).  It  is  difficult  to  foresee 
the right moment for an ideal neutralization.

With TCA, no neutralization can reverse the proteinic 
coagulation; therefore the total amount of TCA applied 
on the skin has to be perfectly calculated, in relation with 
the  skin  permeability.  The  TCA  application  technique 
has to be perfect for even penetration. Resorcine and sal-
icilyc  acid  are  phenol  derivatives,  not  widely  used  out 
of the United States. Treatments of large surfaces using 
phenol  derivatives  are  suspected  to  potentially  induce 
toxic reactions. TCA and AHAs, on the other hand, are 
not toxic products.

Figure 53.2  Erythema: intraepidermal peeling.

Main types of peels: Alpha hydroxy acid peels, alpha ceto 
acids,  trichloracetic  acid  (TCA),  resorcine  peels,  and 
 salicylic acid can be used.

Action  mode:  We  have  roughly  seen  how  AHAs  work. 
TCA  is  a  proteocoagulant  chemical.  When  in  con-
tact  with  proteins,  it  coagulates  them,  modifying  their 

Depth 3—Basal Layer Peel: HS
This is a very interesting peel level, since it is easily reached 
and gives good results. Stratum corneum cells are completely 
removed; keratinocytes are largely damaged up to the level of 
basal layer keratinocytes (depth 3 in the graph) (Figure 53.3).

 
500 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Desquamation:  Looks  like  a  sunburn  desquamation, 
allowing a social life in the majority of cases.

Risks  and  problems:  Basal  layer  peels  are  usually  not 
dangerous  peels.  The  application  technique  is  impor-
tant since a perfect protocol is very secure. If the peel 
application  is  a  little  bit  too  strong,  basal  layer  peel-
ing  can  nevertheless  give  the  start  to  a  vicious  cycle 
of  inflammation  based  on  free  radicals  liberation  that 
induces  cells  damage,  etc.  If  we  allow  this  inflamma-
tory vicious cycle to begin, melanocytes could react and 
cause  post-inflammatory  hyperpigmentation  (PIH). 
Cases of PIH have been seen, making the control of this 
post-peel  inflammatory  vicious  cycle  necessary.  No 
 herpes   prevention  is  necessary.  Problems  are  mainly 
linked  to  too-strong  melanocyte  stimulation,  without 
adequate treatment, or to an irregular application, too-
deep  application,  or  infectious  rebounds  in  cases  of 
acne. Pre-peel skin conditioning can be used from this 
point if the peel used does not penetrate evenly or does 
not control the post-peel inflammatory reaction. Using 
Easy TCA peel, no pre-peel conditioning is necessary. 
Except in cases of deep scratching and/or strong local 
infection,  no  scar  is  to  be  anticipated  from  this  peel 
depth.

Figure 53.3  Before and after four sessions of Easy TCA (Skin 
Tech), one peel every week, basal layer depths.

Epidermis  is  nevertheless  not  completely  destroyed, 
since many keratinocytes—less damaged by UVs—are living 
in deep epidermal papillae; skin regeneration is fast and easy.
Basal layer peels can be used as serial peels for treating 
skin aging (Glogau 1–2), fine lines, epidermal melasma, kera-
toses,  and  acne  (from  black  dots  up  to  papule-pustule  acne). 
Together with a good control of melanin synthesis (blending 
bleaching cream*), a TCA basal layer peel can treat many cases 
of  melasma.  If  attention  is  paid  to  adequately  clean  the  skin 
(remove  black  dots,  open  microcysts  etc.)  and  if  the  patient 
applies  disinfecting  creams  and  creams  limiting  sebum 
production,  than  we  can  treat  active  acne,  usually  without 
antibiotics.†

Main  types  of  peels:  AHAs  should  not  be  used  at  this 
depth  since  this  is  the  border  after  which  AHA’s  side 
effects are prone to appear, are difficult to treat, and are 
inconvenience  for  the  patient’s  social  life.  TCA  repre-
sents the best choice for this depth, if the right concen-
tration, formula, and post-peel care are selected.

Action mode: We have seen (see depth 2) the TCA action 
mode:  keratinocyte  destruction  induces  a  basal  layer 
strong  reaction,  dramatically  stimulating  the  turnover 
of basal cells.

Clinical  signs:  TCA  coagulates  proteins  and  its  entry 
through  the  domes  of  papillae  induces  a  specific  pro-
teinic  coagulation;  dermal  protein  coagulation  points 
occur, clinically appearing as little white marks (white 
pinpoints) called “frosting points.”

* Skin Rebirth®
† See www.estetik.com, peelings, treatment tips.

Depth 4—Grenz Zone Peel: HS
This is a very interesting peel level, easy to perform, not very 
painful for the patient, with a low level of risk and pretty good 
results.  Stratum  corneum  and  a  large  part  of  keratinocytes 
are  destroyed.  Acids  penetrate  slightly  into  the  more  super-
ficial  layers  of  papillary  dermis,  eliminating  abnormal  cells 
from  epidermis  (treatment  of  lentigines,  keratoses),  eliminat-
ing  many  keratinocytes  excessively  charged  in  melanin  and 
melanocytes  producing  the  melanine  (melasma).  Grenz  zone 
(German, meaning border area) peel also directly stimulates the 
superficial  coats  of  papillary  dermis,  allowing  a  strong  colla-
gen and elastin deposit into the Grenz zone. These Grenz zone 
peels, together with basal layer peels, are the depths of peel I 
use the most frequently.

Main types of peels: TCA is the must for these depths. AHAs 
are not used because of their irregular penetration, mak-
ing their use risky for Grenz zone peels. Resorcine and 
salicylic acids are difficult to use for reaching exactly the 
Grenz zone. Phenol should be kept for other indications.

Action  mode:  We  have  seen  the  TCA  action  mode.  TCA 
coagulates  keratinocyte  proteins  and  also  dermal  pro-
teins, inducing a wider skin “frosting.”

Clinical  signs:  No  more  pinpoints  of  frosting,  but  “frost-
ing  clouds”  are  seen,  together  with  a  diffuse  erythema 
(Figure 53.4).

Desquamation:  Desquamation  looks  like  a  strong  sun-
burn,  easy  to  live  with  if  the  skin  is  fair.  Nevertheless, 
dead  skin  becomes  dark  brown  on  darker  phototypes 
(Figure 53.5).

Risks and problems: The patient’s social life, especially dark 
phototype patients, can be difficult for a few days. At the 
same time, the risk of PIH becomes higher, making “pig-
ment  synthesis  sedation”  quite  interesting  before  and 
after this peel depth. PIH prevention is mandatory if the 

 
CHEMICAL PEELS 

  501

wrinkles or skin sagging. When strictly respected, this depth 
is safe regarding scarring: scars should never appear when a 
peel is strictly limited to the level of papillary dermis.

Main  types  of  peels:  AHAs,  Salicylic  acid  peels,  alpha 
keto  acids,  and  resorcine  are  not  good  choices.  Phenol 
sometimes has been used to perform a depth 5 peel, but 
the  related  (cardiac,  renal,  hepatic)  toxicity  makes  me 
avoid its use at this depth. TCA peel, if correctly applied, 
remains the master choice for a safe and efficient papil-
lary dermis peel.

Action  mode:  The  TCA  action  mode  has  been  described 
above.

Clinical signs: After application, frosting clouds progres-
sively or rapidly become a pink-white uniform frosting 
that can progressively or rapidly turn into a pure white 
frosting (Figure 53.6).

Why progressively or rapidly? Passing from clouds to 
even  frosting  is  progressive  when  we  use  relatively  low 
concentrations, as Unideep* (23% w/w) (Figure 53.7). This 
concentration allows the doctor to stop his (very safe) appli-
cation as soon as the desired frosting appears. Conversely, 
an even pure white frosting rapidly appears when using 
higher TCA concentrations, like 35% or 40% (w/w). In this 
case, it is not possible to stop the TCA action. It can be com-
pared to initiating an artificial fire: we know how big the 
firecracker is, but we are not sure about the final result of 
the spectacle. Nevertheless, when the fuse is inflamed, it is 
impossible to stop it or modify the course of future events. 
Identically, to believe that it is possible to undo (by neu-
tralization) what TCA has done is a deep misunderstand-
ing.  Frosting  appears  as  pink-white  as  long  as  the  acids 
did  not  coagulate  the  blood  vessel  proteins.  When  acids 
have been strong enough to coagulate the well-defended 
perivascular area, blood cannot pass beyond the top of the 
dermal  papillae,  close  to  the  epidermis  basal  layer,  and 
frosting tonality passes from pink-white to pure-white.

At the same time as the acids penetrate dermis, they 
coagulate proteins, sticking epidermis to dermis, and the 
sign of “epidermal sliding” appears. This sign will last 
for a while and disappear when dermal edema is strong 
enough for tenting the epidermis over it.

Desquamation:  Is  quite  important,  as  it  looks  like  a 
snake changing its skin and lasts from about 6 days to 
8–12 days (usual TCA in water solution, pharmacy made) 
(Unideep peel, SkinTech) (Figure 53.8). Social life is usu-
ally  possible  during  the  first  evening,  but  not  from  the 

Figure 53.6 

“Frosting Clouds”: Easy Tca Grenz Zone Peel.

* See www.skintech.info

Figure 53.4  Basal layer peeling: frosting points.

Figure 53.5  Desquamation after Easy TCA up to Grenz zone.

patient is phototype Fitzpatrick 4 or more, or works out-
side in a sunny environment. Infections are uncommon 
at  this  depth,  since  the  immune  system  is  still  widely 
valid. Herpes prevention is not yet obligatory, except in 
special cases of frequent, recurrent herpes attacks. Other 
problems are the same as for basal layer peels.

Depth 5—Papillary Dermis Peel: S
Depth 5 peel is the dividing line between secure and insecure 
depths. Here we reach positive limits in the sense that a depth 
5 peel is able to treat many skin defects such as lentigines, solar 
keratoses,  melasma,  freckles,  and  fine  lines.  Negative  limits 
are that since a papillary dermis peel is not able to treat real 

 
502 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 53.7  Frosting of Unideep Papillary Dermis Peel.

Figure  53.8  Desquamation  Day  4  After  Unideep  Papillary 
Dermis.

next morning. Days 2 to 6 are days of reclusion, during 
which skin will largely peel in more or less dark plaques, 
in relation with the phototype.

Risks and problems: The most immediate risk consists of 
infections:  viruses,  bacteria,  and  mycoses  find  the  skin 
totally open and without defenses. It is easy for them to 
penetrate and locally proliferate. It is therefore manda-
tory to prevent viral infections using herpes prevention 
(valacyclovir i.e., 3–4 days before and 4–5 days after peel). 
Bacterial and mycotic infections can be avoided by strict 
control of medical hands and material cleanliness as well 
as by avoiding any other source of iatrogenic infections. 
The patient has to be aware to wash his hands before any 
contact  with  his  skin  (like  scratching),  to  avoid  direct 
contact with mammal or non-mammal pets, and to call 
the doctor for any question or inconvenience that could 
arise.  Scratching  the  skin  after  papillary  dermis  peel 
usually  induces  infection.  Non-  or  badly  treated  infec-
tions could induce PIH, depigmentation, or scarring.

Another risk comes from the fact that not every peel-
ing solution is able to evenly penetrate the skin. Simple 
TCA-in-water solutions irregularly penetrate the tissues 
and can give uneven results: some areas are too deeply 
treated  (causing  local  erythema,  pigmentations,  depig-
mentations, infections, scarring.)

The  real  action  of  TCA  being  largely  hidden  during 
the application process, damage can occur that the practi-
tioner cannot see immediately and hence  cannot correct. 

Therefore, the concentration of the peeling solution and, 
more important, the total amount of TCA applied on the 
skin during a period of time, has to be strictly calculated 
before application. No neutralization of TCA is possible, 
as will be explained later.

When  using  a  simple  TCA-in-water  solution,  skin 
conditioning  is  mandatory  for  four  main  reasons:  to 
allow  a  more  even  penetration,  to  allow  a  deeper  pen-
etration and hence a better result, to keep melanocytes in 
rest and limit the occurence of PIH, and to stimulate the 
basal layer turnover and facilitate post-peel skin regen-
eration.  Mixtures  of  AHAs,  tretinoine,  and  hydroqui-
none are often used for this purpose.

Depths 6–7—Reticulary Dermis Peel: QS–D
(Range  is  from  “QS”—the  risks  largely  depend  on  many 
parameters, controllable or not, to “D”—it is always dangerous 
to perform such a deep peel, but it can be done in some cases.) 
Reticular dermis peel is a kind of Holy Grail of peeling: this 
depth  of  peel  allows  treating  nearly  every  pigment  problem: 
it  tenses  the  skin  and  removes  wrinkles.  Nevertheless,  thick 
and oily skins are not the best candidates for a reticular dermis 
peel  since  these  skins  resist  very  well  to  the  action  of  acids. 
Unfortunately folds usually resist the action of deep peels. Very 
often, we have to discuss with the patient the choice between 
two  therapeutic  options:  surgical  lifting  or  deep  peeling.  At 
Hera Clinic (Empuriabrava, Spain), our first guide is a simple 
decision table (Table 53.1). Naturally, this has to be adapted to 
the specific skin and situation. The global meaning is that we 
will not recommend a phenol peel to a patient with thick sag-
ging skin and no sun aging problem. Conversely, we will not 
recommend surgery to a patient with thin skin, without sag-
ging but with important pigment or sun aging problems.The 
quest for the Holy Grail is a risky trip, as also is deep reticular 
peeling.  Not  only  does  the  selected  peeling  solution  have  to 
be perfectly adapted to the doctor’s and the patient’s aims, but 
also  the  application  technique  and  post-peel  care  have  to  be 
totally  professionally  done.  Full-face  reticular  peel  is  a  very 
aggressive  treatment  that  leaves  no  room  for  improvisation. 
Any mistake can cause scarring, and pigmentary problems are 
frequent.  Nevertheless,  reticular  peels  are  pearls  in  the  right 
hands and the right circumstances.

Main  types  of  peels:  Two  main  molecules  are  used  for 
reaching this depth: TCA and phenol. I really appreciate 
concentrated  TCA  for  performing  focal  deep  peels,  for 
deeply treating lentigine and keratoses less than 1 cm in 
diameter (Only Touch, for example, is a 45% w/w TCA), 
but  I  would  not  be  keen  to  use  it  for  large  areas,  as  a 
full face peel. In this case, phenol seems to be better; its 
activity depth can be better kept under control and the 
results  are  definitively  better,  even  at  similar  depth  as 
TCA. Phenol seems to have a better “rebuilding effect” 
on  the  skin  than  TCA.  My  best  phenol  peel  is  actually 

Table 53.1  Problems and Preferred Treatments

Problem

Preferred Treatment

Pigmentary 
problems
Sagging skin

Peelings

Surgery

Pigmentary and 

1/ surgery wait 6 months  

sagging

Thick skin

Thin skin

2/ phenol peel

Peeling

Surgery

 
Lip  and  Eyelid  Formula  (SkinTech),  which  is  an  oil  of 
phenol,  penetrating  slowly  into  the  skin,  which  limits 
its general toxicity (giving the liver, lungs, and kidneys 
more time for detoxifying it) and allows a longer contact 
time between phenol and the skin proteins, inducing a 
potential  larger  protein  coagulation  and  hence  a  better 
result (Figure 53.9).

Action  mode:  Phenol  is  proteolytic  or  proteocoagulant, 
depending  on  the  concentration.  Higher  concentra-
tions are proteocoagulant and lower concentrations are 
proteolytic.  For  peeling  purposes,  the  best  concentra-
tion range is 40% – 60% (w/w). Nevertheless, many sub-
stances can interfere with its action and speed up or slow 
down its penetration. These substances are described at 
greater length in (1).

Clinical signs: Acids reach reticular dermis after having 
largely coagulated papillary dermis, showing a pink- or 
pure-white frosting (depending of the concentration, an 
agressive  peel  will  develop  an  immediate  pure-white 
frosting,  without  passing  through  a  pink-white  one). 
After the typical papillary dermis frosting, the tonality 
quickly will shift to a grey-white or grey frosting.

It is possible to reach this depth by applying various 
acids  concentrations;  nevertheless,  I  have  always  felt 
more comfortable using less concentrated products, but 
applying more coats. Indeed, when we are using proteo-
coagulant products, the final result depends on the total 
amount of active acid molecules that have been able to 
interact with skin proteins. A very strong and aggressive 
peeling solution could induce a superficial thick coagu-
lation,  only  letting  pass  the  acids  at  the  level  of  higher 
skin permeability, which could induce irregular results 
and local overpeeling. When using a progressive appli-
cation technique, we can always decide to apply no more 
acid on the higher permeability areas, and keep applying 

Figure  53.9  Frosting  of  Otp  +/-  Desquamation  Secondary  to 
Intraepidermic Peel. Abbreviation: Otp, Only Touch Peel.

CHEMICAL PEELS 

  503

on the areas where we did not see the desired frosting 
appear.  Doing  that  has  allowed  me  to  have  zero  over-
peels in the last 20 years.

Desquamation:  Desquamation  is  huge,  always  forcing  a 
social retirement of 7–8 days. Dead skin layers should be 
left in place as a natural protection and only extracted at 
around day 6 or 7, as long as this extraction is easy and 
atraumatic.  Phenol  peel  can  be  used  under  a  complete 
24-hour  occlusion,  inducing  a  maceration  of  the  upper 
coats of the skin. During occlusion, skin melts (in open 
techniques, skin usually  dries)  and has  to  be protected 
by  using,  i.e.  Bismuth  subgallate  powder.  From  day  5 
or 6, sterile petrolatum jelly can be applied on the dead 
skin  to  help  with  desquamation.  Occlusion  causes  the 
phenol peel to be deeper and more efficient. TCA occlu-
sion does not have the same result.

Risks  and  problems:  Histologically,  there  is  only  one 
reticular dermis, situated between papillary dermis and 
subcutaneous  tissues.  However,  with  peels,  we  have  to 
consider that we face two different depths.

Into  the  more  superficial  reticular  dermis,  overall  at 
the face level, we still can find keratinocytes (mainly at 
the level of hair roots and sebaceous glands—sebocytes 
are  phenotypically  differentiated  keratinocytes,  able  to 
undifferentiate into normal keratinocyctes when neces-
sary to repair the skin). Superficial reticular dermis still 
has material to rebuild the skin. Deep reticular dermis is 
empty of this reservoir but contains big fibroblasts, also 
differentiated to be able to synthetize a thick bundle of 
collagen that will stick to the neighbor fibroblast. In addi-
tion, they are considered contractile nonmuscular cells, 
able to contract when necessary. They are one of the main 
things  responsible  of  the  scarring  process:  when  these 
cells  are  strongly  stimulated  during  a   self-maintained 
inflammatory vicious cycle, scarring can appear.

Problems: All possible side affects can appear when using 
deep peeling. Pigment problems are frequent, since deep 
TCA kills melanocytes and phenol can make them impo-
tent,  unable  to  synthesize  melanin.  As  a  result,  many 
cases  of  unaesthetic  depigmentation  have  been  seen  in 
the  past.  A  new  formulation  (Lip  and  Eyelid  Formula, 
SkinTech)  seems  to  be  much  safer  in  this  regard,  since 
it induces mainly PIH, which is easy to treat, other than 
“porcelain  skin,”  which  cannot  be  treated.  Table  53.2 
summarizes many of the possible side effects.

ABOUT ACID NEUTRALIZATION
Acid  neutralization  is  a  recurrent  problem.  Why  neutralize? 
What to neutralize? How to do it? When to do it? Together with 
dermatological  use  of  AHAs  appeared  the  notion  of  neutral-
ization;  pre-existing  peels  (i.e.  phenol  derivatives  and  TCA) 
had  not  been  and  could  not  be  neutralized,  since  proteoco-
agulant  molecules  definitively  interact  with  skin’s  proteins 
and combine with them, forming a kind of conglomerate that 
cannot be separated. As a result of this interaction, non-AHA 
acids  are  largely  and  automatically  neutralized  and  trapped 
into  destroyed  proteins  in  which  tridimentional  structures 
have  changed,  inducing  the  well-known  sign  of  “frosting.” 
Neutralization  of  proteocoagulant  acids  is  therefore  impos-
sible  after  their  action  has  begun.  At  a  maximum  we  could 
neutralize an eventual floating excess over the skin, before this 
excess can penetrate the skin.

 
504 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 53.2  Possible Side Effects

Locoregional side effects

Insufficient results

Regional side effects

Larynx oedema

Post inflammatory hyperpigmentations

Long lasting face oedema

General side effects (phenol)

Symptoms occurring rapidly

Neurological problems: headaches, 

acouphens, hypoacousy, paresthesies, 
muscle hypotony, stupor

Melanotoxicity (up to porcelaine skin)

Dynamic wrinkles resurgence

Digestive problems: Nauseas, Vomit, Pain 

in belly, diarrhoeas

Cardio vascular problems: Arrythmias, 

Asystoly

Symptoms occurring later

Nephropathy

Hepatopathy

Hemoglobinury, Methemoglobinury

Demarcation line

Erythema

Télangiectasies

Not even complexion

Scars ( + ectropion or entropion )

Prurit

Scratching lesions

Bactérian, viral, mycotic surinfections

Acné, milium grains

Conjunctivitis

Iritis, opacification of cornea

Post peel pain

Sun sensibilitéy

Dilation of pores

Petechies, purpura

Is  this  even  really  possible?  This  idea  of  neutralizing 
proteocoagulant acids (as is TCA) is in reality extremely tricky 
since we have to introduce a time scale in our discussion: the 
appearance of a frosting is a signature of past events. The frost-
ing that we see right now does not represent what is actually 
happening, but what happened into the skin some time ago*. 
Frosting  events  have  some  kind  of  invisible  inertia;  they  are 
not  immediately-appearing  phenomenons;  proteocoagulation 
will continue going on during the neutralization process. It is 
therefore very risky to apply too much of the phenol derivative 
or  TCA  acid  on  the  skin,  thinking  that  it  will  be  possible  to 
neutralize it after seeing a frosting to appear. That is the best 
way to cause overpeeling. To try to neutralize TCA after seeing 
a frosting could be compared to trying to stop an arrow just 
before it touches the target. In addition, neutralizing a proteo-
coagulant acid will never reverse the potential damage caused 
to cellular proteins or matrix proteins. When an acid combines 
with amino acids into a protein, it is transformed to a salt that 
sticks  to  this  amino  acid  and  modifies  the  volumetric,  tridi-
mentional, proteinic appearance.

This is why a safe behavior is to rub on the skin the right 
amount of acids to get the desired frosting, without any neu-
tralization. Remember that only a few seconds are necessary 
for  proteocoagulant  acids  to  pass  through  epidermis:  that  is 

* The frosting we see in T(0) results from a past action of the acids into 
the skin. It can be compared to the fact that the starlight that we see 
has been emitted millions years ago (the age of universe being sup-
posed to be at least 17,300,000,000 years). What we see in the night sky 
can have been emitted in the past by a star that is now dead and maybe 
now transformed into a black hole after a last fantastic explosion fol-
lowed by a contraction to infinite levels of energy. The frosting we see 
in T(0) results from a past action of the acids into the skin.

why  phenol  induces  a  skin  anaesthesy  only  12  seconds  after 
its application! †

We have also seen that AHAs have a very low proteoco-
agulant power; they do not easily combine with proteins. Their 
natural neutralization by the skin can only be done by using 
the  skin  buffer  potential,  which  is  too  slow-acting.  Without 
neutralization,  pure,  non-partially  neutralized  AHAs  would 
eventually burn the skin.

We  cannot  neutralize  an  acid  by  adding  water  to  it. 
When we pour water in a recipient containing an acid solution, 
we only dilute the acid; a huge dilution is necessary in order to 
lower the resulting pH. Pouring water on the face after peeling, 
cannot  therefore  be  considered  as  neutralization.  Pouring  a 
basic solution in a recipient containing acid will induce chemi-
cal acid-base reactions; the acid will become a salt that has no 
more protons to liberate in solution and therefore is no more 
acid.  Neutralization  changes  the  chemical  structure  of  acids. 
Simple sodium bicarbonate in a saturated solution can be used 
to neutralize AHAs.

Finally,  the  answers  to  the  questions  at  the  beginning 
of  this  section  are  simple:  we  neutralize  AHAs,  but  we  can-
not  neutralize  proteocoagulant  molecules.  A  slightly  basic 
solution, in good volume, will be poured on the skin until the 
end  of  the  chemical  reaction  (usually  seen  as  little  bubbles). 
Neutralization of AHAs should begin as soon as an erythema 
can be seen and before any frosting appears.

We  touch  here  the  big  question:  when  to  neutralize 
AHAs?  Too-early  neutralization  does  not  allow  enough  time 
for acids to interact with the skin, and the result will be very 
poor.  A  too-late  neutralization  allows  acids  to  burn  the  skin 
and  induces  many  side  effects.  That  is  why  the  industry 

† That fast, phenol coagulates sensitive nerve sensors, inducing local 
anesthesia.

 
proposes  partially  neutralized  AHAs  (  pH  2.5,  3,  3.5)  which 
are less dangerous and can be washed with simple water, since 
they are between 10 and 1000* times less aggressive (efficient) 
than pure AHA solution, without partial pre-neutralization.

There is one exception, called Easy Phytic Solution (EPS). 
In spite of the solution’s very acid pH (0.5–1) and a total con-
centration  of  acids  of  average  60%,  this  AHA  medical  device 
does not need to be neutralized. The time-controlled technol-
ogy  permits  slow  release,  complete  progressive  penetration, 
and full action of all acids. Absence of neutralization = absence 
of problems and greater efficacy. The best indications are acne 
and photoaging prevention and treatment. EPS is made up of 
three AHAs: glycolic acid, lactic acid, and mandelic acid. AHA 
is adsorbed on the polar groups of keratin chains and inhibits 
the  reactions  between  these  groups.  This  improves  elasticity 
of  the  skin,  and  alpha  hydroxy  acids  are  better  for  that  than 
beta hydroxyl acids because the alpha position of the hydroxyl 
group allows a better penetration between keratin chains than 
the beta position. The three AHAs show different velocities of 
penetration through the skin. The smallest one, glycolic acid, 
penetrates  first,  followed  by  the  lactic,  followed  by  the  man-
delic. These acids begin their action at the level of the upper 
layers  of  the  epidermis.  Because  there  is  no  neutralization, 
they  continue  their  action,  going  down  inside  the  epidermis 
and reaching the dermis, slowly and without ever passing the 
capacity of natural neutralization by the skin itself, so, the acids 
of  EPS  progressively  lose  their  aggressiveness  into  the  skin, 
producing their full activity. Phytic acid is not an AHA, but a 
big molecule of inositol hexaphosphoric acid considered as an 
excellent antioxidant and an antityrosinase. It binds out iron. In 
our point of view, phytic acid is unable to produce any peeling 
effect, so why do we find phytic acid in this solution? Actually, 
every peel produces an inflammation; this inflammation pro-
duces  free  radicals  (FR)  and  vasodilatation.  Vasodilatation 
brings more oxygen in situ allowing the formation of more FR. 
FR binds immediately with the closest structure, damaging it. 
So a peel always promotes the skin regeneration but induces a 
lot of FR that can damage the structures that are supposed to 
regenerate the skin during the post-peel period. The actual sci-
entific understanding of the aging processes generally blames 
FR as one of the major causes of cell degeneration. It is impor-
tant to fight these FR during the post-peel period. Phytic acid 
slowly  penetrates  the  skin,  after  the  three  AHAs  of  the  EPS 
solution have opened it, and can be present in the skin when 
FR are produced in parallel to the inflammation. Scavenging 
FR  cuts  the  vicious  cycle  of  inflammation-vasodilatation-FR 
and scavenges the FR produced post-peel.

It  is  known  that  AHAs  make  a  thicker  epidermis  and 
produce  more  polymuccosaccharids  in  the  dermis  and  a  bet-
ter quality elastin. The density of papillary dermis collagen is 
better, and patients under EPS describe a tightening sensation 
after peeling and a visible difference of the aspect of the skin.

How  to  use  it?  Cleanse  the  skin  twice  with  SkinTech’s 
cleanser foam, rinse and dry. Apply a maximum total volume 
of 2.5 cc of EPS on the face, using a little cotton ball, poured 
once only into the peeling solution. Apply it in successive coats, 
massaging the face between every coat for uniform coverage.

When the patient says he feels a tingling sensation, apply 
the  last  coat,  using  the  same  cotton  ball,  No  frosting  at  all 
should occur. Two or three coats are usually sufficient. In the 
event  of  accidental  frosting,  neutralize  immediately  (sodium 

* Logarithmic relation between pH and agressivity: pH 3 is 10 times 
less aggressive than pH 2, 100 times less than pH 1.

CHEMICAL PEELS 

  505

bicarbonate solution). DO NOT NEUTRALIZE. For more infor-
mation about details of the application technique, please refer 
to the packaging insert or to www.skintech.info.

Another way to manage the peeling neutralization is to 
do it with a neutralizer that modifies its color, depending on 
the  skin  pH.  This  is  what  has  been  recently  done  with  Easy 
Droxy versicolor peel, a medical device patented by SkinTech 
Pharma  Group  (Spain).  A  neutralizing  blue  cream  is  applied 
to  the  skin  at  the  end  of  the  peeling  procedure.  This  cream 
neutralizes  the  skin  and  becomes  yellow  as  long  as  the  skin 
is acid. When the skin is at pH 7, the cream passes from blue 
to green. When the skin pH is over 7, the cream simply stays 
blue. The endpoint of the neutralization is achieved when the 
cream becomes green or stays blue, and this allows control of 
the uniformity of the neutralization process.

ABOUT TCA
Many books have been written about TCA-in-water application 
techniques so I will not go into great detail here. Nevertheless, 
I would like to point out few important things.

The  main  questions  of  beginners  are:  What  is  the  best 
TCA  concentration?  How  many  coats?  How  often?  How  and 
when to neutralize? These are not the good questions since the 
answers would give an appearance of an easy cooking recipe 
to be inflexibly respected.

The easiest of these questions to answer is about when to 
neutralize. TCA action cannot really be neutralized. See above.
The best TCA concentration is the one we selected, that 
simple. The point is to know how to select a TCA concentration 
and  how  to  calculate  it.  I  largely  explained  in  my  Textbook  of 
Chemical Peels (1) why I prefer to use a weight by weight (w/w)† 
calculation and not a weight by volume (w/v) or a volume by 
volume  (v/v)  one.  In  short,  we  are  using  chemical  products 
and  we  should  keep  our  calculations  scientifically  reproduc-
ible and totally correct. Only the w/w calculation makes sense 
from this point of view, even if the w/v or the v/v is more com-
mon in the United States.

The  second  point  is  to  select  the  right  concentration 
for  the  patient.  Remember  two  points:  first,  a  thick-skinned 
patient will need more acid than a thin-skinned patient; sec-
ond, the most important is the total quantity of acid that is able 
to  interact  with  proteins.  Too-concentrated  acid  applied  on  a 
thin skin will burn it immediately but will do a great job on a 
thick, oily skin. Looking at the thickness of the skinfold on the 
area of the malar bone gives us a simple clinical appreciation 
of skin thickness: if the fold is one cm thick, the skin should 
be “normal”; less than 1 cm, the skin is thin, more than 1 cm, 
the skin is thick. Thin skin is more sensitive to acids than thick 
skin, so this can help us to select the concentration.

Transepidermal acid penetration does not only depend 
on  skin  thickness,  it  also  depends  on  the  type  of  acid  itself 
(a  little  acid  will  penetrate  faster  than  a  big  one—long  fatty 
acids for example, penetrate more slowly through the skin than 

† Indeed, a 40% TCA solution could be calculated in many ways: 40 gr 
TCA + 60 gr water or 40 gr TCA + 100 mL water or 40 gr TCA + the 
necessary quantity of water for obtaining a final 100 mL solution or 
even,  100  gr—or  100  mL—of  any  of  the  above  described  solutions, 
diluted  with  water  in  w/w,  w/v  or  w+v.  This  makes  too  many  pos-
sibilities, too many ways to create errors. For more reproducible peel-
ings, I definitively selected the w/w concentration. For me, 40% TCA 
is always 40 gr of fresh TCA crystals mixed with 60 gr of water to do a 
final weight of 100 gr. This is a true 40%.

 
506 

 TEXTBOOK OF COSMETIC DERMATOLOGY

the little lactic acid). Transepidermal penetration also depends 
on  the  skin  permeability,  on  the  pre-peel  skin  condition-
ing.  A  thick  oily  skin*,  after  skin  conditioning†  and  acetone‡
degreasing  can  become  as  permeable  as  a  thin  skin.  A  skin 
dermabrasion (preferently using 3M wet or dry sandpaper 200) 
easily removes the stratum corneum and greatly deepens the 
action  of  the  acids.  I  use  this  quite  difficult  technique  that 
I call “anterior chemabrasion” together with Easy TCA peel in 
the treatment of acne scars and old atrophic and deep stretch 
marks, with splendid results.

We can see that many events are able to modify the skin 
permeability:  did  the  patient  do  a  scrub  to  have  clean  skin 
before seeing you? The skin will be more permeable. Did the 
patient wax the face before peeling for depilation? More per-
meability!  Did  the  patient  apply  an  oily  moisturizing,  a  sun-
screen, a gel containing hyaluronic acid before coming? These 
will reduce skin permeability.

How  many  coats  to  apply?  Every  peeler  would  like  to 
have a clear and simple answer to this question. Unfortunately, 
the number of coats depends on what is described above about 
skin permeability. It also depends on the TCA concentration of 
the solution. Note also that considering concentration alone is 
tricky because there are so many variants that the problem of 
concentration is only a small part of the global decision.

Globally,  we  can  go  two  different  ways.  The  first  one 
consists of guessing what will be the right concentration for a 
single patient’s skin … and praying for days, hoping that there 
was no mistake and that the acid will stop its action at the right 
depth.  The  second  one,  that  I  naturally  prefer,  is  to  use  very 
few  different  concentrations  (three  different  concentrations) 
and  progressively  apply  several  coats  until  the  desired  kind 
of frosting appears. This way always brings my peel exactly to 
the desired level, without possibility of mistake.

Let’s take an example: Patient with normal thickness and 
permeability  skin,  phototype  2,  pre-peel  classical  condition-
ing, and we would like to reach the Grenz zone: the very good 
and easy case! I can decide to apply a 30% TCA (yes, but w/w? 
w/v?  etc.).  What  I  cannot  decide  is  about  how  deep  this  acid 
will penetrate by itself: I just can rub the product on the skin 
and see the result at the end, knowing that more than one coat 
of a 30% w/w TCA solution on such a skin can be dangerous, or 
conversely, it can be insufficient. We will see the action of the 
acid solution, but only when the eventual damage is done and 
irreversible. This is why there are so many reports of skin dam-
age after TCA peel, and this is why some authors erroneously 
claim that TCA is not adapted to melasma treatment. It is nev-
ertheless only a question of application technique and pre-peel 
decisions. A 30% w/w TCA solution rubbed once on a normal 
thickness skin after pre-peel conditioning usually gives a pink-
white uniform frosting, showing a papillary dermis penetra-
tion. We overpassed our target that was Grenz zone.

Another possibility for the same patient is to use a lower 
concentration  TCA  solution,  let’s  say  a  15%  w/w   solution. 
A first coat induced only erythema: we understand from this 
that  the  skin  was  less  permeable  than  guessed  and  that  we 
reached the epidermal level only. When the skin will be dried 

by  evaporation,  we  will  apply  another  coat  of  the  same  acid 
solution: the skin will show little “frosting points” and we will 
deduce that it has reached the basal layer depth. A next coat 
would induce a cloudy frosting, sign of the penetration of the 
acids into the Grenz zone. When we see these frosting clouds, 
we  stop  the  TCA  solution  application  and  we  know  that  the 
peel has reached exactly the desired depth. Easy, isn’t it?

Usually,  peelers  focus  their  attention  on  good  pre-peel 
conditioning for better and more even penetration and faster 
regeneration. Nevertheless, closer attention should be paid to 
the immediate post-peel events, to the inflammatory reaction 
that  began  immediately  after  the  first  contact  with  the  first 
drop of acid applied on the skin.

This inflammatory reaction is necessary but dangerous. 
A peel that would induce no inflammatory reaction would also 
not be efficient, since inflammation is the real skin rebuilding 
source. At the same time, if this inflammation is uncontrolled, 
if it is self maintained, it enters into a vicious cycle in which 
the free radicals and the pro-inflammatory components liber-
ated from cell destruction induce more cell damage and more 
inflammation. This inflammatory vicious cycle is responsible, 
i.e, for a long stimulation of melanocytes that will respond by 
synthesising more melanin and inducing PIH.

It  is  easily  understandable  that  a  peel  can  be  a  booby 
trap:  you  think  that  your  chemist  prepared  a  30%  mass  by 
volume but he did it w/w (which is stronger); or your patient 
had a virtual mesotherapy§ or a depilation face wax the day 
before  the  peel:  the  patient’s  skin  will  be  permeabilized, 
acids  will  penetrate  faster  and  deeper  and  you  will  get  (not 
surprisingly),  an  overpeel  and  side  effects.  I  have  progres-
sively  solved  this  problem  by  using  a  safer  and  easier  for-
mula:  Easy  TCA  peel¶.  This  formula  allows  me  to  avoid  the 
long  and  uncomfortable  pre-peel  conditioning  phase  in  the 
great majority of cases** since it can be applied using the pro-
gressive   technique  explained  above;  since  it  uses  a  specific 
post-peel  mask,  able  to  control  the  post-peel  inflammatory 
reaction;  since  it  will  be  repeated  once  a  week  for  4  weeks.  
Every  peel,  done  up  to  frosting  points  or  maximum  local 
frosting clouds, treats an eventual pigment rebound induced 
by the  preceding peel.

The  Easy  TCA  post-peel  mask  is  a  quite  complex  for-
mula,  containing  vitamins,  trace  elements,  a  lot  of  strong 
antioxidants,  tretinoine  precursors,  selenio-methionin,  anti-
tyrosinases,  etc.  This  cream  is  applied  once  by  the  practitio-
ner  immediately  after  the  desired  frosting  has  been  seen.  It 
immediately scavenges FRs, stopping the excess of immediate 
inflammatory reaction at the same time as the burning sensa-
tion induced by the easy TCA peel solution. It brings into the 
skin elements that can help it to regenerate faster, and lowers 
the tyrosinase activity. Post-peel penetration of ingredients is 
dramatically modified by the previous application of the peel-
ing solution. The post-peel rate of penetration is much higher 
than the normal skin rate. The skin is much more permeable 
during the close post-peel period: sebum and corneocytes no 
longer act as a barrier and purely water soluble ingredients can 
rapidly pass trough this modified epidermis.

* Skinfold = more than 1 cm
† Glycolic acid to reduce stratum corneum thickness + tretinoine for 
stimulating  basal  layer  turnover  and  regeneration  and  for  reducing 
the stratum corneum permeability: this kind of pre-peel conditioning 
makes the skin much more permeable.
‡ Note that acetone not only degreases skin but also begins a protein 
denaturation that makes the skin more permeable.

§ Virtual mesotherapy: slight abrasion using sandpaper, application of 
specific  vitamins  and  other  elements  on  the  skin,  use  of  Excellderm 
(non-thermogenic radiofrequencies for inducing an intracellular pen-
etration). Aestheticdermal.com
¶ see Textbook of Chemical Peels or www.skintech.info
** I would use a pre-peel conditioning only in specific cases, as can be 
a phototype 4 or 5 patient with a long history of familial melasma.

 
So, high quantities of stimulating factors and antioxidants 
can  reach  the  dermis.  It  is  clinically  evident  that  the  residual 
inflammatory  reaction  is  strong  enough  for  stimulating  the 
skin  architectural  rebuilding,  but  not  strong  and  long  enough 
for stimulating melanocytes or for slowing down the basal layer 
regenerative event sequences. Colleagues often ask to me how 
and  why  this  cream  can  immediately  stop  the  burning  sensa-
tion, even if it is not a neutralizer (this cream is not a basic one) 
and if the frosting signs continue to appear normally, even after 
having applied the post-peel mask. I unfortunately cannot sci-
entifically  answer  this  question  but  have  a  theory:  my  under-
standing  is  that  the  post-peel  mask  antioxidant   properties  are 
such that they break the pro-inflammatory immediate post-peel 
reaction.  It  is  well  known  that  inflammatory  reaction  usually 
represents a big part of pain.

So  to  summarize:  After  having  used  many  different 
peeling formulas and spending post-peel nights of insomnia, 
I  decided  that  it  should  be  possible  to  use  TCA  without  the 
post-therapeutic nightmare. This is what brought me this Easy 
TCA formula: it is easy to do (10 minutes as a maximum for face 
and neck), not expensive, not painful (never needs any kind of 
anesthesia  or  painkiller),  no  skin  conditioning  (peeling  solu-
tion and post-peel mask do this), patient’s social life is possible 
(desquamation looks like a sunburn), no phototype limitation 
(phototype allowed: from 1 to 6), very little percentage of side 
effects (average 1.7% transitory side effects, duration less than 
8  days*).  This  peel,  applied  according  to  different  protocols, 
allows for a wide spectrum of depths of action and therapeutic 
indications  from  active  acne  to  pigmentation  and  acne  scars, 
photoaging  and  deep,  old  stretch  marks†.  It  can  be  applied 
to both face and body. In addition, it can be used during the 
same  session  with  laser,  IPL,  mesotherapy,  radiofrequencies, 
depilation, botulinic toxin‡ , surgery, and telangiectasies treat-
ment. Even hyaluronic acid injections for wrinkle treatment is 
allowed, immediately before Easy TCA Peel§.

In the same time, I decided to stop trying to guess what 
would be the best concentration of TCA for a patient, but only 
use  the  Easy  TCA  solution,  which  I  progressively  apply  the 
necessary number of coats to get the desired frosting.

In  the  preceding  paragraphs,  I  mentioned  using  only 
three different concentrations, and this will now be clarified. 
The  main  peel  I  use,  on  about  80%–85  %  of  my  patients,  is 
Easy TCA Solution, containing vitamins, antioxidants, AHAs 
and saponines, together with 15% w/w TCA. This peel ben-
efits  from  the  important  post-peel  mask  protection  against 
post-peel inflammatory reactions and immediately stopping 
post-peel burning. Depending on the number of coats I pass 

* Unpublished statistic established on a total amount of 5000 peeling 
sessions in Clinica Hera, Empuriabrava, Spain: 28 transitory easy to 
treat side effects. No definitive side effect.
†  See:  www.estetik.com,  left  column,  treatment  tips,  peelings:  you’ll 
find  there  a  complete  description  of  active  acne,  stretch  marks, 
melasma treatments, together with the protocol for local phenol peel 
around eyes and lips.
‡ Ten minutes after botulinic toxin injection, Easy TCA (as basal layer 
peel)  can  be  performed.  We  never  saw  migration  or  shorter  results 
after this association.
§ As everybody did, I also read the HA notice for injection, which says 
not to perform peelings after HA injections. Nevertheless, this recom-
mendation  is  valid  only  because  of  the  huge  release  of  free  radicals 
after  usual  peelings.  Free  radicals  rapidly  damage  the  HA  polymer, 
breaking it and making his life shorter. Easy TCA post-peel mask scav-
enges free radicals at the same time they are produced, which can stop 
self-maintained free radical reactions, able to damage HA polymer.

CHEMICAL PEELS 

  507

on the skin, I drive my peel into epidermis, basal layer, Grenz 
zone, or even papillary dermis. Nevertheless, papillary der-
mis peel needs many coats of Easy TCA and this is uncom-
fortable for the patient. This is why I use a derivative of Easy 
TCA  when  I  want  to  reach  the  papillary  dermis:  Unideep¶ 
has the same structure as Easy TCA. It is a peeling solution 
form  which  ingredients  we  can  find  23%  w/w  TCA  and  an 
adapted  post-peel  mask  with  the  same  aim  as  Easy  TCA. 
Sometimes, I need to go very deep into the skin for treating 
focal old lentigine or solar keratoses: naturally, we often can 
do  it  using  successive  focal  coats  of  Easy  TCA  or  Unideep, 
but  the  work  is  easier  when  using  Only  Touch  Peel  (OTP): 
it has same qualitative base solution than Unideep but con-
tains 45% w/w TCA. OTP has no post-peel mask and has to 
be  used  in  combination  with  Easy  TCA  for  avoiding  post-
peel inflammation. Indeed, OTP without Easy TCA induces 
PIH  in  more  than  60%  of  the  cases.  When  done  immedi-
ately  before  Easy  TCA,  the  percentage  of  PIH  is  much  less 
prevalent:  a  maximum  of  10%,  if  the  protocol  is  respected, 
even  less  if  the  patient  does  not  scratch  the  scabs.  OTP  can 
be  used  on  small  surfaces  only:  it  is  always  a  focal  peel-
ing  for  treating  lesions  with  diameter  than  1  cm.  OTP  is 
applied,  avoiding  excess  product,  with  a  fine  cotton  bud  or 
a wooden toothpick or skewer. Touch the lesion to be treated 
quickly,  precisely,  and  once  only  with  the  chosen  applica-
tor  and  wait  until  the  acid  solution  has  dried  completely.  
A significant frosting will appear quickly on the face, slowly 
on the body. If no such frosting occurs, however, repeat the 
application  cautiously  a  few  minutes  after  the  solution  has 
dried.  Immediately  after  the  frosting  occurs,  apply  the  first 
of the four basic protocols of Easy TCA on the entire treated 
area, including the one where OTP has just been applied, in 
order to obtain an even result and limit the risk of side effects.

HOW PAINFUL IS TCA APPLICATION?
The burning sensation of TCA application is clearly linked to 
its concentration and to the skin permeability. One coat of 30% 
TCA will be very painful on thin skin, but very tolerable when 
applied on thick and oily skin. On the same patient, a 30% peel 
will be more painful compared to a 20 or 15%.

An elegant solution has been recently launched by Skin 
Tech  Pharma  Group:  the  medical  device  Easy  TCA  Peel  Pain 
Control®. The peel is on average 25% more aggressive than the 
classical Easy TCA® 15%, but is 90% less painful. Frosting is 
achieved more easily and the patient only experiences a begin-
ning burning sensation during the first 10 seconds, or after the 
third  coat  (when  the  peel  is  voluntarily  done  up  to  the  pap-
illary  dermis).  This  lack  of  burning  sensation  provides  total 
comfort to the patient.

PEELS AND FIBROBLASTS
Dermal  fibroblasts  represent  a  major  cell,  not  only  in  the 
understanding  of  peels:  their  correct  stimulation  by  any 
means would lead to good skin rejuvenation. Fibroblasts have 
a  dendritic  appearance,  like  Langerhans  cells,  but  have  no 
immunological known function. Fibroblasts synthesise all the 
intercellular  matrix  components  and  play  a  vital  role  during 
the  formation  and  the  contraction  of  the  granulation  tissues 
that appear during the wound healing processes and post-peel 
regeneration events. Huge morphologic variations exist within 

¶ Easy TCA, Unideep and Only Touch are peelings developed by Skin 
Tech, based on my own formulas.

 
508 

 TEXTBOOK OF COSMETIC DERMATOLOGY

this  cellular  population:  papillary  dermis  shows  little  hori-
zontal  fibroblasts  (4–7  microns),  their  dendrites  have  contact 
with several collagen fibers. Stimulation of these fibroblasts is 
responsible  for  a  dense  deposit  of  horizontal  neo  collagen  in 
the top of the papillary dermis.

Medium-depth  dermis  and  deep  dermis  show  larger 
fibroblasts, with a variable orientation. Dendrites have contact 
with  one  big  bundle  of  collagen  only.  The  very  deep  dermis, 
at the limit of hypodermis, contains very large fibroblasts (16 
microns)  with  long  dendrites  (up  to  180  microns),  forming  a 
continuous net.

Inflammatory reactions and healing processes induce the 
appearance  of  many  hybrid  cells,  called  myofibroblasts.  These 
are phenotypically modified fibroblasts having some character-
istics of muscle cells and which are responsible of the retraction 
processes  during  skin  healing.  Cytoplasms  of  myofibroblasts 
contain myofilaments connected with cell membranes, respon-
sible for cell contraction and eventual scarring processes.

“Normal depth” peels will stimulate the full population 
of fibroblasts without overstimulating myofibroblasts. They give 
a better skin tension, without scarring (up to papillary dermis 
peels). Too-superficial peels (intraepidermal peels) are only able 
to  slightly  stimulate  fibroblasts  synthesis:  the  result  on  skin 
tension is weak. Deep peels will strongly stimulate fibroblasts 
and myofibroblasts, inducing a tridimensional tensing effect on 
facial tissues, giving a well-done phenol peel. Too-deep  peeling, 
locally hypodermal peels, focal overpeels, leave the skin without 
any other regeneration possibility than the strong myofibroblas-
tic  contraction,  bringing  about  unaesthetic  scarring  processes. 
We can therefore easily understand that scars only occur when 
something  wrong  has  happened  to  the  skin:  it  can  be  a  prob-
lem induced by the physician having applied a too-concentrated 
solution  or  a  too-strong  pre-peel  conditioning,  or  by  a  patient 
having scratched and infected newly peeled skin*.

Nevertheless,  it  is  largely  admitted  that  the  papillary 
dermis  is  the  limit  from  which  the  scarring  process  can  be 
switched  on.  This  means  that  as  long  as  a  peeling  does  not 
enter into reticular dermis, there is no danger of scarring. The 
problem  here  is  how  to  strictly  limit  the  penetration  of  acids 
until the desired depth. One of the possible answers has been 
described in the TCA paragraph.

ABOUT PHENOL
Many  things  have  been  said  about  this  molecule,  some  true 
and others only urban legends. One example of truth: it is pos-
sible to iron completely the upper lip, using phenol peel. One 
example of legend: the patient can die right after the very first 
contact with the first drop of phenol. I will not say much about 
phenol peels, since a little part of a short chapter is not the right 
place for learning about it. Nevertheless, let’s divide our phe-
nol paragraph in two parts: local phenol and full-face phenol.

Local  phenol  is  a  very  simple  procedure,  the  fastest  of 
all  peels,  and  it  gives  amazing  results.  Chemical  blepharo-
plasty and/or cheiloplasty (lip procedures) are easy to perform 
with  phenol.  The  quantities  necessary  are  largely  under  the 
threshold of toxicity and new formulas (see in the beginning 
of this chapter) are considered as self-blocking at the level of 
the  upper  part  of  reticular  dermis  .  Moreover,  new  formulas 
no longer induce “porcelain skin,” and skin tanning can still 
be possible in the future. Local phenol peels are therefore one 

* Some genetic disorders make the skin prone for post-peel scarring, 
like Ehler Danlos syndrome. Insulin-dependent diabetes is also a risk 
factor for deep peels. See Deprez 2016 (1) for more side effects.

of our frequent treatments for deep wrinkles of the upper lip, 
the eyelid area, and in some cases wrinkles between eyebrows, 
on the top of the nose pyramid. Lower lip and mental area are 
much  more  difficult  to  treat  with  local  phenol.  Often,  at  this 
level, a deep mechanical abrasion has to be used after phenol 
peel in order to achieve good results.

Special attention has to be paid to the patient selection: 
phototypes  2  and  3  are  the  best  patients  but  patients  show-
ing  yellowish  sun-damaged  skin  should  be  avoided  since 
post-phenol  skin  regeneration  will  completely  renew  the 
treated skin and it will appear like a baby skin surrounded by  
irregular-color skin (Figures 53.10–53.12). The case of freckles 
is also a trap. These clear phototypes are good indications, but 
freckles will completely disappear at the level of phenol peel 
and not on the rest of the skin. In these cases, a local phenol 
peel can be tried, together with a papillary dermis peel on the 
rest of the face, calling attention of the patient that, even in this 

Figure 53.10  Before local phenol (Lip and Eyelid Formula—Skin 
Tech).

Figure  53.11  Eight  days  after  local  phenol  lower  eyelid—
Unideep on the rest of the face for uniformization.

 
CHEMICAL PEELS 

  509

appear in the sky as a shooting star: while we would look in 
this  direction,  we  are  at  risk  of  falling  into  dangerous  traps. 
Exploration  of  the  world  of  peeling  has  to  be  done  carefully, 
progressively, using good material, having at our disposal the 
necessary  experience  for  passing  from  one  step  to  the  other. 
In  short:  deep  full-face  phenol  or  chemoabrasive  techniques 
for stretch marks should not be the first peel we ever do. The 
problem will not be the procedure itself but what we will have 
to face and the problems we will have to solve later. The door 
of the world of peeling should open on VHS or HS peels only, 
and beginners should use depth 1 to 3 peels first, trying deeper 
treatments only when they are fully experienced.

REFERENCES

1. Deprez P. Textbook of Chemical Peels, 2nd edition. Boca Raton, FL: 

CRC Press, 2016.

BIBLIOGRAPHY
Alberts  B,  Bray  D,  Lewis  J,  et  al.  Biologie  Moleculaire  De  La  Cellule. 

2nd edition. Medecine-sciences, Flammarion.

Berne MB, Levy NL. Physiology. 3rd edition. 1993.
Briden  ME.  Alpha-hydroxyacid  chemical  peeling  agents:  Case 
studies  and  rationale  for  safe  and  effective  use.  Cutis  2004;  
73(2 suppl):18–24.

Brody  H-J.  Peeling  Chimique  de  moyenne  profondeur.  J  Med  Esth 

et Chir Derm 1987; 14(56):313–8.

Bulengo-Ransby  SM,  Griffiths  CE,  Kimbrough-Green  CK,  et  al. 
Retinoic  acid  treatment  for  hyperpigmented  lesions  caused  by 
inflammation  of  the  skin  in  black  patients.  N  Engl  J  Med  1993; 
328(20):1486–7.

El Samahy MH, Ghoz MM, Ramzy N. Morphological investigation of 
chemical peel on photodamaged facial skin. Int J Cosmet Sci 1998; 
20(5):269–82.

Fain-Maurel MA. Biologie de la cellule. Ed Breal, Rosny, 1994.
Farnes  SW,  Setness  PA.  Retinoid  therapy  for  aging  skin  and  acne. 

Postgrad Med 1992; 92(6):191–6,199–200.

Fischer  TC,  Perosino  E,  Poli  F,  et  al.  for  the  Cosmetic  Dermatology 
European Expert Group. Chemical peels in aesthetic dermatology: 
An update 2009. J Eur Acad Dermatol Venereol 2009; Sept 8.
Gilchrest  BA.  Retinoids  and  photodamage.  Br  J  Dermatol  1992; 

127(suppl 41):14–20.

Giroud JP, Mathe G, Meyniel G. Pharmacologie clinique. In: Schmitt H, 
ed. Elements de pharmacologie. 5th edition. pp. 1590–1591.
Griffiths CE, Goldfarb MT, Finkel LJ. Retinoic acid treatment of hyper-
pigmented  lesions  associated  with  photoaging  in  Chinese  and 
Japanese persons. J Am Acad Dermatol 1994; 30(1):76–84.
Hardman  JG,  Limbird  LE,  Gilman AG,  eds.  Goodman  &  Gilman’s  The 
Pharmacological Basis of Therapeutics. Vol 2, 8th edition. New York: 
McGraw Hill, 2001.

Khunger  N;  IADVL  Task  Force.  Standard  guidelines  of  care  for  
J  Dermatol  Venereol  Leprol  2008; 

Indian 

chemical  peels. 
74(suppl):S5–12.

Kligman AM, Topical tretinoin can correct the structural abnormalities 

of human photoaged skin. In: Elson ML, ed.

Evaluation and Treatment of the Aging Face. New York: Springer, 1995; 

pp. 16–20.

Leterrier  F,  Gary-Bobo  Cl.  Biologie  membranaire,  structure  et 
dynamique des membranes biologiques. Ed. des sciences et des 
arts, Hermann, 1989.

Rapaport  MJ,  Kramer  F.  Exacerbation  of  facial  herpes  simplex  after 
phenolic face peels. J Dermatol Surg Oncol 1984; 10(1):57–8.
Schmitt D. Biologie de la peau (INSERM U.346). Les editions INSERM, 

1995.

Shalita A. Le vieillissement cutane et son traitement par la tretinoıne. 

J Med Est et Chir Derm 1988; 15(60):313–6.

Stegman SJ. A comparative histologic study of the effects of three peel-
ing agents and dermabrasion on normal and sun damaged skin. 
Aesthetic Plast Surg 1982; 6(3):123–35.

Figure  53.12  Eight  months  after  local  phenol  lower  eyelid  and 
Unideep.

case, a demarcation line can be seen between the area treated 
by phenol and the one treated by TCA.

The post-peel period is dramatically important: see your 
patient nearly every day during the first week; this will allow 
you  to  detect  infections,  abnormal  reactions,  etc.  For  more 
 practical information, please refer to the website www. estetik.
com,  left  column:  “Peelings”  and  “Treatment  Tips.”  There  can 
be found clear tables about how to do the peel and the post-peel.
Full face peeling is another story, since the phenol toxicity 
has  to  be  avoided  or  even  treated  in  exceptional  cases.  Even  if 
some physicians still feel comfortable in doing it as an office pro-
cedure, as in the past, I would strongly  recommend performing 
this kind of peel in a secure surgical  environment, with the help of 
a trained anaesthetist (nerve blocks  associated to a deep sedation 
or neuroleptanalgesy). Nothing usually happens but all the lights 
are red and we have to be very  careful, since an accident would 
never  be  forgiven.  Strict  application  rules  have  to  be  followed. 
The  post-peel  period  after  phenol  peel  is  quite  uncomfortable 
for the patient, it looks like after a deep ablative CO2 laser pro-
cedure. Procedure is specific, many details have to be respected 
if we want to do it very safely, and post-peel is difficult. I cannot 
describe here the full process of a full-face phenol peel and how to 
avoid all the traps. Nevertheless, Deprez 2016 (1) contains approx-
imately 200 pages dedicated to all aspects of phenol and phenol  
derivatives-peel procedures.

Regardless,  full  face  phenol  peeling  is  one  of  the  most 
satisfying  treatments  I  perform:  many  patients  look  15  or  20 
years younger after a phenol peel. Skin aging goes many years 
back and goes on from there: the patient never again has as old 
a skin as they had before the peel. Full-face phenol peel can be 
combined with surgery, but not at the same time. When neces-
sary, we perform a face lift as the first procedure and a phenol 
peel  as  second  treatment,  6  months  later,  in  order  to  achieve 
complete  face  rejuvenation.  At  the  same  time,  we  treat  neck, 
décolleté, and hands by other procedures.

CONCLUSIONS
The world of peeling continues to be discovered; its  treasures 
are  able  to  make  a  large  majority  of  our  patients  happy. 
Nevertheless, we cannot begin our exploration of these treat-
ments,  groping  our  way  along,  following  any  light  that  can 

 
54

Lasers and Light Sources for Vascular and 
Pigmented Components of Photoaging

Anne Marie Mahoney and Robert A. Weiss

INTRODUCTION
Photoaging-related changes most commonly occur on the face, 
however,  areas  such  as  the  chest  and  legs  are  also  frequently 
involved. Two clinical manifestations of photoaging for which 
patients often present for treatment are vascular and pigmented 
lesions.  Facial  telangiectasias  are  the  most  common  vascular 
lesion related to photoaging in Caucasians. In contrast, Asians 
with  photodamage  present  more  frequently  with  UV-induced 
pigmentation problems. The most common pigmentation con-
cerns  are  lentigines,  keratoses,  and  Hori's  macules  (1).  This 
chapter reviews current treatment modalities of these common 
problems.

VASCULAR LESIONS
The  term  telangiectasia  refers  to  superficial  cutaneous  vessels 
visible to the human eye (2). These vessels measure 0.1 mm to 
1.0  mm  in  diameter  and  represent  a  dilated  venule,  capillary, 
or arteriole (Figure 54.1). The vessel type determines the clini-
cal  presentation  of  telangiectasias.  Arteriolar  telangiectasias 
are small in diameter, bright red in color, and do not protrude 
above  the  skin  surface.  Venule-derived  telangiectasias  are 
wider, blue in color, and often protrude above the skin surface. 
Telangiectasias arising at the capillary loop initially present as 
fine, red lesions, but with time they often enlarge and become 
purple or blue in color (2).

There  are  four  classifications  of  telangiectasias  based 
upon  clinical  morphology:  1)  simple  or  linear,  2)  arborizing, 

3) spider, and 4) papular. Linear and arborizing telangiectasias 
with red coloration are very common on the face, particularly 
on  the  nose  and  midface  regions.  These  lesions  are  also  seen 
relatively  frequently  on  the  legs.  In  addition,  patients  experi-
ence enlargement of slightly larger venulectases. These appear 
as purplish vessels on the cheeks, periorbital region, and ver-
million. Papular telangiectasias are typically manifestations of 
genetic  syndromes,  such  as  Osler-Weber-Rendu  syndrome,  or 
occur in the setting of collagen vascular diseases. They are less 
frequently related to photoaging. Cherry hemangiomas are also 
seen, which are small round red-to-purple dome-shaped vascu-
lar ectasias scattered anywhere on the face or body. All forms of 
telangiectasias are thought to occur through the release or acti-
vation of vasoactive substances under the influence of a variety 
of factors, such as anoxia, hormones, chemicals, infection, and 
physical factors such as UV radiation, with resultant capillary 
or venular neogenesis (3).

Spider telangiectasias of the face are most commonly seen 
in patients with fair skin of Fitzpatrick Types I and II, indicative 
of  this  group's  increased  susceptibility  to  UV  damage.  Facial 
telangiectasias are especially common on the nasal ala, dorsal 
nose, and mid cheeks and are probably due to UV-induced ves-
sel wall weakness that leads to persistent arteriolar vasodilation. 
Sun exposure damages and weakens collagen with cumulative 
exposures, resulting in ectasia. Additionally, there is a relatively 
high incidence of rosacea on the face, which may have a promi-
nent telangiectatic component (Figure 54.2). Rosacea consists of 

(a)

(b)

(a) Telangiectasias on the cheek of a Caucasian female consistent with the early stages of photoaging. (b) The same 
Figure 54.1 
patient following treatment with IPL has fewer visible vessels and smoother skin. IPL with double-pulse 570-nm filter, 2.4-msec + 
6-msec pulse with 10-msec delay, and a fluence of 29J/cm2 was used.

 
 
LASERS AND LIGHT SOURCES FOR VASCULAR AND PIGMENTED COMPONENTS OF PHOTOAGING  

 511

(a)

(b)

Figure 54.2  Rosacea is thought to result in part from photoaging. IPL treatments reduce intensity and duration of flushing that 
worsens telangiectasias in rosacea. Before (a) and after (b) three treatments with Vasculight IPL (Lumenis, Santa Clara, CA) using 
a 550-nm filter, double pulse of 2.4- and 7-msec, delay of 10 msec, and a fluence of 27–29J/cm2.

frequent flushing associated with telangiectasias, papules, and 
pustules. It is the repeated flushing in rosacea, often caused by 
exercise, alcohol, and spicy food, which leads to the develop-
ment of telangiectasias. Genetic factors also play a large role, 
as  the  rosy  cheek  appearance  passes  from  one  generation  to 
the  next  in  individuals  susceptible  to  rosacea.  Aging  of  the 
skin,  particularly  photoaging,  causes  more  telangiectasias  as 
collagen  breakdown  ensues  (4).  Repeated  trauma  to  the  face 
will  also  induce  localized  erythema  and  ultimately  vascular 
dilatation.

Fortunately,  the  treatment  of  facial  telangiectasias  is 
relatively safe and more predictable than treatment of telan-
giectasias on other sites, particularly the legs. This is attrib-
utable  to  several  factors.  One  is  the  ability  of  facial  skin  to 
heal quickly with fewer propensities toward scarring when 
treated  with  a  similar  depth  of  injury  than  other  locations. 
Treatment results are often seen much more quickly as heal-
ing  is  much  faster  on  the  well-oxygenated  skin  of  the  face. 
Facial  vessels  also  have  the  advantage  of  a  more  consistent 
depth than the legs. The vascular walls themselves are much 
thinner  and  uniform,  and  hydrostatic  pressure  plays  no 
major  role  in  pathogenesis.  Occasionally,  arterial  pressure 
is a factor as seen in spider angiomata with a small central 
arteriole.  This  is  important  when  deciding  on  a  method  of 
treatment,  as  sclerotherapy  into  a  bright  red  arteriolar  fed 
vessel  on  the  cheek  incurs  more  risks  of  necrosis  than  the 
use of laser or light to shut down the branches and shrink the 
arteriolar component.

Patients with telangiectasia of various types present for 
treatment  primarily  because  of  cosmetic  concerns;  therefore, 
it is important that the procedure be relatively risk-free with-
out unsightly scarring. Various modalities can be used to treat 
telangiectasia  on  the  face  or  other  regions.  Several  of  these 
modalities  will  be  discussed  in  more  detail  in  this  chapter, 
including  electrodessication,  sclerotherapy,  and  a  variety  of 
lasers including the pulse-dye laser (PDL), long-pulse dye laser 
(LPDL), argon laser, frequency doubled neodymium:yttrium-
aluminum-garnet laser (532Nd:YAG), intense pulsed light (IPL) 
in all its forms, and a variety of 1064nm long-pulsed Nd:YAG 
lasers (1064Nd:YAG).

ELECTROSURGERY
Electrodessication is commonly used to treat facial telangiec-
tasia because the device is readily available and relatively low 
cost, making it an accessible and affordable treatment world-
wide. Electrodessication is a process in which heat is generated 
from resistance of tissues to the passage of a highly damped 
current from a single electrode. Dehydration occurs in the tis-
sue immediately adjacent to the needle point, and as cellular 
fluids  are  evaporated,  tissue  destruction  results.  The  vessel 
must be cauterized or electrocoagulated every 2 to 3 mm with 
very low amperage current (1–2 amps). Some degree of epider-
mal necrosis occurs due to the nonspecific nature of cauteriza-
tion. Multiple treatments are typically necessary for successful 
treatment.  Punctate  white  or  pigmented  scars  may  occur  if 
excessive thermal damage occurs. Groove type scars along the 
nasal  ala  are  the  most  common  adverse  effect  of  electrodes-
sication.

Using  the  lowest  effective  fluence  and  the  finest  elec-
trodes  produces  optimal  results.  Electrodes  that  are  coated 
with Teflon so that only the tip of the electrode or one side of 
the electrode is exposed tend to provide the safest treatment. 
In addition, use of a bipolar current (with the patient grounded 
to a plate at a distance from the treated area) allows for effec-
tive  treatment  with  a  lower  fluence.  With  bipolar  treatment, 
the  current  passes  through  the  cannulated  vessel  for  several 
millimeters  with  relative  selectivity.  When  performed  with 
care, electrodessication is effective, but is best reserved for the 
smallest  of  telangiectasia.  This  technique  has  been  popular-
ized by Kobayashi who reports excellent results (5).

Serious adverse effects from electrosurgery such as dis-
turbance of pacemakers and implantable cardio-defibrillators 
are  extremely  rare.  To  prevent  disruption  to  electric  currents 
in  these  devices,  short  bursts  are  recommended  with  mini-
mal power settings. Rare instances of pacemaker interference 
with skipped beats and reprogramming have been reported in 
a  survey  of  dermatologic  surgeons  performing  electrocoagu-
lation  during  cutaneous  surgery.  An  incidence  of  0.8  cases/ 
100  years  of  surgical  practice  occurred,  but  may  not  be  rep-
resentative  of  all  patients  undergoing  electrodessication  of  
telangiectasia (6).

 
512 

 TEXTBOOK OF COSMETIC DERMATOLOGY

LASERS
There are multiple lasers available for destroying facial telan-
giectasia. These lasers act by selectively heating the vessel to 
cause  its  destruction  through  the  absorption  of  laser  energy 
by oxygenated and deoxygenated hemoglobin. The advantages 
and disadvantages of presently available lasers are described 
below.

Several  factors  must  be  considered  in  selecting  an 
appropriate  laser  for  telangiectasia  treatment.  In  general,  the 
choice of wavelength(s) and pulse duration are related to the 
type and size of target vessel treated. Deeper vessels require 
a longer wavelength to allow penetration to their depth. Pulse 
duration must be matched to vessel size, as the larger the ves-
sel diameter, the longer the pulse duration required to effec-
tively  thermally  damage  the  vessel.  The  relative  importance 
of  hemoglobin  absorption  peaks  in  green  (541  nm),  yellow  
(585–595 nm) and red to infrared (800–1000 nm) shifts as the 
depth and size of blood vessel changes. Absorption by hemo-
globin  in  the  long  visible  to  near  infrared  range  appears  to 
become  more  important  for  vessels  over  0.5  mm  and  at  least 
0.5 mm below the skin surface (7).

It  is  important  to  note  that  while  laser  treatment  of 
facial telangiectasias has yielded excellent results, the use of 
lasers to treat leg telangiectasias has been far less successful 
than sclerotherapy. This is likely related to insufficient ves-
sel destruction by lasers, competition for the laser absorption 
from overlying melanin, and the failure of lasers to treat the 
increased  hydrostatic  pressure  from  the  “feeding”  venous 
system.

Continuous Wave Lasers

Carbon Dioxide Lasers
Carbon dioxide (CO2) lasers were used early on in an effort to 
obliterate telangiectatic vessels by means of precise vaporiza-
tion  without  significant  damage  to  adjacent  tissue.  Unfortu-
nately, because the CO2laser is so well-absorbed by water in the 
epidermis and dermis overlying the blood vessel, non-specific 
thermal  injury  is  guaranteed  regardless  of  whether  pulsed 
or continuous wave sources are used (8). All reported studies 
demonstrate unsatisfactory cosmetic results (9). Treated areas 
show  multiple  hypopigmented  punctate  scars  with  either 
minimal  resolution  of  the  treated  vessel  or  neovasculariza-
tion adjacent to the treatment site. Because of its non-selective 
action, the CO2laser has no advantage over the electrodessica-
tion needle and is associated with more adverse effects.

Argon Laser
Argon (488 and 514 nm) and argon pumped continuous wave 
dye lasers (515–590 nm) are well-absorbed by hemoglobin and 
penetrate to the depth of mid-dermal vessels, over 1 mm into 
skin. Treatment parameters vary and laser powers of 0.8 w to 
2.9  w,  exposure  times  of  50  milliseconds  (msec),  0.2  seconds 
(sec),  0.3  sec,  and  continuous  and  spot  sizes  of  0.1  mm  and 
1  mm  have  been  used.  Although  the  success  rate  in  treating 
facial telangiectasia is acceptable (10,11), pitted and depressed 
scars, hypopigmentation, hyperpigmentation, and recurrence 
of veins have been noted. In addition, when compared to the 
PDL, the latter is more efficacious.

Adverse  healing  consequences  occur  with  the  argon 
laser  due  to  competition  for  absorption  of  its  wavelength  
(411 nm and 514 nm) from epidermal melanin as well as radial 
diffusion and dissipation of heat from the target blood vessels 
secondary to long pulse durations. Both of these factors result 

in  relatively  nonspecific  thermal  destruction  and  thus  this 
laser is not recommended.

KTP 532nm Green Lasers
KTP crystals are highly reliable, convenient to work with, and 
easily available to laser manufacturers. While the mechanisms 
of these devices vary, each produce millisecond domain pulses 
at  532  nm.  Pulsing  in  milliseconds  allows  vessel  coagulation 
to occur without producing purpura. The various KTP lasers 
available differ in the spot size, which ranges from 0.5 to 4 mm 
in diameter.

Results of treatment of facial vessels have been excellent 
(12). KTP is typically used with a 2-mm spot, 10–20 msec pulse 
duration and 10–15 J/cm2 of fluence. Cooling appears to be of 
significant benefit in protecting the epidermis, thus allowing 
use  of  higher,  more  effective  fluencies.  A  randomized  split 
face  study  using  a  larger  spot  size  (5  mm),  pulse  duration  of 
18–20  msec  and  fluence  of  8–11  J/cm2  was  compared  to  PDL 
and at 3 week follow-up there was a higher rate of clearance of 
facial telangiectasias in those treated with the KTP versus PDL 
(85%  vs.  75%)  (13).  In  addition,  a  recent  study  of  647  patients 
revealed  that  78%  of  patients  demonstrated  clearance  or 
marked  improvement  in  vascular  lesions  after  6  weeks.  In 
this same retrospective review, 6% of patients reported minor 
adverse effects and there was only a single report of bruising; 
there were no major adverse effects (14).

Flashlamp Pumped-Pulsed Dye Laser
The traditional pulsed dye laser (PDL) (585 nm, 450 μsec pulse 
duration) is highly effective in treating a variety of cutaneous 
vascular lesions, including PWS and facial telangiectasia. The 
original  PDL  was  developed  for  the  treatment  of  port  wine 
stains in children, where the average vessel is superficial and 
has  a  diameter  of  100  um  and  an  average  depth  of  0.46  mm. 
Modern-day  PDL  is  delivered  entirely  differently,  using 
595  nm,  1.5–20  msec  pulse  durations  and  synchronized  skin 
cooling with a cooling spray or airstream.

In  preliminary  animal  studies  in  the  rabbit  ear  vein, 
approximately 50% of vessels treated with an effective concen-
tration  of  sclerosant  demonstrated  extravasated  RBCs,  while 
after PDL treatment, extravasated RBCs were apparent in only 
30% of vessels treated (15). Rabbit ear vein treatment with the 
PDL resulted in a relative decrease in perivascular inflamma-
tion compared to vessels treated with sclerotherapy alone.

The  PDL  treatment  technique  involves  delivering  a 
series  of  pulses  overlapping  10%–50%,  tracing  the  vessels  to 
be  treated  with  a  2,  3,  5,  7,  10  mm  or  elliptical  delivery  spot, 
and treating an area of interlacing telangiectasia with overlap-
ping spots to cover the involved area. Delivery energies range 
from 5.0 to 14.0 J/cm2 depending on the spot size used and are 
adjusted  according  to  vessel  response.  The  end-point  is  pur-
pura or vessel spasm.

Purpura  is  a  common  occurrence  after  treatment  with 
traditional  PDL  with  short  pulse  durations,  but  is  much  less 
common with pulse durations longer than 6 msec. Initial stud-
ies  using  the  0.45-msec  pulse  duration  flashlamp  pumped-
pulsed dye laser (FLPD) laser demonstrated high efficacy, but 
it was complicated by purpura that lasted for 1–2 weeks (16). In 
this study 182 patients treated with the 0.45-msec pulse laser 
at  6–7.75  J/cm2  with  a  5-mm  diameter  spot  size  were  evalu-
ated. Seventy six to 100% clearance was obtained in 83.5% of 
patients with the remainder having 51%–75% clearance.

A technique to increase efficacy and decrease purpura is 
to use double and triple pulses (pulse stacking) at sub- purpuric 

 
LASERS AND LIGHT SOURCES FOR VASCULAR AND PIGMENTED COMPONENTS OF PHOTOAGING  

 513

fluences. Tanghetti used pulse stacking to increase efficacy on 
photoaging with reduced side effects, but found that multiple 
treatments with or without pulse stacking had excellent results 
on the signs and symptoms of photoaging including telangiec-
tasias (17).

Long-Pulse Dye Lasers
Based  on  the  theory  of  selective  photothermolysis,  the  pre-
dicted pulse duration ideally suited for thermal destruction of 
vessels the size of leg telangiectasia (0.1–several mm in diam-
eter) is in the 1–50 msec domain (18). Newer LPDLs with vari-
able  pulse  durations  as  long  as  40  msec  (V-Beam  Perfecta™, 
Syneron/Candela,  Wayland,  MA  and  Cynergy™,  Cynosure, 
Chelmsford, MA) are now available. Each device uses a rhoda-
mine dye to produce wavelengths of 585–595 nm. These longer 
pulse durations and longer wavelengths improve our ability to 
treat deeper, larger caliber vessels.

Newer FLPD lasers that extend the pulse duration to 1.5, 
3,  6,  10,  20,  and  40  msec  and  use  dynamic  or  continuous  air 
cooling have eliminated most of the pain and have minimized 
purpura associated with the first-generation FLPD lasers. Typ-
ical fluences of 10 J/cm2 with a 10 msec spot size usually result 
in  90%  resolution  of  facial  telangiectasias  in  one  treatment 
with  minimal  pain  and  purpura  (Figure  54.3).  Improvement 
in rough texture and pigmentation of photoaging is also seen.
Treatment  of  leg  telangiectasias  with  this  method  has 
not produced satisfactory results, even with the use of longer 
pulsing. A study evaluating the LPDL of 595 nm using two dif-
ferent fluences of 20 J/cm2 and 24 J/cm2 demonstrated that after 
two treatments at 6 month follow-up, there was a 50% improve-
ment in leg telangiectasias in 77% and 85%, respectively (19). In 
a single treatment of vessels less than 0.4 mm in diameter using 
the  595  nm,  1.5-msec  PDL  (Cynosure)  and  an  experimental  
595 nm, 4-msec PDL, clearing rates were not clinically signifi-
cant with either device, and the rates of both hypopigmentation 
and hyperpigmentation were significant (20). Despite advances 
in laser therapy, sclerotherapy remains the gold standard for 
treatment of leg telangiectasias.

The Copper-Vapor Laser
The copper-vapor laser operates at two specific wavelengths, 
578  nm  (yellow)  and  511  nm  (green)  and  delivers  a  “quasi-
continuous  wave”  composed  of  pulsed  laser  light  energy 

in  20-nanosecond  pulses  at  a  frequency  of  15,000  pulses  per  
second. This train of pulses interacts with tissue in the same 
manner  as  a  continuous  beam  because  of  the  accumulation 
of heat with the large number of pulses delivered. Due to the 
resulting  thermal  diffusion,  it  is  necessary  to  electronically 
gate the pulse to a 20–50 msec duration.

These refinements should allow this laser to work within 
the  thermal  relaxation  time  of  telangiectasia  (21).  When  the 
laser is used with these refinements, it is somewhat safer and 
more effective than the argon laser for treatment of facial tel-
angiectasia.  It  also  has  the  advantage  of  leaving  very  minor 
superficial  crusts  overlying  treated  vessels  in  contrast  to  the 
very visible dark purpuric impact spots of the FLPD laser.

Long Pulse Nd:YAG 1064nm
Long pulsed 1064-nm lasers have recently been developed in 
an effort to target deep, relatively large caliber cutaneous ves-
sels.  This  wavelength  achieves  deep  penetration  and  is  not 
absorbed by melanin, thus allowing treatment of more darkly 
pigmented  individuals.  High  energies  must  be  utilized  for 
adequate penetration. Only with sufficient fluence and facilita-
tion of heat dissipation can the posterior wall of a larger diam-
eter (1–2 mm) vessel filled with deoxygenated hemoglobin be 
reached and heated.

The newer pulsed 1064-nm lasers have pulse durations 
between 1–200 msec (Vasculight™, Lumenis, Santa Clara, CA; 
Cool  Touch  Varia™,  CoolTouch  Corp,  Roseville,  CA;  Lyra™, 
Laserscope Lyra, San Jose, CA; Coolglide™, Altus, Burlingame, 
CA). Large-caliber vessels > 0.5 mm in diameter respond best 
to  these  lasers,  however,  recent  data  suggests  that  by  using 
smaller  spots  and  higher  fluences  even  small  vessels  will 
respond.  In  initial  studies  with  a  first-generation  1064-nm 
fixed 6-mm spot delivery handpiece, optimal settings were flu-
ences of 80–120 J/cm2 and single-pulse durations of 10–30 msec 
(22). Experience indicated an approximately 75% resolution of 
leg telangiectasias at 3 months using 16-msec pulse durations 
with fluences of 130–140 J/cm2 (22).

Larger violaceous vessels of the face may be treated with 
these  devices  (Figure  54.4).  The  fluence  must  be  lowered  by 
30%–40%  for facial vessels as compared  to the  legs.  A recent 
study of facial telangiectasias on the nasal alae and tip demon-
strated that vessels ranging in size from 0.2–0.3 mm decreased 
in size by 92% (23).

(a)

(b)

Figure 54.3  Treatment with the long-pulsed dye laser (V-Star, Cynosure, Chelmsford, MA) improved this patient's telengiecta-
sias, skin texture, and pigmentation. (2-msec duration, 2.5J, 10-mm spot, and three passes. (a) Pretreatment. (b) After treatment.

 
  
514 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure  54.4  Larger  facial  veins  can  be  treated  with  the  1064-nm  Nd:YAG  laser  (Vasculight,  Lumenis,  Santa  Clara,  CA). 
(a)  Pretreatment. (b) 50% improvement 2 months after treatment.

It  should  be  kept  in  mind  that  treatment  with  long 
pulse  1064-nm  laser  is  relatively  painful,  and  both  cool-
ing  and   topical  anesthesia  should  be  employed  to  minimize  
discomfort. Stacked pulsing CANNOT be performed with 1064 
nm as there is high risk of heat buildup and skin breakdown, 
and 1064 nm should never be used faster than 1 Hz pulse rate 
and pulse positioning should never be closer than 1 mm apart. 
For patient comfort, epidermal cooling can be contact cooling 
or cryogen spray, which can be programmed both before and 
after  the  laser  pulse.  The  concept  behind  applying  the  spray 
after the cooling pulse is for "thermal quenching" (U.S. Patent 
# 6451007, Koop, Baumgardener and Weiss) of the heat released 
from  larger  vessels  following  the  laser  heating.  Topical  lido-
caine has also proven efficacious in reducing pain (24).

INTENSE PULSED LIGHT SOURCE
The  high-intensity  pulsed  light  (IPL)  source  was  developed 
as  a  device  to  treat  ectatic  blood  vessels  using  non-coherent 
light  emanating  from  a  filtered  flashlamp  (Lumenis  One™, 
Lumenis,  Santa  Clara,  CA).  Although  Lumenis  is  the  largest 
and  most  well  known  of  the  IPL  device  manufactures,  other 
manufactures of pulsed light devices include Energis Technol-
ogy, Swansea, UK, marketing an Energis Elite IPL system for 
hair  removal  only,  and  Danish  Dermatologic  Development, 
Hoersholm,  Denmark  which  markets  the  Elipse  system  for 
hair  and  vascular  indications.  The  Energis  system  is  a  low-
output device, with 5–19 J/cm2 output, spot size of 10 x 50 mm, 
pulse train length of 15–40 msec and pulses per train of 4 to 
5. There is a fixed delay between pulses of 1.5 msec. By com-
parison, the Lumenis device is a high-output device with up to 
90 J/cm2 output, spot size of 8 x 35 mm, variable pulse lengths 
of 2–40 msec, and infinitely variable delay between pulses of 
1 to 1000 msec.

Selectivity  for  IPL  is  achieved  primarily  by  manipulat-
ing pulse durations to match thermal relaxation times of ves-
sels larger than 0.2 mm and by using filters to remove lower 
wavelengths of visible light. Fluence can be very high with the 
unit delivering up to 90 J/cm2. Sequential pulsing of 1–12 msec 
duration  separated  and  synchronized  with  1–100  msec  rest 
intervals delivers wavelengths of 515–1000 nm. It is most com-
monly used with the 550 and 570 nm filters to deliver the yel-
low and red wavelengths and some infrared. The ability of IPL 
to produce a non-coherent light as a continuous spectrum lon-

ger than 550 nm was thought to have multiple advantages over 
a  single-wavelength  laser  system.  These  advantages  include 
absorption by both oxygenated and deoxygenated hemoglobin 
and  absorption  by  larger  blood  vessels  located  deeper  in  the 
dermis. In reality, the primary advantage has been larger spot 
size and relatively low incidence of purpura on facial telangi-
ectasia.

For  facial  telangiectasia,  our  experience  has  been  that 
the 550 nm, 560 nm or 570 nm produce optimal results. When 
treating darker skin types and larger blood vessels, we choose 
a longer cut-off filter. For telangiectasia-predominant photoag-
ing, the typical pulse durations are 2.4 msec + 6.0 msec with 
a 10-msec delay between pulses. The delay between pulses is 
increased to 20–30 msec in darker skin types as they are more 
prone to thermal injury. Typical pulse durations are 2.4 msec 
+  4.0  msec  (double  pulse)  with  a  10-msec  delay  between  the 
pulses for pigmentation predominant photoaging. Typical flu-
ences  range  from  24–38  J/cm2  again  related  to  the  sensitivity 
of the skin and the degree of epidermal cooling. To minimize 
non-specific epidermal damage, the crystal is placed on a layer 
of ice-cold clear gel 2–3 mm in thickness for non-cooled crys-
tals  (floating  technique).  When  using  the  Quantum  IPL  with 
a thermoelectrically cooled crystal, a thin layer of gel is used 
with the crystal resting directly on the skin, with the crystal at 
maximal cooling (direct contact technique).

Studies  on  the  treatment  of  leg  telangiectasia  and  poi-
kiloderma of Civatte have proven the efficacy as well as limi-
tations  of  IPL  technology.  Few  studies  have  evaluated  IPL 
efficacy purely on facial telangiectasia. Most studies with the 
IPL  comment  on  its  photorejuvenation  effects  that  include 
elimination of lentigines, reduction of pore size, and minimiza-
tion of fine wrinkles in addition to treatment of telangiectasia 
(Figure 54.5). Results from studies evaluating the IPL's efficacy 
for treating telangiectasias have been consistently promising. 
Bitter reported that the IPL used in “FotoFacial settings” pro-
duced > 75% improvement in telangiectasia in 38% of patients 
and > 50% reduction in telangiectasia in 70% of patients (25). 
Tanghetti performed a split-face randomized study comparing 
the  efficacy  of  PDL  versus  IPL  for  the  treatment  of  facial  tel-
angiectasias based on the Telangiectasia Grading Scale (TGS); 
she found that for both devices the mean TGS score was 3.3 at 
3-month follow-up, demonstrating that IPL may be as effective 
as PDL (26).

 
 
 
LASERS AND LIGHT SOURCES FOR VASCULAR AND PIGMENTED COMPONENTS OF PHOTOAGING  

 515

(a)

(b)

Figure 54.5  Poikilodermatous type of photoaging of the chest including telangiectasias and pigmentation. (a) Pretreatment of 
chest and neck areas. (b) Following one IPL treatment. Note the disappearance of cherry hemangiomas on the right side of the 
chest.

Another  IPL  device  (Ellipse  Flex,  Danish  Dermato-
logic  Development,  Hoersholm,  Denmark)  was  used  in  27 
patients with facial telangiectasia. This IPL has a lower cut-off 
at  555  nm  as  well  as  an  upper  cut-off  filter  at  950  nm  with  a 
median wavelength at 705 nm delivered through a 10 x 48 mm 
crystal light guide. Fluences required to produce a slight blu-
ing of the vessels ranged 13–22 J/cm2. Pulse durations were 10 
msec for vessels < 0.4 mm in diameter, and pulse durations of 
15 and 30 msec were used for larger vessels. Patients received 
from 1–4 treatments with an average of 2.54 treatments. Sev-
enty  nine  percent  of  patients  had  greater  than  50%  clearing 
with 38% having 75 to 100% clearance (27).

The  development  of  the  short  pulse-long  pulse  pro-
tocol  utilizing  2.4–3  msec  and  7  msec  pulses  separated  by  a 
10–20 msec delay employing the 560-nm or 570-nm filter has 
yielded the best results for leg veins using the IPL device (28). 
By combining a shorter pulse (2.4–3 msec) with a longer pulse 
(7–10  msec)  it  is  theoretically  possible  to  ablate  smaller  and 
larger  vessels  overlying  one  another  in  the  dermis.  Smaller, 
more superficial vessels absorb the shorter pulses more selec-
tively, while the longer pulses are absorbed by the larger diam-
eter,  deeper  vessels.  New  contact  epidermal  cooling  devices 
improve treatment results by allowing larger fluences with less 
risk to the epidermis.

THE ROLE OF COOLING
The concept of cooling the skin in an effort to protect the epi-
dermis during laser treatment of dermal targets was first stud-
ied by Gilchrest, who incorporated the use of ice prior to argon 
laser  treatment  of  port  wine  stains  (29).  Skin  cooling  during 
skin  laser  therapy  offers  multiple  benefits,  including  cool-
ing  and  protecting  the  epidermis,  preventing  other  collateral 
dermal damage, and also reducing the discomfort associated 
with treatment. Cooling is especially critical in the treatment 
of larger telangiectasia due to the high fluencies required for 
efficacy. By cooling the skin, collateral injury is limited.

Several  cooling  modalities  have  been  used  including 
water-cooled  chambers  applied  directly  to  the  skin  through 
which  the  laser  beam  is  directed,  cooling  coupling  gels,  and 
refrigerated spray cooling devices. Preliminary results suggest 

that cooling helps to spare epidermal damage, hence allowing 
use of higher fluencies and yielding more damage of the tar-
geted  vessels  and  achieving  a  greater  degree  of  clearing  per 
treatment (30,31). Cooling has a minor role in the treatment of 
pigmented lesions.

PIGMENTED LESIONS
Pigmented lesions are another common manifestation of pho-
todamage  for  which  patients  often  present  to  dermatologists 
for  treatment.  Sun  damage  induces  pigmentation  changes  in 
several  manners.  In  the  development  of  ephilides  (freckles), 
the  pattern  of  melanin  deposition  is  altered.  Ephilides  clas-
sically occur in a photodistributed pattern, favoring the face, 
shoulders, and extensor arms, and darken with increased sun 
exposure. Lentigos are the most common photoaging-associate  
pigmented  lesions  and  occur  due  to  UV-induced  melanocyte 
proliferation.  The  treatment  of  ephilides  and  lentigos  will  be 
the focus of this section.

Q-Switched Lasers
Several  laser  systems  have  been  shown  to  be  effective  in  the 
treatment of lentigines. These systems include the 510-nm PDL, 
the frequency doubled Q-switched (QS) Neodynium:Yttrium-
Aluminum-Garnet 532 nm (QS 532 nm Nd:YAG) laser, the QS 
Ruby laser, and the QS Alexandrite laser (32) (Figure 54.6). As 
in most aesthetic procedures, the risk of adverse effects is an 
important consideration. Dark-skinned patients have a higher 
epidermal  melanin  content  and  are  more  likely  to  develop 
complications  such  as  hyperpigmentation.  Studies  of  the  use 
of Q-switched lasers in dark-skinned patients have indicated 
that the risk of post-inflammatory hyperpigmentation (PIH) is 
approximately 10% to 40% (33).

QS  ruby  and  QS  Alexandrite  wavelengths  are  well 
absorbed  by  melanin.  The  greater  depth  of  penetration  can 
be a disadvantage because there is a potential for permanent 
follicular  melanocytic  damage  causing  leukotrichia  when  a 
high fluence is used. When QS lasers have been compared to 
long pulsed lasers, interesting findings regarding optimal effi-
cacy  and  adverse  effects  have  been  shown.  An  in  vivo  study 

 
  
516 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 54.6  Solar lentigo. (a) Before treatment. (b) Following one treatment with Q-switched Ruby laser at 4 J/cm2.

(a)

(b)

of 34 patients compared a QS 532-nm Nd:YAG laser to a long 
pulse 532-nm Nd:YAG laser (34). Results showed that the long 
pulse  532-nm  laser  (6.5  J/cm2,  2-mm  spot  size,  2-msec  pulse 
duration)  resulted  in  a  lower  risk  of  PIH  when  used  to  treat 
lentigines in Asians.

Q-Switching versus Millisecond  
Pulse Durations
QS lasers generate high-energy radiation with very short pulse 
duration.  This  produces  intense  energy  that  leads  to  a  rapid 
rise  in  temperature  (one  thousand  degrees  Celsius)  within 
the  target  subcellular  chromophore.  As  the  laser  pulse  dura-
tion is shorter than the thermal relaxation time of the target, 
a  temperature  gradient  develops  between  the  target  and  its 
 surrounding  tissue  (35).  When  the  temperature  gradient  col-
lapses,  it  generates  localized  shockwaves  causing  the  frag-
mentation of its targets. This photomechanical reaction leads 
to melanosome disruption that occurs after nanosecond pulse 
durations of Q-switching (36).

Picosecond Lasers
Very  recently  it  has  been  recognized  that  picosecond  lasers, 
which were developed for tattoo removal, can be quite effec-
tive  for  the  treatment  of  photo-induced  hyperpigmentation 
(37). The pulse duration of a picosecond is at a minimum ten 
times shorter or quicker than that of the QS lasers. This faster 
pulse  duration  results  in  enhanced  melanosome  destruction. 
The  wavelengths  of  light  that  are  available  in  picosecond 
include 532 nm, 755 nm, and 1064 nm; however, it is the 755 nm 
that has been used for treatment of hyperpigmentation. Weiss 
et  al  have  reported  that  adding  a  focused  lens  array  which 
divides the picosecond 755 nm into 140 microbeams shows sig-
nificant improvement for photoaging and fine wrinkles, based 
on physician and patient assessment (Weiss et al, LSM 2015, in 
press). This study resulted in FDA clearance for wrinkles, and 
results showed that a 755-nm picosecond laser can be used to 
treat  solitary,  discrete  solar  lentigines  to  diffuse  dyspigmen-
tation.  Picosecond  755-nm  laser  coupled  with  a  focused  lens 
array  achieves  significant  improvement  for  photoaging  with 
less downtime and less pain then other modalities. Figure 54.7 
shows one of the patient results from the study (Weiss et all, 
LSM 2015, in press).

IPL
Photothermal effects, such as those produced by the IPL, were 
initially considered more efficacious when treating lentigines. 
Some  promoted  the  concept  that  the  photomechanical  effect 
of QS lasers was undesirable for lentigines and this has been 
confirmed  by  a  number  of  investigators  (38).  Use  of  IPL  for 
photoaging  in  Asians  has  been  shown  to  increase  collagen 
and  decrease  melanin  without  significant  adverse  effects  in 
the  treatment  areas  and  relatively  high  patient  satisfaction 
rates  (39).  There  have  been  few  reports  of  IPL-induced  long 
term hyperpigmentation (40,41), although temporary hypopig-
mentation is a well-recognized side effect. To minimize risks 
of  scarring,  it  is  important  to  select  a  pulse  duration  that  is 
shorter than the thermal relaxation time of the epidermis. The 
epidermal  relaxation  time  is  estimated  to  be  approximately 
10  msec  if  the  epidermal  thickness  is  100  um,  so  that  pulse 
durations of less than 10 msec with IPL are preferred for pig-
mented lesions (42).

SELECTING THE LASER
When  treating  epidermal  pigmented  lesions  such  as  lentigi-
nes,  patients  should  be  informed  about  advantages  and  dis-
advantages of each mode of treatment. IPL typically results in 
little  downtime  and  may  also  improve  rhytids.  Lasers,  how-
ever, may be the preferred choice for patients in terms of fewer 
treatments and cost effectiveness. Test areas with two differ-
ent devices may be performed. If a test spot clearance is satis-
factory, without development of PIH, then it is best to use the 
device that performed best. Patients are advised that clearance 
may take 1 to 4 sessions. If PIH develops at any time during 
the treatment phase, treatment is stopped, hydroquinone or an 
equivalent  is  applied  daily,  and  the  patient  is  followed  until 
resolution of PIH occurs. Typically we use IPL if multiple pig-
mented lesions are scattered around the face, but QS Ruby if a 
few isolated lentigines are targeted.

PRE-TREATMENT AND  
POST-TREATMENT CONSIDERATIONS
One  cannot  overemphasize  the  importance  of  pre-treatment 
skin preparation to patients planning to undergo laser or light 

 
  
LASERS AND LIGHT SOURCES FOR VASCULAR AND PIGMENTED COMPONENTS OF PHOTOAGING  

 517

(a)

(b)

Figure  54.7  56  year  old  patient  with  significant  photoaging,  (a)  Before,  (b)  Results  after  four  treatments  with  755  nm  using 
FOCUS handpiece, 5000 pulses, fluence of 0.57 J/cm2 using a 6-mm handpiece.

treatment  for  pigmented  components  and  vascular  compo-
nents of photoaging. The use of topical bleaching agents such 
as hydroquinone, vitamins C and E, and UVA/UVB sunscreens 
of  SPF  30  or  higher  should  be  initiated  2  weeks  prior  to  the 
laser/IPL surgery and then resumed 5 to 7 days post- treatment 
or  when  epidermal  crusting  resolves.  Treatment  should  con-
tinue for at least 6 months after a course of treatment. Use of 
suncreens should become a lifelong habit.

SUMMARY
Treatment of vascular and pigmented lesions in adults can be 
very  successful.  Practically  all  laser  devices  available  in  the 
visible  light  range,  except  for  red,  produce  good  results  on 
facial  vascular  lesions.  Q-switching  is  an  important  tool  for 
treatment of pigmentation. Knowledge of the lesion type and 
differences in response by size and location can assist in select-
ing  the  procedure  most  likely  to  achieve  successful  results. 
Wavelengths  of  lasers  may  be  fine-tuned  for  size  or  color  of 
individual telangiectasias. Although electrocautery is used fre-
quently, a more selective method such as laser or IPL is usually 
a better choice, with far less risk of scarring. Larger cavernous 
lesions may require deeper penetration of 1064 nm (infrared) 
wavelengths used cautiously. The benefit of IPL in photoaging 
is the smoothing of skin and reduction of irregular pigmenta-
tion in addition to treatment of vascular lesions.  Considering 
the skin type of the patient, the nature of the lesion, and per-
forming  test  areas  when  indicated  can  ultimately  lead  to  an 
effective and safe treatment of pigmented and vascular lesions 
due to photoaging.

REFERENCES

1. Marmon S, Shek SY, Yeung CK, Chan NP, Chan JC, Chan HH. 
Evaluating  the  safety  and  efficacy  of  the  1,440-nm  laser  in 
the treatment of photodamage in Asian skin.  Lasers Surg Med 
2014;46(5):375–9.

2.  Weiss  RA  WM,  Beasely  KL.  Sclerotherapy  and  Vein  Treatment. 

2nd edition. China: McGraw Hill; 2012.

3.  Cribier B. Pathophysiology of rosacea: Redness, telangiectasia, 
and rosacea. Ann Dermatol Venereol 2011; 138 Suppl 3:S184–91.
4.  Glogau RG. Aesthetic and anatomic analysis of the aging skin. 

Semin Cutan Med Surg 1996; 15(3):134–8.

5.  Kobayashi  T.  Electrosurgery  using  insulated  needles:  Treat-
ment of telangiectasias. J Dermatol Surg Oncol 1986; 12(9):936–42.
6.  El-Gamal HM, Dufresne RG, Saddler K. Electrosurgery, pace-
makers  and  ICDs:  A  survey  of  precautions  and  complica-
tions experienced by cutaneous surgeons. Dermatol Surg 2001; 
27(4):385–90.

7.  Hare McCoppin HH, Goldberg DJ. Laser treatment of facial tel-
angiectases: An update. Dermatol Surg 2010; 36(8):1221–30.
8.  Apfelberg DB. Side effects, sequelae, and complications of car-
bon dioxide laser resurfacing. Aesthet Surg J 1997; 17(6):365–72.
9. Apfelberg DB, Maser MR, Lash H, White DN, Flores JT. Use of 
the argon and carbon dioxide lasers for treatment of superficial 
venous varicosities of the lower extremity. Lasers Surg Med 1984; 
4(3):221–31.

  10.  Broska  P,  Martinho  E,  Goodman  MM.  Comparison  of  the 
argon  tunable  dye  laser  with  the  flashlamp  pulsed  dye  laser 
in treatment of facial telangiectasia. J Dermatol Surg Oncol 1994; 
20(11):749–53.

  11.  Ross M, Watcher MA, Goodman MM. Comparison of the flash-
lamp  pulsed  dye  laser  with  the  argon  tunable  dye  laser  with 
robotized  handpiece  for  facial  telangiectasia.  Lasers  Surg  Med 
1993; 13(3):374–8.

 
 
 
 
 
 
 
 
  
518 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  12.  Clark  C,  Cameron  H,  Moseley  H,  Ferguson  J,  Ibbotson  SH. 
Treatment of superficial cutaneous vascular lesions: Experience 
with the KTP 532 nm laser. Lasers Med Sci 2004; 19(1):1–5.
  13.  Uebelhoer NS, Bogle MA, Stewart B, Arndt KA, Dover JS. A split-
face  comparison  study  of  pulsed  532-nm  KTP  laser  and  595-
nm  pulsed  dye  laser  in  the  treatment  of  facial    telangiectasias 
and diffuse telangiectatic facial erythema. Dermatol Surg 2007; 
33(4):441–8.

  14.  Becher  GL,  Cameron  H,  Moseley  H.  Treatment  of  superficial 
vascular  lesions  with  the  KTP  532-nm  laser:  Experience  with 
647 patients. Lasers Med Sci 2014; 29(1):267–71.

  15.  Goldman MP, Fitzpatrick RE. Pulsed-dye laser treatment of leg 
telangiectasia: With and without simultaneous sclerotherapy. J 
Dermatol Surg Oncol 1990; 16(4):338–44.

  16.  Ruiz-Esparza  J,  Goldman  MP,  Fitzpatrick  RE,  Lowe  NJ,  Behr 
KL. Flash lamp-pumped dye laser treatment of telangiectasia. J 
Dermatol Surg Oncol 1993; 19(11):1000–3.

  17.  Tanghetti  EA,  Sherr  EA,  Alvarado  SL.  Multipass  treatment  of 
photodamage  using  the  pulse  dye  laser.  Dermatol  Surg  2003; 
29(7):686–90; discussion 90–1.

  18.  Liu  A,  Moy  RL,  Ross  EV,  Hamzavi  I,  Ozog  DM.  Pulsed  dye 
laser  and  pulsed  dye  laser-mediated  photodynamic  therapy 
in the treatment of dermatologic disorders. Dermatol Surg 2012; 
38(3):351–66.

  19.  Buscher BA, McMeekin TO, Goodwin D. Treatment of leg tel-
angiectasia  by  using  a  long-pulse  dye  laser  at  595  nm  with 
and  without  dynamic  cooling  device.  Lasers  Surg  Med  2000; 
27(2):171–5.

  20.  Alora  MB,  Stern  RS,  Arndt  KA,  Dover  JS.  Comparison  of  the 
595 nm long-pulse (1.5 msec) and ultralong-pulse (4 msec) lasers 
in the treatment of leg veins. Dermatol Surg 1999; 25(6):445–9.

  21.  Owen  WR,  Hoppe  E.  Copper  bromide  laser  for  facial  telangi-
ectasia: A dose response evaluation. Australas J Dermatol 2012; 
53(4):281–4.

  22.  Weiss  RA,  Weiss  MA.  Early  clinical  results  with  a  multiple 
synchronized pulse 1064 NM laser for leg telangiectasias and 
reticular veins. Dermatol Surg 1999; 25(5):399–402.

  23.  Lee JH, Na SY, Choi M, Park HS, Cho S. Long-pulsed Nd:YAG 
laser: Does it give clinical benefit on the treatment of resistant 
telangiectasia? J Eur Acad Dermatol Venereol 2012; 26(10):1280–4.
  24.  Bonaparte  JP,  Ellis  DE.  Discomfort  during  periorbital  and  lat-
eral temporal laser vein treatment: A double-blind randomized 
controlled trial. Plast Reconstr Surg Glob Open 2014; 2(5):e159.

  25.  Bitter  PH.  Noninvasive  rejuvenation  of  photodamaged  skin 
using serial, full-face intense pulsed light treatments. Dermatol 
Surg 2000; 26(9):835–42; discussion 43.

  26.  Tanghetti EA. Split-face randomized treatment of facial telangi-
ectasia comparing pulsed dye laser and an intense pulsed light 
handpiece. Lasers Surg Med 2012; 44(2):97–102.

  27.  Bjerring  P,  Christiansen  K,  Troilius  A.  Intense  pulsed  light 
source for treatment of facial telangiectasias. J Cosmet Laser Ther 
2001; 3(4):169–73.

  28.  Weiss RA, Sadick NS. Epidermal cooling crystal collar device for 
improved results and reduced side effects on leg telangiectasias 
using intense pulsed light. Dermatol Surg 2000;26(11):1015–8.

  29.  Gilchrest  BA,  Rosen  S,  Noe  JM.  Chilling  port  wine  stains 
improves  the  response  to  argon  laser  therapy.  Plast  Reconstr 
Surg 1982; 69(2):278–83.

  30.  Bernstein EF, Noyaner-Turley A, Renton B. Treatment of spider 
veins  of  the  lower  extremity  with  a  novel  532  nm  KTP  laser. 
Lasers Surg Med 2014; 46(2):81–8.

  31.  Hammes S, Roos S, Raulin C, Ockenfels HM, Greve B. Does dye 
laser treatment with higher fluences in combination with cold 
air cooling improve the results of port-wine stains? J Eur Acad 
Dermatol Venereol 2007; 21(9):1229–33.

  32.  Polder  KD,  Landau  JM,  Vergilis-Kalner  IJ,  Goldberg  LH, 
 Friedman PM, Bruce S. Laser eradication of pigmented lesions: 
A review. Dermatol Surg 2011; 37(5):572–95.

  33.  Wang  CC,  Chen  CK.  Effect  of  spot  size  and  fluence  on 
Q-switched  alexandrite  laser  treatment  for  pigmentation  in 
Asians: A randomized, double-blinded, split-face comparative 
trial. J Dermatolog Treat 201223(5):333–8.

  34.  Chan HH, Fung WK, Ying SY, Kono T. An in vivo trial compar-
ing the use of different types of 532 nm Nd:YAG lasers in the 
treatment of facial lentigines in Oriental patients. Dermatol Surg 
2000; 26(8):743–9.

  35.  Jones  CE,  Nouri  K.  Laser  treatment  for  pigmented  lesions:  A 

review. J Cosmet Dermatol 2006; 5(1):9–13.

  36.  Anderson  RR,  Margolis  RJ,  Watenabe  S,  Flotte  T,  Hruza  GJ, 
Dover  JS.  Selective  photothermolysis  of  cutaneous  pigmenta-
tion by Q-switched Nd:YAG laser pulses at 1064, 532, and 355 
nm. J Invest Dermatol 1989; 93(1):28–32.

  37.  Bernstein  EF,  Schomacker  KT,  Basilavecchio  LD,  Plugis  JM, 
Bhawalkar JD. A novel dual-wavelength, Nd:YAG, picosecond-
domain laser safely and effectively removes multicolor tattoos. 
Lasers Surg Med 2015.

  38.  Kono  T,  Manstein  D,  Chan  HH,  Nozaki  M,  Anderson  RR. 
Q-switched ruby versus long-pulsed dye laser delivered with 
compression for treatment of facial lentigines in Asians. Lasers 
Surg Med 2006; 38(2):94–7.

  39.  Li YH, Wu Y, Chen JZ, Zhu X, Xu YY, Chen J, et al. A split-face 
study  of  intense  pulsed  light  on  photoaging  skin  in  Chinese 
population. Lasers Surg Med 2010; 42(2):185–91.

  40.  Lin  JY,  Chan  HH.  Pigmentary  disorders  in  Asian  skin: 
 Treatment  with  laser  and  intense  pulsed  light  sources.  Skin 
Therapy Lett 2006; 11(8):8–11.

  41.  Kawada  A,  Shiraishi  H,  Asai  M,  Kameyama  H,  Sangen  Y, 
 Aragane Y, et al. Clinical improvement of solar lentigines and 
ephelides  with  an  intense  pulsed  light  source.  Dermatol  Surg 
2002; 28(6):504–8.

  42.  Anderson  RR,  Parrish  JA.  The  optics  of  human  skin.  J  Invest 

Dermatol 1981; 77(1):13–9.

 
55

Nonablative Laser Rejuvenation

Christian R. Halvorson, Karen L. Beasley, and Robert A. Weiss

BACKGROUND
The development of fractional photothermolysis is one of the 
most important discoveries in the field of laser medicine and 
surgery. This concept has revolutionized laser skin resurfac-
ing. Previously patients could only significantly enhance their 
skin through fully ablative lasers, like the 10,600-nm carbon 
dioxide  (CO2)  or  the  2940-nm  erbium-doped  yttrium  alumi-
num garnet (Er:YAG) lasers. These laser treatments required 
at  least  1  to  2  weeks  of  recovery  depending  on  the  depth  of 
resurfacing and the type of laser utilized. With deeper resur-
facing  procedures,  patients  could  experience  considerable 
discomfort and side effects. Results could be exceptional but 
patients  soon  became  aware  of  the  potential  disadvantages 
of  aggressive  procedures.  Besides  the  potential  side  effects 
of infection or permanent scarring, many patients who were 
treated  with  deep  CO2  laser  resurfacing  experienced  pro-
longed erythema of the skin for 6 months to a year. Many also 
developed unexpected permanent hypopigmentation of their 
treated skin (1,2). In addition, patients also became aware of 
the  stark  contrast  between  their  beautiful  resurfaced  facial 
skin, which was now adjacent to their severely sun-damaged 
neck  and  chest.  Fully  ablative  laser  resurfacing  was  fraught 
with  severe  complications  when  used  off  the  face.  Darker 
skin types were not candidates for the procedure. With these 
limitations,  traditional  deep  ablative  resurfacing  began  to 
decrease in popularity.

Nonablative  infrared  lasers  were  developed  in  hopes  of 
remodeling  and  rejuvenating  the  skin  with  fewer  side  effects. 
Infrared  lasers,  like  the  1320-nm  neodymium:yttrium  alumi-
num garnet (Nd:YAG), 1450-nm diode and 1540-nm erbium:glass 
lasers  were  developed.  These  lasers  demonstrated  modest 
improvements in fine rhytides and acne scars (3–5). Additionally, 
these lasers were able to produce results in patients with darker 
skin types (6). But the results from these nonablative lasers often 
paled in comparison to traditional ablative procedures, leading 
patients and physicians to seek more efficacious treatments and 
resulting in the development of newer, more effective lasers and 
delivery systems. A comparison of types of ablative and nonab-
lative lasers is shown diagrammatically in Figure 55.1.

Despite  the  more  limited  efficacy  of  nonablative  treat-
ments, it is important to consider the risk-benefit ratio of a laser 
procedure and the potential for post-procedure down time. In 
our current culture, many patients do not want to take the risk 
of a serious side effect in exchange for a cosmetic improvement. 
Furthermore,  many  patients  have  busy  work  or  social  sched-
ules that do not allow for extended recovery times. Nonablative 
fractional laser (NAFL) resurfacing allows for real results with 
less  side  effects  and  downtime.  This  technology  also  allows 
for  the  treatment  of  darker  skin  types  and  can  successfully 
treat a multitude of skin conditions and body areas. The dis-
advantages, compared with ablative resurfacing, are the need 
to return for multiple treatments and the decrease in efficacy.

Ablative
resurfacing
(CO2 & 2.94 Erb:YAG)
10–200 microns

Superficial fractional
ablative resurfacing
(CO2 & 2.94 Erb:YAG)
10–70 microns

Non-ablative
fractional resurfacing
600–1000 microns

Ablative fractional
resurfacing
600–1000 microns

Figure  55.1  Schematic  representation  of  laser  impact  from  several  lasers:  (a)  Ablative  resurfacing  (CO2  and  2.94  Erb:YAG) 
10–200 microns; (b) superficial ablative resurfacing (CO2 and 2.94 Erb:YAG) 10–200 microns; (c) non-ablative fractional  resurfacing 
(thermal only without vaporization) 600–1000 microns; (d) ablative fractional resurfacing, 600–1000 microns. (From Beasley KL, 
Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. Boca 
Raton, FL: CRC Press, 2013; pp. 178–91. With permission.)

520 

 TEXTBOOK OF COSMETIC DERMATOLOGY

the 

FRACTIONAL PHOTOTHERMOLYSIS
During 
laser  creates 
fractional  photothermolysis, 
 microscopic  noncontiguous  columns  of  thermal  injury  in 
the  dermis,  referred  to  as  microthermal  zones  (MTZ)  (7) 
(see Figure 55.2). Each MTZ is surrounded by a limited zone of 
heat-shocked tissue as well as a larger zone of healthy unaffected 
tissue. The MTZ allows for transport and extrusion of necrotic 
dermal  content  through  the  compromised  dermal  epidermal 
junction (8). The precise nature of the coagulated tissue allows 
for quicker healing and recovery (7–9). Immunohistochemical 
studies have shown increased collagen III production around 
treated MTZs by 7 days and replacement of damaged collagen 
in the MTZs by 3 months post treatment. In addition, histology 
also  reveals  that  there  is  a  localized,  well-controlled  melanin 
release and transport mechanism using microscopic exudative 
necrotic debris (MEND) as the vehicle for pigmentary redistri-
bution (9). In other words, NAFL resurfacing improves pigmen-
tation by shuttling the melanin through the MENDs where it 
is  exfoliated  off  the  skin.  The  initial  paper  by  Manstein  et  al. 
also reported that there was little to no pigmentary alteration 
in dark skinned patients when utilizing laser treatments with 
low to medium MTZ densities per treatment (7). This essential 
combination of creating a precise injury that has an enhanced 
healing rate coupled with the ability to build collagen and redis-
tribute pigment is the hallmark of fractional photothermolysis.

NONABLATIVE FRACTIONAL LASERS (NAFL)
Two  main  NAFL  families  currently  dominate  the  world  laser 
market:  the  Solta  family  of  nonablative  fractional  lasers  (Solta 
Medical, Inc., Hayward, CA) and the Palomar family of nonabla-
tive fractional lasers, which were acquired by Cynosure in 2013 
(Cynosure, Inc., Westford, MA). Both families contain a variety of 
effective nonablative resurfacing lasers. The laser wavelengths 
used in both families are in the infrared region of the light spec-
trum  and  utilize  water  as  their  tissue  target  or  chromophore. 
The  families  differ  by  using  slightly  different  wavelengths  in 
their respective lasers. But the most striking difference between 
the  two  families  is  the  manner  in  which  the  laser  energy  is 
delivered to the skin. Besides these two main families, there is a 
multi-wavelength nonablative fractional laser also by Cynosure, 

a fractional 910-nm laser by Syneron Medical Ltd. (Irvine, CA), a 
fractional Q-switched 1064-nm by Alma Lasers (Buffalo Grove, 
IL),  and  a  new  1440-nm  home-use  device  by  Tria  Beauty,  Inc. 
(Dublin,  CA).  There  are  also  other  NAFLs  that  are  marketed 
outside the United States or that are currently in development.

THE SOLTA FAMILY OF NAFL
The Solta family consists of the Fraxel division of laser devices  
and  the  Clear  +  Brilliant™  laser  system.  The  Fraxel  division 
includes the Fraxel 1550-nm laser, the Fraxel DUAL 1550/ 1927-nm 
laser,  a  stand-alone  Fraxel  1927-nm  laser,  and  the  Fraxel  re:fine 
1410-nm  laser,  which  is  mostly  marketed  outside  of  the  United 
States. All of the Fraxel laser systems have an interface that allows 
for a customized treatment by controlling the pulse energy, treat-
ment  level,  and  number  of  passes  (see  Figure  55.3).  The  pulse 
energy is delivered in millijoules (mJ) and it controls the depth 
of penetration or the depth of the MTZ. Different depths of the 
skin  can  be  treated  for   different  indications  (see  Figure  55.4). 
The  treatment  level  (TL)  is  the  percentage  of  skin  treated  or 

Figure  55.3  Treatment  screen  of  a  1550-nm  nonablative 
fractional  laser.  (From  Beasley  KL,  Weiss  RA,  In:  Goldman 
MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser 
and Energy Devices for the Skin. Boca Raton, FL: CRC Press, 
2013; pp. 178–91. With permission.)

1550 nm wavelength

Pigment, tone/texture – Superﬁcial

Mild rhytids – Mid-range

Moderate rhytids – Mid-deep range

Acne scars and surgical scars – Deep

Depth of lesion

Figure 55.2  Microthermal zones of damage from a 1550-nm 
nonablative fractional laser. (From Beasley KL, Weiss RA, In: 
Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, 
eds. Laser and Energy Devices for the Skin. Boca Raton, FL: 
CRC Press, 2013; pp. 178–91. With permission.)

Figure  55.4  Approximate  depths  of  thermal  impact  by 
fluence.  (From  Beasley  KL,  Weiss  RA,  In:  Goldman  MP, 
Fitzpatrick  RE,  Ross  VE,  Kilmer  SL,  Weiss  RA,  eds.  Laser 
and Energy Devices for the Skin. Boca Raton, FL: CRC Press, 
2013; pp. 178–91. With permission.)

 
covered  by  MTZs   during  one   treatment  session  and  it  controls 
the  aggressiveness of  treatment. The number of passes is also set 
during the  procedure. A pass is defined as a single unidirectional 
motion over the skin that lays down one row of MTZs. On average, 
6–8  passes  are  performed.  Additional  passes  can  be  applied  to 
 individual areas of scarring or deep lines. The total energy deliv-
ered per treatment session is constant regardless of the number of 
passes. For example, the quantity of energy per pass decreases as 
the number of passes increase. Alternately, the quantity of energy 
per pass increases as the number of passes decrease. To increase 
patient comfort, a higher  number of passes with less density of 
MTZ per each pass can be performed. Typically, passes are deliv-
ered by alternating  horizontal and perpendicular passes within 
one cosmetic unit at a time. Before a laser treatment series begins, 
the skin  surface can be measured and an estimated energy total 
kilojoule (kJ) of the treatment can be computed by the laser treat-
ment screen according to the set treatment parameters.

All  of  the  Solta  lasers  have  a  continuous  motion  hand-
piece, which is equipped with rollers. The Fraxel laser treatment 
tip comes in two different sizes, 15 mm and 7 mm. Smaller cos-
metic units like the eyelid, nose, or lip can be treated with the  
smaller tip (see Figure 55.5). The Clear + Brilliant system™ is a 
nonablative fractional 1440-nm laser. It is based on the technology 
of the Fraxel lasers and has a similar, yet more simplified inter-
face. In all the NAFL devices by Solta Medical, the handpieces 
should be positioned perpendicular to the skin and should not 
be lifted while the footswitch is depressed. Handpiece velocity 
is also measured on the laser during treatment. Passes should 
be  smooth  and  controlled  and  stay  within  the  recommended 
velocity levels. If the treatment passes are delivered too fast, the 
laser  microdots  become  oval  rather  than  round  and  therefore 
the energy delivered may be reduced by up to 50%, which leads 
to undertreatment. As with the stamping technique of deliver-
ing fractional laser, the pulses delivered by the rolling technique 
may  not  be  uniformly  distributed.  Some  pulses  overlap  while 
others are adjacent and some are farther apart.

FRACTIONAL 1550-NM LASER
The  Fraxel  1550-nm  laser,  which  is  the  most  extensively  stud-
ied  nonablative  resurfacing  laser,  was  introduced  in  2006.  It  is 
indicated for moderate skin damage resurfacing for periorbital 

NONABLATIVE LASER REJUVENATION 

 521

wrinkles,  pigmented  lesions,  dyschromia,  scars,  melasma,  and 
actinic keratoses. It can deliver laser energy ranging from 4 to 70 
mJ. Its treatment levels range from 5% to 48% coverage. Maximum 
absorption depth into the skin is estimated to be 1400–1500 µm 
deep. As discussed previously, different depths of the skin can 
be  treated  for  different  indications  and  treatment  levels  can 
be  adjusted  to  determine  the  aggressiveness  of  treatment.  For 
example, to target a deep scar with the Fraxel 1550-nm laser, a 
higher energy like 50–70 mJ would be selected. An example of 
an aggressive treatment level would be 12 and would cover 35% 
of the facial skin in one treatment. In patients with darker skin 
types  (Fitzpatrick  types  IV–VI),  the  density  must  be  delivered 
at a lower treatment level, such as 4%–6% or 11%–17% coverage, 
to reduce the chances of postinflammatory hyperpigmentation 
(PIH). See recommended treatment settings in Table 55.1.

Figure  55.5  Tip  for  rolling  nonablative  fractional  device. 
This must be replaced every 5-10 treatments. (From Beasley 
KL,  Weiss  RA,  In:  Goldman  MP,  Fitzpatrick  RE,  Ross  VE, 
Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the 
Skin.  Boca  Raton,  FL:  CRC  Press,  2013;  pp.  178–91.  With 
permission.)

Table 55.1  Fraxel 1550-nm Laser Treatment Settings

Indication

Mild-Moderate Parameters

Pulse Energy (Depth)

Treatment Level (Coverage)

Fitzpatrick Skin Phototype I–III
General Resurfacing (pigmented lesions, textural irregularities, fine lines)
Face

10–25 mJ

Eyelids (within orbital rim)

Off-face

Deep Wrinkles, Acne Scars
Face

Off-face

10–20 mJ

10–25 mJ

25–70 mJ

25–40 mJ

Melasma (evaluate patient after each treatment, 2–3 treatments)
Face

6–15 mJ

Surgical scars

40–70 mJ

Fitzpatrick Skin Phototype IV–VI
General Resurfacing (pigmented lesions, textural irregularities, fine lines)

4–8 (11%–23%)

4–7 (11%–20%)

4–7 (11%–20%)

5–9 (14%–26%)

4–8 (11%–23%)

5–8 (14%–23%)

5–8 (14%–23%)

10–25 mJ

3–7 (9%–20%)

(Continued )

 
522 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 55.1  Fraxel 1550-nm Laser Treatment Settings (Continued )

Indication

Mild-Moderate Parameters

Pulse Energy (Depth)

Treatment Level (Coverage)

Eyelids (within orbital rim)
Off-face
Deep Wrinkles, Acne Scars
Face
Off-face
Melasma (evaluate patient after each treatment, 2–3 treatments)
Face
Surgical scars

10–20 mJ
10–25 mJ

25–70 mJ
25–40 mJ

6–15 mJ

3–6 (9%–17%)
3–6 (9%–17%)

4–7 (11%–20%)
4–6 (11%–17%)

3–7 (9%–20%)

40–70 mJ
Source: From Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. 
Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.

4–7 (11%–20%)

FRACTIONAL 1550-NM AND 1927-NM LASERS
Fraxel DUAL 1550/1927 was introduced in October 2009. Both 
lasers  are  housed  in  the  same  platform  and  function  inde-
pendently  of  each  other  so  that  a  fully  1550-nm  or  1927-nm 
treatment  may  be  performed.  Additionally,  both  lasers  can 
be  layered  on  top  of  each  other  for  a  combination  treatment. 
The  thulium  1927-nm  wavelength  has  a  higher  absorption 
coefficient for water than the 1550-nm wavelength so it has a 
greater  ability  to  target  the  epidermis.  Figure  55.6  illustrates 
the absorption of the two wavelengths. Energy fluences for the 
1927-nm laser range from 5 to 20 mJ and the TL ranges from 20 
to 70% coverage. It has a maximum depth of penetration of 200 
µm into the skin. Therefore, this wavelength is more effective in 
treating epidermal processes, like actinic keratoses. An average 
energy and treatment level for a patient with a Fitzpatrick skin 
type I –III would be 10–20 mJ and a TL of 3–6 that corresponds 
to 30%–45% coverage. See recommended treatment settings in 
Table 55.2. In 2011, the Fraxel 1927-nm laser became available in 
a stand-alone laser platform. The 1927-nm wavelength is cur-
rently FDA-approved in the treatment of actinic keratoses.

The 1550-nm and the 1927-nm lasers can be combined for 
a  “DUAL”  resurfacing  treatment.  When  combining  the  wave-
lengths, 2–4 passes of 1550-nm are performed over the treatment 

1500

1250

1000

750

500

250

)

m
µ
(
h
t
p
e
D
n
o
i
s
e
L

0

0

1550nm

Dermis

1927nm

10

20

30

40

50

60

70

80

Pulse Energy (mJ)

Epidermis

Figure  55.6  Comparison  of  thermal  impact  depths  for  
1550-nm vs. 1927-nm lasers. (From Beasley KL, Weiss RA, In: 
Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, 
eds. Laser and Energy Devices for the Skin. Boca Raton, FL: 
CRC Press, 2013; pp. 178–91. With permission.)

area  to  target  the  dermis  and  then  2–4  passes  of  1927-nm  are 
performed  to  provide  an  epidermal  treatment.  Laser  energies 
and treatment levels are set lower than if the lasers are used sep-
arately. Our experience has taught us to use caution when treat-
ing with both wavelengths on the same day. Recovery times and 
discomfort may be greater than if the lasers were used individu-
ally. See recommended treatment settings in Table 55.3.

FRACTIONAL 1440-NM LASER
The Clear + Brilliant system™ is a fractional diode 1440-nm 
laser that was launched in May 2011. It is indicated for gen-
eral skin resurfacing. The laser has a fixed spot size of 140 µm.  
Energy  can  be  delivered  on  a  low  (4  mJ),  medium  (7  mJ), 
or  high  (9  mJ)  level.  The  depth  of  penetration  ranges  from 
280 to 390 µm depending on the energy level used. The low  
level setting corresponds to 4% coverage, the medium level 
corresponds to 7% coverage, and the high level corresponds 
to  9%  coverage.  It  utilizes  a  disposable  treatment  tip  per 
treatment. It can be used in all skin types, although we have 
experience  with  other  1440-nm  devices  and  find  that  the 
risk of postinflammatory hyperpigmentation is higher with 
1440-nm than with 1540–1500-nm devices. It is marketed as 
a  preventative  laser  treatment  and  it  provides  a  superficial 
treatment with minimal down time. It is marketed to medi-
cal spas primarily.

THE CYNOSURE ICON (FORMERLY 
PALOMAR) FAMILY OF NAFL
With  the  acquisition  of  Palomar,  the  Cynosure  family 
(Cynosure,  Inc.,  Westford,  MA)  of  nonablative  fractional 
lasers (NAFL) now includes primarily a 1540-nm erbium:glass 
laser, with different sets of delivery lenses. These devices are 
based on the stamping mode of delivering fractional energy 
with  the  microdots  of  energy  coming  through  microlens 
arrays.  The  latest  generation  of  Cynosure’s  NAFL  is  avail-
able through the Palomar Icon™ Aesthetic System platform, 
which  has  four  unique  1540-nm  handpiece  microlenses: 
the  original  10  mm  and  15  mm  microlenses,  the  15  mm  XF 
Microlens, and the XD Microlens. Figure 55.7 illustrates the 
Icon 1540-nm interface. Furthermore, the new XD Microlens 
can be used on any of the previous generation 1440-nm and 
1540-nm  fractional  handpieces  with  the  appropriate  soft-
ware and factory calibration.

The original fractional microlenses are composed of a 
microlens array that delivers a lattice of optical microbeams 

 
 
 
Table 55.2  Fraxel 1927 nm-Laser Treatment Settings

Indication

MODERATE PARAMETERS

Pulse Energy (Depth)

Treatment Level (Coverage)

NONABLATIVE LASER REJUVENATION 

 523

Fitzpatrick Skin Phototype I–IV
General Resurfacing
Face

Eyelids (within orbital rim)

Off-Face

Fitzpatrick Skin Phototype I–III
Actinic Keratosis
Face

Off-face

5–20 mJ

5–20 mJ

5–15 mJ

10–20 mJ

10–20 mJ

1–5 (20%–40%)

1–4 (20%–35%)

1–4 (20%–35%)

3–5 (30%–40%)

2–4 (25%–35%)

Source: From Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. 
Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.

Table 55.3  Fraxel 1550-nm /1927-nm DUAL Laser Treatment Settings

1550 nm and 1927 nm treatment parameters

Indication

Moderate Parameters: 1550 Nm

Moderate Parameters: 1927 Nm

Total Coverage

Pulse Energy 
(Depth)

Treatment Level 
(Coverage)

Pulse Energy 
(Depth)

Treatment Level 
(Coverage)

Fitzpatrick Skin Phototype I–III
General Resurfacing
Face

Eyelids (within orbital rim)

Off-face

10–25 mJ

10–20 mJ

10–25 mJ

3–5 (9%–14%)

2–4 (7%–11%)

1–3 (5%–9%)

Fitzpatrick Skin Phototype IV–VI
General Resurfacing
Face

10–25 mJ

Eyelids (within orbital rim)

Off-face

10–20 mJ

10–25 mJ

1–4 (5%–11%)

1–3 (5%–9%)

1–3 (5%–9%)

5–20 mJ

5–20 mJ

5–20 mJ

5–20 mJ

5–20 mJ

5–20 mJ

1–3 (20%–30%)

1–3 (20%–30%)

1–2 (20%–25%)

1–3 (20%–30%)

1–3 (20%–30%)

1–2 (20%–25%)

(30%–40%)

(30%–35%)

(25%–35%)

(25%–35%)

(25%–35%)

(20%–30%)

Source: From Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. 
Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.

that create microdenatured columns in the skin. The micro-
lens  is  responsible  for  taking  a  single  beam  of  laser  energy 
and separating it into smaller laser beams at a predetermined 
pitch. See Figure 55.8a/b for photos of the original microlens. 
The  XD  Microlens  is  a  chilled  12 × 12  mm  square  sapphire 
contact  window  that  is  composed  of  49  micro-compression 
pins  each  co-aligned  with  a  microbeam.  Figure  55.9  depicts 
the  XD  Microlens  tip,  which  allows  for  much  deeper  (XD  = 
extra  deep)  penetration  of  energy  by  compression  of  water 
from the upper layers of dermis. This new microlens is used 
with  manual  compression  into  the  skin  to  achieve  deeper 
penetration of laser energy into the dermis. Figure 55.10 illus-
trates  the  effect  on  skin  after  compression  with  the  XD  tip. 
The act of compression displaces water into interstitial spaces 
of the skin. With less water to absorb, the scattering of laser 
light is reduced which enables increased absorption of light 
by  deeper  targets.  The  compression  into  the  skin  not  only 
enhances beam penetration, but it also enhances skin cooling 
due  to  less  heating  in  the  epidermis.  Better  cooling  means 
decreased epidermal temperature and injury. Clinically, this 
translates into fewer side effects, less downtime, and a more 
comfortable  treatment.  The  XF  optic  provides  higher  cover-
age per pulse compared to the original optics, allowing faster 
treatment times, similar to 1440-nm but with the added ben-
efit of increased depth due to the increased penetration of the 
1540-nm wavelength.

Figure 55.7  Treatment screen for a 1540-nm fractional laser. 
Here each pulse is 15 ms and each thermal zone is 50 mJ/cm2. 
Coverage is determined by the percent overlap of each stamp. 
(From  Beasley  KL,  Weiss  RA,  In:  Goldman  MP,  Fitzpatrick 
RE,  Ross  VE,  Kilmer  SL,  Weiss  RA,  eds.  Laser  and  Energy 
Devices for the Skin. Boca Raton, FL: CRC Press, 2013; pp. 
178–91. With permission.)

 
524 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

(a)  Microlens  array  for  a  stamped  1540-nm  nonablative  fractional  laser;  (b)  15  mm  handpiece  lens  array.  (From 
Figure  55.8 
Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the 
Skin. Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.)

Figure  55.9  XD  optic  showing  optical  prongs  to  displace 
water out of tissue. (From Beasley KL, Weiss RA, In: Goldman 
MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser 
and Energy Devices for the Skin. Boca Raton, FL: CRC Press, 
2013; pp. 178–91. With permission.)

Figure  55.10  XD  optical  prong  pattern  after  30  seconds  of 
compression  on  the  skin.  (From  Beasley  KL,  Weiss  RA,  In: 
Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, 
eds. Laser and Energy Devices for the Skin. Boca Raton, FL: 
CRC Press, 2013; pp. 178–91. With permission.)

These laser treatments are customized by controlling the 
microbeam energy, the amount of overlap between pulses, and 
the number of passes. The pulse energy is delivered in milli-
joules per microbeam (mJ/mb) and it controls the depth of pen-
etration or the depth of the MTZ. Energies should be adjusted 
for  the  skin  condition  being  treated.  Lower  energies  are  uti-
lized  for  more  superficial  conditions  and  higher  energies, 
which  penetrate  deeper,  are  utilized  for  deeper  indications. 
The percentage of skin treated or covered by MTZs during one 
treatment session is determined by the amount of overlapping 
passes performed with the stamping technique of the micro-
lens.  More  overlapping  and  passes  increase  the  aggressive-
ness of treatment (total surface coverage). Additionally, use of 
manual  compression  with  the  standard  and  XD  Microlens  is 
suspected to increase penetration of laser energy into the skin.

Regardless of tip or wavelength utilized, the laser pro-
cedure is delivered in a stamped method. Multiple stamps are 
delivered onto the skin with varying amounts of overlap. Rows 
of  stamps  are  performed  in  a  single  cosmetic  unit  at  a  time. 
The  rows  may  be  overlapped  from  0%  to  50%  depending  on 
the wavelength, the microlens used, the desired total coverage, 
and the rate at which the coverage is administered. One pass 
is completed when the entire cosmetic unit is covered by the 
stamps. Passes are then alternated between perpendicular and 
horizontal  directions.  This  is  also  known  as  the  tile  cascade 
method (see Figure 55.11). One to five passes are typically per-
formed, depending on the total desired coverage. It is impor-
tant to keep the treatment tip in full continuous contact with 
the skin during each laser pulse. As with the roller technique 
for  delivering  fractionated  laser  pulses,  when  overlapping 

 
 
stamped pulses you also produce laser impact sites, which are 
not evenly distributed on the skin surface.

FRACTIONAL 1540-NM LASER
The  1540-nm  original  microlenses  utilized  in  the  Palomar 
StarLux™ and Artisan™ and now the Icon laser platforms are 
available in two sizes: a flat, circular 10 mm tip with a micro-
beam  density  of  100  microbeams  per/cm2  and  a  flat,  circular 
15 mm tip with a microbeam density of 320 microbeams per/
cm2. The pulse durations are adjustable to 10 or 15 milliseconds 
(ms).  The  10  mm  tip  can  deliver  energies  between  14–70  mJ/
mb, with a smaller number of higher energy laser beams that 
penetrate  deeper  with  a  wider  coagulation  column  diameter 

Figure  55.11  Tile  cascade  pattern  for  a  stamping  nonabla-
tive fractional laser showing 50% overlap pulse to pulse. (From 
Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, 
Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. 
Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.)

NONABLATIVE LASER REJUVENATION 

 525

compared to the 15 mm tip. The 15 mm tip can deliver  energies 
between 3–15 mJ/mb. The standard 10 mm tip averages a 725 
µm depth of penetration while the 15 mm tip averages a 600 
µm  depth  of  penetration.  See  Table  55.4  for  recommended 
treatment settings.

The  Palomar  Icon  Aesthetic  System  can  use  a  stan-
dard  10  mm  or  15  mm  handpiece,  but  additionally  has  the 
12 × 12 mm XD Microlens (25 microbeams/cm2) and the 15 mm 
XF Microlens (115 microbeams/cm2). The XD Microlens deliv-
ers laser energies from 20–70 mJ/mb. The XF Microlens emits 
energies from 6–60 mJ/mb. The XF Microlens provides higher 
coverage  per  pulse  compared  to  the  original  optics  allowing 
fast  treatment  coverage  comparable  to  the  1440-nm  with  the 
added  benefit  of  increased  depth.  Average  depth  of  penetra-
tion of the microbeam is approximately 750 µm for the XF and 
1060 µm for the XD Microlens. Pulse stacking has been stud-
ied with the XD Microlens. For example, three stacked pulses 
with the Lux 1540 XD tip have reached depths of 1900 µm into 
the  dermis.  Settings  for  the  XD  Microlens  are  typically  from 
40–70  mJ/mb.  Three  to  six  passes  with  overlap  ranging  from 
10%–50%  depending  on  the  desired  total  coverage  and  clini-
cal condition treated can be utilized. See Table 55.5 for recom-
mended treatment settings.

THE MULTI-WAVELENGTH FRACTIONAL 
1440/1320-NM LASER
The  Affirm™  Multiplex  laser  (Cynosure,  Inc.)  is  a  fractional 
laser the emits a combination of 1440-nm and 1320-nm Nd:YAG 
wavelengths.  The  Multiplex  technology  is  defined  as  the 
sequential emission of two laser wavelengths using one laser 
fiber.  It  has  a  diffractive  lens  array  that  consists  of  1000  dif-
fractive elements per cm2 to affect more surface area per single 
pulse. The laser uses combined apex pulse (CAP) technology. 
CAP technology reportedly delivers apex pulses of high-fluence 

Table 55.4  StarLux 1540-nm Laser Treatment Settings

Superficial/Moderate Corrections

Deep Corrections

Handpiece (mm)

Millijoules per microbeam

Pulse width (ms)

Passes (20%–50% overlap)

Number of treatments

Treatment intervals (weeks)

15

6–15

5–10

2–5

3–5

3–4

10

25–50

5–10

2–4

3–5

3–4

Source: From Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. 
Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.

Table 55.5 

Icon 1540-nm Laser Treatment Settings

Millijoules per microbeam

Pulse width (ms)

Number of passes 

(20%–50% overlap)
Number of treatments

Treatment intervals

15-mm tip

10-mm tip

XD Microlens

XF Microlens

10–15

10–15

3–4

2–5

40–70

10–15

3–6

2–5

40–70

15

3–6

2–5

30–50

10–15

1–2

1–2

3–4 weeks

3–4 weeks

3–4 weeks

1–3 months

Source: From Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices for the Skin. 
Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.

 
526 

 TEXTBOOK OF COSMETIC DERMATOLOGY

regions  for  collagen  remodeling  and  low-fluence  regions  to 
stimulate  collagen  growth.  The  1440-nm  wavelength  heats  a 
column of tissue to a depth of 300 µm and the 1320-nm wave-
length penetrates deeper. Cynosure’s Smart Cool™ air cooling 
system attaches to the handpiece to protect and cool the skin. 
Usually, topical anesthesia is not necessary. A 14 mm spot size 
is used; usually 2 passes are suggested with 15%–20% overlap. 
Four to six treatments spaced 3–6 weeks apart are necessary for 
improvement in superficial scars and photodamage. The 1440-
nm laser has a maximum energy of 8 J and the 1320-nm laser 
has a maximum energy of 14 J. Typical treatment parameters 
for skin rejuvenation would be 2–3 J/cm2 for the 1440-nm com-
ponent and 6–10 J/cm2 for the 1320-nm component.

OTHER FRACTIONAL LASERS
A fractional Q-switched ruby laser (TattooStar FRx, Asclepion 
Laser  Technologies,  Jena,  Germany)  has  been  reported  to 
improve melasma in Korean patients (12). A 1540-nm fractional 
erbium:glass  laser  (Mosaic,  Lutronic  Co.,  Ltd.,  Seoul,  South 
Korea) has been studied in the treatment of male and female 
pattern hair loss and in skin rejuvenation (13-15). The 1540-nm 
and 1340-nm fractional lasers are available through the DEKA 
Dot platform (DEKA laser, Firenze, Italy). In the United States, 
there  is  a  also  a  fractional  910-nm  laser  by  Syneron  Medical 
Ltd.  and  a  fractional  Q-Switched  1064-nm  by  Alma  Lasers, 
which  has  been  shown  to  improve  superficial  rhytides  (16). 
A home-use device (Tria Age-Defying Eye Wrinkle Correcting 
Laser,  Tria  Beauty,  Inc.,  Dublin,  CA)  has  also  been  recently 
FDA-cleared  and  is  marketed  for  the  treatment  of  multiple 
signs of facial aging. Prototypes of a fractional 1940-nm and a 
1208-nm laser have also been studied.

CLINICAL CONSIDERATIONS
Before initiating a NAFL treatment series, several clinical con-
siderations  need  to  be  carefully  examined.  Specifically,  the 
treating physician and support staff should carefully consult 
with each patient about the indications for treatment, expected 
results of treatment, and review the treatment process in detail.
Also, a medical history and physical examination must be 
performed to identify contraindications or impediments to treat-
ment. Patient selection for NAFL resurfacing is very important. 
The ideal candidate has mild to moderate skin damage or dis-
coloration. Those with severely damaged skin, deep acne scars/
wrinkles,  or  extreme  laxity  will  benefit  more  from  an  ablative 
fractional/fully  ablative  or  surgical  procedure.  Patients  must 
also be counseled to have realistic expectations of the treatment 
results.  NAFL  resurfacing  yields  slow  gradual  improvement 
over  a  series  of  treatments.  Reduction  of  fine  lines  and  scars 
occur but they are not completely removed. Definitive improve-
ment in brown pigmentation and actinic keratoses can be seen 
but patients must be counseled that they may recur with contin-
ued sun exposure and time. Daily sun protection is necessary 
for all patients post-treatment. Also, the final results from treat-
ment may take 3–6 months after the last treatment. This time is 
necessary to achieve the full effect of collagen remodeling from 
the  NAFL.  During  the  consultation,  the  treatment  experience 
is also discussed in detail. Patients are instructed that a series 
of  treatments  will  be  necessary.  Usually,  the  treatment  can  be 
accomplished over two to five sessions spaced 4–6 weeks apart, 
depending  on  the  clinical  indication.  Topical  anesthetic  will 
be applied to the treatment area for approximately 60 minutes 
before  the  laser  treatment  and  the  treatment  itself  will  take 

20–40 minutes depending on surface area treated. Cool air and 
cold ice rollers can be used to increase comfort during the treat-
ment. A prickly heat sensation or a zap of heat can be felt on the 
skin depending on which NAFL system is used during the treat-
ment. Pain levels appear to be roughly equivalent in treatment-
naïve patients and those with a history of past laser treatments 
(17). Post-treatment, patients may feel like they have a sunburn. 
Redness and swelling should be expected initially. Skin dryness 
with a flaky dot appearance can last a few days up to 2 weeks 
depending  on  treatment  intensity  and  also  body  area  treated. 
During  the  consultation,  side  effects  are  discussed,  a  medical 
history is reviewed, and physical examination of the treatment 
area  is  performed.  Contraindications  include  oral  retinoid  use 
within the last 6 months, predisposition to keloid formation or 
excessive scarring, and lesions that appear to be suspicious for 
malignancy  in  the  treatment  area.  I  would  also  include  recent 
sun exposure or tanned skin, pregnancy, an active infection in 
the  treatment  area,  or  a  medical  condition  that  compromises 
healing time or predisposes to infection. Determining any his-
tory  of  herpes  simplex  virus  (HSV)  infection  is  a  mandatory 
portion  of  the  medical  history  as  reactivation  of  the  virus  can 
occur with NAFL treatment. Pretreatment with an oral antivi-
ral is recommended. For darker skin types or patients prone to 
hyperpigmentation,  pre-  and  post-treatment  with  a  hydroqui-
none bleaching cream is recommended and strict sun protection 
is discussed with all patients.

TREATMENT PREPARATION
To prepare for NAFL treatment, patients are asked to remove 
all jewelry and makeup and to cleanse their skin with a mild 
cleanser.  Consents  are  reviewed  and  signed.  Premedication 
with an oral antiviral for patients with a history of HSV is doc-
umented.  Pretreatment  standardized  photographs  are  taken. 
My  practice  primarily  uses  the  Visia™  and  IntelliStudio™ 
(Canfield  Scientific,  Inc.,  Fairfield,  NJ)  systems.  The  treatment 
area is wiped with 70% isopropyl alcohol and allowed to dry. 
A  moderately  thick  (¼ inch) amount of a topical anesthetic  is 
applied.  We  use  a  compounded  topical  anesthetic  with  15% 
lidocaine and 5% prilocaine in an ointment base for the treat-
ment of the face or localized body area. A two treatment area 
restriction  should  be  considered  when  using  such  stronger, 
compounded  topical  anesthetic  agents.  Lidocaine  overdose  is 
possible and lidocaine toxicity has been reported during NAFL 
treatment  (18).  The  fractional  laser  consensus  panel  recom-
mends to limit the area to 300–400 cm2 to minimize potential 
lidocaine toxicity (19). If larger skin surfaces are to be treated, a 
standard topical anesthetic cream can be utilized like lidocaine 
5% cream (L.M.X.5, Ferndale Healthcare Inc., Ferndale, MI). The 
topical anesthetic should be blended into the perimeter of the 
anticipated treatment area to ensure comfort. After 60 minutes, 
the topical anesthetic is removed with a dry gauze pad. Use of 
eye protection for the patient, practitioner, and support staff is 
mandatory during the NAFL treatment. If the eyelid skin inside 
the  orbital  rim  is  to  be  treated,  intraocular  metal  eye  shields 
should be inserted. Handpieces are sanitized with Sani-Cloth® 
(Professional Disposables International, Inc., Orangeburg, NY) 
before  each  treatment.  Laser  system  tests  are  performed  to 
ensure a properly performing laser. A paper test strip is avail-
able with use with the Fraxel laser systems (see Figure 55.12).

When  treating  the  patient  with  any  NAFL,  divide 
the  treatment  area  into  smaller  cosmetic  units.  For  example, 
the cosmetic units of the forehead, cheeks, nose, lip, and chin 
are treated as separate areas. These units can be customized to 

 
NONABLATIVE LASER REJUVENATION 

 527

 corticosteroids and bleaching agents to take advantage of this 
opportunity for enhanced epidermal absorption.

COMPLICATIONS
Complications are a possibility with any nonablative fractional 
laser treatment, even though the potential for and the incidence 
of  serious  side  effects  are  exponentially  less  than  with  tradi-
tional ablative resurfacing. Nonablative skin resurfacing has a 
low complication rate. Most side effects are transient in nature. 
Possible  side  effects  include  erythema,  swelling,  blistering, 
scarring,  infection,  pigmentary  changes,  herpes  reactivation, 
and acne flare-up. Transient erythema and swelling is normal 
and the patient should be instructed to expect this. In a review 
of  short-term  adverse  effects  from  1550-nm  NAFL  treatment 
by Fisher et al., all patients displayed post-treatment erythema, 
and edema was present in 82% of patients (22). Prolonged ery-
thema,  massive  swelling,  blistering  and  subsequent  scarring 
can occur if aggressive treatment parameters are utilized and 
overheating  of  the  skin  occurs.  These  side  effects  can  be  eas-
ily  avoided  with  prudent  selection  of  treatment  parameters. 
Infection  is  rarely  seen  with  nonablative  fractional  resurfac-
ing.  Hyperpigmentation  definitely  occurs  and  is  more  preva-
lent with darker skin types (IV–V). In a retrospective review of 
Fitzpatrick  skin  types  IV–VI  treated  with  a  1550-nm  erbium-
doped  fractional  nonablative  laser  (Fraxel  Re:Store  SR  1550; 
Solta Medical, Inc., Hayward, CA), PIH occurred in 5 out of 115 
total laser sessions (4%), with only one case lasting longer than 
a month (2 months total) (23). This can be reduced with pre- and 
post-treatment with hydroquinone bleaching agents and strict 
sun  protection.  Also,  treatment  densities  and  fluencies  must 
be  lowered  to  reduce  this  side  effect.  Reactivation  of  herpes 
simplex  is  another  real  side  effect.  Patients  who  are  prone  to 
herpes simplex should be pretreated with oral antivirals. There 
have also been three cases of herpes zoster along the trigeminal 
nerve which have been reported after NAFL Acneifrom erup-
tions can also occur. If patients are prone to acne, they can be 
treated  with  oral  antibiotics,  like  minocycline  or  doxycycline 
and/or a topical antibiotics, such as clindamycin. The nonabla-
tive resurfacing complication rate has been studied over several 
years (25–27). A retrospective study of 961 nonablative 1550-nm 
laser  treatments  recorded  a  7.6%  complication  rate  (27).  The 
two most common complications encountered were acneiform 
eruptions and herpes simplex reactivation. However, these were 
only encountered at a 1.87% and 1.77% rate respectively. Rarely, 
ulceration can occur, as reported recently in two cases of stable 
surgical  scars  that  ulcerated  following  nonablative  fractional 
resurfacing with a 1550-nm device (Fraxel Re:Store) (28). Both of 
these cases involved the use of intralesional lidocaine for pre-
treatment  anesthesia.  Overall,  NAFL  is  a  very  safe  treatment 
and has minimal side effects at the recommended settings.

CLINICAL APPLICATIONS
Nonablative lasers have been used to treat an expansive range 
of conditions. Numerous clinical studies have shown its effec-
tiveness in a variety of treatments (19,29,30). The main areas of 
treatment include photodamage and wrinkling, scars, stretch 
marks, pigmentary disorders, and actinic keratoses. Evolving 
applications  include  the  enhancement  of  drug  and  topical 
product  delivery,  which  takes  advantage  of  increased  per-
meability  of  the  epidermis  and  dermis  after  treatment.  Case 
reports have also shown NAFL treatment to be useful in mis-
cellaneous other applications that include improving residual 

Figure 55.12  Test strip utilized with Fraxel laser systems.

the preferences of the individual practitioner. Completely treat 
one cosmetic unit at a time. Be careful not to overlap treatment 
between  the  individual  cosmetic  units  that  could  cause  over 
treatment.  In  my  practice,  we  use  forced  cold  air  during  the 
treatment, which has been shown to reduce pain but can also 
affect the thermal laser injury (20).

POST-CARE ROUTINE
After the NAFL treatment is concluded, patients receive a light-
emitting diode treatment (Gentlewaves, LLC, Virginia Beach, 
VA)  to  reduce  the  intensity  and  duration  of   post-treatment 
 erythema (21). They are also treated with a thermal water spray 
(Avene Thermal Water, Pierre Fabre Dermo Cosmétique USA, 
Parsippany,  NJ)  to  alleviate  discomfort,  and  a  physical  sun-
block is applied before they leave the office. The next treatment 
is scheduled in 3–6 weeks.

Gentle post-care at home is paramount. In my practice, 
we  supply  our  patients  with  a  skin  care  kit  to  be  used  dur-
ing their laser treatment series. It consists of a gentle cleanser, 
non-occlusive  moisturizer,  thermal  water  spray,  and  a  physi-
cal sunblock. Post-care instructions are reviewed verbally with 
the patient and they are also sent home with written instruc-
tions. The patient is instructed to cleanse the treated area twice 
a  day  with  the  gentle  cleanser  and  immediately  apply  the 
gentle  moisturizer.  The  broad-spectrum  sun  protection  must 
be applied before exposure to sunlight and reapplied as neces-
sary. Patients can also apply cool compresses or cold packs and 
spray their face with the thermal water spray as needed to help 
reduce  swelling  and  discomfort.  Narcotic  pain  medication  is 
rarely  necessary,  but  over-the-counter  acetaminophen  can  be 
taken if needed. Patients should sleep with their head elevated 
for the first few nights to help diminish swelling. They should 
avoid vigorous exercise or activity while swollen or red. They 
should  avoid  smoking  and  excessive  alcohol  consumption. 
Strict sun protection must be observed using a broad-spectrum 
SPF of 30 or greater. Direct sun exposure should be avoided for 
3 months post-treatment. Topical products and medications can 
usually be restarted 3–7 days post-treatment depending on the 
level of treatment and sensitivity of the patient. Those patients 
prone to PIH or who are being treated for melasma will restart 
a topical hydroquinone cream 1 to 4 days post-procedure.

Ablative  and  nonablative  fractional  lasers  are  increas-
ingly being utilized for enhanced topical drug delivery. This 
concept can be utilized in post-treatment care, and in our prac-
tice we frequently apply a topical serum containing L-ascorbic 
acid,  alpha  tocopherol,  and  ferulic  acid,  as  well  as  topical 

 
528 

 TEXTBOOK OF COSMETIC DERMATOLOGY

hemangiomas,  minocycline  induced  pigmentation,  nevus  of 
Ota,  granuloma  annulare,  and  male  and  female  pattern  hair 
loss, among other applications described below (13,14,31–34).

PHOTODAMAGE
Many studies have examined nonablative fractional resurfacing 
of the face and non-facial skin for improvement in sun-induced 
discoloration and wrinkles. In 2007, Wanner et al. examined 50 
patients with mild to moderate photodamage, rhytides, and dys-
pigmentation who received three successive treatments with a 
1550-nm erbium-doped laser (Fraxel SR750, Reliant Technologies, 
Inc.,* Mountain View, CA) (35). At least 51%–75% improvement in 
photodamage was observed in 73% and 55% of facial and non-
facial  (chest  and  neck)  treated  skin  at  the  9-month  follow-up. 
Fractional  laser  photothermolysis  for  photoaging  of  the  hands 
has also been examined in a small cohort of patients by Jih et al. 
(36). In this study, ten patients were randomized to receive five 
NAFL treatments with a 1550-nm laser (Fraxel SR) to either their 
left or right hand. Statistically significant improvements in skin 
pigmentation and skin texture were noted at the 1- and 3-month 
follow-up  visits.  Skin  biopsies  were  also  taken  at  baseline  and 
at 1- and 3-month follow-up visits. The post-treatment biopsies 
showed thickening of the epidermis and notably increased colla-
gen density in the papillary and upper reticular dermis. Moreover, 
the  study  was  safe  and  showed  limited  side  effects.  In  2010,  a 
1550-nm  laser  consensus  panel  published  their  recommended 

* Reliant Technologies, Inc. was acquired by Solta Medical, Inc. in 2008

treatment settings for photoaging (19). The panel recommended 
settings of 10–20 mJ of energy with a treatment level of 7–11 to 
improve  dyschromia  in  patients  with  Fitzpatrick  skin  types  
I–III. For rhytides, specifically in the periorbital region, the con-
sensus  recommended  settings  of  30–70  mJ  of  energy  using  a 
TL  of  7–11  with  eight  passes.  For  dyschromia  of  the  neck  and 
chest  the  panel  recommended  10–40  mJ  of  energy  using  a  TL 
of 7–11 and eight passes for Fitzpatrick skin types I–III. Newer 
versions of the 1550-nm laser, as well as other NAFLs of other 
wavelengths, have been developed since the consensus meeting. 
Hopefully another consensus meeting will be planned that will 
include  recommended  treatment  guidelines  for  all  NAFL  sys-
tems. Results using a 1550-nm laser for the treatment of photo-
damage on the chest are shown in Figure 55.13.

In 2014, Brauer et al. examined a 1927-nm nonablative thu-
lium laser for the treatment of photo-induced pigmentation (Fraxel 
DUAL,  1550/1927  Laser  System,  Solta  Medical,  Inc.,  Hayward, 
CA) (37). Forty patients with photo-induced facial pigmentation 
received two treatments at an energy level of 10 mJ, coverage of 
40%, and 4–6 passes. At 1 and 3 months after the second treat-
ment, overall improvement was graded as moderate to very sig-
nificant in 82% and 69% of subjects, respectively. Lentigines and 
ephelides also showed moderate to very significant improvement 
in 68% and 51% of subjects at 1 and 3 months follow-up, respec-
tively. Treatments were well-tolerated with a mean pain sensation 
of 4.3 on a 10-point scale, with no serious adverse events. A clini-
cal example of results with this device is shown in Figure 55.14.

(a)

(b)

(a)

(b)

Figure  55.13  Photodamage  of  the  chest  (a)  before  and  (b) 
after two treatments with a 1550-nm device. (From Beasley KL, 
Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, 
Weiss RA, eds. Laser and Energy Devices for the Skin. Boca 
Raton, FL: CRC Press, 2013; pp. 178–91. With permission.)

Improvement in pigmentation (a) before and (b) 
Figure 55.14 
after one treatment with a 1927-nm device. (From Beasley KL, 
Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, 
Weiss RA, eds. Laser and Energy Devices for the Skin. Boca 
Raton, FL: CRC Press, 2013; pp. 178–91. With permission.)

 
In  2014,  Marmon  et  al.  reported  mild  improvement  in 
skin  texture,  pigmentation,  and  wrinkling  when  treating 
Asian  subjects  with  a  1440-nm  diode-based  nonablative  frac-
tional  laser  (Clear  +  Brilliant™  Laser  System,  Solta  Medical, 
Inc., Hayward, CA) (38). In this study, ten Chinese subjects with 
Fitzpatrick  skin  types  III–V  received  four  treatments  spaced 
2 weeks apart. Side effects most often included erythema and 
edema, which were transient in all, with one patient develop-
ing  a  discrete  area  of  postinflammatory  hyperpigmentation 
that resolved by the end of the study. The authors suggest that 
this low energy, less intense treatment may be a good option 
for  skin  of  color  patients  who  may  have  only  a  mild  degree 
of photodamage. This same laser has also been evaluated as a 
treatment for large pores. In a 2013 study, Saedi et al. reported 
20 patients who received six treatments spaced 2 weeks apart 
at  the  highest  tolerable  energy  (39).  Utilizing  pore  scores  cal-
culated  with  use  of  the  Visia-CR  imaging  system  (Canfield 
Scientific,  Inc.,  Fairfield,  NJ),  the  study  found  a  17%  average 
reduction  in  pore  score,  which  was  statistically  significant. 
Subjects and investigators also scored their improvement, with 
both groups rating the appearance of pores, skin texture, and 
overall appearance as moderate to markedly improved.

Photodamage  can  also  be  addressed  with  a  new,  FDA-
cleared  1440-nm  home-use  device  (Tria  Age-Defying  Eye 
Wrinkle  Correcting  Laser,  Tria  Beauty,  Inc.,  Dublin,  CA). 
Rahman et al. recently reported significant improvement uti-
lizing  this  device  for  periorbital  wrinkles  in  45  subjects  who 
treated  themselves  daily  for  8  weeks  (40).  The  subjects  were 
followed for 12 weeks after the final treatment, with improve-
ment being sustained in 81% of subjects. Treatments were gen-
erally about 1 minute per eye and were well tolerated with no 
serious adverse events.

NAFL  treatments  can  also  be  combined  with  other 
modalities on the same day for the treatment of photoaging. In 
2012, Kearney et al. reported synergistic results when IPL was 
combined  with  a  1550-nm  fractional  device  (Fraxel  Re:Store)
(41).  In  our  practice,  we  commonly  combine  IPL  with  the 
 1927-nm thulium laser in a single treatment session.

SCARS
Improvement  in  scars  may  significantly  improve  a  patient’s 
self-esteem and quality of life. Common causes of scars include 
surgery,  trauma,  and  acne.  Two  main  categories  of  scars 
include  atrophic  and  hypertrophic  scars.  They  can  vary  in 
color from white to red to brown. In 2007, an initial pilot study 
by Vasily studied 31 subjects with 13 surgical scars and 18 trau-
matic scars utilizing the Lux 1540-nm 10 mm  handpiece (42). 
Treatments utilized laser energies in the range of 30–60 mJ, a 10 
ms pulse duration, and three to five passes, with a series of one 
to eight treatments being performed. A blinded observer noted 
51%–75%  improvement  in  scars  at  1-month  post-treatment  in 
59% of patients. The most improvement was seen after the first 
three treatments. These results have further been confirmed in 
a more recent study utilizing a NAFL for the treatment of sur-
gical scars and skin grafts following Mohs surgery (43). NAFL 
treatment  of  surgical  scars  has  also  been  compared  to  and 
outperformed the standard scar treatment of pulsed dye laser 
(PDL) (44). This was shown in a randomized, blinded split-scar 
study performed in 12 patients comparing a 1550-nm erbium-
doped fiber laser (Fraxel SR) against the 595-nm V-Beam PDL 
(Candela Corporation, Inc., Wayland, MA). Fluences of 70 mJ, 
TL 8, and 16 passes were performed on the NAFL side and 7.5 J/
cm2, pulse duration of 0.45 ms, and a spot size of 10×3 mm were 

NONABLATIVE LASER REJUVENATION 

 529

performed on the PDL side. After a series of four treatments, 
greater overall mean improvement was seen in the NAFL side 
(75.6%) compared to the PDL side (53.9%).

Hypopigmented scars, hypertrophic scars, and traumatic 
thermal  burn  scars  have  also  been  studied  in  small  cohorts 
and have demonstrated improvement with NAFL (45–49). In a 
study by Massaki et al., 14 patients with hypopigmented scars 
were treated with an erbium-doped 1550-nm fractionated laser 
in  combination  with  either  topical  bimatoprost  twice  daily 
plus  topical  tretinoin  0.05%  or  pimecrolimus  1%  cream  daily 
for those who could not tolerate tretinoin. After a mean of 4.5 
treatment sessions, follow-up results 4 weeks after the last treat-
ment  revealed  significant  improvement  in  scar  pigmentation 
(greater than > 50%) in 12 of 14 patients with improved clini-
cal scores that persisted for a mean follow-up of 20.1 months. 
The 1550-nm NAFL consensus panel recommended settings of 
50–70 mJ of energy with a TL of 7–11 for skin types I–III in the 
treatment of surgical scars (19). Flattening and improvement in 
hypopigmentation of a scar is shown in Figure 55.15.

Nonablative 

fractional  resurfacing  has  also  been 
reported  to  be  effective  in  the  treatment  of  contracted  scars. 
In a 2015 case report, Finney et al. reported improvement in a 
contracted right lower extremity scar following treatment with 
the  Fraxel  DUAL  (50).  The  patient  underwent  six  treatments 
spaced  4–8  weeks  apart,  receiving  three  treatments  with  the 
1927-nm  thulium  laser  (10  mJ,  30%  density,  eight  passes)  and 
three  with  the  1550-nm  laser  (40  mJ,  17%–26%  density,  eight 
passes).  Following  the  treatments,  the  patient  had  subjective 
and objective improvement in their range of motion, as well as 
50%–75% improvement in scar texture and discoloration.

Like  surgical  scars,  acne  scars  can  be  cosmetically  and 
psychologically  disturbing  to  patients.  NAFL  therapy  has 
been proven successful in the treatment of acne scars. In 2008, 
Weiss  et  al.  presented  a  retrospective  analysis  of  over  500 
acne scar treatments with the Lux 1540-nm laser (51). The flu-
ences  used  were  50–70  mJ  with  a  minimum  of  three  passes. 
Results assessed by blinded photographic evaluation showed 
a median of 50%–75% improvement in acne scars with 85% of 
patients  rating  their  skin  as  improved.  In  2012,  Bencini  et  al. 
evaluated 87 acne scar patients with moderate to severe acne 
scarring  who  were  treated  with  the  same  device  (52).  Four 
passes with 50% overlap at 15 ms pulse duration with energies 
ranging from 50–60 mJ were utilized. At 6 months follow-up, 
80/87 (92%) of patients had marked improvement and 7/87 (8%) 
showed  a  moderate  improvement  as  graded  by  two  blinded 
independent physicians. In a more recent study by Sardana et 
al., use of the Lux 1540-nm laser with a 10-mm handpiece was 
found  to  markedly  improve  atrophic  acne  scars,  particularly 
boxcar  scars  (53).  In  this  study,  35  patients  received  six  treat-
ments  with  four  passes  per  treatment  and  energies  ranging 
from 70–100 mJ. At 6 months follow-up, there was a reduction 
in mean counts of ice-pick, rolling, and boxcar scars, although 
only  boxcar  scars  showed  a  statistically  significant  reduction 
(52.9%).  Additionally,  46.7%  of  patients  reported  moderate 
improvement  of  25%–50%,  26.7%  reported  marked  improve-
ment of 51%–75%, and 3.3% reported near total improvement. 
Acne  scars  have  also  been  studied  with  the  Fraxel  1550-nm 
SR750 by Alster et al. (54). Fifty-three patients with acne scar-
ring received three laser treatments. Ninety percent of patients 
were found to have 51%–75% improvement by an independent 
observer.

Nonablative  fractional  laser  treatments  can  also  be  uti-
lized for the treatment of postinflammatory erythema second-
ary to acne. In a 2014 study by Park et al., 12 Korean patients 

 
530 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 55.15  Flattening and improvement in hypopigmentation of a scar (a) before and (b) after several 1550-nm treatments. 
(From Beasley KL, Weiss RA, In: Goldman MP, Fitzpatrick RE, Ross VE, Kilmer SL, Weiss RA, eds. Laser and Energy Devices 
for the Skin. Boca Raton, FL: CRC Press, 2013; pp. 178–91. With permission.)

with  acne  erythema  received  a  total  of  three  split-face  treat-
ments  with  a  1550-nm  erbium:glass  nonablative  fractional 
laser and a PDL (55). Both treated sides had statistically signifi-
cant improvement in erythema, with no significant difference 
between them. Patients rated their improvement as either good 
or excellent in 91.7% of the fractional treated side, and 75% of 
the PDL-treated side.

The  1550-nm  laser  consensus  panel  meeting  recom-
mended treatment settings for acne scars that depended on skin 
type  (19).  They  recommended  settings  of  30–70  mJ  at  TL  7–11 
for 8–12 passes for skin types I–III and 30–70 mJ, TL 4–5 and 8 
passes for skin types IV–V. We presently employ the Icon system 
with the 1540-nm XD handpiece for scars and anecdotally have 
seen responses for scars resistant to all other NAFL devices.

STRIAE
Striae are disrupted areas of collagen in the skin that can occur 
during growth spurts, topical and oral steroid use, and condi-
tions  of  hormonal  change  like  pregnancy.  It  is  estimated  that 
75%–90%  of  women  develop  some  degree  of  stretch  marks 
during  pregnancy.  Previous  treatments  have  been  ineffec-
tive or inconsistent and not suitable for all skin types (56). The 
Palomar† 1540-nm NAFL is currently the only laser to gain FDA 
clearance  for  the  treatment  of  striae.  One  of  the  first  studies 
with the Lux 1540-nm laser evaluated 51 subjects with striae of 
the abdomen, legs, buttocks, arms, and flanks (57). Fluences of 
35–55 mJ with a 10 mm tip or 12–14 mJ with a 15 mm tip were 
utilized.  Two  to  four  treatments  were  performed.  Patient  and 
independent observer evaluations noted improvements of 50% 
or  greater  in  all  patients  at  6  months  past  the  last  treatment. 
More recently, Wang et al. compared the clinical efficacy of the 
Lux 1540-nm with a low energy 1410-nm nonablative fractional 
laser (Emerge™, Cynosure, Inc., Westford, MA)(58). Ten patients 
with abdominal striae were treated, with half of their abdomens 

† Reliant Technologies, Inc. was acquired by Solta Medical, Inc. in 2008

being treated with the 1540-nm device (XD: 50 mJ, 15 ms pulse 
duration, 2 passes; XF: 50 mJ, 15 ms pulse duration, two passes, 
25%  total  density)  and  the  other  half  being  treated  with  the 
1410-nm device (30 J, 5 passes, 16% density). Six treatments were 
performed  2–6  weeks  apart,  with two blinded  dermatologists 
scoring  the  photographs.  All  patients  demonstrated  clinical 
improvement, with “good” or “excellent” improvement seen in 
33% of those treated with the 1540-nm device and 28% of those 
treated with the 1410-nm device. “Mild” or “fair” improvement 
was seen in 66% of those treated with 1540-nm and 72% of those 
treated  with  1410-nm.  These  differences  were  not  statistically 
significant. All patients were either “very satisfied” or “moder-
ately satisfied.” Of note, transient hyperpigmentation appeared 
to last longer in those treated with the 1410-nm device.

Fraxel 1550-nm NAFL has also been studied in the treat-
ment of striae even though it is not FDA-approved for this indi-
cation. Twenty patients with striae were studied over six laser 
treatments.  Randomly  selected  photos  of  eight  patients  were 
chosen from the study and an independent observer rated a 26%–
50% level of overall improvement in five out of eight patients (59). 
In  a  separate  study,  Guimarães  et  al.  treated  10  cases  of  striae 
on  the  breasts  following  breast  augmentation  with  a  1550-nm 
erbium:glass laser (Sellas, Dinona Inc., Seoul, South Korea)(60). 
Each patient underwent four to eight treatments at 4-week inter-
vals, with fluences of 80–100 mJ, a density of 100 points per area, 
and one treatment pass. Responses were graded by subjects and 
two plastic surgeons 4 weeks following the last treatment ses-
sion, with 50% of graded scores being between 9 and 10 on a 0 
(no improvement) to 10 (total improvement) scale. Nonablative 
1550-nm  treatments  have  also  been  compared  to  ablative  CO2 
fractional laser resurfacing in Asian patients with striae on the 
abdomen, both with significant clinical and histologic improve-
ment.  There  was  no  significant  difference  in  clinically  efficacy 
between the modalities based on blinded physician evaluations 
(61). The 1550-nm NAFL consensus panel recommended settings 
of 40 mJ, TL 10 for eight passes in skin types I–III and reducing 
the TL to 4–7 in darker skin types (19). When treating striae, a 

 
 
 
laser test area is always suggested. Pre- and post-treatment with 
a  hydroquinone  bleaching  cream  is  suggested  in  darker  skin 
types and areas prone to prolonged PIH, like the legs.

PIGMENTARY DISORDERS
Increased pigmentation of the skin, as seen in photodamage and 
melasma,  has  shown  improvement  through  NAFL  treatment. 
Melasma can be quite distressing to patients and is notoriously 
difficult  to  treat.  It  is  a  chronic  skin  condition  seen  primarily 
in female patients. It presents as a brown patchy discoloration 
over  sun-exposed  areas  like  the  cheeks,  forehead,  upper  lip 
and  sometimes  arms.  Contributing  factors  include  sun  expo-
sure, hormones, pregnancy, and genetics (62). Many therapeutic 
modalities have been investigated over the years but none have 
been shown to be uniformly successful (63,64). When the first 
1550-nm laser was released, several melasma studies were initi-
ated. The first pilot study was by Rokhsar et al. using a 1550-nm 
laser  on  10  patients  (65).  It  showed  some  success  with  60%  of 
patients demonstrating excellent clearing and 30% of patients 
demonstrating  mild  improvement.  Another  study  compared 
1550-nm  laser  resurfacing  with  a  topical  bleaching  cream 
through a split-face study (66). The patients in the study showed 
preference  to  the  topical  bleaching  cream  side  over  the  1550-
nm NAFL side. The 1927-nm laser is not approved for melasma 
but  initial  reports  seem  promising.  An  initial  pilot  study  by 
Polder et al. used the Fraxel 1927-nm thulium laser in the treat-
ment of 18 patients with melasma (67). They performed three 
to four treatments using 10–20 mJ of energy, a TL correspond-
ing  to  20%–45%  coverage,  and  eight  passes.  Using  the  stan-
dard  Melasma  Area  and  Severity  Index  (MASI)  and  blinded 
independent  photographic  review  of  standardized  photos, 
they reported a 51% reduction in the MASI scores at 1-month 
follow-up. There was still a 33% and a 34% reduction of MASI 
score at 3- and 6-months follow-up, respectively. More recently, 
a  retrospective  analysis  of  20  patients  treated  with  the  same 
device found that 60% of subjects had more than 50% clearance 
of their melasma at 4 weeks after a single laser treatment (68). 
At  4  weeks  after  the  treatment,  mean  MASI  scores  improved 
by  35%,  and  by  53.8%  at  the  6-  to  12-month  follow-up  visit. 
Treatment  settings  included  fluences  between  10–20  mJ,  with 
60%–70%  surface  area  coverage,  and  total  energies  ranging 
between 1.72 to 4.42 kJ. Notably, 7 of 15 patients who success-
fully followed up had recurrence of their melasma with time. 
Although NAFL treatment has shown success in the treatment 
of melasma, its long-term efficacy is still limited by the inherent 
recurrence rate of melasma. In some patients with melasma, we 
have  also  noted  increased  hyperpigmentation  and  prolonged 
erythema  after  NAFL  treatment.  Most  NAFL  and  other  laser 
treatments for melasma work best when combined with topical 
depigmenting skin care and aggressive sun protection.

ACTINIC KERATOSES
An  actinic  keratosis  (AK)  is  a  precancerous,  epidermal,  scaly 
macule or papule that occurs on sun-damaged skin. Treatment 
of these lesions is indicated, as there is potential for them to prog-
ress  into  invasive  squamous  cell  carcinoma.  The  1550-nm  and 
the  1927-nm  wavelengths  have  been  studied  and  have  shown 
success in the treatment of these precancerous growths. Initially, 
the  1550-nm  fractional  laser  (Fraxel  Re:Store)  was  investigated 
in a small group of men with AKs (69). These men underwent 
five nonablative resurfacing laser treatments every 2 to 4 weeks. 
Energies  ranged  from  20–70  mJ  during  the  treatment  but  the 

NONABLATIVE LASER REJUVENATION 

 531

majority of treatments were performed at 70 mJ. Treatment level 
11  was  utilized  and  8–10  passes  were  performed.  A  baseline 
biopsy was performed and then repeated at the 3-month follow-
up visit, immediately adjacent to the initial biopsy site. AKs were 
counted at 1-, 3-, and 6-month follow-up visits. There was clinical 
improvement after each session, although histologically, precan-
cerous changes were still evident. At the 1-, 3-, and 6-month vis-
its, actinic keratosis percent reduction from baseline was 73.1%, 
66.2%, and 55.6%, respectively. With the introduction of the 1927-
nm thulium fractional laser, more AK treatment studies began. 
This  superficial  wavelength  selectively  targets  the  epidermis 
and upper dermis and was postulated to have greater efficacy in 
the treatment of the mostly epidermal AKs. Weiss et al. studied 
24 subjects with facial AKs receiving up to four treatments with 
a  1927-nm  fractional  laser  (Fraxel  DUAL)(70).  One  month  after 
the final treatment, average AK clearance was 91.3% by an inde-
pendent physician assessment. At 6 months after the treatment, 
average  AK  clearance  was  86.6%.  Histologic  clearance  of  AKs 
was also documented in 87.5% of those subjects who were biop-
sied. They found this treatment to be well tolerated by patients, 
without incidents of infection, scarring, or pigmentary changes. 
Friedman et al. performed split-face laser treatment of AKs using 
a 1550-nm laser in combination with the 1927-nm laser versus the 
1927-nm laser alone (71). They found that the side treated with 
1927-nm alone had greater clinical reduction in AKs as well as 
improvement  in  sun-induced  pigmentation.  The  1927-nm  laser 
has also been applied to the treatment of AKs of the lip, other-
wise known as actinic cheilitis (72). This condition is notoriously 
hard to treat, prone to recurrence, and can be quite painful for 
patients. Anolik et al. performed a retrospective chart analysis of 
a small group of actinic cheilitis patients and found that after 1–2 
treatments  patients  were  improved  by  50%–75%  or  75%–100% 
as rated by blinded, non-treating staff dermatologists (73). The 
procedure was well tolerated by patients and had much less side 
effects  when  compared  to  ablation,  surgery,  or  treatment  with 
topical chemotherapeutic agents or immune modulators.

Nonablative 

fractional  resurfacing  has  also  been 
reported to be safely and effectively combined with fractional 
ablative therapy for the treatment of actinic keratoses. In 2015, 
Ortiz et al. reported a 91% clearance rate in AKs treated with a 
hybrid 1470/2940-nm fractional laser when utilized on 115 AKs 
located on the scalp, chest, forearms, and dorsal hands (74).

ENHANCEMENT IN DELIVERY OF 
TOPICAL DRUGS AND PRODUCTS
Research  in  this  application  of  fractional  lasers  is  still  in  its 
infancy but there is expanding evidence supporting its role in 
a  variety  of  applications,  particularly  with  ablative  fractional 
devices.  One  area  of  particular  promise  is  the  use  of  ablative 
and  nonablative  fractional  resurfacing  for  enhancement  of 
photodynamic therapy (PDT), as laser pretreatment offers the 
potential of increased ALA uptake with shortened incubation 
and potentially improved clinical outcomes. Enhanced absorp-
tion  of  ALA  has  been  demonstrated  in  an  in  vivo  study  that 
showed skin pretreated with a 1550-nm fractional erbium:glass 
laser  (Mosaic)  followed  by  topical  5-aminolevulinic  acid  had 
a  statistically  significant  increase  in  porphyrin  fluorescence 
compared to areas not exposed to the laser (75). In my practice, 
we often pre-treat our PDT patients with two to four passes of 
NAFL, which allows for faster penetration of topical levulinic 
acid. This is especially helpful in areas like the arms and legs in 
which incubation time with levulinic acid would otherwise be 
hours. Enhancement of platelet-rich plasma (PRP) treatment of 

 
532 

 TEXTBOOK OF COSMETIC DERMATOLOGY

the skin has also been studied in NAFL (15). The study showed 
that when PRP was combined with NAFL with a 1550-nm laser 
(Mosaic), patient satisfaction and skin elasticity increased while 
erythema  index  of  the  skin  decreased.  Histologically,  those 
patients who were treated with PRP plus NAFL demonstrated 
increased length of the dermal epidermal junction, increased 
amounts  of  collagen,  and  increased  numbers  of  fibroblasts 
compared to patients treated with fractional laser alone.

OTHER CLINICAL INDICATIONS
Nonablative  lasers  have  also  been  reported  to  be  effective  in 
the  treatment  of  a  variety  of  other  conditions.  In  2014,  Hsu 
et al. reported favorable outcomes using a 1450-nm diode laser 
for the treatment of xanthoma disseminatum (76). This same 
laser  has  also  been  reported  to  effectively  treat  xanthelasma 
palpebrarum (77). Beleznay et al. reported a case of lupus mili-
aris disseminatus faciei treated with nonablative fractionated 
resurfacing utilizing a novel 1565-nm device (78). Nonablative 
fractional  resurfacing  utilizing  the  Lux  1540-nm  laser  with 
the XD handpiece has also been shown to be effective in the 
treatment of iatrogenic hypopigmentation secondary to intra-
lesional  steroid  injections  (79).  In  2014,  Emer  et  al.  reported 
improvement in a case of lupus pernio using combined pulsed 
dye laser and nonablative fractional resurfacing (Fraxel DUAL) 
(80). In 2013, Narinesingh et al. reported improvement in the 
waffle pattern of a meshed skin graft following treatment with 
a 1540-nm fractionated erbium: glass laser (81). Macular sebor-
rheic  keratoses  have  been  shown  to  be  safely  and  effectively 
treated  with  a  1927  thulium  fiber  laser  (82).  Isolated  steato-
cystoma multiplex has also been reported to be substantially 
improved with two treatments of a 1450-nm diode laser and a 
1550-nm fractionated erbium-doped fiber laser (83).

CONCLUSIONS
Fractional  photothermolysis,  and  its  application  of  NAFL 
skin  resurfacing,  is  still  considered  a  leading  groundbreak-
ing technology. Both the stamping modes and the continuous 
motion handpiece with rollers are effective methods to deliver 
the energy. New understanding and engineering has allowed 
the development of optics that drive energy more deeply and 
more safely to obtain better results on scars and other clinical 
problems. NAFL’s proven efficacy in a multitude of skin condi-
tions leads us to utilize NAFL as an integral part of our daily 
practice  of  dermatology  and  medicine.  Clinical  applications 
include among others, photodamage, wrinkling, scars, stretch 
marks, pigmentary disorders, and actinic keratosis. Study after 
study  demonstrates  that  fractional  resurfacing  is  effective, 
safe, and has minimal side effects. NAFL will continued to be 
studied and is still in its infancy when related to enhancement 
of topical therapies

REFERENCES

1.  Bernstein LJ, Kauvar AN, Grossman MC, Geronemus RG. The 
short- and long-term side effects of carbon dioxide laser resur-
facing. Dermatol Surg 1997; 23(7):519–25.

2.  Helm  TN,  Jr  SS.  Alabaster  skin  after  CO2  laser  resurfacing: 
Evidence for suppressed melanogenesis rather than just mela-
nocyte destruction. Cutis 2006; 77(1):15–7.

3.  Bhatia  AC,  Dover  JS,  Arndt  KA,  Stewart  B,  Alam  M.  Patient 
satisfaction  and  reported  long-term  therapeutic  efficacy  asso-
ciated with 1,320 nm Nd:YAG laser treatment of acne scarring 
and photoaging. Dermatol Surg 2006; 32(3):346–52.

4.  Tanzi EL, Alster TS. Comparison of a 1450-nm diode laser and a 
1320-nm Nd:YAG laser in the treatment of atrophic facial scars: 
A prospective clinical and histologic study. Dermatol Surg 2004; 
30(2 Pt 1):152–7.

5.  Lupton  JR,  Williams  CM,  Alster  TS.  Nonablative  laser  skin 
resurfacing using a 1540 nm erbium glass laser: A clinical and 
histologic analysis. Dermatol Surg 2002; 28(9):833–5.

6.  Chan HH, Lam LK, Wong DS, Kono T, Trendell-Smith N. Use of 
1,320 nm Nd:YAG laser for wrinkle reduction and the treatment 
of  atrophic  acne  scarring  in  Asians.  Lasers  Surg  Med  2004; 
34(2):98–103.

7.  Manstein  D,  Herron  GS,  Sink  RK,  Tanner  H,  Anderson  RR. 
Fractional  photothermolysis:  A  new  concept  for  cutaneous 
remodeling  using  microscopic  patterns  of  thermal  injury. 
Lasers Surg Med 2004; 34(5):426–38.

8.  Hantash  BM,  Bedi  VP,  Sudireddy  V,  Struck  SK,  Herron  GS, 
Chan KF. Laser-induced transepidermal elimination of dermal 
content  by  fractional  photothermolysis.  J  Biomed  Optics  2006; 
11(4):041115.

9.  Laubach  HJ,  Tannous  Z,  Anderson  RR,  Manstein  D.  Skin 
responses to fractional photothermolysis. Lasers Surg Med 2006; 
38(2):142–9.

  10.  Leyden J, Stephens TJ, Herndon JH, Jr. Multicenter clinical trial 
of  a  home-use  nonablative  fractional  laser  device  for  wrinkle 
reduction. J Am Acad Dermatol 2012; 67(5):975–84.

  11.  Peterson JD, Goldman MP. Rejuvenation of the aging chest: A 

review and our experience. Dermatol Surg 2011; 37(5):555–71.

  12.  Jang  WS,  Lee  CK,  Kim  BJ,  Kim  MN.  Efficacy  of  694-nm 
Q-switched  ruby  fractional  laser  treatment  of  melasma  in 
female Korean patients. Dermatol Surg 2011; 37(8):1133–40.
  13.  Lee  GY,  Lee  SJ,  Kim  WS.  The  effect  of  a  1550  nm  fractional 
erbium-glass  laser  in  female  pattern  hair  loss.  J  Eur  Acad 
Dermatol Venereol 2011; 25(12):1450–4.

  14.  Kim WS, Lee HI, Lee JW, Lim YY, Lee SJ, Kim BJ, et al. Fractional 
photothermolysis  laser  treatment  of  male  pattern  hair  loss. 
Dermatol Surg 2011; 37(1):41–51.

  15.  Shin MK, Lee JH, Lee SJ, Kim NI. Platelet-rich plasma combined 
with  fractional  laser  therapy  for  skin  rejuvenation.  Dermatol 
Surg 2012; 38(4):623–30.

  16.  Luebberding  S,  Alexiades-Armenakas  MR.  Fractional,  nonab-
lative  Q-switched  1,064-nm  neodymium  YAG  laser  to  rejuve-
nate photoaged skin: A pilot case series. J Drugs Dermatol 2012; 
11(11):1300–4.

  17.  Kakar R, Ibrahim O, Disphanurat W, Pace N, West DP, Kwasny M, 
et al. Pain in naive and non-naive subjects undergoing nonab-
lative skin tightening dermatologic procedures: A nested ran-
domized control trial. Dermatol Surg 2014; 40(4):398–404.
  18.  Marra DE, Yip D, Fincher EF, Moy RL. Systemic toxicity from 
topically applied lidocaine in conjunction with fractional pho-
tothermolysis. Arch Dermatol 2006; 142(8):1024–6.

  19.  Sherling  M,  Friedman  PM,  Adrian  R,  Burns  AJ,  Conn  H, 
Fitzpatrick R, et al. Consensus recommendations on the use of an 
erbium-doped  1,550-nm  fractionated  laser  and  its  applications 
in dermatologic laser surgery. Dermatol Surg 2010; 36(4):461–9.

  20.  Fisher GH, Kim KH, Bernstein LJ, Geronemus RG. Concurrent 
use  of  a  handheld  forced  cold  air  device  minimizes  patient 
discomfort  during  fractional  photothermolysis.  Dermatol  Surg 
2005; 31(9 Pt 2):1242–3; discussion 4.

  21.  Alster  TS,  Wanitphakdeedecha  R.  Improvement  of  postfrac-
tional laser erythema with light-emitting diode photomodula-
tion. Dermatol Surg 2009; 35(5):813–5.

  22.  Fisher GH, Geronemus RG. Short-term side effects of fractional 
photothermolysis. Dermatol Surg 2005; 31(9 Pt 2):1245–9; discus-
sion 9.

  23.  Clark CM, Silverberg JI, Alexis AF. A retrospective chart review 
to  assess  the  safety  of  nonablative  fractional  laser  resurfac-
ing  in  Fitzpatrick  skin  types  IV  to  VI.  J  Drugs  Dermatol  2013; 
12(4):428–31.

  24.  Firoz  BF,  Katz  TM,  Goldberg  LH,  Geronemus  RG,  Polder 
KD,  Friedman  PM.  Herpes  zoster  in  the  distribution  of  the 

 
 
 
 
 
 
 
 
 
 
NONABLATIVE LASER REJUVENATION 

 533

trigeminal nerve after nonablative fractional photothermolysis 
of the face: Report of 3 cases. Dermatol Surg 2011; 37(2):249–52.

versus  pulsed  dye  laser:  A  randomized  controlled  trial. 
Dermatol Surg 2009; 35(8):1172–80.

  25.  Metelitsa  AI,  Alster  TS.  Fractionated  laser  skin  resurfac-
ing  treatment  complications:  A  review.  Dermatol  Surg  2010; 
36(3):299–306.

  26.  Vaiyavatjamai  P,  Wattanakrai  P.  Side  effects  and  complica-
tions of fractional 1550-nm erbium fiber laser treatment among 
Asians. J Cosmet Dermatol 2011; 10(4):313–6.

  27.  Graber EM, Tanzi EL, Alster TS. Side effects and complications 
of fractional laser photothermolysis: experience with 961 treat-
ments. Dermatol Surg 2008; 34(3):301–5; discussion 5–7.

  28.  Chuang GS, Manstein D, Tannous Z, Avram MM. Ulceration of 
mature  surgical  scars  following  nonablative  fractional  photo-
thermolysis  associated  with  intralesional  lidocaine  injections. 
Dermatol Surg 2012; 38(11):1879–81.

  29.  Tierney  EP,  Kouba  DJ,  Hanke  CW.  Review  of  fractional 
 photothermolysis: Treatment indications and efficacy. Dermatol 
Surg 2009; 35(10):1445–61.

  30.  Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum 
of laser skin resurfacing: Nonablative, fractional, and ablative 
laser  resurfacing.  J  Am  Acad  Dermatol  2008;  58(5):719–37;  quiz 
38–40.

  31.  Blankenship  CM,  Alster  TS.  Fractional  photothermolysis  of 
residual hemangioma. Dermatol Surg 2008; 34(8):1112–4.
  32.  Izikson  L,  Anderson  RR.  Resolution  of  blue  minocycline  pig-
mentation of the face after fractional photothermolysis. Lasers 
Surg Med 2008; 40(6):399–401.

  33.  Liu  A,  Hexsel  CL,  Moy  RL,  Ozog  DM.  Granuloma  annulare 
successfully  treated  using  fractional  photothermolysis  with  a 
1,550-nm erbium-doped yttrium aluminum garnet fractionated 
laser. Dermatol Surg 2011; 37(5):712–5.

  34.  Kouba  DJ,  Fincher  EF,  Moy  RL.  Nevus  of  Ota  successfully 
treated  by  fractional  photothermolysis  using  a  fractionated 
1440-nm Nd:YAG laser. Arch Dermatol 2008; 144(2):156–8.
  35.  Wanner  M,  Tanzi  EL,  Alster  TS.  Fractional  photothermolysis: 
Treatment  of  facial  and  nonfacial  cutaneous  photodamage 
with a 1,550-nm erbium-doped fiber laser. Dermatol Surg 2007; 
33(1):23–8.

  36.  Jih  MH,  Goldberg  LH,  Kimyai-Asadi  A.  Fractional  photother-
molysis for photoaging of hands. Dermatol Surg 2008; 34(1):73–8.
  37.  Brauer  JA,  McDaniel  DH,  Bloom  BS,  Reddy  KK,  Bernstein  LJ, 
Geronemus  RG.  Nonablative  1927  nm  fractional  resurfacing 
for the treatment of facial photopigmentation. J Drugs Dermatol 
2014; 13(11):1317–22.

  38.  Marmon S, Shek SY, Yeung CK, Chan NP, Chan JC, Chan HH. 
Evaluating the safety and efficacy of the 1,440-nm laser in the 
treatment of photodamage in Asian skin. Lasers Surg Med 2014; 
46(5):375–9.

  39.  Saedi N, Petrell K, Arndt K, Dover J. Evaluating facial pores and 
skin  texture  after  low-energy  nonablative  fractional  1440-nm 
laser treatments. J Am Acad Dermatol 2013; 68(1):113–8.

  40.  Rahman  Z,  Dhawan  S,  Starr  J,  Ostrowski  R.  Evaluation  of  a 
compact  home-use  1440  nm  non-ablative  fractional  laser  to 
treat periorbital wrinkles. Research presented at the 2015 meet-
ing  of  the  American  Society  for  Laser  Medicine  and  Surgery, 
Kissimmee, FL.

  41.  Kearney  C,  Brew  D.  Single-session  combination 

treat-
ment  with  intense  pulsed  light  and  nonablative  fractional 
 photothermolysis:  A  split-face  study.  Dermatol  Surg  2012; 
38(7 Pt  1):1002–9.

  42.  Vasily  DB,  Cerino  ME,  Ziselman  EM,  Zeina  ST.  Non-ablative 
fractional  resurfacing  of  surgical  and  post-traumatic  scars.  J 
Drugs Dermatol 2009; 8(11):998–1005.

  43.  Verhaeghe E, Ongenae K, Dierckxsens L, Bostoen J, Lambert J. 
Nonablative  fractional  laser  resurfacing  for  the  treatment 
of  scars  and  grafts  after  Mohs  micrographic  surgery:  A  ran-
domized  controlled  trial.  J  Eur  Acad  Dermatol  Venereol  2013; 
27(8):997–1002.

  44.  Tierney  E,  Mahmoud  BH,  Srivastava  D,  Ozog  D,  Kouba  DJ. 
Treatment  of  surgical  scars  with  nonablative  fractional  laser 

  45.  Haedersdal M, Moreau KE, Beyer DM, Nymann P, Alsbjorn B. 
Fractional  nonablative  1540  nm  laser  resurfacing  for  thermal 
burn  scars:  A  randomized  controlled  trial.  Lasers  Surg  Med 
2009; 41(3):189–95.

  46.  Niwa  AB,  Mello  AP,  Torezan  LA,  Osorio  N.  Fractional  photo-
thermolysis  for  the  treatment  of  hypertrophic  scars:  Clinical 
experience of eight cases. Dermatol Surg 2009; 35(5):773–7; dis-
cussion 7–8.

  47.  Glaich AS, Rahman Z, Goldberg LH, Friedman PM. Fractional 
resurfacing for the treatment of hypopigmented scars: A pilot 
study. Dermatol Surg 2007; 33(3):289–94; discussion 93–4.
  48.  Waibel J, Wulkan AJ, Lupo M, Beer K, Anderson RR. Treatment 
of burn scars with the 1,550 nm nonablative fractional Erbium 
Laser. Lasers Surg Med 2012; 44(6):441–6.

  49.  Massaki  AB,  Fabi  SG,  Fitzpatrick  R.  Repigmentation  of 
hypopigmented  scars  using  an  erbium-doped  1,550-nm  frac-
tionated  laser  and  topical  bimatoprost.  Dermatol  Surg  2012; 
38(7 Pt 1):995–1001.

  50.  Finney  R,  Torbeck  R,  Saedi  N.  Non-ablative  fractional  resur-
facing  in  the  treatment  of  scar  contracture.  Lasers  Surg  Med 
2015.

  51.  Weiss RA, Weiss MA, Beasley KL. Long term experience with 
fixed  array  1540  fractional  erbium  laser  for  acne  scars.  Lasers 
Surg Med 2008; 68:27.

  52.  Bencini  PL,  Tourlaki  A,  Galimberti  M,  Longo  C,  Pellacani  G, 
De Giorgi V, et al. Nonablative fractional photothermolysis for 
acne scars: Clinical and in vivo microscopic documentation of 
treatment efficacy. Dermatol Ther 2012; 25(5):463–7.

  53.  Sardana K, Manjhi M, Garg VK, Sagar V. Which type of atro-
phic acne scar (ice-pick, boxcar, or rolling) responds to nonab-
lative  fractional  laser  therapy?  Dermatol  Surg  2014;  40(3): 
288–300.

  54.  Alster TS, Tanzi EL, Lazarus M. The use of fractional laser pho-
tothermolysis for the treatment of atrophic scars. Dermatol Surg 
2007; 33(3):295–9.

  55.  Park  KY,  Ko  EJ,  Seo  SJ,  Hong  CK.  Comparison  of  fractional, 
nonablative, 1550-nm laser and 595-nm pulsed dye laser for the 
treatment of facial erythema resulting from acne: A split-face, 
evaluator-blinded, randomized pilot study. J Cosmet Laser Ther 
2014; 16(3):120–3.

  56.  Elsaie ML, Baumann LS, Elsaaiee LT. Striae distensae (stretch 
marks) and different modalities of therapy: An update. Dermatol 
Surg 2009; 35(4):563–73.

  57.  de  Angelis  F,  Kolesnikova  L,  Renato  F,  Liguori  G.  Fractional 
nonablative  1540-nm  laser  treatment  of  striae  distensae  in 
Fitzpatrick skin types II to IV: Clinical and histological results. 
Aesthet Surg J 2011; 31(4):411–9.

  58.  Wang  K,  Ross  N,  Osley  K,  Frank  M,  Uitto  J,  Sahu  J,  Saedi  N. 
Evaluation of  a 1540 nm and a  1410 nm non-ablative fraction-
ated laser for the treatment of striae. Research presented at the 
2015 meeting of the American Society for Laser Medicine and 
Surgery, Kissimmee, FL.

  59.  Stotland M, Chapas AM, Brightman L, Sukal S, Hale E, Karen J, 
et  al.  The  safety  and  efficacy  of  fractional  photothermolysis 
for  the  correction  of  striae  distensae.  J  Drugs  Dermatol  2008; 
7(9):857–61.

  60.  Guimaraes PA, Haddad A, Sabino Neto M, Lage FC, Ferreira LM. 
Striae distensae after breast augmentation: Treatment using the 
nonablative  fractionated  1550-nm  erbium  glass  laser.  Plastic 
Reconstruct Surg 2013; 131(3):636–42.

  61.  Yang YJ, Lee GY. Treatment of striae distensae with nonablative 
fractional  laser  versus  ablative  CO(2)  fractional  laser:  A  ran-
domized controlled trial. Ann Dermatol 2011; 23(4):481–9.
  62.  Sheth  VM,  Pandya  AG.  Melasma:  A  comprehensive  update: 

Part I. J Am Acad Dermatol2011; 65(4):689–97; quiz 98.

  63.  Tierney EP, Hanke CW. Review of the literature: Treatment of 
dyspigmentation  with  fractionated  resurfacing.  Dermatol  Surg 
2010; 36(10):1499–508.

 
534 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  64.  Sheth  VM,  Pandya  AG.  Melasma:  A  comprehensive  update: 

Part II. J Am Acad Dermatol 2011; 65(4):699–714; quiz 5.

  65.  Rokhsar  CK,  Fitzpatrick  RE.  The  treatment  of  melasma  with 
fractional photothermolysis: A pilot study. Dermatol Surg 2005; 
31(12):1645–50.

  66.  Kroon  MW,  Wind  BS,  Beek  JF,  van  der  Veen  JP,  Nieuweboer-
Krobotova  L,  Bos  JD,  et  al.  Nonablative  1550-nm  fractional 
laser  therapy  versus  triple  topical  therapy  for  the  treatment 
of  melasma:  A  randomized  controlled  pilot  study.  J  Am  Acad 
Dermatol 2011; 64(3):516–23.

  67.  Polder  KD,  Bruce  S.  Treatment  of  melasma  using  a  novel 
 1,927-nm fractional thulium fiber laser: A pilot study. Dermatol 
Surg 2012; 38(2):199–206.

  68.  Niwa  Massaki  AB,  Eimpunth  S,  Fabi  SG,  Guiha  I,  Groff  W, 
Fitzpatrick  R.  Treatment  of  melasma  with  the  1,927-nm  frac-
tional thulium fiber laser: A retrospective analysis of 20 cases 
with long-term follow-up. Lasers Surg Med 2013; 45(2):95–101.

  69.  Katz TM, Goldberg LH, Marquez D, Kimyai-Asadi A, Polder KD, 
Landau JM, et al. Nonablative fractional photothermolysis for 
facial actinic keratoses: 6-month follow-up with histologic eval-
uation. J Am Acad Dermatol 2011; 65(2):349–56.

  70.  Weiss ET, Brauer JA, Anolik R, Reddy KK, Karen JK, Hale EK, 
et al. 1927-nm fractional resurfacing of facial actinic keratoses: 
A promising new therapeutic option. J Am Acad Dermatol 2013; 
68(1):98–102.

  71.  Friedman  PM,  Landau  JM,  Moody  MN,  et  al.  1550  nm  and 
1927 nm fractional laser resurfacing for the treatment of actinic 
keratosis and photodamage: A comparative study. Lasers Surg 
Med 2011; 43:926.

  72.  Ghasri P, Admani S, Petelin A, Zachary CB. Treatment of actinic 
cheilitis  using  a  1,927-nm  thulium  fractional  laser.  Dermatol 
Surg 2012; 38(3):504–7.

  73.  Anolik R, Friedman PM, Weiss ET, et al. Non-ablative fractional 
resurfacing  with  the  1927  thulium  laser  is  an  effective,  well-
tolerated  treatment  for  actinic  cheilitis.  Lasers  Surg  Med  2011; 
43:927.

  74.  Ortiz A Brown M. Hybrid fractional ablative and non-ablative 
resurfacing  of  actinic  keratoses  on  the  trunk  and  extremities. 

Electronic poster presented at the 2015 meeting of the American 
Society for Laser Medicine and Surgery, Kissimmee, FL.
  75.  Lim HK, Jeong KH, Kim NI, Shin MK. Nonablative fractional 
laser as a tool to facilitate skin penetration of 5-aminolaevulinic 
acid with minimal skin disruption: A preliminary study.  Br J 
Dermatol 2014; 170(6):1336–40.

  76.  Hsu  MC,  Lee  CH,  Chen  GS,  Wu  CY.  Nonablative  1,450-nm 
diode  laser  treatment  for  xanthoma  disseminatum.  Dermatol 
Surg 2014; 40(12):1423–5.

  77.  Park  EJ,  Youn  SH,  Cho  EB,  Lee  GS,  Hann  SK,  Kim  KH,  et  al. 
Xanthelasma  palpebrarum  treatment  with  a  1,450-nm-diode 
laser. Dermatol Surg 2011; 37(6):791–6.

  78.  Beleznay K, Friedmann DP, Liolios AM, Perry A, Goldman MP. 
Lupus  miliaris  disseminatus  faciei  treated  with  1,565  nm 
nonablative fractionated laser resurfacing: A case report. Lasers 
Surg Med 2014; 46(9):663–5.

  79.  Gan  SD,  Bae-Harboe  YS,  Graber  EM.  Nonablative  fractional 
resurfacing for the treatment of iatrogenic hypopigmentation. 
Dermatol Surg 2014; 40(1):87–9.

  80.  Emer J, Uslu U, Waldorf H. Improvement in lupus pernio with 
the  successive  use  of  pulsed  dye  laser  and  nonablative  frac-
tional resurfacing. Dermatol Surg 2014; 40(2):201–2.

  81.  Narinesingh S, Lewis S, Nayak BS. Use of 1540nm fractionated 
erbium:glass laser for split skin graft resurfacing: A case study. 
J Wound Care 2013; 22(9):510–3.

  82.  Polder KD, Mithani A, Harrison A, Bruce S. Treatment of macu-
lar seborrheic keratoses using a novel 1927-nm fractional thu-
lium fiber laser. Dermatol Surg 2012; 38(7 Pt 1):1025–31.

  83.  Moody MN, Landau JM, Goldberg LH, Friedman PM.  1,450-nm 
diode  laser  in  combination  with  the  1550-nm  fractionated 
erbium-doped  fiber  laser  for  the  treatment  of  steatocystoma 
multiplex: A case report. Dermatol Surg 2012; 38(7 Pt 1):1104–6.

  84.  Beasley  KL,  Weiss  RA,  Nonablative  fractional  lasers.  In: 
Goldman  MP,  Fitzpatrick  RE,  Ross  VE,  Kilmer  SL,  Weiss  RA, 
eds. Laser and Energy Devices for the Skin. Boca Raton: CRC Press 
2013; pp. 178–91.

 
56

Cryolipolysis for Non-Surgical Fat Reduction

Christine C. Dierickx

INTRODUCTION
Liposuction  is  the  second  most  popular  aesthetic  surgery 
procedure with 1.4 million procedures worldwide in 2015 (1). 
As  patients  seek  to  reduce  subcutaneous  fat  resistant  to  diet 
and exercise, there has been increased interest in non-surgical 
alternatives  because  of  risks  from  invasive  surgical  proce-
dures,  anesthesia,  and  downtime  for  recovery.  According  to 
the American Society of Aesthetic Plastic Surgeons, there were 
135,448 non-surgical fat reduction procedures in 2014, includ-
ing cryolipolysis, high intensity focused ultrasound, and dia-
thermy  heating.  In  2015,  there  were  160,763  such  procedures, 
reflecting  an  18.7%  increase  in  non-surgical  body  contouring 
procedures (2).

Numerous  non-invasive  body  reshaping  technologies 
have  been  studied,  including  low  level  laser  therapy,  ultra-
sound, radiofrequency, diathermy heating, and infrared light. 
This chapter focuses on cryolipolysis, the most widely used (3) 
and well-established non-surgical body contouring procedure 
(Figure 56.1).

BACKGROUND
History
There  have  been  numerous  published  clinical  observations 
describing  adipose  tissue  sensitivity  to  cold,  inducing  pan-
niculitis, a localized inflammation in subcutaneous fat. In 1902, 
there  were  reports  of  firm  nodules  noted  under  the  chins  of 
children in response to acute cold injury (4). There were also 
case reports of cold-induced panniculitis in children, teenag-
ers, and adults (5–10). The unique case report of “popsicle pan-
niculitis”  was  reported  in  1970  for  an  infant  that  developed 
a red, indurated nodule and subsequent fat loss in the cheek 
after sucking on a popsicle (11). Researchers Dieter Manstein, 
MD,  PhD  and  R.  Rox  Anderson,  MD  of  the  Wellman  Center 
for Photomedicine at Massachusetts General Hospital, a teach-
ing affiliate of Harvard Medical School, drew upon these case 
reports and recognized the potential for controlled cooling to 
selectively target undesirable adipose tissue.

Pre-Clinical and Clinical Studies
In 2008, Manstein et al. published a seminal cryolipolysis proof-
of-concept porcine study (12) and results were confirmed in a 
subsequent porcine study by Zelickson et al (13). The pre-clinical 
studies investigated the effect of controlled surface cooling and 
the resulting damage to subcutaneous fat. Porcine pre-clinical 
studies were conducted for initial exploration, dosimetry evalu-
ation, and safety assessment measuring lipid levels. The inves-
tigators  found  that  selective  reduction  in  superficial  fat  was 
achieved by the cryolipolysis procedure without causing injury 

BODY  SCULPTING
175,000     total procedures

24,000 liposuction
24,000 liposuction

89,000 cryolipolysis
89,000 cryolipolysis
“fat-freezing’’
“fat-freezing’gggggggg ’

242 ,000 laser lipolysis
24,000 laser lipolysis

38,000 non-invasive
38,000 non-invasive
treatment of fat and cellulite
treatment of fat and cellulite

Figure  56.1  Cryolipolysis  accounted  for  51%  of  all  body 
contouring  procedures.  (Courtesy  of  the  ASDS  2013  Survey 
on Dermatologic Procedures.)

to the epidermis or dermis (12–13). The investigators found that 
80% of the superficial fat layer was removed at 3.5 months post-
treatment for a total fat loss of 40% (12). Figure 56.2 shows gross 
pathology with significant fat reduction visible in the cryolipol-
ysis-treated porcine adipose tissue.

Histological  analysis  from  the  porcine  models  found 
that  controlled,  selective  cooling  could  be  utilized  to  induce 
an  inflammatory  response  in  the  subcutaneous  fat  approxi-
mately  24  hours  following  the  cold  treatment.  Time  course 
evaluation  found  that  the  inflammatory  response  intensi-
fied  as  adipocytes  were  surrounded  by  histiocytes,  neutro-
phils,  lymphocytes,  and  other  mononuclear  cells,  leading  to 
subsequent   digestion  of  the  fat  cells.  The  inflammatory  pro-
cess  was  found  to  decline  90  days  post-treatment,  as  shown 
in  Figure  56.3.  It  appeared  that  the  lipids  remained  trapped 

536 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Figure 56.2  Gross pathology sections of cryolipolysis treated porcine tissue showing reductions in superficial fat layer 90 days 
after treatment. (From Zelickson B et al., Dermatol Surg; 35(10):1462–70, 2009. With permission.)

within the subcutaneous tissue until they were digested and 
cleared  by  a  natural  inflammatory  process.  This  resorption 
took  place  over  more  than  90  days,  resulting  in  a  very  grad-
ual displacement of the lipids. The pre-clinical safety studies 
established no effect on serum lipid levels in the animal mod-
els,  while  attaining  significant  reduction  in  subcutaneous  fat 
without damaging the skin (12–13).

Thereafter, clinical studies demonstrated safety and effi-
cacy  in  human  subjects.  Clinical  studies  were  carried  out  to 
investigate the efficacy of cryolipolysis to the flanks and back 
in  32  subjects  with  efficacy  assessed  by  ultrasound  measure-
ment  of  the  fat  layer,  pre-  and  post-treatment  clinical  photo-
graph comparison, and physician assessment. The study found 
an average fat reduction of 22.4% in subjects assessed 4 months 
post-treatment  (14).  A  separate  flank  cryolipolysis  study  of  10 
subjects  assessed  efficacy  and  effect  on  nerve  fibers  follow-
ing cryolipolysis. The investigators found an average fat layer 
reduction of 25.5% at 6 months post-treatment. While approxi-
mately  one-third  of  the  subjects  experienced  transient  reduc-
tion  in  sensation  in  the  treated  site,  all  subjects  experienced 
restoration of sensation within 7 weeks (mean 3.6 weeks) (15). 
Numerous clinical study publications on over 4000 study sub-
jects  have  reported  on  the  safety,  efficacy,  and  tolerability  of 
cryolipolysis for fat reduction in a variety of areas including the 
abdomen, flanks, inner thighs, outer thighs, back, arms, pseu-
dogynecomastia, banana rolls, and knees (16–27).

Cryolipolysis  is  approved  for  fat  reduction  in  over 
70  countries  worldwide  including  China,  Canada,  Europe, 
Brazil, and Australia. Cryolipolysis received FDA clearance for 
fat  reduction  for  the  flanks  in  2010,  for  the  abdomen  in  2012, 
for the thighs in 2014, the submental area in 2015, and the back, 
bra area, and underneath the buttocks in 2016. It is cleared in 
Taiwan for the flanks and abdomen.

Mechanism of Action
Controlled  cooling  for  selective  damage  of  subcutaneous  fat 
is based upon the premise that lipid-rich adipocytes are more 
susceptible to cold injury than water-based cells; this is related 
to the higher phase transition temperature of lipids compared 
to water. Intracellular “lipid ice” is believed to form approxi-
mately 10°C degrees warmer than water ice (12, 28). Figure 56.4 
shows the crystallization of porcine fat at various temperatures 

(12).  The  images  were  obtained  by  cross- polarized  micros-
copy  of  a  1  mm  quartz  cuvette  filled  with  heated  pig  lard. 
Needle-like  crystals  are  visible  at  room  temperature  storage 
and  cloudy  crystallization  of  the  porcine  fat  is  shown  when 
the temperature is lowered to 10.3°C. The lipid crystallization 
shown in these images demonstrates the higher phase transi-
tion  temperature  for  adipocytes  which  leads  to  their  greater 
susceptibility to cold injury.

Cryolipolysis  induces  apoptosis,  a  natural  form  of  cell 
death, causing a wound healing cascade which results in the 
eventual  clearing  of  apoptotic  bodies  through  the  lymphatic 
system  (12).  As  opposed  to  necrosis  caused  by  acute  injury, 
apoptosis is programmed cell death which is a normal part of 
cellular homeostasis. During apoptosis, a defined sequence of 
morphological  and  biochemical  events  occur,  such  as  mem-
brane blebbing, shrinkage of the cell, aggregation of chroma-
tin, and the appearance of apoptotic bodies (29–31).

Experimental studies have confirmed that cryolipolysis 
induces apoptosis, a natural form of cell death, which causes 
a  wound  healing  cascade  and  the  eventual  clearing  of  the 
apoptotic bodies through the lymphatic system. By immuno-
histochemical  stain  for  Caspase-3  activity  and  H&E  stain  to 
examine  cellular  morphology,  histological  analysis  provides 
evidence  of  apoptosis  following  cryolipolysis  treatment.  As 
shown in Figure 56.5, human fat treated by cryolipolysis was 
harvested  post-treatment,  fixed,  sectioned,  and  stained  with 
cleaved  Caspase-3  antibody,  an  immunohistochemical  assay 
specific for an apoptosis enzyme. Sequential activation of cas-
pases plays a central role in the execution phase of cell apop-
tosis. Human adipose tissue harvested following cryolipolysis 
shows evidence of cells undergoing apoptosis compared to the 
untreated control tissue.

Histology analysis using H&E stain further illuminates 
the cryolipolysis mechanism of action. Human abdomen tissue 
treated 2 weeks prior to harvest, Figure 56.6, shows adipocyte 
death by apoptosis and initiation of the phagocytosis process. 
The apoptosis is evidenced in the “blebbing” of cellular mem-
branes, resulting in misshapen fat cells. Phagocytosis is shown 
by  the  presence  of  multinucleated  macrophages  which  will 
engulf and digest dead adipocytes.

In  summary,  histology  studies  provide  experimental 
evidence, both by Caspase-3 and H&E stains, that cryolipolysis 

 
CRYOLIPOLYSIS FOR NON-SURGICAL FAT REDUCTION 

 537

(a)

(c)

(e)

(b)

(d)

(f )

Figure 56.3  Progression of inflammatory response in cryolipolysis treated porcine tissue: (a) 3 days, (b) 7 days, (c) 14 days, 
(d) 30 days, (e) 60 days, and (f) 90 days. (From Zelickson B et al., Dermatol Surg; 35(10):1462–70, 2009. With permission.)

induces adipocyte death by apoptosis. Histology demonstrates 
the  Caspase-3  activity  indicative  of  apoptosis  and  the  resul-
tant apoptotic cellular morphology, phagocytosis process, and 
eventual clearing of the affected adipocytes.

CLINICAL TECHNIQUE
The  cryolipolysis  system  (CoolSculpting,  ZELTIQ  Aesthetics) 
consists of a control unit and portfolio of applicators for vari-
ous  treatment  areas  (Figure  56.7).  There  are  several  vacuum 

applicators which pull the targeted tissue into a cup and apply 
surface  cooling  from  parallel  panels.  The  vacuum  applica-
tor  sizes  and  cup  curvature  accommodate  a  range  of  patient 
sizes and treatment areas, such as abdomens and inner thighs. 
A  non-vacuum  conformable  surface  cryolipolysis  applicator 
allows treatment of fibrous, non-pinchable fat in areas such as 
the outer thigh “saddlebag” bulges.

The  most  popular  treatment  areas  are  the  flanks  and 
abdomen,  followed  by  the  back,  thighs,  arms,  and  chest. 
Potential treatment areas are shown in Figure 56.8.

 
538 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure 56.4  Microscopic images of frozen porcine fat. (a) Needle-like crystals at 21°C after storage overnight at room  temperature. 
(b) Cloudy crystallization at 10.3°C with cooling rate of approximately 10 °C/minute. Bar represents 1 mm. (From Manstein D et al., 
Lasers Surg Med; 40:595–604, 2008. With permission.)

(a)

(b)

Figure  56.5 
 cryolipolysis treatment. (b) Untreated control tissue.

(a)  Human  abdominal  tissue  stained  with  Caspase-3  assay  showing  evidence  of  apoptosis  2  days  following 

m
m
5
0

.

Presence of multi-
nucleated macrophages
that will eventually engulf
and digest dead
adipocytes

Change in cell membrane
shape indicating onset of
apoptosis

Adipocytes being
digested by
macrophages

Figure 56.6  Human abdominal tissue harvested 14 days post-treatment showing evidence of adipocyte death by apoptosis and 
initiation of the phagocytosis process.

 
CRYOLIPOLYSIS FOR NON-SURGICAL FAT REDUCTION 

 539

CoolFit

CoolSmooth

CoolCurve+

CoolCore

CoolMax

» CoolSculpting system 

» CoolSculpting patient pager

Figure 56.7  Cryolipolysis system consists of a control unit and applicators for various treatment areas. (Courtesy of CoolSculpting 
by ZELTIQ Aesthetics.)

as the upper arms and inner thighs, the flat cup vacuum appli-
cator is appropriate. To reduce a double chin, the small cup vac-
uum applicator is appropriate. The subcutaneous fat should be 
pinchable and readily drawn into the vacuum applicator cup. 
For fibrous, non-pinchable areas, such as the outer thighs, the 
non-vacuum  conformable  surface  cryolipolysis  applicator  can 
be  applied.  For  larger  bulges,  multiple  applicator  placements 
may be needed to adequately cover the target area.

Assessment Technique
For the assessment, patients should be undressed to allow the 
clinician to fully view the potential treatment areas relative to 
the whole body. The patient should be asked to indicate his/
her areas of concern in order to develop a treatment plan. The 
areas  of  concern  should  be  firmly  pinched  to  assess  whether 
the subcutaneous fat can be treated using a vacuum cup appli-
cator.  The  clinician  should  notice  the  orientation  with  which 
the  fat  presents  on  the  patient’s  body;  templates  can  be  used 
to plan applicator placements and mark the body. Figure 56.9 
demonstrates  the  assessment  and  marking  techniques  and 
resultant marked treatment plan on a patient’s abdomen.

TREATMENT METHOD
Once the assessment and planning is complete, the treatment 
procedure can begin (Figure 56.10). To ensure safety, a protec-
tive gelpad is first draped over the treatment area. The clini-
cian  should  ensure  that  the  entire  treatment  area  is  covered 
by the gelpad to prevent freeze injury to the skin. The gelpad 
should be carefully smoothed to remove trapped air bubbles.

Next,  the  applicator  should  be  positioned  over  the 
marked  treatment  area  and  vacuum  suction  should  be  initi-
ated  to  engage  the  targeted  subcutaneous  fat.  The  clinician 
should visually observe the tissue draw into the vacuum cup 
to ensure that sufficient draw is achieved. In general, the tis-
sue  should  fill  at  least  half  of  the  vacuum  cup,  reaching  the 
horizontal retaining bar between the parallel cooling panels. 
If  insufficient  tissue  fills  the  cup,  the  vacuum  suction  can  be 
turned off, the applicator and gelpad removed, a new gelpad 

Figure  56.8  Cryolipolysis  has  been  used  to  non-invasively 
reduce fat in the abdomen, flanks, thighs, back, arms, knees, 
submental area, and chest.

Patient Selection
While it is not an appropriate treatment for weight loss and obe-
sity, cryolipolysis is a safe and  effective fat reduction method 
for appropriate patients. The key patient selection criterion is 
whether the tissue can be drawn into a vacuum cup or whether 
the  treatment  area  can  be  covered  by  the  non-vacuum  sur-
face applicator. For areas such as the abdomen and flanks, the 
curved cup vacuum applicators are appropriate. For areas such 

 
540 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(c)

(e)

(b)

(d)

(f )

Figure 56.9  Assessment and treatment planning technique for a patient’s abdomen: (a) assess lower abdomen; (b) mark lower 
right; (c) mark lower left; (d) assess upper abdomen; (e) mark upper abdomen; (f) marked abdomen.

placed over the treatment area, the applicator should be repo-
sitioned, and vacuum suction should be reinitiated. In the case 
of the non-vacuum conformable surface applicator, the applica-
tor  is  secured  with  straps  rather  than  vacuum  suction.  Once 
the applicator is secured to the patient, the cooling cycle can 
be initiated.

The  patient  should  be  comfortably  positioned  on  the 
treatment bed. Generally, the patients find the treatment very 
tolerable  and  are  able  to  engage  in  activities  such  as  reading 
or  sleeping  during  the  treatment.  Current  vacuum  applica-
tor  treatments  are  35–60  minutes  and  the  non-vacuum  treat-
ment  is  75  minutes  duration.  When  the  vacuum  applicator 
is  removed,  patients  will  typically  see  a  very  stiff,  red  tissue 
mass  which  gradually  thaws  as  shown  in  Figure  56.11.  It  is 
 recommended that the cold, stiff tissue is vigorously massaged 
for  2  minutes  immediately  post-treatment  to  enhance  treat-
ment efficacy (32).

SIDE EFFECTS
Cryolipolysis treatment side effects are typically mild and self-
resolving. During treatment, the patients will experience sensa-
tions of pulling and pinching, when using a vacuum applicator. 
As  the  cooling  plates  lower  tissue  temperature,  there  will  be 
cold,  tingling,  stinging  sensations,  sometimes  described  as 
aching and cramping. These sensations will usually subside as 
the treatment area becomes cool and numb. Immediately after 
treatment, the treatment area will be cold, red, and firm. There 
may be some transient blanching and mild bruising. As blood 
perfuses the treatment site, there will be tingling and stinging 
sensations.  Finally,  it  is  important  to  prepare  the  patient  for 
common  side  effects  in  the  days  and  weeks  after  treatment. 
There may be continued redness, bruising, and swelling. The 
treatment area will be ender with ongoing sensations of itch-
ing, sensitivity, and tingling. Numbness in the treatment site 
may last several weeks but will self-resolve.

 
CRYOLIPOLYSIS FOR NON-SURGICAL FAT REDUCTION 

 541

(a)

(c)

(e)

(b)

(d)

(f )

Figure 56.10  Treatment method for inner thigh cryolipolysis. (a) Treatment area is assessed with the patient standing and the 
untreated leg slightly raised. (b) The peak of the treatment site is marked. (c) The gelpad is placed over the treatment area, ensur-
ing the peak of the bulge is covered. (d) The CoolFit applicator is placed over the treatment area. (e) During the treatment, the 
patient is seated with the leg slightly bent. (f) After treatment, the treatment area is massaged for 2 minutes.

 
542 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(c)

(b)

(d)

Figure  56.11  Post-treatment  photographs  of  an  abdomen  treatment  demonstrate  the  stiff  “butter  stick”  nature  of  the  tissue 
(a) immediately following cryolipolysis, followed by resolution at (b) 2, (c) 4, and (d) 6 minutes. (From Dierickx CC et al., Dermatol 
Surg 2013; 39(8):1209–16, 2013. With permission.)

The aforementioned side effects are common and should 
be discussed with patients to help them understand what they 
are  likely  to  experience  during  and  after  cryolipolysis  treat-
ment. There are also very rare side effects associated with cryo-
lipolysis. Vasovagal symptoms, such as dizziness, nausea, and 
fainting,  may  occur  during  or  immediately  after  treatment. 
Late-onset  pain  may  begin  several  days  post-treatment  and 
last several weeks, causing intense pain in the treatment site. 
Subcutaneous indurations, hardness and nodules in the treat-
ment site, may occur but will resolve spontaneously, typically 
in 3–6 months. Hyperpigmentation may occur after treatment 
but  will  self-resolve.  And  the  most  serious  rare  side  effect  is 
paradoxical adipose hyperplasia, a visible enlargement in the 
treatment area which may develop 4–5 months post-treatment 
and require surgical intervention.

EFFICACY
Cryolipolysis  efficacy  has  been  measured  by  several  tech-
niques  including  ultrasound  and  caliper  measurements,  cir-
cumferential  measurements,  3D  quantification  of  volume 
reduction,  and  blinded,  independent  review  of  clinical  pho-
tographs.  From  published  clinical  studies  compiled  in  Table 
56.1,  the  mean  ultrasound  measurements  of  fat  thickness 
reduction ranged from 1.9 to 8.3 mm and 10.3% to 25.5%. The 
mean caliper measurements of fat thickness reduction ranged 

from  14.7%  to  23.0%  reduction.  Single  studies  showed  mean 
0.9 cm  circumferential reduction in the inner thigh, 2.4 cm cir-
cumferential reduction in the flanks, and 39.6 cm3 volumetric 
 reduction in treated flanks. Blinded, independent photo review 
was conducted in several studies with correct identification of 
 baseline photographs ranging from 79.0% to 94.4%.

Based  on  the  compilation  of  these  various  studies,  the 
overall  mean  ultrasound  fat  layer  reduction  thickness  was 
20.5%  and  4.6  mm.  Compiled  mean  caliper  fat  layer  reduc-
tion was 22.5%. The independent photo review was 88.4% cor-
rect, on average. Representative efficacy results are shown in 
Figures 56.12 through 56.17.

CLINICAL PEARLS
The key steps for cryolipolysis success are patient counseling 
and realistically setting expectations. In the patient consulta-
tions, it is important to inform patients of the sensations they 
will experience during and after cryolipolysis, so they will be 
well-prepared  and  not  fearful  of  the  unfamiliar  sensations. 
Also,  it’s  important  to  set  realistic  expectations  for  cryolipol-
ysis  results.  In  general,  patient  selection  is  important  since 
there will be modest reductions in fat and cryolipolysis should 
not  be  regarded  as  a  method  for  weight  loss.  When  putting 
together  a  treatment  plan,  some  patients  may  need  multiple 
treatments over the same area or treatments over several areas 

 
CRYOLIPOLYSIS FOR NON-SURGICAL FAT REDUCTION 

 543

Table 56.1  Efficacy Measurements Summarized

Efficacy 
Measurement 
Method

Treatment Sites

Reference

n

Mean Value

Ultrasound fat layer 

Inner thighs

reduction (%)

Abdomen

Abdomen

Abdomen

Various

Boey et al., 2014

Sasaki et al., 2014

Boey et al., 2014

Boey and 

Wasilenchuk, 
2014

Kotlus and Mok, 

2013

Ultrasound fat layer 
reduction (mm)

Pseudogynecomastia Munavalli, 2013

Flanks and back

Dover et al., 2009

Flanks

Flanks

Inner thighs

Outer thighs

Various

Burns et al., 2010

Coleman et al., 2009

Boey et al., 2014

Stevens et al., 2014

Kotlus and Mok, 

2013

Inner thighs

Zelickson et al., 

2015

Abdomen

Boey et al., 2014

Abdomen

Caliper fat layer 
reduction (%)

Various

Various

Boey and 

Wasilenchuk, 
2014

Sasaki et al., 2014

Dierickx et al., 2013

Abdomen and flanks

Shek et al., 2012

Abdomen

Shek et al., 2012

Flanks

Shek et al., 2012

Independent photo 

Flanks

review (%)

Outer thighs

Inner thighs

Flanks

Flanks

Garibyan et al., 2014

Stevens et al., 2014

Zelickson et al., 

2015

Kaminer et al., 2009

Bernstein et al., 

2014

Pseudogynecomastia Munavalli, 2013

Circumferential 
reduction (cm)

Abdomen

Inner thighs

3D circumferential 

Flanks

measurement (cm)

Mayoral et al., 2012

Zelickson et al., 

2015

Brightman and 

Geronemus, 2011

11

6

10

10

59

18

10

41

9

11

40

59

43

10

10

85

518

21

10

6

11

40

43

50

10

18

20

43

1

20%

19.6%

14.9%
(massage)

10.3%
(non-massage)

25%

18.3%

22.4%

17.6%

25.5%

3.3 mm

2.6 mm

8.3 mm

2.6 mm

2.7 mm 
(massage)

1.9 mm
(non-massage)

21.5%

23%

14.7%
(one tx)

21.2%
(two tx)

17.7%
(two tx)

79%

87%

91.0%

92%

94.4%

80%

86%

0.9 cm

2.4 cm

Compilation 
Mean

20.5%

Range

10.3%–
25.5%

4.6 mm

1.9–8.3 mm

22.5%

14.7%–
23.0%

88.4%

79.0%–
94.4%

0.9 cm

2.4 cm

n/a

n/a

n/a

3D volumetric 

measurement 
(cm3)

Flanks

Garibyan et al., 2014

11

39.6 cm3

39.6 cm3

in  order  to  achieve  their  body  contouring  goals.  These  plans 
should be discussed with the patient ahead of time to ensure 
realistic expectations and patient satisfaction.

One  additional  clinical  tip  is  the  management  of  late-
onset pain, one of the rare side effects mentioned previously. 

Late-onset  pain  has  been  described  as  deep  pain,  stabbing, 
shooting, and burning sensations, hypersensitivity, and severe 
pins and needles. Many practitioners have reported successful 
mitigation of these intense pain sensations by having patients 
wear compression garments, icing the treatment area, applying 

 
544 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure  56.12  Abdominal  treatment  (a)  before  and  (b)  3  months  after  treatment  showing  visible  reduction  in  adipose  tissue. 
Caliper measurements showed 2.1 cm reduction.

(a)

(b)

Figure  56.13  Flank  treatment  (a)  before  and  (b)  2.5  months  after  treatment,  showing  visible  reduction  in  excess  fat.  Caliper 
 measurements showed 1.1 cm reduction.

(a)

(b)

Figure 56.14  Unilateral treatment of right outer thigh. (a) Pre-treatment and (b) 4 months post-treatment, demonstrating  reduction 
of “saddlebag” bulge. (From Stevens WG, Bachelor EP, Aesthet Surg J; 35(1):66–71, 2015. With permission.)

 
CRYOLIPOLYSIS FOR NON-SURGICAL FAT REDUCTION 

 545

(a)

(c)

(b)

(d)

Figure 56.15 
Zelickson BD et al., Lasers Surg Med Jan 13, 2015. With permission.)

Inner thigh treatment (a,b) before and (c,d) 4 months after treatment, showing reduced inner thigh contour. (From 

(a)

(b)

Figure 56.16  Male chest (a) before and (b) 2 months after single cycle cryolipolysis treatment. (From Stevens WG, Pietrzak LK, 
Spring MA, Aesthet Surg J; 33(6):835–46, 2013. With permission.)

 
546 

 TEXTBOOK OF COSMETIC DERMATOLOGY

(a)

(b)

Figure  56.17  Upper  arm  treatment  (a)  before  and  (b)  4  months  after  treatment,  showing  aesthetically  pleasing  reduction  in 
 subcutaneous fat. (From Stevens WG, Pietrzak LK, Spring MA, Aesthet Surg J; 33(6):835–46, 2013. With permission.)

heating pads, stretching, using sleep aids at night, and taking 
prescription analgesics.

CONCLUSION
Cryolipolysis  has  proven  to  be  a  popular  non-invasive  body 
contouring  method  with  reports  of  over  3,000,000  treatment 
cycles  worldwide.  In  addition  to  being  a  popular  treatment, 
cryolipolysis has clinically proven safety, efficacy, and patient 
tolerability.  Based  upon  scientific  evidence  of  adipocyte  sus-
ceptibility to cold injury, this novel method of controlled cool-
ing can reduce subcutaneous fat without surgical intervention. 
With  proper  patient  assessment,  treatment  planning,  and 
applicator  placement,  high  patient  satisfaction  and  aestheti-
cally pleasing body contouring results can be achieved.

REFERENCES

1.  International  Society  of  Aesthetic  Plastic  Surgery  (ISAPS) 
Survey on Aesthetic/Cosmetic Procedures Performed in 2015.
2.  American  Society  for  Aesthetic  Plastic  Surgery  (ASAPS) 

Cosmetic Surgery National Data Bank Statistics for 2015.

3.  American Society for Dermatologic Surgery (ASDS) Survey on 

Dermatologic Procedures for 2013.

4.  Hochsinger C. Über eine akute kongelative Zellgewebsverhärtung 
in  der  Submentalregion  bei  Kindern.  Mschr  Kinderheilk  1902; 
1:323–7.

5.  Haxthausen  H.  Adiponecrosis  e  frigore.  Br  J  Dermatol  1941; 

53:83–9.

6.  Collins  HA,  Stahlman  M,  Scott  HW  Jr.  The  occurrence  of 
 subcutaneous  fat  necrosis  in  an  infant  following  induced 
 hypothermia used as an adjuvant in cardiac surgery. Ann Surg 
1953; 138:880–5.

7.  Rotman  H.  Cold  panniculitis  in  children.  Adiponecrosis  E 

 frigore of Haxthausen. Arch Dermatol 1966; 94:720–1.

8.  Duncan WC, Freeman RG, Heaton CL. Cold panniculitis. Arch 

Dermatol 1966; 94:722–4.

9.  Solomon  LM,  Beerman  H.  Cold  panniculitis.  Arch  Dermatol 

1963; 88:897–900.

  10.  Beachman BE, Cooper PH, Buchanan CS, Weary PE. Equestrian 

cold panniculitis in women. Arch Dermatol 1980; 116(9):1025–7.

  12.  Manstein D, Laubach H, Watanabe K, Farinelli W, Zurakowski 
D,  Anderson  RR.  Selective  cryolysis:  A  novel  method  of  non-
invasive fat removal. Lasers Surg Med 2008; 40:595–604.

  13.  Zelickson  B,  Egbert  BM,  Preciado  J,  et  al.  Cryolipolysis  for 
 noninvasive  fat  cell  destruction:  Initial  results  from  a  pig 
model. Dermatol Surg 2009; 35(10):1462–70.

  14.  Dover J, Burns J, Coleman S, Fitzpatrick R, Gardner J, Goldberg 
D,  et  al.  A  prospective  clinical  study  of  non-invasive  cryoli-
polysis for subcutaneous fat layer reduction: Interim report of 
 available subject data. Lasers Surg Med 2009; S21:45.

  15.  Coleman  SR,  Sachdeva  K,  Egbert  BM,  Preciado  J,  Allison  J. 
Clinical efficacy of non-invasive cryolipolysis and its effects on 
peripheral nerves. Aesthetic Plast Surg 2009; 33:482–8.

  16.  Bernstein  EF,  Bloom  JD,  Basilavecchio  LD,  Plugis  JM.  Non-
invasive  fat  reduction  of  the  flanks  using  a  new  cryolipolysis 
applicator  and  overlapping,  two-cycle  treatments.  Lasers  Surg 
Med. 2014 Dec; 46(10):731–5.

  17.  Stevens  WG,  Bachelor  EP.  Cryolipolysis  conformable  surface 
applicator  for  non-surgical  fat  reduction  in  lateral  thighs. 
Aesthet Surg J. 2015 Jan; 35(1):66–71.

  18.  Carruthers  J,  Stevens  WG,  Carruthers  A,  Humphrey  S. 
tightening.  Dermatol  Surg  2014 

Cryolipolysis  and  skin 
Dec; 40(Suppl 12):S184–9.

  19.  Boey  GE,  Wasilenchuk  JL.  Fat  Reduction  in  the  inner  thigh 
using  a  prototype  cryolipolysis  applicator.  Dermatol  Surg  2014 
Sep; 40(9):1004–9.

  20.  Sasaki  GH,  Abelev  N,  Tevez-Ortiz  A.  Noninvasive  selective 
cryolipolysis and reperfusion recovery for localized natural fat 
reduction and contouring. Aesthet Surg J 2014; 34(3):420–31.
  21.  Garibyan L, Sipprell WH 3rd, Jalian HR, Sakamoto FH, Avram 
M,  Anderson  RR.  Three-dimensional  volumetric  quantifica-
tion  of  fat  loss  following  cryolipolysis.  Lasers  Surg  Med.  2014; 
46(2):75–80.

  22.  Jalian HR, Avram MM, Garibyan L, Mihm MC, Anderson RR. 
Paradoxical  adipose  hyperplasia  after  cryolipolysis.  JAMA 
Dermatol 2014; 150(3):317–9.

  23.  Stevens  WG,  Pietrzak  LK,  Spring  MA.  Broad  Overview  of  a 
clinical and commercial experience with CoolSculpting. Aesthet 
Surg J 2013; 33(6):835–46.

  24.  Dierickx  CC,  Mazer  JM,  Sand  M,  Koenig  S,  Arigon  V. 
Safety,   tolerance,  and  patient  satisfaction  with  noninvasive 
 cryolipolysis. Dermatol Surg 2013; 39(8):1209–16.

  11.  Epstein EH Jr, Oren ME. Popsicle panniculitis. N Engl J Med. 

  25.  Bernstein EF. Longitudinal evaluation of cryolipolysis efficacy: 

1970; 82:966–7.

Two case studies. J Cosmet Dermatol 2013; 12(2):149–52.

 
 
 
 
 
 
 
 
 
 
CRYOLIPOLYSIS FOR NON-SURGICAL FAT REDUCTION 

 547

  26.  Munavalli  GS,  Panchaprateep  R.  Cryolipolysis  for  targeted 
fat  reduction  and  improved  appearance  of  the  enlarged  male 
breast. Dermatol Surg 2015; 41(9):1043–51. 

  27.  Zelickson  BD,  Burns  AJ,  Kilmer  SL.  Cryolipolysis  for  safe 
and  effective  inner  thigh  fat  reduction.  Lasers  Surg  Med  2015; 
47(2):120–7. 

  28.  Svenstrup  G,  Bruggemann  DB,  Kristensen  L,  Risbo  J, 
Skibsted  LH.  The  influence  of  pretreatment  on  pork  fat 
 crystallization. Eur J Lipid Sci Technol 2005; 107(9):607–15.
  29.  Della-Fera MA, Qian H, Baile CA (2001) Adipocyte apoptosis in 
the regulation of body fat mass by leptin. Diabetes Obes Metab 
2001; 3:299–310.

  30.  Herold C, Rennekampff HO, Ohm L, et al (2012) Apoptosis in 
extracorporeal preserved inguinal fat flaps of the rat. Apoptosis 
2012; 17:400–9.

A  4-month  study  of  safety  and  efficacy.  Lasers  Surg  Med.  2014 
Jan; 46(1):20–6.

  33.  Kotlus BS, Mok C. Evaluation of cryolipolysis for subcutaneous 

fat reduction. Am J Cosmet Surg 2013; 30(2):89–93.

  34.  Burns JA, Allison J, Bachelor E, Dover J, Coleman S, Fitzpatrick 
R,  et  al.  Analysis  of  side  effects  of  non-invasive  cryolipoly-
sis  for  subcutaneous  fat  layer  reduction:  Interim  report  from 
 controlled clinical trials. Lasers Surg Med 2010; 42(S22):21.
  35.  Shek SY, Chan NPY, Chan HL. Non-invasive cryolipolysis for 
body  contouring  in  Chinese:  A  first  commercial  experience. 
Lasers Surg Med 2012; 44(2):125–30.

  36.  Kaminer  M,  Weiss  R,  Newman  J,  Allison  J.  Visible  Cosmetic 
Improvement  with  Cryolipolysis:  Photographic  Evidence. 
Presented at the Annual Meeting of the American Society for 
Dermatologic Surgery, 2009, Phoenix, AZ.

  31.  Kothakota  S,  Azuma  T,  Reinhard  C,  et  al  (1997)  Caspase- 
3-generated  fragment  of  gelsolin:  Effector  of  morphological 
change in apoptosis. Science 1997; 278:294–8.

  37.  Mayoral F, Kaminer M, Kilmer S, Weiss R, Zelickson B. Effect of 
multiple cryolipolysis treatments on the abdomen. Lasers Surg 
Med 2012; 44(S24):15.

  32.  Boey  GE,  Wasilenchuk 

JL.  Enhanced  clinical  outcome 
with  manual  massage  following  cryolipolysis  treatment: 

  38.  Brightman  L,  Geronemus  R.  Can  second  treatment  enhance 
clinical results in cryolipolysis? Cosmet Dermatol 2011; 24(2):85–8.

 
Section VII

Assessment Techniques

57

Using the Behind-the-Knee Test to Evaluate 
Lotion Transfer from Products to Skin

Miranda A. Farage

INTRODUCTION
Manufacturers of consumer products consistently look for new 
ways in which their products may provide benefits to the con-
sumer. A growing trend for absorbent consumer products is to 
incorporate  lotions  and  emollients  on  the  surface  to  improve 
overall  consumer  comfort  during  product  use.  There  are  a 
number  of  examples  of  such  products  currently  on  the  mar-
ket.  Facial  tissues  impregnated  with  lotion  have  been  shown 
to facilitate the healing of redness and dryness that may occur 
to  the  area  around  the  nose  as  a  result  of  repeated  wiping 
when  suffering  from  a  cold  or  allergy  (1).  Benefits  of  topical 
administration of skin protectants from baby diaper topsheets 
clinically  reduced  skin  erythema  and  skin  barrier  damage 
in  infants  (2).  Petrolatum  emollient  impregnated  in  diapers 
reduced  skin  surface  roughness,  skin  erythema,  and  diaper 
dermatitis  compared  to  identical  diapers  without  emollient 
(3,4).  A  combined  zinc  oxide/petrolatum  (ZnO/Pet)  formula-
tion was demonstrated to actually protect skin from damage 
when  subsequently  challenged  with  a  model  irritant  (0.5% 
sodium lauryl sulfate) under 24-h occlusive patch (5). The pro-
tective  effects  of  this  technology  also  provide  advantages  in 
feminine protection products (6). More recently, a cumulative 
irritation study was conducted on lotioned feminine pads (7). 
Volunteer subjects were patched on the upper arm for 21-days. 
Cumulative irritation scores for the sites patched with the sam-
ple feminine pads with lotion were significantly lower than the 
sites patched with feminine pads without lotion.

Lotion  transfer  is  primarily  a  surface  phenomenon. 
Molecules  of  lotion  on  the  surface  of  the  product  transfer  to 
the surface of the skin. Once on the skin surface, the lotion acts 
as a barrier to moisture loss and provides lubrication (8). It fol-
lows that, in order for lotion technologies to provide benefits 
for absorbent products, the lotion must first be able to transfer 
to the skin surface. While this point may seem obvious, it pro-
vides a unique challenge when dealing with absorbent prod-
ucts.  After  all,  the  main  function  of  the  product  is  to  absorb 
material, not release it to the skin. A reliable means to measure 
the  relative  quantities  of  various  lotions  which  transfer  from 
absorbent products, and the potential effects of other product 
characteristics, is key in the development of lotion-containing 
products  that  will  provide  skin  benefits.  Measuring  lotion 
transfer from absorbent consumer products in a traditional in-
use study has proven to be challenging. Differing use patterns 
and habits among panelists often leads to a high degree of vari-
ability in the results.

A  modification  of  the  behind-the-knee  (BTK)  protocol 
has  been  utilized  to  evaluate  lotion  transfer  from  emollient-
coated  menstrual  pads  and  pantiliners.  The  BTK  protocol 

using the popliteal fossa as a test site was originally  developed 
to   evaluate  both  the  inherent  chemical  irritation,  and  the 
potential for mechanical irritation of substrates and products 
that come into prolonged or repeated contact with the skin (9). 
However, we have found that this method effectively measures 
the  amount  of  lotion  formulations  that  transfer  to  the  skin 
with  greater  consistency  and  reliability  than  measurements 
conducted  in  the  course  of  clinical  in-use  studies  (10).  When 
coupled  with  evaluations  for  skin  effects,  the  visual  benefits 
from lotioned absorbent products can be demonstrated.

METHODS
Both  the  BTK  and  clinical  in-use  protocols  were  conducted 
in  accordance  with  the  Declaration  of  Helsinki,  and  were 
reviewed  and  accepted  by  the  Institutional  Review  Board  of 
the research facility (11). All subjects reviewed and signed an 
informed  consent  prior  to  the  study.  Subjects  were  excluded 
from  participation  in  the  study  if  they  had  a  history  of  sen-
sitivity  to  skin  tapes,  bandages  or  adhesives,  if  they  had  any 
condition in the test area which would prevent the collection 
tapes from adhering to the skin (i.e. piercings, wounds, etc.), or 
if they were currently menstruating.

Test Products
Menstrual  pads  and  pantiliners  are  constructed  of  a  surface 
layer (topsheet), an absorbent core, and a moisture-imperme-
able  backing  (12).  The  topsheets  are  made  from  non-woven 
polyethylene-based or polypropylene-based copolymeric fab-
rics,  perforated  polyethylene  films,  or  some  combination  of 
these.  The  absorbent  core  may  consist  of  cellulose  fluff  pulp, 
or superabsorbent gel materials (AGM) designed to hold larger 
volumes  of  fluid.  In  addition,  some  menstrual  products  con-
tain emollients on the surface to reduce skin irritation during 
use. These are applied in stripes on the topsheet that may vary 
in  number,  position  and  size.  Test  products  used  in  specific 
studies are detailed in the appropriate figure or table captions.

Pressure Measurement
Pressure  sensors  (Tekscan®  Prosthetic  Model  9801,  Tekscan, 
Inc., South Boston, MA) were applied to the test areas. Currently 
marketed feminine hygiene pads were worn by the panelists in 
the traditional way, i.e., as in an in-use clinical study, and in a 
BTK  application  (13).  Pressure  was  measured  as  participants 
engaged in three normal activities for 2-minute time periods: 
walking, sitting, and standing. The average pressure data col-
lected for all three pads in both the genital and BTK locations 
was determined.

552 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Lotion Measurement
Lotion  was  quantified  by  gas  chromatography  with  flame 
ionization detection. The thin film  dressing tapes  containing 
lotion  from  either  the  BTK  or  clinical  in-use  wear  protocols 
were  extracted  for  30  min  on  a  wrist  action  shaker  using  10 
mL of diluent. The extracts were passed through a 0.45 µm fil-
ter  (13  mm  Acrodisc®  Syringe  Filters  with  GHP  Membrane, 
Pall Corporation, East Hills, NY). Samples and standards were 
then  passed  through  a  gas  chromatographic  column  (a  con-
stant flow of 1.5 mL/min, initial oven at an initial temperature 
of  100°C,  with  an  increase  in  temperature  of  10°C/min  up  to 
200°C, then 15°C/min up to the detector temperature of 325°C). 
Behenyl  alcohol,  a  component  of  all  the  lotion  formulations, 
served as a marker for lotion transfer. A calibration curve was 
generated based on the three standard concentrations of behe-
nyl alcohol. (0.1, 0.05, and 0.004 mg/mL behenyl alcohol in 1L of 
hexane containing 50 mg tricosanol). The mass of lotion trans-
ferred was determined from the mass of behenyl alcohol and 
its  concentration  in  the  of  lotion  formulation.  Recovery  was 
90%–110%, based on spiking of the collection tape.

lotion 

BTK Lotion Transfer Protocol
The  BTK 
transfer  protocol  has  been  described 
 previously (8). Panels of healthy adults were enrolled for partici-
pation. Subjects were instructed to refrain from using lotions, 
creams,  or  any  other  skin  preparation  on  the  area  of  the  skin 
to which product was to be applied. Subjects with preexisting 
irritation or discomfort in the area behind the knee or leg vari-
cosities were excluded. To collect transferred lotion, sections of 
waterproof, thin film dressing tape (Tegaderm™ tape, 3M™, St. 
Paul, MN) were applied on the popliteal fossa of each leg. Test 
pad samples were placed on top of the collection tapes and held 
in  place  on  the  popliteal  fossa  by  an  elastic  knee  band  of  the 
appropriate size. Samples were placed randomly on the right or 
left test sites. Following application of the pads, subjects left the 
test facility and participated in normal daily activities. Specific 
protocol modifications for individual studies are detailed in the 
appropriate figure or table captions. One-way analysis of vari-
ance (ANOVAs) were conducted for the 3- and 6-hour data. A 
two-way  ANOVA  was  used  to   compare  time  (two  measure-
ments), treatment (six pads), and their interaction. All computa-
tions were carried out using PC SAS®, Version 9.2.

Clinical In-Use Protocol
The clinical in-use protocol has also been described previously 
(10).  Healthy,  adult,  non-menstruating  female  subjects,  ages 
18–55, were enrolled. The subjects were randomized into three 
groups of 12 each, and each group was assigned to wear two of 
the six test products (i.e., feminine protection pads with lotion) 
in  random  order.  A  crossover  design  with  a  24-hour  washout 
period was used for the  pairwise comparisons,  such  that each 
subject served as her own control. Consequently, the study had 
two phases, each involving 24 hours of pad wear time with one of 
the two comparison products to which the subject was assigned.
Immediately  prior  to  the  start  of  phase  one,  pubic  hair 
present  on  the  site  of  application  was  clipped  by  the  study 
technician.  Four  sections  (22  mm  ×  44  mm)  of  the  thin  film 
dressing  tape  were  applied  to  each  side  of  the  labia  majora 
(two per side) oriented parallel to the vaginal opening. Panties 
and test pads were dispensed, and the subjects wore the pads 
for 3 hours. During this time, subjects participated in normal 
activities of daily living. After 3 hours of wear, two of the four 
tape sections (in random order) were removed for determining 
lotion  transfer.  An  activity  log  for  the  3-hour  wear  time  was 

completed.  After  removal  of  two  sections  of  collection  tape, 
the  same  fresh  test  product  was  reapplied  as  needed  by  the 
test subject for the remainder of the total 24-hour test period 
(approximately  21  additional  hours  of  wear  time).  Subjects 
were  given  enough  test  products  so  that  they  could  change 
pads  at  approximately  3-  to  5-hour  intervals  and  once  after 
overnight wear during the test period. The subjects kept a test 
product use log to record the times when each test product was 
removed,  and  the  total  number  of  pads  used.  After  the  pads 
had been worn for a total of 24 hours, subjects returned to the 
test facility, and the two remaining sections of collection tape 
were removed, to complete phase one. Following the 24-hour 
“washout”  period,  the  entire  process  was  repeated  for  phase 
two using  a different  product.  The  3- and 24-hour data were 
analyzed  using  two-way  ANOVA,  involving  period  (i.e.,  pre- 
and  post-crossover),  treatment,  and  their  interaction.  For  the 
combined data, a two-way ANOVA was used involving hour 
(i.e., 3- and 24-hour measurements) and treatment.

It  should  be  noted  that  the  clinical  in-use  study  was  a 
crossover  design.  Subjects  used  one  test  product  in  phase 
1,  and  another  product  in  phase  two  after  a  24-hr  washout 
period. To determine whether the washout period was effec-
tive,  results  were  evaluated  separately  for  the  same  products 
used during the first test period (phase 1) versus the second test 
period  (phase  2).  Significant  differences  between  the  amount 
of lotion transferred when the products were used first (phase 
1) compared to the same products used second (phase 2), indi-
cated the washout period was not effective. In these instances 
the 3-hour data were treated separately. For the 24-hour data, 
there were no significant differences for products tested dur-
ing  phase  1  vs.  phase  2.  Therefore,  the  24-hour  data  for  both 
phases were combined.

Arm Patch Protocol
To  examine  the  potential  effects  of  lotions  as  a  barrier  to 
prevent irritation, testing was carried out on the upper arm in 
a previously described protocol (14). For each subject, test sites 
equally spaced along the upper arms (from shoulder to elbow) 
were identified. Each site consisted of a measured area circum-
scribed  using  indelible  markers.  On  each  arm,  sample  place-
ment for test and control samples was random. Designated test 
sites were pretreated with weighed amounts of lotion formu-
lations  applied  to  the  center  of  the  test  sites.  Care  was  taken 
to be consistent in the amount of pressure used and the dura-
tion of the application. The lotion was allowed to penetrate the 
test sites for 10 minutes prior to further treatment. Lotion was 
not  applied  to  the  control  sites.  After  lotion  pretreatment,  all 
test  sites  received  a  0.3-mL  patch  of  0.5%  sodium  lauryl  sul-
fate (SLS) using a commercially available patch (Webril patch, 
Professional  Medical  Products  Company).  Patches  were  in 
place for 24 hours. Evaluations of reactions on the test and con-
trol sites were conducted after a 30-minute acclimation period 
in  a  temperature-  and  humidity-controlled  room.  Sites  were 
evaluated for transepidermal water loss (TEWL) using an evap-
orimeter  (Dermalab,  Cortex  Technology,  Denmark),  and  for 
erythema by visual assessment using the BTK grading scale of 
0–4, where “0” is no apparent cutaneous involvement and “4” 
is moderate-to-severe spreading erythema (15). Test sites were 
evaluated prior to any treatment (baseline values) 30 minutes 
after removal of the 24-hour patch with SLS or saline, and daily 
thereafter for a total of 4 days. The average of all scores post 
baseline (PBA, or post-baseline average) was determined and 
differences between treatments were compared by ANOVA on 
ranks for erythema and nonparametric analysis of  covariance 

 
USING THE BEHIND-THE-KNEE TEST TO EVALUATE LOTION TRANSFER FROM PRODUCTS TO SKIN 

 553

(ANCOVA)  with  baseline  values  as  a  variable  for  TEWL. 
Results were unadjusted for multiple comparisons.

Modified Forearm Controlled 
Application Test Protocol
The  modified  forearm  controlled  application  test  (mFCAT) 
protocol has been described previously (1,16,17). Two test sites 
were  identified  and  demarcated  on  the  volar  surface  of  each 
forearm.  Treatment  and  sample  placement  was  randomized 
among the four total test sites. In two of the four demarcated 
test sites, the skin of the forearm was pretreated with 24-hour 
patch of 0.1% SLS on study day 1. On days 2  and 3,  the fore-
arms were wiped in a controlled manner with lotioned femi-
nine pads. Treatment with the samples on day 2 consisted of 
a total of 120 swipes/test site. One swipe was equal to a back-
and-forth  motion  with  sufficient  pressure  to  insure  direct 
contact with the skin. Five fresh pads were used to adminis-
ter the 120 swipes (24 per pad). On day 3 a total of 60 swipes/
test site were done. Once again, five fresh pads were used to 
administer the 60 swipes (12 per pad). Evaluations of reactions 
on the test and control sites were conducted after a 20-minute 
acclimation period in a temperature- and humidity-controlled 
room for each subject. TEWL measurement and visual assess-
ment for erythema was conducted as described above. Dryness 
was  evaluated  on  a  scale  of  0–6,  with  “0”  indicating  perfect 
skin  and  “6”  indicating  severe  scaling  with  bleeding  cracks 
(1).  Reactions  at  test  sites  were  evaluated  prior  to  any  treat-
ment (baseline value), after patching with SLS (post-irritation 
value), and before and after swiping with product. Differences 
between  the  two  lotion  treatments  were  compared  using 
stratified Cochran-Mantel-Haenszel (CMH) for erythema and 
 dryness, and Wilcoxon signed rank for TEWL.

RESULTS
Comparing Relative Pressure on Test Samples
As  mentioned  above,  lotion  transfer  is  primarily  a  surface 
 phenomenon where molecules of the lotion on the surface of 

the product transfer to the surface of the skin (8). It follows that 
the amount of pressure exerted on the test sample could signif-
icantly alter the amount of lotion that is transferred. In order to 
validate the use of the BTK in lotion transfer we compared the 
pressure on test samples using the two application methods—
in-use  and  BTK  (13).  Currently  marketed  feminine  hygiene 
pads were worn by the panelists in the traditional way, i.e., as 
in an in-use clinical study, and in a BTK application. Pressure 
was measured as participants engaged in three normal activi-
ties for 2-minute time periods: walking, sitting, and standing. 
The average pressure data collected for all three pads in both 
the genital and BTK locations are shown in Figure 57.1. In both 
protocols, the pressure was relatively small (i.e., under 1 psi). 
For  all  three  sample  products,  pressure  measured  at  about 
0.2 psi in both the BTK and the in-use protocol when subjects 
were standing or walking. When sitting, pressures were higher 
in both protocols: 0.5–0.8 psi in the BTK and 0.4–0.5 psi in the 
in-use clinical. The results obtained in this study confirm that 
pressure exerted from feminine hygiene pads in the BTK clini-
cal test model is comparable to real product wear conditions; 
pressure  was  virtually  identical  for  standing  and  walking 
positions, and somewhat higher for the sitting position.

Transfer as a Function of the 
Amount of Lotion on the Pad
Since lotion transfer is a surface phenomenon, there will be a 
range of concentrations of lotion on the pad where the amount 
of  transferred  lotion  will  increase  proportionally.  There  will 
also  be  a  range  of  concentrations  where  no  additional  lotion 
will transfer, i.e., where the surface of the collection tape is full. 
In this range, additional lotion, either from an increase in con-
centration  on  the  pad,  extended  wear  time,  or  from  multiple 
applications of fresh pads, will not result in additional lotion 
transferred  to  the  collection  tape.  Studies  were  conducted  to 
define the range of lotion concentrations and exposure dura-
tions that could be utilized in the BTK.

A  test  product  series  was  constructed  to  evaluate  the 
effective  concentration  range  for  lotion  transfer  (18).  These 

BTK

In-use

Standing

Walking

Sitting

)
i
s
p
(
e
r
u
s
s
e
r
P

1.00

0.80

0.60

0.40

0.20

0.00

0
8
0

.

0
5
0

.

7
6
0

.

0
4
0

.

4
5
0

.

2
4
0

.

8
1
0

.

7
1
0

.

0
2
0

.

9
1
0

.

4
2
0

.

1
2
0

.

8
1
0

.

6
1
0

.

7
1
0

.

7
1
0

.

0
2
0

.

8
1
0

.

Maxi pad Ultra thin

pad

Foam
core pad

Maxi pad Ultra thin

pad

Foam
core pad

Maxi pad Ultra thin

pad

Foam
core pad

Figure 57.1  Comparison of pressure exerted by the sample in the BTK and in-use clinical studies. Participants engaged in three 
normal activities for 2-minute time periods: standing (n = 3), walking (n = 4), and sitting (n = 4). Multiple pressure readings were taken 
for each participant during the 2-minute activity interval and averaged for the individual. Individual averages were used to calculate 
an overall average pressure in psi. This study has been detailed in an earlier publication (13).

 
 
554 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Absorbent = Cellulose

)
E
S
–
/
+
m
c
q
s
/
g
u
(
d
e
r
r
e
f
s
n
a
r
t
n
o
i
t
o
L

100

90

80

70

60

50

40

30

20

10

0

Lotion transfer, 3-hr (µg/sq cm)
Lotion on pad (mg/pad)

1
0.3
0.8

2
22.1
11.2

3
42.1
23.3

4
59.4
33.0

5
69.5
41.8

6
77.8
53.3

7
89.8
62.0

70

60

50

40

30

20

10

0

)
g
m

(
d
a
p
n
o
n
o
i
t
o
L

Figure 57.2  Lotion transfer as a function of starting amount on pad. Lotion transfer from Test Product Series I was evaluated 
using the BTK. These test products were identical in construction, with a cellulose absorbent core and a pad thickness of 7 mm. 
Lotion was applied to the pads in a regular configuration of 5 stripes of 5 mm width each. The amount of lotion on the pads ranged 
from 0.8 to 62 mg/pad, as shown in the table at the bottom of the graph. Two sections of collection tape were affixed to the skin 
at each test site, followed by application of the test product samples. After 3 hours of exposure in the BTK, the test sample was 
removed,  and  one  piece  of  collection  tape  was  removed  from  each  test  site  for  analysis.  A  fresh  test  product  was  applied  for 
3 more hours (i.e., a total of 6 hours of application), following which the second collection tape was removed and analyzed. The 
amount of lotion transferred (in µg/cm2) is compared to the starting amount of lotion on the pad (in mg/pad) for each of the test 
products. This study has been detailed in an earlier publication (18).

menstrual  pad  samples  (Test  Product  Series  I)  were  identical 
in  every  respect  except  the  amount  or  lotion  applied  to  the 
 surface. As shown in Figure 57.2, for this range of lotion con-
centrations (0.8–62 mg/pad, as shown in the table at the bottom 
of the graph), the amount of lotion which transferred to the col-
lection tape in the BTK after a 3-hour application was directly 
proportional to the amount which was applied to the pad. The 
6-hour  sample  application  showed  similar  results  (data  not 
shown).  The  data  confirm  that  the  range  of  lotion   quantities 
tested  (0.8–62  mg/pad)  resulted  in  effective  transfer  of  the 
lotion to the surface in a linear fashion.

Transfer as a Function of Duration of Exposure
This test was conducting using identical pantiliner test  product 
samples with different durations of exposure in the BTK. The 
pantiliner test product contained 22.7 mg/pad on the surface, 
and samples were evaluated after 6, 9.5, and 24 hours. As shown 
in Figure 57.3, the product transferred increasing amounts of 
lotion with longer durations of exposure: 66.12 ± 5.23 µg/cm2 of 
lotion with 6-hour exposure, 82.64 ± 6.54 µg/cm2 at 9.5 hours, 
and 95.73 ± 5.23 µg/cm2 at 24 hours.

Influence of the Absorbent 
Core on Lotion Transfer
The  two  basic  options  for  absorbent  cores  have  very   different 
chemical  and  absorbent  characteristics.  Cellulose  material 
absorbs  by  capillary  action  whereas  AGM  absorbs  by  ionic 
action. If the lotion is composed of nonpolar components, AGM 
will have a lower affinity for the lotion and therefore release it 
more easily. Thus, the type of absorbent core would be expected 
to influence the amount of lotion that will transfer from the prod-
uct. Further, because of the superior absorbent qualities of AGM, 

)
2

m
c
/
g
µ

(

t
n
u
o
m
a
r
e
f
s
n
a
r
T

120.00

100.00

80.00

60.00

40.00

20.00

0.00

66.12

82.64

95.73

6 Hours

9.5 Hours
Duration of exposure

24 Hours

Figure  57.3  Lotion  transfer  as  a  function  of  duration  of 
exposure.  Lotion  transfer  was  evaluated  in  the  BTK  from 
a  pantiliner  test  product  with  an  AGM  absorbent  core  and 
a  pad  thickness  of  1.8  mm.  Lotion  was  applied  in  10  stripes 
of  4  mm  width  each  in  the  crosswise  direction  on  the  prod-
uct.  The  total  lotion  concentration  on  the  pantiliners  was  
22.7 mg/pad. Two sections of collection tape were affixed to the 
skin at each test site, followed by application of the test product 
samples, followed by application of the pantiliner test product 
samples. After 6 hours, one sample was removed and one of 
the  two  sections  of  tape  on  that  side  was   carefully  collected 
for analysis. The same pantiliner sample was placed back on 
the same site for a further 3.5 hours. At this time (i.e., after 9.5 
hours  of  exposure  on  that  site),  this  same  pantiliner  sample 
was removed and the other tape section on that side  collected 
for analysis. After 24 hours, the pantiliner on the other leg was 
removed and both collection tape sections were removed.

 
 
 
 
 
 
 
 
 
 
 
USING THE BEHIND-THE-KNEE TEST TO EVALUATE LOTION TRANSFER FROM PRODUCTS TO SKIN 

 555

pads constructed with this material can be much thinner than 
those constructed with cellulose cores (2 mm compared to 7–9 
mm, respectively). The three AGM pads were only 2 mm thick, 
whereas those with cellulose cores ranged from 7 to 9 mm thick.
A  second  test  product  series  (Test  Product  Series  II) 
was constructed to compare a number of product differences, 
including  the  cellulose  and  AGM  cores,  pad  thickness,  and 
lotion concentrations and stripe configuration (10,19). The three 
cellulose core products constructed for the test had concentra-
tions of lotion of 63.7, 60.0, and 57.0 mg/pad. The three AGM 
products  contained  40.0,  33.9,  and  30.1  mg/pad  lotion.  These 
products  were  tested  in  both  the  BTK  and  a  clinical   in-use 
study to measure lotion transfer.

In  the  BTK,  pads  with  an  AGM  core  transferred  more 
lotion than those with the more traditional cellulose absorbent 
core. Figure 57.4a shows data from both the 3-hour and 6-hour 
collection. As shown, even though the cellulose pads had more 
lotion applied to the surface, they tended to transfer less lotion 
to the collection tapes than the AGM pads.

The clinical in-use study results showed a similar trend, 
although  the  data  were  less  consistent  (Figure  57.4b).  No 
particular  trend  was  obvious  at  the  3-hour  collection  point. 
However,  after  24-hour  exposure,  the  AGM  pads  released 
similar amounts of lotion compared to the cellulose pad, even 
though  the  starting  amounts  on  the  AGM  pads  were  greatly 
reduced compared to the cellulose pads.

)
E
S
±
m
c
q
s
/
g
u
(
d
e
r
r
e
f
s
n
a
r
t
n
o
i
t
o
L

210

180

150

120

90

60

30

0

Lotion transfer, 3-hr (µg/sq cm)
Lotion transfer, 6-hr (µg/sq cm)
Lotion on pad (mg/pad)

)
E
S
±
m
c
q
s
/
g
u
(
d
e
r
r
e
f
s
n
a
r
t
n
o
i
t
o
L

350

300

250

200

150

100

50

0

Lotion transfer, 3-hr (µg/sq cm)
Lotion transfer, 24-hr (µg/sq cm)
Lotion on pad (mg/pad)

Absorbent = Cellulose

Absorbent = AGM

S vs Q, P < 0.02
S vs E, P < 0.02

C vs K, P < 0.0001

B vs K, P < 0.0001

S

78.8
149.9
63.7

QE

62.4
111.5
60.0

C

52.6
105.8
57.0

85.3
185.8
40.0

(a)

B

80.1
170.0
33.9

K

48.2
105.6
30.1

Absorbent = Cellulose

Absorbent = AGM

S

64.5
279.7
63.7

QE

61.2
246.8
60.0

C

53.7
23.5.0
57.0

40.5
260.5
40.0

(b)

B

62.3
204.9
33.9

K

29.7
202.8
30.1

70

60

50

40

30

20

10

0

)
d
a
p
/
g
m

(
d
a
p
n
o
n
o
i
t
o
L

70

60

50

40

30

20

10

0

)
d
a
p
/
g
m

(
d
a
p
n
o
n
o
i
t
o
L

Figure 57.4  Lotion transfer as a function of absorbent material. Lotion transfer from Test Product Series II was evaluated using 
the BTK and the clinical in-use protocol. The figure shows the amount of lotion transferred (in µg/cm2) compared to the starting 
amount of lotion on the pad (in mg/pad) for both types of absorbent cores: Cellulose and AGM. The three cellulose core products 
(S, Q, and E) had pad thicknesses of 7, 9, and 6 mm, with lotion concentrations of 63.7, 57.0, and 57.0 mg/pad. The three AGM 
products (C, B, and K) had pad thicknesses of 2 mm, with lotion concentrations of 40.0, 33.9, and 30.1 mg/pad. This study has 
been detailed in earlier publications (10,19). (a) Lotion transfer after 3 and 6 hours in the BTK protocol. Pairwise comparisons 
resulted  in  the  significant  differences  shown.  (b)  Lotion  transfer  after  3  and  24  hours  in  the  clinical  in-use  protocol.  Pairwise 
 comparisons resulted in no significant differences. (Only Phase 1 of the cross-over study is reported for the 3-hr timepoint.)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
556 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Influence of Pad Thickness on Lotion Transfer
The most likely explanation for the results shown in Figure 57.4 
is  the  chemical  differences  between  the  AGM  and  cellulose 
materials. However, an alternative possibility is that the AGM 
pads transfer more lotion because they are thinner. If this were 
the  case  and  thinner  pads  transfer  lotion  better,  one  would 
expect  that  transfer  from  the  cellulose  core  pads  would  be 
smallest from pad Q (at 9 mm thick), intermediate from pad S 
(at 7 mm thick) and greatest from pad E (at 6 mm thick). This 
was not the case, as shown in the Figure 57.5. Among the cel-
lulose core products (S, Q, and E), the one with the most lotion 
on the pad to start (pad S with 63.7 mg lotion and a thickness of 
7 mm) transferred directionally more lotion to the skin in both 
the BTK and clinical, although the differences were not statisti-
cally significant in either protocol. The thicker cellulose pad Q 
(9 mm) and the thinner cellulose pad E (6 mm) both transferred 
an amount that was directionally less than pad S.

Comparison of the Two Test Protocols 
for Measuring Lotion Transfer: 
BTK vs. Clinical In-Use
When the two test methods for measuring lotion transfer were 
compared,  the  BTK  and  the  clinical  in-use  studies  yielded 
similar  results;  however,  the  BTK  was  more  consistent.  This 

is  undoubtedly  due  to  the  greater  number  of  variables  that 
impact  the  in-use  studies  that  do  not  impact  the  BTK  proto-
col (reviewed in Table 57.1). First, for the 24-hour test time, the 
number of pads used differs for different panelists. Differences 
in  daily  activities  may  also  influence  transfer  amounts.  In 
addition, even though the panelists all wear the identical type 
of  panties  issued  by  the  test  facility,  the  amount  of  pressure 
on the test site would vary depending on the fit of the panties 
(tight or loose) and the clothing preferences of the panelists (i.e., 
pantyhose, tight jeans, or skirts). Further, the pressure would 
change throughout the 24-hour period as the panelist changes 
from regular clothing to loose-fitting sleepwear. The protocol 
used in the BTK would result in a more consistent degree of 
pressure for individual panelists throughout the course of the 
study.  Finally,  the  clinical  protocol  design  results  in  a  high 
potential for removal of transferred lotion from the tapes dur-
ing bathroom visits and other activities. Obviously some exter-
nal factors, such as sweating, must have had an effect on the 
amount of lotion either transferred to the tape or the amount 
remaining on the tape at the 3-hour time point in the clinical 
study. Supporting this notion is the observation that with some 
individual panelists, the amount of lotion transferred after 24 
hours  was  actually  less  than  that  transferred  after  3  hours 
(data not shown).

)
E
S
–
/
+
m
c
q
s
/
g
µ

(

d
e
r
r
e
f
s
n
a
r
t
n
o
i
t
o
L

100

90

80

70

60

50

40

30

20

10

0

Lotion transfer - BTK (3-hr)
Lotion transfer - clinical (3-hr)
Pad thickness (mm)

Absorbent = Cellulose

Absorbent = AGM

Q vs S p = 0007

E vs S p = 0002

K vs C p < 0.0001
K vs B p < 0.0001

Q

62.4
61.2
9

S

78.8
64.5
7

E

52.6
53.7
6

C

85.3
40.5
2

B

80.1
62.3
2

K

48.2
29.7
2

10

9

8

7

6

5

4

3

2

1

0

)

m
m

(
s
s
e
n
k
c
i
h
t
d
a
P

Figure 57.5  Lotion transfer as a function of pad thickness. Lotion transfer (in µg/cm2) from Test Product Series II, as measured in 
the BTK and clinical in-use studies after 3 hours of collection, is shown as a function of the thickness of the test pads (in mm). The 
test pads were described in Figure 57.4 caption. This study has been detailed in earlier publications (10,19). Pairwise comparisons 
of lotion transfer after 3 hours in the BTK protocol resulted in the significant differences shown. Lotion transfer after 3 and 24 hours 
in the clinical in-use protocol. Pairwise comparisons in the in-use clinical resulted in a significant difference between products Q 
and S (p = 0.0017). This study has been detailed in earlier publications (10,19).

Table 57.1  Characteristics of the Two Clinical Test Protocols

BTK -Lotion Transfer Clinical Test

In-Use Clinical

Varying number of applications over the 24 hour test period.
Conducting different activities during the test would have minimal 

Varying number of applications over the 24 hour test period.
The effects of different activities on lotion transfer are unknown.

effects due to the method of product application.

Application pressure of the sample is similar for all panelists due to 

Application pressure of the sample will vary among panelists 

the use of elastic knee braces in application.

Application pressure of the sample for each panelist is consistent 

throughout the duration of the test.

depending on the fit of panties and clothing choices.

Application pressure of the sample for each panelist throughout 
the test as the panelists change clothing, particularly as the 
panelists dress in loose-fitting sleepwear.

There is no potential for accidental removal of the transferred lotion 

There is potential for accidental removal of the transferred lotion 

by the panelists.

during bathroom visits and other activities.

 
 
 
 
 
 
 
 
USING THE BEHIND-THE-KNEE TEST TO EVALUATE LOTION TRANSFER FROM PRODUCTS TO SKIN 

 557

Skin Benefits of Lotion at 
Transferred Concentrations
Lotion transfer is measured by the transfer or lotion from an 
absorbent product to the surface of the collection tape. In order 
to evaluate the potential benefits of lotion at these quantities, 
we conducted arm patch tests using a model irritant (SLS) on 
skin  sites  pretreated  with  lotion  in  various  quantities.  In  the 
first study, the effect of lotion as an irritant barrier was evalu-
ated. Two different lotion formulations were applied to demar-
cated skin sites on the upper arm at concentrations of 165, 495, 
and  825  µg/cm2  (14).  Sites  were  then  patched  with  0.3  mL  of 

0.5%  SLS  for  24  hours.  The  resulting  erythema  and  change 
in TEWL are presented in Figure 57.6. Both lotions produced 
a  dose-dependent  decrease  in  the  effects  of  the  irritant  as 
assessed by both the erythema (Figure 57.6a) and the change 
in TEWL (Figure 57.6b).

In the second study, the effect of lotion as a moisture bar-
rier was evaluated. A prototype test lotion was applied at four 
concentrations; 170, 140, 110, and 80 µg/cm2. One site was left 
untreated with lotion to serve as a control. After lotion treat-
ment,  patches  consisting  of  pantiliner  cutouts  saturated  with 
saline  were  applied  for  3  hours.  TEWL  measurements  were 

)
E
S
±
n
a
e
M

(
a
m
e
h
t
y
r
E

2.00

1.60

1.20

0.80

0.40

0.00

Positive
control

Low lotion +
SLS

Medium
lotion + SLS

High lotion +
SLS

Negative
control

Lotion S
Lotion Q

1.82
1.79

1.46
1.53

1.05
1.18

(a)

0.88
0.90

0.13
0.13

)
E
S
±
n
a
e
M

(
L
W
E
T
n

i

e
g
n
a
h
C

30.0

20.0

10.0

0.00

Positive
control

Low lotion +
SLS

Medium
lotion + SLS

High lotion +
SLS

Negative
control

Lotion S
Lotion Q

27.4
26.7

12.3
168

10.5
10.6

(b)

8.5
8.6

3.2
2.7

Figure  57.6  Effects  of  different  lotion  amounts  on  lotion  barrier  effects.  Arm  patch  studies  were  conducted  on  the  lotion 
 formulations Q and S. Test sites were pretreated with three concentrations of lotion (low = 165 µg/cm2, medium = 495 µg/cm2, 
high  =  825  µg/cm2),  then  patched  with  0.3mL  of  0.5%  SLS.  Control  sites  received  no  pretreatment.  The  positive  control  was 
patched with SLS. The negative control was patched with saline. Sites were evaluated for erythema (a) and TEWL (b). The average 
of all scores post baseline are plotted. (a) Erythema: Means for all treatments with lotions S and Q (high, medium, and low) were 
significantly lower than the mean for the positive control (p ≤ 0.05). (b) Change in TEWL: The change in means for all treatments 
with lotions S and Q (high, medium, and low) were significantly lower than for the positive control (p ≤ 0.05). This study has been 
detailed in an earlier publication (14).

 
 
 
 
 
 
 
 
 
558 

 TEXTBOOK OF COSMETIC DERMATOLOGY

conducted  prior  to  any  treatment  (baseline),  immediately 
after  patch  removal.  A  reduction  of  the  TEWL  value  reflects 
reduced water uptake by the skin and thus protection against 
over hydration. The results shown in Figure 57.7 indicate that 
all  lotion  concentrations  provided  protection  against  mois-
ture uptake by the skin. TEWL measurements taken immedi-
ately after patch removal (0 minutes) at all lotion-treated sites 
showed  a  significantly  lower  increase  in  TEWL  compared  to 
the non–lotion-treated site. Subsequent measurements taken at 
5, 10, and 15 minutes after patch removal (data not shown) indi-
cated  that  the  TEWL  had  recovered  substantially  at  all  sites, 
including the non–lotion-treated sites. However the site treated 
with 170 µg/cm2 continued to have a significantly lower TEWL 
than the non-lotion control site.

The potential of lotioned products to have healing effects 
on irritated skin were evaluated using an mFCAT protocol (20). 
Identified sites on the forearm were patched with a model irri-
tant (0.1% SLS) for 24 hours on day 1. On days 2 and 3 patching, 
the test sites treated by swiping lotioned feminine pads on the 
patched sites in a manner described in the “methods" section. 
Figure  57.8  presents  resulting  evaluations  for  erythema,  dry-
ness, and TEWL. Prior to any treatment there was no evidence 
of  erythema  or  dryness  at  any  of  the  test  sites  (baseline  val-
ues).  After  application  of  the  SLS  irritant  patch  for  24  hours, 
the skin sites showed a low level of irritation, as reflected by 
increases  in  mean  scores  for  erythema,  dryness,  and  TEWL 
(shown as post-irritation values). Test sites patched with saline 
instead of SLS showed no evidence of irritation. The first treat-
ment with either test product (post-treatment 1 values) did not 
reduce the level of erythema at the test sites (Figure 57.8a), but 

did reduce the level of dryness (Figure 57.8b). TEWL was not 
affected by the first treatment (Figure 57.8c). With the second 
treatment  both  test  products  reduced  the  levels  of  erythema 
and dryness, indicating that the application of lotion promoted 
a return toward baseline values (shown as pre-treatment 2 and 
post-treatment 2 values). TEWL was not demonstrably affected 
by the second treatment.

Other investigations have provided evidence of skin ben-
efits from topically applied lotion. Feminine pads were used in 
forearm  application  where  pads  were  swiped  across  the  sur-
face  of  the  skin  in  a  controlled  fashion  (8).  The  coefficient  of 
friction  was  evaluated  as  an  indication  of  the  resulting  skin 
moisturization at 5 and 10 minutes after treatment. Compared 
to two control sites (i.e., no treatment or treatment with a non-
lotioned  test  pad),  sites  treated  with  lotioned  pads  showed  a 
significant increase in skin moisturization at both time points, 
as indicated by an increase in the coefficient of friction.

CONCLUSIONS
Both  the  BTK  and  the  clinical  protocol  provide  a  means  of 
evaluating  the  transfer  of  lotion  formulations  from  feminine 
protection  pads.  However,  this  adaptation  of  the  BTK  test 
method  provides  more  consistent  results  at  a  fraction  of  the 
cost. Further, we have developed a number of simple test pro-
tocols to determine the potential benefits of lotion on the skin 
at  amounts  comparable  to  the  transfer  amounts  determined 
in the BTK. This includes protocols to evaluate moisture bar-
rier effects, visible signs of irritation, and healing effects after 
application of an irritant.

)
E
S
±
n
a
e
M

(
e
n

i
l

e
s
a
b
m
o
r
f
L
W
E
T
n

i

e
g
n
a
h
C

70

60

50

40

30

20

10

0

110 vs 0, p = 0.0002

170 vs 140, p = 0.0357
170 vs 80, p = 0.196
170 vs 0, p = 0.0001

80 vs 0, p = 0.0070

140 vs 0, p = 0.0035

0

140
80
110
Lotion concentration ((cid:31) g/cm2)

170

Figure 57.7  Effects of lotion on moisture barrier. Areas on the volar surface of the forearm of adult, female volunteer subjects 
were treated with four levels of a prototype test lotion (170, 140, 110 and 80 µg/cm2). One site was left untreated with lotion to serve 
as a control. Following the application of the lotion, patches made of full-thickness cutouts from the pantiliner were pre-wetted with 
water and applied to the skin test sites. The wet patches were kept in place for 3 h. TEWL measurements were conducted prior to 
any treatment and immediately after pantiliner removal. The change in TEWL from baseline for each lotion concentration is plotted. 
Statistical analyses were conducted using generalized linear mixed models (GLMM) with subject as a random effect and baseline 
TEWL as a covariate. Results were adjusted for a small sample bias (21).

 
 
 
 
 
 
 
 
USING THE BEHIND-THE-KNEE TEST TO EVALUATE LOTION TRANSFER FROM PRODUCTS TO SKIN 

 559

Irritant

Lotion
Tratment 1

Lotion
Tratment 2

Final

)
E
S
±
n
a
e
M

(
a
m
e
h
t
y
r
E

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0.0

Baseline

Post-irritation

Post
treatment 1

Pre-
treatment 2

Post
treatment 2

SLS + Pad S
SLS + Pad Q
Saline + Pad S
Saline + Pad Q

0.00
1.00

0.00
0.00

1.03
1.06

0.00
0.00

1.16
1.19

0.03
0.06

(a)

0.72
0.91

0.00
0.00

0.57
0.67

0.00
0.05

)
E
S
±
n
a
e
M

(

s
s
e
n
y
r

D

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0.0

Irritant

Lotion
Tratment 1

Lotion
Tratment 2

Baseline

Post-irritation

Post
treatment 1

Pre-
treatment 2

Post
treatment 2

SLS + Pad S
SLS + Pad Q
Saline + Pad S

Saline + Pad Q

0.00
1.06

0.06

0.12

1.13
1.25

0.00

0.00

1.63
1.88

0.00

0.00

0.56
0.50

0.06

0.06

(b)

0.13
0.20

0.00

0.00

Irritant

Lotion
Tratment 1

Lotion
Tratment 2

Final

0.27
0.37

0.03
0.00

Final

Final

0.20
0.27

0.06

0.06

Final

)
E
S
±
n
a
e
M

(
L
W
E
T

25

20

15

10

5

0

Baseline

Post-irritation

S, + SLS

Q, + SLS
S, no SLS
Q, no SLS

5.1

4.6

4.3

5.2

16.3

16.8

3.5

3.6

Post
treatment 1
16.4

Pre-
treatment 2
9.9

Post
treatment 2
8.6

19.8

2.8

3.2

11.3

3.4

3.7

(c)

9.0

3.2

3.3

Final

8.6

7.9

3.8

3.9

Figure 57.8  Healing effects of lotion on skin compromised with an irritant in the mFCAT. Modified FCAT studies were conducted 
on two products with different lotion formulations (Q and S). Test sites on the volar forearm were pretreated via 24-h patch with 
0.1 percent SLS. Control sites were treated with saline. On days 2 and 3, the forearms were wiped in a controlled manner with test 
pads Q or S, as described in the methods sections. Reactions were evaluated for erythema (a), dryness (b), and TEWL (c). The 
graph shows the mean scores for each day before and after treatment with lotioned product. There were no significant differences 
between the two test pads in mean erythema, dryness, or TEWL. This study has been detailed in an earlier publication (14).

 
 
 
 
 
 
 
 
 
 
560 

 TEXTBOOK OF COSMETIC DERMATOLOGY

REFERENCES

1.  Farage  MA,  Ebrahimpour  A,  Steimle  B,  Englehart  J,  Smith  D. 
Evaluation of lotion formulations on irritation using the modi-
fied  forearm-controlled  application  test  method.  Skin  Res 
Technol 2007; 13:268.

2.  Baldwin  S,  Odio  MR,  Haines  SL,  O’Connor  RJ,  Englehart  JS, 
Lane AT. Skin benefits from continuous topical administration 
of a zinc oxide/petrolatum formulation by a novel disposable 
diaper. J Eur Acad Dermatol Venereol 2001; 15(Suppl 1):5.

3.  Odio  MR,  O’Connor  RJ,  Sarbaugh  F,  Baldwin  S.  Continuous 
topical administration of a petrolatum formulation by a novel 
disposable  diaper.  1.  Effect  on  skin  surface  microtopography. 
Dermatology 2000; 200:232.

4.  Odio  MR,  O’Connor  RJ,  Sarbaugh  F,  Baldwin  S.  Continuous 
topical administration of a petrolatum formulation by a novel 
disposable diaper. 2. Effect on skin condition. Dermatology 2000; 
200:238.

5.  Odio  M,  Friedlander  SF.  Diaper  dermatitis  and  advances  in 

 diaper technology. Curr Opin Pediatr 2000; 12:342.

6.  Vieira  L,  Avila  E,  Warren  R,  Odio  M,  Farage  MA.  Lotion 
 technology applied to pads: A different way of thinking about 
pads  and  women  vulva  skin.  Abstract.  Intl  J  Gynecol  Obstet 
2003; 83:85.

7.  Farage MA, Warren R. Emollients on the genital area. In: Surber 
C, Elsner P, Farage MA, eds. Topical Applications and the Mucosa. 
Switzerland: Basel. 2011; p. 101.

8.  Farage MA, Berardesca E, Maibach H. Skin moisturization and 
frictional effects of an emollient-treated menstrual pad with a 
foam core. Cutan Ocul Toxicol 2009; 28:25.

9.  Farage  MA.  The  Behind-the-Knee  test:  An  efficient  model  for 
evaluating mechanical and chemical irritation. Skin Res Technol 
2006; 12:73.

  10.  Farage  MA.  Evaluating  lotion  transfer  to  skin  from  feminine 

protection products. Skin Res Technol 2008; 14:35.

  11.  World  Medical  Association  World  Medical  Association 
Declaration of Helsinki: Ethical principles for medical research 
involving human subjects. JAMA 2000; 284:3043.

  12.  Farage MA. A behind-the-scenes look at the safety assessment 
of feminine hygiene pads. Ann N Y Acad Sci 2006; 1092:66.
  13.  Farage  MA,  Tucker  HL,  Wang  F.  Assessment  of  pressure 
 generated by catamenial pads in genital and behind-the-knee 
sites in vivo. Open J Obstet Gynecol 2012; 2:116.

  14.  Farage  MA,  Wang  B,  Miller  KW,  Berardesca  E,  Wilhelm  K-P, 
Maibach HI. Test models to measure visible effects of lotion on 
skin: Protection, healing, and dryness. Household Personal Care 
Today 2012; 1:62.

  15.  Farage MA, Gilpin DA, Enane NA, Baldwin S. Development of a 
new test for mechanical irritation: Behind the knee as a test site. 
Skin Res Technol 2001; 7:193.

  16.  Farage  MA.  Development  of  a  modified  forearm  controlled 
application  test  method  for  evaluating  the  skin  mildness  of 
 disposable wipe products. J Soc Cosmet Chem 2000; 51:153.
  17.  Ertel  KD,  Keswick  BH,  Bryant  PB.  A  forearm  controlled 
 application  technique  for  estimating  the  relative  mildness  of 
personal cleansing products. J Soc Cosmet Chem 1995; 46:67.
  18.  Farage  MA.  Evaluating  lotion  transfer  from  products  to  skin 

using the behind-the-knee test. Skin Res Technol 2010; 16:243.

  19.  Farage  MA.  Using  the  behind-the-knee  test  to  evaluate  lotion 
transfer  from  products  to  skin.  In:  Baran  R,  and  Maibach  HI, 
eds. Handbook of Cosmetic Dermatology. 4th edition. Boca Raton, 
FL: CRC Press, 2010, p. 52.

  20.  Farage  MA,  Segarra  VS,  Bramante  M,  Elsner  P,  Maibach  HI. 
Dermatological  testing  of  an  emollient-treated  menstrual 
pad  with  a  novel  foam  absorbent  core.  Cutan  Ocul  Toxicol 
2008; 27:333.

  21.  Morel JG, Bokossa MC, Neerchal NK. Small sample correction 
for the variance of GEE estimators. Biomet J 2003; 45:395.

 
 
 
 
 
 
 
 
 
 
58

Assessing the Efficacy of Moisturizers

Whitney Hannon

INTRODUCTION
This chapter gives an introductory background to  practitioners 
in  cosmetic  dermatology  who  wish  to  better  understand 
the  science  behind  efficacy  claims  for  moisturizers.  In  an 
age  of   evidence-based  medicine  and  savvy  consumers,  it  is 
 increasingly  important  to  be  able  to  understand,  critically 
evaluate, and summarize the experiments used to evaluate the 
efficacy of moisturizers.

One  of  the  first  challenges  to  the  clinician  is  actually 
obtaining information about moisturizer efficacy. Most of the 
studies are not published because they are proprietary infor-
mation. Information can be requested from companies but can 
be time-consuming to obtain. The information that is readily 
available  is  often  incomplete  (for  example,  only  available  in 
abstract form) or in difficult or expensive to access journals or 
books. Once an article is obtained, the clinician is faced with 
the  second  challenge  of  understanding  a  study  that  is  often 
filled with technical jargon and unfamiliar instruments. Once 
the study is deciphered, the third challenge is for the clinician 
to critically appraise the validity of the information. For exam-
ple, the clinician needs to ask, “Was the experimental design of 
this study of sufficient quality to warrant trusting the conclu-
sions?” Examples of recommended moisturizer study designs 
are summarized by Grove (1). Fourthly, complex machines are 
often used to make skin measurements. The clinician needs to 
ask, “Was the machine used properly in this experiment?” and 
on a more advanced level, “did this machine really  accurately 

measure  the  variable  claimed  during  the  experiment?” 
A checklist of other important questions to ask when assessing 
the performance and validity of a machine has been developed 
by Serup (2).

Besides  the  difficulties  mentioned,  there  are  other 
 significant  but  more  subtle  issues  that  need  to  be  taken  into 
account. For example, moisturizers are often complex mixtures 
of  ingredients  that  may  have  interactive  properties.  In  other 
words, the composition of a moisturizer is more complex than 
simply  the  sum  of  its  independent  ingredients.  Interactions 
may  occur  between  water-binding  substances  (3)  and  theo-
retically also between any of the other ingredients including 
the  vehicle.  In  addition,  it  has  been  observed  that  the  indi-
vidual  component  has  different  properties  when  measured 
 individually than when measured as part of a combination (4).
In  summary,  the  quest  to  obtain  reliable,  useful  infor-
mation on the efficacy of moisturizers encounters three main 
categories of difficulties: problems with the availability/acces-
sibility of information, problems with the experimental design, 
and problems with the measurement technologies. Table 58.1 
lists specific issues in each of these categories, and the impli-
cations  that  these  problems  could  have  on  the  interpretation 
and validity of the information. This chapter attempts to assist 
the busy clinician to overcome these challenges by reviewing 
the  literature,  translating  some  of  the  jargon  and  identifying 
some  of  the  most  useful  and  comprehensive  evidence-based 
references.

Table 58.1  Problems with Moisturizer Efficacy Studies

Issues

Information access

Journals/books not easily accessible; full details 
not published

Implications

Missing data, publication bias

Experimental design
Patient selection

Study size
Controls

Volunteers
Histories not clearly stated, age/sex not always 

May not be representative of consumer population.
Population in unknown; biased population; clinical 

stated

extrapolation is difficult

Tends to be small
Often inadequate
Most studies only measured on one side rather 

May not be enough subjects to satisfy study objective
Cannot account for changes during experiment
Need to control for variation on different sides of body

than contralateral side

Often not stated whether or not other 

moisturizers/beauty products were used

Effects may be due to other moisturizers

Materials studied

Often studies not blinded and no placebo group
Materials used or concentrations not always 

Potential for bias
Cannot compare studies easily; moisturizer effects are 

stated

Range of concentrations often was not studied
Complex mixtures studied, not broken down into 
parts so that they could be compared and 
evaluated

presumably dose-responsive
No information on dose-response
Unable to separate effects

(Continued)

562 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.1  Problems with Moisturizer Efficacy Studies (Continued)

Issues

Implications

Measurements

Not enough time points
Often did not assess both TEWL and SC at the 

Gaps in information about time-course
Cannot make conclusions about hydration state

Statistics

General

Bioengineering 

methods

Operator-dependent

same time

Three-prong approach often not used: panelist 
self-appraisal, expert grader evaluation and 
relevant instrumental measures

Statistics not always used to analyze data
If statistics used, p values not always stated
Not enough studies
Few materials studied

Comparisons have no scientific basis
No knowledge of level of significance
No verification of findings
Large amount of materials have unknown efficacy

Potentially improper use of machines
Some studies have no statement of ambient 

Misleading data
Misleading data

conditions

Source: Hannon W, in Textbook of Cosmetic Dermatology, Fourth Edition, Robert Baran and Howard I Maibach, eds., London: Informa Health Care, 
2009. Also some information in original table was derived from text of Grove GL, in Clinical Safety and Efficacy Testing of Cosmetics, C Waggoner, 
ed., New York: Marcel Dekker, 1990, 121-48.

SUMMARY OF BIOENGINEERING 
TECHNIQUES
A  variety  of  bioengineering  techniques  have  been  used  to 
assess the efficacy of moisturizers on the human stratum cor-
neum. These techniques can be divided into measurements of:

1.  Skin surface contour
2.  Desquamation
3.  Elasticity (parallel to skin plane)
4.  Elasticity (perpendicular to skin plane)
5.  Other mechanical techniques
Indirect electrical properties
6. 
7.  Spectroscopy or thermal transfer
8.  Transepidermal water loss (TEWL)
9.  Stratum corneum imaging
10.  Optical characterization of skin properties

The Appendix to this chapter gives details of the  techniques, 
some  of  the  researchers  involved  in  the  development  of  the 
technology, names of different machines, variables measured, 
principles behind the technologies, and their respective advan-
tages and disadvantages.

Many  authors  (5–7)  have  reviewed  and  compared 
these  technologies.  Marks  (8)  took  a  unique  approach  by 
using  an  arbitrary  scale  to  compare  the  reproducibility,  sen-
sitivity,  and  directness  of  measurement,  capability  for  quan-
tization,   standardization,  cost-effectiveness,  ease  of  use,  and 
convenience.

SUMMARY OF EFFICACY DATA BASED 
ON STUDY TYPE, BIOENGINEERING 
TECHNIQUE, AND MOISTURIZER TYPE
Gabard (9) proposed a useful classification for studies on the 
efficacy of moisturizers. He divides the studies into five main 
types:

1.  Single application to normal skin
2.  Multiple applications of moisturizers over time to normal 

skin

3.  Moisturizer applied to experimentally irritated skin (one 

large irritant insult)

4.  Moisturizer applied to experimentally irritated skin (mild 

irritant applied repeatedly over time)

5.  Clinical  studies  in  which  moisturizer  was  applied  to 

groups of patients with various conditions

To allow evidence-based comparisons, studies can be further 
divided  by  the  bioengineering  technique  used  to  assess  the 
moisturizer  and  types  of  moisturizer  studied.  Some  of  the 
more  comprehensive  reviews  that  include  these  important 
variables and their conclusions are summarized in Table 58.2 
and the paragraphs that follow.

Agner  (10)  reviewed  the  literature  on   moisturizer  effi-
cacy  studies  and  summarized  the  findings.  Studies  reported 
were of Gabard study experimental design type 1, 2, 3, 4, and 5. 
The bioengineering technique used in these studies was pre-
dominantly TEWL. Various proprietary formulations of mois-
turizers were reported in the studies.

Hannon (11) reviewed moisturizer efficacy data as mea-
sured by the indirect electrical techniques (capacitance, conduc-
tance, impedance) in detail and identified 20 studies of Gabard 
study design type 1 (single application of moisturizer to normal 
skin). The conclusions are summarized as follows. Glycerol, urea, 
and petrolatum were the best-studied substances. One applica-
tion of urea, glycerol, petrolatum, hyaluronic acid, or hydroge-
nated phosphotidylcholine was capable of increasing stratum 
corneum hydration for at least several hours: urea for at least 
6 hours even if washed off, glycerol for at least 6 hours even if 
wiped off, and petrolatum for at least 2 hours (but not if it is 
wiped off). Water itself had a hydrating effect in the short term 
but eventually resulted in dehydration. The studies had many 
limitations, especially in the area of controls. For example, many 
studies did not  control for vehicle type (a very important variable) 
or ingredient interactions. Others failed to control for the follow-
ing complexities  associated with indirect electric measurements: 
for example, that 1) the capacitance ratio (moisturizer-treated-
skin  capacitance/untreated-skin capacitance) varies over time 
depending on type of moisturizer, or 2) electrical readings are 
not always proportional to the water present depending on the 
substance, or 3) each component of a moisturizer has its own elec-
trical properties that can be a source of false positive results (12).
Sivamani  (13)  reviewed  moisturizer  efficacy  data  as 
measured  by  various  mechanical  (tribological)  techniques 

 
Table 58.2  Selected Evidence Based Reviews of Moisturizer Efficacy Data

ASSESSING THE EFFICACY OF MOISTURIZERS 

 563

Review Author

Agner

year

2002

1,2,3,4,5

Gabard Classification 
of Studies Reviewed

Bioengineering Techniques 
Utilized In Studies

TEWL, electrical conductance, 
electrical capacitance, laser 
Doppler flowmetry, colorimetry

Indirect electrical techniques 
(capacitance, conductance, 
impedance)

Torsional skin elasticity
Mechanical (tribological)
TEWL, electrical capacitance, 
laser Doppler, colorimetry

Moisturizers Studied

Various proprietary formulations and 

others

Glycerol, urea, petrolatum, hyaluronic 

acid, hydrogenated 
phosphidylcholine and others
Glycerol, lactic acid, petrolatum
Various
Various proprietary formulations, 
Dimethicone, xantham gum, 
petrolatum and others

Hannon

2004

1

Agache
Sivamani
Yokota

2006
2006
2006

1,2
1,2
3,4

Fluhr

2008

5 (psoriasis)

TEWL, capacitance, evaporimetry

Urea, alpha-hydroxyacids (glycolic 

Crowther

Bauer

Crozier
Greenfield

Hon

Loden

2009

2010

2010
2012

2012

2012

1,2,3,4

5 (OIHD)

Confocal Raman 

microspectroscopy

TEWL

2,3,4
1,2,3,4,5
(hand eczema and 

ichthyosis)

5 (atopic dermatitis)

1,2,3,4,5
(atopic dermatitis, 

ichthyosis)

TEWL
TEWL, electrical capacitance, 

confocal Raman spectroscopy

TEWL, D-squame, evaporimeter, 
stereoimage optical topometer

TEWL

acid, lactic acid)
Omega fatty acids
niacinamide

Various proprietary formulations and 

barrier creams

Various proprietary formulations
Urea, ammonium lactate, lactic acid, 
petrolatum, various proprietary 
formulations and others
Rosmarinic acid and various 
proprietary formulations

Lipids, borage oils, fish oil, petrolatum, 

sunflower oil, canola oil, urea, 
glycerin, mineral oil, lactic acid, 
ammonium lactate, PCA, various 
proprietary formulations and others

and  found  that  there  were  limited  studies  for  Gabard  type  1 
and  type  2  experimental  designs.  Sivamani  concluded  that 
the water and moisturizers had similar effects on the friction 
coefficient except the effects of the creams/emollient lasted for 
hours and the water effects only lasted 5–20 minutes. Important 
variables in studies included the temperature of creams, ana-
tomic location, age of patient, and design of the test apparatus.
Agache  (14)  reviewed  moisturizer  efficacy  data  as  mea-
sured  by  torsional  measurements  of  skin  elasticity  (twistom-
etry)  for  both  Gabard  type  1  and  type  2  experimental  study 
designs.  The  conclusions  were  based  on  a  limited  number  of 
studies.  Some  of  the  results  were  somewhat  contradictory.  In 
most studies, glycerol and lactic acid had longer lasting effects 
than petrolatum. In one study, glycerol demonstrated increased 
elasticity up to 1 week. Other important variables noted were an 
increase in skin temperature with increased elasticity.

Yokota  (15)  systematically  reviewed  the  literature  pub-
lished between 1992 and 2006 on the efficacy of the moisturiz-
ers in prevention and treatment of irritant dermatitis on normal 
skin. Results were ten studies with Gabard type 3 experimental 
design. The studies included outcomes measured by the follow-
ing  bioengineering  techniques:  TEWL,  electrical  capacitance, 
and laser Doppler colorimetry. The studies involved moisturiz-
ers of various proprietary formulations, dimethicone, and others, 
as well as vehicles and controls. Conclusions from the quantita-
tive analysis were that direct comparisons between studies were 
difficult  due  to  study  designs  that  involved  different  anatomic 
sites and exposure durations. Two of the most comparable stud-
ies, however, by different authors, reported contradictory results.
Fluhr  (16)  reviewed  the  literature  for  moisturizer  effi-
cacy data in psoriasis (Gabard type 5 studies). Bioengineering 

methods used in the studies were TEWL and capacitance. He 
summarized  the  known  studies  for  the  following  moisturiz-
ers:  urea,  alpha-hydroxyacids  (glycolic  acid  and  lactic  acid), 
and omega-fatty acids.

Crowther  (17)  reviewed  moisturizer  efficacy  data  as 
measured  by  confocal  Raman  microspectroscopy  for  Gabard 
study design types 1, 2, 3, 4. Conclusions were that little differ-
ence was observed in moisturization on day 1. Over a 2-week 
period, use of moisturizers containing niacinamide was asso-
ciated with increased total skin hydration. Important variables 
to control included osmotic changes in skin based on moistur-
izer  properties  and  changes  in  stratum  corneum  thickness 
based on different types of moisturizers.

Bauer  (20)  conducted  a  Cochrane  systematic  review 
on  occupational  irritant  hand  dermatitis  (OIHD)  treatments 
including  moisturizers  and  barrier  creams.  Four  random-
ized  controlled  trials  (RCTs)  were  identified.  Bioengineering 
techniques  for  measurements  were  predominantly  TEWL. 
Moisturizers  studied  were  various  proprietary  formulations. 
Of the four identified RCTs, one RCT of Gabard type 5 is rel-
evant to the current review. This crossover design RCT showed 
that during the moisturizer use phase of the study, there were 
no cases of OIHD. However in the control phase of the study 
(no moisturizer use), 19 out of 93 participants developed OIHD.
Crozier  (18)  conducted  a  structured  systemic  review  of 
the literature published from 2000 to 2010 on skin care regimes 
for  normal  term  infants.  Nine  studies  of  Gabard  types  2,  3 
and 4 were identified. One study by Bartels (19) of 64 full term 
newborns  divided  into  four  groups  reported  lower  TEWL  in 
newborns  that  were  treated  with  a  proprietary  moisturizer 
compared with those treated with a control of no moisturizing 

 
564 

 TEXTBOOK OF COSMETIC DERMATOLOGY

cream.  The  other  eight  studies  involved  washing  products 
only without use of moisturizers and therefore were not of rel-
evance to the current review.

Greenfield  (23)  reviewed  moisturizer  efficacy  data  for 
Gabard type 1, 2, 3, 4, and 5 studies. The Gabard type 5 studies 
reviewed included the conditions of hand eczema and ichthy-
osis.  Bioengineering  techniques  used  to  assess  efficacy  were 
TEWL,  electrical  capacitance,  and  confocal  Raman  spectros-
copy. The following moisturizers were reviewed:  petrolatum, 
urea, lactic acid, and ammonium lactate and as well as some 
proprietary combinations.

Hon  (21)  reviewed  moisturizer  efficacy  data  for  atopic 
dermatitis  (Gabard  type  5).  The  following  bioengineering 
techniques  were  used  to  assess  efficacy:  TEWL,  D-squame, 
evaporimeter, and stereoimage optical topometer. Various pro-
prietary moisturizers and rosmarinic acid were studied.

Loden  (22)  reviewed  moisturizer  efficacy  data  for 
Gabard type 1, 2, 3, 4, and 5 studies. The Gabard type 5  studies 
that were reviewed included conditions such as ichthyosis and 
atopic dermatitis. The bioengineering technique used to assess 
efficacy  in  the  majority  of  studies  was  TEWL.  The  following 
moisturizers  were  reviewed:  borage  oil,  fish  oil,  petrolatum, 
sunflower  oil,  canola  oil,  urea,  glycerin,  mineral  oil,  lactic 
acid, ammonium lactate, and PCA as well as some proprietary 
formulations.

In  summary,  there  have  been  some  detailed  reviews 
of  moisturizer  efficacy  studies  that  employ  bioengineer-
ing   techniques  for  assessment.  More  work  is  needed  to  fully 
 summarize and analyze the extent of available information.

APPENDIX: BIOENGINEERING TECHNIQUES 
FOR ASSESSING MOISTURIZER EFFICACY

1.  Skin surface contour evaluation (Table 58.3)
2.  Desquamation (Table 58.4)
3.  Mechanical bioengineering techniques to measure elastic-

ity (parallel to skin surface plane) (Table 58.5)

4.  Mechanical bioengineering techniques measuring elastic-

ity (perpendicular to skin surface plane) (Table 58.6)

5.  Other mechanical properties (Table 58.7)
6.  Indirect electrical properties (Table 58.8)
7.  Spectroscopy or thermal transfer (Table 58.9)
8.  Transepidermal water loss (TEWL) (Table 58.10)
9.  Stratum corneum imaging (Table 58.11)
10.  Optical characterization of skin properties (Table 58.12)

The Tables that follow (Table 58.3 through Table 58.12) describe 
each  technique,  developer/machines,  parameters  measured/
calculated, principles, advantages and disadvantages.

Table 58.3  Bioengineering Techniques for Skin Surface Contour Evaluation

Technique

Developer/
Machines

Parameters
Measured/ 
Calculated

Low-power surface 
magnification (24)

8× lens 

magnifier

Skin surface 
contour

Profilometry 

(Mechanical)

Perth-o-Meter 
(1971) (25)

Surfometer 

(1975) (26)

Skin surface 
contour; 
roughness 
parameter

Surfcom 

(1979) (27)

Talysurf 

(1979) (28)

Anaglypho-
graphe 
(1982) (29)

Principles

Advantages

Disadvantages

Can visualize 
epidermis, 
epidermal–dermal 
junction and 
papillary dermis. 
Easy, non-invasive 
method. Augments 
naked-eye 
observation skills.

Replica 

measurements 
give absolute data. 
Can evaluate 
hydration status.

Place mineral oil on 
skin; cover with 
coverslip; observe 
skin under low power.

Cast replica of skin in 
silicone rubber is 
measured with a 
computerized stylus 
instrument, which 
produces plots of 
data. Valley and peak 
profile of SC flattens 
with hydration.

Technique has learning curve. 

Hard to visualize dry, scaly skin 
with this technique.

Complex and slow process. 

The application of silicone rubber 
may disrupt the surface; fine 
lines may be effaced 
when rubber cools; 
scales may be removed 
from subject. Needs a 
smooth, even surface (too many 
hair follicles, scars, tattoos, 
detergents, skin damage, or 
scaling can increase 
error). Stylus geometry 
can introduce errors (30). 
Sources of inter-observer 
variability are high-pass 
filters, low-pass filters and 
sampling intervals (30). 
Expensive (31). Profilometry 
can identify products that 
decrease amount of wrinkles but 
does not reveal mechanisms or 
safety of these products (irritants, 
for example, decrease wrinkling). 
Results in 2D only; show 
topography in one direction only.

Acquistion time = 8 minutes
Accuracy <10–3 mm

(Continued)

 
Table 58.3  Bioengineering Techniques for Skin Surface Contour Evaluation (Continued)

ASSESSING THE EFFICACY OF MOISTURIZERS 

 565

Technique

Profilometry 
(optical)

Developer/
Machines

Corcuff  

(1981) (32)

Parameters
Measured/ 
Calculated

Principles

Advantages

Disadvantages

Skin surface 
contour; 
roughness 
parameters; 
wrinkle

Cast replica of skin in 
silicone rubber is 
measured with an 
optical scanner (laser 
beam).

Gives absolute data; 
operating time 
reduced over 
mechanical 
method; non-
contact sensor; 3D 
data possible; fast 
acquisition time = 
< 1 minute.

Laser profilometry 
with densitometry

Gormley 

Contour; 

Photographic negative of 

Rapid measurement 

(1985) (33)

Barton  

(1987) (34)

roughness 
parameters; 
wrinkle 
quantification

Complex and slow process. The 
application of silicone rubber 
may disrupt the surface. Needs a 
smooth, even surface (too many 
hair follicles, scars, detergents, 
skin damage, or scaling can 
increase error); also unable to 
measure soft, fragile, liquid, high 
temperature objects; does not 
measure in real time; availability 
is limited due to sophistication.

Accuracy = 10–3 mm
Only provides a reconstruction 
and not an exact image, so 
smaller features may be 
overshadowed by larger ones 
and omitted from analysis (35). 
Less sensitive in screening 
normal volunteers. Very slow 
acquisition time = 10–30 
minutes. Cannot measure soft, 
fragile, liquid objects and 
objects at high temperature.

of skin surface relief 
without 
cumbersome 
equipment (35). 
Good for following 
clinical progression 
of scaling disorders. 
Most accurate of all 
profilometry 
techniques (10–5 
mm). Can plot 105 
points.

Can determine 

Accuracy = 5 × 10–3 mm

altitude at each 
point. Plots more 
points (106) than 
any other 
proliferometry 
method. Fast 
acquisition = 
1 minute.

Measures small 

Very shallow depth of field (500 

micrometers)

Accuracy= 10 × 10–3 mm

Inconvenient. Technique less 
useful for very dry skin.

plane area of 1 
cm2. Can plot 105 
points. Very fast 
acquisition 
= <1min,

More objective, 

quantifiable images 
(shape, color) than 
clinic notes. 
Interactive; can be 
queried, altered, 
analyzed 
automatically and 
rapidly in real time. 
Permanent record; 
data easily stored. 
In vivo, direct 
measurement of 
surface possible. 
Good for evaluation 
of low to moderate 
dryness.

(Continued)

skin taken under 
standard light (oblique 
illumination with 
incident angle of 25°). 
Shadows formed are 
scanned 
microdensitometrically 
by a computer and 
gray level assigned. 
The relief is 
reconstructed indirectly 
from gray level and 
using appropriate 
algorithms, slopes and 
roughness parameters 
of relief can be 
calculated.

Calculates a phase 
image from the 
interference fringe 
image projection.

Measures the variation 
of absorbance which 
is related to 
transparency and 
therefore thickness of 
the replica according 
to Beer–Lambert’s law.

Using video camera, 
can record skin 
surface features 
directly. Signal is 
digitized using a 
high-speed analog/
digital converter and 
arranged into an array 
of picture points. The 
picture points are 
introduced into a 
digital image 
processor that 
interfaces with a 
minicomputer. Filters 
(mathematical sieves) 
can be used to 
enhance detail.

Proliferometry
(interference)

Surface 

contour

Altmeyer 

(1995) (119) 
Lagarde 
(2001) (120) 
Dermatop 
(Eotech)

Transparency 

De Paepe 

(transmission) 
proliferometry

(2001) (121)

Skin 

visiometer 
SV600

Thickness, 
surface 
contour

In vivo image 

Picton (1976) 

Surface 

analysis (digital 
image 
processing)

(36)

contour

Taylor (1978) 

(37)

Quantimet 

(36)
Magiscan 
(37)

 
566 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.3  Bioengineering Techniques for Skin Surface Contour Evaluation (Continued)

Developer/
Machines

Parameters
Measured/ 
Calculated

Principles

Advantages

Disadvantages

Technique

Scanning 

Marshall 

Surface 

Low magnification 

Good for the 

microdensitometry 
of 
macrophotographs

(1983) (123)

contour; 
roughness 
parameters

assessment of 
clinical progression 
in patients with 
scaling disorders.

photomicrographs are 
taken under 
standardized light 
scanned with 
microdensitometer 
which records 
shadows and 
highlights and 
produces a contour 
line similar to 
profilometry.

Not so good for normal skin 
assessment; still needs 
additional improvements.

Note: Topography measurements can be used to demonstrate changes in amount of wrinkling and state of stratum corneum hydration as noted by 
attenuation of the relief due to increase in turgor.

Table 58.4  Bioengineering Techniques to Measure Desquamation (38)

Technique

References

Principles

Advantages

Disadvantages

Squametry of tape 

strippings

Wolf (1936) (39)
Jenkins (1969) (40)

Sticky slide (38)

Goldschmidt (1967), 

Dermatology Lab and 
Supply Co

Skin surface biopsy with 

Marks (1971) (42)

microscopy

Simple, non-invasive, 

Need to assure clean 

painless, more 
reproducible, 
objective and 
consistent than 
traditional grading 
systems.

More reproducible, 
objective and 
consistent than 
traditional clinical 
grading systems. 
Quantification/
standardization of 
desquamation 
possible. More 
quantitative than skin 
scraping because 
fixed area is sampled 
and loss of material to 
air currents is more 
controlled.

Simple, non-invasive, 
painless. Removes 
more stratum 
corneum than 
pressure-sensitive 
adhesives.

conditions. Tapes not 
necessarily well 
characterized in terms 
of component 
properties. Need to 
precut tape under 
clean conditions; all 
squametry techniques 
are better as a 
screen for dry skin 
than as a 
quantitative method to 
assess skin 
moisturizers (106).

Prepared slides have 
limited life due to 
gradual air oxidation 
of adhesive surface. 
Need skill and 
practice to perform. 
Need careful storage 
and handling to 
prevent 
contamination.

More difficult to 

standardize. Skill 
involved.

Tape pressed against 
skin; outermost 
portion of skin sticks 
to tape and keeps 
topographical 
relationship and 
desquamation 
pattern. Tapes are 
processed. Scales are 
sized and counted. 
Samples stained and 
viewed with 
microscope (visual 
scoring).

Prepare slide by coating 
with adhesive solution 
and allow organic 
solid to evaporate. 
Press on skin, leave 
on skin for a few 
seconds, remove and 
process.

Cyanoacrylate glue is 
spread on a flexible 
plastic slide and 
applied firmly to skin 
for 30 sec. Three to 
five layers of 
corneocytes are 
detached, stained, 
viewed under 
microscope, and 
classified into one of 
5 xerosis 
classifications.

(Continued)

 
Table 58.4  Bioengineering Techniques to Measure Desquamation (38) (Continued)

Technique

References

Principles

Advantages

Disadvantages

ASSESSING THE EFFICACY OF MOISTURIZERS 

 567

D-Squame® (CuDerm Co, 
Dallas, TX) analysis 
using light transmission

Serup (1989) (103)

D-Squame (CuDerm Co, 
Dallas, TX) analysis 
using image analysis

Schatz (1993) (105)

Small transparent tape 
discs are pressed 
against the skin; 
analysis of discs 
using light 
transmission.

Small transparent tape 
discs are pressed 
against the skin; 
analysis of discs 
using image analysis.

Adhesive disc squametry 

Pierard (1992) (104)

Small transparent 

combined with 
Chromameter (Minolta) 
and image analysis

adhesive discs are 
pressed against skin. 
Corneocytes stained 
and viewed under 
microscope, and 
intensity of stain. 
measured with a 
chromameter. 
Quantitative 
xerosis (based on 
stain intensity). 
Image analysis 
reveals number, 
thickness and size of 
squames.

Simple, non-invasive, 

painless; 
standardized, easy to 
use.

Small disc size prone to 
sampling error. May 
need to delipidize skin 
to remove scales.

Image analysis can be 
expensive but more 
cost-effective 
machines are being 
developed (107).

Small disc size more 
prone to sampling 
error. May need to 
delipidize skin to 
remove scales more 
effectively. Image 
analysis is expensive/
technical luxury (41).

Chromometry may add 
additional precision.

Simple, non-invasive, 
painless. Allows 
quantitative 
assessments of 
xerosis. Eliminates 
many of difficulties 
involved with tape and 
sticky slides because 
it is specially 
formulated and readily 
available. Three 
standard sizes. Easy 
storage and use.

Table 58.5  Mechanical Bioengineering Techniques to Measure Elasticity (Parallel to Skin)

Technique

Parameters 
Measured

Machines Available/
Developer

Principles

Advantages

Disadvantages

Extensometry

Material 

Extensiometer ® 

The arms of two strain 

Can be hand-held. 

constants

(Thacker 1977) 
(43)

Gunner (1978) (44)

In vivo 
measurements 
possible.

gauges are stuck to the 
skin surface using 
adhesive tape. By means 
of a lead screw and carrier, 
a motor and gear 
combination moves one 
arm away from the other at 
a constant rate, stretching 
the skin between the tabs. 
The separation of tabs is 
measured with a linear 
variable differential 
transformer (LVDT) 
transducer, and the force 
developed in the skin is 
measured by strain gauges 
attached to the reduced 
sections of the arms. 
Recoil apparatus can be 
installed to measure 
extension–time 
characteristics of skin 
when deforming force is 
removed (44).

Strain gauges are 
stiff, and may 
impose frictional 
forces. Some 
systems are bulky 
and not convenient 
for clinical use. 
Technique deforms 
fiber network in 
skin so sequential 
measurements 
may be 
increasingly 
effected by prior 
measurements.

(Continued)

 
568 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.5  Mechanical Bioengineering Techniques to Measure Elasticity (Parallel to Skin) (Continued)

Technique

Parameters 
Measured

Machines Available/
Developer

Principles

Advantages

Disadvantages

Hargens  

(1977) (45)

Gas-bearing 

Dynamic 

electrodynamo-
meter (GBE)

spring rate 
(DSR) 
(analogous 
to Young’s 
elastic 
modulus); 
loss angle 
(stiffness, 
softness, 
and 
compliance)

Linear skin 

rheometer 
(LSR)

DSR

Matts et al  

(1998) (86)

GBE measures 

Good for 

May measure 

displacement of skin in 
response to a rapidly 
oscillating force placed 
next to its surface. 
Dynamic stress–strain 
loop appears on 
oscilloscope, which can 
be analyzed. Application 
of moisturizer to the skin 
surface results in a 
decrease in the DSR and 
a concomitant increase in 
the loss angle.

dermal compo-
nents as well. 
Changes 
perceived by 
trained subjects 
may not corre-
spond to GBE 
measurements. 
Manual stretch-
ing of skin can 
change baseline. 
Thickness of SC, 
size, and 
geometric 
arrangement of 
corneocytes, and 
chemical 
composition 
differences may 
influence 
measure-
ments (45).

quantifying 
stiffness in 
surface plane of 
skin, i.e. 
SC. High 
degree of 
correlation 
between 
elastic modulus 
measurements 
and visual 
assessments of 
skin by a 
trained grader. 
Sensitive 
enough to 
measure 
changes in SC 
induced by 
topically applied 
agents or 
mechanical 
disruption (45). 
Can apply small 
forces. 
Measurement is 
direct rather 
than implied 
from 
inference, as 
is the case with 
electrical 
conductivity or 
sonic 
propagation.

More compact, 
efficient with 
greater inherent 
accuracy than 
the GBE and 
reduced service 
requirements. It 
can differentiate 
between varying 
degrees of SC 
hydration (87).

Not readily 
available. 
Technique 
deforms fiber 
network in skin 
so sequential 
measurements 
may be 
increasingly 
effected by prior 
measurements.

Has the same measuring 

principles as GBE 
but none of the 
components. Instead 
of a magnet/solenoid 
as in the GBE, there is a 
force-controlled 
miniature DC 
servo, gearing, and 
lead screw. Instead of the 
linear variable 
differential transformer, 
there is a calibrated load 
beam. The 
machine interfaces with a 
portable computer 
containing user-friendly 
software.

(Continued)

 
Table 58.5  Mechanical Bioengineering Techniques to Measure Elasticity (Parallel to Skin) (Continued)

ASSESSING THE EFFICACY OF MOISTURIZERS 

 569

Parameters 
Measured

Machines Available/
Developer

Principles

Advantages

Disadvantages

Technique

Torque meters 

(disproportional 
strain 
measurements)

Torque and 
phase 
angle-
extensibility 
(resistance 
to stretch), 
viscoelastic 
properties

Vlasblom (1967) 

Disc attached to skin with 

(46)

Finlay (1970) (47) 
Twistometre® 
(Leveque, 
L’Oreal); Dermal 
Torque Meter ® 
(Dia-stron Ltd, 
Andover, UK)
Barbenel (1977) 

(48)

adhesive. Weak, constant 
torque applied to rotating 
disc. Movement of disc 
monitored by rotational 
sensor. Fixed guard ring 
delineates area. When 
distance between disc 
and guard ring is less 
than 1 mm, extensibility 
reflects SC resistance to 
stretch. Microprocessor 
computes main 
parameters. Immediate 
rotation corresponds to 
immediate extensibility, 
followed by slow increase 
corresponding to 
“creeping” of the viscous 
and plastic skin 
characteristics.

Sensitive in both 
short- and 
long-term 
studies rating 
hydrating 
efficacy. Clear 
correlation 
between SC 
extensibility and 
severity of 
dryness. 
Measurements 
made parallel to 
skin surface, so 
effect of links 
between dermis 
and hypodermis 
are minimized. 
Can be used to 
describe 
mechanical 
changes in skin 
with aging, sun 
exposure, and 
scleroderma 
(49). Weibull or 
extreme-value 
distribution is 
more accurate 
and sensitive 
than other 
torsion 
methods (47).
Can study elastic 

tissues or 
viscous 
parameters in 
living soft tissue.

Standardization not 

yet complete 
(47). Technique 
deforms fiber 
network in skin 
so sequential 
measurements 
may be 
increasingly 
effected by prior 
measurements.

Technical difficulties 
still need to be 
overcome. 
Technique 
deforms fiber 
network in skin 
so sequential 
measurements 
may be 
increasingly 
effected by prior 
measurements.

Mechanical 
impedance

Point 

impedance

Franke (1950) (50)
Von Gierke  
(1952) (51)
Swept-frequency 
viscoelasto-
meter (51)

Impedance head is 
mounted on an 
electromagnetic actuator 
or shaker, which is driven 
by a swept sinuisoidal 
voltage. Corrected force 
and velocity signals are 
inputed into RMS circuits 
and then to a log-ratio 
amplifier to obtain output 
proportional to log 
mechanical impedance. 
Phase angle between 
force and velocity signals 
obtained via a phase 
meter. Phase angle and 
log-impedance used as 
vertical drive signals to a 
multichannel display 
multiplexor on an XY 
storage display 
oscilloscope. Horizontal 
drive obtained from 
frequency to voltage 
converter and log-
amplifier. Thus real-time 
plots of log Z vs log of 
frequency can be 
obtained.

 
570 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.6  Mechanical Bioengineering Techniques Measuring Elasticity (Acting Perpendicular to Plane of Skin Surface) (53)

Technique

Suction chamber 
(disproportional 
superficial 
strain)

Machines/
Developer

Cutometer (SEM 
474 (Courage 
and Khazaka); 
Cutometer ® 
580MPA (134)

Parameters 
Measured/
Calculated

Stiffness 

(distensibility, 
resilient 
distensibility, 
hysteresis); 
elasticity 
(relative 
elastic 
retraction 
[RER])

Principles

Advantages

Disadvantages

More useful for 

Type of strain 

A suction probe is applied 
vertically on the skin 
with a constant 
pressure. The amount of 
skin elevation is 
measured using an 
optical system, which 
measures the decrease 
in intensity of an 
infrared beam. The 
instrument interfaces 
with an IBM personal 
computer, and standard 
software provided 
allows the storage of 
data concerning 
important variables and 
graphical display of 
stress-vs-strain and 
strain-vs-time curves.

cosmetological 
purposes, 
which aim to 
measure 
mechanical 
properties of 
epidermis and 
papillary 
dermis. 
Measurements 
can be 
enhanced by 
use of optical 
elastography 
(132). 
Cutometer ® 
580MPA (134) 
was developed 
for use on the 
foot.

Suction chamber 
(proportional 
full-thickness 
strain)

Material 

Grahame (1970) 

constants 
(stiffness, 
resilience, 
distensibility); 
hysteresis; 
elasticity 
(RER)

(54); Gniadecka, 
Serup 
(Dermaflex A, 
Denmark) (88), 
Serup 
(Dermalab) (89)

Dermagraph

Distensibility, 

relaxation, and 
elasticity

Sclerimeter ® (90); 
Dermagraph (91)

A suction probe is placed 
directly on the skin. An 
electronic sensor in the 
probe measures the 
amount of skin elevation 
by measuring the 
electric capacitance 
between the skin 
surface and the 
electrode placed in the 
top of the suction 
chamber. The data are 
collected and can be 
visualized. Skin 
distensibility and 
hysteresis 
increase slightly after 
epidermal 
moisturizing (55).

Larger probe is 

more useful for 
medical and 
dermatological 
applications, 
for example in 
scleroderma 
and chronically 
inflamed skin; 
Dermalab can 
be mounted 
with special 
probes to 
measure 
TEWL and skin 
hydration as 
well.

A vacuum probe is 

Good intra- and 

placed on skin. Constant 
vacuum is applied for 6 
sec and the amount of 
aspirated skin (mm) is 
measured 
(distention phase). 
There is then a 4-sec 
phase of slow 
relaxation (elastic 
retraction).

interrater 
realiability. Able 
to measure 
accurately and 
rapidly different 
areas relevant 
to patients with 
scleroderma.

measured may be 
irrelevant to 
common practice. 
May still measure 
mechanical 
properties of the 
deeper layers of 
dermis and 
subcutis to an 
unknown 
extent; limited in 
range of 
viscoelasticity; 
complex 
measuring units; 
data can be difficult 
to interpret; cannot 
measure 
viscoelasticity 
of more rigid 
skin; cannot 
evaluate skin 
anisotrophy; 
seforms skin 
making sequential 
measurements 
difficult.

Correlation of 
separate 
parameters of skin 
mechanical 
properties with 
structural elements 
of skin not fully 
elucidated. Must 
control for 
numerous 
biological and 
environmental 
variables (56). 
Must avoid 
repeated 
measurements at 
same site for at 
least 1 hour due 
to skin 
deformation.

Not readily available, 
some anatomic 
areas more difficult 
to measure 
reliably; normal 
skin more difficult 
to measure reliably. 
Deforms skin, 
making sequential 
measurements 
difficult.

(Continued)

 
Table 58.6  Mechanical Bioengineering Techniques Measuring Elasticity (Acting Perpendicular to Plane of Skin Surface) (53) 
(Continued)

ASSESSING THE EFFICACY OF MOISTURIZERS 

 571

Technique

Levarometry, 
tonometry

Parameters 
Measured/
Calculated

Index of 

deformability; 
skin 
extensibility 
(skin 
slackness); 
biological 
elasticity

Machines/
Developer

Levometer:Dikstein 
(1979) (57) and 
Gartstein (1990) 
(58)

Tonometry; Pierard 

(1980) (59)

Ballistometry (61)

Coefficient of 
restitution 
(amount of 
energy 
returned to the 
tissue)

Tosti (1977) (62); 
Ballistometer

Integrated Dynamic 

Rebound 
analyzer (IDRA) 
PC-based 
ballistomer (94)

Indentometry (63) Skin 

Schade 

compressibility

(Elastometer, 
1912); Kirk (1949); 
Tregear (1965); 
Robertson (1969); 
Daly (1974); 
Pierard (1984); 
Dikstein (1981)

Principles

Advantages

Disadvantages

Not currently 

commercially 
available. Deforms 
skin, making 
sequential 
measurements 
difficult.

The method is 
sensitive and 
reproducible. 
Topical 
applications or 
environmental 
conditions 
probably do not 
affect 
measurements 
(60). Highly 
discriminating 
between old and 
young skin and 
old female and 
old male skin.

Non-invasive. Easy 

Cannot obtain data 

on status of 
stratum corneum, 
as one can from 
shear 
measurement. 
Gives only an 
indirect indication 
of underlying 
tissue changes.

Deforms skin, 

making sequential 
measurements 
difficult.

Not the best method 
to discriminate 
between old and 
young skin or 
female and male 
skin.

Deforms skin, 

making sequential 
measurements 
difficult.

to use. No 
probes attached 
to skin. 
Instrument is 
cheaper than 
dynamometer. 
Good for 
measuring 
elastic 
parameters in 
deeper dermal 
structures. Can 
measure 
differences in 
elastic modulus 
between young 
and old, various 
body sites and 
changes after 
pharmaceutical 
treatment. Can 
obtain a lot of 
data quickly.

Good for 

measuring 
water state of 
ground 
substance–
elastin network 
in dermis; most 
useful in 
evaluating 
edematous 
skin conditions 
and altered 
water handling 
of the dermis.

The skin is attached 

(using Perspex disc and 
double adhesive tape 
(Dikstein), or 
cyanoacrylate (Pierard), 
or vacuum (Gartstein) 
with (Pierard) or without 
(Dikstein) a guard ring) 
to a counterbalanced 
measuring rod. Different 
weights can be applied, 
elevating the skin. For 
Dikstein’s levarometer, 
the rod is attached to a 
linear variable 
differential transformer, 
and this output is 
recorded graphically.
Measurement of a drop 
impact of a body onto 
the skin

A circular piece of plastic 
material attached to a 
weighted metal rod is 
applied perpendicularly 
to the skin to indent the 
skin. The rod is 
counterbalanced so that 
the net pressure in the 
system is a given value. 
The measuring rod is 
loaded with specially 
constructed weights 
increasing the baseline 
pressure to the desired 
level (57). The rod is 
attached to a linear 
variable differential 
transformer, and the 
output of the deformation 
curve can be plotted 
using various methods.

 
Very simple to use, 

Measurements 

572 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.7  Other Mechanical Bioengineering Techniques

Technique

Coefficient-of-

friction devices

Parameters 
Measured/
Calculated

Coefficient of 
friction 
(oiliness/
greasiness)

Machines/
Developer

Rotating wheel 

(Teflon Newcastle 
friction meter); 
resolving ground 
glass disc; sliding 
sled, modified 
viscometer

Principles

Friction of human skin in 
vivo can be measured 
by determining how 
much force is required 
to drag object across 
skin surface; smoother 
or drier skin 
theoretically needs 
less force.

Advantages

Good for 

screeningtopicals for 
after-feel greasiness 
(64). Some machines 
are portable. 
Measurements with 
Newcastle machine 
can correlate with 
sensory scores of 
smoothness.

Scratch-

resistance test

Hardness, 
softness

Prall (1973) (95)

Durometer (92)

Hardness

Durometer model 
1700 type 00 
(Rex Gauge)(93)

A stylus just visibly 
scratches skin; 
measure lowest 
pressure load.

A calibrated gauge with 
spring loaded interior 
that senses hardness by 
placing an indentation 
load on the specimen. It 
registers linearly the 
relative degree of 
hardness on a scale of 
units 0–100.

Can reveal underlying 
defects not seen at 
first glance.

portable, hand-held; 
highly reproducible. 
Good for measuring 
scleroderma, 
lipodermatosclerosis, 
and neuropathic foot 
hyperkeratosis.

Microintentometer

Pliability, 

Identometer (96) 

Indentation of the SC by 

One of the few 

hardness

(Guibarra, 1979); 
Microindentometer 
(97)(Graves, 2002)

a needle is opposed by 
the horny layer, and 
this force of reaction is 
monitored by a force 
tranducer.

devices available to 
measure pliability 
and hardness of 
SC.

Acoustic 

Softness, 

Tronnier (1952) 

Vibration device in 

Can be used as 

spectrometer 
(65)

(66); Potts (1985) 
(67); Torgalkar 
(1981) (65)

hydration 
level; energy 
loss of 
viscous 
component 
of skin; 
elastic 
modulus

predictive measure. 
Indirect measure of 
hydration state. 
Correlated with 
subjective 
assessments of 
moisturization.

audible range gives 
small-amplitude 
oscillations normal to 
skin surface with 
second stylus as 
comparison. Spectrum 
analyzer can calculate 
time for shear waves to 
travel and degree of 
amplitude dampening; 
resonance frequency 
can be measured. The 
more SC hydration, the 
lower the resonance 
frequency. Energy loss 
can also be calculated. 
Can be used as 
predictive measure. 
Indirect measure of 
hydration state. 
Correlated with 
subjective 
assessments of 
moisturization.

Disadvantages

Interpretation of 
differences in 
frictional 
properties 
between 
products are 
very complex. 
Moisturizers can 
increase friction 
as a result of 
increased 
contact area. 
Lubricants make 
skin more 
slippery.
Somewhat 
invasive.

should be made 
in the supine 
position. May be 
insensitive in 
areas with 
decreased 
subcutaneous 
tissue.

Must immobilize 
area that is 
being measured 
since movement 
or vibration will 
alter 
measurements. 
Needs further 
development to 
eliminate inertial 
artifacts.
Thickness of 
horny layer, 
thickness and 
tension of the 
skin and nature 
of underlying 
tissues can be 
sources of error.

(Continued)

 
Table 58.7  Other Mechanical Bioengineering Techniques (Continued)

ASSESSING THE EFFICACY OF MOISTURIZERS 

 573

Technique

Viscoelasticity 
skin analyzer 
(VESA)

Parameters 
Measured/
Calculated

Elasticity, shear 

waves 
propagation 
(SWP)

Machines/
Developer

Sarvazyan (1990) 
(112); Vexler 
(1999) (113)

Tactile sensor
(Venustrom®) 

(100)

Omata (1999) (99); 
Sakai (2000) 
(100)

Changes in 
resonant 
frequency 
(∆f) correlate 
with spring 
constant k 
and stiffness; 
elasticity

Cohesography

Intracorneal 
cohesion 
measurements

Nicholls (1971); 

Marks (1977) (31)

Reviscometer ® 

Resonance 

RVM600

(133)

running time 
(RRT)

Principles

Advantages

Disadvantages

Probe consists of three 

piezoelectric 
transducers (central 
transmitter with two 
receivers equidistant 
on either side). 
Transmitter produces a 
tangential oscillatory 
deformation on the 
surface of the skin 
(SWP) in the acoustic 
frequency range. SWP 
is calculated from the 
time of flight of signal 
to transmitter. Average 
reading displayed on 
LCD.

Sensor with resonant 

frequency is pressed 
and released from the 
skin at a constant rate. 
Depth and pressure 
are determined 
allowing hysteresis 
curve /∆f calculation.

After hydrating SC, there 
is a drop in intracorneal 
cohesion. Drop follows 
same magnitude as 
flattening in surface 
contour, and changes 
are of same order of 
magnitude (31).

RRT is inversely related 
to skin stiffness (133).

Allows anisotrophic 
measurements; 
compact; portable, 
user-friendly; high 
accuracy; 
reproducible 
readings; 
measurements 
using this 
technique do not 
deform the skin as 
with distortion, 
rotation, stretch or 
suction so 
sequential 
measurements are 
possible; allows 
measurements of 
upper skin layers 
without influence of 
subdermis.

Simple; allows rapid 
determination of 
multiple stiffness 
parameters; 
correlated with 
firmness 
(dehydration of 
skin), ratio of acidic 
amino acids, and 
elasticity.
Able to assess 

hydrating agents.

Better able to 
discriminate 
between 
experimental 
treatments than 
cutometer. 
Measurements 
most sensitive on 
transverse forearm 
(133).

Not readily 
available.

Significance of 
correlation 
needs further 
investigation.

Not generally 

commercially 
available (31).

Sensitivity may 

differ depending 
on anatomic site 
(133).

Table 58.8 

 Indirect Electrical Bioengineering Techniques

Technique

Developer/Machines

Principles

Advantages

Disadvantages

Clar (1975) (138)

Low-frequency 
impedance 
(frequency 
domain)

Impedance drops with 
increasing hydration. 
Frequency-domain 
approaches examine 
the response of skin to 
sinusoidal stimulating 
frequencies.

Low frequencies give 

Need liquid junction. 

most informative data 
about physiological 
condition of skin overall 
because charge 
carriers can travel more 
time before field 
reverses (47).

Electrodes are occlusive. 
Long time needed for data 
collection (>20 min). Agents 
other than water can lower 
impedance. Measurements 
are quantitative rather than 
qualitative.

(Continued)

 
574 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.8 

 Indirect Electrical Bioengineering Techniques (Continued)

Technique

Developer/Machines

Principles

Advantages

Disadvantages

Tregear (1965) (68)

High-frequency 
impedance 
(3.5mHz) 
(frequency 
domain)

Impedance 

(capacitance 
calculated)

Nova DPM-9003 
(Dermal Phase 
Meter)

Impedance drops with 
increasing hydration. 
Impedance decreased 
with increasing 
frequency. Higher 
frequency, more skin 
penetration.

Integrates selected 
measurements at 
varying frequencies of 
the applied alternating 
current. Capacitance is 
calculated from the 
signal phase delay 
using a proprietary chip. 
Final readout is in 
arbitrary units related to 
capacitance.

Impedance 
(surface 
characterizing)

Surface-

characterizing 
impedance 
monitor (SCIM) 
(Servo-Med, 
Sweden)

Impedance is dependent 
on tissue hydration, 
composition, and 
condition. SCIM 
measures impedance 
magnitude and phase at 
31 frequencies to five 
selectable depths.

Capacitance

Corneometer 

Capacitance increases 

(Courage and 
Khazaka, 
Germany)

with increasing 
hydration. The 
Corneometer uses 
variable frequencies in 
the low-frequency range 
(40–75Hz); <75 
dehydrated skin; 75–90 
skin with tendency to 
dehydrate, >90 normal 
skin (arbitrary units) 
(35).

Conductance

Skicon 100, 200 

(Masuda, IBS Co, 
Ltd)

Uses a fixed frequency 
(3.5mHz) to measure 
conductance and 
capacitance separately.

Provides information on 
deeper levels of skin; 
can use dry electrodes.

Good for assessing 

highly hydrated skin 
due to low variability of 
readings (69). Due to 
monofrequency 
approach, subject to 
less error, less 
confounding variables, 
and has increased 
sensitivity and 
specificity (less 
false-positives and 
false-negatives) when 
compared with 
single-frequency 
machines; handling 
easy due to small 
dimensions and low 
weight.

Uses the intrinsically 
more informative 
multifrequency 
approach, which is 
independent of 
changes in sweat gland 
activity, skin 
temperature, 
confounding variables. 
Allows electrical 
impedance 
spectroscopy of 
selected layers.

Easy to operate. Highly 
reproducible (35,69). 
Short measuring time 
(1s). Economical (69). 
Useful for extremely 
dry scaly skin. 
Information can be 
enhanced and 
nonhomogeneity of 
skin can be accounted 
for by using 
capacitance images for 
example SkinChip  
(129).

Dry electrodes can be 
used. Correlates well 
with water content of 
superficial and deep 
SC layers. Suitable to 
assess the hydration 
dynamics of the SC 
induced in the skin. Not 
affected by electrolyte-
rich solutions (71).

Occludes site. Depth of SC not 
well defined. Agents other 
than water can affect 
readings. Pressure of probe 
and dermal irritants can 
influence readings. Cannot 
measure resistance and 
capacitance separately at 
high frequencies.

Less sensitive for grading the 

dry state than the 
Corneometer (72). Agents 
other than water affect 
measurements.

Same disadvantages as with 
many electrical methods. 
Must use probe correctly 
(perpendicular, with correct 
pressure); wait 5s between 
repeating measurements on 
same site to avoid occlusion. 
Measurement failures with 
wet surface, dirt. Must 
perform measurements 
under appropriate ambient 
conditions (<22°C and 
= 60% RH).

Confined to measurement of 
variation in SC between 
initial and final states (35). 
Poor sensitivity to hydration 
process taking place in SC 
of normal skin because 
optimal range of water 
content in the SC for the 
capacitance method is much 
lower than for high-
frequency conductance 
methods.

Single-frequency approach 
subject to more error, 
confounding variables, 
decreased sensitivity and 
specificity (increased 
false-positives and false-
negatives) when compared 
with multifrequency 
machines (47). Current must 
propagate at least 5 mm to 
obtain reliable values.

(Continued)

 
Table 58.8 

 Indirect Electrical Bioengineering Techniques (Continued)

Technique

Developer/Machines

Principles

Advantages

Disadvantages

ASSESSING THE EFFICACY OF MOISTURIZERS 

 575

High-frequency 

Jacques (1979) 

Dielectric probe response 

microwave (GHz)

(124)

Wavetek 1005

(DPR) (70) a 
percentage based on 
the probe’s response to 
skin versus a drop of 
water. A signal swept 
several mHz around a 
GHz resonates in a 
cable. Charged grid 
contacts skin, water 
absorbs energy and 
produces a standing 
wave shift, detection of 
which is adjusted to be 
linearly proportional to 
hydration level.

DPR is not a true hydration 

percentage.

Detects quantitative 
differences. Rapid 
quantitation. Unaffected 
by topicals. SC probe 
depth varies. DPR 
basic unit is useful for 
comparisons.

Millimeter wave 
reflectivity

Alexseev, Szabo, 
Ziskin (2008) 
(131)

Analysis of reflection of 

Good for measuring 

Not so sensitive for areas of 

areas of thick stratum 
corneum such as 
palms in vivo.

thin skin.

millimeter (mm) 
wavelength 
electromagnetic waves. 
Amount of reflection 
depends on electric 
property of skin 
(permittivity). Permittivity 
depends on free water 
content of skin. Free 
water content can be 
calculated from 
permittivity values using 
skin mode (131).

Note: The general advantages of these techniques are that they provide easy to measure, continuous data on skin hydration status and are readily 
available commercially.

Table 58.9  Bioengineering Techniques Based on Spectroscopy or Thermal Transfer

Technique

Developer/Machines

Principles

Advantages

Disadvantages

Fourier-transformed 

1970s

infrared spectroscopy 
(ATR-FTIR) 
(attenuated total 
reflectance)

Beam of polychromatic IR 
light is shone through a 
zinc or germanium 
selenide crystal applied to 
skin surface. Crystal 
creates 5–20 reflections, 
and absorption cycles 
between crystal and skin. 
Reflected beam is 
detected by 
spectrophotometer, 
Fourier transform of beam 
gives IR spectrum with 
bands of absorption in 
SC. Ratio of areas of 
amide I and II bands 
(peaks) provides relative 
SC water content. Amide I 
at 1645 cm (44) is 
overlapped by band of 
protein-associated water, 
and thus will change with 
protein water content, 
whereas amide II at 
1545cm (44) is not 
influenced by water (35).

In vivo, direct measurement of 

Expensive. Need 

water. Quantitative, 
theoretical relationship 
between measured 
parameter and water 
concentration understood.

signal averaging 
during time 
when site is 
occluded, since 
water content 
changes during 
measurements. 
Depth of 
penetration can 
vary with 
parameters. 
Bands from 
interfering 
substances 
could obscure 
amide bands. IR 
beam is weak 
(5–20µm) 
penetrator. Data 
only pertain to 
superficial SC.

(Continued)

 
576 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.9  Bioengineering Techniques Based on Spectroscopy or Thermal Transfer (Continued)

Technique

Developer/Machines

Principles

Advantages

Magnetic resonance 

spectroscopy (MRS)/
nuclear magnetic 
resonance 
spectroscopy(NMR-S)

Foreman (1970s, in 
vitro) (115); Cuono 
(1988, in vitro); 
Klein (1988, in 
vitro); Zemtsov 
(1989, in vivo)

Near infrared 

spectroscopy (NIR)

Putnam (1972) (73), 

Osberghaus (1978) 
(74)

Rigal (1992) (122)
NIRS5000 

Spectrophotometer

Multiphoton laser 
tomography

DermaInspect®
Konig, Riemann 
(2003) (113)

Same principles as MRI 
apply except that the 
magnetic resonance 
signal is used to construct 
a magnetic resonance 
spectroscopic spectrum. 
MRS spectra can be 
obtained from protons as 
well as 13C or 31P. 31P 
provides information 
about intercellular pH, 
tissue turnover rate, and 
tissue bioenergetics (ATP, 
Pi, phosphocreatine).

NIR penetrates deep into 
skin. Two absorption 
bands are used at 1100 
nm (minimal skin 
absorbance) and 1936 
nm (strong absorption 
band by water molecules). 
The difference in 
absorbance at the two 
wavelengths is well 
correlated to clinical 
scores for skin dryness.

Femtosecond near-infrared 
(NIR) laser scanning 
system based on 
two-photo excited 
autofluorescence. 
Nonlinear induced 
autofluorescence comes 
from endogenous 
fluorophores such as 
NAD(P)H, flavins, elastin, 
porphyrin, and melanin. 
Addition of second 
harmonic generation 
(SHG) can be used to 
detect collagen. 
Fluorescence lifetime 
imaging (FLIM) allows 4D 
imaging (3 dimensions 
plus time) (137).

Disadvantages

Still experimental. 

Expensive. 
Limited 
availability. MRI 
images prone to 
motion artifacts. 
Underlying 
tissue may 
cause data 
contamination. 
Not portable; 
heavy 
measuring 
apparatus limits 
measurement to 
forearms only.

Gives information about 
presence of chemical 
species as well as 
environment in which these 
materials exist and how this 
is changing over time. 
Quantifies hydration in both 
epidermis and superficial 
dermis. Metabolic, 
functional, and structural 
information is possible. May 
be able to quantify specific 
tissue composition of 
hemoglobin, melanin, 
elastin; more precise and 
reproducible than 
capacitance or TTT; one of 
the few direct methods; 
considered a reference 
technique.

Gives information on 

Topical agents 

may introduce 
error. 
Complicated 
and costly. 
Abrupt relative 
humidity 
variations may 
introduce error.

molecular constitution of 
skin. Measures stratum 
corneum, epidermal and 
dermal water. Under certain 
conditions, exact 
quantitative relationship 
between IR absorption and 
water concentration in the 
stratum corneum (67). Can 
be used in clinical studies 
with the fiberoptic probe 
(Smartprobe™) to calculate 
changes in % relative 
humidity (%RH) (127).

Permits avoidance of 

chemometric manipulation 
in data analysis (needed in 
most other techniques 
used). Direct correlation 
with visual dryness 
assessment scores. Had 
better linear regression for 
%RH scores when 
compared with conductance 
and visual dryness scores 
(127).

Noninvasive, ultrahigh 

Expensive.

subcellular resolution up to 
200 µm.1 (37). Compact. 
More consistent results than 
cutometer and reviscometer 
(130).

(Continued)

 
ASSESSING THE EFFICACY OF MOISTURIZERS 

 577

Table 58.9  Bioengineering Techniques Based on Spectroscopy or Thermal Transfer (Continued)

Technique

Developer/Machines

Principles

Advantages

Photo-acoustic 

spectroscopy (PAS)

Rosencwaig (1977) 
(75); Campbell 
(1979); Simon 
(1981)

Can quantitatively measure in 
vivo, and no contact needed 
between probe and skin. 
Good for investigation of the 
horny layer (76). One of the 
most depth-sensitive 
methods.

Skin is exposed to IR 

radiation (heat). Depth of 
penetration of a periodic 
heat wave into a solid 
depends on its frequency. 
Radiation is absorbed by 
water in the SC at that 
depth. The superposition 
of thermal waves causes 
periodic temperature/
pressure fluctuations at 
the surface of the skin, 
which can be detected as 
sound by a microphone in 
a closed photoacoustic 
cell. Signal produced 
depends on both optical 
and thermal properties of 
a sample.

Disadvantages

Not readily 

available. More 
technical 
developments 
needed.

Optothermal infrared 

Frodin (1988) (98)

Technique derived from 

spectrometry (OTIS)

Transient thermal 
transfer (TTT)

Soumet (1986) (114) 

Hydrascan 
(Laboratoire 
Dermscan France)

photoacoustic 
spectroscopy, based on 
detection of heat 
generated in a sample 
due to absorption of 
periodic monochromatic 
radiation with a 
wavelength of 1940 nm, a 
specific absorption band 
for water. The heat is 
conducted to a sapphire 
plate in contact with the 
skin and transparent to 
the radiation directed to 
the test area. The plate 
expands and is 
transformed to an 
electrical signal by an 
annular piezo-electric 
crystal cemented to the 
plate’s edge.

TTT is the property of one 
body exchanging heat 
with another when they 
are in contact. The skin 
temperature is measured. 
A stimulator then 
generates a thermal 
pulse that propagates 
through the epidermis to 
be picked up by a sensor. 
The difference in 
temperature is 
proportional to water 
content. The signal is 
analyzed and processed 
with electronic and data 
processing equipment. A 
series of three successive 
thermal pulses from three 
increasing powers 
provides hydration 
measurements from three 
epidermal depths.

By varying the chopper 
frequency, possible to 
measure at different 
thicknesses of the stratum 
corneum.

Not possible to 
determine 
absolute values 
for skin water 
content.

Precise measurements at 

In vivo 

different depths is possible; 
explores deeper depths 
than capacitance. Small 
sensor size allows 
measurements on lips, 
eyes, nails which are not 
possible with either 
capacitance or MRI.

repeatability 
coefficient of 
variation is not 
as good as MRI 
but better than 
capacitance. 
Analytic 
variability is not 
as good as 
capacitance or 
MRI; indirect 
technique; slow 
data acquisition 
because 
requires a 
minimum of 10 
minutes per 
depth 
measured.

 
578 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.10  Bioengineering Techniques to Measure Transepidermal Water Loss (TEWL) (77)

Machine/Developer

Principles

Advantages

Disadvantages

Evaporimeter 

(ServoMed, Sweden)

Tewameter (Courage-
Khazaka Electronic, 
Germany)

Probe with two pairs of humidity 
transducers and thermistor 
measures the partial water vapor 
pressure at two points (3 and 6 
mm) above skin. Rate of 
evaporation (g/m2/h) calculated 
from difference in partial water 
vapor pressure between these 
points. Probe has surface area 
1.13cm2. Normal TEWL between 
2 and 5g/m2/h.

Same principle of measurement as 
Evaporimeter except sensors 
are at 3 and 8 mm above skin, 
and probe has surface area of 
0.79cm2.

Derma Lab®
System with TEWL and 

computerized 
evaporimetry

(Cortex Technology, 

Denmark, 1999)(108)

Similar to ServoMed Evaporimeter. 
Probe is open cylinder placed 
perpendicular to skin site. 
Sensors at fixed distances. Can 
be standalone or equipped with 
personal computer interface.

VapoMeter (Delfin 
Technology Ltd, 
Finland)(125)

Uses unventilated chamber 
method of measurement.

Can evaluate products whose 
mode of action is occlusion. 
Accurate. Convenient to use. 
Inexpensive to operate (31).

Strictly speaking, does not 

measure skin hydration. Many 
factors can affect 
measurements, and they 
need careful monitoring. 
Evaporimeter may 
underestimate water 
evaporation rate at high 
TEWL (77).

More recent design; measures 

Strictly speaking, does not 

probe temperature and graphs 
TEWL over time; more 
complete, somewhat more 
convenient, less sensitive to air 
turbulence than Evaporimeter 
(77).

Convenient monitoring of 

evaporative loss rates in real 
time so any undesirable 
influences due to air currents, 
probe movements are readily 
apparent and their impact on 
measurements instantaneously 
determined as well as 
retrospectively analyzed. 
Increased reproducibility and 
sensitivity.

Closed chamber technology 

allows more mobile, flexible 
use of instrument. Less 
vulnerable to external air 
movements. Self-contained 
battery powered.

measure skin hydration. Many 
factors can affect 
measurements, and they 
need careful monitoring. 
Newer instrument, so less 
well studied.

Possible additional increased 
expense and complexity.

Problems with water vapor 
accumulation as with all 
closed chamber techniques.

Problems with water vapor 
accumulation as with all 
closed chamber techniques. 
Somewhat less mobile than 
VapoMeter.

Aquaflux (Biox Systems 

Uses condenser-chamber method 

Closed chamber technology 

Ltd, UK)(125)

of measurement.

allows more mobile, flexible 
use of instrument. Less 
vunerable to external air 
movements. Benchtop; sensors 
protected from contamination 
and can maintain 
measurement geometry.

Table 58.11  Bioengineering Techniques to Image Stratum Corneum

Technique

Developer/
Machines

High-frequency 

Alexander 

(20mHz) 
ultrasound, A 
mode

(1979); Muller 
(1985); 
machines: 
DUB20 
(Taberna pro 
medicum, 
Germany); 
Dermascan C 
(Cortex 
Technology, 
Denmark) 
(78)

Principles

Advantages

Disadvantages

Good for whole-skin 
visualization. Can 
differentiate epidermis 
from dermis in some 
cases. Can follow aging, 
sunlight damage, 
scleroderma, steroid 
atrophy.

Difficult to measure water 

quantitatively from 
images. Motion creates 
artifacts. Encoding 
process can distort 
space. Difficult to 
visualize very thin sites.

A (amplitude) mode can measure 
the thickness of the skin layers. 
Adaptations to skin need a 
strongly dampened high-frequency 
ultrasound detector with very short 
impulses produced by ceramic or 
piezoelectric polymer transducers 
in order to detect as many echoes 
generated from as many interfaces 
as possible. The receptors made 
up of a device protecting against 
emitter overcharge, a wide-band 
radiofrequency amplifier, and a 
detector of radiofrequency signals. 
Signals are viewed on an 
oscilloscope.

(Continued)

 
ASSESSING THE EFFICACY OF MOISTURIZERS 

 579

Table 58.11  Bioengineering Techniques to Image Stratum Corneum (Continued)

Technique

Developer/
Machines

Principles

Advantages

Disadvantages

High-frequency 

DUB20 

In B (brightness) mode, a 

(20mHz) 
ultrasound, 
B mode

(Taberna pro 
medicum, 
Germany); 
Dermascan C 
(Cortex 
Technology, 
Denmark) 
(78)

succession of signal lines in A 
mode is acquired and 
reconstructed into a 2D image. B 
scans are oriented in the x or y 
direction.

High-resolution 
magnetic 
resonance 
imaging 
(MRI)

1987–1988 

Conventional MRI equipment 

Hyde (79), 
Querleux 
(80), Bittoun 
(80); (Skin 
Imaging 
Modele, 
France)

adapted to reduce field of view 
and pixel size using surface coils. 
Small surface radiofrequency coil 
to improve the signal-to-noise 
ratio. Bittoun made further 
advances by using the device with 
a 1.5T system, obtaining very 
high-resolution images of normal 
skin as well as calculations of T1 
and T2 (80).

Table 58.12  Optical Techniques for Characterization of Skin Properties

Useful to measure thickness 
and depth of skin cancers. 
Appearance of non-
echogenic band in upper 
dermis may be more 
sensitive marker of aging 
than skin thickness. 
Distinguishes skin irritation 
versus allergic reactions. 
Ultrasound waves 
theoretically carry 
information on elastic 
properties.
More adapted to 

visualization of whole skin. 
Epidermis can be clearly 
delineated and analyzed to 
an axial spatial resolution 
of 35–70µm. Able to 
measure water directly 
and quantitatively in vivo. 
Can study proton-
exchange phenomenon. 
Repeated measurements 
over time in vivo.

Difficult to measure water 

quantitatively from 
images. Motion creates 
artifacts. Encoding 
process can distort 
space. Information on 
how ultrasound waves 
carry information on 
skin elastic properties 
cannot yet be 
interpreted. More 
research needed

Errors introduced by very 
short T2, chemical shift 
and partial-volume 
effect can overestimate 
epidermal thickness. 
Artifacts also caused 
by motion and spatial 
distortions introduced 
by encoding. Clinical 
utility limited by high 
cost, cumbersome 
equipment.

Machines/
Developer

Principles

Advantages

Disadvantages

Petran (1968); 

A focused spot of light scans 

Excellent axial (spatial) 

Artifacts caused by 

Technique

In vivo confocal 
microscopy/ 
confocal scanning 
laser microscopy 
(CSLM)

Corcuff 
(1993); 
Tandem 
Scanning 
microscope 
(Tracor 
Northern)

In vivo fiberoptic 

Stratum® 

fluorescence laser 
scanning 
microscopy

(Suihko 2005) 
(128)

the sample. Reflected light in 
focal plane passes through a 
pinhole in front of a 
photomultiple/TV camera 
detector. Images received 
are perfectly focused 
because almost all of the 
reflected light from above 
and below the plane in focus 
is blocked. The Nipkow disc 
has 2000 pinholes arranged 
in Archimede spirals, and 
allows lightening spot 
scanning and reflected-light 
formation, which can be 
collected by a TV camera. 
After computer processing, a 
volume representation can 
be obtained.

Confocal microscope adapted 
for study of skin and mucous 
membranes using fiberoptics 
and fluorophores. Light 
source is a 488 laser. 
Fluorescein sodium used as 
the fluorophore (intradermal 
injection or topical skin 
application) (128).

resolution (1µm). Makes 
horizontal optical sections. 
Very good at visualizing SC. 
Preserves natural tonicity of 
skin, hydration of cells, and 
contrast of structures. 
Possible to measure SC 
thickness in vivo. Sharp 
focused; allows study for first 
time of previously elusive 
stratum lucidum and stratum 
granulosum. Can visualize 
RBC in capillaries. Excellent 
reproducibility. Can work in 
4D space (volume and time) 
at the microscopic level 
non-invasively.

Flexible hand-held system can 
be used on any site including 
mucous membranes. 
Fluorescein sodium is safe 
for use in vivo. Magnification 
1000×. Produces horizontal 
(en face) images. Cellular 
and some subcellular 
resolution is possible (128). 
Good for kinetic studies of 
substances applied on or into 
epidermis (126).

motion and spatial 
distortions introduced 
by encoding. Present 
section thickness 
that can be imaged is 
limited to 150 µm 
(82). Still needs 
optical improvements 
to increase signal-to-
noise ratio on images 
of inner epidermis. 
Optical sectioning is 
limited by 
transparency of 
tissue, scattering and 
absorption of light in 
the sample, working 
distance, and 
numerical aperture of 
the sample (82).

Same as CSLM. 

Intradermal injection 
of fluorophore 
requires some skill.

(Continued)

 
580 

 TEXTBOOK OF COSMETIC DERMATOLOGY

Table 58.12  Optical Techniques for Characterization of Skin Properties (Continued)

Advantages

Depth resolution of 5 

micrometers; able to 
measure concentration 
profiles; quantitatively and 
qualitatively accurate when 
compared with gold standard 
x-ray microanalysis. Only in 
vivo method to analyze skin 
molecular composition as a 
function of distance to skin 
surface with similar detail 
and resolution.

Better resolution than MRI or 
high resolution ultrasound; 
resolution to cellular level = 
10–15 micrometers. 
Maximum imaging depth is 
1.2–2 mm. Lateral resolution 
is 15 micrometers. Real time 
imaging. Fiberoptic systems 
allow better access to 
normally difficult to access 
areas of skin; non-invasive 
so allows monitoring of 
inflammation over time; can 
objectively monitor treatment 
effect.

Disadvantages

Expensive, limited 

availability.

Expensive; limited 

availability; not good 
enough resolution to 
judge grade of 
melanocytic tumors; 
axial and lateral 
resolution is inferior 
to CSLM; allows 
visualization of 
architectural changes 
but not single cells. 
Only able to image 
stratum corneum on 
palms and soles due 
to increased 
thickness.

Changes in refractive index can 
be used to monitor hydration 
status, effect of moisturizers.

Topical agents may 

cause a change in 
reflectivity. Very 
indirect method.

Technique

Machines/
Developer

Principles

In vivo confocal 

Raman 
microspectroscopy

Caspers (1998) 
(110); (2001) 
(111)

In vivo optical 
coherence 
tomography 
(102,109) (OCT)

Fercher (1988) 
(117); Huang 
(1991) (101)

Ellipsometry

Jasperson 

(1969) (83)

In vivo optical method based 
on inelastic light scatter 
rather than absorption 
(vibrational spectroscopy). 
Skin Raman spectrum are 
measured; signal is 
analyzed to extract 
information.

Technique based on the 
Michelson principle of 
inferometry. OCT uses light 
in the near infrared range. 
Gel interface couples probe 
to skin. Light source (LED) 
emits a broad band light into 
fiber; coupler directs one 
portion into reference arm. 
Diverging light beams are 
relayed via both objectives 
to the skin probe and 
reflecting mirror. Detector 
signals are converted from 
optical to electrical signals. 
Thickness measurements 
are calculated using 
software.

Monochromatic light passes 
through a plane polarizer 
oriented at 45° with respect 
to the incidence plane. 
Polarizer output is fed into a 
photoelastic modulator 
composed of a piezoelastic 
crystal oscillating at a 
particular frequency. Output 
of the modulator passes 
through collimater side of 
ellipsometer to skin of 
interest. Reflected light goes 
to telescopic side of 
spectrometer and is directed 
through a second polarizer 
to a photomultiplier tube 
(PMT). PMT output and 
reference signal enter a 
lock-in amplifier, which gives 
intensity readings for the 
ellipsometric parameters. A 
computer program 
calculates the refractive 
index. Measures refractive 
index.

Skin critical surface 
tension (CST)

Jacobi (1949); 
Schneider 
(1951); Ginn 
(1968); El 
Khyat (1996) 
(84)

Droplets of standard liquids 

Can quantify surface energy 

Requires some skill on 

applied to skin and viewed 
under microscope. Critical 
surface tension can be 
calculated using Zisman 
technique; also can measure 
wettability.

phenomenon resulting from 
sweat, serum, and emulsion 
application as well as 
interactions. Can quantify 
wettability.

the part of the 
operator.

 
CONCLUSIONS
There  are  multiple  challenges  facing  the  clinician  who  wishes 
to  understand  the  scientific  basis  behind  moisturizer  efficacy 
claims,  including  access  to  information,  understanding  the 
information, and making sure the study design and technologies 
used are valid. There is an urgent need to perform meta-analyses 
(quantitative  and/or  qualitative)  of  the  moisturizer  studies  cat-
egorized by study type, bioengineering technique, ingredients, 
and clinical population in order to have more clinically relevant 
information on the efficacy of moisturizers. For those interested 
in  exploring  the  topic  of  moisturizers  or  non-invasive  bioengi-
neering techniques more profoundly, some textbook and journal 
references have been listed in the Additional Reading section.

REFERENCES

1.  Grove GL. Noninvasive techniques for assessing  moisturizers. 
In:  Waggoner  C,  ed.  Clinical  Safety  and  Efficacy  testing  of 
Cosmetics. New York: Marcel Dekker, 1990; pp. 121–48.

2.  Serup  J.  How  to  choose  and  use  non-invasive  methods.  In: 
Serup  J,  Jemec  GBE,  Grove  G,  eds.  Handbook  of  Non-Invasive 
Methods and The Skin. Boca Raton, FL: CRC Press, 2006; pp. 9–13.
3.  Swanbeck  G.  Carbamide  and  other  active  substances  in 
moisturizers.  Abstract  of  paper  presented  at  the  Regional 
Symposium on Rationales behind Moisturizers in Dermatology, 
Copenhagen, Denmark, June 1989. Bioeng Skin 1988; 4:383.

4.  Loden  M,  Lindberg  M.  The  influence  of  a  single  application 
of  different  moisturizers  on  the  skin  capacitance.  Acta  Derm 
Venerol 1991; 71:79–82.

5.  Borroni G, Zaccone C, Vignati G. Dynamic measurements. In: 
Elsner  P,  Berardesca  E,  Maibach  HI,  eds.  Bioengineering  of  the 
Skin: Water and the Stratum Corneum. Boca Raton, FL: CRC Press, 
1994; pp. 217–22.

6.  Stab F, Sauermann G, Hoppe U. Evaluation of moisturizers. In: 
Wilhelm  KP,  Berardesca  E,  Maibach  HI,  eds.  Bioengineering  of 
the Skin: Skin Surface Imaging and Analysis. Boca Raton, FL: CRC 
Press, 1997; pp. 315–30.

7.  Barel  AO.  Product  testing:  moisturizers.  In:  Wilhelm  KP, 
Berardesca  E,  Maibach  HI,  eds.  Bioengineering  of  the  Skin:  Skin 
Surface Imaging and Analysis. Boca Raton, FL: CRC Press, 2002; 
pp. 241–56.

8.  Marks  R.  Methods  to  evaluate  the  effects  of  skin  surface 
 modifiers. In: Frost P, Horwitz SN, eds. Principles of Cosmetics for 
the Dermatologist. St Louis, MO: CV Mosby, 1982; pp. 50–8.

9.  Gabard  B.  Testing  the  efficacy  of  moisturizers.  In:  Elsner  P, 
Berardesca E, Maibach HI, eds. Bioengineering of the Skin: Water 
and  the  Stratum  Corneum.  Boca  Raton,  FL:  CRC  Press,  1994; 
pp. 147–70.

  10.  Agner T, Held E. Moisturizers: Evidence for efficacy. In: Maibach 
HI, Bashir SJ, McKibbon A, eds. Evidence Based Dermatology 1st 
edition. Hamilton, Ontario, Canada: Decker, 2002; pp. 233–43.

  11.  Hannon  W,  Maibach  HI.  Efficacy  of  moisturizers  assessed 
through bioengineering techniques. In: Baran R,  Maibach HI, 
eds.  Textbook  of  Cosmetic  Dermatology.  3rd  edition.  London: 
Informa Health Care, 2004; pp. 573–612.

  12.  Jemec B. Inherent capacitance of moisturizer creams: A source 
of  false  positive  results.  Skin  Pharmacol  App  Skin  Physiol  2000; 
13:182–7.

  13.  Sivamani R, Wu G, Maibach HH, Gitis NV. Tribological studies 
on skin: Measurement of the coefficient of friction, “In: Serup J, 
Jemec GBE, Grove G, eds. Handbook of Non-Invasive Methods and 
The Skin. Boca Raton, FL: CRC Press, 2006: pp. 215–24.

  14.  Agache  P.  Twistometry  measurements  of  skin  elasticity.  In: 
Serup  J,  Jemec  GBE,  Grove  G,  eds.  Handbook  of  Non-Invasive 
Methods  and  The  Skin.  Boca  Raton,  FL:  CRC  Press,  2006: 
pp. 601–16.

  15.  Yokota M, Maibach HI. Moisturizer effect on irritant dermati-
tis: An overview. Evidence on preventing and treating irritant 
dermatitis. Contact Dermatitis 2006; 55:65–72.

ASSESSING THE EFFICACY OF MOISTURIZERS 

 581

  16.  Fluhr  J,  Cavallotti  C,  Berardesca  E.  Emollients,  moisturizers 
and keratolytic agents in psoriasis. Clin Dermatol 2008; 26:380–6.
  17.  Crowther  JM,  Matts  PJ.  Measuring  water  gradients  using 
confocal  Raman  microscopy.  In:  Rawlings  AV,  Leyden  JJ,  eds. 
Skin  Moisturization.  New  York:  Informa  Health  Care,  2009; 
pp. 427–31.

  18.  Crozier K, MacDonald S. Effective skin care regimes for term 

newborn. Evidence-Based Midwifery 2010; 8:128–35.

  19.  Bartels  NG,  Scheufele  R,  Prosch  F,  Schink  T,  Proquitte  H, 
Wauer  RR,  Blume-Peytavi  U.  Effect  of  standardized  skin-care 
regimens on neonatal barrier function in different body areas. 
Pediatr Dermatol 2010; 27:1–8.

  20.  Bauer A, Schmitt J, Bennett C, Coenraads PJ, Elsner P, English J, 
Williams  HC.  Interventions  for  preventing  occupational 
 irritant hand dermatitis. Cochrane Database Sys Rev 2010; 6:Art 
No: CD004414. DOI:10.1002/14651858.CD004414.pub2.

  21.  Hon  KLE,  Leung  AKE.  Use  of  moisturizers  in  patients  with 
atopic  dermatitis.  In:  Loden  M,  Maibach  HI,  eds.  Treatment  of 
Dry Skin Syndrome. The Art and Science of Moisturizers. New York, 
NY: Springer, 2012; pp. 59–76.

  22.  Loden M. Effects of moisturizers on epidermal barrier  function. 

Clin Dermatol 2012; 30:286–96.

  23.  Greenfield NP, Maibach HI. A dermatologic view-moisturizers: 
Evidence for efficacy. Cosmet Toiletries 127 (2012): 854–8.
  24.  Katz HI, Lindholm JS. In: Serup J, Jemec GBE, eds. Handbook of 
Non-Invasive  Methods  and  the  Skin  Boca  Raton,  FL:  CRC  Press, 
1995; pp. 49–55.

  25.  Kadner H, Bieshold C. Dermatol Monatsschr 1971; 157:758–9.
  26.  Marks R, Pearse AD. Br J Dermatol 1975; 92:651–7.
  27.  Ishida  T,  Kashibuchi  M,  Morita  K,  Yuasa  S.  Cosmetics  and 

Toiletries 1979; 94:39–47.

  28.  Makki S, Barbenel JC, Agache P. Acta Derm Venerol (Stockh) 1979; 

59:285–91.

  29.  Aubert  L,  Brun  A,  Grollier  JF,  Leveque  JL.  Cosmet  Technol  Sci 

1982; 3:365–70.

  30.  Connemann BJ, Busche H, Kreusch J, Wolff HH. Skin Res Technol 

1996; 2:40–8.

  31.  Marks R. In: Frost P, Horwitz SN, eds. Principles of Cosmetics for 

the Dermatologist. St. Louis, MO: Mosby, 1982; pp. 50–8.

  32.  Corcuff P, de Rigal J, Leveque JL. Bioeng Skin 1981; 4:16–31.
  33.  Barton SP, Marshall RJ, Marks R. Bioeng Skin 1987; 3:93–107.
  34.  Gormley DE. In: Proceedings of Bioengineering and the Skin, San 

Francisco Meeting, September 1985.

  35.  Black  D,  Diridollou  S.  Lagarde  JM,  Gall  Y.  In:  Baran  R, 
Maibach  HI,  eds.  Cosmetic  Dermatology,  2nd  edition.  London: 
Martin Dunitz, 1998; pp. 125–50.

  36.  Picton W, Devitt H, Forgie MA. Br J Dermatol 1976; 95:341–8.
  37.  Taylor  CJ,  Brunt  JN,  Dixon  RN,  Gregory  PJ.  Pract  Metallogr 

1978; 8:433.

  38.  Miller  DL.  In:  Serup  J,  Jemec  GBE,  eds.  Handbook  of  Non-
Invasive Methods and the Skin. Boca Raton, FL: CRC Press, 1995; 
pp. 149–51.

  39.  Wolf J. Z Mikrosk Anat Forsch 1936; 46:170.
  40.  Jenkins HL, Tresise JA. J Soc Cosmet Chem 1969; 20:1.
  41.  Kligman AM, Schatz H, Manning S, Stoudemayer T. In: Frosch 
PJ, Kligman AM, eds. Noninvasive Methods for the Quantification 
of Skin Functions. New York: Springer-Verlag, 1993; pp. 309–16.

  42.  Marks R, Dawber RPR. Br J Dermatol 1971; 84:117–23.
  43.  Thacker JG, Iachetta FA, Allaire FA, et al. Rev Sci Instrum 1977; 

48:181.

  44.  Gunner CW, Williams EW, Greaves M, Hutton WC, Burlin TE. 
In: Marks R, Payne PA, eds. Bioengineering and the Skin. Boston: 
MTP Press, 1981; pp. 31–43.

  45.  Christensen MS, Hargens CW, Nacht S, Gans EH. J Invest Derm 

1977; 69:282–6.

  46.  Vlasblom  DC.  Skin  elasticity.  PhD  Thesis,  University  of 

Utrecht, 1967.

  47.  Salter  DC.  In:  Elsner  P,  Berardesca  E,  Maibach  HI,  eds. 
Bioengineering of the Skin: Water and the Stratum Corneum. Boca 
Raton, FL: CRC Press, 1994; pp. 205–16.

 
 
 
 
 
 
 
 
 
 
582 

 TEXTBOOK OF COSMETIC DERMATOLOGY

  48.  Barbenel JC. Evans JH. J Invest Dermatol 1977; 69:318–20.
  49.  Lévêque  JL.  In:  Baran  R,  Maibach  HI,  eds.  Cosmetic 
Dermatology, 2nd edition. London: Martin Dunitz, 1998; Chap 
46, pp. 537–544.

  50.  Franke EK. J Appl Physiol 1950; 3:582.
  51.  Von Gierke HE. Oestreicher HI, Franke EK, et al. J Appl Physiol 

  81.  Querleux  B,  Yassine  MM,  Darrasse  L,  et  al.  Bioeng  Skin  1988; 

4:1–14.

  82.  Corcuff P, Lévêque JL. Dermatology 1993; 186:50–4.
  83.  Jasperson SN, Schatterly SE. Rev Sci Instrum 1969; 40:761.
  84.  El  Khyat  A,  Mavon  A,  Leduc  M,  et  al.  Skin  Res  Technol  1996; 

2:91–6.

1952; 4:886.

  85.  Gunner CW, Hutton WC, Burlin TE. Med Biol Eng Comput 1979; 

  52.  Thompson DE, Hussein HMG, Perritt RQ. In: Marks R, Payne PA, 
eds. Bioengineering and the Skin. Boston: MTP Press, 1981:103–13.
  53.  Wilhelm KP, Cua AB, Maibach HI. In: Frosch PJ, Kligman AM, 
eds. Non-Invasive Methods for the Quantification of Skin Functions. 
New York: Springer-Verlag, 1993; pp. 191–203.

  54.  Grahame R. Clin Sci 1970; 39:223–38.
  55.  Jemec GBE, Jemec B, Jemec BIE, Serup J. Plast Reconstruct Surg 

1990; 85:100–3.

  56.  Gniadecka M, Serup J. In: Serup J, Jemec GBE, eds. Handbook of 
Non-Invasive Methods and the Skin. Boca Raton, FL: CRC Press, 
1995; pp. 329–34.

  57.  Dikstein  S,  Hartzshtark  A.  In:  Marks  R,  Payne  PA,  eds. 
Bioengineering  and  the  Skin.  Boston:  MTP  Press,  1981;  
pp. 45–53.

  58.  Gartstein  V,  Elsau  WH.  In:  Proceeding  of  the  8th  International 
Symposium on Bioengineering and the Skin, Stresa, 1990; p. 70.

  59.  Pierard GE. Bioeng Skin Newsl 1980; 2:31.
  60.  Manny-Aframian  V,  Dikstein  S.  In:  Serup  J,  Jemec  GBE,  eds. 
Handbook of Non-Invasive Methods and the Skin. Boca Raton, FL: 
CRC Press, 1995; pp. 345–7.

17:142.

  86.  Matts PJ, Goodyer E. J Cosmet Sci 1998; 49:321.
  87.  Matts PJ. In: Elsner P, Berardesca E, Wilhelm KP, Maibach HI, 
eds. Bioengineering of the Skin: Skin Biomechanics. Boca Raton, FL: 
CRC Press, 2002; pp. 99–109.

  88.  Serup J, Northeved A. J Dermatol 1985; 12:52–62.
  89.  Serup  J.  In:  Elsner  P,  Berardesca  E,  Wilhelm  KP,  Maibach  HI, 
eds. Bioengineering of the Skin: Skin Biomechanics. Boca Raton, FL: 
CRC Press, 2002; pp. 117–21.

  90.  Hauselmann  HJ,  Renfer  K,  Seifert  B,  Bruhlmann  P, 
Seitz  J,  Ruetschi  CH,  Michel  BA.  Curr  Prob  Dermatol  1998; 
26:134–44.

  91.  Hauselmann  HJ,  Huber  K,  Seifert  B,  Michel  B.  In:  Elsner  P, 
Berardesca  E,  Wilhelm  KP,  Maibach  HI,  eds.  Bioengineering  of 
the  Skin:  Skin  Biomechanics.  Boca  Raton,  FL:  CRC  Press,  2002; 
pp. 123–38.

  92.  Falanga V, Bucalo B. JAAD 1993; 29:47.
  93.  Romanelli M. Falanga V. In: Elsner P, Berardesca E, Wilhelm KP, 
Maibach  HI,  eds.  Bioengineering  of  the  Skin:  Skin  Biomechanics. 
Boca Raton, FL: CRC Press, 2002; pp. 139–45.

  61.  Hargens  CW.  In:  Serup  J,  Jemec  GBE,  eds.  Handbook  of  Non-
Invasive Methods and the Skin. Boca Raton, FL: CRC Press, 1995; 
pp. 359–66.

  94.  Pugliese  PT,  Potts  JR.  In:  Elsner  P,  Berardesca  E,  Wilhelm  KP, 
Maibach  HI,  eds.  Bioengineering  of  the  Skin:  Skin  Biomechanics. 
Boca Raton, FL: CRC Press, 2002; pp. 147–59.

  62.  Tosti A, Compagno G, Fazzini ML, Villardita S. J Invest Dermatol 

1977; 69:315–17.

  63.  Manny-Aframian  V,  Dikstein  S.  In:  Serup  J,  Jemec  GBE,  eds. 
Handbook of Non-Invasive Methods and the Skin. Boca Raton, FL: 
CRC Press, 1995; pp. 349–52.

  64.  Nacht S, Close J-A, Yeung D, Gans EG. J Soc Cosmet Chem 1981; 

32:55–65.

  95.  Prall JK. J Soc Cosmet Chem 1973; 24:693.
  96.  Guibarra  E,  Nicholls  S,  Marks  R.  Bioengin  Skin  Newsl  

1979; 2:29.

  97.  Graves CJ, Edwards C. In: Elsner P, Berardesca E, Wilhelm KP, 
Maibach  HI,  eds.  Bioengineering  of  the  Skin:  Skin  Biomechanics. 
Boca Raton, FL: CRC Press, 2002; pp. 161–78.

  98.  Frodin  T,  Helander  P,  Molin  L,  Skogh  M.  Bioeng  Skin  1988; 

  65.  Torgalkar AM. In: Marks R, Payne PA, eds. Bioengineering and 

4:115–30.

the Skin. Boston: MTP Press, 1981; pp. 55–65.

  99.  Sasai S, Zhen YX, Suetake T, Tanita Y, Omata S, Tagami. Skin Res 

  66.  Tronnier H, Wagener HH. Dermatologica 1952; 104:135–51.
  67.  Potts RO, Christman DA, Buras EM. J Biomech 1983; 16:362–72.
  68.  Tregear RT. Nature 1965; 205:600.
  69.  Distante F, Berardesca E. In: Berardesca E, Elsner P, Wilhelm KP, 
Maibach  HI,  eds.  Bioengineering  of  the  Skin:  Methods  and 
Instrumentation. Boca Raton, FL: CRC Press, 1995; pp. 5–12.
  70.  Jacques SL, A linear measurement of the water content of the 
stratum  corneum  of  human  skin  using  a  microwave  probe. 
Presented  at  the  32nd  Annual  Conference  on  Engineering  in 
Medicine and Biology, Denver, CO, 1979.

  71.  Tagami  H.  In:  Elsner  P,  Berardesca  E,  Maibach  HI,  eds. 
Bioengineering of the Skin: Water and the Stratum Corneum. Boca 
Raton, FL: CRC Press, 1994; pp. 59.

  72.  Gabard B, Treffel P. In: Elsner P, Berardesca E, Maibach HI, eds. 
Bioengineering of the Skin: Water and the Stratum Corneum. Boca 
Raton, FL: CRC Press, 1994; pp. 147–70.
  73.  Putnam NA. J Soc Cosmet Chem 1972; 23:209–26.
  74.  Osberghaus R, Glohuber C, van Raay HG, Braig S. J Soc Cosmet 

Chem 1978; 29:133–46.

  75.  Rosencwaig A, Pines E. J Invest Dermatol 1977; 69:296–8.
  76.  Kolmel K, Nicolaus A, Giese K. Bioeng Skin 1985; 1:125–31.
  77.  Barel AO, Clarys P. In: Serup J, Jemec GBE, eds. Handbook of Non-
Invasive Methods and the Skin. Boca Raton, FL: CRC Press, 1995; 
pp. 179–95.

Technol 1999; 5:237–46.

  100.  Sakai S, Shu S, Endo Y, Matsue K, Tagami H, Inoue S. Skin Res 

Technol 2000; 6:128–34.

  101.  Huang D, Swanson EA, Lin CP, et al. Science 1991; 254:1178–81.
  102.  Gladkova ND, Petrova GA, Nikulin NK, et al. Skin Res Technol 

2000; 6:6–16;

  103.  Serup  J,  Winther  A,  Blichmann  C.  Clin  Exp  Dermatol  1989; 

14:277–82.

  104.  Pierard  GE,  Pierard-Franchimont  C,  Saint-Leger  D,  Kligman 

AM. J Soc Cosmet Chem 1992; 44:297–305;

  105.  Schatz  H,  Kligman  AM,  Manning  S,  Stoudemeyer  T.  J  Soc 

Cosmet Chem 1993; 47:53–63

  106.  De Paepe K, Janssens K, Hachem JP, Roseeuw D, Rogiers V. Skin 

Res Tech 2001; 71:184–92

  107.  Wilhelm  KP,  Kaspar  K,  Schumann  F,  Articus  K.  Skin  Res  Tech 

2002; 8:98–105.

  108.  Grove GL, Grove MJ, Zerweck C, Pierce E. Skin Res Tech 1999; 

5:1–8.

  109.  Pagnoni  A,  Knuettel  A,  Welker  P,  Rist  M,  Stoudemeyer  T, 

Kolbe L, Sadiq I, Kligman A. Skin Res Tech 1999; 5:83–7.

  110.  Caspers  PJ,  Lucassen  GW,  Wolthius  R,  Bruining  HA,  Puppels 

GJ. Biospectroscopy 1998; 4:531–9.

  111.  Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ. 

J Invest Dermatol 2001; 116:434–43

  78.  El-Gammal  S,  Auer  T,  Hoffmann  K,  et  al.  In:  Frosch  PJ, 
Kligman AM, eds. Non-Invasive Methods for the Quantification of 
Skin Functions. New York: Springer-Verlag, 1993; pp. 104–29.

  112.  Sarvazyan AP, Ponomarjev VP, Vucelic D, Popovich G, Vexler A. 
Method and device for acoustic testing of elasticity in biological 
tissues. USA Patent 1990; No 4, 947, 851.

  79.  Hyde JS, Tesmanowicz H, Kneeland BJ. Magn Reson Med 1987; 

  113.  Vexler  A,  Polyansky  I,  Gorodetsky  R.  J  Invest  Dermatol  1999; 

5:449–61.

113:732–9.

  80.  Bittoun  J,  Saint-James  H,  Querleux  BG.  Radiology  1990; 

  114.  Soumet  JL,  Dittmar  A,  Leftheriotis  G.  Int  J  Microcirc  1986; 

176:457–60.

5:73–83.

 
  115.  Foreman MI. Biochim Biophys Acta 1976; 437:599–603.
  116.  Girard P, Beraud A, Sirvent A. Skin Res Tech 2000; 6:205–13.
  117.  Fercher AF, Mengedoht K, Werner W. Opt Letter 1988; 13:186–8.
  118.  Welzel J. Skin Res Tech 2001; 7:1–9.
  119.  Altmeyer  P,  Erbler  H,  Kromer  T,  Duwe  HP,  Hoffman  K.  Acta 

Derm Venerol 1995; 75:193–7.

  120.  Lagarde JM, Rouvrais C, Black D, Diridollou S, Gall Y. Skin Res 

Tech 2001; 7:112–121.

  121.  De  Paepe  K  Lagarde  JM,  Gall  Y,  Roseeuw  D,  Rogiers  V.  Arch 

Skin Res 2000; 10:500–10.

  122.  Rigal J. Losch MJ, Bazin R, Camus C, Sturelle C, Deschamps V. 
IFSCC International Congress Yokohama 1992; 3:1131–46.
  123.  Marshall R, Marks R. Assessment of skin surface by scanning 
densitometry  of  macrophotography.  Clin  Exp  Dermatol  1983; 
8:121–7.

  124.  Jacques SL. IEEE Eng Med Bio Soc Conf 1979; 180–182.
  125.  Imhof  RE,  Xiao  P,  De  Jesus  MEP,  Ciortea  LI,  Berg  EP.  New 
developments in skin barrier measurements. In: Rawlings AV, 
Leyden  JJ,  eds.  Skin  Moisturization.  London:  Informa  Health 
Care, 2009; pp. 463–79.

  126.  Lademan  J,  Otberg  N,  Richter  H,  Meyer  L,  Audring  H, 
Teichmann  A,  Knuttel  STA,  Sterry  W.  Skin  Res  Tech  2007; 
13:119–32

  127.  Kilpatrick-Liverman L, Kazmi P, Wolff E, Polefka TG. Skin Res 

Tech 2006; 12:162–9.

  128.  Suihko C, Swindle LD, Thomas SG, Serup J. Skin Res Tech 2005; 

11:254–67.

  129.  Batisse D, Giron F, Leveque JL. Skin Res Tech 2006; 12:99–104.
  130.  Koehler  MJ,  Preller  A,  Kindler  N,  Elsner  P,  Konig  P,  Konig  K, 

Buckle R, Kaatz MK. Skin Res Tech 2009; 15:357–63.

  131.  Alekseev SI, Szabo I, Ziskin MC. Skin Res Tech 2008; 14:390–6.
  132.  Zhang Y, Brodell RT, Mostow EN, Vinyard CJ, Marie H. Skin Res 

Tech 2009; 15:271–82.

  133.  Paye  M,  Mac-Mary  S,  Elkhyat  A,  Tarrit  C,  Mermet  P, 

Humbert PH. Skin Res Tech 2007; 13:343–9.

  134.  Hashmi F, Malone-Lee J. Skin Res Tech 2007; 13:252–8.
  135.  Lee HK, Seo YK, Baek JH, Koh JS. Skin Res Tech 2007; 14:8–12.

ASSESSING THE EFFICACY OF MOISTURIZERS 

 583

  136.  Konig K, Riemann I. High resolution multiphoton tomography 
of human skin with subcellular spatial resolution and picosec-
ond time resolution. J Biomed Opt 2003; 8:432–9.

  137.  Kobow  J,  Harzic  RL,  Martin  S,  Ehler  A,  Riemann  I,  Konig  K. 
DermaInspect®:  In  vivo  high  resolution  multiphoto  tomogra-
phy  of  human  skin.  18  Aug.  2009.  Available  at:  http://www 
.focusonmicroscopy.org/2005/PDF/022_Kobow.pdf
  138.  Clar E, Her CP, Sturelle CG. J Soc Cosm Chem 1975; 26:337–53.

ADDITIONAL READING
Loden, Marie, Howard I. Maibach. Treatment of Dry Skin Syndrome. 
The  Art  and  Science  of  Moisturizers.  New  York,  NY:  Springer-
Verlag, 2012.

Penzer, Rebecca, Steven Esser, Susan McGuire, Noreen Nichol, Jill Peter. 
British Dermatology Nursing Group. Best practices in Emollient 
Therapy. Dermatologic Nursing 11 (2012): S1–19.

Fluhr,  Joachim.  Practical  Aspects  of  Cosmetic  Testing:  How  to  Set  Up  a 
Scientific  Study  in  Skin  Physiology.  Berlin,  Germany:  Springer-
Verlag, 2011.

Barel, Andre O., Marc Paye, Howard I. Maibach. Handbook of Cosmetic 
Science  and  Technology.  3rd  edition.  New  York,  NY:  Informa 
Healthcare, 2009.

Rawlings, Anthony V., James J. Leyden. Skin Moisturization. 2nd edition. 

New York, NY: Informa Healthcare, 2009.

Serup,  Jorgen,  Gregor  B.E.  Jemec,  Gary  L.  Grove.  Handbook  of  Non-
Invasive Methods and the Skin. 2nd edition. Boca Raton, FL: CRC 
Press, 2006.

Loden, Marie, Howard I. Maibach. Dry Skin and Moisturizers: Chemistry 
and Function. 2nd edition. Boca Raton, FL: CRC Press, 2005.
Fluhr,  Joachim,  Peter  Elsner,  Enzo  Berardesca,  Howard  Maibach. 
Bioengineering  of  the  Skin:  Water  and  the  Stratum  Corneum.  2nd 
edition. Boca Raton, FL: CRC Press LLC, 2005.

Agache,  Pierre,  Philippe  Humbert.  Measuring  the  Skin:  Noninvasive 
Investigations,  Physiology,  Normal  Constants.  Berlin,  Germany: 
Springer-Verlag, 2004.

 
AA, see Azelaic acid
AAG, see Androgenogenetic alopecia
a-Aminolevulinic acid (ALA), 442
ABA, see Aldobionic acids
Abdominal treatment, cryolipolysis, 542, 544
Aberrant plasmin activity, in epidermis, 118
Ablative mesotherapy, 431
Ablative ultrapulse laser therapy, 217
Abnormal hairs, 230
Abnormal keratinization, 56, 167
AbobotulinumtoxinA (ABO), 459
Abrasive nail files, 266
ABS, see Acrylonitrile butadiene styrene
Absorbent core, on lotion transfer, 554–555
Acacia nilotica, 155
Accelerated weathering, 232
ACDS, see American Contact Dermatitis 

Society

Acetone, 279–281
Acid-based primer, 279
Acid neutralization, 503–505
Acid strength, of organic hydroxyacid, 59
Acne

chemical peeling, 386–387
hydroxyacids, 63
stratum corneum, 130–131
treatment of, 171–172

Acnegenesis, 302–303
Acneic inflammatory lesions, improvement 

of, 108
Acne keloidalis, 394
Acne scarring, 387
Acrylic acid, 278, 290
Acrylic nail extensions, 273
Acrylonitrile butadiene styrene (ABS), 276
Actinic keratoses (AK), 531

chronicity and secondary prevention, 

214–215
diagnosis of, 214
hydroxyacid, 65
multiple, non-hyperkeratotic, 216–217
nonablative laser rejuvenation, 531
photodynamic therapy, 444–445
therapeutic perspectives, 217
treatment algorithm for, 215, 216

Acute angioedema-type hypersensitivity, 

475

Acute formaldehyde reaction, 284
AD, see Atopic dermatitis
Adapalene, 332, 363
Adenosine monophosphate disodium salt, 

332

Adherent scalp flaking scores (ASFS), 254
Adipokine, 308
Adverse skin effects

acnegenesis and comedogenesis, 302–303
contact urticaria, 303–304
photoreactions, 304
primary dermal irritation, 301–302
sensory irritation, 302
Affirm™ Multiplex laser, 525
African hair, 390, 392
AG, see Ascorbyl gluocoside
Aging

definition of, 143

Index

of female reproductive system, 424
of hair, 231–232

AHAs, see Alpha-hydroxy acids
Airborne contact dermatitis, 271, 285
AK, see Actinic keratoses
ALA, see a-Aminolevulinic acid
5-ALA, see 5-Aminolevulinic acid
Aldaric acid, 57
Aldobionic acids (ABA), 58
Aldonic acid, 57
Alduronic acid, 57–58
Alkyl α-hydroxyacids, 57
Allergic contact dermatitis, 148–149, 277
Allergic rhinitis score (ARS), 161
Alltrans retinoic acid (ATRA), 88
Alopecia, 426
Alpha-hydroxy acids (AHAs), 178, 287, 291, 

301, 498

Ambulatory phlebectomy, 318
American Contact Dermatitis Society 

(ACDS), 301

5-Aminolevulinic acid (5-ALA), 157
Amphoteric surfactant, 60, 237
AMPLI RF, see Automatic multifrequency 
and low impedance radio frequency
Analysis of covariance (ANCOVA), 552–553
Analysis of variance (ANOVA), 552
Ancillary skin care products

astringents, 178
face masks, 180–181
facial scrubs, 179–180
mechanized skin care devices, 180
ANCOVA,  see Analysis of covariance
Androgenetic alopecia, 394, 415
Androgenogenetic alopecia (AAG), 426
Anionic emulsifiers, 290
Anisopoikilocytotic adipocytes, 308
Anodal electrical stimulation, 489
ANOVAs, see Analysis of variance
Antagonistic acetoxyacids, 66
Anticellulite products
classification of, 309
etiopathogenesis, 308–309
noninvasive techniques, 309–310
therapies, 310–311

Anti-dandruff shampoo, 237, 252
Antimicrobial activity, 491–492
Antioxidants, 65–66, 187

activities, 104
constitutive skin antioxidant network, 

80–82

dietary components, 188
effects of environmental stressors on, 

82–83
evaluation of, 85
nonsteroidal anti-inflammatory drugs, 

187–188

photoprotection of human skin, 83–85
properties, 59
reactive oxygen species, 80
in skin, 410–412

Anti-stress activity, 104
Apoptosis, 536
Apple acid, 57
Aralkyl α-hydroxyacids, 57

585

Arborizing telangiectasias, 510
Arbutin, 154, 332
Areolar layer, 308
Argon laser, 512
Arm patch protocol, 552–553
ARS, see Allergic rhinitis score
Arteriolar telangiectasias, 510
Artificial nails, 220, 264, 276–279
removing sculptured, 279

ASA, see Ascorbic acid
Ascorbic acid (ASA), 153, 332
Ascorbyl gluocoside (AG), 154
ASFS, see Adherent scalp flaking scores
Asian hair, 390, 392–394
Astringents, 178
Asymmetric smile, 466
Atopic dermatitis (AD), 130

pruritus, 158
psoriasis, 161–163

ATRA, see Alltrans retinoic acid
Automated phototrichograms, 416–417
Automatic multifrequency and low 

impedance radio frequency (AMPLI 
RF), 310

Azelaic acid (AA), 172, 331, 363–364
Azzalure®, 459

Bacterial biofilms, 491
Baphicacavthus cusia, 162
Barrier function, stratum corneum, 132–133
Barrier recovery test, 117
Basal cell carcinomas (BCCs), 186, 193, 194, 

444

Basal layer peel, 499–500
Base coats, nail, 269–271
Basement membrane (BM), in photo-aged 

skin, 120–121

BBI, see Bowman-Birk protease inhibitor
BCCs, see Basal cell carcinomas
BCOP,  see Bovine corneal opacity and 

permeability test
BCSO, see Blackcurrant seed oil
Becker nevus, 340
Behind-the-knee (BTK) test, 51

lotion transfer, see Lotion transfer
methods of, 551–553
pressure on test samples, 553
skin benefits of, 557–558

Bend of elbow, washing test on, 21
1,4-Benzoquinone molecule, 76
Benzoyl peroxide (BPO), 171–172, 360–361
Beta-carotene, 71
BHA, see β-Hydroxyacids
Biochemical action, 62–63
Biochemistry, hydroxyacids, 59
Bio-Electric Imager®, 482
Bioelectricity

antimicrobial activity, 491–492
biomimetic electricity, 483, 492–496
bone regenration, 487–488
cellular effects of, 485–487
electric air bath, 481
innate electrical system, 482
ion transport properties, 482–483

586 

 INDEX

microcurrent therapy, 490–491
ranges and cell proliferation, 488
skin wounds and skin aging, 483–485
tissue engineering, 490
transcutaneous electrotherapy and 
delivery enhancement, 482

wound healing enhancement, 489–490

Bioengineering techniques, 562
indirect electrical, 573–575
measure desquamation, 566–567
measure elasticity, 567–571
mechanical, 571–573
skin surface contour evaluation, 564–566
spectroscopy/thermal transfer, 575–577
stratum corneum imaging, 578–579
transepidermal water loss, 578
Biological action, hydroxyacid, 62
Biomimetic electricity, for dermatological 

applications, 483, 492–496

Biomimetic electric stimulation, 481
Biomineral complex

biomimetic-electricity delivery systems, 

492

Café-au-lait macules, 340
Caffeine, 188
Calcium hydroxylapatite (CaHA), 477–479
Calibrated electrical stimulation of skin, 52
Camellia sinensis, see Green tea
Camouflaging, 336
CAMVA,  see Chorioallantoic membrane 

vascular assay

Canfield EpiLume®, 416
Carbohydrate metabolism, 59
Carbon dioxide (CO2) lasers, 512
Carotenoids, 188
Cassia fistula, 154–156
Cathodal electrical stimulation, 489
Cationic emulsifiers, 290
Cationic water-soluble polymers, 29
Caucasian hair, 390–394
Causative ingredients, 149
CCCA, see Central centrifugal cicatricial 

alopecia

14C-Ciclopirox penetration, 36, 39–40
CCN1, see Cysteine-rich protein 61
CDLQI, see Children’s dermatology life 

clinical safety and tolerability of, 

quality index

493–494

skin anti-aging of, 494–496
in vitro biological responses of, 492–493

Bionic acid, 58
Bismuth oxychloride, 269
BKT, see Behind-the-knee
Blackcurrant seed oil (BCSO), 160
Blood vessel reactivity, 404, 406–407
Blowdrying hair, 244
BO, see Borage oil
Bocoture®, 459
Body hair, 395–396
Body lotions

adverse reactions, 304–305
advertising, 298–300
alleviating dry skin, 291–294
consumers’ skin condition, 301
ingredients for, 288–291
instrumental evaluations of, 295–297
lotion composition, 300–301
predicting adverse skin effects, 301–304
preventing primary irritation, 294
and skin, 287–288
trained expert sensory panel, 298
user evaluation of, 297–298

Bone regenration, influenced by electric 

fields, 487–488

BoNT-A, see Botulinum neurotoxin type A
Borage oil (BO), 160–161
Botanicals, role in cosmeceuticals, 182–183
Botulinum neurotoxin type A (BoNT-A), 

259, 459, 467

adjunctive treatments, 466–467
contraindications/limitations, 461–462
facial asymmetry, 465–466
hyperhidrosis, 467–468
lower face, 464–465
middle face, 464
pharmacology and mechanism of action, 

459

platysmal bands and décolleté wrinkles, 

466

reconstitution and dose equivalence, 

459–461

upper face, 462–464

Bovine collagen, 473
Bovine corneal opacity and permeability 

test (BCOP), 305

Bowen disease, 446–447
Bowman-Birk protease inhibitor (BBI), 94
BPO, see Benzoyl peroxide
Browning reaction, 174
BTK, see Behind-the-knee
Butylhydroxytoluene, 279

Cellular necrosis, 442
Cellular retinoic acid binding proteins 

(CRABP), 88

Cellulite, 309, 431
Cellulosic polymers, 290
Centella asiatica, 310
Central centrifugal cicatricial alopecia 

(CCCA), 393, 395

Ceramide-acid-base, 125
Ceramides

biosynthesis of, 132–135
ethnicity, 132
human stratum corneum, 126
lipid organization in, 128–129
nomenclature, 124
normal-phase liquid chromatography, 123
nuclear magnetic resonance, 128
physical properties of, 129
variations in, 129–132

CES, see Cranial electrotherapy stimulation
Chamois buffers, 267
Chemical depilatories function, 325–326
Chemical peeling, 386

acid neutralization, 503–505
depths of peels, 498–503
and fibroblasts, 507–508
phenol, 508–509
trichloracetic acid, 505–507

Chemical relaxers, 393
Chemi-osmotic theory, 487
Cherry hemangiomas, 510
Children’s dermatology life quality index 

(CDLQI), 161

C3H6O3, see Dihydroxyacetone
Chorioallantoic membrane vascular assay 

(CAMVA), 305

Chromhidrosis, 342
Chronic inflammation, atopic dermatitis, 160
Chronicity, actinic keratoses, 215–216
Chronic low back pain, 491
Chronic telogen effluvium, 413
CI, see Color index
Ciclopirox, 155
CIT, see Cumulative irritation test
Citrate cycle, energy production, 59
Classical mesotherapy, 432
Cleansing cloth, 179
Cleansing products, 169
Climateric hyperkeratosis, 427
Climateric keratodermas, 427
Climateric syndrome, 424
Climbazole, 253
Clinical efficacy, of retinol, 89–91
Closed-chamber instruments, 28–29

Clostridium botulinum, 459
CLSM, see Confocal laser scanning 

microscopy

Coal tar, 253–255
CO2 lasers, see Carbon dioxide lasers
Collagen

fibers, 259
production, 103
synthesis, 490

Colorant powders, 264
Colorants, see Coloration additives
Coloration additives, 269
Colored polymer powders, 277
Colored UV gels, 264, 280
Colorimetric assay, 145–146
Color index (CI), 269
Color stabilizers, 269
Color-treated hair, shampoos for, 237
Comedogenesis, 302–303, 303
Comedolytic agents, 171
Compact stratum corneum, 425
Condenser-chamber method, 29
Conditioners, 237–243
Conditioning shampoos, 237
Confocal laser scanning microscopy 

(CLSM), 34, 168

Confounding lifestyle factors, 49
Congenital dermal hypermelanocytosis, 340
Constitutional dry skin, 167
Constitutive skin antioxidant network, 

80–82

Consumers’ skin condition, role of, 301
Contact dermatitis, 385
Contact urticaria, 272, 279, 303–304
Continuous wave lasers, 512–514
Conventional “facelift” procedures, 261
Conventional injection technique, 462
Cooling, role of, 515
Copper-vapor laser, 513
Corneocyte counting, 255
Corneocyte desquamation, 167
Corneocytes, 404–405
Corneofix®, 295
Corneofix F20, 168
Corneometer, 20
Corneometer CM 825, 168
Corneometer units (CU), 25
Corneosurfametry, 130
Cortex, 228–229, 392
Cortex moutan, 161
Cortex phellodendri, 161
Cosmeceuticals

botanical role of, 182–183
cosmetic labeling standards, 183–184
regulatory oversight of, 182

Cosmetic cryotherapy

acne, 454
complications, 456–457
lesion selection, 452–453
mechanism of action, 451
seborrheic keratosis, 455
tattoos, 456
technique and terminology, 450–451
tissue injury, 451–452
vascular lesions, 453–454
vascular stasis and occlusion, 452
viral warts, 454–455

Cosmetic product labeling, 183–184
Cosmetic skin parameters

climatic data, 16
laser profilometry, 16–17
outcomes, 21–26
Rz parameter, 17
in vivo topometry of, 17–21

Cotton-tipped dipstick, 451
Covalentlybound ceramides, 125
COX-2, see Cyclooxygenase-2
CPDs, see Cyclobutane pyrimidine dimers

 
CRABP, see Cellular retinoic acid binding 

proteins

Cranial electrotherapy stimulation (CES), 

491

Critical wavelength (CW) test, 186
Cross-section trichometer, 419
Croton lechleri, 182
Crow’s feet lines, 260, 262463
Cryolipolysis, 539

assessment and treatment planning, 540
clinical technique, 537–539
efficacy, 542
mechanism of action, 536–537
patient expectations, 542–543, 546
pre-clinical studies, 535–536
side effects, 540–542
treatment for, 539–540

Cryoprobe, 451
Cryosurgery, 354, 453, 457
Cryosurgical treatments, 450
Cryotherapy, 215, 217
CU, see Corneometer units
Cultured keratinocytes, 96
Cumulative irritation test (CIT), 301
Curling irons, 244
Cutaneous appendages, 384–385
Cutaneous microcirculation, 9
Cutaneous microvasculature, 7–8
Cuticle, hair, 228, 392
Cuticle, nail

removers and softeners, 272–273
trimmers, 267
Cutometer®, 297
Cutters, nail, 266
CW, see Critical wavelength test
Cyclobutane pyrimidine dimers (CPDs), 185
Cyclooxygenase-2 (COX-2), 96, 187
Cypraea moneta, 386
Cystamine, 332
Cysteamine, 332
Cysteine-rich protein 61 (CCN1), 89
Cytokinins biology, 113

Damaged corneocytes, 296
Dandruff, 131, 248
Dandruff, treatment considerations, 255
Dark skin, 385
Dark-skinned swine, 94
DBT, see Dibutyl phthalate
DC, see Diflucortolone-21-valerate
Décolleté wrinkles, 466
Decoration of nail, 264–266
Deep dermal collagen remodeling, 263
Deep venous thrombosis (DVT), 313
Dehydroepiandrosterone (DHEA), 425
DEJ, see Dermo epidermal junction
Delayed hair growth, 94–96
Delta fiber, 52
Deoxycholate, 432
Depigmenting agents

combination therapies, 333–334
dermabrasion, 334–335
hydroquinone derivatives, 331
phenolic compounds, 330–331
retinoid monotherapy, 332–333
Depressor angulis oris, 464–465
Depressor septi nasi m., 464
DermaCorder™, 486
Dermaflex®, 297
DermaLab, 168
Dermal extracellular matrix production, 493
Dermal fibroblasts, 507–508
Dermal hypermelanocytosis, 340
Dermal matrix enhancement, 96
Dermal Torque Meter, 297
Dermaroller®, 437
Dermatitis papillaris capillitii, 394

Dermatitis, to dihydroxyacetone, 176
Dermatological indications, 63–64
Dermatology treatments

atopic dermatitis, see Atopic dermatitis
hyperpigmentation, 153–155
onychomycosis, 155–158
Dermo-electroporation, 433
Dermo epidermal junction (DEJ), 387
DES1, see Dihydro CER desaturase
DES2, see Dihydro CER hydroxylase
Desquamation index (DI), 295
Detergent, cause of dry skin, 117
Deutsche Industrie Norm (DIN), 17
DF, see Dissecting folliculitis
D-gluconic acid, 58
DHA, see Dihydroxyacetone
DHEA, see Dehydroepiandrosterone
DI, see Desquamation index
Diastron, 417
Dibutyl phthalate (DBT), 268
Diclofenac, 216
Dietary agents, 187–188
Dietary soy, 93
Differential scanning calorimetry (DSC), 128
Diflucortolone-21-valerate (DC), 160
Dihydro CER desaturase (DES1), 128
Dihydro CER hydroxylase (DES2), 128
Dihydrotestosterone, 415
Dihydroxyacetone (DHA), 20–21, 336

application of, 175
chemical structure of, 174
dermatitis to, 176

DIN, see Deutsche Industrie Norm
Dipstick technique, 451
Directional cellular locomotion, 487
Direct manual hair count, 416
Disinfection container, 267
Disinfection, nail, 274
Dissecting folliculitis (DF), 394
DNA-based identification techniques, 251
DNA repair enzymes, 217
Domain mosaic model, 129
Dorfman-Charainin syndrome, 130
Dosing procedures, nail plate, 34, 36
Double-blind study, 254
Dried nail, 276
Drug-induced pigmentation, 341
Drug-induced sensitivity, 49
Drug penetration, into human nail, 39
Dry skin, 63, 117, 167
alleviate, 291–294
t-AMCHA methylamide, 119–120
treatment of, 170–171
urokinase in, 118

DSC, see Differential scanning calorimetry
D-Squame®, 168, 295
DVT, see Deep venous thrombosis
Dyes, 269
Dyschromia

camouflaging, 336
lasers and phototherapy, 335
pathophysiology of, 330
surgical approaches, 335–336
tattoos, 342–343
Dyskeratosis, 341–342
Dysport, 459
Dystrophic nails, with subungual 
hyperkeratosis, 283

Earth-based masks, 181
Econazole concentration, 39
Ectoin, 170
Ectopic contact dermatitis, 285
EFAs, see Essential fatty acids
Efinaconazole, 157
Eflornithine cream, 326, 426
EGCG, see Epigallocatechin gallate

INDEX 

 587

Elastic fiber network, 259
Elastic recovery/extensibility, skin, 407–409
Elastin enhancement, 103–104
Electric air bath, 481
Electrical properties of skin, 168
Electric fields

bone regenration influenced by, 487–488
tissues/organs affected by, 488

Electric neurostimulation, 481
Electric torpedo fish, 481
Electrodessication, 511
Electron spin resonance (ESR) spectroscopy, 

85

Electro Pressure Regeneration Therapy 

(EPRT) device, 490

Electrospray ionization-mass spectrometry 

(ESI-MS), 123
Electrosurgery, 511
Electrosurgical epilation, 326
ELM, see Epiluminescence microscopy
Emery boards, 266
Emollients, 289
Emulsifiers, 289–290
Endogenous electric fields, 487
Endothelin-B receptors, 8
Endovenous chemo-ablation techniques, 

313–317

Endovenous laser treatment (EVLT), 317
Environmental stressors, 82–83
Epidermabrasion, 179
Epidermal cooling devices, 515
Epidermal hypertrophy, 118
Epidermal thinning, 425
Epidermosides, 124
Epigallocatechin gallate (EGCG), 83–85
Epilator, 326
Epiluminescence microscopy (ELM), 416
EPO, see Evening primrose oil
EPRT device, see Electro Pressure 

Regeneration Therapy device

ER, see Estrogen receptors
ERT, see Estrogen replacement therapy
Erythema, 50
ESI-MS, see Electrospray ionization-mass 

spectrometry

ESR, see Electron spin resonance 

spectroscopy

Essential fatty acids (EFAs), 159, 289
Estradiol, 425
Estriol, 425
Estrogen, in topical treatments, 425–426
Estrogen receptors(ER), 415
Estrogen replacement therapy (ERT), 

424–426

Ethnic cosmetics

aging and rejuvenation, 387
chemical peeling, 386–387
cutaneous appendages, 384–385
skin color, 384
skin disease, 385–386
sun protection, 386

Ethnic skin

antioxidant status, 410–411
blood vessel reactivity, 404, 406–407
corneocyte variability, 404–405
effects on, 109
elastic recovery/extensibility, 407–409
facial pore size, 411
lipid content, 408–410
methods, 398
pH gradient, 408
transepidermal water loss (TEWL), 

398–401

water content, 399, 401–404
Ethyl methacrylate monomer, 279
Eucalyptus citriodora, 156
Evening primrose oil (EPO), 160
Evernia prunastri, 149

 
588 

 INDEX

EVLT, see Endovenous laser treatment
Evolence®, 473
Excessive hair

causes of, 321–324
cosmetic procedures for removal of, 

324–325
shaving, 325–327

Exfoliants, 178
Exogenous ochronosis, 386
Extrinsic skin aging, 64–66
Eye irritation, 304–305
Eyelashes, 395–396
Eyelid dermatitis, 271, 282

Face masks, 180
Facial asymmetry, 465–466
Facial hirsutism, 426
Facial lengtigines, reduction of, 105
Facial peeling, 454
Facial pore size, 411
Facial scrubs, 179
Facial telangiectasias, 510–512
Facial wrinkles, 462, 466
Fair Packaging and Labeling Act (FPLA), 183
Fast optical in vivo topometry (FOIT), 17–21
FD, see Folliculitis decalvans
FDA, see Food and Drug Administration
FD&C Act, see Federal Food, Drug, and 

Cosmetic Act

FDD, see Frequency distribution of depth
Federal Food, Drug, and Cosmetic Act 

(FD&C Act), 183
Female hair with aging

clinical manifestations of, 413–415
efficacy measures of, 416–419
mechanisms of, 415–416

Female pattern hair loss (FPHL), 413–414
Feminine-care products, 50
Ferric ferrocyanide, 269
Ferulic acid, 202–204
Fibered cloths, 179
Fibroblastic phase, 353
Fibroblasts, 262, 507–508
Field of cancerization, actinic keratoses, 214, 

215

Film-drying accelerant, 269–270
Film formers, 268
Film modifiers, 268
Finasteride, 426
Flank treatment, cryolipolysis, 544
Flashlamp pumped-pulsed dye laser 

(FLDP), 512–513

Flat irons, 244
Flat lesions, 455
FLDP,  see Flashlamp pumped-pulsed dye 

laser
Flos lonicerae, 161
Fluid mosaic model, 128
Fluorescent-style UV nail lamps, 221
Fluorescent tubes, 220
5-Fluorouracil, 216
Foam Sclerotherapy, 315–316
FOIT, see Fast optical in vivo topometry
Follicular unit (FU) density, 391
Folliculitis decalvans (FD), 395
Folliculitis keloidalis, see Acne keloidalis
Fontana-Mason staining, 94
Food and Drug Administration (FDA), 93
Forehead lines, 462–463
Forehead wrinkles, 90
Formaldehyde, 284, 291, 302–303
Formalin, 285
Fourier transform infrared (FTIR) 

spectroscopy, 128
4-n-Butylresorcinol, 331
Four-week laxity clinical study, 495–496
FPHL, see Female pattern hair loss

FPLA, see Fair Packaging and Labeling Act
Fractional 1440-nm laser, 522
Fractional 1540-nm laser, 525
Fractional 1550-nm laser, 521–522
Fractional photothermolysis, 519, 520
Fractional Q-switched ruby laser, 526
Fragrance allergic patient, 149–151
Fragrance ingredients

adverse reactions to, 148
allergic contact dermatitis to, 149

Frail nails, 266
Fraxel division, 520
Fraxel DUAL 1550/1927 lasers, 522
Free fatty acids, in human stratum corneum, 

127, 129

Freeze-thaw cycle (FTC), 450
Frequency distribution of depth (FDD), 19
Frozen porcine fat, 538
Fruit acid, 57
FTC, see Freeze-thaw cycle
FTIR spectroscopy, see Fourier transform 

infrared spectroscopy
FU density, see Follicular unit density
Functional magnetic resonance imaging, 52
Functional skin properties, 48
Fungus identification methods, 33

GAGs, see Glycosaminoglycans
Galvanic current, 492
Gamma-linolenic acid (GLA), 160
Gel matrix, 59
Genistein, 207–209
Genital discomfort, 426
Gentian violet (GV), 160
Gingival smile, 465
GLA, see Gamma-linolenic acid
Glabellar lines, 462
Glabellar m., 462
Glutathione (GSH), 81–82, 84
Gluteofemoral adipocytes, 432
Gluteraldehdye, 278
Glyceraldehyde, 174
Glycerides, 289
Glycerol monothioglycolate (GMTG), 394
Glycolic acid, 56, 57, 365
Glycosaminoglycans (GAGs), 59, 171
GMTG, see Glycerol monothioglycolate
Greasy skin, 167–168, 171
Green tea, 83–84, 182
Grenz zone peel, 500–501
GSH, see Glutathione
GV,  see Gentian violet

HA, see Hyaluronic acid
Hair

biochemistry, 392
care and styling, 393
characteristics, 392–393
conditioners, 237–243
cosmetic aspects of, 227–231
cosmetic products for, 235
count, 107, 327
damage, 232–235
density, 231, 391
diameter and texture, 230–231
excessive, see Excessive hair
gels, 246
greying, 415
growth, 391–392, 419
phenotype, 232
shaft changes, 414
shampoos, 235–237
straightening, 244–245
styling, 243, 245–246
types of, 231
volume, 243–244, 244

HAIR-AN, see Hyperandrogenism, insulin 
resistance, and acanthosis nigricans 
syndrome

Hair regrowth

automated phototrichograms, 416
combination measures, 419
diameter, 416–418

Hairspray, 246
Halo nevus, 338
Handheld reusable textured cleansing pads, 

180

Hand lotions, see Body lotions
Hard keratin, 32
HASI, see Hyperhidrosis Area and Severity 

Index

HB-EGF, see Heparin-binding–epidermal 

growth factor
Hemosiderosis, 341
Heparin-binding–epidermal growth factor 

(HB-EGF), 88

Herba menthae, 161
4-hexyl-1,3-phenylenediol, 144–145
HGA, see Homogentisic acid
HH, see Hyperhidrosis
Hidradenitis suppurativa (HS), 350
age and sex distribution, 369
cosmetics of, 371
treatment of, 369–371

High-grit boards, 266
Hippophae rhamnoides, 154–155
Hirsutism, 321–322, 426
Hollow microneedles, 439
Homogentisic acid (HGA), 386
Hormonal skin aging, 424–425
Hormone replacement therapy (HRT), 425
Horny cells, 385
Hot combing, 393
HPV,  see Human papilloma virus
HQ, see Hydroquinone
HRIPT, see Human repeated insult patch
HRT, see Hormone replacement therapy
HS, see Hidradenitis suppurativa
Human abdominal tissue, 536, 538
Human-derived collagen, 473
Human fingernail plates, 34
Human forearm biopsy, 73
Human papilloma virus (HPV), 215
Human periorbital wrinkle
aged skin aspect, 259–260
aligned collagen layer, 262
computer model of, 261–262
implications, 262–263
local differences in, 260–261

Human repeated insult patch (HRIPT), 

301–302

Human scalp hair

care and styling, 393–394
characteristics of, 392–393
color, 392
density of, 391
ethnic variations in, 394–395
growth, 391–392
shape and thickness, 390–391

Humectants, 170–171, 289
Hyaluronic acid (HA), 167, 216, 473–476
Hydrating products, 169
Hydrocolloid masks, 181
Hydrogen sulfide, 365
Hydroquinone (HQ), 76, 276, 282, 330–331
Hydroxyacids, 56

bioavailable concentration, 59–60
biochemistry, 59
cosmetic and dermatological indications, 

63–64

differences of, 66–68
α-hydroxyacids, 56–57, 58
β-hydroxyacids, 57
intrinsic and extrinsic skin aging, 64–66

 
mechanisms of action, 62–63
optimal release formulation, 60
physicochemical properties, 58–59
polyhydroxy acids, 57–58
topical actions, 60–62

Isoflavones, 101, 426
Isolated actinic keratosis, 215
Isolated hyperkeratotic actinic keratosis, 215
Isolated onycholysis, 285
Isotretinoin, 362

β-Hydroxyacids (BHA), 57, 178
β-Hydroxybutanoic acid, 57
β-Hydroxybutyric acid, see 

β-Hydroxybutanoic acid

Hyperandrogenism, insulin resistance, and 

acanthosis nigricans (HAIR-AN) 
syndrome, 321
Hyperhidrosis (HH), 467–468
Hyperhidrosis Area and Severity Index 

(HASI), 467

Hyperkeratotic actinic keratosis, 215
Hyperkeratotic wart, 454
Hyperpigmentation, 94, 105, 153–155, 451
Hypertonic saline, 315
Hypertrichosis, 322–324, 426
Hypertrophic scars, 529
Hypopigmentation, 385, 529

Ichthyoses, 129–130
Idebenone, 77–78, 84

skincare delivery of, 78

Idiopathic guttate hypomelanosis, 341
IFRA, see International Fragrance 

Association

IκB kinases (IKK), 143
IKK, see IκB kinases
Imidazole antimycotic agent, 253
Imiquimod, 216
Immediate pigment darkening (IPD), 185
Impedence microscopy (IS), 33
INCI, see International Cosmetic Ingredient; 
International Nomenclature of 
Cosmetic Ingredients

INCO, see IncobotulinumtoxinA
IncobotulinumtoxinA (INCO), 459
Indigo naturalis, 162
Indoor tanning, 189
Inflammatory phase, 353
Infraorbital rhytides, 463
Ingenol mebutate, 216–217
Ingredient classes
emollients, 289
emulsifiers, 289–290
minor components, 290–291
water, 288–289
water-soluble polymers, 290

Injectable silicone, 479
Inner thigh treatment, cryolipolysis, 544
Inorganic agents, of sunscreens, 194–195
In-plane microneedles, 436
Integumentary system, 261
Intense pulsed light (IPL), 336, 511, 514–515
Intensive conditioners, 239
Intercellular lipids, 28, 45, 250
International Cosmetic Ingredient (INCI), 

288

International Fragrance Association (IFRA), 

151

International Nomenclature of Cosmetic 
Ingredients (INCI), 268, 284

Intra-arterial injection, 475–476
Intradermal botulinum toxin, 172
Intra-epidermal secondary factors, 117
Intraepidermic peel, 498–499
Intralesional injection, 354
Intrinsic antifungal potency, 255
Intrinsic skin aging, 64–66
IPD, see Immediate pigment darkening
IPL, see Intense pulsed light
Irritant dermatitis, 7–8
Irritant test, 45, 47
IS, see Impedence microscopy

KA, see Kojic acid
Keloidalis nuchae, see Acne keloidalis
Keloids, 456

clinical aspects, 349–350
histologic examination of, 350–352
hypertrophic scars vs., 349
pathogenesis, 352–353
treatment of, 354–358

Keratinization, 60
Keratinocytes, 404
destruction, 452
differentiation, ceramides on, 134–135
proliferation of, 117–118
Keratolytic treatment, of acne

azelaic acid, 363–364
benzoyl peroxide, 360–361
retinoids, see Retinoids
salicylic acid, 364
sulfur, 365

Ketoconazole, 253, 254
Kinetin

chemistry, 113
clinical studies, 114–115
exact mechanism of, 113–114

Kligman formulation, 386
Kligman’s formula, 333
Kojic acid (KA), 331
KTP 532nm green lasers, 512
Kunitztype trypsin inhibitor, 94

Lactic acid, 171
Lactone form, 58
Lamellar bodies, see Membrane-coating 

granules
Laminin 332, 121–122
Lanolin, 289
Lanugo hair, 228
L-ascorbic acid, see Vitamin C
Laser Doppler flowmetry (LDF), 309
Laser Doppler velocimetry (LDV), 406
Laser profilometry, 16–17
Laser therapy, onychomycosis, 157–158
Late-onset pain, 542, 543
Layered haircut, 393
LCD, see Liquor carbonis detergens
LDF, see Laser doppler flowmetry
LDV,  see Laser Doppler velocimetry
LE, see Lupus erythematosus
Leave-in conditioners, 239
LED-style nail lamps, 278, 280
Leg telangiectasias, 513
Lentigines, 340
L-ergothioneine, 84
Levator labii superioris m., 464
Light emitting diodes (LED) UV nail lamps, 

221

Linear density diameter, hair, 417
Linear telangiectasias, 510
Lipid content, skin, 408–410
Lipolytic stimulation, 431
Lipometer, 169
Lipophilic compounds, 71
Liquid nitrogen cryotherapy, 334–335
Liquiritin, 333
Liquor carbonis detergens (LCD), 160
Local anesthetics block response, 50
Local phenol, 508
Long-lasting fillers, 476–479
Long nail, 264
Long pulsed 1064-nm lasers, 513–514

INDEX 

 589

Long-pulse dye laser, 513
Lotion composition, 300–301
Lotion measurement, 552
Lotion transfer

absorbent core on, 554–555
durations of exposure, 554
on pad samples, 553–554
pad thickness on, 556
skin benefits of, 557–558

Lower face, 464–465
Low-grit boards, 266
Low intensity electricity, 491
LPG endermologie, 310
L-selenomethionine, 205–207
Luna stain, 103
Lupus erythematosus (LE), 424
Lycopene, 188

Macrophotographic manual hair count, 416
Magnetic resonance imaging (MRI), 

309–310

Magnolignan, 332
Mahonia aquifolium, 161–162
Maillard reaction, 174
MAL, see Methyl aminolevulinate
Malassezia furfur, 248
Malassezia globosa, 251
Malassezia yeast, 168
Male skin, age-related changes in
mechanical properties, 380
methods, 377
pH value, 378–379
sebum excretion, 379–380
skin barrier function, 378
wrinkle development, 380–381

Maltobionic acid, 59
Marionette lines, 464
Massage treatment, 310
Mass balance, of radioactivity recovery, 

36, 37

Masseteric hypertrophy, 465
Matrix metalloproteinases (MMPs), 

88–89, 120

MBEH, see Monobenzylether of 

hydroquinone

MCG, see Membrane-coating granules
MC1R, see Melanocortin 1 receptor
Mechanism of action, self-tanning products, 

174–175

MED, see Minimal erythema dose
Medium-grit boards, 266
Medulla, 229, 392
MEHQ, see Methyl ethyl hydroquinone
Melanex, 105
Melanin, 153, 384, 392
Melanocortin 1 receptor (MC1R), 188
Melanocytes, 386, 392
Melanocyte-stimulating hormone (MSH), 13
Melanoderma, 330
Melanogenesis inhibition, 493
Melanoidins, 336
Melanoma, 193–194
Melanosomes, 392
Melasma, 153, 387
Membrane-coating granules (MCG), 

123–124, 127

MEND, see Microscopic exudative necrotic 

debris

Menopausal dry skin, 425
Menopausal skin thinning, 425
Menopause, 415

hormonal replacement therapy, 424
hormonal skin aging, 424–425
hormone regimens, 425–426
hormone replacement therapy, 425
phytoestrogens, 426

Mentalis, 464–465

 
590 

 INDEX

Mesotherapy, 311

for fat deposits, 431–432
skin renjuvenation, 432–434

Multiple hyperkeratotic actinic keratoses, 

217

Multi-wavelength fractional 1440/1320-nm 

Metabolism of retinol, 88
Methacrylate liquid/powder, 276
4-Methoxy Potassium Salicylate (4-MSK), 

laser, 525–526

Muscular pumping, 309
Myroxylon pereirae, 149

332

Methyl aminolevulinate (MAL), 442
Methylene glycol, 270, 284–285
Methyl ethyl hydroquinone (MEHQ), 276, 

282

Methylxanthines, 310
METS, see Microcurrent stimulation
mFCAT, see Modified forearm controlled 

application test

MIC, see Minimum inhibitory concentration
Microampere current, 490
Microbiological contamination, 270
Microcomedo, 360
Microcurrent electrical therapy, 490–491
Microcurrent stimulation (METS), 488
Microdermabrasion, 180
Microneedle

cosmetic uses, 437–439
safety of, 439
strategies for drug delivery, 437

Microneedle-based devices, 437
Microneedle rollers, 436
Microorganisms, 291
Microscopic exudative necrotic debris 

(MEND), 520

Microthermal zones (MTZ), 520
Mid-angle sunlight, 223
Middle face, 464
Millisecond pulse durations, 516
Mineral oil, 289
Miniature needles, 436
Minimal erythema dose (MED), 185
Minimum inhibitory concentration (MIC), 

33, 38–39

Minor components, 290–291
Misuse, body lotions, 301
Mitochondrial DNA (mtDNA), 80
Mitochondrial lipid peroxidation, 76
Mitochondrial theory, of aging, 76
MMEH, see Monomethyl of hydroquinone
MMPs, see Matrix metalloproteinases
Mode of action, 236, 238–239
Modern nail art, 264
modified forearm controlled application test 

(mFCAT), 553

MoistureMeter SC-4, 168
Moisture/smooth hair, 241
Moisturization balance, in combination 

skin, 108–109
Moisturizer efficacy

advertising claims made for, 298–299
alleviating dry skin, 291–294
bioengineering techniques, 562
data, 562–564
instrumental evaluations of, 295–297
problems with, 561–562
product evaluation by trained expert, 298
user evaluation of, 297–298
Moisturizing shampoos, 237
Monobenzylether of hydroquinone (MBEH), 

331, 337

Monomethyl of hydroquinone 

(MMEH), 331

Monometric cyanoacrylate, 283
Mottled pigmentation, 387
Mousses, 246
MSH, see Melanocyte-stimulating hormone
4-MSK, see 4-Methoxy Potassium Salicylate
mtDNA, see Mitochondrial DNA
MTS-Roller™, 439
MTZ, see Microthermal zones
Mud packs, see Earth-based masks

NAAs, see N-acetylamino acids
N-acetylamino acids (NAAs), 66–67
N-acetyl compounds, 66–67
N-acylpeptides (NAP), 67–68
NAD, see National Advertising Division
NAFL, see Nonablative fractional lasers
Nail

base and top coats, 269–271
chemical properties, 32–33
coloration additives, 269
decoration of, 264–266
items for, 266–267
nail varnish basics, 268
potential for injury/infection, 273–274
reactions to applied cosmetics, 271–273
solvents and diluents, 268–269
texture of, 266
toiletries and cosmetics, 267
treatment of, 283–285

Nail buffers, 267
Nail creams, 270–271
Nail incubation, 34–36
Nail keratin granulation, 272
Nail penetration

antifungal efficacy coefficient, comparison 

of, 40

14C-econzaole, profile of, 38
nail lacquer formulations, 37
nail permeation testing and sampling, 33
nail plate and bed, hydration of, 36
noninvasive diagnostic tools for 
onychomycosis, 33–36

physical and chemical properties of, 32–33
radiolabeled drug penetration, 39

Nail plate

hydration of, 36
lipid pathway in, 32
staining, 272
ventral/intermediate, 35–36

Nail sampling, 35–37
Nail varnish, 270, 279

basics, 268
dermatitis, 271–272
diluents and solvents, 268–269
formulation, 267
Nail whitener, 267
NAP,  see N-acylpeptides
Narrow band ultraviolet B (NBUVB) 

courses, 222

Nasal tip droop, 464
Nasal wrinkles, 464
NASHA, see Non–animal-sourced 
hyaluronic acid gel

National Advertising Division (NAD), 299
National Organic Program (NOP), 183
Natural moisturizing factors (NMFs), 

127, 169, 171

NBUVB courses, see Narrow band 
ultraviolet B courses

Necrosis, 536
Netherton syndrome, 130
Neurogenic causality, 52
Neurogenic inflammation, 52
Nevus depigmentosus, 338
Nevus spilus, 340
NFκB, see Nuclear factor kappa B
1927-nm lasers, 522
Nippers, 266
Nitrocellulose, 268
Nitroethane poisoning, 279

NMFs, see Natural moisturizing factors
NMR, see Nuclear magnetic resonance
NMSC, see Nonmelanoma skin cancer
Nodular basal cell carcinoma, 446
No-light cyanoacrylate gels, 280, 283
Nonablative fractional lasers (NAFL), 520

cynosure icon family of, 522–525
Solta family of, 520–521

Nonablative infrared lasers, 519
Nonablative laser rejuvenation, 519
cynosure icon family, 522–525
fractional 1540-nm laser, 525
fractional photothermolysis, 520
Fraxel 1550-nm laser, 521–522
multi-wavelength fractional 1440/1320-nm 

laser, 525–526
1927-nm lasers, 522
nonablative fractional lasers, solta family 

of, 520–521

photodamage, 528–529
pigmentary disorders, 531
post-care routine, 527
scars, 529–530
striae, 530–531

Nonablative photorejuvenation, 387
Non allergic reactions, nail, 279–281
Non-amphoteric system, 60
Non–animal-sourced hyaluronic acid gel 

(NASHA), 474

Non-denatured soy, in skin care
clinical efficacy of, 105–109
composition, 96–102
and delayed hair growth, 94–96
and dermal matrix enhancement, 96
early utilization of, 93–94
human health, 93
for human topical applications, 102–103
preclinical results of, 103–105
proteins, 94

Nonhyperkeratotic actinic keratosis, 215
Nonhypertrophic acne scarring, 387
Noninvasive diagnostic tools, for 

onychomycosis
methodology, 34–36
results of, 36

Noninvasive techniques, 391
Nonionic emulsifiers, 290
Nonionic shampoo, 237
Nonkeratinized vulvar skin, 49
Nonmelanoma skin cancer (NMSC), 188, 221

development, 96

Nonmethacrylic acid primers, 276–277
Non-nitrated cellulosic, 268
Nonrepaired damage, of mitochondrial 

DNA, 76

Non-scalp seborrheic dermatitis, 252
Nonsteroidal anti-inflammatory drugs 

(NSAIDs), 187–188

NOP,  see National Organic Program
Normal-phase liquid chromatography 

(NPLC), 123

Normal skin, 167

treatment of, 169–170

Nova Dermal Phase Meter DPM 9003, 168
NovaTM, 297
NPLC, see Normal-phase liquid 
chromatography

NSAIDs, see Nonsteroidal anti-inflammatory 

drugs

Nuclear factor kappa B (NFκB)

activation under skin aging, 144
homeostasis, 143–144
signaling, 143

Nuclear magnetic resonance (NMR), 128

Oats, 159
Occlusive moisturizing ingredients, 171

 
Occupational irritant hand dermatitis 

(OIHD), 563

Ochronosis, 341
OCT, see Optical coherence tomography
OFDA, see Optical fiber diameter assessment
OIHD, see Occupational irritant hand 

dermatitis

Oil inclusion, conditioning products in, 239
Omega-hydroxy ceramides, 126
OnabotulinumtoxinA (ONA), 459
Onycholysis, 264, 273, 277–279, 282, 284
Onychomycosis, 64, 447

alternative treatments for, 159
Ciclopirox, 155
noninvasive diagnostic tools for, 33–36
tavaborole, 157
tea tree oil, 155–156
topical therapy for, 32
Vicks® VapoRub, 156–157

Onychoschizia, 266
Open-chamber instruments, 28
Open spray liquid nitrogen, 454
Optical coherence tomography (OCT), 

33–34, 168, 387

Optical devices, 310
Optical fiber diameter assessment (OFDA), 

417–418

Optical techniques, for skin 

characterization, 579–580

Optimal metal ions, 102
Optimal release formulation, 60
ORAC, see Oxygen radical absorbance 

capacity
Orbicularis oris m., 464
Osler-Weber-Rendu syndrome, 510
OTC products, see Over-the-counter 

products
Oval-shaped nails, 264
Over-the-counter (OTC) products, 385–386
Oxidation, 59
Oxygen radical absorbance capacity 

(ORAC), 85

Pain sensation for skin, 11
Palomar Icon Aesthetic System, 525
Panniculitis, 535
Papillary dermis peel, 501–502
Papular telangiectasias, 510
PAR-2,  see Protease-activated receptor-2
Paronychia, 277, 282, 284
Partial neutralization, 60
Paste masks, see Earth-based masks
Pathological nails, cosmetics for
adverse reactions, 281–283
allergic reactions, 277–279
artificial nails, 276–277
nail hardeners and treatments, 283–285
non allergic reactions, 279–281
removable UV gels, 281

PCOS, see Polycystic ovary syndrome
PCPC, see Personal Care Products Council
PDD, see Photodynamic diagnosis
PDT, see Photodynamic therapy
Pedicure implements, 267
Pentaherbs (PTH), 161
Percutaneous water loss, 425
Perfumes

allergic contact dermatitis, 148–149
applications of, 148
causative ingredients, 149
fragrance allergic patient, 149–151
interventions and regulations, 151

Perifolliculitis capitis abscedens et 

suffodiens, see Dissecting folliculitis

Perimenopause, 415, 424
Perioral area, 464
Periorbital feet lines, 463

Permanent fillers, 479
Peroxisome proliferator-activated receptors 

Pigmentary mosaicism, 340
Pigmentation, 269

INDEX 

 591

(PPAR), 134, 310

Personal Care Products Council (PCPC), 288
Pesticide residues, 289
Petrolatum, 289
PGE2, see Prostaglandin E2
PHA, see Polyhydroxy acids
Phagocytosis, 536
Pharmacological agents, 310
Phenol, 508–509
Phenotype, 232
pH gradient, skin, 408
Phloretin, 203–204
Phospholipids, 101
Phosphotidylcholine, 432
Photoaging, 88–91, 120, see also Antioxidants

clinical manifestations of, 510
Photocarcinogenesis, 76, 193–194
Photodamage, 199, 528–529, see also 

Sunscreen

antioxidants and dietary agents, 187–188
education and prevention of, 189
ferulic acid, 202–203
genistein, 207–209
phloretin, 203–204
protection from visible light and infrared 

radiation, 188–189

selenium, 204–206
signs, 90
solar exposure, 185–186
sunscreen, 186–187
ultraviolet radiation mechanisms, 185
vitamin C, 199–200
vitamin D, 187
vitamin E, 200–202

Photodynamic diagnosis (PDD), 446
Photodynamic therapy (PDT), 157, 217, 437, 

531

effects on tissues, 442
indications in dermatology, 444–447
light source, 443–444
oxygen, 444
and pain, 448
photosensitizing agents, 442–443
in practice, 447–448
Photoinitators (PI), 220
Photoplethysmography (PPG), 406
Photoprotection

of human skin, 83–85
physical methods of, 187
Photoprotective products, 170
Photoreactions, ingredients, 304
photosensitizing agents, 442–443
Phototherapy treatment, of pigmentary 

disorders, 335

Phototrichograms

hair, 417
scalp hair, 391
pH values, 378–379

in skin surface, 384

Physicochemical properties, 58–59
Phytoestrogens, 426
Phytosterols, 101
PI, see Photoinitators
Picosecond lasers, 516
Picotage, 432
Piebaldism, 338
PIF, see Product information file
Pigmentary disorders, 531
Pigmentary lesions, treatment of, 515–516

dark rings, 340–341
dyskeratosis, 341–342
hypopigmented striae and iatrogenic 

leukoderma, 341

melasma, 336–337
solar lentigines, 338–339
vitiligo, 337–338

hair shaft, 415–416

PIH, see Post-inflammatory 

hyperpigmentation

Pilocarpine iontophoresis, sweat test, 5
Pilosebaceous unit, 11–13
Pineal hormone melatonin, 84
Pityrosporum, 248
PL, see Polypodium leucotomos
Placebo cream, 425
Plantar warts, 454
Plasmin

in dry skin, 117–120
in skin aging, 120–122

Plasminogen activator, 118, 119
Plasticizers, 268
Plastic tips, 276
Platysmal bands, 466
PLE, see Protein-losing enteropathy
Plicometry, 309
PLLA, see Poly-L-lactic acid
PMH, see Progressive macular 
hypomelanosis

PMMA, see Polymethylmethacrylate
PMS, see Polymultichrome stain
Poikiloderma of civatte, 340
Polidocanol (POL), 315
Polycarboxy α-hydroxyacids, 57
Polycystic ovary syndrome (PCOS), 321
Polydatin, 170
Polyhydroxy acids (PHA), 57–58
Poly-L-lactic acid (PLLA), 476
Polymer-based microneedle roller, 437
Polymerization of nail coating, 220–221
Polymer nails, 279
Polymethylmethacrylate (PMMA), 479
Polymultichrome stain (PMS), 295
Polyols, 171
Polyphenols, 83–84, 96
Polypodium leucotomos (PL), 188
Polyunsaturated fatty acids (PUFAs), 171, 

188

Pomades, 246
Pomegranate extract, 170
Popliteal fossa, 551
Porcine collagen, 473
Porcine fat, 538
Porcine tissue, 535–536
Porosity, of hair, 392
Porphyrias, 424
Post-inflammatory hyperpigmentation 
(PIH), 109, 334, 385–386, 387

Postinflammatory pigmentation, 341
Postmenopausal alopecia, 427
Postmenopausal facial hirsutism, 426
Postmenopausal vulval atrophy, 426
Postmenopausal women

parallels bone loss in, 425
skin aging in, 426
Postmenopause, 424
Postpartum telogen effluvium, 413
Post-peel period, 509
Postulated activation, of antioxidants, 81
Potentiated pyrithione zinc formulas, 

253–254

PPAR,  see Peroxisome proliferator-activated 

receptors

PPG, see Photoplethysmography
Preformed artificial nails, 281–283
Premarin, 425
Premenopause, 424
Pre-peel conditioning, 498
Preservatives, 290–291, 302
Press-on nail extender, 273
Prevelle® Silk, 474
Primary dermal irritation, 301–302
Primary irritation, 293–294

 
592 

 INDEX

Product information file (PIF), 299
Progressive macular hypomelanosis (PMH), 

341

Proliferative phase, see Fibroblastic phase
Prolonged paresthesia, 277, 279
Pro Mechanica® software, 261
Pronounced idiosyncratic edema, 456
Proper curing, of nail coatings, 220
Propionibacterium acnes, 167, 303, 360, 361
Proprietary gamma irradiation, 99
Prostaglandin E2 (PGE2), 187
Prosthetic nail, 277
Protease-activated receptor-2 (PAR-2), 94, 

384

Protective property of sunscreen, 186–187
Protein-losing enteropathy (PLE), 188
Proteoglycans, 167
Protoporphyrin IX absorption, 444
Pro urokinase-type plasminogen activator 

(Pro-uPA), 118

Pruritus, 64, 158, 162–163
Pseudoceramides, 291
Pseudochromhidrosis, 342
Pseudofolliculitis barbae, 387, 394
Pseudomonas, 273
Psoriasis, 129–130, 161–163
Psoriatic skin, 118
Psychotherapy, 427
Pterygium inversum, 284
PUFAs, see Polyunsaturated fatty acids
Purpura, 512
Pushers, 267
Pyrithione zinc (ZPT), 252–253, 254–255
Pyrrolidone carboxylic acid, 171

QoL, see Quality of life
QRA, see Quantitative risk assessment
QSPR model, see Quantitative structure–
activity relationship model

Q-switched lasers, 515–516
Quality of life (QoL), 298–299, 369
Quantitative risk assessment (QRA), 302
Quantitative structure–activity relationship 

(QSPR) model, 33

Rabbit ear model, cosmetic ingredients in, 

304
Racket nails, 276
Radiation therapy, 357–358
Radiesse®, 477–479
Radio frequency (RF), 387
Raman spectroscopy, 128
Randomized controlled trials (RCTs), 

369–370, 563

Randomized double-blind study, 255
Ra parameter, 17
RAR, see Retinoic acid receptors
RARs, see Retinoic acid receptors
RBP,  see Retinol-binding protein
RCTs, see Randomized controlled trials
Reactive nitrogen species (RNS), 80, 82, 84
Reactive oxygen species (ROS), 65, 80, 185, 

231

Refsum disease, 130
Rel homology, 143
Repeated insult patch test (RIPT), 102
Repeated nasal flare, 464
Repeated short-term occlusive irritation test 

(ROIT), 294

Repigmentation, 452
RES, see Resveratrol
Research Institute for Fragrance Materials 

(RIFM), 302

Resistance, water, 401
Resorcinol, 365
Restylane injection, 475

Resveratrol (RES), 170, 188
Reticulary dermis peel, 502–503
Retinoic acid receptors (RARs), 71, 361–362
Retinoid metabolic pathways, 72
Retinoids, 71, 88–91, 355, 361–362, 385

adapalene, 363
tazarotene, 362–363
tretinoin, 362

Retinoid-sensitive models, 74
Retinol

biological effect on skin, 88–89
clinical aspects of, 89–91
metabolism of, 88

Retinol-binding protein (RBP), 88
Retinol-cytoplasmic retinol-binding protein, 71
Retinol esters, molecular biology of, 71–72
Retinyl esters

biochemistry and molecular biology of, 

71–72

potential to break retinoid efficacy to 
irritation correlation with, 72–74

Retinyl propionate, and related retinoids, 

71–74

RF, see Radio frequency
Rhinophyma, 455
Rhizoma atractylodis, 161
RIFM, see Research Institute for Fragrance 

Materials

RIPT, see Repeated insult patch test
RNS, see Reactive nitrogen species
ROIT, see Repeated short-term occlusive 

irritation test

Rooster comb–derived fillers, 474
ROS, see Reactive oxygen species
Rosacea, 63
RRR-α-tocopherol, 200–202
Rubber-based masks, 180–181
Rz parameter, 17

SA, see Salicylic acid; Senescent alopecia
Salicylic acid (SA), 253, 364, see also 

β-Hydroxy acids

Sanitation, nail, 274
Savin patterns of hair loss, 414
SC, see Stratum corneum
Scars, 371, 529–530
SCC, see Squamous cell carcinoma
Sclerotherapy chemo-ablation techniques, 

313–317

Scoring for atopic dermatitis (SCORAD) 

scale, 159–161

Scoring system, 77
Scrubbing pads, 180
Sculpted nail, 277
Sculptra®, 476–477
Sculptured artificial nails, 277, 278
SDA, see Spectrum descriptive analysis
SE, see Sebum excretion
Seborrheic dermatitis, 168, 248

treatment of, 172

Seborrheic keratosis, 339, 455
Sebufix F16, 169
Sebumeter SM 810, 169
Sebum excretion (SE), 379–380

measurement of, 169

Sebum output, quantification of, 169
Sebum production, 108–109
Sebum regulator, 172
Sebum secretion, 167
Sebutape®, 51, 169
Secondary prevention, actinic keratoses, 

215–216

Selenium, 204–206

with vitamin E, 206–207
Selenium sulfide, 253, 254–255
Self-tanning products
application of, 175

indications, 175–176
mechanism of action, 174–175
safety, 176

Semi-automated phototrichograms, see 

Automated phototrichograms

Semipermanent fillers, 476–479
SENEB, see Subepidermal nonechogenic 

band

Senescent alopecia (SA), 413, 415
Senescent signals, 415
Senile xerosis, 131
Sensitive skin

factors in, 47–50
sensory effects and objective signs, 50
zeroing in on biological origin, 50–52
Sensitization-delayed (Type IV) contact 

hypersensitivity, 302

Sensitization testing, 302
Sensory functions of skin
autonomic function, 11
thermal response to stimulation, 

10–11

thermoregulatory, 8–10

Sensory irritation, 302
Serine palmitoyl transferase (SPT), 129
Sesamol, 170
Seven-irritant panel, 47
Shampoos, 235–237
Short microneedles, 437
Siderosis, 341
Silicone oil, 269
Silicones, 239, 289
Silicon gel, 354
Single gel phase model, 129
Sjögren-Larsson syndrome, 130
Skicon®, 297
Skicon 200, 168
Ski-jump nails, 276
Skin aging, 88–89, 387, 424–425

new target for, 144–146
NFκB activation under, 144

Skin barrier function, 378
“Skin battery,” 483
Skin biopsies, 90
Skin brightness measurement, 169
Skin cancer, see Sunscreen
Skin care additives, 291
Skin care devices, 180–181
Skin care products

acne treatment, 171–172
care of dry skin, 170–171
care of greasy skin, 171
care of normal skin, 169–170
different types of skin, 167–168
methods for evaluating skin 

characteristics, 168–169

sebum regulator, 172
soybeans in, see non-denatured soy, in 

skin care
Skin color, 11, 12, 384
Skin conductance, 399
Skin disease

exogenous ochronosis, 386
irritation and stinging, 385
post-inflammatory hyperpigmentation 

(PIH), 385–386

Skin dryness, 295
Skin elasticity, 297
Skin firming, enhancement in, 108
Skin glycosaminoglycan composition, 

259

Skin homeostasis, 143–144
Skin hydration measurements, 168
Skin innervation, 411
Skin irritation, 385, 399
Skin lipids, 384
Skin maximization study, 78
Skin peeling, 60–62

 
Skin physiology

biochemical composition of, 3–5
functional differences, 5–7
sebaceous glands, 11–13
sensory functions, 8–11

Skin radiance, 90
Skin rejuvenation, 387
Skin renjuvenation, mesotherapy for, 

432–434
Skin smoothing, 63
Skin stinging, 385
Skin surface morphology, evaluation of, 168
Skin surface texture, treatment with 

hydration, 378, 379
lipid composition, 132
of microneedles, 439
sphingolipid, 4
structure, 384
urokinase activity in, 118

Stratum corneum’s surface, 295–296
Streptococcal-derived fillers, 474
Streptococcus thermophilus, 134
Striae, 530–531
Styling problems, 243
Styling products, 245–246
Subcutaneous fat, 535–536, 539, 546

t-AMCHA methyamide, 120

layer, 259

INDEX 

 593

TF resin, see Tosylamide/formaldehyde resin
Thermal sensation for skin, 11
Thermocouple device, 451
Thermography, 309
Thermoplastic resin, 271
Thigh circumference measurement, 309
Thimble-shaped finger, 279
Thinning of nail plate, 278
Thioctic acid, 333
Thiol antioxidants, 84
Thiol retention activity, 104
Thixotropic systems, 269
Thulium 1927-nm wavelength, 522
Tight braids, 393
Timed spot freeze technique, 450–451
Tissue engineering, 490
Tissue-type plasminogen activator (tPA), 118
α-Tocopherol, 81–85
Tocopherols, molecular structures of, 201
Toenails, 267
Toluenesulfonamide/formaldehyde resin 

(TSFR), 268
Top coats, 269–271
Topical antibiotics, 172
Topical keratolytics, 360
Tosylamide/formaldehyde resin (TF), 268
Toxicology, of body lotions

adverse reactions, 304–305
adverse skin effects, 301–304
lotion composition, 300–301
skin condition, 301

tPA,  see Tissue-type plasminogen activator
Traction alopecia, 393
Traditional Chinese herbal medicine 

(TCHM), 161

Traditional pulsed dye laser, 512
Tranexamic acid, 332
trans-4-(aminomethyl) cyclohexane 

carboxylic acid (t-AMCHA), 117–118

TranScreen-NTM, 33
Transcutaneous electrotherapy, 482
Transdermal drug delivery, 436
Transepidermal penetration, 506
Transepidermal water loss (TEWL), 378, 

Subepidermal nonechogenic band (SENEB), 

387
Sulfur, 365
Sunburn cells, 64–65
Sun protection, 386
Sun protection factor (SPF), 186, 195
Sunscreen, 186–187, 194–196

activity, 175
human factors in, 196–197
ultraviolet radiation, 193–194

Superficial basal cell carcinoma, 445–446
Superficial peelings, 365
Superficial thrombophlebitis, 316–317
Superoxide dismutase (SOD), 80–82, 84

in kinetin, 113
Suppuration, 371
Suprabasal keratinocytes, 88
Surface corneocyte integrity, 296
Surface nail damage, 281
Surface washing procedures, nail plate, 34, 

36

Surgical ligation, 317–318
Surgical subcision, 311
SVCT, see Sodium dependent vitamin C 

transporter
Sweat secretion rates, 5–7
Syncope, 456
Synergistic compositions, 62

t-AMCHA, see trans-4-(aminomethyl) 

cyclohexane carboxylic acid

t-AMCHA methylamide, 119–120
Tantalizing clues, 50
Tape strippings, stratum corneum, 124, 131, 

398–401, 552

biological background, 28
measurement of, 28–29, 169
parameter in skin research, 30
skin, 29

133

TAPS, see Tetracetylphytosphingosine
Tartaric acid, 57
TAS, see Terminal amino silicones
Tattoos, 456
Tavaborole, 157
Tazarotene, 332, 362–363
TCHM, see Traditional Chinese herbal 

medicine

TE, see Telogen effluvium
Tea tree oil, 155–156
Teflon nail, 276, 277
Telangiectasia vein, 510
epidemiology, 312
sclerotherapy/endovenous chemo-

ablation techniques, 313–317
venous anatomy and physiology of, 313

Telangiectatic matting, 316
Telogen effluvium (TE), 413
Temporary fillers, 473–476
Tensile strength, of hair, 393
TEP,  see Transepithelial potential
Terminal amino silicones (TAS), 238
Terminal hair shaft, 228
Test products of behind-the-knee test, 551
Test reactions to ingredients, 303
Tetracetylphytosphingosine (TAPS), 134
TEWL, see Transepidermal water loss
Textured cloths, 179

Transepithelial potential (TEP), 483
Traumatic injuries, nail, 273–274
Traumatic thermal burn scars, 529
Treatment algorithm for actinic keratosis, 

215, 216
Tretinoin, 172, 332, 362
Trichloracetic acid, 505–507
Trichophyton rubrum, 155–158
TrichoScan®, 391, 416
Triethanolamine, 273
Triglycerides, 289
TRP-1, see Tyrosinase-related protein
Trypsin inhibitory activity, of non-

denatured soy, 103

Tryptophan fluorescence, 90
TSFR, see Toluenesulfonamide/
formaldehyde resin

Twelve-week placebo-controlled anti-aging 

study, 494

Tyndall effect, 475
Tyrosinase activity, potent inhibitors of, 144
Tyrosinase-related protein (TRP-1), 331

Ultra-low intensity electricity therapy, 482
Ultrasensitive vibrating probe technique, 

484

Ultrasonography, 309
Ultrasound (US), 309, 387

Skin thickness, 60, 425
Skin xerosis, 132
SLS, see Sodium lauryl sulfate
Smell, 371
SOD, see Superoxide dismutase
Sodium dependent vitamin C transporter 

(SVCT), 82

Sodium lactate, 171
Sodium lauryl sulfate (SLS), 117, 398
Sodium morrhuate, 315
Soft keratin, 32
Soft tissue augmentation

evolution of fillers and, 473
long-lasting/semipermanent fillers, 

476–479

permanent fillers, 479
temporary fillers, 473–476

Solar exposure, 185–186
Solar keratosis, 65
Solar lentigines, 338–339, 387
Solid crystal, 289
Solid microneedles, 436, 437–439
Solta lasers, 521
Sonicating electric toothbrushes, 180
Soybean oil, 93
Soybean plant, 93
Soybean trypsin inhibitor (STI), 94
Soy isoflavones, 102
Soy proteins, 94

isolate/hydrolysate, 93

Spectroscopic methods, for skin 
microstructure, 296

Spectrum descriptive analysis (SDA), 298
SPF, see Sun protection factor
Sphingolipids, 134–135
Sphingosine, 128
Spider nevi, 453
Spider telangiectasias, 510
Spider veins, treatment of, 313
Spinocellular carcinoma, see Squamous cell 

carcinoma

Spray-on tanning formulations, 175
Spritz, see Hairspray
SPT, see Serine palmitoyl transferase
Squamometry, 255
Squamous cell carcinoma (SCC), 186, 193, 

194, 214, 446

lesions, 96

Ssurface erythema, 248
Standard pyrithione zinc formulas, 253–254
Staphylococcus aureus, 160, 273, 395
Staphylococcus epidermidis, 273
Static electricity generators, 481
Stearalkonium hectorite, 269
Stereoisomers, 58
Sterilization, nail, 274
STI, see Soybean trypsin inhibitor
Stick-on nail dressings, 273
Straight Caucasian hair, 390
Straightening, 244–245
Stratum corneum (SC), 28, 32, 38, 250, 302, 

436

barrier function, 59–60, 117
ceramides, see Ceramides

 
594 

 INDEX

Ultraviolet A (UVA), 193–196
Ultraviolet B (UVB), 193–196
Ultraviolet-induced damage, reduction of, 

106

Ultraviolet (UV) radiation, 193–194
Ultraviolet radiation (UVR), 80, 82–84

mechanisms of, 185
Under-eye wrinkles, 90
Ungual drug permeability, limitations of, 33
Unilateral treatment, cryolipolysis, 544
United States Department of Agriculture 

(USDA), 182

United States, hand and body lotions in, 

287, 288

Unstable electron transfer, 76
uPA,  see Urokinase-type plasminogen 

activator

Upper arm treatment, cryolipolysis, 544
Upper face, 462–464
Urea hydrates, 171
Urokinase activity

in dry skin, 117–120
in skin aging, 120–122

Urokinase-type plasminogen activator 

(uPA), 118

Urticaria, 313
US, see Ultrasound
USDA, see United States Department of 

Agriculture

Use of testing, assess adverse reactions, 

304–305
UVA,  see Ultraviolet A
UVA/UVB protection, 106
UVB, see Ultraviolet B
UVB-induced skin damage, reduction in, 

104

UV bulbs, 278
UV-cured (meth)acrylic nails, 281
UV-curing gels, 279–280
UV gel polish/manicure, 270, 280–281
UV gels, 281
UV nail lamps, 220

proper polymerization, 220–221
safety of, 221–223

UV nail lights vs. natural sunlight, 223
UV penetration, 278
UVR, see Ultraviolet radiation
UV radiation, see Ultraviolet radiation

Vitamin D, 187
Vitamin E, 83, 200–202

selenium with, 206–207
vitamin C with, 202–203

Vaginal dryness, 426
Validated assessment scales (VAS), 380–381
Varicose vein

historical aspects, 312
modern minimally invasive surgical 

approaches for, 317–318

venous anatomy and physiology of, 313

VAS,  see Validated assessment scales
Vascular endothelial growth factor (VEGF), 

104

Vascular lesions, 453–454, 510–511
Vascular stasis, 452
Vasoactive response, 49
Vasovagal symptoms, cryolipolysis, 542
VEGF, see Vascular endothelial growth 

factor

Velasmooth, 310
Vellus hair, 228, 391
Venule-derived telangiectasias, 510
Verrucae vulgares, see Warts
Very long chain fatty acids (VLCFA), 127
Vicks® VapoRub, 156–157
Videodermoscopy, 391
Villus hair, 396
Vinyl-based masks, 180–181
Viral infection, actinic keratoses, 214
Viral warts, 454–455
Viscosity modifiers, 269
Visible light–induced skin oxidative stress, 

reduction in, 105

Visible light, protection from, 188–189
Visioscan® VC98, 168, 296
Vistabel®, 459
Vistabex®, 459
Vitamin B12, 158–159, 163
Vitamin C, 83, 199–200

with ferulic acid, 203–204
with vitamin E, 202–203

Vitamins, 170, 188
VLCFA, see Very long chain fatty acids
Vocal anesthesia, 448
Volume control

of hair health, 241, 243–244

Vulva, 49
Vulvar atrophy, 426

Warts, 63–64, 273
Water-based nail varnishes, 270
Water content (WC), 399, 401–404

of skin, 297, 384

Water-soluble polymers, 290
Water vapor, 29
Wattage, 220–222
Waxes, 246
Wax masks, 180
WC, see Water content
Weathering, process of, 232
Wettability, skin, 169
Winter xerosis, 131–132
Wound healing enhancement, 489–490
Wounding epidermis, plasmin, 118
Wrinkle, 380

development, 380–381

Wrinkles, 65

aspect of aged skin, 259–260
compared to surounding skin, 

260–261

implications for treatment of, 

262–263

Xenon halogens, 443
Xerosis, see Dry skin

Zeatin, 113
ZPT, see Pyrithione zinc

 
